WO2017070633A2 - Evolved cas9 proteins for gene editing - Google Patents

Evolved cas9 proteins for gene editing Download PDF

Info

Publication number
WO2017070633A2
WO2017070633A2 PCT/US2016/058345 US2016058345W WO2017070633A2 WO 2017070633 A2 WO2017070633 A2 WO 2017070633A2 US 2016058345 W US2016058345 W US 2016058345W WO 2017070633 A2 WO2017070633 A2 WO 2017070633A2
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
cas9 protein
acid sequence
nos
Prior art date
Application number
PCT/US2016/058345
Other languages
French (fr)
Other versions
WO2017070633A3 (en
Inventor
David R. Liu
Johnny Hao HU
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Priority to EP16794114.5A priority Critical patent/EP3365357B1/en
Priority to CN201680075426.0A priority patent/CN108699116A/en
Priority to US15/770,076 priority patent/US20190225955A1/en
Priority to JP2018521045A priority patent/JP7109784B2/en
Publication of WO2017070633A2 publication Critical patent/WO2017070633A2/en
Publication of WO2017070633A3 publication Critical patent/WO2017070633A3/en
Priority to JP2022058736A priority patent/JP2022124487A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005Cytidine deaminase (3.5.4.5)

Definitions

  • Targeted editing of nucleic acid sequences is a highly promising approach for the study of gene function and also has the potential to provide new therapies for human genetic diseases.
  • An ideal nucleic acid editing technology possesses three characteristics: (1) high efficiency of installing the desired modification; (2) minimal off-target activity; and (3) the ability to be programmed to edit precisely any site in a given nucleic acid, e.g., any site within the human genome.
  • NHEJ and HDR are stochastic processes that typically result in modest gene editing efficiencies as well as unwanted gene alterations that can compete with the desired alteration.
  • 8 Since many genetic diseases in principle can be treated by effecting a specific nucleotide change at a specific location in the genome (for example, a C to T change in a specific codon of a gene associated with a disease), 9 the development of a programmable way to achieve such precise gene editing would represent both a powerful new research tool, as well as a potential new approach to gene editing-based human therapeutics.
  • Cas9 can be targeted to virtually any target sequence by providing a suitable guide RNA
  • Cas9 technology is still limited with respect to the sequences that can be targeted by a strict requirement for a protospacer-adj acent motif (PAM), typically of the nucleotide sequence 5'-NGG-3', that must be present immediately adjacent to the 3 '-end of the targeted DNA sequence in order for the Cas9 protein to bind and act upon the target sequence.
  • PAM protospacer-adj acent motif
  • the PAM requirement thus limits the sequences that can be efficiently targeted by Cas9 proteins.
  • CRISPR clustered regularly interspaced short palindromic repeat
  • sgRNA RNA molecule
  • the target DNA sequence must be both complementary to the sgRNA and also contain a "protospacer-adj acent motif (PAM) at the 3 '-end of the complementary region in order for the system to function. 14
  • PAM protospacer-adj acent motif
  • novel Cas9 variants that exhibit activity on target sequences that do not include the canonical PAM sequence (5'-NGG-3', where N is any nucleotide) at the 3 '-end.
  • Such Cas9 variants are not restricted to target sequences that include the canonical PAM sequence at the 3 '-end.
  • Streptococcus pyogenes Cas9 has been mostly widely used as a tool for genome engineering.
  • This Cas9 protein is a large, multi- domain protein containing two distinct nuclease domains. Point mutations can be introduced into Cas9 to abolish nuclease activity, resulting in a dead Cas9 (dCas9) that still retains its ability to bind DNA in a sgRNA-programmed manner.
  • dCas9 dead Cas9
  • such Cas9 variants when fused to another protein or domain, can target that protein to virtually any DNA sequence simply by co-expression with an appropriate sgRNA.
  • this disclosure also comtemplates fusion proteins comprising such Cas9 variants and a DNA modifying domain ⁇ e.g., a deaminase, a nuclease, a nickase, a recombinase, a methyltransferase, a methylase, an acetylase, an acetyltransferase, a transcriptional activator, or a transcriptional repressor domain), as well as the use of such fusion proteins in correcting mutations in a genome ⁇ e.g., the genome of a human subject) that are associated with disease, or generating mutations in a genome ⁇ e.g., the human genome) to decrease or prevent expression of a gene.
  • a DNA modifying domain e.g., a deaminase, a nuclease, a nickase, a recombinase, a methyltransferase, a
  • any of the Cas9 proteins provided herein may be fused to a protein that has an enzymatic activity.
  • the enzymatic activity modifies a target DNA.
  • the enzymatic activity is nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity or glycosylase activity.
  • the enzymatic activity is nuclease activity.
  • the nuclease activity introduces a double strand break in the target DNA.
  • the enzymatic activity modifies a target polypeptide associated with the target DNA.
  • the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity,
  • the target polypeptide is a histone and the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity or deubiquitinating activity.
  • any of the Cas9 proteins provided herein may be fused to a protein that has an enzymatic activity.
  • the enzymatic activity modifies a polypeptide associated with DNA (e.g. a histone).
  • the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity (i.e., ubiquitination activity), deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity glycosylation activity (e.g., from O-GlcNAc transferase) or deglycosylation activity.
  • ubiquitin ligase activity i.e., ubiquitination activity
  • deubiquitinating activity i.e., ubiquitinating activity
  • adenylation activity deadenylation activity
  • SUMOylating activity deSUMOylating activity
  • the enzymatic activities listed herein catalyze covalent modifications to proteins. Such modifications are known in the art to alter the stability or activity of the target protein (e.g., phosphorylation due to kinase activity can stimulate or silence protein activity depending on the target protein). Of particular interest as protein targets are histones. Histone proteins are known in the art to bind DNA and form complexes known as nucleosomes. Histones can be modified (e.g., by methylation, acetylation, ubuitination, phosphorylation) to elicit structural changes in the surrounding DNA, thus controlling the accessibility of potentially large portions of DNA to interacting factors such as transcription factors, polymerases and the like.
  • a single histone can be modified in many different ways and in many different combinations (e.g., trimethylation of lysine 27 of histone 3, H3K27, is associated with DNA regions of repressed transcription while trimethylation of lysine 4 of histone 3, H3K4, is associated with DNA regions of active transcription).
  • a site-directed modifying polypeptide with hi stone-modifying activity finds use in the site specific control of DNA structure and can be used to alter the histone modification pattern in a selected region of target DNA. Such methods find use in both research and clinical applications.
  • the deaminase domain catalyzes the removal of an amine group from a molecule.
  • cytidine deaminase domains deaminate cytosine to yield uracil.
  • the nuclease domain has enzymatic activity and may cleave phosphodiester bonds between the nucleotide subunits of nucleic acids.
  • recombinase domains which recombine specific sequences of DNA, may be used to manipulate the structure of genomes and to control gene expression.
  • methylase domains may be utilized to methylate their respective substrates, while acetylase domains may be used to acetylate their respective substrates.
  • acetyltransferase domains may be used to transfer an acetyl group.
  • examples of acetyltransferase molecules include, but are not limited to, histone acetyltransferases (e.g., CBP histone acetyltransferase), choline acetyltransferase,
  • Transcriptional activator domains are regions of a transcription factor which may activate transcription from a promoter through an interaction or multiple interactions with a DNA binding domain, general transcription factors, and RNA polymerase.
  • Transcriptional repressor domins are regions of a transcription factor which may repress transcription from a protomer through an interaction or multiple interactions with a DNA binding domain, general transcription factors, and RNA polymerase.
  • the potential of the Cas9 system for genome engineering is immense. Its unique ability to bring proteins to specific sites in a genome programmed by the sgRNA can be developed into a variety of site-specific genome engineering tools beyond nucleases, including transcriptional activators, transcriptional repressors, hi stone-modifying proteins, integrases, deaminases, and recombinases. 11 Some of these potential applications have recently been implemented through dCas9 fusions with transcriptional activators to afford RNA-guided transcriptional activators, 17 ' 18 transcriptional repressors, 16 ' 19 ' 20 and chromatin modification enzymes. 21 Simple co-expression of these fusions with a variety of sgRNAs results in specific expression of the target genes. These seminal studies have paved the way for the design and construction of readily programmable sequence-specific effectors for the precise manipulation of genomes.
  • Some aspects of this disclosure provide strategies, systems, proteins, nucleic acids, compositions, cells, reagents, methods, and kits that are useful for the targeted binding, editing, and/or cleaving of nucleic acids, including editing a single site within a subject's genome, e.g., a human subject's genome.
  • recombinant Cas9 proteins comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten mutations as compared to a naturally occurring Cas9 protein, and that exhibit activity on target sequences that do not include the canonical PAM (5 '-NGG-3 ', where N is any nucleotide) at the 3 '-end. Examples of such Cas9 protein mutations are given in Tables 3, 5, 8, and 9.
  • fusion proteins of Cas9 and nucleic acid editing enzymes or enzymatic domains, e.g., deaminase domains are provided.
  • methods for targeted nucleic acid binding, editing, and/or cleaving are provided.
  • reagents and kits for the generation of targeted nucleic acid binding, editing, and/or cleaving proteins e.g., fusion proteins of Cas9 variants and nucleic acid editing enzymes or domains, are provided.
  • Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 80%, at least 85%>, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences set forth in SEQ ID NOs:
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of S.
  • pyogenes Cas9 having the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the recombinant Cas9 protein comprises a RuvC and an HNH domain.
  • the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, K294R, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • Cas9 proteins comprising an amino acid sequence that is at least 80%>, at least 85%>, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences set forth in SEQ ID NOs:
  • amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262; and wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein.
  • the Cas9 protein comprises a RuvC and an HNH domain.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X267G, X294R, X405I, X409I, X480K, X543D, X694I, X1219V, X1224K, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, S267G, K294R, F405I, S409I, E480K, E543D, M694I, E1219V, N1224K, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in in SEQ ID NOs: 10-262.
  • A262T from a first amino acid residue (e.g., A) to a second amino acid residue (e.g., T)
  • A amino acid residue
  • second amino acid residue e.g., T
  • a mutation of an alanine to a threonine e.g., a A262T mutation
  • Additional similar amino acid pairs include, but are not limited to, the following:
  • any amino of the amino acid mutations provided herein from one amino acid to a threonine may be an amino acid mutation to a serine.
  • any amino of the amino acid mutations provided herein from one amino acid to an arginine may be an amino acid mutation to a lysine.
  • any amino of the amino acid mutations provided herein from one amino acid to an isoleucine may be an amino acid mutation to an alanine, valine, methionine, or leucine.
  • any amino of the amino acid mutations provided herein from one amino acid to a lysine may be an amino acid mutation to an arginine.
  • any amino of the amino acid mutations provided herein from one amino acid to an aspartic acid may be an amino acid mutation to a glutamic acid or asparigine.
  • any amino of the amino acid mutations provided herein from one amino acid to a valine may be an amino acid mutation to an alanine, isoleucine, methionine, or leucine.
  • any amino of the amino acid mutations provided herein from one amino acid to a glycine may be an amino acid mutation to an alanine. It should be appreciated, however, that additional conserved amino acid residues would be recognized by the skilled artisan and any of the amino acid mutations to other conserved amino acid residues are also within the scope of this disclosure.
  • the Cas9 protein is a Cas9 domain of a fusion protein.
  • the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the mutation is X1219A, X1219I, X1219M, or X1219L.
  • the amino acid sequence of the Cas9 protein comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the mutation is E1219A, E1219I, E1219M or E1219L.
  • the amino acid sequence of the Cas9 protein comprises an X480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the mutation is X480R.
  • the amino acid sequence of the Cas9 protein comprises an E480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the mutation is E480R.
  • the amino acid sequence of the Cas9 protein comprises an X543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the mutation isX543N.
  • the amino acid sequence of the Cas9 protein comprises an E543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
  • the mutation is E543N.
  • the amino acid sequence of the Cas9 protein comprises the mutations X480K, X543D, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations X267G, X294R, X480K, X543D, X1219V, X1224K, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations X262T, X405I, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations E480K, E543D, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises the mutations K294R, E480K, E543D, E1219V, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises the mutations K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises the mutations S267G, K294R, E480K, E543D, E1219V, N1224K, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises the mutations A262T, F405I, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the HNH nuclease domain of Cas9 functions to cleave the DNA strand complementary to the guide RNA (gRNA). Its active site consists of a ⁇ -metal fold, and its histidine 840 activates a water molecule to attack the scissile phosphate, which is more electrophilic due to coordination with a magnesium ion, resulting in cleavage of the the 3 '-5' phosphate bond.
  • gRNA guide RNA
  • the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262. In some embodiments, the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
  • the RuvC domain of Cas9 cleaves the non-target DNA strand. It is encoded by sequentially disparate sites which interact in the tertiary structure to form the RuvC cleaveage domain and consists of an RNase H fold structure.
  • the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
  • the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
  • the Cas9 protein comprises one or more mutations that affects (e.g., inhibits) the ability of Cas9 to cleave one or both strands of a DNA duplex.
  • the Cas9 protein comprises a DIOA and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the Cas9 protein comprises a DIOXi and/or a H840X 2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein Xi is any amino acid except for D, and X 2 is any amino acid except for H.
  • the Cas9 protein comprises an DIOA mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises a D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the Cas9 protein of the present disclosure exhibits activity, for example, increased binding, on a target sequence that does not include the canonical PAM sequence (5'-NGG-3') at its 3 '-end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
  • Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
  • Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits increased activity on a target sequence that does not comprise the canonical PAM sequence (5'-NGG-3') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided in SEQ ID NO: 9.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two,
  • the Streptococcus pyogenes Cas9 comprises a RuvC and an HNH domain.
  • the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9
  • the Cas9 protein may exhibit increased binding to the target sequence, may exhibit increased nuclease activity at the target sequence, or may exhibit an increase in other activities, depending on whether the Cas 9 protein is fused to an additional domain, such as an enzyme that has enzymatic activity.
  • the enzymatic activity modifies a target DNA.
  • the enzymatic activity is nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity or glycosylase activity.
  • the enzymatic activity is nuclease activity.
  • the nuclease activity introduces a double strand break in the target DNA.
  • the enzymatic activity modifies a target polypeptide associated with the target DNA.
  • the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity,
  • the target polypeptide is a histone and the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity or deubiquitinating activity.
  • any of the Cas9 protein is fused to a protein that has an enzymatic activity.
  • the enzymatic activity modifies a polypeptide associated with DNA (e.g. a histone).
  • the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity (i.e., ubiquitination activity), deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity glycosylation activity (e.g., from O-GlcNAc transferase) or deglycosylation activity.
  • the enzymatic activities listed herein catalyze covalent modifications to proteins. Such modifications are known in the art to alter the stability or activity of the target protein (e.g., phosphorylation due to kinase activity can stimulate or silence protein activity depending on the target protein). Of particular interest as protein targets are histones. Histone proteins are known in the art to bind DNA and form complexes known as nucleosomes. Histones can be modified (e.g., by methylation, acetylation, ubuitination, phosphorylation) to elicit structural changes in the surrounding DNA, thus controlling the accessibility of potentially large portions of DNA to interacting factors such as transcription factors, polymerases and the like.
  • a single histone can be modified in many different ways and in many different combinations (e.g., trimethylation of lysine 27 of histone 3, H3K27, is associated with DNA regions of repressed transcription while trimethylation of lysine 4 of histone 3, H3K4, is associated with DNA regions of active transcription).
  • a site-directed modifying polypeptide with hi stone-modifying activity finds use in the site specific control of DNA structure and can be used to alter the histone modification pattern in a selected region of target DNA. Such methods find use in both research and clinical applications.
  • the Cas9 protein exhibits activity on a target sequence having a 3' end that is not directly adjacent to, or does not have the canonical PAM sequence (5'-NGG-3 '), that is at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 50- fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence.
  • the 3 '-end of the target sequence is directly adjacent to an AGC, GAG, TTT, GTG, CAA CAC, GAT, TAA, ACG, CGA, or CGT sequence.
  • the Cas9 protein activity is measured by a nuclease assay or a nucleic acid binding assay, which are known in the art and would be apparent to the skilled artisan.
  • the Cas9 protein may be fused to one or more domains that confer an activity to the protein, such as a nucleic acid editing activity ⁇ e.g., deaminase activity or transcriptional activation activity), which may be measured ⁇ e.g., by a deaminase assay or transcriptional activation assay).
  • the Cas9 protein is fused to a deaminase domain and its activity may be measured using a deaminase assay.
  • the Cas9 protein is fused to a transcriptional activation domain and its activity may be measured using a transcriptional activation assay, for example, reporter activation assay where the reporter, e.g., GFP or luciferase, among others, is expressed in response to Cas9 binding to a target sequence.
  • a transcriptional activation assay for example, reporter activation assay where the reporter, e.g., GFP or luciferase, among others, is expressed in response to Cas9 binding to a target sequence.
  • the amino acid sequence of the Cas9 protein comprises any of the mutations provided herein.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X267G, X294R, X405I, X409I, X480K, X543D, X694I, X1219V, X1224K,
  • the mutations may be A262T, S267G, K294R, F405I, S409I, E480K, E543D, M694I, E1219V, N1224K, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises any of the mutations provided herein.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • X represents any amino acid.
  • the mutations may be A262T, K294R, S409I, E480K, E543D, M694I, or E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises an X1219V mutation or an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises an X480K mutation or an E480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises an X543D mutation or a E543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 comprises the mutations X480K, X543D, and X1219V; or the mutations E480K, E543D, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V; or the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, X1256K, and X1362P; or the mutations K294R, E480K, E543D, E1219V, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, and X1256K, or mutations K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations X267G, X294R, X480K, X543D, X1219V, X1224K, and X1256K; or the mutations S267G, K294R, E480K, E543DE1219V, N1224K, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • the amino acid sequence of the Cas9 protein comprises the mutations X262T, X405I, X409I, X480K, X543D, X694I, and X1219V; or the mutations A262T, F405I, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
  • amino acid sequence of the HNH domain is at least
  • the amino acid sequence of the HNH domain is identical to the amino acid sequence of any of the HNH domains of SEQ ID NOs: 9-262.
  • amino acid sequence of the RuvC domain is at least
  • the amino acid sequence of the RuvC domain is identical to the amino acid sequence of any of the RuvC domains of SEQ ID NOs: 9-262.
  • the Cas9 protein comprises at D10A and/or a H840A mutation in the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the Cas9 protein comprises a D10X 1 and/or a H840X 2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X 1 is any amino acid except for D, and wherein X 2 is any amino acid except for H.
  • the Cas9 protein comprises an D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the Cas9 protein comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • fusion proteins comprising a Cas9 protein as provided herein that is fused to a second protein, thus forming a fusion protein.
  • the second protein is fused to the N-terminus of the Cas9 protein.
  • the second protein is fused to the C-terminus of the Cas9 protein.
  • the Cas9 domain and the effector domain are fused via a linker.
  • the linker may be as simple as a covalent bond, or it may be a polymeric linker many atoms in length.
  • the linker is a polpeptide or based on amino acids. In other embodiments, the linker is not peptide-like.
  • the linker is a covalent bond (e.g., a carbon-carbon bond, disulfide bond, carbon-heteroatom bond, etc.). In certain embodiments, the linker is a carbon-nitrogen bond of an amide linkage. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymeric (e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid.
  • the linker comprises an aminoalkanoic acid (e.g., glycine, ethanoic acid, alanine, beta-alanine, 3-aminopropanoic acid, 4-aminobutanoic acid, 5-pentanoic acid, etc.).
  • the linker comprises a monomer, dimer, or polymer of aminohexanoic acid (Ahx).
  • the linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane).
  • the linker comprises a polyethylene glycol moiety (PEG).
  • the linker comprises amino acids.
  • the linker comprises a peptide. In certain embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring.
  • the linker may included funtionalized moieties to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile may be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and
  • the linker comprises a chemical group or molecule linking two molecules or moieties, e.g., two domains of a fusion protein, such as, for example, a nuclease-inactive Cas9 domain and a effector domain (e.g., a deaminase domain).
  • the linker comprises one or more amino acid resudues.
  • the limker may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25, 30, 35, 40, 45, 50, or more amino acid residues.
  • the linker is 3, 9, 16, or 21 amino acids in length.
  • the linker comprises a (GGGGS)n (SEQ ID NO: 5), a (G) context, an (EAAAK) n (SEQ ID NO: 6), a (GGS) protest, an
  • SGSETPGTSESATPES SEQ ID NO: 7 (also referred to as XTEN), or an (XP) n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30.
  • linker comprises a (GGS) 3 motif or a
  • Some aspects of this disclosure provide fusion proteins comprising a Cas9 protein as provided herein that is fused to a second protein, thus forming a fusion protein.
  • the second protein is fused to the N-terminus of the Cas9 protein.
  • the second protein is fused to the C-terminus of the Cas9 protein.
  • the Cas9 domain and the effector domain are fused via a nuclear localization sequence (NLS), for example a NLS comprising the amino acid sequence PKKKRKV (SEQ ID NO: 299), MD SLLMNRRKFL YQFKNVRWAKGRRET YLC (SEQ ID NO: 300), or SPKKKRKVEAS (SEQ ID NO: 284).
  • NLS nuclear localization sequence
  • a NLS may be combined with any of the linkers listed above.
  • the effector domain comprises an enzymatic domain.
  • the effector domain comprises a nuclease, a nickase, a recombinase, a deaminase, a methyltransferase, a methylase, an acetylase, an acetyltransferase, a
  • transcriptional activator or a transcriptional repressor domain, which may have nuclease activity, nickase activity, recombinase activity, deaminase activity, methyltransferase activity, methylase activity, acetylase activity, acetyltransferase activity transcriptional activation activity or transcriptional repression activity, respectively.
  • the effector domain is a effector domain.
  • the effector domain is a deaminase domain.
  • the deaminase is a cytosine deaminase or a cytidine deaminase.
  • the deaminase is an apolipoprotein B mRNA- editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBECl deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3 A deaminase. In some embodiments, the deaminase is an APOBECl deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3 A deaminase. In some embodiments, the deamin
  • the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID).
  • AID activation-induced deaminase
  • the effector domain is at least 80%, at least 85%>, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the deaminase domain of any one of SEQ ID NOs: 263-281.
  • the deaminase is a cytidine deaminase. In some embodiments, the deaminase is an
  • APOBEC apolipoprotein B mRNA-editing complex
  • the deaminase is an APOBECl family deaminase.
  • the deaminase is an activation-induced cytidine deaminase (AID).
  • the deaminase is an ACF1/ASE deaminase.
  • the deaminase is an adenosine deaminase.
  • the deaminase is an AD AT family deaminase.
  • Some aspects of this disclosure provide fusion proteins comprising a Cas9 protein fused to a effector domain, e.g., a deaminase, and a uracil glycosylase inhibitor (UGI).
  • a effector domain e.g., a deaminase
  • UGI uracil glycosylase inhibitor
  • Some aspects of this disclosure are based on the recognition that such fusion proteins may exhibit an increased nucleic acid editing efficiency as compared to fusion proteins not comprising an UGI domain. Domains such as the deaminase domains and UGI domains have been described and are within the scope of this disclosure. For example domains such as deaminase domains and UGI domains have been described in Provisional Application Nos.
  • the effector domain of the fusion protein is a nuclease domain.
  • the nuclease domain is a Fokl DNA cleavage domain.
  • the fusion protein dimerizes.
  • the dimer of the fusion protein is active. For example, two Fokl DNA cleavage domains may dimerize to cleave a nucleic acid.
  • the Cas9 protein is fused to a second Cas9 protein.
  • the second Cas9 protein is the Cas9 protein of any one of claims 1-345.
  • the second Cas9 protein is fused to the N-terminus of the fusion protein.
  • the second Cas9 protein is fused to the C-terminus of the fusion protein.
  • the Cas9 protein and the second Cas9 protein are fused via a second linker.
  • the second linker comprises a (GGGGS) n (SEQ ID NO: 5), a (G) context, an (EAAAK) n (SEQ ID NO: 6), a (GGS) context, an SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP) n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30.
  • the second linker comprises a (GGS) 3 motif.
  • the target sequence is a DNA sequence.
  • the target sequence is a sequence in the genome of a mammal.
  • the target sequence is a sequence in the genome of a human.
  • the 3 '-end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3').
  • Some aspects of this disclosure provide methods of using the Cas9 proteins, fusion proteins, or complexes provided herein. For example, some aspects of this disclosure provide methods comprising contacting a DNA molecule (a) with a Cas9 protein or a fusion protein as provided herein and a guide RNA, wherein the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence; or (b) with a Cas9 protein, a Cas9 fusion protein, or a Cas9 protein or fusion protein complex with a gRNA as provided herein.
  • the 3 '-end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3'). In some embodiments, the 3 '-end of the target sequence is immediately adjacent to an AGC, GAG, TTT, GTG, or CAA sequence. In some
  • the target DNA sequence comprises a sequence associated with a disease or disorder. In some embodiments, the target DNA sequence comprises a point mutation associated with a disease or disorder. In some embodiments, the activity of the Cas9 protein, the Cas9 fusion protein, or the complex results in correction of the point mutation. In some embodiments, the step of contacting is performed in vivo in a subject.
  • kits comprising a nucleic acid construct, comprising (a) a nucleotide sequence encoding a Cas9 protein or a Cas9 fusion protein as provided herein; and (b) a heterologous promoter that drives expression of the sequence of (a).
  • the kit further comprises an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow the cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.
  • Some aspects of this disclosure provide vectors comprising such polynucleotides.
  • the vector comprises a heterologous promoter driving expression of the polynucleotide.
  • Some aspects of this disclosure provide cells comprising any of the Cas9 proteins, fusion proteins, nucleic acid molecules, and/or a vectors as provided herein.
  • the summary above is meant to illustrate, in a non-limiting manner, some of the embodiments, advantages, features, and uses of the technology disclosed herein. Other embodiments, advantages, features, and uses of the technology disclosed herein will be apparent from the Detailed Description, the Drawings, the Examples, and the Claims.
  • Figure 1 shows the activity of wild-type Streptococcus pyogenes Cas9 on canonical PAM libraries and non-canonical PAM libraries.
  • Figure 2 shows the activity of exemplary evolved Cas9 clones on a PAM library after directed evolution.
  • Figure 3 shows a comparison of wild-type and evolved Cas9 in a mammalian
  • FIGs 4 A to 4B show the binding activity of Cas9 (pJH306) and evolved
  • FIG. 4A is a graph representing Cas9 binding activity as a function of % cells above the background
  • Figure 4B is a graph showing Cas9 binding activity as a function of mean fluorescence.
  • Cas9 proteins used in these experiments were dCas9 proteins fused to a VPR transcriptional activator.
  • Figures 5A to 5B show the binding activity of wild type dCas9-VPR
  • FIG. 5A is a graph representing Cas9 binding activity as a function of % cells above background fluorescence.
  • Figure 5B is a graph showing Cas9 binding activity as a function of mean fluorescence. Cas9 proteins used in these experiments were dCas9 proteins fused to VPR.
  • Figure 6 shows dCas9-VPR on all 64 PAM sequences as demonstrated by mean fluorescence on transfected cells gated by iRFP fluorescence.
  • WT dCas9-VPR is pJH306.
  • FIG. 7 shows in vitro cutting assay.
  • WT is wild-type Cas9 (SEQ
  • Figure 8 shows a Cas9 fusion protein that can be used to modulate PAM specificity.
  • a linked Cas9-dCas9 system that could be used for increasing Cas9 targeting to non-canonical PAMs is shown.
  • dCas9 binding to 5'-NGG-3 ' or another PAM could localize Cas9 to an area close to target 2. This localization could help Cas9 cut a previously inaccessible PAM.
  • Figures 9A to 9B show dCas9-VPR binding activity on the NNNNN PAM
  • Figure 9A is a graph representing dCas9-VPR binding activity on the NNNNN PAM library as a function of the % cells above background fluorescence.
  • Figure 9B is a graph representing dCas9-VPR binding activity on the NNNNN PAM library as a function of mean fluorescence.
  • Figure 10 shows Cas9 cutting activity using % of cells with GFP loss as a readout.
  • Cas9 proteins were tested with two sgRNAs, which either targeted the canonical 5'- NGG-3 ' PAM or a GAT PAM within a GFP gene.
  • Figure 11 illustrates double-stranded DNA substrate bound by Cas9:DNA editing enzyme: sgRNA complexes.
  • the DNA editing enzyme may be, without limitation, a nuclease, nickase, recombinase, deaminase, methyltransferase, methylase, acetylase, or acetyltransferase.
  • Figures 12A to 12D show the results of the PAM depletion assay.
  • pJH760 was tested in the PAM depletion assay on four new targets: re2 (Figure 12 A), VEGF (Figure 12B), CLTA ( Figure 12C), and CCR5D ( Figure 12D).
  • Figure 13 shows GFP cutting in mammalian cells.
  • Figure 14 shows the results of a PAM depletion assay to test pJH760 (xCas9 v 1.0) on the re2 target.
  • Figure 15 shows the results of a PAM depletion assay to test pJH760 (xCas9 vl .0) on the VEGF target.
  • Figure 16 shows the results of a PAM depletion assay to test pJH760 (xCas9 vl .0) on the CLTA target.
  • Figure 17 shows the results of a PAM depletion assay to test pJH760 (xCas9 vl .0) on the CCR5D target.
  • Figure 18 shows the results of a PAM depletion assay to test four xCas9v3 mutants on the re2 target.
  • Figure 19 shows the results of a PAM depletion assay to test four xCas9v3 mutants on the VEGF target.
  • Figure 20 shows the results of a PAM depletion assay to test four xCas9v3 mutants on the CLTA target.
  • Cas9 or “Cas9 nuclease” refers to an RNA-guided nuclease comprising a Cas9 protein, or a fragment thereof (e.g., a protein comprising an active or inactive DNA cleavage domain of Cas9, and/or the gRNA binding domain of Cas9).
  • a Cas9 nuclease is also referred to sometimes as a casnl nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease.
  • CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids).
  • CRISPR clusters contain spacers, sequences
  • CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA).
  • crRNA CRISPR RNA
  • tracrRNA trans-encoded small RNA
  • rnc endogenous ribonuclease 3
  • Cas9 protein The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA.
  • Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer.
  • RNA single guide RNAs
  • sgRNA single guide RNAs
  • gNRA single guide RNAs
  • Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self.
  • Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., "Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti et al, J.
  • Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus . Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference.
  • a Cas9 nuclease has an inactive ⁇ e.g., an inactivated) DNA cleavage domain.
  • a nuclease-inactivated Cas9 protein may interchangeably be referred to as a
  • DNA cleavage domain of Cas9 is known to include two subdomains, the UNH nuclease subdomain and the RuvCl subdomain.
  • the UNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvCl subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations DIOA and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al, Science. 337:816-821(2012); Qi et al, Cell. 28; 152(5): 1173-83 (2013).
  • proteins comprising fragments of Cas9 are provided.
  • a protein comprises one of two Cas9 domains: (1) the gRNA binding domain of Cas9; or (2) the DNA cleavage domain of Cas9.
  • proteins comprising Cas9 or fragments thereof are referred to as "Cas9 variants.”
  • a Cas9 variant shares homology to Cas9.
  • a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95%) identical, at least about 96%> identical, at least about 97%> identical, at least about 98%> identical, at least about 99%> identical, at least about 99.5%> identical, or at least about 99.9%> to wild type Cas9.
  • the Cas9 variant comprises a fragment of Cas9 ⁇ e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70%) identical, at least about 80%> identical, at least about 90%> identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding fragment of wild type Cas9.
  • wild type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence:
  • NC 017053.1 SEQ ID NO: l (nucleotide); SEQ ID NO:2 (amino acid)).
  • wild type Cas9 corresponds to, or comprises SEQ ID NO:
  • wild type Cas9 corresponds to Cas9 from
  • Streptococcus pyogenes NCBI Reference Sequence: NC_002737.2, SEQ ID NO: 282 (nucleotide); and Uniport Reference Sequence: Q99ZW2, SEQ ID NO: 9 (amino acid).
  • siTGLYETRiDLSQLGGD (SEQ ID NO: 9) (single underline: HNH domain; double underline: RuvC domain)
  • Cas9 refers to Cas9 from: Coryne bacterium ulcer ans
  • NCBI Refs NC_015683.1, NC_017317.1
  • Coryne bacterium diphtheria NCBI Refs:
  • NCBI Ref NC 017861.1
  • Spiroplasma taiwanense NCBI Ref:
  • NC_021846.1 Streptococcus iniae
  • NCBI Ref NC_021314.1
  • Belliella baltica NCBI Ref: NC_018010.1
  • Psychroflexus torquisl NCBI Ref: NC_018721.1
  • thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1);
  • NCBI Ref Campylobacter jejuni (NCBI Ref: YP_002344900.1); or Neisseria, meningitidis (NCBI Ref: YP 002342100.1) or to a Cas9 from any of the organisms listed in Example 3.
  • dCas9 corresponds to, or comprises in part or in whole, a Cas9 amino acid sequence having one or more mutations that inactivate the Cas9 nuclease activity.
  • a dCas9 domain comprises D10A and/or H840A mutation.
  • Cas9 corresponds to, or comprises in part or in whole, a Cas9 amino acid sequence having one or more mutations that alter Cas9's nuclease activity.
  • Cas9 may be a Cas9 nickase, which is a version of Cas9 that generates a single-stranded DNA break at a specific location based on a co-expressed gRNA-defined target sequence, rather than a double-strand DNA break.
  • a Cas9 domain comprises D10A mutation (e.g., SEQ ID NO: 301) and/or an H840A mutation (e.g., SEQ ID NO: 302).
  • Exemplary Cas9 nickases are shown below. However, it should be appreciated that additional Cas9 nickases that generate a single-stranded DNA break of a DNA duplex would be apparent to the skilled artisan and are within the scope of this disclosure.
  • siTGLYETRiDLSQLGGD SEQ ID NO: 301 (single underline: HNH domain; double underline: RuvC domain)
  • siTGLYETRiDLSQLGGD SEQ ID NO: 302 (single underline: HNH domain; double underline: RuvC domain)
  • dCas9 variants having mutations other than D10A and
  • H840A are provided, which, e.g., result in nuclease-inactivated Cas9 (dCas9).
  • Such mutations include other amino acid substitutions at D10 and H820, or other substitutions within the nuclease domains of Cas9 (e.g., substitutions in the HNH nuclease subdomain and/or the RuvCl subdomain).
  • variants or homologues of dCas9 are provided which are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to SEQ ID NO: 9.
  • variants of dCas9 are provided having amino acid sequences which are shorter, or longer than SEQ ID NO: 9, by about 5 amino acids, by about 10 amino acids, by about 15 amino acids, by about 20 amino acids, by about 25 amino acids, by about 30 amino acids, by about 40 amino acids, by about 50 amino acids, by about 75 amino acids, by about 100 amino acids, or more.
  • Cas9 fusion proteins as provided herein comprise the full-length amino acid sequence of a Cas9 protein, e.g., one of the sequences provided above. In other embodiments, however, fusion proteins as provided herein do not comprise a full- length Cas9 sequence, but only a fragment thereof.
  • a Cas9 fusion protein provided herein comprises a Cas9 fragment, wherein the fragment binds crRNA and tracrRNA or a sgRNA, but does not comprise a functional nuclease domain, e.g., it comprises only a truncated version of a nuclease domain or no nuclease domain at all.
  • a Cas9 fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type Cas9 protein.
  • a Cas9 fragment comprises at least at least 100 amino acids in length. In some embodiments, the Cas9 fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, or at least 1600 amino acids of a corresponding wild type Cas9 protein.
  • the Cas9 fragment comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at leat 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues of a corresponding wild type Cas9 protein.
  • Cas9 refers to Cas9 from: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC 017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisl (NCBI Ref: NC_018721.1); Streptococcus
  • thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1);
  • NCBI Ref Campylobacter jejuni
  • NCBI Ref Neisseria, meningitidis
  • deaminase or “deaminase domain,” as used herein, refers to a protein or enzyme that catalyzes a deamination reaction.
  • the deaminase or deaminase domain is a cytidine deaminase, catalyzing the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively.
  • the deaminase or deaminase domain is a cytosine deaminase, catalyzing the hydrolytic deamination of cytosine to uracil.
  • the deaminase or deaminase domain is a naturally-occuring deaminase from an organism, such as a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase or deaminase domain is a variant of a naturally-occuring deaminase from an organism, that does not occur in nature.
  • the deaminase or deaminase domain is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%), or at least 99.5% identical to a naturally-occuring deaminase from an organism.
  • an effective amount refers to an amount of a biologically active agent that is sufficient to elicit a desired biological response.
  • an effective amount of a nuclease may refer to the amount of the nuclease that is sufficient to induce cleavage of a target site specifically bound and cleaved by the nuclease.
  • an effective amount of a fusion protein provided herein e.g., of a fusion protein comprising a nuclease-inactive Cas9 domain and a effector domain (e.g., a deaminase domain) may refer to the amount of the fusion protein that is sufficient to induce editing of a target site specifically bound and edited by the fusion protein.
  • an agent e.g., a fusion protein, a nuclease, a deaminase, a recombinase, a hybrid protein, a protein dimer, a complex of a protein (or protein dimer) and a polynucleotide, or a polynucleotide
  • an agent e.g., a fusion protein, a nuclease, a deaminase, a recombinase, a hybrid protein, a protein dimer, a complex of a protein (or protein dimer) and a polynucleotide, or a polynucleotide
  • the desired biological response e.g., on the specific allele, genome, or target site to be edited
  • the cell or tissue being targeted e.g., a cell or tissue being targeted
  • sequences are immediately adjacent, when the nucleotide at the 3 '-end of one of the sequences is directly connected to nucleotide at the 5'-end of the other sequence via a phosphodiester bond.
  • linker refers to a chemical group or a molecule linking two molecules or moieties, e.g., two domains of a fusion protein, such as, for example, a nuclease-inactive Cas9 domain and a effector domain (e.g., a deaminase domain).
  • a linker joins a gRNA binding domain of an RNA-programmable nuclease, including a Cas9 nuclease domain, and the catalytic domain of a nucleic-acid editing protein.
  • a linker joins a dCas9 and a nucleic-acid editing protein.
  • the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two.
  • the linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein).
  • the linker is an organic molecule, group, polymer, or chemical moiety.
  • the linker is 5-100 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.
  • mutation refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4 th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)).
  • nucleic acid and “nucleic acid molecule,” as used herein, refer to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides.
  • polymeric nucleic acids e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage.
  • nucleic acid refers to individual nucleic acid residues ⁇ e.g. nucleotides and/or nucleosides).
  • nucleic acid refers to an oligonucleotide chain comprising three or more individual nucleotide residues.
  • oligonucleotide and
  • nucleic acid can be used interchangeably to refer to a polymer of nucleotides ⁇ e.g., a string of at least three nucleotides).
  • nucleic acid encompasses RNA as well as single and/or double-stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule.
  • a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or including non-naturally occurring nucleotides or nucleosides.
  • nucleic acid DNA
  • RNA and/or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc.
  • nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications.
  • a nucleic acid sequence is presented in the 5' to 3 ' direction unless otherwise indicated.
  • a nucleic acid is or comprises natural nucleosides ⁇ e.g.
  • nucleoside analogs ⁇ e.g., 2-aminoadenosine, 2- thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2- aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7- deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)-methylguanine, and 2-thiocy
  • tracrRNA a single guide RNA (sgRNA), or a guide RNA (gRNA).
  • sgRNA single guide RNA
  • gRNA guide RNA
  • proliferative disease refers to any disease in which cell or tissue homeostasis is disturbed in that a cell or cell population exhibits an abnormally elevated proliferation rate.
  • Proliferative diseases include hyperproliferative diseases, such as pre-neoplastic hyperplastic conditions and neoplastic diseases.
  • Neoplastic diseases are characterized by an abnormal proliferation of cells and include both benign and malignant neoplasias. Malignant neoplasia is also referred to as cancer.
  • protein refers to a polymer of amino acid residues linked together by peptide (amide) bonds.
  • the terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long.
  • a protein, peptide, or polypeptide may refer to an individual protein or a collection of proteins.
  • One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc.
  • a protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex.
  • a protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide.
  • a protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof.
  • fusion protein refers to a hybrid polypeptide which comprises protein domains from at least two different proteins.
  • One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy- terminal (C-terminal) protein thus forming an "amino-terminal fusion protein” or a "carboxy- terminal fusion protein,” respectively.
  • a protein may comprise different domains, for example, a nucleic acid binding domain (e.g., the gRNA binding domain of Cas9 that directs the binding of the protein to a target site) and a nucleic acid cleavage domain or a catalytic domain of a nucleic-acid editing protein.
  • a protein comprises a proteinaceous part, e.g., an amino acid sequence constituting a nucleic acid binding domain, and an organic compound, e.g., a compound that can act as a nucleic acid cleavage agent.
  • a protein is in a complex with, or is in association with, a nucleic acid, e.g., RNA.
  • Any of the proteins provided herein may be produced by any method known in the art.
  • the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker.
  • RNA-programmable nuclease and "RNA-guided nuclease” are used interchangeably herein and refer to a nuclease that forms a complex with ⁇ e.g., binds or associates with) one or more RNA that is not a target for cleavage.
  • an RNA-programmable nuclease when in a complex with an RNA, may be referred to as a nuclease:RNA complex.
  • the bound RNA(s) is referred to as a guide RNA
  • gRNAs can exist as a complex of two or more RNAs, or as a single RNA molecule. gRNAs that exist as a single RNA molecule may be referred to as single-guide RNAs (sgRNAs), though "gRNA” is used interchangeably to refer to guide RNAs that exist as either single molecules or as a complex of two or more molecules.
  • sgRNAs single-guide RNAs
  • gRNAs that exist as single RNA species comprise two domains: (1) a domain that shares homology to a target nucleic acid ⁇ e.g., and directs binding of a Cas9 complex to the target); and (2) a domain that binds a Cas9 protein.
  • domain (2) corresponds to a sequence known as a tracrRNA, and comprises a stem-loop structure.
  • domain (2) is identical or homologous to a tracrRNA as provided in Jinek et al, Science 337:816-821(2012), the entire contents of which is incorporated herein by reference.
  • Other examples of gRNAs ⁇ e.g., those including domain 2) can be found in U.S. Provisional Patent Application, U.S. S.N. 61/874,682, filed September 6, 2013, entitled “Switchable Cas9 Nucleases and Uses Thereof," and U.S. Provisional Patent Application, U.S.S.N.
  • a gRNA comprises two or more of domains (1) and (2), and may be referred to as an "extended gRNA.”
  • an extended gRNA will, e.g., bind two or more Cas9 proteins and bind a target nucleic acid at two or more distinct regions, as described herein.
  • the gRNA comprises a nucleotide sequence that complements a target site, which mediates binding of the nuclease/RNA complex to said target site, providing the sequence specificity of the nuclease:RNA complex.
  • the RNA- programmable nuclease is the (CRISPR-associated system) Cas9 endonuclease, for example Cas9 (Csnl) from Streptococcus pyogenes (see, e.g., "Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti J.
  • RNA-programmable nucleases ⁇ e.g., Cas9
  • RNA-programmable nucleases such as Cas9, for site-specific cleavage ⁇ e.g., to modify a genome
  • Methods of using RNA-programmable nucleases, such as Cas9, for site-specific cleavage ⁇ e.g., to modify a genome are known in the art (see e.g., Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013); Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, W.Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system.
  • the term "subject,” as used herein, refers to an individual organism, for example, an individual mammal.
  • the subject is a human.
  • the subject is a non-human mammal.
  • the subject is a non-human primate.
  • the subject is a rodent.
  • the subject is a sheep, a goat, a cattle, a cat, or a dog.
  • the subject is a vertebrate, an amphibian, a reptile, a fish, an insect, a fly, or a nematode.
  • the subject is a research animal.
  • the subject is genetically engineered, e.g., a genetically engineered non-human subject.
  • the subject may be of either sex, of any age, and at any stage of development.
  • target site refers to a sequence within a nucleic acid molecule that is deaminated by a deaminase or a fusion protein comprising a deaminase (e.g., a dCas9- deaminase fusion protein provided herein).
  • treatment refers to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment refers to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment may be administered after one or more symptoms have developed and/or after a disease has been diagnosed.
  • treatment may be administered in the absence of symptoms, e.g., to prevent or delay onset of a symptom or inhibit onset or progression of a disease.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.
  • recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as compared to any naturally occurring sequence.
  • nucleic acid editing enzyme refers to proteins that are able to modify a nucleic acids or one or more nucleotide bases of a nucleic acid.
  • a nucleic acid editing enzyme is a deaminase, which can catalyze C to T or G to A changes.
  • Other suitable nucleid acid editing enzyme that may be used in accordance with this disclosure include, without limitation, a nuclease, nickase, recombinase, deaminase, methyltransferase, methylase, acetylase, or acetyltransferase.
  • Some aspects of this disclosure provide recombinant Cas9 proteins that efficiently target DNA sequences that do not comprise the canonical PAM sequence (5 '- NGG-3 ', where N is any nucleotide, for example A, T, G, or C) at their 3 '-ends.
  • the Cas9 proteins provided herein comprise one or more mutations identified in directed evolution experiments using a target sequence library comprising randomized PAM sequences.
  • the recombinant non-PAM restricted Cas9 proteins provided herein are useful for targeting DNA sequences that do not comprise the canonical PAM sequence at their 3 '-end and thus greatly extend the usefulness of Cas9 technology for gene editing.
  • Some aspects of this disclosure provide fusion proteins that comprise a Cas9 protein and an effector domain, for example, a DNA-editing domain, such as, e.g., a deaminase domain.
  • a DNA-editing domain such as, e.g., a deaminase domain.
  • the deamination of a nucleobase by a deaminase can lead to a point mutation at the specific residue, which is referred to herein as nucleic acid editing.
  • Fusion proteins comprising a Cas9 protein or variant thereof and a DNA-editing domain can thus be used for the targeted editing of nucleic acid sequences.
  • Such fusion proteins are useful for targeted editing of DNA in vitro, e.g., for the generation of mutant cells or animals; for the introduction of targeted mutations, e.g., for the correction of genetic defects in cells ex vivo, e.g., in cells obtained from a subject that are subsequently re-introduced into the same or another subject; and for the introduction of targeted mutations, e.g., the correction of genetic defects or the introduction of deactivating mutations in disease-associated genes in a subject in vivo.
  • the Cas9 protein of the fusion proteins described herein does not have any nuclease activity but instead is a Cas9 fragment or a dCas9 protein. Methods for the use of Cas9 fusion proteins as described herein are also provided.
  • Non-limiting, exemplary nuclease-inactive Cas9 proteins are provided herein.
  • nuclease-inactive Cas9 protein is the D10A/H840A Cas9 protein mutant:
  • siTGLYETRiDLSQLGGD SEQ ID NO:262; see, e.g., Qi et al, Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;
  • nuclease-inactive Cas9 proteins will be apparent to those of skill in the art based on this disclosure.
  • Such additional exemplary suitable nuclease- inactive Cas9 proteins include, but are not limited to, D10A, D839A, H840A, N863A, D10A/D839A, D10A/H840A, D10A/N863A, D839A/H840A, D839A/N863A,
  • D10A/D839A/H840A, and D10A/D839A/H840A/N863A mutant proteins See, e.g., Prashant et al, CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology . 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference).
  • Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences provided in SEQ ID NOs: 10-262, wherein the Cas9 protein comprises a RuvC and an HNH domain, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations at an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs:
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, K294R, S409I, E480K, E543D, M694I, or E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the amino acid sequence of the Cas9 protein comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
  • the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 10-262.
  • the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
  • the Cas9 protein comprises a D10A and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
  • Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits activity (e.g., increased activity) on a target sequence that does not comprise the canonical PAM (5'-NGG-3 ') at its 3 '-end as compared to Streptococcus pyogenes
  • the Cas9 protein exhibits activity on a target sequence having a 3 '-end that is not directly adjacent to the canonical PAM sequence (5'-NGG-3 ') that is at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 50-fold, at least 100- fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence.
  • the 3 '-end of the target sequence is directly adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
  • the Cas9 protein activity is measured by a nuclease assay, a deamination assay, or a transcriptional activation assay.
  • the transcriptional activation assay is a reporter activation assay, such as a GFP activation assay. Exemplary methods for measuring binding activity (e.g., of Cas9) using transcriptional activation assays are known in the art and would be apparent to the skilled artisan.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, K294R, S409I, E480K, E543D, M694I, or E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the amino acid sequence of the Cas9 comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 2, 4, or 9.
  • the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 10-262.
  • the Cas9 protein comprises a D10A and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
  • Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3 '-end as compared to Streptococcus pyogenes Cas9 as provided by SEQ
  • the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9.
  • the Cas9 protein comprises a D10A and a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-
  • the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9.
  • the Cas9 protein comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the Cas9 further comprises a histidine residue at position 840 as provided in SEQ ID NO: 9, or a corresponding histidine residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the presence of the catalytic residue H840 allows Cas9 to cleave the non-targeted strand, i.e., the strand bound by the sgRNA.
  • a Cas9 having an amino acid residue other than histidine at position 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding amino acid sequence provided in SEQ ID NOs: 10-262 may be changed or reverted such that amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding amino acid sequence provided in SEQ ID NOs: 10-262 is histidine.
  • Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
  • Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9; wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, and 1256 of the amino acid sequence provided in SEQ ID NO: 9; wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein; and wherein the recombinant Cas9 protein exhibits activity (e.g., increased activity) on a target sequence that does not comprise the canonical PAM (5'-NGG-3 ') at its 3 '-end as compared to Streptococcus pyogenes Ca
  • the Cas9 protein exhibits an activity on a target sequence having a 3 '-end that is not directly adjacent to the canonical PAM sequence (5'- NGG-3 ') that is at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence.
  • the 3 '-end of the target sequence is directly adjacent to an AAA, AAC, AAG, AAT, CAA, CAC, CAG, CAT, GAA, GAC, GAG, GAT, TAA, TAC, TAG, TAT, ACA, ACC, ACG, ACT, CCA, CCC, CCG, CCT, GCA, GCC, GCG, GCT, TCA, TCC, TCG, TCT, AGA, AGC, AGT, CGA, CGC, CGT, GGA, GGC, GGT, TGA, TGC, TGT, ATA, ATC, ATG, ATT, CTA, CTC, CTG, CTT, GTA, GTC, GTG, GTT, TTA, TTC, TTG, or TTT PAM sequence.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X267G, X294R, X405I, X409I, X480K, X543D, X694I, X1219V, X1224K, X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid at the corresponding position.
  • the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, S267G, K294R, F405I, S409I, E480K, E543D, M694I, E1219V, N1224K, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the amino acid sequence of the Cas9 protein comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the amino acid sequence of the Cas9 protein comprises an X480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the amino acid sequence of the Cas9 protein comprises an E480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises an X543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
  • the amino acid sequence of the Cas9 protein comprises an E543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the Cas9 protein comprises the combination of mutations selected from the group consisting of (X480K, X543D, and X1219V); (X262T, X409I, X480K, X543D, X694I, and X1219V); (X294R, X480K, X543D, X1219V, X1256K, and X1362P); (X294R, X480K, X543D, X1219V, and X1256K);
  • the amino acid sequence of the Cas9 protein comprises the combination of mutations selected from the group consisting of (E480K, E543D, and E1219V); (A262T, S409I, E480K, E543D, M694I, and E1219V); (K294R, E480K, E543D, E1219V, Q1256K, and L1362P); (K294R, E480K, E543D, E1219V, and Q1256K); (S267G, K294R, E480K, E543DE1219V, N1224K, and Q1256K); and (A262T, F405I, S409I, E480K, E543D, M694I, and E1219V) of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 2, 4, or 9.
  • the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9.
  • the Cas9 protein comprises a D10A and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises a D10A and an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the Cas9 protein comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
  • Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
  • Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits increased activity on a target sequence that does not include the canonical PAM (5'-NGG-3') at its 3 '-end as compared to
  • the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9.
  • the Cas9 protein comprises a D10A and a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
  • Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations at an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3 ') at its 3 '-end as compared to
  • the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9.
  • the Cas9 protein comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the Cas9 further comprises a histidine residue at position 840 as provided in SEQ ID NO: 9, or a
  • a Cas9 having an amino acid residue other than histidine at position 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding amino acid sequence provided in SEQ ID NOs: 10-262 may be changed or reverted such that amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding amino acid sequence provided in SEQ ID NOs: 10-262 is histidine.
  • fusion proteins comprising a Cas9 protein as provided herein that is fused to a second protein, or a "fusion partner", such as an effector domain, thus forming a fusion protein.
  • the effector domain is fused to the N-terminus of the Cas9 protein.
  • the effector domain is fused to the C-terminus of the Cas9 protein.
  • the Cas9 protein and the effector domain are fused to each other via a linker. Suitable strategies for generating fusion proteins according to aspects of this disclosure using linkers or without the use of linkers will also be apparent to those of skill in the art in view of the instant disclosure and the knowledge in the art.
  • the linker comprises a (GGGGS)n (SEQ ID NO: 5), a (G) n , an (EAAAK) n (SEQ ID NO: 6), a (GGS) n , an
  • the effector domain comprises an enzymatic domain.
  • Suiable effector domains include, without limitation a nuclease, nickase, recombinase, deaminase, methyltransferase, methylase, acetylase, acetyltransferase, transcriptional activator, and transcriptional repressor.
  • the linker may be as simple as a covalent bond, or it may be a polymeric linker many atoms in length.
  • the linker is a polpeptide or based on amino acids. In other embodiments, the linker is not peptide-like.
  • the linker is a covalent bond ⁇ e.g., a carbon-carbon bond, disulfide bond, carbon-heteroatom bond, etc.).
  • the linker is a carbon-nitrogen bond of an amide linkage.
  • the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker.
  • the linker is polymeric ⁇ e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid. In certain embodiments, the linker comprises an aminoalkanoic acid ⁇ e.g., glycine, ethanoic acid, alanine, beta-alanine, 3-aminopropanoic acid, 4-aminobutanoic acid, 5- pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminohexanoic acid (Ahx).
  • Ahx aminohexanoic acid
  • the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring.
  • the linker may included funtionalized moieties to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile may be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and isothiocyanates.
  • the effector domain comprises a effector enzyme.
  • effector enzymes that may be used in accordance with this disclosure include nucleases, nickases, recombinases, and deaminases. However additional effector enzymes would be apparent to the skilled artisan and are within the scope of this disclosure.
  • the effector domain comprises a domain that modulates transcriptional activity. Such transcriptional modulating domains may be, without limitation, a transcriptional activator or transcriptional repressor domain.
  • the effector domain is a effector domain. In some embodiments, the effector domain is a deaminase domain. In some embodiments, the deaminase is a cytosine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC 1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC 1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase
  • the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID).
  • AID activation-induced deaminase
  • the effector domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the deaminase domain of any one of SEQ ID NOs: 263-281.
  • the effector domain is a nuclease domain.
  • the nuclease domain is a Fokl DNA cleavage domain.
  • this disclosure provides dimers of the fusion proteins provided herein, e.g., dimers of fusion proteins may include a dimerizing nuclease domain.
  • the Cas9 protein comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%), at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences provided in SEQ ID NOs: 10-262, wherein the Cas9 protein comprises a RuvC and an HNH domain, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and
  • the Cas9 protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3 '-end
  • Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
  • the Cas9 protein comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%), at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences provided in SEQ ID NOs: 10-262, wherein the Cas9 protein comprises a RuvC and an HNH domain, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and where
  • the Cas9 protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, , comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, and 1256 of the amino acid sequence provided in SEQ ID NO: 9; wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein; and wherein the recombinant Cas9 protein exhibits increased activity on a target sequence that does not include the canonical PAM (5'-NGG-3') at its 3 '-
  • fusion proteins comprising (i) a nuclease-inactive Cas9 protein; and (ii) a effector domain.
  • the effector domain is a DNA-editing domain.
  • the effector domain possesses deaminase activity.
  • the effector domain comprises or is a deaminase domain.
  • the deaminase is a cytidine deaminase.
  • the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase.
  • APOBEC apolipoprotein B mRNA-editing complex
  • the deaminase is an APOBEC 1 family deaminase. In some embodiments, the deaminase is an activation-induced cytidine deaminase (AID).
  • AID activation-induced cytidine deaminase
  • nucleic-acid editing domains as well as Cas9 fusion proteins including such domains are described in detail herein. Additional suitable effector domains will be apparent to the skilled artisan based on this disclosure.
  • the nucleid-acid editing domain is a Fokl nuclease domain.
  • the instant disclosure provides Cas9:effector domain fusion proteins of various configurations.
  • the effector domain is fused to the N-terminus of the Cas9 protein.
  • the effector domain is fused to the C-terminus of the Cas9 protein.
  • the Cas9 protein and the effector domain are fused via a linker.
  • the linker comprises (GGGGS) n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n , orSGSETPGTSESATPES (SEQ ID NO: 7) motif (see, e.g., Guilinger JP, Thompson DB, Liu DR.
  • n is independently an integer between 1 and 30.
  • n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, or, if more than one linker or more than one linker motif is present, any combination thereof. Additional suitable linker motifs and linker configurations will be apparent to those of skill in the art.
  • suitable linker motifs and configurations include those described in Chen et al, Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013; 65(10): 1357- 69, the entire contents of which are incorporated herein by reference. Additional suitable linker sequences will be apparent to those of skill in the art based on the instant disclosure and knowledge in the art.
  • the general architecture of exemplary Cas9 fusion proteins provided herein comprises the structure:
  • FIG. 11 provides a schematic representation of a Cas9 protein fused to an effector domain ⁇ e.g., rAPOBECl) in complex with sgRNA and bound to the target nucleic acid sequence.
  • any of the fusion proteins provided herein may comprise one or more nuclear localization sequence (NLS).
  • a nuclear localization sequence refers to an amino acid sequence that promotes importation of a protein, for example any of the fusion proteins provided herein having an NLS, into the cell nucleus ⁇ e.g., via nuclear transport).
  • an NLS comprises one or more short amino acid sequences of positively charged lysines or arginines exposed on the protein surface.
  • Nuclear localization seuqneces are known in the art and would be apparent to the skilled artisan. For example nuclear localization sequences have been described in Kalderon D., et al, "A short amino acid sequence able to specify nuclear location".
  • a NLS comprises the amino acid sequence PKKKRKV (SEQ ID NO: 299) or
  • MDSLLMNRRKFLYQFKNVRWAKGRRETYLC SEQ ID NO: 300.
  • Exemplary features that may be present are localization sequences, such as nuclear localization sequences, cytoplasmic localization sequences, export sequences, such as nuclear export sequences, or other localization sequences, as well as sequence tags that are useful for solubilization, purification, or detection of the fusion proteins.
  • localization sequences such as nuclear localization sequences, cytoplasmic localization sequences, export sequences, such as nuclear export sequences, or other localization sequences, as well as sequence tags that are useful for solubilization, purification, or detection of the fusion proteins.
  • localization signal sequences and sequences of protein tags include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc-tags, calmodulin- tags, FLAG-tags, hemagglutinin (HA)-tags, polyhistidine tags, also referred to as histidine tags or His-tags, maltose binding protein (MBP)-tags, nus-tags, glutathione-S-transferase (GST)-tags, green fluorescent protein (GFP)-tags, thioredoxin-tags, S-tags, Softags ⁇ e.g., Softag 1, Softag 3), strep-tags , biotin ligase tags, FlAsH tags, V5 tags, and SBP-tags.
  • BCCP biotin carboxylase carrier protein
  • MBP maltose binding protein
  • GST glutathione-S-transferase
  • GFP green fluorescent protein
  • Softags ⁇ e.g., Softa
  • any of the nuclear localization sequences provided herein may be fused to the fusion protein in any suitable localization.
  • the NLS is fused N-terminal to the Cas9 protein of the fusion protein.
  • the NLS is fused C-terminal to the Cas9 protein of the fusion protein.
  • the NLS is fused N-terminal to the effector domain of the fusion protein.
  • the NLS is fused C-terminal to the effector domain of the fusion protein.
  • the effector domain is a deaminase.
  • the general architecture of exemplary Cas9 fusion proteins with a deaminase domain comprises the structure:
  • NLS is a nuclear localization signal
  • NH 2 is the N-terminus of the fusion protein
  • COOH is the C-terminus of the fusion protein.
  • a linker is inserted between the Cas9 protein and the deaminase domain.
  • any of the "]-[" may be one or more linkers.
  • the NLS is located C-terminal of the deaminase and/or the Cas9 domain. In some embodiments, the NLS is located between the deaminase and the Cas9 domain. Additional features, such as sequence tags, may also be present.
  • One exemplary suitable type of effector domain includes cytosine deaminases, for example, of the APOBEC family.
  • APOBEC cytosine deaminase enzymes encompasses eleven proteins that serve to initiate mutagenesis in a controlled and beneficial manner. 29
  • AID activation- induced cytidine deaminase
  • the apolipoprotein B editing complex 3 (APOBEC3) enzyme provides protection to human cells against a certain HIV-1 strain via the deamination of cytosines in reverse- transcribed viral ssDNA.
  • a recent crystal structure of the catalytic domain of APOBEC3G revealed a secondary structure comprised of a five-stranded ⁇ -sheet core flanked by six a-helices, which is believed to be conserved across the entire family.
  • the active center loops have been shown to be responsible for both ssDNA binding and in determining "hotspot" identity.
  • Overexpression of these enzymes has been linked to genomic instability and cancer, thus highlighting the importance of sequence-specific targeting. 35
  • Some aspects of this disclosure provide a systematic series of fusions between Cas9 and deaminase domains, e.g., cytosine deaminase enzymes such as APOBEC enzymes, or adenosine deaminase enzymes such as AD AT enzymes, that has been generated in order to direct the enzymatic activities of these deaminases to a specific site in genomic DNA.
  • cytosine deaminase enzymes such as APOBEC enzymes
  • adenosine deaminase enzymes such as AD AT enzymes
  • Cas9 as the recognition agent are two-fold: (1) the sequence specificity of Cas9 can be easily altered by simply changing the sgRNA sequence; and (2) Cas9 binds to its target sequence by denaturing the dsDNA, resulting in a stretch of DNA that is single- stranded and therefore a viable substrate for the deaminase. It will be understood that other catalytic domains, or catalytic domains from other deaminases, can also be used to generate fusion proteins with Cas9, and that the disclosure is not limited in this regard.
  • deaminase fusion proteins can efficiently deaminate nucleotides at positions 3-11 according to the numbering scheme in Figure 11. It should be appreciated that a person of skill in the art will be able to design suitable guide RNAs to target the fusion proteins to a target sequence that comprises a nucleotide to be deaminated. Both PAM-dependent Cas9 proteins or Cas9 proteins that can target PAM-less target sequences as provided herein, can be employed for deamination of a target nucleotide.
  • nucleic-acid editing domains e.g., deaminases and deaminase domains, that can be fused to Cas9 domains according to aspects of this disclosure are provided below.
  • deaminase require a Zn 2+ -coordinating motif (His-X-Glu-X 23- 26 -Pro-Cys-X 2-4 -Cys; SEQ ID NO: 283) and bound water molecule for catalytic activity.
  • the Glu residue acts to activate the water molecule to a zinc hydroxide for nucleophilic attack in the deamination reaction.
  • the active domain of the respective sequence can be used, e.g., the domain without a localizing signal (nuclear localizing signal, without nuclear export signal, cytoplasmic localizing signal).
  • Dog AID MP SLLMKQRKFLYHFKNVRWAKGRHET YLC YVVKRRD S AT SF SLDFGHLRNKSGC HVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGYPNLSLRIFAAR LYFCEDRKAEPEGLRRLHRAGVQIAF TFKDYFYCWNTFVE REKTFKAWEGLHEN SVRLSROLRRILLPLYEVDDLRDAFRTLGL (SEQ ID NO: 265)
  • Bovine AID
  • Rat APOBEC-3 [00169]
  • Green monkey APOBEC-3G [00172] Green monkey APOBEC-3G:
  • Human APOBEC-1 (italic: nucleic acid editing domain) [00180] Human APOBEC-1 :
  • fusion proteins as provided herein comprise the full- length amino acid of a effector domain, e.g., one of the sequences provided above. In other embodiments, however, fusion proteins as provided herein do not comprise a full-length sequence of a effector domain, but only a fragment thereof.
  • a fusion protein provided herein comprises a Cas9 protein and a fragment of a effector domain, e.g., wherein the fragment comprises a effector domain.
  • Exemplary amino acid sequences of effector domains are shown in the sequences above as italicized letters, and additional suitable sequences of such domains will be apparent to those of skill in the art.
  • Additional suitable nucleic-acid editing domain e.g., deaminase domain sequences, that can be used according to aspects of this disclosure, e.g., that can be fused to a nuclease-inactive Cas9 protein, will be apparent to those of skill in the art based on this disclosure.
  • additional domain sequences include deaminase domain sequences that are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similar to the sequences provided herein.
  • Additional suitable Cas9 proteins, variants, and sequences will also be apparent to those of skill in the art. Examples of such additional suitable Cas9 proteins include, but are not limited to Cas9 proteins with the following mutations: D10A,
  • D10A/D839A/H840A, and D10A/D839A/H840A/N863A See, e.g., Prashant et al, CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838 the entire contents of which are incorporated herein by reference).
  • the Cas9 fusion protein comprises: (i) Cas9 protein; and (ii) a transcriptional activator domain.
  • the transcriptional activator domain comprises a VPR.
  • VPR is a VP64-SV40-P65-RTA tripartite activator.
  • VPR compises a VP64 amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 292:
  • VPR comprises a VP64 amino acid sequence as set forth in SEQ ID NO: 293 :
  • VPR compises a VP64-SV40-P65-RTA amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 294:
  • VPR comprises a VP64-SV40-P65-RTA amino acid sequence as set forth in SEQ ID NO: 295:
  • fusion proteins comprising a transcription activator.
  • the transcriptional activator is VPR.
  • the VPR compsises a wild type VPR or a VPR as set forth in SEQ ID NO: 293.
  • the VPR proteins provided herein include fragments of VPR and proteins homologous to a VPR or a VPR fragment.
  • a VPR comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 293.
  • a VPR comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 293 or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO: 293.
  • proteins comprising VPR or fragments of VPR or homologs of VPR or VPR fragments are referred to as "VPR variants.”
  • a VPR variant shares homology to VPR, or a fragment thereof.
  • a VPR variant is at least about 70% identical, at least about 80% identical, at least about 90%) identical, at least about 95% identical, at least about 96% identical, at least about 97%) identical, at least about 98%> identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to a wild type VPR or a VPR as set forth in SEQ ID NO: 293.
  • the VPR variant comprises a fragment of VPR, such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding fragment of wild type VPR or a VPR as set forth in SEQ ID NO: 293.
  • the VPR comprises the amino acid sequence set forth in SEQ ID NO: 293.
  • the VPR comprises an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 292.
  • a VPR is a VP64-SV40-P65-RTA triple activator.
  • the VP64-SV40-P65-RTA comprises a VP64-SV40-P65-RTA as set forth in SEQ ID NO: 295.
  • the VP64-SV40-P65-RTA proteins provided herein include fragments of VP64-SV40-P65-RTA and proteins homologous to a VP64-SV40-P65-RTA or a VP64-SV40-P65-RTA fragment.
  • a VP64-SV40-P65-RTA comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 295.
  • a VP64-SV40-P65-RTA comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 295 or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO: 295.
  • proteins comprising VP64-SV40-P65-RTA or fragments of VP64-SV40-P65-RTA or homologs of VP64-SV40-P65-RTA or VP64-SV40- P65-RTA fragments are referred to as "VP64-SV40-P65-RTA variants.”
  • a VP64-SV40-P65- RTA variant shares homology to VP64-SV40-P65-RTA, or a fragment thereof.
  • a VP64-SV40-P65-RTA variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97%) identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to a VP64-SV40-P65-RTA as set forth in SEQ ID NO: 295.
  • the VP64-SV40-P65-RTA variant comprises a fragment of VP64-SV40-P65-RTA, such that the fragment is at least about 70% identical, at least about 80%) identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding fragment of a VP64-SV40-P65-RTA as set forth in SEQ ID NO: 295.
  • the VP64-SV40-P65-RTA comprises the amino acid sequence set forth in SEQ ID NO: 295.
  • the VP64-SV40-P65-RTA comprises an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 294.
  • fusion proteins comprising (i) a Cas9 protein; and (ii) a effector domain.
  • the fusion proteins provided herein further include (iii) a DNA-binding protein, for example, a zinc-finger domain, a TALE, or a second Cas9 protein.
  • fusing a DNA- binding protein e.g., a second Cas9 protein
  • a fusion protein comprising (i) a protein; and (ii) a effector domain
  • the second Cas9 protein is any of the Cas9 proteins provided herein.
  • the second Cas9 protein is fused to the fusion protein N-terminal to the Cas9 protein.
  • the second Cas9 protein is fused to the fusion protein C-terminal to the Cas9 protein.
  • the Cas9 proteinand the second Cas9 protein are fused via a linker.
  • complexes comprising any of the fusion proteins provided herein, a first guide RNA bound to the Cas9 protein of the fusion protein, and a second guide RNA bound to the second Cas9 protein of the fusion protein.
  • the first guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a first target sequence and the second guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a second target sequence.
  • the first guide RNA and/or the second guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long. In some embodiments, the first guide RNA and the second guide RNA are different.
  • the first guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a first target sequence
  • the second guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a second target sequence.
  • the first target sequence and the second target sequence are different.
  • the first target sequence and the second target sequence are DNA sequences.
  • the first target sequence and the second target sequence are in the genome of a mammal. In some embodiments, the first target sequence and the second target sequence are in the genome of a human. In some embodiments, the first target sequence is within 30 nucleotides of the second target sequence. In some embodiments, the 3' end of the first target sequence is not immediately adjacent to the canonical PAM sequence (5 '-NGG-3 '). In some embodiments, the 3' end of the second target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3 '). [00194] In some embodiments, the general architecture of exemplary Cas9 fusion proteins provided herein is of the structure:
  • H 2 is the N-terminus of the fusion protein
  • COOH is the C-terminus of the fusion protein.
  • the "]-[" used in the general architecture above indicates the presence of an optional linker sequence.
  • the general architecture of exemplary Cas9 fusion proteins provided herein is of the structure:
  • the second Cas9 is a dCas9 protein.
  • the general architecture of exemplary Cas9 fusion proteins provided herein comprises a structure as shown in Figure 8. It should be appreciated that any of the proteins provided in any of the general architectures of exemplary Cas9 fusion proteins may be connected by one or more of the linkers provided herein. In some embodiments, the linkers are the same. In some embodiments, the linkers are different.
  • the fusion proteins further comprise a nuclear targeting sequence, for example a nuclear localization sequence.
  • fusion proteins provided herein further comprise a nuclear localization sequence (NLS).
  • NLS nuclear localization sequence
  • the NLS is fused to the N-terminus of the fusion protein.
  • the NLS is fused to the C-terminus of the fusion protein.
  • the NLS is fused to the N-terminus of the second Cas9 protein.
  • the NLS is fused to the C-terminus of the second Cas9 protein.
  • the NLS is fused to the N-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of the effector domain. In some embodiments, the NLS is fused to the C-terminus of the effector domain. In some embodiments, the NLS is fused to the N- terminus of the UGI protein. In some embodiments, the NLS is fused to the C-terminus of the UGI protein. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusioin protein without a linker.
  • fusion proteins comprising a Cas9 protein fused to a effector domain, e.g., a deaminase, and a uracil glycosylase inhibitor (UGI).
  • a uracil glycosylase inhibitor e.g., a uracil glycosylase inhibitor (UGI).
  • the fusion protein comprises the structure:
  • the fusion proteins do not comprise a linker sequence. In some embodiments, one or both of the optional linker sequences are present. [00196] In some embodiments, the fusion protein further comprises a second Cas9 protein.
  • the second Cas9 protein may be any of the Cas9 proteins provided herein.
  • fusion protein comprises the structure:
  • the "-" used in the general architecture above indicates the presence of an optional linker sequence.
  • the fusion proteins comprising a UGI further comprise a nuclear targeting sequence, for example a nuclear localization sequence.
  • fusion proteins provided herein further comprise a nuclear localization sequence (NLS).
  • NLS nuclear localization sequence
  • the NLS is fused to the N-terminus of the fusion protein.
  • the NLS is fused to the C-terminus of the fusion protein.
  • the NLS is fused to the N-terminus of the UGI protein.
  • the NLS is fused to the C-terminus of the UGI protein.
  • the NLS is fused to the N-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of the deaminase. In some embodiments, the NLS is fused to the C-terminus of the deaminase. In some embodiments, the NLS is fused to the N-terminus of the second Cas9. In some embodiments, the NLS is fused to the C-terminus of the second Cas9. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusioin protein without a linker.
  • the UGI comprises a wild type UGI or a UGI as set forth in SEQ ID NO: 553.
  • the UGI proteins provided herein include fragments of UGI and proteins homologous to a UGI or a UGI fragment.
  • a UGI comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 553.
  • a UGI comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 553 or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO: 553.
  • proteins comprising UGI or fragments of UGI or homologs of UGI or UGI fragments are referred to as "UGI variants.”
  • a UGI variant shares homology to UGI, or a fragment thereof.
  • a UGI variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to a wild type UGI or a UGI as set forth in SEQ ID NO: 553.
  • the UGI variant comprises a fragment of UGI, such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding fragment of wild type UGI or a UGI as set forth in SEQ ID NO: 553.
  • the UGI comprises the following amino acid sequence: >sp
  • Suitable UGI protein and nucleotide sequences are provided herein and additional suitable UGI sequences are known to those in the art, and include, for example, those published in Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J. Biol. Chem.
  • uracil glycosylase inhibitors may be uracil glycosylase inhibitors.
  • other proteins that are capable of inhibiting (e.g., sterically blocking) a uracil-DNA glycosylase base-excision repair enzyme are within the scope of this disclosure.
  • a uracil glycosylase inhibitor is a protein that binds DNA.
  • a uracil glycosylase inhibitor is a protein that binds single-stranded DNA.
  • a uracil glycosylase inhibitor may be a Erwinia tasmaniensis single- stranded binding protein.
  • the single-stranded binding protein comprises the amino acid sequence (SEQ ID NO: 303).
  • a uracil glycosylase inhibitor is a protein that binds uracil.
  • a uracil glycosylase inhibitor is a protein that binds uracil in DNA.
  • a uracil glycosylase inhibitor is a catalytically inactive uracil DNA-glycosylase protein.
  • a uracil glycosylase inhibitor is a catalytically inactive uracil DNA-glycosylase protein that does not excise uracil from the DNA.
  • a uracil glycosylase inhibitor is a UdgX.
  • the UdgX comprises the amino acid sequence (SEQ ID NO: 304).
  • a uracil glycosylase inhibitor is a catalytically inactive UDG.
  • a catalytically inactive UDG comprises the amino acid sequence (SEQ ID NO: 305). It should be appreciated that other uracil glycosylase inhibitors would be apparent to the skilled artisan and are within the scope of this disclosure.
  • Erwinia tasmaniensis SSB (themostable single-stranded DNA binding protein) MASRGVNKVILVGNLGQDPEVRYMPNGGAVANITLATSESWRDKQTGETKEKTEW HRVVLFGKLAEVAGEYLRKGSQVYIEGALQTRKWTDQAGVEKYTTEVVVNVGGT MQMLGGRSQGGGASAGGQNGGSNNGWGQPQQPQGGNQFSGGAQQQARPQQQPQ QNNAPANNEPPIDFDDDIP (SEQ ID NO: 303)
  • UdgX (binds to Uracil in DNA but does not excise)
  • UDG catalytically inactive human UDG, binds to Uracil in DNA but does not excise
  • high fidelity Cas9 proteins have decreased electrostatic interactions between the Cas9 protein and a sugar-phosphate backbone of a DNA, as compared to a wild-type Cas9 domain.
  • any of the Cas9 proteins provided herein comprise one or more mutations that decrease the association between the Cas9 protein and a sugar-phosphate backbone of a DNA.
  • any of the Cas9 proteins provided herein comprise one or more mutations that decrease the association between the Cas9 protein and a sugar-phosphate backbone of a DNA by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%.
  • any of the Cas9 proteins provided herein comprise one or more of a N497X, a R661X, a Q695X, and/or a Q926X mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid.
  • any of the Cas9 proteins provided herein comprise one or more of a N497A, a R661 A, a Q695A, and/or a Q926A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the Cas9 protein comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
  • the Cas9 protein comprises the amino acid sequence as set forth in SEQ ID NO: 306.
  • High fidelity Cas9 proteins have been described in the art and would be apparent to the skilled artisan. For example, high fidelity Cas9 proteins have been described in Kleinstiver, B.P., et al. "High-fidelity CRISPR-Cas9 nucleases with no detectable genome- wide off-target effects.” Nature 529, 490-495 (2016); and Slaymaker, I.M., et al.
  • Cas9 domain where mutations relative to Cas9 of SEQ ID NO: 9 are shown in bold and underlines.
  • Cas9 proteins that have different PAM specificities.
  • Cas9 proteins such as Cas9 from S. pyogenes (spCas9)
  • spCas9 require a canonical NGG PAM sequence to bind a particular nucleic acid region. This may limit the ability to of the Cas9 protein to bind to a particular nucleotide sequence within a genome.
  • any of the Cas proteins provided herein may be capable of binding a nucleotide sequence that does not contain a canonical (e.g., NGG) PAM sequence.
  • Cas9 proteins that bind non-canonical PAM sequences have been described in Kleinstiver, B.
  • the Cas9 protein is a Cas9 protein from Staphylococcus aureus (SaCas9).
  • the SaCas9 protein is a nuclease active SaCas9, a nuclease inactive SaCas9 (SaCas9d), or a SaCas9 nickase (SaCas9n).
  • the SaCas9 comprises the amino acid sequence SEQ ID NO: 307.
  • the SaCas9 comprises a N579X mutation of SEQ ID NO: 307, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 9-262, wherein X is any amino acid except for N.
  • the SaCas9 comprises a N579A mutation of SEQ ID NO: 307, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the SaCas9 protein, the SaCas9d protein, or the SaCas9n protein can bind to a nucleic acid seuqnce having a non-canonical PAM.
  • the SaCas9 protein, the SaCas9d protein, or the SaCas9n protein can bind to a nucleic acid sequence having a NNGRRT PAM sequence.
  • the SaCas9 protein comprises one or more of a E781X, N967X, or R1014X mutation of SEQ ID NO: 307, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid.
  • the SaCas9 protein comprises one or more of a E781K, N967K, or R1014H mutation of SEQ ID NO: 307, or one or more corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the SaCas9 protein comprises a E781K, a N967K, and a R1014H mutation of SEQ ID NO: 307, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262. It should be appreciated that these mutations may be combined with any of the other mutations provided herein
  • the Cas9 protein of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 307-309.
  • the Cas9 protein of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 307-309.
  • the Cas9 protein of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 307-309.
  • VKSKKHPQIIKKG (SEQ ID NO: 307)
  • Residue N579 of SEQ ID NO: 307 which is underlined and in bold, may be mutated (e.g., to a A579) to yield a SaCas9 nickase.
  • VKSKKHPQIIKKG (SEQ ID NO: 308).
  • Residue A579 of SEQ ID NO: 308, which can be mutated from N579 of SEQ ID NO: 307 to yield a SaCas9 nickase, is underlined and in bold.
  • VKSKKHPQIIKKG (SEQ ID NO: 309).
  • Residue A579 of SEQ ID NO: 309 which can be mutated from N579 of SEQ ID NO: 307 to yield a SaCas9 nickase, is underlined and in bold.
  • Residues K781, K967, and H1014 of SEQ ID NO: 309 which can be mutated from E781, N967, and R1014 of SEQ ID NO: 307 to yield a SaKKH Cas9 are underlined and in italics.
  • the Cas9 protein is a Cas9 protein from Streptococcus pyogenes (SpCas9).
  • the SpCas9 protein is a nuclease active SpCas9, a nuclease inactive SpCas9 (SpCas9d), or a SpCas9 nickase (SpCas9n).
  • the SpCas9 comprises the amino acid sequence SEQ ID NO: 9.
  • the SpCas9 comprises a D10X mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid except for D.
  • the SpCas9 comprises a D10A mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the SpCas9 protein, the SpCas9d protein, or the SpCas9n protein can bind to a nucleic acid seuqnce having a non-canonical PAM.
  • the SpCas9 protein, the SpCas9d protein, or the SpCas9n protein can bind to a nucleic acid sequence having a NGG, a NGA, or a NGCG PAM sequence.
  • the SpCas9 protein comprises one or more of a Dl 135X, R1335X, and
  • the SpCas9 protein comprises one or more of a Dl 135E, R1335Q, and T1337R mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the SpCas9 protein comprises a Dl 135E, a R1335Q, and a T1335R mutation of SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the SpCas9 protein comprises one or more of a Dl 135X, R1335X, and T1337X mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid.
  • the SpCas9 protein comprises one or more of a Dl 135V, R1335Q, and T1337R mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the SpCas9 protein comprises a Dl 135V, a R1335Q, and a T1337R mutation of SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the SpCas9 protein comprises one or more of a D1135X, G1218X, R1335X, and T1337X mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid.
  • the SpCas9 protein comprises one or more of a D1135V, G1218R, R1335Q, and T1337R mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
  • the SpCas9 protein comprises a Dl 135V, a G1218R, a R1335Q, and a T1337R mutation of SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262. It should be appreciated that these mutations may be combined with any of the other mutations provided herein
  • the Cas9 protein of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 9, 310-313.
  • the Cas9 domain of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 9, 310-313.
  • the Cas9 domain of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 9, 310-313.
  • Residues El 134, Q1334, and R1336 of SEQ ID NO: 311, which can be mutated from Dl 134, R1334, and T1336 of SEQ ID NO: 9 to yield a SpEQR Cas9, are underlined and in bold.
  • Residues VI 134, Q1334, and R1336 of SEQ ID NO: 312, which can be mutated from Dl 134, R1334, and T1336 of SEQ ID NO: 9 to yield a SpVQR Cas9, are underlined and in bold.
  • Residues VI 134, R1217, Q1334, and R1336 of SEQ ID NO: 313, which can be mutated from Dl 134, G1217, R1334, and T1336 of SEQ ID NO: 9 to yield a SpVRER Cas9, are underlined and in bold.
  • Some aspects of this disclosure provide complexes comprising a Cas9 protein or a Cas9 fusion protein as provided herein, and a guide RNA bound to the Cas9 protein or the Cas9 fusion protein.
  • the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence.
  • the guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long.
  • the guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a target sequence.
  • the target sequence is a DNA sequence. In some embodiments, the target sequence is a sequence in the genome of a mammal. In some embodiments, the target sequence is a sequence in the genome of a human. In some embodiments, the 3' end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3').
  • Some aspects of the disclosure provide complexes comprising a first guide RNA bound to a Cas9 protein of a fusion protein, and a second guide RNA bound to a second Cas9 protein of the fusion protein.
  • the first guide RNA is about 15- 100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a first target sequence and the second guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a second target sequence.
  • the first guide RNA and/or the second guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long. In some embodiments, the first guide RNA and the second guide RNA are different.
  • the first guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a first target sequence and wherein the second guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a second target sequence.
  • first target sequence and the second target sequence are different.
  • the first target sequence and the second target sequence are DNA sequences.
  • the first target sequence and the second target sequence are in the genome of a mammal.
  • the first target sequence and the second target sequence are in the genome of a human.
  • the first target sequence is within at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the second target sequence.
  • the 3 '-end of the first target sequence is not immediately adjacent to the canonical PAM sequence (5'- NGG-3 ').
  • the 3'-end of the second target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3 ').
  • Some aspects of this disclosure provide methods of using the Cas9 proteins, fusion proteins, or complexes provided herein. For example, some aspects of this disclosure provide methods comprising contacting a DNA molecule (a) with any of the the Cas9 proteins or fusion proteins provided herein, and with at least one guide RNA, wherein the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence; or (b) with a Cas9 protein, a Cas9 fusion protein, or a Cas9 protein or fusion protein complex with at least one gRNA as provided herein.
  • the 3' end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3 '). In some embodiments, the 3' end of the target sequence is immediately adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
  • the target DNA sequence comprises a sequence associated with a disease or disorder. In some embodiments, the target DNA sequence comprises a point mutation associated with a disease or disorder. In some embodiments, the activity of the Cas9 protein, the Cas9 fusion protein, or the complex results in a correction of the point mutation. In some embodiments, the target DNA sequence comprises a T ⁇ C point mutation associated with a disease or disorder, and wherein the deamination of the mutant C base results in a sequence that is not associated with a disease or disorder. In some
  • the target DNA sequence encodes a protein and wherein the point mutation is in a codon and results in a change in the amino acid encoded by the mutant codon as compared to the wild-type codon.
  • the deamination of the mutant C results in a change of the amino acid encoded by the mutant codon.
  • the deamination of the mutant C results in the codon encoding the wild-type amino acid.
  • the contacting is in vivo in a subject.
  • the subject has or has been diagnosed with a disease or disorder.
  • the disease or disorder is cystic fibrosis, phenylketonuria, epidermolytic hyperkeratosis (EHK), Charcot- Marie-Toot disease type 4J, neuroblastoma (NB), von Willebrand disease (vWD), myotonia congenital, hereditary renal amyloidosis, dilated cardiomyopathy (DCM), hereditary lymphedema, familial Alzheimer's disease, HIV, Prion disease, chronic infantile neurologic cutaneous articular syndrome (CINCA), desmin-related myopathy (DRM), a neoplastic disease associated with a mutant PI3KCA protein, a mutant CTNNB1 protein, a mutant HRAS protein, or a mutant p53 protein.
  • the fusion protein is used to introduce a point mutation into a nucleic acid by deaminating a target nucleobase, e.g., a C residue.
  • the deamination of the target nucleobase results in the correction of a genetic defect, e.g., in the correction of a point mutation that leads to a loss of function in a gene product.
  • the genetic defect is associated with a disease or disorder, e.g., a lysosomal storage disorder or a metabolic disease, such as, for example, type I diabetes.
  • the methods provided herein are used to introduce a deactivating point mutation into a gene or allele that encodes a gene product that is associated with a disease or disorder.
  • methods are provided herein that employ a Cas9 DNA editing fusion protein to introduce a deactivating point mutation into an oncogene ⁇ e.g., in the treatment of a proliferative disease).
  • a deactivating mutation may, in some embodiments, generate a premature stop codon in a coding sequence, which results in the expression of a truncated gene product, e.g., a truncated protein lacking the function of the full-length protein.
  • the purpose of the methods provide herein is to restore the function of a dysfunctional gene via genome editing.
  • the Cas9 deaminase fusion proteins provided herein can be validated for gene editing-based human therapeutics in vitro, e.g., by correcting a disease-associated mutation in human cell culture. It will be understood by the skilled artisan that the fusion proteins provided herein, e.g., the fusion proteins comprising a Cas9 domain and a nucleic acid deaminase domain can be used to correct any single point T -> C or A -> G mutation. In the first case, deamination of the mutant C back to U corrects the mutation, and in the latter case, deamination of the C that is base-paired with the mutant G, followed by a round of replication, corrects the mutation.
  • An exemplary disease-relevant mutation that can be corrected by the provided fusion proteins in vitro or in vivo is the H1047R (A3140G) polymorphism in the PI3KCA protein.
  • the phosphoinositide-3 -kinase, catalytic alpha sub unit (PI3KCA) protein acts to phosphorylate the 3 -OH group of the inositol ring of phosphatidylinositol.
  • the PI3KCA gene has been found to be mutated in many different carcinomas, and thus it is considered to be a potent oncogene. 50
  • the A3140G mutation is present in several NCI-60 cancer cell lines, such as, for example, the HCT116, SKOV3, and T47D cell lines, which are readily available from the American Type Culture Collection (ATCC). 51
  • a cell carrying a mutation to be corrected e.g., a cell carrying a point mutation, e.g., an A3140G point mutation in ex on 20 of the PI3KCA gene, resulting in a H1047R substitution in the PI3KCA protein
  • an expression construct encoding a Cas9 deaminase fusion protein and an appropriately designed sgRNA targeting the fusion protein to the respective mutation site in the encoding PI3KCA gene.
  • Control experiments can be performed where the sgRNAs are designed to target the fusion enzymes to non-C residues that are within the PI3KCA gene.
  • Genomic DNA of the treated cells can be extracted, and the relevant sequence of the PI3KCA genes PCR amplified and sequenced to assess the activities of the fusion proteins in human cell culture.
  • PI3KCA is provided for illustration purposes and is not meant to limit the instant disclosure.
  • the skilled artisan will understand that the instantly disclosed DNA-editing fusion proteins can be used to correct other point mutations and mutations associated with other cancers and with diseases other than cancer including other proliferative diseases.
  • the instant disclosure provides methods for the treatment of a subject diagnosed with a disease associated with or caused by a point mutation that can be corrected by a Cas9 DNA editing fusion protein provided herein.
  • a method is provided that comprises administering to a subject having such a disease, e.g., a cancer associated with a PI3KCA point mutation as described above, an effective amount of a Cas9 deaminase fusion protein that corrects the point mutation or introduces a deactivating mutation into the disease-associated gene.
  • the disease is a
  • the disease is a genetic disease. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease. Other diseases that can be treated by correcting a point mutation or introducing a deactivating mutation into a disease-associated gene will be known to those of skill in the art, and the disclosure is not limited in this respect.
  • the instant disclosure provides methods for the treatment of additional diseases or disorders, e.g., diseases or disorders that are associated or caused by a point mutation that can be corrected by deaminase-mediated gene editing.
  • additional diseases e.g., diseases or disorders that are associated or caused by a point mutation that can be corrected by deaminase-mediated gene editing.
  • Some such diseases are described herein, and additional suitable diseases that can be treated with the strategies and fusion proteins provided herein will be apparent to those of skill in the art based on the instant disclosure.
  • Exemplary suitable diseases and disorders are listed below. It will be understood that the numbering of the specific positions or residues in the respective sequences depends on the particular protein and numbering scheme used. Numbering might be different, e.g., in precursors of a mature protein and the mature protein itself, and differences in sequences from species to species may affect numbering.
  • Suitable diseases and disorders include, without limitation, cystic fibrosis (see, e.g., Schwank et al, Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell stem cell. 2013; 13 : 653-658; and Wu et. al., Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell stem cell.
  • phenylketonuria e.g., phenylalanine to serine mutation at position 835 (mouse) or 240 (human) or a homologous residue in phenylalanine hydroxylase gene (T>C mutation) - see, e.g., McDonald et al, Genomics.
  • EHK epidermolytic hyperkeratosis
  • accession number P04264 in the UNIPROT database at www[dot]uniprot[dot]org; chronic obstructive pulmonary disease (COPD) - e.g., leucine to proline mutation at position 54 or 55 (if counting the initiator methionine) or a homologous residue in the processed form of ⁇ , ⁇ - antitrypsin or residue 78 in the unprocessed form or a homologous residue (T>C mutation) - see, e.g., Poller et al, Genomics.
  • COPD chronic obstructive pulmonary disease
  • accession number POlOl l in the UNIPROT database See also accession number POlOl l in the UNIPROT database; Charcot-Marie-Toot disease type 4J - e.g., isoleucine to threonine mutation at position 41 or a homologous residue in FIG4 (T>C mutation) - see, e.g., Lenk et al., PLoS Genetics. 2011 ; 7: el002104; neuroblastoma (NB) - e.g., leucine to proline mutation at position 197 or a homologous residue in Caspase-9 (T>C mutation) - see, e.g., Kundu et al, 3 Biotech.
  • NB neuroblastoma
  • von Willebrand disease e.g., cysteine to arginine mutation at position 509 or a homologous residue in the processed form of von Willebrand factor, or at position 1272 or a homologous residue in the unprocessed form of von Willebrand factor (T>C mutation) - see, e.g., Lavergne et al, Br. J. Haematol.
  • hereditary renal amyloidosis e.g., stop codon to arginine mutation at position 78 or a homologous residue in the processed form of apolipoprotein All or at position 101 or a homologous residue in the unprocessed form (T>C mutation) - see, e.g., Yazaki et al, Kidney Int. 2003; 64: 11-16; dilated cardiomyopathy (DCM) - e.g., tryptophan to Arginine mutation at position 148 or a homologous residue in the FOXD4 gene (T>C mutation), see, e.g., Minoretti et. al., Int. J.
  • DCM dilated cardiomyopathy
  • hereditary lymphedema - e.g., histidine to arginine mutation at position 1035 or a homologous residue in VEGFR3 tyrosine kinase (A>G mutation)
  • A>G mutation hereditary lymphedema - e.g., histidine to arginine mutation at position 1035 or a homologous residue in VEGFR3 tyrosine kinase
  • familial Alzheimer's disease - e.g., isoleucine to valine mutation at position 143 or a homologous residue in presenilinl (A>G mutation) see, e.g., Gallo et. al., J. Alzheimer 's disease.
  • Prion disease e.g., methionine to valine mutation at position 129 or a homologous residue in prion protein (A>G mutation) - see, e.g., Lewis et. al., J. of General Virology. 2006; 87: 2443-2449; chronic infantile neurologic cutaneous articular syndrome (CINCA) - e.g., Tyrosine to Cysteine mutation at position 570 or a homologous residue in cryopyrin (A>G mutation) - see, e.g., Fujisawa et. al. Blood.
  • CINCA chronic infantile neurologic cutaneous articular syndrome
  • DRM desmin-related myopathy
  • A>G mutations which may be corrected using any of the Cas9 fusion proteins provided herein.
  • Provided herein are the names of these genes, their respective SEQ ID NOs, their gene IDs, and sequences flanking the mutation site. See Tables 4 and 5.
  • the mutations provided in Tables 4 and 5 may be corrected using the Cas9 fusions provided herein, which are able to bind to target sequences lacking the canonical PAM sequence.
  • a Cas9-deaminase fusion protein demostrates activity on non-canonical PAMs and therefore can correct all the pathogenic T>C or A>G mutations listed in Tables 4 and 5 (SEQ ID NOs: 674-2539 and 3144-5083), respectively.
  • a Cas9-deaminase fusion protein recognizes canonical PAMs and therefore can correct the pathogenic T>C or A>G mutations with canonical PAMs, e.g., 5'-NGG-3'.
  • RNA e.g., a gRNA
  • a target site e.g., a site comprising a point mutation to be edited
  • a guide RNA typically comprises a tracrRNA framework allowing for Cas9 binding, and a guide sequence, which confers sequence specificity to the Cas9:effector domain fusion protein.
  • the guide RNA comprises a structure 5 '-[guide sequence]- guuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuu uuu-3 ' (SEQ ID NO: 285),
  • the guide sequence comprises a sequence that is complementary to the target sequence.
  • the guide sequence is typically 20 nucleotides long.
  • suitable guide RNAs for targeting Cas9: effector domain fusion proteins to specific genomic target sites will be apparent to those of skill in the art based on the instant disclosure.
  • Such suitable guide RNA sequences typically comprise guide sequences that are complementary to a nucleic sequence within 50 nucleotides upstream or downstream of the target nucleotide to be edited.
  • kits comprising a nucleic acid construct, comprising (a) a nucleotide sequence encoding a Cas9 protein or a Cas9 fusion protein as provided herein; and (b) a heterologous promoter that drives expression of the sequence of (a).
  • the kit further comprises an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow the cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.
  • Some aspects of this disclosure provide polynucleotides encoding a Cas9 protein of a fusion protein as provided herein. Some aspects of this disclosure provide vectors comprising such polynucleotides. In some embodiments, the vector comprises a heterologous promoter driving expression of polynucleotide.
  • Some aspects of this disclosure provide cells comprising a Cas9 protein, a fusion protein, a nucleic acid molecule, and/or a vector as provided herein.
  • a 3'- NNN PAM library was built for each protospacer target sequence.
  • the canonical PAM sequence is 5 '-NOGS', ⁇ e.g., an exemplary [Doench ⁇ -rcanonical PA Ml target sequence could be 5'- ⁇ AAGAGAGACAGTAC ATGCCCl-rNGGl-3 ' (SEQ ID NO: 291)), the 3 TSiNN PAM libraries for each protospacer target sequence contained a fully random PAM sequence, e.g., for Doenchl 5 '-AAGAGAGACAGTACATGCCCNNN-3 ' (SEQ ID NO: 290), wherein N represents any nucleotide.
  • the NNN PAM libraries thus included every possible
  • Each PAM library was cloned into a plasmid comprising such a weak promoter, where the [target sequence] -[PAM library] nucleic acid sequences served as the sequence targeted by an sgRNA.
  • a PAM library was cloned into the promoter for The co-dCas9 assay was run on all four protospacer targets for both the canonical PAM and the random PAM library.
  • Figure 1 shows the activity of wild-type S. pyogenes Cas9 on PAM Libraries.
  • the accessory plasmid (accessory plasmid, AP), under the control of a promoter that is transcriptionally activated by co-dCas9.
  • the PAM library was cloned into the promoter region of the accessory plasmid.
  • Host cells used for the directed evolution of Cas9 proteins without PAM restriction were provided that harbored the accessory plasmid.
  • the amount of infectious phage particles produced by a given host cell thus depends on the activity of the co-dCas9 fusion protein encoded by the selection phage on the promoter of the accessory plasmid, which is required for the production of pill protein.
  • the accessory plasmid thus confers a selective advantage to those selection phages encoding co-dCas9 fusion protein variants with an increased activity on different non-canonical PAM sequences.
  • a lagoon was provided and a flow of host cells comprising the accessory plasmid was generated through the lagoon.
  • the host cells were contacted with the selection phagemid, resulting in a population of selection phage propagating in the flow of host cells in the lagoon.
  • Phage-infected host cells were removed from the lagoon and fresh, uninfected host cells were fed into the lagoon at a rate resulting in the average time a host cell remained in the lagoon being shorter than the average time between cell division of the host cells, but longer than the average Ml 3 phage life cycle time.
  • the host cells in the lagoon were incubated under conditions resulting in an increased mutation rate.
  • the host cells were harboring a mutagenesis plasmid (MP), which increased the mutagenesis rate, thus introducing mutations in the co-dCas9 fusion protein encoded by the selection phagemid during the phage life cycle.
  • MP mutagenesis plasmid
  • the host cells in the lagoon cannot accumulate mutations resulting from the increased mutation rate conferred by the mutagenesis plasmid in their genome or on the accessory plasmid.
  • the selection phage replicate in the lagoon in the flow of host cells and thus accumulate mutations over time, resulting in the generation of new, evolved co-dCas9 fusion protein variants.
  • any of these evolved co-dCas9 fusion protein variants includes a mutation that confers an increased activity on the accessory plasmid comprising the PAM library, this will directly translate into the generation of more pill by a host cell infected with a selection phage encoding the respective co-dCas9 fusion protein variant.
  • the production of more pill will, in turn, result in the generation of more infectious selection phage particles, which, over time, results in a competitive advantage of the mutant selection phage harboring such beneficial mutations over selection phage not harboring such mutations.
  • the selective pressure exerted by the accessory plasmid will, therefore, result in selection phage having acquired beneficial mutations being the predominant species replicating in the flow of host cells, while selection phage with no mutations or with detrimental mutations will be washed out of the lagoon.
  • a number of selection phage clones was isolated from a directed evolution experiment using a PAM library accessory plasmid as described above.
  • the mutations identified in the Cas9 amino acid sequence of some exemplary clones is provided below in Table l(residue numbering according to SEQ ID NO: 9):
  • Clones 1-4 were tested in the co-dCas9 luciferase activation assay described above. When tested on the PAM library as a whole, the different clones showed an improvement in luciferase expression ( Figure 2 - Cas9 activity of exemplary evolved clones on PAM library after directed evolution).
  • Selection phage harboring a co-dCas9 fusion protein with a dCas9 sequence provided as SEQ ID NO: 8 with D10A and H840A mutations was propagated overnight in 1030 host cells together with MP6 mutagenesis plasmid in the presence of arabinose in order to create a library of mutated selection phage encoding a library of co-dCas9 fusion protein variants.
  • PHI was expressed from a separate plasmid in the host cells during this initial diversification stage.
  • 1030 host cells harboring an accessory plasmid comprising an NNN PAM library cloned into a weak promoter as the guide RNA target sequence and a mutagenesis plasmid were grown to log phase, and used as the source of host cells to create a flow of host cells through a lagoon.
  • the cells in the lagoon were infected with the diversified selection phage from the overnight incubation.
  • the host cells in the lagoon were contacted with arabinose in order to maintain a high level of expression of the mutagenic genes from the mutagenesis plasmid.
  • the initial phage titers were about 10 8 pfu/mL.
  • a PACE experiment was performed for each of the four NNN-PAM libraries ([Doench 1]-[NNN-PAM], [Doench 2]- [NNN-PAM], [G7]-[NNN-PAM], and [VEGF target] -[NNN-PAM] cloned into an accessory plasmid driving pill expression from a weak promoter as described above.
  • the phage titers were monitored during the PACE experiments. A slow drop in phage titers to 10 4 pfu/mL was observed.
  • the phage population was isolated from the lagoon at that point, and grown on 2208 host cells containing a separate source of pill (psp-driven pill). After this low- stringency propagation period, a 1 : 100 dilution of the supernatant was added to fresh host cells harboring the accessory plasmid as the only source of pill in a new lagoon, and the PACE experiments were continued. No drop in phage titers was observed after this low- stringency incubation in 2208 cells.
  • Cas9 Mammalian GFP Activation Both wild-type dCas9 (SEQ ID NO: 9) and the evolved Cas9 clones were tested in a dCas9-GFP assay in Hek293T cells. The cells were contacted with a reporter construct in which a GFP-encoding sequence was driven from a weak promoter that includes a [gRNA target sequence]-[PAM] sequence. Fusion proteins of dCas9 (wild-type and PACE variants) attached to the transcriptional activator VP64-p65- Rta (VPR) were generated, and the various dCas9-VPR variants were tested for their capacity to activate the GFP reporter in HEK293 cells.
  • Hek293T were transfected with four separate plasmids: a dCas9-VPR expression plasmid; a plasmid expressing the sgRNA targeting the gRNA target sequence of the GFP reporter plasmid; the GFP reporter plasmid; and an iRFP transfection control.
  • the HEK293 cells were contacted with a GFP reporter included a TAA PAM, and in another experiment, the HEK293 cells were contacted with a population of reporter plasmids containing an NNN PAM library. Cells were harvested 48 hours after transfection and GFP expressing cells were quantified using a BD LSR- FORTESSA cell analyzer.
  • FIG. 3 Figure 3 - Cas9 Mammalian GFP Activation. Compared with WT Cas9, the evolved Cas9s showed much higher activity on both the TAA PAM (21.08% vs. 0.60% of cells above negative control) and a library of NNN PAM (22.76% vs. 3.38% of cells above negative control).
  • nuclease-active Cas9 proteins were generated based on the sequence provided in , i.e., without the D10A and H840A mutations, but harboring the various PACE mutations.
  • the evolved Cas9 variants were tested in a Cas9 GFP assay, assessing the capacity of the evolved Cas9 protein variants to target and inactivate an emGFP gene integrated into the genome of HEK293 cells using a guide RNA targeting a sequence with a noncanonical PAM.
  • S. pyogenes Cas9 with D10 and H840 residues marked with an asterisk following the respective amino acid residues SEQ ID NO: 9
  • the D10 and H840 residues of SEQ ID NO: 9 may be mutated to generate a nuclease inactive Cas9 (e.g., to D10A and H840A) or to generate a nickase Cas9 (e.g., to D10A with H840; or to D10 with H840A).
  • the HNH domain (bold and underlined) and the RuvC domain (boxed) are identified.
  • the residues found mutated in the clones isolated from the various PACE experiments amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 are identified with an asterisk following the respective amino acid residue.
  • This disclosure provides Cas9 variants in which one or more of the amino acid residues identified by an asterisk are mutated as described herein.
  • the D10 and H840 residues are mutated, e.g., to an alanine residue
  • the Cas9 variants provided include one or more additional mutations of the amino acid residues identified by an asterisk as provided herein.
  • the D10 residue is mutated, e.g., to an alanine residue
  • the Cas9 variants provided include one or more additional mutations of the amino acid residues identified by an asterisk as provided herein.
  • a number of Cas9 sequences from various species were aligned to determine whether corresponding homologous amino acid residues can be identified in other Cas9 proteins, allowing the generation of Cas9 variants with corresponding mutations of the homologous amino acid residues.
  • the alignment was carried out using the NCBI Constraint- based Multiple Alignment Tool (COBALT(accessible at st-va.ncbi. nlm.nih.gov/tools/cobalt), with the following parameters. Alignment parameters: Gap penalties -11,-1; End-Gap penalties -5,-1.
  • CDD Parameters Use RPS BLAST on; Blast E-value 0.003; Find conserveed columns and Recompute on.
  • Query Clustering Parameters Use query clusters on; Word Size 4; Max cluster distance 0.8; Alphabet Regular.
  • Sequence 1 SEQ ID NO: 10
  • Sequence 2 SEQ ID NO: 11
  • Sequence 3 SEQ ID NO: 12
  • the alignment demonstrates that amino acid sequences and amino acid residues that are homologous to a reference Cas9 amino acid sequence or amino acid residue can be identified across Cas9 sequence variants, including, but not limited to Cas9 sequences from different species, by identifying the amino acid sequence or residue that aligns with the reference sequence or the reference residue using alignment programs and algorithms known in the art.
  • This disclosure provides Cas9 variants in which one or more of the amino acid residues identified by an asterisk in SEQ ID NO: 9 are mutated as described herein.
  • the residues in Cas9 sequences other than SEQ ID NO: 9 that correspond to the residues identified in SEQ ID NO: 9 by an asterisk are referred to herein as "homologous" or
  • corresponding residues Such homologous residues can be identified by sequence alignment, e.g., as described above, and by identifying the sequence or residue that aligns with the reference sequence or residue.
  • mutations in Cas9 sequences other than SEQ ID NO: 9 that correspond to mutations identified in SEQ ID NO: 9 herein e.g., mutations of residues 10, 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 840, 1219, and 1329 in SEQ ID NO: 9, are referred to herein as "homologous" or "corresponding" mutations.
  • the mutations corresponding to the D10A mutation in SI for the four aligned sequences above are D10A for S2, D9A for S3, and D13A for S4; the corresponding mutations for H840A in SI are H850A for S2, H842A for S3, and H560 for S4; the corresponding mutation for X1219V in SI are X1228V for S2, X1226 for S3, and X903 V for S4, and so on.
  • Residues corresponding to amino acid residues 10, 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 840, 1219, and 1329 in SEQ ID NO: 9 are boxed in SEQ ID NO: 10 in the alignments, allowing for the identification of the corresponding amino acid residues in the aligned sequences.
  • Cas9 variants with one or more mutations in amino acid residues homologous to amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of SEQ ID NO: 9 are provided herein.
  • the Cas9 variants provided herein comprise mutations corresponding to the D10A and the H840A mutations in SEQ ID NO: 9, resulting in a nuclease-inactive dCas9, and at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations of amino acid residues homologous to amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of SEQ ID NO: 9.
  • Cas9 variants with one or more mutations in amino acid residues homologous to amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of SEQ ID NO: 9 are provided herein.
  • the Cas9 variants provided herein comprise mutations corresponding to the D10A mutations in SEQ ID NO: 9, resulting in a partially nuclease-inactive dCas9, wherein the Cas9 can nick the non-target strand but not the targeted strand, and at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations of amino acid residues homologous to amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of SEQ ID NO: 9.
  • SEQ ID NO WP_045635197.1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus mitis] SEQ ID NO : 12 5AXW_A Cas9, Chain A, Crystal Structure [Staphylococcus Aureus] SEQ ID NO: 13
  • WP 001040087 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 49
  • WP 001040090 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 52
  • WP 001040091 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 53
  • WP 001040092 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 54
  • WP 001040094 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 55
  • WP 001040095 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 56
  • WP 047207273 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 82
  • CCW42055.1 CRISPR-associated protein, SAG0894 family [Streptococcus agalactiae ILRI112] SEQ ID NO: 91 WP_003041502.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus anginosus] SEQ ID NO 92 WP_037593752.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus anginosus] SEQ ID NO 93 WP_049516684.1 CRISPR-associated protein Csnl [Streptococcus anginosus] SEQ ID NO: 94

Abstract

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for enginerring Cas9 and Cas9 variants that have increased activity on target sequences that do not contain the canonical PAM sequence. In some embodiments, fusion proteins comprising such Cas9 variants and nucleic acid editing domains, e.g., deaminase domains, are provided.

Description

EVOLVED CAS9 PROTEINS FOR GENE EDITING
RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent applications, U.S. S.N. 62/245,828 filed October 23, 2015, U.S. S.N. 62/279,346 filed January 15, 2016, U.S. S.N. 62/311,763 filed March 22, 2016, U.S. S.N. 62/322,178 filed April 13, 2016, U.S. S.N. 62/357,352 filed June 30, 2016, U.S. S.N. 62/370,700 filed August 3, 2016, U.S. S.N. 62/398,490 filed September 22, 2016, U.S. S.N. 62/408,686 filed October 14, 2016, and U.S. S.N. 62/357,332 filed June 30, 2016; each of which is incorporated herein by reference
BACKGROUND OF THE INVENTION
[0002] Targeted editing of nucleic acid sequences, for example, the targeted cleavage or the targeted introduction of a specific modification into genomic DNA, is a highly promising approach for the study of gene function and also has the potential to provide new therapies for human genetic diseases.1 An ideal nucleic acid editing technology possesses three characteristics: (1) high efficiency of installing the desired modification; (2) minimal off-target activity; and (3) the ability to be programmed to edit precisely any site in a given nucleic acid, e.g., any site within the human genome.2 Current genome engineering tools, including engineered zinc finger nucleases (ZFNs),3 transcription activator like effector nucleases (TALENs),4 and most recently, the RNA-guided DNA endonuclease Cas9,5 effect sequence-specific DNA cleavage in a genome. This programmable cleavage can result in mutation of the DNA at the cleavage site via non-homologous end joining (NHEJ) or replacement of the DNA surrounding the cleavage site via homology-directed repair (HDR).6'7
[0003] One drawback of the current technologies is that both NHEJ and HDR are stochastic processes that typically result in modest gene editing efficiencies as well as unwanted gene alterations that can compete with the desired alteration.8 Since many genetic diseases in principle can be treated by effecting a specific nucleotide change at a specific location in the genome (for example, a C to T change in a specific codon of a gene associated with a disease),9 the development of a programmable way to achieve such precise gene editing would represent both a powerful new research tool, as well as a potential new approach to gene editing-based human therapeutics.
[0004] Another drawback of current genome engineering tools is that they are limited with respect to the DNA sequences that can be targeted. When using ZNFs or TALENS, a new protein must be generated for each individual target sequence. While Cas9 can be targeted to virtually any target sequence by providing a suitable guide RNA, Cas9 technology is still limited with respect to the sequences that can be targeted by a strict requirement for a protospacer-adj acent motif (PAM), typically of the nucleotide sequence 5'-NGG-3', that must be present immediately adjacent to the 3 '-end of the targeted DNA sequence in order for the Cas9 protein to bind and act upon the target sequence. The PAM requirement thus limits the sequences that can be efficiently targeted by Cas9 proteins.
SUMMARY OF THE INVENTION
[0005] Significantly, 80-90% of protein mutations responsible for human disease arise from the substitution, deletion, or insertion of only a single nucleotide.6 Most current strategies for single-base gene correction include engineered nucleases (which rely on the creation of double-strand breaks, DSBs, followed by stochastic, inefficient homology- directed repair, HDR), and DNA-RNA chimeric oligonucleotides.22 The latter strategy involves the design of a RNA/DNA sequence to base pair with a specific sequence in genomic DNA except at the nucleotide to be edited. The resulting mismatch is recognized by the cell's endogenous repair system and fixed, leading to a change in the sequence of either the chimera or the genome. Both of these strategies suffer from low gene editing efficiencies and unwanted gene alterations, as they are subject to both the stochasticity of HDR and the competition between HDR and non-homologous end-joining, NHEJ.23-25 HDR efficiencies vary according to the location of the target gene within the genome,26 the state of the cell cycle,27 and the type of cell/tissue.28 The development of a direct, programmable way to install a specific type of base modification at a precise location in genomic DNA with enzyme-like efficiency and no stochasticity therefore represents a powerful new approach to gene editing-based research tools and human therapeutics.
[0006] The clustered regularly interspaced short palindromic repeat (CRISPR) system is a recently discovered prokaryotic adaptive immune system10 that has been modified to enable robust and general genome engineering in a variety of organisms and cell lines.11 CRISPR-Cas (CRISPR-associated) systems are protein-RNA complexes that use an RNA molecule (sgRNA) as a guide to localize the complex to a target DNA sequence via base- pairing.12 In the natural systems, a Cas protein then acts as an endonuclease to cleave the targeted DNA sequence.13 The target DNA sequence must be both complementary to the sgRNA and also contain a "protospacer-adj acent motif (PAM) at the 3 '-end of the complementary region in order for the system to function.14 The requirement for a PAM sequence limits the use of Cas9 technology, since not all desired targeted sequences include a PAM sequence at the 3 '-end and thus cannot efficiently be targeted by wild-type Cas9 proteins.
[0007] Provided herein are novel Cas9 variants that exhibit activity on target sequences that do not include the canonical PAM sequence (5'-NGG-3', where N is any nucleotide) at the 3 '-end. Such Cas9 variants are not restricted to target sequences that include the canonical PAM sequence at the 3 '-end.
[0008] Among the known Cas proteins, Streptococcus pyogenes Cas9 has been mostly widely used as a tool for genome engineering.15 This Cas9 protein is a large, multi- domain protein containing two distinct nuclease domains. Point mutations can be introduced into Cas9 to abolish nuclease activity, resulting in a dead Cas9 (dCas9) that still retains its ability to bind DNA in a sgRNA-programmed manner.16In principle, such Cas9 variants, when fused to another protein or domain, can target that protein to virtually any DNA sequence simply by co-expression with an appropriate sgRNA. Thus, this disclosure also comtemplates fusion proteins comprising such Cas9 variants and a DNA modifying domain {e.g., a deaminase, a nuclease, a nickase, a recombinase, a methyltransferase, a methylase, an acetylase, an acetyltransferase, a transcriptional activator, or a transcriptional repressor domain), as well as the use of such fusion proteins in correcting mutations in a genome {e.g., the genome of a human subject) that are associated with disease, or generating mutations in a genome {e.g., the human genome) to decrease or prevent expression of a gene.
[0009] In some embodiments, any of the Cas9 proteins provided herein may be fused to a protein that has an enzymatic activity. In some embodiments, the enzymatic activity modifies a target DNA. In some embodiments, the enzymatic activity is nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity or glycosylase activity. In some cases, the enzymatic activity is nuclease activity. In some cases, the nuclease activity introduces a double strand break in the target DNA. In some cases, the enzymatic activity modifies a target polypeptide associated with the target DNA. In some cases, the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity,
SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, mynstoylation activity or demyristoylation activity. In some cases, the target polypeptide is a histone and the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity or deubiquitinating activity.
[0010] In some embodiments, any of the Cas9 proteins provided herein may be fused to a protein that has an enzymatic activity. In some embodiments, the enzymatic activity modifies a polypeptide associated with DNA (e.g. a histone). In some embodiments, the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity (i.e., ubiquitination activity), deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity glycosylation activity (e.g., from O-GlcNAc transferase) or deglycosylation activity. The enzymatic activities listed herein catalyze covalent modifications to proteins. Such modifications are known in the art to alter the stability or activity of the target protein (e.g., phosphorylation due to kinase activity can stimulate or silence protein activity depending on the target protein). Of particular interest as protein targets are histones. Histone proteins are known in the art to bind DNA and form complexes known as nucleosomes. Histones can be modified (e.g., by methylation, acetylation, ubuitination, phosphorylation) to elicit structural changes in the surrounding DNA, thus controlling the accessibility of potentially large portions of DNA to interacting factors such as transcription factors, polymerases and the like. A single histone can be modified in many different ways and in many different combinations (e.g., trimethylation of lysine 27 of histone 3, H3K27, is associated with DNA regions of repressed transcription while trimethylation of lysine 4 of histone 3, H3K4, is associated with DNA regions of active transcription). Thus, a site-directed modifying polypeptide with hi stone-modifying activity finds use in the site specific control of DNA structure and can be used to alter the histone modification pattern in a selected region of target DNA. Such methods find use in both research and clinical applications.
[0011] In some embodiments, the deaminase domain catalyzes the removal of an amine group from a molecule. In further embodiments, cytidine deaminase domains deaminate cytosine to yield uracil. In other embodiments, the nuclease domain has enzymatic activity and may cleave phosphodiester bonds between the nucleotide subunits of nucleic acids. In some embodiments, recombinase domains, which recombine specific sequences of DNA, may be used to manipulate the structure of genomes and to control gene expression. In further embodiments, methylase domains may be utilized to methylate their respective substrates, while acetylase domains may be used to acetylate their respective substrates. In other embodiments, acetyltransferase domains may be used to transfer an acetyl group. Examples of acetyltransferase molecules include, but are not limited to, histone acetyltransferases (e.g., CBP histone acetyltransferase), choline acetyltransferase,
chloramphenicol acetytransferase, serotonic N-acetyltransferase, NatA acetyltransferase, and NatB acetyltransferase. The disclosure also contemplates transcriptional activator and transcriptional repressor domains. Transcriptional activator domains are regions of a transcription factor which may activate transcription from a promoter through an interaction or multiple interactions with a DNA binding domain, general transcription factors, and RNA polymerase. Transcriptional repressor domins are regions of a transcription factor which may repress transcription from a protomer through an interaction or multiple interactions with a DNA binding domain, general transcription factors, and RNA polymerase.
[0012] The potential of the Cas9 system for genome engineering is immense. Its unique ability to bring proteins to specific sites in a genome programmed by the sgRNA can be developed into a variety of site-specific genome engineering tools beyond nucleases, including transcriptional activators, transcriptional repressors, hi stone-modifying proteins, integrases, deaminases, and recombinases.11 Some of these potential applications have recently been implemented through dCas9 fusions with transcriptional activators to afford RNA-guided transcriptional activators,17'18 transcriptional repressors,16'19'20 and chromatin modification enzymes.21 Simple co-expression of these fusions with a variety of sgRNAs results in specific expression of the target genes. These seminal studies have paved the way for the design and construction of readily programmable sequence-specific effectors for the precise manipulation of genomes.
[0013] Some aspects of this disclosure provide strategies, systems, proteins, nucleic acids, compositions, cells, reagents, methods, and kits that are useful for the targeted binding, editing, and/or cleaving of nucleic acids, including editing a single site within a subject's genome, e.g., a human subject's genome. In some embodiments, recombinant Cas9 proteins are provided that comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten mutations as compared to a naturally occurring Cas9 protein, and that exhibit activity on target sequences that do not include the canonical PAM (5 '-NGG-3 ', where N is any nucleotide) at the 3 '-end. Examples of such Cas9 protein mutations are given in Tables 3, 5, 8, and 9. In some embodiments, fusion proteins of Cas9 and nucleic acid editing enzymes or enzymatic domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid binding, editing, and/or cleaving are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid binding, editing, and/or cleaving proteins, e.g., fusion proteins of Cas9 variants and nucleic acid editing enzymes or domains, are provided.
[0014] Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 80%, at least 85%>, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences set forth in SEQ ID NOs:
9- 262, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of S. pyogenes Cas9 having the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the recombinant Cas9 protein comprises a RuvC and an HNH domain. In some embodiments, the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein. In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid. In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, K294R, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0015] Other aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 80%>, at least 85%>, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences set forth in SEQ ID NOs:
10- 262, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262; and wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein. In some embodiments, the Cas9 protein comprises a RuvC and an HNH domain. In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X267G, X294R, X405I, X409I, X480K, X543D, X694I, X1219V, X1224K, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid. In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, S267G, K294R, F405I, S409I, E480K, E543D, M694I, E1219V, N1224K, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in in SEQ ID NOs: 10-262.
[0016] It should be appreciated that any of the amino acid mutaions described herein,
(e.g., A262T) from a first amino acid residue (e.g., A) to a second amino acid residue (e.g., T) may also include mutations from the first amino acid residue to an amino acid residue that is similar to (e.g., conserved) the second amino acid residue. For example, a mutation of an alanine to a threonine (e.g., a A262T mutation) may also be a mutation from an alanine to an amino acid that is similar in size and chemical properties to a threonine, for example, serine. Additional similar amino acid pairs include, but are not limited to, the following:
phenylalanine and tyrosine; asparagine and glutamine; methionine and cysteine; aspartic acid and glutamic acid; and arginine and lysine. The skilled artisan would recognize that such conservative amino acid substitutions will likely have minor effects on protein structure and are likely to be well tolerated without compromising function. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to a threonine may be an amino acid mutation to a serine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to an arginine may be an amino acid mutation to a lysine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to an isoleucine, may be an amino acid mutation to an alanine, valine, methionine, or leucine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to a lysine may be an amino acid mutation to an arginine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to an aspartic acid may be an amino acid mutation to a glutamic acid or asparigine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to a valine may be an amino acid mutation to an alanine, isoleucine, methionine, or leucine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to a glycine may be an amino acid mutation to an alanine. It should be appreciated, however, that additional conserved amino acid residues would be recognized by the skilled artisan and any of the amino acid mutations to other conserved amino acid residues are also within the scope of this disclosure.
[0017] In some embodiments, the Cas9 protein is a Cas9 domain of a fusion protein.
In some embodiments, the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid. In some embodiments, the mutation is X1219A, X1219I, X1219M, or X1219L.
[0018] In some embodiments, the amino acid sequence of the Cas9 protein comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the mutation is E1219A, E1219I, E1219M or E1219L.
[0019] In some embodiments, the amino acid sequence of the Cas9 protein comprises an X480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid. In some embodiments, the mutation is X480R.
[0020] In some embodiments, the amino acid sequence of the Cas9 protein comprises an E480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the mutation is E480R.
[0021] In some embodiments, the amino acid sequence of the Cas9 protein comprises an X543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid. In some embodiments, the mutation isX543N.
[0022] In some embodiments, the amino acid sequence of the Cas9 protein comprises an E543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the mutation is E543N.
[0023] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X480K, X543D, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0024] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0025] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0026] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0027] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X267G, X294R, X480K, X543D, X1219V, X1224K, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0028] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X262T, X405I, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0029] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations E480K, E543D, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0030] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0031] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations K294R, E480K, E543D, E1219V, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0032] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0033] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations S267G, K294R, E480K, E543D, E1219V, N1224K, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0034] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations A262T, F405I, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0035] The HNH nuclease domain of Cas9 functions to cleave the DNA strand complementary to the guide RNA (gRNA). Its active site consists of a ββα-metal fold, and its histidine 840 activates a water molecule to attack the scissile phosphate, which is more electrophilic due to coordination with a magnesium ion, resulting in cleavage of the the 3 '-5' phosphate bond. In some embodiments, the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262. In some embodiments, the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
[0036] The RuvC domain of Cas9 cleaves the non-target DNA strand. It is encoded by sequentially disparate sites which interact in the tertiary structure to form the RuvC cleaveage domain and consists of an RNase H fold structure. In some embodiments, the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262. In some embodiments, the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
[0037] In some embodiments, the Cas9 protein comprises one or more mutations that affects (e.g., inhibits) the ability of Cas9 to cleave one or both strands of a DNA duplex. In some embodiments, the Cas9 protein comprises a DIOA and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises a DIOXi and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein Xi is any amino acid except for D, and X2 is any amino acid except for H. In some embodiments, the Cas9 protein comprises an DIOA mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises a D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0038] In some embodiments, the Cas9 protein of the present disclosure exhibits activity, for example, increased binding, on a target sequence that does not include the canonical PAM sequence (5'-NGG-3') at its 3 '-end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
[0039] Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits increased activity on a target sequence that does not comprise the canonical PAM sequence (5'-NGG-3') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided in SEQ ID NO: 9. In some embodiments, the Streptococcus pyogenes Cas9 comprises a RuvC and an HNH domain. In other embodiments, the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9
[0040] As one example, the Cas9 protein may exhibit increased binding to the target sequence, may exhibit increased nuclease activity at the target sequence, or may exhibit an increase in other activities, depending on whether the Cas 9 protein is fused to an additional domain, such as an enzyme that has enzymatic activity. In some embodiments, the enzymatic activity modifies a target DNA. In some embodiments, the enzymatic activity is nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity or glycosylase activity. In some cases, the enzymatic activity is nuclease activity. In some cases, the nuclease activity introduces a double strand break in the target DNA. In some cases, the enzymatic activity modifies a target polypeptide associated with the target DNA. In some cases, the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity,
SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity or demyristoylation activity. In some cases, the target polypeptide is a histone and the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity or deubiquitinating activity.
[0041] In some embodiments, any of the Cas9 protein is fused to a protein that has an enzymatic activity. In some embodiments, the enzymatic activity modifies a polypeptide associated with DNA (e.g. a histone). In some embodiments, the enzymatic activity is methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity (i.e., ubiquitination activity), deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity glycosylation activity (e.g., from O-GlcNAc transferase) or deglycosylation activity. The enzymatic activities listed herein catalyze covalent modifications to proteins. Such modifications are known in the art to alter the stability or activity of the target protein (e.g., phosphorylation due to kinase activity can stimulate or silence protein activity depending on the target protein). Of particular interest as protein targets are histones. Histone proteins are known in the art to bind DNA and form complexes known as nucleosomes. Histones can be modified (e.g., by methylation, acetylation, ubuitination, phosphorylation) to elicit structural changes in the surrounding DNA, thus controlling the accessibility of potentially large portions of DNA to interacting factors such as transcription factors, polymerases and the like. A single histone can be modified in many different ways and in many different combinations (e.g., trimethylation of lysine 27 of histone 3, H3K27, is associated with DNA regions of repressed transcription while trimethylation of lysine 4 of histone 3, H3K4, is associated with DNA regions of active transcription). Thus, a site-directed modifying polypeptide with hi stone-modifying activity finds use in the site specific control of DNA structure and can be used to alter the histone modification pattern in a selected region of target DNA. Such methods find use in both research and clinical applications.
[0042] In some embodiments, the Cas9 protein exhibits activity on a target sequence having a 3' end that is not directly adjacent to, or does not have the canonical PAM sequence (5'-NGG-3 '), that is at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 50- fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence.
[0043] In some embodiments, the 3 '-end of the target sequence is directly adjacent to an AGC, GAG, TTT, GTG, CAA CAC, GAT, TAA, ACG, CGA, or CGT sequence.
[0044] In some embodiments, the Cas9 protein activity is measured by a nuclease assay or a nucleic acid binding assay, which are known in the art and would be apparent to the skilled artisan. As provided herein, the Cas9 protein may be fused to one or more domains that confer an activity to the protein, such as a nucleic acid editing activity {e.g., deaminase activity or transcriptional activation activity), which may be measured {e.g., by a deaminase assay or transcriptional activation assay). In some embodiments, the Cas9 protein is fused to a deaminase domain and its activity may be measured using a deaminase assay. In some embodiments, the Cas9 protein is fused to a transcriptional activation domain and its activity may be measured using a transcriptional activation assay, for example, reporter activation assay where the reporter, e.g., GFP or luciferase, among others, is expressed in response to Cas9 binding to a target sequence.
[0045] In some embodiments, the amino acid sequence of the Cas9 protein comprises any of the mutations provided herein. For example, in some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X267G, X294R, X405I, X409I, X480K, X543D, X694I, X1219V, X1224K,
X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid. In other embodiments, the mutations may be A262T, S267G, K294R, F405I, S409I, E480K, E543D, M694I, E1219V, N1224K, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0046] In some embodiments, the amino acid sequence of the Cas9 protein comprises any of the mutations provided herein. For example, in some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid. In other
embodiments, the mutations may be A262T, K294R, S409I, E480K, E543D, M694I, or E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0047] In some embodiments, the amino acid sequence of the Cas9 protein comprises an X1219V mutation or an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0048] In some embodiments, the amino acid sequence of the Cas9 protein comprises an X480K mutation or an E480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0049] In some embodiments, the amino acid sequence of the Cas9 protein comprises an X543D mutation or a E543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0050] In some embodiments, the amino acid sequence of the Cas9 comprises the mutations X480K, X543D, and X1219V; or the mutations E480K, E543D, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0051] In some embodiments, the amino acid sequence of the Cas9 comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V; or the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0052] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, X1256K, and X1362P; or the mutations K294R, E480K, E543D, E1219V, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0053] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, and X1256K, or mutations K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
[0054] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X267G, X294R, X480K, X543D, X1219V, X1224K, and X1256K; or the mutations S267G, K294R, E480K, E543DE1219V, N1224K, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0055] In some embodiments, the amino acid sequence of the Cas9 protein comprises the mutations X262T, X405I, X409I, X480K, X543D, X694I, and X1219V; or the mutations A262T, F405I, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
[0056] In some embodiments, the amino acid sequence of the HNH domain is at least
80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262. In some embodiments, the amino acid sequence of the HNH domain is identical to the amino acid sequence of any of the HNH domains of SEQ ID NOs: 9-262.
[0057] In some embodiments, the amino acid sequence of the RuvC domain is at least
80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262. In some embodiments, the amino acid sequence of the RuvC domain is identical to the amino acid sequence of any of the RuvC domains of SEQ ID NOs: 9-262.
[0058] In some embodiments, the Cas9 protein comprises at D10A and/or a H840A mutation in the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises a D10X1 and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X1 is any amino acid except for D, and wherein X2 is any amino acid except for H. In some embodiments, the Cas9 protein comprises an D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the Cas9 protein comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[0059] Some aspects of this disclosure provide fusion proteins comprising a Cas9 protein as provided herein that is fused to a second protein, thus forming a fusion protein. In some embodiments, the second protein is fused to the N-terminus of the Cas9 protein. In some embodiments, the second protein is fused to the C-terminus of the Cas9 protein. In some embodiments, the Cas9 domain and the effector domain are fused via a linker. The linker may be as simple as a covalent bond, or it may be a polymeric linker many atoms in length. In certain embodiments, the linker is a polpeptide or based on amino acids. In other embodiments, the linker is not peptide-like. In certain embodiments, the linker is a covalent bond (e.g., a carbon-carbon bond, disulfide bond, carbon-heteroatom bond, etc.). In certain embodiments, the linker is a carbon-nitrogen bond of an amide linkage. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymeric (e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid. In certain embodiments, the linker comprises an aminoalkanoic acid (e.g., glycine, ethanoic acid, alanine, beta-alanine, 3-aminopropanoic acid, 4-aminobutanoic acid, 5-pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminohexanoic acid (Ahx). In certain embodiments, the linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane). In other embodiments, the linker comprises a polyethylene glycol moiety (PEG). In other embodiments, the linker comprises amino acids. In certain embodiments, the linker comprises a peptide. In certain embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring. The linker may included funtionalized moieties to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile may be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and
isothiocyanates.
[0060] In some embodiments, the linker comprises a chemical group or molecule linking two molecules or moieties, e.g., two domains of a fusion protein, such as, for example, a nuclease-inactive Cas9 domain and a effector domain (e.g., a deaminase domain). In some embodiments, the linker comprises one or more amino acid resudues. For example, the limker may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25, 30, 35, 40, 45, 50, or more amino acid residues. In some embodiments, the linker is 3, 9, 16, or 21 amino acids in length. In some embodiments, the linker comprises a (GGGGS)n (SEQ ID NO: 5), a (G)„, an (EAAAK)n (SEQ ID NO: 6), a (GGS)„, an
SGSETPGTSESATPES (SEQ ID NO: 7) (also referred to as XTEN), or an (XP)n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30. In some embodiments, wherein the linker comprises a (GGS)3 motif or a
SGSETPGTSESATPES (SEQ ID NO: 7) (XTEN) motif.
[0061] Some aspects of this disclosure provide fusion proteins comprising a Cas9 protein as provided herein that is fused to a second protein, thus forming a fusion protein. In some embodiments, the second protein is fused to the N-terminus of the Cas9 protein. In some embodiments, the second protein is fused to the C-terminus of the Cas9 protein. In some embodiments, the Cas9 domain and the effector domain are fused via a nuclear localization sequence (NLS), for example a NLS comprising the amino acid sequence PKKKRKV (SEQ ID NO: 299), MD SLLMNRRKFL YQFKNVRWAKGRRET YLC (SEQ ID NO: 300), or SPKKKRKVEAS (SEQ ID NO: 284). In some embodiments, a NLS may be combined with any of the linkers listed above.
[0062] In some embodiments, the effector domain comprises an enzymatic domain.
In some embodiments, the effector domain comprises a nuclease, a nickase, a recombinase, a deaminase, a methyltransferase, a methylase, an acetylase, an acetyltransferase, a
transcriptional activator, or a transcriptional repressor domain, which may have nuclease activity, nickase activity, recombinase activity, deaminase activity, methyltransferase activity, methylase activity, acetylase activity, acetyltransferase activity transcriptional activation activity or transcriptional repression activity, respectively. In some embodiments, the effector domain is a effector domain. In some embodiments, the effector domain is a deaminase domain. In some embodiments, the deaminase is a cytosine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA- editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBECl deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3 A deaminase. In some embodiments, the deaminase is an
APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). In some embodiments, the effector domain is at least 80%, at least 85%>, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the deaminase domain of any one of SEQ ID NOs: 263-281. In some embodiments, the deaminase is a cytidine deaminase. In some embodiments, the deaminase is an
apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBECl family deaminase. In some embodiments, the deaminase is an activation-induced cytidine deaminase (AID). In some embodiments, the deaminase is an ACF1/ASE deaminase. In some embodiments, the deaminase is an adenosine deaminase. In some embodiments, the deaminase is an AD AT family deaminase.
[0063] Some aspects of this disclosure provide fusion proteins comprising a Cas9 protein fused to a effector domain, e.g., a deaminase, and a uracil glycosylase inhibitor (UGI). Some aspects of this disclosure are based on the recognition that such fusion proteins may exhibit an increased nucleic acid editing efficiency as compared to fusion proteins not comprising an UGI domain. Domains such as the deaminase domains and UGI domains have been described and are within the scope of this disclosure. For example domains such as deaminase domains and UGI domains have been described in Provisional Application Nos. : 62/245,828, filed October 23, 2015, 62/279,346 filed January 15, 2016, 62/311,763 filed March 22, 2016, 62/322, 178 filed April 13, 2016, 62/357,352 filed June 30, 2016, 62/370,700 filed August 3, 2016, 62/398,490 filed September 22, 2016, and 62/408,686 filed October 14, 2016; the entire contents of each is incorporated by reference herein. It should be appreciated that the deaminase domains and UGI domains described in the foregoing references are within the scope of this disclosure and may be fused with any of the Cas9 proteisn provided herein.
[0064] In some embodiments, the effector domain of the fusion protein is a nuclease domain. In some embodiments, the nuclease domain is a Fokl DNA cleavage domain. In some embodiments, the fusion protein dimerizes. In certain embodiments, the dimer of the fusion protein is active. For example, two Fokl DNA cleavage domains may dimerize to cleave a nucleic acid.
[0065] In some embodiments, the Cas9 protein is fused to a second Cas9 protein. In some embodiments, the second Cas9 protein is the Cas9 protein of any one of claims 1-345. In some embodiments, the second Cas9 protein is fused to the N-terminus of the fusion protein. In some embodiments, the second Cas9 protein is fused to the C-terminus of the fusion protein. In some embodiments, the Cas9 protein and the second Cas9 protein are fused via a second linker. In some embodiments, the second linker comprises a (GGGGS)n (SEQ ID NO: 5), a (G)„, an (EAAAK)n (SEQ ID NO: 6), a (GGS)„, an SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP)n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30. In some embodiments, the second linker comprises a (GGS)3 motif.
[0066] Some aspects of this disclosure provide complexes comprising a Cas9 protein, or a Cas9 fusion protein as provided herein, and a guide RNA bound to the Cas9 protein, or the Cas9 fusion protein. [0067] In some embodiments, the target sequence is a DNA sequence. In some embodiments, the target sequence is a sequence in the genome of a mammal. In some embodiments, the target sequence is a sequence in the genome of a human. In some embodiments, the 3 '-end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3').
[0068] Some aspects of this disclosure provide methods of using the Cas9 proteins, fusion proteins, or complexes provided herein. For example, some aspects of this disclosure provide methods comprising contacting a DNA molecule (a) with a Cas9 protein or a fusion protein as provided herein and a guide RNA, wherein the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence; or (b) with a Cas9 protein, a Cas9 fusion protein, or a Cas9 protein or fusion protein complex with a gRNA as provided herein. In some embodiments, the 3 '-end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3'). In some embodiments, the 3 '-end of the target sequence is immediately adjacent to an AGC, GAG, TTT, GTG, or CAA sequence. In some
embodiments, the target DNA sequence comprises a sequence associated with a disease or disorder. In some embodiments, the target DNA sequence comprises a point mutation associated with a disease or disorder. In some embodiments, the activity of the Cas9 protein, the Cas9 fusion protein, or the complex results in correction of the point mutation. In some embodiments, the step of contacting is performed in vivo in a subject.
[0069] Some aspects of this disclosure provide kits comprising a nucleic acid construct, comprising (a) a nucleotide sequence encoding a Cas9 protein or a Cas9 fusion protein as provided herein; and (b) a heterologous promoter that drives expression of the sequence of (a). In some embodiments, the kit further comprises an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow the cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.
[0070] Some aspects of this disclosure provide polynucleotides encoding any of the
Cas9 proteins, Cas9 fusion proteins, or guide RNA bound to the Cas9 protein or Cas9 fusion protein provided herein. Some aspects of this disclosure provide vectors comprising such polynucleotides. In some embodiments, the vector comprises a heterologous promoter driving expression of the polynucleotide.
[0071] Some aspects of this disclosure provide cells comprising any of the Cas9 proteins, fusion proteins, nucleic acid molecules, and/or a vectors as provided herein. [0072] The summary above is meant to illustrate, in a non-limiting manner, some of the embodiments, advantages, features, and uses of the technology disclosed herein. Other embodiments, advantages, features, and uses of the technology disclosed herein will be apparent from the Detailed Description, the Drawings, the Examples, and the Claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0073] Figure 1 shows the activity of wild-type Streptococcus pyogenes Cas9 on canonical PAM libraries and non-canonical PAM libraries.
[0074] Figure 2 shows the activity of exemplary evolved Cas9 clones on a PAM library after directed evolution.
[0075] Figure 3 shows a comparison of wild-type and evolved Cas9 in a mammalian
GFP activation assay.
[0076] Figures 4 A to 4B show the binding activity of Cas9 (pJH306) and evolved
Cas9 proteins with an 5'-NGG-3 ' PAM sequence using GFP as a readout. On 5'-NGG-3 ' PAMs, many of the evolved Cas9 proteins showed increased Cas9 binding activity relative to wild-type Cas9 based on an increase in GFP fluorescence signal. Figure 4A is a graph representing Cas9 binding activity as a function of % cells above the background
fluorescence. Figure 4B is a graph showing Cas9 binding activity as a function of mean fluorescence. Cas9 proteins used in these experiments were dCas9 proteins fused to a VPR transcriptional activator.
[0077] Figures 5A to 5B show the binding activity of wild type dCas9-VPR
(pJH306) and evolved dCas9-VPR proteins with an NNN PAM sequence using GFP as a readout. On a library of NNN PAMs, many of the evolved Cas9 proteins showed increased Cas9 binding activity relative to wild-type Cas9 based on an increase in GFP fluorescence signal. Figure 5A is a graph representing Cas9 binding activity as a function of % cells above background fluorescence. Figure 5B is a graph showing Cas9 binding activity as a function of mean fluorescence. Cas9 proteins used in these experiments were dCas9 proteins fused to VPR.
[0078] Figure 6 shows dCas9-VPR on all 64 PAM sequences as demonstrated by mean fluorescence on transfected cells gated by iRFP fluorescence. WT dCas9-VPR is pJH306.
[0079] Figure 7 shows in vitro cutting assay. On the gel, WT is wild-type Cas9 (SEQ
ID NO: 9), and 1 is Cas9 (SEQ ID NO: 9) with the E1219V mutation.
[0080] Figure 8 shows a Cas9 fusion protein that can be used to modulate PAM specificity. One possible configuration for a linked Cas9-dCas9 system that could be used for increasing Cas9 targeting to non-canonical PAMs is shown. dCas9 binding to 5'-NGG-3 ' or another PAM could localize Cas9 to an area close to target 2. This localization could help Cas9 cut a previously inaccessible PAM.
[0081] Figures 9A to 9B show dCas9-VPR binding activity on the NNNNN PAM
Library. Figure 9A is a graph representing dCas9-VPR binding activity on the NNNNN PAM library as a function of the % cells above background fluorescence. Figure 9B is a graph representing dCas9-VPR binding activity on the NNNNN PAM library as a function of mean fluorescence.
[0082] Figure 10 shows Cas9 cutting activity using % of cells with GFP loss as a readout. Cas9 proteins were tested with two sgRNAs, which either targeted the canonical 5'- NGG-3 ' PAM or a GAT PAM within a GFP gene.
[0083] Figure 11 illustrates double-stranded DNA substrate bound by Cas9:DNA editing enzyme: sgRNA complexes. The DNA editing enzyme may be, without limitation, a nuclease, nickase, recombinase, deaminase, methyltransferase, methylase, acetylase, or acetyltransferase.
[0084] Figures 12A to 12D show the results of the PAM depletion assay. pJH760 was tested in the PAM depletion assay on four new targets: re2 (Figure 12 A), VEGF (Figure 12B), CLTA (Figure 12C), and CCR5D (Figure 12D).
[0085] Figure 13 shows GFP cutting in mammalian cells.
[0086] Figure 14 shows the results of a PAM depletion assay to test pJH760 (xCas9 v 1.0) on the re2 target.
[0087] Figure 15 shows the results of a PAM depletion assay to test pJH760 (xCas9 vl .0) on the VEGF target.
[0088] Figure 16 shows the results of a PAM depletion assay to test pJH760 (xCas9 vl .0) on the CLTA target.
[0089] Figure 17 shows the results of a PAM depletion assay to test pJH760 (xCas9 vl .0) on the CCR5D target.
[0090] Figure 18 shows the results of a PAM depletion assay to test four xCas9v3 mutants on the re2 target.
[0091] Figure 19 shows the results of a PAM depletion assay to test four xCas9v3 mutants on the VEGF target.
[0092] Figure 20 shows the results of a PAM depletion assay to test four xCas9v3 mutants on the CLTA target. DEFINITIONS
[0093] As used herein and in the claims, the singular forms "a," "an," and "the" include the singular and the plural reference unless the context clearly indicates otherwise. Thus, for example, a reference to "an agent" includes a single agent and a plurality of such agents.
[0094] The term "Cas9" or "Cas9 nuclease" refers to an RNA-guided nuclease comprising a Cas9 protein, or a fragment thereof (e.g., a protein comprising an active or inactive DNA cleavage domain of Cas9, and/or the gRNA binding domain of Cas9). A Cas9 nuclease is also referred to sometimes as a casnl nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease. CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences
complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3 '-5' exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs ("sgRNA", or simply "gNRA") can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M., Chylinski K., Fonfara I, Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the entire contents of which are hereby incorporated by reference. Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self. Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., "Complete genome sequence of an Ml strain of Streptococcus pyogenes." Ferretti et al, J. J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K., Primeaux C, Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P., Qian Y., Jia H.G., Najar F.Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S.W., Roe B.A., McLaughlin R.E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E., Chylinski K., Sharma CM., Gonzales K., Chao Y., Pirzada Z.A., Eckert M.R., Vogel J., Charpentier E., Nature 471 :602-607(201 1); and "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Jinek M., Chylinski K., Fonfara I, Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the entire contents of each of which are incorporated herein by reference). Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus . Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference. In some embodiments, a Cas9 nuclease has an inactive {e.g., an inactivated) DNA cleavage domain.
[0095] A nuclease-inactivated Cas9 protein may interchangeably be referred to as a
"dCas9" protein (for nuclease-"dead" Cas9). Methods for generating a Cas9 having an inactive DNA cleavage domain are known (See, e.g., Jinek et al, Science. 337:816- 821(2012); Qi et al, "Repurposing CRISPR as an RNA-Guided Platform for Sequence- Specific Control of Gene Expression" (2013) Cell. 28; 152(5): 1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to include two subdomains, the UNH nuclease subdomain and the RuvCl subdomain. The UNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvCl subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations DIOA and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al, Science. 337:816-821(2012); Qi et al, Cell. 28; 152(5): 1173-83 (2013).
[0096] In some embodiments, proteins comprising fragments of Cas9 are provided.
For example, in some embodiments, a protein comprises one of two Cas9 domains: (1) the gRNA binding domain of Cas9; or (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9 or fragments thereof are referred to as "Cas9 variants." A Cas9 variant shares homology to Cas9. For example a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95%) identical, at least about 96%> identical, at least about 97%> identical, at least about 98%> identical, at least about 99%> identical, at least about 99.5%> identical, or at least about 99.9%> to wild type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 {e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70%) identical, at least about 80%> identical, at least about 90%> identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding fragment of wild type Cas9. In some embodiments, wild type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence:
NC 017053.1, SEQ ID NO: l (nucleotide); SEQ ID NO:2 (amino acid)).
AT G GAT AAGAAAT AC T C AAT AG G C T T AGAT AT C G G C AC AAAT AG C GT C G GAT G G G C G GT GAT C AC T GAT GAT TAT AAGGTTCCGTCTAAAAAGTTCAAGGTTCTGGGAAATACAGACCGCCACAGTATCAAAAAAAATCTTATAGGGGCT CTTTTATTTGGCAGTGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGACAGCTCGTAGAAGGTATACACGTCGG AAGAAT C GT AT T T GT TAT C T AC AG GAGAT τ T T T T C AAAT GAGAT G G C GAAAGT AGAT GAT AGT T T C T T T CAT C GA C T T GAAGAGT CTTTTTTGGTG GAAGAAGAC AAGAAG CAT GAAC GT CAT C C TAT T T T T G GAAAT AT AGT AGAT GAA GT T G C T TAT CAT GAGAAAT AT C C AAC TAT C TAT CAT C T G C GAAAAAAAT T G G C AGAT T C T AC T GAT AAAG C G GAT TTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCGTGGTCATTTTTTGATTGAGGGAGATTTAAAT C C T GAT AAT AGT GAT GT G GAC AAAC TAT T TAT C C AGT T G GT AC AAAT C T AC AAT C AAT TAT T T GAAGAAAAC C C T AT T AAC G C AAGT AGAGT AGAT G C T AAAG C GAT TCTTTCTG C AC GAT T GAGT AAAT C AAGAC GAT T AGAAAAT C T C ATTGCTCAGCTCCCCGGTGAGAAGAGAAATGGCTTGTTTGGGAATCTCATTGCTTTGTCATTGGGATTGACCCCT AAT T T T AAAT C AAAT T T T GAT T T G G C AGAAGAT G C T AAAT T AC AG C T T T C AAAAGAT AC T T AC GAT GAT GAT T T A GATAATTTATTGGCGCAAATTGGAGATCAATATGCTGATTTGTTTTTGGCAGCTAAGAATTTATCAGATGCTATT T T AC T T T C AGAT AT C C TAAGAGT AAAT AGT GAAAT AAC T AAG G C T C C C C TAT C AG C T T C AAT GAT T AAG C G C T AC GAT GAAC AT CAT C AAGAC T T GAC T C T T T T AAAAG CTTTAGTTC GAC AAC AAC T T C C AGAAAAGT AT AAAGAAAT C T T T T T T GAT C AAT C AAAAAAC G GAT AT G C AG GT TAT AT T GAT G G G G GAG C T AG C C AAGAAGAAT T T TAT AAAT T T ATCAAACCAATTTTAGAAAAAATGGATGGTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGCTGCGC AAGCAACGGACCTTTGACAACGGCTCTATTCCCCATCAAATTCACTTGGGTGAGCTGCATGCTATTTTGAGAAGA C AAGAAGAC T T T T AT C CAT T T T T AAAAGAC AAT C GT GAGAAGAT T GAAAAAAT CTTGACTTTTC GAAT T C C T T AT TATGTTGGTCCATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCGGAAGTCTGAAGAAACAATTACCCCA TGGAATTTTGAAGAAGTTGTCGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGCATGACAAACTTTGATAAA AAT C T T C C AAAT GAAAAAGT AC T AC C AAAAC AT AGT T T G C T T TAT GAGT AT TTTACGGTT TAT AAC GAAT T GAC A AAG GT C AAAT AT GT T AC T GAG G GAAT G C GAAAAC C AG CAT T T C T T T C AG GT GAAC AGAAGAAAG C CAT T GT T GAT TTACTCTT C AAAAC AAAT C GAAAAGT AAC C GT T AAG C AAT T AAAAGAAGAT T AT T T C AAAAAAAT AGAAT GT T T T GAT AGT GT T GAAAT T T C AG GAGT T GAAGAT AGAT T T AAT G C T T CAT TAGGCGCCTAC CAT GAT T T G C T AAAAAT T AT T AAAGAT AAAGAT T T T T T G GAT AAT GAAGAAAAT GAAGAT AT C T T AGAG GAT AT T GT T T T AAC AT T GAC C T T A T T T GAAGAT AG G G G GAT GAT T GAG GAAAGAC T T AAAAC AT AT G C T C AC C T C T T T GAT GAT AAG GT GAT GAAAC AG CTTAAACGTCGCCGTTATACTGGTTGGGGACGTTTGTCTCGAAAATTGATTAATGGTATTAGGGATAAGCAATCT GGCAAAACAATATTAGATTTTTTGAAATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGAT AGT T T GAC AT T T AAAGAAGAT AT T C AAAAAG C AC AG GT GT C T G GAC AAG G C CAT AGT T T AC AT GAAC AGAT T G C T AACTTAGCTGGCAGTCCTGCTATTAAAAAAGGTATTTTACAGACTGTAAAAATTGTTGATGAACTGGTCAAAGTA AT G G G G CAT AAG C C AGAAAAT AT C GT TAT T GAAAT G G C AC GT GAAAAT C AGAC AAC T C AAAAG G G C C AGAAAAAT T C G C GAGAG C GT AT GAAAC GAAT C GAAGAAG GT AT C AAAGAAT TAG GAAGT C AGAT T C T T AAAGAG CAT C C T GT T GAAAAT ACT CAATT GCAAAAT GAAAAG C T C TAT C T C TAT TAT C T AC AAAAT G GAAGAGAC AT GTAT GT GGACCAA GAAT T AGAT AT T AAT C GT T T AAGT GAT TAT GAT GT C GAT CACAT T GT T C CACAAAGT T T CAT TAAAGAC GAT T CA ATAGACAATAAGGTACTAACGCGTTCTGATAAAAATCGTGGTAAATCGGATAACGTTCCAAGTGAAGAAGTAGTC AAAAAGAT GAAAAAC TAT T G GAGAC AAC T T C T AAAC G C C AAGT T AAT C AC T C AAC GT AAGT T T GAT AAT T T AAC G AAAGCTGAACGTGGAGGTTTGAGTGAACTTGATAAAGCTGGTTTTATCAAACGCCAATTGGTTGAAACTCGCCAA AT C AC T AAG CAT GT G G C AC AAAT T T T G GAT AGT C G CAT GAAT AC T AAAT AC GAT GAAAAT GAT AAAC T TAT T C GA GAGGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAAAAGATTTCCAATTCTATAAAGTACGT GAGAT T AAC AAT T AC CAT CAT G C C CAT GAT G C GTAT C T AAAT GCCGTCGTTG GAAC T G C T T T GAT T AAGAAAT AT CCAAAACTTGAATCGGAGTTTGTCTATGGTGATTATAAAGTTTATGATGTTCGTAAAATGATTGCTAAGTCTGAG C AAGAAAT AG G C AAAG C AAC C G C AAAAT AT TTCTTTTACTC T AAT AT CAT GAAC T T C T T C AAAAC AGAAAT T AC A CTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAGAAATTGTCTGGGATAAA GGGCGAGATTTTGCCACAGTGCGCAAAGTATTGTCCATGCCCCAAGTCAATATTGTCAAGAAAACAGAAGTACAG ACAGGCGGATTCTCCAAGGAGTCAATTTTACCAAAAAGAAATTCGGACAAGCTTATTGCTCGTAAAAAAGACTGG GATCCAAAAAAATATGGTGGTTTTGATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAA G G GAAAT C GAAGAAGT T AAAAT C C GT T AAAGAGT T AC T AG G GAT C AC AAT TAT G GAAAGAAGT T C C T T T GAAAAA AAT C C GAT T GAC T T T T T AGAAG C T AAAG GAT AT AAG GAAGT T AAAAAAGAC T T AAT CAT T AAAC T AC C T AAAT AT AGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTGCCGGAGAATTACAAAAAGGAAATGAGCTG GCTCTGCCAAGCAAATATGTGAATTTTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGAT AAC GAAC AAAAAC AAT TGTTTGTG GAG C AG CAT AAG CAT TAT T T AGAT GAGAT TAT T GAG C AAAT C AGT GAAT T T T C T AAG C GT GT TAT T T T AG C AGAT G C C AAT T T AGAT AAAGT TCTTAGTG CAT AT AAC AAAC AT AGAGAC AAAC C A ATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACGAATCTTGGAGCTCCCGCTGCTTTTAAATAT TTTGATACAACAATTGATCGTAAACGATATACGTCTACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAATCC ATCACTGGTCTTTATGAAACACGCATTGATTTGAGTCAGCTAGGAGGTGACTGA (SEQ ID NO : 1 )
MDKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFGSGETAEATRLKRTARRRYTRR KNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLADSTDKAD LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQIYNQLFEENPINASRVDAKAILSARLSKSRRLENL IAQLPGEKRNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI LLSDILR SEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKF IKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY YVGPLARGNSRFAWMTRKSEETITPWNFEEWDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELT KVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGAYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDRGMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQS GKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGHSLHEQIANLAGSPAIKKGILQTVKIVDELVKV MGHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQ ELDINRLSDYDVDHIVPQSFIKDDSIDNKVLTRSDKNRGKSDNVPSEEWKKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR EINNYHHAHDAYLNAWGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQ IVKKTEVQTGGFSKESILPKRNSDKLIARKKDW DPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKY FLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEF SKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGD (SEQ ID NO : 2 )
(single underline: HNH domain; double underline: RuvC domain)
[0097] In some embodiments, wild type Cas9 corresponds to, or comprises SEQ ID
NO:3 (nucleotide) and/or SEQ ID NO: 4 (amino acid):
ATGGATAAAAAGTATTCTATTGGTTTAGACATCGGCACTAATTCCGTTGGATGGGCTGTCATAACCGATGAATAC AAAGTACCTTCAAAGAAATTTAAGGTGTTGGGGAACACAGACCGTCATTCGATTAAAAAGAATCTTATCGGTGCC CTCCTATTCGATAGTGGCGAAACGGCAGAGGCGACTCGCCTGAAACGAACCGCTCGGAGAAGGTATACACGTCGC AAGAACCGAATATGTTACTTACAAGAAATTTTTAGCAATGAGATGGCCAAAGTTGACGATTCTTTCTTTCACCGT TTGGAAGAGTCCTTCCTTGTCGAAGAGGACAAGAAACATGAACGGCACCCCATCTTTGGAAACATAGTAGATGAG GTGGCATATCATGAAAAGTACCCAACGATTTATCACCTCAGAAAAAAGCTAGTTGACTCAACTGATAAAGCGGAC CTGAGGTTAATCTACTTGGCTCTTGCCCATATGATAAAGTTCCGTGGGCACTTTCTCATTGAGGGTGATCTAAAT CCGGACAACTCGGATGTCGACAAACTGTTCATCCAGTTAGTACAAACCTATAATCAGTTGTTTGAAGAGAACCCT ATAAATGCAAGTGGCGTGGATGCGAAGGCTATTCTTAGCGCCCGCCTCTCTAAATCCCGACGGCTAGAAAACCTG ATCGCACAATTACCCGGAGAGAAGAAAAATGGGTTGTTCGGTAACCTTATAGCGCTCTCACTAGGCCTGACACCA AATTTTAAGTCGAACTTCGACTTAGCTGAAGATGCCAAATTGCAGCTTAGTAAGGACACGTACGATGACGATCTC GACAATCTACTGGCACAAATTGGAGATCAGTATGCGGACTTATTTTTGGCTGCCAAAAACCTTAGCGATGCAATC CTCCTATCTGACATACTGAGAGTTAATACTGAGATTACCAAGGCGCCGTTATCCGCTTCAATGATCAAAAGGTAC GATGAACATCACCAAGACTTGACACTTCTCAAGGCCCTAGTCCGTCAGCAACTGCCTGAGAAATATAAGGAAATA TTCTTTGATCAGTCGAAAAACGGGTACGCAGGTTATATTGACGGCGGAGCGAGTCAAGAGGAATTCTACAAGTTT ATCAAACCCATATTAGAGAAGATGGATGGGACGGAAGAGTTGCTTGTAAAACTCAATCGCGAAGATCTACTGCGA AAGCAGCGGACTTTCGACAACGGTAGCATTCCACATCAAATCCACTTAGGCGAATTGCATGCTATACTTAGAAGG CAGGAGGATTTTTATCCGTTCCTCAAAGACAATCGTGAAAAGATTGAGAAAATCCTAACCTTTCGCATACCTTAC TATGTGGGACCCCTGGCCCGAGGGAACTCTCGGTTCGCATGGATGACAAGAAAGTCCGAAGAAACGATTACTCCA TGGAATTTTGAGGAAGTTGTCGATAAAGGTGCGTCAGCTCAATCGTTCATCGAGAGGATGACCAACTTTGACAAG AATTTACCGAACGAAAAAGTATTGCCTAAGCACAGTTTACTTTACGAGTATTTCACAGTGTACAATGAACTCACG AAAGTTAAGTATGTCACTGAGGGCATGCGTAAACCCGCCTTTCTAAGCGGAGAACAGAAGAAAGCAATAGTAGAT CTGTTATTCAAGACCAACCGCAAAGTGACAGTTAAGCAATTGAAAGAGGACTACTTTAAGAAAATTGAATGCTTC GATTCTGTCGAGATCTCCGGGGTAGAAGATCGATTTAATGCGTCACTTGGTACGTATCATGACCTCCTAAAGATA ATTAAAGATAAGGACTTCCTGGATAACGAAGAGAATGAAGATATCTTAGAAGATATAGTGTTGACTCTTACCCTC TTTGAAGATCGGGAAATGATTGAGGAAAGACTAAAAACATACGCTCACCTGTTCGACGATAAGGTTATGAAACAG TTAAAGAGGCGTCGCTATACGGGCTGGGGACGATTGTCGCGGAAACTTATCAACGGGATAAGAGACAAGCAAAGT GGTAAAACTATTCTCGATTTTCTAAAGAGCGACGGCTTCGCCAATAGGAACTTTATGCAGCTGATCCATGATGAC TCTTTAACCTTCAAAGAGGATATACAAAAGGCACAGGTTTCCGGACAAGGGGACTCATTGCACGAACATATTGCG AATCTTGCTGGTTCGCCAGCCATCAAAAAGGGCATACTCCAGACAGTCAAAGTAGTGGATGAGCTAGTTAAGGTC ATGGGACGTCACAAACCGGAAAACATTGTAATCGAGATGGCACGCGAAAATCAAACGACTCAGAAGGGGCAAAAA AACAGTCGAGAGCGGATGAAGAGAATAGAAGAGGGTATTAAAGAACTGGGCAGCCAGATCTTAAAGGAGCATCCT GT G GAAAAT AC C C AAT T G C AGAAC GAGAAAC TTTACCTC TAT T AC C T AC AAAAT G GAAG G GAC AT GT AT GT T GAT C AG GAAC T G GAC AT AAAC C GT T TAT C T GAT T AC GAC GT C GAT C AC AT T GT AC C C C AAT C C T T T T T GAAG GAC GAT T C AAT C GAC AAT AAAGT G C T T AC AC G C T C G GAT AAGAAC C GAG G GAAAAGT GAC AAT GT T C C AAG C GAG GAAGT C GT AAAGAAAAT GAAGAAC TAT T G G C G G C AG C T C C T AAAT G C GAAAC T GAT AAC G C AAAGAAAGT T C GAT AAC T T A ACTAAAGCTGAGAGGGGTGGCTTGTCTGAACTTGACAAGGCCGGATTTATTAAACGTCAGCTCGTGGAAACCCGC C AAAT C AC AAAG CAT GT T G C AC AGAT AC T AGAT T C C C GAAT GAAT AC GAAAT AC GAC GAGAAC GAT AAG C T GAT T CGGGAAGTCAAAGTAATCACTTTAAAGTCAAAATTGGTGTCGGACTTCAGAAAGGATTTTCAATTCTATAAAGTT AG G GAGAT AAAT AAC T AC C AC CAT G C G C AC GAC G C T TAT C T T AAT GCCGTCGTAGG GAC C G C AC T CAT T AAGAAA TACCCGAAGCTAGAAAGTGAGTTTGTGTATGGTGATTACAAAGTTTATGACGTCCGTAAGATGATCGCGAAAAGC GAAC AG GAGAT AG G C AAG G C T AC AG C C AAAT AC T T C T T T TAT T C T AAC AT TAT GAAT T T C T T T AAGAC G GAAAT C AC T C T G G C AAAC G GAGAGAT AC G C AAAC GAC C T T T AAT T GAAAC C AAT G G G GAGAC AG GT GAAAT C GT AT G G GAT AAGGGCCGGGACTTCGCGACGGTGAGAAAAGTTTTGTCCATGCCCCAAGTCAACATAGTAAAGAAAACTGAGGTG CAGACCGGAGGGTTTTCAAAGGAATCGATTCTTCCAAAAAGGAATAGTGATAAGCTCATCGCTCGTAAAAAGGAC TGGGACCCGAAAAAGTACGGTGGCTTCGATAGCCCTACAGTTGCCTATTCTGTCCTAGTAGTGGCAAAAGTTGAG AAGGGAAAATCCAAGAAACTGAAGTCAGTCAAAGAATTATTGGGGATAACGATTATGGAGCGCTCGTCTTTTGAA AAGAAC C C CAT C GAC T T C C T T GAG G C GAAAG GT T AC AAG GAAGT AAAAAAG GAT C T CAT AAT T AAAC T AC C AAAG TATAGTCTGTTTGAGTTAGAAAATGGCCGAAAACGGATGTTGGCTAGCGCCGGAGAGCTTCAAAAGGGGAACGAA CTCGCACTACCGTCTAAATACGTGAATTTCCTGTATTTAGCGTCCCATTACGAGAAGTTGAAAGGTTCACCTGAA GAT AAC GAAC AGAAG C AAC TTTTTGTT GAG C AG C AC AAAC AT TAT C T C GAC GAAAT C AT AGAG C AAAT T T C G GAA T T C AGT AAGAGAGT CAT C C T AG C T GAT G C C AAT C T G GAC AAAGT AT T AAG C G CAT AC AAC AAG C AC AG G GAT AAA CCCATACGTGAGCAGGCGGAAAATATTATCCATTTGTTTACTCTTACCAACCTCGGCGCTCCAGCCGCATTCAAG TAT T T T GAC AC AAC GAT AGAT C G C AAAC GAT AC AC T T C T AC C AAG GAG GT G C T AGAC G C GAC AC T GAT T C AC C AA T C CAT C AC G G GAT TAT AT GAAAC T C G GAT AGAT T T GT C AC AG CTTGGGGGT GAC G GAT C C C C C AAGAAGAAGAG G AAAGT C T C GAG C GAC T AC AAAGAC CAT GAC G GT GAT T AT AAAGAT CAT GAC AT C GAT T AC AAG GAT GAC GAT GAC
AAGGCTGCAGGA (SEQ ID NO: 3)
MDKKYS I GLAI GTNSVGWAVITDEYKVPSKKFKVLGNTDRHS I KKNLI GALLFDSGETAEATRLKRTARRRYTRR KNRI CYLQEI FSNEMAKVDDS FFHRLEES FLVEEDKKHERHPI FGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD LRLIYLALAHMI KFRGHFLI EGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAI LSARLSKSRRLENL IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQI GDQYADLFLAAKNLSDAI LLSDI LR TEITKAPLSASMI KRYDEHHQDLTLLKALVRQQLPEKYKEI FFDQSKNGYAGYI DGGASQEEFYKF I KPI LEKMDGTEELLVKLNREDLLRKQRTFDNGS I PHQIHLGELHAI LRRQEDFYPFLKDNREKI EKI LTFRI PY YVGPLARGNSRFAWMTRKSEETITPWNFEEWDKGASAQS FI ERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELT KVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKI ECFDSVEI SGVEDRFNASLGTYHDLLKI I KDKDFLDNEENEDI LEDIVLTLTLFEDREMI EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGI RDKQS GKTI LDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGS PAI KKGI LQTVKWDELVKV MGRHKPENIVI EMARENQTTQKGQKNSRERMKRI EEGI KELGSQI LKEHPVENTQLQNEKLYLYYLQNGRDMYVD QELDINRLSDYDVDHIVPQS FLKDDS I DNKVLTRSDKNRGKSDNVPSEEWKKMKNYWRQLLNAKLITQRKFDNL TKAERGGLSELDKAGFI KRQLVETRQITKHVAQI LDSRMNTKYDENDKLI REVKVITLKSKLVSDFRKDFQFYKV REINNYHHAHDAYLNAWGTALI KKYPKLESEFVYGDYKVYDVRKMIAKSEQEI GKATAKYFFYSNIMNFFKTEI TLANGEI RKRPLI ETNGETGEIVWDKGRDFATVRKVLSMPQ IVKKTEVQTGGFSKES I LPKRNSDKLIARKKD WDPKKYGGFDS PTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERS S FEKNPI DFLEAKGYKEVKKDLI I KLPK YSLFELENGRKRMLASAGELQKGNELALPSKY FLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEI I EQI SE FSKRVI LADANLDKVLSAYNKHRDKPI REQAENI IHLFTLTNLGAPAAFKYFDTTI DRKRYTSTKEVLDATLIHQ
S ITGLYETRI DLSQLGGD (SEQ ID NO:4)
(single underline: HNH domain; double underline: RuvC domain)
[0098] In some embodiments, wild type Cas9 corresponds to Cas9 from
Streptococcus pyogenes (NCBI Reference Sequence: NC_002737.2, SEQ ID NO: 282 (nucleotide); and Uniport Reference Sequence: Q99ZW2, SEQ ID NO: 9 (amino acid).
AT G GAT AAGAAAT AC T C AAT AG G C T T AGAT AT C G G C AC AAAT AG C GT C G GAT G G G C G GT GAT C AC T GAT GAAT AT AAGGTTCCGTCTAAAAAGTTCAAGGTTCTGGGAAATACAGACCGCCACAGTATCAAAAAAAATCTTATAGGGGCT CTTTTATTTGACAGTGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGACAGCTCGTAGAAGGTATACACGTCGG AAGAAT C GT AT T T GT TAT C T AC AG GAGAT τ T T T T C AAAT GAGAT G G C GAAAGT AGAT GAT AGT T T C T T T CAT C GA C T T GAAGAGT CTTTTTTGGTG GAAGAAGAC AAGAAG CAT GAAC GT CAT C C TAT T T T T G GAAAT AT AGT AGAT GAA GT T G C T TAT CAT GAGAAAT AT C C AAC TAT C TAT CAT C T G C GAAAAAAAT T G GT AGAT T C T AC T GAT AAAG C G GAT TTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCGTGGTCATTTTTTGATTGAGGGAGATTTAAAT C C T GAT AAT AGT GAT GT G GAC AAAC TAT T TAT C C AGT T G GT AC AAAC C T AC AAT C AAT TAT T T GAAGAAAAC C C T AT T AAC G C AAGT G GAGT AGAT G C T AAAG C GAT TCTTTCTG C AC GAT T GAGT AAAT C AAGAC GAT T AGAAAAT C T C ATTGCTCAGCTCCCCGGTGAGAAGAAAAATGGCTTATTTGGGAATCTCATTGCTTTGTCATTGGGTTTGACCCCT AAT T T T AAAT C AAAT T T T GAT T T G G C AGAAGAT G C T AAAT T AC AG C T T T C AAAAGAT AC T T AC GAT GAT GAT T T A GATAATTTATTGGCGCAAATTGGAGATCAATATGCTGATTTGTTTTTGGCAGCTAAGAATTTATCAGATGCTATT T T AC T T T C AGAT AT C C T AAGAGT AAAT AC T GAAAT AAC T AAG G C T C C C C TAT C AG C T T C AAT GAT T AAAC G C T AC GAT GAAC AT CAT C AAGAC T T GAC T C T T T T AAAAG CTTTAGTTC GAC AAC AAC T T C C AGAAAAGT AT AAAGAAAT C T T T T T T GAT C AAT C AAAAAAC G GAT AT G C AG GT TAT AT T GAT G G G G GAG C T AG C C AAGAAGAAT T T TAT AAAT T T ATCAAACCAATTTTAGAAAAAATGGATGGTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGCTGCGC AAGCAACGGACCTTTGACAACGGCTCTATTCCCCATCAAATTCACTTGGGTGAGCTGCATGCTATTTTGAGAAGA C AAGAAGAC T T T T AT C CAT T T T T AAAAGAC AAT C GT GAGAAGAT T GAAAAAAT CTTGACTTTTC GAAT T C C T T AT TATGTTGGTCCATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCGGAAGTCTGAAGAAACAATTACCCCA TGGAATTTTGAAGAAGTTGTCGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGCATGACAAACTTTGATAAA AAT C T T C C AAAT GAAAAAGT AC T AC C AAAAC AT AGT T T G C T T TAT GAGT AT TTTACGGTT TAT AAC GAAT T GAC A AAG GT C AAAT AT GT T AC T GAAG GAAT G C GAAAAC C AG CAT T T C T T T C AG GT GAAC AGAAGAAAG C CAT T GT T GAT TTACTCTT C AAAAC AAAT C GAAAAGT AAC C GT T AAG C AAT T AAAAGAAGAT T AT T T C AAAAAAAT AGAAT GT T T T GAT AGT GT T GAAAT T T C AG GAGT T GAAGAT AGAT T T AAT G C T T CAT TAGGTACCTAC CAT GAT T T G C T AAAAAT T AT T AAAGAT AAAGAT T T T T T G GAT AAT GAAGAAAAT GAAGAT AT C T T AGAG GAT AT T GT T T T AAC AT T GAC C T T A T T T GAAGAT AG G GAGAT GAT T GAG GAAAGAC T T AAAAC AT AT G C T C AC C T C T T T GAT GAT AAG GT GAT GAAAC AG CTTAAACGTCGCCGTTATACTGGTTGGGGACGTTTGTCTCGAAAATTGATTAATGGTATTAGGGATAAGCAATCT GGCAAAACAATATTAGATTTTTTGAAATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGAT AGT T T GAC AT T T AAAGAAGAC AT T C AAAAAG C AC AAGT GT C T G GAC AAG G C GAT AGT T T AC AT GAAC AT AT T G C A AATTTAGCTGGTAGCCCTGCTATTAAAAAAGGTATTTTACAGACTGTAAAAGTTGTTGATGAATTGGTCAAAGTA AT G G G G C G G CAT AAG C C AGAAAAT AT C GT TAT T GAAAT G G C AC GT GAAAAT C AGAC AAC T C AAAAG G G C C AGAAA AAT T C G C GAGAG C GT AT GAAAC GAAT C GAAGAAG GT AT C AAAGAAT TAG GAAGT C AGAT T C T T AAAGAG CAT C C T GTT GAAAAT ACT CAATT GCAAAAT GAAAAG C T C TAT C T C TAT TAT C T C C AAAAT G GAAGAGAC AT GTAT GT GGAC CAAGAAT T AGAT AT T AAT C GT T T AAGT GAT TAT GAT GT C GAT CACAT T GT T C CACAAAGT T T CCTTAAAGAC GAT TCAATAGACAATAAGGTCTTAACGCGTTCTGATAAAAATCGTGGTAAATCGGATAACGTTCCAAGTGAAGAAGTA GT C AAAAAGAT GAAAAAC TAT T G GAGAC AAC T T C T AAAC G C C AAGT T AAT C AC T C AAC GT AAGT T T GAT AAT T T A ACGAAAGCTGAACGTGGAGGTTTGAGTGAACTTGATAAAGCTGGTTTTATCAAACGCCAATTGGTTGAAACTCGC C AAAT C AC T AAG CAT GT G G C AC AAAT T T T G GAT AGT C G CAT GAAT AC T AAAT AC GAT GAAAAT GAT AAAC T TAT T C GAGAG GT T AAAGT GAT T AC C T T AAAAT C T AAAT TAGTTTCT GAC T T C C GAAAAGAT T T C C AAT T C T AT AAAGT A CGTGAGATTAACAATTACCATCATGCCCATGATGCGTATCTAAATGCCGTCGTTGGAACTGCTTTGATTAAGAAA TATCCAAAACTTGAATCGGAGTTTGTCTATGGTGATTATAAAGTTTATGATGTTCGTAAAATGATTGCTAAGTCT GAG C AAGAAAT AG G C AAAG C AAC C G C AAAAT AT TTCTTTTACTC T AAT AT CAT GAAC T T C T T C AAAAC AGAAAT T ACACTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAGAAATTGTCTGGGAT AAAGGGCGAGATTTTGCCACAGTGCGCAAAGTATTGTCCATGCCCCAAGTCAATATTGTCAAGAAAACAGAAGTA C AGAC AG G C G GAT T C T C C AAG GAGT C AAT T T T AC C AAAAAGAAAT T C G GAC AAG C T TAT T G C T C GT AAAAAAGAC TGGGATCCAAAAAAATATGGTGGTTTTGATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAA AAAG G GAAAT C GAAGAAGT T AAAAT C C GT T AAAGAGT T AC T AG G GAT C AC AAT TAT G GAAAGAAGT T C C T T T GAA AAAAAT C C GAT T GAC T T T T T AGAAG C T AAAG GAT AT AAG GAAGT T AAAAAAGAC T T AAT CAT T AAAC T AC C T AAA TATAGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTGCCGGAGAATTACAAAAAGGAAATGAG CTGGCTCTGCCAAGCAAATATGTGAATTTTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAA GAT AAC GAAC AAAAAC AAT TGTTTGTG GAG C AG CAT AAG CAT TAT T T AGAT GAGAT TAT T GAG C AAAT C AGT GAA T T T T C T AAG C GT GT TAT T T T AG C AGAT G C C AAT T T AGAT AAAGT TCTTAGTG C AT AT AAC AAAC AT AGAGAC AAA CCAATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACGAATCTTGGAGCTCCCGCTGCTTTTAAA T AT T T T GAT AC AAC AAT T GAT C GT AAAC GAT AT AC GT C T AC AAAAGAAGT T T T AGAT GCCACTCTTATC CAT C AA TCCATCACTGGTCTTTATGAAACACGCATTGATTTGAGTCAGCTAGGAGGTGACTGA (SEQ ID NO: 282)
MDKKYS I GLDI GTNSVGWAVITDEYKVPSKKFKVLGNTDRHS I KKNLI GALLFDSGETAEATRLKRTARRRYTRR KNRI CYLQEI FSNEMAKVDDS FFHRLEES FLVEEDKKHERHPI FGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD LRLIYLALAHMI KFRGHFLI EGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAI LSARLSKSRRLENL IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQI GDQYADLFLAAKNLSDAI LLSDI LR TEITKAPLSASMI KRYDEHHQDLTLLKALVRQQLPEKYKEI FFDQSKNGYAGYI DGGASQEEFYKF I KPI LEKMDGTEELLVKLNREDLLRKQRTFDNGS I PHQIHLGELHAI LRRQEDFYPFLKDNREKI EKI LTFRI PY YVGPLARGNSRFAWMTRKSEETITPWNFEEWDKGASAQS FI ERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELT KVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKI ECFDSVEI SGVEDRFNASLGTYHDLLKI I KDKDFLDNEENEDI LEDIVLTLTLFEDREMI EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGI RDKQS GKTI LDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGS PAI KKGI LQTVKWDELVKV MGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVD QELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEWKKMKNYWRQLLNAKLITQRKFDNL TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKV REINNYHHAHDAYLNAWGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI TLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQ IVKKTEVQTGGFSKESILPKRNSDKLIARKKD WDPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGELQKGNELALPSKY FLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISE FSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ
siTGLYETRiDLSQLGGD (SEQ ID NO: 9) (single underline: HNH domain; double underline: RuvC domain)
[0099] In some embodiments, Cas9 refers to Cas9 from: Coryne bacterium ulcer ans
(NCBI Refs: NC_015683.1, NC_017317.1); Coryne bacterium diphtheria (NCBI Refs:
NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1);
Prevotella intermedia (NCBI Ref: NC 017861.1); Spiroplasma taiwanense (NCBI Ref:
NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisl (NCBI Ref: NC_018721.1); Streptococcus
thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1);
Campylobacter jejuni (NCBI Ref: YP_002344900.1); or Neisseria, meningitidis (NCBI Ref: YP 002342100.1) or to a Cas9 from any of the organisms listed in Example 3.
[00100] In some embodiments, dCas9 corresponds to, or comprises in part or in whole, a Cas9 amino acid sequence having one or more mutations that inactivate the Cas9 nuclease activity. For example, in some embodiments, a dCas9 domain comprises D10A and/or H840A mutation. dCas9 (D10A and H840A):
MDKKYSIGLA*IGTNSVG AVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTR
RKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNI*VDEVAYHEKYPTIYH*LRKKLVDSTD KADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVD*KLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRR LENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDA*KLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK* NLSDAILLSDILR TEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQ EEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGS*IPHQIHLGELHAILRRQEDFYPFLKDNREKIEKI LTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE*WDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEY FTVYNELTKVKYVTEGMRKPAFLSGE*QKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASL GTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG*RLSRK LINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQG|DSLHEHIANLAGSPAIKKGILQT| IVKWDELVKVMGRHKPENIVIEMALRENQTTQKGQKNSRA
LQNGRDMYVDQELDI_ LSDYDVDAIVPQSFLKDDSID_raV^
LITQRKFDNLTKAERG|GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSD| |FRKDFQFYKVREINNYHHAHDAYLNAWGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS| |NIMNFFKTEITLANGEIRKRPLIETNGETGEI DKGRDFATVRKVLSMPQ IVKKTEVQT|GGFSKESILPKRN SDKLIARKKDWDPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEV KKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY FLYLASHYEKLKGSPEDNEQKQLFVEQHKHY LDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTK EVLDATLIHQSITGLYETRIDLSQLGGD
(SEQ ID NO: 8) (single underline: HNH domain; double underline: RuvC domain)
[00101] In some embodiments, Cas9 corresponds to, or comprises in part or in whole, a Cas9 amino acid sequence having one or more mutations that alter Cas9's nuclease activity. In some embodiments, Cas9 may be a Cas9 nickase, which is a version of Cas9 that generates a single-stranded DNA break at a specific location based on a co-expressed gRNA-defined target sequence, rather than a double-strand DNA break. For example, in some embodiments, a Cas9 domain comprises D10A mutation (e.g., SEQ ID NO: 301) and/or an H840A mutation (e.g., SEQ ID NO: 302). Exemplary Cas9 nickases are shown below. However, it should be appreciated that additional Cas9 nickases that generate a single-stranded DNA break of a DNA duplex would be apparent to the skilled artisan and are within the scope of this disclosure.
Cas9 D10A nickase:
MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRR KNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI LLSDILR TEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKF IKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY YVGPLARGNSRFAWMTRKSEETITPWNFEEWDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELT KVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQS GKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKWDELVKV MGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVD QELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEWKKMKNYWRQLLNAKLITQRKFDNL TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKV REINNYHHAHDAYLNAWGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI TLANGEIRKRPLIETNGETGEI DKGRDFATVRKVLSMPQ IVKKTEVQTGGFSKESILPKRNSDKLIARKKD WDPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGELQKGNELALPSKY FLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISE FSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ
siTGLYETRiDLSQLGGD (SEQ ID NO: 301) (single underline: HNH domain; double underline: RuvC domain)
Cas9 H840A nickase:
MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRR KNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI LLSDILR TEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKF IKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY YVGPLARGNSRFAWMTRKSEETITPWNFEEWDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELT KVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQS GKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKWDELVKV MGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVD QELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEWKKMKNYWRQLLNAKLITQRKFDNL TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKV REINNYHHAHDAYLNAWGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI TLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQ IVKKTEVQTGGFSKESILPKRNSDKLIARKKD WDPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGELQKGNELALPSKY FLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISE FSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ
siTGLYETRiDLSQLGGD (SEQ ID NO: 302) (single underline: HNH domain; double underline: RuvC domain)
[00102] In other embodiments, dCas9 variants having mutations other than D10A and
H840A are provided, which, e.g., result in nuclease-inactivated Cas9 (dCas9). Such mutations, by way of example, include other amino acid substitutions at D10 and H820, or other substitutions within the nuclease domains of Cas9 (e.g., substitutions in the HNH nuclease subdomain and/or the RuvCl subdomain). In some embodiments, variants or homologues of dCas9 (e.g., variants of SEQ ID NO: 9) are provided which are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to SEQ ID NO: 9. In some embodiments, variants of dCas9 (e.g., variants of SEQ ID NO: 9) are provided having amino acid sequences which are shorter, or longer than SEQ ID NO: 9, by about 5 amino acids, by about 10 amino acids, by about 15 amino acids, by about 20 amino acids, by about 25 amino acids, by about 30 amino acids, by about 40 amino acids, by about 50 amino acids, by about 75 amino acids, by about 100 amino acids, or more.
[00103] In some embodiments, Cas9 fusion proteins as provided herein comprise the full-length amino acid sequence of a Cas9 protein, e.g., one of the sequences provided above. In other embodiments, however, fusion proteins as provided herein do not comprise a full- length Cas9 sequence, but only a fragment thereof. For example, in some embodiments, a Cas9 fusion protein provided herein comprises a Cas9 fragment, wherein the fragment binds crRNA and tracrRNA or a sgRNA, but does not comprise a functional nuclease domain, e.g., it comprises only a truncated version of a nuclease domain or no nuclease domain at all. Exemplary amino acid sequences of suitable Cas9 domains and Cas9 fragments are provided herein, and additional suitable sequences of Cas9 domains and Cas9 fragments will be apparent to those of skill in the art. In some embodiments, a Cas9 fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type Cas9 protein. In some embodiments, a Cas9 fragment comprises at least at least 100 amino acids in length. In some embodiments, the Cas9 fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, or at least 1600 amino acids of a corresponding wild type Cas9 protein. In some embodiments, the Cas9 fragment comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at leat 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues of a corresponding wild type Cas9 protein.
[00104] Cas9.In some embodiments, Cas9 refers to Cas9 from: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC 017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisl (NCBI Ref: NC_018721.1); Streptococcus
thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1);
Campylobacter jejuni (NCBI Ref: YP_002344900.1); or Neisseria, meningitidis (NCBI Ref: YP_002342100.1).
[00105] The term "deaminase" or "deaminase domain," as used herein, refers to a protein or enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase or deaminase domain is a cytidine deaminase, catalyzing the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively. In some embodiments, the deaminase or deaminase domain is a cytosine deaminase, catalyzing the hydrolytic deamination of cytosine to uracil. In some embodiments, the deaminase or deaminase domain is a naturally-occuring deaminase from an organism, such as a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase or deaminase domain is a variant of a naturally-occuring deaminase from an organism, that does not occur in nature. For example, in some embodiments, the deaminase or deaminase domain is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%), or at least 99.5% identical to a naturally-occuring deaminase from an organism.
[00106] The term "effective amount," as used herein, refers to an amount of a biologically active agent that is sufficient to elicit a desired biological response. For example, in some embodiments, an effective amount of a nuclease may refer to the amount of the nuclease that is sufficient to induce cleavage of a target site specifically bound and cleaved by the nuclease. In some embodiments, an effective amount of a fusion protein provided herein, e.g., of a fusion protein comprising a nuclease-inactive Cas9 domain and a effector domain (e.g., a deaminase domain) may refer to the amount of the fusion protein that is sufficient to induce editing of a target site specifically bound and edited by the fusion protein. As will be appreciated by the skilled artisan, the effective amount of an agent, e.g., a fusion protein, a nuclease, a deaminase, a recombinase, a hybrid protein, a protein dimer, a complex of a protein (or protein dimer) and a polynucleotide, or a polynucleotide, may vary depending on various factors such as, for example, on the desired biological response, e.g., on the specific allele, genome, or target site to be edited; on the cell or tissue being targeted; and on the agent being used.
[00107] The term "immediately adjacent" as used in the context of two nucleic acid sequences refers to two sequences that directly abut each other as part of the same nucleic acid molecule and are not separated by one or more nucleotides. Accordingly, sequences are immediately adjacent, when the nucleotide at the 3 '-end of one of the sequences is directly connected to nucleotide at the 5'-end of the other sequence via a phosphodiester bond.
[00108] The term "linker," as used herein, refers to a chemical group or a molecule linking two molecules or moieties, e.g., two domains of a fusion protein, such as, for example, a nuclease-inactive Cas9 domain and a effector domain (e.g., a deaminase domain). In some embodiments, a linker joins a gRNA binding domain of an RNA-programmable nuclease, including a Cas9 nuclease domain, and the catalytic domain of a nucleic-acid editing protein. In some embodiments, a linker joins a dCas9 and a nucleic-acid editing protein. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two. In some embodiments, the linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5-100 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.
[00109] The term "mutation," as used herein, refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)).
[00110] The terms "nucleic acid" and "nucleic acid molecule," as used herein, refer to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, "nucleic acid" refers to individual nucleic acid residues {e.g. nucleotides and/or nucleosides). In some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms "oligonucleotide" and
"polynucleotide" can be used interchangeably to refer to a polymer of nucleotides {e.g., a string of at least three nucleotides). In some embodiments, "nucleic acid" encompasses RNA as well as single and/or double-stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or including non-naturally occurring nucleotides or nucleosides. Furthermore, the terms "nucleic acid," "DNA," "RNA," and/or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the 5' to 3 ' direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides {e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxy cytidine); nucleoside analogs {e.g., 2-aminoadenosine, 2- thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2- aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7- deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g., phosphorothioates and 5'-N-phosphoramidite linkages). In some embodiments, an RNA is an RNA associated with the Cas9 system. For example, the RNA may be a CRISPR RNA (crRNA), a trans-encoded small RNA
(tracrRNA), a single guide RNA (sgRNA), or a guide RNA (gRNA).
[00111] The term "proliferative disease," as used herein, refers to any disease in which cell or tissue homeostasis is disturbed in that a cell or cell population exhibits an abnormally elevated proliferation rate. Proliferative diseases include hyperproliferative diseases, such as pre-neoplastic hyperplastic conditions and neoplastic diseases. Neoplastic diseases are characterized by an abnormal proliferation of cells and include both benign and malignant neoplasias. Malignant neoplasia is also referred to as cancer.
[00112] The terms "protein," "peptide," and "polypeptide" are used interchangeably herein, and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an individual protein or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof. The term "fusion protein" as used herein refers to a hybrid polypeptide which comprises protein domains from at least two different proteins. One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy- terminal (C-terminal) protein thus forming an "amino-terminal fusion protein" or a "carboxy- terminal fusion protein," respectively. A protein may comprise different domains, for example, a nucleic acid binding domain (e.g., the gRNA binding domain of Cas9 that directs the binding of the protein to a target site) and a nucleic acid cleavage domain or a catalytic domain of a nucleic-acid editing protein. In some embodiments, a protein comprises a proteinaceous part, e.g., an amino acid sequence constituting a nucleic acid binding domain, and an organic compound, e.g., a compound that can act as a nucleic acid cleavage agent. In some embodiments, a protein is in a complex with, or is in association with, a nucleic acid, e.g., RNA. Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)), the entire contents of which are incorporated herein by reference.
[00113] The term "RNA-programmable nuclease," and "RNA-guided nuclease" are used interchangeably herein and refer to a nuclease that forms a complex with {e.g., binds or associates with) one or more RNA that is not a target for cleavage. In some embodiments, an RNA-programmable nuclease, when in a complex with an RNA, may be referred to as a nuclease:RNA complex. Typically, the bound RNA(s) is referred to as a guide RNA
(gRNA). gRNAs can exist as a complex of two or more RNAs, or as a single RNA molecule. gRNAs that exist as a single RNA molecule may be referred to as single-guide RNAs (sgRNAs), though "gRNA" is used interchangeably to refer to guide RNAs that exist as either single molecules or as a complex of two or more molecules. Typically, gRNAs that exist as single RNA species comprise two domains: (1) a domain that shares homology to a target nucleic acid {e.g., and directs binding of a Cas9 complex to the target); and (2) a domain that binds a Cas9 protein. In some embodiments, domain (2) corresponds to a sequence known as a tracrRNA, and comprises a stem-loop structure. For example, in some embodiments, domain (2) is identical or homologous to a tracrRNA as provided in Jinek et al, Science 337:816-821(2012), the entire contents of which is incorporated herein by reference. Other examples of gRNAs {e.g., those including domain 2) can be found in U.S. Provisional Patent Application, U.S. S.N. 61/874,682, filed September 6, 2013, entitled "Switchable Cas9 Nucleases and Uses Thereof," and U.S. Provisional Patent Application, U.S.S.N. 61/874,746, filed September 6, 2013, entitled "Delivery System For Functional Nucleases," the entire contents of each are hereby incorporated by reference in their entirety. In some embodiments, a gRNA comprises two or more of domains (1) and (2), and may be referred to as an "extended gRNA." For example, an extended gRNA will, e.g., bind two or more Cas9 proteins and bind a target nucleic acid at two or more distinct regions, as described herein. The gRNA comprises a nucleotide sequence that complements a target site, which mediates binding of the nuclease/RNA complex to said target site, providing the sequence specificity of the nuclease:RNA complex. In some embodiments, the RNA- programmable nuclease is the (CRISPR-associated system) Cas9 endonuclease, for example Cas9 (Csnl) from Streptococcus pyogenes (see, e.g., "Complete genome sequence of an Ml strain of Streptococcus pyogenes." Ferretti J. J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K., Primeaux C, Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P., Qian Y., Jia H.G., Najar F.Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S.W., Roe B.A., McLaughlin R.E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663 (2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E., Chylinski K., Sharma CM., Gonzales K., Chao Y., Pirzada Z.A., Eckert M.R., Vogel J., Charpentier E., Nature 471 : 602-607 (2011); and "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Jinek M., Chylinski K., Fonfara I, Hauer M., Doudna J. A., Charpentier E. Science 337:816-821 (2012), the entire contents of each of which are incorporated herein by reference.
[00114] Because RNA-programmable nucleases {e.g., Cas9) use RNA:DNA
hybridization to target DNA cleavage sites, these proteins are able to be targeted, in principle, to any sequence specified by the guide RNA. Methods of using RNA-programmable nucleases, such as Cas9, for site-specific cleavage {e.g., to modify a genome) are known in the art (see e.g., Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013); Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, W.Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013); Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013); Dicarlo, J.E. et al. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic acids research (2013); Jiang, W. et al. RNA-guided editing of bacterial genomes using CRISPR- Cas systems. Nature biotechnology 31, 233-239 (2013); the entire contents of each of which are incorporated herein by reference).
[00115] The term "subject," as used herein, refers to an individual organism, for example, an individual mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a rodent. In some embodiments, the subject is a sheep, a goat, a cattle, a cat, or a dog. In some embodiments, the subject is a vertebrate, an amphibian, a reptile, a fish, an insect, a fly, or a nematode. In some
embodiments, the subject is a research animal. In some embodiments, the subject is genetically engineered, e.g., a genetically engineered non-human subject. The subject may be of either sex, of any age, and at any stage of development.
[00116] The term "target site" refers to a sequence within a nucleic acid molecule that is deaminated by a deaminase or a fusion protein comprising a deaminase (e.g., a dCas9- deaminase fusion protein provided herein).
[00117] The terms "treatment," "treat," and "treating," refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. As used herein, the terms "treatment," "treat," and "treating" refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed and/or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, e.g., to prevent or delay onset of a symptom or inhibit onset or progression of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.
[00118] The term "recombinant" as used herein in the context of proteins or nucleic acids refers to proteins or nucleic acids that do not occur in nature, but are the product of human engineering. For example, in some embodiments, a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as compared to any naturally occurring sequence.
[00119] The term "nucleic acid editing enzyme" as used herein refers to proteins that are able to modify a nucleic acids or one or more nucleotide bases of a nucleic acid. For example, in some embodiments, a nucleic acid editing enzyme is a deaminase, which can catalyze C to T or G to A changes. Other suitable nucleid acid editing enzyme that may be used in accordance with this disclosure include, without limitation, a nuclease, nickase, recombinase, deaminase, methyltransferase, methylase, acetylase, or acetyltransferase.
DETAILED DESCRIPTION OF CERTAIN EMBOD EVENTS OF THE INVENTION
[00120] Some aspects of this disclosure provide recombinant Cas9 proteins that efficiently target DNA sequences that do not comprise the canonical PAM sequence (5 '- NGG-3 ', where N is any nucleotide, for example A, T, G, or C) at their 3 '-ends. In some embodiments, the Cas9 proteins provided herein comprise one or more mutations identified in directed evolution experiments using a target sequence library comprising randomized PAM sequences. The recombinant non-PAM restricted Cas9 proteins provided herein are useful for targeting DNA sequences that do not comprise the canonical PAM sequence at their 3 '-end and thus greatly extend the usefulness of Cas9 technology for gene editing.
[00121] Some aspects of this disclosure provide fusion proteins that comprise a Cas9 protein and an effector domain, for example, a DNA-editing domain, such as, e.g., a deaminase domain. The deamination of a nucleobase by a deaminase can lead to a point mutation at the specific residue, which is referred to herein as nucleic acid editing. Fusion proteins comprising a Cas9 protein or variant thereof and a DNA-editing domain can thus be used for the targeted editing of nucleic acid sequences. Such fusion proteins are useful for targeted editing of DNA in vitro, e.g., for the generation of mutant cells or animals; for the introduction of targeted mutations, e.g., for the correction of genetic defects in cells ex vivo, e.g., in cells obtained from a subject that are subsequently re-introduced into the same or another subject; and for the introduction of targeted mutations, e.g., the correction of genetic defects or the introduction of deactivating mutations in disease-associated genes in a subject in vivo. Typically, the Cas9 protein of the fusion proteins described herein does not have any nuclease activity but instead is a Cas9 fragment or a dCas9 protein. Methods for the use of Cas9 fusion proteins as described herein are also provided.
[00122] Non-limiting, exemplary nuclease-inactive Cas9 proteins are provided herein.
One exemplary suitable nuclease-inactive Cas9 protein is the D10A/H840A Cas9 protein mutant:
MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRR KNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI LLSDILR TEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKF IKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY YVGPLARGNSRFAWMTRKSEETITPWNFEEWDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELT KVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQS GKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKWDELVKV MGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVD QELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEWKKMKNYWRQLLNAKLITQRKFDNL TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKV REINNYHHAHDAYLNAWGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI TLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQ IVKKTEVQTGGFSKESILPKRNSDKLIARKKD WDPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGELQKGNELALPSKY FLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISE FSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ
siTGLYETRiDLSQLGGD (SEQ ID NO:262; see, e.g., Qi et al, Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;
152(5): 1173-83, the entire contents of which are incorporated herein by reference).
[00123] Additional suitable nuclease-inactive Cas9 proteins will be apparent to those of skill in the art based on this disclosure. Such additional exemplary suitable nuclease- inactive Cas9 proteins include, but are not limited to, D10A, D839A, H840A, N863A, D10A/D839A, D10A/H840A, D10A/N863A, D839A/H840A, D839A/N863A,
D10A/D839A/H840A, and D10A/D839A/H840A/N863A mutant proteins (See, e.g., Prashant et al, CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology . 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference).
Recombinant Cas9 proteins
[00124] Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences provided in SEQ ID NOs: 10-262, wherein the Cas9 protein comprises a RuvC and an HNH domain, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations at an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein.
[00125] In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid at the corresponding position.
[00126] In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, K294R, S409I, E480K, E543D, M694I, or E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the amino acid sequence of the Cas9 protein comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[00127] In some embodiments, the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9. In some embodiments, the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 10-262. In some embodiments, the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9. In some embodiments, the Cas9 protein comprises a D10A and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
Recombinant Cas9 proteins with activity on non-canonical PAMs
[00128] Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits activity (e.g., increased activity) on a target sequence that does not comprise the canonical PAM (5'-NGG-3 ') at its 3 '-end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
[00129] In some embodiments, the Cas9 protein exhibits activity on a target sequence having a 3 '-end that is not directly adjacent to the canonical PAM sequence (5'-NGG-3 ') that is at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 50-fold, at least 100- fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence. In some embodiments, the 3 '-end of the target sequence is directly adjacent to an AGC, GAG, TTT, GTG, or CAA sequence. In some embodiments, the Cas9 protein activity is measured by a nuclease assay, a deamination assay, or a transcriptional activation assay. In some embodiments, the transcriptional activation assay is a reporter activation assay, such as a GFP activation assay. Exemplary methods for measuring binding activity (e.g., of Cas9) using transcriptional activation assays are known in the art and would be apparent to the skilled artisan. For example, methods for measuring Cas9 activity using the tripartite activator VPR have been described in Chavez A., et al., "Highly efficient Cas9- mediated transcriptional programming." Nature Methods 12, 326-328 (2015); the entire contents of which are incorporated by reference herein.
[00130] In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid at the corresponding position.
[00131] In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, K294R, S409I, E480K, E543D, M694I, or E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the amino acid sequence of the Cas9 comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[00132] In some embodiments, the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 2, 4, or 9. In some embodiments, the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises a D10A and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[00133] Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3 '-end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9. In some embodiments, the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9. In some embodiments, the Cas9 protein comprises a D10A and a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[00134] Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3 '-end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9. In some embodiments, the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9. In some embodiments, the Cas9 protein comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 further comprises a histidine residue at position 840 as provided in SEQ ID NO: 9, or a corresponding histidine residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262. Without wishing to be bound by any particular theory, the presence of the catalytic residue H840 allows Cas9 to cleave the non-targeted strand, i.e., the strand bound by the sgRNA. In some embodiments, a Cas9 having an amino acid residue other than histidine at position 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding amino acid sequence provided in SEQ ID NOs: 10-262 may be changed or reverted such that amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding amino acid sequence provided in SEQ ID NOs: 10-262 is histidine.
[00135] Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9; wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, and 1256 of the amino acid sequence provided in SEQ ID NO: 9; wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein; and wherein the recombinant Cas9 protein exhibits activity (e.g., increased activity) on a target sequence that does not comprise the canonical PAM (5'-NGG-3 ') at its 3 '-end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
[00136] In some embodiments, the Cas9 protein exhibits an activity on a target sequence having a 3 '-end that is not directly adjacent to the canonical PAM sequence (5'- NGG-3 ') that is at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence. In some embodiments, the 3 '-end of the target sequence is directly adjacent to an AAA, AAC, AAG, AAT, CAA, CAC, CAG, CAT, GAA, GAC, GAG, GAT, TAA, TAC, TAG, TAT, ACA, ACC, ACG, ACT, CCA, CCC, CCG, CCT, GCA, GCC, GCG, GCT, TCA, TCC, TCG, TCT, AGA, AGC, AGT, CGA, CGC, CGT, GGA, GGC, GGT, TGA, TGC, TGT, ATA, ATC, ATG, ATT, CTA, CTC, CTG, CTT, GTA, GTC, GTG, GTT, TTA, TTC, TTG, or TTT PAM sequence.
[00137] In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X267G, X294R, X405I, X409I, X480K, X543D, X694I, X1219V, X1224K, X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid at the corresponding position.
[00138] In some embodiments, the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, S267G, K294R, F405I, S409I, E480K, E543D, M694I, E1219V, N1224K, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the amino acid sequence of the Cas9 protein comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. [00139] In some embodiments, the amino acid sequence of the Cas9 protein comprises an X480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the amino acid sequence of the Cas9 protein comprises an E480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[00140] In some embodiments, the amino acid sequence of the Cas9 protein comprises an X543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a
corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the amino acid sequence of the Cas9 protein comprises an E543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[00141] In some embodiments, the amino acid sequence of the Cas9 protein comprises the combination of mutations selected from the group consisting of (X480K, X543D, and X1219V); (X262T, X409I, X480K, X543D, X694I, and X1219V); (X294R, X480K, X543D, X1219V, X1256K, and X1362P); (X294R, X480K, X543D, X1219V, and X1256K);
(X267G, X294R, X480K, X543D, X1219V, X1224K, and X1256K); and (X262T, X405I, X409I, X480K, X543D, X694I, and X1219V) of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the amino acid sequence of the Cas9 protein comprises the combination of mutations selected from the group consisting of (E480K, E543D, and E1219V); (A262T, S409I, E480K, E543D, M694I, and E1219V); (K294R, E480K, E543D, E1219V, Q1256K, and L1362P); (K294R, E480K, E543D, E1219V, and Q1256K); (S267G, K294R, E480K, E543DE1219V, N1224K, and Q1256K); and (A262T, F405I, S409I, E480K, E543D, M694I, and E1219V) of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[00142] In some embodiments, the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 2, 4, or 9. In some embodiments, the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9. In some embodiments, the Cas9 protein comprises a D10A and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises a D10A and an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the Cas9 protein comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
[00143] Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits increased activity on a target sequence that does not include the canonical PAM (5'-NGG-3') at its 3 '-end as compared to
Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9. In some embodiments, the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9. In some embodiments, the Cas9 protein comprises a D10A and a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
[00144] Some aspects of this disclosure provide recombinant Cas9 proteins comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of
Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations at an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3 ') at its 3 '-end as compared to
Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9. In some embodiments, the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 2, 4, or 9. In some embodiments, the Cas9 protein comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 further comprises a histidine residue at position 840 as provided in SEQ ID NO: 9, or a
corresponding histidine residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262. Without wishing to be bound by any particular theory, the presence of the catalytic residue H840 allows Cas9 to cleave the non-targeted strand, i.e., the strand bound by the sgRNA. In some embodiments, a Cas9 having an amino acid residue other than histidine at position 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding amino acid sequence provided in SEQ ID NOs: 10-262 may be changed or reverted such that amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding amino acid sequence provided in SEQ ID NOs: 10-262 is histidine.
Cas9 fusion proteins
[00145] Some aspects of this disclosure provide fusion proteins comprising a Cas9 protein as provided herein that is fused to a second protein, or a "fusion partner", such as an effector domain, thus forming a fusion protein. In some embodiments, the effector domain is fused to the N-terminus of the Cas9 protein. In some embodiments, the effector domain is fused to the C-terminus of the Cas9 protein. In some embodiments, the Cas9 protein and the effector domain are fused to each other via a linker. Suitable strategies for generating fusion proteins according to aspects of this disclosure using linkers or without the use of linkers will also be apparent to those of skill in the art in view of the instant disclosure and the knowledge in the art. For example, Gilbert et al, CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013; 154(2):442-51, showed that C-terminal fusions of Cas9 with VP64 using 2 NLS's as a linker (SPKKKRKVEAS, SEQ ID NO: 284), can be employed for transcriptional activation. Mali et al, CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat
Biotechnol. 2013; 31(9):833-8, reported that C-terminal fusions with VP64 without linker can be employed for transcriptional activation. And Maeder et al, CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10: 977-979, reported that C- terminal fusions with VP64 using a Gly4Ser (SEQ ID NO: 5) linker can be used as transcriptional activators. Recently, dCas9- Fokl nuclease fusions have successfully been generated and exhibit improved enzymatic specificity as compared to the parental Cas9 enzyme (In Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to Fokl nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82, and in Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, Goodwin MJ, Aryee MJ, Joung JK. Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome editing. Nat Biotechnol. 2014; 32(6):569-76. PMID: 24770325 a
SGSETPGTSESATPES (SEQ ID NO: 7) or a GGGGS„ (SEQ ID NO: 5) linker was used in FokI-dCas9 fusion proteins, respectively). In some embodiments, the linker comprises a (GGGGS)n (SEQ ID NO: 5), a (G)n, an (EAAAK)n (SEQ ID NO: 6), a (GGS)n, an
SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP)n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30. In some embodiments, the effector domain comprises an enzymatic domain. Suiable effector domains include, without limitation a nuclease, nickase, recombinase, deaminase, methyltransferase, methylase, acetylase, acetyltransferase, transcriptional activator, and transcriptional repressor.
[00146] The linker may be as simple as a covalent bond, or it may be a polymeric linker many atoms in length. In certain embodiments, the linker is a polpeptide or based on amino acids. In other embodiments, the linker is not peptide-like. In certain embodiments, the linker is a covalent bond {e.g., a carbon-carbon bond, disulfide bond, carbon-heteroatom bond, etc.). In certain embodiments, the linker is a carbon-nitrogen bond of an amide linkage. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymeric {e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid. In certain embodiments, the linker comprises an aminoalkanoic acid {e.g., glycine, ethanoic acid, alanine, beta-alanine, 3-aminopropanoic acid, 4-aminobutanoic acid, 5- pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminohexanoic acid (Ahx). In certain embodiments, the linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane). In other embodiments, the linker comprises a polyethylene glycol moiety (PEG). In other embodiments, the linker comprises amino acids. In certain embodiments, the linker comprises a peptide. In certain
embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring. The linker may included funtionalized moieties to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile may be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and isothiocyanates.
[00147] In some embodiments, the effector domain comprises a effector enzyme.
Suitable effector enzymes that may be used in accordance with this disclosure include nucleases, nickases, recombinases, and deaminases. However additional effector enzymes would be apparent to the skilled artisan and are within the scope of this disclosure. In other embodiments, the effector domain comprises a domain that modulates transcriptional activity. Such transcriptional modulating domains may be, without limitation, a transcriptional activator or transcriptional repressor domain.
[00148] In some embodiments, the effector domain is a effector domain. In some embodiments, the effector domain is a deaminase domain. In some embodiments, the deaminase is a cytosine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC 1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an
APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID).
[00149] In some embodiments, the effector domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the deaminase domain of any one of SEQ ID NOs: 263-281.
[00150] In some embodiments, the effector domain is a nuclease domain. In some embodiments, the nuclease domain is a Fokl DNA cleavage domain. In some embodiments, this disclosure provides dimers of the fusion proteins provided herein, e.g., dimers of fusion proteins may include a dimerizing nuclease domain.
[00151] In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%), at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences provided in SEQ ID NOs: 10-262, wherein the Cas9 protein comprises a RuvC and an HNH domain, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein. In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and wherein the recombinant Cas9 protein exhibits activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3 '-end as compared to
Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
[00152] In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%), at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of Cas9 as provided by any of the sequences provided in SEQ ID NOs: 10-262, wherein the Cas9 protein comprises a RuvC and an HNH domain, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein. In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, , comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, and 1256 of the amino acid sequence provided in SEQ ID NO: 9; wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein; and wherein the recombinant Cas9 protein exhibits increased activity on a target sequence that does not include the canonical PAM (5'-NGG-3') at its 3 '-end, as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
[00153] Some aspects of this disclosure provide fusion proteins comprising (i) a nuclease-inactive Cas9 protein; and (ii) a effector domain. In some embodiments, the effector domain is a DNA-editing domain. In some embodiments, the effector domain possesses deaminase activity. In some embodiments, the effector domain comprises or is a deaminase domain. In some embodiments, the deaminase is a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC 1 family deaminase. In some embodiments, the deaminase is an activation-induced cytidine deaminase (AID). Some nucleic-acid editing domains as well as Cas9 fusion proteins including such domains are described in detail herein. Additional suitable effector domains will be apparent to the skilled artisan based on this disclosure. In some embodiments, the nucleid-acid editing domain is a Fokl nuclease domain.
[00154] The instant disclosure provides Cas9:effector domain fusion proteins of various configurations. In some embodiments, the effector domain is fused to the N-terminus of the Cas9 protein. In some embodiments, the effector domain is fused to the C-terminus of the Cas9 protein. In some embodiments, the Cas9 protein and the effector domain are fused via a linker. In some embodiments, the linker comprises (GGGGS)n (SEQ ID NO: 5), (G)n, (EAAAK)n (SEQ ID NO: 6), (GGS)n, orSGSETPGTSESATPES (SEQ ID NO: 7) motif (see, e.g., Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to Fokl nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577- 82; the entire contents are incorporated herein by reference), or an (XP)n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30. In some embodiments, n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, or, if more than one linker or more than one linker motif is present, any combination thereof. Additional suitable linker motifs and linker configurations will be apparent to those of skill in the art. In some embodiments, suitable linker motifs and configurations include those described in Chen et al, Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013; 65(10): 1357- 69, the entire contents of which are incorporated herein by reference. Additional suitable linker sequences will be apparent to those of skill in the art based on the instant disclosure and knowledge in the art.
[00155] In some embodiments, the general architecture of exemplary Cas9 fusion proteins provided herein comprises the structure:
[NH2]-[effector domain]-[Cas9]-[COOH] or
[ H2]-[Cas9]-[effector domain] -[COOH],
wherein H2 is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. Figure 11 provides a schematic representation of a Cas9 protein fused to an effector domain {e.g., rAPOBECl) in complex with sgRNA and bound to the target nucleic acid sequence.
[00156] In some embodiments, any of the fusion proteins provided herein may comprise one or more nuclear localization sequence (NLS). As used herein, a nuclear localization sequence refers to an amino acid sequence that promotes importation of a protein, for example any of the fusion proteins provided herein having an NLS, into the cell nucleus {e.g., via nuclear transport). Typically, an NLS comprises one or more short amino acid sequences of positively charged lysines or arginines exposed on the protein surface. Nuclear localization seuqneces are known in the art and would be apparent to the skilled artisan. For example nuclear localization sequences have been described in Kalderon D., et al, "A short amino acid sequence able to specify nuclear location". Cell (1984) 39 (3 Pt 2): 499-509; Dingwall C, et al, "The nucleoplasmin nuclear location sequence is larger and more complex than that of SV-40 large T antigen". J Cell Biol. (1988) 107 (3): 841-9;
Makkerh LP., et al, "Comparative mutagenesis of nuclear localization signals reveals the importance of neutral and acidic amino acids". Curr Biol. (1996) 6 (8): 1025-7; and Ray M., et al., "Quantitative tracking of protein trafficking to the nucleus using cytosolic protein delivery by nanoparticle-stabilized nanocapsules". Bioconjug. Chem. (2015) 26 (6): 1004-7; the entire contents of each are incorporated by reference herein. Additional nuclear localization sequences are described, for example, in Plank et al, PCT/EP2000/011690, the entire contents are incorporated by reference herein. In some embodiments, a NLS comprises the amino acid sequence PKKKRKV (SEQ ID NO: 299) or
MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 300).
[00157] Exemplary features that may be present are localization sequences, such as nuclear localization sequences, cytoplasmic localization sequences, export sequences, such as nuclear export sequences, or other localization sequences, as well as sequence tags that are useful for solubilization, purification, or detection of the fusion proteins. Suitable
localization signal sequences and sequences of protein tags are provided herein, and include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc-tags, calmodulin- tags, FLAG-tags, hemagglutinin (HA)-tags, polyhistidine tags, also referred to as histidine tags or His-tags, maltose binding protein (MBP)-tags, nus-tags, glutathione-S-transferase (GST)-tags, green fluorescent protein (GFP)-tags, thioredoxin-tags, S-tags, Softags {e.g., Softag 1, Softag 3), strep-tags , biotin ligase tags, FlAsH tags, V5 tags, and SBP-tags.
Additional suitable sequences will be apparent to those of skill in the art and are within the scope ofthis disclosure.
[00158] Any of the nuclear localization sequences provided herein may be fused to the fusion protein in any suitable localization. For example, to promote translocation of the fusion protein into a cell nucleus without compromising function of the fusion protein. In some embodiments, the NLS is fused N-terminal to the Cas9 protein of the fusion protein. In some embodiments, the NLS is fused C-terminal to the Cas9 protein of the fusion protein. In some embodiments, the NLS is fused N-terminal to the effector domain of the fusion protein. In some embodiments, the NLS is fused C-terminal to the effector domain of the fusion protein.
[00159] In some embodiments, the effector domain is a deaminase. For example, in some embodiments, the general architecture of exemplary Cas9 fusion proteins with a deaminase domain comprises the structure:
[NH2]-[NLS]-[Cas9]-[deaminase]-[COOH],
[NH2]-[NLS]-[deaminase]-[Cas9]-[COOH],
[NH2]-[Cas9]-[NLS]-[deaminase]-[COOH],
[NH2]-[deaminase]-[NLS]-[Cas9]-[COOH],
[NH2]-[deaminase]-[Cas9]-[NLS]-[COOH], or [ H2]-[Cas9]-[deaminase]-[ LS]-[COOH],
wherein NLS is a nuclear localization signal, NH2 is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. In some embodiments, a linker is inserted between the Cas9 protein and the deaminase domain. In some embodiments, any of the "]-[" may be one or more linkers. In some embodiments, the NLS is located C-terminal of the deaminase and/or the Cas9 domain. In some embodiments, the NLS is located between the deaminase and the Cas9 domain. Additional features, such as sequence tags, may also be present.
[00160] One exemplary suitable type of effector domain includes cytosine deaminases, for example, of the APOBEC family. The apolipoprotein B mRNA-editing complex
(APOBEC) family of cytosine deaminase enzymes encompasses eleven proteins that serve to initiate mutagenesis in a controlled and beneficial manner.29 One family member, activation- induced cytidine deaminase (AID), is responsible for the maturation of antibodies by converting cytosines in ssDNA to uracils in a transcription-dependent, strand-biased fashion.30 The apolipoprotein B editing complex 3 (APOBEC3) enzyme provides protection to human cells against a certain HIV-1 strain via the deamination of cytosines in reverse- transcribed viral ssDNA.31 These proteins all require a Zn2+-coordinating motif (His-X-Glu- X23-26-Pro-Cys-X2-4-Cys; SEQ ID NO: 283) and bound water molecule for catalytic activity. The Glu residue acts to activate the water molecule to a zinc hydroxide for nucleophilic attack in the deamination reaction. Each family member preferentially deaminates at its own particular "hotspot," ranging from WRC (W is A or T, R is A or G) for hAID, to TTC for hAPOBEC3F.32 A recent crystal structure of the catalytic domain of APOBEC3G revealed a secondary structure comprised of a five-stranded β-sheet core flanked by six a-helices, which is believed to be conserved across the entire family.33 The active center loops have been shown to be responsible for both ssDNA binding and in determining "hotspot" identity.34 Overexpression of these enzymes has been linked to genomic instability and cancer, thus highlighting the importance of sequence-specific targeting.35
[00161] Some aspects of this disclosure provide a systematic series of fusions between Cas9 and deaminase domains, e.g., cytosine deaminase enzymes such as APOBEC enzymes, or adenosine deaminase enzymes such as AD AT enzymes, that has been generated in order to direct the enzymatic activities of these deaminases to a specific site in genomic DNA. The advantages of using Cas9 as the recognition agent are two-fold: (1) the sequence specificity of Cas9 can be easily altered by simply changing the sgRNA sequence; and (2) Cas9 binds to its target sequence by denaturing the dsDNA, resulting in a stretch of DNA that is single- stranded and therefore a viable substrate for the deaminase. It will be understood that other catalytic domains, or catalytic domains from other deaminases, can also be used to generate fusion proteins with Cas9, and that the disclosure is not limited in this regard.
[00162] Some aspects of this disclosure are based on the recognition that
cas9: deaminase fusion proteins can efficiently deaminate nucleotides at positions 3-11 according to the numbering scheme in Figure 11. It should be appreciated that a person of skill in the art will be able to design suitable guide RNAs to target the fusion proteins to a target sequence that comprises a nucleotide to be deaminated. Both PAM-dependent Cas9 proteins or Cas9 proteins that can target PAM-less target sequences as provided herein, can be employed for deamination of a target nucleotide.
[00163] Some exemplary suitable nucleic-acid editing domains, e.g., deaminases and deaminase domains, that can be fused to Cas9 domains according to aspects of this disclosure are provided below. Typically, deaminase require a Zn2+-coordinating motif (His-X-Glu-X23- 26-Pro-Cys-X2-4-Cys; SEQ ID NO: 283) and bound water molecule for catalytic activity. The Glu residue acts to activate the water molecule to a zinc hydroxide for nucleophilic attack in the deamination reaction. It will be understood that, in some embodiments, the active domain of the respective sequence can be used, e.g., the domain without a localizing signal (nuclear localizing signal, without nuclear export signal, cytoplasmic localizing signal).
[00164] Human AID:
MDSLLMNRRKFLYQFKNWWAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNGC HVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTAR LYFCEDRKAEPEGLRRLHRAGVQIAF TFKDYFYCWNTFVENHERTFKAWEGLHEN SVRLSROLRRILLPLYEVDDLRDAFRTLGL (SEQ ID NO: 263)
(underline: nuclear localization signal; double underline: nuclear export signal)
[00165] Mouse AID:
MDSLLMKQKKFLYHFKNVRWAKGRHETYLCYVVKRRDSATSCSLDFGHLRNKSGC HVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVAEFLRWNPNLSLRIFTAR LYFCEDRKAEPEGLRRLHRAGVQIGFMTFKDYFYCWNTFVENRERTFKAWEGLHEN SVRLTROLRRILLPLYEVDDLRDAFRMLGF (SEQ ID NO: 264)
(underline: nuclear localization signal; double underline: nuclear export signal)
[00166] Dog AID: MP SLLMKQRKFLYHFKNVRWAKGRHET YLC YVVKRRD S AT SF SLDFGHLRNKSGC HVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGYPNLSLRIFAAR LYFCEDRKAEPEGLRRLHRAGVQIAF TFKDYFYCWNTFVE REKTFKAWEGLHEN SVRLSROLRRILLPLYEVDDLRDAFRTLGL (SEQ ID NO: 265)
(underline: nuclear localization signal; double underline: nuclear export signal)
[00167] Bovine AID:
MP SLLKKOROFLYOFKNVRWAKGRFIET YLC YVVKRRD SPT SF SLDFGHLRNK AGC HVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGYPNLSLRIFTAR LYFCDKERKAEPEGLRRLHRAGVQIAFMTFKDYFYCWNTFVENHERTFKAWEGLHE NSVRLSROLRRILLPLYEVDDLRDAFRTLGL (SEQ ID NO: 266)
(underline: nuclear localization signal; double underline: nuclear export signal)
[00168] Mouse APOBEC-3 :
MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPV SLHHG KNKD IH^^
ATHHNLSLDIF S SRLYNVQDPETQQNLCRLVQEGAQ VAAMDLYEFKKCWKKFVDN GGRRFRPWKRLLTNFRYQD SKLQEILRPC YIP VP S S S S S TL SNICLTKGLPETRF C VEG RRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGK QHAEILFLDKIRSMELSQ VTITCYL TTFS C WCAWQL AAFKRDRPDLILHIYT SRL YFHW KRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRL RRIKESWGLQDLVNDFGNLQLGPPMS (SEQ ID NO: 267)
(italic: nucleic acid editing domain)
[00169] Rat APOBEC-3 :
MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLRYAIDRKDTFLCYEVTRKDCDSPVS LHHGVFKNKD IH^^
THHNLSLDIF S SRL YNIRDPENQQNLCRL VQEGAQ VAAMDL YEFKKCWKKF VDNGG RRFRPWKKLLTNFRYQD SKLQEILRPC YIP VP S S S S STLSNICLTKGLPETRFC VERRR VHLLSEEEFYSQFYNQRVKHLCYYHGVKPYLCYQLEQFNGQAPLKGCLLSEKGKQH AEILFLDnRSMELSQVIITCYL SPCPNC AW QLAAFKRD ^O JLmYT m^YFi KR PFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLHR
n ESWGLQDLVNDFGNLQLGPPMS (SEQ ID NO: 268)
(italic: nucleic acid editing domain) [00170] Rhesus macaque APOBEC-3G:
MVEPMDPRTFVS FNK PILSGLNTVWLCCEVKTKDPSGPPLDAKIFQGKVYSKAKY
HPEMRFLRWFHKWROLHHDOEYKVTWYVSWSPCTRCANSyAT^ AKmKYT TJFyA
RLYYFWKPDYQQALRILCQKRGGPHATMKIMNYNEFQDCW KFVDGRGKPFKPRN LPKHYTLLQATLGELLRHLMDPGTFTS FN KPWVSGQHETYLCYKVERLHNDT
WVPL^QHKG^LR^QAP^JRGWKGRHAELCFLDLIPFWKLDGQQYRVTCFTSWSPCFS
CAQEMAKFISNNEHVSLCIFAARIYDDQGRYQEGLRALHRDGAKIAMMNYSEFEYC
WDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI (SEQ ID NO: 269)
(italic: nucleic acid editing domain; underline: cytoplasmic localization signal)
[00171] Chimpanzee APOBEC-3G:
MKPHFRNPVERMYQDTFSDNFYNRPILSHRNTVWLCYEVKTKGPSRPPLDAKIFRGQ YYSK KYHPEMPJ^FHWFSKWRKLHmOEYEVT iSWSPCTKCTm)yAT¥ AEmKy TLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKF NYDEFQHCWSKFVYSQRE LFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTSNFNNELWVRGRHETYLCYEVERL HNDTW VLLNQRRGFLCNQ APHKHGFLEGRH^ELC JZ) VIPFWKLDLHQDYR VTCFTS f ^PC ^CAQEMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLAKAGAKISF TYSE FKHCWDTFVDHQGCPFQPWDGLEEHSQALSGRLRAILQNQGN (SEQ ID NO: 270) (italic: nucleic acid editing domain; underline: cytoplasmic localization signal)
[00172] Green monkey APOBEC-3G:
MNPQIRNMVEQMEPDIFVYYFNNRPILSGRNTVWLCYEVKTKDPSGPPLDANIFQGK YFEAKOHPEMKFLHWFRKWROLHRDOEYEVTWYVSWSPCTRCANSYAT^ AEmKy
TLTIFVARLYYFWKPDYQQALRILCQERGGPHATMKFMNYNEFQHCWNEFVDGQG
KPFKPRKNLPKHYTLLHATLGELLRHVMDPGTFTSNFNNKPWVSGQRETYLCYKVE
RSHNDTWVLLNQimGFLRNQAPDRHGFPKGRH^EJC J^^
^fKSPC ^CAQKMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLHRDGAKIAVMNY SEFEYCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI (SEQ ID NO: 271)
(italic: nucleic acid editing domain; underline: cytoplasmic localization signal)
[00173] Human APOBEC-3G:
MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLDAKIFRGO
YYSE KYHPEMPJ^FHWFSKWRKLHmOEYEVTWYISWSPCTKCTRDMATE AEmKy TLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRE LFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNEPWVRGRHETYLCYEVERM IINDTW VLLNQRRGFLCNQ APHKHGFLEGRH^£JC JL> VIPFWKLDLDQDYR VTCFTS ^PC ^CAQEMAKFISK KHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISF TYSE FKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN (SEQ ID NO: 272) (italic: nucleic acid editing domain; underline: cytoplasmic localization signal)
[00174] Human APOBEC-3F:
MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPRLDAKIFRGQ
YYSQmmiAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDCyAKLAEF AE P^yT
TISAARLYYYWERDYRRALCRLSQAGARVKF DDEEFAYCWENFVYSEGQPFMPW
YKFDDNYAFLHRTLKEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVK
IIHSPVSWKRG RNQVDPETHCH^/iRC J^W C/J^
GEVAEFLARHSNVNLTIFTARLYYFWDTDYQEGLRSLSQEGASVEF GYKDFKYCW ENF V YNDDEPFKP WKGLK YNFLFLD SKLQEILE (SEQ ID NO: 273)
(italic: nucleic acid editing domain)
[00175] Human APOBEC-3B:
MNPQIRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLLWDTGVFR
GQYY^K^QYHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDCYAKLAEF SE P^ VTLTISAARLYYYWERDYRRALCRLSQAGARVTFMDYEEFAYCWENFVYNEGQQF MPWYKFDENYAFLHRTLKEILRYLMDPDTFTFNFNNDPLVLRRRQTYLCYEVERLD NGTWVLMDQHMGFLCNEAKNLLCGFYGi^EJi^J^^
C ^f GCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSF TY DEFEYCWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQNQGN (SEQ ID NO: 274) (italic: nucleic acid editing domain)
[00176] Human APOBEC-3C:
MNPQIRNPMKAMYPGTFYFQFKNLWEANDRNETWLCFTVEGIKRRSVVSWKTGVF RNQ VD SETHCHAERCFLSWFCDDILSPNTKYQ VTWYTSWSPCPDCAGEV AEF ARHSN VNLTIF T ARL Y YF Q YPC YQEGLRSL S QEGV A VEF D YEDFK YC WENF V YNDNEPFKP WKGLKTNFRLLKRRLRESLQ (SEQ ID NO: 275)
(italic: nucleic acid editing domain) [00177] Human APOBEC-3A:
MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLH
^QAKWA^CG^YGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAF Q ENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSF TYDEFKHCWDTFVDHQGC PFQPWDGLDEHSQALSGRLRAILQNQGN (SEQ ID NO: 276)
(italic: nucleic acid editing domain)
[00178] Human APOBEC-3H:
MALLTAETFRLQFNNKRRLRRPYYPRKALLCYQLTPQNGSTPTRGWE KKKC/il/i/ CFINEIKSMGLDETQCYQVTCYL SPCSSC AWE VD^JKAHDm^ GJFA RLYYHWC KPQQKGLRLLCGSQVPVEVMGFPKFADCWE FVDHEKPLSF PYKMLEELDKNSRA IKRRLERIKIPGVRAQGRYMDILCDAEV (SEQ ID NO: 277)
(italic: nucleic acid editing domain)
[00179] Human APOBEC-3D:
MNPQIRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLLWDTGVFR
Figure imgf000062_0001
KVTKFLAEHPNVTLTISAARLYYYRDRDWRWVLLRLHKAGARVKIMDYEDFAYCW ENFVCNEGQPFMPWYKFDDNYASLHRTLKEILRNPMEAMYPHIFYFHFKNLLKACG RNESWLCFTMEVTKHHSA RKRGVFRNQVDPEra
EFr^re^C ECAGEVAEFLARHSNVNLTIFTARLCYFWDTDYQEGLCSLSQEGAS VKF GYKDFVSCWKNFVYSDDEPFKPWKGLQTNFRLLKRRLREILQ (SEQ ID NO: 278)
(italic: nucleic acid editing domain) [00180] Human APOBEC-1 :
MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRKIWRSSGKN TTNHVEVNFIKKF T SERDFHP SMS C SITWFL S W SPC WEC S Q AIREFL SRHPGVTL VI Y V ARLFWHMDQQNRQGLRDLVNSGVTIQF RASEYYHCWRNFVNYPPGDEAHWPQY PPLWMMLYALELHCIILSLPPCLKISRRWQNHLTFFRLHLQNCHYQTIPPHILLATGLI HPSVAWR (SEQ ID NO: 279) [00181] Mouse APOBEC-1 :
MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSVWRHTSQN TS HVEVNFLEKFTTERYFRPNTRCSITWFLSWSPCGECSRAITEFLSRHPYVTLFIYIA RLYHHTDQR RQGLRDLISSGVTIQF TEQEYCYCWR FVNYPPS EAYWPRYPHL WVKLYVLELYCIILGLPPCLKILRRKQPQLTFFTITLQTCHYQRIPPHLLWATGLK
(SEQ ID NO: 280)
[00182] Rat APOBEC-1 :
MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT KHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLW VRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK (SEQ ID NO: 281)
[00183] In some embodiments, fusion proteins as provided herein comprise the full- length amino acid of a effector domain, e.g., one of the sequences provided above. In other embodiments, however, fusion proteins as provided herein do not comprise a full-length sequence of a effector domain, but only a fragment thereof. For example, in some embodiments, a fusion protein provided herein comprises a Cas9 protein and a fragment of a effector domain, e.g., wherein the fragment comprises a effector domain. Exemplary amino acid sequences of effector domains are shown in the sequences above as italicized letters, and additional suitable sequences of such domains will be apparent to those of skill in the art.
[00184] Additional suitable nucleic-acid editing domain, e.g., deaminase domain sequences, that can be used according to aspects of this disclosure, e.g., that can be fused to a nuclease-inactive Cas9 protein, will be apparent to those of skill in the art based on this disclosure. In some embodiments, such additional domain sequences include deaminase domain sequences that are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similar to the sequences provided herein. Additional suitable Cas9 proteins, variants, and sequences will also be apparent to those of skill in the art. Examples of such additional suitable Cas9 proteins include, but are not limited to Cas9 proteins with the following mutations: D10A,
D10A/D839A/H840A, and D10A/D839A/H840A/N863A (See, e.g., Prashant et al, CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838 the entire contents of which are incorporated herein by reference).
[00185] Additional suitable strategies for generating fusion proteins comprising a Cas9 protein and an effector domain, such as a DNA-editing domain, will be apparent to those of skill in the art based on this disclosure in combination with the general knowledge in the art. Suitable strategies for generating fusion proteins according to aspects of this disclosure using linkers or without the use of linkers will also be apparent to those of skill in the art in view of the instant disclosure and the knowledge in the art. For example, Gilbert et al, CRISPR- mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;
154(2):442-51, showed that C-terminal fusions of Cas9 with VP64 using 2 NLS's as a linker (SPKKKRKVEAS, SEQ ID NO: 284), can be employed for transcriptional activation. Mali et al, Cas9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9): 833-8, reported that C-terminal fusions with VP64 without linker can be employed for transcriptional activation. And Maeder et al, CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10: 977-979, reported that C-terminal fusions with VP64 using a Gly4Ser (SEQ ID NO: 5) linker can be used as transcriptional activators. Recently, dCas9- Fokl nuclease fusions have successfully been generated and exhibit improved enzymatic specificity as compared to the parental Cas9 enzyme (In Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to Fokl nuclease improves the specificity of genome modification. Nat.
Biotechnol. 2014; 32(6):577-82, and in Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, Goodwin MJ, Aryee MJ, Joung JK. Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome editing. Nat. Biotechnol. 2014; 32(6):569-76. PMTD: 24770325 a SGSETPGTSESATPES (SEQ ID NO: 7) or a GGGGS (SEQ ID NO: 5) linker was used in FokI-dCas9 fusion proteins, respectively).
[00186] In some embodiments, the Cas9 fusion protein comprises: (i) Cas9 protein; and (ii) a transcriptional activator domain. In some embodiments, the transcriptional activator domain comprises a VPR. VPR is a VP64-SV40-P65-RTA tripartite activator. In some embodiments, VPR compises a VP64 amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 292:
GAGGCCAGCGGTTCCGGACGGGCTGACGCATTGGACGATTTTGATCTGGATATGC TGGGAAGTGACGCCCTCGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCT TGATGACTTTGACCTCGACATGCTCGGCAGTGACGCCCTTGATGATTTCGACCTG GACATGCTGATTAACTCTAGATAG (SEQ ID NO: 292) [00187] In some embodiments, VPR comprises a VP64 amino acid sequence as set forth in SEQ ID NO: 293 :
EASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDL DMLINSR (SEQ ID NO: 293)
[00188] In some embodiments, VPR compises a VP64-SV40-P65-RTA amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 294:
TCGCCAGGGATCCGTCGACTTGACGCGTTGATATCAACAAGTTTGTACAAAAAAG
CAGGCTACAAAGAGGCCAGCGGTTCCGGACGGGCTGACGCATTGGACGATTTTG
ATCTGGATATGCTGGGAAGTGACGCCCTCGATGATTTTGACCTTGACATGCTTGG
TTCGGATGCCCTTGATGACTTTGACCTCGACATGCTCGGCAGTGACGCCCTTGAT
GATTTCGACCTGGACATGCTGATTAACTCTAGAAGTTCCGGATCTCCGAAAAAGA
AACGCAAAGTTGGTAGCCAGTACCTGCCCGACACCGACGACCGGCACCGGATCG
AGGAAAAGCGGAAGCGGACCTACGAGACATTCAAGAGCATCATGAAGAAGTCC
CCCTTCAGCGGCCCCACCGACCCTAGACCTCCACCTAGAAGAATCGCCGTGCCCA
GCAGATCCAGCGCCAGCGTGCCAAAACCTGCCCCCCAGCCTTACCCCTTCACCAG
CAGCCTGAGCACCATCAACTACGACGAGTTCCCTACCATGGTGTTCCCCAGCGGC
CAGATCTCTCAGGCCTCTGCTCTGGCTCCAGCCCCTCCTCAGGTGCTGCCTCAGG
CTCCTGCTCCTGCACCAGCTCCAGCCATGGTGTCTGCACTGGCTCAGGCACCAGC
ACCCGTGCCTGTGCTGGCTCCTGGACCTCCACAGGCTGTGGCTCCACCAGCCCCT
AAACCTACACAGGCCGGCGAGGGCACACTGTCTGAAGCTCTGCTGCAGCTGCAG
TTCGACGACGAGGATCTGGGAGCCCTGCTGGGAAACAGCACCGATCCTGCCGTG
TTCACCGACCTGGCCAGCGTGGACAACAGCGAGTTCCAGCAGCTGCTGAACCAG
GGCATCCCTGTGGCCCCTCACACCACCGAGCCCATGCTGATGGAATACCCCGAG
GCCATCACCCGGCTCGTGACAGGCGCTCAGAGGCCTCCTGATCCAGCTCCTGCCC
CTCTGGGAGCACCAGGCCTGCCTAATGGACTGCTGTCTGGCGACGAGGACTTCAG
CTCTATCGCCGATATGGATTTCTCAGCCTTGCTGGGCTCTGGCAGCGGCAGCCGG
GATTCCAGGGAAGGGATGTTTTTGCCGAAGCCTGAGGCCGGCTCCGCTATTAGTG
ACGTGTTTGAGGGCCGCGAGGTGTGCCAGCCAAAACGAATCCGGCCATTTCATCC
TCCAGGAAGTCCATGGGCCAACCGCCCACTCCCCGCCAGCCTCGCACCAACACC
AACCGGTCCAGTACATGAGCCAGTCGGGTCACTGACCCCGGCACCAGTCCCTCA
GCCACTGGATCCAGCGCCCGCAGTGACTCCCGAGGCCAGTCACCTGTTGGAGGA
TCCCGATGAAGAGACGAGCCAGGCTGTCAAAGCCCTTCGGGAGATGGCCGATAC
TGTGATTCCCCAGAAGGAAGAGGCTGCAATCTGTGGCCAAATGGACCTTTCCCAT
CCGCCCCCAAGGGGCCATCTGGATGAGCTGACAACCACACTTGAGTCCATGACC GAGGATCTGAACCTGGACTCACCCCTGACCCCGGAATTGAACGAGATTCTGGAT ACCTTCCTGAACGACGAGTGCCTCTTGCATGCCATGCATATCAGCACAGGACTGT CCATCTTCGACACATCTCTGTTTTGA (SEQ ID NO: 294)
[00189] In some embodiments, VPR comprises a VP64-SV40-P65-RTA amino acid sequence as set forth in SEQ ID NO: 295:
SPGIRRLDALISTSLYKKAGYKEASGSGRADALDDFDLDMLGSDALDDFDLDMLGS DALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEK RKRTYETFKSFMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYD EFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQ AVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQ LLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDF SSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGS PWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQ AVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLT PELNEILDTFLNDECLLHAMHISTGLSIFDTSLF (SEQ ID NO: 295)
[00190] Some aspects of this disclosure provide fusion proteins comprising a transcription activator. In some embodiments, the transcriptional activator is VPR. In some embodiments, the VPR compsises a wild type VPR or a VPR as set forth in SEQ ID NO: 293. In some embodiments, the VPR proteins provided herein include fragments of VPR and proteins homologous to a VPR or a VPR fragment. For example, in some embodiments, a VPR comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 293. In some embodiments, a VPR comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 293 or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO: 293. In some embodiments, proteins comprising VPR or fragments of VPR or homologs of VPR or VPR fragments are referred to as "VPR variants." A VPR variant shares homology to VPR, or a fragment thereof. For example a VPR variant is at least about 70% identical, at least about 80% identical, at least about 90%) identical, at least about 95% identical, at least about 96% identical, at least about 97%) identical, at least about 98%> identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to a wild type VPR or a VPR as set forth in SEQ ID NO: 293. In some embodiments, the VPR variant comprises a fragment of VPR, such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding fragment of wild type VPR or a VPR as set forth in SEQ ID NO: 293. In some embodiments, the VPR comprises the amino acid sequence set forth in SEQ ID NO: 293. In some embodiments, the VPR comprises an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 292.
[00191] In some embodiments, a VPR is a VP64-SV40-P65-RTA triple activator. In some embodiments, the VP64-SV40-P65-RTA comprises a VP64-SV40-P65-RTA as set forth in SEQ ID NO: 295. In some embodiments, the VP64-SV40-P65-RTA proteins provided herein include fragments of VP64-SV40-P65-RTA and proteins homologous to a VP64-SV40-P65-RTA or a VP64-SV40-P65-RTA fragment. For example, in some embodiments, a VP64-SV40-P65-RTA comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 295. In some embodiments, a VP64-SV40-P65-RTA comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 295 or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO: 295. In some embodiments, proteins comprising VP64-SV40-P65-RTA or fragments of VP64-SV40-P65-RTA or homologs of VP64-SV40-P65-RTA or VP64-SV40- P65-RTA fragments are referred to as "VP64-SV40-P65-RTA variants." A VP64-SV40-P65- RTA variant shares homology to VP64-SV40-P65-RTA, or a fragment thereof. For example a VP64-SV40-P65-RTA variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97%) identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to a VP64-SV40-P65-RTA as set forth in SEQ ID NO: 295. In some embodiments, the VP64-SV40-P65-RTA variant comprises a fragment of VP64-SV40-P65-RTA, such that the fragment is at least about 70% identical, at least about 80%) identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding fragment of a VP64-SV40-P65-RTA as set forth in SEQ ID NO: 295. In some embodiments, the VP64-SV40-P65-RTA comprises the amino acid sequence set forth in SEQ ID NO: 295. In some embodiments, the VP64-SV40-P65-RTA comprises an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 294.
[00192] Some aspects of this disclosure provide fusion proteins comprising (i) a Cas9 protein; and (ii) a effector domain. In some aspects, the fusion proteins provided herein further include (iii) a DNA-binding protein, for example, a zinc-finger domain, a TALE, or a second Cas9 protein. Without wishing to be bound by any particular theory, fusing a DNA- binding protein (e.g., a second Cas9 protein) to a fusion protein comprising (i) a protein; and (ii) a effector domain may be useful for improving specificity of the fusion protein to a target nucleic acid sequence, or for improving specificity or binding affinity of the fusion protein to bind a target nucleic acid sequence that does not contain the canonical PAM (5'-NGG-3 ') sequence. In some embodiments, the second Cas9 protein is any of the Cas9 proteins provided herein. In some embodiments, the second Cas9 protein is fused to the fusion protein N-terminal to the Cas9 protein. In some embodiments, the second Cas9 protein is fused to the fusion protein C-terminal to the Cas9 protein. In some embodiments, the Cas9 proteinand the second Cas9 protein are fused via a linker.
[00193] Further provided herein are complexes comprising any of the fusion proteins provided herein, a first guide RNA bound to the Cas9 protein of the fusion protein, and a second guide RNA bound to the second Cas9 protein of the fusion protein. In some embodiments, the first guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a first target sequence and the second guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a second target sequence. In some embodiments, the first guide RNA and/or the second guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long. In some embodiments, the first guide RNA and the second guide RNA are different. In some embodiments, the first guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a first target sequence, and wherein the second guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a second target sequence. In some embodiments, the first target sequence and the second target sequence are different. In some embodiments, the first target sequence and the second target sequence are DNA sequences. In some
embodiments, the first target sequence and the second target sequence are in the genome of a mammal. In some embodiments, the first target sequence and the second target sequence are in the genome of a human. In some embodiments, the first target sequence is within 30 nucleotides of the second target sequence. In some embodiments, the 3' end of the first target sequence is not immediately adjacent to the canonical PAM sequence (5 '-NGG-3 '). In some embodiments, the 3' end of the second target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3 '). [00194] In some embodiments, the general architecture of exemplary Cas9 fusion proteins provided herein is of the structure:
[ H2]-[effector domain]-[Cas9]-[second Cas9 protein]-[COOH];
[ H2]-[second Cas9 protein]-[Cas9]-[effector domain]-[COOH];
[ H2]-[Cas9]-[effector domain]-[second Cas9 protein]-[COOH];
[ H2]-[second Cas9 protein]-[effector or domain] -[Cas9] -[COOH];
[ H2]-[UGI]-[effector domain]-[Cas9]-[second Cas9 protein]-[COOH];
[ H2]-[UGI]-[second Cas9 protein] -[Cas9]- [effector domain]-[COOH];
[ H2]-[UGI]-[Cas9]-[effector domain]-[second Cas9 protein]-[COOH];
[ H2]-[UGI]-[second Cas9 protein] -[effector domain]-[Cas9]-[COOH];
[ H2]-[effector domain]-[Cas9]-[second Cas9 protein]-[UGI]-[COOH];
[ H2]-[second Cas9 protein]-[Cas9]-[effector domain]-[UGI]-[COOH];
[ H2]-[Cas9]-[effector domain]-[second Cas9 protein]-[UGI]-[COOH]; or
[ H2]-[second Cas9 protein]-[effector domain]-[Cas9]-[UGI]-[COOH];
wherein H2 is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. In some embodiments, the "]-[" used in the general architecture above indicates the presence of an optional linker sequence. In other examples, the general architecture of exemplary Cas9 fusion proteins provided herein is of the structure:
[NH2]-[effector domain]-[Cas9]-[second Cas9 protein]-[COOH];
[NH2]-[second Cas9 protein]-[Cas9]-[effector domain]-[COOH];
[NH2]-[Cas9]-[effector domain]-[second Cas9 protein]-[COOH];
[NH2]-[second Cas9 protein]-[effector domain]-[Cas9]-[COOH];
[NH2]-[UGI]-[effector domain]-[Cas9]-[second Cas9 protein]-[COOH],
[NH2]-[UGI]-[second Cas9 protein] -[Cas9]- [effector domain]-[COOH];
[NH2]-[UGI]-[Cas9]-[effector domain]-[second Cas9 protein]-[COOH];
[NH2]-[UGI]-[second Cas9 protein] -[effector domain]-[Cas9]-[COOH];
[NH2]-[effector domain]-[Cas9]-[second Cas9 protein]-[UGI]-[COOH];
[NH2]-[second Cas9 protein]-[Cas9]-[effector domain]-[UGI]-[COOH];
[NH2]-[Cas9]-[effector domain]-[second Cas9 protein]-[UGI]-[COOH]; or
[NH2]-[second Cas9 protein]-[effector domain]-[Cas9]-[UGI]-[COOH];
wherein NH2 is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. In some embodiments, the "-" used in the general architecture above indicates the presence of an optional linker sequence. In some embodiments, the second Cas9 is a dCas9 protein. In some examples, the general architecture of exemplary Cas9 fusion proteins provided herein comprises a structure as shown in Figure 8. It should be appreciated that any of the proteins provided in any of the general architectures of exemplary Cas9 fusion proteins may be connected by one or more of the linkers provided herein. In some embodiments, the linkers are the same. In some embodiments, the linkers are different. In some embodiments, one or more of the proteins provided in any of the general architectures of exemplary Cas9 fusion proteins are not fused via a linker. In some embodiments, the fusion proteins further comprise a nuclear targeting sequence, for example a nuclear localization sequence. In some embodiments, fusion proteins provided herein further comprise a nuclear localization sequence (NLS). In some embodiments, the NLS is fused to the N-terminus of the fusion protein. In some embodiments, the NLS is fused to the C-terminus of the fusion protein. In some embodiments, the NLS is fused to the N-terminus of the second Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of the second Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of the effector domain. In some embodiments, the NLS is fused to the C-terminus of the effector domain. In some embodiments, the NLS is fused to the N- terminus of the UGI protein. In some embodiments, the NLS is fused to the C-terminus of the UGI protein. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusioin protein without a linker.
Uracil glycosylase inhibitor fusion proteins
[00195] Some aspects of this disclosure provide fusion proteins comprising a Cas9 protein fused to a effector domain, e.g., a deaminase, and a uracil glycosylase inhibitor (UGI). In some embodiments, the fusion protein comprises the structure:
[deaminase]-[optional linker sequence]-[Cas9]-[optional linker sequence] -[UGI];
[deaminase]-[optional linker sequence]-[UGI]-[optional linker sequence]-[Cas9];
[UGI]-[optional linker sequence]-[deaminase]-[optional linker sequence]-[Cas9];
[UGI]-[optional linker sequence]-[Cas9]-[optional linker sequence]-[deaminase];
[Cas9]-[optional linker sequence]-[deaminase]-[optional linker sequence]-[UGI]; or
[Cas9]-[optional linker sequence]-[UGI]-[optional linker sequence]-[deaminase]. In some embodiments, the fusion proteins do not comprise a linker sequence. In some embodiments, one or both of the optional linker sequences are present. [00196] In some embodiments, the fusion protein further comprises a second Cas9 protein. For example, the second Cas9 protein may be any of the Cas9 proteins provided herein. In some embodiments, fusion protein comprises the structure:
[deaminase]-[Cas9]-[UGI]; [deaminase]-[UGI]-[Cas9];
[UGI]-[deaminase]-[Cas9];
[UGI]-[Cas9]-[deaminase];
[Cas9]-[deaminase]-[UGI];
[Cas9]-[UGI]-[deaminase];
[second Cas9]-[deaminase]-[Cas9]-[UGI];
[second Cas9]-[deaminase]-[UGI]-[Cas9];
[second Cas9]-[UGI]-[deaminase]-[Cas9];
[second Cas9]-[UGI]-[Cas9]-[deaminase];
[second Cas9]-[Cas9]-[deaminase]-[UGI];
[second Cas9]-[Cas9]-[UGI]-[deaminase];
[deaminase]-[second Cas9]-[Cas9]-[UGI];
[deaminase]-[second Cas9]-[UGI]-[Cas9];
[UGI]-[second Cas9]-[deaminase]-[Cas9];
[UGI]-[second Cas9]-[Cas9]-[deaminase];
[Cas9]-[second Cas9]-[deaminase]-[UGI];
[Cas9]-[second Cas9]-[UGI]-[deaminase]
[deaminase]-[Cas9]-[second Cas9]-[UGI];
[deaminase]-[UGI]-[second Cas9]-[Cas9];
[UGI]-[deaminase]-[second Cas9]-[Cas9];
[UGI]-[Cas9]-[second Cas9]-[deaminase];
[Cas9]-[deaminase]-[second Cas9]-[UGI];
[Cas9]-[UGI]-[second Cas9]-[deaminase];
[deaminase]-[Cas9]-[UGI]-[second Cas9];
[deaminase]-[UGI]-[Cas9]-[second Cas9];
[UGI]-[deaminase]-[Cas9]-[second Cas9];
[UGI]-[Cas9]-[deaminase]-[second Cas9];
[Cas9]-[deaminase]-[UGI]-[second Cas9]; or
[Cas9]-[UGI]-[deaminase]-[second Cas9].
In some embodiments, the "-" used in the general architecture above indicates the presence of an optional linker sequence. In some embodiments, the fusion proteins comprising a UGI further comprise a nuclear targeting sequence, for example a nuclear localization sequence. In some embodiments, fusion proteins provided herein further comprise a nuclear localization sequence (NLS). In some embodiments, the NLS is fused to the N-terminus of the fusion protein. In some embodiments, the NLS is fused to the C-terminus of the fusion protein. In some embodiments, the NLS is fused to the N-terminus of the UGI protein. In some embodiments, the NLS is fused to the C-terminus of the UGI protein. In some embodiments, the NLS is fused to the N-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of the deaminase. In some embodiments, the NLS is fused to the C-terminus of the deaminase. In some embodiments, the NLS is fused to the N-terminus of the second Cas9. In some embodiments, the NLS is fused to the C-terminus of the second Cas9. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusioin protein without a linker.
[00197] In some embodiments, the UGI comprises a wild type UGI or a UGI as set forth in SEQ ID NO: 553. In some embodiments, the UGI proteins provided herein include fragments of UGI and proteins homologous to a UGI or a UGI fragment. For example, in some embodiments, a UGI comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 553. In some embodiments, a UGI comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 553 or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO: 553. In some embodiments, proteins comprising UGI or fragments of UGI or homologs of UGI or UGI fragments are referred to as "UGI variants." A UGI variant shares homology to UGI, or a fragment thereof. For example a UGI variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to a wild type UGI or a UGI as set forth in SEQ ID NO: 553. In some embodiments, the UGI variant comprises a fragment of UGI, such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding fragment of wild type UGI or a UGI as set forth in SEQ ID NO: 553. In some embodiments, the UGI comprises the following amino acid sequence: >sp|P14739|UNGI_BPPB2 Uracil-DNA glycosylase inhibitor
MT LSDIIEKETGKQLVIQESILMLPEEVEEVIG KPESDILVHTAYDESTDENVMLLT SD APEYKP W AL VIQD SNGE KIKML (SEQ ID NO: 553)
[00198] Suitable UGI protein and nucleotide sequences are provided herein and additional suitable UGI sequences are known to those in the art, and include, for example, those published in Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J. Biol. Chem.
264: 1163-1171(1989); Lundquist et al., Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J. Biol. Chem. 272:21408- 21419(1997); Ravishankar et al., X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nucleic Acids Res. 26:4880-4887(1998); and Putnam et al., Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J. Mol. Biol. 287:331-346(1999), the entire contents of each are incorporated herein by reference.
[00199] It should be appreciated that additional proteins may be uracil glycosylase inhibitors. For example, other proteins that are capable of inhibiting (e.g., sterically blocking) a uracil-DNA glycosylase base-excision repair enzyme are within the scope of this disclosure. In some embodiments, a uracil glycosylase inhibitor is a protein that binds DNA. In some embodiments, a uracil glycosylase inhibitor is a protein that binds single-stranded DNA. For example, a uracil glycosylase inhibitor may be a Erwinia tasmaniensis single- stranded binding protein. In some embodiments, the single-stranded binding protein comprises the amino acid sequence (SEQ ID NO: 303). In some embodiments, a uracil glycosylase inhibitor is a protein that binds uracil. In some embodiments, a uracil glycosylase inhibitor is a protein that binds uracil in DNA. In some embodiments, a uracil glycosylase inhibitor is a catalytically inactive uracil DNA-glycosylase protein. In some embodiments, a uracil glycosylase inhibitor is a catalytically inactive uracil DNA-glycosylase protein that does not excise uracil from the DNA. For example, a uracil glycosylase inhibitor is a UdgX. In some embodiments, the UdgX comprises the amino acid sequence (SEQ ID NO: 304). As another example, a uracil glycosylase inhibitor is a catalytically inactive UDG. In some embodiments, a catalytically inactive UDG comprises the amino acid sequence (SEQ ID NO: 305). It should be appreciated that other uracil glycosylase inhibitors would be apparent to the skilled artisan and are within the scope of this disclosure. Erwinia tasmaniensis SSB (themostable single-stranded DNA binding protein) MASRGVNKVILVGNLGQDPEVRYMPNGGAVANITLATSESWRDKQTGETKEKTEW HRVVLFGKLAEVAGEYLRKGSQVYIEGALQTRKWTDQAGVEKYTTEVVVNVGGT MQMLGGRSQGGGASAGGQNGGSNNGWGQPQQPQGGNQFSGGAQQQARPQQQPQ QNNAPANNEPPIDFDDDIP (SEQ ID NO: 303)
UdgX (binds to Uracil in DNA but does not excise)
MAGAQDFVPHTADLAELAAAAGECRGCGLYRDATQAVFGAGGRSARF MIGEQPG DKEDLAGLPFVGPAGRLLDRALEAADIDRDALYVTNAVKHFKFTRAAGGKRRIHKT P SRTEVVACRPWLIAEMT S VEPD VVVLLGAT AAK ALLGNDFRVTQFIRGEVLHVDD V PGDPALVATVHPSSLLRGPKEERESAFAGLVDDLRVAADVRP (SEQ ID NO: 304)
UDG (catalytically inactive human UDG, binds to Uracil in DNA but does not excise)
MIGQKTL YSFF SP SP ARKRHAP SPEP AVQGTGVAGVPEESGD AA AIP AKK AP AGQEE
PGTPPSSPLSAEQLDRIQRNKAAALLRLAARNVPVGFGESWKKHLSGEFGKPYFIKL
MGFVAEERKHYTVYPPPHQVFTWTQMCDIKDVKVVILGQEPYHGPNQAHGLCFSV
QRPVPPPPSLENIYKELSTDIEDFVHPGHGDLSGWAKQGVLLLNAVLTVRAHQANSH
KERGWEQFTDAVVSWLNQNSNGLVFLLWGSYAQKKGSAIDRKRHHVLQTAHPSPL
SVYRGFFGCRHFSKTNELLQKSGKKPIDWKEL (SEQ ID NO: 305)
High Fidelity Cas9
[00200] Some aspects of the disclosure provide high fidelity Cas9 proteins. In some embodiments, high fidelity Cas9 proteins have decreased electrostatic interactions between the Cas9 protein and a sugar-phosphate backbone of a DNA, as compared to a wild-type Cas9 domain. In some embodiments, any of the Cas9 proteins provided herein comprise one or more mutations that decrease the association between the Cas9 protein and a sugar-phosphate backbone of a DNA. In some embodiments, any of the Cas9 proteins provided herein comprise one or more mutations that decrease the association between the Cas9 protein and a sugar-phosphate backbone of a DNA by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%. In some embodiments, any of the Cas9 proteins provided herein comprise one or more of a N497X, a R661X, a Q695X, and/or a Q926X mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid. In some embodiments, any of the Cas9 proteins provided herein comprise one or more of a N497A, a R661 A, a Q695A, and/or a Q926A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the Cas9 protein comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262. In some embodiments, the Cas9 protein comprises the amino acid sequence as set forth in SEQ ID NO: 306. High fidelity Cas9 proteins have been described in the art and would be apparent to the skilled artisan. For example, high fidelity Cas9 proteins have been described in Kleinstiver, B.P., et al. "High-fidelity CRISPR-Cas9 nucleases with no detectable genome- wide off-target effects." Nature 529, 490-495 (2016); and Slaymaker, I.M., et al. "Rationally engineered Cas9 nucleases with improved specificity." Science 351, 84-88 (2015); the entire contents of each are incorporated herein by reference. It should be appreciated that, based on the present disclosure and knowledge in the art, that mutations in any Cas9 protein may be generated to make high fidelity Cas9 proteins that have decreased electrostatic interactions between the Cas9 protein and a sugar-phosphate backbone of a DNA, as compared to a wild- type Cas9 domain.
Cas9 domain where mutations relative to Cas9 of SEQ ID NO: 9 are shown in bold and underlines.
MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGE T AE ATRLi¾T ARRR YTRRKNRIC YLQEIF SNEMAK VDD SFFHRLEE SFL VEEDKKHE RHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEG DLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLP GEKKNGLF GNLI AL SLGLTPNFK SNFDL AED AKLQL SKDT YDDDLDNLL AQIGDQ Y A DLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQR TFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFA WMTRKSEETITPWNFEEVVDKGASAQSFIERMTAFDKNLPNEKVLPKHSLLYEYFTV YNELTKVK Y VTEGMRKP AFL S GEQKK AIVDLLFKTNRK VT VKQLKED YFKKIECFD SVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL KTYAHLFDDKVMKQLKRRRYTGWGALSRKLINGIRDKQSGKTILDFLKSDGFANRN FMALIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL
Q EKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSID KVLTRSDK RGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD LTKAERGGLSELDKAGFIK
RQLVETRAITKHVAQILDSRMNTKYDE DKLIREVKVITLKSKLVSDFRKDFQFYKV
REF NYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
ATAKYFFYSNF NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM
PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV
AKVEKGKSKKLKSVKELLGITF ERSSFEK PIDFLEAKGYKEVKKDLIIKLPKYSLFE
LENGRKRMLASAGELQKG ELALPSKYVNFLYLASHYEKLKGSPED EQKQLFVEQ
HKHYLDEIIEQISEFSKRVILADA LDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA
P A AFK YFDTTIDRKRYT S TKE VLD ATLIHQ S ITGL YETRIDL S QLGGD (SEQ ID NO:
306)
Cas9 Proteins with Reduced PAM Exclusivity
[00201] Some aspects of the disclosure provide Cas9 proteins that have different PAM specificities. Typically, Cas9 proteins, such as Cas9 from S. pyogenes (spCas9), require a canonical NGG PAM sequence to bind a particular nucleic acid region. This may limit the ability to of the Cas9 protein to bind to a particular nucleotide sequence within a genome. Accordingly, in some embodiments, any of the Cas proteins provided herein may be capable of binding a nucleotide sequence that does not contain a canonical (e.g., NGG) PAM sequence. For example, Cas9 proteins that bind non-canonical PAM sequences have been described in Kleinstiver, B. P., et al., "Engineered CRISPR-Cas9 nucleases with altered PAM specificities" Nature 523, 481-485 (2015); and Kleinstiver, B. P., et al., "Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition" Nature Biotechnology 33, 1293-1298 (2015); the entire contents of each are hereby incorporated by reference.
[00202] In some embodiments, the Cas9 protein is a Cas9 protein from Staphylococcus aureus (SaCas9). In some embodiments, the SaCas9 protein is a nuclease active SaCas9, a nuclease inactive SaCas9 (SaCas9d), or a SaCas9 nickase (SaCas9n). In some embodiments, the SaCas9 comprises the amino acid sequence SEQ ID NO: 307. In some embodiments, the SaCas9 comprises a N579X mutation of SEQ ID NO: 307, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 9-262, wherein X is any amino acid except for N. In some embodiments, the SaCas9 comprises a N579A mutation of SEQ ID NO: 307, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the SaCas9 protein, the SaCas9d protein, or the SaCas9n protein can bind to a nucleic acid seuqnce having a non-canonical PAM. In some embodiments, the SaCas9 protein, the SaCas9d protein, or the SaCas9n protein can bind to a nucleic acid sequence having a NNGRRT PAM sequence. In some embodiments, the SaCas9 protein comprises one or more of a E781X, N967X, or R1014X mutation of SEQ ID NO: 307, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid. In some embodiments, the SaCas9 protein comprises one or more of a E781K, N967K, or R1014H mutation of SEQ ID NO: 307, or one or more corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the SaCas9 protein comprises a E781K, a N967K, and a R1014H mutation of SEQ ID NO: 307, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262. It should be appreciated that these mutations may be combined with any of the other mutations provided herein
[00203] In some embodiments, the Cas9 protein of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 307-309. In some embodiments, the Cas9 protein of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 307-309. In some embodiments, the Cas9 protein of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 307-309.
Exemplary SaCas9 sequence
KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRR RRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRG VHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSF RFKTS DYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWY EMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENV FKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAE LLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDEL WHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKK YGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKL HDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKK GNRTPFQ YLS S SD SKIS YETFKKHILNLAKGKGRISKTKKE YLLEERDINRF S VQKDFI RNLVDTRYATRGLMNLLRSYFRVN LDVKVKSINGGFTSFLRRKWKFKKERNKG
YKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIF
ITPHQIKHIKDFKDYKYSHRVDKKP RELINDTLYSTRKDDKGNTLIVNNLNGLYDK
D DKLKKLINKSPEKLLMYHHDPQTYQKLKLF EQYGDEK PLYKYYEETGNYLTK
YSKKDNGPVIKKIKYYG KLNAHLDITDDYPNSR KVVKLSLKPYRFDVYLDNGVY
KFVTVKNLDVn KENYYEVNSKCYEEAKKLKKISNQAEFIASFYN DLIKINGELYRV
IGVN DLLl^ffiVNMroiTYREYLE MNDKRPPRIIKTIASKTQSIKKYSTDILG LYE
VKSKKHPQIIKKG (SEQ ID NO: 307)
Residue N579 of SEQ ID NO: 307, which is underlined and in bold, may be mutated (e.g., to a A579) to yield a SaCas9 nickase.
Exemplary SaCas9n sequence
KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRR
RRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRG
VHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSF RFKTS
DYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWY
EMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENV
FKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAE
LLDQIAKILTIYQ S SEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNL SLK AINLILDEL
WHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKK
YGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKL
HDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEEASKK
GNRTPFQ YLS S SD SKIS YETFKKHILNLAKGKGRISKTKKE YLLEERDINRF S VQKDFI
NRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKG
YKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIF
ITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYDK
DNDKLKKLINKSPEKLLMYHHDPQTYQKLKLFMEQYGDEKNPLYKYYEETGNYLTK
YSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVY
KFVTVKNLDVn KENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRV
IGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYE
VKSKKHPQIIKKG (SEQ ID NO: 308).
Residue A579 of SEQ ID NO: 308, which can be mutated from N579 of SEQ ID NO: 307 to yield a SaCas9 nickase, is underlined and in bold. Exemplary SaKKH Cas9
KRNYILGLDIGITSVGYGiroYETRDVroAGVRLFKEANVEN EGRRSKRGARRLKRR
RRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRG
VHNVNEVEEDTG ELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSF RFKTS
DYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWY
EMLMGHCTYFPEELRSVKYAYNADLYNAL DLNNLVITRDE EKLEYYEKFQIIENV
FKQKKKPTLKQIAKEILV EEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAE
LLDQIAKILTIYQ S SEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNL SLK AINLILDEL
WHTNDNQIAIF RLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKK
YGLP DIIIELAREKNSKDAQKMINEMQKR RQT ERIEEIIRTTGKENAKYLIEKIKL
HDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEEASKK
G RTPFQ YLS S SD SKIS YETFKKHILNLAKGKGRISKTKKE YLLEERDINRF S VQKDFI RNLVDTRYATRGLMNLLRSYFRVN LDVKVKSINGGFTSFLRRKWKFKKER KG
YKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIF
ITPHQIKHIKDFKDYKYSHRVDKKP R LINDTLYSTRKDDKGNTLIVNNLNGLYDK
D DKLKKLINKSPEKLLMYHHDPQTYQKLKLF EQYGDEK PLYKYYEETGNYLTK
YSKKDNGPVIKKIKYYG KLNAHLDITDDYPNSR KVVKLSLKPYRFDVYLDNGVY
KFVTVKNLDVn KENYYEVNSKCYEEAKKLKKISNQAEFIASFY DLIKINGELYRV
IGVNNDLLNRIEVNMIDITYREYLENMNDKRPPZ/IIKTIASKTQSIKKYSTDILGNLYE
VKSKKHPQIIKKG (SEQ ID NO: 309).
Residue A579 of SEQ ID NO: 309, which can be mutated from N579 of SEQ ID NO: 307 to yield a SaCas9 nickase, is underlined and in bold. Residues K781, K967, and H1014 of SEQ ID NO: 309, which can be mutated from E781, N967, and R1014 of SEQ ID NO: 307 to yield a SaKKH Cas9 are underlined and in italics.
[00204] In some embodiments, the Cas9 protein is a Cas9 protein from Streptococcus pyogenes (SpCas9). In some embodiments, the SpCas9 protein is a nuclease active SpCas9, a nuclease inactive SpCas9 (SpCas9d), or a SpCas9 nickase (SpCas9n). In some embodiments, the SpCas9 comprises the amino acid sequence SEQ ID NO: 9. In some embodiments, the SpCas9 comprises a D10X mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid except for D. In some embodiments, the SpCas9 comprises a D10A mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the SpCas9 protein, the SpCas9d protein, or the SpCas9n protein can bind to a nucleic acid seuqnce having a non-canonical PAM. In some embodiments, the SpCas9 protein, the SpCas9d protein, or the SpCas9n protein can bind to a nucleic acid sequence having a NGG, a NGA, or a NGCG PAM sequence. In some embodiments, the SpCas9 protein comprises one or more of a Dl 135X, R1335X, and
T1337X mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid. In some embodiments, the SpCas9 protein comprises one or more of a Dl 135E, R1335Q, and T1337R mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the SpCas9 protein comprises a Dl 135E, a R1335Q, and a T1335R mutation of SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the SpCas9 protein comprises one or more of a Dl 135X, R1335X, and T1337X mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid. In some embodiments, the SpCas9 protein comprises one or more of a Dl 135V, R1335Q, and T1337R mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the SpCas9 protein comprises a Dl 135V, a R1335Q, and a T1337R mutation of SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the SpCas9 protein comprises one or more of a D1135X, G1218X, R1335X, and T1337X mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X is any amino acid. In some embodiments, the SpCas9 protein comprises one or more of a D1135V, G1218R, R1335Q, and T1337R mutation of SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262. In some embodiments, the SpCas9 protein comprises a Dl 135V, a G1218R, a R1335Q, and a T1337R mutation of SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262. It should be appreciated that these mutations may be combined with any of the other mutations provided herein
[00205] In some embodiments, the Cas9 protein of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 9, 310-313. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 9, 310-313. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 9, 310-313.
Exemplary SpCas9
MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGE
T AE ATRLKRT ARRR YTRRK RIC YLQEIF S EMAK VDD SFFHRLEE SFL VEEDKKHE
RHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEG
DLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLP
GEKKNGLFG LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD LLAQIGDQYA
DLFLAAK LSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE
KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKL REDLLRKQR
TFDNGSIPHQIHLGELHAILRRQEDFYPFLKD REKIEKILTFRIPYYVGPLARGNSRFA
WMTRKSEETITPW FEEVVDKGASAQSFIERMT FDKNLP EKVLPKHSLLYEYFTV
YNELTKVK Y VTEGMRKP AFL S GEQKK AIVDLLFKT RK VT VKQLKED YFKKIECFD
SVEISGVEDRFNASLGTYHDLLKIIKDKDFLD EE EDILEDIVLTLTLFEDREMIEERL
KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFA RN
FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK
VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL
Q EKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSID KVLTRSDK RGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD LTKAERGGLSELDKAGFIK
RQLVETRQITKHVAQILDSRMNTKYDE DKLIREVKVITLKSKLVSDFRKDFQFYKV
REr NYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
ATAKYFFYSNF NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM
PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV
AKVEKGKSKKLKSVKELLGITF ERSSFEK PIDFLEAKGYKEVKKDLIIKLPKYSLFE
LENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ
HKHYLDEIIEQISEFSKRVILADA LDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA
P A AFK YFDTTIDRKRYT S TKE VLD ATLIHQ S ITGL YETRIDL S QLGGD (SEQ ID NO: 9)
Exemplary SpCas9n
DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA E ATRLKRT ARRR YTRRKNRIC YLQEIF SNEMAK VDD SFFHRLEESFL VEEDKKHERH PIFGNIVDEVAYHEKYPTrYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDL NPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGE KKNGLFGNLIALSLGLTP FKS FDLAEDAKLQLSKDTYDDDLD LLAQIGDQYADL
FLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKY
KEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKL REDLLRKQRTF
DNGSIPHQIHLGELHAILRRQEDFYPFLKD REKIEKILTFRIPYYVGPLARGNSRFAW
MTRKSEETITPW FEEVVDKGASAQSFIERMT FDK LP EKVLPKHSLLYEYFTVY ELTK VK Y VTEGMRKP AFL S GEQKK AIVDLLFKTNRK VT VKQLKED YFKKIECFD S
VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL
KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFA RN
FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK
VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL
Q EKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSID KVLTRSDK RGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD LTKAERGGLSELDKAGFIK
RQLVETRQITKHVAQILDSRMNTKYDE DKLIREVKVITLKSKLVSDFRKDFQFYKV
REF NYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
ATAKYFFYSNF NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM
PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV
AKVEKGKSKKLKSVKELLGITF ERSSFEK PIDFLEAKGYKEVKKDLIIKLPKYSLFE
LENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ
HKHYLDEIIEQISEFSKRVILADA LDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA
P A AFK YFDTTIDRKRYT S TKE VLD ATLIHQ S ITGL YETRIDL S QLGGD (SEQ ID NO:
310)
Exemplary SpEQR Cas9
DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA E ATRLKRT ARRRYTRRKNRIC YLQEIF SNEMAKVDD SFFHRLEESFL VEEDKKHERH PIFGNIVDEVAYHEKYPTrYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDL NPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGE KKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADL FLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKY KEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVY NELTK VKY VTEGMRKP AFL S GEQKK AIVDLLFKTNRK VT VKQLKED YFKKIECFD S VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFA RN
FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK
VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL
Q EKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSID KVLTRSDK RGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD LTKAERGGLSELDKAGFIK
RQLVETRQITKHVAQILDSRMNTKYDE DKLIREVKVITLKSKLVSDFRKDFQFYKV
REF NYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
ATAKYFFYSNF NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM
PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFESPTVAYSVLVV
AKVEKGKSKKLKSVKELLGITF ERSSFEK PIDFLEAKGYKEVKKDLIIKLPKYSLFE
LENGRKRMLASAGELQKG ELALPSKYVNFLYLASHYEKLKGSPED EQKQLFVEQ
HKHYLDEIIEQISEFSKRVILADA LDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA
PAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO:
311)
Residues El 134, Q1334, and R1336 of SEQ ID NO: 311, which can be mutated from Dl 134, R1334, and T1336 of SEQ ID NO: 9 to yield a SpEQR Cas9, are underlined and in bold.
Exemplary SpVQR Cas9
DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSn KNLIGALLFDSGETA E ATRLKRT ARRRYTRRKNRIC YLQEIF SNEMAKVDD SFFHRLEESFL VEEDKKHERH PIFGNIVDEVAYHEKYPTrYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDL NPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGE KKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADL FLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKY KEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVY NELTK VK Y VTEGMRKP AFL S GEQKK AIVDLLFKTNRK VT VKQLKED YFKKIECFD S VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDK NRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIK RQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKV
REF NYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
ATAKYFFYSNF NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM
PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVV
AKVEKGKSKKLKSVKELLGITF ERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFE
LENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ
HKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA
PAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO:
312)
Residues VI 134, Q1334, and R1336 of SEQ ID NO: 312, which can be mutated from Dl 134, R1334, and T1336 of SEQ ID NO: 9 to yield a SpVQR Cas9, are underlined and in bold.
Exemplary SpVRER Cas9
DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSn KNLIGALLFDSGETA E ATRLKRT ARRRYTRRKNRIC YLQEIF SNEMAK VDD SFFHRLEESFL VEEDKKHERH PIFGNIVDEVAYHEKYPTrYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDL NPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGE KKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADL FLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKY KEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVY NELTK VK Y VTEGMRKP AFL S GEQKK AI VDLLFKTNRK VT VKQLKED YFKKIECFD S VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDK NRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIK RQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKV REF NYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK ATAKYFFYSNFMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVV AKVEKGKSKKLKSVKELLGITFMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFE LENGRKRMLASARELQKG ELALPSKYVNFLYLASHYEKLKGSPED EQKQLFVEQ HKHYLDEIIEQISEFSKRVILADA LDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKEYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO: 313)
[00206] Residues VI 134, R1217, Q1334, and R1336 of SEQ ID NO: 313, which can be mutated from Dl 134, G1217, R1334, and T1336 of SEQ ID NO: 9 to yield a SpVRER Cas9, are underlined and in bold.
Cas9 complexes with guide RNAs
[00207] Some aspects of this disclosure provide complexes comprising a Cas9 protein or a Cas9 fusion protein as provided herein, and a guide RNA bound to the Cas9 protein or the Cas9 fusion protein. In some embodiments, the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence. In some embodiments, the guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long. In some embodiments, the guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a target sequence. In some
embodiments, the target sequence is a DNA sequence. In some embodiments, the target sequence is a sequence in the genome of a mammal. In some embodiments, the target sequence is a sequence in the genome of a human. In some embodiments, the 3' end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3').
[00208] Some aspects of the disclosure provide complexes comprising a first guide RNA bound to a Cas9 protein of a fusion protein, and a second guide RNA bound to a second Cas9 protein of the fusion protein. In some embodiments, the first guide RNA is about 15- 100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a first target sequence and the second guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a second target sequence. In some embodiments, the first guide RNA and/or the second guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long. In some embodiments, the first guide RNA and the second guide RNA are different. In some embodiments, the first guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a first target sequence and wherein the second guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a second target sequence.
[00209] In some embodiments, first target sequence and the second target sequence are different. In some embodiments, the first target sequence and the second target sequence are DNA sequences. In some embodiments, the first target sequence and the second target sequence are in the genome of a mammal. In some embodiments, the first target sequence and the second target sequence are in the genome of a human. In some embodiments, the first target sequence is within at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, or 200 nucleotides of the second target sequence. In some embodiments, the 3 '-end of the first target sequence is not immediately adjacent to the canonical PAM sequence (5'- NGG-3 '). In some embodiments, the 3'-end of the second target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3 ').
Methods of using Cas9 fusion proteins
[00210] Some aspects of this disclosure provide methods of using the Cas9 proteins, fusion proteins, or complexes provided herein. For example, some aspects of this disclosure provide methods comprising contacting a DNA molecule (a) with any of the the Cas9 proteins or fusion proteins provided herein, and with at least one guide RNA, wherein the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence; or (b) with a Cas9 protein, a Cas9 fusion protein, or a Cas9 protein or fusion protein complex with at least one gRNA as provided herein. In some embodiments, the 3' end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3 '). In some embodiments, the 3' end of the target sequence is immediately adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
[00211] In some embodiments, the target DNA sequence comprises a sequence associated with a disease or disorder. In some embodiments, the target DNA sequence comprises a point mutation associated with a disease or disorder. In some embodiments, the activity of the Cas9 protein, the Cas9 fusion protein, or the complex results in a correction of the point mutation. In some embodiments, the target DNA sequence comprises a T→C point mutation associated with a disease or disorder, and wherein the deamination of the mutant C base results in a sequence that is not associated with a disease or disorder. In some
embodiments, the target DNA sequence encodes a protein and wherein the point mutation is in a codon and results in a change in the amino acid encoded by the mutant codon as compared to the wild-type codon. In some embodiments, the deamination of the mutant C results in a change of the amino acid encoded by the mutant codon. In some embodiments, the deamination of the mutant C results in the codon encoding the wild-type amino acid. In some embodiments, the contacting is in vivo in a subject. In some embodiments, the subject has or has been diagnosed with a disease or disorder. In some embodiments, the disease or disorder is cystic fibrosis, phenylketonuria, epidermolytic hyperkeratosis (EHK), Charcot- Marie-Toot disease type 4J, neuroblastoma (NB), von Willebrand disease (vWD), myotonia congenital, hereditary renal amyloidosis, dilated cardiomyopathy (DCM), hereditary lymphedema, familial Alzheimer's disease, HIV, Prion disease, chronic infantile neurologic cutaneous articular syndrome (CINCA), desmin-related myopathy (DRM), a neoplastic disease associated with a mutant PI3KCA protein, a mutant CTNNB1 protein, a mutant HRAS protein, or a mutant p53 protein.
[00212] Some embodiments provide methods for using the Cas9 DNA editing fusion proteins provided herein. In some embodiments, the fusion protein is used to introduce a point mutation into a nucleic acid by deaminating a target nucleobase, e.g., a C residue. In some embodiments, the deamination of the target nucleobase results in the correction of a genetic defect, e.g., in the correction of a point mutation that leads to a loss of function in a gene product. In some embodiments, the genetic defect is associated with a disease or disorder, e.g., a lysosomal storage disorder or a metabolic disease, such as, for example, type I diabetes. In some embodiments, the methods provided herein are used to introduce a deactivating point mutation into a gene or allele that encodes a gene product that is associated with a disease or disorder. For example, in some embodiments, methods are provided herein that employ a Cas9 DNA editing fusion protein to introduce a deactivating point mutation into an oncogene {e.g., in the treatment of a proliferative disease). A deactivating mutation may, in some embodiments, generate a premature stop codon in a coding sequence, which results in the expression of a truncated gene product, e.g., a truncated protein lacking the function of the full-length protein.
[00213] In some embodiments, the purpose of the methods provide herein is to restore the function of a dysfunctional gene via genome editing. The Cas9 deaminase fusion proteins provided herein can be validated for gene editing-based human therapeutics in vitro, e.g., by correcting a disease-associated mutation in human cell culture. It will be understood by the skilled artisan that the fusion proteins provided herein, e.g., the fusion proteins comprising a Cas9 domain and a nucleic acid deaminase domain can be used to correct any single point T -> C or A -> G mutation. In the first case, deamination of the mutant C back to U corrects the mutation, and in the latter case, deamination of the C that is base-paired with the mutant G, followed by a round of replication, corrects the mutation.
[00214] An exemplary disease-relevant mutation that can be corrected by the provided fusion proteins in vitro or in vivo is the H1047R (A3140G) polymorphism in the PI3KCA protein. The phosphoinositide-3 -kinase, catalytic alpha sub unit (PI3KCA) protein acts to phosphorylate the 3 -OH group of the inositol ring of phosphatidylinositol. The PI3KCA gene has been found to be mutated in many different carcinomas, and thus it is considered to be a potent oncogene.50 In fact, the A3140G mutation is present in several NCI-60 cancer cell lines, such as, for example, the HCT116, SKOV3, and T47D cell lines, which are readily available from the American Type Culture Collection (ATCC).51
[00215] In some embodiments, a cell carrying a mutation to be corrected, e.g., a cell carrying a point mutation, e.g., an A3140G point mutation in ex on 20 of the PI3KCA gene, resulting in a H1047R substitution in the PI3KCA protein, is contacted with an expression construct encoding a Cas9 deaminase fusion protein and an appropriately designed sgRNA targeting the fusion protein to the respective mutation site in the encoding PI3KCA gene. Control experiments can be performed where the sgRNAs are designed to target the fusion enzymes to non-C residues that are within the PI3KCA gene. Genomic DNA of the treated cells can be extracted, and the relevant sequence of the PI3KCA genes PCR amplified and sequenced to assess the activities of the fusion proteins in human cell culture.
[00216] It will be understood that the example of correcting point mutations in
PI3KCA is provided for illustration purposes and is not meant to limit the instant disclosure. The skilled artisan will understand that the instantly disclosed DNA-editing fusion proteins can be used to correct other point mutations and mutations associated with other cancers and with diseases other than cancer including other proliferative diseases.
[00217] The successful correction of point mutations in disease-associated genes and alleles opens up new strategies for gene correction with applications in therapeutics and basic research. Site-specific single-base modification systems like the disclosed fusions of Cas9 and deaminase enzymes or domains also have applications in "reverse" gene therapy, where certain gene functions are purposely suppressed or abolished. In these cases, site-specifically mutating Tip (TGG), Gin (CAA and CAG), or Arg (CGA) residues to premature stop codons (TAA, TAG, TGA) can be used to abolish protein function in vitro, ex vivo, or in vivo.
[00218] The instant disclosure provides methods for the treatment of a subject diagnosed with a disease associated with or caused by a point mutation that can be corrected by a Cas9 DNA editing fusion protein provided herein. For example, in some embodiments, a method is provided that comprises administering to a subject having such a disease, e.g., a cancer associated with a PI3KCA point mutation as described above, an effective amount of a Cas9 deaminase fusion protein that corrects the point mutation or introduces a deactivating mutation into the disease-associated gene. In some embodiments, the disease is a
proliferative disease. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease. Other diseases that can be treated by correcting a point mutation or introducing a deactivating mutation into a disease-associated gene will be known to those of skill in the art, and the disclosure is not limited in this respect.
[00219] The instant disclosure provides methods for the treatment of additional diseases or disorders, e.g., diseases or disorders that are associated or caused by a point mutation that can be corrected by deaminase-mediated gene editing. Some such diseases are described herein, and additional suitable diseases that can be treated with the strategies and fusion proteins provided herein will be apparent to those of skill in the art based on the instant disclosure. Exemplary suitable diseases and disorders are listed below. It will be understood that the numbering of the specific positions or residues in the respective sequences depends on the particular protein and numbering scheme used. Numbering might be different, e.g., in precursors of a mature protein and the mature protein itself, and differences in sequences from species to species may affect numbering. One of skill in the art will be able to identify the respective residue in any homologous protein and in the respective encoding nucleic acid by methods well known in the art, e.g., by sequence alignment and determination of homologous residues. Exemplary suitable diseases and disorders include, without limitation, cystic fibrosis (see, e.g., Schwank et al, Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell stem cell. 2013; 13 : 653-658; and Wu et. al., Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell stem cell. 2013; 13 : 659-662, neither of which uses a deaminase fusion protein to correct the genetic defect); phenylketonuria - e.g., phenylalanine to serine mutation at position 835 (mouse) or 240 (human) or a homologous residue in phenylalanine hydroxylase gene (T>C mutation) - see, e.g., McDonald et al, Genomics. 1997; 39:402-405; Bernard-Soulier syndrome (BSS) - e.g., phenylalanine to serine mutation at position 55 or a homologous residue, or cysteine to arginine at residue 24 or a homologous residue in the platelet membrane glycoprotein IX (T>C mutation) - see, e.g., Noris et al, British Journal of Haematology. 1997; 97: 312-320, and Ali et al. , Hematol. 2014; 93 : 381- 384; epidermolytic hyperkeratosis (EHK) - e.g., leucine to proline mutation at position 160 or 161 (if counting the initiator methionine) or a homologous residue in keratin 1 (T>C mutation) - see, e.g., Chipev et al, Cell. 1992; 70: 821-828, see also accession number P04264 in the UNIPROT database at www[dot]uniprot[dot]org; chronic obstructive pulmonary disease (COPD) - e.g., leucine to proline mutation at position 54 or 55 (if counting the initiator methionine) or a homologous residue in the processed form of α,ι- antitrypsin or residue 78 in the unprocessed form or a homologous residue (T>C mutation) - see, e.g., Poller et al, Genomics. 1993; 17: 740-743, see also accession number POlOl l in the UNIPROT database; Charcot-Marie-Toot disease type 4J - e.g., isoleucine to threonine mutation at position 41 or a homologous residue in FIG4 (T>C mutation) - see, e.g., Lenk et al., PLoS Genetics. 2011 ; 7: el002104; neuroblastoma (NB) - e.g., leucine to proline mutation at position 197 or a homologous residue in Caspase-9 (T>C mutation) - see, e.g., Kundu et al, 3 Biotech. 2013, 3:225-234; von Willebrand disease (vWD) - e.g., cysteine to arginine mutation at position 509 or a homologous residue in the processed form of von Willebrand factor, or at position 1272 or a homologous residue in the unprocessed form of von Willebrand factor (T>C mutation) - see, e.g., Lavergne et al, Br. J. Haematol. 1992, see also accession number P04275 in the UNIPROT database; 82: 66-72; myotonia congenital - e.g., cysteine to arginine mutation at position 277 or a homologous residue in the muscle chloride channel gene CLCN1 (T>C mutation) - see, e.g., Weinberger et al, The J. of Physiology. 2012; 590: 3449-3464; hereditary renal amyloidosis - e.g., stop codon to arginine mutation at position 78 or a homologous residue in the processed form of apolipoprotein All or at position 101 or a homologous residue in the unprocessed form (T>C mutation) - see, e.g., Yazaki et al, Kidney Int. 2003; 64: 11-16; dilated cardiomyopathy (DCM) - e.g., tryptophan to Arginine mutation at position 148 or a homologous residue in the FOXD4 gene (T>C mutation), see, e.g., Minoretti et. al., Int. J. ofMol. Med. 2007; 19: 369-372; hereditary lymphedema - e.g., histidine to arginine mutation at position 1035 or a homologous residue in VEGFR3 tyrosine kinase (A>G mutation), see, e.g., Irrthum et al, Am. J. Hum. Genet. 2000; 67: 295-301; familial Alzheimer's disease - e.g., isoleucine to valine mutation at position 143 or a homologous residue in presenilinl (A>G mutation), see, e.g., Gallo et. al., J. Alzheimer 's disease. 2011; 25: 425-431; Prion disease - e.g., methionine to valine mutation at position 129 or a homologous residue in prion protein (A>G mutation) - see, e.g., Lewis et. al., J. of General Virology. 2006; 87: 2443-2449; chronic infantile neurologic cutaneous articular syndrome (CINCA) - e.g., Tyrosine to Cysteine mutation at position 570 or a homologous residue in cryopyrin (A>G mutation) - see, e.g., Fujisawa et. al. Blood. 2007; 109: 2903-2911; and desmin-related myopathy (DRM) - e.g., arginine to glycine mutation at position 120 or a homologous residue in α,Β crystallin (A>G mutation) - see, e.g., Kumar et al, J. Biol. Chem. 1999; 274: 24137-24141. The entire contents of all references and database entries is incorporated herein by reference.
[00220] The instant disclosure provides lists of genes comprising pathogenic T>C or
A>G mutations, which may be corrected using any of the Cas9 fusion proteins provided herein. Provided herein, are the names of these genes, their respective SEQ ID NOs, their gene IDs, and sequences flanking the mutation site. See Tables 4 and 5. Without wishing to be bound by any particular theory, the mutations provided in Tables 4 and 5 may be corrected using the Cas9 fusions provided herein, which are able to bind to target sequences lacking the canonical PAM sequence. In some embodiments, a Cas9-deaminase fusion protein demostrates activity on non-canonical PAMs and therefore can correct all the pathogenic T>C or A>G mutations listed in Tables 4 and 5 (SEQ ID NOs: 674-2539 and 3144-5083), respectively. In some embodiments, a Cas9-deaminase fusion protein recognizes canonical PAMs and therefore can correct the pathogenic T>C or A>G mutations with canonical PAMs, e.g., 5'-NGG-3'. It should be appreciated that a skilled artisan would understand how to design an RNA {e.g., a gRNA) to target any of the Cas9 proteins or fusion proteins provided herein to any target sequence in order to correct any of the mutations provided herein, for example, the mutations provided in Tables 4 and 5. It will be apparent to those of skill in the art that in order to target a Cas9:effector domain fusion protein as disclosed herein to a target site, e.g., a site comprising a point mutation to be edited, it is typically necessary to co-express the Cas9:effector domain fusion protein together with a guide RNA, e.g., an sgRNA. As explained in more detail elsewhere herein, a guide RNA typically comprises a tracrRNA framework allowing for Cas9 binding, and a guide sequence, which confers sequence specificity to the Cas9:effector domain fusion protein. In some embodiments, the guide RNA comprises a structure 5 '-[guide sequence]- guuuuagagcuagaaauagcaaguuaaaauaaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuu uuu-3 ' (SEQ ID NO: 285),
wherein the guide sequence comprises a sequence that is complementary to the target sequence. The guide sequence is typically 20 nucleotides long. The sequences of suitable guide RNAs for targeting Cas9: effector domain fusion proteins to specific genomic target sites will be apparent to those of skill in the art based on the instant disclosure. Such suitable guide RNA sequences typically comprise guide sequences that are complementary to a nucleic sequence within 50 nucleotides upstream or downstream of the target nucleotide to be edited.
Kits, vectors, cells
[00221] Some aspects of this disclosure provide kits comprising a nucleic acid construct, comprising (a) a nucleotide sequence encoding a Cas9 protein or a Cas9 fusion protein as provided herein; and (b) a heterologous promoter that drives expression of the sequence of (a). In some embodiments, the kit further comprises an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow the cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.
[00222] Some aspects of this disclosure provide polynucleotides encoding a Cas9 protein of a fusion protein as provided herein. Some aspects of this disclosure provide vectors comprising such polynucleotides. In some embodiments, the vector comprises a heterologous promoter driving expression of polynucleotide.
[00223] Some aspects of this disclosure provide cells comprising a Cas9 protein, a fusion protein, a nucleic acid molecule, and/or a vector as provided herein.
[00224] The description of exemplary embodiments of the reporter systems herein is provided for illustration purposes only and not meant to be limiting. Additional reporter systems, e.g., variations of the exemplary systems described in detail above, are also embraced by this disclosure.
EXAMPLES
EXAMPLE 1: PACE Evolution of a Cas9 Without PAM Sequence Restriction
[00225] Building PAM Libraries. Four different protospacer target sequences were synthesized: Doench 1 - 5 '- AAGAGAGAC AGT AC ATGCCC-3 '(SEQ ID NO: 286);
Doench 2 - 5'-GGAGCCCACCGAGTACCTGG-3 '(SEQ ID NO: 287); G7' - 5'- AGTCTCCTCAGC AAAACGAA-3 '(SEQ ID NO: 288); and VEGF Target 2 - 5'- GACCCCCTCCACCCCGCCTC-3 ' (SEQ ID NO: 289). For each protospacer target sequence, a 3'- NNN PAM library was built. While the canonical PAM sequence is 5 '-NOGS', {e.g., an exemplary [Doench Π-rcanonical PA Ml target sequence could be 5'- Γ AAGAGAGACAGTAC ATGCCCl-rNGGl-3 ' (SEQ ID NO: 291)), the 3 TSiNN PAM libraries for each protospacer target sequence contained a fully random PAM sequence, e.g., for Doenchl 5 '-AAGAGAGACAGTACATGCCCNNN-3 ' (SEQ ID NO: 290), wherein N represents any nucleotide. The NNN PAM libraries thus included every possible
combination of PAM sequences at the 3 ' end of the respective protospacer target sequence.
[00226] Testing the Activity of Cas9 on PAM Libraries in a co-dCas9 luciferase assay. Cas9 activity was tested using a bacterial luciferase activation assay in which a fusion protein of the ω subunit of Escherichia coli RNA polymerase (rpoZ) to dCas9 (see, e.g., Bikard et al., Nucleic Acids Res. 2013 Aug; 41(15): 7429-7437) drives the production of luciferase encoded by a nucleic acid under the control of a weak promoter comprising a sequence targeted by an sgRNA. Each PAM library was cloned into a plasmid comprising such a weak promoter, where the [target sequence] -[PAM library] nucleic acid sequences served as the sequence targeted by an sgRNA. A PAM library was cloned into the promoter for The co-dCas9 assay was run on all four protospacer targets for both the canonical PAM and the random PAM library. Figure 1 shows the activity of wild-type S. pyogenes Cas9 on PAM Libraries.
[00227] Evolution of Cas9 on PAM Libraries. S. pyogenes dCas9 was fused to the ω unit of RNA polymerase. The resulting co-dCas9 fusion protein was cloned into an M13 phage-based selection phagemid (SP), comprising the entire M13 phage genome except for a functional version of the gene encoding pill, a gene essential for the generation of infectious phage particles. The phage gene encoding pill was provided on a separate plasmid
(accessory plasmid, AP), under the control of a promoter that is transcriptionally activated by co-dCas9. The PAM library was cloned into the promoter region of the accessory plasmid. Host cells used for the directed evolution of Cas9 proteins without PAM restriction were provided that harbored the accessory plasmid. Upon infection with a selection phage, the amount of infectious phage particles produced by a given host cell thus depends on the activity of the co-dCas9 fusion protein encoded by the selection phage on the promoter of the accessory plasmid, which is required for the production of pill protein. The accessory plasmid thus confers a selective advantage to those selection phages encoding co-dCas9 fusion protein variants with an increased activity on different non-canonical PAM sequences.
[00228] A lagoon was provided and a flow of host cells comprising the accessory plasmid was generated through the lagoon. The host cells were contacted with the selection phagemid, resulting in a population of selection phage propagating in the flow of host cells in the lagoon. Phage-infected host cells were removed from the lagoon and fresh, uninfected host cells were fed into the lagoon at a rate resulting in the average time a host cell remained in the lagoon being shorter than the average time between cell division of the host cells, but longer than the average Ml 3 phage life cycle time.
[00229] In order to generate Cas9 variants during a directed evolution experiment, the host cells in the lagoon were incubated under conditions resulting in an increased mutation rate. The host cells were harboring a mutagenesis plasmid (MP), which increased the mutagenesis rate, thus introducing mutations in the co-dCas9 fusion protein encoded by the selection phagemid during the phage life cycle. Because the flow rate of host cells through the lagoon results in the average time a host cell remains in the lagoon being shorter than the average time between host cell divisions, the host cells in the lagoon cannot accumulate mutations resulting from the increased mutation rate conferred by the mutagenesis plasmid in their genome or on the accessory plasmid. The selection phage, however, replicate in the lagoon in the flow of host cells and thus accumulate mutations over time, resulting in the generation of new, evolved co-dCas9 fusion protein variants.
[00230] If any of these evolved co-dCas9 fusion protein variants includes a mutation that confers an increased activity on the accessory plasmid comprising the PAM library, this will directly translate into the generation of more pill by a host cell infected with a selection phage encoding the respective co-dCas9 fusion protein variant. The production of more pill will, in turn, result in the generation of more infectious selection phage particles, which, over time, results in a competitive advantage of the mutant selection phage harboring such beneficial mutations over selection phage not harboring such mutations. After a period of time, the selective pressure exerted by the accessory plasmid will, therefore, result in selection phage having acquired beneficial mutations being the predominant species replicating in the flow of host cells, while selection phage with no mutations or with detrimental mutations will be washed out of the lagoon.
[00231] Because the co-dCas9 fusion protein activity on the PAM library was very low at the beginning of the experiment, multiple rounds of overnight propagation of the selection phagemid in host cells harboring an accessory plasmid containing the PAM library were carried out to evolve Cas9 variants that show increased activity on noncanonical PAM sequences. At the end of a directed evolution experiment, the evolved population of selection phage was isolated from the lagoon, and a representative number of clones was analyzed to detect Cas9 variants having beneficial mutations. While all mutations observed confer a beneficial phenotype, mutations shared by more than one clone, or by all clones, are of particular interest. [00232] Mutations from Cas9 PACE. A number of selection phage clones was isolated from a directed evolution experiment using a PAM library accessory plasmid as described above. The mutations identified in the Cas9 amino acid sequence of some exemplary clones is provided below in Table l(residue numbering according to SEQ ID NO: 9):
Figure imgf000095_0001
Table 1 - Cas9 mutations identified in PACE (residue numbering according to SEQ ID NO: 9.
[00233] Clones 1-4 were tested in the co-dCas9 luciferase activation assay described above. When tested on the PAM library as a whole, the different clones showed an improvement in luciferase expression (Figure 2 - Cas9 activity of exemplary evolved clones on PAM library after directed evolution).
[00234] Improvement of Cas9 activity on non-canonical PAM sequences.
The activity of evolved Cas9 proteins on target sequences with noncanonical PAMs was evaluated in more detail. The relative activity of Clone 4, harboring 1122, D182, and E1219V mutations, for various [Doench 2 (5 '-GGAGCCC ACCGAGTACCTGG-3 ' (SEQ ID NO: 287))]-[PAM] target sequences was tested in the co-dCas9 luciferase activation assay and compared to the activity of wild-type dCas9.
[00235] Improvement of Cas9 activity on non-canonical PAM sequences.
The activity of evolved Cas9 proteins on target sequences with noncanonical PAMs was evaluated in more detail. The relative activity of Clone 4, harboring 1122, D182, and E1219V mutations, for various [Doench 2 (5 '-GGAGCCC ACCGAGTACCTGG-3 '(SEQ ID NO: 287))]-[PAM] target sequences was tested in the co-dCas9 luciferase activation assay and compared to the activity of wild-type dCas9. The data are shown in Table 2.
Clone 4 dCas9 Wild-type dCas9
PAM
Luciferase Activity Luciferase Activity
GTC 44.84 4.07
AGC 25.01 4.42 GAG 186.22 73.60
TTT 36.49 3.96
GTG 119.53 6.86
AGG 238.29 244.27
CAA 13.90 5.28
Table 2 - Relative activity of clone 4 on various PAM sequences.
EXAMPLE 2: PACE Evolution of a Cas9 Without Any PAM Sequence Restriction
[00236] Because the activity of the co-dCas9 fusion protein on the NNN-PAM libraries was very low, a second round of PACE experiments was performed, in which an initial phase of diversification of the co-dCas9 fusion protein population was carried out in the absence of selective pressure by providing a source of pill that did not depend on co-dCas9 fusion protein activity. The initial diversification stage allows mutations to develop that may not be accessible in a PACE experiment where selective pressure is applied throughout the experiment.
[00237] Selection phage harboring a co-dCas9 fusion protein with a dCas9 sequence provided as SEQ ID NO: 8 with D10A and H840A mutations was propagated overnight in 1030 host cells together with MP6 mutagenesis plasmid in the presence of arabinose in order to create a library of mutated selection phage encoding a library of co-dCas9 fusion protein variants. PHI was expressed from a separate plasmid in the host cells during this initial diversification stage. After overnight (12h) diversification, 1030 host cells harboring an accessory plasmid comprising an NNN PAM library cloned into a weak promoter as the guide RNA target sequence and a mutagenesis plasmid were grown to log phase, and used as the source of host cells to create a flow of host cells through a lagoon. The cells in the lagoon were infected with the diversified selection phage from the overnight incubation. The host cells in the lagoon were contacted with arabinose in order to maintain a high level of expression of the mutagenic genes from the mutagenesis plasmid.
[00238] The initial phage titers were about 108 pfu/mL. A PACE experiment was performed for each of the four NNN-PAM libraries ([Doench 1]-[NNN-PAM], [Doench 2]- [NNN-PAM], [G7]-[NNN-PAM], and [VEGF target] -[NNN-PAM] cloned into an accessory plasmid driving pill expression from a weak promoter as described above. The phage titers were monitored during the PACE experiments. A slow drop in phage titers to 104 pfu/mL was observed. The phage population was isolated from the lagoon at that point, and grown on 2208 host cells containing a separate source of pill (psp-driven pill). After this low- stringency propagation period, a 1 : 100 dilution of the supernatant was added to fresh host cells harboring the accessory plasmid as the only source of pill in a new lagoon, and the PACE experiments were continued. No drop in phage titers was observed after this low- stringency incubation in 2208 cells.
[00239] One exemplary PACE experiment that was run for 72 hours. After that period of time, 24 surviving clones were isolated from the lagoon, sequenced, and characterized. The mutations identified included A262T, K294R, S409I, M694I, E480K, E543D, and E1219V (amino acid numbering according to SEQ ID NO: 9). In another exemplary experiment, surviving clones were isolated after 15 days of incubation. Activity of the identified dVas9 mutants was characterized in a co-dCas9 luciferase assay. Clones with the best co-dCas9 fusion protein activity on noncanonical PAM target sequences had the following mutations: E480K, E543D, E1219V, and T1329.
[00240] Cas9 Mammalian GFP Activation. Both wild-type dCas9 (SEQ ID NO: 9) and the evolved Cas9 clones were tested in a dCas9-GFP assay in Hek293T cells. The cells were contacted with a reporter construct in which a GFP-encoding sequence was driven from a weak promoter that includes a [gRNA target sequence]-[PAM] sequence. Fusion proteins of dCas9 (wild-type and PACE variants) attached to the transcriptional activator VP64-p65- Rta (VPR) were generated, and the various dCas9-VPR variants were tested for their capacity to activate the GFP reporter in HEK293 cells.
[00241] Hek293T were transfected with four separate plasmids: a dCas9-VPR expression plasmid; a plasmid expressing the sgRNA targeting the gRNA target sequence of the GFP reporter plasmid; the GFP reporter plasmid; and an iRFP transfection control. In one experiment, the HEK293 cells were contacted with a GFP reporter included a TAA PAM, and in another experiment, the HEK293 cells were contacted with a population of reporter plasmids containing an NNN PAM library. Cells were harvested 48 hours after transfection and GFP expressing cells were quantified using a BD LSR- FORTESSA cell analyzer.
[00242] Figure 3 - Cas9 Mammalian GFP Activation. Compared with WT Cas9, the evolved Cas9s showed much higher activity on both the TAA PAM (21.08% vs. 0.60% of cells above negative control) and a library of NNN PAM (22.76% vs. 3.38% of cells above negative control).
[00243] Evolved Cas9 Cutting Activity on Target Sequences with noncanonical
PAM. In order to demonstrate that the PACE mutations universally confer Cas9 activity without PAM restriction, nuclease-active Cas9 proteins were generated based on the sequence provided in , i.e., without the D10A and H840A mutations, but harboring the various PACE mutations. The evolved Cas9 variants were tested in a Cas9 GFP assay, assessing the capacity of the evolved Cas9 protein variants to target and inactivate an emGFP gene integrated into the genome of HEK293 cells using a guide RNA targeting a sequence with a noncanonical PAM. It was observed that 6.45% of cells showed loss of GFP expression when contacted with a wild-type nuclease-active Cas9 (SEQ ID NO: 9), while 54.55% of cells contacted with the evolved Cas9 (E480K, E543D, E1219V, and T1329) showed a loss of GFP expression.
EXAMPLE 3: Cas9 variants without PAM Restrictions
[00244] The beneficial mutations conferring Cas9 activity on noncanonical PAM sequences were mapped to a S. pyogenes wild-type sequence. Below is an exemplary Cas9 sequence (S. pyogenes Cas9 with D10 and H840 residues marked with an asterisk following the respective amino acid residues, SEQ ID NO: 9). The D10 and H840 residues of SEQ ID NO: 9 may be mutated to generate a nuclease inactive Cas9 (e.g., to D10A and H840A) or to generate a nickase Cas9 (e.g., to D10A with H840; or to D10 with H840A). The HNH domain (bold and underlined) and the RuvC domain (boxed) are identified. The residues found mutated in the clones isolated from the various PACE experiments, amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 are identified with an asterisk following the respective amino acid residue.
MDKKYSIGLD*IGTNSVG AVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTR
RKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNI*VDEVAYHEKYPTIYH*LRKKLVDSTD
KADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVD*KLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRR
LENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDA*KLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK*
NLSDAILLSDILR TEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQ
EEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGS*IPHQIHLGELHAILRRQEDFYPFLKDNREKIEKI
LTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE*WDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEY
FTVYNELTKVKYVTEGMRKPAFLSGE*QKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASL
GTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG*RLSRK
LINGIRDKQSGKTILDFLKSDGFANRNFM*QLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQ|
|TVKVVDELVKVMGRHKPENIVIEMA1RENQTTQ
YLQNGRDMYVDQELDI1SRRLSDYDVDH*IVPQSFLKDD^
AKLITQRKFDNLTKAERG|GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLV| |SDFRKDFQFYKVREINNYHHAHDAYLNAWGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFF| |YSNIMNFFKTEITLANGEIRKRPLIETNGETGEI DKGRDFATVRKVLSMPQ IVKKTEVQT|GGFSKESILPK RNSDKLIARKKDWDPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYK EVKKDLIIKLPKYSLFELENGRKRMLASAGE*LQKGNELALPSKY FLYLASHYEKLKGSPEDNEQKQLFVEQH KHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDT*TIDRKRY TSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO : 9 )
[00245] The beneficial mutations conferring Cas9 activity on noncanonical PAM sequences were mapped to additional exemplary wild-type Cas9 sequences. The HNH domain (bold and underlined) and the RuvC domain (boxed) are identified. The residues homologous to the residues found mutated in SEQ ID NO: 9, amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 are identified with an asterisk following the respective amino acid residue. In addition, amino acid residues 10 and 840, which are mutated in dCas9 protein variants, are also identified by an asterisk.
Figure imgf000099_0001
297)
Figure imgf000099_0002
298)
>gi 504540549 ref _014727651.1 type -guided endonuclease Cas9 [Streptococcus thermophilus ] MTKPYSIGLD*IGTNSVG AVITDNYKVPSKK KVLGNTSKKYIKKNLLGVLLFDSGITAEGRRLKRTARRRYTR
RRNRILYLQEIFSTEMATLDDAFFQRLDDSFLVPDDKRDSKYPIFGNL*VEEKAYHDEFPTIYH*LRKYLADSTK KADLRLVYLALAHMIKYRGHFLIEGEFNSKNNDIQ*KNFQDFLDTYNAI FESDLSLENSKQLEEIVKDKISKLEK KDRILKLFPGEKNSGIFSEFLKLIVGNQADFRKCFNLDEKA*SLHFSKESYDEDLETLLGYIGDDYSDVFLKAK* KLYDAILLSGFLTVTDNETEAPLSSAMIKRYNEHKEDLALLKEYIRNISLKTYNEVFKDDTKNGYAGYIDGKTNQ EDFYVYLKNLLAEFEGADYFLEKIDREDFLRKQRTFDNGS*IPYQIHLQEMRAILDKQAKFYPFLAKNKERIEKI LTFRIPYYVGPLARGNSDFAWSIRKRNEKITPWNFED*VIDKESSAEAFINRMTSFDLYLPEEKVLPKHSLLYET FNVYNELTKVRFIAESMRDYQFLDSK*QKKDIVRLYFKDKRKVTDKDIIEYLHAIYGYDGIELKGIEKQFNSSLS TYHDLLNIINDKEFLDDSSNEAIIEEIIHTLTIFEDREMIKQRLSKFENIFDKSVLKKLSRRHYTGWG*KLSAKL INGIRDEKSGNTILDYLIDDGISNRNFM*QLIHDDALSFKKKIQKAQIIGDE|D"KGNIKEWKSLPGSPAIKKGIL| |QSIKIVDELVKVMGGRKPESIWEMA|RENQYTNQGKSNSQQRLKRLEKSLKELGSKILKENIPAKLSKID NALQ ITORLYLYYLQNGKDMYTGDDLDIDRLSNYDIDH*IIPQAFLKDNSID-^VLVSSAS-^GKSDDFPSLEVVKKRKT FWYQLLKSKLISQRKFDNLTKAERG|GLLPEDKAGFIQRQLVETRQITKHVARLLDEKFNNKKDENNRAVRTVKII| |TLKSTLVSQFRKDFELYKVREINDFHHAHDAYLNAVIASALLKKYPKLEPEFVYGDYPKYNSFRERKSATEKVYF| |YSNIMNIFKKSISLADGRVIERPLIE EETGESVWNKESDLATVRRVLSYPQ WKKVEEQN|HGLDRGKPKGL FNANLSSKPKPNSNENLVGAKEYLDPKKYGGYAGISNSFAVLVKGTIEKGAKKKITNVLEFQGISILDRINYRKD KLNFLLEKGYKDIELIIELPKYSLFELSDGSRRMLASILSTNNKRGE*IHKGNQIFLSQKFVKLLYHAKRISNTI NENHRKYVENHKKEFEELFYYILEFNENYVGAKKNGKLLNSAFQSWQNHSIDELCSSFIGPTGSERKGLFELTSR GSAADFEFLGV*KIPRYRDYTPSSLLKDATLIHQSVTGLYETRIDLAKLGEG (SEQ ID NO: 260)
>gi 924443546 | Staphylococcus Aureus Cas9
GSHMKRNYILGLD*IGITSVGYGIIDYETRDVIDAGVRLFKEA VENNEGRRSKRGARRLKRRRRHRIQRVKKLL
FDYNLLTDHSELSGINP*YEARVKGLSQKLSEEEFSAALLHLAKRRGVHN EVEEDTGNELST*KEQISRNSKA LEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGS PFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYY*EKFQIIENVFKQKKK PTLKQIAKEIL EEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEEL TNLNSELTQEEIEQISNLKGYTGTH*NLSLKAINLILDELWHTNDNQIAI FNRL*KLVPKKVDLSQQK|EIPTTLV| |DDFILSPWKRSFIQSIKVINAIIKKYGLPNDIIIELA|REKNSKDAQKMINEMQKRNRQT ERIEEIIRTTGKEN AKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLITOPFNYEVDH*IIPRSVSFDNSF KVLVKQEEASKKG RTPFQ YLSSSDSKISYETFKKHILNLAKGKGRISKTKKE|YLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFR| |WNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAES| |MPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYST|RKDDKGNTLI NLNGLYDKDNDK LKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAH LDITDDYPNS*RNKWKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYE SKAYEEAKKLKKISNQAEFIA SFYNNDLIKINGELYRVIG NDLLNRIE MIDITYREYLEN*MNDKRPPRIIKTIASKTQSIKKYSTDILGNL YEVKSKKHPQIIKKG (SEQ ID NO: 261)
[00246] This disclosure provides Cas9 variants in which one or more of the amino acid residues identified by an asterisk are mutated as described herein. In some embodiments, the D10 and H840 residues are mutated, e.g., to an alanine residue, and the Cas9 variants provided include one or more additional mutations of the amino acid residues identified by an asterisk as provided herein. In some embodiments, the D10 residue is mutated, e.g., to an alanine residue, and the Cas9 variants provided include one or more additional mutations of the amino acid residues identified by an asterisk as provided herein.
[00247] A number of Cas9 sequences from various species were aligned to determine whether corresponding homologous amino acid residues can be identified in other Cas9 proteins, allowing the generation of Cas9 variants with corresponding mutations of the homologous amino acid residues. The alignment was carried out using the NCBI Constraint- based Multiple Alignment Tool (COBALT(accessible at st-va.ncbi. nlm.nih.gov/tools/cobalt), with the following parameters. Alignment parameters: Gap penalties -11,-1; End-Gap penalties -5,-1. CDD Parameters: Use RPS BLAST on; Blast E-value 0.003; Find Conserved columns and Recompute on. Query Clustering Parameters: Use query clusters on; Word Size 4; Max cluster distance 0.8; Alphabet Regular.
[00248] An exemplary alignment of four Cas9 sequences is provided below. The Cas9 sequences in the alignment are: Sequence 1 (SI): SEQ ID NO: 10 | WP_010922251 | gi 499224711 | type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]; Sequence 2 (S2): SEQ ID NO: 11 | WP_039695303 | gi 746743737 | type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus gallolyticus]; Sequence 3 (S3): SEQ ID NO: 12 | WP_045635197 | gi 782887988 | type II CRISPR RNA-guided endonuclease Cas9
[Streptococcus mitis]; Sequence 4 (S4): SEQ ID NO: 13 | 5AXW_A | gi 924443546 | Staphylococcus Aureus Cas9. The HNH domain (bold and underlined) and the RuvC domain (boxed) are identified for each of the four sequences. Amino acid residues 10, 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 840, 1219, and 1329 in SI and the homologous amino acids in the aligned sequences are identified with an asterisk following the respective amino acid residue.
51 1 —MDKK-YSIGLD*IGT SVGWAVITDEYKVPSKKFKVLGNTDRHSIKKHLI—GALLFDSG—ETAEATRLKRTARRRYT 73
52 1 —MTKKNYSIGLD*IGT SVGWAVITDDYKVPAKK KVLGNTDKKYIKKNLL—GALLFDSG—ETAEATRLKRTARRRYT 74
53 1 —Μ-ΚΚ0Υ3Ι0ίΡ*Ι0Τ 3ν0ΓΑνΐΤΡΡΥΚνΡ3ΚΚίΙΚνί0 ΤΡΚΚΓΙΚΚΗίΙ—GALLFDEG—TTAEARRLKRTARRRYT 73
54 1 GSHMKRNYILGLP*IGITSVGYGII—PYET RPVIPAGVRLFKEA VENNEGRRSKRGARRLKR 61
51 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNI*VDEVAYHEKYPTIYH*LRKKLVDSTDKADLRL 153
52 75 RRKNRLRYLQEIFA EIAKVDESFFQRLDESFLTDDDKTFDSHPIFGNK*AEEDAYHQKFPTIYH*LRKHLADSSEKADLRL 154
53 74 RRKNRLRYLQEIFSEEMSKVDSSFFHRLDDSFLIPEDKRESKYPIFATL*TEEKEYHKQFPTIYH*LRKQLADSKEKTDLRL 153
54 62 RRRHRIQRVKKLL FDYNLLTD HSELSGINP*YEARVKGLSQKLSEEE 107
51 154 IYLALAHMIKFRGHFLIEGDLNPDNSDVD*KLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEK 233
52 155 VYLALAHMIKFRGHFLIEGELNAENTDVQ*KIFADFVGVYNRTFDDSHLSEITVDVASILTEKISKSRRLENLIKYYPTEK 234
53 154 IYLALAHMIKYRGHFLYEEAFDIKNNDIQ^KIFNEFISIYDNTFEGSSLSGQNAQVEAIFTDKISKSAKRERVLKLFPDEK 233
54 108 FSAALLHLAKRRG VHN EVEEDT 131
51 234 KNGLFGNLIALSLGLTPNFKSNFDLAEDA*KLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK*NLSDAILLSDILRWTEIT 313
52 235 KNTLFGNLIALALGLQPNFKTNFKLSEDA*KLQFSKDTYEEDLEELLGKIGDDYADLFTSAK*NLYDAILLSGILTVDDNST 314
53 234 STGLFSEFLKLIVGNQADFKKHFDLEDKA*PLQFSKDTYDEDLENLLGQIGDDFTDLFVSAK*KLYDAILLSGILTVTDPST 313
54 132 GNELS T*KEQISRN 144
51 314 KAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKM—DGTEELLV 391
52 315 KAPLSASMIKRYVEHHEDLEKLKEFIKANKSELYHDIFKDKNKNGYAGYIENGVKQDEFYKYLKNILSKIKIDGSDYFLD 394 S3 314 KAPLSASMIERYENHQNDLAALKQFIKNNLPEKYDEVFSDQSKDGYAGYIDGKTTQE FYKYIKNLLSKF—EGTDYFLD 391
S4 145 SKALEEKYVAELQ LERLKKDG 165
SI 392
S2 395
S3 392
S4 166 —EVRGSINRFKTSD- -YVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGP—GEGSPFGW- -K 227
SI 472
S2 475
S3 472
S4 228 <EW- YEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVI RDENEK LEYY*EKFQIIEN 289
SSII 555522 LFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR FNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFED 628
S2 554 VFKENRKVTKEKLLNYLNKEFPEYRIKDLIGLDKENKSFNASLGTYHDLKKIL-DKAFLDDK EEVIEDIIKTLTLFED 632
S3 552
S4 290 -ENAELLDQIAKIL IYQS 363
SI 629
S2 633
S3 628
S4 364 -LWHTNDNQIAIFNRL^KLVP 428
SI 708 QKGQKNSRER 781
S2 712 NRGRSQSQQRL 784
S3 707 ARGKKNSQQRY 779
SS44 442299 -KKVDLSQQK|EIPTTLVDDFILSPWKRSFIQSIKVINAIIKKYG—LPNDIIIELA|REKNSKDAQKMINEMQKR RQT 505
SI 782 -KEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSD- -YDVDH*IVPQSFLKDD 850
S2 785 KKLQNSLKELGSNIL EEKPSYIEDKVENSHLQ DQLFLYYIQNGKDMYTGDELDIDHLSD- -YDIDH*IIPQAFIKDD 860
S3 780 [EDSLKILASGL DSNILKENPTD QLQ DRLFLYYLQNGKDMYTGEALDINQLSS- -YDIDH*IIPQAFIKDD 852
S4 506 -ENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLN PF YEVDH*IIPRSVSFDN 570
SI 851 SID KVLTRSDKNRGKSDI PSEEVVKK KNYWRQLLNAKLITQRKFDN-LTKAERGlGL-SELD- -KAGFIKRQLV| 922
S2 8611 SID RVLTSSA NRGKSDDVPSLDIVRARKAEWVRLYKSGLISKRKFDN-LTKAERGGL-TEAD- -KAGFIKRQLV| 932
S3 853 SLD RVLTSSKD RGKSD VPSIEWQKRKAFWQQLLDSKLISERKF -LTKAERG|GL-DERD- -KVGFIKRQLV| 924
SS44 557711 SFNNKVLVKOEEASKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKE|YLLEERDINRFSVQKDFINRNLA/| 650
SI 923 ETRQI KHVAQILDSRMNTKYDENDKLIREVKVI LKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAWGTALIKKYP| 1002
S2 933 ETRQI KHVAQILDARFNTEHDENDKVIRDVKVI LKSNLVSQFRKDFEFYKVREINDYHHAHDAYLNAWGTALLKKYP 1012
S3 925 ETRQI KHVAQILDARYNTE EKDKKNRTVKII LKSNLVSNFRKEFRLYKVREINDYHHAHDAYLNAWAKAILKKYP 1004
S4 651 DTRYATRGLMNLLRSYFR - -NLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIA- 712
SI 1003 KLESEFVYGDYKVYDVRKMIAKSEQ—EIGKATAKYFFYSNIMNFFKTEI LANGEIRKRPLIETNGETGEIVWDKG- 1077
S2 1013 KLASEFVYGEYKKYDIRKFI NSSD KATAKYFFYSNLMNFFKTKVKYADGTVFERPIIETNAD-GEIAWNKQ 1083
S3 1005 KLEPEFVYGEYQKYDLKRYISRSKDPKEVEKATEKYFFYSNLLNFFKEEVHYADG IVKRENIEYSKDTGEIAWNKE- 1081
S4 713 -NADFIFKEWKKLDKAKKVMENQM- -FEEKQAESMPEIETEQEYKEIFITPHQIK 764
SSII 11007788 I RDFATVRKVLSMPQWIVKKTEVQT|GGFSKESILPKRNSDKLIARKKD WDPKKYGGFDSPTVAYSVLWAKV 1149 52 1084 I IDFEKVRKVLSYPQWIVKKVETQT|GGFSKESILPKGDSDKLIPRKTKKVYWDTKKYGGFDSPTVAYSVFWADV 1158
53 1082 I KDFAIIKKVLSLPQVNIVKKREVQT|GGFSKESILPKGNSDKLIPRKTKDILLDTTKYGGFDSPVIAYSILLIADI 1156
54 765 |HIKDFKDYKYSHRVDKKPNRELINDTLYST|RKDDKGNTLIVNNLNGLYDKDNDKL KKLIN-KSP EKLLMYHH 835
51 1150 EKGKSKKLKSVKELLGI IMERSSFEKNPI-DFLEAKG YKEVKKDLIIKLPKYSLFELENGRKRMLASAGE*LQKG 1223
52 1159 EKGKAKKLKTVKELVGISIMERSFFEENPV-EFLENKG YHNIREDKLIKLPKYSLFEFEGGRRRLLASASE*LQKG 1232
53 1157 EKGKAKKLKTVKTLVGI IMEKAAFEENPI-TFLENKG YHNVRKENILCLPKYSLFELENGRRRLLASAKE*LQKG 1230
54 836 DPQTYQKLK LIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNS*RNKV 907
51 1224 NELALPSKY FLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKH 1297
52 1233 NEMVLPGYLVELLYHAHRADNF NS EYLNYVSEHKKEFEKVLSCVEDFANLYVDVEKNLSKIRAVADSM 1301
53 1231 NEIVLPVYLTTLLYHSKNVHKL DEPGHLEYIQKHRNEFKDLLNLVSEFSQKYVLADANLEKIKSLYADN 1299
54 908 VKLSLKPYRFD-VYLDNGVYKFV TVKNLDVIK—KENYYE SKAYEEAKKLKKISNQAEFIASFYNNDLIKING 979
51 1298 RDKPIREQAENIIHLFTLTNLGAPAAFKYFDT*TIDRKRYTSTKEVLDATLIHQSIT GLYETRI DLSQL 1365
52 1302 DNFSIEEISNSFINLLTLTALGAPADFNFLGE*KIPRKRYTSTKECLNATLIHQSIT GLYETRI DLSKL 1369
53 1300 EQADIEILA SFINLLTFTALGAPAAFKFFGK*DIDRKRYTTVSEILNATLIHQSIT GLYETWI DLSKL 1367
54 980 ELYRVIGVNNDLLNRIEVNMIDITYR-EYLEN*MNDKRPPRIIKTIASKT QSIKKYSTDILGNLYEVKSKKHPQIIKK 1055
SI 1366 GGD 1368
S2 1370 GEE 1372
S3 1368 GED 1370
S4 1056 G— 1056
[00249] The alignment demonstrates that amino acid sequences and amino acid residues that are homologous to a reference Cas9 amino acid sequence or amino acid residue can be identified across Cas9 sequence variants, including, but not limited to Cas9 sequences from different species, by identifying the amino acid sequence or residue that aligns with the reference sequence or the reference residue using alignment programs and algorithms known in the art. This disclosure provides Cas9 variants in which one or more of the amino acid residues identified by an asterisk in SEQ ID NO: 9 are mutated as described herein. The residues in Cas9 sequences other than SEQ ID NO: 9 that correspond to the residues identified in SEQ ID NO: 9 by an asterisk are referred to herein as "homologous" or
"corresponding" residues. Such homologous residues can be identified by sequence alignment, e.g., as described above, and by identifying the sequence or residue that aligns with the reference sequence or residue. Similarly, mutations in Cas9 sequences other than SEQ ID NO: 9 that correspond to mutations identified in SEQ ID NO: 9 herein, e.g., mutations of residues 10, 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 840, 1219, and 1329 in SEQ ID NO: 9, are referred to herein as "homologous" or "corresponding" mutations. For example, the mutations corresponding to the D10A mutation in SI for the four aligned sequences above are D10A for S2, D9A for S3, and D13A for S4; the corresponding mutations for H840A in SI are H850A for S2, H842A for S3, and H560 for S4; the corresponding mutation for X1219V in SI are X1228V for S2, X1226 for S3, and X903 V for S4, and so on.
[00250] A total of 250 Cas9 sequences (SEQ ID NOs: 10-262) from different species were aligned using the same algorithm and alignment parameters outlined above. Amino acid residues homologous to residues 10, 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 840, 1219, and 1329 were identified in the same manner as outlined above. The alignments are provided below. The HNH domain (bold and underlined) and the RuvC domain (boxed) are identified for each of the four sequences. Residues corresponding to amino acid residues 10, 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 840, 1219, and 1329 in SEQ ID NO: 9 are boxed in SEQ ID NO: 10 in the alignments, allowing for the identification of the corresponding amino acid residues in the aligned sequences.
[00251] Cas9 variants with one or more mutations in amino acid residues homologous to amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of SEQ ID NO: 9 are provided herein. In some embodiments, the Cas9 variants provided herein comprise mutations corresponding to the D10A and the H840A mutations in SEQ ID NO: 9, resulting in a nuclease-inactive dCas9, and at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations of amino acid residues homologous to amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of SEQ ID NO: 9.
[00252] Cas9 variants with one or more mutations in amino acid residues homologous to amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of SEQ ID NO: 9 are provided herein. In some embodiments, the Cas9 variants provided herein comprise mutations corresponding to the D10A mutations in SEQ ID NO: 9, resulting in a partially nuclease-inactive dCas9, wherein the Cas9 can nick the non-target strand but not the targeted strand, and at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations of amino acid residues homologous to amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of SEQ ID NO: 9. WP_010922251.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 10 WP_039695303.1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus gallolyticus ] SEQ ID NO WP_045635197.1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus mitis] SEQ ID NO : 12 5AXW_A Cas9, Chain A, Crystal Structure [Staphylococcus Aureus] SEQ ID NO: 13
WP_009880683.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 14 WP_010922251.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 15 WP_011054416.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 16 WP_011284745.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 17 WP_011285506.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 18 WP_011527619.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 19 WP_012560673.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 20 WP_014407541.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 21 WP_020905136.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 22 WP_023080005.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 23 WP_023610282.1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus pyogenes ] SEQ ID NO: 24 WP_030125963.1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus pyogenes ] SEQ ID NO: 25 WP_030126706.1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus pyogenes ] SEQ ID NO: 26 WP_031488318.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 27 WP_032460140.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 28 WP_032461047.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 29 WP_032462016.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 30 WP_032462936.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 31 WP_032464890.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 32 WP_033888930.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 33 WP_038431314.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 34 WP_038432938.1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus pyogenes ] SEQ ID NO: 35 WP_038434062.1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus pyogenes ] SEQ ID NO: 36 BAQ51233.1 CRISPR-associated protein, Csnl family [Streptococcus pyogenes] SEQ ID NO: 37 KGE60162.1 hypothetical protein MGAS2111_0903 [Streptococcus pyogenes MGAS2111] SEQ ID NO: 3 KGE60856.1 CRISPR-associated endonuclease protein [Streptococcus pyogenes SS1447] SEQ ID NO: 39 WP_002989955.1 MULTISPECIES type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus] SEQ ID NO WP_003030002.1 MULTISPECIES type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus] SEQ ID NO WP_003065552.1 MULTISPECIES type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus] SEQ ID NO WP_001040076.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 43 WP_001040078.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 44 WP_001040080.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 45 WP_001040081.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 46 WP_001040083.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 47 WP 001040085.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO
WP 001040087 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 49
WP 001040088 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 50
WP 001040089 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 51
WP 001040090 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 52
WP 001040091 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 53
WP 001040092 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 54
WP 001040094 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 55
WP 001040095 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO: 56
WP 001040096 1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 57
WP "001040097 1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO 58
WP "001040098 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 59
WP "001040099 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 60
WP "001040100 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 61
WP "001040104 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 62
WP "001040105 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 63
WP "001040106 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 64
WP "001040107 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 65
WP "001040108 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 66
WP "001040109 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 67
WP "001040110 1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO 68
WP "015058523 1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO 69
WP "017643650 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 70
WP "017647151 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 71
WP "017648376 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 72
WP "017649527 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 73
WP "017771611 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 74
WP "017771984 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 75
CFQ25032.1 CRISPR-associated protein [Streptococcus agalactiae] SEQ ID NO: 76
CFV16040.1 CRISPR-associated protein [Streptococcus agalactiae] SEQ ID NO: 77
KLJ37842.1 CRISPR-associated protein Csnl [Streptococcus agalactiae] SEQ ID NO: 78
KLJ72361.1 CRISPR-associated protein Csnl [Streptococcus agalactiae] SEQ ID NO: 79
KLL20707.1 CRISPR-associated protein Csnl [Streptococcus agalactiae] SEQ ID NO: 80
KLL42645.1 CRISPR-associated protein Csnl [Streptococcus agalactiae] SEQ ID NO: 81
WP 047207273 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 82
WP "047209694 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 83
WP "050198062 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 84
WP "050201642 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 85
WP "050204027 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 86
WP "050881965 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus agalactiae] SEQ ID NO 87
WP_050886065.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO
AHN30376.1 CRISPR-associated protein Csnl [Streptococcus agalactiae 138P] SEQ ID NO: 89
EA078426.1 reticulocyte binding protein [Streptococcus agalactiae H36B] SEQ ID NO: 90
CCW42055.1 CRISPR-associated protein, SAG0894 family [Streptococcus agalactiae ILRI112] SEQ ID NO: 91 WP_003041502.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus anginosus] SEQ ID NO 92 WP_037593752.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus anginosus] SEQ ID NO 93 WP_049516684.1 CRISPR-associated protein Csnl [Streptococcus anginosus] SEQ ID NO: 94
GAD46167.1 hypothetical protein ANG6_0662 [Streptococcus anginosus T5] SEQ ID NO: 95
WP_018363470.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus caballi] SEQ ID NO: 96 WP_003043819.1 type II CRISPR RNA- guided endonuclease Cas9 Streptococcus canis] SEQ ID NO: 97
WP_006269658.1 type II CRISPR RNA- guided endonuclease Cas9 Streptococcus constellatus] SEQ ID NO 98 WP_048800889.1 type II CRISPR RNA- guided endonuclease Cas9 Streptococcus constellatus] SEQ ID NO 99 WP_012767106.1 type II CRISPR RNA- guided endonuclease Cas9 Streptococcus dysgalactiae] SEQ ID NO 100 WP_014612333.1 type II CRISPR RNA- guided endonuclease Cas9 Streptococcus dysgalactiae] SEQ ID NO 101 WP_015017095.1 type II CRISPR RNA- guided endonuclease Cas9 Streptococcus dysgalactiae] SEQ ID NO 102 WP_015057649.1 type II CRISPR RNA- guided endonuclease Cas9 Streptococcus dysgalactiae] SEQ ID NO 103 WP_048327215.1 type II CRISPR RNA- guided endonuclease Cas9 Streptococcus dysgalactiae] SEQ ID NO 104 WP_049519324.1 CRISPR-associated protein Csnl [Streptococcus dysgalactiae] SEQ ID NO: 105
WP_012515931.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus equi] SEQ ID NO 106
WP_021320964.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus equi] SEQ ID NO 107
WP_037581760.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus equi] SEQ ID NO 108
WP_004232481.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus equinus] SEQ ID NO: 109 WP_009854540.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus gallolyticus ] SEQ ID NO 110 WP_012962174.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus gallolyticus ] SEQ ID NO 111 WP_039695303.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus gallolyticus ] SEQ ID NO 112 WP_014334983.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus infantarius ] SEQ ID NO: 113 WP_003099269.1 type II CRISPR RNA-guided endonuclease Cas9 Streptococcus iniae] SEQ ID NO: 114
AHY15608.1 CRISPR- -associated protein Csnl [Streptococcus iniae] SEQ ID NO: 115
AHY17476.1 CRISPR- -associated protein Csnl [Streptococcus iniae] SEQ ID NO: 116
ESR09100.1 hypothetical protein IUSA1_08595 [Streptococcus iniae IUSA1] SEQ ID NO: 117
AGM98575.1 CRISPR-associated protein Cas9/Csnl, subtype II/NMEMI [Streptococcus iniae SF1] SEQ ID NO: 118 ALF27331.1 CRISPR-associated protein Csnl [Streptococcus intermedius] SEQ ID NO: 119
WP_018372492.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus massiliensis ] SEQ ID NO: 120 WP_045618028.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus mitis ] SEQ ID NO: 121
WP_045635197.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus mitis ] SEQ ID NO: 122
WP_002263549.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO 123 WP_002263887.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO 124 WP_002264920.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO 125 WP 002269043.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO 126
WP 002269448.1 type II CRISPR RNA-guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 127
WP "002271977. 1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus mutans ] SEQ ID NO: 128
WP "002272766. 1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus mutans ] SEQ ID NO: 129
WP "002273241. 1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus mutans ] SEQ ID NO: 130
WP "002275430. 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 131
WP "002276448. 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 132
WP "002277050. 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 133
WP "002277364. 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 134
WP "002279025. 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 135
WP "002279859. 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 136
WP "002280230. 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 137
WP "002281696. 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 138
WP "002282247. 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 139
WP 002282906. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 140
WP "002283846. , 1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus mutans ] SEQ ID NO: 141
WP "002287255. , 1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus mutans ] SEQ ID NO: 142
WP "002288990. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 143
WP "002289641. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 144
WP "002290427. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 145
WP "002295753. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 146
WP "002296423. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 147
WP "002304487. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 148
WP "002305844. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 149
WP "002307203. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 150
WP "002310390. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 151
WP "002352408. , 1 type II CRISPR RNA- guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 152
WP "012997688. .1 type II CRISPR RNA- guided endonuclease Cas9 [Streptococcus mutans ] SEQ ID NO: 153
WP "014677909. .1 type II CRISPR RNA- -guided endonuclease Cas9 [Streptococcus mutans ] SEQ ID NO: 154
WP "019312892. .1 type II CRISPR RNA- -guided endonuclease Cas9 [Streptococcus mutans ] SEQ ID NO: 155
WP "019313659. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 156
WP "019314093. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 157
WP "019315370. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 158
WP "019803776. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 159
WP "019805234. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 160
WP "024783594. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 161
WP "024784288. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 162
WP "024784666. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 163
WP "024784894. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 164
WP "024786433. .1 type II CRISPR RNA- -guided endonuclease Cas9 [ Streptococcus mutans ] SEQ ID NO: 165
WP_049473442 1 CRISPR-associated protein Csnl [Streptococcus mutans] SEQ ID NO: 166
WP_049474547 1 CRISPR-associated protein Csnl [Streptococcus mutans] SEQ ID NO: 167
EMC03581.1 hypothetical protein SMU69_09359 [Streptococcus mutans NLML4] SEQ ID NO: 168
WP 000428612 1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus oralis] SEQ ID NO: 169
WP "000428613 1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus oralis] SEQ ID NO: 170
WP "049523028 1 CRISPR-associated protein Csnl [Streptococcus parasanguinis ] SEQ ID NO: 171
WP "003107102 1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus parauberis] SEQ ID NO: 172
WP "054279288 1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus phocae] SEQ ID NO 173
WP "049531101 1 CRISPR-associated protein Csnl [Streptococcus pseudopneumoniae] SEQ ID NO 174
WP "049538452 1 CRISPR-associated protein Csnl [Streptococcus pseudopneumoniae] SEQ ID NO 175
WP "049549711 1 CRISPR-associated protein Csnl [Streptococcus pseudopneumoniae] SEQ ID NO 176
WP "007896501 1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pseudoporcinus ] SEQ ID NO: 177
EFR44625.1 CRISPR-associated protein, Csnl family [Streptococcus pseudoporcinus SPIN 20026] SEQ ID NO: 178 WP_002897477 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sanguinis] SEQ ID NO 179 WP_002906454 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sanguinis] SEQ ID NO 180 WP_009729476 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sp. F0441] SEQ ID NO 181 CQR24647.1 CRISPR-associated protein [Streptococcus sp FF10] SEQ ID NO: 182
WP 000066813 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sp. M334] SEQ ID NO: 183
WP "009754323 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sp taxon 056] SEQ ID NO 184
WP "044674937 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis] SEQ ID NO
WP "044676715 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis] SEQ ID NO
WP "044680361 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis] SEQ ID NO
WP "044681799 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis] SEQ ID NO
WP "049533112 CRISPR-associated protein Csnl [Streptococcus suis] SEQ ID NO: HΪ9
WP "029090905 type II CRISPR RNA-guided endonuclease Cas9 [Brochothrix thermosphacta] SEQ ID NO: 190
WP "006506696 type II CRISPR RNA-guided endonuclease Cas9 [ Catenibacterium mitsuokai] SEQ ID NO: 191
AIT42264.1 Cas9hc:NLS:HA [Cloning vector pYB196] SEQ ID NO: 192
WP_034440723 type II CRISPR endonuclease Cas9 [ Clostridiales bacterium S5-A11] SEQ ID NO: 193
AKQ21048.1 Cas9 [CRISPR-mediated gene targeting vector p (bhsp68-Cas 9 ) ] SEQ ID NO: 194
WP_004636532 type II CRISPR RNA-guided endonuclease Cas9 [ Dolosigranulum pigrum] SEQ ID NO: 195
WP_002364836 MULTISPECIES : type II CRISPR RNA-guided endonuclease Cas9 [ Enterococcus ] SEQ ID NO: 196
WP_016631044 MULTISPECIES : type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus] SEQ ID NO: 197
EMS75795.1 hypothetical protein H318 06676 [Enterococci s durans IPLA 655] SEQ ID NO: 198
WP_002373311 type II CRISPR RNA-guided endonuclease Cas9 [ Enterococcus faecalis ] SEQ ID NO 199
WP_002378009 type II CRISPR RNA-guided endonuclease Cas9 [ Enterococcus faecalis ] SEQ ID NO 200
WP_002407324 type II CRISPR RNA-guided endonuclease Cas9 [ Enterococcus faecalis ] SEQ ID NO 201
WP_002413717 type II CRISPR RNA-guided endonuclease Cas9 [ Enterococcus faecalis ] SEQ ID NO 202
WP_010775580 type II CRISPR RNA-guided endonuclease Cas9 [ Enterococcus faecalis ] SEQ ID NO 203
WP 010818269 type II CRISPR RNA-guided endonuclease Cas9 [ Enterococcus faecalis ] SEQ ID NO 204
WP_010824395 1 type II CRISPR RNA--guided endonuclease Cas9 Enterococcus faecalis ] SEQ ID NO 205
WP_016622645 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecalis ] SEQ ID NO 206
WP_033624816 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecalis ] SEQ ID NO 207
WP_033625576 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecalis ] SEQ ID NO 208
WP_033789179 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecalis ] SEQ ID NO 209
WP_002310644 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecium] SEQ ID NO 210
WP_002312694 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecium] SEQ ID NO 211
WP_002314015 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecium] SEQ ID NO 212
WP_002320716 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecium] SEQ ID NO 213
WP_002330729 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecium] SEQ ID NO 214
WP_002335161 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecium] SEQ ID NO 215
WP_002345439 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecium] SEQ ID NO 216
WP_034867970 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecium] SEQ ID NO 217
WP_047937432 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus faecium] SEQ ID NO 218
WP_010720994 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus hirae] SEQ ID NO 219
WP_010737004 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus hirae] SEQ ID NO 220
WP_034700478 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus hirae] SEQ ID NO 221
WP_007209003 1 type II CRISPR RNA- -guided endonuclease Cas9 Enterococcus italicus] SEQ ID NO: 222
WP_023519017 1 type II CRISPR RNA- -guided endonuucclleeaassee CCaass99 [Enterococcus mundtii] SEQ ID NO: 223
WP_010770040 1 type II CRISPR RNA- -guided endonuucclleeaassee CCaass99 [Enterococcus phoeniculicola] SEQ ID NO
WP_048604708 1 type II CRISPR RNA- -guided endonuucclleeaassee CCaass99 [Enterococcus sp. AMI] SEQ ID NO: 225
WP_010750235 1 type II CRISPR RNA- -guided endonuucclleeaassee CCaass99 [Enterococcus villorum] SEQ ID NO: 226
AII16583.1 Cas9 endonuclease [Expression veeccttoorr ppCCaass99]] SEQ ID NO: 227
WP_029073316 1 type II CRISPR RNA- -guided endonuucclleeaassee CCaass99 [Kandleria vitulina] SEQ ID NO: 228
WP_031589969 1 type II CRISPR RNA- -guided endonuucclleeaassee CCaass99 [Kandleria vitulina] SEQ ID NO: 229
KDA45870.1 CRISPR-associated protein Cas9/Csnl, subtype II/NMEMI [Lactobacillus animalis] SEQ ID NO:
WP_039099354 type II CRISPR RNA-guided endonuclease Cas9 [Lactobacillus curvatus] SEQ ID NO: 231
AKP02966.1 hypothetical protein ABB45 04605 [Lactobacillus farciminis] SEQ ID NO: 232
WP_010991369 type II CRISPR RNA-guided endonuclease Cas9 [Listeria innocua] SEQ ID NO: 233
WP_033838504 type II CRISPR RNA-guided endonuclease Cas9 [Listeria innocua] SEQ ID NO: 234
EHN60060.1 CRISPR-associated protein, Csnl family [Listeria innocua ATCC 33091] SEQ ID NO: 235
EFR89594.1 crispr-associated protein, Csnl family [Listeria innocua FSL S4-378] SEQ ID NO: 236
WP_038409211 type II CRISPR RNA-guided endonuclease Cas9 [Listeria ivanovii] SEQ ID NO: 237
EFR95520.1 crispr-associated protein Csnl [Listeria ivanovii FSL F6-596] SEQ ID NO: 238
WP_003723650 typ II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO 239
WP_003727705 typ II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO 240
WP_003730785 typ II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO 241
WP_003733029 typ II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO 242
WP 003739838 typ II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO 243
WP_014601172 s] SEQ ID NO 244 WP_023548323 s] SEQ ID NO 245 WP_031665337 s] SEQ ID NO 246 WP_031669209 s] SEQ ID NO 247 WP_033920898 s] SEQ ID NO 248 AKI42028.1 CRISPR-associated protein [Listeria monocytogenes] SEQ ID NO: 249
AKI50529.1 CRISPR-associated protein [Listeria monocytogenes] SEQ ID NO: 250
EFR83390.1 crispr-associated protein Csnl [Listeria monocytogenes FSL F2-208] SEQ ID NO: 251 WP_046323366 1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria seeligeri] SEQ ID NO: 252 AKE81 Oil.1 Cas9 [Plant multiplex genome editing vector pYLCRISPR/Cas9Pubi-H] SEQ ID NO: 253 CU082355.1 Uncharacterized protein conserved in bacteria [Roseburia hominis] SEQ ID NO: 254 WP_033162 7.1 type II CRISPR RNA-guided endonuclease Cas9 [Sharpea azabuensis] SEQ ID NO: 255 AGZ01981.1 Cas9 endonuclease [synthetic construct] SEQ ID NO: 256
AKA60242.1 nuclease deficient Cas9 [synthetic construct] SEQ ID NO: 257
AKS40380.1 Cas9 [Synthetic plasmid pFC330] SEQ ID NO: 258
4UN5 B Cas9 Chain B, Crystal Structure SEQ ID NO: 259
WP_0109222 51 MDKK-YSIGL^|lGTNSVG AVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA—EATRLKRTARRRYT 73
WP_039695303 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA—EATRLKRTARRRYT 74
WP_045635197 K-KG-YSIGLDIGTNSVGFAVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA—EARRLKRTARRRYT 73
5AXW_A MKRN-YILGLDIGITSVGYGII—DYET RDVIDA GVRLFKEANVEnnEGRRSKRGARRLKR 61
WP_0098806 83
WP_010922251 MDKK-YSIGLDIGTNSVGWAVITDEYKVPS KKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_011054416 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKLKGLGNTDRHGIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_011284745 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_011285506 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_011527619 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGEIA- -EATRLKRTARRRYT 73
WP_012560673 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_014407541 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFGSGETA- -EATRLKRTARRRYT 73
WP_020905136 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_023080005 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKLKVLGNTDRHGIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_023610282 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKLKVLGNTDRHGIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_030125963 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_030126706 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHGIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_031488318 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_032460140 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_032461047 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_032462016 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP 032462936 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP_032464890 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGEIA—EATRLKRTARRRYT 73 WP_03 3888930
WP_03 8431314 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA—EATRLKRTARRRYT 73 WP_03 8432938 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA—EATRLKRTARRRYT 73 WP_03 8434062 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA—EATRLKRTARRRYT 73 BAQ51 233
KGE60 162
KGE60 856
WP_00 29899 55 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGEIA- -EATRLKRTARRRYT 73 WP_00 3030002 MDQK-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKQSI KKNLLGALLFDSGETA- -EATRLKRTARRRYT 73 WP_00 3065552 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYI KKNLLGALLFDSGETA- -EATRLKRTARRRYT 74 WP_00 1040076 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKIRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040078 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040080 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040081 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040083 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040085 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040087 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040088 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040089 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040090 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040091 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040092 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040094 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040095 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040096 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040097 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040098 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040099 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040100 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040104 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP_00 1040105 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTSRRRYT 73 WP_00 1040106 MNKP-YSIGLDIGTNSVGYSWTDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -SDRRLKRTARRRYT 73 WP_00 1040107 MNKP-YSIGLDIGTNSVGYSWTDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -SDRRLKRTARRRYT 73 WP_00 1040108 MNKP-YSIGLDIGTNSVGYSWTDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -SDRRLKRTARRRYT 73 WP_00 1040109 MNKP-YSIGLDIGTNSVGYSWTDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -SDRRLKRTARRRYT 73 WP_00 1040110 MNKP-YSIGLDIGTNSVGYSWTDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -SDRRLKRTARRRYT 73 WP_01 5058523 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73 WP 01 7643650 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYI KKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
WP 017647151 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73
WP 017648376 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -SDRRLKRTARRRYT 73
WP 017649527 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
WP 017771611 1 MNKP- YSIGLDIGTNSVGYSWTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -SDRRLKRTARRRYT 73
WP 017771984 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
CFQ25032 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
CFV16040 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
KLJ37842 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
KLJ72361 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
KLL20707 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
KLL42645 1 MNKP- YSIGLDIGTNSVGYSWTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -SDRRLKRTARRRYT 73
WP 047207273 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGRNTA- -ADRRLKRTARRRYT 73
WP 047209694 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
WP 050198062 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
WP 050201642 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
WP 050204027 1 MNKP- YSIGLDIGTNSVGYSWTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -SDRRLKRTARRRYT 73
WP 050881965 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
WP 050886065 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
AHN30376 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
EA078426 1 MNKP- YSIGXDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRTARRRYT 73
CCW42055 1 MNKP- YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA- -ADRRLKRIARRRYT 73
WP 003041502 1 MNQK- YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA- -EATRLKRTARRRYT 73
WP 037593752 1 MKKE- YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA- -EATRLKRTARRRYT 74
WP 049516684 1 MKKE- YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA- -EATRLKRTARRRYT 74
GAD46167 1 MKKE- YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA- -EATRLKRTARRRYT 73
WP 018363470 1 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA- -EATRLKRTARRRYT 74
WP 003043819 1 MEKK- YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTNRKSIKKNLMGALLFDSGETA- -EATRLKRTARRRYT 73
WP 006269658 1 MGKP- YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA- -EATRLKRTARRRYT 73
WP 048800889 1 MTQK- YSIGLDIGTNSVGWAIVTDDYKVPAKKMKILGNTNKQYIKKNLLGALLFDSGETA- -KATRLKRTARRRYT 73
WP 012767106 1 MDKK- YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP 014612333 1 MDKK- YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP 015017095 1 MDKK- YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP 015057649 1 MDKK- YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP 048327215 1 MDKK- YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP 049519324 1 MDKK- YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73
WP 012515931 1 MKKP- YTIALDIGTNSVGWVWTDDYRVPTKKMKVLGNTERKTIKKNLIGALLFDSGDTA- -EGTRLKRTARRRYT 73
WP 021320964 1 MKKP- YTIALDIGTNSVGWVWTDDYRVPTKKMKVLGNTERKTIKKNLIGALLFDSGDTA- -EGTRLKRTARRRYT 73
WP 037581760 1 MKKP- YTIALDIGTNSVGWVWTDDYRVPTKKMKVLGNTERKTIKKNLIGALLFDSGDTA- -EGTRLKRTARPRYT 73
WP 004232481 1 M-EKtYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA- -EATRLKRAARRRYT 73
WP_009854540 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA- -EATRLKRTARRRYT 74 WP_01 2962174 MTEKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDNGETA- -EATRLKRTARRRYT 74 WP_03 9695303 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA- -EATRLKRTARRRYT 74 WP_01 4334983 M-EKsYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA- -EVTRLKRTARRRYT 73 WP_00 3099269 MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA- -EATRLKRTTRRRYT 73 AHY15 608 MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA- -EATRLKRTTRRRYT 73 AHY17 476 MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA- -EATRLKRTTRRRYT 73 ESR09 100
AGM98 575 MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSI KKNLIGALLFDNGETA-- EATRLKRTTRRRYT 73 ALF27 331 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_01 83724 92 MKKP-YSIGLDIGTNSVGWAWMEDYKVPSKKMKVLGNTDKQSIKKNLIGALLFDSGETAv- -ERRLNRTTSRRYD 73 WP_04 5618028 NNKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLLGALLFDEGTTA-- EDRRLKRTARRRYT 74 WP_04 5635197 K-KG-YSIGLDIGTNSVGFAVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA-- EARRLKRTARRRYT 73 WP_00 2263549 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2263887 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2264920 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2269043 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2269448 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2271977 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2272766 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2273241 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2275430 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- ADRRLKRTARRRYT 73 WP_00 2276448 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2277050 MKKS-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2277364 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- ADRRLKRTARRRYT 73 WP_00 2279025 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2279859 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2280230 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- ADRRLKRTARRRYT 73 WP_00 2281696 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- ADRRLKRTARRRYT 73 WP_00 2282247 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2282906 MKKP-YSIGLDIGTNSVGWSWTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2283846 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2287255 MKKP-YSIGLDIGTNSVGWAWTDDYKVSAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2288990 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2289641 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTTRRRYT 73 WP_00 2290427 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2295753 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP_00 2296423 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73 WP 00 2304487 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA-- EDRRLKRTARRRYT 73
WP_002305844 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_00 2307203 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_00 2310390 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_00 2352408 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_01 2997688 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA ADRRLKRTARRRYT 73 WP_01 4677909 MKKP-YSIGLDIGTNSVGWAWTDDYKVPDKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_01 9312892 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA ADRRLKRTARRRYT 73 WP_01 9313659 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_01 9314093 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_01 9315370 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_01 9803776 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_01 9805234 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_02 4783594 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_02 4784288 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTARRRYT 73 WP_02 4784666 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA ADRRLKRTARRRYT 73 WP_02 4784894 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTTRRRYT 73 WP_02 4786433 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA ADRRLKRTARRRYT 73 WP_04 9473442 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA ADRRLKRTARRRYT 73 WP_04 9474547 MKKP-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA EDRRLKRTTRRRYT 73 EMC03 581 MDL IGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA ADRRLKRTARRRYT 66 WP_00 04286 12 ENKN-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA EARRLKRTARRRYT 74 WP_00 0428613 ENKN-YSIGLDIGTNSVGWSVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA EARRLKRTARRRYT 74 WP_04 9523028 K-KP-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTNKESIKKNLIGALLFDAGNTA ADRRLKRTARRRYT 73 WP_00 3107102 MKVLGNTDRQTVKKNMIGTLLFDSGETA EARRLKRTARRRYT 42 WP_05 4279288 -KKS-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTSRQSIKKNMIGALLFDEGGPA ASTRVKRTTRRRYT 75 WP_04 9531101 SNKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA EDRRLKRTARRRYT 74 WP_04 9538452 SNKP-YSIGLDIGTNSVGWVIITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA EDRRLKRTARRRYT 74 WP_04 9549711 SNKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMTVLGNTDKHFIKKNLIGALLFDEGTTA EDRRLKRTARRRYT 74 WP_00 7896501 —YS-YSIGLDIGTNSVGWAVINEDYKVPAKKMTVFGNTDRKTIKKNLLGTVLFDSGETA QARRLKRTNRRRYT 75 EFR44 625 MLGTVLFDSGETA QARRLKRTNRRRYT 27 WP_00 28974 77 K-KP-YSIGLDIGTNSVGWAWTDDYKVPAKKMRVFGDTDRSHIKKNLLGTLLFDDGNTA ESRRLKRTARRRYT 73 WP_00 2906454 K-KP-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA EDRRLKRTSRRRYT 73 WP_00 9729476 ENKN-YSIGLDIGTNSVGWSVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA EARRLKRTARRRYT 74 CQR24 647 MKKP-YSIGLDIGTNSVGWSWTDDYKVPAKKMKVLGNTDKEYIKKNLIGALLFDSGETA EATRMKRTARRRYT 73 WP_00 00668 13 SNKS-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA EDRRLKRTARRRYT 74 WP_00 9754323 NNNN-YSIGLDIGTNSVGWAVITDDYKVPSKKMRVLGNTDKRFIKKNLIGALLFDEGTTA EDRRLKRTARRRYT 74 WP_04 4674937 MKKK-YAIGIDIGTNSVGWSWTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA ENRRLKRTARRRYT 73 WP_04 4676715 MKKK-YAIGIDIGTNSVGWSWTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA ENRRLKRTARRRYT 73 WP 04 4680361 MKKK-YAIGIDIGTNSVGWSWTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA ENRRLKRTARRRYT 73
WP_044681799 MKKK-YAIGIDIGTNSVGWSWTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA- -ENRRLKRTARRRYT 73 WP_04 9533112 MDQK-YSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA- -EATRLKRTARRRYT 73 WP_02 9090905 MWGVSLFEAGKTA- -AERRGYRSTRRRLN 27 WP_00 6506696 I-VD-YCIGLDLGTGSVGWAWDMNHRLMKRN GKHLWGSRLFSNAETA- -ANRRASRSIRRRYN 60 AIT42 264 MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73 WP_03 44407 23 -MKN-YTIGLDIGTNSVGWAVIKDDLTLVRKKIKISGNTDKKEVKKNLWGSFLFEQGDTA- -QDTRVKRIARRRYE 72 AKQ21 048 MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- -EATRLKRTARRRYT 73 WP_00 46365 32 MQKN-YTIGLDIGTNSVGWAVMKDDYTLIRKRMKVLGNTDIKKIKKNFWGVRLFDEGETA- -KETRLKRGTRRRYQ 73 WP_00 2364836 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA- -EDRRLKRTARRRIS 73 WP_01 6631044 MRLFEEGHTA- -EDRRLKRTARRRIS 24 EMS75 795
WP_00 23733 11 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_00 2378009 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_00 2407324 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_00 2413717 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_01 0775580 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_01 0818269 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_01 0824395 MKKD-YVIGLDIGSNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_01 6622645 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_03 3624816 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_03 3625576 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_03 3789179 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA EDRRLKRTARRRIS 73 WP_00 2310644 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA EARRSKRTARRRLA 73 WP_00 2312694 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA EARRSKRTARRRLA 73 WP_00 2314015 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA EARRSKRTARRRLA 73 WP_00 2320716 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA EARRSKRTARRRLA 73 WP_00 2330729 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA EARRSKRTARRRLA 73 WP_00 2335161 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA EARRSKRTARRRLA 73 WP_00 2345439 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA EARRSKRTARRRLA 73 WP_03 4867970 MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA EFRRTKRTNRRRLA 73 WP_04 7937432 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA EARRSKRTARRRLA 73 WP_01 0720994 MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA EFRRTKRTNRRRLA 73 WP_01 0737004 MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA EFRRTKRTNRRRLA 73 WP_03 4700478 MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA EFRRTKRTNRRRLA 73 WP_00 7209003 MKND-YTIGLDIGTNSVGYSWTDDYKVISKKMNVFGNTEKKSIKKNFWGVRLFESGQTA QEARMKRTSRRRIA 73 WP_02 3519017 MEKE-YTIGLDIGTNSVGWAVLTDDYRLVARKMSIQGDSNRKKIKKNFWGARLFEEGKTA QFRRIKRTNRRRIA 73 WP_01 0770040 MKKE-YTIGLDIGTNSVGWAVLTENYDLVKKKMKVYGNTETKYLKKNLWGVRLFDEGETA ADRRLKRTTRRRYS 73 WP_04 8604708 MGKE-YTIGLDIGTNSVGWAVLQEDLDLVRRKMKVYGNTEKNYLKKNFWGVDLFDEGMTA KDTRLKRTTRRRYF 73 WP 01 0750235 MNKA-YTLGLDIGTNSVGWAWTDDYRLMAKKMPVHSKMEKKKIKKNFWGARLFDEGQTA EERRNKRATRRRLR 73
AII16583 ADKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA- EATRLKRTARRRYT 112
WP_029073 316 NNKI-YNIGLDIGDASVGWAWDEHYNLLKRH GKHMWGSRLFTQANTA- VERRSSRSTRRRYN 65
WP_031589969 NNKI-YNIGLDIGDASVGWAWDEHYNLLKRH GKHMWGSRLFTQANTA- VERRSSRSTRRRYN 65
KDA45870 LKKD-YSIGLDIGTNSVGHAWTDDYKVPTKKMKVFGDTSKKTIKKNMLGVLLFNEGQTA- ADTRLKRGARRRYT 74
WP_039099 354 MSRP-YNIGLDIGTSSIGWSWDDQSKLVSVR GKYGYGVRLYDEGQTA- AERRSFRTTRRRLK 61
AKP02966 KEQP-YNIGLDIGTGSVGWAVTNDNYDLLNIK KKNLWGVRLFEGAQTA- KETRLNRSTRRRYR 64
WP_010991 369 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKIAGDSEKKQIKKNFWGVRLFDEGQTA- ADRRMARTARRRIE 73
WP_033838504 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKIAGDSEKKQIKKNFWGVRLFDEGQTA- ADRRMARTARRRIE 73
EHN60060 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKIAGDSEKKQIKKNFWGVRLFDEGQTA- ADRRMARTARRRIE 76
EFR89594
WP_038409 211 1 MRKP-YTIGLDIGTNSVGWAVLTDQYNLVKRKMKVAGSAEKKQIKKNFWGVRLFDEGEVA—AGRRMNRTTRRRIE 73
EFR95520
WP_003723 650 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA—VDRRMNRTARRRIE 73
WP_003727705 MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA—VDRRMNRTARRRIE 73
WP_003730785 MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA—VDRRMNRTARRRIE 73
WP_003733029 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKISGDSEKKQIKKNFWGVRLFEKGETA—AKRRMSRTARRRIE 73
WP_003739838 MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDEGETA—ADRRMNRTARRRIE 73
WP_014601172 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA—VDRRMNRTARRRIE 73
WP_023548323 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA—VDRRMNRTARRRIE 73
WP_031665337 MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA—VDRRMNRTARRRIE 73
WP_031669209 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKISGDSEKKQIKKNFWGVRLFEKGETA—AKRRMSRTARRRIE 73
WP_033920898 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA—VDRRMNRTARRRIE 73
AKI42028 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA—VDRRMNRTARRRIE 76
AKI50529 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA—VDRRMNRTARRRIE 76
EFR83390
WP_046323 366 MKKP-YTIGLDIGTNSVGWAALTDQYDLVKRKMKVAGNSEKKQIKKNLWGVRLVDEGKTA—AHRRVNRTTRRRIE 73
AKE81011 ADKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA—EATRLKRTARRRYT 89
CU082355 I-VD-YCIGLDLGTGSVGWAWDMNHRLMKRN GKHLWGSRLFSNAETA—ATRRSSRSIRRRYN 64
WP_033162 KDIR-YSIGLDIGTNSVGWAVMDEHYELLKKG NHHMWGSRLFDAAEPA—ATRRASRSIRRRYN 65
AGZ 01981 ADKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA—EATRLKRTARRRYT 106
AKA60242 MDKK-YSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA—EATRLKRTARRRYT 73
AKS40380 MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA—EATRLKRTARRRYT 73
4UN5 B MDKK-YSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA—EATRLKRTARRRYT 77
WP_010922251 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE-SFLV- H ERHPIFGN[I]V-DEVAYHEKYPTIY|H|LRKKLV 143
WP_039695303 75 RRKNRLRYLQEIFANEIAKVDESFFQRLDE-SFLT- F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 144
WP_045635197 74 RRKNRLRYLQEIFSEEMSKVDSSFFHRLDD-SFLI- E SKYPIFATLT-EEKEYHKQFPTIYHLRKQLA 143
5AXW_A 62 RRRHRIQRVKKLLFD YNLLTDhSELS G —NPYEARVK GLSQKLS 104
WP_0098806 83
WP_010922251 74 RRKNRI CYLQEI FSNEMAKVDDS FFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP_011054416 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_011284745 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP_011285506 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP_011527619 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP_012560673 74 RRKNRICYLQEI FSNEIAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_014407541 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_020905136 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP_023080005 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_023610282 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_030125963 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP_030126706 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_031488318 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_032460140 74 RRKNRICYLQEI FSNEIAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_032461047 74 RRKNRICYLQEI FSNEIAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_032462016 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP_032462936 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLA 143
WP_032464890 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV- EEDKK H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP_033888930
WP_038431314 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE-SFLV—EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143
WP_038432938 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE-SFLV—EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143
WP_038434062 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE-SFLV—EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143
BAQ51233 1 MAKVDDSFFHRLEE-SFLV—EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 54
KGE60162
KGE60856
WP_0029899 55 74 RRKNRICYLQEI FSNEMAKVDDSFFHRLEE- SFLV—EEDKK- H ERHPIFGNIV- -DEVAYHEKYPTIYHLRKKLV 143
WP_003030002 74 RRRNRLRYLQEI FAEEMNKVDENFFQRLDD- SFLV—DEDKR- G ERHPIFGNIA- AEVKYHDDFPTIYHLRKHLA 143
WP_003065552 75 RRKNRLRYLQEI FAEEMTKVDESFFQRLDE- SFLRwdDDNKK- L GRYPIFGNKA- DWKYHQEFPTIYHLRKHLA 146
WP_001040076 74 RRRNRILYLQEI FAEEMSKVDDSFFHRLED- SFLV—EEDKR- G SKYPIFATLQ- EEKYYHEKFPTIYHLRKELA 143
WP_001040078 74 RRRNRILYLQEI FAEEMSKVDDSFFHRLED- SFLV—EEDKR- G SKYPIFATLQ- EEKDYHEKFPTIYHLRKELA 143
WP_001040080 74 RRRNRILYLQEI FAEEMSKVDDSFFHRLED- SFLV—EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP_001040081 74 RRRNRILYLQEI FAEEMSKVDDSFFHRLED- SFLV—EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP_001040083 74 RRRNRILYLQEI FAEEMSKVDDSFFHRLED- SFLV—EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 001040085 74 RRRNRILYLQEI FAEEMSKVDDSFFHRLED- SFLV—EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 001040087 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV--EEDKR- G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143
WP 001040088 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 001040089 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 001040090 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 001040091 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 001040092 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 001040094 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKYYHEKFPTIYHLRKELA 143
WP 001040095 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKYYHEKFPTIYHLRKELA 143
WP 001040096 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKYYHEKFPTIYHLRKELA 143
WP 001040097 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKYYHEKFPTIYHLRKELA 143
WP 001040098 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKYYHEKFPTIYHLRKELA 143
WP 001040099 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKYYHEKFPTIYHLRKELA 143
WP 001040100 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKYYHEKFPTIYHLRKELA 143
WP 001040104 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYXIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 001040105 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 001040106 74 CRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 001040107 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 001040108 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 001040109 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 001040110 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 015058523 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 017643650 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKYYHEKFPTIYHLRKELA 143
WP 017647151 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 017648376 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 017649527 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFPTIYHLRKELA 143
WP 017771611 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 017771984 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
CFQ25032 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
CFV16040 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
KLJ37842 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
KLJ72361 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
KLL20707 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
KLL42645 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 047207273 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 047209694 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ- EEKYYHEKFPTIYHLRKELA 143
WP 050198062 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 050201642 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 050204027 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EDDKR- G SKYPIFATMQ- EEKDYHEKFPTIYHLRKELA 143
WP 050881965 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ- EEKDYHEKFSTIYHLRKELA 143
WP 050886065 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV--EEDKR- G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143
AHN30376 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143
EA078426 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143
CCW42055 74 RRRNRILYLQEIFAEKMSKVDDSFFHRLED- SFLV- -EEDKR- G SKYPIFATLQ-EEKDYHEKFPTIYHLRKELA 143
WP 0030415 02 74 RRRNRLRYLQEIFAEEMMQVDESFFQRLDD- SFLV- -DEDKR- G ERHPI FGNIA-AEVKYHDEFPTIYHLRKHLA 143
WP 0375937 52 75 RRKNRLRYLQEI FTEEMNKVDENFFQRLDD- SFLV- -EEDKQ- G SKYPIFGTLK-EEKEYHKKFKTIYHLREELA 144
WP 0495166 84 75 RRRNRLRYLQEIFAEEMMQVDESFFQRLDD- SFLV- -EEDKR- G SRYPI FGNIA-AEVKYHDDFPTIYHLRKHLV 144
GAD46167 74 RRKNRLRYLQEI FTEEMNKVDENFFQRLDD- SFLV- -EEDKQ- G SKYPIFGTLK-EEKEYHKKFKTIYHLREELA 143
WP 0183634 70 75 RRKNRLRYLQDIFTEEMAKVDDSFFQRLDE- SFLT- -DNDKN- F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 144
WP 0030438 19 74 RRKNRIRYLQEIFANEMAKLDDSFFQRLEE- SFLV- -EEDKK- -N ERHPIFGNLA-DEVAYHRNYPTIYHLRKKLA 143
WP 0062696 58 74 RRKNRLRYLQEI FTGEMNKVDENFFQRLDD- SFLV- -DEDKR- G EHHPIFGNIA-AEVKYHDDFPTIYHLRRHLA 143
WP 0488008 89 74 RRKNRLRYLQEIFIEEMNKVDENFFQRLDD- SFLV- -TEDKR- G SKYPIFGTLK-EEKEYYKEFETIYHLRKRLA 143
WP 0127671 06 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE- SFLV- -EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143
WP 0146123 33 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE- SFLV- -EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143
WP 0150170 95 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE- SFLV- -EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143
WP 0150576 49 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE- SFLV- -EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143
WP 0483272 15 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE- SFLV- -EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143
WP 0495193 24 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE- SFLV- -EEDKK- H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143
WP 0125159 31 74 RRKNRLRYLKEI FTEEMAKVDDGFFQRLED- SFYV- -LEDKE- G NKHPIFANLA-DEVAYHKKYPTIYHLRKELV 143
WP 0213209 64 74 RRKNRLRYLKEI FTEEMAKVDDGFFQRLED- SFYV- -LEDKE- G NKHPIFANLA-DEVAYHKKYPTIYHLRKELV 143
WP 0375817 60 74 RRKNRLRFLKEI FTEEMAKVDDGFFQRLED- SFYV- -LEDKE- G NKHPIFANLA-DEVAYHKKYPTIYHLRKELV 143
WP 0042324 81 74 RRKNRLRYLQEIFAKEMAKVDESFFQRLEE- SFLT- -DDDKT- F DSHPIFGNKA-EEDTYHQEFPTIYHLRKHLA 143
WP 0098545 40 75 RRKNRLRYLQEIFAEEMTKVDESFFYRLDE- SFLT- -TDEKD- F ERHPIFGNKA-EEDAYHQKFPTIYHLRNYLA 144
WP 0129621 74 75 RRKNRLRYLQEIFAEEMAKVDESFFYRLDE- SFLT- -TDDKD- F ERHPIFGNKA-DEIKYHQEFPTIYHLRKHLA 144
WP 0396953 03 75 RRKNRLRYLQEIFANEIAKVDESFFQRLDE- SFLT- -DDDKT- F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 144
WP 0143349 83 74 RRKNRLRYLQEIFAKEMTKVDESFFQRLEE- SFLT- -DDDKT- F DSHPIFGNKA-EEDAYHQKFPTIYHLRKYLA 143
WP 0030992 69 74 RRKYRIKELQKIFSSEMNELDIAFFPRLSE- SFLV- -SDDKE- F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA 143
AHY15608 74 RRKYRIKELQKIFSSEMNELDIAFFPRLSE- SFLV- -SDDKE- F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA 143
AHY17476 74 RRKYRIKELQKIFSSEMNELDIAFFPRLSE- SFLV- -SDDKE- F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA 143
ESR09100
AGM98575 74 RRKYRIKELQKIFSSEMNELDIAFFPRLSE- SFLV- -SDDKE- F ENHPIFGNLK- DEITYHNDYPTIYHLRQTLA 143
ALF27331 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP 0183724 92 74 RRRNRIRYLQHIFAEEMNRADENFFHRLKE- SFFV- -EEDKT- Y SKYPIFGTLE- EEKNYHKNYPTIYHLRKTLA 143
WP 0456180 28 75 RRKNRLRYLQEI FTEEMSKVDI SFFHRLDD- SFLV- -PEDKR- G SKYPIFATLE- EEKEYHKNFPTIYHLRKHLA 144
WP 0456351 97 74 RRKNRLRYLQEIFSEEMSKVDSSFFHRLDD- SFLI- -PEDKR- E SKYPIFATLT- EEKEYHKQFPTIYHLRKQLA 143
WP 0022635 49 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP 0022638 87 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP 0022649 20 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLDE- SFLT- -DDDKN- F DSYPIFGNKA- EEDAYHQKFPTIYHLRKHLA 143
WP 0022690 43 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP 002269448 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV--TEDKR- G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143
WP "0022 71977 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 72766 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 73241 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 75430 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 76448 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 77050 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLDE- SFLT- -DDDKN- F DSHPIFGNKA- EEDAYHQKFPTIYHLRKHLA 143
WP "0022 77364 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 79025 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- FFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 79859 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLDE- SFLT- -DDDKN- F DSHPIFGNKA- EEDAYHQKFPTIYHLRKHLA 143
WP "0022 80230 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 81696 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 82247 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLDE- SFLT- -DDDKN- F DSHPIFGNKA- EEDAYHQKFPTIYHLRKHLA 143
WP "0022 82906 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 83846 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 87255 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 88990 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 89641 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 90427 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 95753 74 RRRNRILYLQEIFSEEMGKVNDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0022 96423 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0023 04487 74 RRRNRILYLQEIFAEEMMQVDESFFQRLDD- SFLV- -EEDKR- G SRYPIFGTLK- EEKKYHKEFKTIYHLREKLA 143
WP "0023 05844 74 RRRNRILYLQEIFSEEMDKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0023 07203 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0023 10390 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0023 52408 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0129 97688 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "θ146 77909 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0193 12892 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0193 13659 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0193 14093 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0193 15370 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ECHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0198 03776 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0198 05234 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0247 83594 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0247 84288 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLDE- SFLT- -DDDKN- F DSHPIFGNKA- EEDAYHQKFPTIYHLRKHLA 143
WP "0247 84666 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0247 84894 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV- -TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
WP "0247 86433 74 RRRNRILYLQEIFAEEMNKVDDSFFHRLDE- SFLT- -DDDKN- F DSHPIFGNKA- EEDAYHQKFPTIYHLRKHLA 143
WP 049473442 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV--TEDKR- G ERHPIFGNLE-EEVKYYENFPTIYHLRQYLA 143
WP 049474547 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED- SFLV-- TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 143
EMC03581 67 RRRNRILYLQEIFAEEMSKVDDSFFHRLED- SFLV-- TEDKR- G ERHPIFGNLE- EEVKYHENFPTIYHLRQYLA 136
WP 000428612 75 RRKNRLRYLQEIFAEEMSKVDSSFFHRLDD- SFLI— PEDKK- G SKYPIFATLI- EEKEYHKQFPTIYHLRKQLA 144
WP 000428613 75 RRKNRLRYLQEIFAEEMSKVDSSFFHRLDD- SFLI— PEDKR- G SKYPIFATLA- EEKEYHKQFPTIYHLRKQLA 144
WP 049523028 74 RRRNRILYLQEIFAAEMNKVDESFFHRLDD- SFLV-- PEDKR- G SKYPIFGTLE- EEKEYHKQFPTIYYLRKILA 143
WP 003107102 43 RRINRIKYLQSIFDDEMSKIDSAFFQRIKD- SFLV-- PDDKN- D DRHPIFGNIK- DEVDYHKNYPTIYHLRKKLA 112
WP 054279288 76 RRKNRLCYLRDIFESEMHTIDKHFFLRLED- SFLH-- KSDKR- Y EAHPIFGTLQ- EEKAYHDNYPTIYHLRKALA 145
WP 049531101 75 RRKNRLRYLQEIFSEEISKVDNSFFHRLDD- SFLV-- PEDKR- G SKYPIFATLT- EEKEYYKQFPTIYHLRKQLA 144
WP 049538452 75 RRKNRLRYLQEIFAEEMNKVDSSFFHRLDD- SFLV-- PEDKR- G SKYPIFATLA- EEKEYHKNFPTIYHLRKQLA 144
WP 049549711 75 RRKNRLRYLQEIFSGEMSKVDSSFFHRLDD- SFLV-- PEDKR- G SKYPIFATLV- EEKEYHKQFPTIYHLRKQLA 144
WP 007896501 76 RRRYRLCQLQNIFATEMVKVDDTFFQRLSE- SFFY-- YQDKA- F DKHPIFGNSK- EERAYHKTYPTIYHLRKDLA 145
EFR44625 28 RRRYRLCQLQNIFATEMVKVDDTFFQRLSE- SFFY-- YQDKA- F DKHPIFGNSK- EERAYHKTYPTIYHLRKDLA 97
WP 002897477 74 RRRNRILYLQEIFTESMNEIDESFFHRLDD- SFLV-- PEDKR- G SKYPIFATLQ- EEKEYHKQFPTIYHLRKQLA 143
WP 002906454 74 RRKNRLRYLQEIFSEEISKLDSSFFHRLDD- SFLV-- PEDKR- G SKYPIFATLE- EEKEYHKKFPTIYHLRKHLA 143
WP 009729476 75 RRKNRLRYLQEIFSEEIGKVDSSFFHRLDD- SFLI— PEDKR- G SKYPIFATLA- EEKKYHKQFPTIYHLRKQLA 144
CQR24647 74 RRRNRILYLQDIFSPELNQVDESFLHRLDD- SFLVa- -EDKR- G ERHVIFGNIA- DEVKYHKEFPTIYHLRKHLA 143
WP 000066813 75 RRKNRLRYLQEIFSQEISKVDSSFFHRLDD- FFLV-- PEDKR- G SKYPIFATLV- EEKEYHKKFPTIYHLRKHLA 144
WP 009754323 75 RRKNRLRYLQEIFAEEMSKVDSSFFHRLDD- SFLV-- PEDKS- G SKYPIFATLA- EEKEYHKKFPTIYHLRKHLA 144
WP 044674937 74 RRRNRILYLQEIFAEEINKIDDSFFQRLDD- SFLIv- -EDKQ- G SKHPIFGTLQ- EEKKYHKQFPTIYHLRKQLA 143
WP 044676715 74 RRRNRILYLQEIFAEEINKIDDSFFQRLDD- SFLIv- -EDKQ- G SKHPIFGTLQ- EEKEYHKQFPTIYHLRKQLA 143
WP 044680361 74 RRRNRILYLQEIFAEEINKIDDSFFQRLDD- SFLIv- -EDKQ- G SKHPIFGTLQ- EEKEYHKQFPTIYHLRKQLA 143
WP 044681799 74 RRRNRILYLQEIFAEEINKIDDSFFQRLDD- SFLIv- -EDKQ- G SKHPIFGTLQ- EEKKYHKQFPTIYHLRKQLA 143
WP 049533112 74 RRRNRLRYLQEI FAEEMNKVDENFFQRLDD- SFLV-- DEDKR- G ERHPIFGNIA- AEVKYHDDFPTIYHLRKHLA 143
WP 029090905 28 HRKFRLRLLEDMFEKEILSKDPSFFIRLKE- AFLSpkDEQKQ- F LFNDKDyTDADYYEQYKTIYHLRYDLI 100
WP 006506696 61 KRRERIRLLRAILQDMVLEKDPTFFIRLEHtSFLD-- EEDKA: .G DNYNLFIDEDfNDYTYYHKYPTIYHLRKALC 139
AIT42264 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE- SFLV-- EEDKK- H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP 034440723 73 RRRFRIRELQKIFDKSMGEVDSNFFHRLDE- SFLV-- EEDKE- Y SKYPIFSNEK- EDKNYYDKYPTIYHLRKDLA 142
AKQ21048 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE- SFLV-- EEDKK- H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 143
WP 004636532 74 RRRNRLIYLQDIFQQPMLAIDENFFHRLDD- SFFV-- PDDKS- Y DRHPIFGSLE- EEVAYHNTYPTIYHLRKHLA 143
WP 002364836 74 RRRNRLRYLQAFFEEAMTDLDENFFARLQE- SFLV-- PEDKK- w HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP 016631044 25 RRRNRLRYLQAFFEEAMTDLDENFFARLQE- SFLV-- PEDKK- w HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 94
EMS75795
WP 002373311 74 RRRNRLRYLQAFFEEAMTDLDENFFARLQE- SFLV-- PEDKK- W HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP 002378009 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE- SFLV-- PEDKK- W HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP 002407324 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE- SFLV-- PEDKK- W HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP 002413717 74 RRRNRLRYLQAFFEEAMTDLDENFFARLQE- SFLV-- PEDKK- W HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP 010775580 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE- SFLV-- PEDKK- W HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP 010818269 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE- SFLV-- PEDKK- W HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP 010824395 74 RRRNRLRYLQAFFEEAMTDLDENFFARLQE- SFLV--PEDKK- ■w HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA 143
WP "016622645 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE- SFLV- -PEDKK- ■w HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP "033624816 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE- SFLV- -PEDKK- ■w HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP "033625576 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE- SFLV- -PEDKK- ■w HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP "033789179 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE- SFLV- -PEDKK- ■w HRHPIFAKLE- DEVAYHETYPTIYHLRKKLA 143
WP "002310644 74 RRRQRILELQKIFAPEILKIDEHFFARLNE- SFLV- -LDEKK- Q SRHPVFATIK- QEKSYHQTYPTIYHLRQALA 143
WP "002312694 74 RRRQRILELQKIFAPEILKIDEHFFARLNE- SFLV- -PDEKK- Q SRHPVFATIK- QEKSYHQTYPTIYHLRQALA 143
WP "002314015 74 RRRQRILELQKIFAPEILKIDEHFFARLNE- SFLV- -LDEKK- Q SRHPVFATIK- QEKSYHQTYPTIYHLRQALA 143
WP "002320716 74 RRRQRILELQKIFAPEILKIDEHFFARLNE- SFLV- -LDEKK- Q SRHPVFATIK- QEKSYHQTYPTIYHLRQALA 143
WP "002330729 74 RRRQRILELQKIFAPEILKIDEHFFARLNE- SFLV- -LDEKK- Q SRHPVFATIK- QEKSYHQTYPTIYHLRQALA 143
WP "002335161 74 RRRQRILELQKIFAPEILKIDEHFFARLNE- SFLV- -LDEKK- Q SRHPVFATIK- QEKSYHQTYPTIYHLRQALA 143
WP "002345439 74 RRRQRILELQKIFAPEILKIDEHFFARLNE- SFLV- -LDEKK- Q SRHPVFATIK- QEKSYHQTYPTIYHLRQALA 143
WP "034867970 74 RRKYRLSKLQDLFAEELCKQDDCFFVRLEE- SFLV- -PEEKQ- Y KPASIFPTLE- EEKEYYQKYPTIYHLRQKLV 143
WP "047937432 74 RRRQRILELQKIFAPEILKIDEHFFARLNE- SFLV- -LDEKK- Q SRHPVFATIK- QEKSYHQTYPTIYHLRQALA 143
WP "010720994 74 RRKYRLSKLQDLFAEELCKQDDCFFVRLEE- SFLV- -PEEKQ- Y KPASIFPTLE- EEKEYYQKYPTIYHLRQKLV 143
WP "010737004 74 RRKYRLSKLQDLFAEELCKQDDCFFVRLEE- SFLV- -PEEKQ- Y KPASIFPTLE- EEKEYYQKYPTIYHLRQKLV 143
WP "034700478 74 RRKYRLSKLQDLFAEELCKQDDCFFVRLEE- SFLV- -PEEKQ- Y KPASIFPTLE- EEKEYYQKYPTIYHLRQKLV 143
WP "007209003 74 RRKNRICYLQEIFQPEMNHLDNNFFYRLNE- SFLVa —DDAK- Y DKHPIFGTLD- EEIHFHEQFPTIYHLRKYLA 143
WP "023519017 74 RRRQRVLALQDIFAEEIHKKDPNFFARLEE- GDRV- -EADKR- F AKFPVFATLS- EEKNYHRQYPTIYHLRHDLA 143
WP "010770040 74 RRRNRICRLQDLFTEEMNQVDANFFHRLQE- SFLV- -PDEKE- F ERHAIFGKME- EEVSYYREFPTIYHLRKHLA 143
WP "048604708 74 RRRQRISYLQTFFQEEMNRIDPNFFNRLDE- SFLI- -EEDKL- S ERHPIFGTIE- EEVAYHKNYATIYHLRKELA 143
WP "010750235 74 RRKYRILELQKIFSEEILKKDSHFFARLDE- SFLI- -PEDKQ- Y ARFPIFPTLL- EEKAYYQNYPTIYHLRQKLA 143
AII16583 113 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE- SFLV- -EEDKK- H ERHPIFGNIV- DEVAYHEKYPTIYHLRKKLV 182
WP 029073316 66 KRRERIRLLRGIMEDMVLDVDPTFFIRLANvSFLD- -QEDKKd .K SNYNLFIDKDfNDKTYYDKYPTIYHLRKHLC 144
WP "031589969 66 KRRERIRLLREIMEDMVLDVDPTFFIRLANvSFLD- -QEDKKd .K SNYNLFIDKDfNDKTYYDKYPTIYHLRKHLC 144
KDA45870 75 RRKNRLRYLQEI FAPALAKVDPNFFYRLEE- SSLVa —EDKK- Y DVYPIFGKRE- EELLYHDTHKTIYHLRSELA 144
WP 039099354 62 RRKWRLGLLREIFEPYITPVDDTFFLRKKQ- SNLS- -PKDQR- K -QTSLFNDRT- -DRAFYDDYPTIYHLRYKLM 132
AKP02966 65 RRKNRINWLNEIFSEELANTDPSFLIRLQN- SWVSkkDPDRK- R DKYNLFIDNPyTDKEYYREFPTIFHLRKELI 137
WP 010991369 74 RRRNRISYLQGIFAEEMSKTDANFFCRLSD- SFYV- -DNEKR- N SRHPFFATIE- EEVEYHKNYPTIYHLREELV 143
WP "033838504 74 RRRNRISYLQGIFAEEMSKTDANFFCRLSD- SFYV- -DNEKR- N SRHPFFATIE- EEVEYHKNYPTIYHLREELV 143
EHN60060 77 RRRNRISYLQGIFAEEMSKTDANFFCRLSD- SFYV- -DNEKR- N SRHPFFATIE- EEVEYHKNYPTIYHLREELV 146
EFR89594
WP 038409211 74 RRRNRIAYLQEI FAAEMAEVDANFFYRLED- SFYI- -ESEKR- SRHPFFATIE-EEVAYHEEYKTIYHLREKLV 143
EFR95520
WP 003723650 74 RRRNRI SYLQEI FAVEMANIDANFFCRLND- SFYV- -DSEKR- N SRHPFFATIE- EEVAYHDNYRTIYHLREKLV 143
WP "003727705 74 RRRNRI SYLQEI FAVEMANIDANFFCRLND- SFYV- -DSEKR- N SRHPFFATIE- EEVAYHKNYRTIYHLREELV 143
WP "003730785 74 RRRNRI SYLQEI FAVEMANIDANFFCRLND- SFYV- -DSEKR- N SRHPFFATIE- EEVAYHKNYRTIYHLREELV 143
WP "003733029 74 RRRNRI SYLQEI FAIQMNEVDDNFFNRLKE- SFYA- -ESDKK- Y NRHPFFGTVE- EEVAYYKDFPTIYHLRKELI 143
WP "003739838 74 RRRNRI SYLQEI FALEMANIDANFFCRLND- SFYV- -DSEKR- N SRHPFFATIE- EEVAYHKNYRTIYHLREELV 143
WP_014601172 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV—DSEKR N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143
WP_023548323 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV—DSEKR N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143
WP_031665337 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV—DSEKR N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143
WP_031669209 74 RRRNRISYLQEIFAIQMNEVDDNFFNRLKE-SFYA—ESDKK Y NRHPFFGTVE-EEVAYYKDFPTIYHLRKELI 143
WP_033920898 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV—DSEKR N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143
AKI42028 77 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV—DSEKR N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 146
AKI50529 77 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV—DSEKR N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 146
EFR83390
WP_046323366 74 RRRNRISYLQEIFTAEMFEVDANFFYRLED-SFYI—ESEKR Q SRHPFFATIE-EEVAYHENYRTIYHLREKLV 143
AKE81011 90 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV—EEDKK H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 159
CU082355 65 KRRERIRLLRAILQDMVLEKDPTFFIRLEHtSFLD—EEDKAkylG DNYNLFIDEDfNDYTYYHKYPTIYHLRKALC 143
WP_033162887 66 KRRERIRLLRDLLGDMVMEVDPTFFIRLLNvSFLD—EEDKQknlG DNYNLFIEKDfNDKTYYDKYPTIYHLRKELC 144
AGZ01981 107 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV—EEDKK H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 176
AKA60242 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV—EEDKK H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143
AKS40380 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV—EEDKK H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143
4UN5 B 78 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV—EEDKK H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 147
WP 010922251 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD-LNPDNSDV|JKL- -FIQLVQTYNQL- -FEEN- INASGVDAK-—AI 211
WP "039695303 145 DSSEKADLRLVYLALAHMI KFRGHFLI EGE- LNAENTDVQKI- -FADFVGVYNRT- -FDDS- H LSEITVDVA- — SI 212
WP "045635197 144 DSKEKTDLRLIYLALAHMI KYRGHFLYEEA- FDIKNNDIQKI- -FNEFISIYDNT- -FEGS- S LSGQNAQVE- —AI 211
Figure imgf000125_0001
WP 009880683
WP "010922251 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 211
WP "011054416 144 DSTDKVDLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "011284745 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 211
WP "011285506 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 211
WP "011527619 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 211
WP "012560673 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "014407541 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQIYNQL- -FEEN- - INASRVDAK- —AI 211
WP "020905136 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 211
WP "023080005 144 DSTDKVDLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "023610282 144 DSTDKVDLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "030125963 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 211
WP "030126706 144 DSTDKVDLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "031488318 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "032460140 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "032461047 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGG- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "032462016 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INANGVDAK- —AI 211
WP "032462936 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "032464890 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 211
WP "033888930 1 — PDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 36
WP "038431314 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "038432938 144 DSTDKVDLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
WP "038434062 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASRVDAK- —AI 211
BAQ51233 55 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- INASGVDAK- —AI 122
KGE60162
KGE60856
WP 002989955 144 DSTDKADLRLIYLALAHMI KFRGHFLI EGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 211
WP "003030002 144 DISQKADLRLVYLALAHMIKFRGHFLIEGQ- LKAENTNVQAL- -FKDFVEVYDKT- -VEES- H LSEMTVDAL—SI 211
WP "003065552 147 DSSEKADLRLVYLALAHMIKFRGHFLIEGE- LNAENTDVQKI- -FADFVGVYDRT- -FDDS- H LSEITVDAA- —SI 214
WP "001040076 144 DKKEKADLRLVYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEIFDTT- -FENN- D LLSQDVDVE- —AI 212
WP "001040078 144 DKQEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEIFDTT- -FENN- H LLSQNVDVE- —AI 212
WP "001040080 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ- -YQDFLEIFNIT- -FENN- D LLSQNVDVE- —AI 212
WP "001040081 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ- -YQDFLEIFNTI- -FENN- D LLSQNVDVE- —AI 212
WP "001040083 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040085 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP 001040087 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE-—AI 212
WP "001040088 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040089 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040090 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040091 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040092 144 DKKEKADLRLVYLALAHI IKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEIFDTS- -FENN- H LLSQNVDVE- —AI 212
WP "001040094 144 DKKEKADLRLIYLALAHI IKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEI FDTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040095 144 DKKEKADLRLIYLALAHI IKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEI FDTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040096 144 DKKEKADLRLIYLALAHI IKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEI FDTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040097 144 DKKEKADLRLIYLALAHI IKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEI FDTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040098 144 DKKEKADLRLIYLALAHI IKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEI FDTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040099 144 DKKEKADLRLIYLALAHI IKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEI FDTT- -FENN- D LLSQNVDVE- —AI 212
WP 001040100 144 DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEIFDTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040104 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040105 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "001040106 144 DKKEKANLRLVYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDVE- —GI 212
WP "001040107 144 DKKEKADLRLVYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDVE- —GI 212
WP "001040108 144 DKKEKADLRLVYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDVE- —GI 212
WP "001040109 144 DKKEKANLRLVYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDVE- —GI 212
WP "001040110 144 DKKEKANLRLVYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDVE- —GI 212
WP "015058523 144 DKKEKADLRLVYLALAHI IKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEIFDTS- -FENN- H LLSQNVDVE- —AI 212
WP "017643650 144 DKKEKADLRLIYLALAHI IKFRGHFLIEDDrFDVRNTDIQKQ- -YQAFLEI FDTT- -FENN- D LLSQNVDVE- —AI 212
WP "017647151 144 DKKEKADLRLFYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDIE- —GI 212
WP "017648376 144 DKKEKADLRLFYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDVE- —GI 212
WP "017649527 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "017771611 144 DKKEKADLRLVYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDVE- —GI 212
WP "017771984 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
CFQ25032 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- -D LLSQNVDVE- —AI 212
CFV16040 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- -D LLSQNVDVE- —AI 212
KLJ37842 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- -D LLSQNVDVE- —AI 212
KLJ72361 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- -D LLSQNVDVE- —AI 212
KLL20707 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
KLL42645 144 DKKEKANLRLVYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDVE- —GI 212
WP 047207273 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "047209694 144 DKKEKADLRLIYLALAHI IKFRGHFLIEDDs FDVRNTDIQKQ- -YQAFLEI FDTT- -FENN- D LLSQNVDVE- —AI 212
WP "050198062 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "050201642 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP "050204027 144 DKKEKANLRLVYLALAHI IKFRGHFLIEDDs FDVRNTDIQRQ- -YQAFLEI FDTT- -FENN- H LLSQNIDVE- —GI 212
WP "050881965 144 DKKEKADLRLIYIALAHI IKFRGHFLIEDDs FDVRNTDI SKQ- -YQDFLEIFNTT- -FENN- D LLSQNVDVE- —AI 212
WP 050886065 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ -YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212
AHN30376 144 DKKEKADLRLVYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ -YQAFLEIFDTS- -FENN- H LLSQNVDVE- - -AI 212
EA078426 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ -YQDFLEIFNTT- -FENN- D LLSQNVDVE- - -AI 212
CCW42055 144 DKKEKADLRLVYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ -YQAFLEIFDTT- -FENN- H LLSQNVDVE- - -AI 212
WP 0030415 02 144 DISQKADLRLVYLALAHMIKFRGHFLIEGQ- LKAENTNVQAL -FKDFVEVYDKT- -VEES- H LSEITVDAL- - -SI 211
WP "0375937 52 145 NSKEKADLRLVYLALAHMIKFRGHFLYEGD- LKAENTDVQAL -FKDFVEEYDKT- -IEES- H LSEITVDAL- - -SI 212
WP "0495166 84 145 DISQKADLRLVYLALAHMIKFRGHFLIEGQ- LKAENTNVQAL -FKDFVEVYDKT- -VEES- H LSEMTVDAL- - -SI 212
GAD46167 144 NSKEKADLRLVYLALAHMIKFRGHFLYEGD- LKAENTDVQAL -FKDFVEEYDKT- -IEES- H LSEITVDAL- - -SI 211
WP 0183634 70 145 DSTEKADLRLVYLALAHMIKFRGHFLIEGE- LNAENTDVQKL -FTDFVGVYDRT- -FDDS- H LSEITVDAA- - -SI 212
WP "0030438 19 144 DSPEKADLRLIYLALAHIIKFRGHFLIEGK- LNAENSDVAKL -FYQLIQTYNQL- -FEES- - LDEIEVDAK- - -GI 211
WP "0062696 58 144 DTSKKADLRLVYLALAHMIKFRGHFLYEGD- LKAENTDVQAL -FKDFVEEYDKT- -IEES- H LSEITVDAL- - -SI 211
WP "0488008 89 144 DSTGKVDLRLVYLALAHMIKFRGHFLIEGQ- LKAENTDVQTL -FNDFVEVYDKT- -IEES- H LAEITVDAL- - -SI 211
WP "0127671 06 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDMDKL -FIQLVQTYNQL- -FEEN- - INASRVDAK- - -AI 211
WP "0146123 33 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDVDKL -FIQLVQTYNQL- -FEEK- - INASGVDAK- - -AI 211
WP "0150170 95 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDMDKL -FIQLVQTYNQL- -FEEN- - INASRVDAK- - -AI 211
WP "0150576 49 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDMDKL -FIQLVQTYNQL- -FEEN- - INASRVDAK- - -AI 211
WP "0483272 15 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDMDKL -FIQLVQTYNQL- -FEEN- - INASRVDAK- - -AI 211
WP "0495193 24 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDVDKL -FIQLVQTYNQL- -FEEN- - INASRVDAK- - -AI 211
WP "0125159 31 144 DNPQKADLRLIYLAVAHIIKFRGHFLIEGT- LSSKNNNLQKS -FDHLVDTYNLL- -FEEQ- - LLTEGINAK- - -EL 211
WP "0213209 64 144 DNPQKADLRLIYLAVAHIIKFRGHFLIEGT- LSSKNNNLQKS -FDHLVDTYNLL- -FEEQ- - LLTEGINAK- - -EL 211
WP "0375817 60 144 DNPQKADLRLIYLAVAHIIKFRGHFLIEGT- LSSKNNNLQKS -FDHLVDTYNLL- -FEEQ- - LLTEGINAK- - -EL 211
WP "0042324 81 144 DSPEKVDLRLVYLALAHMIKFRGHFLIEGQ- LNAENTDVQKI -FADFVGVYDRT- -FDDS- H LSEITVDAA- - -SI 211
WP "0098545 40 145 DSSEKADLRLVYLALAHMIKYRGHFLIEGK- LNAENTDVQKL -FTDFVGVYDRT- -FDDS- H LSEITVDVA- - -ST 212
WP "0129621 74 145 DSHEKADLRLIYLALAHMIKFRGHFLIEGE- LNAENTDVQKL -FEAFVEVYDRT- -FDDS- N LSEITVDAS- - -SI 212
WP "0396953 03 145 DSSEKADLRLVYLALAHMIKFRGHFLIEGE- LNAENTDVQKI -FADFVGVYNRT- -FDDS- H LSEITVDVA- - -SI 212
WP "0143349 83 144 DSQEKADLRLVYLALAHMIKYRGHFLIEGE- LNAENTDVQKL -FNVFVETYDKI- -VDES- H LSEIEVDAS- - -SI 211
WP "0030992 69 144 DSDQKADLRLIYLALAHIIKFRGHFLIEGN- LDSENTDVHVL -FLNLVNIYNNL- -FEED- - VETASIDAE- - -KI 211
AHY15608 144 DSDQKADLRLIYLALAHIIKFRGHFLIEGN- LDSENTDVHVL -FLNLVNIYNNL- -FEED- VETASIDAE- - -KI 211
AHY17476 144 DSDQKADLRLIYLALAHIIKFRGHFLIEGN- LDSENTDVHVL -FLNLVNIYNNL- -FEED- - VETASIDAE- - -KI 211
ESR09100
AGM98575 144 DSDQKADLRLIYLALAHIIKFRGHFLIEGN- LDSENTDVHVL -FLNLVNIYNNL- -FEED- - VETASIDAE- - -KI 211
ALF27331 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL -FQEFLAVYDNT- -FENS- S LQEQNVQVE- - -EI 211
WP 0183724 92 144 DTPDKMDIRLIYLALAHIIKYRGHFLIEGD- LDIENIGIQDS -FKSFIEEYNTQ- -FGTK- - -LDSTTKVE- - -AI 209
WP "0456180 28 145 DSKEKADFRLIYLALAHIIKYRGHFLYEES- FDIKNNDIQKI -FNEFISIYDNT- -FEGS- s LNGQNAQVE- - -AI 212
WP "0456351 97 144 DSKEKTDLRLIYLALAHMIKYRGHFLYEEA- FDIKNNDIQKI -FNEFISIYDNT- -FEGS- s LSGQNAQVE- - -AI 211
WP "0022635 49 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL -FQEFLAVYDNT- -FENS- s LQEQNVQVE- - -EI 211
WP "0022638 87 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL -FQEFLAVYDNT- -FENS- s LQEQNVQVE- - -EI 211
WP "0022649 20 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE- LNAENTDVQKL -FADFVGVYDRT- -FDDS- H LSEITVDAS- - -SI 211
WP "0022690 43 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL -FQEFLAVYDNT- -FENS- S LQEQNVQVE- - -EI 211
WP 002269448 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE-—EI 211
WP "0022 71977 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 72766 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 73241 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 75430 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 76448 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 77050 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE- LNAENTDVQKL- -FADFVGVYDRT- -FDDS- H LSEITVDAS- — SI 211
WP "0022 77364 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 79025 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 79859 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE- LNAENTDVQKL- -FADFVGVYDRT- -FDDS- H LSEITVDAS- — SI 211
WP "0022 80230 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 81696 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 82247 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE- LNAENTDVQKL- -FADFVGVYDRT- -FDDS- H LSEITVDAS- — SI 211
WP "0022 82906 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 83846 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 87255 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 88990 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0022 89641 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0022 90427 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0022 95753 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0022 96423 144 DNPEKTDLRLVYLALAHIIKFGGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0023 04487 144 NSTEKADLRLVYLSLAHMIKFRGHFLIEGQ- LKAENTNVQAL- -FKDFVEVYDKT- -VEES- H LSEMTVDAL- — SI 211
WP "0023 05844 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0023 07203 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQKL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
WP "0023 10390 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0023 52408 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0129 97688 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "θ146 77909 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0193 12892 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0193 13659 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0193 14093 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQKL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0193 15370 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0198 03776 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0198 05234 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0247 83594 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0247 84288 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE- LNAENTDVQKL- -FADFVGVYDRT- -FDDS- H LSEITVDAS- — SI 211
WP "0247 84666 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0247 84894 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- s LQEQNVQVE- —EI 211
WP "0247 86433 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE- LNAENTDVQKL- -FADFVGVYDRT- -FDDS- H LSEITVDAS- — SI 211
WP 049473442 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE-—EI 211
WP "049474547 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 211
EMC03581 137 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK- FDTRNNDVQRL- -FQEFLAVYDNT- -FENS- S LQEQNVQVE- —EI 204
WP 000428612 145 DSKEKTDLRLIYLALAHMIKYRGHFLYEDT- FDIKNNDIQKI- -FNEFISIYNNT- -FEGN- S LSGQNVQVE- —AI 212
WP "000428613 145 DSKEKTDLRLIYLALAHMIKYRGHFLYEDT- FDIKNNDIQKI- -FSEFISIYDNT- -FEGS- S LSGQNAQVE- —AI 212
WP "049523028 144 DSKEKVDLRLIYLALAHIIKYRGHFLYEDS- FDIKNNDIQKI- -FNEFTILYDNT- -FEES- S LSKGNAQVE- —EI 211
WP "003107102 113 DSDEKADLRLIYLALAHIIKFRGHFLIEGD- LDSQNTDVNAL- -FLKLVDTYNLM- -FEDD- - IDTQTIDAT- —VI 180
WP "054279288 146 DNTEKADLRLIYLALAHIIKFRGHFLIEGA- LSANNTDVQQL- -VHALVDAYNIM- -FEED- LDIEAIDVK- —AI 213
WP "049531101 145 DSKEKADLRLIYLTLAHMIKYRGHFLYEES- FDIKNNDIQKI- -FNEFISIYDNT- -FEGS- S LSGQNAQVE- —AI 212
WP "049538452 145 DSKEKADLRLIYLALAHMIKYRGHFLYEEA- FDIKNNDIQKI- -FNEFINIYDNT- -FEGS- s LSGQNEQVE- —AI 212
WP "049549711 145 DSKEKADLRLIYLVLAHMIKYRGHFLYEEA- FDIKNNDIQKI- -FNEFISIYDNT- -FEGS- s LSGQNAQVE- —TI 212
WP "007896501 146 DRDQKADLRLIYLALSHIIKFRGHFLIEGK- LNSENTDVQKL- -FIALVTVYNLL- -FEEE- - IAGETCDAK- —AL 213
EFR44625 98 DRDQKADLRLIYLALSHIIKFRGHFLIEGK- LNSENTDVQKL- -FIALVTVYNLL- -FEEE- IAGETCDAK- —AL 165
WP 002897477 144 DSKEKSDVRLIYLALAHMIKYRGHFLYEET- FDIKNNDIQKI- -FNEFINIYDNT- -FEGS- s LSGQNAQVE- —AI 211
WP "002906454 144 DSKEKTDLRLIYLALAHMIKYRGHFLYEES- FDIKNNDIQKI- -FNEFISIYDNT- -FEGS- s LSGQNAQVE- —AI 211
WP "009729476 145 DSKEKTDLRLIYLALAHMIKYRGHFLYEEA- FDIKNNDIQKI- -FNEFISIYNNT- -FEGN- s LSGQNVQVE- —AI 212
CQR24647 144 DSSEKADLRLVYLALAHIIKYRGHFLIDEP- IDIRNMNSQNL- -FKEFLLAFDGI- -QVDC- Y LASKHTDIS- —GI 211
WP 000066813 145 DSKEKTDLRLIYLALAHMIKYRGHFLYEES- FDIKNNDIQKI- -FSEFISIYDNT- -FEGK- s LSGQNAQVE- —AI 212
WP "009754323 145 DSKEKADLRLIYLALAHITKYRGHFLYEEA- FDIKNNDIQKI- -FNEFINIYDNT- -FEGS- s LSGQNAQVE- —AI 212
WP "044674937 144 DSSQKADIRLIYLALAHIIKYRGHFLFEGD- LKSENKDVQHL- -FNDFVEMFDKT- -VEGS- Y LSENLPNVA- —DV 211
WP "044676715 144 DSSQKADIRLIYLALAHIIKYRGHFLFEGD- LKSENKDVQHL- -FNDFVEMFDKT- -VEGS- Y LSENLPNVA- —DV 211
WP "044680361 144 DSSQKADIRLIYLALAHIIKYRGHFLFEGD- LKSENKDVQHL- -FNDFVEMFDKT- -VEGS- Y LSENLPNVA- —DV 211
WP "044681799 144 DSSQKADIRLIYLALAHIIKYRGHFLFEGD- LKSENKDVQHL- -FNDFVEMFDKT- -VEGS- Y LSENLPNVA- —DV 211
WP "049533112 144 DISQKADLRLVYLALAHMIKFRGHFLIEGQ- LKAENTNVQAL- -FKDFVEVYDKT- -VEES- H LSEMTVDAL—SI 211
WP "029090905 101 SQHRQFDIREVYLAIHHLIKYRGHFIYEDQtFTTDGNQLQHH- -IKAIITMINST1 NR- II PETIDINvfeKI 171
WP "006506696 140 ESTEKADPRLIYLALHHIVKYRGNFLYEGQkFNMDASNIEDK- -LSDIFTQFTSFnnlPYEdD —KKNLEIL- —EI 210
AIT42264 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- INASGVDAK- —AI 211
WP 034440723 143 DSNQKADLRLIYLALAHMIKYRGHFLIEGD- LKMDGISISES- -FQEFIDSYNEVcaLEDE- N NDELLTQIE- —NI 217
AKQ21048 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN- - INASGVDAK- —AI 211
WP 004636532 144 DNPEKADLRLVYTALAHIVKYRGHFLIEGE- LNTENTSISET- -FEQFLDTYSDI- -FKEQ- - LVGDISKVE- —EI 210
WP "002364836 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKEQ- -FQQFMIIYNQT- - VNGeS PLPESVLIE- —EE 217
WP "016631044 95 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENTSVKDQ- -FQQFMVIYNQT- -FVNGeS PLPESVLIE- —EE 168
EMS75795
WP 002373311 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENTSVKEQ- -FQQFMVIYNQT- - VNGeS PLPESVLIE- —EE 217
WP "002378009 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKEQ- -FQQFMIIYNQT- -FVNGeS PLPESVLIE- —EE 217
WP "002407324 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKEQ- -FQQFMIIYNQT- -FVNGeS PLPESVLIE- —EE 217
WP "002413717 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKEQ- -FQQFMIIYNQT- -FVNGeS PLPESVLIE- —EE 217
WP "010775580 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKEQ- -FQQFMIIYNQT- -FVNGeS PLPESVLIE- —EE 217
WP "010818269 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKEQ- -FQQFMIIYNQT- -FVNGeS PLPESVLIE- —EE 217
WP 010824395 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENTSVKDQ--FQQFMVIYNQT--F GeS PLPESVLIE-—EE 217
WP "016622645 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKEK- -FQQFMIIYNQT- -F GeG PLPESVLIE- —EE 217
WP "033624816 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKDQ- -FQQFMVIYNQT- -F GeS PLPESVLIE- —EE 217
WP "033625576 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKEQ- -FQQFMIIYNQT- -F GeS PLPESVLIE- —EE 217
WP "033789179 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK- LSTENISVKEQ- -FQQFMIIYNQT- -FWGeS PLPESVLIE- —EE 217
WP "002310644 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE- LNTENSSVTET- -FRQFLSTYNQQ- -FSEA-D KLDEAVDCS- —FV 216
WP "002312694 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE- LNTENSSVTET- -FRQFLSTYNQQ- -FSEA-G KLDEAVDCS- —FV 216
WP "002314015 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE- LNTENSSVTET- -FRQFLSTYNQQ- -FSEA-D KLDEAVDCS- —FV 216
WP "002320716 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE- LNTENSSVTET- -FRQFLSTYNQQ- -FSEA-D KLDEAVDCS- —FV 216
WP "002330729 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE- LNTENSSVTET- -FRQFLSTYNQQ- -FSEA-D KLDEAVDCS- —FV 216
WP "002335161 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE- LNTENSSVTET- -FRQFLSTYNQQ- -FSEA-D KLDEAVDCS- —FV 216
WP "002345439 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE- LNTENSSVTET- -FRQFLSTYNQQ- -FSEA-D KLDEAVDCS- —FV 216
WP "034867970 144 DSTEKEDLRLVYLALAHLLKYRGHFLFEGD- LDTENTSIEES- -FRVFLEQYSKQ- -SDQP— -LIVHQPVL- —TI 209
WP "047937432 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE- LNTENSSVTET- -FRQFLSTYNQQ- -FSEA-D KLDEAVDCS- —FV 216
WP "010720994 144 DSTEKGDLRLVYLALAHLLKYRGHFLFEGD- LDTENTSIEES- -FRVFLEQYGKQ- -SDQP— -LIVHQPVL- —TI 209
WP "010737004 144 DSTEKEDLRLVYLALAHLLKYRGHFLFEGD- LDTENTSIEES- -FRVFLEQYSKQ- -SDQP— -LIVHQPVL- —TI 209
WP "034700478 144 DSTEKEDLRLVYLALAHLLKYRGHFLFEGD- LDTENTSIEES- -FRVFLEQYGKQ- -SDQP— -LIVHQPVL- —TI 209
WP "007209003 144 DGDEKADLRLVYLAIAHIIKFRGNFLIEGE- LNTENNSVIELs —KVFVQLYNQT1 -SELE— FIDESIDFS- —EV 214
WP "023519017 144 NSKEQADIRLVYLAIAHCLKYRGHFLFEGE- LDTENTSVTEN- -YQQFLQAYQQF- -FPEP— -IGDLDDAV- —PI 209
WP "010770040 144 DTSEQADLRLVYLALAHIVKYRGHFLIEGE- LNTENSSVSET- -FRTFIQVYNQI- -FRENe- PLAVPDNIE- —EL 212
WP "048604708 144 DAEEKADLRLVYLALAHIIKYRGHFLIEGR- LSTENTSTEET- -FKTFLQKYNQT- -FN PVDETISIG- —SI 208
WP "010750235 144 DSTEKADIRLVYLALAHMIKYRGHFLFEGE- LDTENTSVEET- -FKEFIDIYNEQ- -FEEG— -IIFYKDIP- —LI 209
AII16583 183 DSTDKADLRLIYLALAHMIKFRGHFLIEGD- LNPDNSDVDKL- -FIQLVQTYNQL- -FEEN— INASGVDAK- —AI 250
WP 029073316 145 ESKEKEDPRLIYLALHHIVKYRGNFLYEGQkFSMDVSNIEDK- -MIDVLRQFNEInlFEYVeD —KKIDEVL- —NV 215
WP "031589969 145 ESKEKEDPRLIYLALHHIVKYRGNFLYEGQkFSMDVSNIEDK- -MIDVLRQFNEInlFEYVeD —KKIDEVL- —NV 215
KDA45870 145 NNDRPADLRLVYLALAHIIKYRGNFLLEGE- IDLRTTDINKV- -FAEFSETLNEN- -SDEN1G KLDVA- —DI 209
WP 039099354 133 TEKRQFDIREIYLAMHHIVKYRGHFLNEAPvSSFKSSEINLVahFDRLNTIFADL- -FSESgF -TDKLAEVK- —AL 206
AKP02966 138 INKNKADIRLVYLALHNILKYRGNFTYEHQkFNISTLNSNLS- —KELIELNQQLikYDIS— -FPDNCDWNhisDI 208
WP 010991369 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA- LDTQNTSVDGI- -YKQFIQTYNQV- -FASGiE KLEDNKDVA- —KI 217
WP "033838504 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA- LDTQNTSVDGI- -YKQFIQTYNQV- -FASGiE KLEDNKDVA- —KI 217
EHN60060 147 NSSEKADLRLVYLALAHIIKYRGNFLIEGA- LDTQNTSVDGI- -YKQFIQTYNQV- -FASGiE KLEDNKDVA- —KI 220
EFR89594
WP 038409211 144 NSSDKADLRLVYLALAHIIKYRGNFLIEGM- LDTKNTSVDEV- -FKQFIQTYNQI- -FASDiE RLEENKEVA- —EI 217
EFR95520
WP 003723650 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA- LDTKNTSVDEV- -YKQFIETYNQV- -FMSNiE KVEENIEVA- —NI 217
WP "003727705 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA- LDTKNTSVDEV- -YKQFIQTYNQV- -FMSNiE KVEENTEVA- —SI 217
WP "003730785 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA- LDTKNTSVDEV- -YKQFIQTYNQV- -FMSNiE KVEENTEVA- —SI 217
WP "003733029 144 DSQKKADLRLVYLALAHIIKYRGHFLIEGA- LDTKNTSIDEM- -FKQFLQIYNQV- -FANDiE KTEKNQEVA- —QI 217
WP "003739838 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA- LDTKNTSVDGV- -YKQFIQTYNQV- -FISNiE KMEENTTVA- —DI 217
WP 014601172 144 NSSEKADLRLVYLALAHI IKYRGNFLIEGA- LDTKNTSVDGV- -YEQFIQTYNQV- -FMSNiE KVEENIEVA-
WP 023548323 144 NSSEKADLRLVYLALAHI IKYRGNFLIEGA- LDTKNTSVDGV- -YEQFILTYNQV- -FMSNiE KVEENIEVA-
WP 031665337 144 NSSEKADLRLVYLALAHI IKYRGNFLIEGA- LDTKNTSVDGV- -YEQFIQTYNQV- -FMSNiE KVEENIEVA-
WP 031669209 144 DSQKKADLRLVYLALAHI IKYRGHFLIEGA- LDTKNTSIDEM- -FKQFLQIYNQV- -FANDiE KTEKNQEVA-
WP 033920898 144 NSSEKADLRLVYLALAHI IKYRGNFLIEGA- LDTKNTSVDGV- -YEQFIQTYNQV- -FMSNiE KVEENIEVA-
AKI42028 147 NSSEKADLRLVYLALAHI IKYRGNFLIEGA- LDTKNTSVDGV- -YEQFIQTYNQV- -FMSNiE KVEENIEVA-
AKI50529 147 NSSEKADLRLVYLALAHI IKYRGNFLIEGA- LDTKNTSVDGV- -YEQFIQTYNQV- -FMSNiE KVEENIEVA-
EFR83390
WP 046323366 144 NSSDKADLRLVYLALAHIIKYRGNFLIEGK-LDTKNTSVDEV- -FKQFIKTYNQV—FASDiE RIEENNEVA-
AKE81011 160 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL- -FIQLVQTYNQL—FEEN— INASGVDAK-
CU082355 144 ESTEKADPRLIYLALHHIVKYRGNFLYEGQkFNMDASNIEDK- -LSDVFTQFADFnnlPYEdD —KKNLEIL-
WP 033162887 145 ENKEKADPRLIYLALHHIVKYRGNFLYEGQsFTMDNSDIEER- -LNSAIEKFMSIneFDNRiV —SDINSMI-
AGZ 01981 177 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL- -FIQLVQTYNQL—FEEN— INASGVDAK-
AKA60242 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL- -FIQLVQTYNQL—FEEN— INASGVDAK-
AKS40380 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL- -FIQLVQTYNQL—FEEN— INASGVDAK-
4UN5 B 148 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL- -FIQLVQTYNQL—FEEN— INASGVDAK-
WP 010922251 212 LSAR-LSKSRRLENLIAQ-L- PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-H5H--KLQ--LSKDTYDDDLDN 277
WP "039695303 213 LTEK- ISKSRRLENLIKY- Y- PT EKKNTLFGNLIALALGLQPNFKTNF- -KLSED- -A— -KLQ- -FSKDTYEEDLEE 278
WP "045635197 212 FTDK- ISKSAKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEDK- -A— -PLQ- -FSKDTYDEDLEN 277
Figure imgf000132_0001
WP "010922251 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "011054416 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "011284745 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "011285506 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "011527619 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "012560673 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "014407541 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "020905136 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "023080005 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "023610282 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "030125963 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "030126706 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "031488318 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "032460140 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "032461047 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "032462016 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "032462936 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALLLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "032464890 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "033888930 37 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 102
WP "038431314 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "038432938 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -T— -KLQ- -LSKDTYDDDLDN 277
WP "038434062 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
BAQ51233 123 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 188
KGE60162
KGE60856
WP 002989955 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP "003030002 212 LTEK- VSKSRRLENLIAH- Y- PA EKKNTLFGNLIALSLGLQPNFKTNF- -QLSED- -A— -KLQ- -FSKDTYEEDLEG 277
WP "003065552 215 LTEK- ISKSRRLENLIKY- Y- PT EKKNTLFGNLIALALGLQPNFKMNF- -KLSED- -A— -KLQ- -FSKDSYEEDLGE 280
WP "001040076 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- -T— -PLQ- -FAKDSYDEDLEN 278
WP "001040078 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- -T— -PLQ- -FAKDSYDEDLEN 278
WP "001040080 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- -T— -PLQ- -FAKDSYDEDLEN 278
WP "001040081 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- -T— -PLQ- -FAKDSYDEDLEN 278
WP "001040083 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- -T— -PLQ- -FAKDSYDEDLEN 278
WP "001040085 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- -T— -PLQ- -FAKDSYDEDLEN 278
WP 001040087 213 LTDK- ISKSAKKDRILAQ-Y-PN QKSTGI FAEFLKLIVGNQADFKKYF--NLEDK--T-—PLQ--FAKDSYDEDLEN 278
WP 001040088 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040089 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040090 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040091 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040092 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040094 213 LTDK- ISKSAKKDRILAR- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040095 213 LTDK- ISKSAKKDRILAR- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040096 213 LTDK- ISKSAKKDRILAR- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040097 213 LTDK- ISKSAKKDRILAR- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040098 213 LTDK- ISKSAKKDRILAR- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- -T- —PLQ- -FAKDSYDEDLEN 278
WP 001040099 213 LTDK- ISKSAKKDRILAR- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040100 213 LTDK- ISKSAKKDRILAR- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040104 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040105 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040106 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040107 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040108 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040109 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 001040110 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 015058523 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- -T- —PLQ- -FAKDSYDEDLEN 278
WP 017643650 213 LTDK- ISKSAKKDRILAR- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 017647151 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 017648376 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 017649527 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 017771611 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 017771984 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
CFQ25032 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
CFV16040 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
KLJ37842 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
KLJ72361 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- -T- —PLQ- -FAKDSYDEDLEN 278
KLL20707 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
KLL42645 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 047207273 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 047209694 213 LTDK- ISKSAKKDRILAR- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 050198062 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 050201642 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 050204027 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 050881965 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- T- —PLQ- -FAKDSYDEDLEN 278
WP 050886065 213 LTDK-ISKSAKKDRILAQ-Y- PN QKSTGI FAEFLKLIVGNQADFKKYF--NLEDK--T---PLQ--FAKDSYDEDLEN 278
AHN30376 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- -T- - -PLQ- -FAKDSYDEDLEN 278
EA078426 213 LTDK- ISKSAKKDRILAQ- Y- PN QKSTGI FAEFLKLIVGNQADFKKYF- -NLEDK- -T- - -PLQ- -FAKDSYDEDLEN 278
CCW42055 213 LTDK- ISKSAKKDRILAQ- Y- PD QKSTGI FAEFLKLIVGNQADFKKHF- -NLEDK- -T- - -PLQ- -FAKDSYDEDLEN 278
WP 0030415 02 212 LTEK- VSKSRRLENLIAH- Y- PA EKKNTLFGNLIALFLGLQPNFKTNF- -QLSED- -A- - -KLQ- -FSKDTYEEDLEG 277
WP 0375937 52 213 LTEK- VSKSSRLENLIAH- Y- PT EKKNTLFGNLIALSLGLQPNFKTNF- -QLSED- -A- - -KLQ- -FSKDTYEEDLEE 278
WP 0495166 84 213 LTEK- VSKSRRLENLVEC- Y- PT EKKNTLFGNLIALSLGLQPNFKTNF- -QLSED- -A- - -KLQ- -FSKDTYEEDLEG 278
GAD46167 212 LTEK- VSKSSRLENLIAH- Y- PT EKKNTLFGNLIALSLGLQPNFKTNF- -QLSED- -A- - -KLQ- -FSKDTYEEDLEE 277
WP 0183634 70 213 LTEK- ISKSRRLENLINN- Y- PK EKKNTLFGNLIALALGLQPNFKTNF- -KLSED- -A- - -KLQ- -FSKDTYEEDLEE 278
WP 0030438 19 212 LSAR- LSKSKRLEKLIAV- F- PN EKKNGLFGNIIALALGLTPNFKSNF- -DLTED- -A- - -KLQ- -LSKDTYDDDLDE 277
WP 0062696 58 212 LTEK- VSKSSRLENLIAH- Y- PT EKKNTLFGNLIALSLDLHPNFKTNF- -QLSED- -A- - -KLQ- -FSKDTYEEDLEG 277
WP 0488008 89 212 LTEK- VSKSRRLENLVKC- Y- PT EKKNTLFGNLIALSLGLQPNFKTNF- -QLSED- -A- - -KLQ- -FSKDTYEEDLEE 277
WP 0127671 06 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A- - -KLQ- -LSKDTYDDDLDN 277
WP 0146123 33 212 LSAR- LSKSKRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A- - -KLQ- -LSKDTYDDDLDN 277
WP 0150170 95 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A- - -KLQ- -LSKDTYDDDLDN 277
WP 0150576 49 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A- - -KLQ- -LSKDTYDDDLDN 277
WP 0483272 15 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A- - -KLQ- -LSKDTYDDDLDN 277
WP 0495193 24 212 LSAR- LSKSRRLENLIAQ- L- PG EKRNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A- - -KLQ- -LSKDTYDDDLDN 277
WP 0125159 31 212 LSAA- LSKSKRLENLISL- I- PG QKKTGIFGNIIALSLGLTPNFKANF- -GLSKD- -V- - -KLQ- -LAKDTYADDLDS 277
WP 0213209 64 212 LSAA- LSKSKRLENLISL- I- PG QKKTGIFGNIIALSLGLTPNFKANF- -GLSKD- -V- - -KLQ- -LAKDTYADDLDS 277
WP 0375817 60 212 LSAA- LSKSKRLENLISL- I- PG QKKTGIFGNIIALSLGLTPNFKANF- -GLSKD- -V- - -KLQ- -LAKDTYADDLDS 277
WP 0042324 81 212 LTEK- ISKSRRLENLIKQ- Y- PT EKKNTLFGNLVALALGLQPNFKTNF- -KLSED- -A- - -KLQ- -FSKDTYDEDLEE 277
WP 0098545 40 213 LTEK- ISKSRRLENLIKY- Y- PT EKKNTLFGNLIALALGLQPNFKMNF- -KLSED- -A- - -KLQ- -FSKDTYEEDLEE 278
WP 0129621 74 213 LTEK- FSKSRRLENLIKH- Y- PT EKKNTLFGNLVALALGLQPNFKTSF- -KLSED- -A- - -KLQ- -FSKDTYEEDLEE 278
WP 0396953 03 213 LTEK- ISKSRRLENLIKY- Y- PT EKKNTLFGNLIALALGLQPNFKTNF- -KLSED- -A- - -KLQ- -FSKDTYEEDLEE 278
WP 0143349 83 212 LTEK- VSKSRRLENLIKQ- Y- PT EKKNTLFGNLIALALGLQPNFKTNF- -KLSED- -A- - -KLQ- -FSKDTYEEDLEE 277
WP 0030992 69 212 LTSK- TSKSRRLENLIAE- I- PN QKRNMLFGNLVSLALGLTPNFKTNF- -ELLED- -A- - -KLQ- -ISKDSYEEDLDN 277
AHY15608 212 LTSK- TSKSRRLENLIAE- I- PN QKRNMLFGNLVSLALGLTPNFKTNF- -ELLED- -A- - -KLQ- -ISKDSYEEDLDN 277
AHY17476 212 LTSK- TSKSRRLENLIAE- I- PN QKRNMLFGNLVSLALGLTPNFKTNF- -ELLED- -A- - -KLQ- -ISKDSYEEDLDN 277
ESR09100
AGM98575 212 LTSK- TSKSRRLENLIAE- I- PN QKRNMLFGNLVSLALGLTPNFKTNF- -ELLED- -A- - -KLQ- -ISKDSYEEDLDN 277
ALF27331 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- - -PLQ- -FSKDTYEEELEV 277
WP 0183724 92 210 FTEN- SSKAKRVETILGL- F- PD ETAAGNLDKFLKLMLGNQADFKKVF- -DLEEK- -iTLQ- -FSKDSYEEDLEL 275
WP 0456180 28 213 FTDK- ISKSAKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A- - -PLQ- -FSKDTYDEDLEN 278
WP 0456351 97 212 FTDK- ISKSAKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEDK- -A- - -PLQ- -FSKDTYDEDLEN 277
WP 0022635 49 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- - -PLQ- -FSKDTYEEELEV 277
WP 0022638 87 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- - -PLQ- -FSKDTYEEELEV 277
WP 0022649 20 212 LTEK- ISKSRRLEKLINN- Y- PK EKKNTLFRNLVALSLGLQPNFKTNF- -KLSED- -A- - -KLQ- -FSKDTYEEDLEE 277
WP 0022690 43 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- - -PLQ- -FSKDTYEEELEV 277
WP 002269448 212 LTDK- ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK--A-—PLQ--FSKDTYEEELEV 277
WP "002271977 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEDLEE 277
WP "002272766 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEDLEE 277
WP "002273241 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002275430 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002276448 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002277050 212 LTEK- ISKSRRLEKLINN- Y- PK EKKNTLFGNLIALSLGLQPNFKTNF- -KLSED- -A- —KLQ- -FSKDTYEEDLEE 277
WP "002277364 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002279025 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002279859 212 LTEK- ISKSRRLEKLINN- Y- PK EKKNTLFGNLIALSLGLQPNFKTNF- -KLSED- -A- —KLQ- -FSKDTYEEELEV 277
WP "002280230 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002281696 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002282247 212 LTEK- ISKSRRLEKLINN- Y- PK EKKNTLFGNLIALSLGLQPNFKTNF- -KLSED- -A- —KLQ- -FSKDTYEEDLEE 277
WP "002282906 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002283846 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDIYEEELEV 277
WP "002287255 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002288990 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDIYEEELEV 277
WP "002289641 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGCFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002290427 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDIYEEELEV 277
WP "002295753 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002296423 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDIYEEELEV 277
WP "002304487 212 LTEK- VSKSRRLENLVEC- Y- PT EKKNTLFGNLIALSLGLQPNFKTNF- -QLSED- -A- —KLQ- -FSKDTYEEDLEG 277
WP "002305844 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "002307203 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -LSKDTYEEELEV 277
WP "002310390 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDIYEEELEV 277
WP "002352408 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDIYEEELEV 277
WP "012997688 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "014677909 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDIYEEELEV 277
WP "019312892 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "019313659 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIIGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "019314093 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -LSKDTYEEELEV 277
WP "019315370 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "019803776 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -V- —PLQ- -FSKDTYEEELEV 277
WP "019805234 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDIYEEELEV 277
WP "024783594 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "024784288 212 LTEK- ISKSRRLEKLINN- Y- PK EKKNTLFGNLIALSLGLQPNFKTNF- -KLSED- -A- —KLQ- -FSKDTYEEDLEE 277
WP "024784666 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "024784894 212 LTDK- ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A- —PLQ- -FSKDTYEEELEV 277
WP "024786433 212 LTEK- ISKSRRLEKLINN- Y- PK EKKNTLFGNLIALSLGLQPNFKTNF- -KLSED- -A- —KLQ- -FSKDTYEEDLEE 277
WP 049473442 212 LTDK--ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK--A—-PLQ--FSKDTYEEDLEE 277
WP 049474547 212 LTDK- -ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A— -PLQ- -FSKDTYEEELEV 277
EMC03581 205 LTDK- -ISKSAKKDRVLKL- F- PN EKSNGRFAEFLKLIVGNQADFKKHF- -ELEEK- -A— -PLQ- -FSKDTYEEELEV 270
WP 000428612 213 FTDK- -ISKSAKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A— -PLQ- -FSRDTYDEDLEN 278
WP 000428613 213 FTDK- -ISKSAKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLGEK- -A— -PLQ- -FSKDTYDEDLEN 278
WP 049523028 212 FTDK- -ISKSAKRDRVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A— -PLQ- -FSKDTYEEDLES 277
WP 003107102 181 LTEK- -MSKSRRLENLIAK- I- PN QKKNTLFGNLISLSLGLTPNFKANF- -ELSED- -A— -KLQ- -ISKESFEEDLDN 246
WP 054279288 214 LTEK- -ISKTRRLENLISN- I- PG QKKNGLFGNLIALSLGLTPNFKSHF- -NLPED- -A— -KLQ- -LAKDTYDEELNN 279
WP 049531101 213 FTDK- -ISKSTKRERVLKL- F- PD QKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A— -PLQ- -FSKDTYDEDLEN 278
WP 049538452 213 FSDK- -ISKSAKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A— -PLQ- -FSKDTYDEDLEN 278
WP 049549711 213 FTDK- -ISKSAKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLGEK- -A— -PLQ- -FSKDTYDEDLEN 278
WP 007896501 214 LTAK- -TSKSKRLESLISE- F- PG QKKNGLFGNLLALALGLRPNFKSNF- -GLSED- -A— -KLQ- -ITKDTYEEELDN 279
EFR44625 166 LTAK- -TSKSKRLESLISE- F- PG QKKNGLFGNLLALALGLRPNFKSNF- -GLSED- -A— -KLQ- -ITKDTYEEELDN 231
WP 002897477 212 FTDK- -ISKSAKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A— -PLQ- -FSKDTYDEELEN 277
WP 002906454 212 FTDK- -ISKSTKRERVLKL- F- SD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A— -PLQ- -FSKDTYDEDLEN 277
WP 009729476 213 FTDK- -ISKSAKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A— -PLQ- -FSRDTYDEDLEN 278
CQR24647 212 ITAK- -ISKSRKVEAVLEQ- F- PD QKKNSFFGNMVSLVFGLMPNFKSNF- -ELDED- -A— -KLQ- -FSRDSYDEDLEN 277
WP 000066813 213 FTDK- -ISKSTKRERVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A— -PLQ- -FSKDTYDEDLEN 278
WP 009754323 213 FTGK- -ISKSVKREHVLKL- F- PD EKSTGLFSEFLKLIVGNQADFKKHF- -DLEEK- -A— -SLQ- -FSKDTYDEDLEN 278
WP 044674937 212 LVEK- -VSKSRRLENILHY- F- PN EKKNGLFGNFLALALGLQPNFKTNF- -ELAED- -A— -KIQ- -FSKETYEEDLEE 277
WP 044676715 212 LVEK- -VSKSRRLENILHY- F- PN EKKNGLFGNFLTLALGLQPNFKTNF- -ELAED- -A— -KIQ- -FSKETYEEDLEE 277
WP 044680361 212 LVEK- -VSKSRRLENILHY- F- PN EKKNGLFGNFLALALGLQPNFKTNF- -ELAED- -A— -KIQ- -FSKETYEEDLEE 277
WP 044681799 212 LVEK- -VSKSRRLENILHY- F- PN EKKNGLFGNFLALALGLQPNFKTNF- -ELAED- -A— -KIQ- -FSKETYEEDLEE 277
WP 049533112 212 LTEK- -VSKSRRLENLIAH- Y- PA EKKNTLFGNLIALSLGLQPNFKTNF- -QLSED- -A— -KLQ- -FSKDTYEEDLEG 277
WP 029090905 172 LLDRmMNRSSKVKFLIEL- TG KQDKPLLKELFNLIVGLKAKPASIFe QENlAtivETM-nMSTEQVQLDLLT 243
WP 006506696 211 LKKP- -LSKKAKVDEVMTL- IaPE KDYKSAFKELVTGIAGNKMNVTKMIlcEPIKQ- -Gds -EIK1kFSDSNYDDQFSE 283
AIT42264 212 LSAR- -LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP 034440723 218 FKQD- -ISRSKKLDQAIAL- F- QG -KRQSLFGIFLTLIVGNKANFQKIF- -NLEDD- iKLD- -LKEEDYDENLEE 283
AKQ21048 212 LSAR- -LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
WP 004636532 211 LSSK- -QSRSRKHEQIMAL- F- PN ENKLGNFGRFMMLIVGNTSNFKPVF- -DLDDE- -Y— -KLK- -LSDETYEEDLDT 276
WP 002364836 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A— -KI—tYASESYEEDLEG 283
WP 016631044 169 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A— -KI—tYASESYEEDLEG 234
EMS75795 1 -A— -KIQ- -LSKESYEEELES 20
WP 002373311 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A— -KI—tYASESYEEDLEG 283
WP 002378009 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A— -KI—tYASESYEEDLEG 283
WP 002407324 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A— -KI—tYASESYEEDLEG 283
WP 002413717 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A— -KI—tYASESYEEDLEG 283
WP 010775580 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A— -KIKitYASESYEEDLEG 285
WP 010818269 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A— -KI—tYASESYEEDLEG 283
WP 010824395 218 LTEK--ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE--A-—KI—tYASESYEEDLEG 283
WP "016622645 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A- —KI—tYASESYEEDLEG 2 83
WP "033624816 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A- —KI—tYASESYEEDLEG 2 83
WP "033625576 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A- —KI—tYASESYEEDLEG 2 83
WP "033789179 218 LTEK- -ASRTKKSEKVLQQ- F- PQ EKANGLFGQFLKLMVGNKADFKKVF- -GLEEE- -A- —KI—tYASESYEEDLEG 2 83
WP "002310644 217 FTEK- -MSKTKKAETLLKY- F- PH EKSNGYLSQFIKLMVGNQGNFKNVF- -GL-EE- -A- —KLQ- -FSKETYEEDLEE 2 81
WP "002312694 217 FTEK- -MSKTKKAETLLKY- F- PH EKSNGYLSQFIKLMVGNQGNFKNVF- -GL-EEeA- —KLQ- -FSKETYEEDLEE 2 82
WP "002314015 217 FTEK- -MSKTKKAETLLKY- F- PH EKSNGYLSQFIKLMVGNQGNFKNVF- -GL-EEeA- —KLQ- -FSKETYEEDLEE 2 82
WP "002320716 217 FTEK- -MSKTKKAETLLKY- F- PH EKSNGYLSQFIKLMVGNQGNFKNVF- -GL-EEeA- —KLQ- -FSKETYEEDLEE 2 82
WP "002330729 217 FTEK- -MSKTKKAETLLKY- F- PH EKSNGYLSQFIKLMVGNQGNFKNVF- -GL-EE- -A- —KLQ- -FSKETYEEDLEE 2 81
WP "002335161 217 FTEK- -MSKTKKAETLLKY- F- PH EKSNGYLSQFIKLMVGNQGNFKNVF- -GL-EEeA- —KLQ- -FSKETYEEDLEE 2 82
WP "002345439 217 FTEK- -MSKTKKAETLLKY- F- PH EKSNGYLSQFIKLMVGNQGNFKNVF- -GL-EEeA- —KLQ- -FSKETYEEDLEE 2 82
WP "034867970 210 LTDK- -LSKTKKVEEILKY- Y- PT EKINSFFAQCLKLIVGNQANFKRIF- -DLEAE- -V- —KLQ- -FSKETYEEDLES 2 75
WP "047937432 217 FTEK- -MSKTKKAETLLKY- F- PH EKSNGYLSQFIKLMVGNQGNFKNVF- -GL-EEeA- —KLQ- -FSKETYEEDLEE 2 82
WP "010720994 210 LTDK- -LSKTKKVEEILKY- Y- PT EKINSFFAQCLKLIVGNQANFKRIF- -DLEAE- -V- —KLQ- -FSKETYEEDLES 2 75
WP "010737004 210 LTDK- -LSKTKKVEEILKY- Y- PT EKINSFFAQCLKLIVGNQANFKRIF- -DLEAE- -V- —KLQ- -FSKETYEEDLES 2 75
WP "034700478 210 LTDK- -LSKTKKVEEILKY- Y- PT EKINSFFAQCLKLIVGNQANFKRIF- -DLEAE- -V- —KLQ- -FSKETYEEDLES 2 75
WP "007209003 215 LTQQ- -LSKSERADNVLKL- F- PD EKGTGIFAQFIKLIVGNQGNFKKVF- -QLEED- -qKLQ- -LSTDDYEENIEN 2 80
WP "023519017 210 LTER- -LSKAKRVEKVLAY- Y- PS EKSTGNFAQFLKLMVGNQANFKKTF- -DLEEE- -M- —KLN- -FTRDCYEEDLNE 2 75
WP "010770040 213 FSEK- -VSRARKVEAILSV- Y- SE EKSTGTLAQFLKLMVGNQGRFKKTF- -DLEED- -G- —IIQ- -IPKEEYEEELET 2 78
WP "048604708 209 FADK- -VSRAKKAEGVLAL- F- PD EKRNGTFDQFLKMIVGNQGNFKKTF- -ELEED- -A- —KLQ- -FSKEEYDESLEA 2 74
WP "010750235 210 LTDK- -LSKSKKVEKILQY- Y- PK EKTTGCLAQFLKLIVGNQGNFKQAF- -HLDEE- -V- —KIQ- -ISKETYEEDLEK 2 75
AII16583 251 LSAR- -LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A- —KLQ- -LSKDTYDDDLDN 3 16
WP 029073316 216 LKEP- -LSKKHKADKAFAL- FdTT KDNKAAYKELCAALAGNKFNVTKMLkeAELHD- -EdekDISfkFSDATFDDAFVE 2 89
WP "031589969 216 LKEP- -LSKKHKAEKAFAL- FdTT KDNKAAYKELCAALAGNKFNVTKMLkeAELHD- -EdekDISfkFSDATFDDAFVE 2 89
KDA45870 210 FKDNtFSKTKKSEELLKL- SG -KKNQLAHQLFKMMVGNMGSFKKVL- -GTDEE- -hKLS- -FGKDTYEDDLND 2 75
WP 039099354 207 LLDNhQSASNRQRQALLLiYtPS KQNKAIATELLKAILGLKAKFNVLT- -GIEAEdVktwTLT- -FNAENFDEEMVK 2 85
AKP02966 209 LIGR- -GNATQKSSNILNN- F- -T KETKKLLKEVINLILGNVAHLNTIFktSLTKDeE- —KLS- -FSGKDIESKLDD 2 78
WP 010991369 218 LVEK- -VTRKEKLERILKL- Y- PG EKSAGMFAQFISLIVGSKGNFQKPF- -DLIEK- -S- —DIE- -CAKDSYEEDLES 2 83
WP "033838504 218 LVEK- -VTRKEKLERILKL- Y- PG EKSAGMFAQFISLIVGSKGNFQKPF- -DLIEK- -S- —DIE- -CAKDSYEEDLES 2 83
EHN60060 221 LVEK- -VTRKEKLERILKL- Y- PG EKSAGMFAQFISLIVGSKGNFQKPF- -DLIEK- -s- —DIE- -CAKDSYEEDLES 2 86
EFR89594 1 LKL- Y- PG EKSTGMFAQFISLIVGSKGNFQKPF- -DLIEK- -s- —DIE- -CAKDSYEEDLES 5 2
WP 038409211 218 LSEK- -LTRREKLDKILKL- Y- TG EKSTGMFARFINLIIGSKGDFKKVF- -DLDEK- -A- —EIE- -CAKDTYEEDLEA 2 83
EFR95520
WP 003723650 218 LAGK- -FTRREKFERILQL- Y- PG EKSTGMFAQFISLIVGSKGNFQKVF- -DLIEK- -T- —DIE- -CAKDSYEEDLET 2 83
WP "003727705 218 LAGK- -FTRREKFERILRL- Y- PG EKSTGMFAQFISLIVGNKGNFQKVF- -NLVEK- -T- —DIE- -CAKDSYEEDLEA 2 83
WP "003730785 218 LAGK- -FTRREKFERILRL- Y- PG EKSTGMFAQFISLIVGNKGNFQKVF- -NLVEK- -T- —DIE- -CAKDSYEEDLEA 2 83
WP "003733029 218 LAEK- -FTRKDKLDKILSL- Y- PG EKTTGVFAQF I IVGSTGKFKKHF- -NLHEK- -K- —DIN- -CAEDTYDTDLES 2 83
WP "003739838 218 LAGK- -FTRKEKLERILQL- Y- PG EKSTGMFAQFISLIVGSKGNFQKVF- -DLVEK- -T- —DIE- -CAKDSYEEDLEA 2 83
WP 014601172 218 LAGK- FTRREKFERILQL-Y- PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK--T—-DIE--CAKDSYEEDLEA 283
WP 023548323 218 LAGK- FTRREKFERILQL- Y- PG EKSTGMFAQFISLIVGSKGNFQKVF- -DLIEK- -T— -DIE- -CAKDSYEEDLET 283
WP 031665337 218 LAGK- FTRREKFERILQL- Y- PG EKSTGMFAQFISLIVGSKGNFQKVF- -DLIEK- -T— -DIE- -CAKDSYEEDLET 283
WP 031669209 218 LAEK- FTRKDKLDKILSL- Y- PG EKTTGVFAQF I IVGSTGKFKKHF- -NLHEK- -K— -DIN- -CAEDTYDTDLES 283
WP 033920898 218 LARK- FTRREKFERILQL- Y- PG EKSTGMFAQFISLIVGSKGNFQKVF- -DLIEK- -T— -DIE- -CAKDSYEEDLET 283
AKI42028 221 LAGK- FTRREKFERILQL- Y- PG EKSTGMFAQFISLIVGSKGNFQKVF- -DLIEK- -T— -DIE- -CAKDSYEEDLEA 286
AKI50529 221 LARK- FTRREKFERILQL- Y- PG EKSTGMFAQFISLIVGSKGNFQKVF- -DLIEK- -T— -DIE- -CAKDSYEEDLET 286
EFR83390
WP 046323366 218 FSEK- LTKREKLDKILNL- Y- PN EKSTDLFAQFI SLUGSKGNFKKFF- -NLTEK- -T— -DIE- -CAKDSYEEDLEV 283
AKE81011 228 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 293
CU082355 215 LKKP- LSKKAKVDEVMAL- IsPE KEFKSAYKELVTGIAGNKMNVTKMIlcESIKQ- -Gds -EIKlkFSDSNYDDQFSE 287
WP 033162887 216 LSKI- YQRSKKADDLLKI- MnPT KEEKAAYKEFTKALVGLKFNISKMIlaQEVKK- -Gdt -DIVleFSNANYDSTIDE 288
AGZ 01981 245 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 310
AKA60242 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
AKS40380 212 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 277
4UN5 B 216 LSAR- LSKSRRLENLIAQ- L- PG EKKNGLFGNLIALSLGLTPNFKSNF- -DLAED- -A— -KLQ- -LSKDTYDDDLDN 281
WP 010922251 278 LLAQIGDQYADLFLAA[K]NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "039695303 279 LLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN- KSELYHDIFKDKNK 357
WP "045635197 278 LLGQIGDDFTDLFVSAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQNDLAALKQFIKNN- LPEKYDEVFSDQSK 356
5AXW A 158 LERLKKDG- EVR 168
WP 009880683 1 LSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 40
WP "010922251 278 LLAQIGDQYADLFLAAKNLSDAILLSDI LRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "011054416 278 LLAQIGDQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "011284745 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "011285506 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "011527619 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "012560673 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "014407541 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "020905136 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "023080005 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "023610282 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "030125963 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKASLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "030126706 278 LLAQIGDQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "031488318 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "032460140 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "032461047 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "032462016 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "032462936 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "032464890 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "033888930 103 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 181
WP "038431314 278 LLAQIGDQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "038432938 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "038434062 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
BAQ51233 189 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 267
KGE60162
KGE60856
WP 002989955 278 LLAQIGDQYADLFLAAKNLSDAILLSDI LRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP "003030002 278 LLGEIGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKLKDFIKVN- APDQYNAIFKDKNK 356
WP "003065552 281 LLGKIGDDYADLFTSAKNLYDAILLSGILIVDDNSTKAPLSASMIKRYVEHQEDLEKLKEFIKAN- KSELYHDIFKDKNK 359
WP "001040076 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- LPEKYQEIVADSSK 357
WP "001040078 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- LPEKYQEIFADSSK 357
WP "001040080 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- LPEKYQEIFADSSK 357
WP "001040081 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- LPEKYQEIFADSSK 357
WP "001040083 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- LPEKYQEIFADSSK 357
WP "001040085 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- LPEKYQEIFADSSK 357
WP 001040087 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS--LPEKYQEIFADSSK 357
WP "001040088 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040089 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040090 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040091 279 LLRQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040092 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSAYMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040094 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQHYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040095 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040096 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040097 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040098 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040099 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040100 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040104 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040105 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "001040106 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP "001040107 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP "001040108 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP "001040109 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP "001040110 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP "015058523 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "017643650 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "017647151 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP "017648376 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP "017649527 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "017771611 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTALSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP "017771984 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
CFQ25032 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKASLSDSMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
CFV16040 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
KLJ37842 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
KLJ72361 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
KLL20707 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
KLL42645 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP 047207273 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "047209694 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "050198062 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "050201642 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP "050204027 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFTDSSK 357
WP "050881965 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS- -LPEKYQEIFADSSK 357
WP 050886065 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357
AHN30376 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357
EA078426 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357
CCW42055 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357
WP 003041502 278 LLGEVGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKFEDFIKVN-ALDQYNAIFKDKNK 356
WP 037593752 279 LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK 357
WP 049516684 279 LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APAQYDDIFKDETK 357
GAD46167 278 LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK 356
WP 018363470 279 LLGKIGDDYADLFTSSKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKTQ 357
WP 003043819 278 LLGQIGDQYADLFSAAKNLSDAILLSDILRSNSEVTKAPLSASMVKRYDEHHQDLALLKTLVRQQ-FPEKYAEIFKDDTK 356
WP 006269658 278 FLGEVGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK 356
WP 048800889 278 LLGKIGDDYADLFTSAKNLYDTILLSGILAVDDNSTKALLSASMIKRYEEHQKDLKKLKDFIKVN-APAQYDDIFKDETK 356
WP 012767106 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356
WP 014612333 278 LLAQIGNQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356
WP 015017095 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356
WP 015057649 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356
WP 048327215 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356
WP 049519324 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356
WP 012515931 278 LLAQIGDQYADLFLAAKNLSDAILLSDILTESDEITRAPLSASMVKRYREHHKDLVTLKTLIKDQ-LPEKYQEIFLDKTK 356
WP 021320964 278 LLAQIGDQYADLFLAAKNLSDAILLSDILTESDEITRAPLSASMVKRYREHHKDLVTLKTLIKDQ-LPEKYQEIFLDKTK 356
WP 037581760 278 LLAQIGDQYADLFLAAKNLSDAILLSDILTESDEITRAPLSASMVKRYREHHKDLVTLKTLIKDQ-LPEKYQEIFLDKTK 356
WP 004232481 278 LLGKIGDDYADLFTAAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYEEHHEDLEKLKTFIKVN-NFDKYHEIFKDKSK 356
WP 009854540 279 LLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKNK 357
WP 012962174 279 LIGKIGDEYADLFTSAKNLYDAILLSGILTVADNTTKAPLSASMIKRYNEHQVDLKKLKEFIKNN-ASDKYDEIFNDKDK 357
WP 039695303 279 LLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKNK 357
WP 014334983 278 LLGKVGDDYADLFISAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKIN-KLKLYHDIFKDKTK 356
WP 003099269 278 LLAQIGDQYADLFIAAKKLSDAILLSDI ITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK 356
AHY15608 278 LLAQIGDQYADLFIAAKKLSDAILLSDI ITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK 356
AHY17476 278 LLAQIGDQYADLFIAAKKLSDAILLSDI ITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK 356
ESR09100
AGM98575 278 LLAQIGDQYADLFIAAKKLSDAILLSDI ITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ- I PEKYKEI FDNKEK 356
ALF27331 278 LLAQIEDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP 018372492 276 LLSKIDEEYAALFDLAKKVYDAVLLSNILTVKEKNTKAPLSASMIKRYEEHKDDLKAFKRFFRER- LPEKYETMFKDLTK 354
WP 045618028 279 LLVQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIDRYENHQKDLAALKQFIKTN- LPEKYDEVFSDQSK 357
WP 045635197 278 LLGQIGDDFTDLFVSAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQNDLAALKQFIKNN- LPEKYDEVFSDQSK 356
WP 002263549 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP 002263887 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP 002264920 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN- KPELYHDIFKDETK 356
WP 002269043 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP 002269448 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356
WP "0022 71977 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 72766 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 73241 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 75430 278 LLTQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 76448 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 77050 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN- KPELYHDIFKDETK 356
WP "0022 77364 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 79025 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 79859 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 80230 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 81696 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 82247 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN- KPELYHDIFKDETK 356
WP "0022 82906 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 83846 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 87255 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 88990 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 89641 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 90427 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 95753 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0022 96423 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0023 04487 278 LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYKEHKEELAAFKRFIKEK- LPKKYEEIFKDDTK 356
WP "0023 05844 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0023 07203 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0023 10390 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0023 52408 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0129 97688 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "θ146 77909 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0193 12892 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0193 13659 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTQAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0193 14093 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0193 15370 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0198 03776 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0198 05234 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0247 83594 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0247 84288 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN- KPELYHDIFKDETK 356
WP "0247 84666 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLVQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0247 84894 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK- LSDKYNEVFSDVSK 356
WP "0247 86433 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN- KPELYHDIFKDETK 356
WP 049473442 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356
WP "04947 4547 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK- LSDKYNEVFSDVSK 356
EMC03581 271 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK- LSDKYNEVFSDVSK 349
WP 00042 8612 279 LLGQIGDDFADLFVAAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLATLKQFIKTN- LPEKYDEVFSDQSK 357
WP "00042 8613 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLAVLKQFIKNN- LPEKYDEVFSDQSK 357
WP "04952 3028 278 LLGQIGDVYADLFWAKKLYDAILLAGILSVKDPGTKAPLSASMIERYDNHQNDLSALKQFVRRN- LPEKYAEVFSDDSK 356
WP "00310 7102 247 LLAQIGDQYADLFIAAKNLSDAILLSDILTVKG TKAPLSASMVQRFNEHQDDLKLLKKLVKVQ- LPEKYKEIFDIKDK 325
WP "05427 9288 280 LLTQIGDEYADLFLSAKNLSDAILLSDILTVNGDGTQAPLSASLIKRYEEHRQDLALLKQMFKEQ- LPDLYRDVFTDENK 358
WP "04953 1101 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLAALKQFIKNN- LPEKYDEVFSDQSK 357
WP "04953 8452 279 LLGQIGDGFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYQNHQNDLASLKQFIKNN- LPEKYDEVFSDQSK 357
WP "04954 9711 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLTTLKQFIKNN- LPEKYDEVFSDQSK 357
WP "00789 6501 280 LLAEIGDHYADLFLAAKNLSDAILLSDILTLSDENTRAPLSASMIKRYEEHQEDLALLKKLVKEQ- MPEKYWEI FSNAKK 358
EFR44625 232 LLAEIGDHYADLFLAAKNLSDAILLSDILTLSDENTRAPLSASMIKRYEEHQEDLALLKKLVKEQ- MPEKYWEI FSNAKK 310
WP 00289 7477 278 LLGQIGDDFADLFLIAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLAALKQFIKNN- LPEKYVEVFSDQSK 356
WP "00290 6454 278 LLGQIGDGFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQEDLAALKQFIKNN- LSEKYAEVFSDQSK 356
WP "00972 9476 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTNPSTKAPLSASMIERYENHQKDLASLKQFIKNN- LPEKYDEVFSDQSE 357
CQR24647 278 LLGIIGDEYADVFVAAKKVYDSILLSGILTTNNHSTKAPLSASMIDRYDEHNSDKKLLRDFIRTNi .GKEVFKEVFYDTSK 357
WP 00006 6813 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVKDLSTKAPLSASMIERYENHQKDLAALKQFIQNN- LQEKYDEVFSDQSK 357
WP "00975 4323 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQEDLAALKQFIKNN- LPEKYAEVFSDQSK 357
WP "04467 4937 278 LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHKKDLALLKNFIHQN- LSDSYKEVFNDKLK 356
WP "04467 6715 278 LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHQKDLALLKNFIHQN- LSDSYKEVFNDKLK 356
WP "04468 0361 278 LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHQKDLALLKNFIHQN- LSDSYKEVFNDKLK 356
WP "04468 1799 278 LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHKKDLALLKNFIHQN- LSDSYKEVFNDKLK 356
WP "04953 3112 278 LLGEIGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKLKDFIKVN- APDQYNAI FKDKNK 356
WP "02909 0905 244 LADVLADEEYDLLLTAQKIYSAIILDESMDGYEYFA EAKKESYRKHQEELVLVKKMLKSNa LITNDERAKF EY 315
WP "00650 6696 284 VEKDLGE-YVEFVDALHNVYSWVELQTIMGATHTD-NASISEAMVSRYNKHHDDLKLLKDCIKNN- VPNKYFDMFRNDSE 360
AIT42264 278 LLAQIGDQYADLFLAAKNLSDAILLSDILR TEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP 03444 0723 284 LLSNIDEGYRDVFLQAKNVYNAIELSKILKTDGKETKAPLSAQMVELYNQHREDLKKYKDYIKAY- LPEKYGETFKDATK 362
AKQ21048 278 LLAQIGDQYADLFLAAKNLSDAILLSDILR TEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
WP 00463 6532 277 LLGMTDDVFLDVFMAAKNVYDAVEMSAIISTDTGNSKAVLSNQMINFYDEHKVDLAQLKQFFKTH- LPDKYYECFSDPSK 355
WP "00236 4836 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN- CPDEYDNLFKNEQK 362
WP "01663 1044 235 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN- CPDEYDNLFKNEQK 313
EMS "75795 21 LLEKSGEEFRDVFLQAKKVYDAILLSDILSTKKQNSKAKLSLGMIERYDSHKKDLEELKQFVKAN- LPEKTAIFFKDSSK 99
WP 00237 3311 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN- CPDEYDNLFKNEQK 362
WP "00237 8009 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN- CPDEYDNLFKNEQK 362
WP "00240 7324 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN- CPDEYDNLFKNEQK 362
WP "00241 3717 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN- CPDEYDNLFKNEQK 362
WP "01077 5580 286 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN- CPDEYDNLFKNEQK 364
WP "01081 8269 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN- CPDEYDNLFKNEQK 362
WP 010824395 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK 362
WP "016622645 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSYAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK 362
WP "033624816 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK 362
WP "033625576 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK 362
WP "033789179 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK 362
WP "002310644 282 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 360
WP "002312694 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361
WP "002314015 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361
WP "002320716 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361
WP "002330729 282 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 360
WP "002335161 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361
WP "002345439 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361
WP "034867970 276 LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTKAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK 354
WP "047937432 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361
WP "010720994 276 LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTQAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK 354
WP "010737004 276 LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTKAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK 354
WP "034700478 276 LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTQAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK 354
WP "007209003 281 LLAIIGDEYGDIFVAAQNLYQAILLAGILTSTEK-TRAKLSASMIQRYEEHAKDLKLLKRFVKEH IPDKYAEIFNDATK 358
WP "023519017 276 LLEKTSDDYAELFLKAKGVYDAILLSQILSKSDDETKAKLSANMKLRFEEHQRDLKQLKELVRRD LPKKYDDFFKNRSK 354
WP "010770040 279 LLAIIGDEYAEIFSATKSVYDAVALSGILSVTDGDTKAKLSASMVERYEAHQKDLVQFKQFIRKE LPEMYAPIFRDNSV 357
WP "048604708 275 LLGEIGDEYADVFEAAKNVYNAVELSGILTVTDNSTKAKLSASMIKRYEDHKTDLKLFKEFIRKN LPEKYHEI FNDKNT 353
WP "010750235 276 LLRKSNEEMIDVFLQVKKVYDAILLSDILSTKMKDTKAKLSAGMIERYQNHKKDLEELKQFVRAH-LHEKVTVFFKDSSK 354
AII16583 317 LLAQIGDQYADLFLAAKNLSDAILLSDILR TEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 395
WP_029073316 290 KQPLLGD-CVEFIDLLHDIYSWVELQNILGSAHTS-EPSISAAMIQRYEDHKNDLKLLKDVIRKY-LPKKYFEVFRDEKS 366
WP_031589969 290 KQPLLGD-CVEFIDLLHDIYSWVELQNILGSAHTS-EPSISAAMIQRYEDHKNDLKLLKDVIRKY-LPKKYFEVFRDEKS 366
KDA45870 276 LLAEAGDQYLDIFVAAKKVYDAAILASILDVKDTQTKTVFSQAMIERYEEHQKDLIELKRVFKKY-LPEKCHDFFSE-PK 353
WP_039099354 286 LESSLDDNAHQIIESLQELYSGVLLAGIVPENQSLS QAMITKYDDHQKHLKMLKAVREAL-APEDRQRLKQAYDQ 359
AKP02966 279 LDSILDDDQFTVLDTANRIYSTITLNEIL NGESYFSMAK QYENHAIDLCKLRDMWHTT KNEKAV-GLSR 348
WP_010991369 284 LLALIGDEYAELFVAAKNAYSAWLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK 362
WP_033838504 284 LLALIGDEYAELFVAAKNAYSAWLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK 362
EHN60060 287 LLALIGDEYAELFVAAKNAYSAWLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK 365
EFR89594 53 LLALIGDEYAELFVAAKNAYSAWLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK 131
WP_038409211 LLAKIGDEYAEIFVAAKSTYNAWLSNIITVTDTETKAKLSASMIERFDKHAKDLKRLKAFFKMQ-LPEKFNEVFNDIEK 362 EFR95520
WP 003723650 2En LLAIIGDEYAELFVAAKNTYNAWLSSIITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI 362
WP "003727705 2Eu LLAIIGDEYAELFVAAKNTYNAWLSSIITVTATETNAKLSASMIERFDAHEKELGELKAFIKLH-LPKQYQEIFNNAEI 362
WP "003730785 2Eu LLAIIGDEYAELFVAAKNTYNAWLSSIITVTATETNAKLSASMIERFDAHEKELGELKAFIKLH-LPKQYQEIFNNAEI 362
WP "003733029 21 34 LLAIIGDEFAEVFVAAKNAYNAWLSNIITVTDSTTRAKLSASLIERFENHKEDLKKMKRFVRTY-LPEKYDEIFDDTEK 362
WP "003739838 2iu LLAIIGDEYAELFVAAKNTYNAWLSSIITVTDTETNAKLSASMIERFDAHEKDLSELKAFIKLH-LPKQYEEIFSNVAI 362
WP 014601172 284 LLAI IGDEYAELFVAAKNTYNAWLSSI ITVTATETNAKLSASMIERFDAHEKDLGELKAFIKLH- LPKQYQEI FNNAAI 362
WP 023548323 2 84 LLAI IGDEYAELFVAAKNTYNAWLSSI ITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN- LPKQYEEI FSNAAI 362
WP 031665337 2 84 LLAI IGDEYAELFVAAKNTYNAWLSSI ITVNDTETNAKLSASMIERFDAHEKDLVELKAFIKLN- LPKQYEEI FSNAAI 362
WP 031669209 2 84 LLAI IGDEFAEVFVAAKNAYNAWLSNI ITVTDSTTRAKLSASLIERFENHKEDLKKMKRFVRTY- LPEKYDEIFDDTEK 362
WP 033920898 2 84 LLAI IGDEYAELFVAAKNTYNAWLSSI ITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN- LPKQYEEI FSNAAI 362
AKI42028 2 87 LLAI IGDEYAELFVAAKNTYNAWLSSI ITVTATETNAKLSASMIERFDAHEKDLGELKAFIKLH- LPKQYQEI FNNAAI 365
AKI50529 2 87 LLAI IGDEYAELFVAAKNTYNAWLSSI ITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN- LPKQYEEI FSNAAI 365
EFR83390
WP 046323366 2 84 LLARVGDEYAEIFVAAKNAYNAWLSSIITVSNTETKAKLSASMIERFDKHDKDLKRMKAFFKVR- LPENFNEVFNDVEK 362
AKE81011 2 94 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 372
CU082355 2 88 VENDLGE-YVEFIDSLHNIYSWVELQTIMGATHTD-NASISEAMVSRYNKHHEDLQLLKKCIKDN- VPKKYFDMFRNDSE 364
WP 033162887 2 89 LQSELGE-YIEFIEMLHNIYSWVELQAILGATHTD-NPSISAAMVERYEEHKKDLRVLKKVIREE- LPDKYNEVFRKDNR 365
AGZ 01981 3 11 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 389
AKA60242 2 78 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
AKS40380 2 78 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 356
4UN5 B 2 82 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ- LPEKYKEIFFDQSK 360
WP 010922251 357 --NGYAG YIDG G ASQEEFYKFIKPILEK--M--DGTEELLv--KLNREDLLRKQRTFDNG|S|IPHQIHLGEL 419
WP 039695303 358 - -NGYAG YIEN G VKQDEFYKYLKNILSK- -IkiDGSDYFL— DKIEREDFLRKQRTFDNGSIPHQIHLQEM 422
WP "045635197 357 - -DGYAG YIDG K TTQETFYKYIKNLLSK- -F- -EGTDYFL— DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
5AXW A 169 c SINR 1 oQ PJJiViAV7"V Έ1 Δ 183
WP 009880683 41 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 103
WP "010922251 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "011054416 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPYQIHLGEL 419
WP "011284745 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "011285506 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "011527619 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "012560673 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "014407541 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "020905136 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "023080005 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPYQIHLGEL 419
WP "023610282 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPYQIHLGEL 419
WP "030125963 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "030126706 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPYQIHLGEL 419
WP "031488318 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "032460140 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "032461047 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "032462016 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "032462936 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "032464890 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNRKDLLRKQRTFDNGSIPHQIHLGEL 419
WP "033888930 182 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 244
WP "038431314 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "038432938 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPYQIHLGEL 419
WP "038434062 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
BAQ51233 268 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 330
KGE60162
KGE60856
WP 002989955 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLa- -KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP "003030002 357 - -KGYAG YIEN G VKQDEFYKYLKGILLQ- -I- -NGSGDFL— DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419
WP "003065552 360 - -NGYAG YIEN G VKQDEFYKYLKNTLSK- -Ia —GSDYFL— DKIEREDFLRKQRTFDNGSIPHQIHLQEM 422
WP "001040076 358 - -DGYAG YIEG K TNQEAFYKYLSKLLTK- -Q- -EGSEYFL— EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP "001040078 358 - -DGYAG YIEG K TNQEAFYKYLSKLLTK- -Q- -EDSENFL— EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP "001040080 358 - -DGYAG YIEG K TNQEAFYKYLSKLLTK- -Q- -EDSENFL— EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP "001040081 358 - -DGYAG YIEG K TNQEAFYKYLSKLLTK- -Q- -EDSENFL— EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP "001040083 358 - -DGYAG YIEG K TNQEAFYKYLSKLLTK- -Q- -EDSENFL— EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP "001040085 358 - -DGYAG YIEG K TNQEAFYKYLSKLLTK- -Q- -EDSENFL— EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040087 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040088 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040089 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040090 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040091 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040092 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040094 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040095 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040096 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040097 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040098 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040099 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040100 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040104 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040105 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040106 358 —DGYAG YIEG K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040107 358 —DGYAG YIEG K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040108 358 —DGYAG YIEG K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040109 358 —DGYAG YIEG K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 001040110 358 —DGYAG YIEG K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 015058523 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 017643650 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 017647151 358 —DGYAG YIEG K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 017648376 358 —DGYAG YIEG K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 017649527 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 017771611 358 —DGYAG YIEG K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 017771984 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
CFQ25032 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
CFV16040 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
KLJ37842 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
KLJ72361 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
KLL20707 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
KLL42645 358 —DGYAG YIEG K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 047207273 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 047209694 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 050198062 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 050201642 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 050204027 358 —DGYAG YIES K TNQGAFYKYLSKLLTK- Q- -EGSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 050881965 358 —DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 050886065 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
AHN30376 358 - -DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSEYFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
EA078426 358 - -DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EDSENFL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
CCW42055 358 - -DGYAG YIEG K TNQEAFYKYLSKLLTK- Q- -EGSEYLL- -EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420
WP 003041502 357 - -KGYAG YIES G VKQDEFYKYLKGILLQ- I- -NGSGDFL- -DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 037593752 358 - -KGYAG YIES G VEQDEFYKYLKGILLK- I- -NGSGDFL- -DKIDCEDFLRKQRTFDNGSIPHQIHLQEM 420
WP 049516684 358 - -NGYAG YIEN G VKQDEFYKYLKNTLSK- I- -DGSDYFL- -DKIDREDFLRKQRTFDNGSIPHQIHLQEM 420
GAD46167 357 - -KGYAG YIES G VEQDEFYKYLKGILLK- I- -NGSGDFL- -DKIDCEDFLRKQRTFDNGSIPHQIHLQEM 419
WP 018363470 358 - -NGYAG YIEN G VKQDEFYKYLKGILTK- I- -NGSDYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 003043819 357 - -NGYAG YVGI G ATQEEFYKFIKPILEK- M- -DGAEELLa —KLNRDDLLRKQRTFDNGSIPHQIHLKEL 429
WP 006269658 357 - -KGYAS YIES G VKQDEFYKYLKGILLK- I- -NGSGDFL- -DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 048800889 357 - -NGYAG YIEN G VKQDEFYKYLKNTLSK- I- -DGSGYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 012767106 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- M- -DGTEELLa —KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP 014612333 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- M- -DGTEELLa —KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP 015017095 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- M- -DGTEELLa —KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP 015057649 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- M- -DGTEELLa —KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP 048327215 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- M- -DGTEELLa —KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP 049519324 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- M- -DGTEELLa —KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP 012515931 357 - -NGYAG YIEG Q VSQEEFYKYLKPILAR- L- -DGSEPLL1 —KIDREDFLRKQRTFDNGSIPHQIHLEEL 419
WP 021320964 357 - -NGYAG YIEG Q VSQEEFYKYLKPILAR- L- -DGSEPLL1 —KIDREDFLRKQRTFDNGSIPHQIHLEEL 419
WP 037581760 357 - -NGYAG YIEG Q VSQEEFYKYLKPILAR- L- -DGSEPLL1 —KIDREDFLRKQRTFDNGSIPHQIHLEEL 419
WP 004232481 357 - -NGYAG YIEN G VKQDI FYKHLKSI I SE- K- -NGGQYFL- -DKIEREDFLRKQRTFDNGSIPYQIHLQEM 419
WP 009854540 358 - -NGYAG YIEN G VKQDEFYKYLKNTLSK- I- -DGSDYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 012962174 358 - -NGYAG YIEN G VKQDEFYKYLKTTLSK- I- -DGSDYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 039695303 358 - -NGYAG YIEN G VKQDEFYKYLKNILSK- IkiDGSDYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 422
WP 014334983 357 - -NGYAG YIDN G VKQDEFYKYLKTILTK- I- -DDSDYFL- -DKIERDDFLRKQRTFDNGSIPHQIHLQEM 419
WP 003099269 357 - -NGYAG YIDG K TSQEEFYKYIKPILLK- L- -DGTEKLIs —KLEREDFLRKQRTFDNGSIPHQIHLNEL 419
AHY15608 357 - -NGYAG YIDG K TSQEEFYKYIKPILLK- L- -DGTEKLIs —KLEREDFLRKQRTFDNGSIPHQIHLNEL 419
AHY17476 357 - -NGYAG YIDG K TSQEEFYKYIKPILLK- L- -DGTEKLIs —KLEREDFLRKQRTFDNGSIPHQIHLNEL 419
ESR09100
AGM98575 357 - -NGYAG YIDG K TSQEEFYKYIKPILLK- L- -DGTEKLIs —KLEREDFLRKQRTFDNGSIPHQIHLNEL 419
ALF27331 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I- -EGSGYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 018372492 355 - -PSYAA YVSG A VTEDDFYKFSKGLLID- V- -EGAEYFL- -EKIEREDFLRKQRTFDNGAIPNQVHVKEL 432
WP 045618028 358 - -DGYAG YIDG K TTQEAFYKYIKNLLSK- L- -EGADYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 045635197 357 - -DGYAG YIDG K TTQETFYKYIKNLLSK- F- -EGTDYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 002263549 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I- -EGSGYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 002263887 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I- -EGSGYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 002264920 357 - -NGYAG YIEN G VKQDEFYKYLKNTLSK- I- -AGSDYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 002269043 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I- -EGSGYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 002269448 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002271977 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002272766 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002273241 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002275430 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002276448 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002277050 357 - -NGYAG YIEN G VKQDEFYKYLKNTLSK- I -AGSDYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002277364 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002279025 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002279859 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002280230 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002281696 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002282247 357 - -NGYAG YIEN G VKQDEFYKYLKNTLSK- I TGSDYFL—DQIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002282906 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002283846 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002287255 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002288990 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002289641 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002290427 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002295753 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002296423 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002304487 357 - -NGYAG YVGA D ATEEEFYKYVKGILNK- V EGADVWL—DKIDREDFLRKQRTFDNGSI PHQIHLQEM 429
WP "002305844 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002307203 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002310390 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "002352408 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "012997688 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "014677909 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "019312892 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "019313659 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "019314093 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "019315370 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGNGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "019803776 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "019805234 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "024783594 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "024784288 357 - -NGYAG YIEN G VKQDEFYKYLKNTLSK- I TGSDYFL—DQIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "024784666 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "024784894 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I EGSGYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP "024786433 357 - -NGYAG YIEN G VKQDEFYKYLKNTLSK- I -AGSDYFL—DKIEREDFLRKQRTFDNGSI PHQIHLQEM 419
WP 049473442 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 049474547 357 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I- -EGSGYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
EMC03581 350 - -DGYAG YIDG K TNQEAFYKYLKGLLNK- I- -EGSGYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 412
WP 000428612 358 - -DGYAG YIDG K TTQESFYKYIKNLLSK- F- -EGADYFL- -EKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 000428613 358 - -DGYAG YIDG K TTQEAFYKYIKNLLSK- F- -EGTDYFL- -EKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 049523028 357 - -DGYAG YIDG K TTQEGFYKYIKNLISK- I- -EGAEYFL- -EKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 003107102 326 - -NGYAG YING K TSQEDFYKYIKPILSK- L- -KGAESLIs —KLEREDFLRKQRTFDNGSIPHQIHLNEL 388
WP 054279288 359 - -DGYAG YISG K TSQEAFYKYIKPILET- L- -DGAEDFLt —KINREDFLRKQRTFDNGSIPHQIHLGEL 421
WP 049531101 358 - -EGYAG YIDS K TTQEAFYKYIKNLLSK- I- -DGADYLL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 049538452 358 - -DGYAG YVDG K TTQEAFYKYIKNLLSK- F- -EGADYFL- -EKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 049549711 358 - -DGYAG YIDG K TTQEAFYKYIKNLLSK- F- -EGTDYFL- -EKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 007896501 359 - -NGYAG YIEG K VSQEDFYRYIKPILSR- L- -KGGDEFLa —KIDRDDFLRKQRTFDNGSIPHQIHLKEL 421
EFR44625 311 - -NGYAG YIEG K VSQEDFYRYIKPILSR- L- -KGGDEFLa —KIDRDDFLRKQRTFDNGSIPHQIHLKEL 373
WP 002897477 357 - -DGYAG YIDG K TTQEAFYKYIKNLLSK- F- -EGADYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 002906454 357 - -DGYAG FIDG K TTQEAFYKYIKNLLSK- L- -EGADYFL- -NKIEREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 009729476 358 - -DGYAG YIDG K TTQETFYKYIKNLLSK- F- -EGADYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
CQR24647 358 - -NGYAG YIDG K TNQEDFYKYLKNLLQK- V- -DGGDYFI- -EKIEREDFLRKQRTFDNGSIPHQVHLDEM 420
WP 000066813 358 - -DGYAG YIDG K TTQEAFYKYIKNLLSK- F- -EGADYFL- -DKIEREDFLKKQRTFDNGSIPHQIHLQEM 420
WP 009754323 358 - -DGYAG YIDG K TTQEAFYKYIKNLLSK- F- -EGADYFL- -DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420
WP 044674937 357 - -DGYAG YIEG K TTQENFYRFIKKAIEK- I- -EGSDYFI- -DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 044676715 357 - -DGYAG YIEG K TTQENFYRFIKKAIEK- I- -EGSNYFI- -DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 044680361 357 - -DGYAG YIEG K TTQENFYRFIKKAIEK- I- -EGSNYFI- -DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 044681799 357 - -DGYAG YIEG K TTQENFYRFIKKAIEK- I- -EGSDYFI- -DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 049533112 357 - -KGYAG YIEN G VKQDEFYKYLKGILLQ- I- -NGSGDFL- -DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419
WP 029090905 316 fyTDYIG YEES K SKEERLFKHIELLLAKeNvlTTVEHALleKNITFASLLPLQRSSRNAVIPYQVHEKEL 403
WP 006506696 361 ksKGYYN YINR K APVDEFYKYVKKCIEK- VdtPEAKQILn —DIELENFLLKQNSRTNGSVPYQMQLDEM 429
AIT42264 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- M- -DGTEELLv —KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP 034440723 363 - -NGYAG YIDG K TSQEDFYKFVKAQLKG- eENGEYFL- -EAIENENFLRKQRSFYNGVIPYQIHLQEL 425
AKQ21048 357 - -NGYAG YIDG G ASQEEFYKFIKPILEK- M- -DGTEELLv —KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
WP 004636532 356 - -NGYAG YIDG K TNQEDFYKYIEKVMKT- IksDKKDYFL- -DKIDREVFLRKQRSFYNSVIPHQIHLQEM 420
WP 002364836 363 - -DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 016631044 314 - -DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 378
EMS75795 100 - -NGYAG YIDG K TTQEDFYKFLKKELNG- I- -AGSERFM- -EKVDQENFLLKQRTTANGVIPHQVHLTEL 162
WP 002373311 363 - -DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 002378009 363 - -DGYAG YITH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 002407324 363 - -DGYAG YITH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 002413717 363 - -DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 010775580 365 - -DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 429
WP 010818269 363 - -DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 010824395 363 —DGYAG YITH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 016622645 363 —DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 033624816 363 —DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 033625576 363 —DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 033789179 363 —DGYAG YIAH A VSQLKFYQYVKKIIQD- I- -AGAEYFL- -EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427
WP 002310644 361 —NGYAG YIEG H ATQEDFYKFVKKELTG- I- -RGSEVFL- -TKIEQENFLRKQRTFDNGVIPHQIHLTEL 423
WP 002312694 362 —NGYAG YIEG H ATQEAFYKFVKKELTG- I- -RGSEVFL- -TKIEQENFLRKQRTFDNGVIPHQIHLSEL 424
WP 002314015 362 —NGYAG YIEG H ATQEDFYKFVKKELTG- I- -RGSEVFL- -TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424
WP 002320716 362 —NGYAG YIEG H ATQEDFYKFVKKELTG- I- -RGSEVFL- -TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424
WP 002330729 361 —NGYAG YIEG H ATQEDFYKFVKKELTG- I- -RGSEVFL- -TKIEQENFLRKQRTFDNGVIPHQIHLTEL 423
WP 002335161 362 —NGYAG YIEG H ATQEDFYKFVKKELTG- I- -RGSEVFL- -TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424
WP 002345439 362 —NGYAG YIEG H ATQEDFYKFVKKELTG- I- -RGSEVFL- -TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424
WP 034867970 355 —NGYAG YIKG K TTQEEFYKFVKKELSG- V- -VGSEPFL- -EKIDQETFLLKQRTYTNGVIPHQVHLIEL 417
WP 047937432 362 —NGYAG YIEG H ATQEDFYKFVKKELTG- I- -RGSEVFL- -TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424
WP 010720994 355 —NGYAG YIKG K TTQEEFYKFVKKELSG- V- -VGSEPFL- -EKIDQETFLLKQRTYTNGVIPHQVHLIEL 417
WP 010737004 355 —NGYAG YIKG K TTQEEFYKFVKKELSG- V- -VGSEPFL- -EKIDQETFLLKQRTYTNGVIPHQVHLIEL 417
WP 034700478 355 —NGYAG YIKG K TTQEEFYKFVKKELSG- V- -VGSEPFL- -EKIDQETFLLKQRTYTNGVIPHQVHLIEL 417
WP 007209003 359 —NGYAG YIDG K TKEEEFYKYLKTTLVQ- kSGYQYFI- -EKIEQENFLRKQRIYDNGVIPHQVHAEEL 421
WP 023519017 355 —NGYAG YVKG K ATQEDFYKFLRTELAG- L- -EESQSIM- -EKIDLEIYLLKQRTFANGVIPHQIHLVEM 417
WP 010770040 358 —SGYAG YVEN S VTQAEFYKYIKKAIEK- V- -PGAEYFL- -EKIEQETFLDKQRTFNNGVI PHQIHLEEL 422
WP 048604708 354 —DGYAG YIDN S TSQEKFYKYITNLIEK- I- -DGAEYFL- -KKIENEDFLRKQRTFDNGIIPHQIHLEEL 418
WP 010750235 355 —DGYAG YIDG K TTQADFYKFLKKELTG- V- -PGSEPML- -AKIDQENFLLKQRTPTNGVIPHQVHLTEF 417
AII16583 396 —NGYAG YIDG G ASQEEFYKFIKPILEK- M- -DGTEELL —KLNREDLLRKQRTFDNGSIPHQIHLGEL 458
WP 029073316 367 kkNNYCN YINH K TPVDEFYKYIKKLIEK- IddPDVKTILn —KIELESFMLKQNSRTNGAVPYQMQLDEL 435
WP 031589969 367 kkNNYCN YINH K TPVDEFYKYIKKLIEK- IddPDVKTILn —KIELESFMLKQNSRTNGAVPYQMQLDEL 435
KDA45870 354 -iSGYAG YIDG K VSEEDFYKYTKKTLKG- I- -PETEEILq —KIDANNYLRKQRTFDNGAIPHQVHLKEL 417
WP 039099354 360 YVDG K -SKEDFYGDITKALKNnPdhPIVSEIKk —LIELDQFMPKQRTKDNGAIPHQLHQQEL 425
AKP02966 349 —QAYDD YINK K KELYTSLKKFLKVaLp -TNLAKEAe -EKISKGTYLVKPRNSENGWPYQLNKIEM 415
WP 010991369 363 —HGYAG YIDG - TKQADFYKYMKMTLEN- I- -EGADYFI- -AKIEKENFLRKQRTFDNGAIPHQLHLEEL 425
WP 033838504 363 —HGYAG YIDG - TKQADFYKYMKMTLEN- I- -EGADYFI- -AKIEKENFLRKQRTFDNGAIPHQLHLEEL 425
EHN60060 366 —HGYAG YIDG - TKQADFYKYMKMTLEN- I- -EGADYFI- -AKIEKENFLRKQRTFDNGAIPHQLHLEEL 428
EFR89594 132 —HGYAG YIDG - TKQADFYKYMKTTLEN- I- -EGADYFI- -AKIEKENFLRKQRTFDNGAIPHQLHLEEL 194
WP 038409211 363 —DGYAG YIDG - TTQEKFYKYMKKMLAN- I- -DGADYFI- -DQIEEENFLRKQRTFDNGTIPHQLHLEEL 425
EFR95520 1 - MKKMLAN- I- -DGADYFI- -DQIEEENFLRKQRTFDNGTIPHQLHLEEL 44
WP 003723650 363 —DGYAG YIDG - TKQVDFYKYLKTILEN- I- -EGSDYFI- -AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425
WP 003727705 363 —DGYAG YIDG - TKQVDFYKYLKTTLEN- V- -EGADYFI- -TKIEEENFLRKQRTFDNGVIPHQLHLEEL 425
WP 003730785 363 —DGYAG YIDG - TKQVDFYKYLKTTLEN- V- -EGADYFI- -TKIEEENFLRKQRTFDNGVIPHQLHLEEL 425
WP 003733029 363 —HGYAG YISG - TKQADFYKYMKATLEK- I- -EGADYFI- -AKIEEENFLRKQRTFDNGVIPHQLHLEEL 425
WP 003739838 363 —DGYAG YIDG - TKQVDFYKYLKTLLEN- I- -EGADYFI- -AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425
WP 014601172 363 —DGYAG YIDG - TKQVDFYKYLKTILEN--I--EGADYFI---AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425
WP 023548323 363 —DGYAG YIDG - TKQVDFYKYLKTTLEN- -V- -EGADYFI-- -TKIEEENFLRKQRTFDNGVIPHQLHLEEL 425
WP 031665337 363 —DGYAG YIDG - TKQVDFYKYLKTILEN- -I- -EGSDYFI-- -AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425
WP 031669209 363 —HGYAG YISG - TKQADFYKYMKATLEK- -I- -EGADYFI-- -AKIEEENFLRKQRTFDNGVIPHQLHLEEL 425
WP 033920898 363 —DGYAG YIDG - TKQVDFYKYLKTILEN- -I- -EGADYFI-- -AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425
AKI42028 366 —DGYAG YIDG - TKQVDFYKYLKTILEN- -I- -EGADYFI-- -AKIEEENFLRKQRTFDNGAIPHQLHLEEL 428
AKI50529 366 —DGYAG YIDG - TKQVDFYKYLKTILEN- -I- -EGADYFI-- -AKIEEENFLRKQRTFDNGAIPHQLHLEEL 428
EFR83390
WP 046323366 363 —DGYAG YIEG - TKQEAFYKYMKKMLEH- -V- -EGADYFI-- -NQIEEENFLRKQRTFDNGAIPHQLHLEEL 425
AKE81011 373 —NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- --KLNREDLLRKQRTFDNGSIPHQIHLGEL 435
CU082355 365 kvKGYYN YINR K APVDEFYKFVKKCIEK- -VdtPEAKQILh- --DIELENFLLKQNSRTNGSVPYQMQLDEM 433
WP 033162887 366 klHNYLG YIKY D TPVEEFYKYIKGLLAK- -VdtDEAREILe- --RIDLEKFMLKQNSRTNGSIPYQMQKDEM 434
AGZ 01981 390 —NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- --KLNREDLLRKQRTFDNGSIPHQIHLGEL 452
AKA60242 357 —NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- --KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
AKS40380 357 —NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- --KLNREDLLRKQRTFDNGSIPHQIHLGEL 419
4UN5 B 361 —NGYAG YIDG G ASQEEFYKFIKPILEK- -M- -DGTEELLv- --KLNREDLLRKQRTFDNGSIPHQIHLGEL 423
WP 010922251 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWMTR KSEETITPWNFE|E|WDKGA
WP "039695303 423 HAILRRQGDYYPFLKE- -KQD RIEKILTFRIPYYVGPL VRKE )-- SRFAWAEY RSDEKITPWNFDKVIDKEK
WP "045635197 420 NAILRRQGEYYPFLKD- -NKE KIEKILTFRIPYYVGPL ARGNί— RDFAWLTR :NSDEAIRPWNFEEIVDKAS
5AXW A 184 KQLLKVQKAYHQLDQSfi—D TYIDLLETRRTYYEGPG Eg- SPFGWKDI
WP 009880683 104 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "010922251 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "011054416 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "011284745 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "011285506 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "011527619 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "012560673 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "014407541 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "020905136 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "023080005 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "023610282 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "030125963 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "030126706 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "031488318 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "032460140 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "032461047 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "032462016 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "032462936 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "032464890 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "033888930 245 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "038431314 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "038432938 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
WP "038434062 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
BAQ51233 331 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG- n- SRFAWMTR KSEETITPWNFEEWDKGA
KGE60162
KGE60856
WP 002989955 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n -SRFAWMTR- KSEETITPWNFEEWDKGA
WP "003030002 420 HAILRRQEEHYPFLKE- -NQD KIEKILTFRIPYYVGPL ARKG- -SRFAWAEY- KADEKITPWNFDDILDKEK
WP "003065552 423 HAILRRQGDYYPFLKE- -NQD RIEKILTFRIPYYVGPL ARKD- -SRFSWAEY- HSDEKITPWNFDKVIDKEK
WP "001040076 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- KTDDSIRPWNFEDLVDKEK
WP "001040078 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- KTDDSIRPWNFEDLVDKEK
WP "001040080 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- KTDDSIRPWNFEDLVDKEK
WP "001040081 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- KTDDSIRPWNFEDLVDKEK
WP "001040083 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- KTDDSIRPWNFEDLVDKEK
WP "001040085 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- KTDDSIRPWNFEDLVDKEK
WP 001040087 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 4E37
WP "001040088 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4E 37
WP "001040089 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040090 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040091 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040092 421 KAIIRRQSEYYPFLKE- -NQD KIEKILTFRIPYYVGPL ARGN- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040094 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040095 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040096 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040097 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040098 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040099 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040100 421 RAIIRRQSEYYPLLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040104 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040105 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "001040106 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP "001040107 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP "001040108 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP "001040109 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP "001040110 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP "015058523 421 KAIIRRQSEYYPFLKE- -NQD KIEKILTFRIPYYVGPL ARGN- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "017643650 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "017647151 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP "017648376 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP "017649527 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "017771611 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP "017771984 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
CFQ25032 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
CFV16040 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
KLJ37842 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
KLJ72361 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
KLL20707 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
KLL42645 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP 047207273 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "047209694 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "050198062 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "050201642 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP "050204027 421 KAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEELVDKEA 4 E 37
WP "050881965 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK- -SDFAWMTR- - -KTDDSIRPWNFEDLVDKEK 4 E 37
WP 050886065 421 KDIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK-- SDFAWMTR—-KTDDSIRPWNFEDLVDKEK 487
AHN30376 421 KAIIRRQSEYYPFLKE- -NQD KIEKILTFRIPYYVGPL ARGN-- SDFAWMTR— -KTDDSIRPWNFEDLVDKEK 4 87
EA078426 421 KAIIRRQSEYYPFLKE- -NQD RIEKILTFRIPYYIGPL AREK-- SDFAWMTR— -KTDDSIRPWNFEDLVDKEK 4 87
CCW42055 421 RAIIRRQSEYYPFLKE- -NLD RIEKILTFRIPYYVGPL AREK-- SDFAWMTR— -KTDDSIRPWNFEELVDKEA 4 87
WP 0030415 02 420 HAILRRQGEHYPFLKE- -NQD KIEKILTFRIPYYVGPL ARKG-- SRFAWAEY— -KADEKITPWNFDDILDKEK 4 86
WP 0375937 52 421 HAILRRQGEHYPFLKE- -NQD KIEKILTFRIPYYVGPL ARKG-- SRFAWAEY— -KADEKITPWNFDDILDKEK 4 87
WP 0495166 84 421 HAILRRQGEHYPFLKE- -NQD KIEKILTFRIPYYVGPL ARKG-- SRFAWAEY— -KADEKITPWNFDDILDKEK 4 87
GAD46167 420 HAILRRQGEHYPFLKE- -NQD KIEKILTFRIPYYVGPL ARKG-- SRFAWAEY— -KADEKITPWNFDDILDKEK 4 86
WP 0183634 70 421 HAILRRQGDYYPFLKE- -NQE EIEKILTFRIPYYVGPL ARKD-- SRFAWAEY— -RSDEKITPWNFDKVIDKEK 4 87
WP 0030438 19 430 HAILRRQEEFYPFLKE- -NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWLTR— -KSEEAITPWNFEEWDKGA 4 96
WP 0062696 58 420 HAILRRQGEHYPFLKE- -NQD KIEKILTFRIPYYVGPL ARKG-- SRFAWAEY— -KADEKITPWNFDDILDKEK 4 86
WP 0488008 89 420 HAILRRQGEHYPFLKE- -NQD KIEKILTFRIPYYVGPL VRKG-- SRFAWAEY— -KADEKITPWNFDDILDKEK 4 86
WP 0127671 06 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWMTR— -KSEETITPWNFEEWDKGA 4 86
WP 0146123 33 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWMTR— -KSEETITPWNFEEWDKGA 4 86
WP 0150170 95 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWMTR— -KSEETITPWNFEEWDKGA 4 86
WP 0150576 49 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWMTR— -KSEETITPWNFEEWDKGA 4 86
WP 0483272 15 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWMTR— -KSEETITPWNFEEWDKGA 4 86
WP 0495193 24 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWMTR— -KSEETITPWNFEEWDKGA 4 86
WP 0125159 31 420 HAILRRQEVFYPFLKD- -NRK KIESLLTFRIPYYVGPL ARG-h- SRFAWVKR— -KFDGAIRPWNFEEIVDEEA 4 86
WP 0213209 64 420 HAILRRQEVFYPFLKD- -NRK KIESLLTFRIPYYVGPL ARG-h- SRFAWVKR— -KFDGAIRPWNFEEIVDEEA 4 86
WP 0375817 60 420 HAILRRQEVFYPFLKD- -NRK KIESLLTFRIPYYVGPL ARG-h- SRFAWVKR— -KFDGAIRPWNFEEIVDEEA 4 86
WP 0042324 81 420 RTILRRQGEYYPFLKE- -NQA KIEKILTFRIPYYVGPL ARKN-- SRFAWAKY— -HSDEPITPWNFDEWDKEK 4 86
WP 0098545 40 421 HAILRRQGDYYPFLKE- -KQD RIEKILTFRIPYYVGPL VRKD-- SRFAWAEY— -RSDEKITPWNFDKVIDKEK 4 87
WP 0129621 74 421 HAILRRQGEHYAFLKE- -NQA KIEKILTFRIPYYVGPL ARKN-- SRFAWAEY— -HSDEKITPWNFDEIIDKEK 4 87
WP 0396953 03 423 HAILRRQGDYYPFLKE- -KQD RIEKILTFRIPYYVGPL VRKD-- SRFAWAEY— -RSDEKITPWNFDKVIDKEK 4 89
WP 0143349 83 420 HSILRRQGDYYPFLKE- -NQA KIEKILTFRIPYYVGPL ARKD-- SRFAWANY— -HSDEPITPWNFDEWDKEK 4 86
WP 0030992 69 420 KAIIRRQEKFYPFLKE- -NQK KIEKLFTFKIPYYVGPL ANG-q- SSFAWLKR— -QSNESITPWNFEEWDQEA 4 86
AHY15608 420 KAIIRRQEKFYPFLKE- -NQK KIEKLFTFKIPYYVGPL ANG-q- SSFAWLKR— -QSNESITPWNFEEWDQEA 4 86
AHY17476 420 KAIIRRQEKFYPFLKE- -NQK KIEKLFTFKIPYYVGPL ANG-q- SSFAWLKR— -QSNESITPWNFEEWDQEA 4 86
ESR09100
AGM98575 420 KAIIRRQEKFYPFLKE- -NQK KIEKLFTFKIPYYVGPL ANG-q- SSFAWLKR— -QSNESITPWNFEEWDQEA 4 86
ALF27331 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYIGPL ARGK-- SDFSWLSR— -KSADKITPWNFDEIVDKES 4 86
WP 0183724 92 433 QAIILNQSKYYPFLAE- -NKE KIEKILTFRIPYYVGPL ARGN-- SSFAWLQR— -KSDEAIRPWNFEQWDMET 4 99
WP 0456180 28 421 NAIIRRQGEHYPFLQE- -NKE KIEKILTFRIPYYVGPL ARGN-- RDFAWLTR— -NSDQAIRPWNFEEIVDKAR 4 87
WP 0456351 97 420 NAILRRQGEYYPFLKD- -NKE KIEKILTFRIPYYVGPL ARGN-- RDFAWLTR— -NSDEAIRPWNFEEIVDKAS 4 86
WP 0022635 49 420 RAI IRRQAEFYPFLAD- -NQD RIEKLLTFRIPYYVGPL ARGK-- SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP 0022638 87 420 RAI IRRQAEFYPFLAD- -NQD RIEKLLTFRIPYYVGPL ARGK-- SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP 0022649 20 420 HAILRRQGDYYPFLKE- -NQD RIEKILTFRIPYYVGPL ARGK-- SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP 0022690 43 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK-- SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP 002269448 420 RAI IRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR—-KSADKITPWNFDEIVDKES 486
WP "0022 71977 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 72766 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 73241 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 75430 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 76448 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 77050 420 HAILRRQGDYYPFLKE- -NQD RIEKILTFRIPYYVGPL ARKN- -SRFAWAEY— -HSDEAVMPWNFDQVIDKES 4 86
WP "0022 77364 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 79025 420 RAIIRRQSEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 79859 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 80230 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 81696 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 82247 420 HAILRRQGDYYPFLKE- -NQD RIEKILTFRIPYYVGPL ARKN- -SRFAWAEY— -HSDEAVTPWNFDQVIDKES 4 86
WP "0022 82906 420 RAI IRRQAEFYPFLAD- -NQD RIEKLLTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 83846 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 87255 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 88990 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 89641 420 RAI IRRQAEFYPFLAD- -NQD RIEKLLTFRIPYYVGPL ASGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 90427 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 95753 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0022 96423 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0023 04487 430 HAILRRQGEHYPFLKE- -NQD RIEKILTFRIPYYVGPL VRKG- -SRFAWAEY— -KADEKITPWNFDDILDKEK 4 96
WP "0023 05844 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0023 07203 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0023 10390 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0023 52408 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0129 97688 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "θ146 77909 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0193 12892 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0193 13659 420 RAI IRRQAEFYPFLAD- -NQD RIEKLLTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0193 14093 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0193 15370 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0198 03776 420 RAI IRRQAEFYPFLAD- -NQD RIEKLLTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0198 05234 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0247 83594 420 RAI IRRQAEFYPFLAD- -NQD RIEKLLTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0247 84288 420 HAILRRQGDYYPFLKE- -NQD RIEKILTFRIPYYVGPL ARKN- -SRFAWAEY— -HSDEAVTPWNFDQVIDKES 4 86
WP "0247 84666 420 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0247 84894 420 RAI IRRQAEFYPFLAD- -NQD RIEKLLTFRIPYYVGPL ASGK- -SDFAWLSR— -KSADKITPWNFDEIVDKES 4 86
WP "0247 86433 420 HAILRRQGDYYPFLKE- -NQD RIEKILTFRIPYYVGPL ARKN- -SRFAWAEY— -HSDEAVTPWNFDQVIDKES 4 86
WP 049473442 420 RAI IRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK-- SDFAWLSR—-KSADKITPWNFDEIVDKES 486
WP "049474547 420 RAI IRRQAEFYPFLAD- -NQD RIEKLLTFRIPYYVGPL ASGK-- SDFAWLSR— -KSADKITPWNFDEIVDKES 486
EMC03581 413 RAI IRRQAEFYPFLAD- -NQD RIEKILTFRIPYYVGPL ARGK-- SDFAWLSR— -KSADKITPWNFDEIVDKES 479
WP 000428612 421 NAILRRQGEHYPFLKE- -NKE KIEKILTFRIPYYVGPL ARGN-- RDFAWLTR— -NSDQAIRPWNFEEIVDKAS 487
WP "000428613 421 NAILRRQGEHYPFLKD- -NKE RIEKILTFRIPYYVGPL ARGN-- RDFAWLTR— -NSDEAIRPWNFEEIVDKAS 487
WP "049523028 420 NAILRHQGEYYPFLKE- -NKD KIEQILTFRIPYYVGPL ARGN-- SDFAWLSR— -NSDEAIRPWNFEEMVDKSS 486
WP "003107102 389 KSIIRRQEKYYPFLKD- -KQV RIEKIFTFRIPYFVGPL ANG-n- SSFAWVKR— -RSNESITPWNFEEWEQEA 455
WP "054279288 422 QAILERQQAYYPFLKD- -NQE KIEKILTFRIPYYIGPL ARG-n- SRFAWLTR— -TSDQKITPWNFDEMVDQEA 488
WP "049531101 421 NAILRRQGEHYPFLKE- -NRE KIEKILTFRIPYYVGPL ARGN-- RDFAWLTR— -NSDQAIRPWNFEEIVDKAS 487
WP "049538452 421 NAILRRQGEHYPFLKE- -NKE KIEKILTFRIPYYVGPL ARGN-- RDFAWLTR— -NSDQAIRPWNFEEIVDKAS 487
WP "049549711 421 NAILRRQGEHYPFLKE- -NKE KIEKILTFRIPYYVGPL ARGN-- RDFAWLTR— -NSDQAIRPWNFEEIVDKAS 487
WP "007896501 422 HAILRRQEKYYPFLAE- -QKE KIEQLLCFRIPYYVGPL AKGGn- SSFAWLKR— -RSDEPITPWNFKDWDEEA 489
EFR44625 374 HAILRRQEKYYPFLAE- -QKE KIEQLLCFRIPYYVGPL AKGGn- SSFAWLKR— -RSDEPITPWNFKDWDEEA 441
WP 002897477 420 NAILRRQGEHYPFLKE- -NRE KIEKILTFRIPYYVGPL ARDN-- RDFSWLTR— -NSDEPIRPWNFEEWDKAR 486
WP "002906454 420 NAILRRQGEHYLFLKE- -NRE KIEKILAFRI PYYVGPL ARGN-- RDFAWLTR— -NSDQAIRPWNFEEWDKAS 486
WP "009729476 421 NAILRRQGEHYPFLKE- -NKE KIEKILTFRIPYYVGPL ARGN-- RDFAWLTR— -NSDQAIRPWNFEEIVDKAS 487
CQR24647 421 KAILRRQGEFYPFLKE- -NAE KIQQILTFKI PYYVGPL ARGN-- SRFAWASY— -NSNEKMTPWNFDNVIDKTS 487
WP 000066813 421 NAIIRRQGEHYPFLQE- -NKE KIEKILTFRIPYYVGPL ARGN-- GDFAWLTR— -NSDQAIRPWNFEEIVDQAS 487
WP "009754323 421 NAILRRQGEHYPLLKE- -NKE KIEKILTFRIPYYVGPL ARGN-- RDFAWLTR— -NSDQAIRPWNFEEIVDKAS 487
WP "044674937 420 HAI IRRQAEFYPFLVE- -NQD KIEKILTFRIPYYVGPL ARGK-- SEFAWLNR— -KSDEKIRPWNFDEMVDKET 486
WP "044676715 420 HAI IRRQAEFYPFLVE- -NQD KIEKILTFRIPYYVGPL ARGK-- SEFAWLNR— -KSDEKIRPWNFDEMVDKET 486
WP "044680361 420 HAI IRRQAEFYPFLVE- -NQD KIEKILTFRIPYYVGPL ARGK-- SEFAWLNR— -KSDEKIRPWNFDEMVDKET 486
WP "044681799 420 HAI IRRQAEFYPFLVE- -NQD KIEKILTFRIPYYVGPL ARGK-- SEFAWLNR— -KSDEKIRPWNFDEMVDKET 486
WP "049533112 420 HAILRRQEEHYPFLKE- -NQD KIEKILTFRIPYYVGPL ARKG-- SRFAWAEY— -KADEKITPWNFDDILDKEK 486
WP "029090905 404 VAILENQATYYPFLLE- -QKD NIHKLLTFRI PYYVGPL ADQKd- SEFAWMVR— -KQAGKITPFNFEEMVDIDA 471
WP "006506696 430 IKIIDNQAEYYPILKE- -KRE QLLSILTFRIPYYFGPL ETSEh- AWIKRlegKENQRILPWNYQDIVDVDA 498
AIT42264 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWMTR— -KSEETITPWNFEEWDKGA 486
WP 034440723 426 TAVLDQQEKHYSFLKE- -NRD KI I SLLTFRI PYYVGPL AKGE-- SRFAWLER—sNSEEKIKPWNFDKIVDIDK 493
AKQ21048 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n- SRFAWMTR— -KSEETITPWNFEEWDKGA 486
WP 004636532 421 QAILDRQSQYYPFLAE- -NRD KIESLVTFRI PYYVGPL TVSDq- SEFAWMER— -QSDEPIRPWNFDEIVNKER 488
WP "002364836 428 QAIIHRQAAYYPFLKE- -NQE KIEQLVTFRI PYYVGPL SKGDa- STFAWLKR— -QSEEPIRPWNLQETVDLDQ 495
WP "016631044 379 QAIIHRQAAYYPFLKE- -NQE KIEQLVTFRI PYYVGPL SKGDa- STFAWLKR— -QSEEPIRPWNLQETVDLDQ 446
EMS75795 163 KAIIERQKPYYPSLEE- -ARD KMIRLLTFRI PYYVGPL AQGEetSSFAWLER— -KTPEKVTPWNATEVIDYSA 231
WP 002373311 428 QAIIHRQAAYYPFLKE- -NQE KIEQLVTFRI PYYVGPL SKGDa- STFAWLKR— -QSEEPIRPWNLQETVDLDQ 495
WP "002378009 428 QAIIHRQAAYYPFLKE- -NQE KIEQLVTFRI PYYVGPL SKGDa- NTFAWLKR— -QSEEPIRPWNLQETVDLDQ 495
WP "002407324 428 QAIIHRQAAYYPFLKE- -NQE KIEQLVTFRI PYYVGPL SKGDa- STFAWLKR— -QSEEPIRPWNLQETVDLDQ 495
WP "002413717 428 QAIIHRQAAYYPFLKE- -NQE KIEQLVTFRI PYYVGPL SKGDa- STFAWLKR— -QSEEPIRPWNLQETVDLDQ 495
WP "010775580 430 QAIIHRQAAYYPFLKE- -NQK KIEQLVTFRI PYYVGPL SKGDa- STFAWLKR— -QSEEPIRPWNLQETVDLDQ 497
WP "010818269 428 QAIIHRQAAYYPFLKE- -NQE KIEQLVTFRI PYYVGPL SKGDa- STFAWLKR— -QSEEPIRPWNLQETVDLDQ 495
WP 010824395 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR QSEEPIRPWNLQETVDLDQ 495
WP "016622645 428 QAIIHRQAAYYPFLKE- -NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR QSEEPIRPWNLQETVDLDQ 495
WP "033624816 428 QAIIHRQAAYYPFLKE- -NQK KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR QSEEPIRPWNLQETVDLDQ 495
WP "033625576 428 QAIIHRQAAYYPFLKE- -NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR QNEKPIRPWNLQETVDLDQ 495
WP "033789179 428 QAIIHRQAAYYPFLKE- -NQK KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR QSEEPIRPWNLQETVDLDQ 495
WP "002310644 424 RAIIANQKKHYPFLKE- -EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR KSEEKIKPWNLPEIVDMEG 492
WP "002312694 425 RAIIANQKKHYPFLKE- -EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR KSEEKIKPWNLPEIVDMEG 493
WP "002314015 425 RAIIANQKKHYPFLKE- -EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR KSEEKIKPWNLPEIVDMEG 493
WP "002320716 425 RAIIANQKKHYPFLKE- -EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR KSEEKIKPWNLPEIVDMEG 493
WP "002330729 424 RAIIANQKKHYPFLKE- -EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR KSEEKIKPWNLPEIVDMEG 492
WP "002335161 425 RAIIANQKKHYPFLKE- -EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR KSEEKIKPWNLPEIVDMEG 493
WP "002345439 425 RAIIANQKKHYPFLKE- -EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR KSEEKIKPWNLPEIVDMEG 493
WP "034867970 418 KAIIDQQKQHYPFLEE- -AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER KTAEKINPWNFSEWDIEK 486
WP "047937432 425 RAIIANQKKHYPFLKE- -EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR KSEEKIKPWNLPEIVDMEG 493
WP "010720994 418 KAIIDQQKQHYPFLEE- -AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER KTAEKINPWNFSEWDIEK 486
WP "010737004 418 KAIIDQQKQHYPFLEE- -AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER KTAEKINPWNFSEWDIEK 486
WP "034700478 418 KAIIDQQKQHYPFLEE- -AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER KTAEKINPWNFSEWDIEK 486
WP "007209003 422 RAILRKQEKYYSFLKE- -NHE KIEQIFKVRIPYYVGPL AKHNeqSRFAWNIR KSDEPIRPWNMNDWDENA 490
WP "023519017 418 REIMDRQKRFYPFLKG- -AQG KIEKLLTFRIPYYVGPL AQEGq-SPFAWIKR KSPSQITPWNFAEWDKEN 485
WP "010770040 423 EAIIQKQATYYPFLAD- -NKE EMKQLVTFRIPYYVGPL ADGN—SPFAWLER ISSEPIRPGNLAEWDIKK 489
WP "048604708 419 KAILHHQAMYYPFLQE- -KFS NFVDLLTFRIPYYVGPL ANGN—SRFSWLSR KSDEPIRPWNLAEWDLSK 485
WP "010750235 418 KAIIDQQKQYYPFLEK- -SKE KMIQLLTFRIPYYVGPL AQDKetSSFAWLER KTTEKIKPWNAKDVIDYGA 486
AII16583 459 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR KSEETITPWNFEEWDKGA 525
WP 029073316 436 NKILENQSVYYSDLKD- -NED KIRSILTFRIPYYFGPL ITKDr—QFDWIIKkegKENERILPWNANEIVDVDK 506
WP "031589969 436 NKILENQSVYYSDLKD- -NED KIRSILTFRIPYYFGPL ITKDr—QFDWIIKkegKENERILPWNANEIVDVDK 506
KDA45870 418 VAIVENQGKYYPFLRE- -NKD KFEKILNFRIPYYVGPL ARGN—SKFAWLTR—a-GEGKITPYNFDEMIDKET 484
WP 039099354 426 DRIIENQQQYYPWLAE- 1NPN KLDELVAFRVPYYVGPL QQQSsdAKFAWMIR KAEGQITPWNFDDKVDRQA 509
AKP02966 416 EKIIDNQSQYYPFLKE- -NKE KLLSILSFRIPYYVGPL -QSSekNPFAWMER KSNGHARPWNFDEIVDREK 483
WP 010991369 426 EAILHQQAKYYPFLKE- -NYD KIKSLVTFRIPYFVGPL ANGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 492
WP "033838504 426 EAILHQQAKYYPFLKE- -NYD KIKSLVTFRIPYFVGPL ANGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 492
EHN60060 429 EAILHQQAKYYPFLKE- -NYD KIKSLVTFRIPYFVGPL ANGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 495
EFR89594 195 EAILHQQAKYYPFLKE- -NYD KIKSLVTFRIPYFVGPL ANGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 261
WP 038409211 426 EAILHQQAKYYPFLRK- -DYE KIRSLVTFRIPYFIGPL ANGQ—SDFAWLTR KADGEIRPWNIEEKVDFGK 492
EFR95520 45 EAILHQQAKYYPFLRK- -DYE KIRSLVTFRIPYFIGPL ANGQ—SDFAWLTR KADGEIRPWNIEEKVDFGK 111
WP 003723650 426 EAIIHQQAKYYPFLKE- -DYD KIKSLVTFRIPYFVGPL ANGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 492
WP "003727705 426 EAILHQQAKYYPFLRE- -GYD KIKSLVTFRIPYFVGPL ANGQ—SEFAWLTR KDDGEIRPWNIEEKVDFGK 492
WP "003730785 426 EAILHQQAKYYPFLRE- -GYD KIKSLVTFRIPYFVGPL ANGQ—SEFAWLTR KDDGEIRPWNIEEKVDFGK 492
WP "003733029 426 EAILHQQAKYYPFLRE- -DYE KIKSLVTFRIPYFVGPL AKGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 492
WP "003739838 426 EAILHQQAKYYPFLKE- -AYD KIKSLVTFRIPYFVGPL ANGQ—SDFAWLTR KADGEIRPWNIEEKVDFGK 492
WP 014601172 426 EAIIHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 492
WP 023548323 426 EAILHQQAKYYPFLRE- -DYE KIKSLVTFRIPYFVGPL AKGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 492
WP 031665337 426 EAIIHQQAKYYTFLKE- -DYD KIKSLVTFRIPYFVGPL ANGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 492
WP 031669209 426 EAILHQQAKYYPFLRE- -DYE KIKSLVTFRIPYFVGPL AKGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 492
WP 033920898 426 EAIIHQQAKYYPFLRE- -DYE KIKSLVTFRIPYFVGPL AKGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 492
AKI42028 429 EAIIHQQAKYYPFLRE- -DYE KIKSLVTFRIPYFVGPL AKGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 495
AKI50529 429 EAIIHQQAKYYPFLRE- -DYE KIKSLVTFRIPYFVGPL AKGQ—SEFAWLTR KADGEIRPWNIEEKVDFGK 495
EFR83390
WP 046323366 426 EAILHQQAKYYPFLKV- -DYE KIKSLVTFRIPYFVGPL ANGQ—SEFSWLTR KADGEIRPWNIEEKVDFGK 492
AKE81011 436 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR KSEETITPWNFEEWDKGA 502
CU082355 434 IKI IDNQAKYYPVLKE- -KRE QLLSILTFRIPYYFGPL ETSEh AWIKRlegKENQRILPWNYQDTVDVDA 502
WP 033162887 435 IQIIDNQSVYYPQLKE- -NRD KLISILEFRIPYYFGPL AHSE FAWIKKfedKQKERILPWNYDQIVDIDA 503
AGZ 01981 453 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR KSEETITPWNFEEWDKGA 519
AKA60242 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR KSEETITPWNFEEWDKGA 486
AKS40380 420 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR KSEETITPWNFEEWDKGA 486
4UN5 B 424 HAILRRQEDFYPFLKD- -NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR KSEETITPWNFEEWDKGA 490
WP 010922251 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSG[ QKKAIVDLLFK--TNR--KVTV 561
WP "039695303 490 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN- -EQGKES-FFDSNMKQEIFDHVFK- -ENR- KVTK 563
WP "045635197 48 7 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA- -EGLRDYqFLDSGQKKQIVNQLFK- -ENR- KVTE 561
5AXW A 230 —KEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITR- -DENEKLeYYE KFQIIENVFK- -QKK- KPTL 299
WP 009880683 171 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 245
WP "010922251 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "011054416 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "011284745 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "011285506 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "011527619 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "012560673 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "014407541 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "020905136 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "023080005 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "023610282 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "030125963 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "030126706 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "031488318 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPeFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "032460140 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "032461047 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "032462016 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "032462936 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "032464890 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "033888930 312 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 386
WP "038431314 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "038432938 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "038434062 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
BAQ51233 398 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 472
KGE60162
KGE60856
WP 002989955 48 7 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP "003030002 48 7 SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKYVN- -EQGEAK-FFDANMKQEIFDHVFK- -ENR- KVTK 560
WP "003065552 490 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN- -EQGKDS-FFDSNMKQEIFDHVFK- -ENR- KVTK 563
WP "001040076 48 8 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP "001040078 48 8 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP "001040080 48 8 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP "001040081 48 8 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP "001040083 48 8 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP "001040085 48 8 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040087 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561
WP 001040088 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040089 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040090 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040091 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040092 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNVKQEIFDGVFK- -EHR- KVSK 561
WP 001040094 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP 001040095 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP 001040096 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP 001040097 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP 001040098 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP 001040099 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP 001040100 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP 001040104 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040105 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040106 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040107 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040108 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040109 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 001040110 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 015058523 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNVKQEIFDGVFK- -EHR- KVSK 561
WP 017643650 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP 017647151 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 017648376 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 017649527 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 017771611 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 017771984 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
CFQ25032 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
CFV16040 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
KLJ37842 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
KLJ72361 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
KLL20707 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
KLL42645 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 047207273 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 047209694 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA- -EGFKDFqFLNRKQKETIFNSLFK- -EKR- KVTE 562
WP 050198062 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 050201642 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 050204027 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 050881965 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
WP 050886065 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561
AHN30376 4 88 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNVKQEIFDGVFK- -EHR- KVSK 561
EA078426 4 88 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EHR- KVSK 561
CCW42055 4 88 SAEAFIHCMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN- -EQGETY-FFDSNIKQEIFDGVFK- -EYR- KVSK 561
WP 003041502 4 87 SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKYVN- -EQGEAK-FFDANMKQEIFDHVFK- -ENR- KVTK 560
WP 037593752 4 88 SAEKFITRMTLNDLYLPEEKVLPKHSPLYETFTVYNELTKVKYVN- -EQGEAK-FFDTNMKQEIFDHVFK- -ENR- KVTK 561
WP 049516684 4 88 SAEKFITRMTLNDLYLPEEKVLPKHSPLYETFTVYNELTKVKYVN- -EQGEAK-FFDTNMKQEIFDHVFK- -ENR- KVTK 561
GAD46167 4 87 SAEKFITRMTLNDLYLPEEKVLPKHSPLYETFTVYNELTKVKYVN- -EQGEAK-FFDTNMKQEIFDHVFK- -ENR- KVTK 560
WP 018363470 4 88 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETFAVYNELTKVKYVN- -EQGKDS-FFDSNMKQEIFDHVFK- -ENR- KVTK 561
WP 003043819 4 97 SAQSFIERMTNFDEQLPNKKVLPKHSLLYEYFTVYNELTKVKYVT- -ERMRKPeFLSGEQKKAIVDLLFK- -TNR- KVTV 571
WP 006269658 4 87 SAEKFITRMTLNDLYLPEEKVLPKHSPLYEAFTVYNELTKVKYVN- -EQGEAK-FFDTNMKQEIFDHVFK- -ENR- KVTK 560
WP 048800889 4 87 SAEKFITRMTLNDLYLPEEKVLPKHSLLYEIFTVYNELTKVKYVN- -EQGEAK-FFDANMKQEIFDHVFK- -ENP- KVTK 560
WP 012767106 4 87 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPeFLSGKQKEAIVDLLFK- -TNR- KVTV 561
WP 014612333 4 87 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPeFLSGKQKEAIVDLLFK- -TNR- KVTV 561
WP 015017095 4 87 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPeFLSGKQKEAIVDLLFK- -TNR- KVTV 561
WP 015057649 4 87 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPeFLSGKQKEAIVDLLFK- -TNR- KVTV 561
WP 048327215 4 87 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPeFLSGKQKEAIVDLLFK- -TNR- KVTV 561
WP 049519324 4 87 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT- -EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 561
WP 012515931 4 87 SAQIFIEKMTKNDLYLPNEKVLPKHSLLYETFTVYNELTKVKYAT- -EGMTRPqFLSADQKQAIVDLLFK- -TNR- KVTV 561
WP 021320964 4 87 SAQIFIEKMTKNDLYLPNEKVLPKHSLLYETFTVYNELTKVKYAT- -EGMTRPqFLSADQKQAIVDLLFK- -TNR- KVTV 561
WP 037581760 4 87 SAQIFIEKMTKNDLYLPNEKVLPKHSLLYETFTVYNELTKVKYAT- -EGMTRPqFLSADQKQAIVDLLFK- -TNR- KVTV 561
WP 004232481 4 87 SAEKFITRMTLNDLYLPEEKVLPKHSYVYETFAVYNELTKIKYVN- -EQGKSF-FFDANMKQEI FDHVFK- -ENR- KVTK 560
WP 009854540 4 88 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN- -EQGKES-FFDSNMKQEIFDHVFK- -ENR- KVTK 561
WP 012962174 4 88 SAEKFITRMTLNDLYLPEEKVLPKHSLVYETYTVYNELTKVKYVN- -EQGKSN-FFDANMKQEI FEHVFK- -ENR- KVTK 561
WP 039695303 4 90 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN- -EQGKES-FFDSNMKQEIFDHVFK- -ENR- KVTK 563
WP 014334983 4 87 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETFTVYNELTKIKYVN- -EQGESF-FFDANMKQEI FDHVFK- -ENR- KVTK 560
WP 003099269 4 87 SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT- -EGMKRPvFLSSEDKEEI LLFK- -KER- KVTV 561
AHY15608 4 87 SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT- -EGMKRPvFLSSEDKEEI LLFK- -KER- KVTV 561
AHY17476 4 87 SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT- -EGMKRPvFLSSEDKEEI LLFK- -KER- KVTV 561 ESR09100
AGM98575 4 87 SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT- -EGMKRPvFLSSEDKEEI LLFK- -KER- KVTV 561
ALF27331 4 87 SAEAFINRMTNYDLYLPNQKVLPRHSLLYEKFTVYNELTKVKYKT- -EQGKTA-FFDANMKQEI FDGVFK- -VYR- KVTK 560
WP 018372492 5 00 SASRFIERMTLHDLYLPDEKVLPRHSLIYEKYTVFNELTKVRFTP- -EGGKEV-YFSKTDKENIFDSLFK- -RYR- KVTK 573
WP 045618028 4 88 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA- -EGLRDYqFLDSGQKQQIVTQLFK- -EKR- KVTE 562
WP 045635197 4 87 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA- -EGLRDYqFLDSGQKKQI QLFK- -ENR- KVTE 561
WP 002263549 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA-FFDANMKQEI FDGVFK- -VYR- KVTK 560
WP 002263887 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELIKVKYKT- -EQGKTA-FFDANMKQEI FDGVFK- -VYR- KVTK 560
WP 002264920 4 87 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA-FFDANMKQEI FDGVFK- -VYR- KVTK 560
WP 002269043 4 87 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA-FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP 002269448 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA- FFDANMKQEIFDGVFK--VYR-KVTK 560
WP "0022 71977 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 72766 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 73241 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 75430 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 76448 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 77050 4 87 SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT- -EIGEAK- FFDANLKQEIFDGLFK- -HER- KVTK 560
WP "0022 77364 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 79025 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGETA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 79859 4 87 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 80230 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 81696 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 82247 4 87 SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT- -EIGEAK- FFDANLKQEIFDGLFK- -HER- KVTK 560
WP "0022 82906 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 83846 4 87 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 87255 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 88990 4 87 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 89641 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 90427 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 95753 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0022 96423 4 87 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0023 04487 4 97 SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKYVN- -EQGEAK- FFDANMKQEIFDHVFK- -ENR- KVTK 570
WP "0023 05844 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0023 07203 4 87 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0023 10390 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0023 52408 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0129 97688 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "θ146 77909 4 87 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0193 12892 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0193 13659 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0193 14093 4 87 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0193 15370 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0198 03776 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0198 05234 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0247 83594 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0247 84288 4 87 SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT- -EIGEAK- FFDANLKQEIFDGLFK- -HER- KVTK 560
WP "0247 84666 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0247 84894 4 87 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT- -EQGKTA- FFDANMKQEIFDGVFK- -VYR- KVTK 560
WP "0247 86433 4 87 SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT- -EIGEAK- FFDANLKQEIFDGLFK- -HER- KVTK 560
WP_049473442 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT EQGKTA-FFDANMKQEIFDGVFK -VYR-KVTK 560 WP_049474547 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT EQGKTA-FFDANMKQEIFDGVFK -VYR- KVTK 560 EMC03581 480 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT EQGKTA-FFDANMKQEIFDGVFK -VYR- KVTK 553 WP_00 0428612 488 SAESFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLRDYqFLDSRQKKDIFYTLFK eDKR- KVTE 564 WP_000428613 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLRDYqFLDSGQKKQIVTQLFK -EKR- KVTE 562 WP_049523028 487 SAEDFIHRMTNYDLYLPEEKVLPKHSLLYETFTVYNELTKVKYIA EGMKDYqFLDSGQKKQI QLFK -EKR- KVTE 561 WP_003107102 456 SAKVFIERMTNFDTYLPEEKVLPKHSLLYEMFTVYNELTKVKYQA EGMRKPeFLSSEEKIEIVSNLFK -TER- KVTV 530 WP_054279288 489 SAQAFIERMTNFDEYLPQEKVLPKHSLTYEYFTVYNELTKVKYVT EGMTKPeFLSAGQKEQIVELLFK -KYR- KVTV 563 WP_049531101 488 SAEAFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLRDYqFLDSGQKKKIINQLFK -EKR- KVTE 562 WP_049538452 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLRDYqFLDSGQKKQI QLFK -EKR- KVTE 562 WP_049549711 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLRDYqFLDSGQKKQI QLFK -EKR- KVTE 562 WP_007896501 490 SAQAFIEGMTNYDTYLPEEKVLPKHSPLYEMFTVYNELTKVKYIA ENMTKP1YLSAEQKEAIIDHLFK -QTR- KVTV 564 EFR44625 442 SAQAFIEGMTNYDTYLPEEKVLPKHSPLYEMFTVYNELTKVKYIA ENMTKP1YLSAEQKEAIIDHLFK -QTR- KVTV 516 WP_00 2897477 487 SAEDFIHRMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLRDYqFLDSGQKKQIWQLFK -EKR- KVTE 561 WP_002906454 487 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLRDYqFLDSGQKKQIWQLFK -DKR- KVTE 561 WP_009729476 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLRDYqFLDSGQKKQIVTQLFK -EKR- KVTE 562 CQR24647 488 SAQAFIERMTNNDLYLPDQKVLPKHSLLYQKFAVYNELTKIKYVT ETGEAR-LFDVFLKKEIFDGLFK -KER- KVTK 561 WP_00 0066813 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLTRYqFLDKKQKKDIFDTFFK eNKR- KVTE 564 WP_009754323 488 SAESFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA EGLRDYqFFDSGQKKQIWQLFK -EKR- KVTE 562 WP_044674937 4i Ϊ7 SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVKFIA EGMRDYqFLDSGQKKDIVKTLFK -TKR- KVTA 561 WP_044676715 4iΪ7 SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVRYVT EQGKSF-FFDANMKQEI FDGVFK -VYR- KVTK 560 WP_044680361 4iΪ7 SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVRYVT EQGKSF-FFDANMKQEI FDGVFK -VYR- KVTK 560 WP_044681799 4iΪ7 SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVKFIA EGMRDYqFLDSGQKKDIVKTLFK -TKR- KVTA 561 WP_049533112 4iΪ7 SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKY EQGEAK-FFDANMKQEI FDHVFK -ENR- KVTK 560 WP_029090905 472 SSEAFIKRMTNKCTYLIHEDVIPKHSFSYAKFEVLNELNKIRLDG KP—IDIPLKKRIFEGLFL —EKtKVTQ 540 WP_006506696 499 TAEGFIKRMRSYCTYFPDEEVLPKNSLIVSKYEVYNELNKIRVDD kLLEVDVKNDIYNELFM -KNK- TVTE 567 AIT42264 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT EGMRKPaFLSGEQKKAIVDLLFK -TNR- KVTV 561 WP_03 4440723 494 SAELFIENLTSRDTYLPDEPVLPKRSLIYQKFTIFNELTKISYID ERGILQ-NFSSREKIAI FNDLFK —NKsKVTK 567 AKQ21048 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT EGMRKPaFLSGEQKKAIVDLLFK -TNR- KVTV 561 WP_00 4636532 489 SAEKFIERMTNMDTYLLEEKVLPKRSLLYQTFEVYNELTKVRYTN EQGKTE-KLNRQQKAEIIETLFK qKNR- -VRE 562 WP_002364836 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD DRGIKA-NFSGKEKEKIFDYLFK -TRR- KVKK 569 WP_016631044 447 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD DRGIKA-NFSGKEKEKIFDYLFK -TRR- KVKK 520 EMS75795 232 SAMKFIQRMINYDTYLPTEKVLPKHSILYQKYTIFNELTKVAYKD ERGIKH-QFSSKEKREIFKELFQ -KQR- KVTV 305 WP_00 2373311 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD DRGIKA-NFSGKEKEKIFDYLFK -TRR- KVKK 569 WP_002378009 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD DRGIKA-NFSGKEKEKIFDYLFK -TRR- KVKK 569 WP_002407324 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD DRGIKA-NFSGKEKEKIFDYLFK -TRR- KVKK 569 WP_002413717 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD DRGIKA-NFSGKEKEKIFDYLFK -TRR- KVKK 569 WP_010775580 498 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD DRGIKA-NFSGKEKEKIFDYLFK -TRR- KVKK 571 WP 010818269 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD DRGIKA-NFSGKEKEKIFDYLFK -TRR- KVKK 569
WP 010824395 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD—DRGIKA-NFSGKEKEKIFDYLFK--TRR- KVKK 569
WP 016622645 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD— DRGIKA- NFSGKEKEKIFDYLFK- -TRR- KVKK 569
WP 033624816 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD— DRGIKA- NFSGKEKEKIFDYLFK- -TRR- KVKK 569
WP 033625576 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD— DRGIKA- NFSGKEKEKIFDYLFK- -TRR- KVKK 569
WP 033789179 496 SATAFIERMTNFDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD— DRGIKA- NFSGKEKEKIFDYLFK- -TRR- KVKK 569
WP 002310644 493 SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD— ERGQMN- YFSSIEKKEIFHELFE- -KNR- KVTK 566
WP 002312694 494 SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD— ERGQMN- YFSSIEKKEIFHELFE- -KNR- KVTK 567
WP 002314015 494 SAVRFIERMNNTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD— ERGQMN- YFSSIEKKEIFHELFE- -KNR- KVTK 567
WP 002320716 494 SAVRFIERMINTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD— ERGQMN- YFSSIEKKEIFHELFE- -KNR- KVTK 567
WP 002330729 493 SAVRFIERMINTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD— ERGQMN- YFSSIEKKEIFHELFE- -KNR- KVTK 566
WP 002335161 494 SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD— ERGQMN- YFSSIEKKEIFHELFE- -KNR- KVTK 567
WP 002345439 494 SAVRFIERMINTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD— ERGQMN- YFSSIEKKEIFHELFE- -KNR- KVTK 567
WP 034867970 487 SAMRFIQRMTKQDTYLPTEKVLPKNSLLYQKYMIFNELTKVSYKD— ERGVKQ- YFSGDEKQQIFKQLFQ- -KERgKITV 561
WP 047937432 494 SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD— ERGQMN- YFSSIEKKEIFHELFE- -KNR- KVTK 567
WP 010720994 487 SAMRFIQRMTKQDTYLPTEKVLPKNSLFYQKYMIFNELTKVSYKD— ERGVKQ- YFSGDEKQQIFKQLFQ- -KERgKITV 561
WP 010737004 487 SAMRFIQRMTKQDTYLPTEKVLPKNSLLYQKYMIFNELTKVSYKD— ERGVKQ- YFSGDEKQQIFKQLFQ- -KERgKITV 561
WP 034700478 487 SAMRFIQRMTKQDTYLPTEKVLPKNSLLYQKYMIFNELTKVSYKD— ERGVKQ- YFSGDEKQQIFKQLFQ- -KERgKITV 561
WP 007209003 491 SAVAFIERMTIKDIYL-NENVLPRHSLIYEKFTVFNELTKVLYAD— DRGVFQ- RFSAEEKEDIFEKLFK- -SER- KVTK 563
WP 023519017 486 SAIEFIERMTNQDTYLPKEKVLPKQSLIYQRFMIFNELTKVSYTD— ERGKSH- YFSSEQKRKIFNELFK- -QHP- RVTE 559
WP 010770040 490 SATKFIERMTNFDTYLPTEKVLPKHSMIYEKYMVYNELTKVSYVD— ERGMNQ- RFSGEEKKQIVEELFK- -QSR- KVTK 563
WP 048604708 486 SAELFIERMTNFDLYLPSEKVLPKHSMLYEKYTVYNELTKVTYKD— EQGKVQ- NFSSEEKERIFIDLFK- -QHR- KVTK 559
WP 010750235 487 SATKFIQRMINYDTYLPTEKVLPKYSMLYQKYTIFNELTKVAYKD— DRGIKH- QFSSEEKLRIFQELFK- -KQR- RVTK 560
AII16583 526 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT— EGMRKPaFLSGEQKKAIVDLLFK- -TNR- KVTV 600
WP 029073316 507 TADEFIKRMRNFCTYFPDEPVLAKNSLTVSKYEVLNEINKLRIND— hLIKRDIKDKMLHTLFM- -DHK- SISA 575
WP 031589969 507 TADEFIKRMRNFCTYFPDEPVMAKNSLTVSKYEVLNEINKLRIND— hLIKRDMKDKMLHTLFM- -DHK- SISA 575
KDA45870 485 SAEDFIKRMTINDLYLPTEPVLPKHSLLYERYTIFNELAGVRYVT— ENGEAK- YFDAQTKRSIFE-LFK1 —DR- KVSE 557
WP 039099354 510 SANEFIKRMTTTDTYLLAEDVLPKQSLIYQRFEVLNELNGLKIDD— QPITTE- LKQAI FTDLFM- —QKt :SVTV 578
AKP02966 484 SSNKFIRRMTVTDSYLVGEPVLPKNSLIYQRYEVLNELNNIRITEnl KTNPTGsRLTVETKQHIYNELFK- -NYK- KITV 560
WP 010991369 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN— DQGKTS- YFSGQEKEQIFNDLFK- -QKR- KVKK 566
WP 033838504 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN— DQGKTS- YFSGQEKEQIFNDLFK- -QKR- KVKK 566
EHN60060 496 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN— DQGKTS- YFSGQEKEQIFNDLFK- -QKR- KVKK 569
EFR89594 262 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN— DQGKTS- YFSGQEKEQIFNDLFK- -QKR- KVKK 335
WP 038409211 493 SAIDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID— DQGKTH- HFSGQEKQQIFNGLFK- -QQR- KVKK 566
EFR95520 112 SAIDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID— DQGKTH- HFSGQEKQQIFNGLFK- -QQR- KVKK 185
WP 003723650 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID— DQGKTN- YFSGREKQQVFNDLFK- -QKR- KVKK 566
WP 003727705 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID— DQGKTN- YFSGREKQQIFNDLFK- -QKR- KVKK 566
WP 003730785 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID— DQGKTN- YFSGREKQQIFNDLFK- -QKR- KVKK 566
WP 003733029 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID— DQGKTN- YFSGQEKQQIFNDLFK- -QKR- KVKK 566
WP 003739838 493 SAVDFIEKMTNKDTYLPKENVLPKHSLYYQKYMVYNELTKVRYID— DQGKTN- YFSGQEKQQIFNDYFK- -QKR- KVSK 566
WP_014601172 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID—DQGKTN-YFSGQEKQQI FNDLFK- QKR- KVKK 566 WP_02 3548323 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID—DQGKTN-YFSGQEKQQI FNDLFK- QKR- KVKK 566 WP_03 1665337 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID—DQGKTN-YFSGQEKQQI FNDLFK- QKR- KVKK 566 WP_03 1669209 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID—DQGKTN-YFSGQEKQQI FNDLFK- QKR- KVKK 566 WP_03 3920898 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID—DQGKTN-YFSGQEKQQI FNDLFK- QKR- KVKK 566 AKI42 028 496 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID—DQGKTN-YFSGQEKQQI FNDLFK- QKR- KVKK 569 AKI50 529 496 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID—DQGKTN-YFSGQEKQQI FNDLFK- QKR- KVKK 569 EFR83 390 1 IFNDLFK- QKR- KVKK 14 WP_04 6323366 493 SAIDFIEKMTNKDTYLPKENVLPKHSMCYQKYMVYNELTKIRYTD—DQGKTH-YFSGQEKQQI FNDLFK- QKR- KVKK 566 AKE81 Oil 503 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT—EGMRKPaFLSGEQKKAIVDLLFK- TNR- KVTV 577 CU082355 503 TAEGFIKRMRSYCTYFPDEEVLPKNSLIVSKYEVYNELNKIRVDD kLLEVDVKNDIYNELFM- KNK- TVTE 571 WP_033162 7 504 TAEGFIERMKNTGTYFPDEPVMAKNSLTVSKFEVLNELNKIRING kLIAVETKKELLSDLFM- KNK- TITD 572 AGZ01981 520 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT—EGMRKPaFLSGEQKKAIVDLLFK- TNR- KVTV 594 AKA60242 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT—EGMRKPaFLSGEQKKAIVDLLFK- TNR- KVTV 561 AKS40380 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT—EGMRKPaFLSGEQKKAIVDLLFK- TNR- KVTV 561 4UN5 491 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT—EGMRKPaFLSGEQKKAIVDLLFK- TNR- KVTV 565
WP 010922251 562 KQLKEDYFKK--IECFDSVEISGVEDR—-FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "039695303 564 EKLLNYLNKE- -FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH 637
WP "045635197 562 KDIIHYLHN— -VDGYDGIELKGIEKQ— -FNASLSTYHDLLKIIKDK EFMDDAKNEAILENIVHTLTIFEDREMIK 632
5AXW A 300 KQIAKEIL e —EDIKGYRVTSTGKPe- —FTNLKVYHDIKDITARK ENAELLDQIAKILTIYQSSEDIQ 368
WP 009880683 246 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 317
WP "010922251 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "011054416 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "011284745 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "011285506 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "011527619 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "012560673 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "014407541 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGAYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDRGMIE 633
WP "020905136 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "023080005 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNTSLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP "023610282 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNTSLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP "030125963 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "030126706 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "031488318 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "032460140 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "032461047 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "032462016 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "032462936 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP "032464890 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "033888930 387 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 458
WP "038431314 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "038432938 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNTSLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP "038434062 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
BAQ51233 473 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 544
KGE60162
KGE60856
WP 002989955 562 KQLKEDYFKK- -IECFDSVEISGVEDR— -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP "003030002 561 DKLLNYLNKE- -FEEFRIVNLTGLDKEnkAFNSSLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 634
WP "003065552 564 EKLLNYLNKE- -FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH 637
WP "001040076 563 KDIISFLNK— -VDGYEGIAIKGIEKQ— -FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIK 632
WP "001040078 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040080 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040081 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040083 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIIQTLTLFEDREMIK 635
WP "001040085 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP 001040087 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040088 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040089 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040090 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040091 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040092 562 KQLLDFLAKE- -FEEFRIVDVTGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTITLFEDREMIK 635
WP "001040094 563 KDIISFLNK— -VDGYEGIAIKGIEKQ FNASLSTYHDLKKIL- GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632
WP "001040095 563 KDIISFLNK— -VDGYEGIAIKGIEKQ FNASLSTYHDLKKIL- GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632
WP "001040096 563 KDIISFLNK— -VDGYEGIAIKGIEKQ FNASLSTYHDLKKIL- GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632
WP "001040097 563 KDIISFLNK— -VDGYEGIAIKGIEKQ FNASLSTYHDLKKIL- GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632
WP "001040098 563 KDIISFLNK— -VDGYEGIAIKGIEKQ FNASLSTYHDLKKIL- GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632
WP "001040099 563 KDIISFLNK— -VDGYEGIAIKGIEKQ FNASLSTYHDLKKIL- GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632
WP "001040100 563 KDIISFLNK— -VDGYEGIAIKGIEKQ FNASLSTYHDLKKIL- GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632
WP "001040104 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040105 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040106 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040107 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040108 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040109 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "001040110 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "015058523 562 KQLLDFLAKE- -FEEFRIVDVTGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTITLFEDREMIK 635
WP "017643650 563 KDIISFLNK— -VDGYEGIAIKGIEKQ FNASLSTYHDLKKIL- GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632
WP "017647151 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "017648376 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "017649527 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "017771611 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "017771984 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
CFQ25032 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
CFV16040 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
KLJ37842 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
KLJ72361 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
KLL20707 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
KLL42645 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP 047207273 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "047209694 563 KDIISFLNK— -VDGYEGIAIKGIEKQ FNASLSTYHDLKKIL- GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632
WP "050198062 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "050201642 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "050204027 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP "050881965 562 KKLLDFLAKE- -YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP 050886065 562 KKLLDFLAKE—YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
AHN30376 562 KQLLDFLAKE—FEEFRIVDVTGLDKEnkAFNAS LGTYHDLKKI L- DK DFLDNPDNESILEDIVQTITLFEDREMIK 635
EA078426 562 KKLLDFLAKE—YEEFRIVDVIGLDKEnkAFNAS LGTYHDLEKI L- DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
CCW42055 562 KQLLDFLAKE—FEEFRIVDVTGLDKEnkAFNAS LGTYHDLEKI L- GK DFLDNPDNESILEDIVQTLTLFEDREMIK 635
WP 003041502 561 DKLLNYLNKE—FEEFRIVNLTGLDKEnkVFNSS LGTYHDLRKI L- NK SFLDNKENAQIIEDIIQTLTLFEDREMIR 634
WP 037593752 562 DKLLNYLNKE—FEEFRIVNLTGLDKEnkAFNSS LGTYHDLRKI L- DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 635
WP 049516684 562 DKLLNYLNKE—FEEFRIVNLTGLDKEnkAFNAS LGTYHDLRKI L- DK SFLDDKVNEKIIEDIIQTLTLFEDREMIR 635
GAD46167 561 DKLLNYLNKE—FEEFRIVNLTGLDKEnkAFNSS LGTYHDLRKI L- DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 634
WP 018363470 562 EKLLNYLDKE—FPEYRIQDLVGLDKEnkSFNAS LGTYHDLKKI L- DK SFLDDKVNEEVIEDIIKTLTLFEDREMIQ 635
WP 003043819 572 KQLKEDYFKK—IECFDSVEIIGVEDR FNAS LGTYHDLLKI IKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 643
WP 006269658 561 DKLLNYLNKE—FEEFRIVNLTGLDKEnkAFNSS LGTYHDLRKI L- DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 634
WP 048800889 561 DKLLNYLDKE—FDEFRIVDLTGLDKEnkAFNAS LGTYHDLRKI L- DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 634
WP 012767106 562 KQLKEDYFKK—IECFDSVEISGVEDR FNAS LGTYHDLLKI IKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP 014612333 562 KQLKEDYFKK—IECFDSVEISGVEDR FNAS LGTYHDLLKI IKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP 015017095 562 KQLKEDYFKK—IECFDSVEISGVEDR FNAS LGTYHDLLKI IKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP 015057649 562 KQLKEDYFKK—IECFDSVEISGVEDR FNAS LGTYHDLLKI IKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP 048327215 562 KQLKEDYFKK—IECFDSVEISGVEDR FNAS LGTYHDLLKI IKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP 049519324 562 KQLKEDYFKK—IECFDSVEISGVEDR FNAS LGTYHDLLKI IKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633
WP 012515931 562 KQLKENYFKK—IECWDSVEITGVEDS FNAS LGTYHDLLKI IQDK DFLDNPDNQKIIEDIILTLTLFEDKKMIS 633
WP 021320964 562 KQLKENYFKK—IECWDSVEITGVEDS FNAS LGTYHDLLKI IQDK DFLDNPDNQKIIEDIILTLTLFEDKKMIS 633
WP 037581760 562 KQLKENYFKK—IECWDSVEITGVEDS FNAS LGTYHDLLKI IQDK DFLDNPDNQKIIEDIILTLTLFEDKKMIS 633
WP 004232481 561 AKLLSYLNNE—FEEFRINDLIGLDKDskSFNAS LGTYHDLKKI L- DK SFLDDKTNEQIIEDIVLTLTLFEDRDMIH 634
WP 009854540 562 EKLLNYLNKE—FPEYRIKDLIGLDKEnkSFNAS LGTYHDLKKI L- DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH 635
WP 012962174 562 DKFLNYLNKE—FPEYRIQDLIGLDKEnkSFNAS LGTYHDLKKI L- DK SFLDDKTNETIIEDIIQTLTLFEDRDMIR 635
WP 039695303 564 EKLLNYLNKE—FPEYRIKDLIGLDKEnkSFNAS LGTYHDLKKI L- DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH 637
WP 014334983 561 AKLLSYLNNE—FEEFRINDLIGLDKDskSFNAS LGTYHDLKKI L- DK SFLDDKTNGQIIEDIVLTLTLFEDRDMIH 634
WP 003099269 562 KQLKEEYFSK—MKCFHTVTILGVEDR FNAS LGTYHDLLKI FKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE 633
AHY15608 562 KQLKEEYFSK—MKCFHTVTILGVEDR FNAS LGTYHDLLKI FKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE 633
AHY17476 562 KQLKEEYFSK—MKCFHTVTILGVEDR FNAS LGTYHDLLKI FKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE 633
ESR09100
AGM98575 562 KQLKEEYFSK—MKCFHTVTILGVEDR FNASLGTYHDLLKI FKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE 633
ALF27331 561 DKLMDFLEKE—FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP 018372492 574 RKLKDFIEKElgYGYIDIDNIKGVEEQ FNASYTTYQDLLKIIGDK EFLDNEENKDLLEEIIYILTVFEDRKMIE 647
WP 045618028 563 KDIIQYLHN VDSYDGIELKGIEKQ FNASLSTYHDLLKI IKDK EFMDDSKNEAILENIVHTLTIFEDREMIK 633
WP 045635197 562 KDIIHYLHN VDGYDGIELKGIEKQ FNASLSTYHDLLKI IKDK EFMDDAKNEAILENIVHTLTIFEDREMIK 632
WP 002263549 561 DKLMDFLEKE—FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP 002263887 561 DKLMDFLEKE—FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP 002264920 561 DKLMDFLEKE—FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP 002269043 561 DKLMDFLEKE—FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP 002269448 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL--DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 71977 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 72766 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 73241 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 75430 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 76448 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 77050 561 KKLRTFLDKN- -FDEFRIVDIQGLDKEteTFNASYATYQDLLKVi: KDK VFMDNPENAEILENIVLTLTLFEDREMIK 635
WP "0022 77364 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 79025 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 79859 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 80230 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 81696 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 82247 561 KKLRTFLDKN- -FDEFRIVDIQGLDKEteTFNASYATYQDLLKVi: KDK VFMDNPENAEILENIVLTLTLFEDREMIK 635
WP "0022 82906 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 83846 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 87255 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 88990 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 89641 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 90427 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 95753 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0022 96423 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0023 04487 571 DKLLNYLNKE- -FEEFRI LTGLDKEnkVFNSSLGTYHDLRKIL- -NK SFLDNKENEQIIEDIIQTLTLFEDREMIR 644
WP "0023 05844 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0023 07203 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0023 10390 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0023 52408 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0129 97688 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "θ146 77909 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0193 12892 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0193 13659 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0193 14093 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0193 15370 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0198 03776 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0198 05234 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0247 83594 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0247 84288 561 KKLRTFLDKN- -FDEFRIVDIQGLDKEteTFNASYATYQDLLKVi: KDK VFMDNPENAEILENIVLTLTLFEDREMIK 635
WP "0247 84666 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0247 84894 561 DKLMDFLEKE- -FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL- -DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP "0247 86433 561 KKLRTFLDKN- -FDEFRIVDIQGLDKEteTFNASYATYQDLLKVi: KDK VFMDNPENAEILENIVLTLTLFEDREMIK 635
WP 049473442 561 DKLMDFLEKE—FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
WP 049474547 561 DKLMDFLEKE—FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634
EMC03581 554 DKLMDFLEKE—FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 627
WP 000428612 565 KDIIQYLHT-- -VDGYDGIELKGIEKQ- -FNASLSTYHDLLKIIKDK EFMDDPNNEEILENIVHTLTIFEDREMIK 635
WP 000428613 563 KDIIQFLHN-- -VDGYDGIELKGIEKQ- -FNASLSTYHDLLKIIKDK EFMDDSKNEEILENIVHTLTIFEDREMIK 633
WP 049523028 562 KDIIHYLHN-- -VDGYDGIELKGIEKH- -FNSSLSTYHDLLKIIKDK EFMDDPKNEEIFENIVHTLTIFEDRVMIK 632
WP 003107102 531 KQLKENYFNK- -IRCLDSITISGVEDK- -FNASLGTYHDLLNI IKNQ KILDDEQNQDSLEDIVLTLTLFEDEKMIA 602
WP 054279288 564 KQLKEDFFSK—IECFDTVDISGVEDK- -FNASLGTYHDLLKIIKDK AFLDNSENENIIEDIILTLTLFEDKEMIA 635
WP 049531101 563 KDLIHYLHN VDGYDGIELKGIEKQ- -FNASLSTYHDLLKIIKDK RFMDEPKNQEILENIVHTLTIFEDREMIK 633
WP 049538452 563 KDIIQYLHN VDGYDGIELKGIEKQ- -FNASLSTYHDLLKIIKDK EFMDDSKNEEILENIVHTLTIFEDREMIK 633
WP 049549711 563 KDIIHYLHT VDGYDGIELKGIEKQ- -FNASLSTYHDLLKIIKDK EFMDDSKNEAILENIVHTLTIFEDREMIK 633
WP 007896501 565 KDLKEKYFSQ—IEGLENVDVTGVEGA- -FNASLGTYNDLLKIIKDK AFLDDEANAEILEEIVLILTLFQDEKLIE 636
EFR44625 517 KDLKEKYFSQ—IEGLENVDVTGVEGA- -FNASLGTYNDLLKIIKDK AFLDDEANAEILEEIVLILTLFQDEKLIE 588
WP 002897477 562 KDIIHYLHN VDGYDGIELKGIEKQ- -FNANLSTYHDLLKITKDK EFMDDPKNEEILENIVHTLTIFEDREMIK 632
WP 002906454 562 KDIIHYLHN VDGYDGIELKGIEKQ- -FNASLSTYHDLLKIIKDK EFMDNPKNGEILENIIHTLTIFEDREMIK 632
WP 009729476 563 KDIIQFLHN VDGYDGIELKGIEKQ- -FNASLSTYHDLLKIIKDK AFMDDAKNEAILENIVHTLTI FEDREMIK 633
CQR24647 562 KKILNFLDKN—FDEFRITDIQGLDNEtgNFNASYGTYHDLLKIIGDK EFMDSSDNVDVLEDIVLSLTLFEDREMIK 636
WP 000066813 565 KDIIHYLHN VDGYDGIELKGIEKQ FNASLSTYHDLLKIIKDK AFMDDSKNEEILENI IHTLTI FEDREMIK 635
WP 009754323 563 KDIIHYLHN VDGYDGIELKGIEKQ FNASLSTYHDLLKIIKDK EFMDNHKNQEILENIVHTLTI FEDREMIK 633
WP 044674937 562 KDIKAYL-EN—SNGYAGVELKGLEEQ FNASLPTYHDLLKILRDK AFIDAEENQEILEDIVLTLTLFEDREMIR 632
WP 044676715 561 EKLMDFLGKE—FDEFRIVDLLGLDKDnkSFNASLGTYHDLKKIV-SK DLLDNPENEDILENWLTLTLFEDREMIR 634
WP 044680361 561 EKLMDFLGKE—FDEFRIVDLLGLDKDnkSFNASLGTYHDLKKIV-SK DLLDNPENEDILENWLTLTLFEDREMIR 634
WP 044681799 562 KDIKAYL-EN—SNGYAGVELKGLEEQ FNASLPTYHDLLKILRDK AFIDAEENQEILEDIVLTLTLFEDREMIR 632
WP 049533112 561 DKLLNYLGKE—FDEFRIVDLTGLDKEnkVFNSSLGTYHDLRKIL-DK SFLDNKENEQIIEDIIQTLTLFEDREMIR 634
WP 029090905 541 TSLKKWLAEH EHMTVSWQGTQKEt-EFATSLQAFHRFVKI F-DR ETVSNPANEEMFEKIIYWSTVFEDKKIMR 612
WP 006506696 568 KKLKNWLVNNqcCS—KDAEIKGFQKEn-QFSTSLTPWIDFTNIFGKI DQSNFDLIENIIYDLTVFEDKKIMK 637
AIT42264 562 KQLKEDYFKK—IECFDSVEISGVEDR- --FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP 034440723 568 NQLVKYIENK EQIIAPEIKGIEDS- --FNSNYSTYIDLSKIPDMK —LLEKDEDEILEEIIKILTIFEDRKMRK 637
AKQ21048 562 KQLKEDYFKK—IECFDSVEISGVEDR- --FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
WP 004636532 563 KDIANYLEQ YGYVDGTDIKGVEDK- --FNASLSTYNDLAKIDGAK AYLDDPEYADVWEDIIKILTIFEDKAMRK 633
WP 002364836 570 KDIIQFYRNE—YN-TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP 016631044 521 KDIIQFYRNE—YN-TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 592
EMS75795 306 KKLQQFLSAN—YN-IEDAEILGVDKA- --FNSSYATYHDFLDLAKPN ELLEQPEMNAMFEDIVKILTI FEDREMIR 381
WP 002373311 570 KDIIQFYRNE -YN-TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP 002378009 570 KDIIQFYRNE YN-TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP 002407324 570 KDIIQFYRNE YN-TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP 002413717 570 KDIIQFYRNE YN-TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP 010775580 572 KDIIQFYRNE YN-TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 643
WP 010818269 570 KDIIQFYRNE YN-TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP 010824395 570 KDIIQFYRNE--YN--TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP "016622645 570 KDIIQFYRNE- -YN- -TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP "033624816 570 KDIIQFYRNE- -YN- -TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP "033625576 570 KDIIQFYRNE- -YN- -TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP "033789179 570 KDIIQFYRNE- -YN- -TEIVTLSGLEED- -QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641
WP "002310644 567 KDLQEFLYLK- -YD- -IKHAELSGIEKA- —FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 641
WP "002312694 568 KDLQEFLYLK- -YD- -IKHAELSGIEKA- —FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642
WP "002314015 568 KDLQEFLYLK- -YD- -IKHAELSGIEKA- —FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642
WP "002320716 568 KDLQEFLYLK- -YD- -IKHAELSGIEKA- —FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642
WP "002330729 567 KDLQEFLYLK- -YD- -IKHAELSGIEKA- —FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 641
WP "002335161 568 KDLQEFLYLK- -YD- -IKHAELSGIEKA- —FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642
WP "002345439 568 KDLQEFLYLK- -YD- -IKHAELSGIEKA- —FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642
WP "034867970 562 KKLQNFLYTH- -YH- -IENAQIFGIEKA- —FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK 637
WP "047937432 568 KDLQEFLYLK- -YD- -IKHAELSGIEKA- —FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642
WP "010720994 562 KKLQNFLYTH- -YH- -IENAQIFGIEKA- —FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK 637
WP "010737004 562 KKLQNFLYTH- -YH- -IENAQIFGIEKA- —FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK 637
WP "034700478 562 KKLQNFLYTH- -YH- -IENAQIFGIEKA- —FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK 637
WP "007209003 564 KKLENYLRIE1 3ISSPSVKGIEEQ- —FNANFGTYLDLKKFDELH PYLDDEKYQDTLEEVIKVLTVFEDRSMIQ 634
WP "023519017 560 KQLRKFLELN- -EQ- -IDSTEIKGIETS- —FNASYSTYHDLLKLS TLLDDPDMTTMFEEIIKILTIFEDREMIR 631
WP "010770040 564 KLLEKFLSNE- -FG- -LVDVAIKGIE-T- -SFNAGYGTYHDFLKIGITR EQLDKEENSETLEEIVKILTVFEDRKMIR 634
WP "048604708 560 KDLSNFLRNE- -YN- -LDDVIIDGIE-N- -KFNASFNTYHDFLKLKIDP KVLDDPANEPMFEEIVKILTIFEDRKMLR 630
WP "010750235 561 KKLQHFLSAN- -YN- -IEDAEILGVDKV- —FNSSYATYHDFLELAKPY ELLEQPEMEEMFEDIVKIITIFEDREMVR 636
AII16583 601 KQLKEDYFKK- -IECFDSVEISGVEDR- —FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 672
WP 029073316 576 NAMKKWLVKNqyFSNTDDIKIEGFQKEn -ACSTSLTPWIDFTKIFGEI NNSNYELIEKIIYDVTVFEDKKILR 647
WP "031589969 576 NAMKKWLVKNqyFSNTDDIKIEGFQKEn -ACSTSLTPWIDFTKIFGKI NESNYDFIEKIIYDVTVFEDKKILR 647
KDA45870 558 KMVIKHLKW- -MPAIRIQALKGLDNGk —FNASYGTYKDLVDMGVAP ELLNDEVNSEKWEDIIKTLTIFEGRKLIK 630
WP 039099354 579 KNIQDYLVSEk —RYASRPAITGLSDEnk-FNSRLSTYHDLKTIVGDA —VDDVDKQADLEKCIEWSTIFEDGKIYS 650
AKP02966 561 KKLTKWLIAQg YYKNPILIGLSQKd -EFNSTLTTYLDMKKIFGSS -FMENNKNYNQIEELIEWLTIFEDKQILN 632
WP 010991369 567 KDLELFLRNM- -SH- -VESPTIEGLE-D- -SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK 637
WP "033838504 567 KDLELFLRNM- -SH- -VESPTIEGLE-D- -SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK 637
EHN60060 570 KDLELFLRNM- -SH- -VESPTIEGLE-D- -SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK 640
EFR89594 336 KDLELFLRNM- -SH- -VESPTIEGLE-D- -SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK 406
WP 038409211 567 KDLERFLYTI- -NH- -IESPTIEGVE-D- -AFNSSFATYHDLQKGGVTQ EILDNPLNADMLEEIVKILTVFEDKRMIK 637
EFR95520 186 KDLERFLYTI- -NH- -IESPTIEGVE-D- -AFNSSFATYHDLQKGGVTQ EILDNPLNADMLEEIVKILTVFEDKRMIK 256
WP 003723650 567 KDLELFLRNI- -NH- -IESPTIEGLE-D- -SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKPMIK 637
WP "003727705 567 KDLELFLRNI- -NH- -IESPTIEGLE-D- -SFNASYATYHDLLKVGLKQ EILDNPLNTEILEDIVKILTVFEDKRMIK 637
WP "003730785 567 KDLELFLRNI- -NH- -IESPTIEGLE-D- -SFNASYATYHDLLKVGLKQ EILDNPLNTEILEDIVKILTVFEDKRMIK 637
WP "003733029 567 KDLELFLRNI- -NQ- -IESPTIEGLE-D- -SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637
WP "003739838 567 KDLEQFLRNM- -SH- -IESPTIEGLE-D- -SFNSSYATYHDLLKVGIKQ EVLENPLNTEMLEDIVKILTVFEDKRMIK 637
WP 014601172 567 KDLELFLRNI- -NH-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKPMIK 637
WP 023548323 567 KDLELFLRNI- -NH-VESPTIEGLE-D-- SFNASYATYHDLMKVGIKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637
WP 031665337 567 KDLELFLRNI- -NQ--IESPTIEGLE-D-- SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637
WP 031669209 567 KDLELFLRNI- -NQ--IESPTIEGLE-D-- SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637
WP 033920898 567 KDLELFLRNI- -NH-VESPTIEGLE-D-- SFNASYATYHDLMKVGIKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637
AKI42028 570 KDLELFLRNI- -NH-IESPTIEGLE-D-- SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKPMIK 640
AKI50529 570 KDLELFLRNI- -NH-VESPTIEGLE-D-- SFNASYATYHDLMKVGIKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 640
EFR83390 15 KDLELFLRNI- -NQ-IESPTIEGLE-D-- SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 85
WP 046323366 567 KDLELFLYNM- -NH-VESPTVEGVE-D-- AFNSSFTTYHDLQKVGVPQ EILDDPLNTEMLEEIIKILTVFEDKRMIN 637
AKE81011 578 KQLKEDYFKK- -IECFDSVEISGVEDR-- -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 649
CU082355 572 KKLKNWL NqcCR—KDAEIKGFQKEn- QFSTSLTPWIDFTNIFGKI DQSNFDLIEKIIYDLTVFEDKKIMK 641
WP 033162887 573 KKLKDWLVTHqyYDINEELKIEGYQKDl- QFSTSLAPWIDFTKIFGEI NASNYQLIEKIIYDISIFEDKKILK 644
AGZ 01981 595 KQLKEDYFKK—IECFDSVEISGVEDR-- -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 666
AKA60242 562 KQLKEDYFKK—IECFDSVEISGVEDR-- -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
AKS40380 562 KQLKEDYFKK—IECFDSVEISGVEDR-- -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633
4UN5 B 566 KQLKEDYFKK—IECFDSVEISGVEDR-- -FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 637
WP 010922251 634 ERLKTYAHLFDDKVMKQLKR-RRYTGW(G|RLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNF0QLIHDDSL 702
WP "039695303 638 ERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG— -SANRNFMQLINDDTL 706
WP "045635197 633 QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGICDK QTGNTILDYLI DDG— -KINRNFMQLINDDGL 701
5AXW A 369 EELTNLNSELTQEEIEQISN1KGYTGTHNLSLKAINLILDE 426
WP 009880683 318 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 386
WP "010922251 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "011054416 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "011284745 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "011285506 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "011527619 634 ERLKTYAHLFDDKVMKQLKR-RRYTVWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "012560673 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "014407541 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "020905136 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "023080005 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLINDDSL 702
WP "023610282 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLINDDSL 702
WP "030125963 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "030126706 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "031488318 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "032460140 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "032461047 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "032462016 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "032462936 634 ERLKKYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "032464890 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "033888930 459 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 527
WP "038431314 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "038432938 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLINDDSL 702
WP "038434062 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
BAQ51233 545 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 613
KGE60162
KGE60856
WP 002989955 634 ERLKTYAHLFDDKVMKQLKR- RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
WP "003030002 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG— -YANRNFMQLINDDAL 703
WP "003065552 638 ERLQKYSDIFTADQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG— -SANRNFMQLINDDTL 706
WP "001040076 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG— -SANRNFMQLIKDAGL 701
WP "001040078 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG— -RSNRNFMQLINDDGL 704
WP "001040080 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG— -RSNRNFMQLINDDGL 704
WP "001040081 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG— -RSNRNFMQLINDDGL 704
WP "001040083 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG— -RSNRNFMQLINDDGL 704
WP "001040085 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG— -RSNRNFMQLINDDGL 704
WP 001040087 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "001040088 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "001040089 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "001040090 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "001040091 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "001040092 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDR ESQKTILDYLI SDG RANRNFMQLINDDGL 704
WP "001040094 633 KRLDIYKDFFTESQLKKLYR RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG SANRNFMQLIKDAGL 701
WP "001040095 633 KRLDIYKDFFTESQLKKLYR RHYTGWERLSAKLINGIRNK ENQKTILDYLI DDG SANRNFMQLIKDAGL 701
WP "001040096 633 KRLDIYKDFFTESQLKKLYR RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG SANRNFMQLIKDAGL 701
WP "001040097 633 KRLDIYKDFFTESQLKKLYR RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG SANRNFMQLIKDAGL 701
WP "001040098 633 KRLDIYKDFFTESQLKKLYR RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG SANRNFMQLIKDAGL 701
WP "001040099 633 KRLDIYKDFFTESQLKKLYR RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG SANRNFMQLIKDAGL 701
WP "001040100 633 KRLDIYKDFFTESQLKKLYR RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG SANRNFMQLIKDAGL 701
WP "001040104 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "001040105 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "001040106 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG RANRNFMQLIHDDGL 704
WP "001040107 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG RANRNFMQLIHDDGL 704
WP "001040108 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG RANRNFMQLIHDDGL 704
WP "001040109 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG RANRNFMQLIHDDGL 704
WP "001040110 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG RANRNFMQLIHDDGL 704
WP "015058523 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDR ESQKTILDYLI SDG RANRNFMQLINDDGL 704
WP "017643650 633 KRLDIYKDFFTESQLKKLYR RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG SANRNFMQLIKDAGL 701
WP "017647151 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG KSNRNFMQLIHDDGL 704
WP "017648376 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG KSNRNFMQLIHDDGL 704
WP "017649527 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "017771611 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG RANRNFMQLIHDDGL 704
WP "017771984 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
CFQ25032 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
CFV16040 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
KLJ37842 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
KLJ72361 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
KLL20707 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 718
KLL42645 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG RANRNFMQLIHDDGL 704
WP 047207273 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "047209694 633 KRLDIYKDFFTESQLKKLYR RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG SANRNFMQLIKDAGL 701
WP "050198062 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "050201642 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP "050204027 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG RANRNFMQLIHDDGL 704
WP "050881965 636 KRLENYKDLFTESQLKKLYR RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG RSNRNFMQLINDDGL 704
WP_050886065 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG—-RSNRNFMQLINDDGL 704
AHN30376 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDR ESQKIILDYLI SDG— -RANRNFMQLINDDGL 704
EA078426 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG— -RSNRNFMQLINDDGL 704
CCW42055 636 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG— -SANRNFMQLIKDAGL 704
WP_003041502 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG— -YANRNFMQLINDDAL 703
WP_037593752 636 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG— -YANRNFMQLINDDAL 704
WP_049516684 636 QRLQKYSDIFTTQQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG— -YANRNFMQLINDDAL 704
GAD46167 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG— -YANRNFMQLINDDAL 703
WP 018363470 636 QRLQKYSDIFTKQQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG— -SANRNFMQLINDDAL 704
WP "003043819 644 ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKMINGIRDK QSGKTILDFLK -DGf- —SNRNFMQLIHDDSL 712
WP "006269658 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG— -YANRNFMQLINDDAL 703
WP "048800889 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILEYLV DDG— -YANRNFMQLINDDTL 703
WP "012767106 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLINDDSL 702
WP "014612333 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLINDDSL 702
WP "015017095 634 ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFIQLIHDDSL 702
WP "015057649 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLINDDSL 702
WP "048327215 634 ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFIQLIHDDSL 702
WP "049519324 634 ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFIQLIHDDSL 702
WP "012515931 634 KRLDQYAHLFDKWLNKLER-HHYTGWGRLSGKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDSEL 702
WP "021320964 634 KRLDQYAHLFDKWLNKLER-HHYTGWGRLSGKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDSEL 702
WP "037581760 634 KRLDQYAHLFDKWLNKLER-HHYTGWGRLSGKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDSEL 702
WP "004232481 635 ERLQKYSDIFTSQQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDFLI DDG— -DANRNFMQLINDDSL 703
WP "009854540 636 ERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG— -SANRNFMQLINDDTL 704
WP "012962174 636 QRLQKYSDIFTPQQLKKLER-RHYTGWGRLSYKLINGIRNK ENGKSILDYLI DDG— -YANRNFMQLISDDTL 704
WP "039695303 638 ERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG— -SANRNFMQLINDDTL 706
WP "014334983 635 ERLQKYSDFFTSQQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDFLI DDG— -HANRNFMQLINDESL 703
WP "003099269 634 RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv- —ANRNFMQLINDSSL 702
AHY15608 634 RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv- —ANRNFMQLINDSSL 702
AHY17476 634 RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv- —ANRNFMQLINDSSL 702 ESR09100
AGM98575 634 RRLVKYADVFEKSVLKKLKK- RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv- —ANRNFMQLINDSSL 702
ALF27331 635 KRLENYSDLLTKEQVKNLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG— -NSNRNFMQLINDDAL 703
WP_018372492 648 KRLSELNIPFENKIIKKLAR-KKYTGWGNLSRKLIDGIRNR ETNRTILGHLI DDGf- —SNRNLMQLINDDGL 716
WP_045618028 634 QRLAHYASIFDEKVIKALTR-RHYTGWGKLSAKLINGIYDK QSKKTILDYLI DDG— -EINRNFMQLINDDGL 702
WP_045635197 633 QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGICDK QTGNTILDYLI DDG— -KINRNFMQLINDDGL 701
WP_002263549 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG— -NSNRNFMQLINDDAL 703
WP_002263887 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG— -NSNRNFMQLINDDAL 703
WP_002264920 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG— -NSNRNFMQLINDDAL 703
WP 002269043 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG— -NSNRNFMQLINDDAL 703
WP 002269448 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG-—NSNRNFMQLINDDAL 703
WP "002271977 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002272766 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002273241 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002275430 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002276448 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002277050 636 QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA- —QSNRNLMQLITDDNL 704
WP "002277364 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002279025 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002279859 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002280230 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002281696 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002282247 636 QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA- —QSNRNLMQLITDDNL 704
WP "002282906 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002283846 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002287255 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002288990 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002289641 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002290427 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002295753 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002296423 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002304487 645 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRDK QSNKTILGYLI DDG- —YSNRNFMQLINDDAL 713
WP "002305844 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002307203 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002310390 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "002352408 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG- —NSNRNFMQLINDDAL 703
WP "012997688 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "014677909 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "019312892 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "019313659 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "019314093 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG- —NSNRNFMQLINDDAL 703
WP "019315370 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG- —NSNRNFMQLINDDAL 703
WP "019803776 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "019805234 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "024783594 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "024784288 636 QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA- —QSNRNLMQLITDDNL 704
WP "024784666 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "024784894 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG- —NSNRNFMQLINDDAL 703
WP "024786433 636 QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA- —QSNRNLMQLITDDNL 704
WP_049473442 635 KRLENYSDLLTKEQVKKLER RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG NSNRNFMQLINDDAL 703
WP_049474547 635 KRLENYSDLLTKEQVKKLER RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG NSNRNFMQLINDDAL 703
EMC03581 628 KRLENYSDLLTKEQVKKLER RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG NSNRNFMQLINDDAL 696
WP_000428612 636 QRLAQYDSLFDEKVIKALTR RHYTGWGKLSSKLINGIRDK QTGKTILDYLM DDG YNNRNFMQLINDDEL 704
WP_000428613 634 QRLAQYDSLFDEKVIKALIR RHYTGWGKLSAKLIDGICDK QTGNTILDYLI DDG KNNRNFMQLINDDGL 702
WP_049523028 633 QRLNQYDSIFDEKVIKALTR RHYTGWGKLSAKLINGIRDK KTSKTILDYLI DDG YSNRNFMQLINDDGL 701
WP_003107102 603 KRLSKYESIFDPSILKKLKK RHYTGWGRLSQKLINGIRDK QTGKTILDFLI -DGq ANRNFMQLINDPSL 671
WP_054279288 636 NRLAVYEDLFDQNVLKQLKR RHYTGWGRLSKQLINGMRDK HTGKTILDFLK -DGf INRNFMQLINDDNL 704
WP_049531101 634 QRLAQYASIFDEKVIKTLTR RHYTGWGKLSAKLINCIRDR KTGKTILDYLI DDG YNNRNFMQLINDDGL 702
WP_049538452 634 QRLAQYDSIFDEKVIKALTR RHYTGWGKLSAKLINGIRDK QTGKTILDYLI DDG YSNRNFMQLINDDGL 702
WP_049549711 634 QRLAQYDSLFDKKVIKALTR RHYTGWGKLSAKLINGICDK QTGNTILDYLI DDG EINRNFMQLINDDGL 702
WP 007896501 637 KRLAKYANLFEKSVLKKLRK RHYRGWGRLSRQLIDGMKDK ASGKTILDFLK -DDf ANRNFIQLINDSSL 705
EFR44625 589 KRLAKYANLFEKSVLKKLRK RHYRGWGRLSRQLIDGMKDK ASGKTILDFLK -DDf ANRNFIQLINDSSL 657
WP_002897477 633 QRLAQYDTLFDEKVIKALTR RHYTGWGKLSAKLINGIRDK QSGKTILDYLI DDD KINRNFMQLINDDGL 701
WP_002906454 633 QRLAQYDTLFDEKVIKALTR RHYTGWGKLSAKLINGIRDK QTGKTILEYLI DDG DCNRNFMQLINDDGL 701
WP_009729476 634 QRLAQYDSLFDEKVIKALTR RHYTGWGKLSAKLINGISDK QTGNTILDYLI DDG EINRNFMQLINDDGL 702
CQR24647 637 QRLLKYEDIFSKKVIANLTR RHYTGWGRLSAKLINGIKDK HSRKTILDYLI DDG HSNRNFMQLINDDNL 705
WP_000066813 636 QRLAQYDSLFDEKVIKALTR RHYTGWGKLSAKLINGIRDK KSGKTILDYLI DDG EINRNFMQLIHDDGL 704
WP_009754323 634 QRLAQYDSIFDEKVIKALTR RHYTGWGKLSAKLINGICDK KTGKTILDYLI DDG YNNRNFMQLINDDGL 702
WP_044674937 633 KRLEKYKDILTEEQRKKLER RHYTGWGRLSAKLINGILDK VTRKTILGYLI DDG TSNRNFMQLINDDTL 701
WP_044676715 635 KRLEKYKDVLTEEQRKKLER RHYTGWGRLSAKLINGIRDK VTRKTILDYLI DDG TSNRNFMQLINDDTL 703
WP_044680361 635 KRLEKYKDVLTEEQRKKLER RHYTGWGRLSAKLINGIRDK VTRKTILDYLI DDG TSNRNFMQLINDDTL 703
WP_044681799 633 KRLEKYKDILTEEQRKKLER RHYTGWGRLSAKLINGILDK VTRKTILGYLI DDG TSNRNFMQLINDDTL 701
WP_049533112 635 QRLQKYSDIFTKAQLKKLER CHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG YANRNFMQLINDDAL 703
WP_029090905 613 RKLSEYPQLTEQQQVQLAQV -RFRGWGRLSQRLINRIKTP EDHKLSINEIL QTNENFMQIIRNKDY 682
WP 006506696 638 RRLKKKYALPDDKVKQILKL -KYKDWSRLSKKLLDGIVAD SV—TVLDVLE SRLNLMEIINDKDL 705
AIT42264 634 ERLKTYAHLFDDKVMKQLKR RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf ANRNFMQLIHDDSL 702
WP_034440723 638 RQLMKFKDKLSEKAINQLSK KHYTGWGQLSEKLINGIRDE QSNKTILDYLI DNGcpkNMNRNFMQLINDDTL 710
AKQ21048 634 ERLKTYAHLFDDKVMKQLKR RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf ANRNFMQLIHDDSL 702
WP_004636532 634 KQLQTYSDTLSPEILKKLER KHYTGWGRFSKKLINGLRDE GSNKTILDYLK DEGssgPTNRNFMQLIRDNTL 706
WP_002364836 642 TQLSTFKGQFSAEVLKKLER KHYTGWGRLSKKLINGIYDK ESGKTILGYLI DDGvs kHYNRNFMQLINDSQL 714
WP_016631044 593 TQLSTFKGQFSAEVLKKLER KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvs kHYNRNFMQLINDSQL 665
EMS75795 382 TQLKKYQSVLGDGFFKKLVK KHYTGWGRLSERLINGIRDK KTNKTILDYLI DDDfpyNRNRNFMQLINDDSL 454
WP 002373311 642 TQLSTFKGQFSAEVLKKLER KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvs kHYNRNFMQLINDSQL 714
WP "002378009 642 TQLSTFKGQFSAEVLKKLER KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvs kHYNRNFMQLINDSQL 714
WP "002407324 642 TQLSTFKGQFSAEVLKKLER KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvs kHYNRNFMQLINDSQL 714
WP "002413717 642 TQLSTFKGQFSAEVLKKLER KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvs kHYNRNFMQLINDSQL 714
WP "010775580 644 TQLSTFKGQFSEEVLKKLER KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvs kHYNRNFMQLINDSQL 716
WP "010818269 642 TQLSTFKGQFSAEVLKKLER KHYTGWGRLSKKLINGIYDK ESGKTILGYLI DDGvs kHYNRNFMQLINDSQL 714
WP 010824395 642 TQLSTFKGQFSAEVLKKLER- KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvs kHYNRNFMQLINDSQL 714
WP "016622645 642 TQLSTFKGQFSAEVLKKLER- KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvs kHYNRNFMQLINDSQL 714
WP "033624816 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvs kHYNRNFMQLINDSQL 714
WP "033625576 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvs kHYNRNFMQLINDSQL 714
WP "033789179 642 TQLSTFKGQFSEEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvs kHYNRNFMQLINDSQL 714
WP "002310644 642 TRLSHHEATLGKHIIKKLTK- KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 714
WP "002312694 643 TRLSHHEATLGKHIIKKLTK- KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715
WP "002314015 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715
WP "002320716 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715
WP "002330729 642 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 714
WP "002335161 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715
WP "002345439 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNCMQLINDDSL 715
WP "034867970 638 HQLSKYQEVFGEKLLKEFAR- KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL 710
WP "047937432 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715
WP "010720994 638 HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL 710
WP "010737004 638 HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL 710
WP "034700478 638 HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL 710
WP "007209003 635 NQLEQLPLNLSTKTIKALSR- RKYTGWGRLSARLIDGIHDK NSGKTILDYLI DESdsylVNRNFMQLINDDHL 707
WP "023519017 632 EQLKPYETVLGLPAIKKLAK- KHYTGWGRLSEKMIQGMREK QSRKTILDYLI DDDfpcNRNRNFMQLINDDHL 704
WP "010770040 635 EQLKKYTYLFDEEVLKKLER- RHYTGWGRLSAKLLIGIKEK RTHKTILDYLI DDGgkqPINRNLMQLINDSDL 707
WP "048604708 631 EQLSKFSDRLSEKTIKDLER- RHYTGWGRLSAKLINGIHDK QSNKTILDYLI DDApkkNINRNFMQLINDNRL 703
WP "010750235 637 TQLKKYQRILGEEIFKKLVK- KKYTGWGRLSKRLINGIRDQ KTNKTILDYLI DDDfpyNRNRNFMQLINDDHL 709
AII16583 673 ERLKTYAHLFDDKVMKQLKR- RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf ANRNFMQLIHDDSL 741
WP_029073316 648 RRLKKEYDLDEEKIKKILKL- -KYSGWSRLSKKLLSGIKTK RTPETVLEVME TNMNLMQVINDEKL 717
WP_031589969 648 RRLKKEYDLDEEKIKKILKL- -KYSGWSRLSKKLLSGIKTK RTPETVLEVME TNMNLMQVINDEKL 717
KDA45870 631 RRLENYRDFLGEDILRKLSR- KKYTGWGRLSAKLLDGIYDK KTHKTILDCLM EDYs QNFMQLINDDTY 698
WP_039099354 651 AKLNEIDWLTDQQRVQLAAK- -RYRGWGRLSAKLLTQIVN- ANGQRIMDLLW TTDNFMRIVHSE— 712
AKP02966 633 EKLHSSNYSYTSDQIKKISN- MRYKGWGRLSKKILTCITTE TNTPKSLQLSN -DLm-wTTNNNFI SI I SNDKY 706
WP_010991369 638 EQLQQFSDVLDGWLKKLER- RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG LNRNLMQLINDSNL 706
WP_033838504 638 EQLQQFSDVLDGWLKKLER- RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG LNRNLMQLINDSNL 706
EHN60060 641 EQLQQFSDVLDGWLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG LNRNLMQLINDSNL 709
EFR89594 407 EQLQQFSDVLDGWLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG LNRNLMQLINDSNL 475
WP_038409211 638 EQLQSFSDVLDGTILKKLER- RHYTGWGRLSAKLLTGIRDK HSHLTILDYLM DDG LNRNLMQLINDSNL 706
EFR95520 257 EQLQSFSDVLDGTILKKLER- RHYTGWGRLSAKLLTGIRDK HSHLTILDYLM DDG LNRNLMQLINDSNL 325
WP_003723650 638 EQLQQFSDVLDGGVLKKLER- RHYTGWGRLSAKLLVGIREK QSHLTILDYLM DDG LNRNLMQLINDSNL 706
WP_003727705 638 EQLEQFSDVLDGWLKKLER- RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG LNRNLMQLINDSNL 706
WP_003730785 638 EQLEQFSDVLDGWLKKLER- RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG LNRNLMQLINDSNL 706
WP_003733029 638 EQLQQFSDVLDGWLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG LNRNLMQLINDSNL 706
WP 003739838 638 EQLQQFSDVLDGAVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG LNRNLMQLINDSNL 706
WP_014601172 638 EQLQQFSDVLDGGVLKKLER-RHYTGWGRLSAKLLVGIREK QSHLTILDYLM DDG——LNRNLMQLINDSNL 706
WP_023548323 638 EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG— —LNRNLMQLINDSNL 706
WP_031665337 638 EQLQQFSDVLDGWLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILEYLM DDG— —LNRNLMQLINDSNL 706
WP_031669209 638 EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG— —LNRNLMQLINDSNL 706
WP_033920898 638 EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG— —LNRNLMQLINDSNL 706
AKI42028 641 EQLQQFSDVLDGGVLKKLER-RHYTGWGRLSAKLLVGIREK QSHLTILDYLM DDG— —LNRNLMQLINDSNL 709
AKI50529 641 EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG— —LNRNLMQLINDSNL 709
EFR83390 86 EQLQQFSDVLDGWLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILEYLM DDG— —LNRNLMQLINDSNL 154
WP_046323366 638 ERLQEFSNVLDEAVLKKLER-RHYTGWGRLSAKLLIGIRDK ESHLTILDYLM DDK— —HNRNLMQLINDSNL 706
AKE81011 650 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 718
CU082355 642 RRLKKKYALPDDKIKQILKL--KYKDWSRLSKKLLDGIVAD SV—TVLDVLE —SRLNLMEIINDKEL 709
WP_033162887 645 RRLKKVYQLDDLLVDKILKL--NYTGWSRLSEKLLTGMTAD KA—TVLFVLE —SNKNLMEI INDEKL 712
AGZ01981 667 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 735
AKA60242 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
AKS40380 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 702
4UN5 B 638 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf- —ANRNFMQLIHDDSL 706
WP 010922251 703 TFKEDIQKAQVSG- -QG|DS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMA|RENQ TTQKGQKNS 777
WP "039695303 707 PFKQIIQKSQWG- -DVDD-1EAWHDLPGSPAIKKGILQSVKIVDELVKVMG-GNPDNIVIEMARENQ TTNRGRSQS 780
WP "045635197 702 SFKEIIQKAQVIG- -KTDD-VKQWQELSGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS 775
5AXW A 427 VPKKVDLSQQKEI- -—PT TLVDDFILSPWKRSFIQSIKVINAIIKKYG—LPNDIIIELAREKN S 487
WP 009880683 387 TFKEDLQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 461
WP "010922251 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "011054416 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "011284745 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "011285506 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "011527619 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "012560673 703 TFKEDLQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "014407541 703 TFKEDIQKAQVSG- -QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776
WP "020905136 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "023080005 703 TFKEAIQKAQVSG- -QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776
WP "023610282 703 TFKEAIQKAQVSG- -QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776
WP "030125963 703 TFKEDLQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "030126706 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "031488318 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "032460140 703 TFKEDLQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "032461047 703 TFKEDLQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "032462016 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "032462936 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "032464890 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "033888930 528 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 602
WP "038431314 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "038432938 703 TFKEAIQKAQVSG- -QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776
WP "038434062 703 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKIVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
BAQ51233 614 TFKEDIQKAQVSG- -QGDS-LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 688
KGE60162
KGE60856
WP 002989955 703 TFKEDIQKAQVSG- QGDS -LHEHIANLAGSPAI KKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP "003030002 704 SFKEEIARAQIIG- DVDD -IANWHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANI I IEMARENQ MTDKGRRNS 777
WP "003065552 707 PFKQIIQKSQWG- DVDD -IEAWHDLPGSPAIKKGILQSVKIVDELVKVMG-DNPDNIVIEMARENQ TTNRGRSQS 780
WP "001040076 702 SFKPIIDKARTGS- HSDN -LKEVIGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIWEMARENQ TTAKGLSRS 775
WP "001040078 705 SFKSIISKAQAGS- HSDN -LKEWGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040080 705 SFKSIISKAQAGS- HSDN -LKEWGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040081 705 SFKSIISKAQAGS- HSDN -LKEWGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040083 705 SFKSIISKAQAGS- HSDN -LKEWGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040085 705 SFKSIISKAQAGS- HSDN -LKEWGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIWEMARENQ TTNQGRRNS 778
WP 001040087 705 SFKSIISKAQAGS--HSDN-LKEWGELAGSPAIKKGILQSLKIVDELVKVMG--YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040088 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040089 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040090 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKWG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040091 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040092 705 SFKSIISKAQSGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040094 702 SFKPIIDKARTGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTAKGLSRS 775
WP "001040095 702 SFKPIIDKARTGS- -HLDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTAKGLSRS 775
WP "001040096 702 SFKPIIDKARTGS- -HLDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTAKGLSRS 775
WP "001040097 702 SFKPIIDKARTGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTAKGLSRL 775
WP "001040098 702 SFKPIIDKARTGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTAKGLSRS 775
WP "001040099 702 SFKPIIDKARTGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTAKGLSRS 775
WP "001040100 702 SFKPIIDKARTGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTAKGLSRS 775
WP "001040104 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040105 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "001040106 705 SFKPIIDKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQWVEMARENQ TTNQGRRNT 778
WP "001040107 705 SFKPIIDKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQWVEMARENQ TTNQGRRNT 778
WP "001040108 705 SFKPIIDKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQWVEMARENQ TTNQGRRNT 778
WP "001040109 705 SFKPIIDKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQWVEMARENQ TTNQGRRNT 778
WP "001040110 705 SFKPIIDKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQWVEMARENQ TTNQGRRNT 778
WP "015058523 705 SFKSIISKAQSGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "017643650 702 SFKPIIDKARTGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTAKGLSRL 775
WP "017647151 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "017648376 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "017649527 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "017771611 705 SFKPIIDKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQWVEMARENQ TTNQGRRNT 778
WP "017771984 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
CFQ25032 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
CFV16040 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
KLJ37842 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
KLJ72361 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
KLL20707 719 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 792
KLL42645 705 SFKPIIDKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQWVEMARENQ TTNKGRRNT 778
WP 047207273 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "047209694 702 SFKPIIDKARTGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTAKGLSRS 775
WP "050198062 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "050201642 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP "050204027 705 SFKPIIDKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQWVEMARENQ TTNQGRRNT 778
WP "050881965 705 SFKSIISKAQAGS- -HSDN- LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- -YEPEQIWEMARENQ TTNQGRRNS 778
WP 050886065 705 SFKSIISKAQAGS-HSDN--LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- YEPEQIWEMARENQ TTNQGRRNS 778
AHN30376 705 SFKSIISKAQSGS- HSDN--LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- YEPEQIWEMARENQ TTNQGRRNS 778
EA078426 705 SFKSIISKAQAGS- HSDN--LKEWGELAGSPAIKKGILQSLKIVDELVKVMG- YEPEQIWEMARENQ TTNQGRRNS 778
CCW42055 705 SFKSIISKAQSGS- HSDN--LKEWSELAGSPAIKKGILQSLKIVDELVKVMG- YKPEQIWEMARENQ TTNQGRRNS 778
WP 003041502 704 SFKEEIAKAQIIG- DVDD--IANWHDLPGSPAIKKGILQSVKIVDELVKVMG- HNPANIIIEMARENQ TTDRGRRNS 777
WP 037593752 705 SFKEEIARAQIIG- DVDD--IANWHDLPGSPAIKKGILQSVKIVDELVKVMG- HNPANIIIEMARENQ TTDKGRRNS 778
WP 049516684 705 SFKEEIARAQIIG- DVDD--IANWHDLPGSPAIKKGILQSVKIVDELVKVMG- HNPANIIIEMARENQ TTDKGRRNS 778
GAD46167 704 SFKEEIARAQIIG- DVDD--IANWHDLPGSPAIKKGILQSVKIVDELVKVMG- HNPANIIIEMARENQ TTDKGRRNS 777
WP 018363470 705 SFKQIIQEAQWG- DVDD--IETWHDLPGSPAIKKGILQSVKIVDELIKVMG- DNPDNIVIEMARENQ TTNRGRSQS 778
WP 003043819 713 TFKEEIEKAQVSG- QGDS--LHEQIADLAGSPAIKKGILQTVKIVDELVKVMG- HKPENIVIEMARENQ TTTKGLQQS 786
WP 006269658 704 SFKEEIARAQIID- DVDD--IANWHDLPGSPAIKKGILQSVKIVDELVKVMG- HNPANIIIEMARENQ TTDKGRRNS 777
WP 048800889 704 PFKQIIKDAQAID- DVDD--IELIVHDLPGSPAIKKGILQSIKIVDELVKVMG- YNPDNIVIEMARENQ TTTKGRRNS 777
WP 012767106 703 TFKEAIQKAQVSG- QGHS--LHEQIANLAGSPAIKKGILQSVKWDELVKVMG- HKPENIVIEMARENQ TTQKGQKNS 776
WP 014612333 703 TFKEAIQKAQVSG- QGHS--LHEQIANLAGSPAIKKGILQSVKWDELVKVMG- HKPENIVIEMARENQ TTQKGQKNS 776
WP 015017095 703 TFKEAIQKAQVSG- QGHS--LHEQIANLAGSPAIKKGILQSVKWDELVKVMG- HKPENIVIEMARENQ TTQKGQKNS 776
WP 015057649 703 TFKEAIQKAQVSG- QGHS--LHEQIANLAGSPAIKKGILQSVKWDELVKVMG- HKPENIVIEMARENQ TTQKGQKNS 776
WP 048327215 703 TFKEAIQKAQVSG- QGHS--LHEQIANLAGSPAIKKGILQSVKWDELVKVMG- HKPENIVIEMARENQ TTQKGQKNS 776
WP 049519324 703 TFKEAIQKAQVSG- QGHS--LHEQIANLAGSPAIKKGILQSVKWDELVKVMG- HKPENIVIEMARENQ TTQKGQKNS 776
WP 012515931 703 SFIDEIAKAQVIG- KTEY--SKDLVGNLAGSPAIKKGISQTIKIVDELVKIMG- YLPQQIVIEMARENQ TTAQGIKNA 776
WP 021320964 703 SFIDEIAKAQVIG- KTEY--SKDLVGNLASSPAIKKGISQTIKIVDELVKIMG- YLPQQIVIEMARENQ TTAQGIKNA 776
WP 037581760 703 SFIDEIAKAQVIG- KTEY--SKDLVGNLAGSPAIKKGISQTIKIVDELVKIMG- YLPQQIVIEMARENQ TTAQGIKNA 776
WP 004232481 704 SFKTTIQEAQWG- DVDD--IEAWHDLPGSPAIKKGILQSVKIVDELVKVMG- HNPQNIVIEMARENQ ITGYGRNRS 777
WP 009854540 705 PFKQIIQKSQWG- DVDD--IEAWHDLPGSPAIKKGILQSVKIVDELVKVMG- DNPDNIVIEMARENQ TTNRGRSQS 778
WP 012962174 705 PFKQIIKDAQIIG- DIDD--VTSWRELPGSPAIKKGILQSVKIVDELVKVMG- HNPDNIVIEMARENQ TTNRGRNQS 778
WP 039695303 707 PFKQIIQKSQWG- DVDD--IEAWHDLPGSPAIKKGILQSVKIVDELVKVMG- GNPDNIVIEMARENQ TTNRGRSQS 780
WP 014334983 704 SFKTIIQEAQWG- DVDD--IEAWHDLPGSPAIKKGILQSVKIVDELVKVMG- DNPDNIVIEMARENQ TTGYGRNKS 777
WP 003099269 703 DFAKIIKNEQEKTi .KNES--LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG- QNPDNIVIEMARENQ STMQGIKNS 777
AHY15608 703 DFAKIIKNEQEKTiKNES--LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG- QNPDNIVIEMARENQ STMQGIKNS 777
AHY17476 703 DFAKIIKNEQEKTiKNES--LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG- QNPDNIVIEMARENQ STMQGIKNS 777
ESR09100
AGM98575 703 DFAKIIKNEQEKTiKNES- -LEETIANLAGSPAIKKGILQS IKIVDEIVKIMG- QNPDNIVIEMARENQ STMQGIKNS 777
ALF27331 704 SFKEEIAKAQVIG- ETDN--LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP 018372492 717 DFKEIIRKAQTIE- NIDT--NQALVSSLPGSPAIKKGILQSLNIVDEI IAIMG- YAPTNIVIEMARENQ TTQKGRDNS 790
WP 045618028 703 SFKEIIQKAQWG- KTND--VKQWQELPGSPAIKKGILQSIKLVDELVKVMG- HAPESIVIEMARENQ TTARGKKNS 776
WP 045635197 702 SFKEIIQKAQVIG- KTDD--VKQWQELSGSPAIKKGILQSIKIVDELVKVMG- HAPESIVIEMARENQ TTARGKKNS 775
WP 002263549 704 SFKEEIAKAQVIG- ETDN--LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP 002263887 704 SFKEEIAKAQVIG- ETDN--LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP 002264920 704 SFKEEIAKAQVIG- ETDN--LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP 002269043 704 SFKEEIAKAQVIG- ETDN--LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP 002269448 704 SFKEEIAKAQVIG-ETDN-LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIWEMARENQ FTNQGRQNS 777
WP "0022 71977 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 72766 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 73241 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTKQGRRNS 777
WP "0022 75430 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 76448 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTKQGRRNS 777
WP "0022 77050 705 TFKDDIVKAQYVD- NSDD- LHQWQSLAGSPAIKKGILQSLKIVDELVKVMG- KEPEQIWEMARENQ TTAKGRRNS 778
WP "0022 77364 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 79025 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 79859 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 80230 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTKQGRRNS 777
WP "0022 81696 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 82247 705 TFKDDIVKAQYVD- NSDD- LHQWQSLAGSPAIKKGILQSLKIVDELVKVMG- KEPEQIWEMARENQ TTAKGRRNS 778
WP "0022 82906 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 83846 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 87255 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 88990 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 89641 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 90427 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSLAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0022 95753 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTKQGRRNS 777
WP "0022 96423 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0023 04487 714 SFKEEIAKAQVIG- EMDG- LNQWSDIAGSPAIKKGILQSLKIVDELVKVMG- HNPANIVIEMARENQ TTAKGRRSS 787
WP "0023 05844 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTKQGRRNS 777
WP "0023 07203 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0023 10390 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSLAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0023 52408 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGQRNS 777
WP "0129 97688 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "θ146 77909 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0193 12892 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0193 13659 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0193 14093 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0193 15370 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0198 03776 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0198 05234 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSLAIKKGILQNLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0247 83594 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0247 84288 705 TFKDDIVKAQYVD- NSDD- LHQWQSLAGSPAIKKGILQSLKIVDELVKVMG- KEPEQIWEMARENQ TTAKGRRNS 778
WP "0247 84666 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0247 84894 704 SFKEEIAKAQVIG- ETDN- LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG- HQPENIWEMARENQ FTNQGRRNS 777
WP "0247 86433 705 TFKDDIVKAQYVD- NSDD- LHQWQSLAGSPAIKKGILQSLKIVDELVKVMG- KEPEQIWEMARENQ TTAKGRRNS 778
WP_049473442 704 SFKEEIAKAQVIG-ETDN LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIWEMARENQ FTNQGRRNS 777
WP_049474547 704 SFKEEIAKAQVIG-ETDN LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIWEMARENQ FTNQGRRNS 777
EMC03581 697 SFKEEIAKAQVIG-ETDN LNQWSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIWEMARENQ FTNQGRRNS 770
WP_000428612 705 SFKEIIKKAQWG-KTDD VKQWQELPGSPAIKKGILQSIKLVDELVKVMG-HEPESIVIEMARENQ TTARGKKNS 778
WP_000428613 703 SFKEITQKAQWG-KTDD VKQWQELPGSPAIKKGILQSIKIVDELVKVMG-HTPESIVIEMARENQ TTARGKKNS 776
WP_049523028 702 SFKETIQKAQWG-ETND VKQWQELPGSPAIKKGILQSIKIVDELVKVMG-HAPESWIEMARENQ TTNKGKSKS 775
WP_003107102 672 DFASIIKEAQEKTiKSEK LEETIANLAGSPAIKKGILQSVKIVDEWKVMG-YEPSNIVIEMARENQ STQRGINNS 746
WP_054279288 705 SFKEEIKKAQEGG-LKDS INDQIRDLAGSPAIKKGILQTINIVDEIVKIMG-KAPQHIWEMARDVQ KTDIGVKQS 778
WP_049531101 703 SFKEIIQESQWG-KPDD VKQIVQELPGSSAIKKGILQSIKLVDELVKVMG-HDPESIVIEMARENQ TTARGKKNS 776
WP_049538452 703 SFKEIIQKAQVFG-KTND VKQWQELPGSPAIKKGILQSIKIVEELVKVMG-HEPESIVIEMARENQ TTTRGKKNS 776
WP_049549711 703 SFKKIIQKSQWG-ETDD VKQWRELPGSPAIKKGILQSIKIVDELVKVMD-HAPESIVIEMARENQ TTARGKKNS 776
WP 007896501 706 DFEKLIDDAQKKAiKRES LTEAVANLAGSPAIKKGILQSLKWDEIVKVMG-HNPDNIVIEMSRENQ TTAQGLKNA 780
EFR44625 658 DFEKLIDDAQKKAiKRES LTEAVANLAGSPAIKKGILQSLKWDEIVKVMG-HNPDNIVIEMSRENQ TTAQGLKNA 732
WP_002897477 702 SFKEIIQKAQWG-KTDD VKQWQELPGSPAIKKGILQSIKIVDELVKVMG-YALESIVIEMARENQ TTARGKKNS 775
WP_002906454 702 SFKEIIQKAQWG-KTDD VKQWQEIPGSPAIKKGILQSIKIVDELVKVMG-HNPESIVIEMARENQ TTAKGKKNS 775
WP_009729476 703 SFKEIIQKAQWG-KTND VKQWQELPGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS 776
CQR24647 706 SFKDEIANSQVIG-DGDD LHQWQELAGSPAIKKGILQSLKIVDELVKVMG-YNPEQIWEMARENQ TTARGRNNS 779
WP_000066813 705 SFKEIIQKAQVFG-KTND VKQWQELPGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS 778
WP_009754323 703 SFKEIIQKAQWG-KTDD LTQWRELSGSPAIKKGILQSIKIVDELVKIMG-YAPESIVIEMARENQ TTAKGKKNS 776
WP_044674937 702 SFVDEIRLAQGSG-EAED YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIWEMARENQ FTNQGRRNS 775
WP_044676715 704 SFVDEIRLAQGSG-EAED YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIWEMARENQ FTNQGRRNS 777
WP_044680361 704 SFVDEIRLAQGSG-EAED YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIWEMARENQ FTNQGRRNS 777
WP_044681799 702 SFVDEIRLAQGSG-EAED YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIWEMARENQ FTNQGRRNS 775
WP_049533112 704 SFKEEIAKAQVIG-ETDD LNQWSDIAGSPAIKKGILQSLKIVDELVKVMG-YNPANIVIEMARENQ TTDKGRRNS 777
WP_029090905 683 LFKKIIEEQFENEtALLN -KQRIDELAASPANKKGIWQAIKIVKELEKVLQ-QPAENIFIEFARSDE ES KRS 752
WP 006506696 706 GYAQMIEEATSCPeDGKF TYEEVERLAGSPALKRGIWQSLQIVEEITKVMK-CRPKYIYIEFERSEE KERT 776
AIT42264 703 TFKEDIQKAQVSG-QGDS LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP_034440723 711 SFKEKIRKAQDIN-QVND IKEIVKDLPGSPAIKKGIYQSIRIVDEIIRKMK-DRPKNIVIEMARENQ TTQEGKNKS 784
AKQ21048 703 TFKEDIQKAQVSG-QGDS LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
WP_004636532 707 SFKKKIEDAQTIE-DTTH IYDTVAELPGSPAIKKGIRQALKIVEEIIDIIG-YEPENIWEMARESQ TTKKGKDLS 780
WP_002364836 715 SFKNAIQKAQSSE-HEET LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIWEMARENQ TTSTGKRRS 788
WP_016631044 666 SFKNAIQKAQSSE-HEET LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIWEMARENQ TTSTGKRRS 739
EMS75795 455 SFKEELANELALA-GNQS LLEWEALLGSPAIKKGIWQTLKIVEELIEIIG-YNPKNIWEMARENQ RT NRS 524
WP_002373311 715 SFKNAIQKAQSSE-HEET LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIWEMARENQ TTSTGKRRS 788
WP_002378009 715 SFKNAIQKAQSSE-HEET LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIWEMARENQ TTSTGKRRS 788
WP_002407324 715 SFKNAIQKAQSSE-HEET LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIWEMARENQ TTSTGKRRS 788
WP_002413717 715 SFKNAIQKAQSSE-HEET LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIWEMARENQ TTSTGKRRS 788
WP_010775580 717 SFKNAIQKAQSSE-HEET LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIWEMARENQ TTSTGKRRS 790
WP 010818269 715 SFKNAIQKAQSSE-HEET LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIWEMARENQ TTSTGKRRS 788
WP 010824395 715 SFKNAIQKAQSSE--HEET-LSET ELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIWEMARENQ TTSTGKRRS 788
WP "016622645 715 SFKNAIQKAQSSE- -HEET- LSET ELAGSPAIKKGIYQSLKIVDELVAIMG- YAPKRIWEMARENQ TTSTGKRRS 78 8
WP "033624816 715 SFKNAIQKAQSSE- -HEET- LSET ELAGSPAIKKGIYQSLKIVDELVAIMG- YAPKRIWEMARENQ TTSTGKRRS 78 8
WP "033625576 715 SFKNAIQKAQSSE- -HEET- LSET ELAGSPAIKKGIYQSLKIVDELVAIMG- YAPKRIWEMARENQ TTSTGKRRS 78 8
WP "033789179 715 SFKNAIQKAQSSE- -HEET- LSET ELAGSPAIKKGIYQSLKIVDELVAIMG- YAPKRIWEMARENQ TTSTGKRRS 78 8
WP "002310644 715 SFKKEIKKAQMIT- -DTEN- LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG- YEPANIWEMARENQ TTGRGLKSS 78 8
WP "002312694 716 SFKKEIKKAQMIT- -DTEN- LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG- YEPANIWEMARENQ TTGRGLKSS 78 9
WP "002314015 716 SFKKEIKKAQMIT- -DTEN- LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG- YEPANIWEMARENQ TTGRGLKSS 78 9
WP "002320716 716 SFKKEIKKAQMIT- -DTEN- LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG- YEPANIWEMARENQ TTGRGLKSS 78 9
WP "002330729 715 SFKKEIKKAQMIT- -DTEN- LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG- YEPANIWEMARENQ TTGRGLKSS 78 8
WP "002335161 716 SFKKEIKKAQMIT- -DTEN- LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG- YEPANIWEMARENQ TTGRGLKSS 78 9
WP "002345439 716 SFKKEIKKAQMIT- -DTEN- LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG- YEPANIWEMARENQ TTGRGLKSS 78 9
WP "034867970 711 SFKEEIAKATVFS- -KHKS- LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG- YKPKNIVIEMARENQ KT HRT 78 0
WP "047937432 716 SFKKEIKKAQMIT- -DTEN- LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG- YEPANIWEMARENQ TTGRGLKSS 78 9
WP "010720994 711 SFKEEIAKATVFS- -KHKS- LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG- YKPKNIVIEMARENQ KT HRT 78 0
WP "010737004 711 SFKEEIAKATVFS- -KHKS- LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG- YKPKNIVIEMARENQ KT HRT 78 0
WP "034700478 711 SFKEEIAKATVFS- -KHKS- LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG- YKPKNIVIEMARENQ KT HRT 78 0
WP "007209003 708 SFKKIIEDSQPYK- -EQQS- AEEIVSELSGSPAIKKGILQSLKIVDELVAIMG- YKPKNIWEMARENQ TTGRGKQNS 78 1
WP "023519017 705 SFKETIANELIMS- -DSNV- LLDQVKAIPGSPAVKKGIWQSIKIVEEIIGIIG- KAPKNIVIEMARENQ RTSR S 774
WP "010770040 708 SFKSEIAEAQSDM- -NTED- LHEWQNLAGSPAIKKGILQSLKIVDELVDIMG- SLPKNIWEMARENQ TTSRGRTNS 78 1
WP "048604708 704 TFKEEIEKEQLKA- -NSEEsLIEIVQNLAGSPAIKKGIFQSLKIVDELVEIMG- YAPTNIWEMARENQ TTANGRRNS 77 8
WP "010750235 710 SFKEEIAKELTLS- -DKQS- LLEWEAIPGSPAIKKGIWQTLKIVEELIAIIG- YKPKNIVIEMARENQ TTTGGKNRS 78 3
AII16583 742 TFKEDIQKAQVSG- -QGDS- LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 816
WP 029073316 718 GFKKTIDDANSTSvSGKF- SYAEVQELAGSPAIKRGIWQALLIVDEIKKIMK- HEPAHVYIEFARNED KERK 78 8
WP "031589969 718 GFKKTIDDANSTSvSGKF- SYAEVQELAGSPAIKRGIWQALLIVDEIKKIMK- HEPAHVYIEFARNED KERK 78 8
KDA45870 699 SFKETIKNAQVIE- -KEET- LAKTVQELPGSPAIKKGILQSLEIVDEIIKVMG- YKPKSIWEMARETQ —THGTRKR 771
WP 039099354 713 DFDKLITEANQMM- -LAENdVQDVINDLYTSPQNKKALRQILLV DIQKAMKgQAPERILIEFAREDE VNPRLSVQR 78 8
AKP02966 707 DFKNYIENHNLNKnEDQN- ISNLVNDIHVSPALKRGITQSIKIVQEIVKFMG- HAPKYIFIEVTRETK TTSRGKRIQ 78 5
WP 010991369 707 SFKSIIEKEQVTT- -ADKD- IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG- YPPQTIWEMARENQ TTGKGKNNS 78 0
WP "033838504 707 SFKSIIEKEQVTT- -ADKD- IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG- YPPQTIWEMARENQ TTGKGKNNS 78 0
EHN60060 710 SFKSIIEKEQVTT- -ADKD- IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG- YPPQTIWEMARENQ TTGKGKNNS 78 3
EFR89594 476 SFKSIIEKEQVTT- -ADKD- IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG- YPPQTIWEMARENQ TTGKGKNNS 549
WP 038409211 707 SFKSIIEKEQVST- -ADKG- IQSIVAELAGSPAIKKGILQSLKIVDELVGIMG- YPPQTIWEMARENQ TTGKGKNNS 78 0
EFR95520 326 SFKSIIEKEQVST- -ADKG- IQSIVAELAGSPAIKKGILQSLKIVDELVGIMG- YPPQTIWEMARENQ TTGKGKNNS 399
WP 003723650 707 SFKSIIEKEQVST- -TDKD- LQSIVAELAGSPAIKKGILQSLKIVDELVSIMG- YPPQTIWEMARENQ TTGKGKNNS 78 0
WP "003727705 707 SFKSIIEKEQVST- -TDKD- LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG- YPPQTIWEMARENQ TTGKGKNNS 78 0
WP "003730785 707 SFKSIIEKEQVST- -TDKD- LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG- YPPQTIWEMARENQ TTGKGKNNS 78 0
WP "003733029 707 SFKSIIEKEQVST- -TDKD- LQSIVAELAGSPAIKKGILQSLKIVDELVSVMG- YPPQTIWEMARENQ TTNKGKNNS 78 0
WP "003739838 707 SFKSIIEKEQVST- -TDKD- LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG- YPPQTIWEMARENQ TTVKGKNNS 78 0
WP 014601172 707 SFKSIIEKEQVST--TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIWEMARENQ TTGKGKNNS 780
WP 023548323 707 SFKSIIEKEQVST- -ADKD- LQSIVADLAGSPAIKKGILQSLKWEELVSVMG-YPPQTIWEMARENQ TTNKGKNNS 7 80
WP 031665337 707 SFKSIIEKEQVST- -TDKD- LQSIVAELAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIWEMARENQ TTGKGKNNS 7 80
WP 031669209 707 SFKSIIEKEQVST- -ADKD- LQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIWEMARENQ TTNKGKNNS 7 80
WP 033920898 707 SFKSIIEKEQVST- -ADKD- LQSIVADLAGSPAIKKGILQSLKWEELVSVMG-YPPQTIWEMARENQ TTNKGKNNS 7 80
AKI42028 710 SFKSIIEKEQVST- -TDKD- LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIWEMARENQ TTGKGKNNS 7 83
AKI50529 710 SFKSIIEKEQVST- -ADKD- LQSIVADLAGSPAIKKGILQSLKWEELVSVMG-YPPQTIWEMARENQ TTNKGKNNS 7 83
EFR83390 155 SFKSIIEKEQVST- -TDKD- LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIWEMARENQ TTVKGKNNS 228
WP 046323366 707 SFKSIIEKEQVST- -ADKD- IQSIVADLAGSPAIKKGILQSLKIVDELVGIMG-YPPQTIWEMARENQ TTGKGKNNS 7 80
AKE81011 719 TFKEDIQKAQVSG- -QGDS- LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 793
CU082355 710 GYAQMIEEASSCPkDGKF- TYEEVAKLAGSPALKRGIWQSLQIVEEITKVMK-CRPKYIYIEFERSEE KERT 7 80
WP 033162887 713 GYKQIIEESNMQD: LEGPF- KYDEVKKLAGSPAIKRGIWQALLWREITKFMK-HEPSHIYIEFAREEQ KVRK 7 83
AGZ 01981 736 TFKEDIQKAQVSG- -QGDS- LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 8 10
AKA60242 703 TFKEDIQKAQVSG- -QGDS- LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
AKS40380 703 TFKEDIQKAQVSG- -QGDS- LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777
4UN5 B 707 TFKEDIQKAQVSG- -QGDS- LHEHIANLAGSPAIKKGILQTVKWDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 7 81
WP 010922251 778 RERMKRIEEGIK ELGS QILKEHP--VE-—NTQLQ EKLYLYYLQNGRDMYVDQEL--D--I RLSDYDVD|H|I 841
WP 039695303 781 QQRLKKLQNSLK PSYI E DK- -VE- —NSHLQNDQLFLYYIQNGKDMYTGDEL- -D- -IDHLSDYDIDHI 851
WP "045635197 776 QQRYKRIEDSLK ILAS NILKENP- -TD- —NNQLQNDRLFLYYLQNGKDMYTGEAL- -D- -INQLSSYDIDHI 843
5AXW A 488 KDAQKMINEMQK QTNE EIIRTTGk —E- —NAKYLIEKIKLHDMQEGKCLYSLEAIplEdlLNNPFNYEVDHI 561
WP 009880683 462 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 525
WP "010922251 778 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "011054416 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "011284745 778 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "011285506 778 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "011527619 778 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "012560673 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —TTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "014407541 777 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP "020905136 778 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "023080005 777 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP "023610282 777 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP "030125963 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "030126706 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "031488318 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "032460140 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "032461047 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "032462016 778 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "032462936 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "032464890 778 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "033888930 603 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 666
WP "038431314 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "038432938 777 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP "038434062 778 RERMKRIEEGIK ELGS DILKEYP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
BAQ51233 689 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 752
KGE60162 1 -D- -INRLSGYDVDHI 16
KGE60856
WP 002989955 778 RERMKRIEEGIK ELGS QILKEHP- -VE- —NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP "003030002 778 QQRLKLLQDSLK PVNI K N- -VE- —NQQLQNDRLFLYYIQNGKDMYTGETL- -D- -INNLSQYDIDHI 840
WP "003065552 781 QQRLKKLQNSLK PSYI E DK- -VE- —NSHLQNDQLFLYYIQNGKDMYTGDEL- -D- -IDHLSDYDIDHI 851
WP "001040076 776 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDHI 846
WP "001040078 779 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040080 779 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040081 779 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040083 779 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040085 779 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDDLSQYDIDHI 846
WP 001040087 779 RQRYKLLDDGVK NLAS NILKEYP--TD-—NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846
WP "001040088 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040089 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040090 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040091 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040092 77 9 RQRYKLLEDGVK NLAS DILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040094 77 6 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDHI 846
WP "001040095 77 6 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDHI 846
WP "001040096 77 6 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDHI 846
WP "001040097 77 6 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDHI 846
WP "001040098 77 6 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDHI 846
WP "001040099 77 6 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDHI 846
WP "001040100 77 6 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDHI 846
WP "001040104 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040105 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040106 77 9 RQRYKLLEEGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040107 77 9 RQRYKLLEEGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040108 77 9 RQRYKLLEEGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGETL- -D- -IDNLSQYDIDHI 846
WP "001040109 77 9 RQRYKLLEEGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "001040110 77 9 RQRYKLLEEGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "015058523 77 9 RQRYKLLEDGVK NLAS DILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "017643650 77 6 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDLI 846
WP "017647151 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGKAL- -D- -IDNLSQYDIDHI 846
WP "017648376 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGKAL- -D- -IDNLSQYDIDHI 846
WP "017649527 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "017771611 77 9 RQRYKLLEEGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "017771984 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
CFQ25032 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
CFV16040 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
KLJ37842 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
KLJ72361 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
KLL20707 79 3 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 860
KLL42645 77 9 RQRYKLLEEGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP 047207273 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "047209694 77 6 RQRLTTLRESLA NLKS EKKPKYV- -KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL- -D- -IDNLSQYDIDHI 846
WP 050198062 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "050201642 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "050204027 77 9 RQRYKLLEEGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP "050881965 77 9 RQRYKLLDDGVK NLAS NILKEYP- -TD- —NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
WP 050886065 779 RQRYKLLDDGVK NLAS NILKEYP--TD- -NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846
AHN30376 779 RQRYKLLEDGVK NLAS DILKEYP- -TD- -NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDSLSQYDIDHI 846
EA078426 779 RQRYKLLDDGVK NLAS NILKEYP- -TD- -NQALQNERLFLYYLQNGRDMYTGEAL- -D- -IDNLSQYDIDHI 846
CCW42055 779 RQRYKLLDDGVR NLAS NILKEYP- -TD- -NQALQNERLFLYYLQNGRDMYTEKAL- -D- -IDNLSQYDIDHI 846
WP 003041502 778 QQRLKLLQDSLK PVNI K N- -VE- -NQQLQNDRLFLYYIQNGKDMYTGETL- -D- -INNLSQYDIDHI 840
WP 037593752 779 QQRLKLLQDSLK PVNI K N- -VE- -NQQLQNDRLFLYYIQNGKDMYTGETL- -D- -INNLSQYDIDHI 841
WP 049516684 779 QQRLKLLQDSLK PVNI K N- -VE- -NQQLQNDRLFLYYIQNGKDMYTGETL- -D- -INNLSQYDIDHI 841
GAD46167 778 QQRLKLLQDSLK PVNI K N- -VE- -NQQLQNDRLFLYYIQNGKDMYTGETL- -D- -INNLSQYDIDHI 840
WP 018363470 779 QQRLKKLQNSLK PSYI E DK- -VE- -NSHLQNDQLFLYYIQNGKDMYTGDEL- -D- -IDHLSDYDIDHI 849
WP 003043819 787 RERKKRIEEGIK ELES QILKENP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 850
WP 006269658 778 QQRLKLLQDSLK PVNI K N- -VE- -NQQLQNDRLFLYYIQNGKDMYTGETL- -D- -INNLSQYDIDHI 840
WP 048800889 778 QQRLKLLQDSLT PVSI K N- -VE- -NQQLQNDRLFLYYIQNGKDMYTGEEL- -D- -IHHLSDYDIDHI 840
WP 012767106 777 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP 014612333 777 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP 015017095 777 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP 015057649 777 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP 048327215 777 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP 049519324 777 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 840
WP 012515931 777 RQRMRKLEETAK KLGS NILKEHP- -VD- -NSQLQNDKRYLYYLQNGKDMYTGDDL- -D- -IDYLSSYDIDHI 840
WP 021320964 777 RQRMRKLEETAK KLGS NILKEHP- -VD- -NSQLQNDKRYLYYLQNGKDMYTGDDL- -D- -IDYLSSYDIDHI 840
WP 037581760 777 RQRMRKLEETAK KLGS NILKEHP- -VD- -NSQLQNDKRYLYYLQNGKDMYTGDDL- -D- -IDYLSSYDIDHI 840
WP 004232481 778 NQRLKRLQDSLK PSYV D SK- -VE- -NSHLQNDRLFLYYIQNGKDMYTGEEL- -D- -IDHLSDYDIDHI 848
WP 009854540 779 QQRLKKLQSSLK PSYI E DK- -VE- -NSHLQNDQLFLYYIQNGKDMYTGDEL- -D- -IDHLSDYDIDHI 849
WP 012962174 779 QQRLKKLQDSLK PSYI E GK- -VE- -NNHLQDDRLFLYYIQNGKDMYTGDEL- -D- -IDHLSDYDIDHI 849
WP 039695303 781 QQRLKKLQNSLK PSYI E DK- -VE- -NSHLQNDQLFLYYIQNGKDMYTGDEL- -D- -IDHLSDYDIDHI 851
WP 014334983 778 NQRLKRLQDSLK PSYV D SK- -VE- -NSHLQNDRLFLYYIQNGKDMYTGEEL- -D- -IDRLSDYDIDHI 848
WP 003099269 778 RQRLRKLEEVHK NTGS KILKEYN- -VS- -NTQLQSDRLYLYLLQDGKDMYTGKEL- -D- -YDNLSQYDIDHI 841
AHY15608 778 RQRLRKLEEVHK NTGS KILKEYN- -VS- -NTQLQSDRLYLYLLQDGKDMYTGKEL- -D- -YDNLSQYDIDHI 841
AHY17476 778 RQRLRKLEEVHK NTGS KILKEYN- -VS- -NTQLQSDRLYLYLLQDGKDMYTGKEL- -D- -YDNLSQYDIDHI 841
ESR09100
AGM98575 778 RQRLRKLEEVHK NTGS KILKEYN- -VS- -NTQLQSDRLYLYLLQDGKDMYTGKEL- -D- -YDNLSQYDIDHI 841
ALF27331 778 QQRLKGLTDSIK EFGS QILKEHP- -VE- -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP 018372492 791 AQRLKKIEDGIK -LGS DLLKQNP- -IQd- -NKDLQKEKLFLYYMQNGIDLYTGQPLncD- -PDSLAFYDVDHI 857
WP 045618028 777 QQRYKRIEDALK NLAH NILKEHP- -TD- -NIQLQNDRLFLYYLQNGKDMYTGKSL- -D- -INQLSSCDIDHI 844
WP 045635197 776 QQRYKRIEDSLK ILAS NILKENP- -TD- -NNQLQNDRLFLYYLQNGKDMYTGEAL- -D- -INQLSSYDIDHI 843
WP 002263549 778 QQRLKGLTDSIK EFGS QILKEHP- -VE- -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP 002263887 778 QQRLKGLTDSIK EFGS QILKEHP- -VE- -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP 002264920 778 QQRLKGLTDSIK EFGS QILKEHP- -VE- -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP 002269043 778 QQRLKGLTDSIK EFGS QILKEHP- -VE- -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP 002269448 778 QQRLKGLTDSIK EFGS QILKEHP--VE --NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841
WP "002271977 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002272766 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002273241 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002275430 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002276448 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002277050 779 QQRYKRLKEAIK DLNH KILKEHP- -TD - -NQALQNNRLFLYYLQNGRDMYTGESL- -D- -INRLSDYDIDHV 846
WP "002277364 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -HSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002279025 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002279859 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002280230 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002281696 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002282247 779 QQRYKRLKEAIK DLNH KILKEHP- -TD - -NQALQNNRLFLYYLQNGRDMYTGESL- -D- -INRLSDYDIDHV 846
WP "002282906 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002283846 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002287255 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -HSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002288990 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002289641 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002290427 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002295753 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002296423 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002304487 788 QKRYKRLEEAIK DLNH KILKEHP- -TD - -NQALQNDRLFLYYLQNGRDMYTEDPL- -D- -INRLSDYDIDHI 855
WP "002305844 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002307203 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002310390 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "002352408 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "012997688 778 QQRLKGLTDSIK EFGS QILKEHP- -VK - -HSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "014677909 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "019312892 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "019313659 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "019314093 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "019315370 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "019803776 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "019805234 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "024783594 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP "024784288 779 QQRYKRLKEAIK DLNH KILKEHP- -TD - -NQALQNNRLFLYYLQNGRDMYTGESL- -D- -INRLSDYDIDHV 846
WP "024784666 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -HSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP 024784894 778 QQRLKGLTDSIK EFGS QILKEHP- -VE - -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
WP 024786433 779 QQRYKRLKEAIK DLNH KILKEHP- -TD - -NQALQNNRLFLYYLQNGRDMYTGESL- -D- -INRLSDYDIDHV 846
WP 049473442 778 QQRLKGLTDSIK EFGS QILKEHP--VE- -NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841
WP 049474547 778 QQRLKGLTDSIK EFGS QILKEHP- -VE- -NSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 841
EMC03581 771 QQRLKGLTDSIK EFGS QILKEHP- -VE- -HSQLQNDRLFLYYLQNGRDMYTGEEL- -D- -IDYLSQYDIDHI 834
WP 000428612 779 QQRYKRIEDSLK ILAS KILKEHP- -TD- -NIQLQNDRLFLYYLQNGRDMYTGKPL- -D- -INQLSSYDIDHI 846
WP 000428613 777 QQRYKRIEDALK NLAS NILKEHP- -TN- -NIQLQNDRLFLYYLQNGRDMYTGKPL- -D- -INQLSSYDIDHI 844
WP 049523028 776 QQRLKTLSDAIS ELG- NILKEHP- -TD- -NIQLQNDRLFLYYLQNGKDMYTGEAL- -D- -INQLSNYDIDHI 839
WP 003107102 747 RERLRKLEEVHK NIGS KILKEHE- -IS- -NAQLQSDRVYLYLLQDGKDMYTGKDL- -D- -FDRLSQYDIDHI 810
WP 054279288 779 RERMKRVQEVLK KLGS QLLKEHP- -VE- -NFQLQNERLYLYYLQNGKDMYTGEEL- -S- -ISNLSHYDIDHI 842
WP 049531101 777 QQRYKRIEDSLK ILAS NILKEHP- -TD- -NIQLQNDRLFLYYLQNGKDMYTGNPL- -D- -INHLSSYDIDHI 844
WP 049538452 777 QQRYKRIENSLK ILAS KILKEHP- -TD- -NNQLQNDRLFLYYLQNGKDMYTGEAL- -D- -INQLSSCDIDHI 844
WP 049549711 777 QQRYKRIEDSLK ILAS NILKENP- -TD- -NNQLQNDRLFLYYLQNGKDMYTGEAL- -D- -INQLSSYDIDHI 844
WP 007896501 781 RQRLKKIKEVHK KTGS RILEDNSerlT- -NLTLQDNRLYLYLLQDGKDMYTGQDL- -D- -INNLSQYDIDHI 846
EFR44625 733 RQRLKKIKEVHK KTGS RILEDNSerlT- -NLTLQDNRLYLYLLQDGKDMYTGQDL- -D- -INNLSQYDIDHI 798
WP 002897477 776 QQRYKRIEDALK NLAP NILKENP- -TD- -NIQLKNDRLFLYYLQNGKDMYTGKPL- -D- -INQLSSYDIDHI 843
WP 002906454 776 QQRYKRIEDALK NLAP NILKENP- -TD- -NIQLQNDRLFLYYLQNGKDMYTGKAI- -D- -INQLSNYDIDHI 843
WP 009729476 777 QQRYKRIEDSLK ILAS KILKEHP- -TD- -NIQLQNDRLFLYYLQNGKDMYTGEAL- -D- -INQLSSCDIDHI 844
CQR24647 780 QQRLGSLTKAIQ DFGS DILKRYP- -VE- -NNQLQNDQLYLYYLQNGKDMYTGDTL- -D- -IHNLSQYDIDHI 843
WP 000066813 779 QQRYKRIEDSLK NLAS NILKENP- -TD- -NIQLQNDRLFLYYLQNGRDMYTGKPL- -E- -INQLSNYDIDHI 846
WP 009754323 777 QQRYKRIEDALK NLAP TISKENP- -TD- -NIQLQNDRLFLYYLQNGKDMYTGEAL- -D- -INQLSSYDIDHI 844
WP 044674937 776 QQRYKKIENAIK NLNS KILKEYP- -TN- -NQALQNDRLFLYYLQNGKDMYTDEEL- -D- -IDQLSQYDIDHI 843
WP 044676715 778 QQRYKKIENAIK NLNS KILKEYP- -TN- -NQALQNDRLFLYYLQNGKDMYTDEEL- -D- -IDQLSQYDIDHI 845
WP 044680361 778 QQRYKKIENAIK NLNS KILKEYP- -TN- -NQALQNDRLFLYYLQNGKDMYTDEEL- -D- -IDQLSQYDIDHI 845
WP 044681799 776 QQRYKKIENAIK NLNS KILKEYP- -TN- -NQALQNDRLFLYYLQNGKDMYTDEEL- -D- -IDQLSQYDIDHI 843
WP 049533112 778 QQRLKLLQDSLK PVNI K N- -VE- -NQQLQNDRLFLYYIQNGKDMYTGETL- -D- -INNLSQYDIDHI 840
WP 029090905 753 TPRDKFIEKAYA ETDT EHLKELK- —Qr -SKQLSSQRLFLYFIQNGKCMYSGEHL- -D- -IERLDSYEVDHI 823
WP 006506696 777 ESKIKKLENVYK DEQT SVLEELKg -FDn -TKKISSDSLFLYFTQLGKCMYSGKKL- -D- -IDSLDKYQIDHI 849
AIT42264 778 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP 034440723 785 KARLKKIQEGLE NLDS HVEKQAL- —D- -EEMLKSPKYYLYCLQNGKDIYTGKDL- -D- -IGQLQTYDIDHI 848
AKQ21048 778 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
WP 004636532 781 KERLEKLTEAIK EFDG —VKVKD- -LK- -NENLRNDRLYLYYLQNGRDMYTNEPL- -D- -INNLSKYDIDHI 845
WP 002364836 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -S- -LHRLSHYDIDHI 852
WP 016631044 740 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -S- -LHRLSHYDIDHI 803
EMS75795 525 KPRLKALEEALK SFDS PLLKEQP- -VD- -NQALQKDRLYLYYLQNGKDMYTGEAL- -D- -IDRLSEYDIDHI 588
WP 002373311 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -S- -LHRLSHYDIDHI 852
WP 002378009 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -S- -LHRLSHYDIDHI 852
WP 002407324 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -s- -LHRLSHYDIDHI 852
WP 002413717 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -s- -LHRLSHYDIDHI 852
WP 010775580 791 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -s- -LHRLSHYDIDHI 854
WP 010818269 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -s- -LHRLSHYDIDHI 852
WP 010824395 789 IQRLKIVEKAMA EIGS NLLKEQP--TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852
WP 016622645 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -S- -LHRLSHYDIDHI 852
WP 033624816 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -s- -LHRLSHYDIDHI 852
WP 033625576 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -s- -LHRLSHYDIDHI 852
WP 033789179 789 IQRLKIVEKAMA EIGS NLLKEQP- -TT- -NEQLRDTRLFLYYMQNGKDMYTGDEL- -s- -LHRLSHYDIDHI 852
WP 002310644 789 RPRLKALEESLK DFGS QLLKEYP- -TD- -NSSLQKDRLYLYYLQNGRDMYTGAPL- -D- -IHRLSDYDIDHI 852
WP 002312694 790 RPRLKALEESLK DFGS QLLKEYP- -TD- -NSSLQKDRLYLYYLQNGRDMYTGAPL- -D- -IHRLSDYDIDHI 853
WP 002314015 790 RPRLKALEESLK DFGS QLLKEYP- -TD- -NSSLQKDRLYLYYLQNGRDMYTGAPL- -D- -IHRLSDYDIDHI 853
WP 002320716 790 RPRLKALEESLK DFGS QLLKEYP- -TD- -NSSLQKDRLYLYYLQNGRDMYTGAPL- -D- -IHRLSDYDIDHI 853
WP 002330729 789 RPRLKALEESLK DFGS QLLKEYP- -TD- -NSSLQKDRLYLYYLQNGRDMYTGAPL- -D- -IHRLSDYDIDHI 852
WP 002335161 790 RPRLKALEESLK DFGS QLLKEYP- -TD- -NSSLQKDRLYLYYLQNGRDMYTGAPL- -D- -IHRLSDYDIDHI 853
WP 002345439 790 RPRLKALEESLK DFGS QLLKEYP- -TD- -NSSLQKDRLYLYYLQNGRDMYTGAPL- -D- -IHRLSDYDIDHI 853
WP 034867970 781 SPRLKALENGLK QIGS TLLKEQP- -TD- -NKALQKERLYLYYLQNGRDMYTGEPL- -E- -IENLHQYEVDHI 844
WP 047937432 790 RPRLKALEESLK DFGS QLLKEYP- -TD- -NSSLQKDRLYLYYLQNGRDMYTGAPL- -D- -IHRLSDYDIDHI 853
WP 010720994 781 KPRLKALENGLK QIGS TLLKEQP- -TD- -NKALQKERLYLYYLQNGRDMYTGEPL- -E- -IENLHQYEVDHI 844
WP 010737004 781 SPRLKALENGLK QIGS TLLKEQP- -TD- -NKALQKERLYLYYLQNGRDMYTGEPL- -E- -IENLHQYEVDHI 844
WP 034700478 781 KPRLKALENGLK QIGS TLLKEQP- -TD- -NKALQKERLYLYYLQNGRDMYTGEPL- -E- -IENLHQYEVDHI 844
WP 007209003 782 KPRLKGIENGLK EFSD SVLKGSS- -ID- -NKQLQNDRLYLYYLQNGKDMYTGHEL- -D- -IDHLSTYDIDHI 845
WP 023519017 775 RPRLKALEEALK NIDS PLLKDYP- -TD- -NQALQKDRLYLYYLQNGKDMYTGEPL- -E- -IHRLSEYDIDHI 838
WP 010770040 782 NPRMKALEEAMR NLRS NLLKEYP- -TD- -NQALQNDRLYLYYLQNGKDMYTGLDL- -S- -LHNLSSYDIDHI 845
WP 048604708 779 RPRLKNLEKAID DLDS EILKKHP- -VD- -NKALQKDRLYLYYLQNGKDMYTNEEL- -D- -IHKLSTYDIDHI 842
WP 010750235 784 KPRLKSLEEALK NFDS QLLKERP- -VD- -NQSLQKDRLYLYYLQNGKDMYTGESL- -D- -IDRLSEYDIDHI 847
AII16583 817 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 880
WP 029073316 789 DSFVNQMLKLYK DFED EANKHLKg -EDa -KSKIRSERLKLYYTQMGKCMYTGKSL- -D- -IDRLDTYQVDHI 860
WP 031589969 789 DSFVNQMLKLYK DFED EANKHLKg -EDa -KSKIRSERLKLYYTQMGKCMYTGKSL- -D- -IDRLDTYQVDHI 860
KDA45870 772 EDRVQQIVKNLK ELPK P- —S- -NAELSDERKYLYCLQNGRDMYTGAPL- -D- -YDHLQFYDVDHI 833
WP 039099354 789 KRQVEQVYQNI S EL— EIRNELK- --D1 sNSALSNTRLFLYFMQGGRDMYTGDSL- -N- -IDRLSTYDIDHI 856
AKP02966 786 RLQSKLLNKANG -LVP EELKKHKn —D- LSSERIMLYFLQNGKSLYSEESL- -N- -INKLSDYQVDHI 858
WP 010991369 781 RPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELRNNRLYLYYLQNGKDMYTGQDL- -D- -IHNLSNYDIDHI 844
WP 033838504 781 RPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELRNNRLYLYYLQNGKDMYTGQDL- -D- -IHNLSNYDIDHI 844
EHN60060 784 RPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELRNNRLYLYYLQNGKDMYTGQDL- -D- -IHNLSNYDIDHI 847
EFR89594 550 RPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDMYTGQDL- -D- -IHNLSNYDIDHI 613
WP 038409211 781 KPRFISLEKAIK EFGS QILKEHP- -TD- -NQCLKNDRLYLYYLQNGKDMYTGKEL- -D- -IHNLSNYDIDHI 844
EFR95520 400 KPRFISLEKAIK EFGS QILKEHP- -TD- -NQCLKNDRLYLYYLQNGKDMYTGKEL- -D- -IHNLSNYDIDHI 463
WP 003723650 781 KPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHI 844
WP 003727705 781 KPRYKSLEKAIK DFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDIYTGQEL- -D- -IHNLSNYDIDHI 844
WP 003730785 781 KPRYKSLEKAIK DFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDIYTGQEL- -D- -IHNLSNYDIDHI 844
WP 003733029 781 KPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHI 844
WP 003739838 781 RPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELRNNRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHI 844
WP 014601172 781 KPRYKSLEKAIK EFGS KILKEHP--TD- -NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 844
WP 023548323 7 81 KPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHI 844
WP 031665337 7 81 KPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHI 844
WP 031669209 7 81 KPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHI 844
WP 033920898 7 81 KPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHI 844
AKI42028 7 84 KPRYKSLEKAIK EFGS KILKEHP- -TD- -NQELKNNRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHI 847
AKI50529 7 84 KPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHI 847
EFR83390 2 29 RPRYKSLEKAIK EFGS QILKEHP- -TD- -NQELKNNRLYLYYLQNGKDIYTGQEL- -D- -IHNLSNYDIDHI 292
WP 046323366 7 81 KPRFTSLEKAIK ELGS QILKEHP- -TD- -NQGLKNDRLYLYYLQNGKDMYTGQEL- -D- -IHNLSNYDIDHV 844
AKE81011 7 94 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 857
CU082355 7 81 ESKIKKLENVYK DEQT SVLEELKg -FDn -TKKISSDSLFLYFTQLGKCMYSGKKL- -D- -IDSLDKYQIDHI 853
WP 033162887 7 84 ESKIAKLQKIYE NLQT QVYESLKk -EDa -KKRMETDALYLYYLQMGKSMYSGKPL- -D- -IDKLSTYQIDHI 855
AGZ 01981 8 11 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 874
AKA60242 7 78 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDAI 841
AKS40380 7 78 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDHI 841
4UN5 B 7 82 RERMKRIEEGIK ELGS QILKEHP- -VE- -NTQLQNEKLYLYYLQNGRDMYVDQEL- -D- -INRLSDYDVDAI 845
WP 010922251 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP s--EEWKK KN-YWRQLLNAKLITQRKFDNLTKA--ERG|GLSE| 910
WP "039695303 852 IPQAFIKDDSIDNRVLTSSAKNRG- KSDD- -VP s- -LDIVRARKA- EWVRLYKSGLISKRKFDNLTKA- -ERGGLTE 920
WP "045635197 844 IPQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -IEWQKRKA- FWQQLLDSKLISERKFNNLTKA- -ERGGLDE 912
5AXW A 562 IPRSVSFDNSFNNKVLVKQEEASK- KGNR- -TP Fqy-LSSSDSKI- SYETFKKHILNLAKGKGRISKTk -KEYLLEE 632
WP 009880683 526 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWKQLLNAKLITQRKFDNLTKA- -ERGGLSE 594
WP "010922251 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "011054416 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "011284745 842 VPQSFIKDDSIDNKVLTRSDKNRG- KSNN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "011285506 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "011527619 842 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "012560673 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWKQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "014407541 841 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP "020905136 842 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "023080005 841 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP "023610282 841 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP "030125963 842 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "030126706 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "031488318 842 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWKQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "032460140 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWKQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "032461047 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWKQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "032462016 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "032462936 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWKQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "032464890 842 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "033888930 667 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 735
WP "038431314 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "038432938 841 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP "038434062 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWKQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
BAQ51233 753 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 821
KGE60162 17 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 85
KGE60856
WP 002989955 842 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- -YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP "003030002 841 IPQAFIKDNSLDNRVLTRSDKNRG- KSDD- -VP s- -IEWHEMKS- FWSKLLSVKLITQRKFDNLTKA- -ERGGLTE 909
WP "003065552 852 IPQAFIKDDSIDNRVLTSSAKNRG- KSDD- -VP s- -LDIVRARKA- EWVRLYKSGLISKRKFDNLTKA- -ERGGLTE 920
WP "001040076 847 IPQAFIKDDSIDNRVLVSSAKNRG- KSDD- -VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP "001040078 847 IPQAFIKDDSIDNRVLVSSAKNRG- KSDD- -VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP "001040080 847 IPQAFIKDDSIDNRVLVSSAKNRG- KSDD- -VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP "001040081 847 IPQAFIKDDSIDNRVLVSSAKNRG- KSDD- -VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP "001040083 847 IPQAFIKDDSIDNRVLVSSAKNRG- KSDD- -VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP "001040085 847 IPQAFIKDDSIDNRVLVSSAKNRG- KSDD- -VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040087 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915
WP 001040088 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040089 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040090 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040091 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040092 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -IDIVKARKA- FWKKLLDAKLISQRKYDNLTKA- -ERGGLTP 915
WP 001040094 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -VEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040095 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040096 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040097 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -VEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040098 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -VEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040099 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -VEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040100 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -VEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040104 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040105 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040106 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN—VP s- -IDIVKARKA- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040107 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN—VP s- -IDIVKARKA- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040108 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN—VP s- -IDIVKARKA- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040109 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN—VP s- -IDIVKARKA- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 001040110 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN—VP s- -IDIVKARKA- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 015058523 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -IDIVKARKA- FWKKLLDAKLISQRKYDNLTKA- -ERGGLTP 915
WP 017643650 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -VEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 017647151 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 017648376 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 017649527 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 017771611 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN—VP s- -IDIVKARKA- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 017771984 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
CFQ25032 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
CFV16040 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
KLJ37842 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
KLJ72361 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
KLL20707 861 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 929
KLL42645 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN—VP s- -IDIVKARKA- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 047207273 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 047209694 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -VEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 050198062 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 050201642 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 050204027 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN—VP s- -IDIVKARKA- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 050881965 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD—VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 050886065 847 I PQAFIKDDSIDNRVLVSSAKNRG-'KSDD--VP s--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915
AHN30376 847 VPQAFIKDDSIDNRVLVSSAKNRG- KSDD- -VP s- -IDIVKARKA- FWKKLLDAKLISQRKYDNLTKA- -ERGGLTP 915
EA078426 847 I PQAFIKDDSIDNRVLVSSAKNRG- KSDD- -VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
CCW42055 847 I PQAFIKDDSIDNRVLVSSAKNRG- KSDD- -VP s- -LEIVKDCKV- FWKKLLDAKLMSQRKYDNLTKA- -ERGGLTS 915
WP 003041502 841 IPQAYIKDDSFDNRVLTSSSENRG- KSDN- -VP s- -1EWCARKA- DWMRLRKAGLISQRKFDNLTKA- -ERGGLTE 909
WP 037593752 842 I PQAFIKDNSLDNRVLTRSDKNRG- KSDD- -VP s- -IEWHEMKS- FWSKLLSVKLITQRKFDNLTKA- -ERGGLTE 910
WP 049516684 842 I PQAFIKDNSLDNRVLTRSDKNRG- KSDD- -VP s- -IEWHEMKS- FWSKLLSVKLITQRKFDNLTKA- -ERGGLTE 910
GAD46167 841 I PQAFIKDNSLDNRVLTRSDKNRG- KSDD- -VP s- -IEWHEMKS- FWSKLLSVKLITQRKFDNLTKA- -ERGGLTE 909
WP 018363470 850 I PQAFIKDDSIDNRVLTSSAKNRG- KSDD- -VP s- -LGIVRARKA- EWVRLYKSGLISKRKFDNLTKA- -ERGGLTE 918
WP 003043819 851 VPQSFIKDDSIDNKVLTRSVENRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 919
WP 006269658 841 IPQAFIKDNSLDNRVLTRSDKNRG- KSDD- -VP s- -IEWHEMKS- FWSKLLSVKLITQRKFDNLTKA- -ERGGLTE 909
WP 048800889 841 I PQAFIKDDSIDNRVLTSSAKNRG- KSDN- -VP N- -LEWCDRKA- DWIRLREAGLISQRKFDNLTKA- -ERGGLTE 909
WP 012767106 841 VPQSFIKDDSIDNKILTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP 014612333 841 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP 015017095 841 VPQSFIKDDSIDNKVLTRSDKNRG- KSDD- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP 015057649 841 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP 048327215 841 VPQSFIKDDSIDNKVLTRSDKNRG- KSDD- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP 049519324 841 VPQSFIKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 909
WP 012515931 841 IPQSFIKNNSIDNKVLTSQGANRG- KLDN- -VP s- -EAIVRKMKG- YWQSLLRAGAISKQKFDNLTKA- -ERGGLTQ 909
WP 021320964 841 IPQSFIKNNSIDNKVLTSQGANRG- KLDN- -VP s- -EAIVRKMKG- YWQSLLRAGAISKQKFDNLTKA- -ERGGLTQ 909
WP 037581760 841 IPQSFIKNNSIDNKVLTSQGANRG- KLDN- -VP s- -EAIVRKMKG- YWQSLLRAGAISKQKFDNLTKA- -ERGGLTQ 909
WP 004232481 849 I PQAFIKDNSIDNRVLTSSAKNRG- KSDD- -VP s- -IEIVRNRKS- YWYKLYKSGLISKRKFDNLTKA- -ERGGLTE 917
WP 009854540 850 I PQAFIKDDSIDNRVLTSSAKNRG- KSDD- -VP s- -LDIVRARKA- EWVRLYKSGLISKRKFDNLTKA- -ERGGLTE 918
WP 012962174 850 I PQAFIKDDSIDNRVLTSSAKNRG- KSDD- -VP s- -LDIVHDRKA- DWIRLYKSGLISKRKFDNLTKA- -ERGGLTE 918
WP 039695303 852 I PQAFIKDDSIDNRVLTSSAKNRG- KSDD- -VP s- -LDIVRARKA- EWVRLYKSGLISKRKFDNLTKA- -ERGGLTE 920
WP 014334983 849 I PQAFIKDNSIDNKVLTSSAKNRG- KSDD- -VP s- -IEIVRNRRS- YWYKLYKSGLISKRKFDNLTKA- -ERGGLTE 917
WP 003099269 842 I PQSFIKDNSIDNTVLTTQASNRG- KSDN- -VP N- -IETVNKMKS- FWYKQLKSGAISQRKFDHLTKA- -ERGALSD 910
AHY15608 842 I PQSFIKDNSIDNTVLTTQASNRG- KSDN- -VP N- -IETVNKMKS- FWYKQLKSGAISQRKFDHLTKA- -ERGALSD 910
AHY17476 842 I PQSFIKDNSIDNTVLTTQASNRG- KSDN- -VP N- -IETVNKMKS- FWYKQLKSGAISQRKFDHLTKA- -ERGALSD 910
ESR09100
AGM98575 842 I PQSFIKDNSIDNTVLTTQASNRG- KSDN- -VP N- -IETVNKMKS- FWYKQLKSGAISQRKFDHLTKA- -ERGALSD 910
ALF27331 842 I PQAFIKDNSIDNRVLTSSKENRG- KSDD- -VP s- -KDWRKMKS- YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP 018372492 858 VPRSYIKNDSFDNKVLTTSKGNRK- KLDD- -VP A- -KEWEKMEN- TWRRLHAAGLISDIKLSYLMKGe LTE 923
WP 045618028 845 I PQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -LEIVQKRKA- FWQQLLDSKLISERKFNNLTKA- -ERGGLDE 913
WP 045635197 844 I PQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -IEWQKRKA- FWQQLLDSKLISERKFNNLTKA- -ERGGLDE 912
WP 002263549 842 I PQAFIKDNSIDNRVLTSSKENRG- KSDD- -VP s- -KDWRKMKS- YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP 002263887 842 I PQAFIKDNSIDNRVLTSSKENRG- KSDD- -VP s- -KDWRKMKS- YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP 002264920 842 I PQAFIKDNSIDNRVLTSSKENRG- KSDD- -VP s- -KDWRKMKS- YWSKLLSAKLITQRKFDNLTKG- -ERGGLTD 910
WP 002269043 842 I PQAFIKDNSIDNRVLTSSKENRG- KSDD- -VP s- -KDWRKMKS- YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP 002269448 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP s--EDWRKMKS--YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910
WP "002271977 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002272766 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKP- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002273241 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002275430 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKP- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002276448 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002277050 847 IPQAFIKDNSIDNRVLTSS KANRG- KSDD- -VP s- -EDWNRMRP- -FWNKLLSSGLISQRKYNNLTKK- -E LTP 912
WP "002277364 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KNWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002279025 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKP- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002279859 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKG- -ERGGLTD 910
WP "002280230 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002281696 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KNWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002282247 847 IPQAFIKDNSIDNRVLTSS KANRG- KSDD- -VP s- -EDWNRMRP- -FWNKLLSSGLISQRKYNNLTKK- -E LTL 912
WP "002282906 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002283846 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KNWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002287255 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KNWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002288990 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002289641 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002290427 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKG- -ERGGLTD 910
WP "002295753 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002296423 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KNWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002304487 856 IPQAFIKDNSIDNRVLTRS DKNRG- KSDD- -VP s- -EEWHKMKP- -FWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 924
WP "002305844 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002307203 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "002310390 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKG- -ERGGLTD 910
WP "002352408 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "012997688 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KNWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "014677909 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "019312892 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KNWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "019313659 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "019314093 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "019315370 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKP- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "019803776 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "019805234 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKG- -ERGGLTD 910
WP "024783594 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "024784288 847 IPQAFIKDNSIDNRVLTSS KANRG- KSDD- -VP s- -EDWNRMRP- -FWNKLLSSGLISQRKYNNLTKK- -E LTL 912
WP "024784666 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KNWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "024784894 842 IPQAFIKDNSIDNRVLTSS KENRG- KSDD- -VP s- -KDWRKMKS- -YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
WP "024786433 847 IPQAFIKDNSIDNRVLTSS KANRG- KSDD- -VP s- -EDWNRMRP- -FWNKLLSSGLISQRKYNNLTKK- -E LTL 912
WP 049473442 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP s--KDWRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910
WP 049474547 842 IPQAFIKDNSIDNRVLTSSKENRG- KSDD- -VP s- -KDWRKMKS- YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 910
EMC03581 835 IPQAFIKDNSIDNRVLTSSKENRG- KSDD- -VP s- -KNWRKMKS- YWSKLLSAKLITQRKFDNLTKA- -ERGGLTD 903
WP 000428612 847 VPQAFIKDDSLDNRVLTSLKDNRG- KSDN- -VP s- -LEWEKMKT- FWQQLLDSKLISYRKFNNLTKA- -ERGGLDE 915
WP 000428613 845 VPQAFIKDDSLDNRVLTSLKDNRG- KSDN- -VP s- -IEWQKRKA- FWQQLLDSKLISERKFNNLTKA- -ERGGLDE 913
WP 049523028 840 IPQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -LEIVEKMKG- FWQQLLDSKLISERKFNNLTKA- -ERGGLDE 908
WP 003107102 811 IPQSFIKDNSIDNIVLTSQESNRG- KSDN- -VP Y- -IAIVNKMKS- YWQHQLKSGAISQRKFDNLTKA- -ERGGLSE 879
WP 054279288 843 IPRSFIKDDSIDNKVLTRSEHNRG- KTDN- -VP s- -IEWKRMKP- YWQKLLDTKVISQRKFDNLTKA- -ERGGLQE 911
WP 049531101 845 IPQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -LEWQKRKA- FWQQLLESKLISERKFNNLTKA- -ERGGLNE 913
WP 049538452 845 IPQAFIKDDSLDNRVLTSSKENRG- KSDN- -VP c- -LEWDKMKV- FWQQLLDFKLISYRKFNNLTKA- -ERGGLDE 913
WP 049549711 845 IPQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -LEWQKRKA- FWQQLLDSKLISERKFNNLTKAerERDGLNE 915
WP 007896501 847 IPQSFIKDNSIDNLVLTTQKANRG- KSDN- -VP s- -IEWRDMKDrVWRRQLANGAISRQKFDHLTKA- -ERGGLAD 916
EFR44625 799 IPQSFIKDNSIDNLVLTTQKANRG- KSDN- -VP s- -IEWRDMKDrVWRRQLANGAISRQKFDHLTKA- -ERGGLAD 868
WP 002897477 844 IPQAFIKDDSIDNRVLTSSKDNRG- KSDN- -VP s- -LEWQKRKA- FWQQLLDSKLISERKFNNLTKA- -ERGGLDE 912
WP 002906454 844 IPQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -IEWQKRKA- FWQQLLDSKLISERKFNNLTKA- -KRGGLDE 912
WP 009729476 845 IPQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -LEWDKMKV- FWQQLLDSKLISYRKFNNLTKA- -ERGGLNE 913
CQR24647 844 IPQSFIKDNSLDNRVLTNSKSNRG- KSDN- -VP s- -NEWKRMKG- FWLKQLDAKLISQRKFDNLTKA- -ERGGLSA 912
WP 000066813 847 IPQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -LEWEKMKA- FWQQLLDSKLISERKFNNLTKAerERGGLNE 917
WP 009754323 845 IPQAFIKDDSLDNRVLTSSKDNRG- KSDN- -VP s- -LEWKKRKA- FWQQLLDSKLISERKFNNLTKA- -ERGGLDE 913
WP 044674937 844 IPQAFIKDDSLDNKVLTKSAKNRG- KSDD- -VP s- -LEIVHKKKN- FWKQLLDSQLISQRKFDNLTKA- -ERGGLTN 912
WP 044676715 846 IPQAFIKDDSLDNKVLTKSAKNRG- KSDD- -VP s- -LEIVHKKKN- FWKQLLDSQLISQRKFDNLTKA- -ERGGLTN 914
WP 044680361 846 IPQAFIKDDSLDNKVLTKSAKNRG- KSDD- -VP s- -LEIVHKKKN- FWKQLLDSQLISQRKFDNLTKA- -ERGGLTN 914
WP 044681799 844 IPQAFIKDDSLDNKVLTKSAKNRG- KSDD- -VP s- -LEIVHKKKN- FWKQLLDSQLISQRKFDNLTKA- -ERGGLTN 912
WP 049533112 841 IPQAFIKDDSFDNRVLTSSSENRG- KSDN- -VP s- -1EWRARKA- DWMRLRKAGLISQRKFDNLTKA- -ERGGLTE 909
WP 029090905 824 LPQSYIKDNSIENLALVKKVENQR- KKDS11LN s- —SIINQNYS- RWEQLKNAGLIGEKKFRNLTRTk ITD 890
WP 006506696 850 VPQSLVKDDSFDNRVLWPSENQR- KLDDlvVP — -FDIRDKMYR- FWKLLFDHELISPKKFYSLIKTe YTE 916
AIT42264 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP 034440723 849 IPRSFITDNSFDNLVLTSSTVNRG- KLDN- -VP Sp —DIVRQQKG- FWKQLLRAGLMSQRKFNNLTKGk LTD 914
AKQ21048 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
WP 004636532 846 IPQSFTTDNSIDNKVLVSRTKNQGnKSDD- -VP s- -INIVHKMKP- FWRQLHKAGLISDRKFKNLTKA- -EHGGLTE 915
WP 002364836 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKDMKA- YWEKLYAAGLISQRKFQRLTKG- -EQGGLTL 921
WP 016631044 804 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKDMKA- YWEKLYAAGLISQRKFQRLTKG- -EQGGLTL 872
EMS75795 589 IPRSFIVDNSIDNKVLVSSKENRL- KMDD- -VP D- -QKWIRMRR- YWEKLLRANLISERKFAYLTKLe LTP 654
WP 002373311 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KKWKKMKA- YWEKLYAAGLISQRKFQRLTKG- -EQGGLTL 921
WP 002378009 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKDMKA- YWEKLYAAGLISQRKFQRLTKG- -EQGGLTL 921
WP 002407324 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKDMKA- YWEKLYAAGLISQRKFQRLTKG- -EQGGLTL 921
WP 002413717 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKDMKA- YWEKLYAAGLISQRKFQRLTKG- -EQGGLTL 921
WP 010775580 855 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKKMKA- YWEKLYAAGLISQRKFQRLTKG- -EQGGLTL 923
WP 010818269 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKDMKA- YWEKLYAAGLISQRKFQRLTKG- -EQGGLTL 921
WP 010824395 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP s--KEWKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921
WP "016622645 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKDMKA- YWEKLYAAGLISQRKFQRLTKG-- EQGGLTL 921
WP "033624816 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKKMKA- YWEKLYAAGLISQRKFQRLTKG-- EQGGLTL 921
WP "033625576 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKKMKA- YWEKLYAAGLISQRKFQRLTKG-- EQGGLTL 921
WP "033789179 853 IPQSFMKDDSLDNLVLVGSTENRG- KSDD- -VP s- -KEWKKMKA- YWEKLYAAGLISQRKFQRLTKG-- EQGGLTL 921
WP "002310644 853 IPRSFTTDNSIDNKVLVSSKENRL- KKDD- -VP s- -EKWKKMRS- FWYDLYSSKLISKRKLDNLTKIk- LTE 918
WP "002312694 854 IPRSFTTDNSIDNKVLVSSKENRL- KKDD- -VP s- -EKWKKMRS- FWYDLYSSKLISKRKLDNLTKIk- LTE 919
WP "002314015 854 IPRSFTTDNSIDNKVLVSSKENRL- KKDD- -VP s- -EKWKKMRS- FWYDLYSSKLISKRKLDNLTKIk- LTE 919
WP "002320716 854 IPRSFTTDNSIDNKVLVSSKENRL- KKDD- -VP s- -EKWKKMRS- FWYDLYSSKLISKRKLDNLTKIk- LTE 919
WP "002330729 853 IPRSFTTDNSIDNKVLVSSKENRL- KKDD- -VP s- -EKWKKMRS- FWYDLYSSKLISKRKLDNLTKIk- LTE 918
WP "002335161 854 IPRSFTTDNSIDNKVLVSSKENRL- KKDD- -VP s- -EKWKKMRS- FWYDLYSSKLISKRKLDNLTKIk- LTE 919
WP "002345439 854 IPRSFTTDNSIDNKVLVSSKENRL- KKDD- -VP s- -EKWKKMRS- FWYDLYSSKLISKRKLDNLTKIk- LTE 919
WP "034867970 845 IPRSFIVDNSIDDKVLVASKQNQK- KRDD- -VP K- -KQIVNEQRI- FWNQLKEAKLISTKKYAYLTKIe- LTP 910
WP "047937432 854 IPRSFTTDNSIDNKVLVSSKENRL- KKDD- -VP s- -EKWKKMRS- FWYDLYSSKLISKRKLDNLTKIk- LTE 919
WP "010720994 845 IPRSFIVDNSIDNKVLVASKQNQK- KRDD- -VP K- -KQIVNEQRI- FWNQLKEAKLISPKKYAYLTKIe- LTP 910
WP "010737004 845 IPRSFIVDNSIDNKVLVASKQNQK- KRDD- -VP K- -KQIVNEQRI- FWNQLKEAKLISPKKYAYLTKIe- LTP 910
WP "034700478 845 IPRSFIVDNSIDNKVLVASKQNQK- KRDD- -VP N- -KQIVNEQRI- FWNQLKEAKLISPKKYAYLTKIe- LTP 910
WP "007209003 846 IPQSFLTDNSIDNRVLTTSKSNRG- KSDN- -VP s- -EEWRKMDR- FWRKLLNAKLISERKYTNLTKKe- LTE 911
WP "023519017 839 IPRSFIVDNSLDNKVLVSSKVNRG- KLDN- -AP D- -PLWKRMRS- HWEKLHQAKLISDKKLANLTKQn- LTE 904
WP "010770040 846 VPQSFTTDNSLDNRVLVSSKENRG- KKDD- -VP s- -KEWQKNIT- LWETLKNSNLISQKKYDNLTKG-- LRGGLTE 914
WP "048604708 843 I PQSFIVDNSLDNRVLVSSSKNRG- KLDD- -VP s- -KEWKKMRA- FWESLYRSGLISKKKFDNLVKA-- ESGGLSE 911
WP "010750235 848 IPRSFIVDHSLDNKVLVSSKENRL- KKDD- -VP D- -SKWKRMKA- YWEKLLRANLISERKFSYLTKLe- LTD 913
AII16583 881 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA-- ERGGLSE 949
WP 029073316 861 VPQSLLKDDSIDNKVLVLSSENQR- KLDDlvIP — -EMIRNKMFG- FWNKLYENKIISPKKFYSLIKSe- YSD 927
WP "031589969 861 VPQSLLKDDSIDNKVLVLSSENQR- KLDDlvIP — -SSIRNKMYG- FWEKLFNNKIISPKKFYSLIKTe- FNE 927
KDA45870 834 IPQSFLKDDSIENKVLTIKKENVR- KTNG- -LP s- -EAVIQKMGS- FWKKLLDAGAMTNKKYDNLRRNl- -HGGLNE 902
WP 039099354 857 LPQSFIKDNSLDNRVLVSQRMNRS- KADQ- -VP s- -VELGQKMQI- QWEQMLRAGLITKKKYDNLTLNp- 923
AKP02966 859 LPRTYIPDDSLENKALVLAKENQR- KADD11LN s- —NVIDKNLE- RWTYMLNNNMMGLKKFKNLTRRv- ITD 925
WP 010991369 845 VPQSFITDNSIDNLVLTSSAGNRE- KGDD- -VP P- -LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA-- ERGGLTE 913
WP "033838504 845 VPQSFITDNSIDNLVLTSSAGNRE- KGDD- -VP P- -LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA-- ERGGLTE 913
EHN60060 848 VPQSFITDNSIDNLVLTSSAGNRE- KGDD- -VP P- -LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA-- ERGGLTE 916
EFR89594 614 VPQSFITDNSIDNLVLTSSAGNRE- KGND- -VP P- -LEIVQKRKV- FWEKLYQGNLMSKRKFDYLTKA-- ERGGLTE 682
WP 038409211 845 IPQSFITDNSIDNRVLVSSTANRE- KGDN- -VP L- -LEWRKRKA- FWEKLYQAKLMSKRKFDYLTKA-- ERGGLTE 913
EFR95520 464 IPQSFITDNSIDNRVLVSSTANRE- KGDN- -VP L- -LEWRKRKA- FWEKLYQAKLMSKRKFDYLTKA-- ERGGLTE 532
WP 003723650 845 VPQSFITDNSIDNLVLTSSAGNRE- KGGD- -VP P- -LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA-- ERGGLTE 913
WP "003727705 845 VPQSFITDNSIDNLVLTSSAGNRE- KGGD- -VP P- -LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA-- ERGGLTE 913
WP "003730785 845 VPQSFITDNSIDNLVLTSSAGNRE- KGGD- -VP P- -LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA-- ERGGLTE 913
WP "003733029 845 VPQSFITDNSVDNLVLTSSAGNRE- KGDN- -VP P- -LEIVQKRKI- FWEKLYQGNLMSKRKFDYLTKA-- ERGGLTE 913
WP "003739838 845 VPQSFITDNSIDNLVLTSSAGNRE- KGDD- -VP P- -LEIVRKRKV- FWEKLFQGNLMSKRKFDYLTKA-- ERGGLTE 913
WP 014601172 845 VPQSFITDNSIDNLVLTSSAGNRE- KGGD--VP P--LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA--ERGGLTD 913
WP 023548323 845 VPQSFITDNSIDNLVLTSSAGNRE- KGDN- -VP P- -LEIVQKRKI- FWEKLYQGNLMSKRKFDYLTKA- -ERGGLTE 913
WP 031665337 845 VPQSFITDNSIDNLVLTSSAGNRE- KGGD- -VP P- -LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA- -ERGGLTE 913
WP 031669209 845 VPQSFITDNSVDNLVLTSSAGNRE- KGDN- -VP P- -LEIVQKRKI- FWEKLYQGNLMSKRKFDYLTKA- -ERGGLTE 913
WP 033920898 845 VPQSFITDNSIDNLVLTSSAGNRE- KGDN- -VP P- -LEIVQKRKI- FWEKLYQGNLMSKRKFDYLTKA- -ERGGLTE 913
AKI42028 848 VPQSFITDNSIDNLVLTSSAGNRE- KGGD- -VP P- -LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA- -ERGGLTD 916
AKI50529 848 VPQSFITDNSIDNLVLTSSAGNRE- KGDN- -VP P- -LEIVQKRKI- FWEKLYQGNLMSKRKFDYLTKA- -ERGGLTE 916
EFR83390 293 VPQSFITDNSIDNLVLTSSAGNRE- KGDD- -VP P- -LEIVRKRKV- FWEKLYQGNLMSKRKFDYLTKA- -ERGGLTE 361
WP 046323366 845 VPQSFITDNSIDNRVLASSAANRE- KGDN- -VP s- -LEWRKRKV- YWEKLYQAKLMSKRKFDYLTKA- -ERGGLTE 913
AKE81011 858 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 926
CU082355 854 VPQSLVKDDSFDNRVLVLPSENQR- KLDDlvVP — -FDIRDKMYR- FWKLLFDHELISPKKFYSLIKTe YTE 920
WP 033162887 856 LPQSLIKDDSFDNRVLVLPEENQW- KLDSetVP — -FEIRNKMIG- FWQMLHENGLMSNKKFFSLIRTd FSD 922
AGZ 01981 875 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 943
AKA60242 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
AKS40380 842 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 910
4UN5 B 846 VPQSFLKDDSIDNKVLTRSDKNRG- KSDN- -VP s- -EEWKKMKN- YWRQLLNAKLITQRKFDNLTKA- -ERGGLSE 914
WP 010922251 911 |LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY| 981
WP "039695303 921 AD KAGFIKRQLVETRQITKHVAQILDARFNTEHDENDKVIR- -DVKVITLKSNLVSQFRKDF EFYKVREINDY 9 91
WP "045635197 913 RD KVGFIKRQLVETRQITKHVAQILDARYNTEVNEKDKKNR- -TVKIITLKSNLVSNFRKEF RLYKVREINDY 9 83
5AXW A 633 RD QKDFINRNLVDTRYATRGLMNLLRSYFR nlDVKVKSINGGFTSFLRRKW KFKKERNKGYK 7 02
WP 009880683 595 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVRVITLKSKLVSDFRKDF QFYKVREINNY 6 65
WP "010922251 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "011054416 911 LD KVGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVRVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "011284745 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "011285506 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "011527619 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "012560673 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVRVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "014407541 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "020905136 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "023080005 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "023610282 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "030125963 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "030126706 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "031488318 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "032460140 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVRVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "032461047 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVRVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "032462016 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "032462936 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVRVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "032464890 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "033888930 736 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 8 06
WP "038431314 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP "038432938 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "038434062 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
BAQ51233 822 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 8 92
KGE60162 86 LD KVGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVRVITLKSKLVSDFRKDF QFYKVREINNY 1 56 KGE60856
WP 002989955 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP 003030002 910 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGNKRRIR- -NVKIITLKSNLVSNFRKEF ELYKVREINDY 9 80
WP "003065552 921 AD KAGFIKRQLVETRQITKHVAQILDARFNTESDENDKVIR- -DVKVITLKSNLVSQFRKDF EFYKVREINDY 9 91
WP "001040076 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF VFYKIREVNNY 9 86
WP "001040078 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9 86
WP "001040080 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9 86
WP "001040081 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9 86
WP "001040083 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9 86
WP "001040085 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9 86
WP 001040087 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E36
WP 001040088 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040089 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040090 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040091 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040092 916 DD KAGFIQRQLVETRQITKHVARILDERFNNKVDDNNKPIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040094 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040095 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040096 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040097 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040098 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040099 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040100 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040104 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040105 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 001040106 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9E 36
WP 001040107 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9E 36
WP 001040108 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9E 36
WP 001040109 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9E 36
WP 001040110 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9E 36
WP 015058523 916 DD KAGFIQRQLVETRQITKHVARILDERFNNKVDDNNKPIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 017643650 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 017647151 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 017648376 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 017649527 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 017771611 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9E 36
WP 017771984 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
CFQ25032 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
CFV16040 916 DD KARFIQRQLVEIRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
KLJ37842 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTVKSNLVSNFRKEF GFYKIREVNNY 9E 36
KLJ72361 916 DD KARFIQRQLVETRQITKHVARILDELFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
KLL20707 930 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 1000
KLL42645 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9E 36
WP 047207273 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 047209694 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 050198062 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 050201642 916 DD KARFIQRQLVETRQITKHVASILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 050204027 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9E 36
WP 050881965 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9E 36
WP 050886065 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986
AHN30376 916 DD KAGFIQRQLVETRQITKHVARILDERFNNKVDDNNKPIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9 86
EA078426 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 9 86
CCW42055 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR- -KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 9 86
WP 003041502 910 ND KAGFIKRQLVETRQITKHVAQVLDARFNAKHDENKKVIR- -DVKIITLKSNLVSQFRKDF KFYKVREINDY 9 80
WP "037593752 911 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGAQRRIR- -NVKIITLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "049516684 911 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGAQRRIR- -NVKIITLKSNLVSNFRKEF ELYKVREINDY 9 81
GAD46167 910 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGAQRRIR- -NVKIITLKSNLVSNFRKEF ELYKVREINDY 9 80
WP 018363470 919 AD KAGFIKRQLVETRQITKHVAQILDARFNTERDENDKVIR- -DVKVITLKSNLVSQFRKEF KFYKVREINDY 9 89
WP "003043819 920 AD KAGFIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIR- -EVKVITLKSKLVSDFRKDF QLYKVRDINNY 9 90
WP "006269658 910 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGNKRRIR- -NVKIITLKSNLVSNFRKEF ELYKVREINDY 9 80
WP "048800889 910 ND KAGFIHRQLVETRQITKHVAQILDARFNPKRDDNKKVIR- -DVKIITLKSNLVSQFRRDF KLYKVREINDY 9 80
WP "012767106 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "014612333 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "015017095 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "015057649 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "048327215 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "049519324 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 80
WP "012515931 910 VD KAGFIQRQLVETRQITKHVAQILDSRFNTEFDDHNKRIR- -KVHIITLKSKLVSDFRKEF GLYKIRDINHY 9 80
WP "021320964 910 VD KAGFIQRQLVETRQITKHVAQILDSRFNTEFDDHNKRIR- -KVHIITLKSKLVSDFRKEF GLYKIRDINHY 9 80
WP "037581760 910 VD KAGFIQLQLVETRQITKHVAQILDSRFNTEFDDHNKRIR- -KVHIITLKSKLVSDFRKEF GLYKIRDINHY 9 80
WP "004232481 918 TD KAGFIKRQLVETRQITKHVAQILDARFNTKCDENDKVIR- -DVKVITLKSSLVSQFRKEF KFYKVREINDY 9 88
WP "009854540 919 AD KAGFIKRQLVETRQITKHVAQILDARFNTEHDENDKVIR- -DVKVITLKSNLVSQFRKDF EFYKVREINDY 9 89
WP "012962174 919 ND KAGFIKRQLVETRQITKHVAQILDSRFNTERDENDKVIR- -NVKVITLKSNLVSQFRKDF KFYKVREINDY 9 89
WP "039695303 921 AD KAGFIKRQLVETRQITKHVAQILDARFNTEHDENDKVIR- -DVKVITLKSNLVSQFRKDF EFYKVREINDY 9 91
WP "014334983 918 AD KAGFIKRQLVETRQITKHVAQILDARFNTKRDENDKVIR- -DVKVITLKSNLVSQFRKEF KFYKVREINDY 9 88
WP "003099269 911 FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR- -NVKIITLKSKMVSDFRKDF GFYKLREVNDY 9 81
AHY15608 911 FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR- -NVKIITLKSKMVSDFRKDF GFYKLREVNDY 9 81
AHY17476 911 FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR- -NVKIITLKSKMVSDFRKDF GFYKLREVNDY 9 81
ESR09100
AGM98575 911 FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR- -NVKIITLKSKMVSDFRKDF GFYKLREVNDY 9 81
ALF27331 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP 018372492 924 ED KAGFIRRQLVETRQITKHVARLLDEKLNRKKNENGEKLR- -TTKIITLKSVFASRFRANF DLYKLRELNHY 9 94
WP "045618028 914 RD KVGFIKRQLVETRQITKHVAQILDARFNTEVTEKDKKDR- -SVKIITLKSNLVSNFRKEF RLYKVREINDY 9 84
WP "045635197 913 RD KVGFIKRQLVETRQITKHVAQILDARYNTEVNEKDKKNR- -TVKIITLKSNLVSNFRKEF RLYKVREINDY 9 83
WP "002263549 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "002263887 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "002264920 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "002269043 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP 002269448 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981
WP "0022 71977 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 72766 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 73241 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 75430 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 76448 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 77050 913 DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR- -RVKIVTLKSNLVSSFRKEF ELYKVREINDY 9 83
WP "0022 77364 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 79025 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 79859 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 80230 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 81696 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 82247 913 DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR- -RVKIVTLKSNLVSSFRKEF ELYKVREINDY 9 83
WP "0022 82906 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 83846 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 87255 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 88990 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 89641 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 90427 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 95753 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0022 96423 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0023 04487 925 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 95
WP "0023 05844 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0023 07203 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0023 10390 911 DD KAGFIKHQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0023 52408 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0129 97688 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "θ146 77909 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0193 12892 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0193 13659 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0193 14093 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0193 15370 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0198 03776 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0198 05234 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0247 83594 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0247 84288 913 DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR- -RVKIVTLKSNLVSSFRKEF ELYKVREINDY 9 83
WP "0247 84666 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0247 84894 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
WP "0247 86433 913 DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR- -RVKIVTLKSNLVSSFRKEF ELYKVREINDY 9 83
WP 049473442 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981
WP "049474547 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 81
EMC03581 904 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR- -QVKIVTLKSNLVSNFRKEF ELYKVREINDY 9 74
WP 000428612 916 RD KVGFIKRQLVETRQITKHVAQILDARYNTEVNEKDKKNR- -TVKIITLKSNLVSNFRKEF RLYKIREINDY 9 86
WP "000428613 914 RD KVGFIKRQLVETRQITKHVAQILDARFNKEVNEKDKKNR- -TVKIITLKSNLVSNFRKEF RLYKVREINDY 9 84
WP "049523028 909 RD KVGFIKRQLVETRQITKHVAQILDDRFNAEVNEKNQKLR- -SVKIITLKSNLVSNFRKEF GLYKVREINDY 9 79
WP "003107102 880 YD KAGFIKRQLVETRQITKHVAQILNNRFNNNVDDSSKNKR- -PVKIITLKSKMVSDFRKEF GFYKIREVNDY 9 50
WP "054279288 912 SD KANFIQRQLVETRQITKHVAQILDSRFNTERDEKDRPIR- -RVKVITLKSKFVSDFRQDF GFYKLREINDY 9 82
WP "049531101 914 RD KVGFIKRQLVETRQITKHVAQILDSRFNTKVNEKNQKIR- -TVKIITLKSNLVSNFRKEF RLYKVREINDY 9 84
WP "049538452 914 RD KVGFIRRQLVETRQITKHVAQILDSRFNTEVTEKDKKNR- -NVKIITLKSNLVSNFRKEF GLYKVREINDY 9 84
WP "049549711 916 LD KVGFIKRQLVETRQITKHVAQILDARFNKEVTEKDKKNR- -NVKIITLKSNLVSNFRKEF RLYKVREINDY 9 86
WP "007896501 917 SD KARFLRRQLVETRQITKHVAQLLDSRFNSKSNQNKKLAR- -NVKIITLKSKIVSDFRKDF GLYKLREVNNY 9 87
EFR44625 869 SD KARFLRRQLVETRQITKHVAQLLDSRFNSKSNQNKKLAR- -NVKIITLKSKIVSDFRKDF GLYKLREVNNY 9 39
WP 002897477 913 RD KVGFIRRQLVETQQITKNVAQILDARFNTEVKEKNQKIR- -TVKIITLKSNLVSNFRKEF GLYKVREINNY 9 83
WP "002906454 913 RD KVGFIKRQLVETRQITKHVAQLLDTRFNTEVNEENQKIR- -TVKIITLKSNLVSNFRKEF GLYKVREINDY 9 83
WP "009729476 914 LD KVGFIKRQLVETRQITKHVAQILDARFNKEVTEKDKKNR- -TVKIITLKSNLVSNFRKEF ELYKVREINDY 9 84
CQR24647 913 ED KAGFIKRQLVETRQITKHVARILDERFNRDFDKNDKRIR- -NVKIVTLKSNLVSNFRKEF GFYKVREINNF 9 83
WP 000066813 918 LD KVGFIKRQLVETRQITKHVAQFLDARFNKEVTEKDKKNR- -NVKIITLKSNLVSNFRKEF GLYKVREINDY 9 88
WP "009754323 914 RD KVGFIKRQLVETRQITKHVARILDARFNTEVSEKNQKIR- -SVKIITLKSNLVSNFRKEF KLYKVREINDY 9 84
WP "044674937 913 ED KARFIQRQLVETRQITKHVARILDTRFNTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY 9 85
WP "044676715 915 ED KARFIQRQLVETRQITKHVARILDTRFNTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY 9 87
WP "044680361 915 ED KARFIQRQLVETRQITKHVARILDTRFNTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY 9 87
WP "044681799 913 ED KARFIQRQLVETRQITKHVARILDTRFNTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY 9 85
WP "049533112 910 ND KAGFIKRQLVETRQITKHVAQVLDARFNAKHDENKKVIR- -DVKIITLKSNLVSQFRKDF KFYKVREINDY 9 80
WP "029090905 891 RD KEGFIARQLVETRQITKHVTQLLQQEY K-dTTKVFAIKATLVSGLRRKF EFIKNRNVNDY 9 51
WP "006506696 917 RD EERFINRQLVETRQITKNVTQIIEDHYST —TKVAAIRANLSHEFRVKN HIYKNRDINDY 9 76
AIT42264 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP 034440723 915 RD RQQFINRQLVETRQITKHVANLLSHHLNEK KEVG- -EINIVLLKSALTSQFRKKF DFYKVREVNDY 9 80
AKQ21048 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9 81
WP 004636532 916 AD RAHFLNRQLVETRQITKHVANLLDSQYNTAEEQ R- —INIVLLKSSMTSRFRKEF KLYKVREINDY 9 80
WP "002364836 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNANSKE K- -KVQIITLKASLTSQFRSIF GLYKVREVNDY 9 87
WP "016631044 873 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K- -KVQIITLKASLTSQFRSIF GLYKVREVNDY 9 38
EMS75795 655 ED KARFIQRQLVETRQITKHVAAILDQYFN-QPEE-SK-NK- -GIRIITLKSSLVSQFRKTF GINKVREINNH 7 22
WP 002373311 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K- -KVQIITLKASLTSQFRSIF GLYKVREVNDY 9 87
WP "002378009 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K- -KVQIITLKASLTSQFRSIF GLYKVREVNDY 9 87
WP "002407324 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K- -KVQIITLKASLTSQFRSIF GLYKVREVNDY 9 87
WP "002413717 922 ED KAHFIQRQLVETRQITKNVAGILNQRYNANSKE K- -KVQIITLKASLTSQFRSIF GLYKVREVNDY 9 87
WP "010775580 924 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K- -KVQIITLKASLTSQFRSIF GLYKVREVNDY 9 89
WP "010818269 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K- -KVQIITLKASLTSQFRSIF GLYKVREVNDY 9 87
WP 010824395 922 ED KAHFIQRQLVETRQITKNVAGILDQLYNAKSKE K—KVQIITLKASLTSQFRSIF GLYKVREVNDY 987
WP 016622645 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K—KVQIITLKASLTSQFRSIF GLYKVREVNDY 987
WP 033624816 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K—KVQIITLKASLTSQFRSIF GLYKVREVNDY 987
WP 033625576 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K—KVQIITLKASLTSQFRSIF GLYKVREVNDY 987
WP 033789179 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE K—KVQIITLKASLTSQFRSIF GLYKVREVNDY 987
WP 002310644 919 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR—KVRI ITLKSALVSQFRNRF GIYKVREINEY 988
WP 002312694 920 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNDPIR—KVRI ITLKSALVSQFRNRF GIYKVREINEY 989
WP 002314015 920 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR—KVRI ITLKSALVSQFRNRF GIYKVREINEY 989
WP 002320716 920 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR—KVRI ITLKSALVSQFRNRF GIYKVREINEY 989
WP 002330729 919 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR—KVRI ITLKSALVSQFRNRF GIYKVREINEY 988
WP 002335161 920 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR—KVRI ITLKSALVSQFRNRF GIYKVREINEY 989
WP 002345439 920 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR—KVRI ITLKSALVSQFRNRF GIYKVREINEY 989
WP 034867970 911 ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD—GVQI ITLKATLTSQFRQTF GLYKVREINPH 979
WP 047937432 920 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR—KVRI ITLKSALVSQFRNRF GIYKVREINEY 989
WP 010720994 911 ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD—GVQI ITLKATLTSQFRQTF GLYKVREINPH 979
WP 010737004 911 ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD—GVQI ITLKATLTSQFRQTF GLYKVREINPH 979
WP 034700478 911 ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD—GVQI ITLKATLTSQFRQTF GLYKVREINPH 979
WP 007209003 912 SD KAGFLKRQLVETRQITKHVATILDSKFNE—DSNNRDVQ I ITLKSALVSEFRKTF NLYKVREINDL 977
WP 023519017 905 AD KARFIQRQLVETRQITKHVANLLHQHFN-LPEEVSA-TE—KTSIITLKSTLTSQFRQMF DIYKVREINHH 973
WP 010770040 915 DD RAHFIKRQLVETRQITKHVARILDQRFNSQKDEEGKTIR—AVRWTLKSSLTSQFRKQF AIHKVREINDY 985
WP 048604708 912 DD KAGFIHRQLVETRQITKNVARILHQRFNSEKDEEGNLIR—KVRI ITLKSALTSQFRKNY GIYKIREINDY 982
WP 010750235 914 DD KARFIQRQLVETRQITKHVAAILHQYFN-QTQELEK-EK—DIRIITLKSSLVSQFRQVF GIHKVREINHH 982
AII16583 950 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR—EVKVITLKSKLVSDFRKDF QFYKVREINNY 1020
WP 029073316 928 KD KERFINRQIVETRQITKHVAQI I SNHYET TKWTVRADLSHAFRERY HIYKNRDINDF 987
WP 031589969 928 KD QERFINRQIVETRQITKHVAQIIDNHYEN TKWTVRADLSHQFRERY HIYKNRDINDF 987
KDA45870 903 KL KERFIERQLVETRQITKYVAQLLDQRLN—YDGNGVELD-eKIAIVTLKAQLASQFRSEF KLRKVRALNNL 972
WP 039099354 924 -D MKGFINRQLVETRQVIKLATNLLMEQYGED NIELITVKSGLTHQMRTEF DFPKNRNLNNH 990
AKP02966 926 KD KLGFIHRQLVQTSQMVKGVANILNSMYK NQGTTCIQ ARANLSTAFRKAL ELVKNRNINDF 999
WP 010991369 914 AD KARFIHRQLVETRQITKNVANILHQRFNYEKDDHGNTMK—QVRIVTLKSALVSQFRKQF QLYKVRDVNDY 984
WP 033838504 914 AD KARFIHRQLVETRQITKNVANILHQRFNYEKDDHGNTMK—QVRIVTLKSALVSQFRKQF QLYKVRDVNDY 984
EHN60060 917 AD KARFIHRQLVETRQITKNVANILHQRFNYEKDDHGNTMK—QVRIVTLKSALVSQFRKQF QLYKVRDVNDY 987
EFR89594 683 AD KARFIHRQLVETRQITKNVANILHQRFNYGKDDHGNTMK—QVRIVTLKSALVSQFRKQF QLYKVRGVNDY 753
WP 038409211 914 AD KANFIQRQLVETRQITKNVANILYQRFNCKQDENGNEVE—QVRIVTLKSTLVSQFRKQF QLYKVREVNDY 984
EFR95520 533 AD KANFIQRQLVETRQITKNVANILYQRFNCKQDENGNEVE—QVRIVTLKSTLVSQFRKQF QLYKVREVNDY 603
WP 003723650 914 AD KARFIHRQLVETRQITKNVANILYQRFNKETDNHGNTME—QVRIVTLKSALVSQFRKQF QLYKVREVNGY 984
WP 003727705 914 AD KARFIHRQLVETRQITKNVANILHQRFNKETDNHGNTME—QVRIVTLKSALVSQFRKQF QLYKVREVNDY 984
WP 003730785 914 AD KARFIHRQLVETRQITKNVANILHQRFNKETDNHGNTME—QVRIVTLKSALVSQFRKQF QLYKVREVNDY 984
WP 003733029 914 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDGNKDTME—TVRIVTLKSALVSQFRKQF QFYKVREVNDY 984
WP 003739838 914 AD KATFIHRQLVETRQITKNVANILHQRFNNETDNHGNNME—QVRIVMLKSALVSQFRKQF QLYKVREVNDY 984
WP 014601172 914 AD KARFIHRQLVETRQITKNVANILHQRFNNETDNHGNTME- -QVRIVTLKSALVSQFRKQF QLYKVREVNDY 9En
WP 023548323 914 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDDNEDTME- -PVRIVTLKSALVSQFRKQF QLYKVREVNDY 9En
WP 031665337 914 AD KARFIHRQLVETRQITKNVANILHQRFNKETDNHGNTME- -QVRIVTLKSALVSQFRKQF QLYKVREVNDY 9E
WP 031669209 914 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDGNKDTME- -TVRIVTLKSALVSQFRKQF QFYKVREVNDY 9En
WP 033920898 914 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDDNEDTME- -PVRIVTLKSALVSQFRKQF QLYKVREVNDY 9En
AKI42028 917 AD KARFIHRQLVETRQITKNVANILHQRFNNETDNHGNTME- -QVRIVTLKSALVSQFRKQF QLYKVREVNDY 9E 37
AKI50529 917 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDDNEDTME- -PVRIVTLKSALVSQFRKQF QLYKVREVNDY 9E 37
EFR83390 362 AD KARFIHRQLVETRQITKNVANILHQRFNNETDNHGNTME- -QVRIVTLKSALVSQFRKQF QLYKVREVNDY 432
WP 046323366 914 AD KARFIHRQLVETRQITKNVANILHQRFNCKKDESGNVIE- -QVRIVTLKAALVSQFRKQF QLYKVREVNDY 9E 34
AKE81011 927 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 997
CU082355 921 RD EERFINRQLVETRQITKNVTQIIEDHYST TKVAAIRANLSHEFRVKN HIYKNRDINDY 9E 30
WP 033162887 923 KD KERFINRQLVETRQI IKNVAVI INDHYTN TNIVTVRAELSHQFRERY KIYKNRDINDF 9E 32
AGZ 01981 944 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 1014
AKA60242 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9E 31
AKS40380 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9E 31
4UN5 B 915 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR- -EVKVITLKSKLVSDFRKDF QFYKVREINNY 9E 35
WP 010922251 982 HHAHDAYLNAWGTALIKKYPKL-ESEFVYGDYKVYDV s—-EQEi--GK -F- 1051
WP "039695303 9 92 HHAHDAYLNAWGTALLKKYPKL ASEFVYGEYKKYDI s— -SD -YfFYSNLM- 1058
WP "045635197 9 84 HHAHDAYLNAWAKAILKKYPKL EPEFVYGEYQKYDL SkdpKEV— -EK ATEKY- -F- FYSNLL- -NFFKEEVH 1055
5AXW A 7 03 HHAEDALI 1aNADFIFKEWKKLDK Nq-mFE -EK ETEQEykEi FITPHQiKHIKDFKD 771
WP 009880683 6 66 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDI S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 735
WP "010922251 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "011054416 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "011284745 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "011285506 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "011527619 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "012560673 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDI S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "014407541 9 81 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1050
WP "020905136 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "023080005 9 81 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1050
WP "023610282 9 81 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1050
WP "030125963 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "030126706 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "031488318 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "032460140 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDI S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "032461047 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDI S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "032462016 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "032462936 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "032464890 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "033888930 8 07 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 876
WP "038431314 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "038432938 9 81 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1050
WP "038434062 9 82 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV S— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
BAQ51233 8 93 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV s— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 962
KGE60162 1 57 HHAHDAYLNAWGTALIKKYPKL ESEFVYGDYKVYDV s— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 226
KGE60856
WP 002989955 9 82 HHAHDAYLNAWGTALIKKYPKL- ESEFVYGDYKVYDV s— -EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP "003030002 9 81 HHAHDAYLNAWGNALLLKYPQL- EPEFVYGEYPKYN- s— -YR sRK SATEK- -F1FYSNIL- -RFFKKE— 1041
WP "003065552 9 92 HHAHDAYLNAWGTALLKKYPKL- ASEFVYGEYKKYDI s— -SD KATAK- -YfFYSNLM- -NFFKRVIR 1058
WP "001040076 9 87 HHAHDAYLNAWAKAILTKYPQL- EPEFVYGDYPKYN- s— -YKT— -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP "001040078 9 87 HHAHDAYLNAWAKAILTKYPQL- EPEFVYGLYRRKK- L— -SKI— -VR ATRKM- -F- FYSNLM- -NMFKRWR 1057
WP "001040080 9 87 HHAHDAYLNAWAKAILTKYPQL- EPEFVYGDYPKYN- S— -YKT— -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP "001040081 9 87 HHAHDAYLNAWAKAILTKYPQL- EPEFVYGDYPKYN- S— -YKT— -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP "001040083 9 87 HHAHDAYLNAWAKAILTKYPQL- EPEFVYGDYPKYN- s— -YKT— -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP "001040085 9 87 HHAHDAYLNAWAKAILTKYPQL- EPEFVYGDYPKYN- s— -YKT— -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040087 987 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s---YKT---RK ATEKL--F- FYSNIM--NFFKTKVT 1049
WP_001040088 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040089 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040090 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040091 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040092 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040094 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040095 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040096 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040097 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040098 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040099 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040100 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040104 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040105 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040106 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040107 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040108 9 87 HHAHDAYLNAWAKAILTKYPQL EREFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040109 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_001040110 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_015058523 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_017643650 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_017647151 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_017648376 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_017649527 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_017771611 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_017771984 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
CFQ25032 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
CFV16040 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
KLJ37842 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
KLJ72361 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
KLL20707 1 001 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1063
KLL42645 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_047207273 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_047209694 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_050198062 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_050201642 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP_050204027 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP 050881965 9 87 HHAHDAYLNAWAKAILTKYPQL EPEFVYGDYPKYN- s- - -YKT- - -RK ATEKL- -F- FYSNIM- -NFFKTKVT 1049
WP 050886065 987 HHAHDAYLNAWAKAILTKYPQL--EPEFVYGDYPKYN- s-—YKT—-RK ATEKL--F-FYSNIM--NFFKTKVT 1049
AHN30376 9 87 HHAHDAYLNAWAKAILTKYPQL- -EPEFVYGDYPKYN- s- —YKT— -RK ATEKL- -F-FYSNIM- -NFFKTKVT 1049
EA078426 9 87 HHAHDAYLNAWAKAILTKYPQL- -EPEFVYGDYPKYN- s- —YKT— -RK ATEKL- -F-FYSNIM- -NFFKTKVT 1049
CCW42055 9 87 HHAHDAYLNAWAKAILTKYPQL- -EPEFVYGDYPKYN- s- —YKT— -RK ATEKL- -F-FYSNIM- -NFFKTKVT 1049
WP 0030415 02 9 81 HHAHDAYLNAVIGTALLKKYPKL- -ASEFVYGEFKKYDV s- —DK elG KATAK- -YfFYSNLM- -NFFKKEVK 1050
WP 0375937 52 9 82 HHAHDAYLNAWGNALLLKYPQL- -EPEFVYGEYPKYN- s- —YR sRK SATEK- -F1FYSNIL- -RFFKKE— 1042
WP 0495166 84 9 82 HHAHDAYLNAWGNALLLKYPQL- -EPEFVYGEYPKYN- s- —YR sRK SATEK- -F1FYSNIL- -RFFKKE— 1042
GAD46167 9 81 HHAHDAYLNAWGNALLLKYPQL- -EPEFVYGEYPKYN- s- —YR sRK SATEK- -F1FYSNIL- -RFFKKE— 1041
WP 0183634 70 9 90 HHAHDAYLNAWGTALLKKYPKL- -APEFVYGEYKKYDV s- —SDDhseMG KATAK- -YfFYSNLM- -NFFKRVIR 1062
WP 0030438 19 9 91 HHAHDAYLNAWGTALIKKYPKL- -ESEFVYGDYKVYDV s- —EQEi- -GK ATAKR- -F-FYSNIM- -NFFKTEVK 1060
WP 0062696 58 9 81 HHAHDAYLNAWGNALLLKYPQL- -EPEFVYGEYPKYN- s- —YR sRK SATEK- -F1FYSNIL- -RFFKKE— 1041
WP 0488008 89 9 81 HHAHDAYLNAWGTALLKKYPKL- -TSEFVYGEYKKYDV s- —DND—elG KATAK- -YfFYSNLM- -NFFKTEVK 1051
WP 0127671 06 9 81 HHAHDAYLNAWGTALIKKYTKL- -ESEFVYGDYKVYDV s- —EQEi- -GK ATAKR- -F-FYSNIM- -NFFKTEIT 1050
WP 0146123 33 9 81 HHAHDAYLNAWGTALIKKYPKL- -ESEFVYGDYKVYDV s- —EQEi- -GK ATAKR- -F-FYSNIM- -NFFKTEIT 1050
WP 0150170 95 9 81 HHAHDAYLNAWGTALIKKYPKL- -ESEFVYGDYKVYDV s- —EQEi- -GK ATAKR- -F-FYSNIM- -NFFKTEIT 1050
WP 0150576 49 9 81 HHAHDAYLNAWGTALIKKYPKL- -ESEFVYGDYKVYDV s- —EQEi- -GK ATAKR- -F-FYSNIM- -NFFKTEIT 1050
WP 0483272 15 9 81 HHAHDAYLNAWGTALIKKYPKL- -ESEFVYGDYKVYDV s- —EQEi- -GK ATAKR- -F-FYSNIM- -NFFKTEIT 1050
WP 0495193 24 9 81 HHAHDAYLNAWGTALIKKYPKL- -ESEFVYGDYKVYDV s- —EQEi- -GK ATAKR- -F-FYSNIM- -NFFKTEIT 1050
WP 0125159 31 9 81 HHAHDAYLNAWAKAILGKYPQL- -APEFVYGDYPKYN- s- —FKEr- -QK ATQKM- -L-FYSNIL- -KFFKDQES 1043
WP 0213209 64 9 81 HHAHDAYLNAWAKAILGKYPQL- -APEFVYGDYPKYN- s- —FKEr- -QK ATQKT- -L-FYSNIL- -KFFKDQES 1043
WP 0375817 60 9 81 HHAHDAYLNAWAKAILGKYPQL- -APEFVYGDYPKYN- s- —FKEr- -QK ATQKT- -L-FYSNIL- -KFFKDQES 1043
WP 0042324 81 9 89 HHAHDAYLNAWGTALLKKYPKL- -APEFVYGEYKKYDV s- —SDNhseLG KATAK- -YfFYSNLM- -NFFKTEVK 1061
WP 0098545 40 9 90 HHAHDAYLNAWGTALLKKYPKL- -ASEFVYGEYKKYDI s- —SD KATAK- -YfFYSNLM- -NFFKTKVK 1056
WP 0129621 74 9 90 HHAHDAYLNAWGTALLKKYPKL- -APEFVYGEYKKYDI s- —GD KATAK- -YfFYSNLM- -NFFKRVIR 1056
WP 0396953 03 9 92 HHAHDAYLNAWGTALLKKYPKL- -ASEFVYGEYKKYDI s- —SD KATAK- -YfFYSNLM- -NFFKTKVK 1058
WP 0143349 83 9 89 HHAHDAYLNAWGTALLKKYPKL- -TPEFVYGEYKKYDV s- —SDDyseMG KATAK- -YfFYSNLM- -NFFKTEVK 1061
WP 0030992 69 9 82 HHAQDAYLNAWGTALLKKYPKL- -EAEFVYGDYKHYDL P- —DSS1- -GK ATTRM- -F-FYSNLM- -NFFKKEIK 1051
AHY15608 9 82 HHAQDAYLNAWGTALLKKYPKL- -EAEFVYGDYKHYDL P- —DSS1- -GK ATTRM- -F-FYSNLM- -NFFKKEIK 1051
AHY17476 9 82 HHAQDAYLNAWGTALLKKYPKL- -EAEFVYGDYKHYDL P- —DSS1- -GK ATTRM- -F-FYSNLM- -NFFKKEIK 1051
ESR09100
AGM98575 9 82 HHAQDAYLNAWGTALLKKYPKL- -EAEFVYGDYKHYDL P- —DSS1- -GK ATTRM- -F-FYSNLM- -NFFKKEIK 1051
ALF27331 9 82 HHAHDAYLNAVIGKALLGVYPQL- -EPEFVYGDYPHFH- G- —HK eNK ATAKK- -F-FYSNIM- -NFFKKD— 1041
WP 0183724 92 9 95 HHAHDAYLNAWAQALLKVYPKF- -ERELVYGSYVKESI — —FS -RK ATERM- —rMYNNIL- -KFISKD— 1055
WP 0456180 28 9 85 HHAHDPYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL TkdpKEV— -EK ATEKY- -F-FYSNLL- -NFFKEEVH 1056
WP 0456351 97 9 84 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGEYQKYDL SkdpKEV— -EK ATEKY- -F-FYSNLL- -NFFKEEVH 1055
WP 0022635 49 9 82 HHAHDAYLNAVIGKALLGVYPQL- -EPEFVYGDYPHFH- G- —HK eNK ATAKK- -F-FYSNIM- -NFFKKD— 1041
WP 0022638 87 9 82 HHAHDAYLNAVIGKALLGVYPQL- -EPEFVYGDYPHFH- G- —HK eNK ATAKK- -F-FYSNIM- -NFFKKD— 1041
WP 0022649 20 9 82 HHAHDAYLNAVIGKALLGVYPQL- -EPEFVYGDYPHFH- G- —HK eNK ATAKK- -F-FYSNIM- -NFFKKD— 1041
WP 0022690 43 9 82 HHAHDAYLNAVIGKALLGVYPQL- -EPEFVYGDYPHFH- G- —HK eNK ATAKK- -F-FYSNIM- -NFFKKD— 1041
WP 002269448 9E32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G—-HK—-eNK ATAKK--F- FYSNIM--NFFKKD— 1041
WP "002271977 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002272766 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HE— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002273241 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002275430 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HE— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002276448 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002277050 9E 34 HHAHDAYLNAVWKALLVKYPKL EPEFVYGEYPKYN S— -YR— -eRK ATQKM- -F- FYSNIM- -NMFKSKVK 1046
WP "002277364 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002279025 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HE— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002279859 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002280230 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002281696 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002282247 9E 34 HHAHDAYLNAVWKALLVKYPKL EPEFVYGEYPKYN S— -YR— -eRK ATQKM- -F- FYSNIM- -NMFKSKVK 1046
WP "002282906 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002283846 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002287255 9E 32 HHTHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002288990 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002289641 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002290427 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002295753 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002296423 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002304487 996 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKG— 1055
WP "002305844 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002307203 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002310390 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "002352408 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "012997688 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "014677909 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "019312892 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "019313659 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "019314093 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "019315370 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HE— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "019803776 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "019805234 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "024783594 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "024784288 9E 34 HHAHDAYLNAVWKALLVKYPKL EPEFVYGEYLKYN S— -YR— -eRK ATQKM- -F- FYSNIM- -NMFKSKVK 1046
WP "024784666 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "024784894 9E 32 HHAHDAYLNAVIGKALLGVYPQL EPEFVYGDYPHFH G— -HK— -eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
WP "024786433 9E 34 HHAHDAYLNAVWKALLVKYPKL EPEFVYGEYPKYN S— -YR— -eRK ATQKM- -F- FYSNIM- -NMFKSKVK 1046
WP 049473442 9E32 HHAHDAYLNAVIGKALLGVYPQL--EPEFVYGDYPHFH- G HE eNK ATAKK--F-FYSNIM--NFFKKD— 1041
WP "04947 4547 9E 32 HHAHDAYLNAVIGKALLGVYPQL- -EPEFVYGDYPHFH- G HK eNK ATAKK- -F- FYSNIM- -NFFKKD— 1041
EMC03581 975 HHAHDAYLNAVIGKALLGVYPQL- -EPEFVYGDYPHFH- G HK eNK ATAKK- -F- FYSNIM- -NFFKKD— 1034
WP 00042 8612 9E 37 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL SkdpKEI— -EK ATEKY- -F- FYSNLL- -NFFKEEVH 1058
WP "00042 8613 9 i 35 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL SrnpKEV— -EK ATEKY- -F- FYSNLL- -NFFKEEVH 1056
WP "04952 3028 9 i 30 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL TkdpKEI— -EK ATEKY- -F- FYSNLL- -NFFKDKVY 1051
WP "00310 7102 951 HHAHDAYLNAWGTALLKKYPKL- -EAEFVYGDYKHYDL S DTS1- -GK ATAKM- -F- FYSNIM- -NFFKKEVR 1020
WP "05427 9288 9 i 33 HHAHDAYLNAWGTALLKMYPKL- -ASEFVYGDYQKYDL S GKAs- -GH ATAKY- -F- FYSNLM- -NFFKSEVK 1052
WP "04953 1101 9 i 35 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL SrdpKEI— -EK ATEKY- -F- FYSNLL- -NFFKEEVH 1056
WP "04953 8452 9 i 35 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL SkdpKDI— -EK ATEKY- -F- FYSNLL- -NFFKEEVH 1056
WP "04954 9711 9 i 37 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKNDL SkdpKDI— -EK ATEKY- -F- FYSNLL- -NFFKEEVH 1058
WP "00789 6501 9 i 38 HHAHDAYLNAWGTALLKKYPKL- -EAEFVYGDYKHFDL S DPS1- -GK ATAKV- -F- FYSNIM- -NFFKEELS 1057
EFR44625 940 HHAHDAYLNAWGTALLKKYPKL- -EAEFVYGDYKHFDL S DPS1- -GK ATAKV- -F- FYSNIM- -NFFKEELS 1009
WP 00289 7477 9 i 34 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL FkpsKEI— -EK ATEKY- -F- FYSNLL- -NFFKEEVL 1055
WP "00290 6454 9 i 34 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL SkasNTI— -DK ATEKY- -F- FYSNLL- -NFFKEKVR 1055
WP "00972 9476 9 i 35 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL SkdpKEI— -EK ATEKY- -F- FYSNLL- -NFFKEEVH 1056
CQR24647 9 i 34 HHAHDAYLNAWAKALLIRYPKL- -EPEFVYGEYPKYN- S YRE— -RK ATEKM- -F- FYSNIM- -NMFKTTIK 1046
WP 00006 6813 9 i 39 HHAHDAYLNAVLAKAILKKYPKL- -EPEFVYGDYQKYDL SrepKEV— -EK ATQKY- -F- FYSNLL- -NFFKEEVH 1060
WP "00975 4323 9 i 35 HHAHDAYLNAWAKAILKKYPKL- -EPEFVYGDYQKYDL SkdpKEV— -EK ATEKY- -F- FYSNLL- -NFFKEEVH 1056
WP "04467 4937 9 i 36 HHAHDAYLNAWATALLKKYPQL- -APEFVYGDYPKYN- S YKS— -RK ATEKV- -L- FYSNIM- -NFFRRVLV 1048
WP "04467 6715 9 i 38 HHAHDAYLNAWATALLKKYPQL- -APEFVYGDYPKYN- S YKS— -RK ATEKV- -L- FYSNIM- -NFFRRVLV 1050
WP "04468 0361 9 i 38 HHAHDAYLNAWATALLKKYPQL- -APEFVYGDYPKYN- S YKS— -RK ATEKV- -L- FYSNIM- -NFFRRVLV 1050
WP "04468 1799 9 i 36 HHAHDAYLNAWATALLKKYPQL- -APEFVYGDYPKYN- S YKS— -RK ATEKV- -L- FYSNIM- -NFFRRVLV 1048
WP "04953 3112 9 i 31 HHAHDAYLNAVIGTALLKKYPKL- -ASEFVYGEFKKYDV S DK elG KATAK- -YfFYSNLM- -NFFKKEVK 1050
WP "02909 0905 952 HHAQDAFLVAFLGTNITSNYPKI- -EMEYLFKGYQHYLN Ev- -GK AAKPKftF- IVENLS- 1007
WP "00650 6696 977 HHAHDAYIVALIGGFMRDRYPNMhDSKAVYSEYMKMFR NKNd- -QK g FVINSM- -NYPY-EV- 1038
AIT42264 9 i 32 HHAHDAYLNAWGTALIKKYPKL- -ESEFVYGDYKVYDV S EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP 03444 0723 9 i 31 HHAHDAYLNGVIALKLLELYPYM- -AKDLIYGKYSYHRK c JJl\ ATQAK- -Y- KMSNII- -ERFSQDL- 1041
AKQ21048 9 i 32 HHAHDAYLNAWGTALIKKYPKL- -ESEFVYGDYKVYDV S EQEi- -GK ATAKY- -F- FYSNIM- -NFFKTEIT 1051
WP 00463 6532 9 i 31 HHGHDAYLNAWATTIMKVYPNL- -KPQFVYGQYKKTSM FKE— -EK ATARK- -H- FYSNIT- -KFFKKEKV 1042
WP "00236 4836 9 i 38 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQT FKE— -NK ATAKA- -I- IYTNLL- -RFFTED— 1047
WP "01663 1044 939 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQT FKE— -NK ATAKA- -I- IYTNLL- -RFFTED— 998
EMS75795 723 HHAHDAYLNGWAIALLKKYPKL- -EPEFVYGNYTKFNL AT eNK ATAKK- -E- FYSNIL- -RFFEKE— 782
WP 00237 3311 9 i 38 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQA FKE— -NK ATAKT- -I- IYTNLM- -RFFTED— 1047
WP "00237 8009 9 i 38 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQT FKE— -NK ATAKA- -I- IYTNLL- -RFFTED— 1047
WP "00240 7324 9 i 38 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQT FKE— -NK ATAKA- -I- IYTNLL- -RFFTED— 1047
WP "00241 3717 9 i 38 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQT FKE— -NK ATAKA- -I- IYTNLL- -RFFTED— 1047
WP "01077 5580 990 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQA FKE— -NK ATAKA- -I- IYTNLL- -RFFTED— 1049
WP "01081 8269 9E 38 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQT FKE— -NK ATAKA- -I- IYTNLL- -RFFTED— 1047
WP 010824395 988 HHGQDAYLNCWATTLLKVYPNL--APEFVYGEYPKFQT -FKE-—NK ATAKT--I- IYTNLM-RFFTED— 1047
WP 016622645 988 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQT -FKE- —NK ATAKA- -I- IYTNLL- RFFTED— 1047
WP 033624816 988 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQA -FKE- —NK AMAKA- -I- IYTNLL- RFFTED— 1047
WP 033625576 988 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQA -FKE- —NK ATAKA- -I- IYTNLM- RFFTEV— 1047
WP 033789179 988 HHGQDAYLNCWATTLLKVYPNL- -APEFVYGEYPKFQA -FKE- —NK ATAKA- -I- IYTNLL- RFFTED— 1047
WP 002310644 989 HHAHDAYLNGWALALLKKYPQL- -APEFVYGEYLKFNA -HK— -aNK ATVKK- -E- FYSNIM- KFFESD— 1048
WP 002312694 990 HHAHDAYLNGWALALLKKYPQL- -APEFVYGEYLKFNA -HK— -aNK ATVKK- -E- FYSNIM- KFFESD— 1049
WP 002314015 990 HHAHDAYLNGWALALLKKYPQL- -APEFVYGEYLKFNA -HK— -aNK ATVKK- -E- FYSNIM- KFFESD— 1049
WP 002320716 990 HHAHDAYLNGWALALLKKYPQL- -APEFVYGEYLKFNA -HK— -aNK ATVKK- -E- FYSNIM- KFFESD— 1049
WP 002330729 989 HHAHDAYLNGWALALLKKYPQL- -APEFVYGEYLKFNA -HK— -aNK ATVKK- -E- FYSNIM- KFFESD— 1048
WP 002335161 990 HHAHDAYLNGWALALLKKYPQL- -APEFVYGEYLKFNA -HK— -aNK ATVKK- -E- FYSNIM- KFFESD— 1049
WP 002345439 990 HHAHDAYLNGWALALLKKYPQL- -APEFVYGEYLKFNA -HK— -aNK ATVKK- -E- FYSNIM- KFFESD— 1049
WP 034867970 980 HHAHDAYLNGFIANVLLKRYPKL- -APEFVYGKYVKYSL -AR— -eNK ATAKK- -E- FYSNIL- KFLESD— 1039
WP 047937432 990 HHAHDAYLNGVIALALLKKYPQL- -APEFVYGEYLKFNA -HK— -aNK ATVKK- -E- FYSNIM- KFFESD— 1049
WP 010720994 980 HHAHDAYLNGFIANVLLKRYPKL- -APEFVYGKYVKYSL -AR— -eNK ATAKK- -E- FYSNIL- KFLESD— 1039
WP 010737004 980 HHAHDAYLNGFIANVLLKRYPKL- -APEFVYGKYVKYSL -AR— -eNK ATAKK- -E- FYSNIL- KFLESD— 1039
WP 034700478 980 HHAHDAYLNGFIANVLLKRYPKL- -APEFVYGKYVKYSL -AR— -eNK ATAKK- -E- FYSNIL- KFLESD— 1039
WP 007209003 978 HHAHDAYLNAWALSLLRVYPQL- -KPEFVYGEYGKNS- -IHDq —NK ATIKK- —qFYSNIT- RYFASK— 1037
WP 023519017 974 HHAHDAYLNGWAMTLLKKYPKL- -APEFVYGSYIKGDI -NQ— -iNK ATAKK- -E- FYSNIM- KFFESE— 1033
WP 010770040 986 HHGHDAYLNGWANSLLRVYPQL- -QPEFVYGDYPKFNA -YKA- —NK ATAKK- -Q- LYTNIM- KFFAED— 1045
WP 048604708 983 HHAHDAYLNGWATALLKIYPQL- -EPEFVYGEFHRFNA -FKE- —NK ATAKK- -Q- FYSNLM- EFSKSD— 1042
WP 010750235 983 HHAHDAYLNAWALALLKKYPRL- -APEFVYGSFAKFHL -VK— -eNK ATAKK- -E- FYSNIL- KFFEKE— 1042
AII16583 1021 HHAHDAYLNAWGTALIKKYPKL- -ESEFVYGDYKVYDV S— -EQEi —GK ATAKY- -F- FYSNIM- NFFKTEIT 1090
WP 029073316 988 HHAHDAYIATILGTYIGHRFESL- -DAKYIYGEYQKIFR -NKNk —DK KDg FILNSM- RNLYADK- 1052
WP 031589969 988 HHAHDAYIATILGTYIGHRFESL- -DAKYIYGEYKRIFR -QKNk —GK NDg FILNSM- RNIYADK- 1052
KDA45870 973 HHAHDAYLNAWANLIMAKYPEL- -EPEFVYGKYRKTK- -FKG1 —GK ATAKN- —tLYANVL- YFLKENEV 1034
WP 039099354 991 HHAFDAYLTAFVGLYLLKRYPKL- -KPYFVYGEYQKAS- -QQ-- —DK RN- -F- NFL- NGLKKD— 1043
AKP02966 1000 HHAQDAYLASFLGTYRLRRFPTD- -EMLLMNGEYNKFYG —KE1ysKK -SRKN-gF- IISPLV- 1062
WP 010991369 985 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGDYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
WP 033838504 985 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGDYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
EHN60060 988 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGDYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- LFFAQK— 1047
EFR89594 754 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGDYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- LFFAQK— 813
WP 038409211 985 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGDYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- RFFAKE— 1044
EFR95520 604 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGDYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- RFFAKE— 663
WP 003723650 985 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGEYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
WP 003727705 985 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGEYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
WP 003730785 985 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGEYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
WP 003733029 985 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGEYHQFGW -FKA- —NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
WP 003739838 985 HHAHDAYLNGWANTLLKVYPQL- -EPEFVYGEYHQFDW -FKA- —NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
111
WP 014601172 985 HHAHDAYLNGWANTLLKVYPQL-EPEFVYGEYHQFDW FKA—-NK ATAKK--Q- FYTNIM-LFFGQK— 1044
WP 023548323 9 85 HHAHDAYLNGWANTLLKVYPQL-EPEFVYGEYHQFDW FKA— -NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
WP 031665337 9 85 HHAHDAYLNGWANTLLKVYPQL-EPEFVYGEYHQFDW FKA— -NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
WP 031669209 9 85 HHAHDAYLNGWANTLLKVYPQL-EPEFVYGEYHQFDW FKA— -NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
WP 033920898 9 85 HHAHDAYLNGWANTLLKVYPQL-EPEFVYGEYHQFDW FKA— -NK ATAKK- -Q- FYTNIM- LFFAQK— 1044
AKI42028 9 88 HHAHDAYLNGWANTLLKVYPQL-EPEFVYGEYHQFDW FKA— -NK ATAKK- -Q- FYTNIM- LFFGQK— 1047
AKI50529 9 88 HHAHDAYLNGWANTLLKVYPQL-EPEFVYGEYHQFDW FKA— -NK ATAKK- -Q- FYTNIM- LFFAQK— 1047
EFR83390 4 33 HHAHDAYLNGWANTLLKVYPQL-EPEFVYGEYHQFDW FKA— -NK ATAKK- -Q- FYTNIM- LFFAQK— 492
WP 046323366 9 85 HHAHDAYLNCWANTLLKVYPQL-EPEFVYGDYHQFDW FKA— -NK ATAKK- -Q- FYTNIM- LFFAKK— 1044
AKE81011 9 98 HHAHDAYLNAWGTALIKKYPKL-ESEFVYGDYKVYDV EQEi- -GK ATAKY- -F- FYSNIM- NFFKTEIT 1067
CU082355 9 81 HHAHDAYIVALIGGFMRDRYPNMhDSKAVYSEYMKMFR NKNd- -QK g FVINSM- NYPY-EV- 1042
WP 033162887 9 83 HHAHDAYIACIVGQFMHQNFEHL-DAKIIYGQYK KNy- -KK NYg FILNSM- NHLQSDI- 1042
AGZ 01981 1 015 HHAHDAYLNAWGTALIKKYPKL-ESEFVYGDYKVYDV EQEi- -GK ATAKY- -F- FYSNIM- NFFKTEIT 1084
AKA60242 9 82 HHAHDAYLNAWGTALIKKYPKL-ESEFVYGDYKVYDV EQEi- -GK ATAKY- -F- FYSNIM- NFFKTEIT 1051
AKS40380 9 82 HHAHDAYLNAWGTALIKKYPKL-ESEFVYGDYKVYDV EQEi- -GK ATAKY- -F- FYSNIM- NFFKTEIT 1051
4UN5 B 9 86 HHAHDAYLNAWGTALIKKYPKL-ESEFVYGDYKVYDV EQEi- -GK ATAKY- -F- FYSNIM- NFFKTEIT 1055
WP 010922251 1052 GEIRKRPLIE TNGET- 1114
"039695303 1059 T 1120
WP "045635197 1056 YAD- GTIVKRENIE Y-SKDtGE- IAWNKEKDFAIIKKVLS- -LPQVNIVKKREVQT GGFSK ESIL- PKG- 1118
5AXW A 772 YKYsHRVDKKPNRE VNNLN- GL- —YDKDND—KLKKLINkSPEKLLMYHHDPQT —YQK KLIMeQYGd 852
009880683 736 LAN- 798
"010922251 1052 LAN- 1114
"011054416 1052 LAN- 1114
"011284745 1052 LAN- 1114
"011285506 1052 LAN- 1114
"011527619 1052 LAN- 1114
"012560673 1052 LAN- 1114
"014407541 1051 LAN- 1113
"020905136 1052 LAN- 1114
"023080005 1051 LAN- 1113
"023610282 1051 LAN- 1113
"030125963 1052 LAN- 1114
"030126706 1052 LAN- 1114
"031488318 1052 LAN- 1114
"032460140 1052 LAN- 1114
"032461047 1052 LAN- 1114
"032462016 1052 LAN- 1114
"032462936 1052 LAN- 1114
"032464890 1052 LAN- 1114
"033888930 877 LAN- 939
"038431314 1052 LAN- 1114
"038432938 1051 LAN- 1113
"038434062 1052 LAN- 1114
BAQ51233 963 LAN- 1025
227 LAN- 289
KGE60856 1 52
002989955 1052 LAN- 1114
"003030002 1042 DIQ T 1093
WP "003065552 1059 YSN- GKVIVRPWE Y-SKD- TEdlAWDKKSNFRTICKVLS- -YPQVNIVKKVETQT GGFSK ESIL- PKG- 1121
WP "001040076 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- AHG- 1112
WP "001040078 1058 LAD- GSIWRPVIE TGRYM- GK- TAWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- AHG- 1120
WP "001040080 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- AHG- 1112
WP "001040081 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- AHG- 1112
WP "001040083 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- AHG- 1112
WP "001040085 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- AHG- 1112
WP 001040087 1050 LAD-GTVWKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL--AHG- 1112
WP "001040088 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040089 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040090 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040091 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040092 1050 LAD- ETWVKDDIE VNNET- GE- IAWDKKKHFATVRKVLS- -YPQVNIVKKTEVQT GGFSK ESIL- -AHS- 1112
WP "001040094 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040095 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEVQT GGFSK ESIL- -AHG- 1112
WP "001040096 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEVQT GGFSK ESIL- -AHG- 1112
WP "001040097 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040098 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040099 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040100 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040104 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040105 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040106 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040107 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040108 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040109 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "001040110 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "015058523 1050 LAD- ETWVKDDIE VNNET- GE- IAWDKKKHFATVRKVLS- -YPQVNIVKKTEVQT GGFSK ESIL- -AHS- 1112
WP "017643650 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "017647151 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "017648376 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "017649527 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "017771611 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "017771984 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
CFQ25032 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
CFV16040 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
KLJ37842 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
KLJ72361 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
KLL20707 1064 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1126
KLL42645 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP 047207273 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "047209694 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "050198062 1050 LAD- GTWIKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "050201642 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "050204027 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQVNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP "050881965 1050 LAD- GTVWKDDIE VNNDT- GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP_050886065 1050 LAD-GTVWKDDIE VNNDT-GE- IVWDKKKHFATVRKVLS--YPQNNIVKKTEIQT GGFSK ESIL--AHG- 1112
AHN30376 1050 LAD-ETVWKDDIE VNNET-GE- IAWDKKKHFATVRKVLS- -YPQVNIVKKTEVQT GGFSK ESIL- -AHS- 1112
EA078426 1050 LAD-GTVWKDDIE VNNDT-GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
CCW42055 1050 LAD-GTVWKDDIE VNNDT-GE- IVWDKKKHFATVRKVLS- -YPQNNIVKKTEIQT GGFSK ESIL- -AHG- 1112
WP_003041502 1051 FAD-GTWERPDIE T-SED-GE- IAWNKQTDFKIVRKVLS- -YPQVNIVKKTEVQT HGLDR PSPK- -PKP- 1122
WP_037593752 1043 DIQ T-NED-GE- IAWNKEKHIKILRKVLS- -YPQVNIVKKTEEQT GGFSK ESIL- -PKG- 1094
WP_049516684 1043 DIQ T-NED-GE- IAWNKEKHIKILRKVLS- -YPQVNIVKKTEEQT GGFSK ESIL- -PKG- 1094
GAD46167 1042 DIQ T-NED-GE- IAWNKEKHIKILRKVLS- -YPQVNIVKKTEEQT GGFSK ESIL- -PKG- 1093
WP_018363470 1063 YSN-GKVIVRPWE Y-SKDtGE- IAWNKRTDFEKVRKVLS- -YPQVNIVKKVETQT GGFSK ESIL- -PKG- 1125
WP_003043819 1061 LAN-GEIRKRPLIE TNGET-GE- WWNKEKDFATVRKVLA- -MPQVNIVKKTEVQT GGFSK ESIL- -SKR- 1123
WP_006269658 1042 DIQ T-NED-GE- IAWNKEKHIKILRKVLS- -YPQVNIVKKTEEQT GGFSK ESIL- -PKG- 1093
WP_048800889 1052 FAD- GTWERPDIE T-SED-GE- IAWNKQTDFKIVRKVLS- -YPQVNIVKKVEKQT GRFSK ESIL- -PKG- 1113
WP_012767106 1051 LAN- GEIRKRPLIE TNEET-GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GALTN ESIY- -ARG- 1113
WP_014612333 1051 LAN- GEIRKRPLIE TNEET-GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GALTN ESIY- -ARG- 1113
WP_015017095 1051 LAN- GEIRKRPLIE TNEET-GE- IVWNKGRDFATVRKVLS- -MPQVNIVKKTEVQT GALTN ESIY- -ARG- 1113
WP_015057649 1051 LAN- GEIRKRPLIE TNEET-GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GALTN ESIY- -ARG- 1113
WP_048327215 1051 LAN- GEIRKRPLIE TNEET-GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GALTN ESIY- -ARG- 1113
WP_049519324 1051 LAN- GEIRKRPLIE TNEET-GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GALTN ESIY- -ARG- 1113
WP_012515931 1044 L H VNSD- -GE- EIWNANKHLPIIKNVLS- -IPQVNIVKKTEVQT GGFYK ESIL- -SKG- 1094
WP_021320964 1044 L H VNSD- -GE- EIWNANKHLPIIKNVLS- -IPQVNIVKKTEVQT GGFYK ESIL- -SKG- 1094
WP_037581760 1044 L H VNSD- -GE- EIWNANKHLPIIKNVLS- -IPQVNIVKKTEVQT GGFYK ESIL- -SKG- 1094
WP_004232481 1062 YAD- GRVFERPDIE T-NAD-GE- WWNKQRDFNIVRKVLS- -YPQVNIVKKVEVQT GGFSK ESIL- -PKG- 1123
WP_009854540 1057 YAD- GTVFERPIIE T-NAD-GE- IAWNKQIDFEKVRKVLS- -YPQVNIVKKVETQT GGFSK ESIL- -PKG- 1118
WP_012962174 1057 YSN- GKVWRPVIE C-SKDtGE- IAWNKQTDFEKVRRVLS- -YPQVNIVKKVETQT GGFSK ESIL- -PKG- 1119
WP_039695303 1059 YAD- GTVFERPIIE T-NAD-GE- IAWNKQIDFEKVRKVLS- -YPQVNIVKKVETQT GGFSK ESIL- -PKG- 1120
WP_014334983 1062 YAD- GRVFERPDIE T-NAD-GE- WWNKQKDFDIVRKVLS- -YPQVNIVKKVEAQT GGFSK ESIL- -SKG- 1123
WP_003099269 1052 LAD- DTIFTRPQIE VNTET-GE- IVWDKVKDMQTIRKVMS- -YPQVNIVMKTEVQT GGFSK ESIW- -PKG- 1114
AHY15608 1052 LAD- DTIFTRPQIE VNTET-GE- IVWDKVKDMQTIRKVMS- -YPQVNIVMKTEVQT GGFSK ESIW- -PKG- 1114
AHY17476 1052 LAD- DTIFTRPQIE VNTET-GE- IVWDKVKDMQTIRKVMS- -YPQVNIVMKTEVQT GGFSK ESIW- -PKG- 1114
ESR09100
AGM98575 1052 LAD-DTIFTRPQIE VNTET-GE- IVWDKVKDMQTIRKVMS- -YPQVNIVMKTEVQT GGFSK ESIW- -PKG- 1114
ALF27331 1042 DVR T-DKN-GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- -PKG- 1093
WP_018372492 1056 —K K —DQEtGE- IVWDKKEIENIVKKVIY- -SSPVNIVKKREEQS GALFK QSNM- -AVGy 1108
WP_045618028 1057 YAD-GTIVKRENIE Y--SKDtGE- IAWNKEKDFATIKKVLS- -LPQVNIVKKTEEQT GGLFD NNIV- -SKKk 1124
WP_045635197 1056 YAD-GTIVKRENIE Y--SKDtGE- IAWNKEKDFAIIKKVLS- -LPQVNIVKKREVQT GGFSK ESIL- -PKG- 1118
WP_002263549 1042 DVR T--DKN-GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- -PKG- 1093
WP_002263887 1042 DVR T--DKN-GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- -PKG- 1093
WP_002264920 1042 DVR T--DKN-GE- IIWKKDEYISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- -PKG- 1093
WP 002269043 1042 DVR T--DKN-GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- -PKG- 1093
WP 002269448 1042 DVR T-DKN-GE- IIWKKDEHISNIKKVLS--YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002271977 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002272766 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002273241 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002275430 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002276448 1042 DVR T- DRN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002277050 1047 LAD- DQIVERPMIE VNDET- GE- IAWDKTKHITTVKKVLS- -YPQVNIVKKVEEQT GGLFD PKS- 1111
WP "002277364 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002279025 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002279859 1042 DVR T- DKN- GE- IIWKKDEYISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002280230 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002281696 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002282247 1047 LAD- DQIVERPMIE VNDET- GE- IAWDKTKHITTVKKVLS- -YPQVNIVKKVEEQT GGLFD PKS- 1111
WP "002282906 1042 DVR I- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002283846 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002287255 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002288990 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002289641 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002290427 1042 DVR T- DKN- GE- IIWKKDEYISNIKKVLS- -YPQVNIVKKVEEQT GGFFK ESIL- PKG- 1093
WP "002295753 1042 DVR T- DKN- GE- IIWKKDEYISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002296423 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002304487 1056 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1107
WP "002305844 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002307203 1042 DVR T- DKN- GE- IIWKKDEYISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "002310390 1042 DVR T- DKN- GE- IIWKKDEYISNIKKVLS- -YPQVNIVKKVEEQT GGFFK ESIL- PKG- 1093
WP "002352408 1042 DVR T- DKN- GE- IIWKKDEYISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "012997688 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "014677909 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "019312892 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "019313659 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "019314093 1042 DVR T- DKN- GE- IIWKKDEYISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "019315370 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "019803776 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "019805234 1042 DVR T- DKN- GE- IIWKKDEYISNIKKVLS- -YPQVNIVKKVEEQT GGFFK ESIL- PKG- 1093
WP "024783594 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "024784288 1047 LAD- DQIVERPMIE VNDET- GE- IAWDKTKHITTVKKVLS- -YPQVNIVKKVEEQT GGLFD PKS- 1111
WP "024784666 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "024784894 1042 DVR T- DKN- GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP "024786433 1047 LAD- DQIVERPMIE VNDET- GE- IAWDKTKHITTVKKVLS- -YPQVNIVKKVEEQT GGLFD PKS- 1111
111
WP 049473442 1042 DVR T-DKN-GE- IIWKKDEHISNIKKVLS--YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
WP 049474547 1042 DVR T-DKN-GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1093
EMC03581 1035 DVR T-DKN-GE- IIWKKDEHISNIKKVLS- -YPQVNIVKKVEEQT GGFSK ESIL- PKG- 1086
WP 000428612 1059 YAD-GTIVKRENIE Y-SKDtGE- IAWNKEKDFATIKKVLS- -LPQVNIVKKREVQT GGFSK ESIL- PKG- 1121
WP 000428613 1057 YAD-GTIVKRENIE Y-SKDtGE- IAWNKEKDFATIKKVLS- -YPQVNIVKKREVQT GGFSK ESIL- PKG- 1119
WP 049523028 1052 YAD-GTIIQRGNVE Y-SKDtGE- IAWNKKRDFAIVRKVLS- -YPQVNIVKKTEEQT GGFSK ESIL- PKG- 1114
WP 003107102 1021 LAD-GTVITRPQIE TNTET-GE- IVWDKVKDIKTIRKVLS- -IPQINWKKTEVQT GGFSK ESIL- SKR- 1083
WP 054279288 1053 LAN-GNIIKRSPIE VNEET-GE- IVWDKTKDFGTVRKVLS- -APQVNIVKKTEIQT GGFSN ETIL- SKG- 1115
WP 049531101 1057 YAD-GTIVKRENIE Y-SKDtGE- IAWNKEIDFATIRKILS- -LSQVNIVKKTEEQT GGLFD NNIV- SKKk 1124
WP 049538452 1057 YAD-GTIVKRENIE Y-SKDtGE- IAWNKEKDFATIKKILS- -LPQVNIVKKTEEQT GGLFD NNIV- SKKk 1124
WP 049549711 1059 YAD-GTIVKRENIE Y-SKDtGE- IAWNKEKDFATIKKVLS- -YPQVNIVKKTEEQT GGLFD NNIV- SKEk 1126
WP 007896501 1058 LAD-GTLMKRPVIE TNTET-GE- WWDKVKDFKTIRKVLS- -YPQVNIVKKTEIQS GAFSK ESVL- SKG- 1120
EFR44625 1010 LAD-GTLMKRPVIE TNTET-GE- WWDKVKDFKTIRKVLS- -YPQVNIVKKTEIQS GAFSK ESVL- SKG- 1072
WP 002897477 1056 YAD-GTIRKRENIE Y-SKDtGE- IAWDKEKDFATIKKVLS- -YPQVNIVKKREVQT GGFSK ESIL- PKG- 1118
WP 002906454 1056 YAD-GTIKKRENIE Y-SNDtGE- IAWNKEKDFATIKKVLS- -LPQVNIVKKTEEQT GGLFD NNIV- SKKk 1123
WP 009729476 1057 YAD-GTIVKRENIE Y-SKDtGE- IAWNKEKDFATIKKVLS- -LPQVNIVKKREVQT GGFSK ESIL- PKG- 1119
CQR24647 1047 LAD-GRWEKPVIE ANEET-GE- IAWDKTKHFANVKKVLS- -YPQVSIVKKVEEQT GGFSK ESIL- PKG- 1109
WP 000066813 1061 YAD-GTIVKRENIE Y-SKDtGE- IAWNKEKDFATVKKVLS- -LPQVNIVKKTEVQT GGFSK ESIL- PKG- 1123
WP 009754323 1057 YAD-GTIVKRENIE Y-SKDtGE- IAWNKEKDFVTIKKVLS- -YPQVNIVKKREVQT GGFSK ESIL- PKG- 1119
WP 044674937 1049 YSKtGEVRIRPVIE VNKET-GE- IVWDKKSDFRTVRKVLS- -YPQVNWKKVEMQT GGFSK ESIL- QHG- 1112
WP 044676715 1051 YSKtGEVRIRPVIE VNKET-GE- IVWDKKSDFRTVRKVLS- -YPQVNWKKVEMQT GGFSK ESIL- QHG- 1114
WP 044680361 1051 YSKtGEVRIRPVIE VNKET-GE- IVWDKKSDFRTVRKVLS- -YPQVNWKKVEMQT GGFSK ESIL- QHG- 1114
WP 044681799 1049 YSKtGEVRIRPVIE VNKET-GE- IVWDKKSDFKTVRKVLS- -YPQVNWKKVEMQT GGFSK ESIL- QHG- 1112
WP 049533112 1051 FAD-GTWERPDIE T-SED-GE- IAWNKQTDFKIVRKVLS- -YPQVNIVKKTEVQT HGLDR PSPK- PKP- 1122
WP 029090905 1008 -KQ Q —NSTtGE- VKWNPEVDIAKLKRILN- -FKQCNIVRKVEEQS GALFK ETIY- PVEe 1061
WP 006506696 1039 —D GK- LIWNP-DLINEIKKCFY- -YKDCYCTTKLDQKS GQLFN -TVL- SNDa 1084
AIT42264 1052 LAN-GEIRKRPLIE TNGET-GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GGFSK ESIL- PKR- 1114
WP 034440723 1042 LA —NPD-GE- IAWEKDKDLNTIRKVLS- -SKQINIIKKAEEGK GRLFK ETIN- SRPs 1092
AKQ21048 1052 LAN-GEIRKRPLIE TNGET-GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GGFSK ESIL- PKR- 1114
WP 004636532 1043 VNEET-GE- ILWDTERHLSTIKRVLS- -WKQMNIVKKVEKQK GQLWK ETIY- PKG- 1092
WP 002364836 1048 —E P RFTKD-GE- ILWSN-SYLKTIKKELN- -YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 016631044 999 —E P RFTKD-GE- ILWSN-SYLKTIKKELN- -YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1049
EMS75795 783 —E Y SYDEN-GE- IFWDKARHIPQIKKVIS- -SHQVNIVKKVEVQT GGFYK ETVN- PKG- 834
WP 002373311 1048 —E P RFTKD-SE- ILWSN-SYLKTIKKELN- -YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 002378009 1048 —E P RFTKD-GE- ILWSN-SYLKTIKKELN- -YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 002407324 1048 —E P RFTKD-GE- ILWSN-SYLKTIKKELN- -YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 002413717 1048 —E P RFTKD-GE- ILWSN-SYLKTIKKELN- -YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 010775580 1050 —E P RFTKD-GE- ILWSN-SYLKTIKKELN- -YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1100
WP 010818269 1048 —E P RFTKD-GE- ILWSN-SYLKTIKKELN- -YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 010824395 1048 --E- p RFTKD-GE- ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 016622645 1048 - -E- p RFTKD- GE- ILWSN-SYLKTIKKELN- YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 033624816 1048 - -E- p RFTKD- GE- ILWSN-SYLKTIKKELN- YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 033625576 1048 - -E- p RFTKD- GE- ILWSN-SYLKTIKKELN- YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 033789179 1048 - -E- p RFTKD- GE- ILWSN-SYLKTIKKELN- YHQMNIVKKVEVQK GGFSK ESIK- PKG- 1098
WP 002310644 1049 - -T- p VCDEN- GE- I FWDKSKSIAQVKKVIN- HHHMNIVKKTEIQK GGFSK ETVE- PKK- 1100
WP 002312694 1050 - -T- p VCDEN- GE- I FWDKSKSIAQVKKVIN- HHHMNIVKKTEIQK GGFSK ETVE- PKK- 1101
WP 002314015 1050 - -T- p VCDEN- GE- I FWDKSKSIAQVKKVIN- HHHMNIVKKTEIQK GGFSK ETVE- PKK- 1101
WP 002320716 1050 - -T- p VCDEN- GE- I FWDKSKSIAQVKKVIN- HHHMNIVKKTEIQK GGFSK ETVE- PKK- 1101
WP 002330729 1049 - -T- p VCDEN- GE- I FWDKSKSIAQVKKVIN- HHHMNIVKKTEIQK GGFSE ETVE- PKK- 1100
WP 002335161 1050 - -T- p VCDEN- GE- I FWDKSKSIAQVKKVIN- HHHMNIVKKTEIQK GGFSK ETVE- PKK- 1101
WP 002345439 1050 - -T- p VCDEN- GE- I FWDKSKSIAQVKKVIN- HHHMNIVKKTEIQK GGFSK ETVE- PKK- 1101
WP 034867970 1040 - -E- p FCDEN- GE- IYWEKSHHLPRIKKVLS- SHQVNWKKVEQQK GGFYK ETVN- SKE- 1091
WP 047937432 1050 - -T- p VCDEN- GE- I FWDKSKSIAQVKKVIN- HHHMNIVKKTEIQK GGFSK ETVE- PKK- 1101
WP 010720994 1040 - -E- p FCDEN- GE- IYWEKSHHLPRIKKVLS- SHQVNWKKVEQQK GGFYK ETVN- SKE- 1091
WP 010737004 1040 - -E- p FCDEN- GE- IYWEKSHHLPRIKKVLS- SHQVNWKKVEQQK GGFYK ETVN- SKE- 1091
WP 034700478 1040 - -E- p FCDEN- GE- IYWEKSHHLPRIKKVLS- SHQVNWKKVEQQK GGFYK ETVN- SKE- 1091
WP 007209003 1038 - -D- IINDD- GE- ILWNKQETIAQVIKTLG- MHQVNWKKVEIQK GGFSK ESIQ- PKG- 1089
WP 023519017 1034 - -E- 1 ICDEQ- GE- VIWNKKRDLSTIKKTIG- AHQVNIVKKVEKQK GGFYK ETIN- SKA- 1085
WP 010770040 1046 - -A- V IIDEN- GE- ILWDK-KNIATVKKVMS- YPQMNIVKKPEIQT GSFSK ETIK- PKG- 1096
WP 048604708 1043 - -K- V IIDEN- GE- ILWNQ-KKIVTVKKVMN- YRQMNIVKKVEIQK GGFSK ESIL- PKG- 1093
WP 010750235 1043 - -E- Q FCDEN- GE- IFWDKRKHIQQIKKVIS- SHQVNIVKKVEVQT GSFYK ETVN- TKE- 1094
AII16583 1091 LAN- GEIRKRPLIE TNGET- GE- IVWDKGRDFATVRKVLS- MPQVNIVKKTEVQT GGFSK ESIL- PKR- 1153
WP 029073316 1053 - -D- T- GE- WWDP-EWISRIKKCFY- YKDCFVTKKLEENN GSFFN -TVR- PNDe 1099
WP 031589969 1053 - -D- T- GE- IVWDP-NYIDRIKKCFY- YKDCFVTKKLEENN GTFFN -TVL- PNDt 1099
KDA45870 1035 YPF- —WDKARDLPTIKRYLY- RAQVNKVRKAERQT GGFSD EMLV- PKS- 1078
WP 039099354 1044 E LVDEN- TEaVIWNKESGLAYLNKIYQ- FKKILVTREVHENS GALFN QTLYaAKDd 1097
AKP02966 1063 - -N- -GTTQ —DRNtGE- I IWNVG-FRDKILKIFN- YHQCNVTRKTEIKT GQFYD QTIYs PKNp 1118
WP 010991369 1045 - -D- R IIDEN- GE- ILWDK-KYLDTVKKVMS- YRQMNIVKKTEIQK GEFSK ATIK- PKG- 1095
WP 033838504 1045 - -D- R IIDEN- GE- ILWDK-KYLDTVKKVMS- YRQMNIVKKTEIQK GEFSK ATIK- PKG- 1095
EHN60060 1048 - -D- R IIDEN- GE- ILWDK-KYLDTVKKVMS- YRQMNIVKKTEIQK GEFSK ATIK- PKG- 1098
EFR89594 814 - -D- R IIDEN- GE- ILWDK-KYLDTVKKVMS- YRQMNIVKKTEIQK GEFSK ATIK- PKG- 864
WP 038409211 1045 - -N- Q IIDKN- GE- ILWDN-RYLDTIKKVLS- YRQMNIVKKTEIQK GEFSN ATVN- PKG- 1095
EFR95520 664 - -N- Q IIDKN- GE- ILWDN-RYLDTIKKVLS- YRQMNIVKKTEIQK GEFSN ATVN- PKG- 714
WP 003723650 1045 - -E- R IIDEN- GE- ILWDK-KYLETIKKVLD- YRQMNIVKKTEIQK GEFSK ATIK- PKG- 1095
WP 003727705 1045 - -E- R IIDEN- GE- ILWDK-KYLETIKKVLD- YRQINIVKKTEIQK GEFSK ATIK- PKG- 1095
WP 003730785 1045 - -E- R IIDEN- GE- ILWDK-KYLETIKKVLD- YRQINIVKKTEIQK GEFSK ATIK- PKG- 1095
WP 003733029 1045 - -D- R IIDEN- GE- ILWDK-RYLETVKKVLG- YRQMNIVKKTEIQK GEFSN VTPN- PKG- 1095
WP 003739838 1045 - -E- R IIDEN- GE- ILWDK-KYLETIKKVLD- YRQMNIVKKTEIQK GEFSK ATIK- PKG- 1095
WP 014601172 1045 —E- R IIDEN-GE- ILWDK-KYLETIKKVLD--YRQMNIVKKTEIQK GEFSK ATIK- PKG- 1095
WP 023548323 1045 —E- R IIDEN- GE- ILWDK-KYLETIKKVLN- -YRQMNIVKKTEIQK GEFSN QNPK- PRG- 1095
WP 031665337 1045 —E- R IIDEN- GE- ILWDK-KYLETIKKVLD- -YRQMNIVKKTEIQK GEFSK ATIK- PKG- 1095
WP 031669209 1045 —D- R IIDEN- GE- ILWDK-RYLETVKKVLG- -YRQMNIVKKTEIQK GEFSN VTPN- PKG- 1095
WP 033920898 1045 —E- R IIDEN- GE- ILWDK-KYLETIKKVLN- -YRQMNIVKKTEIQK GEFSN QNPK- PRG- 1095
AKI42028 1048 —E- R IIDEN- GE- ILWDK-KYLETIKKVLD- -YRQMNIVKKTEIQK GEFSK ATIK- PKG- 1098
AKI50529 1048 —E- R IIDEN- GE- ILWDK-KYLETIKKVLN- -YRQMNIVKKTEIQK GEFSN QNPK- PRG- 1098
EFR83390 493 —E- R IIDEN- GE- ILWDK-KYLETIKKVLD- -YRQMNIVKKTEIQK GEFSK ATIK- PKG- 543
WP 046323366 1045 —D- R IIDEN- GE- ILWDK-KYLDTIKKVLN- -YRQMNIVKKTEIQK GEFSN ATAN- PKG- 1095
AKE81011 1068 LAN- GEIRKRPLIE TNGET- GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GGFSK ESIL- PKR- 1130
CU082355 1043 —D- GK- LIWNP-DLINEIKKCFY- -YKDCYCTTKLDQKS GQMFN -TVL- PNDa 1088
WP 033162887 1043 —D- T- GE- VMWDP-AKIGKIKSCFY- -YKDVYVTKKLEQNS GTLFN -TVL- PNDa 1089
AGZ 01981 1085 LAN- GEIRKRPLIE TNGET- GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GGFSK ESIL- PKR- 1147
AKA60242 1052 LAN- GEIRKRPLIE TNGET- GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GGFSK ESIL- PKR- 1114
AKS40380 1052 LAN- GEIRKRPLIE TNGET- GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GGFSK ESIL- PKR- 1114
4UN5 B 1056 LAN- GEIRKRPLIE TNGET- GE- IVWDKGRDFATVRKVLS- -MPQVNIVKKTEVQT GGFSK ESIL- PKR- 1118
WP 010922251 1115 --NSD KLIA -RKKDW-DPKKYGGFDSPTVAYSV-LWAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "039695303 1121 - -DSD KLIPRKTkKV-YW- DTKKYGGFDSPTVAYSV- FWAD- -VE- -KGKAKKLKTVKELVGISIME RSFFEE 1185
WP "045635197 1119 - -NSD KLIPRKT -KDILL- DTTKYGGFDSPVIAYSI- LLIAD- -IE- -KGKAKKLKTVKTLVGITIME KAAFEE 1183
5AXW A 853 - -EKN -LYKYYEeTGNYL- —TKYSKKDNGPVIKKI- -KYYGNKLNAHLDITDDYPNS -VKLSL 912
WP 009880683 799 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELVGITIME RSSFEK 860
WP "010922251 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "011054416 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "011284745 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "011285506 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "011527619 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "012560673 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELVGITIME RSSFEK 1176
WP "014407541 1114 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1175
WP "020905136 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGLTIME RSSFEK 1176
WP "023080005 1114 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1175
WP "023610282 1114 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1175
WP "030125963 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "030126706 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "031488318 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "032460140 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELVGITIME RSSFEK 1176
WP "032461047 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELVGITIME RSSFEK 1176
WP "032462016 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "032462936 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "032464890 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "033888930 940 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1001
WP "038431314 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "038432938 1114 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1175
WP "038434062 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
BAQ51233 1026 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1087
KGE60162 290 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 351
KGE60856 53 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 114
WP 002989955 1115 - -NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP "003030002 1094 - -ESD KLIPRKT -KNSYW- NPKKYGGFDSPWAYSI- LVFAD- -VE- -KGKSKKLRKVQDMVGITIME KKRFEK 1158
WP "003065552 1122 - -DSD KLIPRKTkKA-YW- DTKKYGGFDSPTVAYSV- FWAD- -VE- -KGKAKKLKTVKELVGISIME RSFFEE 1186
WP "001040076 1113 - -NSD KLIPRKT -KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP "001040078 1121 - -NSD KLIPRKT -KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSKFEK 1185
WP "001040080 1113 - -NSD KLIPRKT -KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP "001040081 1113 - -NSD KLIPRKT -KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP "001040083 1113 - -NSD KLIPRKT -KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP "001040085 1113 - -NSD KLIPRKT -KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040087 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LWAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040088 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040089 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040090 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040091 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040092 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LVLAD- -IK- -KGKAQKLKTVKELIGITIME RERFEK 1177
WP 001040094 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040095 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040096 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040097 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040098 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040099 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPKVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040100 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040104 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040105 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 001040106 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RFRFEK 1177
WP 001040107 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RFRFEK 1177
WP 001040108 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RFRFEK 1177
WP 001040109 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RFRFEK 1177
WP 001040110 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RFRFEK 1177
WP 015058523 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LVLAD- -IK- -KGKAQKLKTVKELIGITIME RERFEK 1177
WP 017643650 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 017647151 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 017648376 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 017649527 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 017771611 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RFRFEK 1177
WP 017771984 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LVAAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
CFQ25032 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
CFV16040 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
KLJ37842 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
KLJ72361 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
KLL20707 1127 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1191
KLL42645 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RFRFEK 1177
WP 047207273 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 047209694 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 050198062 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 050201642 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 050204027 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RFRFEK 1177
WP 050881965 1113 - -NSD KLIPRKT- KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 050886065 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV- LWAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177
AHN30376 1113 - -NSD KLIPRKT -KDIYL- DPKKYGGFDSPIVAYSV- LVLAD- -IK- -KGKAQKLKTVKELIGITIME RERFEK 1177
EA078426 1113 - -NSD KLIPRKT -KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
CCW42055 1113 - -NSD KLIPRKT -KDIYL- DPKKYGGFDSPIVAYSV- LWAD- -IK- -KGKAQKLKTVTELLGITIME RSRFEK 1177
WP 003041502 1123 - -DSS ENLVGVK -RNL DPKKYGGYAGISNSYAV- LVKAI- -IE- -KGVKKKETMVLEFQGI SILD RITFEK 1185
WP 037593752 1095 - -ESD KLIPRKT -KNSYW- NPKKYGGFDSPWAYSI- LVFAD- -VE- -KGKSKKLRKVQDMVGITIME KKRFEK 1159
WP 049516684 1095 - -ESD KLIPRKT -KNSYW- NPKKYGGFDSPWAYSI- LVFAD- -VE- -KGKSKKLRKVQDMVGITIME KKRFEK 1159
GAD46167 1094 - -ESD KLIPRKT -KNSYW- NPKKYGGFDSPWAYSI- LVFAD- -VE- -KGKSKKLRKVQDMVGITIME KKRFEK 1158
WP 018363470 1126 - -DSD KLIPRKTkKV-LW- EPKKYGGFDSPTVAYSV- LWAD- -VE- -KGKTKKLKTVKELVGISIME RSFFEK 1190
WP 003043819 1124 - -ESA KLIP -RKKGW- DTRKYGGFGSPTVAYSI- LWAK- -VE- -KGKAKKLKSVKVLVGITIME KGSYEK 1185
WP 006269658 1094 - -ESD KLIPRKT -KNSYW- DPKKYGGFDSPWAYSI- LVFAD- -VE- -KGKSKKLRKVQDMVGITIME KKRFEK 1158
WP 048800889 1114 - -DSD KLIARKTkEN-YW- DTKKYGGFDSPTVAYSV- LWAD- -IK- -KGKAKKLKTVKELVGISIME RPFFEK 1178
WP 012767106 1114 - -SFD KLIS -RKHRF- ESSKYGGFGSPTVTYSV- LWAKs kVQ- -DGKVKKIKTGKELIGMTLLD KLVFEK 1177
WP 014612333 1114 - -SFD KLIS -RKHRF- ESSKYGGFGSPTVTYSV- LWAKs kVQ- -DGKVKKIKTGKELIGITLLD KLVFEK 1177
WP 015017095 1114 - -SFD KLIS -RKHRF- ESSKYGGFGSPTVTYSV- LWAKs kVQ- -DGKVKKIKTGKELIGITLLD KLVFEK 1177
WP 015057649 1114 - -SFD KLIS -RKHRF- ESSKYGGFGSPTVTYSV- LWAKs kVQ- -DGKVKKIKTGKELIGITLLD KLVFEK 1177
WP 048327215 1114 - -SFD KLIS -RKHRF- ESSKYGGFGSPTVTYSV- LWAKckVQ- -DGKVKKIKTGKELIGITLLD KLVFEK 1177
WP 049519324 1114 - -SFD KLIS -RKHRF- ESSKYGGFGSPTVTYSV- LWAKs kVQ- -DGKVKKIKTGKELIGITLLD KLVFEK 1177
WP 012515931 1095 - -NSD KLIP -RKNNW- DTRKYGGFDSPTVAYSV- LVIAK- -ME- -KGKAKVLKPVKEMVGITIME RTAFEE 1156
WP 021320964 1095 - -NSD KLIP -RKNNW- DTRKYGGFDSPTVAYSV- LVIAK- -ME- -KGKAKVLKPVKEMVGITIME RIAFEE 1156
WP 037581760 1095 - -NSD KLIP -RKNNW- DTRKYGGFDSPTVAYSV- LVIAK- -ME- -KGKAKVLKPVKEMVGITIME RIAFEE 1156
WP 004232481 1124 - -DSD KLIPRKTkKL-QW- ETQKYGGFDSPTVAYSV- LWAD- -VE- -KGKTRKLKTVKELVGISIME RSSFEE 1188
WP 009854540 1119 - -DSD KLIPRKTkKV-YW- DTKKYGGFDSPTVAYSV- FWAD- -VE- -KGKAKKLKTVKELVGISIME RSFFEE 1183
WP 012962174 1120 - -NSD KLIPRKTkKF-RW- DTPKYGGFDSPNIAYSV- FVIAD- -VE- -KGKAKKLKTVKELVGISIME RSSFEE 1184
WP 039695303 1121 - -DSD KLIPRKTkKV-YW- DTKKYGGFDSPTVAYSV- FWAD- -VE- -KGKAKKLKTVKELVGISIME RSFFEE 1185
WP 014334983 1124 - -DSD KLIPRKTkKV-YW- NTKKYGGFDSPTVAYSV- LWAD- -IE- -KGKAKKLKTVKELVGISIME RSFFEE 1188
WP 003099269 1115 - -DSD KLIA -RKKSW- DPKKYGGFDSPIIAYSV- LWAK- -IA- -KGKTQKLKTIKELVGIKIME QDEFEK 1176
AHY15608 1115 - -DSD KLIA -RKKSW- DPKKYGGFDSPIIAYSV- LWAK- -IA- -KGKTQKLKTIKELVGIKIME QDEFEK 1176
AHY17476 1115 - -DSD KLIA -RKKSW- DPKKYGGFDSPIIAYSV- LWAK- -IA- -KGKTQKLKTIKELVGIKIME QDEFEK 1176
ESR09100 1 QDEFEK
AGM98575 1115 - -DSD KLIA -RKKSW- DPKKYGGFDSPIIAYSV- LWAK- -IA- -KGKTQKLKTIKELVGIKIME QDEFEK 1176
ALF27331 1094 - -NSD KLIPRKT -KKFYW- DTKKYGGFDSPIVAYSI- LVIAN- -IE- -KGKSKKLKLVKDLVGITIME RTIFEK 1158
WP 018372492 1109 - —NN KLIP -RKKDW- SVDKYGGFIEPAESYSLalFYTD- -IN- GKKPKKKSTIIAISRME KKDYEK 1167
WP 045618028 1125 vvDAS KLTPIKS -G L- SPEKYGGYARPTIAYSV- LVIAD- -IE- -KGKAKKLKRIKEMVGITVQD KKKFEA 1188
WP 045635197 1119 - -NSD KLIPRKT -KDILL- DTTKYGGFDSPVIAYSI- LLIAD- -IE- -KGKAKKLKTVKTLVGITIME KAAFEE 1183
WP 002263549 1094 - -NSD KLIPRKT -KKFYW- DTKKYGGFDSPIVAYSI- LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP 002263887 1094 - -NSD KLIPRKT -KKFYW- DTKKYGGFDSPIVAYSI- LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP 002264920 1094 - -DSD KLIPRKT -KKFYW- DTKKYGGFDSPIVAYSI- LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP 002269043 1094 - -NSD KLIPRKT -KKFYW- DTKKYGGFDSPIVAYSI- LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP 002269448 1094 --NSD KLIPRKT- KKFYW-DTKKYGGFDSPIVAYSI -LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002271977 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002272766 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002273241 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002275430 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002276448 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002277050 1112 - -PLE KLVPLKK- AL- NPEKYGGYQKPTTAYPI -LLIVD- TKQLIPISVMD KKRFEQ 1166
WP "002277364 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002279025 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002279859 1094 - -DSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002280230 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002281696 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002282247 1112 - -PLE KLVPLKK- AL- NPEKYGGYQKPTTAYPI -LLIVD- TKQLIPISVMD KKRFEQ 1166
WP "002282906 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002283846 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002287255 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002288990 1094 - -NSY KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002289641 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002290427 1094 - -DSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002295753 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002296423 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002304487 1108 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1172
WP "002305844 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002307203 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002310390 1094 - -DSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "002352408 1094 - -DSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "012997688 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "014677909 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "019312892 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "019313659 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "019314093 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "019315370 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "019803776 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "019805234 1094 - -DSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "024783594 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KSKSKKLKTVKALVGVTIME KMTFER 1158
WP "024784288 1112 - -PLE KLVPLKK- AL- NPEKYGGYQKPTTAYPI -LLIVD- TKQLIPISVMD KKRFEQ 1166
WP "024784666 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "024784894 1094 - -NSD KLIPRKT- KKFYW- DTKKYGGFDSPIVAYSI -LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
WP "024786433 1112 - -PLE KLVPLKK- AL- NPEKYGGYQKPTTAYPI -LLIVD- TKQLIPISVMD KKRFEQ 1166
WP 049473442 1094 —NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158
WP 049474547 1094 —NSD KLIPRKT -KKFYW- DTKKYGGFDSPIVAYSI- LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1158
EMC03581 1087 —NSD KLIPRKT -KKFYW- DTKKYGGFDSPIVAYSI- LVIAD- -IE- -KGKSKKLKTVKALVGVTIME KMTFER 1151
WP 000428612 1122 —NSD KLIPRKT -KDILW- DTTKYGGFDSPVIAYSI- LLIAD- -IE- -KGKAKRLKTVKTLVGITIME KATFEK 1186
WP 000428613 1120 —NSD KLIPRKT -KDILW- ETTKYGGFDSPVIAYSI- LLIAD- -IE- -KGKAKKLKTVKTLVGITIME KAAFEE 1184
WP 049523028 1115 —NSD KLIPRKT -KNVQL- DTTKYGGFDSPVIAYSI- LLVAD- -VE- -KGKSKKLKTVKSLIGITIME KVKFEA 1179
WP 003107102 1084 —DSD KLIP -RKNNW- DPKKYGGFGSPIIAYSV- LWAK- -VT- -KGKSQKTKSVKELVGITIME QNEFEK 1145
WP 054279288 1116 —KSS KLIP -RKNKWrDTTKYGGFNTPTVAYSV- LWAK- -VE- -KGKAKKLKPVKELVGITIME RTKFEA 1178
WP 049531101 1125 vvDAS KLIPIKS -G L- SPEKYGGYARPTIAYSV- LVIAD- -IE- -KGKAKKLKRIKEMVGITIQD KKKFEA 1188
WP 049538452 1125 vvDAS KLIPIKS -G L- SPEKYGGYARPTIAYSV- LVIAD- -IE- -KGKTKKLKRIKEMIGITVQD KKIFES 1188
WP 049549711 1127 vvDAS KLIPIKS -G L- SPEKYGGYARPTIAYSV- LVIAD- -IE- -KGKTKKLKRIKEMVGITIQD KKKFEA 1190
WP 007896501 1121 —NSD KLIE -RKKGW- DPKKYGGFDSPNTAYSI- FWAK- -VA- -KRKAQKLKTVKEIVGITIME QAEYEK 1182
EFR44625 1073 —NSD KLIE -RKKGW- DPKKYGGFDSPNTAYSI- FWAK- -VA- -KRKAQKLKTVKEIVGITIME QAEYEK 1134
WP 002897477 1119 —NSD KLIPRKT -KDILW- DTTKYGGFDSPVIAYSI- LLIAD- -IE- -KGKAKKLKTVKTLVGITIME KAAFEE 1183
WP 002906454 1124 vvDAS KLIPIKS -S L- SPEKYGGYARPTIAYSV- LVIAD- -lEkgKGKAKKLKRIKEIVGITIQD KKKFES 1189
WP 009729476 1120 —NSD KLIPRKT -KDILW- DTTKYGGFDSPVIAYSI- LLIAD- -IE- -KGKAKKLKTVKTLVGITIME KDAFEK 1184
CQR24647 1110 —GSD KLIARKT -KNNYL- STQKYGGFDSPTVAYSI- MFVAD- -IE- -KGKSKRLKTVKEMIGITIME RSRFES 1174
WP 000066813 1124 —NSD KLIPRKT -KEILW- DTTKYGGFDSPVIAYSI- LLIAD- -IE- -KGKAKKLKTVKTLVGITIME KATFEK 1188
WP 009754323 1120 —NSD KLIPRKT -KDILW- DTTKYGGFDSPVIAYSI- LLIAD- -IE- -KGKAKKLKTVKTLVGITIME KAAFEK 1184
WP 044674937 1113 —DSD KLIPRKT -EKFYL- DTKKYGGFDSPTIAYSV- LLIAD- -IE- -KGKAKKLKRVKELIGITIME RMAFEK 1177
WP 044676715 1115 —DSD KLIPRKT -EKFYL- DTKKYGGFDSPTIAYSV- LLIAD- -IE- -KGKAKKLKRVKELIGITIME RMAFEK 1179
WP 044680361 1115 —DSD KLIPRKT -EKFYL- DTKKYGGFDSPTIAYSV- LLIAD- -IE- -KGKAKKLKRVKELIGITIME RMAFEK 1179
WP 044681799 1113 —DSD KLIPRKT -EKFYL- DTKKYGGFDSPTIAYSV- LLIAD- -IE- -KGKAKKLKRVKELIGITIME RMAFEK 1177
WP 049533112 1123 —DSS ENLVGVK -RNL DPKKYGGYAGISNSYAV- LVKAI- -IE- -KGVKKKETMVLEFQGI SILD RITFEK 1185
WP 029090905 1062 —SSS KTIP -LKKHL- DTAIYGGYTA YASYA- —LIQ- -FK- KGRKLK—REIIGIPLAV QTRIDN 1117
WP 006506696 1085 haDKG AWP vNKNRS- DVHKYGGFSG—LQYTI- VA- -lEgqKKKGKKTELVKKISGVPLHL KAASIN 1149
AIT42264 1115 —NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP 034440723 1093 k-KTE KRIP -IKNNL- DPNIYGGYIEEKMAYYI- AInyLE- -NGKTKK AIVGISIKD KKDFEG 1149
AKQ21048 1115 —NSD KLIA -RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
WP 004636532 1093 —DSS KLIP -VKEGM- DPQKYGGLSQVSEAFAV- VIT— -HE- -KGKKKQLK—SDLISIPIVD QKAYEQ 1150
WP 002364836 1099 —PSN KLIP -VKNGL- DPQKYGGFDSPIVAYTV- LF—T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP 016631044 1050 —PSN KLIP -VKNGL- DPQKYGGFDSPWAYTV- LF—T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1107
EMS75795 835 —KPD KLIQ -RKAGW- DVSKYGGFGSPWAYAV- AFI -YE- -KGKAR—KKAKAIEGITIMK QSLFEQ 892
WP 002373311 1099 —PSN KLIP -VKNGL- DPQKYGGFDSPWAYTV- LF—T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP 002378009 1099 —PSN KLIP -VKNGL- DPQKYGGFDSPIVAYTV- LF—T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP 002407324 1099 —PSN KLIP -VKNGL- DPQKYGGFDSPIVAYTV- LF—T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP 002413717 1099 —PSN KLIP -VKNGL- DPQKYGGFDSPWAYTV- LF—T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP 010775580 1101 —PSN KLIP -VKNGL- DPQKYGGFDSPWAYTV- LF—T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1158
WP 010818269 1099 —PSN KLIP -VKNGL- DPQKYGGFDSPIVAYTV- LF—T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP 010824395 1099 --PSN KLIP- VKNGL-DPQKYGGFDSPWAYTV--LF—T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP "016622645 1099 - -PSN KLIP- VKNGL- DPQKYGGFDSPIVAYTV- -LF— T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP "033624816 1099 - -PSN KLIP- VKNGL- DPQKYGGFDSPWAYTV- -LF— T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP "033625576 1099 - -PSN KLIP- VKNGL- DPQKYGGFDSPWAYTV- -LF— T- -HE- -KGK-KPL-IKQEILGITIME KTKFEQ 1156
WP "033789179 1099 - -PSN KLIP- VKNGL- DPQKYGGFDSPWAYTV- -LF— T- -HE- -KGK-KPL-IKQEILGITIME KTRFEQ 1156
WP "002310644 1101 - -DSS KLLP- RKNNW- DPAKYGGLGSPNVAYTV- -AFT- -YE- -KGKAR—KRTNALEGITIME REAFEQ 1158
WP "002312694 1102 - -DSS KLLP- RKNNW- DPAKYGGLGSPNVAYTV- -AFT- -YE- -KGKAR—KRTNALEGITIME REAFEQ 1159
WP "002314015 1102 - -DSS KLLP- RKNNW- DPAKYGGLGSPNVAYTV- -AFT- -YE- -KGKAR—KRTNALEGITIME REAFEQ 1159
WP "002320716 1102 - -DSS KLLP- RKNNW- DPAKYGGLGSPNVAYTV- -AFT- -YE- -KGKAR—KRTNALEGITIME REAFEQ 1159
WP "002330729 1101 - -DSS KLLP- RKNNW- DPAKYGGLGSPNVAYTV- -AFT- -YE- -KGKAR—KRTNALEGITIME REAFEQ 1158
WP "002335161 1102 - -DSS KLLP- RKNNW- DPAKYGGLGSPNVAYTV- -AFT- -YE- -KGKAR—KRTNALEGITIME REAFEQ 1159
WP "002345439 1102 - -DSS KLLP- RKNNW- DPTKYGGLGSPNVAYTV- -AFT- -YE- -KGKAR—KRTNALEGITIME REAFEQ 1159
WP "034867970 1092 - -KPD KLIE- RKNNW- DVTKYGGFGSPVIAYAI- -AFV- -YA- -KGKTQ—KKTRAIEGITIME QAAFEK 1149
WP "047937432 1102 - -DSS KLLP- RKNNW- DPAKYGGLGSPNVAYTV- -AFT- -YE- -KGKAR—KRTNALEGITIME REAFEQ 1159
WP "010720994 1092 - -KPD KLIE- RKNNW- DVTKYGGFGSPVIAYAI- -AFV- -YA- -KGKTQ—KKTKAIEGITIME QAAFEK 1149
WP "010737004 1092 - -KPD KLIE- RKNNW- DVTKYGGFGSPVIAYAI- -AFV- -YA- -KGKTQ—KKTRAIEGITIME QAAFEK 1149
WP "034700478 1092 - -KPD KLIE- RKNNW- DVTKYGGFGSPVIAYAI- -AFV- -YA- -KGKTQ—KKTRAIEGITIME QAAFEK 1149
WP "007209003 1090 - -ESQ KLIR- RKQQW- NTKKYGGFDSPWAYAI- -—LLS- -FD- -KGK-RKARSFK-IVGITIQD RESFEG 1147
WP "023519017 1086 - -NPE KLIP- RKASL- DPLKYGGYGSPLVAYTV- -IFI- -FE- -KGKQK—KVTKGIEGITVME QLRFEQ 1143
WP "010770040 1097 - -DSD KLIS- RKTNW- SPKLYGGFDSPQVAYSV- -II— T- -YE- -KGK-KKVRA-KAIVGITIME QSLFKK 1154
WP "048604708 1094 - -DSD KLIS- RKKEW- DTTKYGGFDSPNVAYSV- -VI— R- -YE- -KGK-TRKLV-KTIVGITIME RAAFEK 1151
WP "010750235 1095 - -KPD KLIK- RKNNW- DVTKYGGFGSPWAYAV- -VFT- -YE- -KGKNH—KKAKAIEGITIME QALFEK 1152
AII16583 1154 - -NSD KLIA- RKKDW- DPKKYGGFDSPTVAYSV- -LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1215
WP 029073316 1100 hsEKG AKVP- — NKLRS- NVHKYGGFEG—LKYSI- VA- -IKgkKKKGKKI IDVNKLVGI PLMY KNVDDE 1164
WP "031589969 1100 nsDKD ATVP- — NKYRS- NVNKYGGFSG—VNSFI- VA- -IKgkKKKGKKVIEVNKLTGIPLMY KNADEE 1164
KDA45870 1079 - -DSG KLLP- RKEGL- DPVKYGGYAKAVESYAV- -LITAD-eVK- -KGKTKKVKT LVNIPIID SKKYEA 1138
WP 039099354 1098 k -ASG QLI PAKQdRPTAL- YGGYSGKTVAYMC- -—IVR- -1KnkKGDLYKVCGVETSWLAQLKQ KKAFLK 1170
AKP02966 1119 k KLIA- QKKDM- DPNIYGGFSGDNKSSIT- -—IVK- -ID- NNKIKPVA—IPIRLIN DK 1172
WP 010991369 1096 - -NSS KLIP- RKTNW- DPMKYGGLDSPNMAYAV- -VI— E- -YA- -KGK-NKLVFEKKIIRVTIME RKAFEK 1154
WP "033838504 1096 - -NSS KLIS- RKTNW- DPMKYGGLDSPNMAYAV- -VI— E- -YA- -KGK-NKLVFEKKIIRVTIME RKAFEK 1154
EHN60060 1099 - -NSS KLIS- RKTNW- DPMKYGGLDSPNMAYAV- -VI— E- -YA- -KGK-NKLVFEKKIIRVTIME RKAFEK 1157
EFR89594 865 - -NSS KLIP- RKTNW- DPMKYGGLDSPNMAYAV- -VI— E- -YA- -KGK-NKLVFEKKIIRVTIME RKAFEK 923
WP 038409211 1096 - -NSS KLIS- RKADW- NPIKYGGFDGSNMAYSI- -VI— E- -YE- -KRK-KKTVIKKELIQINIME RVAFEK 1154
EFR95520 715 - -NSS KLIS- RKADW- NPIKYGGFDGSNMAYSI- -VI— E- -YE- -KRK-KKTVIKKELIQINIME RVAFEK 773
WP 003723650 1096 - -NSS KLIP- RKENW- DPMKYGGLDSPNMAYAV- -II— E- -HA- -KGK-KKIVIEKKLIQINIME RKMFEK 1154
WP "003727705 1096 - -NSS KLIP- RKENW- DPMKYGGLDSPNMAYAV- -II— E- -HA- -KGK-KKIVIEKKLIQINIME RKMFEK 1154
WP "003730785 1096 - -NSS KLIP- RKENW- DPVKYGGLDSPNMAYAV- -II— E- -HA- -KGK-KKIVIEKKLIQINIME RKMFEK 1154
WP "003733029 1096 - -KSN KLIP- RKKDW- DPIKYGGFDGSKMAYAI- -II— E- -YE- -KQK-RKVRIEKKLIQINIME REAFEK 1154
WP "003739838 1096 - -NSS KLIP- RKENW- DPMKYGGLDSPNMAYAV- -II— E- -HA- -KGK-KKWFEKKIIRITIME RKAFEK 1154
WP 014601172 1096 —NSS KLIP- RKENW-DPMKYGGLDSPNMAYAV-II—E--HA--KGK-KKLIFEKKIIRITIME RKMFEK 1154
WP 023548323 1096 —DSS KLIP- KKTNL- NPIKYGGFEGSNMAYAI- II—E- -HE- -KRK-KKVTIEKKLIQINIME RKAFEK 1154
WP 031665337 1096 —NSS KLIP- RKENW- DPMKYGGLDSPNMAYAV- II—E- -HA- -KGK-KRIVIEKKLIQINIME RKMFEK 1154
WP 031669209 1096 —KSN KLIP- RKKDW- DPIKYGGFDGSKMAYAI- II—E- -YE- -KQK-RKVRIEKKLIQINIME REAFEK 1154
WP 033920898 1096 —DSS KLIP- KKTNL- NPIKYGGFEGSNMAYAI- II—E- -HE- -KRK-KKVTIEKKLIQINIME RKAFEK 1154
AKI42028 1099 —NSS KLIP- RKENW- DPMKYGGLDSPNMAYAV- II—E- -HA- -KGK-KKLIFEKKIIRITIME RKMFEK 1157
AKI50529 1099 —DSS KLIP- KKTNL- NPIKYGGFEGSNMAYAI- II—E- -HE- -KRK-KKVTIEKKLIQINIME RKAFEK 1157
EFR83390 544 —NSS KLIP- RKENW- DPMKYGGLDSPNMAYAV- II—E- -HA- -KGK-KKIVIEKKLIQINIME RKMFEK 602
WP 046323366 1096 —NSS KLIP- RKADW- DPIKYGGFDGSNMAYAI- VI—E- -HE- -KRK-KKTVIKKELIQINIME RTAFEK 1154
AKE81011 1131 —NSD KLIA- RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1192
CU082355 1089 hsAKG AVIP- — NKNRK- D KYGGFSG—LQYVI- AA- -lEgtKKKGKKLVKVRKLSGIPLYL KQADIK 1153
WP 033162887 1090 hsEKG ATVP- —1NKYRA- DVHKYGGFGN—VQS11- VA- -lEgkKKKGKKLIDVRKLTSIPLHL KNAPVE 1154
AGZ 01981 1148 —NSD KLIA- RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1209
AKA60242 1115 —NSD KLIA- RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
AKS40380 1115 —NSD KLIA- RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1176
4UN5 B 1119 —NSD KLIA- RKKDW- DPKKYGGFDSPTVAYSV- LWAK- -VE- -KGKSKKLKSVKELLGITIME RSSFEK 1180
WP 010922251 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE LENGRKRMLAS -G|E|LQKGNELALPSKY FLYLA 1239
WP "039695303 1186 NPV- - -EFLE- - -NKGYHN- -I- REDKLIK- -LPKYSLFE FEGGRRRLLAS ASELQKGNEMVLPGYLVELLYHA 1248
WP "045635197 1184 NPI- - -TFLE- - -NKGYHN- -V- RKENILC- -LPKYSLFE LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS 1246
5AXW A 913 KPYrfdVYLD- - -NGVYKFvtV- KNLDVIK- KENYYE — SKAYEEAKK -KKISNQAEFIASFYNNDLIKIN 978
WP 009880683 861 DPV- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKY FLYLA 923
WP "010922251 1177 NPI- - -DFLE- - -AKGYKE- -V- KKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKY FLYLA 1239
WP "011054416 1177 DPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "011284745 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIVK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "011285506 1177 NPI- - -DFLE- - -AKGYKE- -V- KKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "011527619 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "012560673 1177 DPV- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "014407541 1176 NPI- - -DFLE- - -AKGYKE- -V- KKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1238
WP "020905136 1177 NPI- - -DFLE- - -AKGYKE- -V- KKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "023080005 1176 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1238
WP "023610282 1176 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1238
WP "030125963 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "030126706 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "031488318 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "032460140 1177 DPV- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "032461047 1177 DPV- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "032462016 1177 NPI- - -DFLE- - -AKGYKE- -V- KKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "032462936 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "032464890 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "033888930 1002 NPI- - -DFLE- - -AKGYKE- -V- KKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1064
WP "038431314 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "038432938 1176 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1238
WP "038434062 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
BAQ51233 1088 NPI- - -DFLE- - -AKGYKE- -V- KKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1150
KGE60162 352 DPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 414
KGE60856 115 DPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 177
WP 002989955 1177 NPI- - -DFLE- - -AKGYKE- -V- RKDLIIK- -LPKYSLFE —LENGRKRMLAS -GELQKGNELALPSKYWFLYLA 1239
WP "003030002 1159 HPV- - -DFLE- - -QRGYRN- -V- RLEKIIK- -LPKYSLFE LENKRRRLLAS ARELQKGNELVIPQRFTTLLYHS 1221
WP "003065552 1187 NPV- - -EFLE- - -NKGYHN- -I- REDKLIK- -LPKYSLFE FEGGKRRLLAS ASELQKGNEMVIPGHLVKLLYHA 1249
WP "001040076 1178 NPS- - -AFLE- - -SKGYLN- -I- RTDKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP "001040078 1186 NPS- - -AFLE- - -SKGYLN- -I- RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1248
WP "001040080 1178 NPS- - -AFLE- - -SKGYLN- -I- RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP "001040081 1178 NPS- - -AFLE- - -SKGYLN- -I- RADKLII- -LPKYSLFE LENGRRRLLAS AGETIDRLQKGNELALPTQFMKFLYLA 12
WP "001040083 1178 NPS- - -AFLE- - -SKGYLN- -I- RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP "001040085 1178 NPS- - -AFLE- - -SKGYLN- -I- RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040087 1178 NPS-—AFLE---SKGYLN--I -RADKLII--LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040088 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040089 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040090 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040091 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040092 1178 NPS- —AFLE- - -SKGYLN- -I -RTDKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 001040094 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040095 1178 NPS- —AFLE- - -SKGYLN- -I -RTDKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 001040096 1178 NPS- —AFLE- - -SKGYLN- -I -RTDKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 001040097 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS ADELQKGNELALPTQFMKFLYLA 1240
WP 001040098 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040099 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040100 1178 NPS- —AFLE- - -SKGYLD- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040104 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040105 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 001040106 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 001040107 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 001040108 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 001040109 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 001040110 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 015058523 1178 NPS- —AFLE- - -SKGYLN- -I -RTDKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 017643650 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS ADELQKGNELALPTQFMKFLYLA 1240
WP 017647151 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 017648376 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 017649527 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 017771611 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 017771984 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
CFQ25032 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
CFV16040 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
KLJ37842 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
KLJ72361 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
KLL20707 1192 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1254
KLL42645 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 047207273 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 047209694 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 050198062 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 050201642 1178 NPS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 050204027 1178 NPS- —AFLE- - -SKGYLN- -I -RDDKLMI- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
WP 050881965 1178 NLS- —AFLE- - -SKGYLN- -I -RADKLII- -LPKYSLFE LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 050886065 1178 NPS—-AFLE-—SKGYLN--I-RADKLII--LPKYSLFE-—LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
AHN30376 1178 NPS— -AFLE- —SKGYLN- -I- RTDKLII- -LPKYSLFE- —LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240
EA078426 1178 NPS— -AFLE- —SKGYLN- -I- RADKLII- -LPKYSLFE- —LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
CCW42055 1178 NPS— -AFLE- —SKGYLN- -I- RTDKLII- -LPKYSLFE- —LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240
WP 003041502 1186 DKR— -AFLL- —GKGYKD- -I- K—KIIE- -LPKYSLFE- —LKDGSRRMLAS RGEIHKGNELFVPQKFTTLLYHA 1253
WP 037593752 1160 NPV— -DFLE- —QRGYRN- -V- RLEKIIK- -LPKYSLFE- —LENKRRRLLAS ARELQKGNELVI PQRFTTLLYHS 1222
WP 049516684 1160 HPV— -DFLE- —QRGYRN- -V- RLEKIIK- -LPKYSLFE- —LENKRRRLLAS ARELQKGNELVI PQRFTTLLYHS 1222
GAD46167 1159 NPV— -DFLE- —QRGYRN- -V- RLEKIIK- -LPKYSLFE- —LENKRRRLLAS ARELQKGNELVI PQRFTTLLYHS 1221
WP 018363470 1191 NPV— -EFLK- —NKGYQN- -V- QEDKLMK- -LPKYSLFE- —FEGGRRRLLAS ATELQKGNEIMLSAHLVALLYHA 1253
WP 003043819 1186 DPI— -GFLE- —AKGYKD- -I- KKELIFK- -LPKYSLFE- —LENGRRRMLAS —ELQKANELVLPQHLVRLLYYT 1248
WP 006269658 1159 NPV— -DFLE- —QRGYRN- -V- RLEKIIK- -LPKYSLFE- —LENKRRRLLAS AKELQKGNELVI PQRFTTLLYHS 1221
WP 048800889 1179 NPI— -MFLE- —SKGYRN- -I- QKDKLIK- -LPKYSLFE- —FEGGRRRLLAS AVELQKGNEMVLPQYLNNLLYHA 1241
WP 012767106 1178 NPL— -KFIE- —DKGYGN- -V- QIDKCIK- -LPKYSLFE- —FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY— 1245
WP 014612333 1178 NPL— -KFIE- —DKGYGN- -V- QIDKCIK- -LPKYSLFE- —FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY— 1245
WP 015017095 1178 NPL— -KFIE- —DKGYGN- -V- QIDKCIK- -LPKYSLFE- —FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY— 1245
WP 015057649 1178 NPL— -KFIE- —DKGYGN- -V- QIDKCIK- -LPKYSLFE- —FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY— 1245
WP 048327215 1178 NPL— -KFIE- —DKGYGN- -V- QIDKCIK- -LPKYSLFE- —FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY— 1245
WP 049519324 1178 NPL— -KFIE- —DKGYGN- -V- QIDKCIK- -LPKYSLFE- —FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY— 1245
WP 012515931 1157 NPV— -VFLE- —ARGYRE- -I- QEHLIIK- -LPKYSLFE- —LENGRRRLLAS -SELQKGNELFLPVDYMTFLYLA 1219
WP 021320964 1157 NPV— -VFLE- —AKGYRE- -I- QEHLIIK- -LPKYSLFE- —LENGRRRLLAS -SELQKGNELFLPVDYMTFLYLA 1219
WP 037581760 1157 NPV— -VFLE- —AKGYRE- -I- QEHLIIK- -LPKYSLFE- —LENGRRRLLAS -SELQKGNELFLPVDYMTFLYLA 1219
WP 004232481 1189 NPV— -SFLE- —KKGYHN- -V- QEDKLIK- -LPKYSLFE- —FEGGRRRLLAS ATELQKGNEWLPQYMVNLLYHS 1251
WP 009854540 1184 NPV— -EFLE- —NKGYHN- -I- REDKLIK- -LPKYSLFE- —FEGGRRRLLAS ASELQKGNEMVLPGYLVELLYHA 1246
WP 012962174 1185 NPV— -VFLE- —KKGYQN- -V- QEDNLIK- -LPKYSLFE- —FEGGRRRLLAS ASELQKGNEWLSRHLVELLYHA 1247
WP 039695303 1186 NPV— -EFLE- —NKGYHN- -I- REDKLIK- -LPKYSLFE- —FEGGRRRLLAS ASELQKGNEMVLPGYLVELLYHA 1248
WP 014334983 1189 NPV— -SFLE- —KKGYHN- -V- QEDKLIK- -LPKYSLFE- —FEGGRRRLLAS ATELQKGNEVMLPAHLVELLYHA 1251
WP 003099269 1177 DPI— -AFLE- —KKGYQD- -I- QTSSIIK- -LPKYSLFE- —LENGRKRLLAS —ELQKGNELALPNKYVKFLYLA 1239
AHY15608 1177 DPI— -AFLE- —KKGYQD- -I- QTSSIIK- -LPKYSLFE- —LENGRKRLLAS —ELQKGNELALPNKYVKFLYLA 1239
AHY17476 1177 DPI— -AFLE- —KKGYQD- -I- QTSSIIK- -LPKYSLFE- —LENGRKRLLAS —ELQKGNELALPNKYVKFLYLA 1239
ESR09100 9 DPI— -AFLE- —KKGYQD- -I- QTSSIIK- -LPKYSLFE- —LENGRKRLLAS -KELQKGNELALPNKYVKFLYLA 71
AGM98575 1177 DPI— -AFLE- —KKGYQD- -I- QTSSIIK- -LPKYSLFE- —LENGRKRLLAS —ELQKGNELALPNKYVKFLYLA 1239
ALF27331 1159 NPV— -AFLE- —RKGYRN- -V- QEENIVK- -LPKYSLFE- —LENGRRRLLAS ARELQKGNEIVLPNHLGTMLYHA 1221
WP 018372492 1168 EPEr- —FLA- —QKGFER- -V- EKT—IK- -LPKYSLFE- —MEKGRRRLLAS SGELQKGNQVLLPEHLIRLLSYA 1228
WP 045618028 1189 NPI— -AYLE- —ECGYKN- -I- NPNLIIK- -LPKYSLFE- —FNNGQRRLLAS SIELQKGNELIVPYHFTALLYHA 1251
WP 045635197 1184 NPI— -TFLE- —NKGYHN- -V- RKENILC- -LPKYSLFE- —LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS 1246
WP 002263549 1159 DPV— -AFLE- —RKGYRN- -V- QEENIIK- -LPKYSLFK- —LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP 002263887 1159 DPV— -AFLE- —RKGYRN- -V- QEENIIK- -LPKYSLFK- —LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP 002264920 1159 DPV— -AFLE- —RKGYRN- -V- QEENIIK- -LPKYSLFK- —LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP 002269043 1159 DPV— -AFLE- —RKGYRN- -V- QEENIIK- -LPKYSLFK- —LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP 002269448 1159 DPV-—AFLE---RKGYRN--V-QEENIIK--LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002271977 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002272766 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002273241 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002275430 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002276448 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002277050 1167 NPV- —KFLK- - -DKGYQQ- -I- EKNNFVK- -LPKYTLVD- IGNGIKRLWAS SKEVHKGNQLWSKKSQDLLYHA 1229
WP "002277364 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002279025 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002279859 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002280230 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002281696 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002282247 1167 NPV- —KFLK- - -DKGYQQ- -I- EKNNFVK- -LPKYTLVD- IGNGIKRLWAS SKEVHKGNQLWSKKSQDLLYHA 1229
WP "002282906 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002283846 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002287255 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002288990 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002289641 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002290427 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002295753 1159 DPI- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002296423 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002304487 1173 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLETLLYHA 1235
WP "002305844 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002307203 1159 DPI- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002310390 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "002352408 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPDHLGTLLYHA 1221
WP "012997688 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "014677909 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "019312892 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "019313659 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "019314093 1159 DPI- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "019315370 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "019803776 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "019805234 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "024783594 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "024784288 1167 NPV- —KFLK- - -DKGYQQ- -I- EKNNFVK- -LPKYTLVD- IGNGIKRLWAS SKEVHKGNQLWSKKSQDLLYHA 1229
WP "024784666 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "024784894 1159 DPV- —AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP "024786433 1167 NPV- —KFLK- - -DKGYQQ- -I- EKNNFVK- -LPKYTLVD- IGNGIKRLWAS SKEVHKGNQLWSKKSQDLLYHA 1229
WP 049473442 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK- -LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
WP 049474547 1159 DPV- - -AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- -LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221
EMC03581 1152 DPV- - -AFLE- - -RKGYRN- -V- QEENIIK- -LPKYSLFK- -LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1214
WP 000428612 1187 SPI- - -AFLE- - -NKGYHN- -V- RKENILC- -LPKYSLFE- -LKNGRRRMLAS AKELQKGNEIVLPVHLTTLLYHA 1249
WP 000428613 1185 NPI- - -TFLE- - -NKGYHN- -V- RKENILC- -LPKYSLFE- -LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS 1247
WP 049523028 1180 NPV- - -AFLE- - -GKGYQN- -V- VEENIIR- -LPKYSLFE- -LENGRRRMLAS AKELQKGNEMVLPSYLIALLYHA 1242
WP 003107102 1146 DRI- - -TFLE- - -KKGYQD- -I- QESLIIK- -LPKFSLFE- -LENGRKRLLAS —ELQKGNELSLPNKYIQFLYLA 1208
WP 054279288 1179 NPI- - -AFLE- - -SKGYHD- -I- QEHLMIT- -LPKYSLFE- -LENGRRRLLAS —ELQKGNEMVLPQHLVTFLYRV 1241
WP 049531101 1189 NPT- - -AYLE- - -EYGYKN- -I- NPNLIIK- -LPKYSLFK- -FNDGQRRLLAS SIELQKGNELILPYHFTTLLYHA 1251
WP 049538452 1189 NPI- - -AYLE- - -ECGYKN- -I- NPNLIIK- -LPKYSLFE- -FNGGQRRLLAS SIELQKGNELILPYHFTALLYHT 1251
WP 049549711 1191 NPI- - -AYLE- - -ECGYKN- -I- NPNLIIK- -LPKYSLFE- -FNGGQRRLLAS SIELQKGNELILPYHFTALLYHA 1253
WP 007896501 1183 DNI- - -AFLE- - -KKGYQD- -I- QEKLLIK- -LPKYSLFE- -LENGRRRLLAS —EFQKGNELALSGKYMKFLYLA 1245
EFR44625 1135 DNI- - -AFLE- - -KKGYQD- -I- QEKLLIK- -LPKYSLFE- -LENGRRRLLAS —EFQKGNELALSGKYMKFLYLA 1197
WP 002897477 1184 NPI- - -TFLE- - -NKGYHN- -V- RKENILC- -LPKYSLFE- -LENGRRRLLAS AKELQKGNEIVLPVCLTTLLYHS 1246
WP 002906454 1190 NPV- - -TYLE- - -ECGYKN- -I- NSNLIIK- -LPKYSLFE- -FNDGQRRLLAS SIELQKGNELILPYHLTALLYHA 1252
WP 009729476 1185 NPI- - -AFLE- - -NKGYHN- -V- CKENILC- -LPKYSLFE- -LENGRRRLLAS AKELQKCNEIVLPVYLTTLLYHS 1247
CQR24647 1175 NSV- - -TFLE- - -EKGYRN- -I- RENTIIK- -FPKYSLFE- -LENGRRRLLAS AIELQKGNEMFLPQQFVNLLYHA 1237
WP 000066813 1189 NPI- - -TFLE- - -NKGYHN- -V- RKENILC- -LPKYSLFE- -LESGRRRMLAS AKELQKGNEIVLPVYLTTLLYHS 1251
WP 009754323 1185 NPI- - -TFLE- - -NKGYHN- -V- RKENILC- -LPKYSLFE- -LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS 1247
WP 044674937 1178 NPI- - -EFLE- - -HKGYKN- -I- LEKNIIK- -LPKYSLFE- -LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS 1240
WP 044676715 1180 NPI- - -EFLE- - -HKGYKN- -I- LEKNIIK- -LPKYSLFE- -LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS 1242
WP 044680361 1180 NPI- - -EFLE- - -HKGYKN- -I- LEKNIIK- -LPKYSLFE- -LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS 1242
WP 044681799 1178 NPI- - -EFLE- - -HKGYKN- -I- LEKNIIK- -LPKYSLFE- -LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS 1240
WP 049533112 1186 DKR- - -AFLL- - -GKGYKD- -I- K—KIIE- -LPKYSLFE- -LKDGSRRMLAS RGEIHKGNELFVPQKFTTLLYHA 1253
WP 029090905 1118 SETslqAYIA- - -EQIKSE- -VelLN grlLKYQLIS- —NNGNRLYIAG -SERHNARQLIVSDEAAKVIWLI 1181
WP 006506696 1150 EKI- - -NYIE- -eKEGLSD- -VrllK Dn -IP QMIEm DGGEYLLTS —EYVNARQLVLNEKQCALIADI 1211
AIT42264 1177 NPI- - -DFLE- - -AKGYKE- -V- KKDLIIK- -LPKYSLFE- -LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239
WP 034440723 1150 QTT- - -EYLG- - -KIGFNK- -AsIIN S- -FKNYTLFE- -LENGSRRMIVG KGELQKGNQMYLPQNLLEFVYHL 1217
AKQ21048 1177 NPI- - -DFLE- - -AKGYKE- -V- KKDLIIK- -LPKYSLFE- -LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239
WP 004636532 1151 HPT- - -AYLE- - -EAGYNN- -P- TV—LHE- -LFKYQLFE- -LEDGSRRMIAS AKEFQKGNQMVLPLELVELLYHA 1211
WP 002364836 1157 NPI- - -LFLE- - -EKGFLR- -P- RV—LMK- -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 016631044 1108 NPI- - -LFLE- - -EKGFLR- -P- RV—LMK- -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1168
EMS75795 893 DPI- - -GFLS- - -NKGYSN- -V- TKF—IK- -LSKYTLYE- -LENGRRRMVAS -KEAQKANSFILPEKLVTLLYHA 953
WP 002373311 1157 NPI- - -LFLE- - -EKGFLR- -P- RV—LMK- -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 002378009 1157 NPI- - -LFLE- - -EKGFLR- -p- RV—LMK- -LPKYTLYQ- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 002407324 1157 NPI- - -LFLE- - -EKGFLR- -p- RV—LMK- -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 002413717 1157 NPI- - -LFLE- - -EKGFLR- -p- RV—LMK- -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 010775580 1159 NPI- - -LFLE- - -EKGFLR- -p- RV—LMK- -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1219
WP 010818269 1157 NPI- - -LFLE- - -EKGFLR- -p- RV—LMK- -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 010824395 1157 NPI—-LFLE—-EKGFLR--P-RV--LMK—-LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 016622645 1157 NPI— -LFLE— -EKGFLR- -P-RV-- LMK— -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 033624816 1157 NPI— -LFLE— -EKGFLR- -P-RV-- LMK— -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPERLLTLLYHA 1217
WP 033625576 1157 NPI— -LFLE— -EKGFLR- -P-RV-- LMK— -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 033789179 1157 NPI— -LFLE— -EKGFLR- -P-RV-- LMK— -LPKYTLYE- -FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217
WP 002310644 1159 SPV— -LFLK— -NKGYEQ- -A-EIE- -MK— -LPKYALFE- -LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1219
WP 002312694 1160 SPV— -LFLK— -NKGYEQ- -A-EIE- -MK— -LPKYALFE- -LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220
WP 002314015 1160 SPV— -LFLK— -NKGYEQ- -A-EIE- -MK— -LPKYALFE- -LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220
WP 002320716 1160 SPV— -LFLK— -NKGYEQ- -A-EIE- -MK— -LPKYALFE- -LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220
WP 002330729 1159 SPV— -LFLK— -NKGYEQ- -A-EIE- -MK— -LPKYALFE- -LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1219
WP 002335161 1160 SPV— -LFLK— -NKGYEQ- -A-EIE- -MK— -LPKYALFE- -LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220
WP 002345439 1160 SPV— -LFLK— -NKGYEQ- -A-EIE- -MK— -LPKYALFE- -LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220
WP 034867970 1150 DPT— -TFLK— -EKGFPQ- -V-TEF- -IK— -LPKYTLFE- -FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA 1210
WP 047937432 1160 SPV— -LFLK— -NKGYEQ- -A-EIE- -MK— -LPKYALFE- -LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220
WP 010720994 1150 DPT— -TFLK— -DKGFPQ- -V-TEF- -IK— -LPKYTLFE- -FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA 1210
WP 010737004 1150 DPT— -TFLK— -EKGFPQ- -V-TEF- -IK— -LPKYTLFE- -FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA 1210
WP 034700478 1150 DPT— -TFLK— -DKGFPH- -V-TEF- -IK— -LPKYTLFE- -FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA 1210
WP 007209003 1148 NPI1- —YLS— -KKDYHN- —pKVEAI -LPKYSLFE- -FENGRRRMVAS -SETQKGNQLI I PGHLMELLYHS 1208
WP 023519017 1144 DPR— -EFLK— -TKGYEG- -V-KQW- -LI— -LPKYILFE- -AQGGYRRMIAS -QETQKANSLILPENLVTLLYHA 1204
WP 010770040 1155 DPV— -SLLE— -EKGYAN- -P-EV-- LIH— -LPKYTLYE- -LENGRRRLLAS ANEAQKGNQLVLPASLVTLLYHA 1215
WP 048604708 1152 NER— -EFLK— -NKGYQN- -P-QI-- CMK— -LPKYSLYE- -FDDGRRRLLAS AKEAQKGNQMVLPAHLVTFLYHA 1212
WP 010750235 1153 DPI— -SFLI— -EKGYSN- -V-NQF- -IK— -LPKYTLFE- -LANGQRRMLAS -QELQKANSFILPEKLVTLLYHA 1213
AII16583 1216 NPI— -DFLE— -AKGYKE- -V-KKDLIIK— -LPKYSLFE- -LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1278
WP 029073316 1165 TKI— -NYIK—eSEGLEE- -VkllK- —E— -ILKNQLIEi NGGLFYVTS —EIVNARQLILDFNCTRIIDGI 1225
WP 031589969 1165 IKI— -NYLK—qAEDLEE- -VqlGK- —E— -ILKNQLIEk DGGLYYIVA —EIINAKQLILNESQTKLVCEI 1225
KDA45870 1139 DPT— -AYLA— -SRGYTNvtNsFIL- —PKYSLLEd —PEGRRRYLAS -KEFQKANELILPQHLVELLYWV 1199
WP 039099354 1171 QKI-spQFTKv- —KKQKGtiV-KWEDFEv- -IAPHILINq fFDNGQELTLGS HNEQELILDKTAVKLLNGA 1241
AKP02966 1173 KTL—qNWLE— -ENVKHKksIqllK- —Nn- -VPIGQIIY SKKVGLLS -REIANRQQLILPPEHSALLRIL 1237
WP 010991369 1155 DEK— -AFLE— -EQGYRQ- -P-KV-- LAK— -LPKYTLYE- -CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHA 1215
WP 033838504 1155 DEK— -AFLE— -EQGYRQ- -P-KV-- LAK— -LPKYTLYE- -CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHV 1215
EHN60060 1158 DEK— -AFLE— -EQGYRQ- -P-KV-- LAK— -LPKYTLYE- -CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHV 1218
EFR89594 924 DEK— -AFLE— -EQGYRQ- -P-KV-- LAK— -LPKYTLYE- -CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHA 984
WP 038409211 1155 DQK— -AFLE— -EKGYYS- -P-KV-- LTK— -IPKYTLYE- -CENGRRRMLGS ANEAQKGNQMVLPNHLMTLLYHA 1215
EFR95520 774 DQK— -AFLE— -EKGYYS- -P-KV-- LTK— -IPKYTLYE- -CENGRRRMLGS ANEAQKGNQMVLPNHLMTLLYHA 834
WP 003723650 1155 DEE— -AFLE— -EKGYRH- -P-KV-- LTK— -LPKYTLYE- -CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 1215
WP 003727705 1155 DEE— -AFLE— -EKGYHQ- -P-KV-- LTK— -LPKYTLYE- -CEKGRRRMLSS ANEAQKGNQLVLSNHLVSLLYHA 1215
WP 003730785 1155 DEE— -AFLE— -EKGYHQ- -P-KV-- LTK— -LPKYTLYE- -CEKGRRRMLSS ANEAQKGNQLVLSNHLVSLLYHA 1215
WP 003733029 1155 DEK— -TFLE— -EKGYHQ- -P-KV-- LIK— -VPKYTLYE- -CKNGRRRMLGS ANEAHKGNQMLLPNHLMALLYHA 1215
WP 003739838 1155 DEK— -SFLE— -KQGYRQ- -P-KV-- LTK— -LPKYTLYE- -CENGRRRMLAS ANEAQKGNQQVLKGQLITLLHHA 1215
WP 014601172 1155 DEE-—AFLE-—EKGYRH--P-KV—LTK--LPKYTLYE -CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 1215
WP 023548323 1155 DEK- —VFLE- —GKGYHQ- -P- KV—LTK- -LPKYALYE -CENGRRRMLGS ANEVHKGNQMLLPNHLMTLLYHA 1215
WP 031665337 1155 DEE- —AFLE- —EKGYRH- -P- KV—LTK- -LPKYTLYE -CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 1215
WP 031669209 1155 DEK- —TFLE- —EKGYHQ- -P- KV—LIK- -VPKYTLYE -CENGRRRMLGS ANEAHKGNQMLLPNHLMALLYHA 1215
WP 033920898 1155 DEK- —VFLE- —GKGYHQ- -P- KV—LTK- -LPKYALYE -CENGRRRMLGS ANEVHKGNQMLLPNHLMTLLYHA 1215
AKI42028 1158 DEE- —AFLE- —EKGYRH- -P- KV—LTK- -LPKYTLYE -CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 1218
AKI50529 1158 DEK- —VFLE- —GKGYHQ- -P- KV—LTK- -LPKYALYE -CENGRRRMLGS ANEVHKGNQMLLPNHLMTLLYHA 1218
EFR83390 603 DEE- —AFLE- —EKGYRH- -P- KV—LTK- -LPKYTLYE -CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 663
WP 046323366 1155 DQK- —EFLE- —GKGYRN- -P- KV—ITK- -IPKYTLYE -CENGRRRMLGS ANEAQKGNQMVLPNHLMTLLYHA 1215
AKE81011 1193 NPI- —DFLE- —AKGYKE- -V- KKDLIIK- -LPKYSLFE -LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1255
CU082355 1154 EQI- —EYVE- -kEEKLSD- -VkllK Nn -IPLNQLIE -—DGRQYLLTS —ECVNAMQLVLNEEQCKLIADI 1215
WP 033162887 1155 EQL- —SYIAspeHEDLID- -VrlVK E- -ILKNQLIE -—DGGLYYVTS —EYVTARQLSLNEQSCKLISEI 1217
AGZ 01981 1210 NPI- —DFLE- —AKGYKE- -V- KKDLIIK- -LPKYSLFE -LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1272
AKA60242 1177 NPI- —DFLE- —AKGYKE- -V- KKDLIIK- -LPKYSLFE -LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239
AKS40380 1177 NPI- —DFLE- —AKGYKE- -V- KKDLIIK- -LPKYSLFE -LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239
4UN5 B 1181 NPI- —DFLE- —AKGYKE- -V- KKDLIIK- -LPKYSLFE -LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1243
WP 010922251 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH—-RDKPIREq- 1305
WP "039695303 1249 HRAD NFNS-TEYLN- YVSEHKKEFEKVLSCVEDFANLYVDVE—KNLSKIR-A VAD-SM— -DNFSIEE— 1308
WP "045635197 1247 KNVH KLDE-PGHLE- YIQKHRNEFKDLLNLVSEFSQKYVLAD—ANLEKIK-S LYA-DN— -EQADIEI— 1306
5AXW A 979 GELYRVIg NDlLNRIE- -VNMIDITYREYLENMNDKRPPRIIKTiaSKTQSIK-K LYEvKSk- -KHPQIIKkg 1056
WP 009880683 924 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 989
WP "010922251 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "011054416 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "011284745 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "011285506 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "011527619 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "012560673 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "014407541 1239 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1304
WP "020905136 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "023080005 1239 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1304
WP "023610282 1239 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1304
WP "030125963 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "030126706 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "031488318 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "032460140 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "032461047 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "032462016 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "032462936 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "032464890 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "033888930 1065 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1130
WP "038431314 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "038432938 1239 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1304
WP "038434062 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
BAQ51233 1151 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1216
KGE60162 415 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 480
KGE60856 178 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 243
WP 002989955 1240 SHYEKLKgSPEDnEQKQL- FVEQHKHYLDEIIEQISEFSKRVILAD—ANLDKVL-S AYN-KH— -RDKPIREq- 1305
WP "003030002 1222 YQIE KNYE-PEHRE- YVEKHKDEFKELLEYISVFSRKYVLAD—NNLTKIE-M LFS-KN— -KDAEVSS— 1281
WP "003065552 1250 QRIN SFNS-TKYLD- YVSAHKKEFEKVLSCVEDFANLYVDVE—KNLSKIR-A VAD-SM— -DNFSIEE— 1309
WP "001040076 1241 SRYNESKgKPEEiEKKQE- FVNQHVSYFDDI FQI INDFSKRVILAD—ANLEKIN-R LYQ-DNk- -ENIPVDE— 1306
WP "001040078 1249 SRYNESKgKPEEiEKKQE- FVNQHVSYFDDILQLINDFSKRVILAD—ANLEKIN-K LYQ-DNk- -ENISVDE— 1314
WP "001040080 1241 SRYNESKgKPEEiEKKQE- FVNQHVSYFDDILQLINDFSKRVILAD—ANLEKIN-K LYQ-DNk- -ENISVDE— 1306
WP "001040081 1241 SRYNESKgKPEEiEKKQE- FVNQHVSYFDDILQLINDFSKRVILAD—ANLEKIN-K LYQ-DNk- -ENISVDE— 1306
WP "001040083 1241 SRYNESKgKPEEiEKKQE- FVNQHVSYFDDILQLINDFSKRVILAD—ANLEKIN-K LYQ-DNk- -ENISVDE— 1306
WP "001040085 1241 SRYNESKgKPEEiEKKQE- FVNQHVSYFDDILQLINDFSKRVILAD—ANLEKIN-K LYQ-DNk- -ENISVDE— 1306
WP 001040087 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE— 1306
WP 001040088 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040089 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040090 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040091 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040092 1241 SRYNESKgKPEEiEKKQE- -FVNQHISYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYS- DNk- -DNTPVDE— 1306
WP 001040094 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENIPVDE— 1306
WP 001040095 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENIPVDE— 1306
WP 001040096 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENIPVDE— 1306
WP 001040097 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENIPVDE— 1306
WP 001040098 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENIPVDE— 1306
WP 001040099 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENIPVDE— 1306
WP 001040100 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENIPVDE— 1306
WP 001040104 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040105 1241 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040106 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040107 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040108 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040109 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 001040110 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 015058523 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYS- DNk- -DNTPVDE— 1306
WP 017643650 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENIPVDE— 1306
WP 017647151 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 017648376 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 017649527 1241 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 017771611 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 017771984 1241 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
CFQ25032 1241 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
CFV16040 1241 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
KLJ37842 1241 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
KLJ72361 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
KLL20707 1255 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1320
KLL42645 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 047207273 1241 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 047209694 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENIPVDE— 1306
WP 050198062 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 050201642 1241 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 050204027 1241 SRYNELKgKPEEiEQKQE- -FWQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 050881965 1241 SRYNESKgKPEEiEKKQE- -F QHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- K LYQ- DNk- -ENISVDE— 1306
WP 050886065 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN--K LYQ-DNk--ENISVDE— 1306
AHN30376 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- -K LYS- DNk- -DNTPVDE— 1306
EA078426 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQLINDFSKRVILAD- -ANLEKIN- -K LYQ- DNk- -ENISVDE— 1306
CCW42055 1241 SRYNESKgKPEEiEKKQE- -FVNQHVSYFDDILQIINDFSNRVILAD- -ANLEKIN- -K LYQ- DNk- -ENISVDE— 1306
WP 003041502 1254 KRIN NPIN-KDHIE- -YVKKHRDDFKELLNYVLEFNEKYVGAT- -KNGERLK- -E AVA- DF— -DSKSNEE— 1313
WP 037593752 1223 YQIE KNYE-PEHRE- -YVEKHKDEFKELLEYISVFSRKYVLAD- -NNLTKIE- -M LFS- KN— -KDAEVSS— 1282
WP 049516684 1223 YRIE KDYE-PEHRE- -YVEKHKDEFKELLEYISVFSRKYVLAD- -NNLTKIE- -M LFS- KN— -KDAEVSS— 1282
GAD46167 1222 YQIE KNYE-PEHRE- -YVEKHKDEFKELLEYISVFSRKYVLAD- -NNLTKIE- -M LFS- KN— -KDAEVSS— 1281
WP 018363470 1254 HRIG NFNS-AEHLK- -YVSEHKKEFEEVLSCVENFANVYVDVE- -KNLSKIR- -A AAD- SM— -DNFSIEE— 1313
WP 003043819 1249 -KVNSNLK- -s SFD- EQfavSDSIL—1- 1310
WP 006269658 1222 YRIE KDYE-PEHRE- -YVEKHKDEFKELLEYISVFSRKYVLAD- -NNLTKIE- -M LFS- KN— -KDAEVSS— 1281
WP 048800889 1242 HRID NSDN-SEHLK- -YITEHKEEFGKLLSYIENFAKSYVDVD- -KNLEKIQ- -L AVE- KI— -DSFSVKE— 1301
WP 012767106 1246 -HAHKIEsSKE—LEHEA- -YILDHYNDLYQLLSYIERFASLYVDVE- -KNISKVK- -E LFS- NI— -ESYSISEi- 1308
WP 014612333 1246 -HAHKIEsSKE—LEHEA- -YILDHYNDLYQLLSYIERFASLYVDVE- -KNISKVK- -E LFS- NI— -ESYSISEi- 1308
WP 015017095 1246 -HAHKIEsSKE—LEHEA- -YILDHYNDLYQLLSYIERFASLYVDVE- -KNISKVK- -E LFS- NI— -ESYSISEi- 1308
WP 015057649 1246 -HAHKIEsSKE—LEHEA- -YILDHYNDLYQLLSYIERFASLYVDVE- -KNISKVK- -E LFS- NI— -ESYSISEi- 1308
WP 048327215 1246 -HAHKIEsSKE—LEHEA- -YILDHYNDLYQLLSYIERFASLYVDVE- -KNISKVK- -E LFS- NI— -ESYSISEi- 1308
WP 049519324 1246 -HAHKIEsSKE—LEHEA- -YILDHYNDLYQLLSYIERFASLYVDVE- -KNISKVK- -E LFS- NI— -ESYSISEi- 1308
WP 012515931 1220 AHYHELTgSSEDvLRKKY- -FVDRHLHYFDDIIQMINDFAERHILAS- -SNLEKIN- -H TYH- NN— -SDLPVNEr- 1285
WP 021320964 1220 AHYHELTgSSEDvLRKKY- -FVERHLHYFDDIIQMINDFAERHILAS- -SNLEKIN- -H TYH- NN— -SDLPINEr- 1285
WP 037581760 1220 AHYHELTgSSEDvLRKKY- -FVERHLHYFDDIIQMINDFAERHILAS- -SNLEKIN- -H TYH- NN— -SDLPVNEr- 1285
WP 004232481 1252 QHVN NSHK-PEHLN- -YVKQHKDEFKDIFNLIISIARINILKP- -KWDNL-- -IN- EF— -TEYGQED— 1308
WP 009854540 1247 HRAD NFNS-TEYLN- -YVSEHKKEFEKVLSCVEDFANLYVDVE- -KNLSKIR- -A VAD- SM— -DNFSIEE— 1306
WP 012962174 1248 HRVN SFNN-SEHLK- -YVSEHKKEFGEVLSCVENFAKSYVDVE- -KNLGKIR- -A VAD- KI— -DTFSIED— 1307
WP 039695303 1249 HRAD NFNS-TEYLN- -YVSEHKKEFEKVLSCVEDFANLYVDVE- -KNLSKIR- -A VAD- SM— -DNFSIEE— 1308
WP 014334983 1252 HRID SFNS-TEHLK- -YVSEHKKEFEKVLSCVENFSNLYVDVE- -KNLSKVR- -A AAE- SM— -TNFSLEE— 1311
WP 003099269 1240 SHYTKFTgKEEDrEKKRS- -YVESHLYYFDEIMQIIVEYSNRYILAD- -SNLIKIQ- -N LYK- EKd- —NFSIEEq- 1305
AHY15608 1240 SHYTKFTgKEEDrEKKRS- ΤΛζ T 1273
AHY17476 1240 SHYTKFTgKEEDrEKKRS- 1267
ESR09100 72 SHYTKFTgKEEDrEKKRS- -YVESHLYYFDEIMQIIVEYSNRYILAD- -SNLIKIQ- -N LYK- -Ek- -DNFSIEEq- 137
AGM98575 1240 SHYTKFTgKEEDrEKKRS- 1 ~W 1281
ALF27331 1222 KNIH KVDE-PKHLD- -YVKKHKDEFKELLDWSNFSKKNILAE- -SNLEKIE- -E LYA- QN— -NNKDITE— 1281
WP 018372492 1229 KKVDVLVkSKDD DYD- —LEEHRAEFAELLDCIKKFNDMYILAS- -SNMSKIE- -E IYQ- KNi- —DAPIEE— 1289
WP 045618028 1252 QRIN KISE-PIHKQ- -YVETHQSEFKELLTAIISLSKKYI-QK- -PNVESL-- LQQ- AF— -DQSDKDIyq 1310
WP 045635197 1247 KNVH KLDE-PGHLE- -YIQKHRNEFKDLLNLVSEFSQKYVLAD- -ANLEKIK- -s LYA- DN— -EQADIEI— 1306
WP 002263549 1222 KNIH KVDE-PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- -E LYA- QN— -NGEDLKE— 1281
WP 002263887 1222 KNIH KVDE-PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- -E LYA- QN— -NGEDLKE— 1281
WP 002264920 1222 KNIH KVDE-PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- -E LYA- QN— -NGEDLKE— 1281
WP 002269043 1222 KNIH KVDE-PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- -E LYA- QN— -NGEDLKE— 1281
WP 002269448 1222 KNIH-—-KVDE- PKHLD--YVDKHKDEFKELLDWSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281
WP "002271977 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002272766 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002273241 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002275430 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002276448 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002277050 1230 HHL— DN- DYSNE- -YVKNHYQQFDILFNEITSFSKKCKLGK- -EHIQKIE- E AYSkER- - -DSASIEE- - 12 87
WP "002277364 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002279025 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002279859 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002280230 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002281696 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002282247 1230 HHL— DN- DYSNE- -YVKNHYQQFDILFNEITSFSKKCKLGK- -EHIQKIE- E AYSkER- - -DFASIEE- - 12 87
WP "002282906 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002283846 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002287255 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002288990 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002289641 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002290427 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002295753 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002296423 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002304487 1236 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 95
WP "002305844 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002307203 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002310390 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "002352408 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "012997688 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "014677909 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "019312892 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "019313659 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "019314093 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "019315370 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "019803776 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "019805234 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "024783594 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "024784288 1230 HHL— DN- DYSNE- -YVKNHYQQFDILFNEITSFSKKCKLGK- -EHIQKIE- E AYSkER- - -DFASIEE- - 12 87
WP "024784666 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "024784894 1222 KNIH- — -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA-QN- - -NGEDLKE- - 12 81
WP "024786433 1230 HHL— DN- DYSNE- -YVKNHYQQFDILFNEITSFSKKCKLGK- -EHIQKIE- E AYSkER- - -DSASIEE- - 12 87
WP 049473442 1222 KNIH -KVDE- PKHLD--YVDKHKDEFKELLDWSNFSKKYTLAE--GNLEKIK-E LYA--QN---NGEDLKE— 1281
WP "049474547 1222 KNIH -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA- -QN- - -NGEDLKE— 1281
EMC03581 1215 KNIH -KVDE- PKHLD- -YVDKHKDEFKELLDWSNFSKKYTLAE- -GNLEKIK- E LYA- -QN- - -NGEDLKE— 1274
WP 000428612 1250 KNIH -RLDE- PEHLE- -YIQKHRNEFKGLLNLVSEFSQKYVLAD- -ANLEKIK- N LYA- -DN- - -EQADIEI— 1309
WP "000428613 1248 KNVH -KLDE- PEHLE- -YIQKHRNEFKDLLNLVSEFSQKYVLAD- -ANLEKIQ- N LYA- -DN- - -EQADIEI— 1307
WP "049523028 1243 KRIQ -KKDE- PEHLE- -YIKQHHSEFNDLLNFVSEFSQKYVLAE- -SNLEKIK- N LYI- -DN- - -EQTNMEE— 1302
WP "003107102 1209 SRYTSFSgKEEDr 'EKHRH- -FVESHLHYFDEIKDIIADFSRRYILAD- -ANLEKIL- T LYN- -EKn - —QFSIEEq- 1274
WP "054279288 1242 SKRDK—gTQSEnME -YISNHKEKFIEIFHYIIRYAEKNVIKP- -KVIERLN- D TFNqKF- - -NDSDLTE1- 1303
WP "049531101 1252 QRIN -KISE- PIHKQ- -YVETHQSEFEELLTTIISLSKKYI-QK- -PIVESL-- - LQQ- -AF- - -EQADKDIyq 1310
WP "049538452 1252 QRIN -KISE- PIHKQ- -YVEAHQNEFKELLTTIISLSKKYI-QK- -PNVESL-- - LQQ- -AF- - -EQADKDIyq 1310
WP "049549711 1254 QRIN -KFSE- PIHKQ- -YVEAHQNEFKELLTIIISLSKKYI-QK- -PNVESL-- - LHQ- -AF- - -EQADNDIyq 1312
WP "007896501 1246 SRYDKLSsKIESeQQKKL- -FVEQHLHYFDEILDIWKHATCYIKAE- -NNLKKII- s LYK- -KK- - -EAYSINEq- 1311
EFR44625 1198 SRYDKLSsKIESeiQQKKL- -FVEQHLHYFDEILDIWKHATCYIKAE- -NNLKKII- s LYK- -KK- - -EAYSINEq- 1263
WP 002897477 1247 KNLH -KLDE- PEHLE- -YIQKHRNEFKDLLNLVSEFSQKYILAE- -ANLEKIK- D LYA- -DN- - -EQADIEI— 1306
WP "002906454 1253 QRIN -KISE- PIHKQ- -YVEAHQNEFKELLTTIISLSKKYI-QK- -PNVELL-- - LQQ- -AF- - -DQADKDIyq 1311
WP "009729476 1248 KNVH -KLDE- PGHLE- -YIQKHRNEFKDLLNLVSEFSQKYVLAD- -ANLEKIK- N LYA- -DN- - -EQADIEI— 1307
CQR24647 1238 QHAN -KEDS- VI- -YLEKHRHELSELFHHIIGVSEKTILKP- -KVEMTLN- E AFE- -KHf - -EFDEVSE— 1295
WP 000066813 1252 KNVH -KLDE- PEHLE- -YIQKHRYEFKDLLNLVSEFSQKYVLAD- -ANLEKIK- N LYA- -DN- - -EQADIEI— 1311
WP "009754323 1248 KNVH -KLDE- PEHLE- -YIQKHRYEFKDLLNLVSEFSQKYVLAE- -ANLEKIK- s LYV- -DN- - -EQADIEI— 1307
WP "044674937 1241 SNIH -KITE- PIHLN- -YVNKNKHEFKELLRHISDFSTRYILAQ- -DRLSKIE- E LYD- -KN- - -DGDDISD— 1300
WP "044676715 1243 SNIH -KITE- PIHLN- -YVNKNKHEFKELLRHISDFSTRYILAQ- -DRLSKIE- E LYD- -KN- - -DGDDISD— 1302
WP "044680361 1243 SNIH -KITE- PIHLN- -YVNKNKHEFKELLRHISDFSTRYILAQ- -DRLSKIE- E LYD- -KN- - -DGDDISD— 1302
WP "044681799 1241 SNIH -KITE- PIHLN- -YVNKNKHEFKELLRHISDFSTRYILAQ- -DRLSKIE- E LYD- -KN- - -DGDDISD— 1300
WP "049533112 1254 KRIN -NPIN- KDHIE- -YVKKHRDDFKELLNYVLEFNEKYVGAT- -KNGERLK- E AVA- -DF- - -DSKSNEE— 1313
WP "029090905 1182 STKQA— DE- AMFLKyyRLEHLEAVFEEL IRKQAADYQI FE- -KLIKKIEvN FYS- c TYNEk- 1240
WP "006506696 1212 YNAIYKQ -DYDNlDDILMi QLYIELTNKMKVLYPAY-rGIAEKFE- s YW- i SKEEk- 1268
AIT42264 1240 SHYEKLKgSPEDnEQKQL- -FVEQHKHYLDEIIEQISEFSKRVILAD- -ANLDKVL- s AYN- -KH- - -RDKPIREq- 1305
WP 034440723 1218 KHYNE— DE- -TSHK- -FIVEHKAYFDELLNYIVEFANKYLELE- -NSIEKIK- D LYH- gKGPDVEEke 1276
AKQ21048 1240 SHYEKLKgSPEDnEQKQL- -FVEQHKHYLDEIIEQISEFSKRVILAD- -ANLDKVL- s AYN- -KH- - -RDKPIREq- 1305
WP 004636532 1212 NRYDKVK fPDSIE- -YVHDNLAKFDDLLEYVIDFSNKYINAD- -KNVQKIQ- K IYK- -EH- - -GTEDVEL— 1271
WP "002364836 1218 KQCLL— —PNQ- SESLA- -YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- K LFE- -AN- - -QTADVKE— 1277
WP "016631044 1169 KQCLL— —PNQ- SESLA- -YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- K LFE- -AN- - -QTADVKE— 1228
EMS75795 954 QHYDEIAhKESF- D- -YVNDHLSEFREILDQVIDFSNRYTIAA- -KNTEKIA- E LFE- -QN- - -QESTVQS— 1013
WP 002373311 1218 KQCLL— —PNQ- SESLA- -YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- K LFE- -AN- - -QTADVKE— 1277
WP "002378009 1218 KQCLL— —PNQ- SESLA- -YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- K LFE- -AN- - -QTADVKE— 1277
WP "002407324 1218 KQCLL— —PNQ- SESLA- -YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- K LFE- -AN- - -QTADVKE— 1277
WP "002413717 1218 KQCLL— —PNQ- SESLA- -YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- K LFE- -AN- - -QTADVKE— 1277
WP "010775580 1220 KQCLL— —PNQ- SESLA- -YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- K LFE- -AN- - -QTADVKE— 1279
WP "010818269 1218 KQCLL— —PNQ- SESLA- -YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- K LFE- -AN- - -QTADVKE— 1277
WP_010824395 1218 KQCLL-- PNQ- SESLA YVEQHQPEFQEILERWDFAEVHTLAK--SKVQQIV--K LFE-AN—-QTADVKE— 1277 WP_016622645 1218 KQCLL-- PNQ- SESLA YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- -K LFE- AN— -QTADVKE— 1277 WP_033624816 1218 KQCLL-- PNQ- SESLA YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- -K LFE- AN— -QTADVKE— 1277 WP_033625576 1218 KQCLL-- PNQ- SESLA YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- -K LFE- TN— -QTADVKE— 1277 WP_033789179 1218 KQCLL-- PNQ- SESLA YVEQHQPEFQEILERWDFAEVHTLAK- -SKVQQIV- -K LFE- AN— -QTADVKE— 1277 WP_002310644 1220 KQYDEIShKESF- D YVNEHHKEFSEVFARVLEFAGKYTLAE- -KNIEKLE- -K IYK- EN— -QTDDLAK— 1279 WP_002312694 1221 KQYDEIShKESF- D YVNEHHKEFSEVFARVLEFAGKYTLAE- -KNIEKLE- -K IYK- EN— -QTDDLAK— 1280 WP_002314015 1221 KQYDEIShKESF- D Y EHHKEFSEVFARVLEFAGKYTLAE- -KNIEKLE- -K IYK- EN— -QTDDLAK— 1280 WP_002320716 1221 KQYDEIShKESF- D Y EHHKEFSEVFARVLEFAGKYTLAE- -KNIEKLE- -K IYK- EN— -QTDDLAK— 1280 WP_002330729 1220 KQYDEIShKESF- D Y EHHKEFSEVFARVLEFAGKYTLAE- -KNIEKLE- -K IYK- EN— -QTDDLAK— 1279 WP_002335161 1221 KQYDEIShKESF- D Y EHHKEFSEVFARVLEFAGKYTLAE- -KNIEKLE- -K IYK- EN— -QTDDLAK— 1280 WP_002345439 1221 KQYDEIShKESF- D YVNEHHKEFSEVFARVLEFAGKYTLAE- -KNIEKLE- -K IYK- EN— -QTDDLAK— 1280 WP_034867970 1211 QHYDKITyQESF- D Y THLSDFSAILTEVLAFAEKYTLAD- -KNIERIQ- -E LYE- EN— -KYGETSM— 1270 WP_047937432 1221 KQYDEIShKESF- D YVNEHHKEFSEVFARVLEFAGKYTLAE- -KNIEKLE- -K IYK- EN— -QTDDLAK— 1280 WP_010720994 1211 QHYDKITyQESF- D Y THLSDFSAILTEVLAFAEKYTLAD- -KNIERIQ- -E LYE- EN— -KYGEISM— 1270 WP_010737004 1211 QHYDKITyQESF- D YVNTHLSDFSAILTEVLAFAEKYTLAD- -KNIERIQ- -E LYE- EN— -KYGETSM— 1270 WP_034700478 1211 QHYDKITyQESF- D YVNTHLSDFSAILTEVLAFAEKYTLAD- -KNIERIQ- -E LYE- EN— -KYGEISM— 1270 WP_007209003 1209 KKIIN—gKNSD- -SVS YIQNNKEKFREIFEYIVDFSSKYISAD- -ANLNKIE- -K IFE- NNfh KASEqe 1269 WP_023519017 1205 RHYDEINhKVSF- D YVNAHKEGFNDI FDFI SDFGVRYILAP- -QHLEKIK- -V AYE- KN— -KEVDLKE— 1264 WP_010770040 1216 KQVDE-- -DS- GKSEE YVREHRAEFAEILNYVQAFSETKILAN- -KNLQTIL- -K LYE- EN— -KEADIKE— 1274 WP_048604708 1213 KHCNE-- -KP- D-SLK YVTEHQSGFSEIMAHVKDFAEKYTLVD- -KNLEKIL- -s LYA- KN— -MDSEVKE— 1270 WP_010750235 1214 NHYDEIAyKDSY- --D YVNEHFSNFQDILDKVI I FAEKYTSAP- -QKLNQII- -A TYE- KN— -QEADRKI— 1273 All 16583 1279 SHYEKLKgSPEDnEQKQL-- FVEQHKHYLDEIIEQISEFSKRVILAD- -ANLDKVL- -s AYN- KH— -RDKPIREq- 1344 WP_02 9073316 1226 YKAMKYK-NYSElSQEEIm- NVYDI FVEKLKLYYPTY-kNIATNFE- -N FEN- i SDEEk- 1282 WP_031589969 1226 YKAMKYK-NYDNlDSEKIi- DLYRLLINKMELYYPEYrkQLVKKFE- -D LKV- i SIEEk- 1283 KDA45870 1200 NAKDG EQKLE-- DHKAEFKELFDKIMEFADKYWAP- -KNSEKIR- -R LYE- ENq- DATPme 1253 WP_03 9099354 1242 LPLTQ SEeLAEQV-- YDEILDQVMHYFPLYDTNQfrAKLSAGKaA DGN- KMv- QVGQqv 1306 AKP02966 1238 QIPDE DpDQILAf- YDKNILVEILQELITKMKKFYPFY—KNEQEFLaS FNQ- ATTSEk- 1296 WP_01 0991369 1216 ANCEV-- SD- GKSLD- YIESNREMFAELLAHVSEFAKRYTLAE—ANLNKIN-Q LFE- QN— -KEGDIKA— 1274 WP_033838504 1216 ANCEV-- SD- GKSLD- YIESNREMFAELLAHVSEFAKRYTLAE—ANLNKIN-Q LFE- QN— -KEGDIKA— 1274 EHN60060 1219 ANCEV-- SD- GKSLD- YIESNREMFAELLAHVSEFAKRYTLAE—ANLNKIN-Q LFE- QN— -KEGDIKA— 1277 EFR89594 985 ANCEV-- SD- GKSLD- YIESNREMFAELLAHVSEFAKRYTLAE—ANLNKIN-Q LFE- QN— -KEGDIKA— 1043 WP_03 8409211 1216 KNCEA-- ND- GESLA- YIEMHREMFAELLAYI SEFAKRYTLAN—DRLEKIN-M FFE- QN— -KKGDIKV— 1274 EFR95520 835 KNCEA-- ND- GESLA- YIEMHREMFAELLAYI SEFAKRYTLAN—DRLEKIN-M FFE- QN— -KKGDIKV— 893 WP_00 3723650 1216 KNCEA-- SD- GKSLK- YIEAHRETFSELLAQVSEFATRYTLAD—ANLSKIN-N LFE- QN— -KEGDIKA— 1274 WP_003727705 1216 KNCEA-- SD- GKSLK- YIEAHRETFSELLAQVSEFATKYTLAD—ANLSKIN-N LFE- QN— -KEGDIKA— 1274 WP_003730785 1216 KNCEA-- SD- GKSLK- YIEAHRETFSELLAQVSEFATKYTLAD—ANLSKIN-N LFE- QN— -KEGDIKA— 1274 WP_003733029 1216 EKYEA-- ID- GESLA- YIEVHRALFDELLAYISEFARKYTLSN—DRLDEIN-M LYE- RN— -KDGDVKS— 1274 WP 003739838 1216 KNCEA-- SD- GKSLD- YIESNREMFGELLAHVSEFAKRYTLAD—ANLSKIN-Q LFE- QN— -KDNDIKV— 1274
WP 014601172 1216 KNCEA SD-GKSLK--YIEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN--N LFE-QN---KEGDIQA— 1274
WP 023548323 1216 EKREA ID-GESLA- -YIEAHKAVFGELLAHI SEFARKYTLAN- -DKLDEIN- -M LYE- RN- - -KDGDVKS— 1274
WP 031665337 1216 KNCEA SD-GKSLK- -YIEAHRETFSELLAQVSEFATRYTLAD- -ANLSKIN- -N LFE- QN- - -KEGDIKA— 1274
WP 031669209 1216 EKYEA ID-GESLA- -YIEVHRALFDELLAYISEFARKYTLSN- -DRLDEIN- -M LYE- RN- - -KDGDVKS— 1274
WP 033920898 1216 EKREA ID-GESLA- -YIEAHKAVFGELLAHI SEFARKYTLAN- -DKLDEIN- -M LYE- RN- - -KDGDVKS— 1274
AKI42028 1219 KNCEA SD-GKSLK- -YIEAHRETFSELLAQVSEFATRYTLAD- -ANLSKIN- -N LFE- QN- - -KEGDIQA— 1277
AKI50529 1219 EKREA ID-GESLA- -YIEAHKAVFGELLAHI SEFARKYTLAN- -DKLDEIN- -M LYE- RN- - -KDGDVKS— 1277
EFR83390 664 KNCEA SD-GKSLK- -YTEAHRETFSELLAQVSEFATRYTLAD- -ANLSKIN- -N LFE- QN- - -KEGDIKX— 722
WP 046323366 1216 KNCEA SD-GKSLA- -YIESHREMFAELLDSISEFASRYTLAD- -ANLEKIN- -T IFE- QN- - -KSGDVKV— 1274
AKE81011 1256 SHYEKLKgSPEDnEQKQL- -FVEQHKHYLDEIIEQISEFSKRVILAD- -ANLDKVL- -s AYN- KH- - -RDKPIREq- 1321
CU082355 1216 YNAIYKQ-DFDG1DNMLMi QLYLQLIDKLKTLYPIY-mGIVEKFE- -K FVS- i SKEEk- 1272
WP 033162887 1218 YAAMLKK-RYEY1DEEEI f DLYLQLLQKMDTLYPAY-kGIAKRFF- -D FKN- i DWEk- 1274
AGZ 01981 1273 SHYEKLKgSPEDnEQKQL- -FVEQHKHYLDEIIEQISEFSKRVILAD- -ANLDKVL- -s AYN- KH- - -RDKPIREq- 1338
AKA60242 1240 SHYEKLKgSPEDnEQKQL- -FVEQHKHYLDEIIEQISEFSKRVILAD- -ANLDKVL- -s AYN- KH- - -RDKPIREq- 1305
AKS40380 1240 SHYEKLKgSPEDnEQKQL- -FVEQHKHYLDEIIEQISEFSKRVILAD- -ANLDKVL- -s AYN- KH- - -RDKPIREq- 1305
4UN5 B 1244 SHYEKLKgSPEDnEQKQL- -FVEQHKHYLDEIIEQISEFSKRVILAD- -ANLDKVL- -s AYN- KH- - -RDKPIREq- 1309
WP 010922251 1306 -AE---Nil HLFTLTNLGAP-AAFKYFD- -DRK--R--YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365
WP 039695303 1309 ISN- - -SFI NLLTLTALGAP-ADFNFLG- PRK- -R- -YTSTKECL NATLIHQSITGLYETRIDLSKL- - 1369
WP 045635197 1307 LAN- - -SFI NLLTFTALGAP-AAFKFFG- DRK- -R- -YTTVSEIL NATLIHQSITGLYETWIDLSKL- - 1367
5AXW A
WP 009880683 990 -AE- - -Nil HLFTLTNLGAP- AAFKCFD- TTI GRN- -R- -YKSIKEVL DATLIHQSITGLYETRIDLSQL- - 1049
WP 010922251 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 011054416 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 011284745 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATFIHQSITGLYETRIDLSQL- - 1365
WP 011285506 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 011527619 1306 -AE- - -Nil HLFTLTNLGAP-TAFKYFD- TTI DRK- -R- -YTSTKEVL DATFIHQSITGLYETRIDLSQL- - 1365
WP 012560673 1306 -AE- - -Nil HLFTLTNLGAP-AAFKCFD- TTI GRN- -R- -YKSIKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 014407541 1305 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1364
WP 020905136 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 023080005 1305 -AK- - -Nil HLFTLTNLGAP-AAFKYFD- TTI ERN- -R- -YKSIKEVL DATLIHQSITGLYETRIDLSQL- - 1364
WP 023610282 1305 -AK- - -Nil HLFTLTNLGAP-AAFKYFD- TTI ERN- -R- -YKSIKEVL DATLIHQSITGLYEIRIDLSQL- - 1364
WP 030125963 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI GRN- -R- -YKSIKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 030126706 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 031488318 1306 -AE- - -Nil HLFTLTNFGAP-AAFIYFD- TTI GRN- -R- -YKSIKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 032460140 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI GRN- -R- -YKSIKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 032461047 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI GRN- -R- -YKSIKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 032462016 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 032462936 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 032464890 1306 -AE- - -Nil HLFTLTNLGAP-TAFKYFD- TTI DRK- -R- -YTSTKEVL DATFIHQSITGLYETRIDLSQL- - 1365
WP 033888930 1131 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1190
WP 038431314 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1365
WP 038432938 1305 -AK- - -Nil HLFTLTNLGAP-AAFKYFD- TTI ERN- -R- -YKSIKEVL DATLIHQSITGLYETRIDLSQL- - 1364
WP 038434062 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI GRN- -R- -YKSIKEVL DATLIHQSITGLYETRIDLSQL- - 1365
BAQ51233 1217 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 1276
KGE60162 481 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 540
KGE60856 244 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI DRK- -R- -YTSTKEVL DATLIHQSITGLYETRIDLSQL- - 303
WP 002989955 1306 -AE- - -Nil HLFTLTNLGAP-TAFKYFD- TTI DRK- -R- -YTSTKEVL DATFIHQSITGLYETRIDLSQL- - 1365
WP 003030002 1282 LAK- - -SFI SLLTFTAFGAP-AAFNFFG- ENI DRK- -R- -YTSVTECL NATLIHQSITGLYETRIDLSKL- - 1342
WP 003065552 1310 ISN- - -SFI NLLTLTALGAP-ADFNFLG- EKI PRK- -R- -YTSTKECL NATLIHQSITGLYETRIDLSKI- - 1370
WP 001040076 1307 LAN- - -Nil NLFTFTSLGAP-AAFKFFD- KIV- DRK- -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL- - 1367
WP 001040078 1315 LAN- - -Nil NLFTFTSLGAP-AAFKFFD- KIV- DRK- -R- -YTSTKEVL NSTLIHQSITGLYETRIDLSKL- - 1375
WP 001040080 1307 LAN- - -Nil NLFTFTSLGAP-AAFKFFD- KIV- DRK- -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL- - 1367
WP 001040081 1307 LAN- - -Nil NLFTFTSLGAP-AAFKFFD- KIV- DRK- -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL- - 1367
WP 001040083 1307 LAN- - -Nil NLFTFTSLGAP-AAFKFFD- KIV- DRK- -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL- - 1367
WP 001040085 1307 LAN- - -Nil NLFTFTSLGAP-AAFKFFD- KIV- DRK- -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL- - 1367
WP 001040087 1307 LAN---Nil NLFTFTSLGAP--AAFKFFD--KIV--DRK -R--YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040088 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040089 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040090 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040091 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040092 1307 LAK- - -Nil NLFTFTSLGAP- -AAFKFFD- -KSV- -DRK -R- -YTSTKEVL DSTLIHQSITGLYETRIDLGKL— 1367
WP "001040094 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040095 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040096 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040097 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040098 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040099 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHKSITGLYETRIDLGKL— 1367
WP "001040100 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040104 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040105 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040106 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040107 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040108 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "001040109 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQFITGLYETRIDLGKL— 1367
WP "001040110 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "015058523 1307 LAK- - -Nil NLFTFTSLGAP- -AAFKFFD- -KSV- -DRK -R- -YTSTKEVL DSTLIHQSITGLYETRIDLGKL— 1367
WP "017643650 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "017647151 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "017648376 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "017649527 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "017771611 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "017771984 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
CFQ25032 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
CFV16040 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
KLJ37842 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
KLJ72361 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
KLL20707 1321 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1381
KLL42645 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP 047207273 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "047209694 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHKSITGLYETRIDLGKL— 1367
WP "050198062 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "050201642 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "050204027 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP "050881965 1307 LAN- - -Nil NLFTFTSLGAP- -AAFKFFD- -KII- -DRK -R- -YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP 050886065 1307 LAN-—Nil NLFTFTSLGAP--AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
AHN30376 13 07 LAK- —Nil NLFTFTSLGAP- -AAFKFFD- -KSV- -DRK- -R- YTSTKEVL DSTLIHQSITGLYETRIDLGKL— 1367
EA078426 13 07 LAN- —Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK- -R- YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
CCW42055 13 07 LAN- —Nil NLFTFTSLGAP- -AAFKFFD- -KIV- -DRK- -R- YTSTKEVL NSTLIHQSITGLYETRIDLGKL— 1367
WP 003041502 13 14 ICT- —SFL GLFELTSLGSA- -SDFEFLG- -VKI- -PRY- -RdYTPSSLLK DSTLIHQSITGLYETRIDLSKL— 1383
WP 037593752 12 83 LAK- —SFI SLLTFTAFGAP- -AAFNFFG- -ENI- -DRK- -R- YTSVTECL NATLIHQSITGLYETRIDLSKL— 1343
WP 049516684 12 83 LAK- —SFI SLLTFTAFGAP- -AAFNFFG- -ENI- -DRK- -R- YTSVTECL NATLIHQSITGLYETRIDLSKL— 1343
GAD46167 12 82 LAK- —SFI SLLTFTAFGAP- -AAFNFFG- -ENI- -DRK- -R- YTSVTECL NATLIHQSITGLYETRIDLSKL— 1342
WP 018363470 13 14 ISD- —SFI NLLTLTALGAP- -ADFNFLG- -EKI- -PRK- -R- YNSTKECL NATLIHQSITGLYETRIDLSKL— 1374
WP 003043819 13 11 -SN- —SFV SLLKYTSFGAS- -GGFTFLD- -LDVkqGRL- -R- YQTVTEVL DATLIYQSITGLYETRTDLSQL— 1372
WP 006269658 12 82 LAK- —SFI SLLTFTAFGAP- -AAFNFFG- -ENI- -DRK- -R- YTSVTECL NATLIHQSITGLYETRIDLSKL— 1342
WP 048800889 13 02 ISN- —SFI HLLTLTALGAP- -ADFNFLG- -EKI- -PRK- -R- YTSTKECL NATLIHQSITGLYETQTDLSKL— 1362
WP 012767106 13 09 -CS- —SVI NLLTLTASGAP- -ADFKFLG- -TTI- -PRK- -R- YGSPQSIL SSTLIHQSITGLYETRIDLSQL— 1368
WP 014612333 13 09 -CS- —SVI NLLTLTASGAP- -ADFKFLG- -TTI- -PRK- -R- YGSPQSIL SSTLIHQSITGLYETRIDLSQL— 1368
WP 015017095 13 09 -CS- —SVI NLLTLTASGAP- -ADFKFLG- -TTI- -PRK- -R- YGSPQSIL SSTLIHQSITGLYETRIDLSQL— 1368
WP 015057649 13 09 -CS- —SVI NLLTLTASGAP- -ADFKFLG- -TTI- -PRK- -R- YGSPQSIL SSTLIHQSITGLYETRIDLSQL— 1368
WP 048327215 13 09 -CS- —SVI NLLTLTASGAP- -ADFKFLG- -TTI- -PRK- -R- YGSPQSIL SSTLIHQSITGLYETRIDLSQL— 1368
WP 049519324 13 09 -CS- —SVI NLLTLTASGAP- -ADFKFLG- -TTI- -PRK- -R- YGSPQSIL SSTLIHQSITGLYETRIDLSQL— 1368
WP 012515931 12 86 -AE- —Nil NVFTFVALGAP- -AAFKFFD- -ATI- -DRK- -R- YTSTKEVL NATLIHQSVTGLYETRIDLSQL— 1345
WP 021320964 12 86 -AE- —Nil NVFTFVALGAP- -AAFKFFD- -ATI- -DRK- -R- YTSTKEVL NATLIHQSVTGLYETRIDLSQL— 1345
WP 037581760 12 86 -AE- —Nil NVFTFVALGAP- -AAFKFFD- -ATI- -DRK- -R- YTSTKEVL NATLIHQSVTGLYETRIDLSQL— 1345
WP 004232481 13 09 ISSlseSFI NLLKFISFGAP- -GAFKFLK- -LDV- -KQSnlR- YKSTTEAL SATLIHQSVTGLYETRIDLSKL— 1374
WP 009854540 13 07 ISN- —SFI NLLTLTALGAP- -ADFNFLG- -EKI- -PRK- -R- YTSTKECL TATLIHQSITGLYETRIDLSKL— 1367
WP 012962174 13 08 ISI- —SFV NLLTLTALGAP- -ADFNFLG- -EKI- -PRK- -R- YTSTKECL NATLIHQSITGLYETRIDLSKL— 1368
WP 039695303 13 09 ISN- —SFI NLLTLTALGAP- -ADFNFLG- -EKI- -PRK- -R- YTSTKECL NATLIHQSITGLYETRIDLSKL— 1369
WP 014334983 13 12 ISA- —SFI NLLTLTALGAP- -ADFNFLG- -EKI- -PRK- -R- YTSTKECL SATLIHQSVTGLYETRIDLSKL— 1372
WP 003099269 13 06 -AI- —NML NLFTFTDLGAP- -SAFKFFN- -GDI- -DRK- -R- YSSTNEII NSTLIYQSPTGLYETRIDLSKL— 1365
AHY15608
AHY17476
ESR09100 13 8 -AI- —NML NLFTFTDLGAP- -SAFKFFNg —DI- -DRK- -R- YSSTNEII NSTLIYQSPTGLYETRIDLSKL— 197
AGM98575
ALF27331 12 82 LAS- —SFI NLLTFTAIGAP- -AAFKFFD- -NNI- -DRK- -R- YTSTTEIL NATLIHQSITGLYETRIDLSRL— 1342
WP 018372492 12 90 VAR- —SFV -LLNFTMMGAA- -TDFKFFG- -QII- -PRK- -R- YPSTTECL KSTLIHQSVTGLYETRIDLSKL— 1350
WP 045618028 13 11 LSE- —SFI SLLKLISFGAP- -GTFKFLG- -VEI- -SQSnvR- YQSVSSCF NATLIHQSITGLYETRIDLSKL— 1373
WP 045635197 13 07 LAN- —SFI NLLTFTALGAP- -AAFKFFG- -KDI- -DRK- -R- YTTVSEIL NATLIHQSITGLYETWIDLSKL— 1367
WP 002263549 12 82 LAS- —SFI NLLTFTAIGAP- -ATFKFFD- -KNI- -DRK- -R- YTSTTEIL NATLIHQSITGLYETRIDLNKL— 1342
WP 002263887 12 82 LAS- —SFI NLLTFTAIGAP- -ATFKFFD- -KNI- -DRK- -R- YTSTTEIL NATLIHQSITGLYETRIDLNKL— 1342
WP 002264920 12 82 LAS- —SFI NLLTFTAIGAP- -ATFKFFD- -KNI- -DRK- -R- YTSTTEIL NATLIHQSITGLYETRIDLSKL— 1342
WP 002269043 12 82 LAS- —SFI NLLTFTAIGAP- -ATFKFFD- -KNI- -DRK- -R- YTSTTEIL NATLIHQSITGLYETRIDLNKL— 1342
WP 002269448 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD- KNI DRK--R--YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342
WP "002271977 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002272766 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002273241 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002275430 12 82 LSS- - -SFI NLLTFTAIGAP-AAFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002276448 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002277050 12 88 LAD- - -GFI KLLGFTQLGAT-SPFSFLG- IKL- NQK- -Q- -YTGKKDYL EATLIHQSITGLYETRIDLNKL- - 1352
WP "002277364 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002279025 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002279859 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002280230 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002281696 12 82 LSS- - -SFI NLLTFTAIGAP-AAFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002282247 12 88 LAD- - -GFI KLLGFTQLGAT-SPFSFLG- IKL- NQK- -Q- -YTGKKDYL EATLIHQSITGLYETRIDLSKL- - 1352
WP "002282906 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002283846 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002287255 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002288990 12 82 LAS- - -SFI NLLTFTAIGAP-AAFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002289641 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002290427 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002295753 12 82 LAS- - -SFI NLLTFTAIGAP-AAFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002296423 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002304487 12 96 LAS- - -SFI NLLTFTAIGAP-AAFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLNKL- - 1356
WP "002305844 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002307203 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002310390 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "002352408 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "012997688 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "014677909 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "019312892 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "019313659 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLNKL- - 1342
WP "019314093 12 82 LAS- - -SFI NLLTFTAIGAP-AAFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "019315370 12 82 LSS- - -SFI NLLTFTAIGAP-AAFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "019803776 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLNKL- - 1342
WP "019805234 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "024783594 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLNKL- - 1342
WP "024784288 12 88 LAD- - -GFI KLLGFTQLGAT-SPFSFLG- IKL- NQK- -Q- -YTGKKDYL EATLIHQSITGLYETRIDLSKL- - 1352
WP "024784666 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "024784894 12 82 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI DRK- -R- -YTSTTEIL NATLIHQSITGLYETRIDLSKL- - 1342
WP "024786433 12 88 LAD- - -GFI KLLGFTQLGAT-SPFSFLG- IKL- NQK- -Q- -YTGKKDYL EATLIHQSITGLYETRIDLSKL- - 1352
WP 049473442 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD- KNI--DRK- R-YTSTTEIL NATLIHQSITGLYETRIDLSKL— 1342
WP 049474547 1282 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI- -DRK- R-YTSTTEIL KATLIHQSITGLYETRIDLSKL— 1342
EMC03581 1275 LAS- - -SFI NLLTFTAIGAP-ATFKFFD- KNI- -DRK- R-YTSTTEIL NATLIHQSITGLYETRIDLSKL— 1335
WP 000428612 1310 LAN- - -SFI NLLTFTALGAP-AAFKFFG- KDV- -DRK- R-YTTVSEIL NATLIHQSITGLYETRIDLSKL— 1370
WP 000428613 1308 LAN- - -SFI NLLTFTALGAP-AAFKFFG- KDI- -DRK- R-YTTVSEIL NATLIHQSITGLYETRIDLSKL— 1368
WP 049523028 1303 IAN- - -SFI NLLTFTAFGAP-AVFKFFG- KDI- -ERK- R-YSTVTEIL KATLIHQSLTGLYETRIDLSKL— 1363
WP 003107102 1275 -AT- - -NML NLFTFTGLGAP-ATLKFFN- VDI—DRK R-YTSSTEIL NSTLIRQSITGLYETRIDLSKI— 1334
WP 054279288 1304 -SI- - -SFL NLFKFTSFGAP-EKFTFLN- SEIkqDDV R-YRSTKECL NSTLIHQSVTGLYETRIDLSQF— 1365
WP 049531101 1311 LSE- - -SFI SLLKLTSFGAP-GAFRFLG- VEI- SQSnvR-YQSVSSCF NATLIHQSITGLYETRIDLSKL— 1373
WP 049538452 1311 LSE- - -SFI SLLKLTSFGAP-GAFKFLG- VEI- SQSsvR-YKPNSQFL DATLIHQSITGLYETRIDLSKL— 1373
WP 049549711 1313 LSE- - -SFI SLLKLTSFGAP-GAFKFLG- AEI- SQSsvR-YKPNSQFL DTTLIHQSITGLYETRIDLSKL— 1375
WP 007896501 1312 -AL- - -NML NLFIFTSLGAP-STFVFFD- ETI- -DRK- R-YTTSSDVL NGILIQQSITGLYETRIDLSRF— 1371
EFR44625 1264 -AL- -NML NLFIFTSLGAP-STFVFFD- ETI- -DRK- R-YTTSSDVL NGILIQQSITGLYETRIDLSRF— 1323
WP 002897477 1307 LAN- - -SFI NLLTFTALGAP-AAFKFFG- KDV DRK—R-YTTVSEIL NATLIHQSITGLYETRIDLSKL— 1367
WP 002906454 1312 LSE- - -SFI SLLKLTSFGAP-GAFKFLG- VEI- SQSsvR-YKPNSQFL DTTLIHQSITGLYETRIDLSKL— 1374
WP 009729476 1308 LAN- - -SFI NLLTFTALGAP-AAFKFFG- KDV DRK—R-YTTVSEIL NATLIHQSITGLYETRIDLSKL— 1368
CQR24647 1296 LAQ- - -SFI SLLKFTAFGAP-GGFKFLD- ADI- KQSnlR-YQTVTEVL SSTLIHQSVTGLYETRIDLSKL— 1358
WP 000066813 1312 LAN- - -SFI NLLTFTALGAP-AAFKFLG- KDV DRK—R-YTTVSEIL NATLIHQSITGLYETRIDLSKL— 1372
WP 009754323 1308 LAN- - -SFI NLLTFTALGAP-AAFKFFG- KDV -DRK- R-YTTVSEIL NATLIHQSITGLYETRIDLSKL— 1368
WP 044674937 1301 LTS- - -SFV NLLTFTAIGAP-AAFKFLG- SVI- -DRK- R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL— 1361
WP 044676715 1303 LTS- - -SFV NLLTFTAIGAP-AAFKFLG- SVI- -DRK- R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL— 1363
WP 044680361 1303 LTS- - -SFV NLLTFTAIGAP-AAFKFLG- SVI- -DRK- R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL— 1363
WP 044681799 1301 LTS- - -SFV NLLTFTAIGAP-AAFKFLG- SVI- -DRK- R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL— 1361
WP 049533112 1314 ICT- - -SFL GLFELTSLGSA-SDFEFLG- VKI- -PRY- RdYTPSSLLK DSTLIHQSITGLYETRIDLSKL— 1383
WP 029090905 1241 -VK- - —VI ELLKITQANATnGDLKLLK- .— -sNREg -R- LGSVSVAL DFKIINQSVTGLYQSIEDYNN 1300
WP 006506696 1269 -AN- - —II QMLIVMHRGPQnGNIVYDDf -KI-sDRIg -R- LKTKNHNL NIVFISQSPTGIYTKKYKL 1329
AIT42264 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI- -DRK- -R- YTSTKEVL DATLIHQSITGLYETRIDLSQL— 1365
WP 034440723 1277 LVE- - -SFI NLLAITKCGPA-ADITFLG- ΈΚΙ- -SRK- -R- YRSTNCLW GSEVI FQSPTGLYETRLRLE 1335
AKQ21048 1306 -AE- - -Nil HLFTLTNLGAP-AAFKYFD- TTI- -DRK- -R- YTSTKEVL DATLIHQSITGLYETRIDLSQL— 1365
WP 004636532 1272 TVE- - -SFV NLMTFTAMGAP-ATFKFYG- ESI- -TRS- -R- YTSITEFR GSTLIFQSITGLYETRYKL 1329
WP 002364836 1278 IAA- - -SFI QLMQFNAMGAP-STFKFFQ- KDI- -ERA- -R- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 016631044 1229 IAA- - -SFI QLMQFNAMGAP-STFKFFQ- KDI- -ERA- -R- YTSIKEIF DATIIYQSPTGLYETRRKV 1286
EMS75795 1014 LSQ- - -SFI NLMQLNAMGAP-ADFKFFD- VII- -PRK- -R- YPSLTEIW ESTIIYQSITGLRETRTRMATLwd 1076
WP 002373311 1278 IAA- - -SFI QLMQFNAMGAP-STFKFFQ- KDI- -ERA- -R- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 002378009 1278 IAA- - -SFI QLMQFNAMGAP-STFKFFQ- KDI- -ERA- -R- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 002407324 1278 IAA- - -SFI QLMQFNAMGAP-STFKFFQ- KDI- -ERA- -R- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 002413717 1278 IAA- - -SFI QLMQFNAMGAP-STFKFFQ- KDI- -ERA- -R- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 010775580 1280 IAA- - -SFI QLMQFNAMGAP-STFKFFQ- KDI- -ERA- -R- YTSIKEIF DATIIYQSTTGLYETRRKV 1337
WP 010818269 1278 IAA- - -SFI QLMQFNAMGAP-STFKFFQ- KDI- -ERA- -R- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 010824395 1278 IAA—-SFI QLMQFNAMGAP--STFKFFQ--KDI- -ERA- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 016622645 1278 IAA— -SFI QLMQFNAMGAP- -STFKFFQ- -KDI- -ERA- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 033624816 1278 IAA— -SFI QLMQFNAMGAP -STFKFFQ- -KDI- -ERA- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 033625576 1278 IAA— -SFI QLMQFNAMGAP -STFKFFQ- -KDI- -ERA- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 033789179 1278 IAA— -SFI QLMQFNAMGAP -STFKFFQ- -KDI- -ERA- YTSIKEIF DATIIYQSTTGLYETRRKV 1335
WP 002310644 1280 LAS— -SFV NLMQFNAMGAP -ADFKFFD- -V I- -PRK- YTSLTEIW QSTIIHQSITGLYETRIRMGK 1339
WP 002312694 1281 LAS— -SFV NLMQFNAMGAP -ADFKFFD- -V I- -PRK- YTSLTEIW QSTIIHQSITGLYETRIRMGK 1340
WP 002314015 1281 LAS— -SFV NLMQFNAMGAP -ADFKFFD- -V I- -PRK- YTSLTEIW QSTIIHQSITGLYETRIRMGK 1340
WP 002320716 1281 LAS— -SFV NLMQFNAMGAP -ADFKFFD- -V I- -PRK- YTSLTEIW QSTIIHQSITGLYETRIRMGK 1340
WP 002330729 1280 LAS— -SFV NLMQFNAMGAP -ADFKFFD- -VTI- -PRK- YTSLTEIW QSTIIHQSITGLYETRIRMGK 1339
WP 002335161 1281 LAS— -SFV NLMQFNAMGAP -ADFKFFD- -VTI- -PRK- YTSLTEIW QSTIIHQSITGLYETRIRMGK 1340
WP 002345439 1281 LAS— -SFV NLMQFNAMGAP -ADFKFFD- -VTI- -PRK- YTSLTEIW QSTIIHQSITGLYETRIRMGK 1340
WP 034867970 1271 IAQ— -SFL QLLQFNAIGAP- -ADFKFFG- -VTI- -PRK- YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa 1333
WP 047937432 1281 LAS— -SFV NLMQFNAMGAP -ADFKFFD- -VTI- -PRK- YTSLTEIW QSTIIHQSITGLYETRIRMGK 1340
WP 010720994 1271 IAQ— -SFL QLLQFNAIGAP- -ADFKFFG- -VTI- -PRK- YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa 1333
WP 010737004 1271 IAQ— -SFL QLLQFNAIGAP- -ADFKFFG- -VTI- -PRK- YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa 1333
WP 034700478 1271 IAQ— -SFL QLLQFNAIGAP- -ADFKFFG- -VTI- -PRK- YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa 1333
WP 007209003 1270 IAK— -SFI NLLTFTAMGAP- -ADFEFFG- -EKI- -PRK- YVSISEII DAVFIHQSITGLYETRVRLTEV— 1330
WP 023519017 1265 MID— -AIL SLLKFTLFGAS- -VEFKFFD- -IKI- —LK- YKSLTDIW EATIIYQSVTGLYERRVEVRKLwd 1326
WP 010770040 1275 IAE— -SFV NLMKFSAYGAP- -MDFKFFG- -KTI- -PRS- YTSVGELL SATIINQSITGLYETRRKL 1332
WP 048604708 1271 IAQ— -SFV DLMQLNAFGAP- -ADFKFFG- -ETI- -PRK- YTSVNELL EATIINQSITGLYETRRRL 1328
WP 010750235 1274 MAH— -SFV NLMQFNALGAP- -ADFKFFD- -TTI- -TRK- YTSLTEIW QSTIIYQSVTGLYETRRRMADLwd 1336
AII16583 1345 -AE— -Nil HLFTLTNLGAP- -AAFKYFD- -TTI- -DRK- YTSTKEVL DATLIHQSITGLYETRIDLSQL— 1404
WP 029073316 1283 -CE— —VI QMLWMHAGPQnGNITFDDf —KL- sNRLg LNCKTISL TTVFIADSPTGMYSKKYKL 1343
WP 031589969 1284 -CN— —II QILATLHCNSSiGKIMYSDf —KI- sTTIg LNGRTISL DISFIAESPTGMYSKKYKL 1344
KDA45870 1254 LGK— -NFV ELLRYTADGAA- -SDFKFFG- -ENI- -PRK- YNSAGSLL NGTLIYQSKTGLYETRIDLGKL— 1314
WP 039099354 1307 ILDr- V -LIGLHANAAV -SDLGVLKisTPL- -GKM- —QPSGIS DTQIIYQSPTGLFERRVALRDL— 1368
AKP02966 1297 INS1-eELI TLLHANSTSAH- -LIFNNIE-kKAF- -GRK- THGLT DTDFIYQSVTGLYETRIHIE 1356
WP 010991369 1275 IAQ— -SFV DLMAFNAMGAP- -ASFKFFE- -TTI- -ERK- YNNLKELL NSTIIYQSITGLYESRKRL 1332
WP 033838504 1275 IAQ— -SFV DLMAFNAMGAP- -ASFKFFE- -TTI- -ERK- YNNLKELL NSTIIYQSITGLYESRKRL 1332
EHN60060 1278 IAQ— -SFV DLMAFNAMGAP- -ASFKFFE- -TTI- -ERK- YNNLKELL NSTIIYQSITGLYESRKRL 1335
EFR89594 1044 IAQ— -SFV DLMAFNAMGAP- -ASFKFFE- -TTI- -ERK- YNNLKELL NSTIIYQSITGLYESRKRL 1101
WP 038409211 1275 IAK— -SFD KLKVFNAFGAP- -RDFEFFE- -TTI- -KRK- YYNIKELL NATIIYQSITGLYEARKRL 1332
EFR95520 894 IAK— -SFD KLKVFNAFGAP- -RDFEFFE- -TTI- -KRK- YYNIKELL NATIIYQSITGLYEARKRL 951
WP 003723650 1275 IAQ— -SFV DLMAFNAMGAP- -ASFKFFE- -ATI- -DRK- YTNLKELL SSTIIYQSITGLYESRKRL 1332
WP 003727705 1275 IAQ— -SFV DLMAFNAMGAP- -ASFKFFE- -ATI- -DRK- YTNLKELL SSTIIYQSITGLYESRKRL 1332
WP 003730785 1275 IAQ— -SFV DLMAFNAMGAP- -ASFKFFE- -ATI- -DRK- YTNLKELL SSTIIYQSITGLYESRKRL 1332
WP 003733029 1275 IAE— -SFV SLKKFNAFGVH- -QDFSFFG- -TKI- -ERK- DRKLNELL NSTIIYQSITGLYESRKRL 1332
WP 003739838 1275 IAQ— -SFV NLMAFNAMGAP- -ASFKFFE- -ATI- -ERK- YTNLKELL SATIIYQSITGLYEARKRL 1332
7
WP 014601172 1275 IAQ-—SFV DLMAFNAMGAP--ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL 1332
WP 023548323 1275 IAE- —SFV SLKKFNAFGVH- -KDFNFFG- -TTI- -KRK - -R- DRKLKELL NSTIIYQSITGLYESRKRL 1332
WP 031665337 1275 IAQ- —SFV DLMAFNAMGAP- -ASFKFFE- -ATI- -DRK - -R- YTNLKELL SSTIIYQSITGLYESRKRL 1332
WP 031669209 1275 IAE- —SFV SLKKFNAFGVH- -QDFSFFG- -TKI- -ERK - -R- DRKLNELL NSTIIYQSITGLYESRKRL 1332
WP 033920898 1275 IAE- —SFV SLKKFNAFGVH- -KDFNFFG- -TTI- -KRK - -R- DRKLKELL NSTIIYQSITGLYESRKRL 1332
AKI42028 1278 IAQ- —SFV DLMAFNAMGAP- -ASFKFFE- -ATI- -DRK - -R- YTNLKELL SSTIIYQSITGLYESRKRL 1335
AKI50529 1278 IAE- —SFV SLKKFNAFGVH- -KDFNFFG- -TTI- -KRK - -R- DRKLKELL NSTIIYQSITGLYESRKRL 1335
EFR83390 723 IAQ- —SFV DLMVFNAMGAP- -ASFKFFE- -ATI- -DRK - -R- YTNLKELL SSTIIYQSITGLYESRKRL 780
WP 046323366 1275 IAQ- —SFV NLLEFNAMGAP- -ASFKYFE- -TNI- -ERK - -R- YNNLKELL NATIIYQSITGLYEARKRL 1332
AKE81011 1322 -AE- —Nil HLFTLTNLGAP- -AAFKYFD- -TTI- -DRK - -R- YTSTKEVL DATLIHQSITGLYETRIDLSQL— 1381
CU082355 1273 -AN- VI QMLIIMHKGPQnGNIIYDDf —NV-gKRIg -R- LNGRTFYL NIEFISQSPTGIYTKKYKL 1333
WP 033162887 1275 -CD- VI QILIIMHAGPMnGNIMYDDf —KF-tNRIg -R- FTHKNIDL KTTFISTSVTGLFSKKYKL 1335
AGZ 01981 1339 -AE- —Nil HLFTLTNLGAP- -AAFKYFD- -TTI- -DRK - -R- YTSTKEVL DATLIHQSITGLYETRIDLSQL— 1398
AKA60242 1306 -AE- —Nil HLFTLTNLGAP- -AAFKYFD- -TTI- -DRK - -R- YTSTKEVL DATLIHQSITGLYETRIDLSQL— 1365
AKS40380 1306 -AE- —Nil HLFTLTNLGAP- -AAFKYFD- -TTI- -DRK - -R- YTSTKEVL DATLIHQSITGLYETRIDLSQL— 1365
4UN5 B 1310 -AE- —Nil HLFTLTNLGAP- -AAFKYFD- -TTI- -DRK - -R- YTSTKEVL DATLIHQSITGLYETRIDLSQL— 1369
WP 010922251 1366 GGD 1368
WP "039695303 1370 GEE 1372
WP "045635197 1368 GED 1370
5AXW A
WP 009880683 1050 GGD 1052
WP "010922251 1366 GGD 1368
WP "011054416 1366 GGD 1368
WP "011284745 1366 GGD 1368
WP "011285506 1366 GGD 1368
WP "011527619 1366 GGD 1368
WP "012560673 1366 GGD 1368
WP "014407541 1365 GGD 1367
WP "020905136 1366 GGD 1368
WP "023080005 1365 GGD 1367
WP "023610282 1365 GGD 1367
WP "030125963 1366 GGD 1368
WP "030126706 1366 GGD 1368
WP "031488318 1366 GGD 1368
WP "032460140 1366 GGD 1368
WP "032461047 1366 GGD 1368
WP "032462016 1366 GGD 1368
WP "032462936 1366 GGD 1368
WP "032464890 1366 GGD 1368
WP "033888930 1191 GGD 1193
WP "038431314 1366 GGD 1368
WP "038432938 1365 GGD 1367
WP "038434062 1366 GGD 1368
BAQ51233 1277 GGD 1279
KGE60162 541 GGD 543
KGE60856 304 GGD 306
WP 002989955 1366 GGD 1368
WP "003030002 1343 GED 1345
WP "003065552 1371 GEE 1373
WP "001040076 1368 GED 1370
WP "001040078 1376 GED 1378
WP "001040080 1368 GED 1370
WP "001040081 1368 GED 1370
WP "001040083 1368 GED 1370
WP "001040085 1368 GED 1370
WP 001040087 1368 GED 1370
WP "001040088 1368 GGD 1370
WP "001040089 1368 GED 1370
WP "001040090 1368 GED 1370
WP "001040091 1368 GED 1370
WP "001040092 1368 GED 1370
WP "001040094 1368 GED 1370
WP "001040095 1368 GEG 1370
WP "001040096 1368 GEG 1370
WP "001040097 1368 GED 1370
WP "001040098 1368 GED 1370
WP "001040099 1368 GED 1370
WP "001040100 1368 GED 1370
WP "001040104 1368 GED 1370
WP "001040105 1368 GED 1370
WP "001040106 1368 GED 1370
WP "001040107 1368 GED 1370
WP "001040108 1368 GED 1370
WP "001040109 1368 GED 1370
WP "001040110 1368 GED 1370
WP "015058523 1368 GED 1370
WP "017643650 1368 GED 1370
WP "017647151 1368 GED 1370
WP "017648376 1368 GED 1370
WP "017649527 1368 GED 1370
WP "017771611 1368 GED 1370
WP "017771984 1368 GED 1370
CFQ25032 1368 GED 1370
CFV16040 1368 GED 1370
KLJ37842 1368 GED 1370
KLJ72361 1368 GGD 1370
KLL20707 1382 GED 1384
KLL42645 1368 GED 1370
WP 047207273 1368 GED 1370
WP "047209694 1368 GED 1370
WP "050198062 1368 GED 1370
WP "050201642 1368 GED 1370
WP "050204027 1368 GED 1370
WP "050881965 1368 GED 1370
WP 050886065 1368 GED 1370
AHN30376 1368 GED 1370
EA078426 1368 GED 1370
CCW42055 1368 GED 1370
WP 003041502 1384 GED 1386
WP 037593752 1344 GED 1346
WP 049516684 1344 GED 1346
GAD46167 1343 GED 1345
WP 018363470 1375 GEE 1377
WP 003043819 1373 GGD 1375
WP 006269658 1343 GED 1345
WP 048800889 1363 GED 1365
WP 012767106 1369 GGD 1371
WP 014612333 1369 GGD 1371
WP 015017095 1369 GGD 1371
WP 015057649 1369 GGD 1371
WP 048327215 1369 GGD 1371
WP 049519324 1369 GGD 1371
WP 012515931 1346 GEN 1348
WP 021320964 1346 GEN 1348
WP 037581760 1346 GEN 1348
WP 004232481 1375 GEE 1377
WP 009854540 1368 GEE 1370
WP 012962174 1369 GEE 1371
WP 039695303 1370 GEE 1372
WP 014334983 1373 GEE 1375
WP 003099269 1366 GGK 1368
AHY15608
AHY17476
ESR09100 198 GGK 200
AGM98575
ALF27331 1343 GGD 1345
WP 018372492 1351 GEN 1353
WP 045618028 1374 GED 1376
WP 045635197 1368 GED 1370
WP 002263549 1343 GGD 1345
WP 002263887 1343 GGD 1345
WP 002264920 1343 GGD 1345
WP 002269043 1343 GGD 1345
WP 002269448 1343 GGD 1345
WP "002271977 1343 GGD 1345
WP "002272766 1343 GGD 1345
WP "002273241 1343 GGD 1345
WP "002275430 1343 GGD 1345
WP "002276448 1343 GGD 1345
WP "002277050 1353 GGD 1355
WP "002277364 1343 GGD 1345
WP "002279025 1343 GGD 1345
WP "002279859 1343 GGD 1345
WP "002280230 1343 GGD 1345
WP "002281696 1343 GGD 1345
WP "002282247 1353 GGD 1355
WP "002282906 1343 GGD 1345
WP "002283846 1343 GGD 1345
WP "002287255 1343 GGD 1345
WP "002288990 1343 GGD 1345
WP "002289641 1343 GGD 1345
WP "002290427 1343 GGD 1345
WP "002295753 1343 GGD 1345
WP "002296423 1343 GGD 1345
WP "002304487 1357 GGD 1359
WP "002305844 1343 GGD 1345
WP "002307203 1343 GGD 1345
WP "002310390 1343 GGD 1345
WP "002352408 1343 GGD 1345
WP "012997688 1343 GGD 1345
WP "014677909 1343 GGD 1345
WP "019312892 1343 GGD 1345
WP "019313659 1343 GGD 1345
WP "019314093 1343 GGD 1345
WP "019315370 1343 GGD 1345
WP "019803776 1343 GGD 1345
WP "019805234 1343 GGD 1345
WP "024783594 1343 GGD 1345
WP "024784288 1353 GGD 1355
WP "024784666 1343 GGD 1345
WP "024784894 1343 GGD 1345
WP "024786433 1353 GGD 1355
WP 049473442 1343 GGD 1345
WP "049474547 1343 GGD 1345
EMC03581 1336 GGD 1338
WP 000428612 1371 GED 1373
WP "000428613 1369 GED 1371
WP "049523028 1364 GEE 1366
WP "003107102 1335 GGD 1337
WP "054279288 1366 GGD 1368
WP "049531101 1374 GED 1376
WP "049538452 1374 GED 1376
WP "049549711 1376 GED 1378
WP "007896501 1372 GGD 1374
EFR44625 1324 GGD 1326
WP 002897477 1368 GEE 1370
WP "002906454 1375 GED 1377
WP "009729476 1369 GED 1371
CQR24647 1359 GGE 1361
WP 000066813 1373 GED 1375
WP "009754323 1369 GED 1371
WP "044674937 1362 GGD 1364
WP "044676715 1364 GGD 1366
WP "044680361 1364 GGD 1366
WP "044681799 1362 GGD 1364
WP "049533112 1384 GED 1386
WP "029090905
WP "006506696
AIT42264 1366 GGD 1389
WP 034440723
AKQ21048 1366 GGD 1384
WP 004636532 1330 -ED 1332
WP "002364836 1336 -VD 1337
WP "016631044 1287 -VD 1288
EMS75795 1077 GEQ 1079
WP 002373311 1336 -VD 1337
WP "002378009 1336 -VD 1337
WP "002407324 1336 -VD 1337
WP "002413717 1336 -VD 1337
WP "010775580 1338 -VD 1339
WP "010818269 1336 -VD 1337
WP 010824395 1336 -VD 1337
WP "016622645 1336 -VD 1337
WP "033624816 1336 -VD 1337
WP "033625576 1336 -VD 1337
WP "033789179 1336 -VD 1337
WP "002310644
WP "002312694
WP "002314015
WP "002320716
WP "002330729
WP "002335161
WP "002345439
WP "034867970 1334 GEQ 1336
WP "047937432
WP "010720994 1334 GEQ 1336
WP "010737004 1334 GEQ 1336
WP "034700478 1334 GEQ 1336
WP "007209003
WP "023519017 1327 GER 1330
WP "010770040 1333 -VD 1334
WP "048604708 1329 -GD 1330
WP "010750235 1337 GVQ 1339
AII16583 1405 GGD 1424
WP 029073316
WP "031589969
KDA45870
WP 039099354
AKP02966
WP 010991369 1333 -DD 1334
WP "033838504 1333 -DD 1334
EHN60060 1336 -DD 1337
EFR89594 1102 -DD 1103
WP 038409211 1333 -ED 1334
EFR95520 952 -ED 953
WP 003723650 1333 -DD 1334
WP "003727705 1333 -DD 1334
WP "003730785 1333 -DD 1334
WP "003733029 1333 -DN 1334
WP "003739838 1333 -DG 1334
WP 014601172 1333 -DD 1334
WP_023548323 1333 -DS 1334
WP 031665337 1333 -DD 1334
WP 031669209 1333 -DN 1334
WP_033920898 1333 -DS 1334
AKI42028 1336 -DD 1337
AKI50529 1336 -DS 1337
EFR83390 781 -DD 782
WP_046323366 1333 -DD 1334
AKE81011 1382 GGD 1400
CU082355
WP_033162887
AGZ 01981 1399 GGD 1417
AKA60242 1366 GGD 1368
AKS40380 1366 GGD 1376
4UN5 B 1370 GGD 1372
[00253] Additional suitable Cas9 sequences in which amino acid residues homologous to residues 10, 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 840, 1219, and/or 1329 of SEQ ID NO: 9 can be identified are known to those of skill in the art. See, e.g.,
Supplementary Table S2 and Supplementary Figure S2 of Fonfara et al., Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems, Nucl. Acids Res. 2013, doi: 10.1093/nar/gktl074, which are incorporated herein by reference in their entirety. Cas9 variants of the sequences provided herein or known in the art comprising one or more mutations, e.g., at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as provided herein, e.g., of one or more amino acid residue that is homologous to amino acid residue 10, 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 840, 1219, and/or 1329 in SEQ ID NO: 9 are provided by this disclosure, for example, Cas9 variants comprising a A262T, K294R, S409I, E480K, E543D, M694I, and/or E1219V mutation.
EXAMPLE 4: Evolution of Cas9 With Broadened PAM Specificities
[00254] By evolving S. pyogenes Cas9 on a NNN PAM library using PACE, Cas9s with broadened PAM specificities have been evolved with higher activities for many non- canonical PAMs. Such a Cas9 still retains its native DNA binding and cutting activity and can be utilized with all of the current tools available. It has been hypothesized that by modulating Cas9's interactions with the DNA, the PAM specificity of Cas9 can be modified and expanded. Other Cas9s such as Staphylococcus aureus could also be engineered to change and expand their PAM specificity by such a method. Methods to modulate DNA binding such as targeted mutagenesis of the Cas9 protein, fusions to DNA-binding proteins, and the use of multiple Cas9 proteins tethered to each other could also expand the PAMs that can be targeted.
[00255] Cas9 Evolution. After evolution using overnight propagation of the phage with the mutagenesis plasmid (MP), the resultant phages containing mutations, discussed above, in PACE were used. Twenty-four individual phages were sequenced from the PACE run. Mutations found in the Cas9 gene are documented in Table 3 below. The Cas9 gene containing these mutations was cloned out of the phage and into plasmids to test both DNA binding and cutting activity. Table 3 : Cas9 mutations
pJH306
(WT
dCas9- VPR)
pJH407
(WT
Cas9)
pJH562
(dCas9- VPR) E480K E543D E1219V
pJH599
(dCas9- VPR) A262T S409I E480K E543D M694I E1219V
pJH600
(dCas9- VPR) K294R E480K E543D E1219V Q1256K L1362P pJH601
(dCas9- VPR) A262T S409I E480K E543D M694I E1219V
pJH602
(dCas9- VPR) K294R E480K E543D E1219V Q1256K pJH603
(dCas9- VPR) A262T S409I E480K E543D M694I E1219V
pJH604
(dCas9- VPR) S267G K294R E480K E543D E1219V N1224K Q1256K pJH605
(dCas9- VPR) A262T F405I S409I E480K E543D M694I E1219V
pJH760
(pJH599
Minus
VPR,
Nucleas
e
Positive
A262T S409I E480K E543D M694I E1219V
[00256] GFP Activation in Human Cell Culture. Testing was performed on a
reporter with a GFP reporter activated by dCas9-VPR. Testing was performed on 5'-NGG-3' PAM first (Figures 4A and 4B) and then with a library of GFP reporters all containing the same Cas9 target site, but with N N at the PAM position (Figures 5A and 5B). In this
testing, dCas9-VPR was found to activate the GFP signal. Wild-type Cas9 with no mutations (pJH306), Cas9 evolved from overnight propagation (pJH562), and Cas9 evolved from
PACE (pJH599-pJH605) were all tested. Mutations for each Cas9 are documented in Table 3 above.
[00257] dCas9-VPR on all 64 PAM Sequences. pJH306 (WT dCas9-VPR) and pJH599 (WT dCas9-VPR with mutations A262T, S409I, E480K, E543D, M694I, and E1219V) were tested on all 64 PAM sequences (Figure 6). dCas9-VPR was used to activate GFP as before and a different reporter plasmid was used for each well to ascertain the activation efficiency for all 64 different PAM sequences. The mean GFP fluorescence was measured for all transfected cells, as gated by iRFP signal. pJH599 showed either improved or similar levels of activation as compared to pJH306 for all PAM sequences.
[00258] In Vitro Cutting Assay. The ability of expressed and purified WT Cas9 (WT) and Cas 9 with an E1219V mutation (1) to cut DNA with different PAMs was tested (Figure 7). Cas9 was incubated with dsDNA containing the target site. Cutting was measured by running the DNA on a gel to compare the amount of uncut product to the amount of cut products, which run faster due to their smaller size. The E1219V mutation was found to increase Cas9 cutting activity on non-canonical PAMs while maintaining activity on 5 '-NOGS ' PAMs.
[00259] Evolving Different Systems. In addition to S. pyogenes Cas9 evolution, other
Cas9 systems such as S. aureus, S. thermophilus, N. meningitidis, and T. denticola, etc. can be evolved to modify and expand their PAM specificities. The data indicates that, by using a similar system to the S. pyogenes Cas9 evolution, a phage containing the S. aureus Cas9 can also be evolved to expand its PAM specificity.
[00260] Modulating PAM Specificity. By mutating neutral and negatively charged amino acids to positively charged amino acids, Cas9 could be modified to expand the PAMs that can be targeted. Generally, incorporating mutations into Cas9 proteins that generate a net increase in positive charge may increase the affinity of Cas9 to bind DNA. In
combination with the Cas9 mutations provided herein, additional residues that could be mutated for increased PAM targeting in S. pyogenes Cas9 further include ones that have been identified to change the PAM specificity (D1135, G1218, R1333, R1335, T1337)38 and residues that can increase Cas9 activity (S845 and L847) 37. Residues that increase Cas9 specificity such as the mutations of arginine, histidine, and lysine to alanine previously identified37 and the mutations of asparagine, arginine, and glutamine to alanine as previously identified39 could lead to lower tolerability for non-canonical PAMs as these mutations presumably decrease the interactions between the Cas9 and DNA.
[00261] Fusions to Modulate PAM Specificity. Programmable DNA-binding proteins such as zinc-finger domains, TALEs, and other Cas9 proteins could be fused to Cas9 to improve the ability to target nucleotide sequences having canonical or non-canonical PAMs, for example to increase activity, specificity or efficiency. A nuclease-null dCas9 could be fused to a nuclease active Cas9 to increase the ability of the nuclease active Cas9 to target different PAM sequences. One example of a nuclease-null dCas9 fused to a nuclease active Cas9 is shown in Figure 8. Such fusions can be useful for improving the ability to target nucleotide sequences having canonical or non-canonical PAMs. The Cas9s could either be from the same species or from different species. Furthermore, both Cas9s could be nuclease- null dCas9, and could be further fused to effector proteins such as VP64, VP64-p65-Rta, Fokl, GFP and other fluorescent proteins, deaminases, or any of the effector proteins provided herein.
[00262] Using Cas9 to Localize Other Nucleases and Other DNA-Binding
Proteins. Cas9 can also be used to overcome the native binding specificity of other proteins by localizing them to their DNA targets. DNA nucleases, recombinases, deaminases, and other effectors often have a native DNA specificity. Cas9 can be fused to these proteins to overcome and expand their native DNA specificities. gRNAs will target the Cas9 adjacent to the DNA effector's target site and will help to localize them to their target site.
[00263] dCas9-VPR on NNNNN PAM Library. To test that the evolved Cas9s had not picked up specificity in the 4th and 5th PAM positions, dCas9-VPR on a NNNNN PAM library was tested. As seen with the NNN library, most of the constructs (e.g., pJH562, pJ559, pJH600, pJH601, pJH602, pJH603, and pJH605) showed improved activity. pJH599 consistently showed improvement in both the percentage of cells that showed GFP activation (Figure 9A) and the mean fluorescence of those cells that showed GFP activation (Figure 9B).
[00264] Cas9 GFP Cutting. The WT Cas9, pJH407, was compared with a nuclease- positive evolved Cas9, pJH760 (Figure 10). pJH760 contained the same mutations as pJH599 but without the D10A and H480A nuclease-inactivating mutations, and without the VPR fusion. A genomically integrated GFP gene was cut by Cas9 and the activity was measured by the loss of GFP signal in cells. On a site with 5'-NGG-3' PAM, pJH407 and pJH760 showed comparable activity. On a site with GAT PAM, pJH760 showed a significant increase in activity as compared to pJH407.
EXAMPLE 5 Cas9:DNA Editing Enzyme Fusion Proteins
[00265] This disclosure further provides Cas9 fused with a DNA editing enzyme for the targeted editing of DNA sequences. Figure 11 illustrates double stranded DNA substrate binding by DNA editing enzyme-dCas9:sgRNA complexes. The DNA editing enzyme shown is a deaminase. The structures according to Figure 11 are identified in these sequences (36bp: underlined, sgRNA target sequence: bold; PAM: boxed; 21bp: italicized). EXAMPLE 6 PAM Depletion Assay
[00266] In E. coli, a library of PAM sequences are encoded in a plasmid that also contains an antibiotic gene. If the Cas9 can cut the PAM sequences on the plasmid, the plasmid is not replicated and is lost; only plasmids that are uncut remain the population. The plasmids that were cut by the Cas9 can be determined by sequencing the initial plasmid population and the final plasmid population through high throughput sequencing. The proportion of the library consisting of each PAM sequence was obtained by dividing the number of reads containing the PAM sequence by the total number of reads. The depletion score was then calculated by dividing the proportion of the library containing the PAM section before the selection by the proportion of the library containing the PAM sequence after selection. Higher depletion scores signify higher cutting activity by the Cas9 of that particular PAM sequence. The results of the PAM depletion assay are shown in Figure 12.
[00267] A number of PAM sequences that were not cut with the wild-type Cas9 were cut with the evolved Cas9 (xCas9 vl .O, pJH760). Notably, all PAM sequences of the form NGN and NNG, as well as GAA and GAT showed a depletion greater than 10-fold with the xCas9. A single G in either the second or third PAM position could be sufficient for cutting with the newly evolved Cas9, opening up the sequence space significantly for the target sites that can be targeted using Cas9. The PAM depletion scores are given in Table 4.
Table 4. PAM Depletion Scores
Figure imgf000262_0001
TGA 1.72 27.02
GGA 16.03 26.90
AGG 17.80 26.19
TAG 9.54 25.98
CGC 1.76 25.88
AGT 0.97 24.88
CGG 19.03 24.77
AAG 15.40 24.16
GTG 3.76 23.71
ATG 1.26 23.48
GGG 17.59 23.01
TGC 1.71 23.00
TTG 0.98 22.15
GAA 1.04 20.96
AGC 1.43 16.85
GAT 1.02 16.09
CTG 1.29 13.88
CCG 1.02 11.86
CAT 0.99 5.75
CAA 1.00 5.28
GAC 0.98 3.96
TAA 0.97 1.90
AAA 1.02 1.81
TAT 0.95 1.56
CAC 1.01 1.48
GTA 0.94 1.42
AAT 0.98 1.39
GCA 0.98 1.22
ACA 0.95 1.13
AAC 1.08 1.09
TAC 0.92 0.95
ATA 1.04 0.94
GTC 0.99 0.92
GCT 0.99 0.87
TCA 0.94 0.84 CTA 0.95 0.83
GCC 0.99 0.82
GTT 0.97 0.81
TCC 0.98 0.80
ACC 0.96 0.80
CTC 0.92 0.80
CCA 0.97 0.79
CCC 0.95 0.79
CTT 0.96 0.79
ATC 0.96 0.78
CCT 0.94 0.78
ATT 0.93 0.77
ACT 0.89 0.77
TTT 0.94 0.77
TCT 0.95 0.77
TTC 0.96 0.76
TTA 0.94 0.76
EXAMPLE 7: GFP Cutting Mammalian Cells
[00268] Wild-type or evolved Cas9 and gRNAs were transfected into mammalian cells containing a genomically integrated GFP gene. Different gRNAs targeted different sites with different PAM sequences, such that cutting of the GFP by Cas9 would lead to a loss of the GFP signal. The GFP signal was quantified after five days with flow cytometry. As shown in Figure 13, evolved Cas9 cut GFP in mammalian, in line with the results in the GFP activation assay and in the PAM depletion assay. High throughput sequencing around the cut site verified the results seen with the flow cytometer; the indels were proportional to the cutting percentage seen with the flow cytometer.
EXAMPLE 8: Further Evoluation of the HHH Library
[00269] As SpCas9 has a preference for the G residues at the second and third base, evolutation was continued using the end point from the last evolution on a HHH (H = A, C, or T) PAM library. After evolution, 13 colonies were sequenced and a number of new mutations were identified. Three mutations, the E1219V, E480K, and E543D mutations were found in all the clones. A number of the clones either had the S267G/K294R/Q1256K mutations or the A262T/S409I mutations but those mutations were never seen together, suggesting that the clones had taken two divergent paths along the evolutionsary landscape. The new mutations are given in Table 5.
Table 5. New Mutations
Figure imgf000265_0001
Figure imgf000266_0001
EXAMPLE 9: Further Evolved Cas9 Proteins for Gene Editing
[00270] pJH760, described in Example 6, was tested in the PAM depletion assay on a number of new targets. Four new targets were selected: re2
(GGGGC C AC T AGGG AC AGG AT (SEQ ID NO: 314)), a synthetic target previously used for GFP activation in mammalian cells; VEGF (GGGTGGGGGGAGTTTGCTCC (SEQ ID NO: 315)), a target within the VEGF gene, CLTA (GCAGATGTAGTGTTTCCACA (SEQ ID NO: 316)), a target within the CLTA gene; and CCR5D
(TCACTATGCTGCCGCCCAGT (SEQ ID NO: 317)), a target within the CCR5D gene. The results of the PAM depletion assay are given in Figures 14 to 17. It was found that, in addition to the canonical NGG sequence, PAM depletion demonstrates cutting for most NGN and some NNG sequences as well.
[00271] The HUH PAM library was further evolved using the end point from the last evolution on a HHH (H = A, C, or T) PAM library. After evolution, 13 colonies were sequenced and a number of new mutations were identified. Three mutations, the E1219V, E480K, and E543D mutations were found in all the clones. A number of the clones either had the K294R/Q1256K mutations or the A262T/S409I mutations but those mutations were never seen together, suggesting that the clones had taken two divergent paths along the evolutionsary landscape. The new mutations are given in Tables 8 and 9 below.
[00272] As expected, variation in activity was seen with different targets. The PAM depletion assay scores are given in Table 10. NGN consistently showed cutting activity with some targets. Variation was seen amoungst the xCas9 3.x mutants in terms of which mutant had the best activity. Of note, xCas9 3.3 contained the K294R/Q1256K series of mutations, while the other three mutants (3.6, 3.7, and 3.8) contained the A262T/S409I series of mutations. xCas9 3.6 and 3.7 outperformed 3.8. While 3.3 seemed to have the highest activity for most cases, 3.6 and 3.7 performed better on certain PAM sequences. The results of the PAM depletion assays for three of the new targets described above are given in Figures 18 to 20.
[00273] A NNNNN PAM depletion library was constructed. It was assayed to examine any fourth or fifth base specificity. Initial results of the PAM depletion assay show that there is no preference at the fourth and fifth base as expected.
[00274] In summary, E1219V was found to be one of the earliest mutations that fixed in the evoluation. It is close to the PAM sequence in the crystal structure. E480K and E543D were also seen in all of the clones from the early stages of the evolution, and may be important. K294R/Q1256K and A262T/S409I seem to be two divergent paths, and may be important. Their PAM sequence profiles seem to be slightly different, which implies their importance relative to PAM activity determination.
Table 6 Diseases/disorders containging T to C Changes. The table includes human gene mutations that may be corrected by changing a cytosine (C) to a thymine (T). The gene name, gene symbol, and Gene ID are indicated.
Figure imgf000267_0001
(p.Ser72Pro) AGGCTTTGGAGGAAGTCCTGA']
NM_000398.6(CYB5R3):c.382T ['CAAGTTTCCCGCTGGAGGGAAGATGYCTCA
689 >C (p.Serl28Pro) 1727 CYB5R3 GTACCTGGAGAGCATGCAGAT']
NM_000398.6(CYB5R3):c.446T ['GAGTTCCGGGGCCCCAGTGGGCTGCYGGTC
690 >C (p.Leul49Pro) 1727 CYB5R3 TACCAGGGCAAAGGTGATTCG]
NM_000398.6(CYB5R3):c.610T ['GAAGGACCCTGATGACCACACTGTGYGCCA
691 >C (p.Cys204Arg) 1727 CYB5R3 CCTGCTCTTTGCCAACCAGGT']
NM_000398.6(CYB5R3):c.218T ['CCGTCACCCCAGCACATCCTGGGCCYCCCTG
692 >C (p.Leu73Pro) 1727 CYB5R3 TCGGTGAGTCACGCCCCTGC]
NM_000552.3(VWF):c.4883T>C ['CCTGGAGACATCCAGGTGGTGCCCAYTGGA
693 (p.Ilel628Thr) 7450 VWF GTGGGCCCTAATGCCAACGTG]
NM_000552.3(VWF):c.4837T>C ['CTACATGGTCACCGGAAATCCTGCCYCTGAT
694 (p.Serl613Pro) 7450 VWF GAGATCAAGAGGCTGCCTGG]
NM_000552.3(VWF):c.3814T>C ['GGAACCGCCGTTGCACGATTTCTACBGCAGC
695 (p.Cysl272Arg) 7450 VWF AGGCTACTGGACCTGGTCTT']
NM_000552.3(VWF):c.8317T>C ['CAACGATGTGCAGGACCAGTGCTCCYGCTG
696 (p.Cys2773Arg) 7450 VWF CTCTCCGACACGGACGGAGCC]
NM_000552.3(VWF):c.3445T>C ['TGAGTGTGAGTGGCGCTATAACAGCYGTGC
697 (p.Cysl l49Arg) 7450 VWF ACCTGCCTGTCAAGTCACGTG]
NM_000552.3 (VWF) :c .3178T>C ['GAAGCAGACGATGGTGGATTCCTCCYGTAG
698 (p.Cysl060Arg) 7450 VWF AATCCTTACCAGTGACGTCTT']
NM_001042492.2(NFl):c.5858T ['TGTTTGGAATACATGACTCCATGGCYGTCAA
699 >C (p.Leul953Pro) 4763 NF1 ATCTAGTTCGTTTTTGCAAG]
NM_000267.3(NFl):c.l523T>C ['ATTCATGCAGATCCAAAGCTCTTGCYTTGTG
700 (p.Leu508Pro) 4763 NF1 TAAGTATTTTTTTATGAAAT']
NM_000267.3(NFl):c.6200T>C ['ATTTTAGCACGCTACATGCTGATGCYGTCCT
701 (p.Leu2067Pro) 4763 NF1 TCAACAATTCCCTTGATGTG]
NM_000267.3 (NF 1 ) : c.1070T>C ['CTGTTGGGGTTTTTATAGAACCTGCYTTTTA
702 (p.Leu357Pro) 4763 NF1 ATCCAAGTAAGCCATTCTCA']
NM_000267.3(NFl):c.3728T>C ['TCTCAGGATGAACTAGCTCGAGTTCYGGTTA
703 (p.Leul243Pro) 4763 NF1 CTCTGTTTGATTCTCGGCAT']
NM_000308.2(CTSA):c.247T>C ['CTCCGGCTCCAAGCACCTCCACTACYGGTCT
704 (p.Trp83Arg) 5476 CTSA GCCGCCCTGCCTTCTGGGCG]
NM_001127695.1(CTSA):c.707 ['ATCTCCTACAGGCTTTGGTCTTCTCYCCAGA
705 T>C (p.Leu236Pro) 5476 CTSA CCCACTGCTGCTCTCAAAAC]
NM_000308.2(CTSA):c.l271T> ['GATGTAGACATGGCCTGCAATTTCAYGGGG
706 C (p.Met424Thr) 5476 CTSA GATGAGTGGTTTGTGGATTCC]
NM_000405.4(GM2 A) : c.412T> ['GCGTACCTATGGGCTTCCTTGCCACYGTCCC
707 C (p.Cysl38Arg) 2760 GM2A TTCAAAGAAGTAAGTACTTA']
NM_001165974.1 (UROC 1 ) :c .20 13166 ['CCAGAGTTTGCCCAGGAGCTGCAACYGTAC
708 9T>C (p.Leu70Pro) 9 UROC1 GGACACATCTACATGTACCGG]
NM_003730.4(RNASET2):c.550 ['ATATGGAGTGATACCCAAAATCCAGYGCCT
709 T>C (p.Cysl84Arg) 8635 RNASET2 TCCACCAAGCCAGGTTAGACA']
710 NM_199069.1(NDUFAF3):c.2T 25915 NDUFAF3 ['GACTTCGCCGCGCGTTGGTCAGCCAYGGCC >C (p.MetlThr) ACCGCTCTCGCGCTACGTAGC']
NM_178012.4(TUBB2B):c.514T 34773 ['CATGAACACCTTCAGCGTCATGCCCYCACCC
711 >C (p.Serl72Pro) 3 TUBB2B AAGGTGTCAGACACGGTGGT']
NM_178012.4(TUBB2B):c.683T 34773 ['CCCACCTACGGGGACCTCAACCACCYGGTG
712 >C (p.Leu228Pro) 3 TUBB2B TCGGCCACCATGAGCGGGGTC]
NM_178012.4(TUBB2B):c.793T 34773 ['CATGGTGCCCTTCCCTCGCCTGCACYTCTTC
713 >C (p.Phe265Leu) 3 TUBB2B ATGCCCGGCTTCGCGCCCCT']
NM_000110.3(DPYD):c.85T>C ['TCGAACACAAACTCATGCAACTCTGYGTTCC
714 (p.Cys29Arg) 1806 DPYD ACTTCGGCCAAGAAATTAGA']
NM_133459.3(CCBEl):c.520T> 14737 ['CATCCGGGAAGATGATGGGAAGACAYGTAC
715 C (p.Cysl74Arg) 2 CCBE1 CAGGGGAGACAAATATCCCAA']
NM_000035.3(ALDOB):c.442T> ['GAAAGATGGTGTTGACTTTGGGAAGYGGCG
716 C (p.Trpl48Arg) 229 ALDOB TGCTGTGCTGAGGATTGCCGA']
NM_000320.2(QDPR):c.l06T>C ['AACCAAAGCTGTTTTCTCCTTCCAGYGGGTT
717 (p.Trp36Arg) 5860 QDPR GCCAGCGTTGATGTGGTGGA']
NM_173560.3(RFX6):c.380+2T 22254 ['GCAGACACAGCTCACGCTGCAGTGGYGAGA
718 >C 6 RFX6 CTCGCCCGCAGGGTACACTGA']
NM_173560.3(RFX6):c.649T>C 22254 ['AAAATGTACTAATTTTTTAAGGTTTYCTGGA
719 (p.Ser217Pro) 6 RFX6 AGCAAGCTAAAGAATGAGGT']
NM_000037.3(ANKl):c- ['CTGCGGGGCCTGTGACGTGCGGGCCRGGCC
720 108T>C 286 ANK1 CCCGAGGGCCTTATCGGCCCC]
NM_001145308.4(LRTOMT):c.3 22007 ['TCACATCCTCACCACCCTGGACCACYGGAGC
721 13T>C (p.Trpl05Arg) 4 LRTOMT AGCCGCTGCGAGTACTTGAG]
NM_001012515.2(FECH):c.l268 ['CCTGTCTGCAGGGAGACTAAATCCTYCTTCA
722 T>C (p.Phe423Ser) 2235 FECH CCAGCCAGCAGCTGTGACCC]
NM_000140.3(FECH):c.315- ['TATTGAGTAGAAAACATTTCTCAGGYTGCTA
723 48T>C 2235 FECH AGCTGGAATAAAATCCACTT']
NM_024120.4(NDUFAF5):c.686 ['GCTGTCAATGACCTGGGACATCTGCYTGGG
724 T>C (p.Leu229Pro) 79133 NDUFAF5 AGAGCTGGCTTTAATACTCTG]
NM_000277.1(PAH):c.932T>C ['TTACAGGAAATTGGCCTTGCCTCTCYGGGTG
725 (p.Leu311Pro) 5053 PAH CACCTGATGAATACATTGAA']
NM_000277.1 (PAH) : c.764T>C ['GGCCTGCTTTCCTCTCGGGATTTCTYGGGTG
726 (p.Leu255Ser) 5053 PAH GCCTGGCCTTCCGAGTCTTC]
NM_000277.1 (PAH) : c.143 T>C ['TCACTCAAAGAAGAAGTTGGTGCATYGGCC
727 (p.Leu48Ser) 5053 PAH AAAGTATTGCGCTTATTTGAG]
NM_000277. l(PAH):c.1045T>C ['AAAGGCATATGGTGCTGGGCTCCTGBCATCC
728 (p.Ser349Pro) 5053 PAH TTTGGTGAATTACAGGTATG]
NM_000277.1 (P AH) : c.293 T>C ['GCTCTGACAAACATCATCAAGATCTYGAGG
729 (p.Leu98Ser) 5053 PAH CATGACATTGGTGCCACTGTC]
NM_000277.1(PAH):c.734T>C ['TGCACTGGTTTCCGCCTCCGACCTGHGGCTG
730 (p.Val245Ala) 5053 PAH GCCTGCTTTCCTCTCGGGAT']
NM_000277.1 (PAH) : c.194T>C ['GAGAATGATGTAAACCTGACCCACANTGAA
731 (p.Ile65Thr) 5053 PAH TCTAGACCTTCTCGTTTAAAG]
732 NM_000130.4(F5):c.l l60T>C 2153 F5 ['CATTTGGATAATTTCTCAAACCAAAYTGGAA (p.Ile387Thr) AAC ATT AT A AG A A AGTT AT G]
NM_000512.4(GALNS):c.413T> ['AAGGCCGGCTACGTCAGCAAGATTGYCGGC
733 C (p.Vall38Ala) 2588 GALNS AAGTGGTAAGTCTCCTGGCCA]
NM_018077.2(RBM28):c. l052T ['TCCTTTGACTCAGAAGAAGAAGAACYTGGG
734 >C (p.Leu351Pro) 55131 RBM28 GAGCTTCTCCAACAGTTTGGA']
NM_203395.2(IYD):c.347T>C 38943 ['AATGAGCAAGTCCCAATGGAAGTCAYTGAT
735 (p.Ilell6Thr) 4 IYD AATGTCATCAGAACGGCAGGT']
NM_015702.2(MMADHC):c.776 ['CATTTAGGATTCTCTGTTGATGACCYTGGAT
736 T>C (p.Leu259Pro) 27249 MMADHC GCTGTAAAGTGATTCGTCAT']
NM_014165.3 (NDUF AF4) : c.194 ['AAAGATGAAAAGCTGCTGTCGTTTCYAAAA
737 T>C (p.Leu65Pro) 29078 NDUFAF4 GATGTGTATGTTGATTCCAAA']
NM_001136271.2(NKX2- 13781 ['GCAGGTGCTGGCCCTGGAGCGGCGCYTCAA
738 6):c.451T>C (p.Phel51Leu) 4 NKX2-6 GCAGCAGCGGTACCTGTCAGC]
NM_013319.2(UBIADl):c.511T ['TATCTACTTTGGAGGCCTGTCTGGCYCCTTT
739 >C (p.Serl71Pro) 29914 UBIAD1 CTCTACACAGGAGGTAAGAT']
NM_001127628.1(FBPl):c.581T ['TTGTCTAAAAAGGCCATCGGGGAGTYCATTT
740 >C (p.Phel94Ser) 2203 FBP1 TGGTGGACAAGGATGTGAAG]
NM_000046.3(ARSB):c.349T>C ['TTTACAGCACCAAATAATCTGGCCCYGTCAG
741 (p.Cysl l7Arg) 411 ARSB CCCAGCTGTGTTCCTCTGGA']
NM_000046.3 (ARSB) : c.707T>C ['TCTTTCCAGCCTCTGTTTCTCTACCYTGCTCT
742 (p.Leu236Pro) 411 ARSB CCAGTCTGTGCATGAGCCC]
M_000404.2(GLBl):c.l52T>C ['AAGGATGGCCAGCCATTTCGCTACAYCTCA
743 (p.Ile51Thr) 2720 GLB1 GGAAGCATTCACTACTCCCGT']
M_000404.2(GLBl):c.247T>C ['AAGGGGCTGTGTGTGTCTTGGCAGGBATGTG
744 (p.Tyr83His) 2720 GLB1 CCCTGGAACTTTCATGAGCC]
NM_024782.2(NHEJl):c.367T> ['CCTCCCCTTCTATTGGAATTTCCACYGCATG
745 C (p.Cysl23Arg) 79840 NHEJ1 CTAGCTAGTCCTTCCCTGGT']
NM_139241.3(FGD4):c.893T>C 12151 ['CAGAAATTGGCACCATTCCTTAAGABGTATG
746 (p.Met298Thr) 2 FGD4 GAGAATATGTGAAAGGATTT']
NM_020631.4(PLEKHG5):c.l 94 ['TTGGGCCTTCCCTAACCAGGGTCCTYCCTCC
747 0T>C (p.Phe647Ser) 57449 PLEKHG5 TTATCTACCTGAATGAGTTT']
NM_015559.2(SETBPl):c.2612T ['GAGACGATCCCCAGCGACAGCGGCAYTGGG
748 >C (p.Ile871Thr) 26040 SETBP1 ACAGACAACAACAGCACTTCT']
NM_138387.3(G6PC3):c.554T> ['CTCCTAGGCGCTGTCCTGGGCTGGCYGATGA
749 C (p.Leul85Pro) 92579 G6PC3 CTCCCCGAGTGCCTATGGAG']
NM_022489.3 (INF2) :c .556T>C ['CTTCAGCATTGTCATGAACGAGCTCYCCGGC
750 (p.Serl86Pro) 64423 INF2 AGCGACAACGTGCCCTACGT']
NM_022489.3(INF2):c.l25T>C ['GACCCCGAGCTGTGCATCCGGCTGCYCCAG
751 (p.Leu42Pro) 64423 INF2 ATGCCCTCTGTGGTCAACTAC]
NM_018122.4(DARS2):c.492+2 ['TTTGAAATTAAGAACTTCGTGAAGGBACCA
752 T>C 55157 DARS2 ACCTCTGTTATTAATAAAATA']
NM_015272.3(RPGRIPlL):c. l97 ['CCTTCATCCCGAATATAACTTCACTYCTCAA
753 5T>C (p.Ser659Pro) 23322 RPGRIP1L TATCTTGTTCATGTTAATGA]
754 NM_001029871.3(RSPO4):c.319 34363 RSP04 ['CTTCAGCCAGGACTTCTGCATCCGGYGCAAG T>C (p.Cysl07Arg) 7 AGGCAGTTTTACTTGTACAA']
NM_000429.2(MATlA):c.914T> ['GCTGCCCGCTGGGTGGCCAAGTCTCYGGTG
755 C (p.Leu305Pro) 4143 MAT1A AAAGCAGGGCTCTGCCGGAGA']
NM_032581.3(FAM126A):c.l58 ['AACATTTTGTCTTTCTTCTAGTTGCBAGAAC
756 T>C (p.Leu53Pro) 84668 FAM126A CTGTCTGTCACCAGCTCTTT']
NM_006364.2(SEC23 A):c.1144 ['GGGTGATTCTTTCAATACTTCCTTAYTCAAA
757 T>C (p.Phe382Leu) 10484 SEC23A CAAACTTTTCAAAGAGTCTT']
NM_018006.4(TRMU):c.229T> ['CCATCAAGTGTCCTACGTAAAGGAGYATTG
758 C (p.Tyr77His) 55687 TRMU GAATGATGTGTTCAGGTGAGT']
NM_001174089.1(SLC4Al l):c.2 ['CTGCAGGTGCTTCAGCTGCTGCTGCYGTGTG
759 480T>C (p.Leu827Pro) 83959 SLC4A11 CCTTCGGCATGAGCTCCCTG]
NM_001174089.1(SLC4Al l):c.5 ['AGTGACAGGGGTGCGGTACCAGCAGYCGTG
760 89T>C (p.Serl97Pro) 83959 SLC4A11 GCTCTGCATCATGTGAGTTGC]
NM_148960.2(CLDN19):c.269T 14946 ['GCCCTGATGGTGGTGGCCGTGCTCCYGGGCT
761 >C (p.Leu90Pro) 1 CLDN19 TCGTGGCCATGGTCCTCAGC]
NM_153704.5(TMEM67):c.2498 ['AACACAGATGGTCAGACTTTTGAGAYTGCA
762 T>C (p.Ile833Thr) 91147 TMEM67 ATTTCTAACCAGATGAGACAA']
NM_153704.5(TMEM67):c. l769 ['ACAGGTCTTTACTGGCTTATTTTCTYCAAAG
763 T>C (p.Phe590Ser) 91147 TMEM67 TGAGTGAGTTTCTGAATTTT']
NM_153704.5(TMEM67):c. l843 ['AGAACGTTTTGTCACTTATGTTGGAHGTGCC
764 T>C (p.Cys615Arg) 91147 TMEM67 TTTGCTCTGAAGGTAAGTTT']
NM_153704.5(TMEM67):c.755T ['ACATCTTGTCAAGCTCTTGGAAATAYGTGTG
765 >C (p.Met252Thr) 91147 TMEM67 TGATGAACATGAATTCTTAC]
NM_017777.3(MKSl):c.80+2T> ['CCCCGTGCGCAACTTGCGCCTCCGGYAGTCG
766 C 54903 MKS1 CACCGCCCCAGCCCCGAGGC]
NM_001041.3 (SI) :c .1022T>C ['AATTACATGCTCATTTACTTTAAGCYTGTTG
767 (p.Leu341Pro) 6476 SI GACTACCAGCAATGCCAGCA']
NM_001041.3(SI):c.l859T>C ['ATGGAATGGTCTATAACTGGAATGCYGGAG
768 (p.Leu620Pro) 6476 SI TTCAGTTTGTTTGGAATACCT']
NM_015506.2(MMACHC):c.347 ['CACCCCAACCGACGCCCCAAGATCCYGGCC
769 T>C (p.Leul l6Pro) 25974 MMACHC CAGACAGCAGCCCATGTAGCT']
NM_000190.3 (HMB S) :c.739T> ['GCACGATCCCGAGACTCTGCTTCGCYGCATC
770 C (p.Cys247Arg) 3145 HMBS GCTGAAAGGGCCTTCCTGAG]
NM_000190.3 (HMB S) :c .242T> ['GAGAAAAGCCTGTTTACCAAGGAGCYTGAA
771 C (p.Leu81Pro) 3145 HMBS CATGCCCTGGAGAAGAATGAG]
NM_000237.2(LPL):c.662T>C ['ACCAGAGGGTCCCCTGGTCGAAGCAYTGGA
772 (p.Ile221Thr) 4023 LPL ATCCAGAAACCAGTTGGGCAT']
NM_000237.2(LPL):c.337T>C ['AGACTCCAATGTCATTGTGGTGGACYGGCTG
773 (p.Trpl l3Arg) 4023 LPL TCACGGGCTCAGGAGCATTA']
NM_000237.2(LPL):c.755T>C ['AACATTGGAGAAGCTATCCGCGTGAYTGCA
774 (p.Ile252Thr) 4023 LPL GAGAGAGGACTTGGAGGTAAA]
NM_000263.3 (NAGLU) :c .142T ['GCTGGGGCCAGGCCCCGCGGCCGACYTCTC
775 >C (p.Phe48Leu) 4669 NAGLU CGTGTCGGTGGAGCGCGCTCT']
776 NM_000018.3 (AC AD VL) :c .137 37 ACADVL ['GCGTGTGCTCCGAGATCTTCGCATCYTCCGG 2T>C (p.Phe458Leu) ATCTTTGAGGGGACAAATGA]
NM_018105.2(THAPl):c.241T> ['GAAAGAGAATGCTGTGCCCACAATAYTTCTT
111 C (p.Phe81Leu) 55145 THAPl TGTACTGAGCCACATGACAA]
NM_005908.3(MANBA):c. l513 ['AGACAAGAGTCGTCCTTTTATTACGYCCAGT
11% T>C (p.Ser505Pro) 4126 MANBA CCTACAAATGGGGCTGAAAC]
NM_000124.3(ERCC6):c.2960T ['AAGCAGTTTTTGACAAATAGAGTGCYAAAA
119 >C (p.Leu987Pro) 2074 ERCC6 GACCCAAAACAAAGGCGGTTT']
NM_014845.5 (FIG4) : c.122T>C ['GAAACGAAATATCGTGTCTTGAAGAYTGAT
780 (p.Ile41Thr) 9896 FIG4 AGAACAGAACCAAAAGATTTG]
NM_000787.3 (DBH) :c .339+2T> ['GATGGGGACACTGCCTATTTTGCGGYGAGTC
781 C 1621 DBH TCTCCTCCCTGCCAGCTCTC]
NM_000102.3(CYP17Al):c.316 ['TCTAAAGGCAACTCTAGACATCGCGYCCAA
782 T>C (p.Serl06Pro) 1586 CYP17A1 CAACCGTAAGGGTATCGCCTT']
NM_000102.3(CYP17Al):c.l21 ['GGCGCTGCATCACAATGAGAAGGAGYGGCA
783 6T>C (p.Trp406Arg) 1586 CYP17A1 CCAGCCGGATCAGTTCATGCC]
NM_000102.3(CYP17Al):c.l35 ['GAGATCCTGGCCCGCCAGGAGCTCTYCCTCA
784 8T>C (p.Phe453Ser) 1586 CYP17A1 TCATGGCCTGGCTGCTGCAG']
NM_152783.4(D2HGDH):c.l331 72829 ['GGAGATGGTAACCTGCACCTCAATGYGACG
785 T>C (p.Val444Ala) 4 D2HGDH GCGGAGGCCTTCAGCCCCTCG]
NM_000255.3(MUT):c.313T>C ['TCCTACCATGTATACCTTTAGGCCCYGGACC
786 (p.Trpl05Arg) 4594 MUT ATCCGCCAGTATGCTGGTTT']
NM_000411.6(HLCS):c.710T>C ['CTGTACCAGAAGTTCATGGCCTATCYTTCTC
787 (p.Leu237Pro) 3141 HLCS AGGGAGGGAAGGTGTTGGGC]
NM_022132.4(MCCC2):c.499T> ['AATTGCCATGCAAAACAGGCTCCCCYGCAT
788 C (p.Cysl67Arg) 64087 MCCC2 CTACTTAGGCAAGTCACCAGA']
NM_020166.4(MCCCl):c.l310T ['CATTATGACCCCATGATTGCGAAGCYGGTCG
789 >C (p.Leu437Pro) 56922 MCCC1 TGTGGGCAGCAGATCGCCAG]
NM_198578.3(LRRK2):c.6059T 12089 ['ATTGCAAAGATTGCTGACTACGGCAYTGCTC
790 >C (p.Ile2020Thr) 2 LRRK2 AGTACTGCTGTAGAATGGGG]
NM_000022.2(ADA):c.320T>C ['GAGGTGCGGTACAGTCCGCACCTGCYGGCC
791 (p.Leul07Pro) 100 ADA AACTCCAAAGTGGAGCCAATC]
NM_199242.2(UNC13D):c. l208 20129 ['CTGGCCGCCTCATTCAGCTCCCTGCYGACCT
792 T>C (p.Leu403Pro) 4 UNC13D ACGGCCTCTCCCTCATCCGG]
NM_152443.2(RDH12):c.523T> 14522 ['CCCTGCACGGGTGGTTAATGTGTCCYCGGTG
793 C (p.Serl75Pro) 6 RDH12 GCTCACCACATTGGCAAGAT']
NM_020435.3(GJC2):c.857T>C ['TGCCTGCTGCTCAACCTCTGTGAGAYGGCCC
794 (p.Met286Thr) 57165 GJC2 ACCTGGGCTTGGGCAGCGCG]
NM_000159.3(GCDH):c.883T> ['CTTCGGCTGCCTGAACAACGCCCGGYACGG
795 C (p.Tyr295His) 2639 GCDH CATCGCGTGGGGCGTGCTTGG]
NM_000920.3(PC):c.434T>C ['CGGTTTATTGGGCCAAGCCCAGAAGBGGTC
796 (p.Vall45Ala) 5091 PC CGCAAGATGGGAGACAAGGTG]
NM_207118.2(GTF2H5):c.62T> 40467 ['GATCCTGCCATGAAGCAGTTTCTGCYGTACT
797 C (p.Leu21Pro) 2 GTF2H5 TGGATGAGTCCAATGCCCTG]
798 NM_005787.5(ALG3):c.211T>C 10195 ALG3 ['TCTTCTTCCAGACACAGAGATTGACYGGAA (p.Trp71Arg) GGCCTACATGGCCGAGGTAGA]
NM_024514.4(CYP2Rl):c.296T 12022 ['GGCTATGATGTAGTAAAGGAATGCCYTGTTC
799 >C (p.Leu99Pro) 7 CYP2R1 ATCAAAGCGAAATTTTTGCA]
NM_017929.5(PEX26):c.2T>C ['CTGGGCCTTGGACCCGGACTCGTTAYGAAG
800 (p.MetlThr) 55670 PEX26 AGCGATTCTTCGACCTCTGCA]
NM_017929.5 (PEX26) :c .134T> ['CTTCTGGAGGAGGCGGCCGACCTCCYGGTG
801 C (p.Leu45Pro) 55670 PEX26 GTGCACCTGGACTTCCGGGCG]
NM_213599.2(ANO5):c. l066T> 20385 ['TGGTCAGATGATCATGTGCCCACTCBGTGAT
802 C (p.Cys356Arg) 9 AN05 CAAGTGTGTGATTATTGGAG']
NM_022370.3(ROBO3):c.2113T ['CCAGCTGGTGCAAGGTTTCCGGGTGHCTTGG
803 >C (p.Ser705Pro) 64221 ROB03 AGGGTAGCAGGCCCTGAGGG]
NM_022370.3(ROBO3):c. l4T>C ['CTGGGTCGAGCCATGCTGCGCTACCYGCTGA
804 (p.Leu5Pro) 64221 ROB03 AAACGCTGCTGCAGATGAAC]
NM_207352.3 (CYP4V2) : c.332T 28544 ['GTATGTTTTTCTCTTCCTAAGGTAABTTTAAC
805 >C (p.Ilel l lThr) 0 CYP4V2 TAGTTCAAAGCAAATTGAC]
NM_178857.5(RPlLl):c.2878T> ['GTCTCCAGAGGCTGTGGTCCGCGAAYGGCT
806 C (p.Trp960Arg) 94137 RP1L1 GGACAACATTCCAGAAGAGCC]
NM_018668.4(VPS33B):c.89T> ['GCTCGAGACCAGCTCATCTATCTGCYGGAGC
807 C (p.Leu30Pro) 26276 VPS33B AGGTCAGTGCTTGCCTGACG]
NM_024006.5 (VKORC 1 ) : c.134T ['CGGGATTACCGCGCGCTCTGCGACGYGGGC
808 >C (p.Val45Ala) 79001 VKORC 1 ACCGCCATCAGCTGTTCGCGC]
NM_000551.3(VHL):c.334T>C ['TGGCACGGGCCGCCGCATCCACAGCHACCG
809 (p.Tyrl l2His) 7428 VHL AGGT AC GGGCCC GGC GCTT AG]
NM_000551.3(VHL):c.292T>C ['CAACTTCGACGGCGAGCCGCAGCCCYACCC
810 (p.Tyr98His) 7428 VHL AACGCTGCCGCCTGGCACGGG]
NM_000551.3 (VHL) : c.188T>C ['GAGGCCGGGCGGCCGCGGCCCGTGCYGCGC
811 (p.Leu63Pro) 7428 VHL TCGGTGAACTCGCGCGAGCCC]
NM_000551.3(VHL):c.488T>C ['GTGTATACTCTGAAAGAGCGATGCCYCCAG
812 (p.Leul63Pro) 7428 VHL GTTGTCCGGAGCCTAGTCAAG]
M_014874.3(MFN2):c.227T>C ['CCCGTTACCACAGAAGAACAGGTTCBGGAC
813 (p.Leu76Pro) 9927 MFN2 GTCAAAGGTTACCTATCCAAA']
NM_015046.5 (SETX) : c.1166T> ['AACATGTATGAAGAAATGGAAACATYAGCC
814 C (p.Leu389Ser) 23064 SETX AGTGTACTTCAGTCAGATATT']
NM_005609.2(PYGM):c.1187T> ['TGGCCGGTGCACCTCTTGGAGACGCYGCTGC
815 C (p.Leu396Pro) 5837 PYGM CGCGGCACCTCCAGATCATC]
NM_005609.2(PYGM):c.2392T> ['CTTTGACCTGCAGAACCCAAGAGAGHGGAC
816 C (p.Trp798Arg) 5837 PYGM GCGGATGGTGATCCGGAACAT']
NM_213653.3(HFE2):c.842T>C 14873 ['CATGTGGAGATCCAAGCTGCCTACAYTGGC
817 (p.Ile281Thr) 8 HFE2 ACAACTATAATCATTCGGCAG]
NM_213653.3(HFE2):c.238T>C 14873 ['TGGAGGGGTGGGCTCTGGCGGCCTCBGTCG
818 (p.Cys80Arg) 8 HFE2 AGCCCTCCGCTCCTATGCGCT']
NM_213653.3(HFE2):c.302T>C 14873 ['ACCGCCCGCACCTGCCGCGGGGACCYCGCC
819 (p.LeulOlPro) 8 HFE2 TTCCATTCGGCGGTACATGGC]
820 NM_000045.3 (ARG1 ) :c .32T>C 383 ARGl ['GCCAAGTCCAGAACCATAGGGATTAYTGGA (p.IlellThr) GCTCCTTTCTCAAAGGGACAG]
NM_032409.2(PINKl):c.l040T> ['GCCGCCATGATGCTGCTGCAGCTGCYGGAA
821 C (p.Leu347Pro) -1 - GGCGTGGACCATCTGGTTCAA]
NM_153006.2(NAGS):c.l289T> ['GCCAGGTACAACGCCGCCGCCATTCYGACC
822 C (p.Leu430Pro) -1 - ATGGAGCCCGTCCTGGGGGGC]
NM_153006.2(NAGS):c.l450T> ['CCGGGTCACCAACCCCATCAATCCCBGGTAG
823 C (p.Trp484Arg) -1 - GTCCTGCCACTCCCAGCTCT']
NM_001173464.1(KIF21A):c.30 ['AGTATTTCTGATTGTCAGGCCAACAYAATGC
824 29T>C (p.IlelOlOThr) 55605 KIF21A AGATGGAAGAAGCAAAGGTT']
NM_001173464.1(KIF21A):c. l0 ['GTCAGCCCTTCAGACAGAGACTTTAYGGAA
825 67T>C (p.Met356Thr) 55605 KIF21A ACGTTAAACACCCTGAAATAC]
M_000434.3(NEUl):c. l088T> ['TCATGGCGGAAAGAGACAGTCCAGCYATGG
826 C (p.Leu363Pro) 4758 NEU1 CCAGGCCCCAGTGGCTATTCA]
M_000434.3(NEUl):c.718T>C ['CCTCAGCGATGATCATGGTGCCTCCYGGCGC
827 (p.Trp240Arg) 4758 NEU1 TACGGAAGTGGGGTCAGCGG]
NM_000026.2(AD SL) :c .1312T> ['TGATGCCTACTTCAGTCCCATTCACYCCCAG
828 C (p.Ser438Pro) 158 ADSL TTGGATCATTTACTGGATCC]
NM_000026.2(ADSL):c.674T>C ['TCCAAGGTAGAGCAGCTTGACAAGAYGGTG
829 (p.Met225Thr) 158 ADSL ACAGAAAAGGCAGGATTTAAG]
NM_018400.3(SCN3B):c.29T>C ['CCTGCCTTCAATAGATTGTTTCCCCYGGCTT
830 (p.LeulOPro) 55800 SCN3B CTCTCGTGCTTATCTACTGG]
NM_024577.3(SH3TC2):c.505T ['CCTTCCTGTATCAGGAGTCCCAGGTRTATTG
831 >C (p.Tyrl69His) 79628 SH3TC2 TTTCCAGGTGTTTATCATCT']
NM_000243.2(MEFV):c.2177T> ['GTGGGCATCTTCGTGGACTACAGAGHTGGA
832 C (p.Val726Ala) 4210 MEFV AGCATCTCCTTTTACAATGTG]
NM_000483.4(APOC2):c. l42T> ['GGTGAAGGAATCTCTCTCCAGTTACYGGGA
833 C (p.Trp48Arg) -1 - GTCAGCAAAGACAGCCGCCCA']
NM_058172.5 (ANTXR2) : c.566T 11842 ['CTCTTCTTTCTAAAGCTTGAAAGAAYTGCTG
834 >C (p.Ilel89Thr) 9 ANTXR2 ATTCCAAGGAGCAAGTTTTC]
NM_001128085.1(ASPA):c.454 ['TCAGACTTCTCTGGCTCCACTACCCYGCTAC
835 T>C (p.Cysl52Arg) -1 - GTTTATCTGATTGAGCATCC]
NM_022464.4(SILl):c.645+2T> ['TGACTTATGGACGAAGAAATACAGTRCCTG
836 C 64374 SIL1 ATGGACATAATATTCAAGATC]
NM_001037633.1(SILl):c.l370T ['CTGCTGGGCTCTGTCAACAGCTTGCYGAAGG
837 >C (p.Leu457Pro) 64374 SIL1 AGCTGAGATGAGGCCCCACA']
NM_000391.3(TPPl):c.l093T>C ['TCTCTCAGGTGACAGTGGGGCCGGGYGTTG
838 (p.Cys365Arg) 1200 TPP1 GTCTGTCTCTGGAAGACACCA']
NM_182760.3(SUMFl):c. l006T 28536 ['AGTGAAGAAAGGTGGATCCTACATGYGCCA
839 >C (p.Cys336Arg) 2 SUMF1 TAGGGTAAGTCATGTCACTAA']
NM_182760.3(SUMFl):c.463T> 28536 [' CTT AT AGGCTG AG A AGTTT GGC G AC YCCTTT
840 C (p.Serl55Pro) 2 SUMF1 GTCTTTGAAGGCATGTTGAG']
NM_177986.3(DSG4):c.574T>C ['TGCAGATGAAGAAAATCATCTGAATHCTAA
841 (p.Serl92Pro) -1 - AATTGCCTACAAGATCGTCTC]
842 NM_004183.3(BESTl):c.253T> 7439 BEST1 ['CCCCCGCCCCTCCTGCCCAGGCTTCYACGTG C (p.Tyr85His) ACGCTGGTCGTGACCCGCTG]
NM_004183.3(BESTl):c.l22T> ['TATGGCGAGTTCTTAATCTTCCTGCYCTGCT
843 C (p.Leu41Pro) 7439 BEST1 ACTACATCATCCGCTTTATT']
NM_004183.3(BESTl):c.614T> ['CTTGGAGGTCGAATCCGGGACCCTAYCCTGC
844 C (p.Ile205Thr) 7439 BEST1 TCCAGAGCCTGCTGAACGTG]
NM_004183.3 (BEST1) :c.704T> ['TACGACTGGATTAGTATCCCACTGGYGTATA
845 C (p.Val235Ala) 7439 BEST1 CACAGGTGAGGACTAGGCTG]
NM_024312.4(GNPTAB):c.1120 ['TGTTTGTTGTTGTTAAAAGGATGTTYTTCGA
846 T>C (p.Phe374Leu) 79158 GNPTAB AATTTGAGCCACTTGCCTAC]
NM_000158.3(GBEl):c.671T>C ['TATAAACATTTTACATGCAATGTACYACCAA
847 (p.Leu224Pro) 2632 GBE1 GAATCAAAGGCCTTGGTAAG]
NM_017890.4(VPS13B):c.8459T 15768 ['CAGGTGCCATCTTCAAACAGTTCCAYTATTT
848 >C (p.Ile2820Thr) 0 VPS13B ATGTCTGGTGCACAGTTTTG]
NM_000019.3(ACATl):c.935T> ['CTCAATGTTACACCACTGGCAAGAAYAGTA
849 C (p.Ile312Thr) 38 ACAT1 GGTAAGGCCAGGCGAGGTGGC]
NM_020184.3 (CNNM4) :c .971 T ['CTCAGTTTTCCCATTAGCAAGCTCCYGGACT
850 >C (p.Leu324Pro) 26504 CNNM4 TTTTTCTGGGCCAGGAGATT']
NM_001171507.2(MCFD2):c.40 ['GATGACAAGAACAATGATGGATACAYTGAC
851 7T>C (p.Ilel36Thr) 90411 MCFD2 TATGCTGAATTTGCAAAATCA']
NM_174936.3(PCSK9):c.646T> 25573 ['TGTGCCCGAGGAGGACGGGACCCGCYTCCA
852 C (p.Phe216Leu) 8 PCSK9 CAGACAGGTAAGCACGGCCGT']
NM_000419.3(ITGA2B):c. l787 ['GACTTCCGGGACAAGCTGAGCCCCAYTGTG
853 T>C (p.Ile596Thr) 3674 ITGA2B CTCAGCCTCAATGTGTCCCTA']
NM_000419.3 (ITGA2B) : c.641 T ['CCCTTCCAGGCCGGAGAGCTGGTGCYTGGG
854 >C (p.Leu214Pro) 3674 ITGA2B GCTCCTGGCGGCTATTATTTC]
NM_004817.3(TJP2):c.l43T>C ['TCCAAAAGAGGATTTGGAATTGCAGYGTCC
855 (p.Val48Ala) 9414 TJP2 GGAGGCAGAGACAACCCCCAC]
NM_173477.4(USHlG):c.l43T> 12459 ['GCCTACCATGGCAACCTCGAGTCGCYGCGTC
856 C (p.Leu48Pro) 0 USH1G TCATTGTGAGCCGCGGGTGA']
NM_000271.4(NPCl):c.3182T> ['GACGCTCTGAAGAAAGCCCGACTTAYAGCC
857 C (p.Ilel061Thr) 4864 NPC1 AGTAATGTCACCGAAACCATG]
NM_000271.4(NPCl):c.l l33T> ['TTTGTCCGGGTCACAACCAATCCAGYTGACC
858 C (p.Val378Ala) 4864 NPC1 TCTGGTCAGCCCCCAGCAGC]
NM_000271.4(NPCl):c.337T>C ['ACTGAACCTGTTTTGTGAGCTGACAYGTAGC
859 (p.Cysl l3Arg) 4864 NPC1 CCTCGACAGAGTCAGTTTTT']
NM_000543.4(SMPDl):c.911T> ['CGGGCCCTGACCACCGTCACAGCACYTGTG
860 C (p.Leu304Pro) 6609 SMPD1 AGGAAGTTCCTGGGGCCAGTG]
NM_000226.3(KRT9):c.503T>C ['CTCAATTCTCGGCTGGCCTCTTACTYGGATA
861 (p.Leul68Ser) 3857 KRT9 AGGTGCAGGCTCTAGAGGAG]
NM_000226.3(KRT9):c.470T>C ['CTGACTGCTAATGAGAAGAGCACCANGCAG
862 (p.Metl57Thr) 3857 KRT9 GAACTCAATTCTCGGCTGGCC]
NM_000051.3(ATM):c.7967T>C ['CCAGCAGACCAGCCAATTACTAAACYTAAG
863 (p.Leu2656Pro) -1 - AATTTAGAAGATGTTGTTGTC]
864 NM_000487.5(ARSA):c.410T>C 410 ARSA ['GGGGTGGGGCCTGAGGGGGCCTTCCYGCCC (p.Leul37Pro) CCCCATCAGGGCTTCCATCGA']
NM_017653.3(DYM):c.l624T> ['AATGATGTTAGAGATCATCAACTCCYGCCTG
865 C (p.Cys542Arg) 54808 DYM ACAAATTCCCTTCACCACAA']
NM_016038.2(SBDS):c.258+2T ['GACCAAACTGAAATCTGTAAGCAGGYGGGT
866 >C 51119 SBDS AACAGCTGCAGCATAGCTAAC]
NM_001079802.1(FKTN):c.527 ['ACTCATGCGATCCACTTGGTAGTCTYTCATG
867 T>C (p.Phel76Ser) 2218 FKTN AGAGGAGTGGCAACTACCTC]
NM_013382.5 (POMT2) : c.2242T ['GGCAGGACTAAGGTGGCTGGACTCAYGGGA
868 >C (p.Trp748Arg) 29954 POMT2 CTTTTGAGGCCACTGCAAAGA']
NM_024529.4(CDC73):c.l91T> ['ACATTGGATTCCATTTTATTTCTACYTAATA
869 C (p.Leu64Pro) 79577 CDC73 ACGTGCACCTTTCTCATCCT']
NM_000268.3(NF2):c.l079T>C ['ACGAGGGATGAGTTGGAGAGGAGGCYGCTG
870 (p.Leu360Pro) 4771 NF2 CAGATGAAAGAAGAAGCAACA']
NM_000268.3(NF2):c.l604T>C ['GAATACATGGAAAAGAGCAAGCATCYGCAG
871 (p.Leu535Pro) 4771 NF2 GAGCAGCTCAATGAACTCAAG]
NM_000268.3(NF2):c.l85T>C ['CTGGGGCTCCGAGAAACCTGGTTCTYTGGAC
872 (p.Phe62Ser) 4771 NF2 TGCAGTACACAATCAAGGAC]
NM_139248.2(LIPH):c.322T>C 20087 ['AGACATGAACGTAGTTGTTGTTGATYGGAAT
873 (p.Trpl08Arg) 9 LIPH CGAGGAGCTACAACTTTAAT']
NM_015102.4(NPHP4):c.2972T 26173 ['GCCACGCTGGGGGTCGCCGAGTTCTYTGAGT
874 >C (p.Phe991Ser) 4 NPHP4 TTGTGCTTAAGAACCCCCAC]
NM_024105.3(ALG12):c.473T> ['ACCCTCCCGCACTGTCTTGCAGTCCYGCTGG
875 C (p.Leul58Pro) 79087 ALG12 CCCTCGCGGCCTGGCTGCGG]
NM_000280.4(PAX6):c.773T>C ['GTCCCACCTGATTTCCAGGTATGGTYTTCTA
876 (p.Phe258Ser) 5080 PAX6 ATCGAAGGGCCAAATGGAGA']
NM_024426.4(WTl):c. l351T>C ['CTCTGTCCATTTAGGTGTGAAACCAYTCCAG
877 (p.Phe451Leu) 7490 WT1 TGTAAAACTTGTCAGCGAAA']
NM_024426.4(WTl):c. l378T>C ['CCAGTGTAAAACTTGTCAGCGAAAGYTCTCC
878 (p.Phe460Leu) 7490 WT1 CGGTCCGACCACCTGAAGAC]
NM_005957.4(MTHFR):c.968T> ['GTGCCAGGCCTCCACTTCTACACCCYCAACC
879 C (p.Leu323Pro) 4524 MTHFR GCGAGATGGCTACCACAGAG]
NM_016247.3 (IMPG2) :c .370T> ['TCACGCCCAGGAAGTCGATCCCAAARAGTC
880 C (p.Phel24Leu) 50939 IMPG2 CTGAAGGCTTCCCAGACAGCT']
NM_002225.3 (IVD) : c.134T>C ['CCCGTGGACGATGCAATCAATGGGCYAAGC
881 (p.Leu45Pro) 3712 IVD GAGGAGCAGAGGCAGGTGAGG]
NM_001127328.2(ACADM):c.l ['CAGTTAGCTACTGATGCTGTGCAGAYACTTG
882 136T>C (p.Ile379Thr) 34 ACADM GAGGCAATGGATTTAATACA']
NM_001127328.2(ACADM):c.7 ['TTAGGAATTAAACATGGGCCAGCGAYGTTC
883 42T>C (p.Cys248Arg) 34 ACADM AGATACTAGAGGAATTGTCTT']
NM_000016.5(ACADM):c. l99T ['GGAAATCATCCCAGTGGCTGCAGAAYATGA
884 >C (p.Tyr67His) 34 ACADM TAAAACTGGTGAAGTAGGTAT']
NM_000155.3(GALT):c.221T>C ['CCCCGCCATGACCCTCTCAACCCTCBGTGTC
885 (p.Leu74Pro) 2592 GALT CTGGGGCCATCCGAGCCAAC]
886 NM_000155.3 (GALT) :c .512T>C 2592 GALT ['CTCCGTATCCCTATCTGATAGATCTYTGAAA (p.Phel71Ser) ACAAAGGTGCCATGATGGGC]
NM_000155.3 (GALT) :c .580T>C ['CCCTTGACAGGTATGGGCCAGCAGTYTCCTG
887 (p.Phel94Leu) 2592 GALT CCAGATATTGCCCAGCGTGA]
NM_000250.1(MPO):c.752T>C ['ACTCCGGACCAGGAGCGCTCACTCAYGTTC
888 (p.Met251Thr) 4353 MPO ATGCAATGGGGCCAGCTGTTG]
NM_020247.4(ADCK3):c. l398+ ['CTCAGCCAGGAGATTCGGAACGAGGYTTGT
889 2T>C 56997 ADCK3 CTGTGCCAGCAGACAGGTGGG]
NM_000229.1(LCAT):c.508T>C ['GACTGTGCGCGCCGCCCCCTATGACYGGCG
890 (ρ.Τφ170Α¾) 3931 LCAT GCTGGAGCCCGGTGAGTGTCT']
NM_000229.1(LCAT):c.698T>C ['CGCTTTATTGATGGCTTCATCTCTCYTGGGG
891 (p.Leu233Pro) 3931 LCAT CTCCCTGGGGTGGCTCCATC]
NM_000229.1(LCAT):c.524- ['CAGGTGCCCCAGACCCCAGCTGCCCYGACC
892 22T>C 3931 LCAT CCTTCCACCCGCTGCAGGCCA]
NM_000403.3 (GALE) :c.548T>C ['CCACAGACTTGGAACGCAGTGCTGCYGCGC
893 (p.Leul83Pro) 2582 GALE TATTTCAACCCCACAGGTGCC]
NM_000527.4(LDLR):c.694+2T ['ACAAATCTGACGAGGAAAACTGCGGYATGG
894 >C 3949 LDLR GCGGGGCCAGGGTGGGGGCGG]
NM_000375.2(UROS):c.217T>C ['CAGAGCAGTGGAAGCAGCAGAGTTAYGTTT
895 (p.Cys73Arg) 7390 UROS GGAGCAAAACAATAAAACTGA']
NM_000375.2(UROS):c.-26- ['GCTAACATGCTCTTTCTTGGCCTTAYCAGTG
896 177T>C 7390 UROS ACAGGGGTCTTCAGAAAGAA']
NM_000372.4(TYR):c.265T>C ['GCCTTCCGTCTTTTATAATAGGACCYGCCAG
897 (p.Cys89Arg) 7299 TYR TGCTCTGGCAACTTCATGGG']
NM_000017.3(ACADS):c.529T> ['CACCGCCCGGGCCGAGGGCGACTCABGGGT
898 C (ρ.Τφ177Α¾) 35 ACADS TCTGAATGGAACCAAAGCCTG]
NM_000053.3(ATP7B):c.3443T ['GCGCCTCAGCCACTCACGGTTTCCARTCAGC
899 >C (p.Ilel l48Thr) 540 ATP7B ACAGAGAAGGTCTGGGGGAC]
NM_000053.3(ATP7B):c.2123T ['GCCTTCACTGTCCTTGTCTTTCAGCYCCTCG
900 >C (p.Leu708Pro) 540 ATP7B GTGGGTGGTACTTCTACGTT']
NM_000520.4(HEXA):c.1453T> ['AGCAGGGGCTGTTGCCGAAAGGCTGYGGAG
901 C (ρ.Τφ485Α¾) 3073 HEXA CAACAAGTTGACATCTGACCT']
NM_000520.4(HEXA):c.632T>C ['TGGCATCTGGTAGATGATCCTTCCTYCCCAT
902 (p.Phe211Ser) 3073 HEXA ATGAGAGCTTCACTTTTCCA]
NM_000520.4(HEXA):c.538T>C ['CTTGCTGTTGGATACATCTCGCCATYACCTG
903 (p.Tyrl80His) 3073 HEXA CCACTCTCTAGCATCCTGGA']
NM_016335.4(PRODH):c. l322T ['CTGGGCCAGGTATGCGCCCCGCACCRGCTTG
904 >C (p.Leu441Pro) 5625 PRODH GCCCCAAAACACCAGCCCTC]
NM_000152.3(GAA):c.953T>C ['GTGTTCCTGCTAAACAGCAATGCCAYGGGT
905 (p.Met318Thr) 2548 GAA AAGCTGCCCGCCGCCCAGCGC]
NM_012213.2(MLYCD):c. l l9T ['GCGGCCGGCGCCCTGGAGCGGGCCAYGGAC
906 >C (p.Met40Thr) 23417 MLYCD GAGCTGCTGCGCCGCGCGGTG]
NM_012464.4(TLLl):c.713T>C ['AAGAACTGTGATAAATTTGGGATTGYTGTTC
907 (p.Val238Ala) 7092 TLL1 ATGAATTGGGTCATGTGATA']
908 NM_000112.3 (SLC26 A2) : c. - 1836 SLC26A2 ['CCTGCAGCGGCCCGGACCCGAGAGGYGAGA 26+2T>C AGAGGGAAGCGGACCAGGGAA']
NM_138691.2(TMCl):c. l543T> 11753 ['CCCTGCAGATGTACCTCGAGGACCTYGCTGG
909 C (p.Cys515Arg) 1 TMC1 GAAACAATGGTGGGACAGGT']
NM_138694.3(PKHDl):c.10658 ['GTTGTCCTACAAGGAGAGGAGCCCAYTGAA
910 T>C (p.Ile3553Thr) 5314 PKHD1 ATACGCTCAGGTGTTTCCATT']
NM_001034116.1(EIF2B4):c. l3 ['TGCAGATGACCCTGATGATCTGCAAYGTAA
911 93T>C (p.Cys465Arg) 8890 EIF2B4 GCGGGGAGAACATGTTGCGCT']
NM_001034116.1(EIF2B4):c. l4 ['ATCCCTACGGTTGTTGAATCTAGTCYATGAT
912 65T>C (p.Tyr489His) 8890 EIF2B4 GTGACTCCCCCAGAGCTTGT']
NM_018960.4(GNMT):c. l49T> ['ACCGCCGAGTACAAGGCATGGCTGCYTGGG
913 C (p.Leu50Pro) 27232 GNMT CTGCTGCGCCAGCACGGCTGC]
NM_181457.3(PAX3):c.268T>C ['CTGCGTCTCCAAGATCCTGTGCAGGYACCAG
914 (p.Tyr90His) 5077 PAX3 GAGACTGGCTCCATACGTCC]
NM_024301.4(FKRP):c.899T>C ['GAGACCACGCGCTGCTTCGGAACCGYGGTG
915 (p.VaDOOAla) 79147 FKRP GGCGACACGCCCGCCTACCTC]
NM_021020.3(LZTSl):c.85T>C ['TTCGCAGTACAAGCTGCGCAAGTCCYCCCAC
916 (p.Ser29Pro) 11178 LZTS1 CTCAAGAAGCTCAACCGGTA']
NM_005857.4(ZMPSTE24):c.l0 ['TGTACTAGGCCATGAACTGGGGCACYGGAA
917 18T>C (p.Trp340Arg) 10269 ZMPSTE24 GTTGGGACATACAGTCAAAAA']
NM_017838.3(NHP2):c.415T>C ['GCCCCATGAGGAGTACCAGGAGGCTYACGA
918 (p.Tyrl39His) 55651 NHP2 TGAGTGCCTGGAGGAGGTGCA']
NM_000157.3(GBA):c.l448T>C ['GGGATGCATCAGTGCCACTGCGTCCVGGTC
919 (p.Leu483Pro) 2629 GBA GTTCTTCTGACTGGCAACCAG]
NM_001005741.2(GBA):c.751T ['CATCTACCACCAGACCTGGGCCAGAYACTTT
920 >C (p.Tyr251His) 2629 GBA GTGAAGTAAGGGATCAGCAA']
NM_001243133.1(NLRP3):c. l71 11454 ['AAATTCGAAAAGGGGTATTTGATTTYTGTTG
921 8T>C (p.Phe573Ser) 8 NLRP3 TACGTTTCCTCTTTGGCCTG]
NM_001243133.1 (NLRP3 ) : c.926 11454 ['GGCTTCGATGAGCTGCAAGGTGCCTYTGAC
922 T>C (p.Phe309Ser) 8 NLRP3 GAGCACATAGGACCGCTCTGC]
NM_001243133.1(NLRP3):c. l05 11454 ['CTCATCACCACGAGACCTGTGGCCCYGGAG
923 8T>C (p.Leu353Pro) 8 NLRP3 AAACTGCAGCACTTGCTGGAC]
NM_057176.2(BSND):c.35T>C ['GAGAAGACCTTCCGGATCGGCTTCAYTGTGC
924 (p.Ilel2Thr) 7809 BSND TGGGGCTTTTCCTGCTGGCC]
NM_001195794.1(CLRNl):c.48 ['TCTGTTGCAGGCTCCTGTGGCTGTCYTGTCA
925 8T>C (p.Leul63Pro) 7401 CLRN1 TGATATTGTTTGCCTCTGAA']
NM_175073.2(APTX):c.668T>C ['GCTGTGGCCAGGGAACACCTTGAACYCCTT
926 (p.Leu223Pro) 54840 APTX AAGCATATGCACACTGTGGGG]
NM_020365.4(EIF2B3):c. l037T ['CCACCAGTCCATTCGTCAGCCCAGAYTGTCA
927 >C (p.Ile346Thr) 8891 EIF2B3 GCAAACACCTGGTAAGTGCT']
NM_031433.3(MFRP):c.545T>C ['ATCCAGGTGGCCACAGACCATGCAAYACAG
928 (p.Ilel82Thr) -1 - CTCAAGATCGAAGCCCTCAGC]
NM_016180.4(SLC45A2):c. l082 ['AGTGCACACAACTCCACAGAGTTTCYCATCT
929 T>C (p.Leu361Pro) 51151 SLC45A2 ACGAAAGAGGAGTCGAGGTT']
930 NM_006005.3(WFSl):c.2486T> 7466 WFS1 ['AGCCTCATCGAGTTCAGCACCATCCYGGAG C (p.Leu829Pro) GGCCGCCTGGGCAGCAAGTGG]
NM_024960.4(PANK2):c.178T> ['GATCAAAGGAATTTTATACATTGACYCAGTC
931 C (p.Ser60Pro) 80025 PANK2 GGATTCAATGGACGGTCACA]
NM_024960.4(PANK2):c.437T> ['ACCACTTTTGAAGAAGCTCTTGAAAYGGCAT
932 C (p.Metl46Thr) 80025 PANK2 CTCGTGGAGATAGCACCAAA]
NM_020427.2(SLURPl):c.43T> ['TGTGCAGCTGCTGCTCGTGGCAGCCYGGAG
933 C (p.Trpl5Arg) 57152 SLURP 1 CATGGGCTGTGGTGAGTGGGC]
NM_020427.2(SLURPl):c.229T ['GGTGACCCGCTCCTGCTCCAGCTCCYGTGTG
934 >C (p.Cys77Arg) 57152 SLURP 1 GCCACCGACCCCGACAGCAT']
NM_021830.4(C10orf2):c. ll42T ['CTTCGGGAGGAGGTGCTAGGAGAACBGTCA
935 >C (p.Leu381Pro) 56652 ClOorQ AATGTGGAGCAAGCAGCTGGC]
NM_001033855.2(DCLRElC):c. ['CCGGACTCTGGGATCGGCGGCGCTAYGAGT
936 2T>C (p.MetlThr) 64421 DCLRE1C TCTTTCGAGGGGCAGATGGCC]
NM_153741.1(DPM3):c.254T>C ['CAGATACAGGAGGCCCGAGCCGACTYAGCC
937 (p.Leu85Ser) 54344 DPM3 CGCAGGGGGCTGCGCTTCTGA]
M_000441.1 (SLC26 A4) : c.707 ['GCCTTCCAAGTGCTGGTCTCACAGCYAAAG
938 T>C (p.Leu236Pro) 5172 SLC26A4 ATTGTCCTCAATGTTTCAACC]
M_000441.1(SLC26A4):c. l588 ['TGGAAGCATCCCTAGCACAGATATCYACAA
939 T>C (p.Tyr530His) 5172 SLC26A4 AAGTACCAAGAATTACAAAAA']
M_000441.1 (SLC26 A4) : c. - ['CTTTCCCTTCGACCAAGGTGTCTGTYGCTCC
940 103T>C -1 - GTAAATAAAACGTCCCACTG]
NM_000441. l(SLC26A4):c.1003 ['ATTTTTCACTTAAAAACTCACTAGGHTTTTG
941 T>C (p.Phe335Leu) 5172 SLC26A4 CCTCCTGAACTTCCACCTGT']
NM_022458.3(LMBRl):c.423+4 ['AACAAAGATTTTTTTAATATGTTTCYATCCT
942 842T>C 64327 LMBR1 GTGTCACAGTTTGAAATTGT']
NM_022458.3(LMBRl):c.423+4 ['AAAGCTGAGCAACATGACAGCACAAYAGAG
943 808T>C 64327 LMBR1 GAGGAACAAAGATTTTTTTAA']
NM_145693.2(LPINl):c.1441+2 ['GCGACCACCGGGAGATCACGAAAGGYACCG
944 T>C 23175 LPIN1 CGGGCCTCGCGCGGGCGCCCT']
NM_022124.5(CDH23):c.5663T ['AGTGGCTGCAATGCACGCCTCACCTYCAAC
945 >C (p.Phel888Ser) 64072 CDH23 ATCACTGCGGGCAACCGCGAG]
NM_153212.2(GJB4):c.409T>C 12753 ['GTGGACGTACTTGCTGAGCCTCATCYTCAAG
946 (p.Phel37Leu) 4 GJB4 GCCGCCGTGGATGCTGGCTT']
NM_021044.2(DHH):c.2T>C ['TTTTGGCCGAGGTCCGCTGTATCCAYGGCTC
947 (p.MetlThr) 50846 DHH TCCTGACCAATCTACTGCCC]
NM_021044.2(DHH):c.485T>C ['CGCGACCGCAACAAGTATGGGTTGCYGGCG
948 (p.Leul62Pro) 50846 DHH CGCCTCGCAGTGGAAGCCGGC]
NM_020638.2(FGF23):c.287T> ['GTGATGAGCAGAAGATACCTCTGCAYGGAT
949 C (p.Met96Thr) 8074 FGF23 TTCAGAGGCAACATTTTTGGA']
NM_022041.3 (GAN) :c .1268T>C ['TGCTATGCAGCTATGAAAAAGAAAAYCTAC
950 (p.Ile423Thr) 8139 GAN GCCATGGGTGGAGGCTCCTAC]
NM_015665.5(AAAS):c.787T>C ['CAGTGGGGGGCGGCTGCTCTCAGCTYCACC
951 (p.Ser263Pro) 8086 AAAS CGTGGATGCTGCTATCCGGGT']
952 NM_021615.4(CHST6):c.827T> 4166 CHST6 ['TACCGCCTGGTGCGCTTCGAGGACCYGGCG C (p.Leu276Pro) CGGGAGCCGCTGGCAGAAATC]
NM_000368.4(TSCl):c.539T>C ['GTGGCGGAAGTCTATCTCGTCCATCYCCATG
953 (p.Leul80Pro) 7248 TSC1 CCAGTGTGTACGCACTCTTT']
NM_020661.2(AICDA):c.238T> ['CCCTGGCCGCTGCTACCGCGTCACCYGGTTC
954 C (p.Trp80Arg) 57379 AICDA ACCTCCTGGAGCCCCTGCTA']
NM_020661.2(AICD A) : c.317T> ['CTGCGAGGGAACCCCAACCTCAGTCYGAGG
955 C (p.Leul06Pro) 57379 AICDA ATCTTCACCGCGCGCCTCTAC]
NM_020661.2(AICDA):c.452T> ['GATTATTTTTACTGCTGGAATACTTYTGTAG
956 C (p.Phel51Ser) 57379 AICDA AAAACCACGAAAGAACTTTC]
NM_020632.2(ATP6V0A4):c.17 ['ATCATTCTGCAATTTATCCCTGAGAYGATTT
957 39T>C (p.Met580Thr) 50617 ATP6V0A4 TTATCCTGTGTCTGTTTGGA']
NM_054027.4(ANKH):c.143T> ['GCTGTCAAGGAGGATGCAGTCGAGAYGCTG
958 C (p.Met48Thr) 56172 ANKH GCCAGCTACGGGCTGGCGTAC]
NM_054027.4(ANKH):c. l015T> ['TGTTTGATGTCTTTCTCCCCAGCTCYGTTTCG
959 C (p.Cys339Arg) 56172 ANKH TGATGTTTTGGACACCCAA']
NM_054027.4(ANKH):c.1172T> ['GTGAGGGCGCATCTCACCGGGTGGCYGATG
960 C (p.Leu391Pro) -1 - ACACTGAAGAAAACCTTCGTC]
NM_016373.3 (WWOX) : c.872T> ['ACAAAAAACGACTATTGGGCGATGCYGGCT
961 C (p.Leu291Pro) 51741 WWOX TATAACAGGTCCAAGCTCTGC]
NM_021102.3 (SPINT2) : c.337+2 ['CAGCGGATTCCTCTGTCCCAAGTGGYAGGTT
962 T>C 10653 SPINT2 CTTAAAGAGACCCGCGATGG]
NM_014588.5(VSXl):c.50T>C [' G AC GGGC GCACTAGCAGCAGGGC GC YGGTG
963 (p.Leul7Pro) 30813 VSX1 CCTGGCGGTTCCCCTAGGGGC]
NM_006946.2(SPTBN2):c.758T ['GAAAAGGAACTGGGACTTACCAAGCYGCTG
964 >C (p.Leu253Pro) 6712 SPTBN2 GATCCCGAAGGTGGGGCCAGA]
NM_012452.2(TNFRSF13B):c.3 TNFRSF13 ['GCACCCTAAGCAATGTGCATACTTCYGTGAG
965 10T>C (p.Cysl04Arg) 23495 B AACAAGCTCAGGAGCCCAGT']
NM_170784.2(MKKS):c.830T> ['GAAAATGCAGTCTTGGACCAGCTGCYTAAC
966 C (p.Leu277Pro) 8195 MKKS CTAGGAAGGCAGCTAATCAGT']
NM_015717.4(CD207):c.790T> ['AATGGCGTGTCATCCACCCAGGACCRGTCCC
967 C (p.Trp264Arg) 50489 CD207 CTTCCATCCCTGCTTTAGTC]
NM_153717.2(EVC):c.919T>C ['TGTGGAAAAGAAGGAGAGAGAATACYCTGA
968 (p.Ser307Pro) 2121 EVC ACAGCTAATCGATAATGTGCG]
M_014384.2(ACAD8):c.455T> ['AAATTTTGCCCACCGCTCTGTACCAYGGAGA
969 C (p.Metl52Thr) 27034 ACAD8 AGTTTGCTTCCTACTGCCTC]
NM_004924.4(ACTN4):c.784T> ['CGAGAAGGCCATAATGACCTATGTGYCCAG
970 C (p.Ser262Pro) 81 ACTN4 CTTCTACCATGCCTTTTCAGG]
NM_005097.3(LGIl):c. l36T>C ['AGCGAAGCCAAAATGCCCTGCCGTGYGTAC
971 (p.Cys46Arg) 9211 LGI1 TTGTACCAAAGATAATGCTTT']
NM_005097.3(LGIl):c.695T>C ['GCAGAATTTGCAAAGTCTCAAGACCYGCCTT
972 (p.Leu232Pro) 9211 LGI1 ATCAATCATTGTCCATAGAC]
NM_006329.3(FBLN5):c.679T> ['GCAAACCTGCGTCAACACCTACGGCYCTTTC
973 C (p.Ser227Pro) 10516 FBLN5 ATCTGCCGCTGTGACCCAGG']
974 NM_006329.3(FBLN5):c.506T> 10516 FBLN5 ['TTGCTTGCATTTCTGTTTCCAGACAYTGATG C (p.Ilel69Thr) AATGTCGCTATGGTTACTGC]
NM_013339.3(ALG6):c.l432T> ['GTTTTCTGTATTGGTGTGTTTTGTAYCTTGCT
975 C (p.Ser478Pro) 29929 ALG6 TGAACTTCCTGTTCTTCTT']
NM_006899.3(IDH3B):c.395T> ['GAGCTAGCCTCCTATGATATGCGGCYGAGG
976 C (p.Leul32Pro) 3420 IDH3B TAGGTGGTCTGGGTGGGGTGA']
NM_014363.5(SACS):c.5836T> ['AATGGATTATACTTACTATGCAGTAYGGCCC
977 C (p.Trpl946Arg) 26278 SACS GATCCTGATTTAGTTCATGA']
NM_014363.5(SACS):c.9742T> ['AAGTGAGTCTTGGCTTAAGAATGCAYGGCA
978 C (p.Trp3248Arg) 26278 SACS TTTTATTAGTGAATCTGTAAG]
NM_014363.5(SACS):c.3161T> ['CAGATGGTATCAGCTGGTGAACTCTYTGACC
979 C (p.Phel054Ser) 26278 SACS CTGATATAGAAGTACTAAAG]
NM_014324.5(AMACR):c. l54T ['GAGCCGCTTGGGCCGGGGCAAGCGCYCGCT
980 >C (p.Ser52Pro) -1 - AGTGCTGGACCTGAAGCAGCC]
NM_014324.5(AMACR):c.320T ['AATCCAAGGCTTATTTATGCCAGGCYGAGTG
981 >C (p.Leul07Pro) -1 - GATTTGGCCAGTCAGGAAGC]
NM_001040108.1(MLH3):c382 ['GACAGAGGAACAAAGGAGACTCTTAYGGTC
982 6T>C (p.Trpl276Arg) 27030 MLH3 AGTACCACCATGAGAATGTGA']
NM_014336.4(AIPLl):c.715T>C ['TACTCTGATCCTCAACTACTGCCAGYGCCTG
983 (p.Cys239Arg) 23746 AIPL1 CTGAAGAAGGAGGAGTACTA]
NM_001001486.1(ATP2Cl):c.l7 ['CTCTCATTTGCTTTAGCCAGTCGTCYGGGAT
984 51T>C (p.Leu584Pro) 27032 ATP2C1 TGTATTCCAAAACTTCCCAG]
NM_007194.3 (CHEK2) : c.470T> ['GAAGTGGGTCCTAAAAACTCTTACAYTGCAT
985 C (p.Ilel57Thr) 11200 CHEK2 ACATAGAAGATCACAGTGGC]
NM_007255.2(B4GALT7):c.617 ['ACCTATGTCGGCGGCATCCTGCTGCYCTCCA
986 T>C (p.Leu206Pro) 11285 B4GALT7 AGCAGCACTACCGGCTGGTG]
NM_000030.2(AGXT):c.613T>C ['ATCTACAGGCATCGACATCCTGTACYCGGGC
987 (p.Ser205Pro) 189 AGXT TCCCAGAAGGCCCTGAACGC]
NM_000030.2(AGXT):c.731T>C ['AAGCCCTTCTCCTTCTACCTGGACAYCAAGT
988 (p.Ile244Thr) 189 AGXT GGCTGGCCAACTTCTGGGGC]
NM_201253.2(CRBl):c.3122T> ['ACATGGCACGAAGTGACCCTTTCCAYGACA
989 C (p.Metl041Thr) 23418 CRB1 GACCCACTGTCCCAGACCTCC]
NM_201253.2(CRBl):c.3541T> ['ACACTGTGAACTCAACATCGATGAAYGCTTT
990 C (p.Cysl l81Arg) 23418 CRB1 TCAAACCCCTGTATCCATGG']
NM_005094.3(SLC27A4):c.739 ['AGATAAACTGTTCTACATCTACACAYCCGGC
991 T>C (p.Ser247Pro) 10999 SLC27A4 ACCACAGGGCTGCCCAAGGC]
NM_032551.4(KISSlR):c.443T> ['CGCTGGTACGTGACGGTGTTCCCGTYGCGCG
992 C (p.Leul48Ser) 84634 KISS1R CCCTGCACCGCCGCACGCCC]
NM_032551.4(KISSlR):c.305T> ['TGCTGCGTCCCCTTCACGGCCCTGCYGTACC
993 C (p.Leul02Pro) 84634 KISS1R CGCTGCCCGGCTGGGTGCTG]
NM_014270.4(SLC7A9):c.13 IT ['ATCTCCATCATCGTGGGCACCATCAYTGGCT
994 >C (p.Ile44Thr) 11136 SLC7A9 CTGGGATCTTCGTTTCCCCC]
NM_003332.3(TYROBP):c.2T> ['TGGTGTCCAGCAGCATCCGGCTTCAYGGGG
995 C (p.MetlThr) 7305 TYROBP GGACTTGAACCCTGCAGCAGG]
996 NM_000843.3 (GRM6) :c .1214T> -1 - ['CAGGAGGGCAAGGTGCAGTTTGTGAYTGAT C (p.Ile405Thr) GCGGTGTACGCCATTGCCCAC]
NM_022336.3(EDAR):c.259T>C ['GTTTTCCAAAGGAGGCTACCAGATAYGCAG
997 (p.Cys87Arg) 10913 EDAR GCGTCACAAAGACTGTGAGGG]
NM_003835.3(RGS9):c.895T>C ['CCCAACCAAGATGCGAGTGGAACGAYGGGC
998 (p.Tip299Arg) 8787 RGS9 CTTCAACTTCAGCGAATTGAT']
NM_004870.3 (MPDU 1 ) :c .356T> ['CTCCAGACGATCACCATCTGCTTCCYGGTCA
999 C (p.Leul l9Pro) 9526 MPDU1 TGCACTACAGAGGACAGACT']
NM_004870.3(MPDUl):c.2T>C ['ACTGGCGGAAGCTAGCTTTGCAATAYGGCG
1000 (p.MetlThr) 9526 MPDU1 GCCGAGGCGGACGGACCGCTT']
NM_004870.3(MPDUl):c.221T> ['CTGGGAGCCAAGAGTGCTGAAGGGTYGAGT
1001 C (p.Leu74Ser) 9526 MPDU1 CTCCAGTCTGTAATGCTGGAG]
NM_000334.4(SCN4A):c.2078T ['ACGCTGAACATGCTCATCAAGATCAYTGGC
1002 >C (p.Ile693Thr) 6329 SCN4A AATTCAGTGGGGGCGCTGGGT']
NM_006580.3(CLDN16):c.500T ['GCTGGGTTTGGATTTCTCACCCTGCYCCTTG
1003 >C (p.Leul67Pro) 10686 CLDN16 GTCTTGACTGCGTGAAATTC]
NM_006580.3(CLDN16):c.434T ['ATATGCCCTGGTCTTCCAGTGAAGCYGGTGG
1004 >C (p.Leul45Pro) 10686 CLDN16 TAACTCGAGCGTTGATGATT']
NM_003907.2(EIF2B5):c. l882T ['CTTTCTTCCATAGCTGCTAAAGGCCYGGAGC
1005 >C (p.Trp628Arg) 8893 EIF2B5 CCTGTTTTTAGGAACTACAT']
NM_183235.2(RAB27A):c.389T ['TATTGTGAAAACCCAGATATAGTGCYGTGTG
1006 >C (p.Leul30Pro) 5873 RAB27A GAAACAAGAGTGATCTGGAG]
NM_001128227.2(GNE):c.2228 ['CCCGCCCTGCTGGGTGCTGCCAGCAYGGTTC
1007 T>C (p.Met743Thr) 10020 GNE TGGACTACACAACACGCAGG]
NM_004273.4(CHST3):c.776T> ['CGCTGCGGCCCCCTCAACGTGACGCYGGCC
1008 C (p.Leu259Pro) 9469 CHST3 GCAGAGGCCTGCCGCCGCAAG]
NM_004273.4(CHST3):c.920T> ['CTGGTGCGCGACCCCCGGGCCGTGCYGGCC
1009 C (p.Leu307Pro) 9469 CHST3 TCGCGCATGGTGGCCTTCGCC]
NM_004273.4(CHST3):c.857T> ['CGGCAGCTGGAGTTCCTGCAGCCGCYGGCC
1010 C (p.Leu286Pro) 9469 CHST3 GAGGACCCCCGCCTGGACCTG]
NM_172201.1(KCNE2):c. l61T> ['TTCTACTATGTCATCCTGTACCTCAYGGTGA
1011 C (p.Met54Thr) 9992 KCNE2 TGATTGGAATGTTCTCTTTC']
NM_172201. l(KCNE2):c.170T> ['GTCATCCTGTACCTCATGGTGATGAYTGGAA
1012 C (p.Ile57Thr) 9992 KCNE2 TGTTCTCTTTCATCATCGTG]
NM_172201. l(KCNE2):c.178T> ['GTACCTCATGGTGATGATTGGAATGHTCTCT
1013 C (p.Phe60Leu) 9992 KCNE2 TTCATCATCGTGGCCATCCT']
NM_001139.2(ALOX12B):c.l27 ['TCATCCTCCTTGCTCTCCCCACAGCYCCTCA
1014 7T>C (p.Leu426Pro) 242 ALOX12B TCCCCCATACCCGATACACC]
NM_003640.3(IKBKAP):c.2204 ['ATTCGGAAGTGGTTGGACAAGTAAGYGCCA
1015 +6T>C 8518 KBKAP TTGTACTGTTTGCGACTAGTT']
NM_005413.3(SIX3):c.749T>C ['GCCACCGGCCTCACTCCCACACAAGYAGGC
1016 (p.Val250Ala) 6496 SIX3 AACTGGTTTAAGAACCGGCGG]
NM_004820.3(CYP7Bl):c.647T [TTTATTAGTGAGCTAAGAGATGATTYTTTAA
1017 >C (p.Phe216Ser) 9420 CYP7B1 AATTTGATGACAAGTTTGCA']
1018 NM_194248.2(OTOF):c.3032T> 9381 OTOF ['CTGTGTCCCACCTGGGACCAGATGCYGGTGT C fp.LeulOl lPro) TCGACAACCTGGAGCTCTAT']
NM_194248.2(OTOF):c.1544T> ['GACGTGGCCATCGGCACCCACTTCAYTGACC
1019 C (p.Ile515Thr) 9381 OTOF TGCGCAAGATTTCTAATGAC]
NM_004737.4(LARGE):c.l483T ['GATGCTGGAGGCCATCTGCAAGCACYGGGA
1020 >C (p.Trp495Arg) 9215 LARGE GGGGCCCATCAGCCTGGCCCT']
NM_002420.5 (TRPM1 ) : c.296T> ['GAGGCCTCCATGCACAGATATTAAGRGCTTG
1021 C (p.Leu99Pro) 4308 TRPM1 GGGAGTTCCAGCTGCCAATC]
NM_004700.3 (KCNQ4) : c.842T> ['ACCTGTTTGTGTCTCCAGATTACATYGACAA
1022 C (p.Leu281Ser) 9132 KCNQ4 CCATCGGCTATGGTGACAAG]
NM_003839.3(TNFRSFl lA):c.5 TNFRSF11 ['ACTGAACCACCTTTTCCCCCACAGCYGTACC
1023 23T>C (p.Cysl75Arg) 8792 A TTCCTTGGAAAGAGAGTAGA']
NM_030761.4(WNT4):c.35T>C ['CGCTCGTGCCTGCGTTCGCTGCGCCYCCTCG
1024 (p.Leul2Pro) 54361 WNT4 TCTTCGCCGTCTTCTCAGCC]
NM_000050.4(ASSl):c.535T>C ['CATCCCGGTCACTCCCAAGAACCCGYGGAG
1025 (p.Trpl79Arg) 445 ASS1 CATGGATGAGAACCTCATGCA']
NM_002977.3(SCN9A):c.2543T ['ACATTGAACATGCTGATTAAGATCAYTGGTA
1026 >C (p.Ile848Thr) -1 - ACTCAGTAGGGGCTCTAGGT']
NM_002977.3 (SCN9 A) :c.4382T ['TTTCTTTACCTTGGAGGTCAAGACAYCTTTA
1027 >C (p.Ilel461Thr) -1 - TGACAGAAGAACAGAAGAAA']
NM_002977.3 (SCN9 A) :c.647T> ['GGCAATGTTTCAGCTCTTCGAACTTYCAGAG
1028 C (p.Phe216Ser) 6335 SCN9A TATTGAGAGCTTTGAAAACT']
NM_003880.3(WISP3):c.232T> ['AGATGGCTGTGGATGCTGTAAAATCYGTGC
1029 C (p.Cys78Arg) 8838 WISP3 CAAGCAACCAGGGGAAATCTG]
NM_003880.3(WISP3):c.l000T> ['TAAATGGAAGATGCTGTGGATTACAYCTTGT
1030 C (p.Ser334Pro) 8838 WISP3 GTGTGTCAGAGAAACTGCAG]
NM_001457.3(FLNB):c.703T>C ['CGAGCACTCAGTTATGACTTACCTGYCCCAG
1031 (p.Ser235Pro) 2317 FLNB TTCCCCAAAGCCAAGCTCAA']
['GATTTGTTACTGACAAGGCCTAGGGNAAGTT
TTCACAGCCTAAAACACAGT',
'TACAAGACCTAAGTTCCAAGAAGCARCAGTC
CCACAACATTCTGGATCTGC,
'GGTCACCATCATGTCCATAATGCTGYGGTAT
GTAAAAGAGACCTGCCTGAG,
ATGCCTCAGACAAAATTCAAAGCCTRTGTCA
1032 TCAGAGAGTGAAAAGGATAT',
NM_003060.3(SLC22A5):c. l051 'GGCTGTTGTGGGAAATATGGACTCTYGTGGG 1036 T>C (p.Trp351Arg) 6584 SLC22A5 GAATCTCTCCAGATCTTAAG']
NM_000369.2(TSHR):c. l891T> ['TGCCAAGAGGATGGCTGTGTTGATCYTCACC
1037 C (p.Phe631Leu) 7253 TSHR GACTTCATATGCATGGCCCC]
NM_000369.2(TSHR):c. l358T> ['AAACTGAACGTCCCCCGCTTTCTCAYGTGCA
1038 C (p.Met453Thr) 7253 TSHR ACCTGGCCTTTGCGGATTTC]
NM_000369.2(TSHR):c.1526T> ['ACTGTCTTTGCAAGCGAGTTATCGGYGTATA
1039 C (p.Val509Ala) 7253 TSHR CGCTGACGGTCATCACCCTG]
1040 NM_000369.2(TSHR):c.1798T> 7253 TSHR ['AGTTGCCTTCGTCATCGTCTGCTGCYGTTAT C (p.Cys600Arg) GTGAAGATCTACATCACAGT']
NM_000369.2(TSHR):c.1400T> ['GCGGATTTCTGCATGGGGATGTACCYGCTCC
1041 C (p.Leu467Pro) 7253 TSHR TCATCGCCTCTGTAGACCTC]
NM_001003722.1(GLEl):c.2051 ['CAGAAATGTTTGCAACACAAGGACAYTCCT
1042 T>C (p.Ile684Thr) 2733 GLE1 GTCCCCAAGGGCTTTCTGACT']
NM_024009.2(GJB 3 ) :c .101 T>C ['TCCGTGGTGTTCGTCTTCCGGGTGCYGGTAT
1043 (p.Leu34Pro) 2707 GJB3 ACGTGGTGGCTGCAGAGCGC]
NM_001080463.1(DYNC2Hl):c. ['GATTTGCTCAGAGTAGCTGATACAAYTGTAG
1044 3719T>C (p.Ilel240Thr) 79659 DYNC2H1 CCAAAGCTGCCGACCTTAAA']
NM_018129.3 (PNPO) : c.784T>C ['CTGGCTCTATGAGAGACTTGCACCTYAACTC
1045 (p.Ter262Gln) 55163 PNPO TGGGACCTGCTGGCCCAGAG]
NM_003722.4(TP63):c.l033T>C ['CCGACGCTGCTTTGAGGCCCGGATCYGTGCT
1046 (p.Cys345Arg) 8626 TP63 TGCCCAGGAAGAGACAGGAA']
NM_003722.4(TP63):c.l646T>C ['CCTCCGTATCCCACAGATTGCAGCAYTGTCA
1047 (p.Ile549Thr) 8626 TP63 GGTGAGTCCACAGCATGTGC]
NM_003722.4(TP63):c.l738T>C ['CACCATCTATCAGATTGAGCATTACBCCATG
1048 (p.Ser580Pro) 8626 TP63 GATGTAAGTAACTGTTAGAC]
NM_004086.2(COCH):c.349T>C ['CATCCAGTCTCAAATGCTTTCTAGAYGGTCT
1049 (p.Trpl l7Arg) -1 - GCTTCTTTCACAGTAACTAG]
NM_004086.2(COCH):c.l535T> ['GCACCTCTGGATGACCTGAAAGATAYGGCT
1050 C (p.Met512Thr) -1 - TCTAAACCGAAGGAGTCTCAT']
NM_006412.3(AGPAT2):c.683T ['ACAGGAACAGTCACAGTGCAGGTGCYGGAA
1051 >C (p.Leu228Pro) 10555 AGPAT2 GCCATCCCCACCAGCGGCCTC]
NM_003659.3(AGPS):c. l406T> ['AATCAGCTAAGTGTAGCCACATTACYGTTTG
1052 C (p.Leu469Pro) 8540 AGPS AGGGGGATCGTGAGAAGGTT']
NM_004550.4(NDUFS2):c.l237 ['GGGAGAGTTTGGGGTGTACCTGGTGYCTGA
1053 T>C (p.Ser413Pro) 4720 NDUFS2 TGGCAGCAGCCGCCCTTATCG]
NM_006892.3(DNMT3B):c.808 ['CCAGTGGTTTGGCGATGGCAAGTTCYCCGA
1054 T>C (p.Ser270Pro) 1789 DNMT3B GGTGAGTCCGGGGAAGGGCAA']
NM_002538.3(OCLN):c.656T>C 10050 ['CAAATATATGCCCTCTGCAACCAATYTTATA
1055 (p.Phe219Ser) 6658 OCLN CACCTGCAGCTACTGGACTC]
NM_001211.5(BUBlB):c.3035T ['AATGATGAGGCCACAGTGTCTGTTCYTGGG
1056 >C (p.Leul012Pro) -1 - GAGCTTGCAGCAGAAATGAAT']
NM_016203.3 (PRKAG2) :c .1459 ['ACAGAATCTTGCTGCTGAGAAAACAYACAA
1057 T>C (p.Tyr487His) 51422 PRKAG2 TAACCTAGATATCACGGTGAC]
NM_016203.3 (PRKAG2) :c .1642 ['TAGTATTGTGGGTATTATTTCCCTGYCGGAC
1058 T>C (p.Ser548Pro) 51422 PRKAG2 ATTCTGCAAGCCCTGATCCT']
NM_001287.5(CLCN7):c.2297T ['TTCAAGCTGTTCCGGGCCCTGGGCCYGCGGC
1059 >C (p.Leu766Pro) 1186 CLCN7 ACCTGGTGGTGGTGGACAAC]
M_004646.3(NPHSl):c.793T> ['GGCAGGACAGAGCTTGGAGCTGCCGYGCGT
1060 C (p.Cys265Arg) 4868 NPHS1 GGCCCGAGGGGGTAATCCCTT']
NM_003002.3(SDHD):c.416T>C ['CTTTCAGCTTTAACCTTTGCTGGGCYTTGCT
1061 (p.Leul39Pro) 6392 SDHD ATTTCAACTATCACGATGTG]
1062 NM_001164277.1(SLC37A4):c.3 2542 SLC37A4 ['TAATGGCCTGGCCCAGGGGCTGGGCYGGCC 52T>C (p.Tipl l8Arg) CCCATGTGGGAAGGTCCTGCG']
NM_002546.3(TNFRSFl lB):c.3 TNFRSF11 ['GGAAGGGCGCTACCTTGAGATAGAGYTCTG
1063 49T>C (p.Phel l7Leu) 4982 B CTTGAAACATAGGAGCTGCCC]
NM_005422.2(TECTA):c.5509T ['GGGCGTGAGGATCAATGACAGACAGBGCAC
1064 >C (p.Cysl837Arg) 7007 TECTA CGGCATCGAGGGGGAAGATTT']
NM_007262.4(P ARK7) : c.497T> ['CCTGGGACCAGCTTCGAGTTTGCGCYTGCAA
1065 C (p.Leul66Pro) 11315 PARK7 TTGTTGAAGCCCTGAATGGC]
NM_006009.3(TUBAlA):c.l l90 ['GCTCGCCTGGACCACAAGTTTGACCYGATGT
1066 T>C (p.Leu397Pro) 7846 TUBA1A ATGCCAAACGTGCCTTTGTT']
NM_002700.2(POU4F3):c.668T ['CTCAAGATCCCCGGCGTGGGCTCGCYGAGC
1067 >C (p.Leu223Pro) 5459 POU4F3 CAAAGCACCATCTGCAGGTTC]
NM_005025.4(SERPINIl):c.l45 ['TGGTGAAGATGAAAATATTCTCTTCYCTCCA
1068 T>C (p.Ser49Pro) 5274 SERPINI1 TTGAGTATTGCTCTTGCAAT']
NM_001040667.2(HSF4):c.341T ['TTCGTGCGCGGCCGCGAGCAGCTACYGGAG
1069 >C (p.Leul l4Pro) 3299 HSF4 CGCGTGCGGCGCAAGGTGGGG]
NM_002942.4(ROBO2):c.2834T ['AATAGCAACAGTGGCCCAAATGAGAYTGGA
1070 >C (p.Ile945Thr) 6092 ROB02 AATTTTGGCCGTGGAGGTAAG]
NM_000492.3(CFTR):c.3857T> ['ACTTTGCAACAGTGGAGGAAAGCCTYTGGA
1071 C (p.Phel286Ser) 1080 CFTR GTGATACCACAGGTGAGCAAA]
NM_000492.3(CFTR):c.3763T> ['TGGATCAGGGAAGAGTACTTTGTTAYCAGCT
1072 C (p.Serl255Pro) 1080 CFTR TTTTTGAGACTACTGAACAC]
NM_000492.3 (CFTR) :c .3194T> ['ACAAGCTTAAAAGGACTATGGACACBTCGT
1073 C (p.Leul065Pro) 1080 CFTR GCCTTCGGACGGCAGCCTTAC]
NM_000492.3(CFTR):c.3469- ['TGTCTGCCATTCTTAAAAACAAAAAYGTTGT
1074 20T>C 1080 CFTR TATTTTTATTTCAGATGCGA']
NM_005603.4(ATP8Bl):c.863T ['TTTTGGAGAAACACAAGTTTTCCTTYGGATG
1075 >C (p.Leu288Ser) 5205 ATP8B1 CTGATAAAATTTTGTTACGT']
NM_005603.4(ATP8Bl):c.2097+ ['GAGGAGATTGAAAAAGACTTAATTGYGAGT
1076 2T>C 5205 ATP8B1 TTTAGCCTTAATAACTTTTTC]
NM_005603.4(ATP8Bl):c.l982 ['ACCCTATGCCTTTGCTACAAGGAAAYTGAA
1077 T>C (p.Ile661Thr) 5205 ATP8B1 GAAAAAGAATTTACAGAATGG]
['CGCAGCACGGAGTCTCGGCGTCCCAYGGCG
1078 M_005144.4(HR):c.-320T>C 55806 HR CAACCTACGGCCTCGGCCCAG]
NM_003322.4(TULPl):c.l471T ['GGTCACCCAGGCCTCAGTCAAGAACYTCCA
1079 >C (p.Phe491Leu) 7287 TULP1 GATTGTCCACGCTGATGACCG]
NM_003322.4(TULPl):c.l l45T ['CTCCTGGGGAACCGCTTCACGGTCTYTGACA
1080 >C (p.Phe382Ser) 7287 TULP1 ACGGGCAGAACCCACAGCGT']
NM_000455.4(STKl l):c.200T> ['TCTTACGGCAAGGTGAAGGAGGTGCYGGAC
1081 C (p.Leu67Pro) 6794 STK11 TCGGAGACGCTGTGCAGGAGG]
NM_002241.4(KCNJ10):c.418T ['TGGCTTCCGCTACATCAGTGAGGAAYGTCCA
1082 >C (p.Cysl40Arg) 3766 KCNJ10 CTGGCCATTGTGCTTCTTAT']
NM_001172567.1(MYD88):c.31 ['TCTGTAGGCCGACTGCTCGAGCTGCYTACCA
1083 7T>C (p.Leul06Pro) 4615 MYD88 AGCTGGGCCGCGACGACGTG]
1084 NM_000466.2(PEXl):c.l991T> 5189 PEX1 ['CCATCTGTTGTCCTGCTGGATGACCYTGACC C (p.Leu664Pro) TCATTGCTGGACTGCCTGCT']
NM_001303.3(COX10):c.2T>C ['GGAGCGGCCCCAGACTCGTAAATTAYGGCC
1085 (p.MetlThr) 1352 COX10 GCATCTCCGCACACTCTCTCC]
NM_001300.5 (KLF6) : c.346T>C ['TGTCAGCAGCGAATCCTCTGACAGCYCCGA
1086 (p.Serl l6Pro) 1316 KLF6 GGAACTTTCTCCCACGGCCAA']
NM_001300.5 (KLF6) : c.190T>C ['CAAATTTGACAGCCAGGAAGATCTGYGGAC
1087 (p.Trp64Arg) 1316 KLF6 CAAAATCATTCTGGCTCGGGA]
NM_001300.5 (KLF6) : c.506T>C ['CTGTGGGGTTGCGTGCCCGGGGAGCYGCCC
1088 (p.Leul69Pro) 1316 KLF6 TCGCCAGGGAAGGTGCGCAGC]
NM_000085.4(CLCNKB):c. l294 ['CGGGTACTTCATGCCCATCTTTGTCYATGGT
1089 T>C (p.Tyr432His) 1188 CLCN B GAGTCTGGGGTCCTGAGGTT']
NM_000214.2(JAGl):c.110T>C ['TGTGGGGCCTCGGGTCAGTTCGAGTYGGAG
1090 (p.Leu37Ser) 182 JAG1 ATCCTGTCCATGCAGAACGTG]
NM_003865.2(HESXl):c.77T>C ['ACTTGCTCCTTTTCAATTGAGAGAAYCTTAG
1091 (p.Ile26Thr) 8820 HESX1 GACTGGACCAGAAGAAAGAC]
NM_003865.2(HESXl):c.357+2 ['TCATTATTGGGTGAAAAAACTTCCCDCCTGG
1092 T>C 8820 HESX1 TTTTGAGTAAAAGCAGTTCT']
NM_002618.3 (PEX 13 ) :c .977T> ['CTTGATGGCCAAACAACAGGACTTAYACCT
1093 C (p.Ile326Thr) 5194 PEX 13 GCGAATTATGTCAAAATTCTT']
NM_000303.2(PMM2):c.395T> ['AATGGGATGTTAAACGTGTCCCCTAYTGGA
1094 C (p.Ilel32Thr) 5373 PMM2 AGAAGCTGCAGCCAAGAAGAA']
NM_000303.2(PMM2):c.l31T> ['AGGCAGAAGATCAAAATCGGAGTGGYAGGC
1095 C (p.Val44Ala) 5373 PMM2 GGATCGGACTTTGAGAAAGTG]
NM_000104.3(CYPlBl):c.2T>C ['CGCCTTCTCCTCTCTGTCCCCAGCAYGGGCA
1096 (p.MetlThr) 1545 CYP1B1 CCAGCCTCAGCCCGAACGAC]
NM_032977.3(CASP10):c.440T ['AAAGACTCGCTTCCCAAAACTGAAAYGGTG
1097 >C (p.Metl47Thr) 843 C ASP 10 AGTGGGTCATACAGAATGGGT']
NM_003999.2(OSMR):c.2072T> ['GGTTCAGAATGTTGCAAATACAAAAYTGAC
1098 C (p.Ile691Thr) 9180 OSMR AACCCGGAAGAAAAGGCATTG]
NM_000314.6(PTEN):c.370T>C ['TGACAATCATGTTGCAGCAATTCACBGTAAA
1099 (p.Cysl24Arg) 5728 PTEN GCTGGAAAGGGACGAACTGG]
NM_000314.6(PTEN):c.209T>C ['AAAAACCATTACAAGATATACAATCYGTAA
1100 (p.Leu70Pro) 5728 PTEN GTATGTTTTCTTATTTGTATG]
NM_000314.6(PTEN):c.335T>C ['TTTTGTGAAGATCTTGACCAATGGCYAAGTG
1101 (p.Leull2Pro) 5728 PTEN AAGATGACAATCATGTTGCA']
NM_000314.6(PTEN):c.722T>C ['CGACGGGAAGACAAGTTCATGTACTYTGAG
1102 (p.Phe241Ser) 5728 PTEN TTCCCTCAGCCGTTACCTGTG]
NM_006949.3(STXBP2):c.626T ['TTGGCCCACGCCGTCCTGGCCAAGCHGAAC
1103 >C (p.Leu209Pro) 6813 STXBP2 GCCTTCAAGGCAGACACTCCC]
NM_000358.2(TGFBI):c. l619T> ['AACCGGGAAGGAGTCTACACAGTCTYTGCT
1104 C (p.Phe540Ser) 7045 TGFBI CCCACAAATGAAGCCTTCCGA']
NM_000350.2(ABCA4):c.l622T ['CAGCTCACCCAACGTGCCCTCTCTCYACTGG
1105 >C (p.Leu541Pro) 24 ABCA4 AGGAAAACATGTTCTGGGCC]
1106 NM_000350.2(ABCA4):c.5819T 24 ABCA4 ['GGAAATAAAACTGACATCTTAAGGCYACAT >C (p.Leul940Pro) GAACTAACCAAGGTAAGGGAA]
NM_000860.5(HPGD):c.577T>C ['CTTTGTTAACACAGCCATCCTTGAAYCAATT
1107 (p.Serl93Pro) 3248 HPGD GAAAAAGAAGAAAACATGGG]
NM_000223.3 (KRT 12) :c .386T> ['CTTTCTGGATCAGAAAAAGAAACTAYGCAA
1108 C (p.Metl29Thr) 3859 KRT12 AATCTTAATGATAGATTAGCT']
NM_000503.5(EYAl):c.l459T> ['GTTGACACTGGCCCTGAAAGCACTCYCGCTC
1109 C (p.Ser487Pro) 2138 EYA1 ATTCACTCCCGGTGAGGCTC]
NM_000261.1(MYOC):c.l309T ['TGCCTTCATCATCTGTGGCACCTTGYACACC
1110 >C (p.Tyr437His) 4653 MYOC GTCAGCAGCTACACCTCAGC]
NM_000261.1(MYOC):c.l297T ['GTCAGTCGCCAATGCCTTCATCATCYGTGGC
1111 >C (p.Cys433Arg) 4653 MYOC ACCTTGTACACCGTCAGCAG]
NM_130838.1(UBE3A):c.389T> ['GATTATTCCCCTTTAATCCGTGTTAYTGGAA
1112 C (p.Ilel30Thr) 7337 UBE3A GAGTTTTTTCTAGTGCTGAG]
M_000474.3 (TWIST 1 ) : c.392T ['TCGCTGAACGAGGCGTTCGCCGCGCYGCGG
1113 >C (p.Leul31Pro) 7291 TWIST 1 AAGATCATCCCCACGCTGCCC]
NM_000192.3(TBX5):c.l61T>C ['TCCTTCTTGCAGGGCATGGAGGGAAYCAAA
1114 (p.Ile54Thr) 6910 TBX5 GTGTTTCTCCATGAAAGAGAA]
NM_002905.3(RDH5):c.841T>C ['GACTGCTCGACACCCCCGAACCCGCBACAG
1115 (p.Tyr281His) -1 - CCCAGGTTGGGATGCCAAGCT']
NM_001089.2(ABCA3):c.302T> ['GTCACTGAGACAGTGCGCAGGGCACYTGTG
1116 C (p.LeulOlPro) 21 ABC A3 ATCAACATGCGAGGTGAGACA']
NM_001089.2(ABCA3):c.4658T ['ATGGACCCCGTGGCCCGGCGCCTGCYTTGG
1117 >C (p.Leul553Pro) 21 ABC A3 GACACCGTGGCACGAGCCCGA']
NM_001089.2(ABCA3):c.977T> ['ATCGCCGCCTCCTTCATGACCCTGCYCTTCT
1118 C (p.Leu326Pro) 21 ABC A3 GTGTCAAGGTGAGCATGGCG]
NM_005535.2(IL12RBl):c.592T ['CTGCCTCTCCCCAGAGTCCTGCCTCYGCCCC
1119 >C (p.Cysl98Arg) 3594 IL12RB1 CTGGAGATGAATGTGGCCCA]
NM_005055.4(RAPSN):c.41T>C ['ACCAAGCAGCAGATCGAGAAGGGGCYCCAG
1120 (p.Leul4Pro) 5913 RAPSN CTGTACCAGTCCAACCAGACA]
NM_005055.4(RAPSN):c.848T> ['ATCATGACCGAGATCGGAAACCGCCYGGGG
1121 C (p.Leu283Pro) 5913 RAPSN CAGGTGCAGGCGCTGCTGGGT']
NM_005055.4(RAPSN):c.416T> ['AATGCCTTCCTGGGCCTCAGCGTCTYCCAGA
1122 C (p.Phel39Ser) 5913 RAPSN AGGCCCTGGAGAGCTTCGAG]
NM_005570.3(LMANl):c.2T>C ['CTCCTCCGCGTTCCAGAATCCAAGAYGGCG
1123 (p.MetlThr) 3998 LMAN1 GGATCCAGGCAAAGGGGTCTC]
NM_000430.3(PAFAHlBl):c.50 PAFAHIB ['CAGCGGCAAGCTTCTGGCTTCCTGTYCTGCA
1124 5T>C (p.Serl69Pro) 5048 1 GATATGACCATTAAACTATG]
NM_000430.3(PAFAHlBl):c92 PAFAHIB ['GGCTATGAAGAGGCATATTCAGTTTYTAAA
1125 T>C (p.Phe31Ser) 5048 1 AAGGAAGCTGAATTAGATGTG]
NM_006261.4(PROPl):c.263T> ['CAGTTGGAACAGCTGGAGTCAGCCTYTGGG
1126 C (p.Phe88Ser) 5626 PROP1 AGGAACCAGTACCCCGACATC]
NM_175929.2(FGF14):c.449T> ['GAACTTTTTACCCCTGAATGCAAGTYTAAAG
1127 C (p.Phel50Ser) 2259 FGF14 AATCTGTTTTTGAAAATTAT']
1128 NM_004970.2(IGFALS):c.l618T 3483 IGFALS ['GTGGCTGGAGGGTAACCCCTGGGACYGTGG >C (p.Cys540Arg) CTGCCCTCTCAAGGCGCTGCG]
NM_005379.3 (MYO 1 A) : c.2728 ['CCCTTGCCTGTTCCGTCCCTAGACTYCTTCTC
1129 T>C (p.Ser910Pro) 4640 MY01A GGATTCTCCTCCTGACCAA]
NM_006302.2(MOGS):c. l954T> ['GCACTGGGCCCCAGAGCTAGGAGTCYTTGC
1130 C (p.Phe652Leu) 7841 MOGS AGACTTTGGGAACCACACAAA']
NM_001009944.2(PKDl):c.2534 ['TACGTGCCCACCAACGGCTCAGCCTYGGTGC
1131 T>C (p.Leu845Ser) 5310 PKD1 TCCAGGTGGACTCTGGTGCC]
NM_004329.2(BMPRlA):c.370T ['AGCCCAGCTACGCCGGACAATAGAAYGTTG
1132 >C (p.Cysl24Arg) 657 BMPR1A TCGGACCAATTTATGTAACCA']
NM_004329.2(BMPR1 A):c.1409 ['CCGAGTGATCCGTCATACGAAGATAYGCGT
1133 T>C (p.Met470Thr) 657 BMPR1A GAGGTTGTGTGTGTCAAACGT']
NM_000452.2(SLC10A2):c.728 ['GTGGCGGGTTACTCCCTGGGGTTTCYTCTGG
1134 T>C (p.Leu243Pro) 6555 SLC10A2 CTAGAATTGCTGGTCTACCC]
NM_030662.3 (MAP2K2) : c.400T ['CAACTCGCCGTACATCGTGGGCTTCYACGGG
1135 >C (p.Tyrl34His) 5605 MAP2K2 GCCTTCTACAGTGACGGGGA']
NM_033337.2(CAV3):c.260T>C ['CTGCTGGGCGTCCCACTGGCCCTGCHCTGGG
1136 (p.Leu87Pro) 859 CAV3 GCTTCCTGTTCGCCTGCATC]
NM_000388.3 (CASR) : c.2417T> ['CCGGAGAACTTCAATGAAGCCAAGTHCATC
1137 C (p.Phe806Ser) 846 CASR ACCTTCAGCATGCTCATCTTC]
NM_000388.3 (CASR) : c.382T>C ['AATTGATTCTTTGAACCTTGATGAGYTCTGC
1138 (p.Phel28Leu) 846 CASR AACTGCTCAGAGCACATTCC]
NM_000388.3(CASR):c. l835T> ['GAGTTTCTGTCGTGGACGGAGCCCTYTGGGA
1139 C (p.Phe612Ser) 846 CASR TCGCACTCACCCTCTTTGCC]
NM_000388.3 (CASR) : c.2641 T> ['GCGTTGCAGCACCGCAGCTCACGCTYTCAA
1140 C (p.Phe881Leu) 846 CASR GGTGGCTGCCCGGGCCACGCT']
NM_000388.3(CASR):c.374T>C ['CAAAACAAAATTGATTCTTTGAACCYTGATG
1141 (p.Leul25Pro) 846 CASR AGTTCTGCAACTGCTCAGAG']
NM_000388.3 (C ASR) : c.2362T> ['CACCTGCCTGCTGGCTGCCATCTGCYTCTTC
1142 C (p.Phe788Leu) 846 CASR TTTGCCTTCAAGTCCCGGAA']
NM_000388.3 (C ASR) : c.38T>C ['AGCTGCTGCTGGGTCCTCTTGGCACYCACCT
1143 (p.Leul3Pro) 846 CASR GGCACACCTCTGCCTACGGG]
NM_030653.3(DDXl l):c.2271+ ['CTGGCATATTCCAGGTGCATCCAGGYGCGG
1144 2T>C 1663 DDX11 GCGTCATGCTGGGCTTGGGTC]
NM_001001557.2(GDF6):c.866T 39225 ['TTCACCAGATCCCAGCGCAAGAACCYGTTC
1145 >C (p.Leu289Pro) 5 GDF6 GCAGAGATGCGCGAGCAGCTG]
NM_000557.4(GDF5):c.1322T> ['TGCGAGTTCCCATTGCGCTCCCACCYGGAGC
1146 C (p.Leu441Pro) -1 - CCACGAATCATGCAGTCATC]
NM_000392.4(ABCC2):c. l967+ ['TGATTCGGAAGCCACAGTCCGAGAGYGAGT
1147 2T>C 1244 ABCC2 TGCCTTCTTTCCATCCTAATG]
NM_000396.3(CTSK):c.926T>C ['AACTGGGGAAACAAAGGATATATCCYCATG
1148 (p.Leu309Pro) 1513 CTSK GCTCGAAATAAGAACAACGCC]
NM_000304.3(PMP22):c.47T>C ['ATCATCGTCCTCCACGTCGCGGTGCYGGTGC
1149 (p.Leul6Pro) 5376 PMP22 TGCTGTTCGTCTCCACGATC]
1150 NM_000304.3 (PMP22) : c.82T>C 5376 PMP22 ['ATATCTATCTGATTCTCTCTAGCAAYGGATC (p.Trp28Arg) GTGGGCAATGGACACGCAAC]
NM_001453.2(FOXCl):c.335T> ['ATCTACCAGTTCATCATGGACCGCTHCCCCT
1151 C (p.Phel l2Ser) 2296 FOXC1 TCTACCGGGACAACAAGCAG]
NM_001451.2(FOXFl):c.l l38T ['CCAAGACATCAAGCCTTGCGTGATGYGAGG
1152 >C (p.Ter380Arg) 2294 FOXF1 CTGCCGCCGCAGGCCCTCCTG]
NM_006432.3(NPC2):c.l99T>C ['CTCTTTTTTTCTCTTAGATATTCAGYCTAAAA
1153 (p.Ser67Pro) 10577 NPC2 GCAGCAAGGCCGTGGTGCA']
NM_001127221.1 (C ACNA1 A) :c ['CTGAATGTGTTCTTGGCCATCGCTGYGGACA
1154 .2141T>C (p.Val714Ala) 773 CACNA1A ATCTGGCCAACGCCCAGGAG]
NM_001127221.1 (C ACNA1 A) :c ['GGGTACCGCATGGAGATGTCCATTTYCTACG
1155 .4469T>C (p.Phel490Ser) 773 CACNA1A TCGTCTACTTTGTGGTGTTC']
NM_001127221.1 (C ACNA1 A) :c ['ATGCTCTTCTTCATCTATGCCATCAYTGGGA
1156 .5126T>C (p.Ilel709Thr) 773 CACNA1A TGCAGGTGAGTGTCGTGTCC]
NM_000901.4(NR3C2):c.2771T ['CAGAGCTGGCAGAGGTTCTACCAACYGACC
1157 >C (p.Leu924Pro) 4306 NR3C2 AAGCTGCTGGACTCCATGCAT']
NM_000901.4(NR3C2):c.2936T ['GTGGAGTCGGGGAACGCCAAGCCGCYCTAC
1158 >C (p.Leu979Pro) 4306 NR3C2 TTCCACCGGAAGTGACTGCCC]
NM_000339.2(SLC12A3):c.2576 ['CTCACCCTCCTCATTCCCTATCTCCYTGGCC
1159 T>C (p.Leu859Pro) 6559 SLC12A3 GCAAGAGGAGGTGGAGCAAA']
NM_000339.2(SLC12A3):c. l261 ['CTGGGGTGCCTGCGAGGGGCTGGCCYGCAG
1160 T>C (p.Cys421Arg) 6559 SLC12A3 CTATGGCTGGAACTTCACCGA]
NM_000339.2(SLC12A3):c. l868 [TCGGTACAGGCTGGCTCCTACAACCYGGCCC
1161 T>C (p.Leu623Pro) 6559 SLC12A3 TCAGCTACTCGGTGGGCCTC]
NM_000163.4(GHR):c.341T>C ['TCTGCTGGGGAAAACAGCTGTTACTYTAATT
1162 (p.Phel l4Ser) 2690 GHR CATCGTTTACCTCCATCTGG]
NM_000163.4(GHR):c.512T>C ['AGTTTAACTGGGATTCATGCAGATAYCCAA
1163 (p.Ilel71Thr) 2690 GHR GTGAGATGGGAAGCACCACGC]
NM_000525.3(KCNJll):c.440T ['ACTGAGGAGTGCCCACTGGCCATCCYGATC
1164 >C (p.Leul47Pro) 3767 KCNJ11 CTCATCGTGCAGAACATCGTG]
NM_000525.3(KCNJll):c.l24T ['CCGCTTTGTGTCCAAGAAAGGCAACYGCAA
1165 >C (p.Cys42Arg) 3767 KCNJ11 CGTGGCCCACAAGAACATCCG]
NM_001122764.1 (PPOX) :c .35T ['ACCGTGGTCGTGCTGGGCGGAGGCAYCAGC
1166 >C (p.Ilel2Thr) 5498 PPOX GGCTTGGCCGCCAGTTACCAC]
NM_000182.4(H ADH A) : c.1025 ['AAAGAATCAAAGGCCTTGATGGGACYCTAC
1167 T>C (p.Leu342Pro) 3030 HADHA CATGGTCAGGTCCTGTGCAAG]
NM_003476.4(CSRP3):c.l31T> ['CTGGCAGTGGCCTGCAGGAAGGCTCYTGAC
1168 C (p.Leu44Pro) 8048 CSRP3 AGCACGACAGTCGCGGCTCAT']
NM_001204.6(BMPR2):c.367T> ['TTTCTGCTGTTGTAGCACAGATTTAHGTAAT
1169 C (p.Cysl23Arg) 659 BMPR2 GTCAACTTTACTGAGAATTT']
NM_000336.2(SCNNlB):c. l858 ['CATCCCAGGCACCCCGCCCCCCAACYATGA
1170 T>C (p.Tyr620His) 6338 SCNN1B CTCCCTGCGTCTGCAGCCGCT']
NM_002181.3(IHH):c.569T>C ['TCAAAGGCCCACGTGCATTGCTCCGYCAAGT
1171 (p. Vail 90 Ala) 3549 IHH CCGGTGAGCCGCCGCCGGGG]
1172 NM_000193.3 (SHH) : c.349T>C 6469 SHH ['TTTGGCCATCTCGGTGATGAACCAGBGGCCA (p.Trpl l7Arg) GGAGTGAAACTGCGGGTGAC]
NM_000193.3 (SHH):c.995T>C ['GACCGCCGGCTCCTGCCCGCCGCTGYGCAC
1173 (p.Val332Ala) 6469 SHH AGCGTGACCCTAAGCGAGGAG]
NM_000179.2(MSH6):c.2633T> ['AAAATTATAGGGATCATGGAAGAAGBTGCT
1174 C (p.Val878Ala) 2956 MSH6 GATGGTTTTAAGTCTAAAATC]
NM_000098.2(CPT2):c.l342T> ['AACCCTCACTATTGACTGCGTCCAGYTTCAG
1175 C (p.Phe448Leu) 1376 CPT2 AGAGGAGGCAAAGAATTCCT']
NM_007315.3(STATl):c.2117T ['GGAACTGGATATATCAAGACTGAGTYGATT
1176 >C (p.Leu706Ser) 6772 STAT1 TCTGTGTCTGAAGTGTAAGTG]
NM_007315.3(STATl):c. l799T ['AAGGACCAGCAGCCGGGGACCTTCCYGCTG
1177 >C (p.Leu600Pro) 6772 STAT1 CGGTTCAGTGAGAGCTCCCGG]
NM_024420.2(PLA2G4A):c.331 ['AGGGACAGCAACATTTACTGTATCTYCTATG
1178 T>C (p.Serl l lPro) 5321 PLA2G4A AAGGTGGGAGAAAAGAAAGA]
NM_000352.4(ABCC8):c.394T> ['CTATCACAACATCGAGACTTCCAACBTCCCC
1179 C (p.Phel32Leu) 6833 ABCC8 AAGCTGCTAATTGGTAGGTG]
NM_033163.3(FGF8):c.l l8T>C ['GCTGGGCAGGGAGCTCGCTTCCCTGYTCCGG
1180 (p.Phe40Leu) 2253 FGF8 GCTGGCCGGGAGCCCCAGGG]
NM_153767.3(KCNJl):c.l013T ['AACATCTTTCTCATTATAAAGGCACRTGGCA
1181 >C (p.Met338Thr) 3758 KCNJ1 CAGTGAGGGGTCTCCACTTC]
NM_000095.2(COMP):c.982T> ['AACCCACCCTGTCATCCAGGACAACYGCCC
1182 C (p.Cys328Arg) 1311 COMP GCTGGTGCGGAACCCAGACCA']
NM_000095.2(COMP):c.l042T> ['GGACGAGGACAAGTGGGGCGATGCGYGCGA
1183 C (p.Cys348Arg) 1311 COMP CAACTGCCGGTCCCAGAAGAA]
NM_002047.2(GARS):c.548T>C ['ATCCTGGAGATCGATTGCACCATGCYCACCC
1184 (p.Leul83Pro) 2617 GARS CTGAGCCAGTTTTAAAGTGA']
NM_000435.2(NOTCH3):c. l363 ['CCTCGACCGCATAGGCCAGTTCACCYGTATC
1185 T>C (p.Cys455Arg) 4854 NOTCH3 TGTATGGCAGGTGGGTGGTG]
NM_001166107.1(HMGCS2):c.5 ['CTGCTACGGTGGTACTGCCTCCCTCYTCAAT
1186 20T>C (p.Phel74Leu) 3158 HMGCS2 GCTGCCAACTGGATGGAGTC]
NM_001038.5(SCNNlA):c.l477 ['CCAGCTCTCTGCTGGTTACTCACGAYGGCCC
1187 T>C (p.Trp493Arg) 6337 SCNN1A TCGGTGACATCCCAGGTAGA']
NM_000161.2(GCH 1 ) : c.662T>C ['ATGGTAATGCGAGGTGTACAGAAAAYGAAC
1188 (p.Met221Thr) 2643 GCH1 AGCAAAACTGTGACCAGCACA]
NM_000059.3(BRCA2):c.7529T ['CGCGTCTTTCCACAGCCAGGCAGTCYGTATC
1189 >C (p.Leu2510Pro) 675 BRCA2 TTGCAAAAACATCCACTCTG]
NM_000180.3 (GUCY2D) : c.1694 ['GGAGACAGGGTTTGGCTGAAGAAATYCCCA
1190 T>C (p.Phe565Ser) 3000 GUCY2D GGGGATCAGCACATAGCTATC]
NM_000180.3 (GUCY2D) : c.2846 ['AATGGGCAGCGACACGCGGCAGAGAYCGCC
1191 T>C (p.Ile949Thr) 3000 GUCY2D AACATGTCACTGGACATCCTC]
NM_198056.2(SCN5A):c.3963+ ['CTGTCACGATTTGAGGGCATGAGGGYAAGA
1192 2T>C 6331 SCN5A GAGGTGGCTGCCTTCCCACCA']
NM_000335.4(SCN5A):c.5380T ['GAGTGAGGACGACTTCGATATGTTCYATGA
1193 >C (p.Tyrl794His) 6331 SCN5A GATCTGGGAGAAATTTGACCC]
1194 NM_000023.2(SGCA):c.524T>C 6442 SGCA ['CCCGGAGAGCTTCAGCTGCTCAACGYCACCT (p.Vall75Ala) CTGCCTTGGACCGTGGGGGC]
NM_002427.3(MMP13):c.224T> ['AGGCTCCGAGAAATGCAGTCTTTCTYCGGCT
1195 C (p.Phe75Ser) 4322 MMP13 TAGAGGTGACTGGCAAACTT']
NM_002427.3(MMP13):c.221T> ['GAGAGGCTCCGAGAAATGCAGTCTTYCTTC
1196 C (p.Phe74Ser) 4322 MMP13 GGCTTAGAGGTGACTGGCAAA']
NM_002427.3(MMP13):c.272T> ['CTTGACGATAACACCTTAGATGTCAYGAAA
1197 C (p.Met91Thr) 4322 MMP13 AAGCCAAGATGCGGGGTTCCT']
NM_004525.2(LRP2):c.7564T> ['CTCCTTTTGTATGACTAGGTACCTGYACTGG
1198 C (p.Tyr2522His) 4036 LRP2 GCTGACTGGGATACACATGC]
NM_000211.4(ITGB2):c.446T> ['GATGACCTCAGGAATGTCAAGAAGCYAGGT
1199 C (p.Leul49Pro) 3689 ITGB2 GGCGACCTGCTCCGGGCCCTC]
NM_000211.4(ITGB2):c.412T> ['GTACTATCTGATGGACCTCTCCTACYCCATG
1200 C (p.Serl38Pro) 3689 ITGB2 CTTGATGACCTCAGGAATGT']
NM_005502.3(ABCAl):c.4429T ['CAAAATCAAGAAGATGCTGCCTGTGYGTCC
1201 >C (p.Cysl477Arg) 19 ABCAl CCCAGGGGCAGGGGGGCTGCC]
NM_005502.3(ABCAl):c.6026T ['TTGACTGGGAGAGAACACGTGGAGTYCTTT
1202 >C (p.Phe2009Ser) 19 ABCAl GCCCTTTTGAGAGGAGTCCCA']
NM_130439.3(MXIl):c.552+2T ['AACAAAGCCAAAGCACACATCAAGGYGAGA
1203 >C 4601 MXI1 ATTTTTACTTTCAGATTTGCA']
['GTCTTTAGATTTACAGTCCAATGCTYCACTC
1204 m.5874T>C 4579 MT-TY AGCCATTTTACCTCACCCCC]
['CCAACCCCATGGCCTCCATGACTTTYTCAAA
1205 m.7512T>C 4574 MT-TS1 AAGGTATTAGAAAAACCATT']
['AGCCAACCCCATGGCCTCCATGACTYTTTCA
1206 m.7510T>C 4574 MT-TS1 AAAAGGTATTAGAAAAACCA']
['GCCAACCCCATGGCCTCCATGACTTYTTCAA
1207 m.7511T>C 4574 MT-TS1 AAAGGTATTAGAAAAACCAT']
['CCTCCTCAAAGCAATACACTGAAAABGTTTA
1208 m.616T>C 4558 MT-TF GACGGGCTCACATCACCCCA']
['TATCACACCCCATCCTAAAGTAAGGYCAGCT
1209 m.4409T>C 4569 MT-TM AAATAAGCTATCGGGCCCAT']
['AAAGATTAAGAGAACCAACACCTCTYTACA
1210 m.8356T>C 4566 MT-TK GTGAAATGCCCCAACTAAATA]
['AAAGGATAACAGCTATCCATTGGTCYTAGG
1211 m.l2297T>C 4568 MT-TL2 CCCCAAAAATTTTGGTGCAAC]
['CCGGTAATCGCATAAAACTTAAAACYTTAC
1212 m.3271T>C 4567 MT-TL1 AGTCAGAGGTTCAATTCCTCT']
['GGTTTGTTAAGATGGCAGAGCCCGGYAATC
1213 m.3250T>C 4567 MT-TL1 GCATAAAACTTAAAACTTTAC]
['TAAAACTTTACAGTCAGAGGTTCAAYTCCTC
1214 m.3290T>C 4567 MT-TL1 TTCTTAACAACATACCCATG]
['AAATATGTCTGATAAAAGAGTTACTYTGATA
1215 m.4290T>C 4565 MT-TI GAGTAAATAATAGGAGCTTA]
1216 m.4291T>C 4565 MT-TI ['AATATGTCTGATAAAAGAGTTACTTYGATAG AGTAAATAATAGGAGCTTAA]
['ATCTATTGATGAGGGTCTTACTCTTYTAGTA
1217 m.9997T>C 4563 MT-TG TAAATAGTACCGTTAACTTC]
['GGTCTTACTCTTTTAGTATAAATAGYACCGT
1218 m.l0010T>C 4563 MT-TG TAACTTCCAATTAACTAGTT']
['GCTTAAACCCCCTTATTTCTAGGACYATGAG
1219 m.4336T>C 4572 MT-TQ AATCGAACCCATCCCTGAGA']
['CGGACTACAACCACGACCAATGATAYGAAA
1220 m.l4709T>C 4556 MT-TE AACCATCGTTGTATTTCAACT']
['TCAACAGAAACAAAGCATACATCATBATTCT
1221 m.14674T>C 4556 MT-TE CGCACGGACTACAACCACGA']
['GGGACTTAAACCCACAAACACTTAGYTAAC
1222 m.5692T>C 4570 MT-TN AGCTAAGCACCCTAATCAACT']
['GCACCCTAATCAACTGGCTTCAATCYACTTC
1223 m.5728T>C 4570 MT-TN TCCCGCCGCCGGGAAAAAAG]
[TCAACAATAGGGTTTACGACCTCGAYGTTGG
1224 m.2991T>C 4550 MT-RNR2 ATCAGGACATCCCGATGGTG]
['ATCTTCAGCAAACCCTGATGAAGGCYACAA
1225 m.l291T>C 4549 MT-RNR1 AGTAAGCGCAAGTACCCACGT']
['CTGGGATTAGATACCCCACTATGCTYAGCCC
1226 m.l095T>C 4549 MT-RNR1 TAAACCTCAACAGTTAAATC]
['TTATAACAAACCCTGAGAACCAAAAYGAAC
1227 m.8528T>C -1 - GAAAATCTGTTCGCTTCATTC]
['AGCCTACTCATTCAACCAATAGCCCBGGCCG
1228 m.8993T>C 4508 MT-ATP6 TACGCCTAACCGCTAACATT']
['ATTAACCTTCCCTCTACACTTATCAYCTTCA
1229 m.9101T>C 4508 MT-ATP6 CAATTCTAATTCTACTGACT']
['ATCCAAGCCTACGTTTTCACACTTCBAGTAA
1230 m.9176T>C 4508 MT-ATP6 GCCTCTACCTGCACGACAAC]
['AAACCTAGCCATGGCCATCCCCTTAYGAGC
1231 m.8851T>C 4508 MT-ATP6 GGGCACAGTGATTATAGGCTT']
['TACGTTTTCACACTTCTAGTAAGCCYCTACC
1232 m.9185T>C 4508 MT-ATP6 TGCACGACAACACATAATGA']
['ATAGGCTAAATCCTATATATCTTAAYGGCAC
1233 m.7587T>C 4513 MT-C02 ATGCAGCGCAAGTAGGTCTA']
['GGTATGGTCTGAGCTATGATATCAAYTGGCT
1234 m.6742T>C 4512 MT-COl TCCTAGGGTTTATCGTGTGA']
['AAAGAACCATTTGGATACATAGGTAYGGTC
1235 m.6721T>C 4512 MT-COl TGAGCTATGATATCAATTGGC]
['CATGAAACATCCTATCATCTGTAGGYTCATT
1236 m.7275T>C 4512 MT-COl CATTTCTCTAACAGCAGTAA']
['CATCAAGCCCGAATGATATTTCCTAYTCGCC
1237 m.l5572T>C 4519 MT-CYB TACACAATTCTCCGATCCGT']
1238 m.l5197T>C 4519 MT-CYB ['GGCCACAGTAATTACAAACTTACTAYCCGCC ATCCCATACATTGGGACAGA]
['CATCTCCGCATGATGAAACTTCGGCYCACTC
1239 m.l4849T>C 4519 MT-CYB CTTGGCGCCTGCCTGATCCT']
['GCTGTAGTATATCCAAAGACAACCAYCATTC
1240 NC_012920.1 :m.14484T>C 4541 MT-ND6 CCCCTAAATAAATTAAAAAA']
['GTAGTATATCCAAAGACAACCATCAYTCCCC
1241 m.i4487T>C 4541 MT-ND6 CTAAATAAATTAAAAAAACT']
['ATCAGTTCTTCAAATATCTACTCATYTTCCT
1242 m.l2706T>C 4540 MT-ND5 AATTACCATACTAATCTTAG]
['CTCACACCTCATATCCTCCCTACTAYGCCTA
1243 m.l0563T>C 4539 MT-ND4L GAAGGAATAATACTATCGCT']
['ATATTGTGCCTATTGCCATACTAGTYTTTGC
1244 m.l0663T>C 4539 MT-ND4L CGCCTGCGAAGCAGCGGTNG]
['TTACGAGTGCGGCTTCGACCCTATAYCCCCC
1245 m.l0191T>C 4537 MT-ND3 GCCCGCGTCCCTTTCTCCAT']
['ACAACTCAACGGCTACATAGAAAAAYCCAC
1246 m.l0158T>C 4537 MT-ND3 CCCTTACGAGTGCGGCTTCGA']
['CAAGCAACCGCATCCATAATCCTTCYAATAG
1247 m.4681T>C 4536 MT-ND2 CTATCCTCTTCAACAATATA]
['TACCCCCGATTCCGCTACGACCAACYCATAC
1248 m.4160T>C 4535 MT-ND1 ACCTCCTATGAAAAAACTTC]
['GCTTACCGAACGAAAAATTCTAGGCYATAT
1249 m.3394T>C 4535 MT-ND1 ACAACTACGCAAAGGCCCCAA']
['GGTTCAATTCCTCTTCTTAACAACABACCCA
1250 m.3308T>C 4535 MT-ND1 TGGCCAACCTCCTACTCCTC]
['ACTAGTCTCAGGCTTCAACATCGAAYACGCC
1251 m.3949T>C 4535 MT-ND1 GCAGGCCCCTTCGCCCTATT']
NM_003140.2(SRY):c.326T>C ['CTTACTGAAGCCGAAAAATGGCCATYCTTCC
1252 (p.Phel09Ser) 6736 SRY AGGAGGCACAGAAATTACAG]
NM_003140.2(SRY):c.203T>C ['GTGAAGCGACCCATGAACGCATTCAYCGTG
1253 (p.Ile68Thr) 6736 SRY TGGTCTCGCGATCAGAGGCGC]
NM_021083.2(XK):c.880T>C ['ACTCTATACTGGTATCAACATGTTCNGCTGG
1254 (p.Cys294Arg) 7504 XK TCTGCTGTACAGCTGAAAAT']
NM_000354.5 (SERPINA7) : c.74 ['CACCAGATGGAACAATACTATCACCYAGTG
1255 0T>C (p.Leu247Pro) 6906 SERPINA7 GATATGGAATTGAACTGCACA']
M_000044.3 (AR) : c.2033 T>C ['TGTCAGCCCATCTTTCTGAATGTCCYGGAAG
1256 (p.Leu678Pro) 367 AR CCATTGAGCCAGGTGTAGTG]
M_000044.3 (AR) : c.2423 T>C ['ATCACCCCCCAGGAATTCCTGTGCAYGAAA
1257 (p.Met808Thr) 367 AR GCACTGCTACTCTTCAGCATT']
M_000044.3(AR):c.2596T>C ['CTACCAGCTCACCAAGCTCCTGGACYCCGTG
1258 (p.Ser866Pro) 367 AR CAGCCTGTAAGCAAACGATG]
NM_000451.3 (SHOX) :c .877T>C ['GAAGCACGCGGAGGCCCTGGGGCTCYGACC
1259 (p.Ter293Arg) 6473 SHOX CGCCGCGCAGCCCCCCGCGCG]
1260 NM_000330.3(RSl):c.286T>C -1 - ['TTGAGCCGGGCCTTGTTTGCAGTCCRCGAAG (p.Trp96Arg) AATACCAGCCCACATACTGC]
NM_000330.3(RSl):c.38T>C ['ATAGAAGGCTTTTTGTTATTACTTCYCTTTG
1261 (p.Leul3Pro) 6247 RSI GCTATGAAGGTATGTGCTAT']
NM_000330.3(RSl):c.667T>C ['CCGAGCTGAGGCAGGCATCAGGCACRCTTG
1262 (p.Cys223Arg) -1 - CTGACGCACTCCAGCAGCTCC]
NM_002764.3 (PRP S 1 ) :c .344T> ['ATCTCAGCCAAGCTTGTTGCAAATAYGCTAT
1263 C (p.Metl l5Thr) 5631 PRPS1 CTGTAGCAGGTGCAGATCAT']
NM_002764.3(PRPSl):c.455T> ['AATTTGTATGCAGAGCCGGCTGTCCYAAAGT
1264 C (p.Leul52Pro) 5631 PRPS1 GGATAAGGGAGAATATCTCT']
NM_002764.3 (PRP S 1 ) :c .869T> ['TTTCCTTTCTTGCCTTTCTAGGTGAYTGACAT
1265 C (p.Ile290Thr) 5631 PRPS1 CTCTATGATCCTTGCAGAA']
NM_000291.3(PGKl):c.263T>C ['CCAGTTGCTGTAGAACTCAAATCTCYGCTGG
1266 (p.Leu88Pro) 5230 PGK1 GCAAGTAAGTGCCAGGCTCT']
NM_000291.3(PGKl):c.946T>C ['CACCTCTACCCCTCAGGGCTTGGACYGTGGT
1267 (p.Cys316Arg) 5230 PGK1 CCTGAAAGCAGCAAGAAGTA']
NM_000291.3(PGKl):c.758T>C ['CATCATTTTGGCTCCCCTGTGTAGAYTGGCA
1268 (p.Ile253Thr) 5230 PGK1 CTTCTCTGTTTGATGAAGAG]
NM_001122606.1 (L AMP2) :c .96 ['CATTGCAAATAACAATCTCAGCTACYGGGA
1269 1T>C (p.Trp321Arg) 3920 LAMP2 TGCCCCCCTGGGAAGTTCTTA']
NM_000206.2(IL2RG) : c.343 T> ['ATTCTCTGAAGAAATCACTTCTGGCYGTCAG
1270 C (p.Cysl l5Arg) 3561 IL2RG TTGCAAAAAAAGGAGATCCA']
NM_000206.2(IL2RG):c.452T> ['ACACAGATGCTAAAACTGCAGAATCYGGGT
1271 C (p.Leul51Pro) 3561 IL2RG AATTTGGAAAGAAAGGGTCAA']
NM_000194.2(HPRT 1 ) : c.122T> ['GAAAGGGTGTTTATTCCTCATGGACYAATTA
1272 C (p.Leu41Pro) 3251 HPRT1 TGGACAGGTAAGTAAGATCT']
NM_000194.2(HPRT 1 ) : c.170T> ['CTTGCTCGAGATGTGATGAAGGAGAYGGGA
1273 C (p.Met57Thr) 3251 HPRT1 GGCCATCACATTGTAGCCCTC]
NM_000132.3(F8):c.6554T>C ['ATTCGCAGCACTCTTCGCATGGAGTYGATGG
1274 (p.Leu2185Ser) 2157 F8 GCTGTGATTTAAATAGTAAG']
NM_000132.3(F8):c.985T>C ['GGACCTTGGACAGTTTCTACTGTTTYGTCAT
1275 (p.Cys329Arg) 2157 F8 ATCTCTTCCCACCAACATGG]
NM_000132.3(F8):c.5372T>C ['AGAGCAGAAGTTGAAGATAATATCAYGGTG
1276 (p.Metl791Thr) 2157 F8 AGTTAAGGACAGTGGAATTAC]
NM_000132.3(F8):c.l754T>C ['CCTTTCAATATATGTAATTAACAGAYAATGT
1277 (p.Ile585Thr) 2157 F8 CAGACAAGAGGAATGTCATC]
NM_000132.3(F8):c.935T>C ['TCCTTGGAAATCTCGCCAATAACTTYCCTTA
1278 (p.Phe312Ser) 2157 F8 CTGCTCAAACACTCTTGATG]
NM_000132.3(F8):c.980T>C ['TTGATGGACCTTGGACAGTTTCTACYGTTTT
1279 (p.Leu327Pro) 2157 F8 GTCATATCTCTTCCCACCAA']
NM_000132.3(F8):c.l l74T>C ['CTCTCCTTCCTTTATCCAAATTCGCYCAGTTG
1280 (p.Ser392Pro) 2157 F8 CCAAGAAGCATCCTAAAAC]
NM_000132.3(F8):c.l417T>C ['ATCAGGAATCTTGGGACCTTTACTTYATGGG
1281 (p.Tyr473His) 2157 F8 GAAGTTGGAGACACACTGTT']
1282 NM_000132.3(F8):c.l481T>C 2157 F8 ['AATCAAGCAAGCAGACCATATAACAYCTAC (p.Ile494Thr) CCTCACGGAATCACTGATGTC]
NM_000132.3(F8):c.l729T>C ['CCCTCTCCTCATCTGCTACAAAGAAYCTGTA
1283 (p.Ser577Pro) 2157 F8 GATCAAAGAGGAAACCAGGT']
NM_000132.3(F8):c.l958T>C ['CAGTTGTCAGTTTGTTTGCATGAGGYGGCAT
1284 (p.Val653Ala) 2157 F8 ACTGGTACATTCTAAGCATT']
['TTCTGTCTTCTTCTCTGGATATACCYTCAAAC
1285 NM_000132.3(F8):c.2029T>C 2157 F8 ACAAAATGGTCTATGAAGA']
['GTTTCTTTACTTGGGCAAAGGACAGYGGGCC
1286 NM_000132.3(F8):c.6193T>C 2157 F8 CCAAAGCTGGCCAGACTTCA']
NM_007325.4(GRIA3):c.2117T> ['GTGTACGAGAAAATGTGGTCTTACAYGAAA
1287 C (p.Met706Thr) 2892 GRIA3 TCAGCGGAGCCATCTGTGTTT']
NM_000402.4(G6PD):c.1058T> ['GAGGGCGAGGCCACCAAAGGGTACCYGGAC
1288 C (p.Leu353Pro) 2539 G6PD GACCCCACGGTGCCCCGCGGG]
NM_000402.4(G6PD):c.1054T> ['TGGAGAGGGCGAGGCCACCAAAGGGYACCT
1289 C (p.Tyr352His) 2539 G6PD GGACGACCCCACGGTGCCCCG]
NM_001097642.2(GJBl):c.397T ['GGTCCACATCTCAGGGACACTGTGGYGGAC
1290 >C (p.Trpl33Arg) 2705 GJB1 CTATGTCATCAGCGTGGTGTT']
NM_000166.5 (GJB 1 ) :c .407T>C ['TCAGGGACACTGTGGTGGACCTATGYCATC
1291 (p.Vall36Ala) 2705 GJB1 AGCGTGGTGTTCCGGCTGTTG]
NM_000032.4(ALAS2):c.595T> ['TGTGTCCGTCTGGTGTAGTAATGATYACCTG
1292 C (p.Tyrl99His) 212 ALAS2 GGCATGAGCCGACACCCTCA']
NM_020061.5(OPNlLW):c.607 ['CTGGCCCCACGGCCTGAAGACTTCAYGCGG
1293 T>C (p.Cys203Arg) 5956 0PN1LW CCCAGACGTGTTCAGCGGCAG]
NM_000513.2(OPNlMW):c.607 ['CTGGCCCCACGGCCTGAAGACTTCAYGCGG
1294 T>C (p.Cys203Arg) 2652 OPN1MW CCCAGACGTGTTCAGCGGCAG]
NM_000513.2(OPNlMW):c.529 ['GGCCATCGTGGGCATTGCCTTCTCCYGGATC
1295 T>C (p.Trpl77Arg) 2652 OPN1MW TGGGCTGCTGTGTGGACAGC]
NM_000273.2(GPR143):c.397T> ['GCTGTTGTACAGTGCCTGCTTCTGGHGGCTG
1296 C (p.Trpl33Arg) 4935 GPR143 TTTTGCTATGCAGTGGATGC]
NM_000133.3(F9):c.52T>C ['AGAATCACCAGGCCTCATCACCATCYGCCTT
1297 (p.CyslSArg) 2158 F9 TTAGGATATCTACTCAGTGC]
NM_000133.3(F9):c.l058T>C ['TTCCTCAAATTTGGATCTGGCTATGYAAGTG
1298 (p.Val353Ala) 2158 F9 GCTGGGGAAGAGTCTTCCAC]
NM_000133.3(F9):c.l l44T>C ['AGTTCCACTTGTTGACCGAGCCACAHGTCTT
1299 (p.Cys382Arg) 2158 F9 CGATCTACAAAGTTCACCAT']
NM_000133.3(F9):c.l328T>C ['TGTGCAATGAAAGGCAAATATGGAAYATAT
1300 (p.Ile443Thr) 2158 F9 ACCAAGGTATCCCGGTATGTC]
NM_000133.3(F9):c.l357T>C ['TACCAAGGTATCCCGGTATGTCAACYGGATT
1301 (p.Trp453Arg) 2158 F9 AAGGAAAAAACAAAGCTCAC]
NM_000133.3(F9):c.82T>C ['TTTAGGATATCTACTCAGTGCTGAAYGTACA
1302 (p.Cys28Arg) 2158 F9 GGTTTGTTTCCTTTTTTAAA']
['CTGAATTTTGGAAGCAGTATGTTGGYAAGC
1303 NM_000133.3(F9):c.277+2T>C 2158 F9 AATTCATTTTATCCTCTAGCT']
1304 NM_000133.3(F9):c.l031T>C 2158 F9 ['ATTGCTGACAAGGAATACACGAACAYCTTC (p.Ile344Thr) CTCAAATTTGGATCTGGCTAT']
NM_000169.2(GLA):c.484T>C ['CATTGATGCCCAGACCTTTGCTGACYGGGGA
1305 (p.Trpl62Arg) -1 - GTAGATCTGCTAAAATTTGA']
NM_000169.2(GLA):c.806T>C ['TTATTTCATTCTTTTTCTCAGTTAGYGATTGG
1306 (p.Val269Ala) -1 - CAACTTTGGCCTCAGCTGG]
NM_015107.2(PHF8):c.836T>C ['CCAACAAATGCCAATCTGACTCTCTYTGAGT
1307 (p.Phe279Ser) 23133 PHF8 GCTGGAGCAGTTCCTCTAAT']
NM_033290.3(MIDl):c.l877T> ['TATGATGCTTTGAACTCCATCCACCYCTACA
1308 C (p.Leu626Pro) 4281 MIDI CCTTCGACGTCGCATTTGCG]
NM_033290.3(MIDl):c.884T>C ['TTCAAGGTGATGAGGCTTCGCAAACYGGCT
1309 (p.Leu295Pro) 4281 MIDI CAGCAGATTGCAAACTGCAAA']
M_000444.5 (PHEX) : c.755T>C ['CAGTATCGGGATGCCCTTTACAAGTYCATGG
1310 (p.Phe252Ser) 5251 PHEX TGGATACTGCCGTGCTTTTA']
M_000444.5 (PHEX) : c.1664T> ['CTCATAGGATTTCCAGCAGGAGAGCYCCAG
1311 C (p.Leu555Pro) 5251 PHEX AAGCCTTTCTTTTGGGGAACA]
NM_001205019.1(GK):c. l525T> ['AGAAAGTGAAATTCGTTATTCTACAYGGAA
1312 C (p.Trp509Arg) 2710 GK GAAAGCTGTGATGAAGTCAAT']
NM_000475.4(NR0Bl):c.890T> ['AACTGCTGGGCGTCCCTGCTCATGCYTGAGC
1313 C (p.Leu297Pro) 190 NR0B1 TGGCCCAGGACCGCTTGCAG]
NM_000531.5 (OTC) : c.332T>C ['CTTCTGGGAGGACATCCTTGTTTTCYTACCA
1314 (p.Leull lPro) 5009 OTC CACAAGATATTCATTTGGGT']
NM_000531.5 (OTC) : c.134T>C ['CTGAAGGGCCGTGACCTTCTCACTCYAAAA
1315 (p.Leu45Pro) 5009 OTC AACTTTACCGGAGAAGAAATT']
NM_000531.5 (OTC) : c.717+2T> ['TTGGCAGAGCAGTATGCCAAAGAGGYATGC
1316 C 5009 OTC TCTTTACATGTAAAGCTATTA]
NM_001399.4(EDA):c.l81T>C ['CCTCCACCTGCTGACGTTGTGCTGCYACCTA
1317 (p.Tyr61His) 1896 EDA GAGTTGCGCTCGGAGTTGCG]
NM_001015877.1 (PHF6) : c.2T> ['CATTCTAAAGGCAATTTAAAAATCAYGTCA
1318 C (p.MetlThr) 84295 PHF6 AGCTCAGTTGAACAGAAAAAA']
NM_001128834.2(PLPl):c.487T ['CATCACCTATGCCCTGACCGTTGTGYGGCTC
1319 >C (p.Trpl63Arg) 5354 PLP1 CTGGTGTTTGCCTGCTCTGC]
NM_001128834.2(PLPl):c.671T ['CCTGGCAAGGTTTGTGGCTCCAACCYTCTGT
1320 >C (p.Leu224Pro) 5354 PLP1 CCATCTGCAAAACAGCTGAG]
NM_001128834.2(PLPl):c.560T ['AACACCTGGACCACCTGCCAGTCTAYTGCCT
1321 >C (p.Ilel87Thr) 5354 PLP1 TCCCCAGCAAGACCTCTGCC]
NM_001128834.2(PLPl):c.710T ['ATTTTCCTGCAGTTCCAAATGACCTYCCACC
1322 >C (p.Phe237Ser) 5354 PLP1 TGTTTATTGCTGCATTTGTG]
NM_000116.4(TAZ):c.352T>C ['CTCCCACTTCTTCAGCTTGGGCAAGYGTGTG
1323 (p.Cysl l8Arg) 6901 TAZ CCTGTGTGCCGAGGTGAGCT']
NM_000377.2(WAS):c.244T>C ['CTTCGTGAAGGATAACCCCCAGAAGYCCTA
1324 (p.Ser82Pro) 7454 WAS CTTCATCCGCCTTTACGGCCT']
NM_000377.2(WAS):c.809T>C ['AACCTCGACCCAGATCTGCGGAGTCYGTTCT
1325 (p.Leu270Pro) 7454 WAS CCAGGGCAGGAATCAGCGAG]
1326 NM_182680.1(AMELX):c.2T>C -1 - ['CTTACATTTCAGAACCATCAAGAAAYGGGG (p.MetlThr) ACCTGGATTTTATTTGCCTGC]
NM_000074.2(CD40LG) : c.464T ['ACCATGAGCAACAACTTGGTAACCCYGGAA
1327 >C (p.Leul55Pro) 959 CD40LG AATGGGAAACAGCTGACCGTT']
NM_139058.2(ARX):c.98T>C 17030 ['TCCTCCTACTGCATCGACAGCATCCYGGGCC
1328 (p.Leu33Pro) 2 ARX GGAGGAGCCCGTGCAAAATG]
NM_001109878.1(TBX22):c.641 ['TGATCATTTCTCCTCCAGATCATTCYGCAAT
1329 T>C (p.Leu214Pro) 50945 TBX22 CCATGCATAAGTACAAACCC]
NM_000061.2(BTK):c.2T>C ['GGTGAACTCCAGAAAGAAGAAGCTAYGGCC
1330 (p.MetlThr) 695 BTK GCAGTGATTCTGGAGAGCATC]
NM_000061.2(BTK):c. l223T>C ['AAGGACCTGACCTTCTTGAAGGAGCYGGGG
1331 (p.Leu408Pro) 695 BTK ACTGGACAATTTGGGGTAGTG]
NM_000061.2(BTK):c. l516T>C ['GCTGCTAGAGATGTGCAAGGATGTCYGTGA
1332 (p.Cys506Arg) 695 BTK AGCCATGGAATACCTGGAGTC]
NM_000061.2(BTK):c. l625T>C ['GTTGTTAAAGTATCTGATTTCGGCCYGTCCA
1333 (p.Leu542Pro) 695 BTK GGTGAGTGTGGCTTTTTCAT']
NM_000061.2(BTK):c. l741T>C ['CAAGTTCAGCAGCAAATCTGACATTYGGGC
1334 (p.Trp581Arg) 695 BTK TTTTGGTAAGTGGATAAGATT']
NM_000061.2(BTK):c. l955T>C ['TTCAAAATTCTTCTGAGCAATATTCYAGATG
1335 (p.Leu652Pro) 695 BTK TCATGGATGAAGAATCCTGA']
NM_015884.3(MBTPS2):c.l424 ['GATGGACAATGGATTCTAAACTCTTYCTTGG
1336 T>C (p.Phe475Ser) 51360 MBTPS2 ATGCCACCCTTACCTCAGTG]
NM_014009.3 (FOXP3 ) : c.970T> ['GATTCATCCCCACCCTCTGACAGAGYTCCTC
1337 C (p.Phe324Leu) 50943 FOXP3 CACAACATGGACTACTTCAA']
NM_014009.3(FOXP3):c.l099T ['GACACTCAATGAGATCTACCACTGGYTCAC
1338 >C (p.Phe367Leu) 50943 FOXP3 ACGCATGTTTGCCTTCTTCAG]
NM_022567.2(NYX):c.302T>C ['CTGCGCCACAACAACCTGTCCTTCAYCACGC
1339 (p.IlelOlThr) 60506 NYX CCGGCGCCTTCAAGGGCCTG]
NM_003639.4(IKBKG):c.l249T ['CACCCTGCAGATACATGTCATGGAGYGCATT
1340 >C (p.Cys417Arg) 8517 KBKG GAGTAGGGCCGGCCAGTGCA']
NM_006579.2(EBP):c.53T>C ['CCATACTGGCCTCAGCACCTAAGACYGGAC
1341 (p.Leul8Pro) 10682 EBP AACTTTGTACCTAATGACCGC]
NM_003159.2(CDKL5):c.215T> ['CTTCGGACTCTCAAGCAGGAAAACAHTGTG
1342 C (p.Ile72Thr) 6792 CDKL5 GAGTTGAAGGAAGCATTTCGT']
NM_001011658.3(TRAPPC2):c. ['GCCTTAATTATTTCACATATGAGGTYTATTA
1343 248T>C (p.Phe83Ser) -1 - TGCTTCATGACATAAGACAA']
NM_001011658.3(TRAPPC2):c. ['AGTTACCTTTACTAAGAAGGTAAGGRTATGC
1344 238+4T>C -1 - CCCGCAGTGACAAATGCCGA']
NM_003688.3(CASK):c.802T>C ['GGATCCAGCTGAAAGGATCACTGTTYATGA
1345 (p.Tyr268His) 8573 CASK AGCACTGAATCACCCATGGCT']
NM_003688.3(CASK):c.2740T> ['TGAGCTCGTGTGCACAGCCCCACAGYGGGT
1346 C (p.Trp914Arg) 8573 CASK CCCTGTCTCCTGGGTCTATTA']
NM_001159702.2(FHLl):c.457T ['AGGGGAGGACTTCTACTGCGTGACTYGCCA
1347 >C (p.Cysl53Arg) 2273 FHL1 TGAGACCAAGTTTGCCAAGCA']
1348 NM_001159702.2(FHLl):c.310T 2273 FHL1 ['GGAGGACTCCCCCAAGTGCAAGGGGYGCTT >C (p.Cysl04Arg) CAAGGCCATTGTGGCAGGTAC]
NM_001159702.2(FHLl):c.625T ['CACCGCTGTGGAGGACCAGTATTACYGCGT
1349 >C (p.Cys209Arg) 2273 FHL1 GGATTGCTACAAGAACTTTGT']
NM_001363.4(DKCl):c. ll3T>C ['ATACAACACGCTGAAGAATTTCTTANCAAA
1350 (p.Ile38Thr) 1736 DKC1 CCTGAATCCAAAGTTGCTAAG]
NM_178152.2(DCX):c.373T>C ['CTTATTTCTTGCCTTAGGGGAAAGCYATGTC
1351 (p.Tyrl25His) 1641 DCX TGTTCCTCAGACAACTTCTT']
NM_005183.3(CACNAlF):c.226 ['ATCCTGTTGAACGTGTTTCTTGCCAYTGCTG
1352 7T>C (p.Ile756Thr) 778 CACNA1F TGGACAACCTGGCCAGTGGA']
NM_001493.2(GDIl):c.275T>C ['ACAGGGCAGCTGGTAAAGATGCTACYGTAT
1353 (p.Leu92Pro) 2664 GDI1 ACAGAGGTGACTCGCTACCTG]
NM_006517.4(SLC16A2):c. l313 ['ATCATGGCCCCCATTGCATTTGAGCYGGTGG
1354 T>C (p.Leu438Pro) 6567 SLC16A2 GCCCAATGCAGGCCTCACAG]
NM_006517.4(SLC16A2):c.1190 ['CTCCAGGTCCTTTCCTTCCTGCTCCYGGGCC
1355 T>C (p.Leu397Pro) 6567 SLC16A2 TGATGTCCATGATGATTCCC]
NM_006517.4(SLC16A2):c. l481 ['CCCCCCATCATCGGGGCTGTAATCCYCTTCT
1356 T>C (p.Leu494Pro) 6567 SLC16A2 TCGTCCCTCTGATGCATCAA']
NM_004586.2(RPS6KA3):c.803 ['GAAATGCTTACTGGTACACTCCCTTYCCAAG
1357 T>C (p.Phe268Ser) 6197 RPS6KA3 GAAAAGATCGAAAAGAAACA']
NM_000489.4(ATRX):c.4840T> ['AAGTTTTCTTCATACAGTTCTTTTGYGTGAC
1358 C (p.Cysl614Arg) 546 ATRX AAACTGGATTTCAGCACGGC]
NM_000489.4(ATRX):c.6250T> ['GAAGTGGCTTCGAAACATTGACTATYACCGT
1359 C (p.Tyr2084His) 546 ATRX TTAGATGGTTCCACTACTGC]
NM_000489.4(ATRX):c.1226T> ['GATATTAAGAAGGCTCATCTTGCATYGGAA
1360 C (p.Leu409Ser) 546 ATRX GAAGACTTAAATTCCGAGTTT']
NM_000489.4(ATRX):c.6149T> ['CAGTCCCTCATATCTCTGGACTTGAYTGAAG
1361 C (p.Ile2050Thr) 546 ATRX ATTTTCTTGAATTAGCTAGT']
NM_001110556.1(FLNA):c.720
+2T>C 2316 FLNA
NM_001127899.3(CLCN5):c.17 ['AGGTGGGGTGACTCGGATGACTGTTYCTCTT
1362 68T>C (p.Ser590Pro) 1184 CLCN5 GTTGTCATAATGTTTGAACT']
NM_004992.3(MECP2):c.464T> ['GACACATCCCTGGACCCTAATGATTBTGACT
1363 C (p.Phel55Ser) 4204 MECP2 TCACGGTAACTGGGAGAGGG]
NM_001061.4(TBXASl):c.l463 ['TGCCTCGGGGTGCGTCTAGGGCTGCYTGAG
1364 T>C (p.Leu488Pro) 6916 TBXAS1 GTCAAGTTGACACTGCTCCAC]
NM_001061.4(TBXASl):c.248T ['TTTTTTATTCCTCCCAGGTACTATCYTGGTCG
1365 >C (p.Leu83Pro) 6916 TBXAS1 TCGGATGTTTATTGTTATT']
NM_000128.3(Fll):c.901T>C ['TTCTTCATTTTACCATGACACTGATYTCTTGG
1366 (p.Phe301Leu) 2160 Fl l GAGAAGAACTGGATATTGT']
NM_000128.3(Fll):c.l66T>C ['GGTAGTCTGCACTTACCACCCAAGAYGTTTA
1367 (p.Cys56Arg) 2160 Fl l CTCTTCACTTTCACGGCGGA]
NM_000203.4(IDUA):c.l469T> ['AGCCCCGACGGCGAGTGGCGGCGCCYGGGC
1368 C (p.Leu490Pro) 3425 IDUA CGGCCCGTCTTCCCCACGGCA']
1369 NM_000431.3(MVK):c.803T>C 4598 MVK ['ATCGTGGCCCCCCTCCTGACCTCAAYAGATG (p.Ile268Thr) CCATCTCCCTGGAGTGTGAG']
NM_014425.3(INVS):c.l478T> ['TTATGCTTATAGGGAAGAACAGCTTYGCATT
1370 C (p.Leu493Ser) 27130 INVS GGTCCTGCAACAATGGATAC]
NM_000108.4(DLD):c.1178T>C ['GACTACAATTGTGTGCCATCAGTGAYTTACA
1371 (p.Ile393Thr) 1738 DLD CACACCCTGAAGTTGCTTGG']
NM_000170.2(GLDC):c.2T>C ['GGGCAGGGGACGGTGGCCGCGGCCAYGCAG
1372 (p.MetlThr) 2731 GLDC TCCTGTGCCAGGGCGTGGGGG]
NM_000151.3(G6PC):c.229T>C ['AGACTGGCTCAACCTCGTCTTTAAGYGGTAA
1373 (p.Trp77Arg) 2538 G6PC GAACCATATAGAGAGGAGAT']
M_004453.3(ETFDH):c.2T>C ['CCGAGAGTCCTGGTGACTTTGAACAYGCTG
1374 (p.MetlThr) 2110 ETFDH GTGCCGCTAGCCAAGCTGTCC]
NM_000136.2(FANCC):c.l661T ['CTGGCCCGAGAGCTCCTTAAAGAGCYGCGA
1375 >C (p.Leu554Pro) -1 - ACTCAAGTCTAGAAGGCACGC]
NM_000131.4(F7):c.38T>C ['GCCCTCAGGCTCCTCTGCCTTCTGCYTGGGC
1376 (p.Leul3Pro) 2155 F7 TTCAGGGCTGCCTGGCTGCA']
NM_000131.4(F7):c.983T>C ['CCCCTCTGCCTGCCCGAACGGACGTYCTCTG
1377 (p.Phe328Ser) 2155 F7 AGAGGACGCTGGCCTTCGTG]
NM_024649.4(BBSl):c.l553T> ['ACAACCCGTCCTGTCCTGGGGCTGCYGGTCT
1378 C (p.Leu518Pro) -1 - GCTTCCTGTACAACGAGGCG]
NM_000490.4(AVP):c.200T>C ['TGCGCGGACGAGCTGGGCTGCTTCGYGGGC
1379 (p.Val67Ala) 551 AVP ACGGCTGAGGCGCTGCGCTGC]
NM_000490.4(AVP):c.61T>C ['CCTACTGGCCTTCTCCTCCGCGTGCYACTTC
1380 (p.Tyr21His) 551 AVP CAGAACTGCCCGAGGGGCGG]
NM_001692.3(ATP6VlBl):c24 ['GGGACTCAGAGGAGCGGGCAGGTGCYTGAG
1381 2T>C (p.Leu81Pro) 525 ATP6V1B1 GTGGCTGGCACCAAGGCGATT']
NM_003361.3(UMOD):c.649T> ['GGGCGGTGCGCGCATGGCCGAGACCBGCGT
1382 C (p.Cys217Arg) 7369 UMOD GCCAGTCCTGCGCTGCAACAC]
NM_003361.3 (UMOD) :c .376T> ['TAGCCACTGCCACGCCCTGGCCACAYGTGTC
1383 C (p.Cysl26Arg) 7369 UMOD AATGTGGTGGGCAGCTACTT']
NM_003361.3(UMOD):c.943T> ['CAAATCGAATAATGGCAGATGGCACYGCCA
1384 C (p.Cys315Arg) 7369 UMOD GTGCAAACAGGACTTCAACAT']
NM_080911.2(UNG):c.752T>C ['AATCAGAACTCGAATGGCCTTGTTTYCTTGC
1385 (p.Phe251Ser) 7374 UNG TCTGGGGCTCTTATGCTCAG]
NM_199292.2(TH):c.707T>C ['CAGGTGTACCGCCAGCGCAGGAAGCYGATT
1386 (p.Leu236Pro) 7054 TH GCTGAGATCGCCTTCCAGTAC]
NM_001065.3 (TNFRSF1 A) : c.17 TNFRSF1 ['CCACCCTCAAAATAATTCGATTTGCYGTACC
1387 5T>C (p.Cys59Arg) 7132 A AAGTGCCACAAAGGTAGGGG]
NM_001065.3(TNFRSFlA):c.34 TNFRSF1 ['AATGGGTCAGGTGGAGATCTCTTCTYGCACA
1388 9T>C (p.Cysl l7Arg) 7132 A GTGGACCGGGACACCGTGTG]
NM_000546.5(TP53):c.755T>C ['GGCGGCATGAACCGGAGGCCCATCCYCACC
1389 (p.Leu252Pro) 7157 TP53 ATCATCACACTGGAAGACTCC]
NM_000546.5(TP53):c.398T>C ['CAGTACTCCCCTGCCCTCAACAAGAYGTTTT
1390 (p.Metl33Thr) 7157 TP53 GCCAACTGGCCAAGACCTGC]
1391 NM_000546.5(TP53):c.l031T>C 7157 TP53 ['GAGCGCTTCGAGATGTTCCGAGAGCYGAAT (p.Leu344Pro) GAGGCCTTGGAACTCAAGGAT']
NM_001018005.1(TPMl):c.284 ['TCTCTGAACAGACGCATCCAGCTGGYTGAG
1392 T>C (p.Val95Ala) 7168 TPM1 GAAGAGTTGGATCGTGCCCAG]
NM_001159287.1(TPIl):c.832T ['GGGTGGTGCTTCCCTCAAGCCCGAAYTCGTG
1393 >C (p.Phe278Leu) 7167 TPI1 GACATCATCAATGCCAAACA']
NM_003242.5(TGFBR2):c.923T ['AAGCATGAGAACATACTCCAGTTCCYGACG
1394 >C (p.Leu308Pro) 7048 TGFBR2 GCTGAGGAGCGGAAGACGGAG]
NM_000660.5(TGFBl):c.673T> ['CTTTCGCCTTAGCGCCCACTGCTCCYGTGAC
1395 C (p.Cys225Arg) 7040 TGFB1 AGCAGGGATAACACACTGCA']
NM_000660.5(TGFBl):c.241T> ['GCTGCCCGAGGCCGTGCTCGCCCTGYACAA
1396 C (p.Tyr81His) 7040 TGFB1 CAGCACCCGCGACCGGGTGGC]
NM_000660.5 (TGFB 1 ) :c .667T> ['TGAGGGCTTTCGCCTTAGCGCCCACNGCTCC
1397 C (p.Cys223Arg) 7040 TGFB1 TGTGACAGCAGGGATAACAC]
NM_001128177.1(THRB):c.929 ['ATCATCCTCCTCAAAGGCTGCTGCAYGGAG
1398 T>C (p.Met310Thr) 7068 THRB ATCATGTCCCTTCGCGCTGCT']
NM_001128177.1(THRB):c. l33 ['CCGCTTCCTGCACATGAAGGTGGAAYGCCC
1399 6T>C (p.Cys446Arg) 7068 THRB CACAGAACTCTTCCCCCCTTT']
NM_001128177.1(THRB):c. l37 ['CTCTTCCCCCCTTTGTTCTTGGAAGYGTTCG
1400 3T>C (p.Val458Ala) 7068 THRB AGGATTAGACTGACTGGATT']
NM_007313.2(ABLl):c.814T>C ['GAAGCACAAGCTGGGCGGGGGCCAGYACGG
1401 (p.Tyr272His) 25 ABLl GGAGGTGTACGAGGGCGTGTG]
NM_007313.2(ABLl):c.988T>C ['AGGGGTCTGCACCCGGGAGCCCCCGYTCTA
1402 (p.Phe330Leu) 25 ABLl TATCATCACTGAGTTCATGAC]
NM_007313.2(ABLl):c.l l09T> ['ATGGCCACTCAGATCTCGTCAGCCAYGGAG
1403 C (p.Met370Thr) 25 ABLl TACCTGGAGAAGAAAAACTTC]
NM_021961.5(TEADl):c.l261T ['TGAACACGGAGCACAACATCATATTYACAG
1404 >C (p.Tyr?His) 7003 TEAD1 GCTTGTAAAGGACTGAACATG]
NM_001256850.1(TTN):c.2926T ['TGGATACCCATCCCCGACAGTGACAHGGTA
1405 >C (p.Trp976Arg) 7273 TTN CAGGGAAGACTACCAAATCGA']
NM_133378.4(TTN):c.l00163T> ['GAAAACACAGATGACCTGACAACCCYGATC
1406 C (p.Leu33388Pro) -1 - ATCATGGACGTACAGAAACAA']
NM_003235.4(TG):c.3733T>C ['CCCCACAGGCTCTGCCATGCAGCAGYGCCA
1407 (p.Cysl245Arg) 7038 TG ATTGCTGTGCCGCCAGGGCTC]
NM_003235.4(TG):c.3229T>C ['TCTCTCTCCCACAGGCCCGACAACCYGCGAG
1408 (p.Cysl077Arg) 7038 TG AAATCTCGAACCAGTGGGCT']
NM_000733.3(CD3E):c.520+2T ['CGGGTGCTGGCGGCAGGCAAAGGGGYAAGG
1409 >C 916 CD3E CTGTGGAGTCCAGTCAGAGGA]
NM_003000.2(SDHB):c.487T>C ['GCCTTATTTGAAGAAGAAGGATGAAYCTCA
1410 (p.Serl63Pro) 6390 SDHB GGAAGGCAAGCAGCAGTATCT']
NM_003106.3 (SOX2) : c.290T>C ['CCGTTCATCGACGAGGCTAAGCGGCYGCGA
1411 (p.Leu97Pro) -1 - GCGCTGCACATGAAGGAGCAC]
NM_001024858.2(SPTB):c.604T ['TAATGTCACCAACTTTACCTCCAGCYGGAAG
1412 >C (p.Trp202Arg) 6710 SPTB GATGGCTTGGCCTTTAATGC]
1413 NM_001024858.2(SPTB):c.6055 6710 SPTB ['GGTGTGCCAGTTCTCGAGGGATGCCYCTGTG T>C (p.Ser2019Pro) GCTGAGGCGTGGCTGATTGC]
NM_003126.2(SPTAl):c.779T> ['TTGGCTCTCCAGAGACAGAAAGCTCBGTCCA
1414 C (p.Leu260Pro) 6708 SPTA1 ATGCTGCAAACTTACAACGA']
NM_003126.2(SPTAl):c.781T> ['GGCTCTCCAGAGACAGAAAGCTCTGYCCAA
1415 C (p.Ser261Pro) 6708 SPTA1 TGCTGCAAACTTACAACGATT']
NM_003126.2(SPTAl):c.620T> ['AAATTTGAAGACTTCCAAGTGGAGCYGGTA
1416 C (p.Leu207Pro) 6708 SPTA1 GCTAAAGAAGGGAGAGTTGTT']
NM_005633.3(SOSl):c.l294T> ['CGAGATTCAGAAGAATATTGATGGTYGGGA
1417 C (ρ.Τφ432Α¾) 6654 SOS1 GGGAAAAGACATTGGACAGTG]
NM_006920.4(SCNlA):c.3577T ['TGTGGAAGAAGGCAGAGGAAAACAAYGGT
1418 >C (p.Trpl l93Arg) -1 - GGAACCTGAGAAGGACGTGTTT']
NM_006920.4(SCNlA):c.4250T ['TTTGGGTATCTCTCTTTGCTTCAAGYTGTAA
1419 >C (p.Vall417Ala) -1 - GTGAACACTATTTTCTCTGA']
NM_006920.4(SCNlA):c.434T> ['ACTATTTTGACAAACTGTGTGTTTAHGACAA
1420 C (p.Metl45Thr) 6323 SCN1A TGAGTAACCCTCCTGATTGG']
NM_006920.4(SCNlA):c.4462T ['TCTATACTTTGGAGGTCAAGACATCYTTATG
1421 >C (p.Phel488Leu) -1 - ACAGAAGAACAGAAGAAATA']
NM_152296.4(ATPlA3):c.821T ['GGGCTGGAGGTGGGCAAGACGCCCAHCGCC
1422 >C (p.Ile274Thr) 478 ATP 1 A3 ATCGAGATTGAGCACTTCATC]
NM_152296.4(ATPlA3):c.2338 ['CAGCAATATCCCGGAGATCACGCCCYTCCTG
1423 T>C (p.Phe780Leu) 478 ATP 1 A3 CTGTTCATCATGGCCAACAT']
NM_000702.3(ATPlA2):c.2291 ['CCTCAGAATCTCCCCACAGGCCGCCYGATCT
1424 T>C (p.Leu764Pro) 477 ATP1A2 TTGACAACTTGAAGAAATCC]
NM_000702.3(ATPlA2):c.2659 ['ACGGCTACTGGGAATCCGCCTCGACYGGGA
1425 T>C (ρ.Τφ887Α¾) 477 ATP1A2 TGACCGGACCATGAATGATCT']
NM_000702.3 (ATP 1 A2) :c .2192 ['AAGAAGGCTGACATTGGCATTGCCAYGGGC
1426 T>C (p.Met731Thr) 477 ATP1A2 ATCTCTGGCTCTGACGTCTCT']
NM_000702.3(ATPlA2):c.857T ['GGGCGGACACCCATAGCAATGGAGAYTGAA
1427 >C (p.Ile286Thr) 477 ATP1A2 CACTTCATCCAGCTGATCACA']
NM_001035.2(RYR2):c. l298T> ['ATGTTTATGGTTTATTTTAGGGGCCYTGATG
1428 C (p.Leu433Pro) 6262 RYR2 CTCTCAGCAAGAAAGCGAAG]
NM_000540.2(RYRl):c.14693T ['GTGGGTGTCCGGGCTGGCGGAGGCAYTGGG
1429 >C (p.Ile4898Thr) 6261 RYR1 GACGAGATCGAGGACCCCGCG]
NM_000539.3(RHO):c.l33T>C ['GTTCTCCATGCTGGCCGCCTACATGYTTCTG
1430 (p.Phe45Leu) 6010 RHO CTGATCGTGCTGGGCTTCCC]
NM_000321.2(RBl):c. l960+2T> ['CTCTTTCACTGTTTTATAAAAAAGGYTAGTA
1431 C 5925 RBI GATGATTATTTTCAAGAGCA']
NM_000321.2(RBl):c.2134T>C ['TATGATGTGTTCCATGTATGGCATAYGCAAA
1432 (p.Cys712Arg) 5925 RBI GTGAAGAATATAGACCTTAA']
NM_000329.2(RPE65):c.l022T> ['AGATTTGAGTTTGTTTATAATTACTYATATTT
1433 C (p.Leu341Ser) 6121 RPE65 AGCCAATTTACGTGAGAAC]
NM_000322.4(PRPH2):c.554T> ['ATTCAGTGGATCAGCAATCGCTACCYGGACT
1434 C (p.Leul85Pro) 5961 PRPH2 TTTCCTCCAAAGAAGTCAAA']
1435 NM_000322.4(PRPH2):c.2T>C 5961 PRPH2 ['CAACCCGGACTACACTTGGCAAGCAYGGCG (p.MetlThr) CTACTGAAAGTCAAGTTTGAC]
NM_001098668.2(SFTPA2):c.59 72923 ['ACTGAGGGTCCCAGCCCTGGAGACTYCCGC
1436 3T>C (p.Phel98Ser) 8 SFTPA2 TACTCAGATGGGACCCCTGTA']
NM_003018.3(SFTPC):c.218T> ['TTTCCCCAGGTTCTGGAGATGAGCAHTGGGG
1437 C (p.Ile73Thr) 6440 SFTPC CGCCGGAAGCCCAGCAACGC]
NM_003018.3(SFTPC):c.581T> ['AGCACCCTGTGTGGCGAGGTGCCGCYCTACT
1438 C (p.Leul94Pro) 6440 SFTPC ACATCTAGGACGCCTCCGGT']
NM_000055.2(BCHE):c. l004T> ['CTCACTGACATGCCAGACATATTACYTGAAC
1439 C (p.Leu335Pro) 590 BCHE TTGGACAATTTAAAAAAACC]
NM_002739.3(PRKCG):c.355T> ['CCCCACCTTCTGCGACCACTGTGGCYCCCTC
1440 C (p.Serl l9Pro) 5582 PRKCG CTCTACGGGCTTGTGCACCA']
NM_002739.3(PRKCG):c.l927T ['ACAGTGTGGCCGCAGCGGCGAGAACYTTGA
1441 >C (p.Phe643Leu) 5582 PRKCG CAAGTTCTTCACGCGGGCGGC]
NM_000141.4(FGFR2) :c .1018T ['TGTAACTTTTGAGGACGCTGGGGAAYATAC
1442 >C (p.Tyr340His) 2263 FGFR2 GTGCTTGGCGGGTAATTCTAT']
NM_000141.4(FGFR2) :c .1024T ['TTTTGAGGACGCTGGGGAATATACGHGCTTG
1443 >C (p.Cys342Arg) 2263 FGFR2 GCGGGTAATTCTATTGGGAT']
NM_000141.4(FGFR2):c.868T> ['CAGTGATGCCCAGCCCCACATCCAGBGGAT
1444 C (p.Trp290Arg) 2263 FGFR2 CAAGCACGTGGAAAAGAACGG]
NM_000141.4(FGFR2):c.799T> ['CCAAGCCGGACTGCCGGCAAATGCCYCCAC
1445 C (p.Ser267Pro) 2263 FGFR2 AGTGGTCGGAGGAGACGTAGA']
NM_000506.3(F2):c.l l39T>C ['CCTGCTGCCCCTCCCAGGCAGGTGAYGCTTT
1446 (p.Met380Thr) 2147 F2 TCCGGAAGAGTCCCCAGGAG]
NM_000313.3(PROSl):c.l501T ['TTCATTATTTTAAATAGATAATGTABCCAGT
1447 >C (p.Ser501Pro) 5627 PR0S1 GCTGAGGGTTGGCATGTAAA]
NM_002834.3(PTPNll):c.854T> ['TGACCGTGGTCTCTTTTTCTTCTAGNTGATCA
1448 C (p.Phe285Ser) 5781 PTPN11 TACCAGGGTTGTCCTACAC]
NM_002755.3(MAP2Kl):c. l58T ['CAGCAGCGAAAGCGCCTTGAGGCCTYTCTT
1449 >C (p.Phe53Ser) 5604 MAP2K1 ACCCAGAAGCAGAAGGTGGGA']
NM_001042465.1(PSAP):c. l055 ['GCTTTTGACAAAATGTGCTCGAAGCYGCCG
1450 T>C (p.Leu352Pro) 5660 PSAP AAGTCCCTGTCGGAAGAGTGC]
NM_000207.2(INS):c.l43T>C ['TACCTAGTGTGCGGGGAACGAGGCTBCTTCT
1451 (p.Phe48Ser) -1 - ACACACCCAAGACCCGCCGG]
NM_000311.3(PRNP):c.593T>C ['ACCACAACCACCAAGGGGGAGAACTYCACC
1452 (p.Phel98Ser) 5621 PRNP GAGACCGACGTTAAGATGATG]
NM_000371.3(TTR):c.l49T>C ['GGCAGTCCTGCCATCAATGTGGCCGBGCATG
1453 (p.Va OAla) 7276 TTR TGTTCAGAAAGGCTGCTGAT']
NM_000371.3(TTR):c.224T>C ['AGGAAAACCAGTGAGTCTGGAGAGCYGCAT
1454 (p.Leu75Pro) 7276 TTR GGGCTCACAACTGAGGAGGAA']
NM_000371.3(TTR):c.88T>C ['CACCCAGGGCACCGGTGAATCCAAGYGTCC
1455 (p.Cys30Arg) 7276 TTR TCTGATGGTCAAAGTTCTAGA']
NM_000371.3(TTR):c.272T>C ['GAATTTGTAGAAGGGATATACAAAGYGGAA
1456 (p.Val91Ala) 7276 TTR ATAGACACCAAATCTTACTGG]
1457 NM_000371.3(TTR):c.400T>C 7276 TTR ['CACCATTGCCGCCCTGCTGAGCCCCYACTCC (p.Tyrl34His) TATTCCACCACGGCTGTCGT']
NM_000371.3(TTR):c.250T>C ['GCATGGGCTCACAACTGAGGAGGAAYTTGT
1458 (p.Phe84Leu) 7276 TTR AGAAGGGATATACAAAGTGGA]
NM_000371.3(TTR):c.l57T>C ['TGCCATCAATGTGGCCGTGCATGTGHTCAGA
1459 (p.Phe53Leu) 7276 TTR AAGGCTGCTGATGACACCTG]
NM_000371.3(TTR):c.95T>C ['GGCACCGGTGAATCCAAGTGTCCTCYGATG
1460 (p.Leu32Pro) 7276 TTR GTCAAAGTTCTAGATGCTGTC]
NM_000371.3(TTR):c.l91T>C ['GCTGCTGATGACACCTGGGAGCCATYTGCCT
1461 (p.Phe64Ser) 7276 TTR CTGGGTAAGTTGCCAAAGAA']
NM_000371.3(TTR):c.265T>C ['TGAGGAGGAATTTGTAGAAGGGATAYACAA
1462 (p.Tyr89His) 7276 TTR AGTGGAAATAGACACCAAATC]
NM_000217.2(KCNAl):c. l223T ['ATTGCCCTGCCCGTACCTGTCATTGYGTCCA
1463 >C (p.Val408Ala) 3736 KCNA1 ATTTCAACTATTTCTACCAC]
NM_000174.4(GP9):c.212T>C ['CTTCAGTCCGTGCCCCCGGGAGCCTBTGACC
1464 (p.Phe71Ser) 2815 GP9 ACCTGCCCCAGCTGCAGACC]
NM_000174.4(GP9):c.l67T>C ['GCCCTGCCGGCCCGCACCCGCCACCYTCTGC
1465 (p.Leu56Pro) 2815 GP9 TGGCCAACAACAGCCTTCAG]
NM_000174.4(GP9):c.70T>C ['GGCCACCAAGGACTGCCCCAGCCCAYGTAC
1466 (p.Cys24Arg) 2815 GP9 CTGCCGCGCCCTGGAAACCAT']
NM_000174.4(GP9):c.20T>C ['TGTCCCATGCCTGCCTGGGGAGCCCYGTTCC
1467 (p.Leu7Pro) 2815 GP9 TGCTCTGGGCCACAGCAGAG]
NM_001001547.2(CD36):c.760T ['CGATTTTTAAACAGATGCAGCCTCABTTCCA
1468 >C (p.Phe254Leu) 948 CD36 CCTTTTGTTGAGAAAAGCCA']
NM_000212.2(ITGB3):c.2332T> ['CAACCCACTGTATAAAGAGGCCACGYCTAC
1469 C (p.Ser778Pro) -1 - CTTCACCAATATCACGTACCG]
NM_000212.2(ITGB3):c. l76T> ['GCTCCTGTCTTACAGGCCCTGCCTCYGGGCT
1470 C (p.Leu59Pro) 3690 ITGB3 CACCTCGCTGTGACCTGAAG']
NM_000301.3(PLG):c.l771T>C ['AGGGGGGTGTGTGGCCCACCCACATYCCTG
1471 (p.Ser591Pro) 5340 PLG GCCCTGGCAAGTCAGTCTTAG]
NM_001122757.2(POUlFl):c65 ['CAAACTGAAAGCAATATTATCCAAAYGGCT
1472 5T>C (p.Trp219Arg) 5449 POU1F1 GGAGGAAGCTGAGCAAGTAGG]
NM_000293.2(PHKB):c.2923T> ['ACCAACCCTGTCAGATATGACCATGHATGA
1473 C (p.Tyr975His) 5257 PHKB GATGAATTTCTCTCTCCTTGT']
NM_004577.3(PSPH):c.l55T>C ['CTCCCTCCTAGGACACGGCGAGCCAYGGGC
1474 (p.Met52Thr) 5723 PSPH GGGGCAGTGCCTTTCAAAGCT']
NM_000175.3 (GPI) :c .1574T>C ['CTGGGAAAGCAGCTGGCTAAGAAAABAGAG
1475 (p.Ile525Thr) 2821 GPI CCTGAGCTTGATGGCAGTGCT']
NM_000175.3 (GPI) :c .1016T>C ['TTTGGGTGTGAGACACACGCCATGCYGCCCT
1476 (p.Leu339Pro) 2821 GPI ATGACCAGTACCTGCACCGC]
NM_000478.4(ALPL) :c .1306T> ['ACGAGAGAATGTCTCCATGGTGGACYATGG
1477 C (p.Tyr436His) 249 ALPL TGAGACCTCCAGGACCCAGGG]
NM_000478.4(ALPL):c.979T>C ['GATCCTGCGGAAGAACCCCAAAGGCYTCTT
1478 (p.Phe327Leu) 249 ALPL CTTGCTGGTGGAAGGTAGGGA']
1479 NM_018849.2(ABCB4):c. l207T 5244 ABCB4 ['GGAGTTCAATGATGTTCACTTTTCTYACCCT >C (p.Tyr403His) TCTCGAGCTAACGTCAAGGT']
NM_198965.1(PTHLH):c.l79T> ['CAAGATTTACGGCGACGATTCTTCCYTCACC
1480 C (p.Leu60Pro) 5744 PTHLH ATCTGATCGCAGAAATCCAC]
NM_198965.1(PTHLH):c.l31T> ['AGAGCTGTGTCTGAACATCAGCTCCYCCATG
1481 C (p.Leu44Pro) 5744 PTHLH ACAAGGGGAAGTCCATCCAA']
NM_000315.2(PTH):c.52T>C ['AGTTATGATTGTCATGTTGGCAATTYGTTTT
1482 (p.CyslSArg) 5741 PTH CTTACAAAATCGGATGGGAA']
NM_000315.2(PTH):c.67T>C ['GTTGGCAATTTGTTTTCTTACAAAAYCGGAT
1483 (p.Ser23Pro) 5741 PTH GGGAAATCTGTTAAGTAAGT']
NM_003122.4(SPINKl):c.2T>C ['ACCTCTGGACGCAGAACTTCAGCCAYGAAG
1484 (p.MetlThr) 6690 SPINK1 GTAACAGGCATCTTTCTTCTC]
NM_003122.4(SPINKl):c.41T> ['ATCTTTCTTCTCAGTGCCTTGGCCCBGTTGA
1485 C (p.Leul4Pro) 6690 SPINK1 GTCTATCTGGTAAGTGTTGC]
NM_006194.3 (PAX9) : c.62T>C ['GGAGTGTTCGTGAACGGGAGGCCGCYGCCC
1486 (p.Leu21Pro) 5083 PAX9 AACGCCATCCGGCTTCGCATC]
NM_005188.3(CBL):c. ll l lT>C ['TTAATCAAAGGAACAATATGAATTAHACTG
1487 (p.Tyr371His) 867 CBL TGAGATGGGCTCCACATTCCA']
NM_005247.2(FGF3):c.466T>C ['CAGCGCCGAGAGACTGTGGTACGTGYCTGT
1488 (p.Serl56Pro) 2248 FGF3 GAACGGCAAGGGCCGGCCCCG]
NM_005247.2(FGF3):c.l7T>C ['GATGCCACGATGGGCCTAATCTGGCYGCTA
1489 (p.Leu6Pro) 2248 FGF3 CTGCTCAGCCTGCTGGAGCCC]
NM_000222.2(KIT) :c .1676T>C ['CCCATGTATGAAGTACAGTGGAAGGNTGTT
1490 (p.Val559Ala) 3815 KIT GAGGAGATAAATGGAAACAAT']
NM_005249.4(FOXGl):c.643T> ['CATCTACGAGTTCATCATGAAGAACYTCCCT
1491 C (p.Phe215Leu) 2290 FOXG1 TACTACCGCGAGAACAAGCA']
NM_001127500.1(MET):c.3446 ['CAATTTCTGACCGAGGGAATCATCAYGAAA
1492 T>C (p.Metl l49Thr) 4233 MET GATTTTAGTCATCCCAATGTC]
NM_020975.4(RET):c.l858T>C ['CTTCCCTGAGGAGGAGAAGTGCTTCNGCGA
1493 (p.Cys620Arg) 5979 RET GCCCGAAGACATCCAGGGTGA']
NM_020975.4(RET):c.l 900T>C ['CACAGATCCACTGTGCGACGAGCTGNGCCG
1494 (p.Cys634Arg) 5979 RET CACGGTGATCGCAGCCGCTGT']
NM_020975.4(RET):c.2753T>C ['TAGGGTCGGATTCCAGTTAAATGGAYGGCA
1495 (p.Met918Thr) 5979 RET ATTGAATCCCTTTTTGATCAT']
NM_020630.4(RET):c.l852T>C ['CAACTGCTTCCCTGAGGAGGAGAAGNGCTT
1496 (p.Cys618Arg) 5979 RET CTGCGAGCCCGAAGACATCCA']
NM_020630.4(RET):c.l825T>C ['GGGGATTAAAGCTGGCTATGGCACCNGCAA
1497 (p.Cys609Arg) 5979 RET CTGCTTCCCTGAGGAGGAGAA']
NM_013251.3(TAC3):c.269T>C ['ATGCATGACTTCTTTGTGGGACTTAYGGGCA
1498 (p.Met90Thr) 6866 TAC3 AGAGGAGCGTCCAGCCAGGT']
NM_006158.4(NEFL):c.281T>C ['ATCCGCACGCAGGAGAAGGCGCAGCYCCAG
1499 (p.Leu94Pro) 4747 NEFL GACCTCAATGACCGCTTCGCC]
NM_006177.3 (NRL) : c.479T>C ['TGCGGGCGCGACGAGGCGCTGCGGCYGAAG
1500 (p.Leul60Pro) 4901 NRL CAGAGGCGCCGCACGCTGAAG]
1501 NM_000432.3(MYL2):c.52T>C 4633 MYL2 ['AGCCGGGGGCGCCAACTCCAACGTGYTCTC (p.Phel8Leu) CATGTTCGAACAGACCCAAAT']
NM_000257.3(MYH7):c.l046T> ['TTCACTTCAGAGGAGAAAAACTCCAYGTAT
1502 C (p.Met349Thr) 4625 MYH7 AAGCTGACAGGCGCCATCATG]
NM_000257.3(MYH7):c.l594T> ['GCTTCCTCAGCCCATGGGCATCATGYCCATC
1503 C (p.Ser532Pro) 4625 MYH7 CTGGAAGAGGAGTGCATGTT']
NM_000257.3(MYH7):c.5378T> ['AACATGGAACAGACCATTAAGGACCYGCAG
1504 C (p.Leul793Pro) 4625 MYH7 CACCGGCTGGACGAAGCCGAG]
NM_001040113.1(MYHll):c.37 ['GAGGTGGAACATAAGAAGAAGAAGCYGGA
1505 91T>C (p.Leul264Pro) 4629 MYH11 GGCGCAGGTGCAGGAGCTGCAG]
NM_000530.6(MPZ):c.404T>C ['TGTGACGTCAAAAACCCTCCAGACAYAGTG
1506 (p.Ilel35Thr) 4359 MPZ GGCAAGACCTCTCAGGTCACG]
NM_000530.6(MPZ):c.341T>C ['CGCTGGAAGGATGGCTCCATTGTCAYACAC
1507 (p.Ilell4Thr) 4359 MPZ AACCTAGACTACAGTGACAAT']
NM_016835.4(MAPT):c. l839T> ['AGTCCAAGTGTGGCTCAAAGGATAAYATCA
1508 C (p.Asn613=) 4137 MAPT AACACGTCCCGGGAGGCGGCA']
NM_198159.2(MITF):c.l051T> ['GAACAAGGGAACCATCTTAAAAGCAYCCGT
1509 C (p.Ser351Pro) 4286 MITF GGACTATATCCGAAAGTTGCA']
NM_198159.2(MITF):c.l l95T> ['AATGCAGGCTCGAGCTCATGGACTTYCCCTT
1510 C (p.Ser399Pro) 4286 MITF ATTCCATCCACGGGTCTCTG]
NM_000426.3(LAMA2):c.7691T ['ACCAAGAATGAGTCCGGCATCATTCYTTTGG
1511 >C (p.Leu2564Pro) 3908 LAMA2 GAAGTGGAGGGACACCAGCA']
NM_000426.3(LAMA2):c.2584T ['ACAACCCTCTGTACCTGGAGGATCAYGTCA
1512 >C (p.Cys862Arg) 3908 LAMA2 GCCATGCCAATGCAATGACAA']
NM_002435.2(MPI):c.413T>C ['CCCGATGCCAACCACAAGCCAGAGAYGGCC
1513 (p.Metl38Thr) 4351 MPI ATTGCCCTCACCCCCTTCCAG]
NM_000239.2(LYZ):c.221T>C ['GGAGACAGAAGCACTGATTATGGGAYATTT
1514 (p.Ile74Thr) 4069 LYZ CAGATCAATAGCCGCTACTGG]
NM_000239.2(LYZ):c.244T>C ['GATATTTCAGATCAATAGCCGCTACHGGTGT
1515 (p.Trp82Arg) 4069 LYZ AATGATGGCAAAACCCCAGG]
NM_000233.3(LHCGR):c.l627T ['CAATGTGGTGGCCTTCTTCATAATTYGTGCT
1516 >C (p.Cys543Arg) -1 - TGCTACATTAAAATTTATTT']
NM_000233.3(LHCGR):c.l l93T ['AAACTTACAGTGCCTCGTTTTCTCAYGTGCA
1517 >C (p.Met398Thr) -1 - ATCTCTCCTTTGCAGACTTT']
NM_000233.3(LHCGR):c.391T> ['TCCTGTCCCTAATCACAGGAGCATCYGTAAC
1518 C (p.Cysl31Arg) -1 - ACAGGCATCAGAAAGTTTCC]
NM_000233.3(LHCGR):c.l l03T ['GACTTCCTTAGGGTCCTGATTTGGCYGATTA
1519 >C (p.Leu368Pro) -1 - ATATTCTAGCCATCATGGGA']
NM_000233.3(LHCGR):c.l505T ['TCTTCTCTAATTGCTATGTTGCCCCYTGTCGG
1520 >C (p.Leu502Pro) -1 - TGTCAGCAATTACATGAAG]
NM_170707.3(LMNA):c. l589T> ['TGCGGGAACAGCCTGCGTACGGCTCYCATC
1521 C (p.Leu530Pro) 4000 LMNA AACTCCACTGGGGAAGTAAGT']
NM_170707.3(LMNA):c. l l39T> ['GAGATCCACGCCTACCGCAAGCTCTYGGAG
1522 C (p.Leu380Ser) 4000 LMNA GGCGAGGAGGAGAGGTGGGCT']
1523 NM_002292.3(LAMB2):c.961T> 3913 LAMB2 ['CAAACACAACACACGTGGCCTCAACYGCGA C (p.Cys321Arg) GCAGTGTCAGGATTTCTATCG]
NM_000228.2(LAMB3):c.565- ['AAATCCATAAGGTTAAGTTGGACCTRCAGA
1524 3T>C 3914 LAMB 3 GGGAAGGGAAAGAGAAGCGCT']
NM_000421.3(KRT10):c.482T> ['CTGAATGACCGCCTGGCTTCCTACTYGGACA
1525 C (p.Leul61Ser) -1 - AAGTTCGGGCTCTGGAAGAA']
NM_000421.3(KRT10):c.449T> ['CTCTCTGGAAATGAAAAAGTAACCABGCAG
1526 C (p.Metl50Thr) -1 - AATCTGAATGACCGCCTGGCT']
NM_000422.2(KRT17):c.263T> ['CTGGCTGGAGGTGAGAAGGCCACCAHGCAG
1527 C (p.Met88Thr) 3872 KRT17 AACCTCAATGACCGCCTGGCC]
NM_000422.2(KRT17):c.284T> ['ACCATGCAGAACCTCAATGACCGCCHGGCC
1528 C (p.Leu95Pro) 3872 KRT17 TCCTACCTGGACAAGGTGCGT']
NM_000422.2(KRT17):c.296T> ['CTCAATGACCGCCTGGCCTCCTACCYGGACA
1529 C (p.Leu99Pro) 3872 KRT17 AGGTGCGTGCCCTGGAGGAG]
NM_005557.3(KRT16):c.395T> ['CTCAATGACCGCCTGGCCTCCTACCYGGACA
1530 C (p.Leul32Pro) 3868 KRT16 AGGTGCGTGCTCTGGAGGAG]
NM_005557.3(KRT16):c.362T> ['CTGGTGGGCAGTGAGAAGGTGACCAHGCAG
1531 C (p.Metl21Thr) 3868 KRT16 AACCTCAATGACCGCCTGGCC]
NM_000526.4(KRT14):c.l l51T ['ATGATTGGCAGCGTGGAGGAGCAGCYGGCC
1532 >C (p.Leu384Pro) 3861 KRT14 CAGCTCCGCTGCGAGATGGAG]
NM_000526.4(KRT14):c.356T> ['CTGGTGGGCAGTGAGAAGGTGACCAYGCAG
1533 C (p.Metl l9Thr) 3861 KRT14 AACCTCAATGACCGCCTGGCC]
NM_000526.4(KRT14):c.l243T ['GCGGCTGGAGCAGGAGATCGCCACCYACCG
1534 >C (p.Tyr415His) 3861 KRT14 CCGCCTGCTGGAGGGCGAGGA']
NM_153490.2(KRT13):c.356T> ['CTCAACGACCGCCTGGCTTCCTACCYGGAGA
1535 C (p.Leul l9Pro) 3860 KRT13 AGGTGCGCGCCCTGGAGGAG]
NM_002273.3 (KRT8) : c.160T>C ['CTTTCGCGGTGGCCTGGGCGGCGGCHATGGT
1536 (p.Tyr54His) 3856 KRT8 GGGGCCAGCGGCATGGGAGG]
NM_000424.3(KRT5):c.l388T> ['GAGCTCATGAACACCAAGCTGGCCCYGGAC
1537 C (p.Leu463Pro) 3852 KRT5 GTGGAGATCGCCACTTACCGC]
NM_000424.3(KRT5):c.980T>C ['TCTGACACCTCAGTGGTCCTCTCCAHGGACA
1538 (p.Met327Thr) 3852 KRT5 ACAACCGCAACCTGGACCTG]
NM_000424.3(KRT5):c.20T>C ['GCCACCATGTCTCGCCAGTCAAGTGYGTCCT
1539 (p.Val7Ala) 3852 KRT5 TCCGGAGCGGGGGCAGTCGT']
NM_000424.3(KRT5):c.541T>C ['CAAGACCCTCAACAATAAGTTTGCCYCCTTC
1540 (p.Serl81Pro) 3852 KRT5 ATCGACAAGGTGAGCTACGA']
NM_000208.2(INSR):c.779T>C ['TGCGTGGCCTGCCGCAACTTCTACCYGGACG
1541 (p.Leu260Pro) 3643 INSR GCAGGTGTGTGGAGACCTGC]
NM_000208.2(INSR) :c .164T>C ['TTGCATGAGCTGGAGAATTGCTCTGYCATCG
1542 (p.Val55Ala) 3643 INSR AAGGACACTTGCAGATACTC]
NM_002198.2(IRFl):c.31T>C ['CATCACTCGGATGCGCATGAGACCCYGGCT
1543 (p.Trpl lArg) 3659 IRF1 AGAGATGCAGATTAATTCCAA']
NM_000213.3 (ITGB4) : c.467T> ['AACCTCAAGAAGATGGGGCAGAACCYGGGT
1544 C (p.Leul56Pro) 3691 ITGB4 ACGGCAGGGCCAGAGTGGAGG]
1545 NM_000213.3 (ITGB4) : c.1684T> 3691 ITGB4 ['CCGAGGACGCTGCTCCATGGGCCAGYGTGT C (p.Cys562Arg) GTGTGAGCCTGGTTGGACAGG]
NM_000213.3(ITGB4):c. l l2T> ['CTGCAAGAAGGCCCCAGTGAAGAGCYGCAC
1546 C (p.Cys38Arg) 3691 ITGB4 GGAGTGTGTCCGTGTGGATAA]
M_000454.4(SODl):c.338T>C ['ATCTCACTCTCAGGAGACCATTGCAYCATTG
1547 (p.Ilell3Thr) 6647 SOD1 GCCGCACACTGGTGGTAAGT']
M_000454.4(SODl):c.434T>C ['AAGACAGGAAACGCTGGAAGTCGTTYGGCT
1548 (p.Leul45Ser) 6647 SOD1 TGTGGTGTAATTGGGATCGCC]
M_000454.4(SODl):c.455T>C ['CGTTTGGCTTGTGGTGTAATTGGGAYCGCCC
1549 (p.Ilel52Thr) 6647 SOD1 AATAAACATTCCCTTGGATG']
NM_001025107.2(ADAR):c. l88 ['ACCAGACTTTCTTTTTGTAGGTTTCYCTACA
1550 3T>C (p.Leu628Pro) 103 ADAR GTGAGTTAATGAAATACAAC]
NM_001025107.2(ADAR):c.260 ['TCCAAAAAGAACATTTTTCTTCTATYTAAGA
1551 9T>C (p.Phe870Ser) 103 ADAR AGCTCTGCTCCTTCCGTTAC']
NM_002185.3 (IL7R) :c .197T>C ['CCATATTTCAAATTCCAGATTGGTGRTGTTG
1552 (p.Ile66Thr) 3575 IL7R ACATCTGGGTCCTCAAAAGC]
NM_033500.2(HKl):c. l550T>C ['ACTGCAACAGAGAATGGTGACTTCTYGGCC
1553 (p.Leu517Ser) 3098 HK1 CTGGATCTTGGAGGAACCAAT']
NM_000184.2(HBG2):c.- ['CTTCCCCACACTATCTCAATGCAAAYATCTG
1554 228T>C 3048 HBG2 TCTGAAACGGTCCCTGGCTA']
NM_000184.2(HBG2):c. l25T>C ['GTTGTCTACCCATGGACCCAGAGGTYCTTTG
1555 (p.Phe42Ser) 3048 HBG2 ACAGCTTTGGCAACCTGTCC]
NM_000559.2(HBGl):c.- ['TAGCAGTATCCTCTTGGGGGCCCCTYCCCCA
1556 251T>C 3047 HBG1 CACTATCTCAATGCAAATAT']
['TCTCACAAACTAATGAAACCCTGCTYATCTT
1557 NM_000519.3(HBD):c.-127T>C 3045 HBD AAACCAACCTGCTCACTGGA']
NM_000518.4(HBB):c.257T>C ['CACCTGGACAACCTCAAGGGCACCTYTGCC
1558 (p.Phe86Ser) 3043 HBB ACACTGAGTGAGCTGCACTGT']
NM_000518.4(HBB):c.l28T>C ['GTCTACCCTTGGACCCAGAGGTTCTBTGAGT
1559 (p.Phe43Ser) 3043 HBB CCTTTGGGGATCTGTCCACT']
NM_000518.4(HBB):c.337T>C ['ACAGCTCCTGGGCAACGTGCTGGTCYGTGTG
1560 (p.Cysl l3Arg) 3043 HBB CTGGCCCATCACTTTGGCAA']
NM_000518.4(HBB):c.l27T>C ['GGTCTACCCTTGGACCCAGAGGTTCBTTGAG
1561 (p.Phe43Leu) 3043 HBB TCCTTTGGGGATCTGTCCAC']
NM_000518.4(HBB):c.332T>C ['CTCCCACAGCTCCTGGGCAACGTGCYGGTCT
1562 (p.Leull lPro) 3043 HBB GTGTGCTGGCCCATCACTTT']
['GGTGGTGAGGCCCTGGGCAGGTTGGHATCA
1563 NM_000518.4(HBB):c.92+6T>C 3043 HBB AGGTTACAAGACAGGTTTAAG]
NM_000518.4(HBB):c.344T>C ['CTGGGCAACGTGCTGGTCTGTGTGCYGGCCC
1564 (p.Leull5Pro) 3043 HBB ATCACTTTGGCAAAGAATTC]
NM_000517.4(HBA2):c.427T>C ['CACCGTGCTGACCTCCAAATACCGTNAAGCT
1565 (p.Terl43Gln) 3040 HBA2 GGAGCCTCGGTAGCCGTTCC]
NM_000517.4(HBA2):c.2T>C ['CCACAGACTCAGAGAGAACCCACCAYGGTG
1566 (p.MetlThr) 3040 HBA2 CTGTCTCCTGCCGACAAGACC]
1567 NM_000517.4(HBA2):c.89T>C 3040 HBA2 ['GCTGGCGAGTATGGTGCGGAGGCCCYGGAG (p.Leu30Pro) AGGTGAGGCTCCCTCCCCTGC]
NM_006121.3(KRTl):c.482T>C ['CAAGAAGTCACTATCAACCAGAGCCYTCTTC
1568 (p.Leul61Pro) 3848 KRT1 AGCCCCTCAATGTGGAGATT']
NM_006121.3(KRTl):c.l436T> ['ACCAAGCTGGCCCTGGATCTGGAGAYTGCC
1569 C (p.Ile479Thr) 3848 KRT1 ACCTACAGGACCCTCCTGGAG]
NM_006121.3(KRTl):c.l424T> ['GAGCTGATGAACACCAAGCTGGCCCYGGAT
1570 C (p.Leu475Pro) 3848 KRT1 CTGGAGATTGCCACCTACAGG]
NM_001077488.3(GNAS):c.299 ['AAAGTGCAGGACATCAAAAACAACCYGAAA
1571 T>C (p.LeulOOPro) 2778 GNAS GAGGCGATTGAAGTACGTGCT']
NM_000515.4(GHl):c.291+6T> ['AGGAAACACAACAGAAATCCGTGAGYGGAT
1572 C 2688 GH1 GCCTTCTCCCCAGGCGGGGAT']
NM_002087.3 (GRN) : c.2T>C ['TCCTTGGTACTTTGCAGGCAGACCAYGTGGA
1573 (p.MetlThr) 2896 GRN CCCTGGTGAGCTGGGTGGCC]
NM_021957.3(GYS2):c. l447T> ['GGTGATTTTGCACCCAGAGTTTCTAYCCTCC
1574 C (p.Ser483Pro) 2998 GYS2 ACCAGTCCCTTACTACCCAT']
NM_001083112.2(GPD2):c.1904 ['AGGTATAAGAAGAGATTTCATAAGTYTGAT
1575 T>C (p.Phe635Ser) 2820 GPD2 GCAGACCAGAAAGGCTTTATT']
NM_000340. l(SLC2A2):c.1166 ['ATCTTCATGTCAGTGGGACTTGTGCBGCTGG
1576 T>C (p.Leu389Pro) 6514 SLC2A2 TAAGTTTGGTGCCTGCACTG]
NM_005271.3(GLUDl):c.l501T ['GTGTTCTTTTCCCTAATAGGGTGCAYCTGAG
1577 >C (p.Ser501Pro) 2746 GLUD1 AAAGACATCGTGCACTCTGG]
NM_000162.3(GCK):c.391T>C ['CTTCGACTACATCTCTGAGTGCATCYCCGAC
1578 (p.Serl31Pro) 2645 GCK TTCCTGGACAAGCATCAGAT']
NM_001018077.1(NR3Cl):c. l71 ['CTCAACATGTTAGGAGGGCGGCAAGYGATT
1579 2T>C (p.Val571Ala) 2908 NR3C1 GCAGCAGTGAAATGGGCAAAG]
NM_001018077.1(NR3Cl):c.231 ['TCAAATGGAAATATCAAAAAACTTCYGTTTC
1580 8T>C (p.Leu773Pro) 2908 NR3C1 ATCAAAAGTGACTGCCTTAA']
NM_001018077.1(NR3Cl):c.220 ['GGTTGAAAATCTCCTTAACTATTGCYTCCAA
1581 9T>C (p.Phe737Leu) 2908 NR3C1 ACATTTTTGGATAAGACCAT']
NM_002055.4(GFAP):c. l055T> ['CGCCACTTGCAGGAGTACCAGGACCYGCTC
1582 C (p.Leu352Pro) 2670 GFAP AATGTCAAGCTGGCCCTGGAC]
NM_002353.2(TACSTD2):c.557 ['CGGCTCTTCCGCGAGCGCTATCGGCYGCACC
1583 T>C (p.Leul86Pro) 4070 TACSTD2 CCAAGTTCGTGGCGGCCGTG]
NM_000821.6(GGCX):c.896T> ['TTTCTCCCTGCTTTCCTAGGTATGTYCTCCTA
1584 C (p.Phe299Ser) 2677 GGCX CGTCATGCTGGCCAGCAGC]
NM_000145.3(FSHR):c.479T>C ['CAAGATAACATAAACATCCACACAAYTGAA
1585 (p.Ilel60Thr) 2492 FSHR AGAAATTCTTTCGTGGGGCTG]
NM_000145.3(FSHR):c. l634T> ['CTCAATGTCCTGGCCTTTGTGGTCAYCTGTG
1586 C (p.Ile545Thr) 2492 FSHR GCTGCTATATCCACATCTAC]
NM_182925.4(FLT4):c.3131T>C ['AGAGACCTGGCTGCTCGGAACATTCYGCTGT
1587 (p.Leul044Pro) 2324 FLT4 CGGAAAGCGACGTGGTGAAG]
NM_182925.4(FLT4):c.3257T>C ['CTGAAGTGGATGGCCCCTGAAAGCAYCTTC
1588 (p.Ilel086Thr) 2324 FLT4 GACAAGGTGTACACCACGCAG]
1589 NM_023110.2(FGFRl):c.899T> 2260 FGFR1 ['CACATCGAGGTGAATGGGAGCAAGAYTGGC C (p.Ile300Thr) CCAGACAACCTGCCTTATGTC']
NM_023110.2(FGFRl):c.1141T ['CCTGTACCTGGAGATCATCATCTATYGCACA
1590 >C (p.Cys381Arg) 2260 FGFR1 GGGGCCTTCCTCATCTCCTG]
NM_000138.4(FBNl):c.4987T> [TCCTGGAATCTGTGGTCCAGGGACAYGTTAC
1591 C (p.Cysl663Arg) 2200 FBN1 AACACCGTTGGCAACTACAC]
NM_000138.4(FBNl):c.3220T> ['CTGTTTTTGTGCAGACATTGACGAAYGCCGC
1592 C (p.Cysl074Arg) 2200 FBN1 ATATCTCCTGACCTCTGTGG]
NM_000138.4(FBNl):c.3793T> ['TATCCCTGGAGAGTACAGGTGCTTGYGTTAT
1593 C (p.Cysl265Arg) 2200 FBN1 GATGGATTCATGGCATCTGA']
NM_000043.4(FAS):c.532T>C ['ATCCAGATCTAACTTGGGGTGGCTTYGTCTT
1594 (p.Cysl78Arg) 355 FAS CTTCTTTTGCCAATTCCACT']
NM_000043.4(FAS):c.651+2T> ['CATGAATCTCCAACTTTAAATCCTGHAGGTA
1595 C 355 FAS TTGAAATAGGTATCAGCTTT']
NM_000129.3(F13Al):c.728T>C ['ATCCTGGACACTTGCCTGTATGTGAYGGACA
1596 (p.Met243Thr) 2162 F13A1 GAGCACAAATGGACCTCTCT']
NM_000186.3 (CFH) : c.1606T>C ['GCTGAATGACACATTGGACTATGAAYGCCA
1597 (p.Cys536Arg) 3075 CFH TGATGGTTATGAAAGCAATAC]
NM_000123.3(ERCC5):c.2573T ['AAGTTAATAAATTTGGCTTATTTGCYTGGAA
1598 >C (p.Leu858Pro) -1 - GTGATTATACCGAAGGAATA']
NM_000122.1(ERCC3):c.296T> ['CCAGTTTACAAATATGCCCAAGACTYCTTGG
1599 C (p.Phe99Ser) 2071 ERCC3 TGGCTATTGCAGAGCCAGTG]
NM_001113755.2(TYMP):c.854 ['CTGGGTCGCTGCGTGGGCCACGCCCYGGAG
1600 T>C (p.Leu285Pro) 1890 TYMP GTGGAGGAGGCGCTGCTCTGC]
NM_000118.3(ENG):c.2T>C ['CGCACAGGCCCCCACGTGGACAGCAYGGAC
1601 (p.MetlThr) 2022 ENG CGCGGCACGCTCCCTCTGGCT']
NM_203342.2(EPB41):c.2T>C [' AAACC AATC AGAAAAC AC AGGAAC AB GC AC
1602 (p.MetlThr) 2035 EPB41 TGCAAGGTTTCTTTGTTGGAT']
NM_001972.2(ELANE):c.211T> ['CAACTTCGTCATGTCGGCCGCGCACYGCGTG
1603 C (p.Cys71Arg) 1991 ELANE GCGAATGTGTGAGTAGCCGG]
NM_000400.3(ERCC2):c.l454T ['ACCATGGCAACCTTCACCATGACGCYGGCA
1604 >C (p.Leu485Pro) 2068 ERCC2 CGGGTCTGCCTCTGCCCTATG]
NM_000281.3(PCBDl):c.244T> ['CCACATCACGCTGAGCACCCATGAGYGTGC
1605 C (p.Cys82Arg) 5092 PCBD1 CGGCCTTTCAGAACGGGACAT']
NM_001927.3(DES):c. l034T>C ['CCCCCTCTCCTGCAGAACGATTCCCYGATGA
1606 (p.Leu345Pro) 1674 DES GGCAGATGCGGGAATTGGAG]
NM_001927.3(DES):c. ll54T>C ['CTCAAGGATGAGATGGCCCGCCATCYGCGC
1607 (p.Leu385Pro) 1674 DES GAGTACCAGGACCTGCTCAAC]
NM_000498.3(CYPl lB2):c.l l57 ['GTTCTGAAGCACCAAGTCTGAGCTCRCCACT
1608 T>C (p.Val386Ala) -1 - CGCTCCAAAAACAGACCCAC]
NM_000498.3(CYPl lB2):c.l382 ['CGGCGCCTGGCAGAGGCAGAGATGCYGCTG
1609 T>C (p.Leu461Pro) -1 - CTGCTGCACCACGTAAGCAGG]
NM_001886.2(CRYBA4):c.281T ['TACCCCGCCGAGAGGCTCACCTCCTYCCGGC
1610 >C (p.Phe94Ser) 1413 CRYBA4 CTGCGGCCTGTGCTGTAAGT']
1611 NM_001886.2(CRYBA4):c.206T 1413 CRYBA4 ['GGCTTCCAAGGGCAGCAGTACATTCYGGAA >C (p.Leu69Pro) CGAGGCGAATATCCAAGCTGG]
NM_000762.5(CYP2A6):c.670T ['GCAACCCCAGCTCTATGAGATGTTCYCTTCG
1612 >C (p.Ser224Pro) -1 - GTGATGAAACACCTGCCAGG]
NM_000165.4(GJAl):c.52T>C ['ACTCCTTGACAAGGTTCAAGCCTACYCAACT
1613 (p.Serl8Pro) 2697 GJA1 GCTGGAGGGAAGGTGTGGCT']
NM_000165.4(GJAl):c.32T>C ['GACTGGAGCGCCTTAGGCAAACTCCYTGAC
1614 (p.LeullPro) 2697 GJA1 AAGGTTCAAGCCTACTCAACT']
M_004004.5 (GJB2) :c .101 T>C ['CTCCTTTGCAGCCACAACGAGGATCVTAATG
1615 (p.Met34Thr) 2706 GJB2 CGAAAAATGAAGAGGACGGT']
M_004004.5(GJB2):c.229T>C ['CTTCCCCATCTCCCACATCCGGCTAYGGGCC
1616 (p.Trp77Arg) 2706 GJB2 CTGCAGCTGATCTTCGTGTC]
M_004004.5(GJB2):c.269T>C ['ATCTTCGTGTCCACGCCAGCGCTCCYAGTGG
1617 (p.Leu90Pro) 2706 GJB2 CCATGCACGTGGCCTACCGG]
NM_005215.3(DCC):c.503T>C ['AAGTGTGAAGTCATTGGGGAGCCCAYGCCA
1618 (p.Metl68Thr) 1630 DCC ACAATCCACTGGCAGAAGAAC]
NM_001849.3(COL6A2):c.2329 ['GAGTGAAAACCTCTACTCCATCGCCYGCGA
1619 T>C (p.Cys777Arg) 1292 COL6A2 CAAGCCACAGCAGGTGCGCAA']
NM_000090.3(COL3Al):c.582+ ['CTGGTCATCCTGGTTCCCCTGTAAGHATAGC
1620 6T>C 1281 COL3A1 CATTGGTGGTGTTTTCTTCC]
NM_000089.3(COLlA2):c.279+ ['GTTGGACTTGGCCCTGGACCAATGGYATGCT
1621 2T>C 1278 COL1A2 TATCTGTTTATCTTAGCCAA']
NM_000089.3(COLlA2):c.3105 ['TTGCAAGGTCTGCCTGGTATCGCTGYAAGTA
1622 +2T>C 1278 COL1A2 AACTGTAGCCATCTCGCACA]
NM_000088.3(COLlAl):c.4391 ['TTCGACGTTGGCCCTGTCTGCTTCCYGTAAA
1623 T>C (p.Leul464Pro) 1277 COL1A1 CTCCCTCCATCCCAACCTGG]
NM_000493.3 (COL 10 Al ) :c .184 ['AAAGGGACTCATGTTTGGGTAGGCCYGTAT
1624 1T>C (p.Leu614Pro) -1 - AAGAATGGCACCCCTGTAATG]
NM_000493.3 (COL 10 Al ) :c .177 ['TGACCCAAGGACTGGAATCTTTACTYGTCAG
1625 1T>C (p.Cys591Arg) -1 - ATACCAGGAATATACTATTT']
NM_000493.3(COL10Al):c.l95 ['CGATCTCACAGAAAATGACCAGGTGYGGCT
1626 1T>C (p.Trp651Arg) -1 - CCAGCTTCCCAATGCCGAGTC]
NM_000493.3(COL10Al):c.201 ['ATACTCCTCTGAGTATGTCCACTCCYCTTTCT
1627 1T>C (p.Ser671Pro) -1 - CAGGATTCCTAGTGGCTCC]
NM_000493.3(COL10Al):c.l79 ['TCAGATACCAGGAATATACTATTTTYCATAC
1628 8T>C (p.Ser600Pro) -1 - CACGTGCATGTGAAAGGGAC]
NM_020549.4(CHAT):c.629T>C ['ATGTATCTCAACAACCGCCTGGCCCYGCCTG
1629 (p.Leu210Pro) 1103 CHAT TCAACTCCAGCCCTGCCGTG]
NM_020549.4(CHAT):c.914T>C ['ATCATGCCGGAGCCTGAGCACGTCABCGTA
1630 (p.Ile305Thr) 1103 CHAT GCCTGCTGCAATCAGGTAAGC]
NM_020549.4(CHAT):c.l007T> ['GATCTGTTCACTCAGTTGAGAAAGAYAGTC
1631 C (p.Ile336Thr) 1103 CHAT AAAATGGCTTCCAACGAGGAC]
NM_001822.5 (CHN1 ) : c.427T>C ['TGCCAAGATGACGATAAACCCAATTYATGA
1632 (p.Tyrl43His) 1123 CHN1 GCACGTAGGATACACAACCTT']
1633 NM_001904.3(CTNNBl):c. l33T 1499 CTNNB1 ['TTCTGGTGCCACTACCACAGCTCCTBCTCTG >C (p.Ser45Pro) AGTGGTAAAGGCAATCCTGA]
NM_004056.4(CA8):c.298T>C ['ACATATATTTTCTTTTTCAGTTCTTYCGGGAG
1634 (p.SerlOOPro) 767 CA8 GACCATTGCCTCAAGGGCA]
NM_016124.4(RHD):c.329T>C ['CCTTCTGGGAAGGTGGTCATCACACYGTTCA
1635 (p.LeullOPro) 6007 RHD GGTATTGGGATGGTGGCTGG]
NM_015865.6(SLC14Al):c.871 ['CTTTGGACTCTGGGGTTTCAACAGCYCTCTG
1636 T>C (p.Ser291Pro) 6563 SLC14A1 GCCTGCATTGCAATGGGAGG]
NM_001250.5(CD40):c.247T>C ['GACACACTGCCACCAGCACAAATACYGCGA
1637 (p.Cys83Arg) 958 CD40 CCCCAGTGCGTGCGCTGTTGG]
NM_000342.3(SLC4Al):c.2317 ['AGTGTGCGGCTCCCCCACAGGCCTGYCCATC
1638 T>C (p.Ser773Pro) 6521 SLC4A1 CTCATGGAGCCCATCCTGTC]
NM_001681.3 (ATP2 A2) :c .1678 ['GGGTAGTGGCAGCGACACACTGCGAYGCCT
1639 T>C (p.Cys560Arg) 488 ATP2A2 GGCCCTGGCCACTCATGACAA']
NM_001082971.1(DDC):c.925T ['TCCCCACAAATGGCTATTGGTGAATYTTGAC
1640 >C (p.Phe309Leu) 1644 DDC TGTTCTGCCATGTGGTAAGT']
NM_031226.2(CYP19Al):c.743 ['ATACAAAAAGTATGAGAAGTCTGTGYAAGT
1641 +2T>C -1 - AATACAACTTTGGAAGATTTA']
NM_000486.5 (AQP2) : c.646T>C ['ACCCCTGGTGGGCGCCATCCTGGGCYCCCTC
1642 (p.Ser216Pro) -1 - CTCTACAACTACGTGCTGTT']
NM_000041.3 (APOE) : c.388T>C ['GCTGGGCGCGGACATGGAGGACGTGYGCGG
1643 (p.Cysl30Arg) 348 APOE CCGCCTGGTGCAGTACCGCGG]
NM_000041.3 (APOE) : c.137T>C ['TGGCAGAGCGGCCAGCGCTGGGAACYGGCA
1644 (p.Leu46Pro) 348 APOE CTGGGTCGCTTTTGGGATTAC]
NM_000039.1(APOAl):c.220T> ['CTCCAGCCTAAAGCTCCTTGACAACYGGGA
1645 C (p.Trp74Arg) -1 - CAGCGTGACCTCCACCTTCAG]
NM_000039.1(APOAl):c.341T> ['CTGAGGCAGGAGATGAGCAAGGATCYGGAG
1646 C (p.Leul l4Pro) -1 - GAGGTGAAGGCCAAGGTGCAG]
NM_000039.1(APOAl):c.593T> ['TACAGCGACGAGCTGCGCCAGCGCTYGGCC
1647 C (p.Leul98Ser) 335 APOAl GCGCGCCTTGAGGCTCTCAAG]
NM_000416.2(IFNGRl):c.260T ['AATATTTCTCATCATTATTGTAATAYTTCTG
1648 >C (p.Ile87Thr) 3459 IFNGR1 ATCATGTTGGTGATCCATCA]
NM_000488.3 (SERPINC 1 ) : c.114 ['TGTCGATCTGTTCAGCCCTGAAAAGYCCAAA
1649 1T>C (p.Ser381Pro) 462 SERPINC 1 CTCCCAGGTTTGTCTAGGAA']
NM_000488.3 (SERPINC 1 ) : c.442 ['GTTTGACACCATATCTGAGAAAACAYCTGAT
1650 T>C (p.Serl48Pro) 462 SERPINC 1 CAGATCCACTTCTTCTTTGC]
NM_000488.3 (SERPINC 1 ) : c.68 ['AAGGTTTATCTTTTGTCCTTGCTGCYCATTG
1651 T>C (p.Leu23Pro) 462 SERPINC 1 GCTTCTGGGACTGCGTGACC]
NM_000488.3 (SERPINC 1 ) : c.667 ['CAGAGCGGCCATCAACAAATGGGTGYCCAA
1652 T>C (p.Ser223Pro) 462 SERPINC 1 TAAGACCGAAGGCCGAATCAC]
NM_000488.3(SERPINCl):c379 ['TTTTGCTATGACCAAGCTGGGTGCCYGTAAT
1653 T>C (p.Cysl27Arg) 462 SERPINC 1 GACACCCTCCAGCAACTGAT']
NM_001085.4(SERPINA3):c23 ['GATAAGAATGTCATCTTCTCCCCACYGAGCA
1654 3T>C (p.Leu78Pro) 12 SERPINA3 TCTCCACCGCCTTGGCCTTC]
1655 NM_000341.3(SLC3Al):c. l400 6519 SLC3A1 ['AATCAGTATGTCAACGTGATGAACAHGCTTC T>C (p.Met467Thr) TTTTCACACTCCCTGGAACT']
NM_000341.3(SLC3Al):c.2033 ['AATCGAGCATGCTATTCCAGTGTACYGAAC
1656 T>C (p.Leu678Pro) -1 - ATACTGTATACCTCGTGTTAG]
NM_000021.3(PSENl):c.749T> ['CCTGAATGGACTGCGTGGCTCATCTYGGCTG
1657 C (p.Leu250Ser) 5663 PSEN1 TGATTTCAGTATATGGTAAA']
NM_000021.3(PSENl):c.338T> ['TTTTATACCCGGAAGGATGGGCAGCYGTAC
1658 C (p.Leul l3Pro) 5663 PSEN1 GTATGAGTTTTGTTTTATTAT']
NM_000021.3(PSENl):c.497T> ['CTTTTCTAGGTCATCCATGCCTGGCBTATTAT
1659 C (p.Leul66Pro) 5663 PSEN1 ATCATCTCTATTGTTGCTG]
NM_000021.3(PSENl):c.254T> ['TATGGCGCCAAGCATGTGATCATGCYCTTTG
1660 C (p.Leu85Pro) 5663 PSEN1 TCCCTGTGACTCTCTGCATG]
NM_001151.3(SLC25A4):c.293 ['GCCTTCAAGGACAAGTACAAGCAGCYCTTC
1661 T>C (p.Leu98Pro) 291 SLC25A4 TTAGGGGGTGTGGATCGGCAT']
NM_001100.3(ACTAl):c.287T> ['TGGCACCACACCTTCTACAACGAGCYTCGCG
1662 C (p.Leu96Pro) 58 ACTA1 TGGCTCCCGAGGAGCACCCC]
NM_001100.3(ACTAl):c.668T> ['AAGGAGAAGCTGTGCTACGTGGCCCYGGAC
1663 C (p.Leu223Pro) 58 ACTA1 TTCGAGAACGAGATGGCGACG]
NM_000485.2(APRT):c.407T>C ['CTCACCCTCCCATCCCCAGGAACCAYGAAC
1664 (p.Metl36Thr) 353 APRT GCTGCCTGTGAGCTGCTGGGC]
NM_000485.2(APRT):c.329T>C ['CACCACTTCCCACTCCAGGCTGAGCYGGAG
1665 (p.LeullOPro) 353 APRT ATTCAGAAAGACGCCCTGGAG]
NM_001614.3(ACTGl):c.l l09T ['TACGACGAGTCGGGCCCCTCCATCGYCCACC
1666 >C (p.Val370Ala) 71 ACTG1 GCAAATGCTTCTAAACGGAC]
NM_000751.2(CHRND):c.283T ['CCGGCTGAAGTGGAATGCTGAAGAAYTTGG
1667 >C (p.Phe95Leu) 1144 CHRND AAACATCAGTGTCCTGCGCCT']
NM_000751.2(CHRND):c.l88T ['GCCCTGGCCCTCACACTCTCCAACCYCATCT
1668 >C (p.Leu63Pro) 1144 CHRND CCCTGGTGAGAGGCCCTCCG]
NM_001039523.2(CHRNAl):c.9 ['CTCTGTCTTACTGTCTTTGACTGTGYTCCTTC
1669 01T>C (p.Phe301Leu) 1134 CHRNA1 TGGTCATCGTGGAGCTGAT']
NM_001004127.2(ALGl l):c.257 44013 ['GGAGAAAGAGTTTTATGGTGTGCTTYAAGA
1670 T>C (p.Leu86Ser) 8 ALG11 GCCCTGCAGAAAAAGTAGGTA']
['AGAGGGAGCTAGGAGGCTAGCATAGRAAGG
AGARAAGGAAAAAGACTTTGA',
'TATAAAGACTGAGGGGCAAACAGCASGGGA
AATGAGGGGCATAGGGATAAG,
'CGCAGACAGAAGGGCTGGGACGGCTRTCAG
1671 CGCCTGTGCTTCCAAGRTAAG,
NM_002036.3(ACKRl):c.- ATCAGGAAGCCTTACCCCACGCCCAYTGCCT 1674 67T>C 2532 ACKR1 GCACAAGCCTCAGGCCTATG]
NM_014053.3(FLVCRl):c.574T ['CAACTGCCTGGGTGCCTGGATCAAGYGCGG
1675 >C (p.Cysl92Arg) 28982 FLVCR1 CAGTGTGCAGCAGCATCTCTT']
NM_004268.4(MED17):c.1112T ['TGTCCGGAGGACCACCTTTATGTCCYAGAGC
1676 >C (p.Leu371Pro) 9440 MED17 ATAATTTGCATCTACTGATT']
1677 NM_024411.4(PDYN):c.632T>C 5173 PDYN ['CTGTACAAACGCTATGGGGGCTTCTYGCGGC (p.Leu211Ser) GCATTCGTCCCAAGCTCAAG']
NM_000018.3 (ACAD VL) :c .848 ['GTGAAGGAGAAGATCACAGCTTTTGYGGTG
1678 T>C (p.Val283Ala) 37 ACADVL GAGAGGGGCTTCGGGGGCATT']
NM_000021.3(PSENl):c.l l75T> ['GGAGATTTCATTTTCTACAGTGTTCYGGTTG
1679 C (p.Leu392Pro) 5663 PSEN1 GTAAAGCCTCAGCAACAGCC]
NM_000083.2(CLCNl):c.857T> ['CCACACTTCTGTGCCCCTGCAGGAGYGCTAT
1680 C (p.Val286Ala) 1180 CLCN1 TTAGCATCGAGGTCACCTCC]
NM_000083.2(CLCNl):c.920T> ['GTTCGGAACTACTGGAGAGGATTCTYTGCA
1681 C (p.Phe307Ser) 1180 CLCN1 GCCACGTTCAGCGCCTTTGTG]
NM_000157.3(GBA):c.703T>C ['CAATGGAGCGGTGAATGGGAAGGGGYCACT
1682 (p.Ser235Pro) 2629 GBA CAAGGGACAGCCCGGAGACAT']
NM_000166.5(GJBl):c.l45T>C ['AGAGAGTGTGTGGGGTGATGAGAAAYCTTC
1683 (p.Ser49Pro) 2705 GJB1 CTTCATCTGCAACACACTCCA]
['ATATCCCCGTTTACACACAAATTCARCTGAT TCACCTGTTCTCGAATAAAG',
1684 'GAACTTATCATTGCTGCTTTTGATTaagatattggtc
NM_000186.3 (CFH) : c.3590T>C aaagagtacaaact',
1686 (p.Vall l97Ala) 3075 CFH 'ttcagctataatatgaataagaacttggaatcaaacatagagatctagtga']
NM_000195.4(HPSl):c.2003T> ['GGGGATGACAGACAGGTGCAGGGCCRGCAG
1687 C (p.Leu668Pro) 3257 HPS1 CTCGTAGCACCTGACAGCCTC]
NM_000195.4(HPSl):c.716T>C ['GCTGGGGTAGAGGTCCTGAACCAGGRGGAT
1688 (p.Leu239Pro) 3257 HPS1 GAGGGCAAGCAGGTCGGCCGG]
NM_000334.4(SCN4A):c.4468T ['CCTCTTCAACATCGGCCTCCTCCTCYTCCTG
1689 >C (p.Phel490Leu) 6329 SCN4A GTCATGTTCATCTACTCCAT']
NM_000352.4(ABCC8):c.257T> ['ACCTTCATGCTGCTCTTCGTCCTGGBGTGTG
1690 C (p.Val86Ala) 6833 ABCC8 AGATTGCAGAGGGCATCCTG]
NM_000352.4(ABCC8):c.404T> ['ATCGAGACTTCCAACTTCCCCAAGCYGCTAA
1691 C (p.Leul35Pro) 6833 ABCC8 TTGGTAGGTGAGGTGTAGGA']
NM_000352.4(ABCC8):c.674T> ['TTCCTGCAGCCCTTCGTGAATCTGCYGTCCA
1692 C (p.Leu225Pro) 6833 ABCC8 AAGGCACCTACTGGTGGATG]
NM_000430.3(PAFAHlBl):c56 PAFAHIB ['ATTACTTCATAATATATTGCTGTTAYGTGTTT
1693 9-10T>C 5048 1 TAGGCCATGACCACAATGT']
NM_000525.3(KCNJll):c.l03T ['CCGTGCCCGCCAGCGGAGGGCCCGCBTTGT
1694 >C (p.Phe35Leu) 3767 KCNJ11 GTCCAAGAAAGGCAACTGCAA']
NM_000525.3(KCNJll):c.755T ['GTGGGTGGCAACAGCATCTTCCTGGYGGCC
1695 >C (p.Val252Ala) 3767 KCNJ11 CCGCTGATCATCTACCATGTC]
NM_000528.3(MAN2Bl):c2426 ['GGCAGCAGCCTGAGAGATGGCTCGCYGGAG
1696 T>C (p.Leu809Pro) 4125 MAN2B1 CTCATGGTGAGTGGGTCAGAG]
NM_001034850.2(FAM134B):c. ['GACTTTTCAGCTCTTTGTCCTAAGGYATTTTT
1697 873+2T>C 54463 FAM134B TGTTTAGTTTTCAATTTGT']
NM_001457.3(FLNB):c.4804T> ['CTACGGGGGTGACGACATCCCACTTYCTCCT
1698 C (p.Serl602Pro) 2317 FLNB TATCGCATCCGAGCCACACA']
NM_002863.4(PYGL):c.2461T> ['CTCCAGTGACCGAACAATTAAAGAAYATGC
1699 C (p.Tyr821His) 5836 PYGL CCAAAACATCTGGAACGTGGA'] NM_003002.3(SDHD):c.284T>C ['CCTTGCTCTGCGATGGACTATTCCCYGGCTG
1700 (p.Leu95Pro) 6392 SDHD CAGCCCTCACTCTTCATGGT']
NM_004385.4(VCAN):c.4004- ['TAAGTATTGTGAAAACTCTGTTTTTHTCAGG
1701 5T>C 1462 VCAN TCGAATGAGTGATTTGAGTG']
NM_004519.3(KCNQ3):c.925T> ['TGAGACCTATGCAGATGCCCTGTGGYGGGG
1702 C (p.Trp309Arg) 3786 KCNQ3 CCTGGTGAGTCACTACCTTGG]
NM_004937.2(CTNS):c.473T>C ['TCCACCCCCTGCAGTGTCATTGGTCYGAGCT
1703 (p.Leul58Pro) 1497 CTNS TCGACTTCGTGGCTCTGAAC]
NM_006329.3(FBLN5):c.649T> ['GAACGAGTGTGCCACCGAGAACCCCYGCGT
1704 C (p.Cys217Arg) 10516 FBLN5 GCAAACCTGCGTCAACACCTA]
NM_006432.3(NPC2):c.295T>C ['TGATGGTTGTAAGAGTGGAATTAACYGCCCT
1705 (p.Cys99Arg) 10577 NPC2 ATCCAAAAAGACAAGACCTA]
NM_007375.3(TARDBP):c.*83T ['CATGGTAAGTATATTGTAAAATACAYATGTA
1706 >C 23435 TARDBP CTAAGAATTTTCAAAATTGG']
NM_013246.2(CLCFl):c.46T>C ['CTCGTGGGGGATGTTAGCGTGCCTGYGCAC
1707 (p.Cysl6Arg) -1 - GGTGCTCTGGCACCTCCCTGC]
NM_013246.2(CLCFl):c.676T> ['CCTGCACCTGGGGGCTCATGGCTTCYGACTT
1708 C (p.Ter226Arg) -1 - CTGACCTTCTCCTCTTCGCT']
NM_024577.3(SH3TC2):c.l982 ['CTGCCCTTTGCCGAGCGCCTGCAGCYCCTCT
1709 T>C (p.Leu661Pro) 79628 SH3TC2 CTGGACACCCTCCTGCCTCT']
NM_172107.2(KCNQ2):c.2T>C ['CCGGGGCGCCTCCCGCCAGGCACCAYGGTG
1710 (p.MetlThr) 3785 KCNQ2 CAGAAGTCGCGCAACGGCGGC]
M_004304.4(ALK):c.3749T>C ['TGCATTTCCTTTCTTCCCAGAGACAYTGCTG
1711 (p.Ilel250Thr) 238 ALK CCAGAAACTGCCTCTTGACC]
NM_000495.4(COL4A5):c.4690 ['TTCCTTCTCCTTTTCCTTTACCAGAYGTGCAG
1712 T>C (p.Cysl564Arg) 1287 COL4A5 TATGTGAAGCTCCAGCTGT']
NM_000495.4(COL4A5):c.4699 ['CTTTTCCTTTACCAGATGTGCAGTAYGTGAA
1713 T>C (p.Cysl567Arg) 1287 COL4A5 GCTCCAGCTGTGGTGATCGC]
NM_000495.4(COL4A5):c.4756 ['CAGTCAGACGATCCAGATTCCCCATYGTCCT
1714 T>C (p.Cysl586Arg) 1287 COL4A5 CAGGGATGGGATTCTCTGTG]
NM_000495.4(COL4A5):c.4803 ['TAAGAAGCTTAAACTTCAAACAGCTYCTATC
1715 +121T>C 1287 COL4A5 CAAGCACTGTGTTCCCCCTC]
NM_000495.4(COL4A5):c.5032 ['AGACTTGAGGACACGAATTAGCCGAYGTCA
1716 T>C (p.Cysl678Arg) 1287 COL4A5 AGTGTGCATGAAGAGGACATA']
NM_005359.5(SMAD4):c.970T> ['ATTTCCTATAGCTCCTGAGTATTGGYGTTCC
1717 C (p.Cys324Arg) 4089 SMAD4 ATTGCTTACTTTGAAATGGA']
NM_005359.5(SMAD4):c. l087T ['GGACCCTTCTGGAGGAGATCGCTTTYGTTTG
1718 >C (p.Cys363Arg) 4089 SMAD4 GGTCAACTCTCCAATGTCCA']
NM_005359.5(SMAD4):c. l598T ['ATTGAAATTCACTTACACCGGGCCCBCCAGC
1719 >C (p.Leu533Pro) 4089 SMAD4 TCCTAGACGAAGTACTTCAT']
NM_020630.4(RET):c.l831T>C ['TAAAGCTGGCTATGGCACCTGCAACNGCTTC
1720 (p.Cys611Arg) 5979 RET CCTGAGGAGGAGAAGTGCTT']
NM_020630.4(RET):c.l888T>C ['ACCACCCCCACCCACAGATCCACTGYGCGA
1721 (p.Cys630Arg) 5979 RET CGAGCTGTGCCGCACGGTGAT'] NM_000060.3(BTD):c.248T>C ['GCTCTCATCAGCCGCCAAGAGGCCTYGGAG
1722 (p.Leu83Ser) 686 BTD CTCATGAACCAGAACCTTGAC]
NM_000060.3(BTD):c.445T>C ['GAACCCATGCCTGGAGCCTCACCGCYTCAAT
1723 (p.Phel49Leu) 686 BTD GACACAGAGGTGATTCCTGC]
NM_000060.3(BTD):c.743T>C ['TTTGGCATCTTCACATGCTTTGATAYATTGTT
1724 (p.Ile248Thr) 686 BTD CTTTGACCCTGCCATCAGA']
NM_000060.3 (BTD) : c.764T>C ['GATATATTGTTCTTTGACCCTGCCAYCAGAG
1725 (p.Ile255Thr) 686 BTD TCCTCAGAGACTACAAGGTG]
NM_000060.3(BTD):c.833T>C ['ACTGCCTGGATGAACCAGCTCCCACYCTTGG
1726 (p.Leu278Pro) 686 BTD CAGCAATTGAGATTCAGAAA']
NM_000060.3(BTD):c. l096T>C ['CCATAGTAAGTTTTTAAAAATTTTGYCAGGC
1727 (p.Ser366Pro) 686 BTD GATCCGTACTGTGAGAAGGA']
NM_000060.3(BTD):c. l214T>C ['GAGATGATGTATGACAATTTCACCCYGGTCC
1728 (p.Leu405Pro) 686 BTD CTGTCTGGGGAAAGGAAGGC]
NM_000060.3(BTD):c. l252T>C ['GGGAAAGGAAGGCTATCTCCACGTCYGTTC
1729 (p.Cys418Arg) 686 BTD CAATGGCCTCTGCTGTTATTT']
NM_000060.3(BTD):c. l267T>C ['TCTCCACGTCTGTTCCAATGGCCTCYGCTGT
1730 (p.Cys423Arg) 686 BTD TATTTACTTTACGAGAGGCC]
NM_000060.3(BTD):c. l459T>C ['CACGGGGATATTTGAGTTTCACCTGYGGGGC
1731 (p.Trp487Arg) 686 BTD AACTTCAGTACTTCCTATAT']
NM_000155.3(GALT):c.265T>C ['TCCTTGTCGGTAGGTGAATCCCCAGBACGAT
1732 (p.Tyr89His) 2592 GALT AGCACCTTCCTGTTTGACAA']
NM_000155.3(GALT):c.328+2T ['TGCAGCCTGATGCCCCCAGTCCAGGYAACCT
1733 >C 2592 GALT GGCTCCAACTGCTGCTGGGG]
NM_000155.3(GALT):c.336T>C ['GATACTCCTTTACCTCAGGACCCAGYGATCA
1734 (p.Serl l2=) 2592 GALT TCCCCTTTTCCAAGCAAAGT']
NM_000155.3(GALT):c.350T>C ['TCAGGACCCAGTGATCATCCCCTTTYCCAAG
1735 (p.Phel l7Ser) 2592 GALT CAAAGTCTGCTCGAGGAGTC]
NM_000155.3 (GALT) :c .374T>C ['TTCCAAGCAAAGTCTGCTCGAGGAGYCTGG
1736 (p.Vall25Ala) 2592 GALT TAACTATGGATTTCCCCTCTT']
NM_000155.3(GALT):c.425T>C ['TGGTCGGATGTAACGCTGCCACTCAHGTCGG
1737 (p.Metl42Thr) 2592 GALT TCCCTGAGATCCGGGCTGTT']
NM_000155.3(GALT):c.452T>C ['TCGGTCCCTGAGATCCGGGCTGTTGYTGATG
1738 (p.Vall51Ala) 2592 GALT CATGGGCCTCAGTCACAGAG]
NM_000155.3(GALT):c.460T>C ['TGAGATCCGGGCTGTTGTTGATGCABGGGCC
1739 (p.Trpl54Arg) 2592 GALT TCAGTCACAGAGGAGCTGGG]
NM_000155.3(GALT):c.482T>C ['GCATGGGCCTCAGTCACAGAGGAGCYGGGT
1740 (p.Leul61Pro) 2592 GALT GCCCAGTACCCTTGGGTGCAG]
NM_000155.3(GALT):c.499T>C ['AGAGGAGCTGGGTGCCCAGTACCCTYGGGT
1741 (p.Trpl67Arg) 2592 GALT GCAGGTTTGTGAGGTCGCCCC]
NM_000155.3(GALT):c.507+2T ['GGTGCCCAGTACCCTTGGGTGCAGGYTTGTG
1742 >C 2592 GALT AGGTCGCCCCTTCCCCTGGA']
NM_000155.3(GALT):c.509T>C ['GAGCTCCGTATCCCTATCTGATAGAHCTTTG
1743 (p.Ilel70Thr) 2592 GALT AAAACAAAGGTGCCATGATG] ΝΜ_000155.3 (GALT) :c .584T>C ['TGACAGGTATGGGCCAGCAGTTTCCYGCCA
1744 (p.Leul95Pro) 2592 GALT GATATTGCCCAGCGTGAGGAG]
NM_000155.3(GALT):c.650T>C ['TATAAGAGTCAGCATGGAGAGCCCCYGCTA
1745 (p.Leu217Pro) 2592 GALT ATGGAGTACAGCCGCCAGGAG]
NM_000155.3(GALT):c.677T>C ['CTAATGGAGTACAGCCGCCAGGAGCYACTC
1746 (p.Leu226Pro) 2592 GALT AGGAAGGTGGGAGAGAGCCAA']
NM_000155.3(GALT):c.687+2T ['AGCCGCCAGGAGCTACTCAGGAAGGYGGGA
1747 >C 2592 GALT GAGAGCCAAGCCCTGTGTCCC]
NM_000155.3(GALT):c.745T>C ['AGTACTGGTCCCCTTCTGGGCAACAYGGCCC
1748 (p.Trp249Arg) 2592 GALT TACCAGACACTGCTGCTGCC]
NM_000155.3 (GALT) :c .967T>C ['CCATTGGCAGCTGCACGCTCATTACBACCCT
1749 (p.Tyr323His) 2592 GALT CCGCTCCTGCGCTCTGCCAC]
NM_000155.3(GALT):c.980T>C ['CACGCTCATTACTACCCTCCGCTCCYGCGCT
1750 (p.Leu327Pro) 2592 GALT CTGCCACTGTCCGGAAATTC]
NM_000155.3 (GALT) :c.1138T> ['GGACAGGGAGACAGCAACCATCGCCYGACC
1751 C (p.Ter380Arg) 2592 GALT ACGCCGACCACAGGGCCTTGA']
NM_207346.2(TSEN54):c.277T 28398 ['AGAAGAGGGCTTCGTGGAGTTGAAGYCTCC
1752 >C (p.Ser93Pro) 9 TSEN54 CGCGGTGAGCGGCGGGCTCGG]
NM_016269.4(LEFl):c.l81T>C ['CATCAAGTCTTCCTTGGTGAACGAGYCTGAA
1753 (p.Ser61Pro) -1 - ATCATCCCGGCCAGCAACGG]
NM_001928.2(CFD) : c.640T>C ['GGGTGACTCCGGGGGCCCGCTGGTGYGCGG
1754 (p.Cys214Arg) 1675 CFD GGGCGTGCTCGAGGGCGTGGT']
NM_001458.4(FLNC):c.752T>C ['CCCAACGTGGATGAGCATTCTGTTAYGACCT
1755 (p.Met251Thr) 2318 FLNC ACCTGTCCCAGTTCCCCAAG']
NM_000781.2(CYPl lAl):c.665 ['ATTTTTGGGGAGCGCCAGGGGATGCYGGAG
1756 T>C (p.Leu222Pro) 1583 CYP11A1 GAAGTAGTGAACCCCGAGGCC]
['ATAATAATGATGGTTGccaacatgcgctgagtgcttaaaa tgtgccaggta',
'ataaataggtaaagggctttagaattgtgcaccatactcacaaccaccctg'
'cgcagcagattctgttattaaaccccttttacagacgaagttgaggctcac', 'agagattatgtaactcactcaagacaacacagataaaagatgaaactgaat
1757
NM_000782.4(CYP24Al):c.l22 ACAAATTCTACTTACTCCTTTGGGTRAAGCAT 1761 6T>C (p.Leu409Ser) 1591 CYP24A1 ATTCACCCAGAACTGTTGC]
NM_001145661.1 (GAT A2) :c .11 ['CAACGGGGACCCTGTCTGCAACGCCYGTGG
1762 17T>C (p.Cys373Arg) 2624 GATA2 CCTCTACTACAAGCTGCACAA']
NM_004523.3(KIFl l):c.2547+2 ['CAGGAACTTCACAACTTATTGGAGGYAATA
1763 T>C 3832 KIF11 ACTTTGTAAGTGGAACTTACT']
NM_000238.3 (KCNH2) : c.1831 T ['GGGCGGCCCCTCCATCAAGGACAAGBATGT
1764 >C (p.Tyr611His) 3757 KCNH2 GACGGCGCTCTACTTCACCTT']
NM_002465.3(MYBPCl):c.706T ['GGAGGAAGAACCCCAGGTGGACGTAYGGGA
1765 >C (p.Trp236Arg) 4604 MYBPC1 GTTGCTGAAGAACGCGAAACC]
1766 NM_002465.3(MYBPCl):c2566 4604 MYBPC1 ['CATTCCAAGACACCTGAAGCAAACCYATAT T>C (p.Tyr856His) CCGCAGAGTTGGAGAAGCTGT']
NM_005211.3(CSFlR):c.2624T> ['AAACTGGTGAAGGATGGATACCAAAYGGCC
1767 C (p.Met875Thr) 1436 CSF1R CAGCCTGCATTTGCCCCAAAG]
NM_005211.3(CSFlR):c.2381T> [TTGACCAATGGTCATGTGGCCAAGAYTGGG
1768 C (p.Ile794Thr) 1436 CSF1R GACTTCGGGCTGGCTAGGGAC]
NM_003392.4(WNT5A):c.544T ['GCCGCGGGACTGGCTCTGGGGCGGCYGCGG
1769 >C (p.Cysl82Arg) 7474 WNT5A CGACAACATCGACTATGGCTA]
NM_005188.3(CBL):c. ll50T>C ['CTCCACATTCCAACTATGTAAAATABGTGCT
1770 (p.Cys384Arg) 867 CBL GAAAATGATAAGGATGTAAA]
NM_005188.3 (CBL) : c.1186T>C ['TGATAAGGATGTAAAGATTGAGCCCYGTGG
1771 (p.Cys396Arg) 867 CBL ACACCTCATGTGCACATCCTG]
NM_006902.4(PRRXl):c.338T> ['CAGCTGCAGGCTTTGGAGCGTGTCTYTGAGC
1772 C (p.Phel l3Ser) 5396 PRRX1 GGACACACTATCCTGATGCT']
NM_001111035.1(ACP5):c.602T ['GCGGCGGCCAGGGAGGACTACGTGCYGGTG
1773 >C (p.Leu201Pro) -1 - GCTGGCCACTACCCCGTGTGG]
NM_000329.2(RPE65):c.l l02T> ['GGCTCCCCAACCTGAAGTTAGGAGAYATGT
1774 C (p.Tyr368His) 6121 RPE65 ACTTCCTTTGAATATTGACAA']
NM_003172.3(SURFl):c.679T> ['TGAGAACAATCCAGAAAGGAACCACYGGCA
1775 C (p.Trp227Arg) 6834 SURF1 TTATCGAGACCTGGAAGCTAT']
NM_002734.4(PRKAR1 A):c.111 ['CATCCTCAAACGAAACATCCAGCAGYACAA
1776 7T>C (p.Tyr373His) 5573 PRKAR1A CAGTTTTGTGTCACTGTCTGT']
NM_002734.4(PRKARlA):c.980 ['CCATCTTTGCTTTCTCCAGGTGAAAYTGCAC
1777 T>C (p.Ile327Thr) 5573 PRKAR1A TACTGATGAATCGTCCTCGT']
NM_003491.3(NAA10):c.l09T> ['GAAATACTACTTCTACCATGGCCTTYCCTGG
1778 C (p.Ser37Pro) 8260 NAA10 CCCCAGGTGGGCAGCTTCTG]
NM_006306.3(SMClA):c.2351T ['GTGTTTGAAGAGTTTTGTCGGGAGAYTGGTG
1779 >C (p.Ile784Thr) 8243 SMC1A TGCGCAACATCCGGGAGTTT']
NM_000377.2(WAS):c.814T>C ['CGACCCAGATCTGCGGAGTCTGTTCYCCAGG
1780 (p.Ser272Pro) 7454 WAS GCAGGAATCAGCGAGGCCCA]
NM_000377.2(WAS):c.881T>C ['ACCTCTAAACTTATCTACGACTTCAYTGAGG
1781 (p.Ile294Thr) 7454 WAS ACCAGGGTGGGCTGGAGGCT']
['TTGGTGCAACTCCAAATAAAAGTAAYAACC
1782 m.l2338T>C 4540 MT-ND5 ATGCACACTACTATAACCACC]
[TCGAATTTGCAATTCAATATGAAAAYCACCT
1783 m.5814T>C 4511 MT-TC CGGAGCTGGTAAAAAGAGGC]
['GACAACAGAGGCTTACGACCCCTTAYTTACC
1784 m.l2201T>C 4564 MT-TH GAGAAAGCTCACAAGAACTG]
NM_001165899.1(PDE4D):c494 ['GGAGATGACTTGATTGTGACTCCATBTGCTC
1785 T>C (p.Phel65Ser) 5144 PDE4D AGGTAAGCACAGCTTGGTGA]
NM_139125.3(MASPl):c. l888T ['GTTACCCGTGGTGCCTCACGCTGAGYGCAA
1786 >C (p.Cys630Arg) 5648 MASP1 AACTAGCTATGAGTCCCGCTC]
NM_007315.3(STATl):c.520T> ['TTTACAAGATGAATATGACTTCAAAYGCAA
1787 C (p.Cysl74Arg) 6772 STAT1 AACCTTGCAGAACAGAGGTAA']
1788 NM_053025.3(MYLK):c.5275T> -1 - ['TGCTGTGAGAGCCATTGGAAGACTGYCCTCT C (p.Serl759Pro) ATGGCAATGATCTCAGGGCT']
NM_001235.3(SERPINHl):c.23 ['TCACCCGTGGTGGTGGCCTCGTCGCYAGGGC
1789 3T>C (p.Leu78Pro) 871 SERPINHl TCGTGTCGCTGGGCGGCAAG]
NM_005921.1(MAP3Kl):c.566T ['GAGGAACGAATGATCAGGGAGAAACBGAA
1790 >C (p.Leul89Pro) 4214 MAP3K1 GGCAACCTGTATGCCAGCCTGG]
NM_005359.5(SMAD4):c. l499T ['GTTGATGACCTTCGTCGCTTATGCAYACTCA
1791 >C (p.Ile500Thr) 4089 SMAD4 GGATGAGTTTTGTGAAAGGC]
NM_000287.3 (PEX6) : c.1601 T> ['CTGTTGCTCACAGCTGTGGACCTTCYGGGCC
1792 C (p.Leu534Pro) 5190 PEX6 GGGACCGTGATGGGCTGGGT']
NM_004153.3 (ORC 1 ) : c.266T>C ['AAGAAACGTGCTCGAGTACAGTGGTYTGTC
1793 (p.Phe89Ser) 4998 ORC1 CGATTCTGTGAAGTCCCTGCC]
NM_006225.3(PLCDl):c.562T> ['CTCGGCTGTCCTGGCTCTGCAGGAGYGTGAC
1794 C (p.Cysl88Arg) 5333 PLCD1 CACTCCCAGACAGACTCCCT']
NM_021252.4(RAB18):c.619T> ['CTGTGGTGGTTATTGCTCTGTGTTAYAAACT
1795 C (p.Ter207Gln) 22931 RAB18 CTGGGAAATTCCATCTCTTG]
NM_002242.4(KCNJ13):c.722T ['TGGTGTAATGGAGTGATAGTACGTTDGTGG
1796 >C (p.Leu241Pro) -1 - AAAGATGAAGAATGGACATTC]
NM_003072.3 (SMARC A4) :c .30 ['CTGCAGCGAGTGCTCTACCGCCACAYGCAG
1797 32T>C (p.MetlOHThr) 6597 SMARCA4 GCCAAGGGCGTGCTGCTGACT']
NM_013339.3(ALG6):c.391T>C ['GAGATTTCTTTTAAGCAACAACAGTRCAAAA
1798 (p.Tyrl31His) 29929 ALG6 CCACTGCAGGTATGTAAATC]
NM_019885.3(CYP26Bl):c.436 ['TTGCCTCTCTGCCTTCCAGGTCTTCYCCAAG
1799 T>C (p.Serl46Pro) 56603 CYP26B1 ATCTTCAGCCACGAGGCCCT']
NM_020433.4(JPH2):c.421T>C ['GTTCACCAACGGCATGCGCCATGGCYACGG
1800 (p.Tyrl41His) 57158 JPH2 AGTACGCCAGAGCGTGCCCTA]
NM_000199.3(SGSH):c.892T>C ['CCCCAGCGTTTTGGGTGCTCCGGGGRTGACA
1801 (p.Ser298Pro) 6448 SGSH CCAGTAAGGGTTCAGCAGTG]
NM_173170.1(IL36RN):c.80T> ['CTTTATCTGCATAATAACCAGCTTCYAGCTG
1802 C (p.Leu27Pro) 26525 IL36RN GAGGGCTGCATGCAGGGAAG]
NM_016599.4(MYOZ2):c.l42T> ['CAGAGACATCATGTTGGAAGAATTAYCCCA
1803 C (p.Ser48Pro) 51778 MYOZ2 TCTCAGTAACCGTGGTGCCAG]
NM_020191.2(MRPS22):c.644T ['CCAATAATTTTCAAGGAAGAAAATCYTAGG
1804 >C (p.Leu215Pro) 56945 MRPS22 GTAAGGTGACTTAGGTTTTAT']
NM_004278.3 (PIGL) :c .500T>C ['TTGTCCTATCCCTCCTCCAGGGCCCYGCACT
1805 (p.Leul67Pro) 9487 PIGL CAGAAGGGAAGTTACCTAAA]
NM_022445.3 (TPK1 ) : c.119T>C ['ATTTTGTTCTTTCTATTTGAAGCTCYTTTAAG
1806 (p.Leu40Pro) 27010 TPK1 AGCCTGTGCCGATGGAGGT']
NM_020634.1(GDF3):c.914T>C ['TGTCCCTTCTCACTGACCATCTCTCYCAACA
1807 (p.Leu305Pro) 9573 GDF3 GCTCCAATTATGCTTTCATG]
NM_017882.2(CLN6):c.200T>C ['CCCATTCTTCCATTTGCTCCGCAGCYGGTAT
1808 (p.Leu67Pro) 54982 CLN6 TCCCTCTCGAGTGGTTTCCA']
NM_024513.3(FYCOl):c.4127T ['TTTGTGAGGTCCAGCACCTACAGCCYGATCC
1809 >C (p.Leul376Pro) 79443 FYCOl CCATCACTGTGGCCGAGGCA']
1810 NM_006147.3(IRF6):c.65T>C 3664 IRF6 ['CTGGTGGCCCAGGTGGATAGTGGCCYCTAC (p.Leu22Pro) CCTGGGCTCATCTGGCTACAC]
NM_025132.3(WDR19):c.2129T ['GGAAATGTTGGCATAGTGATGTCCTYGGAA
1811 >C (p.Leu710Ser) 57728 WDR19 CAAATAAAGGTAAACAGCATG]
NM_025132.3(WDR19):c.20T> ['TTTATTTTTTAGCGTATTTTCTCACYGCTAGA
1812 C (p.Leu7Pro) 57728 WDR19 AAAGACTTGGCTTGGCGCA']
NM_153026.2(PRICKLEl):c.14 14416 ['AAGTAAAAAATACCAGTCTGATATGYACTG
1813 14T>C (p.Tyr472His) 5 PRICKLE 1 GGCACAGTCACAAGATGGACT']
M_014874.3 (MFN2) :c .1392+2 ['GTAGTCCTCAAGGTTTATAAGAATGWGAGT
1814 T>C 9927 MFN2 CATGGAGCAACAGGTCCTCTT']
M_014874.3(MFN2):c.647T>C ['GAGCTGGACAGCTGGATTGACAAGTYTTGT
1815 (p.Phe216Ser) 9927 MFN2 CTGGATGCTGATGTGTTTGTG]
NM_016097.4(IER3IPl):c.233T ['GTAAACTCAATTGCAATTGTGTTACYTTTAT
1816 >C (p.Leu78Pro) 51124 IER3IP1 TATTTGGATGAATATCAGTG]
NM_018718.2(CEP41):c.l07T> ['TTCGAGCTTCTCAGTATATTTAGTCRTACTGT
1817 C (p.Met36Thr) 95681 CEP41 TACCTAAAAAGAAAATAAG]
NM_022489.3(INF2):c.310T>C ['CCTGCTGCAGCTCACCTGCGTCAGCYGCGTG
1818 (p.Cysl04Arg) 64423 INF2 CGCGCCGTCATGAACTCGCG]
NM_022489.3 (INF2) :c .383 T>C ['AGCAACCAGGGCTACGTGCGCCAGCYCTCC
1819 (p.Leul28Pro) 64423 INF2 CAGGGTGAGCCGCAGTGTGGG]
NM_018713.2(SLC30A10):c.266 ['GGCGCGCTGAGCAACGCGGTCTTCCYCACC
1820 T>C (p.Leu89Pro) 55532 SLC30A10 GCGCTCTGCTTCACCATCTTC]
NM_058246.3(DNAJB6):c.277T ['CAGTCCATTTGAATTTGGCTTCACAYTCCGT
1821 >C (p.Phe93Leu) 10049 DNAJB6 AACCCAGATGATGTCTTCAG]
NM_024753.4(TTC21B):c.2384 ['CAAAAGAATTATCTTTGCTATGACCYGGCTG
1822 T>C (p.Leu795Pro) 79809 TTC21B AGCTCTTATTAAAATTGAAA']
NM_032446.2(MEGF10):c.2320 ['TGACTGCGACCACATTTCTGGGCAGYGTACT
1823 T>C (p.Cys774Arg) 84466 MEGF10 TGCCGCACTGGATTCATGGG']
NM_032446.2(MEGF10):c.976T ['CGTTCTCTGTGCTGAGACCTGCCAGYGTGTC
1824 >C (p.Cys326Arg) 84466 MEGF10 AACGGAGGGAAGTGTTACCA']
NM_024027.4(COLECll):c.505 ['GAAGCGCTACGCGGACGCCCAGCTGYCCTG
1825 T>C (p.Serl69Pro) 78989 COLEC11 CCAGGGCCGCGGGGGCACGCT']
NM_000035.3(ALDOB):c.l027T ['GCCCCAGAAGAACCCGTGTGAACATRCTGT
1826 >C (p.Tyr343His) 229 ALDOB CCTTTGGCCGCCTGGCAGTTA']
NM_012338.3(TSPAN12):c.734 ['CCTTCTATCATAATACAGAGCCCAGRGCAGA
1827 T>C (p.Leu245Pro) 23554 TSPAN12 GTAATGGTGAGAATCATGGC]
NM_001159772.1(CANTl):c.67 12458 ['CTCCTTGCCCAGGCCGCCCACGTACRGACGC
1828 1T>C (p.Leu224Pro) 3 CANT1 TCGTCCTTCACTGCCAGCCA']
NM_001006657.1(WDR35):c.78 ['TGGCATGTACGTAGTAGGCATCCAGYGGAA
1829 1T>C (p.Trp261Arg) 57539 WDR35 CCACATGGGCAGCGTGTTAGC]
NM_000420.2(KEL):c.1790T>C ['TCAACAGTACTGCCTGGGGGCTGCCYCGCCT
1830 (p.Leu597Pro) 3792 KEL GTGACAACCATGCCCTCCAG]
NM_001243473.1(B9Dl):c.400+ ['AGGGCCCAGGTCAGAATGAGGACCTRCCGG
1831 2T>C 27077 B9D1 CCAGGTGAGAAGGGCACGTGC]
1832 NM_015175.2(NBEAL2):c.l l63 23218 NBEAL2 ['ATTGCAGTCCATGTAGTCAGAGTGCYGACCT T>C (p.Leu388Pro) GCATCATGAGTGACTCCCCC']
NM_000196.3(HSDl lB2):c.l01 ['GCTGGCAGCTCGGCCCCGCCGCCGCYATTAC
1833 2T>C (p.Tyr338His) 3291 HSD11B2 CCCGGCCAGGGCCTGGGGCT']
NM_024599.5(RHBDF2):c.557T ['GCTTACCGCCCCCCTCCCTTCCAGAYTGTGG
1834 >C (p.Ilel86Thr) 79651 RHBDF2 ATCCGCTGGCCCGGGGCCGG]
NM_001256714.1(DNAAF3):c.3 35290 ['GGCTCTGTGGATGGACGGCACCTGCYGCGG
1835 86T>C (p.Leul29Pro) 9 DNAAF3 ACCCTGTCCCGAGCGAAGTTC]
NM_020894.2(UVSSA):c.94T>C ['GAAAATGAAGGAACTGAAGAAAATTYGCAA
1836 (p.Cys32Arg) 57654 UVSSA GTATGTCTTAGGGTTCAGTAA']
NM_004453.3 (ETFDH) :c.1130T ['TTGTTTCCTCAGTCTATACCAAAACYCACCT
1837 >C (p.Leu377Pro) 2110 ETFDH TTCCTGGTGGTTTACTAATT']
NM_024306.4(FA2H):c.707T>C ['CTCATCGAGTACCTCATCCACCGCTYCCTGT
1838 (p.Phe236Ser) 79152 FA2H TCCACATGAAGCCCCCCAGC]
NM_001004127.2(ALGl l):c.l l4 ['AAAATAAACATTCCATTTGATGAATYAAAG
1839 2T>C (p.Leu381Ser) -1 - AATTATTTGTCTGAAGCAACA]
NM_021167.4(GATADl):c.304T ['TCGGCTCAGAAACACTAAATACAAAYCTGC
1840 >C (p.Serl02Pro) 57798 GAT AD 1 TCCGGCTGCTGAAAAGAAAGT']
NM_016042.3(EXOSC3):c.712T ['AGTATTTGGAATGAATGGAAGAATAYGGGT
1841 >C (p.Trp238Arg) 51010 EXOSC3 TAAGGCAAAAACCATCCAGCA']
NM_001018005.1(TPMl):c.515 ['CAGGTGGCCCGTAAGCTGGTCATCAYTGAG
1842 T>C (p.Ilel72Thr) 7168 TPM1 AGCGACCTGGAACGTGCAGAG]
NM_001018005.1(TPMl):c.842 ['GAGCTGGACCACGCTCTCAACGATAYGACT
1843 T>C (p.Met281Thr) 7168 TPM1 TCCATGTAAACGTTCATCCAC]
NM_033360.3(KRAS):c.211T>C ['GGAGTACAGTGCAATGAGGGACCAGYACAT
1844 (p.Tyr71His) 3845 KRAS GAGGACTGGGGAGGGCTTTCT']
NM_006218.2(PIK3CA):c. l258T ['TTTTTCTTTGTTTTTTAAGGAACACYGTCCAT
1845 >C (p.Cys420Arg) 5290 PIK3CA TGGCATGGGGAAATATAAA']
NM_006265.2(RAD21):c.l753T ['TGAATCTATCAGTTTGCTTGAGTTAYGTCGA
1846 >C (p.Cys585Arg) -1 - AATACGAACAGAAAACAAGC]
NM_000222.2(KIT):c.l859T>C ['ATTAAGTCAGATGCGGCCATGACTGYCGCT
1847 (p.Val620Ala) 3815 KIT GTAAAGATGCTCAAGCGTAAG]
NM_000076.2(CDKNlC):c.827T ['CGCGCGCTGTCGCCCGCAGATTTCTYCGCCA
1848 >C (p.Phe276Ser) 1028 CDKN1C AGCGCAAGAGATCAGCGCCT']
NM_005691.3(ABCC9):c.3058T ['AGACTATTGGCTGGCCACATGGACAYCGGA
1849 >C (p.Serl020Pro) 10060 ABCC9 GTACAGTATAAACAATACTGG]
NM_012343.3(NNT):c.2930T>C ['ATGCCTGGTCAGCTTAATGTGCTGCYGGCTG
1850 (p.Leu977Pro) 23530 NNT AGGCTGGTGTGCCATATGAC]
NM_024110.4(CARD14):c.467T ['GTGCTGCTGCGGCGGTGCCAGCAGCYGCAG
1851 >C (p.Leul56Pro) 79092 CARD14 GAGCACCTGGGCCTGGCCGAG]
NM_000492.3 (CFTR) :c .1400T> ['GATGGGTTTTATTTCCAGACTTCACYTCTAA
1852 C (p.Leu467Pro) 1080 CFTR TGGTGATTATGGGAGAACTG]
NM_000518.4(HBB):c.2T>C ['CACTAGCAACCTCAAACAGACACCANGGTG
1853 (p.MetlThr) 3043 HBB CATCTGACTCCTGAGGAGAAG]
1854 NM_000518.4(HBB):c.*110T>C 3043 HBB ['CCTTGAGCATCTGGATTCTGCCTAAHAAAAA ACATTTATTTTCATTGCAAT']
['AGTTGGTGGTGAGGCCCTGGGCAGGNTGGT
1855 NM_000518.4(HBB):c.92+2T>C 3043 HBB ATCAAGGTTACAAGACAGGTT']
NM_000206.2(IL2RG):c.455T> ['ACCACATATGCACACATATCTCCAGYGATCC
1856 C (p.Vall52Ala) 3561 IL2RG CCTGGGCTCCAGAGAACCTA']
NM_000244.3 (MENl ) :c .518T>C ['GCTGTGGTTGGGGCCTGCCAGGCCCYGGGT
1857 (p.Leul73Pro) 4221 MENl CTCCGGGATGTCCACCTCGCC]
NM_000256.3(MYBPC3):c.2374 ['CCGCCATCGTAGGCAGGCGGCTCCCVCTGTA
1858 T>C (p.Trp792Arg) 4607 MYBPC3 CTGTGCAGGAGTCCTCTCCC]
NM_002501.3(NFIX):c.l79T>C ['GAGGAGCGGGCGGTGAAGGACGAGCYGCTG
1859 (p.Leu60Pro) 4784 NFIX GGCGAGAAGCCCGAGATCAAG]
NM_005022.3(PFNl):c.341T>C ['CCTCCTCCAGCGCTAGTCCTGCTGAYGGGCA
1860 (p.Metll4Thr) 5216 PFN1 AAGAAGGTGTCCACGGTGGT']
NM_001172567.1(MYD88):c.81 ['CTTGCAGGTGCCCATCAGAAGCGACYGATC
1861 8T>C (p.Leu273Pro) 4615 MYD88 CCCATCAAGTACAAGGCAATG]
NM_001161581.1(POClA):c.39 ['GCCAGTGATGACAAGACTGTTAAGCYGTGG
1862 8T>C (p.Leul33Pro) 25886 POC1A GACAAGAGCAGCCGGGAATGT']
NM_005270.4(GLI2):c.4663T>C ['CCCCCGAAACTCCTTGACCCTGCCCYCCATC
1863 (p.Serl555Pro) 2736 GLI2 CCCGCAGGCATCAGCAACAT']
NM_152296.4(ATPlA3):c.2431 ['CTCCTCCGCCTAGGTCCCTGCCATCYCACTG
1864 T>C (p.Ser811Pro) 478 ATP 1 A3 GCGTACGAGGCTGCCGAAAG]
NM_022787.3(NMNATl):c.838 ['GAGAAACACTGCAGAAGCTAAGACAYAGGA
1865 T>C (p.Ter280Gln) 64802 NMNAT1 ATTCTACAGCATGATATTTCA']
NM_005340.6(HINTl):c.250T> ['ACACTTAATGATTGTTGGCAAGAAAYGTGCT
1866 C (p.Cys84Arg) 3094 HINT1 GCTGATCTGGGCCTGAATAA']
NM_000155.3(GALT):c.416T>C ['TTCCACCCCTGGTCGGATGTAACGCYGCCAC
1867 (p.Leul39Pro) 2592 GALT TCATGTCGGTCCCTGAGATC]
NM_000155.3 (GALT) :c .386T>C ['CTCCCGTCACCACCCAGTAAGGTCAYGTGCT
1868 (p.Metl29Thr) 2592 GALT TCCACCCCTGGTCGGATGTA']
NM_000155.3(GALT):c.680T>C ['ATGGAGTACAGCCGCCAGGAGCTACYCAGG
1869 (p.Leu227Pro) 2592 GALT AAGGTGGGAGAGAGCCAAGCC]
NM_007294.3(BRCAl):c.4986+ ['GCCTGACCCCAGAAGAATTTGTGAGBGTATC
1870 6T>C 672 BRCA1 CATATGTATCTCCCTAATGA']
NM_007294.3(BRCAl):c.5074+ ['CTACTCATGTTGTTATGAAAACAGGYATACC
1871 2T>C 672 BRCA1 AAGAACCTTTACAGAATACC]
NM_007294.3(BRCAl):c.5207T ['GGTTTCTTTCAGCATGATTTTGAAGBCAGAG
1872 >C (p.Vall736Ala) 672 BRCA1 GAGATGTGGTCAATGGAAGA']
NM_002437.4(MPV17):c.186+2 ['TGAAGCCCTGTTGAGGGGAGAACTTRCCAC
1873 T>C 4358 MPV17 AAAGCCACAGCCCAGGGACAC]
NM_002769.4(PRS S 1 ) :c .116T> ['GAGGAGAATTCTGTCCCCTACCAGGYGTCCC
1874 C (p.Val39Ala) -1 - TGAATTCTGGCTACCACTTC]
NM_004211.3(SLC6A5):c. l444 ['GATTTTCTTCTCTTTATCTGCTGCAYGGGGA
1875 T>C (p.Trp482Arg) 9152 SLC6A5 GGCCTGATCACTCTCTCTTC]
1876 NM_005211.3(CSFlR):c.2297T> 1436 CSF1R ['TTCTCCAGCCAAGTAGCCCAGGGCAYGGCC C (p.Met766Thr) TTCCTCGCTTCCAAGAATGTG]
NM_005211.3(CSFlR):c.2546T> ['TATGGCATCCTCCTCTGGGAGATCTYCTCAC
1877 C (p.Phe849Ser) 1436 CSF1R TTGGTGAGCCACTGGGCCCA']
NM_005211.3(CSFlR):c.2603T> ['CTGGTGAACAGCAAGTTCTATAAACBGGTG
1878 C (p.Leu868Pro) 1436 CSF1R AAGGATGGATACCAAATGGCC]
NM_006796.2(AFG3L2):c. l997 ['ATTTTTCAGATTGTTCAGTTTGGCABGAATG
1879 T>C (p.Met666Thr) 10939 AFG3L2 AAAAGGTTGGGCAAATCTCC]
NM_018713.2(SLC30A10):c. l04 ['GTAAGTGGAAAGATTATTGCCACCCYGCAC
1880 6T>C (p.Leu349Pro) 55532 SLC30A10 ATCAAGTATCCTAAGGACAGG]
NM_018713.2(SLC30A10):c.500 ['GCGGAGGGCTGTGTCCCCGGCGCTTYCGGG
1881 T>C (p.Phel67Ser) 55532 SLC30A10 GGGCCTCAGGGCGCGGAGGAC]
NM_000060.3 (BTD) : c.212T>C ['TATGAGCATCCATCCATCCTGAGTCYGAACC
1882 (p.Leu71Pro) 686 BTD CTCTGGCTCTCATCAGCCGC]
NM_000495.4(COL4A5):c.438+ ['TTTCCTGGTTTACAGGGTCCTCCAGYAAGTT
1883 2T>C 1287 COL4A5 ATAAAATTTGGGATTATGAT']
NM_000282.3(PCCA):c.491T>C ['CAGGCAGCAGAAGATGTCGTTTTCAYTGGA
1884 (p.Ilel64Thr) 5095 PCCA CCTGACACACATGCTATTCAA']
NM_000532.4(PCCB):c.1556T> ['ACACGTGCCCGAATCTGCTGTGACCYGGAT
1885 C (p.Leu519Pro) 5096 PCCB GTCTTGGCCAGCAAGAAGGTA]
NM_001099274.1(TINF2):c.860 ['CATAAGGAGCGCCCCACAGTCATGCYGTTTC
1886 T>C (p.Leu287Pro) 26277 TINF2 CCTTTAGGAATCTCGGCTCA']
NM_001099274.1(TINF2):c.862 ['TAAGGAGCGCCCCACAGTCATGCTGYTTCCC
1887 T>C (p.Phe288Leu) 26277 TINF2 TTTAGGAATCTCGGCTCACC]
NM_001363.4(DKCl):c. l049T> ['TCAATGCCTGTAGCTATTGCATTAAYGACCA
1888 C (p.Met350Thr) 1736 DKC1 CAGCGGTCATCTCTACCTGC]
NM_001363.4(DKCl):c. ll93T> ['AAGCTGATGATCAAGCAGGGCCTTCYGGAC
1889 C (p.Leu398Pro) 1736 DKC1 AAGCATGGGAAGCCCACAGAC]
M_004614.4(TK2):c.l56+2T> ['CAGGAAAAAGAGAAAAAATCAGTGGYAAG
1890 C 7084 TK2 TCCCTCTTTTATGTGTACTCTC']
M_004614.4(TK2):c.644T>C ['GAATACCTGGAAGCAATTCACCATCYCCAT
1891 (p.Leu215Pro) 7084 TK2 GAGGAGTGGCTCATCAAAGGC]
NM_024312.4(GNPTAB):c.l208 ['ATCGAAGGGCTGTCCCAGAAGTTTAYTTACC
1892 T>C (p.Ile403Thr) 79158 GNPTAB TAAATGATGATGTCATGTTT']
NM_024312.4(GNPTAB):c.3002 ['TTTGCCTTCTCTTATTTTTATTATCYCATGAG
1893 T>C (p.LeulOOlPro) 79158 GNPTAB TGCAGTGCAGCCACTGAAT']
NM_198253.2(TERT):c.3043T> ['CCGCCATCCTCTCAGGTTTCACGCAYGTGTG
1894 C (p.Cysl015Arg) 7015 TERT CTGCAGCTCCCATTTCATCA']
NM_207352.3 (CYP4V2) : c.1021 28544 ['TACAACTGCAGCTGCAATAAACTGGYCCTTA
1895 T>C (p.Ser341Pro) 0 CYP4V2 TACCTGTTGGGTTCTAACCC']
NM_207352.3(CYP4V2):c.655T 28544 ['TGCTCAAAGTAATGATGATTCCGAGYATGTC
1896 >C (p.Tyr219His) 0 CYP4V2 CGTGCAGTTTATAGGTAAAT']
NM_000335.4(SCN5A):c.5504T ['GCCAAGCCCAACCAGATAAGCCTCAYCAAC
1897 >C (p.Ilel835Thr) 6331 SCN5A ATGGACCTGCCCATGGTGAGT']
1898 NM_001111.4(ADAR):c.2615T> 103 ADAR ['CTCGGCCGCAAGATTCTGGCCGCCAYCATTA C (p.Ile872Thr) TGAAAAAAGACTCTGAGGAC]
NM_004281.3(BAG3):c.l385T> ['ATCGAAGAGTATTTGACCAAAGAGCYGCTG
1899 C (p.Leu462Pro) 9531 BAG3 GCCCTGGATTCAGTGGACCCC]
NM_183075.2(CYP2Ul):c.784T 11361 ['TTTTATGTCACGAGGCCTAGAAATCYGTCTG
1900 >C (p.Cys262Arg) 2 CYP2U1 AACAGTCAAGTCCTCCTGGT']
NM_006177.3 (NRL) : c.287T>C ['TTGGGGCTGAGTCCTGAAGAGGCCAYGGAG
1901 (p.Met96Thr) 4901 NRL CTGCTGCAGGGTCAGGGCCCA']
M_000344.3(SMNl):c.388T>C ['AACCTGTGTTGTGGTTTACACTGGAYATGGA
1902 (p.Tyrl30His) 6606 SMN1 AATAGAGAGGAGCAAAATCT']
NM_152692.4(C1GALT1C1):C.5 C1GALT1 ['AGGAGGAATTGTCTTAAGTGTAGAAYCAAT
1903 77T>C (p.Serl93Pro) 29071 CI GAAAAGACTTAACAGCCTTCT']
NM_024531.4(SLC52A2):c.368 ['TTAGCACTGGCCTTTGTGCTGGCACYGGCAT
1904 T>C (p.Leul23Pro) 79581 SLC52A2 GCTGTGCCTCGAATGTCACT']
NM_001253816.1(SLC52A2):c.l ['GCTCACTGCAGGTCCTTGGCAGGGCYGGGC
1905 016T>C (p.Leu339Pro) 79581 SLC52A2 GGCCTCTCTCTGCTGGGCGTG]
NM_002609.3(PDGFRB):c.l973 ['TCGGAGCTGAAGATCATGAGTCACCYTGGG
1906 T>C (p.Leu658Pro) 5159 PDGFRB CCCCACCTGAACGTGGTCAAC]
NM_020822.2(KCNTl):c.2386T ['CAACAGCTATGAAGACGCCAAGGCCYACGG
1907 >C (p.Tyr796His) 57582 KCNT1 GTTCAAGAACAAGCTGATCAT']
NM_001369.2(DNAH5):c. l l21T ['ACTATAGATCATTTTAATTGCATTTRTAAGT
1908 >C (p.Ile374Thr) 1767 DNAH5 GTAGGAATAGCATCCATCAT']
NM_017802.3(DNAAF5):c.2384 ['GTCCAGTACCTGTACCGAGAGTTGCYGGTTC
1909 T>C (p.Leu795Pro) 54919 DNAAF5 ACCTTGACGATCCAGAGAGG]
NM_006383.3 (CIB2) :c.272T>C ['GAGGGGAACCTCACTTTCAACGACTYTGTG
1910 (p.Phe91Ser) 10518 CIB2 GACATGTTTTCCGTGCTCTGC]
NM_006383.3(CIB2):c.368T>C ['ACAGACTTCAACACTGACAACTTCAYCTGCA
1911 (p.Ilel23Thr) 10518 CIB2 AGGAGGACCTGGAGCTGACG]
NM_005334.2(HCFCl):c.- ['TTAGTTGTTACTTCTTCACACAAGAYGGCGG
1912 970T>C 3054 HCFC1 CTCCCAGGGAGGAGGCATGA']
NM_178012.4(TUBB2B):c.350T 34773 ['GGAGCCGAGCTGGTCGACTCGGTCCYGGAT
1913 >C (p.Leul l7Pro) 3 TUBB2B GTGGTGAGGAAGGAGTCAGAG]
NM_000431.3(MVK):c.764T>C ['GTGGCTGGCGTCAGAAACAGGCTGCYCAAG
1914 (p.Leu255Pro) 4598 MVK GTGACTCTTGTTCCCTTCTTG]
NM_000431.3 (MVK) :c .122T>C ['TTGAACTTGAGAACATTCCTCCGGCYTCAAC
1915 (p.Leu41Pro) 4598 MVK CCCACAGCAATGGGAAAGTG]
NM_000431.3 (MVK) :c.1039+2T ['GTGGCATCACACTCCTCAAGCCAGGYATCCC
1916 >C 4598 MVK GGGGGTAGGTGGGCCAGGCT']
NM_000431.3 (MVK) :c.1094T> ['AAGCAGGCCCTGACCAGCTGTGGCTYTGAC
1917 C (p.Phe365Ser) 4598 MVK TGCTTGGAAACCAGCATCGGT']
NM_004055.4(CAPN5):c.731T> ['ACAGCAGCTGACATGGAGGCCCGCCYGGCG
1918 C (p.Leu244Pro) 726 CAPN5 TGCGGCCTGGTAAAGGGCCAC]
NM_133497.3(KCNV2):c.491T> 16952 ['GCCGTCTTCCAGCTGGTCTACAATTYCTACC
1919 C (p.Phel64Ser) 2 KCNV2 TGTCCGGGGTGCTGCTGGTG']
1920 NM_006567.3(FARS2):c.986T> 10667 FARS2 ['ATGATCCTCTACGACATCCCTGATAYCCGTC C (p.Ile329Thr) TCTTCTGGTGTGAGGACGAG']
NM_020376.3(PNPLA2):c.757+ ['GCCTGCGCTTTCTGCAGCGGAACGGYGCGC
1921 2T>C 57104 PNPLA2 GGACCCGGGCGGGAGAGGGCG]
M_018344.5(SLC29A3):c.607 ['TATGAGGAACTCCCAGGCACTGATAYCAGG
1922 T>C (p.Ser203Pro) 55315 SLC29A3 TGAGAGCCAGGGTCCGGGCAG]
NM_012275.2(IL36RN):c. ll5+6 ['TGCAGGGAAGGTCATTAAAGGTTGGYGATG
1923 T>C 26525 IL36RN AAACATGACCCACTTTCCTTG]
['TTCACACTTCTAGTAAGCCTCTACCYGCACG
1924 m.9191T>C 4508 MT-ATP6 ACAACACATAATGACCCACC]
NM_000108.4(DLD) : c.140T>C ['GTAGTTGATGCTGATGTAACAGTTAYAGGTT
1925 (p.Ile47Thr) 1738 DLD CTGGTCCTGGAGGATATGTT']
NM_000080.3(CHRNE):c.223T> ['AGAGGAGACTCTCACCACTAGCGTCYGGAT
1926 C (p.Trp75Arg) -1 - TGGAATCGTGAGTCAAATCTG]
NM_004376.5(COX15):c.l030T ['TGCCATTACAGTGCTCTACTTCCTCBCTCGG
1927 >C (p.Ser344Pro) 1355 COX15 AGAATTCCCCTTCCTAGAAG']
NM_004333.4(BRAF):c. l403T> ['GGACAAAGAATTGGATCTGGATCATYTGGA
1928 C (p.Phe468Ser) 673 BRAF ACAGTCTACAAGGGAAAGTGG]
NM_004333.4(BRAF):c. l454T> [TTAGGTGATGTGGCAGTGAAAATGTYGAAT
1929 C (p.Leu485Ser) 673 BRAF GTGACAGCACCTACACCTCAG]
NM_005188.3(CBL):c. l201T>C ['GATTGAGCCCTGTGGACACCTCATGYGCAC
1930 (p.Cys401Arg) 867 CBL ATCCTGTCTTACATCCTGGCA']
NM_002834.3(PTPNll):c.211T> ['CTATGACCTGTATGGAGGGGAGAAABTTGC
1931 C (p.Phe71Leu) 5781 PTPN11 CACTTTGGCTGAGTTGGTCCA']
NM_002834.3(PTPNll):c.853T> ['AAATAGATATAAAAACATCCTGCCCBGTAA
1932 C (p.Phe285Leu) 5781 PTPN11 GTATCAATATTCCGCTCAGTA']
NM_002880.3(RAFl):c.769T>C ['AGGTTCCCTCTCCCAGAGGCAGAGGYCGAC
1933 (p.Ser257Pro) 5894 RAF1 ATCCACACCTAATGTCCACAT']
NM_002880.3(RAFl):c.l423T> ['AGTCCTTAACAAGCATTGAGATATAYTTCTC
1934 C (p.Phe475Leu) 5894 RAF1 CATGAAGGCTTAACAGTGAA']
NM_005633.3(SOSl):c.806T>C ['GGCC ATATAGAAGATACAGTAGAAAB GAC A
1935 (p.Met269Thr) 6654 SOS1 GATGAAGGCAGTCCCCATCCA']
NM_005633.3(SOSl):c.l649T> ['ATATCTTTACAGTACCGGAGTACACYGGAA
1936 C (p.Leu550Pro) 6654 SOS1 AGGATGCTTGATGTAACAATG]
NM_005633.3(SOSl):c.2104T> ['TCGGCACTGGGTAGAGCACCACTTCYATGAT
1937 C (p.Tyr702His) 6654 SOS1 TTTGAAAGAGATGCATATCT']
NM_002755.3(MAP2Kl):c.388T ['CAACTCTCCGTACATCGTGGGCTTCYATGGT
1938 >C (p.Tyrl30His) 5604 MAP2K1 GCGTTCTACAGCGATGGCGA]
['TTTCAAGCCAACCCCATGGCCTCCAYGACTT
1939 NC_012920.1 :m.7505T>C 4574 MT-TS1 TTTCAAAAAGGTATTAGAAA']
NM_000084.4(CLCN5):c.674T> ['GTGGCTTGCTGCTGTGGGAACATCCYGTGCC
1940 C (p.Leu225Pro) 1184 CLCN5 ACTGCTTCAACAAATACAGG]
NM_000530.6(MPZ):c.89T>C ['GCAGTGCTGTCCCCGGCCCAGGCCAYCGTG
1941 (p.Ile30Thr) 4359 MPZ GTTTACACCGACAGGGAGGTC]
1942 NM_000530.6(MPZ):c.244T>C 4359 MPZ ['CCCTCATTCCTCATAGATCTTCCACYATGCC (p.Tyr82His) AAGGGACAACCCTACATTGA']
NM_000530.6(MPZ):c.266T>C ['CACTATGCCAAGGGACAACCCTACAHTGAC
1943 (p.Ile89Thr) 4359 MPZ GAGGTGGGGACCTTCAAAGAG]
NM_000748.2(CHRNB2):c.923T ['TACCTCATGTTCACCATGGTGCTTGYCACCT
1944 >C (p.Val308Ala) 1141 CHRNB2 TCTCCATCGTCACCAGCGTG]
NM_003611.2(OFDl):c. ll l+2T ['CGGGGTATACTGGATACACTCAAGGYATCG
1945 >C 8481 OFD1 GATTTAGGCGTATCTGTGTCA']
NM_003611.2(OFDl):c.274T>C ['AAGATGTGGCTATGAATATTCACTTYCTGTT
1946 (p.Ser92Pro) 8481 OFD1 TTCTTTCCAGAAAGTGGTTT']
NM_024408.3 (NOTCH2) : c.1117 ['GCCCCACCCTGTGACAGGTCTCCTGYGTCAT
1947 T>C (p.Cys373Arg) 4853 NOTCH2 CTGGATGATGCATGCATCAG]
NM_024408.3(NOTCH2):c. l438 [TCTGGATAAGATTGGAGGCTTCACAYGTCTG
1948 T>C (p.Cys480Arg) 4853 NOTCH2 TGCATGCCAGGTAAATGGGC]
NM_000540.2(RYRl):c.9242T> ['CCCCGCTGCCCTTCTAGGACAGTGAYGAAGT
1949 C (p.Met3081Thr) 6261 RYR1 CAGGCCCTGAGATCGTGAAG]
NM_000096.3(CP):c.650T>C ['AAAGAAAAACATATTGACCGAGAATYTGTG
1950 (p.Phe217Ser) 1356 CP GTGATGTTTTCTGTGGTGGAT']
NM_000096.3(CP):c.548T>C ['GTGACTAGGATTTACCATTCCCACABTGATG
1951 (p.Ilel83Thr) 1356 CP CTCCAAAAGATATTGCCTCA']
NM_000540.2(RYRl):c.1205T> ['CAGGAGGAGTCCCAGGCCGCCCGCAYGATC
1952 C (p.Met402Thr) 6261 RYR1 CACAGCACCAATGGCCTATAC]
NM_006517.4(SLC16A2):c. l253 ['TTCGGGGGCCTTATCGTCGTCTGTCYTTTCCT
1953 T>C (p.Leu418Pro) 6567 SLC16A2 GGGCCTTTGCGATGGCTTC]
NM_000096.3(CP):c. ll23T>C ['CCGTGGGAAGCATGTTAGACACTACYACAT
1954 (p.Tyr375His) 1356 CP TGCCGCTGAGGAAATCATCTG]
NM_002739.3(PRKCG):c.391T> ['CGGGCTTGTGCACCAGGGCATGAAAHGCTC
1955 C (p.Cysl31Arg) 5582 PRKCG CTGTGAGTGACCTGGGCCTTG]
NM_000116.4(TAZ):c.310T>C ['GACCCCTGCAGCTGCAGACATCTGCYTCACC
1956 (p.Phel04Leu) 6901 TAZ AAGGAGCTACACTCCCACTT']
NM_000138.4(FBNl):c.2341T> ['CAGTCTCCTTTGTGACAATGGACAAYGTAGA
1957 C (p.Cys781Arg) 2200 FBN1 AATACTCCTGGAAGTTTTGT']
NM_000138.4(FBNl):c.4222T> ['CTTTCTGGCTGTAGACCTTGATGAGYGCTCT
1958 C (p.Cysl408Arg) 2200 FBN1 GAGAACCTGAATCTCTGTGG]
NM_000256.3(MYBPC3):c.l351 ['GTAGCACGGAGCTCTTTGTGAAAGGYGGGC
1959 +2T>C 4607 MYBPC3 CTGGGACCTGAGGATGTGGGA']
NM_000256.3(MYBPC3):c3392 ['GACGCGGAAGTAGTAGCCATTGCCARTGAT
1960 T>C (p.Ilel l31Thr) 4607 MYBPC3 GAGCTCTGGCACCACGCAGTG]
NM_000256.3(MYBPC3):c.821+ ['CCTCCTATCAGCCTTCCGCCGCACGYGAGTG
1961 2T>C 4607 MYBPC3 GCCATCCTCAGGGCCTGGGG]
NM_000257.3(MYH7):c.l370T> ['ACCAAGCAGCCACGCCAGTACTTCAYAGGA
1962 C (p.Ile457Thr) 4625 MYH7 GTCCTGGACATCGCTGGCTTC]
NM_000257.3(MYH7):c.2093T> ['ATGCACCAGCTGCGCTGCAATGGTGYGCTG
1963 C (p.Val698Ala) 4625 MYH7 GAGGGCATCCGCATCTGCAGG]
1964 NM_000257.3(MYH7):c.2546T> 4625 MYH7 ['AAGAGTGCAGAAAGAGAGAAGGAGAYGGC C (p.Met849Thr) CTCCATGAAGGAGGAGTTCACA]
NM_000257.3(MYH7):c.2555T> ['GAAAGAGAGAAGGAGATGGCCTCCAHGAA
1965 C (p.Met852Thr) 4625 MYH7 GGAGGAGTTCACACGCCTCAAA']
NM_000257.3(MYH7):c.602T> ['CAGTACTTTGCTGTTATTGCAGCCAYTGGGG
1966 C (p.Ile201Thr) 4625 MYH7 ACCGCAGCAAGAAGGACCAG]
NM_000257.3(MYH7):c.788T> ['ACAGGAAAGTTGGCATCTGCAGACAYAGAG
1967 C (p.Ile263Thr) 4625 MYH7 ACCTGTGAGTGCCATGAATCT']
NM_000260.3 (MY07A) : c.5573 ['CTCCTGCCCCACGTGCAGCGCTTCCYGCAGT
1968 T>C (p.Leul858Pro) 4647 MY07A CCCGAAAGCACTGCCCACTC]
NM_000441. l(SLC26A4):c.164+ ['GGAGAGCCTGGCCAAGTGCTGCAGGYAGCG
1969 2T>C 5172 SLC26A4 GCCGCGCGGGCCTGCGTAGAG]
M_000441.1 (SLC26 A4) : c.2T> ['TCGCTGTCCTCTGGCTCGCAGGTCABGGCAG
1970 C (p.MetlThr) -1 - CGCCAGGCGGCAGGTCGGAG]
M_000441.1(SLC26A4):c.765+ ['AATGGAGTTCTCTCTATTATCTATGYAAGTG
1971 2T>C 5172 SLC26A4 TTGCTTCTTGCTCCAGGGAT']
NM_000551.3(VHL):c.497T>C ['CTGAAAGAGCGATGCCTCCAGGTTGYCCGG
1972 (p.Vall66Ala) 7428 VHL AGCCTAGTCAAGCCTGAGAAT']
NM_001399.4(EDA):c.2T>C ['AGAGAGTGGGTGTCTCCGGAGGCCAYGGGC
1973 (p.MetlThr) 1896 EDA TACCCGGAGGTGGAGCGCAGG]
NM_001943.3(DSG2):c.523+2T ['CTGTTGAAGAGTTGAGTGCAGCACGYAAGA
1974 >C 1829 DSG2 GTCTTTTTTTTTTTTTTTAAT']
NM_004572.3(PKP2):c.2062T> ['TTGCGGACACTTTTGGCGATCAAGGRCAGAT
1975 C (p.Ser688Pro) 5318 PKP2 ACATCCTTATAACAATGGAA']
NM_005633.3(SOSl):c.l310T> [' ATTGATGGTTGGGAGGGAAAAGAC AB TGGA
1976 C (p.Ile437Thr) 6654 SOS1 CAGTGTTGTAATGAATTTATA']
NM_170707.3(LMNA):c.799T> ['GTATAAGAAGGAGCTGGAGAAGACTYATTC
1977 C (p.Tyr267His) 4000 LMNA TGCCAAGGTGCTTGCTCTCGA']
NM_206933.2(USH2A):c.10561 ['TCTTGAAGATACAATTGTCTTAAACYGGAGA
1978 T>C (p.Trp3521Arg) 7399 USH2A AAACCTATACAATCAAATGG]
NM_206933.2(USH2A):c.l606T ['CGACACAACAAGCCAGCCATATAGAYGCCT
1979 >C (p.Cys536Arg) 7399 USH2A CTGCTCCCAGGAGAGCTTCAC]
NM_206933.2(USH2A):c.5857+ [' GTC G AGG AC GT AC A AC AGG AGC AGGY A A AT
1980 2T>C -1 - ACTTATCTTCAAATGCATATG]
NM_000492.3(CFTR):c.l090T> ['CTGGGCTGTACAAACATGGTATGACYCTCTT
1981 C (p.Ser364Pro) 1080 CFTR GGAGCAATAAACAAAATACA']
NM_000548.3(TSC2):c.5150T> ['CCCTTCGTGGCCCGCCAGATGGCCCYGCACG
1982 C (p.Leul717Pro) 7249 TSC2 CAAATGTGAGTGGGGGTGGG]
NM_000548.3(TSC2):c.2410T> ['CCTCATCCACCGCTGTGCCAGCCAGYGCGTC
1983 C (p.Cys804Arg) 7249 TSC2 GTGGCCTTGTCCATCTGCAG]
NM_000548.3(TSC2):c.3106T> ['GGACATGATGGCTCGATACGTCTTCYCCAAC
1984 C (p.Serl036Pro) 7249 TSC2 TTCACGGCTGTCCCGAAGAG]
NM_000212.2(ITGB3):c.2231T> ['GCCGCCCTGCTCATCTGGAAACTCCYCATCA
1985 C (p.Leu744Pro) -1 - CCATCCACGACCGAAAAGAA']
1986 NM_183415.2(UBE3B):c. l741+ 89910 UBE3B ['AGATGATCTGGGATGGAATTGTAGGYAAGA 2T>C GAAAAGGTGTCTGCTGTTGTT']
NM_005120.2(MED12):c.3493T ['CCTTTTAGCTTGTAGTGAACAGGACYCTGAG
1987 >C (p.Serll65Pro) 9968 MED12 CCAGGGGCCCGGCTTACCTG]
NM_001033053.2(NLRPl):c.230 ['CTAGCCCTCCATACCTGGGAGCAGAYGGGG
1988 T>C (p.Met77Thr) 22861 NLRP1 CTGAGGTCACTGTGCGCCCAA]
NM_025152.2(NUBPL):c.815- ['ATGCCTATATGAACTTTTCTGGTTCYAATGG
1989 27T>C 80224 NUBPL ATGTCTGCTGGGCTCTTTTA']
NM_001288953.1(TTC7A):c.236 ['GCGTGGCAGGGCCTGGGCGAGGTGCYGCAG
1990 6T>C (p.Leu789Pro) 57217 TTC7A GCCCAGGGCCAGAACGAGGCT']
NM_014845.5(FIG4):c.524T>C ['TACAGCTATGATTTGTCCCACTCACYTCAAT
1991 (p.Leul75Pro) 9896 FIG4 ATAATCTCACTGTCTTGCGA']
NM_000059.3(BRCA2):c.2T>C [' ATTGGAGGAATATCGTAGGTAAAAAB GCCT
1992 (p.MetlThr) 675 BRCA2 ATTGGATCCAAAGAGAGGCCA]
NM_000059.3(BRCA2):c.316+2 ['TAGATAAATTCAAATTAGACTTAGGYAAGT
1993 T>C 675 BRCA2 AATGCAATATGGTAGACTGGG]
NM_000059.3(BRCA2):c.67+2T ['TTAAGACACGCTGCAACAAAGCAGGHATTG
1994 >C 675 BRCA2 ACAAATTTTATATAACTTTAT']
NM_000059.3(BRCA2):c.7958T ['AGATGCCTAAGCCCAGAAAGGGTGCYTCTT
1995 >C (p.Leu2653Pro) 675 BRCA2 CAACTAAAATACAGGCAAGTT']
NM_000218.2(KCNQl):c. l016T ['TGCTTCTCTGTCTTTGCCATCTCCTHCTTTGC
1996 >C (p.Phe339Ser) 3784 KCNQ1 GCTCCCAGCGGTAGGTGCC]
NM_000218.2(KCNQl):c. l045T
>C (p.Ser349Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c. l052T
>C (p.Phe351Ser) 3784 KCNQ1 []
NM_000218.2(KCNQl):c. l058T
>C (p.Leu353Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c. l541T
>C (p.Ile514Thr) 3784 KCNQ1 []
NM_000218.2(KCNQl):c. l661T
>C (p.Val554Ala) 3784 KCNQ1 []
NM_000218.2(KCNQl):c. l700T ['CTTCTCTCCAGGCTGGACCAGTCCABTGGGA
1997 >C (p.Ile567Thr) 3784 KCNQ1 AGCCCTCACTGTTCATCTCC]
NM_000218.2(KCNQl):c.2T>C
(p.MetlThr) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.341T>
C (p.Leul l4Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.560T> ['GGCTGCCGCAGCAAGTACGTGGGCCYCTGG
1998 C (p.Leul87Pro) 3784 KCNQ1 GGGCGGCTGCGCTTTGCCCGG]
NM_000218.2(KCNQl):c.572T>
C (p.Leul91Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.716T>
C (p.Leu239Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.752T> 3784 KCNQ1 [] C (p.Leu251Pro)
NM_000218.2(KCNQl):c.797T>
C (p.Leu266Pro) 3784 KCNQ1 []
NM_000218.2(KCNQ 1 ) : c.824T>
C (p.Phe275Ser) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.910T>
C (p.Trp304Arg) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.913T>
C (p.Trp305Arg) 3784 KCNQ1 []
NM_000492.3 (CFTR) :c .1021 T> ['CCTCCGGAAAATATTCACCACCATCYCATTC
1999 C (p.Ser341Pro) 1080 CFTR TGCATTGTTCTGCGCATGGC]
NM_000492.3(CFTR):c.l853T> ['TTAAAGAAAGCTGACAAAATATTAAYTTTG
2000 C (p.Ile618Thr) 1080 CFTR CATGAAGGTAGCAGCTATTTT']
NM_000492.3(CFTR):c.2780T> ['TACGTGGGAGTAGCCGACACTTTGCYTGCTA
2001 C (p.Leu927Pro) 1080 CFTR TGGGATTCTTCAGAGGTCTA']
NM_000492.3(CFTR):c.3230T> ['GGACGGCAGCCTTACTTTGAAACTCYGTTCC
2002 C (p.Leul077Pro) 1080 CFTR ACAAAGCTCTGAATTTACAT']
NM_007294.3(BRCAl):c. ll5T> ['GATCAAGGAACCTGTCTCCACAAAGNGTGA
2003 C (p.Cys39Arg) 672 BRCA1 CCACATATTTTGCAAGTAAGT']
NM_007294.3(BRCAl):c. l90T> ['GAAAGGGCCTTCACAGTGTCCTTTABGTAAG
2004 C (p.Cys64Arg) 672 BRCA1 AATGATATAACCAAAAGGTA']
NM_007294.3(BRCAl):c.212+2 ['ATGTAAGAATGATATAACCAAAAGGYATAT
2005 T>C 672 BRCA1 AATTTGGTAATGATGCTAGGT']
NM_007294.3(BRCAl):c.2T>C ['TAAAGTTC ATTGGAAC AGAAAGAAAB GGAT
2006 (p.MetlThr) 672 BRCA1 TTATCTGCTCTTCGCGTTGAA]
NM_007294.3(BRCAl):c.4357+ ['CAGAACAAAGCACATCAGAAAAAGGBGTGT
2007 2T>C 672 BRCA1 ATTGTTGGCCAAACACTGATA']
NM_007294.3(BRCAl):c.5291T ['CTCTTCTTCCAGATCTTCAGGGGGCYAGAAA
2008 >C (p.Leul764Pro) 672 BRCA1 TCTGTTGCTATGGGCCCTTC]
NM_007294.3(BRCAl):c.65T>C ['GTCATTAATGCTATGCAGAAAATCTYAGAGT
2009 (p.Leu22Ser) 672 BRCA1 GTCCCATCTGGTAAGTCAGC]
NM_005236.2(ERCC4):c.689T> ['ATGCTTGCTATACAGACTGCTATACYGGACA
2010 C (p.Leu230Pro) 2072 ERCC4 TTTTAAATGCATGTCTAAAG]
NM_005236.2(ERCC4):c.706T> ['TGCTATACTGGACATTTTAAATGCAYGTCTA
2011 C (p.Cys236Arg) 2072 ERCC4 AAGGAACTAAAATGCCATAA]
NM_000435.2(NOTCH3):c.4556 ['GGCGTGCTGGTGCTCACAGTGCTGCYGCCGC
2012 T>C (p.Leul519Pro) 4854 NOTCH3 CAGAGGAGCTACTGCGTTCC]
NM_153704.5(TMEM67):c. l046 ['GGAAATTTTCTCAAGTGGCAAACTTYAGAA
2013 T>C (p.Leu349Ser) 91147 TMEM67 GGAGGTGTTTTACAGGTAAGC]
NM_001142519.1(FAMl l lA):c. ['GTCTAAAAAAGCAGAAAGTCCAGAGYATGT
2014 1531T>C (p.Tyr511His) 63901 FAMl l lA CCATATGTATACTCAAAGAAG]
NM_014795.3(ZEB2):c.3211T> ['GCGCTTCTCACACTCGGGCTCGTACYCGCAG
2015 C (p.Serl071Pro) 9839 ZEB2 CACATGAATCACAGGTATTC]
2016 NM_001199107.1(TBClD24):c. 57465 TBC1D24 ['CCCCTCTGCTACTTCGCCCGGGTCTYTGACG 686T>C (p.Phe229Ser) TCTTCCTGGTGGAGGGCTAC]
NM_022114.3(PRDM16):c.2660 ['GTGGGAGCCCTGAAGGAGAAGTACCYGCGG
2017 T>C (p.Leu887Pro) 63976 PRDM16 CCGTCCCCGCTGCTCTTCCAC]
NM_001130089.1(KARS):c.517 ['AGCTTCTGGGGGAAAGCTCATCTTCYATGAT
2018 T>C (p.Tyrl73His) 3735 KARS CTTCGAGGAGAGGGGGTGAA']
NM_005689.2(ABCB6):c.1067T ['CTCATCTTCTCCCACCTGCACGAGCYCTCAC
2019 >C (p.Leu356Pro) 10058 ABCB6 TGCGCTGGCACCTGGGGCGC]
NM_001070.4(TUB Gl ) :c .1160T ['CCCCTGTTTTCTGCACACCCCAAGCYCTTCG
2020 >C (p.Leu387Pro) 7283 TUBG1 AGAGAACCTGTCGCCAGTAT']
NM_001283009.1(RTELl):c.373 ['CGGGCCCCTCTCAGCAGGCTGTGTGYGCCA
2021 0T>C (p.Cysl244Arg) -1 - GGGCTGTGGGGCAGAGGACGT']
NM_001135021.1(ELMOD3):c.7 ['ATCACCCACATTGCCATCCAGGCCTYGAGA
2022 94T>C (p.Leu265Ser) 84173 ELMOD3 GAGGAGTGTCTCTCCAGGTGA']
NM_001382.3(DPAGTl):c.503T ['CTACCATCTCTCCCCGCAGGAATCCYGTACT
2023 >C (p.Leul68Pro) 1798 DPAGT1 ATGTCTACATGGGGCTGCTG]
['CCATAAAATTCTTCTTAGTAGCTATYACCTT
2024 m.l0237T>C 4537 MT-ND3 CTTATTATTTGATCTAGAAA']
['TCCCTTCCCCTACTCATCGCACTAAYTTACA
2025 m.l l253T>C 4538 MT-ND4 CTCACAACACCCTAGGCTCA']
['ATCCTTCTTGCTCATCAGTTGATGAYACGCC
2026 m.l2811T>C 4540 MT-ND5 CGAGCAGATGCCAACACAGC]
['ATTCAGCTTCCTACACTATTAAAGTYTACCA
2027 m.l4325T>C 4541 MT-ND6 CAACCACCACCCCATCATAC]
NM_000142.4(FGFR3):c.2419T ['ACCCAGCAGTGGGGGCTCGCGGACGNGAAG
2028 >C (p.Ter807Arg) 2261 FGFR3 GGCCACTGGTCCCCAACAATG]
NM_000370.3(TTPA):c.548T>C ['GTAGCCAAGAAGATTGCTGCTGTACYTACG
2029 (p.Leul83Pro) 7274 TTPA GTAAATGTATATTTTAACTGT']
NM_000375.2(UROS):c.l39T>C ['TGAGTTTTTGTCTCTTCCCAGTTTCYCTGAGA
2030 (p.Ser47Pro) 7390 UROS AGGTAAGGCCTGTTGTGAC]
NM_001006657.1(WDR35):c.l5 ['TCTGGCACCATTCAGAGATACAGTCYACCTA
2031 92T>C (p.Leu531Pro) 57539 WDR35 ATGTTGGTTTGATTCAAAAA']
NM_001876.3(CPTlA):c.l451T ['GCAGATGCGCCGATCGTGGCCCACCYTTGG
2032 >C (p.Leu484Pro) 1374 CPT1A GAGGTGAGTTTTCACACTTTT']
NM_004595.4(SMS):c.449T>C ['GACGAAGATTCACCTTATCAAAATAYAAAA
2033 (p.Ilel50Thr) 6611 SMS ATTCTACACTCGAAGCAGTTT']
NM_005211.3(CSFlR):c.2483T> ['AAGTGGATGGCCCCAGAGAGCATCTYTGAC
2034 C (p.Phe828Ser) 1436 CSF1R TGTGTCTACACGGTTCAGAGC]
NM_170707.3(LMNA):c.644T> ['TCCTTCCTCCAACCCTTCCAGGAGCYGCGTG
2035 C (p.Leu215Pro) 4000 LMNA AGACCAAGCGCCGTCATGAG]
NM_194248.2(OTOF):c.3413T> ['CCACCCTCCAACCTCTCCCAGGTGCYGTTCT
2036 C (p.Leul l38Pro) 9381 OTOF GGGGCCTACGGGACCTAAAG]
NM_000540.2(RYRl):c.14762T ['TACAGGGTGGTCTTCGACATCACCTYCTTCT
2037 >C (p.Phe4921Ser) 6261 RYR1 TCTTCGTCATCGTCATCCTG]
2038 NM_000540.2(RYRl):c.7358T> 6261 RYR1 ['GCCGGCAAGGGTGAGGCCCTGCGGAYCCGC C (p.Ile2453Thr) GCCATCCTCCGCTCCCTTGTG]
NM_000540.2(RYRl):c. l0817T ['GAAGTGTCAGCCGTGCTCTACTACCYGGACC
2039 >C (p.Leu3606Pro) 6261 RYR1 AGGTGGGTGGGGCCGGAGGG]
NM_000540.2(RYRl):c.13703T ['TTTTACACCCTGCGGTTCCTTGCCCYCTTCTT
2040 >C (p.Leu4568Pro) 6261 RYR1 GGCATTTGCCATCAACTTC']
NM_000540.2(RYRl):c. l3949T ['CCCGCCCTGCGGTGTCTGAGCCTCCYGCATA
2041 >C (p.Leu4650Pro) 6261 RYR1 CACTGGTGGCCTTTCTCTGC]
NM_000540.2(RYRl):c.14378T ['GTGTGCCCACAGTCCTTCCTGTACCYGGGCT
2042 >C (p.Leu4793Pro) 6261 RYR1 GGTATATGGTGATGTCCCTC]
NM_015896.3(ZMYND10):c.79 ['CTCAGGGCTTAGCAGCAGGTTGTACRGGGC
2043 7T>C (p.Leu266Pro) 51364 ZMYND10 GATCCACACTTGCCCGTCCAA']
NM_018127.6(EL AC2) : c.460T> ['AAAATACCTCGAAGCAATCAAAATAYTTTCT
2044 C (p.Phel54Leu) 60528 ELAC2 GGTCCATTGAAAGGAATAGA']
NM_199355.2(ADAMTS18):c.6 17069 ADAMTSl ['CCTGCGGGTCACCATCCTCACGTACYGTACA
2045 05T>C (p.Leu202Pro) 2 8 AAAGGACAGCAGAGGAGAAG]
NM_023110.2(FGFRl):c.494T> [TCCCCAGAAAAGATGGAAAAGAAATYGCAT
2046 C (p.Leul65Ser) 2260 FGFR1 GCAGTGCCGGCTGCCAAGACA']
NM_001059.2(TACR3):c.766T> ['CCATATTATCGTCATTATACTGGTGYACTGT
2047 C (p.Tyr256His) 6870 TACR3 TTCCCATTGCTCATCATGGG]
NM_002055.4(GFAP):c. l070T> ['TACCAGGACCTGCTCAATGTCAAGCHGGCC
2048 C (p.Leu357Pro) 2670 GFAP CTGGACATCGAGATCGCCACC]
NM_002055.4(GFAP):c. l076T> ['GACCTGCTCAATGTCAAGCTGGCCCYGGAC
2049 C (p.Leu359Pro) 2670 GFAP ATCGAGATCGCCACCTACAGG]
NM_002055.4(GFAP):c. l096T> ['GGCCCTGGACATCGAGATCGCCACCYACAG
2050 C (p.Tyr366His) 2670 GFAP GAAGCTGCTAGAGGGCGAGGA]
NM_002055.4(GFAP):c.221T>C ['CGGGCCAGTGAGCGGGCAGAGATGAYGGAG
2051 (p.Met74Thr) 2670 GFAP CTCAATGACCGCTTTGCCAGC]
NM_002055.4(GFAP):c.247T>C ['GGAGCTCAATGACCGCTTTGCCAGCYACATC
2052 (p.Tyr83His) 2670 GFAP GAGAAGGTTCGCTTCCTGGA']
NM_002055.4(GFAP):c.269T>C ['AGCTACATCGAGAAGGTTCGCTTCCYGGAA
2053 (p.Leu90Pro) 2670 GFAP CAGCAAAACAAGGCGCTGGCT']
NM_002055.4(GFAP):c.290T>C ['TTCCTGGAACAGCAAAACAAGGCGCYGGCT
2054 (p.Leu97Pro) 2670 GFAP GCTGAGCTGAACCAGCTGCGG]
NM_002055.4(GFAP):c.302T>C ['CAAAACAAGGCGCTGGCTGCTGAGCYGAAC
2055 (p.LeulOlPro) 2670 GFAP CAGCTGCGGGCCAAGGAGCCC]
NM_002055.4(GFAP):c.704T>C ['GCCAAGCCAGACCTCACCGCAGCCCYGAAA
2056 (p.Leu235Pro) 2670 GFAP GAGATCCGCACGCAGTATGAG]
NM_002055.4(GFAP):c.739T>C ['CCGCACGCAGTATGAGGCAATGGCGYCCAG
2057 (p.Ser247Pro) 2670 GFAP CAACATGCATGAAGCCGAAGA']
NM_002055.4(GFAP):c.992T>C ['AGTTATCAGGAGGCGCTGGCGCGGCYGGAG
2058 (p.Leu331Pro) 2670 GFAP GAAGAGGGGCAGAGCCTCAAG]
NM_005554.3 (KRT6 A) :c .1406T ['GAGATCGCCACCTACCGCAAGCTGCBGGAG
2059 >C (p.Leu469Pro) 3853 KRT6A GGTGAGGAGTGCAGGTGGGTA']
2060 NM_005554.3(KRT6A):c.521T> 3853 KRT6A ['CAGATCAAGACCCTCAACAACAAGTBTGCC C (p.Phel74Ser) TCCTTCATCGACAAGGTGAGC]
NM_153490.2(KRT13):c.332T> ['AATGAGAAGATCACCATGCAGAACCYCAAC
2061 C fp.Leul llPro) 3860 KRT13 GACCGCCTGGCTTCCTACCTG]
NM_170707.3(LMNA):c. l619T> ['CCATGTCCCCACCAGGAAGTGGCCAYGCGC
2062 C (p.Met540Thr) 4000 LMNA AAGCTGGTGCGCTCAGTGACT']
NM_000218.2(KCNQl):c.1117T
>C (p.Ser373Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c. l l35T ['TCCCCCTGCCCGACCTCAGACCGCABGGAG
2063 >C (p.Trp379Arg) 3784 KCNQ1 GTGCTATGCTGCCGAGAACCC]
NM_000218.2(KCNQl):c.1165T
>C (p.Ser389Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.1174T
>C (p.Trp392Arg) 3784 KCNQ1 []
NM_000218.2(KCNQl):c. l550T
>C (p.Ile517Thr) 3784 KCNQ1 []
NM_000218.2(KCNQl):c. l696T
>C (p.Ser566Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c. l805T
>C (p.Leu602Pro) -1 - []
NM_000218.2(KCNQl):c.401T>
C (p.Leul34Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.550T> ['CTGGTCCGCCGGCTGCCGCAGCAAGBACGT
2064 C (p.Tyrl84His) 3784 KCNQ1 GGGCCTCTGGGGGCGGCTGCG]
NM_000218.2(KCNQ 1 ) : c.608T>
C (p.Leu203Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.625T>
C (p.Ser209Pro) 3784 KCNQ1 []
NM_000218.2(KCNQ 1 ) : c.742T>
C (p.Trp248Arg) 3784 KCNQ1 []
NM_000218.2(KCNQ 1 ) : c.749T> ['GACCGCCAGGGAGGCACCTGGAGGCHCCTG
2065 C (p.Leu250Pro) 3784 KCNQ1 GGCTCCGTGGTCTTCATCCAC]
NM_000218.2(KCNQ 1 ) : c.829T>
C (p.Ser277Pro) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.832T>
C (p.Tyr278His) 3784 KCNQ1 []
NM_000218.2(KCNQl):c.845T>
C (p.Leu282Pro) 3784 KCNQ1 []
NM_000218.2(KCNQ 1 ) : c.908T>
C (p.Leu303Pro) 3784 KCNQ1 []
NM_000238.3 (KCNH2) : c.122T> ['AACGCTCGGGTGGAGAACTGCGCCGBCATC
2066 C (p.Val41Ala) 3757 KCNH2 TACTGCAACGACGGCTTCTGC]
NM_000238.3 (KCNH2) : c.1238T
>C (p.Leu413Pro) 3757 KCNH2 []
NM_000238.3(KCNH2):c. l279T 3757 KCNH2 [] >C (p.Tyr427His)
NM_000238.3 (KCNH2) : c.1387T
>C (p.Phe463Leu) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.160T>
C (p.Tyr54His) 3757 KCNH2 []
NM_000238.3(KCNH2):c. l655T ['GAGTACGGCGCGGCCGTGCTGTTCTYGCTCA
2067 >C (p.Leu552Ser) 3757 KCNH2 TGTGCACCTTTGCGCTCATC]
NM_000238.3(KCNH2):c. l691T
>C (p.Leu564Pro) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.1700T
>C (p.Ile567Thr) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.1702T
>C (p.Trp568Arg) 3757 KCNH2 []
NM_000238.3(KCNH2):c. l705T
>C (p.Tyr569His) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.1736T
>C (p.Met579Thr) 3757 KCNH2 []
NM_000238.3(KCNH2):c. l778T ['TGGCTGCACAACCTGGGCGACCAGANAGGC
2068 >C (p.Ile593Thr) 3757 KCNH2 AAACCCTACAACAGCAGCGGC]
NM_000238.3(KCNH2):c. l816T
>C (p.Ser606Pro) 3757 KCNH2 []
NM_000238.3(KCNH2):c. l879T ['CTTCAGCAGCCTCACCAGTGTGGGCHTCGGC
2069 >C (p.Phe627Leu) 3757 KCNH2 AACGTCTCTCCCAACACCAA']
NM_000238.3(KCNH2):c. l889T
>C (p.Val630Ala) 3757 KCNH2 []
NM_000238.3(KCNH2):c. l945T
>C (p.Ser649Pro) 3757 KCNH2 []
NM_000238.3(KCNH2):c. l985T
>C (p.Ile662Thr) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.202T>
C (p.Phe68Leu) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.2033 T
>C (p.Leu678Pro) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.206T>
C (p.Leu69Pro) 3757 KCNH2 []
NM_000238.3(KCNH2):c.2078T
>C (p.Leu693Pro) 3757 KCNH2 []
NM_000238.3(KCNH2):c.2309T
>C (p.Val770Ala) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.2414T ['TGGCCTCCAGGGAAGAATGACATCTBTGGG
2070 >C (p.Phe805Ser) 3757 KCNH2 GAGCCTCTGAACCTGTATGCA]
NM_000238.3(KCNH2):c.2452T
>C (p.Ser818Pro) 3757 KCNH2 []
NM_000238.3(KCNH2):c.2573T 3757 KCNH2 [] >C (p.Ile858Thr)
NM_000238.3(KCNH2):c.257T> ['GCTGCCGCGCAGATCGCGCAGGCACBGCTG
2071 C (p.Leu86Pro) 3757 KCNH2 GGCGCCGAGGAGCGCAAAGTG]
NM_000238.3 (KCNH2) : c.260T>
C (p.Leu87Pro) 3757 KCNH2 []
NM_000238.3(KCNH2):c.287T>
C (p.Ile96Thr) 3757 KCNH2 []
NM_000238.3(KCNH2):c.3146T
>C (p.Leul049Pro) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.322T>
C (p.Cysl08Arg) 3757 KCNH2 []
NM_000238.3(KCNH2):c.371T> ['AAGAACGAGGATGGGGCTGTC ATCAB GTTC
2072 C (p.Metl24Thr) 3757 KCNH2 ATCCTCAATTTCGAGGTGGTG]
NM_000238.3(KCNH2):c.65T>
C (p.Phe22Ser) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.86T>
C (p.Phe29Ser) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.872T>
C (p.Met291Thr) 3757 KCNH2 []
NM_000238.3(KCNH2):c.89T>
C (p.Ile30Thr) 3757 KCNH2 []
NM_000238.3 (KCNH2) : c.92T> ['GCCCCCCTAGGCCGTAAGTTCATCABCGCCA
2073 C (p.Ile31Thr) 3757 KCNH2 ACGCTCGGGTGGAGAACTGC]
NM_000891.2(KCN!2):c.301T>
C (p.CyslOlArg) 3759 KCNJ2 []
NM_000891.2(KCN12):c.650T>
C (p.Leu217Pro) 3759 KCNJ2 []
NM_000335.4(SCN5A):c.l l87T
>C (p.Val396Ala) 6331 SCN5A []
NM_000335.4(SCN5A):c.l l90T
>C (p.Ile397Thr) 6331 SCN5A []
NM_000335.4(SCN5A):c.2018T
>C (p.Leu673Pro) 6331 SCN5A []
NM_000335.4(SCN5A):c.2516T
>C (p.Leu839Pro) 6331 SCN5A []
NM_000335.4(SCN5A):c.2551T
>C (p.Phe851Leu) 6331 SCN5A []
NM_000335.4(SCN5A):c.2743T
>C (p.Cys915Arg) 6331 SCN5A []
NM_000335.4(SCN5A):c.2783T
>C (p.Leu928Pro) 6331 SCN5A []
NM_000335.4(SCN5A):c.278T>
C (p.Phe93Ser) 6331 SCN5A []
NM_000335.4(SCN5A):c.2804T 6331 SCN5A [] >C (p.Leu935Pro)
NM_000335.4(SCN5A):c.2944T ['CAAGCGGACCACCTGGGATTTCTGCYGTGGT
2074 >C (p.Cys982Arg) 6331 SCN5A CTCCTGCGGCAGCGGCCTCA]
NM_198056.2(SCN5A):c.3010T ['TGCCGCCCAGGGCCAGCTGCCCAGCYGCAT
2075 >C (p.Cysl004Arg) 6331 SCN5A TGCCACCCCCTACTCCCCGCC]
NM_000335.4(SCN5A):c.3679T ['TTGTCTGCAGGCCTTCGAGGACATCYACCTA
2076 >C (p.Tyrl227His) 6331 SCN5A GAGGAGCGGAAGACCATCAA]
NM_000335.4(SCN5A):c.3713T
>C (p.Leul238Pro) 6331 SCN5A []
NM_000335.4(SCN5A):c.3745T ['TGCCGACAAGATGTTCACATATGTCYTCGTG
2077 >C (p.Phel249Leu) 6331 SCN5A CTGGAGATGCTGCTCAAGTG]
NM_000335.4(SCN5A):c.3929T
>C (p.Leul310Pro) 6331 SCN5A []
NM_000335.4(SCN5A):c.4027T
>C (p.Phel343Leu) 6331 SCN5A []
NM_000335.4(SCN5A):c.4028T
>C (p.Phel343Ser) 6331 SCN5A []
NM_000335.4(SCN5A):c.4034T
>C (p.Leul345Pro) 6331 SCN5A []
NM_000335.4(SCN5A):c.4046T
>C (p.Ilel349Thr) 6331 SCN5A []
NM_000335.4(SCN5A):c.407T>
C (p.Leul36Pro) 6331 SCN5A []
NM_000335.4(SCN5A):c.4340T
>C (p.Ilel447Thr) 6331 SCN5A []
NM_000335.4(SCN5A):c.4415T [TTTATTGGTGTCATCATTGACAACTBCAACC
2078 >C (p.Phel472Ser) 6331 SCN5A AACAGAAGAAAAAGATACGT']
NM_000335.4(SCN5A):c.4453T
>C (p.Phel485Leu) 6331 SCN5A []
NM_198056.2(SCN5A):c.4493T
>C (p.Metl498Thr) 6331 SCN5A []
NM_000335.4(SCN5A):c.4742T
>C (p.Leul581Pro) 6331 SCN5A []
NM_000335.4(SCN5A):c.4778T
>C (p.Phel593Ser) 6331 SCN5A []
NM_000335.4(SCN5A):c.4952T ['CGCACGCTGCTCTTTGCCCTCATGABGTCCC
2079 >C (p.Metl651Thr) 6331 SCN5A TGCCTGCCCTCTTCAACATC]
NM_000335.4(SCN5A):c.5111T
>C (p.Phel704Ser) 6331 SCN5A []
NM_000335.4(SCN5A):c.5179T
>C (p.Cysl727Arg) 6331 SCN5A []
NM_000335.4(SCN5A):c.544T>
C (p.Cysl82Arg) 6331 SCN5A []
2080 NM_000335.4(SCN5A):c.5471T 6331 SCN5A ['TTTGCCGATGCCCTGTCTGAGCCACYCCGTA >C (p.Leul824Pro) TCGCCAAGCCCAACCAGATA]
NM_198056.2(SCN5A):c.5624T ['GAGATGGACGCCCTGAAGATCCAGAHGGAG
2081 >C (p.Metl875Thr) 6331 SCN5A GAGAAGTTCATGGCAGCCAAC]
NM_000335.4(SCN5A):c.635T> ['AGATACACAACTGAATTTGTGGACCHGGGC
2082 C (p.Leu212Pro) 6331 SCN5A AATGTCTCAGCCTTACGCACC]
NM_000335.4(SCN5A):c.689T>
C (p.Ile230Thr) 6331 SCN5A []
NM_198056.2(SCN5A):c.944T>
C (p.Leu315Pro) 6331 SCN5A []
NM_177976.2(ARL6):c.272T>C ['TTACACAGAGAAGGCCAAGCTATTAYTTTTG
2083 (p.Ile91Thr) 84100 ARL6 TCATTGATAGTAGTGATAGA']
NM_000487.5(ARSA):c.899T>C ['TCCCGAGGCGGCTGCTCCGGTCTCTYGCGGT
2084 (p.Leu300Ser) 410 ARSA GTGGAAAGGGAACGACCTAC]
NM_000267.3(NFl):c.l595T>C ['GAATTAATTACAGGGCTCGTCCAACYGGTCC
2085 (p.Leu532Pro) 4763 NF1 CTCAGTCACACATGCCAGAG]
NM_001042492.2(NFl):c.2288T ['CTTCAGAAAAGAGTGATGGCACTGCBGAGG
2086 >C (p.Leu763Pro) 4763 NF1 CGCATTGAGCATCCCACTGCA']
NM_004990.3(MARS):c. l l08T> ['CCTCACCAGAATCACCCAGGACATTYTCCAG
2087 C (p.Phe370Leu) 4141 MARS CAGTTGCTGAAACGAGGTTT']
NM_004990.3(MARS):c. l568T> ['TTCTATGTCTGGTTTGATGCCACTAYTGGCT
2088 C (p.Ile523Thr) 4141 MARS ATCTGTCCATCACAGCCAAC]
NM_006920.4(SCNlA):c.4729T ['GTTCATTGTGCTATTTACTGGAGAGYGTGTA
2089 >C (p.Cysl577Arg) -1 - CTGAAACTCATCTCTCTACG]
NM_006920.4(SCNlA):c.5113T ['TGAGACCTTTGGCAACAGCATGATCYGCCTA
2090 >C (p.Cysl705Arg) -1 - TTCCAAATTACAACCTCTGC]
NM_006920.4(SCNlA):c.838T> ['CAACCTGAGGAATAAATGTATACAAYGGCC
2091 C (p.Trp280Arg) 6323 SCN1A TCCCACCAATGCTTCCTTGGA']
NM_006920.4(SCNlA):c.269T> ['TGTTGTGTTCCTGTCTTACAGACTTYTATAGT
2092 C (p.Phe90Ser) 6323 SCN1A ATTGAATAAAGGGAAGGCC]
NM_006920.4(SCNlA):c.272T> ['TGTGTTCCTGTCTTACAGACTTTTAYAGTATT
2093 C (p.Ile91Thr) 6323 SCN1A GAATAAAGGGAAGGCCATC]
NM_006920.4(SCNlA):c.3827T ['TATTTCACCAATGCCTGGTGTTGGCYGGACT
2094 >C (p.Leul276Pro) -1 - TCTTAATTGTTGATGTAGGT']
NM_006920.4(SCNlA):c.5522T ['CCAAACAAACTCCAGCTCATTGCCAYGGATT
2095 >C (p.Metl841Thr) -1 - TGCCCATGGTGAGTGGTGAC]
NM_006920.4(SCNlA):c.568T> ['AGATTTTACTTTCCTTCGGGATCCAYGGAAC
2096 C (p.Trpl90Arg) 6323 SCN1A TGGCTCGATTTCACTGTCAT']
NM_002608.2(PDGFB):c.356T> ['ATAGACCGCACCAACGCCAACTTCCYGGTG
2097 C (p.Leul l9Pro) 5155 PDGFB TGGCCGCCCTGTGTGGAGGTG]
NM_000833.4(GRIN2A):c.2T>C ['TTGCAGGGACCGTCAGTGGCGACTAYGGGC
2098 (p.MetlThr) 2903 GRIN2A AGAGTGGGCTATTGGACCCTG]
NM_002474.2(MYHl l):c.3791T ['CTCCCCATCGCTGCACTTGGACTGCDGCTCC
2099 >C (p.Leul264Pro) 4629 MYH11 TGCACCTGCGCCTCCAGCTT']
2100 NM_014139.2(SCNl lA):c.2432 11280 SCN11A ['CTCAACCTCTTCATTGCCTTACTGCYCAATT T>C (p.Leu811Pro) CCTTTAGCAATGAGGAAAGA]
NM_006514.3(SCN10A):c.l661 ['GGAGTCAGGGTTGCTGGGTTGAGGARGAGG
2101 T>C (p.Leu554Pro) 6336 SCN10A GCTTCTAGGGAGGGGGCCTTG]
NM_000179.2(MSH6):c.l346T> ['CTTATTGGAGTCAGTGAACTGGGGCYGGTAT
2102 C (p.Leu449Pro) 2956 MSH6 TCATGAAAGGCAACTGGGCC]
NM_000179.2(MSH6):c.4001+2 ['GAATCAGTCACTACGATTATTTCGGYAACTA
2103 T>C 2956 MSH6 ACTAACTATAATGGAATTAT']
NM_000249.3(MLHl):c. l745T> ['GCTTCTTCCTAGGAGCCAGCACCGCYCTTTG
2104 C (p.Leu582Pro) 4292 MLH1 ACCTTGCCATGCTTGCCTTA']
NM_000249.3 (MLH 1 ) : c.2246T> ['CTGCAGCTTGCTAACCTGCCTGATCHATACA
2105 C (p.Leu749Pro) 4292 MLH1 AAGTCTTTGAGAGGTGTTAA']
NM_000249.3(MLHl):c.229T>C ['ACAGAAAGAAGATCTGGATATTGTAYGTGA
2106 (p.Cys77Arg) 4292 MLH1 AAGGTTCACTACTAGTAAACT']
NM_000249.3(MLHl):c.453+2T ['GGCAATCAAGGGACCCAGATCACGGYAAGA
2107 >C 4292 MLH1 ATGGTACATGGGAGAGTAAAT']
NM_000249.3(MLHl):c.739T>C ['AGCCTTCAAAATGAATGGTTACATABCCAAT
2108 (p.Ser247Pro) 4292 MLH1 GCAAACTACTCAGTGAAGAA']
NM_000249.3 (MLH 1 ) : c.790+2T ['GCATCTTCTTACTCTTCATCAACCGHAAGTT
2109 >C 4292 MLH1 AAAAAGAACCACATGGGAAA']
NM_000251.2(MSH2) :c.1319T> ['TTGTTGGCAGTTTTTGTGACTCCTCYTACTG
2110 C (p.Leu440Pro) 4436 MSH2 ATCTTCGTTCTGACTTCTCC]
NM_000251.2(MSH2):c.2005+2 ['AACAGATGTTCCACATCATTACTGGYAAAA
2111 T>C 4436 MSH2 AACCTGGTTTTTGGGCTTTGT']
NM_000251.2(MSH2):c.2089T> ['GGCCCAAATTGGGTGTTTTGTGCCAYGTGAG
2112 C (p.Cys697Arg) 4436 MSH2 TCAGCAGAAGTGTCCATTGT']
NM_000251.2(MSH2):c.560T>C ['CCTGATAATGATCAGTTCTCCAATCBTGAGG
2113 (p.Leul87Pro) 4436 MSH2 CTCTCCTCATCCAGATTGGA']
NM_000251.2(MSH2):c.595T>C ['CCTCATCCAGATTGGACCAAAGGAAYGTGT
2114 (p.Cysl99Arg) 4436 MSH2 TTTACCCGGAGGAGAGACTGC]
NM_000251.2(MSH2):c.929T>C ['TTGGATATTGCAGCAGTCAGAGCCCBTAACC
2115 (p.Leu310Pro) 4436 MSH2 TTTTTCAGGTAAAAAAAAAA']
NM_007294.3(BRCAl):c.134+2 ['AAAGTGTGACCACATATTTTGCAAGBAAGTT
2116 T>C 672 BRCA1 TGAATGTGTTATGTGGCTCC]
NM_001194998.1(CEP152):c.31 ['TATGAGGAAGACATCCTGACTGTACYTGGG
2117 49T>C (p.Leul050Pro) 22995 CEP 152 GTTCTTTTAAGTGATACCCAA']
NM_001271723.1 (FBX038) : c.6 ['AGGGGTGAATGTTCCTGAAATTCCTYGTATC
2118 16T>C (p.Cys206Arg) 81545 FBX038 CCAATGCTAAGGCACCTTTA']
M_014495.3(ANGPTL3):c.883 ['ACATCGAATAGATGGATCACAAAACYTCAA
2119 T>C (p.Phe295Leu) -1 - TGAAACGTGGGAGAACTACAA']
NM_003184.3(TAF2):c.l945T> ['CTCTCATAGCGGAGCTGATACTGCCRCATAA
2120 C (p.Trp649Arg) 6873 TAF2 AATCAGCTTGCTCAAATTCT']
NM_000016.5(ACADM):c.233T ['TTCTTCTAGTATCCAGTCCCCCTAAYTAGAA
2121 >C (p.Ile78Thr) 34 ACADM GAGCCTGGGAACTTGGTTTA']
2122 NM_000019.3(ACATl):c.730+2 38 ACAT1 ['TTCCTGTCACAGTTACAGTAAAAGGYAGAG T>C ATAATGTTCCAAAAAGGATGA]
NM_000143.3(FH):c. l255T>C ['GAAGCATCCCCCAGCAGCCTGGCTGRGTGT
2123 (p.Ser419Pro) 2271 FH AACACATTTTTAATCTTTGAG]
NM_000169.2(GLA):c.899T>C ['GCTCCTTTATTCATGTCTAATGACCYCCGAC
2124 (p.Leu300Pro) -1 - ACATCAGCCCTCAAGCCAAA]
NM_000202.6(IDS):c.587T>C ['GTGCTGGATGTTCCCGAGGGCACCTYGCCTG
2125 (p.Leul96Ser) 3423 IDS ACAAACAGAGCACTGAGCAA]
NM_000252.2(MTMl):c.688T> [TCTGACTTAACCATAGGTGCTGTCAYGGATT
2126 C (p.Trp230Arg) 4534 MTM1 CATCCAGAAAATAAGACGGT']
NM_000277.1 (P AH) : c.638T>C ['GAGTACAATCACATTTTTCCACTTCYTGAAA
2127 (p.Leu213Pro) 5053 PAH AGTACTGTGGCTTCCATGAA']
M_000404.2(GLBl):c.457+2T ['TTCTTCTCCGCTCCTCCGACCCAGGYAGGTT
2128 >C 2720 GLB1 GTTACAGATGTCTTGAGAAG]
NM_000528.3(MAN2Bl):c2436 ['AGAGATGGCTCGCTGGAGCTCATGGYGAGT
2129 +2T>C 4125 MAN2B1 GGGTCAGAGCCCCATCCGAGC]
NM_000531.5 (OTC) : c.540+2T> ['CTGGCTGATTACCTCACGCTCCAGGHTGGTT
2130 C 5009 OTC TATTTATTTGTCTTACAAAA']
NM_001005741.2(GBA):c.667T ['TTCACCGCTCCATTGGTCTTGAGCCRAGTGG
2131 >C (p.Trp223Arg) 2629 GBA GTGATGTCCAGGGGCTGGCA']
NM_000402.4(G6PD):c.473T>C ['CGCCTCAACAGCCACATGAATGCCCYCCAC
2132 (p.Leul58Pro) 2539 G6PD CTGGGGTCACAGGCCAACCGC]
NM_000402.4(G6PD):c.188T>C ['CACCGATGCACCCATGATGATGAATRTGTGT
2133 (p.Ile63Thr) -1 - GTATCCGACTGATGGAAGGC]
NM_006920.4(SCNlA):c.4251+ ['GGGTATCTCTCTTTGCTTCAAGTTGYAAGTG
2134 2T>C -1 - AACACTATTTTCTCTGAATA']
NM_002225.3(IVD):c.465+2T> ['CAGAAAGAGAAGTATCTCCCGAAGGYGAGG
2135 C 3712 IVD AAATGGAAATGTAATACACGC]
NM_003494.3(DYSF):c.1284+2 ['GAGGTCAGCTTTGCGGGGAAAATGGYAAGG
2136 T>C 8291 DYSF AGCAAGGGAGCAGGAGGGTTC]
NM_004006.2(DMD):c.2380+2T ['CCCTGGTGGAACAGATGGTGAATGGYAATT
2137 >C 1756 DMD ACACGAGTTGATTTAGATAAT']
NM_012463.3 (ATP6V0A2) : c.82 ['ACCCGCATCCAGGATCTCTACACTGYGAGTA
2138 5+2T>C 23545 ATP6V0A2 AGCTGGAAGTGGATTGCCTC]
NM_014795.3(ZEB2):c.73+2T> ['AAGCCAATCCCAGGAGGAAAAACGGYAAG
2139 C 9839 ZEB2 AAGCAGCCCGAACCAAACTTTT']
NM_016725.2(FOLRl):c.493+2 ['ACAAGGGCTGGAACTGGACTTCAGGYGAGG
2140 T>C 2348 FOLRl GCTGGGGTGGGCAGGAATGGA']
NM_000056.3(BCKDHB):c.752 ['CCTGTTCTGTATTTAGCGGAAGAAGYCCCTA
2141 T>C (p.Val251Ala) 594 BCKDHB TAGAACCATACAACATCCCA']
NM_175053.3(KRT74):c.821T> 12139 ['TACTGCATCATACAGACACTTGAGGRACTTG
2142 C (p.Phe274Ser) 1 KRT74 ATTTCTTTGTCCAGTGAGTC]
NM_003764.3(STXll):c.l73T> ['GACATTCAGGATGAAAACCAGCTGCYGGTG
2143 C (p.Leu58Pro) 8676 STX11 GCCGACGTGAAGCGGCTGGGA']
2144 M_001044.4(SLC6 A3 ) : c.671 T 6531 SLC6A3 ['CTCTGCAGACGTGGCGTGCTGCACCYCCACC >C (p.Leu224Pro) AGAGCCATGGCATCGACGAC]
NM_015662.2(IFT172):c.5179T ['CTGATGAATTTCAGCACGTCCTGGCRCACTG
2145 >C (p.Cysl727Arg) -1 - GGCTGTGGGAGGTCTGTGAG]
NM_015662.2(IFT172):c.4607T ['GCGCGTGGCATAGTAATGAGCGATCRGCAG
2146 >C (p.Leul536Pro) 26160 IFT172 CATCGTCTTGAACTCCTCATG]
M_014754.2(PTDSSl):c.794T ['ACCGGGAAGATCAAGAGAGCTGTTCYGCAG
2147 >C (p.Leu265Pro) 9791 PTDSS1 TTCACTCCTGCTAGCTGGACC]
M_014714.3(IFT140):c.4078T ['GGACCCCAAGGAGTCCATCAAGCAGYGTGA
2148 >C (p.Cysl360Arg) 9742 IFT140 GCTGCTCCTGGAGGAACCAGA']
NM_000531.5(OTC):c. l005+2T ['GAAAACAGAAAGTGGACAATCATGGYAAGC
2149 >C 5009 OTC AAGAAACAAGGAATGGAGGAT']
NM_000531.5(OTC):c. l018T>C ['GTTGTGTCATCAGGCTGTCATGGTGYCCCTG
2150 (p.Ser340Pro) 5009 OTC CTGACAGATTACTCACCTCA']
NM_000531.5(OTC):c. l022T>C ['TGTCATCAGGCTGTCATGGTGTCCCYGCTGA
2151 (p.Leu341Pro) 5009 OTC CAGATTACTCACCTCAGCTC]
NM_000531.5(OTC):c. l033T>C ['TGTCATGGTGTCCCTGCTGACAGATBACTCA
2152 (p.Tyr345His) 5009 OTC CCTCAGCTCCAGAAGCCTAA']
NM_000531.5(OTC):c. l43T>C ['CGTGACCTTCTCACTCTAAAAAACTYTACCG
2153 (p.Phe48Ser) 5009 OTC GAGAAGAAATTAAATATATG]
NM 000531.5 (OTC) : c.158T>C ['CTAAAAAACTTTACCGGAGAAGAAABTAAA
2154 (p.Ile53Thr) 5009 OTC TATATGCTATGGCTATCAGCA']
NM_000531.5(OTC):c. l67T>C ['TTTACCGGAGAAGAAATTAAATATAYGCTA
2155 (p.Met56Thr) 5009 OTC TGGCTATCAGCAGATCTGAAA']
NM_000531.5(OTC):c. l88T>C ['TATATGCTATGGCTATCAGCAGATCYGAAAT
2156 (p.Leu63Pro) 5009 OTC TTAGGATAAAACAGAAAGGA']
NM_000531.5 (OTC) : c.227T>C ['GTCCTTGATTTATAGTATTTGCCTTYATTGCA
2157 (p.Leu76Ser) 5009 OTC AGGGAAGTCCTTAGGCATG]
NM_000531.5 (OTC) : c.284T>C ['GAGAAAAGAAGTACTCGAACAAGATYGTCT
2158 (p.Leu95Ser) 5009 OTC ACAGAAACAGGTAAGTCCACT']
NM_000531.5(OTC):c.2T>C ['CGTCCTTTACACAATTAAAAGAAGAYGCTGT
2159 (p.MetlThr) 5009 OTC TTAATCTGAGGATCCTGTTA']
NM_000531.5 (OTC) : c.386+2T> ['TGAAAGTCTCACGGACACGGCCCGGYTTGT
2160 C 5009 OTC AAATATTTTCTTCTCTCCAAA']
NM_000531.5 (OTC) : c.392T>C ['TTTTTCTTGGTTTGCCACAGTGTATYGTCTAG
2161 (p.Leul31Ser) 5009 OTC CATGGCAGATGCAGTATTG]
NM_000531.5 (OTC) : c.394T>C ['TTTCTTGGTTTGCCACAGTGTATTGYCTAGC
2162 (p.Serl32Pro) 5009 OTC ATGGCAGATGCAGTATTGGC]
NM_000531.5 (OTC) : c.416T>C ['TTGTCTAGCATGGCAGATGCAGTATYGGCTC
2163 (p.Leul39Ser) 5009 OTC GAGTGTATAAACAATCAGAT']
NM_000531.5(OTC):c.443T>C ['GCTCGAGTGTATAAAC AATCAGATTB GGAC
2164 (p.Leul48Ser) 5009 OTC ACCCTGGCTAAAGAAGCATCC]
NM_000531.5 (OTC) : c.476T>C ['CTGGCTAAAGAAGCATCCATCCCAAYTATC
2165 (p.Ilel59Thr) 5009 OTC AATGGGCTGTCAGATTTGTAC]
2166 NM_000531.5(OTC):c.479T>C 5009 OTC ['GCTAAAGAAGCATCCATCCCAATTANCAAT (p.Ilel60Thr) GGGCTGTCAGATTTGTACCAT']
NM_000531.5 (OTC) : c.490T>C ['ATCCATCCCAATTATCAATGGGCTGYCAGAT
2167 (p.Serl64Pro) 5009 OTC TTGTACCATCCTATCCAGAT']
NM_000531.5 (OTC) : c.526T>C ['CCATCCTATCCAGATCCTGGCTGATYACCTC
2168 (p.Tyrl76His) 5009 OTC ACGCTCCAGGTTGGTTTATT']
NM_000531.5(OTC):c.536T>C ['CAGATCCTGGCTGATTACCTCACGCYCCAGG
2169 (p.Leul79Pro) 5009 OTC TTGGTTTATTTATTTGTCTT']
NM_000531.5 (OTC) : c.577T>C ['CTCTCTGAAAGGTCTTACCCTCAGCBGGATC
2170 (p.Tipl93Arg) 5009 OTC GGGGATGGGAACAATATCCT']
NM_000531.5 (OTC) : c.602T>C ['TGGATCGGGGATGGGAACAATATCCYGCAC
2171 (p.Leu201Pro) 5009 OTC TCCATCATGATGAGCGCAGCG]
NM_000531.5(OTC):c.663+2T> ['CACCTTCAGGCAGCTACTCCAAAGGYAGGG
2172 C 5009 OTC AAACTTTTTGCCTTGAAACTA']
NM_000531.5(OTC):c.779T>C ['GAAGCAGCGCATGGAGGCAATGTATYAATT
2173 (p.Leu260Ser) 5009 OTC ACAGACACTTGGATAAGCATG]
NM_000531.5(OTC):c.793T>C ['AGGCAATGTATTAATTACAGACACTYGGAT
2174 (p.Trp265Arg) 5009 OTC AAGCATGGGACAAGAAGAGGA']
NM_000531.5(OTC):c.803T>C ['TTAATTACAGACACTTGGATAAGCAYGGGA
2175 (p.Met268Thr) 5009 OTC CAAGAAGAGGAGAAGAAAAAG]
NM_000531.5 (OTC) : c.907T>C ['TGCCTCTGACTGGACATTTTTACACBGCTTG
2176 (p.Cys303Arg) 5009 OTC CCCAGAAAGCCAGAAGAAGT']
NM_000531.5 (OTC) : c.947T>C ['CCAGAAGAAGTGGATGATGAAGTCTYTTAT
2177 (p.Phe316Ser) 5009 OTC TCTCCTCGATCACTAGTGTTC]
NM_000322.4(PRPH2):c.637T> ['CCTGGTGGACGGCGTCCCTTTCAGCYGCTGC
2178 C (p.Cys213Arg) 5961 PRPH2 AATCCTAGCTCGCCACGGCC]
NM_000322.4(PRPH2):c.736T> ['CCACCAGACGGAGGAGCTCAACCTGYGGGT
2179 C (p.Trp246Arg) 5961 PRPH2 GCGTGGCTGCAGGGCTGCCCT']
NM_017415.2(KLHL3):c.l l60T
>C (p.Leu387Pro) 26249 KLHL3 []
NM_017415.2(KLHL3):c.l280T
>C (p.Met427Thr) 26249 KLHL3 []
NM_003859.1(DPMl):c.742T>C ['AGAGTCAATAATCCTTTCAAGAAAGRTACTA
2180 (p.Ser248Pro) -1 - TTTCATTTCCTCCCAACTTG]
NM_004826.3(ECELl):c.2278T ['GGGTTCATGGGTGAGTCCTTGGGACRGTGG
2181 >C (p.Cys760Arg) 9427 ECEL1 AAAGCCCGGCCAAACTCCTCA']
NM_014908.3(DOLK):c.2T>C ['GGCCGGAGATGGGCACTCTCGGGTCRTATCT
2182 (p.MetlThr) 22845 DOLK CTAGACCTGGGGCTTCACGG]
M_000404.2(GLB 1 ) :c .922T>C ['TCTTTTGTTTCCTTGTAGGTACATGYTTATAG
2183 (p.Phe308Leu) 2720 GLB1 GTGGGACCAATTTTGCCTA']
NM_012434.4(SLC17A5):c.500 ['TTAGGAGTTGGACCACTCATTGTACYCAGAG
2184 T>C (p.Leul67Pro) 26503 SLC17A5 CACTAGAAGGACTAGGAGAG]
NM_000211.4(ITGB2):c. l877+2 ['CCCCTCACCCTGTGGCAAGTACATGYGAGTG
2185 T>C 3689 ITGB2 CAGGCGGAGCAGGCAGGGCG]
2186 NM_006702.4(PNPLA6):c.3053 10908 PNPLA6 ['ACCTCCATGTTCACTGGGTCTGCCTYTAACC T>C (p.Phel018Ser) GCAGCATCCATCGGGTCTTC']
NM_176787.4(PIGN):c.808T>C [TCTGAAGGATGACCAGCCCCATGGGRACCT
2187 (p.Ser270Pro) 23556 PIGN ACAAATAAGATATAAAGAATA]
NM_001165899.1(PDE4D):c. l85 ['CCATGTCTCCCAGAGGGGATGAACARTATA
2188 0T>C (p.Ile617Thr) 5144 PDE4D GTCTATGAAGCCCACCTAGTT']
NM_005017.3(PCYTlA):c.571T ['CCTTCTGTCCTCTGTGTTGGAGCAARCATGC
2189 >C (p.Phel91Leu) 5130 PCYT1A CTAACTCAGAAACACATACA']
NM_000090.3(COL3Al):c.951+ ['CAGGACTTCCTGGGGCTGCAGTGAGHATAG
2190 6T>C (p.Gly300_Ala317del) 1281 COL3A1 CTGCTAACATCACACAATTAC]
NM_000090.3(COL3Al):c.2022 ['GCACCTGGAGCTCCAGGAGGCAAGGYAGTA
2191 +2T>C (p.Gly660_Lys674del) 1281 COL3A1 TTTCAATTTATTCTCTACCTT']
NM_000090.3(COL3Al):c.951+ ['CGGCCAGGACTTCCTGGGGCTGCAGHGAGT
2192 2T>C (p.Gly300_Ala317del) 1281 COL3A1 ATAGCTGCTAACATCACACAA']
NM_000090.3(COL3Al):c.3093 ['CGAGATGGATCTCCTGGTGGCAAGGBATAA
2193 +2T>C (p.Glyl014_Lysl031del) 1281 COL3A1 TAAACACATGTGCAATTGATT']
NM_000090.3(COL3Al):c.2337 ['CCAGCTGGCCAGCCTGGAGATAAGGYAACC
2194 +2T>C (p.Gly762_Lys779del) 1281 COL3A1 CTTAATACTACCTGGATATAA']
NM_000090.3(COL3Al):c.l761 ['TTCCCCGGTCCTAAAGGAAATGATGBGAGTT
2195 +2T>C (p.Gly555_Asp587del) 1281 COL3A1 CCTTCATTAATTTCTTCAAT']
NM_000090.3(COL3Al):c.3039
+6T>C
(p.Aspl013_Glyl014insVSSSFY ['CTGGTGAACCTGGAAGAGATGTGAGYAGCA
2196 STSQ) 1281 COL3A1 GTTTTTATTCAACCAGCCAGG]
NM_000090.3(COL3Al):c.4399 ['GGACGTTGGCCCTGTTTGCTTTTTAYAAACC
2197 T>C (p.Terl467Gln) 1281 COL3A1 AAACTCTATCTGAAATCCCA']
NM_000090.3(COL3Al):c.2553 ['CCCCCTGGAGGTTCTGGACCTGCTGYAAGTT
2198 +2T>C (p.Gly816_Ala851del) 1281 COL3A1 CCTTCCTCTTTCTCTGTCTA']
NM_001278503.1(STT3A):c. l87 ['TATACTCCAACTGGGGAGTTCCGTGYGGACC
2199 7T>C (p.Val626Ala) 3703 STT3A GTGAAGGTTCTCCAGTGCTG]
NM_000277.1(PAH):c.691T>C ['TAACATTCCCCAGCTGGAAGACGTTYCTCAG
2200 (p.Ser231Pro) 5053 PAH TTCCTGCAGAGTAAGTCCAC]
NM_007294.3(BRCAl):c.5467+ ['GGACAGAGGACAATGGCTTCCATGGBAAGG
2201 2T>C 672 BRCA1 TGCCTGCATGTACCTGTGCTA']
NM_020347.3 (LZTFL 1 ) : c.260T ['ATACCACTTCTCAGCTTGTGCAAACRGCTGT
2202 >C (p.Leu87Pro) 54585 LZTFL 1 CGCAGAAGTAACACATTGGT']
NM_016381.5(TREXl):c.530T> ['CGCCAGCCACAGCCCTGGTGCCTGGYGGCA
2203 C (p.Vall77Ala) 11277 TREXl CACAATGGTGACCGCTACGAC]
M_015474.3(SAMHDl):c. l l06 ['TTTGTGTTGATAAGCTCTACGGTGTRAAGAG
2204 T>C (p.Leu369Ser) 25939 SAMHDl TTGCGAGTGTGGAACATGTC]
NM_005654.5(NR2Fl):c.755T> ['CAGATCACCGACCAGGTGTCCCTGCYACGC
2205 C (p.Leu252Pro) 7025 NR2F1 CTCACCTGGAGCGAGCTGTTC]
NM_003638.2(ITGA8):c.2982+2 ['TGCCTATATATATTTAAAGATACTCRCTACT
2206 T>C 8516 ITGA8 ATGCTTCCTTCTGGGAGTTT']
2207 NM_000321.2(RBl):c.2663+2T> 5925 RBI ['AGGATCAGATGAAGCAGATGGAAGGYAGG C AACCAGTTTTGAATGTTTTCCA']
NM_000321.2(RBl):c. l472T>C ['CATATGTCTTTATTGGCGTGCGCTCYTGAGG
2208 (p.Leu491Pro) 5925 RBI TTGTAATGGCCACATATAGC]
NM_015884.3(MBTPS2):c.l391 ['GCTATTGTTAATGCAGTACCCTGCTYTGCTT
2209 T>C (p.Phe464Ser) 51360 MBTPS2 TGGATGGACAATGGATTCTA']
NM_001739.1(CA5A):c.697T>C ['TCGGTCAGCGGCGGGGTGGTGAGCGRGCCC
2210 (p.Ser233Pro) 763 CA5A GCGTAGGTCCAGTAATCCCAG]
NM_005051.2(QARS):c. l69T>C ['TCCCTGAGTCGGGAGGCCAAGCCATRTAAC
2211 (p.Tyr57His) 5859 QARS AGGATCCCGGTAGCTTTGTCA']
NM_005356.4(LCK):c. l022T>C ['GGCATCAAGTTGACCATCAACAAACYCCTG
2212 (p.Leu341Pro) 3932 LCK GACATGGCAGCCCAAGTAAGG]
NM_021803.3 (IL21 ) : c.146T>C ['TACCAAGTCATTCACATAATTTTTCRGCTGA
2213 (p.Leu49Pro) 59067 IL21 TCAACAATATCTATAAGTTG]
NM_005861.3(STUBl):c.719T> ['TGTGGCAAGATCAGCTTTGAGCTGAYGCGG
2214 C (p.Met240Thr) -1 - GAGCCGTGCATCACGCCCAGT']
NM_032575.2(GLIS2):c.523T>C ['TCAGAACACTTCCCATCCTCCGCAGYGTAAC
2215 (p.Cysl75Arg) 84662 GLIS2 CAGCTCTTTGAGCTCCTGCA']
NM_001101.3(ACTB):c.224T>C ['CTGAAGTACCCCATCGAGCACGGCAYCGTC
2216 (p.Ile75Thr) 60 ACTB ACCAACTGGGACGACATGGAG]
NM_001101.3(ACTB):c.356T>C ['AACCCCAAGGCCAACCGCGAGAAGAYGACC
2217 (p.Metll9Thr) 60 ACTB CAGGTGAGTGGCCCGCTACCT']
NM_003401.3(XRCC4):c. l27T> ['TACACTTACTGATGGTCATTCAGCAYGGACT
2218 C (p.Trp43Arg) 7518 XRCC4 GGGACAGGTAATACTAAAAA]
NM_000051.3(ATM):c.2638+2T ['CTGGAGAGAGCCAAAGTACCATAGGYAAAT
2219 >C 472 ATM ACATATTTACTACTTGGGATT']
NM_000535.5 (PMS2) : c.2T>C ['CGAGGCGGATCGGGTGTTGCATCCAHGGAG
2220 (p.MetlThr) 5395 PMS2 CGAGCTGAGAGCTCGAGGTGA']
NM_015713.4(RRM2B):c.l90T> ['ATGCCACGTACCTCTTCTGCTGTCCRGAAGG
2221 C (p.Trp64Arg) 50484 RRM2B AAGCCTGTGCCTGTTTATAC]
NM_015713.4(RRM2B):c.368T> ['CTCGATGAGAATTTGAAAGCCATAGRAACA
2222 C (p.Phel23Ser) 50484 RRM2B GCGAGCCTCTGGAACCTGCAC]
NM_003122.4(SPINKl):c.194+2 ['TTAAAAGAAACTCAAGTTTGTACTCRCCGAT
2223 T>C 6690 SPINK1 TTTCAAAACATAACACGCAT']
NM_003122.4(SPINKl):c.l60T> ['AAACATAACACGCATTCATTGGGATRAGTAT
2224 C (p.Tyr54His) 6690 SPINK1 TTCCATCAGTCCCACAGACA']
NM_000219.5(KCNEl):c. l58T>
C (p.Phe53Ser) 3753 KCNE1 []
NM_000219.5(KCNEl):c. l76T> ['GCGGATGTAGCTCAGCATGATGCCCRGGGT
2225 C (p.Leu59Pro) 3753 KCNE1 GAAGAAGCCGAAGAATCCCAG]
NM_000219.5 (KCNE 1 ) : c.259T>
C (p.Trp87Arg) 3753 KCNE1 []
NM_017890.4(VPS13B):c.11119 15768 ['CGTTTGTAAAGCACATCTCCAAAGGYAGCG
2226 +2T>C 0 VPS13B GGTTCCGTTCCTTGTAATAAT']
2227 NM_005026.3(PIK3CD):c.l246T 5293 PIK3CD ['CACCTGCCCTGTCCTTCTGCAGGACYGCCCC >C (p.Cys416Arg) ATTGCCTGGGCCAACCTCAT']
NM_000271.4(NPCl):c.2054T> ['TACATTGGGTTGCCCTTGACCCTCAYTGTGA
2228 C (p.Ile685Thr) 4864 NPC1 TTGAAGTCATCCCGTTCCTG]
NM_002633.2(PGMl):c.l547T> ['GGGAGTGCCGGGGCCACCATTCGGCYGTAC
2229 C (p.Leu516Pro) 5236 PGM1 ATCGATAGCTATGAGAAGGAC]
NM_015599.2(PGM3):c.248T>C ['TTGGTTGATCCTTTGGGTGAAATGTYGGCAC
2230 (p.Leu83Ser) 5238 PGM3 CATCCTGGGAGGAACATGCC]
NM_002136.2(HNRNPAl):c.817 ['GAATTACAACAATCAGTCTTCAAATBTTGGA
2231 T>C (p.Phe273Leu) 3178 HNRNPA1 CCCATGAAGGGAGGAAATTT']
NM_002136.2(HNRNPAl):c.841 ['TTTTGGACCCATGAAGGGAGGAAATYTTGG
2232 T>C (p.Phe281Leu) 3178 HNRNPA1 AGGCAGAAGCTCTGGCCCCTA]
NM_001159287.1(TPIl):c.833T ['GGTGGTGCTTCCCTCAAGCCCGAATYCGTGG
2233 >C (p.Phe278Ser) 7167 TPIl ACATCATCAATGCCAAACAA']
NM_130838.1(UBE3A):c.2T>C ['TCTGACGACATTGAAGCTAGCCGAAYGTAA
2234 (p.MetlThr) 7337 UBE3A GTGTAACTTGGTTGAGACTGT']
NM_130838.1(UBE3A):c.710T> ['ATTGAAACTGCCTTTCTCAATGCACHTGTAT
2235 C (p.Leu237Pro) 7337 UBE3A ATTTGTCACCTAACGTGGAA']
M_000414.3(HSD17B4):c.l54 ['AGTGGAGACTGGAATCCCTTACACAYTGAT
2236 7T>C (p.Ile516Thr) 3295 HSD17B4 CCTAACTTTGCTAGTCTAGCA']
NM_022068.3 (PIEZ02) : c.8215T ['GTCCATTTGATCATTGTCTCTGGTGRGCGAT
2237 >C (p.Ser2739Pro) 63895 PIEZ02 ATAGGAATATTAATTTGGCA']
NM_012079.5(DGATl):c.751+2 ['GCACCTCAGGCCCACAGAGGTCCTCRCCGC
2238 T>C 8694 DGAT1 GGTAGGTCAGATTGTCCGGGT']
NM_003108.3(SOXl l):c.l78T> ['GCCGATGAACGCGTTCATGGTATGGYCCAA
2239 C (p.Ser60Pro) 6664 SOX11 GATCGAACGCAGGAAGATCAT']
NM_021072.3(HCNl):c.814T>C 34898 ['TGATGTATGTATCTAATTAACCTTGRAAGTC
2240 (p.Ser272Pro) 0 HCN1 GTAATAAACGCAAGAGACTG]
NM_001079867.1 (PEX2) : c.739T ['CACCAGTGGCAAAGAATGCGCTCTAYGTGG
2241 >C (p.Cys247Arg) 5828 PEX2 AGAGTGGCCCACCATGCCTCA']
NM_022552.4(DNMT3A):c. l94 ['CTGAATGCCCAAGTCCTTCAGCACCRGGAGC
2242 3T>C (p.Leu648Pro) 1788 DNMT3A CCTGCACCAGCCAGCAGACA']
NM_022552.4(DNMT3A):c.270 ['CGCAAAATACTCCTTCAGCGGAGCGRAGAG
2243 5T>C (p.Phe902Ser) 1788 DNMT3A GTGGCGGATGACTGGCACGCT']
NM_018400.3(SCN3B):c.482T> ['GAGGAAGACCAGAAGGATGTACATCRTGAT
2244 C (p.Metl61Thr) 55800 SCN3B TTCTGAGACCACAGAGGTGAA]
NM_000406.2(GNRHR) : c.392T ['TTCTCCATGTATGCCCCAGCCTTCAYGATGG
2245 >C (p.Metl31Thr) 2798 GNRHR TGGTGATCAGCCTGGACCGC]
NM_001030001.2(RPS29):c.l49 ['GCAGACGCCTACCTTAATGAAACCGRTATCC
2246 T>C (p.Ile50Thr) 6235 RPS29 TTCGCGTACTGACGGAAACA']
NM_177550.4(SLC13A5):c. l463 28411 ['CAGGGTACAGGGCAGCATGATGTACRGCGG
2247 T>C (p.Leu488Pro) 1 SLC13A5 ATTGAGGCCGATGGAGCGAGA']
M_004464.3(FGF5):c.520T>C ['TTTTCAAGAAAATAGCTATAATACCBATGCC
2248 (p.Tyrl74His) 2250 FGF5 TCAGCAATACATAGAACTGA']
2249 NM_000051.3 (ATM) : c.4776+2T 472 ATM ['AGAGGACCCTTTTCACTCTTGGAGGYAATAA >C AAATTTCATCATCTACTATT']
NM_002880.3(RAFl):c.l808T> ['GTGTTGGAGCAGCTCAATGGAAGACRGGAT
2250 C (p.Leu603Pro) 5894 RAF1 CTGAAACAAAGCCCAAGAATG]
NM_000251.2(MSH2):c.942+2T ['GTCAGAGCCCTTAACCTTTTTCAGGBAAAAA
2251 >C 4436 MSH2 AAAAAAAAAAAAAAAAAAAA']
NM_001077620.2(PRCD):c.2T> ['GGGAGGGGATGGGGCAGCTGCGCCAYGTGC
2252 C (p.MetlThr) -1 - ACCACCCTTTTCCTGCTCAGC]
NM_001142800.1(EYS):c.9209T 34600 ['AGCCACAAAGTTTTTATGTGGATCARTATCC
2253 >C (p.Ile3070Thr) 7 EYS TCGGAAAGAATTAGACTGTT']
NM_206933.2(USH2A):c.9751T ['TCCTAAATTGACAGGTGAAGTATGCYGTCCA
2254 >C (p.Cys3251Arg) 7399 USH2A GATGAACAGCACAATCGGGT']
NM_000257.3 (MYH7) :c.4442T> ['GAGGCTCGCTCCCTCAGCACAGAGCYCTTCA
2255 C (p.Leul481Pro) -1 - AACTCAAGAACGCCTATGAG]
NM_000257.3(MYH7):c.4835T> ['GAGACACGCAGCCGCAACGAGGCCCYGAGG
2256 C (p.Leul612Pro) -1 - GTGAAGAAGAAGATGGAAGGA]
NM_000257.3(MYH7):c.4937T> ['GAGGCCCAGAAGCAAGTCAAGAGCCYCCAG
2257 C (p.Leul646Pro) -1 - AGCTTGTTGAAGGTACTCACC]
NM 001199138 (NLRC4):c.10 ['AATCTCATGAAGACCCCTCTCTTTGYGGTCA
2258 22T>C (p.Val341Ala) 58484 NLRC4 TCACTTGTGCAATCCAGATG']
NM_000076.2(CDKNlC):c.*5+2 ['GCGCAAGAGGCTGCGGTGAGCCAAGYGAGT
2259 T>C 1028 CDKN1C ACAGCGCACCTGGGGGGGCGC]
NM_003159.2(CDKL5):c.659T> ['CCTGGAGAAAGTGAAATTGACCAACYTTTT
2260 C (p.Leu220Pro) 6792 CDKL5 ACTATTCAGAAGGTGCTAGGA]
NM_005027.3(PIK3R2):c. l202T ['CTCACCTTCTGCTCCGTTGTGGACCYCATCA
2261 >C (p.Leu401Pro) 5296 PIK3R2 ATCACTACCGCCACGAGTCT']
NM_173596.2(SLC39A5):c.911 28337 ['TTCCTGCTCTTTGTGCTGGAGAACAYGCTGG
2262 T>C (p.Met304Thr) 5 SLC39A5 GGCTTTTGCGGCACCGAGGG]
NM_153334.6(SCARF2):c.l90T ['CCTTGCTGCCTCCAGCCAGCGCAGCRCGTGG
2263 >C (p.Cys64Arg) 91179 SCARF2 GCACCTGGGAGCTGCGAGCA']
NM_001288767.1(ARMC5):c.l9 ['GGGGCACTTGTGACCGGCCCGGCGCYGTAC
2264 28T>C (p.Leu643Pro) 79798 ARMC5 GGCCTGCTGACCTATGTGACC]
NM_001288767.1(ARMC5):c.l3 ['CGTGAGGCCATCAACCGGGCCCGACYGCGG
2265 79T>C (p.Leu460Pro) 79798 ARMC5 GATGCTGGTGGCTTGGATCTA]
['ATAATCCTATTTATTACCTCAGAAGYTTTTTT
2266 NC_012920.1 :m.9478T>C 4514 MT-C03 CTTCGCAGGATTTTTCTGA']
['ACTAGTCACAGCCCTATACTCCCTCYACATA
2267 NC_012920.1 :m.11984T>C 4538 MT-ND4 TTTACCACAACACAATGGGG]
NM_014845.5(FIG4):c.50T>C ['ATCAGCTCGGTCCAGAAGCTGGTTCYGTATG
2268 (p.Leul7Pro) 9896 FIG4 AGACTAGAGCTGTGAGTACC]
NM_003159.2(CDKL5):c.145+2 ['TCAAGAAATTCAAGGACAGTGAAGGYAGAT
2269 T>C 6792 CDKL5 ATATATATATATATATATATA']
NM_002775.4(HTRAl):c.l091T ['CCATCTGATAAGATTAAAAAGTTCCYCACG
2270 >C (p.Leu364Pro) 5654 HTRA1 GAGTCCCATGACCGACAGGCC]
2271 NM_021870.2(FGG):c.l210T>C 2266 FGG ['ATCTTCATAGTGGTTTTCTTCATGGRATACC (p.Ser404Pro) ACCGGGTTTTCCAAGTGGCC]
NM_017617.3(NOTCHl):c. l285 ['TCGAAGGAGCCCAGCGTGTTGATGCRCTTGC
2272 T>C (p.Cys429Arg) 4851 NOTCH 1 CCGCATGCTCGCAGGGGTTG]
NM_024915.3 (GRHL2) :c .1192T ['GATGATTCAGATTGACACATACAGTYATAA
2273 >C (p.Tyr398His) 79977 GRHL2 CAATCGTAGCAATAAACCCAT']
NM_002049.3 (GAT Al ) :c .2T>C ['CGCAGGTTAATCCCCAGAGGCTCCAYGGAG
2274 (p.MetlThr) 2623 GATA1 TTCCCTGGCCTGGGGTCCCTG]
NM_002049.3 (GAT Al ) :c .1240T ['TACTGTGGTGGCTCCGCTCAGCTCAYGAGGG
2275 >C (p.Ter414Arg) 2623 GATA1 CACAGAGCATGGCCTCCAGA']
NM_005859.4(PURA):c.299T>C [' GGC GC GGGCGGC A AC A AG AGCC GCC YT ACT
2276 (p.LeulOOPro) 5813 PURA CTCTCCATGTCAGTGGCCGTG]
NM_032374.4(APOPTl):c.353T ['TTCTGGGCAAACCAGAATTTGACTTYTAGTA
2277 >C (p.Phel l8Ser) 84334 APOPTl AGGTAAGTTTAAGTTTTAGA']
NM_032551.4(KISSlR):c.937T> ['TAAGACCTGGGCTCACTGCATGTCCYACAGC
111% C (p.Tyr313His) 84634 KISS1R AACTCCGCGCTGAACCCGCT']
NM_017696.2(MCM9):c.1732+2 25439 ['AAAGCTTGATACGATTAGCAGAAGGYCTAT
2279 T>C 4 MCM9 TTCATTCAGCGAATGATGCTT']
NM_003159.2(CDKL5):c.602T> ['GACATGTGGTCGGTGGGCTGTATTCYTGGGG
2280 C (p.Leu201Pro) 6792 CDKL5 AGCTTAGCGATGGACAGCCT']
NM_005740.2(DNAL4):c.153+2 ['GAGAAATTCTCCAACAACAACGAGGYATTG
2281 T>C 10126 DNAL4 CCAGCAGTGCAGGCGGCCCCT']
NM_201631.3(TGM5):c.763T>C ['TTCAGGATGGCCACGCTGCCCGTCCRCTCCG
2282 (p.Trp255Arg) 9333 TGM5 CAGGGTTGGCGCCGTCTGTG]
NM_201631.3(TGM5):c. l22T>C ['GCTCCGGTTCCTGAAGTACAGGGTGRGGTTG
2283 (p.Leu41Pro) 9333 TGM5 AAGGCCTGGCCCCGGCGAAC]
NM_001287223.1(SCNl lA):c.3 ['TACCTTCATTCCTTCAAACTGGGACRGCGCA
2284 473T>C (p.Leul l58Pro) 11280 SCN11A CGAAGAGGCCTCAGTGCTCG]
NM_001287223.1(SCNl lA):c.l ['GGGCTCTACTCAGTCTTCTTCTTCAYTGTGG
2285 142T>C (p.Ile381Thr) 11280 SCN11A TCATTTTCCTGGGCTCCTTC]
NM_001302946.1(TRNTl):c.668 ['CATGATCCTGAGACTTTGGAAGCAAYTGCA
2286 T>C (p.Ile223Thr) 51095 TRNT1 GAAAATGCAAAAGGCTTGGCT']
NM_001302946.1(TRNTl):c.497 ['TAATGAATAGGTTTTGATGGCACTTYATTTG
2287 T>C (p.Leul66Ser) 51095 TRNT1 ACTACTTTAATGGTTATGAA']
NM_018136.4(ASPM):c.2419+2 25926 ['ATAGACACCTATGGAAAGATGTGGGYAAGA
2288 T>C 6 ASPM AGACTGCAGAAATCTTGACAT']
NM_022455.4(NSDl):c.5885T> ['TGGGGTCTACGGACAAAAACAGATAYTAAA
2289 C (p.Ilel962Thr) 64324 NSD1 AAGGTTAGAAAAAGCTAAATT']
NM_022455.4(NSDl):c.5989T> ['TCAAGAACATGATATCACTAATTTCYATATG
2290 C (p.Tyrl997His) 64324 NSD1 CTCACCCTAGACAAAGTAAG]
NM_133433.3(NIPBL):c.7062+2 ['AAAAAATATGCTGGATTCATTCATGYATGTA
2291 T>C 25836 NIPBL TTTTAACATTTTATAACCTA']
NM_000525.3(KCNJll):c.988T ['GGAGGACGGACGTTACTCTGTGGACYACTC
2292 >C (p.Tyr330His) 3767 KCNJ11 CAAGTTTGGCAACACCGTCAA']
2293 M_004004.5 (GJB2) :c .107T>C 2706 GJB2 ['CTCTTCATTTTTCGCATTATGATCCYCGTTGT (p.Leu36Pro) GGCTGCAAAGGAGGTGTGG]
NM_130838.1(UBE3A):c.2485T ['CTTTAATGTGCTTTTACTTCCGGAAYACTCA
2294 >C (p.Tyr829His) 7337 UBE3A AGCAAAGAAAAACTTAAAGA]
NM_005682.6(ADGRGl):c.l460 ['GCCATCTTCCTGCACTTCTCCCTGCYCACCT
2295 T>C (p.Leu487Pro) 9289 ADGRG1 GCCTTTCCTGGATGGGCCTC]
NM_000430.3(PAFAHlBl):c.84 PAFAHIB ['CCGAGAGCATGAGCATGTGGTAGAAYGCAT
2296 1T>C (p.Cys281Arg) 5048 1 TTCCTGGGCTCCAGAAAGCTC]
NM_001005360.2(DNM2):c.l86 ['GTGGACAGCTGGAAGGCCTCGTTCCYCCGA
2297 2T>C (p.Leu621Pro) 1785 DNM2 GCTGGCGTCTACCCCGAGAAG]
NM_178151.2(DCX):c.683T>C ['CTGGAGACCGGGGTTGTCAAAAAACYCTAC
2298 (p.Leu228Pro) 1641 DCX ACTCTGGATGGAAAACAGGTA']
NM_178151.2(DCX):c.641T>C ['TCTTTTGAGCAAGTCCTCACTGATAYCACAG
2299 (p.Ile214Thr) 1641 DCX AAGCCATCAAACTGGAGACC]
NM_178151.2(DCX):c.412T>C ['AGACAACTTCTTTAAAAAGGTGGAGYACAC
2300 (p.Tyrl38His) 1641 DCX CAAGAATGTCAATCCCAACTG]
NM_178151.2(DCX):c.272T>C ['TTGCTGGCTGACCTGACGCGATCTCYGTCTG
2301 (p.Leu91Pro) 1641 DCX ACAACATCAACCTGCCTCAG]
NM_178151.2(DCX):c.l28T>C ['TGTAGCTTCTACCGAACCAGAACCTYGCAG
2302 (p.Leu43Ser) 1641 DCX GCACTGAGTAATGAGAAGAAA']
NM_178151.2(DCX):c.2T>C ['AGGTCTCTGAGGTTCCACCAAAATAYGGAA
2303 (p.MetlThr) 1641 DCX CTTGATTTTGGACACTTTGAC]
NM_000252.2(MTMl):c.260T> ['TCTTCTCTAATACTTGATGTTCCTCYGGGTGT
2304 C (p.Leu87Pro) 4534 MTM1 GATCTCGAGAATTGAAAAA']
NM_000252.2(MTMl):c.683T> ['AACTTTCTGACTTAACCATAGGTGCYGTCAT
2305 C (p.Leu228Pro) 4534 MTM1 GGATTCATCCAGAAAATAAG]
NM_000252.2(MTMl):c.958T> ['TCATAATATTCATGTTATGCGGGAAYCTTTA
2306 C (p.Ser320Pro) 4534 MTM1 AAAAAAGTGAAGGACATTGT']
NM_000252.2(MTMl):c.1353+2 ['TGTGTGTGGCAAATGTCAAAACAGGYAAGG
2307 T>C 4534 MTM1 AATATGAGGGATGAAAATACA']
NM_000252.2(MTMl):c.l367T> ['GTTTTTGTTTAGTTCCCTACAGCTTYTGAATT
2308 C (p.Phe456Ser) 4534 MTM1 CAATGAACAATTTTTGATT']
NM_000252.2(MTMl):c.l433T> ['CTGTATAGTTGCCGATTTGGTACTTYCTTATT
2309 C (p.Phe478Ser) 4534 MTM1 CAACTGTGAATCTGCTCGA']
NM_000252.2(MTMl):c.l495T> ['GGTTACAGAAAGGACTGTTTCTTTAYGGTCA
2310 C (p.Trp499Arg) 4534 MTM1 CTGATAAACAGTAATAAAGA]
NM_006579.2(EBP):c.310T>C ['TCTCTTCTTTTCTTCAGGGAAAGAGYATGCC
2311 (p.Tyrl04His) 10682 EBP AAGGGAGACAGCCGATACAT']
NM_152296.4(ATPlA3):c.2270 ['GAGCCTGCCTGTGCCACAGGCCGCCYGATCT
2312 T>C (p.Leu757Pro) 478 ATP 1 A3 TCGACAACCTAAAGAAGTCC]
NM_152296.4(ATPlA3):c.l250 ['GTGGCCCTGTCTCACATCGCTGGGCYCTGCA
2313 T>C (p.Leu417Pro) 478 ATP 1 A3 ATCGCGCTGTCTTCAAGGGT']
NM_152296.4(ATPlA3):c.l l44 ['GAACCGCATGACAGTCGCCCACATGYGGTT
2314 T>C (p.Trp382Arg) 478 ATP 1 A3 TGACAACCAGATCCACGAGGC]
2315 NM_152296.4(ATPlA3):c.l l l2 478 ATP 1 A3 ['ATCTGCTCAGATAAGACAGGGACCCYCACT T>C (p.Leu371Pro) CAGAACCGCATGACAGTCGCC]
NM_004963.3(GUCY2C):c.2782 ['CTTTCTGTCCTTCATTTCAGGTCCCYGTGCTG
2316 T>C (p.Cys928Arg) -1 - CTGGAGTTGTGGGAATCAA']
NM_000109.3 (DMD) :c .1700T> ['GTTCACTGCATCTTCTTTTTCTGAARGCCATG
2317 C (p.Leu567Pro) 1756 DMD CACTAAAAAGGCACTGCAA']
NM_001543.4(NDSTl):c.l918T ['CAGCAACTACCCCAGCTCTGAGACCYTTGA
2318 >C (p.Phe640Leu) 3340 NDST1 GGAGATCCAGTTTTTTAATGG]
NM_001999.3(FBN2):c.3740T> ['GGTGTCACAGCCTCCGTTCATTATCRTACAT
2319 C (p.Metl247Thr) 2201 FBN2 TCATCAATATCTGTGAAAAC]
NM_005154.4(USP8):c.2152T> ['ACCTTCCAAACTGAAGCGCTCCTACYCCTCC
2320 C (p.Ser718Pro) 9101 USP8 CCAGATATAACCCAGGCTAT']
NM_000734.3 (CD247) :c.2T>C ['CCTCTTTCTGAGGGAAAGGACAAGAYGAAG
2321 (p.MetlThr) 919 CD247 TGGAAGGCGCTTTTCACCGCG]
NM_000663.4(ABAT):c.l433T> ['AAATCCATTCGTTTCCGTCCCACGCYGGTCT
2322 C (p.Leu478Pro) 18 ABAT TCAGGGATCACCACGCTCAC]
NM_005211.3(CSFlR):c.2717T> ['ACCCACAGACCCACCTTCCAGCAGAYCTGCT
2323 C (p.Ile906Thr) 1436 CSF1R CCTTCCTTCAGGAGCAGGCC]
NM_005211.3(CSFlR):c.2566T> ['CTTGGCCTTTGCAGGGCTGAATCCCYACCCT
2324 C (p.Tyr856His) 1436 CSF1R GGCATCCTGGTGAACAGCAA']
NM_005211.3(CSFlR):c.2480T> ['GTGAAGTGGATGGCCCCAGAGAGCAYCTTT
2325 C (p.Ile827Thr) 1436 CSF1R GACTGTGTCTACACGGTTCAG]
NM_005211.3(CSFlR):c.2450T> ['TGGGGACTGTCATCCCAGGCCCGCCYGCCTG
2326 C (p.Leu817Pro) 1436 CSF1R TGAAGTGGATGGCCCCAGAG]
NM_005211.3(CSFlR):c.l957T> ['GAACATCGTCAACCTTCTGGGAGCCYGTACC
2327 C (p.Cys653Arg) 1436 CSF1R CATGGAGGTAAGGGCCTTGG]
NM_005211.3(CSFlR):c.l745T> ['AAGTGGGAGTTCCCCCGGAACAACCYGCAG
2328 C (p.Leu582Pro) 1436 CSF1R TTTGGTGAGATGGCAGCTCAT']
NM_001563.3(IMPGl):c.461T> ['AATTCCCAGGAGCACCTGGATCTTCYCCAGC
2329 C (p.Leul54Pro) 3617 IMPG1 AGGTGAGCCTAAACACCACA']
NM_001130823.1(DNMTl):c.l5
31T>C (p.Tyr511His) 1786 DNMT1 []
NM_152515.4(CKAP2L):c.2T>C 15046 ['AGCAGCGGTAGGCCCGGGCCCCACCRTGAC
2330 (p.MetlThr) 8 CKAP2L TCTTCAGTGACAGTTTTTCTT']
NM_170707.3(LMNA):c.1968+2 ['GGCAACTCCAGCCCCCGAACCCAGGNGAGT
2331 T>C 4000 LMNA TGTCTCTGCTTTGTCTCCAAA']
NM_153818.1(PEX10):c.890T> ['AGAAACCCCCTGTGCACCCTGTGCCYGGAG
2332 C (p.Leu297Pro) 5192 PEX10 GAGCGCAGGCACCCAACAGCC]
NM_153818.1(PEX10):c.2T>C ['TCGGGACCACCCGAACCCGCGGCCAYGGCC
2333 (p.MetlThr) 5192 PEX10 CCGGCCGCCGCCAGCCCCCCG]
NM_014305.3(TGDS):c.700T>C ['AATGCTTCTACAACATCAGTAGCATRAAGG
2334 (p.Tyr234His) 23483 TGDS AAGTTTCTTGTTTGAAGCCCT']
NM_000256.3(MYBPC3):c2994 ['GTGAACCTTCTCATCCCTTTCCAGGYGGGAC
2335 +2T>C 4607 MYBPC3 TGGCCCCCTTCCCTGTCCCC]
2336 NM_000256.3(MYBPC3):c.l624 4607 MYBPC3 ['CTCATGTGCCCCCCCAGCCAGGCTCDCCCTG +2T>C CACAATGAGCTCAGCCAGCG]
NM_000257.3 (MYH7) :c.2207T> ['GCGGCCATCCCTGAGGGACAGTTCAHTGAT
2337 C (p.Ile736Thr) 4625 MYH7 AGCAGGAAGGGGGCAGAGAAG]
NM_000138.4(FBNl):c.7754T> ['TGCCAGCATGGCTGCCAGAACATCAYTGGG
2338 C (p.Ile2585Thr) 2200 FBN1 GGCTACAGGTGCAGCTGCCCC]
NM_000371.3 (TTR) :c .190T>C ['GGCTGCTGATGACACCTGGGAGCCAYTTGC
2339 (p.Phe64Leu) 7276 TTR CTCTGGGTAAGTTGCCAAAGA']
NM_000126.3 (ETF A) : c.2T>C ['GAGGTTGCGGCGGAAGCGGAGACCAYGTTC
2340 (p.MetlThr) 2108 ETFA CGAGCGGCGGCTCCGGGGCAG]
NM_006493.2(CLN5):c.2T>C ['GCGGGCCGGGCGCGGGGAGGTGTCAYGCGC
2341 (p.MetlThr) 1203 CLN5 CGGAACCTGCGCTTGGGGCCA]
NM_000543.4(SMPDl):c.475T> ['CTCAGTGCTGAGCCCATCTGAGGCCYGTGGC
2342 C (p.Cysl59Arg) 6609 SMPD1 CTGCTCCTGGGCTCCACCTG]
NM_000501.3(ELN):c.889+2T> ['TTCCTGGAATTGGAGGCATCGCAGGYAACA
2343 C 2006 ELN TCTGTCCCAGCAGGGGGCGGG]
NM_000169.2(GLA):c.758T>C ['TGGACATCTTTTAACCAGGAGAGAAYTGTTG
2344 (p.Ile253Thr) -1 - ATGTTGCTGGACCAGGGGGT']
NM_152743.3(BRATl):c.l76T> 22192 ['GAGCACCCCTGCCTGGTGGAGCTGCYGTCCC
2345 C (p.Leu59Pro) 7 BRAT1 ATGTGCTGAAAGTCCAGGAC]
NM_000152.3 (GAA) :c .896T>C ['CTCTACGGGTCTCACCCTTTCTACCBGGCGC
2346 (p.Leu299Pro) 2548 GAA TGGAGGACGGCGGGTCGGCA]
NM_015384.4(NIPBL):c.7637T> ['AATGTGTCCCAGGGTATTTTATTACYTCTCA
2347 C (p.Leu2546Pro) 25836 NIPBL TGTTAAAACAACATTTGAAG]
NM_005641.3(TAF6):c.212T>C ['ATTCTTTAGCTTCAAGGCGTAGTCADTGTCA
2348 (p.Ile71Thr) 6878 TAF6 CTGGTGGTGAGCTTCTGCCG']
NM_170707.3(LMNA):c.710T> ['ATTGACAATGGGAAGCAGCGTGAGTYTGAG
2349 C (p.Phe237Ser) 4000 LMNA AGCCGGCTGGCGGATGCGCTG]
NM_000527.4(LDLR):c.l468T> ['GGACTGGATCCACAGCAACATCTACYGGAC
2350 C (p.Trp490Arg) 3949 LDLR CGACTCTGTCCTGGGCACTGT']
NM_000081.3 (LYST) :c.772T>C ['CATGAACAATTCTCCATTTGACTTAYGTCAT
2351 (p.Cys258Arg) 1130 LYST GTTTTGTTATCTTTATTAGA]
NM_000256.3(MYBPC3):c3796 ['CTTACAGGGCGAGGCACGGTGTGAGYGCCG
2352 T>C (p.Cysl266Arg) 4607 MYBPC3 CCTGGAGGTGCGAGGTGAGGA']
NM_000256.3(MYBPC3):c.3713 ['TTCAGCAAGCAGGGAGTGTTGACTCYGGAG
2353 T>C (p.Leul238Pro) 4607 MYBPC3 ATTAGAAAGCCCTGCCCCTTT']
NM_000256.3(MYBPC3):c.3330 ['CAGAAAGCCGACAAGAAGACCATGGBGAGC
2354 +2T>C 4607 MYBPC3 CCAGGGTCTGGGGTCCCCACG]
NM_000256.3(MYBPC3):c.l696 ['CGCAAAGGACCAGGCGGTGTTCAAAYGTGA
2355 T>C (p.Cys566Arg) 4607 MYBPC3 GGTCTCAGATGAGAATGTTCG]
NM_000256.3(MYBPC3):c.l456 ['ATCGGAGGAGGGGGCGCAAGTCAAABGGTG
2356 T>C (p.Trp486Arg) 4607 MYBPC3 AGTTCCAGAAGCACGGGGCAT']
NM_000256.3(MYBPC3):c.709T ['TGCCCAGCCTGCCTTCACTGGCAGCYACCGC
2357 >C (p.Tyr237His) 4607 MYBPC3 TGTGAGGTGTCCACCAAGGA']
2358 NM_000256.3(MYBPC3):c.467T 4607 MYBPC3 ['GGAGCCCCCGATGACCCCATTGGCCYCTTCG >C (p.Leul56Pro) TGATGCGGCCACAGGATGGC]
NM_000257.3(MYH7):c.2723T> ['GATGCTGAGGAGCGCTGTGATCAGCYGATC
2359 C (p.Leu908Pro) 4625 MYH7 AAAAACAAGATTCAGCTGGAG]
NM_000257.3 (MYH7) :c.2479T> ['TCGGGCCTTCATGGGGGTCAAGAATYGGCC
2360 C (p.Trp827Arg) 4625 MYH7 CTGGATGAAGCTCTACTTCAA']
NM_000257.3(MYH7):c.l400T> ['GTCCTGGACATCGCTGGCTTCGAGAYCTTCG
2361 C (p.Ile467Thr) 4625 MYH7 ATGTGAGTTGGGACCCCTGG]
NM_000257.3(MYH7):c.l048T> ['CACTTCAGAGGAGAAAAACTCCATGYATAA
2362 C (p.Tyr350His) 4625 MYH7 GCTGACAGGCGCCATCATGCA']
NM_000257.3(MYH7):c.730T> ['CGTCCGGAACGACAACTCCTCCCGCYTCGTG
2363 C (p.Phe244Leu) 4625 MYH7 AGTGGTCCCTGACCTTGGCC]
NM_005159.4(ACTCl):c.755T> ['CTGCCTGATGGCCAAGTCATCACTAYTGGCA
2364 C (p.Ile252Thr) -1 - ATGAGCGCTTCCGCTGTCCT']
NM_030662.3(MAP2K2):c. l69T ['GCAGCAGAAGAAGCGGCTGGAAGCCNTTCT
2365 >C (p.Phe57Leu) 5605 MAP2K2 CACCCAGAAAGCCAAGGTCGG]
NM_000169.2(GLA):c.41T>C ['CCAGAACTACATCTGGGCTGCGCGCYTGCG
2366 (p.Leul4Pro) -1 - CTTCGCTTCCTGGCCCTCGTT']
NM_002294.2(LAMP2):c.864+2 ['TATCTAGACTTTGTCTTTGCTGTGGYGAGTA
2367 T>C 3920 LAMP2 ACAGATTTTTTAAAGTTAGG]
NM_000551.3 (VHL) : c.227T>C ['TCGCGCGAGCCCTCCCAGGTCATCTYCTGCA
2368 (p.Phe76Ser) 7428 VHL ATCGCAGTCCGCGCGTCGTG]
NM_000551.3 (VHL) : c.266T>C ['CCGCGCGTCGTGCTGCCCGTATGGCHCAACT
2369 (p.Leu89Pro) 7428 VHL TCGACGGCGAGCCGCAGCCC]
NM_000551.3 (VHL) : c.473 T>C ['GTTTTTGCCCTTCCAGTGTATACTCHGAAAG
2370 (p.Leul58Pro) 7428 VHL AGCGATGCCTCCAGGTTGTC]
NM_000051.3(ATM):c.8584+2T ['GCAGTGTAGCTACTTCTTCTATTGGYAATCT
2371 >C -1 - TCTTGTACATATAGTAGATT']
NM_058216.2(RAD51C):c.404+ ['AGGTGTTGGAAAAACACAATTATGGYAAAA
2372 2T>C 5889 RAD51C TAAAGTGTTCTCCTTTTAAGG]
NM_000455.4(STKl l):c.545T> ['CACAAGGACATCAAGCCGGGGAACCYGCTG
2373 C (p.Leul82Pro) 6794 STK11 CTCACCACCGGTGGCACCCTC]
NM_001199107.1(TBClD24):c. ['GGACAACACGCAGGTGCCCAGCTACYGCCT
2374 313T>C (p.Cysl05Arg) 57465 TBC1D24 GAATGCACGCGGCGAGGGGGC]
NM_000899.4(KITLG):c.98T>C ['ACTGAAGGGATCTGCAGGAATCGTGYGACT
2375 (p.Val33Ala) 4254 KITLG AATAATGTAAAAGACGTCACT']
NM_001195129.1(PRSS56):c.l l 64696 ['GCAGTGCCTGCAGCGCCGGCGGCGAYGCGG
2376 83T>C (p.Cys395Arg) 0 PRSS56 TCAGTTCTGTTCACCCGGACC]
NM_006888.4(CALMl):c.268T> ['TAGTGAAGAAGAAATCCGTGAGGCAYTCCG
2377 C (p.Phe90Leu) 801 CALM1 AGTCTTTGACAAGGTAATCCA']
NM_017534.5(MYH2):c.5609T> ['GAAGATAGAAAGAATATTCTCAGGCYTCAA
2378 C (p.Leul870Pro) -1 - GATTTGGTAGATAAACTTCAG]
NM_003000.2(SDHB):c.574T>C ['CTACGAGTGCATTCTCTGTGCCTGCYGTAGC
2379 (p.Cysl92Arg) 6390 SDHB ACCAGCTGCCCCAGCTACTG]
2380 NM_000314.6(PTEN):c.406T>C 5728 PTEN ['AAAGGGACGAACTGGTGTAATGATAYGTGC (p.Cysl36Arg) ATATTTATTACATCGGGGCAA]
NM_000051.3(ATM):c.2T>C ['ATGTGTGTTCTGAAATTGTGAACCAYGAGTC
2381 (p.MetlThr) 472 ATM TAGTACTTAATGATCTGCTT']
NM_052867.2(NALCN):c.l526T 25923 ['GGTCCTGGAAAAAAGCTTGGGAGTTYGGTT
2382 >C (p.Leu509Ser) 2 NALCN GTATTTACTGCCAGCCTCTTG]
NM_000314.6(PTEN):c.545T>C ['TATGTGTATTATTATAGCTACCTGTYAAAGA
2383 (p.Leul82Ser) 5728 PTEN ATCATCTGGATTATAGACCA']
NM_005957.4(MTHFR):c. l969T ['ACGCAGGGCGTCAGGACGCAGGGTCRTGGA
2384 >C (p.Ter657Arg) 4524 MTHFR GCCTCCGTTTCTCTCGCATTC]
NM_005957.4(MTHFR):c. l883T ['AACCTGGTGGACAATGACTTCCCACYGGAC
2385 >C (p.Leu628Pro) 4524 MTHFR AACTGCCTCTGGCAGGTGGTG]
NM_005957.4(MTHFR):c.1793T ['CTGTGGATTGAGCGGTGGGGAAAGCYGTAT
2386 >C (p.Leu598Pro) 4524 MTHFR GAGGAGGAGTCCCCGTCCCGC]
NM_005957.4(MTHFR):c. l530+ ['AGCGGGGGCTATGTCTTCCAGAAGGYGTGG
2387 2T>C 4524 MTHFR TAGGGAGGCACGGGGTGCCCC]
NM_005957.4(MTHFR):c.388T> ['CCTGGAGACCATCCTGCACATGACCYGCTGC
2388 C (p.Cysl30Arg) 4524 MTHFR CGTCAGCGCCTGGAGGAGAT']
NM_000264.3 (PTCH 1 ) : c.3168+2 ['AACCCCTGGACGGCCGGGATCATTGYGAGT
2389 T>C 5727 PTCH1 GTATTATAAGGGGCTTTGTGG]
NM_000030.2(AGXT):c.302T>C ['GTGCTGGAGCCTGGGGACTCCTTCCYGGTTG
2390 (p.LeulOlPro) 189 AGXT GGGCCAATGGCATTTGGGGG]
NM_000030.2(AGXT):c.322T>C ['CTTCCTGGTTGGGGCCAATGGCATTYGGGGG
2391 (p.Trpl08Arg) 189 AGXT CAGCGAGCCGTGGACATCGG]
NM_000023.2(SGCA):c.371T>C ['ACTCGGCAGAGGCTGGTGCTGGAGAYTGGG
2392 (p.Ilel24Thr) 6442 SGCA GACCCAGAAGGTACCTCTAGC]
NM_016035.4(COQ4):c. l55T>C ['CGCCATCGCCGCGGAGCCGGCGGCCRACAG
2393 (p.Leu52Ser) 51117 COQ4 CCCTTTCTGCAGCGGGGAGGT']
NM_000510.2(FSHB):c.298T>C ['GTATACATACCCAGTGGCCACCCAGYGTCA
2394 (p.CyslOOArg) 2488 FSHB CTGTGGCAAGTGTGACAGCGA']
NM_007374.2(SIX6):c.l l0T>C ['CGCCTGGGTCGCTTCCTCTGGTCGCYGCCCG
2395 (p.Leu37Pro) 4990 SIX6 TGGCCCCTGCGGCCTGCGAG]
NM_000314.6(PTEN):c.202T>C ['AAAGCATAAAAACCATTACAAGATAHACAA
2396 (p.Tyr68His) 5728 PTEN TCTGTAAGTATGTTTTCTTAT']
NM_001103.3(ACTN2):c.683T> ['GAGAAGCACCTGGATATTCCTAAAAYGTTG
2397 C (p.Met228Thr) 88 ACTN2 GATGCTGAAGGTGAGATGAAA']
NM_005249.4(FOXGl):c.700T> ['GCAGAACTCCATCCGCCACAATCTGYCCCTC
2398 C (p.Ser234Pro) 2290 FOXG1 AACAAGTGCTTCGTGAAGGT']
NM_001165963.1(SCNlA):c.40 ['ATTCCATCCATCATGAATGTGCTTCYGGTTT
2399 55T>C (p.Leul352Pro) -1 - GTCTTATATTCTGGCTAATT']
NM_001165963.1(SCNlA):c.26 ['GCTCTGGGAAATTTAACCCTCGTCTYGGCCA
2400 90T>C (p.Leu897Ser) 6323 SCN1A TCATCGTCTTCATTTTTGCC]
NM_001165963.1(SCNlA):c. l2 ['CTAATAAATTTGATCCTGGCTGTGGHGGCCA
2401 65T>C (p.Val422Ala) 6323 SCN1A TGGCCTACGAGGAACAGAAT']
2402 NM_001165963.1(SCNlA):c. lO 6323 SCN1A ['TTTCTTTTACCCCACTTGCAGCCAAYGTCCA 33T>C (p.Cys345Arg) GAGGGATATATGTGTGTGAA]
NM_001165963.1(SCNlA):c.76 ['AGATGTAATGATCCTGACTGTGTTCYGTCTG
2403 9T>C (p.Cys257Arg) 6323 SCN1A AGCGTATTTGCTCTAATTGG]
NM_001165963.1(SCNlA):c.32 ['TTCCGGTTCAGTGCCACCTCTGCCCYGTACA
2404 3T>C (p.Leul08Pro) 6323 SCN1A TTTTAACTCCCTTCAATCCT']
NM_000426.3(LAMA2):c.8282T ['GCAGAATCAGAACCAGCTCTTTTGAYAGGG
2405 >C (p.Ile2761Thr) 3908 LAMA2 AGCAAGCAGTTCGGGCTTTCA']
NM_001199.3(BMPl):c.*241T> ['GTCTGTGACATTTCCTGTTGTGAAGYAAAAG
2406 C 649 BMP1 AGGGACCCCTGCGTCCTGCT']
NM_001987.4(ETV6):c.l046T> ['CTTTGGGATTACGTCTATCAGTTGCYTTCTG
2407 C (p.Leu349Pro) 2120 ETV6 ACAGCCGGTACGAAAACTTC]
M_004974.3(KCNA2):c.788T> ['ATGAACATCATTGACATTGTGGCCAYCATCC
2408 C (p.Ile263Thr) 3737 KCNA2 CCTACTTCATCACCCTGGGG]
NM_002055.4(GFAP):c.791T>C ['GTGTCCCCCACCTAGTTTGCAGACCYGACAG
2409 (p.Leu264Pro) 2670 GFAP ACGCTGCTGCCCGCAACGCG]
NM_002055.4(GFAP):c.239T>C ['GAGATGATGGAGCTCAATGACCGCTYTGCC
2410 (p.Phe80Ser) 2670 GFAP AGCTACATCGAGAAGGTTCGC]
NM_002055.4(GFAP):c.218T>C ['ACCCGGGCCAGTGAGCGGGCAGAGADGATG
2411 (p.Met73Thr) 2670 GFAP GAGCTCAATGACCGCTTTGCC]
NM_001288953.1(TTC7A):c.l91 ['TTTGCCTGATGCCCATGATGCAGACYCTGGT
2412 2T>C (p.Ser638Pro) 57217 TTC7A AAGAACGAGCTCCTTGGGCC]
NM_000257.3(MYH7):c.5117T> ['TCCCGGAAGCTGGCGGAGCAGGAGCYGATT
2413 C (p.Leul706Pro) -1 - GAGACTAGTGAGCGGGTGCAG]
NM_000257.3 (MYH7) :c.4772T> ['ATGGAACAGGCCAAGCGCAACCACCWGCG
2414 C (p.Leul591Pro) -1 - GGTGGTGGACTCGCTGCAGACC]
NM_016218.2(POLK):c.609T>C ['TGAGTCTTGATGAAGCCTACTTGAAYATAAC
2415 (p.Asn203=) 51426 POLK AAAGCACTTAGAAGAAAGAC]
['TATTTTATAATCAATGAATTTGTTCYTTCTGA
2416 NM_016218.2(POLK):c.*66T>C 51426 POLK TTTTAAGTTTGCAGATTTA']
NM_015662.2(IFT172):c.770T> ['AGTCCTGGGGGCCAGTCTGTTGTGCYAGGA
2417 C (p.Leu257Pro) 26160 IFT172 AGTTATGACAGGTAAGTCCCC]
NM_178454.4(DRAM2):c.79T> 12833 ['GACATCTGCTGCTTTCATATTTTCAYACATT
2418 C (p.Tyr27His) 8 DRAM2 ACTGCAGTAACACTCCACCA']
NM_032790.3(ORAIl):c.581T> ['CTCTTCCTAGCTGAGGTGGTGCTGCYCTGCT
2419 C (p.Leul94Pro) 84876 OR All GGGTCAAGTTCTTGCCCCTC]
NM_001135669.1(XPRl):c.434T ['GAGTTCTACCTCAGTCTAATCCTGCYGCAGA
2420 >C (p.Leul45Pro) 9213 XPR1 ACTATCAGGTACTTAGATTC]
NM_001135669.1(XPRl):c.419T ['AAACTGGCCTTCAGTGAGTTCTACCYCAGTC
2421 >C (p.Leul40Pro) 9213 XPR1 TAATCCTGCTGCAGAACTAT']
NM_001135669.1(XPRl):c.653T ['GACAGACAAAAGGCTATGAAGCGTTYACGT
2422 >C (p.Leu218Ser) 9213 XPR1 GTCCCCCCTTTGGGAGCTGCT']
NM_005859.4(PURA):c.218T>C ['CGGGTGGACATCCAGAACAAGCGCTYCTAC
2423 (p.Phe73Ser) 5813 PURA CTGGACGTGAAGCAGAACGCC]
2424 NM_005859.4(PURA):c.563T>C 5813 PURA ['CTGGGCTCCACGCAGGGCCAGACCAYTGCG (p.Ilel88Thr) CTGCCCGCGCAGGGGCTCATC]
NM_001399.4(ED A) :c .396+2T> ['TCTGACTCCCAGGACGGGCACCAGGKGAGT
2425 C 1896 EDA CACCTAGTAGGGGCGGCGGCG]
NM_001848.2(COL6Al):c.957+ ['TCCAGGGGACCCAAGGGCTACAAGGYGAGC
2426 2T>C 1291 COL6A1 GTGGGCTGCTGGGAGGGGGGA']
M_000454.4(SODl):c.341T>C ['TCACTCTCAGGAGACCATTGCATCAYTGGCC
2427 (p.Ilell4Thr) 6647 SOD1 GCACACTGGTGGTAAGTTTT']
NM_020451.2(SEPNl):c.872+2T ['CTTCTACTACACTGTGATGTTCCGGYGAGTG
2428 >C 57190 SEPN1 GGCCACACTGGCTGGCCTGG]
M_004453.3(ETFDH):c.l001T ['GGTCTAGACTATCAGAATCCATACCYGAGTC
2429 >C (p.Leu334Pro) 2110 ETFDH CATTTAGAGAGTTCCAAAGG]
NM_198056.2(SCN5A):c.4299+ ['CAGCTGTGGACTCCAGGGGGGTAGGYTGCC
2430 6T>C 6331 SCN5A ACAGTGGCTTCTTCCACCAAG]
NM_198056.2(SCN5A):c.2291T ['TTCACAGGGATTTTCACAGCAGAGABGACCT
2431 >C (p.Met764Thr) 6331 SCN5A TCAAGATCATTGCCCTCGAC]
NM_198056.2(SCN5A):c.2047T ['AGAGTTAGAGGAGTCTCGCCACAAGBGTCC
2432 >C (p.Cys683Arg) 6331 SCN5A ACCATGCTGGAACCGTCTCGC]
M_004415.2(DSP):c.4961T>C ['GAAAAGCAGAGGACCCAGGAAGAGCYGAG
2433 (p.Leul654Pro) 1832 DSP GAGGCTCTCTTCTGAGGTCGAG]
NM_000238.3(KCNH2):c.2396T ['CGGGGCGACGTCGTCGTGGCCATCCYGGGT
2434 >C (p.Leu799Pro) 3757 KCNH2 ATGGGGTGGGGGGCGGGCACT']
NM_000238.3(KCNH2):c.2366T ['TTCATCTCCCGGGGCTCCATCGAGAYCCTGC
2435 >C (p.Ile789Thr) 3757 KCNH2 GGGGC G AC GTC GTC GTGGC C]
NM_000238.3(KCNH2):c. l945+ ['CTGCGTCATGCTCATTGGCTGTGAGYGTGCC
2436 6T>C 3757 KCNH2 CAGGGGCGGGCGGCGGGGAG]
NM_000238.3(KCNH2):c. l918T ['TCCCAACACCAACTCAGAGAAGATCBTCTCC
2437 >C (p.Phe640Leu) 3757 KCNH2 ATCTGCGTCATGCTCATTGG]
NM_000238.3 (KCNH2) : c.1282T ['CTACACGGCTGTCTTCACACCCTACYCGGCT
2438 >C (p.Ser428Pro) 3757 KCNH2 GCCTTCCTGCTGAAGGAGAC]
NM_000238.3(KCNH2):c. l25T> ['GCTCGGGTGGAGAACTGCGCCGTCAHCTAC
2439 C (p.Ile42Thr) 3757 KCNH2 TGCAACGACGGCTTCTGCGAG]
NM_000218.2(KCNQl):c. l025T ['GTCTTTGCCATCTCCTTCTTTGCGCYCCCAGC
2440 >C (p.Leu342Pro) 3784 KCNQ1 GGTAGGTGCCCCGTGGGTG]
NM_000218.2(KCNQl):c. l251+ ['CCCAAACCCAAGAAGTCTGTGGTGGYGAGT
2441 2T>C 3784 KCNQ1 AGCCCACCTGCCACCAGGGCA']
NM_130799.2(MENl):c.547T>C ['CCTCGCCCTGTCTGAGGATCATGCCYGGGTA
2442 (p.Trpl83Arg) 4221 MEN1 GTGTTTGGGCCCAATGGGGA']
NM_000138.4(FBNl):c.7531T> ['CACCATTGGCGGCTTCACATGCAAAYGTCCT
2443 C (p.Cys2511Arg) 2200 FBN1 CCCGGATTTACCCAACACCA']
NM_000138.4(FBNl):c.7111T> ['ATGCTGCTGTGACGGAGGGAGAGGCYGGGG
2444 C (p.Trp2371Arg) 2200 FBN1 TCCCCACTGTGAGATCTGCCC]
NM_000138.4(FBNl):c.6274T> ['CTGCTGTGCCTTGAAGGGAGAAGGCYGGGG
2445 C (p.Trp2092Arg) 2200 FBN1 AGACCCCTGCGAGCTCTGCCC]
2446 NM_000138.4(FBNl):c.5746T> 2200 FBN1 ['CACAATTGGTTCCTTCAACTGCCGCYGCAAT C (p.Cysl916Arg) CATGGTTTCATCCTTTCTCA]
NM_000138.4(FBNl):c.5726T> ['GGGAATGGAACTTGCCGGAACACAAYTGGT
2447 C (p.Ilel909Thr) 2200 FBN1 TCCTTCAACTGCCGCTGCAAT']
NM_000138.4(FBNl):c.l468+2T ['TGGACCTCCGTGGGGAGTGTATTGGYACGT
2448 >C 2200 FBN1 GATCCATCCTAGGTTGGCACC]
NM_004572.3(PKP2):c.2386T> ['TCTCATTGAAACTACAGCCTCTGCCYGTTAC
2449 C (p.Cys796Arg) 5318 PKP2 ACATTGAACAACATAATCCA']
NM_004333.4(BRAF):c. l783T> ['AGACCTCACAGTAAAAATAGGTGATYTTGG
2450 C (p.Phe595Leu) 673 BRAF TCTAGCTACAGTGAAATCTCG]
NM_000543.4(SMPDl):c.416T> ['GCCGTGTGCCAATCCATTGTCCACCYCTTTG
2451 C (p.Leul39Pro) 6609 SMPD1 AGGATGACATGGTGGAGGTG]
NM_000016.5(ACADM):c.698T ['GAAGCAGATACCCCAGGAATTCAGAHTGGG
2452 >C (p.Ile233Thr) 34 ACADM AGAAAGGTAAAGTATTTATTA]
M_004453.3(ETFDH):c.l852T ['AGGAGGACCTGCTTACAATGGAATGYAAAC
2453 >C (p.Ter618Gln) 2110 ETFDH TGCAGCTAGCCAGTTTCTTTC]
NM_000255.3 (MUT):c.842T>C ['GCCATTCTGGAGCTGGCCTATACTTYAGCAG
2454 (p.Leu281Ser) 4594 MUT ATGGATTGGAGTACTCTAGA']
NM_000277.1 (PAH) : c.2T>C [' AGACCTC ACTCCCGGGGAGCCAGCAB GTCC
2455 (p.MetlThr) 5053 PAH ACTGCGGTCCTGGAAAACCCA]
NM_000017.3(ACADS):c.l057T ['GGCAGCCATGGCCAAGCTGGCCGCCYCGGA
2456 >C (p.Ser353Pro) 35 ACADS GGCCGCGACCGCCATCAGCCA']
NM_002225.3(IVD):c.295+2T> ['GCGTATTGGGCATCACAGCCCCTGGYGAGT
2457 C 3712 IVD ATAGTGTCTTTCCCTAAAAAG]
NM_000030.2(AGXT):c.2T>C ['CGAGCGGCAGGTTGGGTGCGGACCAYGGCC
2458 (p.MetlThr) 189 AGXT TCTCACAAGCTGCTGGTGACC]
NM_000030.2(AGXT):c.77T>C ['CTCTCCATCCCCAACCAGCTCCTGCYGGGGC
2459 (p.Leu26Pro) 189 AGXT CTGGTCCTTCCAACCTGCCT']
NM_000030.2(AGXT):c.449T>C ['GGCCTGGCCCAGCACAAGCCAGTGCYGCTG
2460 (p.Leul50Pro) 189 AGXT TTCTTAACCCACGGGGAGTCG]
NM_000030.2(AGXT):c.497T>C ['TCGTCCACCGGCGTGCTGCAGCCCCHTGATG
2461 (p.Leul66Pro) 189 AGXT GCTTCGGGGAACTCTGCCAC]
NM_000030.2(AGXT):c.661T>C ['CGCCCCTCCAGGGACCTCGCTCATCYCCTTC
2462 (p.Ser221Pro) 189 AGXT AGTGACAAGGCCAAGTGAGT']
NM_000030.2(AGXT):c.757T>C ['CAAGTGGCTGGCCAACTTCTGGGGCYGTGA
2463 (p.Cys253Arg) 189 AGXT CGACCAGCCCAGGATGTGAGG]
NM_000030.2(AGXT):c.806T>C ['CATCACACAATCCCCGTCATCAGCCYGTACA
2464 (p.Leu269Pro) 189 AGXT GCCTGAGAGAGAGCCTGGCC]
NM_000030.2(AGXT):c.851T>C ['CCAGCGCCATCTCCCACACAGGGCCYGGAG
2465 (p.Leu284Pro) 189 AGXT AACAGCTGGCGCCAGCACCGC]
NM_000030.2(AGXT):c.893T>C ['CAGCACCGCGAGGCCGCGGCGTATCYGCAT
2466 (p.Leu298Pro) 189 AGXT GGGCGCCTGCAGGCACTGGGG]
NM_000030.2(AGXT):c.947T>C ['TGAGCCAGGCCCCTCCTGCAGGCGCYCCGG
2467 (p.Leu316Pro) 189 AGXT CTTCCCACAGTCACCACTGTG]
2468 NM_000030.2(AGXT):c.l076T> 189 AGXT ['AGCCCGCCCTGTGCCCCCCAGGTGCYGCGG C (p.Leu359Pro) ATCGGCCTGCTGGGCTGCAAT']
NM_000030.2(AGXT):c.l l51T> ['GTGACGGAGGCCCTGAGGGCGGCCCYGCAG
2469 C (p.Leu384Pro) 189 AGXT CACTGCCCCAAGAAGAAGCTG]
NM_012203.1(GRHPR):c.203T> [TCCGACCACGTGGACAAGAGGATCCYGGAT
2470 C (p.Leu68Pro) 9380 GRHPR GCTGCAGGTGCACACTGGGTG]
NM_012203.1(GRHPR):c.965T> ['CTGGCTGGCCTGAGAGGGGAGCCGAB GCCT
2471 C (p.Met322Thr) 9380 GRHPR AGTGAACTCAAGCTGTAGCCA']
NM_138413.3(HOGAl):c.533T> 11281 ['GTCCCAGCCAACACAGGGCTGGACCYGCCT
2472 C (p.Leul78Pro) 7 HOGA1 GTGGATGCAGTGGTCACGCTT]
NM_138413.3(HOGAl):c.875T> 11281 ['GGGATCCCAGGGCTGAAGAAAATCAYGGAC
2473 C (p.Met292Thr) 7 HOGA1 TGGTTTGGCTACTATGGAGGC]
NM_004370.5(COL12Al):c.700 ['TTCTTGACTGATGCCTCCTGGAGCAYTGGGG
2474 1T>C (p.Ile2334Thr) 1303 COL12A1 ACGATAATTTTAACAAAGTT']
NM_019074.3(DLL4):c.583T>C ['CCTGTGCAAGAAGCGCAATGACCACYTCGG
2475 (p.Phel95Leu) 54567 DLL4 CCACTATGTGTGCCAGCCAGA']
NM_019074.3 (DLL4) :c .1168T> ['CCAGGGGGCCAACTATGCTTGTGAAYGTCC
2476 C (p.Cys390Arg) 54567 DLL4 CCCCAACTTCACCGGCTCCAA']
NM_015909.3(NBAS):c.3164T> ['TCAGAGCTTTTGGAAAAACATGGACYCGAG
2477 C (p.Leul055Pro) 51594 NBAS AAACCAATTTCATTTGTTAAA]
NM_000263.3 (NAGLU) :c .1208T ['GCCTCCTTCCAGGGCCAGCCCTTCAYCTGGT
2478 >C (p.Ile403Thr) 4669 NAGLU GCATGCTGCACAACTTTGGG']
NM_203290.2(POLRlC):c.436T ['TCTACAGTTTCGTCTCCAGGTCAGAYGCACT
2479 >C (p.Cysl46Arg) 9533 POLR1C CGGAACCCCCATGCTGCTAA']
NM_018359.3(UFSP2):c.868T> ['CCAGGGCATATATGGCTATCATCATYATATG
2480 C (p.Tyr290His) -1 - CAGGATCGCATAGATGACAA']
NM_000310.3(PPTl):c.2T>C ['CCGCGGTCATGTGACACAGCGAAGAYGGCG
2481 (p.MetlThr) 5538 PPT1 TCGCCCGGCTGCCTGTGGCTC]
NM_021007.2(SCN2A):c.l271T ['CTAATAAATTTGATCTTGGCTGTGGYGGCCA
2482 >C (p.Val424Ala) 6326 SCN2A TGGCCTATGAGGAACAGAAT']
NM_021007.2(SCN2A):c.2306T ['GTTGACCTGGCCATCACCATCTGCAYTGTCT
2483 >C (p.Ile769Thr) 6326 SCN2A TAAATACACTCTTCATGGCT']
NM_021007.2(SCN2A):c.4308+ ['TATGCAGCTGTTGATTCACGAAATGYAAGTC
2484 2T>C 6326 SCN2A TAGTTAGAGGGAAATTGTTT']
NM_021007.2(SCN2A):c.4718T ['TGGATTAATCTGGTGTTTATTGTTCYGTTCA
2485 >C (p.Leul573Pro) 6326 SCN2A CTGGAGAATGTGTGCTGAAA']
NM_001165963.1(SCNlA):c.55 ['CAGCTCATTGCCATGGATTTGCCCAHGGTGA
2486 67T>C (p.Metl856Thr) -1 - GTGGTGACCGGATCCACTGT']
NM_001165963.1(SCNlA):c. lO ['AATCCCAATTATGGCTACACAAGCTYTGATA
2487 94T>C (p.Phe365Ser) 6323 SCN1A CCTTCAGTTGGGCTTTTTTG]
NM_001165963.1(SCNlA):c.66 [TCGGCATTGAGAACATTCAGAGTTCYCCGA
2488 2T>C (p.Leu221Pro) 6323 SCN1A GCATTGAAGACGATTTCAGTC]
NM_000806.5(GABRAl):c.788T ['ATTCAAACATACCTGCCATGCATAAYGACA
2489 >C (p.Met263Thr) 2554 GABRA1 GTGATTCTCTCACAAGTCTCC]
2490 NM_014191.3(SCN8A):c.4889T 6334 SCN8A ['GCCCGTATTGGGCGCATCTTGCGTCYGATCA >C (p.Leul630Pro) AAGGCGCCAAAGGGATTCGT']
NM_005249.4(FOXGl):c.673T> [TTACTACCGCGAGAACAAGCAGGGCYGGCA
2491 C (p.Trp225Arg) 2290 FOXG1 GAACTCCATCCGCCACAATCT']
NM_017882.2(CLN6):c.486+2T ['AAGAATCTCAAGCCGGAGACGCTGGYGAGG
2492 >C 54982 CLN6 CCACCTCCTGCTCCCTGCCTG]
NM_002693.2(POLG):c.l808T> ['AGGGAAGCCATCCCAGGTAAGTGCCRTGAG
2493 C (p.Met603Thr) 5428 POLG TTTAGGTGTGACCCGCATCTG]
NM_002693.2(POLG):c.l283T> ['AGGCAGGTAGGAGACACCCATCTCCRGCAT
2494 C (p.Leu428Pro) 5428 POLG GCCGGCCAGAGTCACTGGGTG]
NM_018129.3 (PNPO) : c.2T>C ['GGGTCACGTGGCCGGCGGCCCCCCAYGACG
2495 (p.MetlThr) 55163 PNPO TGCTGGCTGCGGGGCGTCACG]
NM_007254.3(PNKP):c.1029+2 ['ACCCCCACCCCCGCCCCAGGGCCTCRCCGGA
2496 T>C 11284 PNKP TCAAAGGCTGGGAGCTCGAA']
NM_172107.2(KCNQ2):c.583T> ['CTCCCAGGGCAACGTCTTTGCCACAYCTGCG
2497 C (p.Serl95Pro) 3785 KCNQ2 CTCCGGAGCCTGCGCTTCCT']
NM_000026.2(AD SL) :c .340T>C ['TATTCACCTTGGTGCTACTTCTTGCYATGTTG
2498 (p.Tyrl l4His) 158 ADSL GAGACAATACTGTAGGCGC]
NM_000026.2(AD SL) :c .1339T> ['CCAGTTGGATCATTTACTGGATCCTYCTTCT
2499 C (p.Ser447Pro) 158 ADSL TTCACTGGTCGTGCCTCCCA']
NM_001356.4(DDX3X):c.704T> ['GGGTCTGGAAAAACTGCAGCATTTCYGTTGC
2500 C (p.Leu235Pro) 1654 DDX3X CCATCTTGAGTCAGATTTAT']
NM_001356.4(DDX3X):c.l l75T ['TAAAAATTTTTTTTCTTTCAGATGCYGGCTC
2501 >C (p.Leu392Pro) 1654 DDX3X GTGATTTCTTAGATGAATAT']
NM_001356.4(DDX3X):c.l541T ['GACATTTCAAATGTGAAACATGTTAYCAATT
2502 >C (p.Ile514Thr) 1654 DDX3X TTGACTTGCCAAGTGATATT']
NM_020533.2(MCOLNl):c.317 ['ACCATCGCCTTCCGACACCTCTTCCYGCTGG
2503 T>C (p.Leul06Pro) 57192 MCOLN1 GCTACTCGGACGGAGCGGAT']
NM_020533.2(MCOLNl):c. l340 ['TACTGCTTCTGTGGCTGGATCGTGCYGGGGC
2504 T>C (p.Leu447Pro) 57192 MCOLN1 CCTATCATGTGAAGGTACAT']
NM_000083.2(CLCNl):c. l283T ['CCCCGCGAAGCCATCAGTACTTTGTYTGACA
2505 >C (p.Phe428Ser) 1180 CLCN1 ACAATACATGGGTGAAACAC]
NM_003995.3(NPR2):c.226T>C ['CAGCTCCGAACTGGAAGGCGCCTGCYCTGA
2506 (p.Ser76Pro) 4882 NPR2 GTACCTGGCACCGCTGAGCGC]
NM_004700.3 (KCNQ4) : c.808T> ['GGACGCCAACTCCGACTTCTCCTCCYACGCC
2507 C (p.Tyr270His) 9132 KCNQ4 GACTCGCTCTGGTGGGGGAC]
NM_004700.3 (KCNQ4) : c.823 T> ['CTTCTCCTCCTACGCCGACTCGCTCYGGTGG
2508 C (p.Trp275Arg) 9132 KCNQ4 GGGACGGTGCGTGAGGGTCT']
NM_005097.3(LGIl):c. l24T>C ['GGGGAAGAAACCAGCGAAGCCAAAABGCCC
2509 (p.Cys42Arg) 9211 LGI1 TGCCGTGTGTACTTGTACCAA']
NM_005572.3(LMNA):c.936+2T ['CAGCTCAGCCAGCTCCAGAAGCAGGYGATA
2510 >C 4000 LMNA CCCCACCTCACCCCTCTCTCC]
NM_006009.3 (TUB Al A) : c .1226 ['AAACGTGCCTTTGTTCACTGGTACGYTGGGG
2511 T>C (p.Val409Ala) 7846 TUBA1A AGGGGATGGAGGAAGGTGAG]
2512 NM_001081550.1(THOC2):c. l3 57187 THOC2 ['GACGTGTTCAATATGTTCTGTTACCYTGGTC 13T>C (p.Leu438Pro) CTCACCTTTCTCACGATCCC]
NM_001081550.1(THOC2):c.30 ['ACATCAACAGAAAACTCCAAATTTTYCCAC
2513 34T>C (p.Serl012Pro) 57187 THOC2 ACTTCTTTGCTATGATCGAGT']
NM_001081550.1(THOC2):c.23 ['GATTATATAAAGCGAGTGCCTTCAAYTGATG
2514 99T>C (p.Ile800Thr) 57187 THOC2 TACTCTGTAATGAATTTCAT']
NM_001356.4(DDX3X):c.l520T ['CAGGTAGCAGCAAGAGGACTGGACAYTTCA
2515 >C (p.Ile507Thr) 1654 DDX3X AATGTGAAACATGTTATCAAT']
NM_000158.3(GBEl):c.691+2T ['TGAATAAAAATCACAGTTATTACTTRCCAAG
2516 >C 2632 GBE1 GCCTTTGATTCTTGGTAGTA']
NM_000719.6(C ACNA1 C) :c .34 ['ATGAACATCTTCGTGGGCTTCGTCAYCGTCA
2517 97T>C (p.Ilell66Thr) 775 CACNA1C CCTTTCAGGAGCAGGGGGAG]
NM_001105.4(ACVRl):c.587T> ['TGTACATCAGGAAGTGGCTCTGGTCYTCCTT
2518 C (p.Leul96Pro) 90 ACVR1 TTCTGGTACAAAGAACAGTG]
NM_024531.4(SLC52A2):c.935 ['CCCTACGGGCGTCTGGCCTACCACCYGGCTG
2519 T>C (p.Leu312Pro) 79581 SLC52A2 TGGTGCTGGGCAGTGCTGCC]
NM_033409.3(SLC52A3):c.224 11327 ['AGCTGCCTTTCCGAAGTGCCCATCAYCTTCA
2520 T>C (p.Ile75Thr) 8 SLC52A3 CCCTGCTGGGCGTGGGAACC]
NM_033409.3(SLC52A3):c.49T 11327 ['GGTCTGCGTCTTCGGAATGGGCTCCYGGGTG
2521 >C (p.Trpl7Arg) 8 SLC52A3 ACCATCAATGGGCTCTGGGT']
NM_133433.3(NIPBL):c.6108+2 ['CCATACCTTACCACTAAATGTAGTGYAAGTA
2522 T>C 25836 NIPBL TAGAGCTGTCTTATTCTTGT']
NM_002397.4(MEF2C):c.2T>C ['CGTAATCTGAATCTTTTTTCTCCCCDTAGTCC
2523 (p.MetlThr) 4208 MEF2C CCGTTTTTCTTCTCTCTCT']
NM_000124.3(ERCC6):c.2551T ['AATACTCGCTGACCCTGCTTGTGCCRTATTT
2524 >C (ρ.Τφ851Α¾) 2074 ERCC6 TCAACAAAGACTCAACAACA']
NM_000208.2(INSR):c.l610+2T ['GTTCATGCTGTTCTACAAAGAGGCGYAAGT
2525 >C 3643 INSR AGAAGAGTTAGAGAGACGCTG]
NM_000071.2(CBS):c.325T>C ['CTCCCGCCCGCGTTGAAGAACTCACRCTTGG
2526 (p.Cysl09Arg) 875 CBS CCACTGGGAGGCAGAGATGA']
NM_004550.4(NDUFS2):c.875T ['CATTATGCTCTCCACAGTGGAGTGAYGCTTC
2527 >C (p.Met292Thr) 4720 NDUFS2 GGGGCTCAGGCATCCAGTGG]
NM_003119.3(SPG7):c.2228T> ['AAGGAAGTGATAAACTATGAGGACAYTGAG
2528 C (p.Ile743Thr) 6687 SPG7 GCTCTCATTGGCCCGCCGCCC]
NM_000546.5(TP53):c.584T>C ['CACACGCAAATTTCCTTCCACTCGGRTAAGA
2529 (p.Ilel95Thr) 7157 TP53 TGCTGAGGAGGGGCCAGACC]
NM_018972.2(GDAPl):c.347T> ['AGGTTAATGCCTGATAAAGAAAGCAKGTAT
2530 C (p.Metl l6Thr) 54332 GDAPl TACCCACGGGTACAACATTAC]
NM_000070.2(C APN3 ) : c.566T> ['TGCCTGCCAACGTACAACAATCAACYGGTTT
2531 C (p.Leul89Pro) 825 CAPN3 TCACCAAGTCCAACCACCGC]
NM_000070.2(CAPN3):c.1117T ['TTAATTCCTCCATTTTCCCACCAGAYGGAAG
2532 >C (ρ.Τφ373Α¾) 825 CAPN3 GACTGGAGCTTTGTGGACAA']
NM_181534.3(KRT25):c.950T> 14718 ['AAATTGTTCTTTTCATACCGTGGCTRGGAGA
2533 C (p.Leu317Pro) 3 KRT25 GACTGAAGTTCAATTTCCAG']
2534 NM_001002294.2(FMO3):c.560 2328 FM03 ['CCAGGTGTATTCAATGGAAAGCGTGBCCTG T>C (p.Vall87Ala) GTGGTTGGCCTGGGGAATTCG']
NM_001080522.2(CC2D2A):c.l ['GAAATTCAAGCTGAAATAAGTGAACYGTTA
2535 676T>C (p.Leu559Pro) 57545 CC2D2A GAAGAGCACACGGAGGAGTAC]
NM_001080522.2(CC2D2A):c.3 ['TACCAAGTCATATTTTCTTCACAGAYTGATG
2536 596T>C (p.Ilel l99Thr) 57545 CC2D2A GAACATTTAAAATAGATATT']
NM_025114.3(CEP290):c.2343T ['CCTGTAACAAATGTATTAAATATTCRTTCTG
2537 >C (p.Asn781=) 80184 CEP290 AGAATTAATGATACTGGCAC]
NM_030578.3(B9D2):c.l07T>C ['CGTTTGGCCCTCCCGCACGCCTGACRGGAGC
2538 (p.Leu36Pro) 80776 B9D2 TTCCATGCCGCCCCTGCAGT']
M_004304.4(ALK):c.3520T>C ['ACATCCCTCTCTGCTCTGCAGCAAAKTCAAC
2539 (p.Phel l74Leu) 238 ALK CACCAGAACATTGTTCGCTG]
Table 7 Diseases/disorders containging A to G Changes. The table includes human gene mutations that may be corrected by changing a guanine (G) to adenine (A). The gene name, gene symbol, and Gene ID are indicated.
Figure imgf000356_0001
2A>G CTGGTGGGGAAGAAGTTTTA]
3156 NM_000398.6(CYB5R3):c.719A> 1727 CYB5R3 ['CGCTTCAAGCTCTGGTACACGCTGGRCAG G (p.Asp240Gly) AGCCCCTGAAGGTGAGTGAGGG]
3157 NM_004628.4(XPC):c.413-24A>G 7508 XPC ['ATTATTATTGTTATTACTATTACTGRTTTTT
AAAAATGCTTGTTGATAGAA']
3158 NM_001134363.2(RBM20):c.l909 28299 RBM20 ['TGGCCCAGAAAGGCCGCGGTCTCGTRGTC A>G (p.Ser637Gly) 6 CGGTGAGCCGGTCACTCTCCCC]
3159 NM_000552.3(VWF):c.2384A>G 7450 VWF ['GAGTGTACCAAAACGTGCCAGAACTRTGA (p.Tyr795Cys) CCTGGAGTGCATGAGCATGGGC]
3160 NM_000552.3(VWF):c. l583A>G 7450 VWF ['ACCTGCGGCCTGTGTGGGAATTACARTGG (p.Asn528Ser) C A ACC AGGGC G AC G ACTTC CTT']
3161 NM_144573.3(NEXN):c.l955A>G 91624 NEXN ['ACTTTCCCAGAAGATGGAGGAGAGTRTAT (p.Tyr652Cys) GTGTAAAGCAGTCAACAATAAA']
3162 NM_000267.3(NFl):c.4267A>G 4763 NF1 ['CGAAAGGGGCTTGAAGTTAATGTCARAGG (p.Lysl423Glu) TGAATTATTTTGATAATCTAGC]
3163 NM_000267.3(NFl):c.l642-8A>G 4763 NF1 ['TCTCTTTGTCTTTCTCTTTTTTAAARAATTC
AGGCTCTGCTGGTTCTTCAT']
3164 NM_000267.3 (NF 1 ) :c .1466 A>G 4763 NF1 ['CCTACAGACCTGGAGACAAGAAGCTRTAA (p.Tyr489Cys) GTATCTTCTCTTGTCCATGGTG]
3165 NM_000267.3(NFl):c.5944-5A>G 4763 NF1 ['AAAAACATGTTATTTTCCTTCTTCARCTAG
ATTACAGATCTGCTTGATGTT']
3166 NM_000308.2(CTSA):c.746+3A>G 5476 CTSA ['TACCATGGCCTTCTGGGGAACAGGTRTGG
GATAGGGCAGTTGGGCAATCTC]
3167 NM_000308.2(CTSA):c.200A>G 5476 CTSA ['CTGGCCAAGCAGCCGTCTTTCCGCCRGTAC (p.Gln67Arg) TCCGGCTACCTCAAAGGCTCC]
3168 NM_000308.2(CTSA):c.1238A>G 5476 CTSA ['CTTTAGAAATACCAGATCCTATTATRTAAT (p.Tyr413Cys) GGAGATGTAGACATGGCCTGC]
3169 NM_000308.2(CTSA):c. l411A>G 5476 CTSA ['CTCCCACATCGCCTTTCTCACGATCRAGGT (p.Lys471Glu) AGGGACTGGGCCTGCTGAGAG]
3170 NM_000353.2(TAT):c.236-5A>G 6898 TAT ['TTCCAAACACAGTAGGGTCCCCTTTYTATG
GGAGGAAAACACAAAAGGAGC]
3171 NM_000097.5(CPOX):c.l210A>G 1371 CPOX ['TAATCTGCTGTATGATCGGGGCACARAGTT (p.Lys404Glu) TGGCCTCTTCACTCCAGGATC]
3172 NM_000317.2(PTS):c.l55A>G 5805 PTS ['AACAATCCAAATGGCCATGGGCACARTTA (p.Asn52Ser) TAAAGGTGAGAGAAAAACTGAT']
3173 NM_000317.2(PTS):c.l39A>G 5805 PTS ['ACTGTTTGGGAAATGCAACAATCCARATG (p.Asn47Asp) GCCATGGGCACAATTATAAAGG]
3174 NM_000317.2(PTS):c.347A>G 5805 PTS ['GAAAATGTAGCTGTTTATATCTGGGRCAAC (p.Aspl l6Gly) CTCCAGAAAGTTCTTCCTGTA']
3175 NM_000320.2(QDPR):c.449A>G 5860 QDPR ['CCCCATTTCCCAGGTATGATCGGGTRCGGC (p.Tyrl50Cys) ATGGCCAAGGGTGCTGTTCAC]
3176 NM_173560.3(RFX6):c.224- 22254 RFX6 ['TCTATTTTTCTTTATCATCCCTTCARCTGGC 12A>G 6 AATCAGAAATGCACTTAAAC]
3177 NM_001999.3(FBN2):c.3725- 2201 FBN2 ['TTCATCAATATCTGTGAAAACAGCAYTGC 15A>G AACCACATTGTCAGGTCTGCTT']
3178 NM_001040613.2(TMEM70):c.*7- 54968 TMEM70 ['GATCCTCTCTCTTTTTTTCCCATTTRGGTGT 2A>G GAAATGTTTCTCTTATTCTA']
3179 NM_152416.3(NDUFAF6):c.296A 13768 NDUFAF6 ['AGGGCCTTTAATGTGGAACTGGCTCRGGCT >G (p.Gln99Arg) 2 GGTATTAAGATACCTTAAAAT']
3180 NM_000140.3 (FECH) :c .1137+3 A> 2235 FECH ['ACTAAAACGATTGTAACACTGTAGAYACC G TTAGAGAACAATGGATTTCCAT']
3181 NM_000277.1(PAH):c.lA>G 5053 PAH ['GAGACCTCACTCCCGGGGAGCCAGCDTGT (p.MetlVal) CCACTGCGGTCCTGGAAAACCC]
3182 NM_000277.1(PAH):c.611A>G 5053 PAH ['TCCTTGTATAAAACCCATGCTTGCTRTGAG (p.Tyr204Cys) TACAATCACATTTTTCCACTT']
3183 NM_000277.1(PAH):c.l241A>G 5053 PAH ['ATACCTCGGCCCTTCTCAGTTCGCTRCGAC (p.Tyr414Cys) CCATACACCCAAAGGATTGAG]
3184 NM_000277.1(PAH):c.662A>G 5053 PAH ['CTTGAAAAGTACTGTGGCTTCCATGRAGAT (p.Glu221Gly) AACATTCCCCAGCTGGAAGAC]
3185 NM_000277.1(PAH):c.916A>G 5053 PAH ['TTCTATTTTCCCCCAATTACAGGAARTTGG (p.Ile306Val) CCTTGCCTCTCTGGGTGCACC]
3186 NM_000277.1(PAH):c.l l69A>G 5053 PAH ['TTCCAGCCCCTGTATTACGTGGCAGRGAGT (p.Glu390Gly) TTTAATGATGCCAAGGAGAAA']
3187 NM_000277.1(PAH):c.l065+3A>G 5053 PAH ['TGTCATCCTTTGGTGAATTACAGGTVTGAC
CTTCACAGGAACCAAGGATAG]
3188 NM_000277.1(PAH):c.227A>G 5053 PAH ['AGACCTTCTCGTTTAAAGAAAGATGVGTA (p.Glu76Gly) TGAATTTTTCACCCATTTGGAT']
3189 NM_000130.4(F5):c.l000A>G 2153 F5 ['CATTAAAAACTGCCCAAAGAAAACCRGGA (p.Arg334Gly) ATCTTAAGAAAATAACTCGTGA']
3190 NM_000130.4(F5):c.5189A>G 2153 F5 ['GGCTCTGCCTGTCGGGCTTGGGCCTRCTAC (p.Tyrl730Cys) TCAGCTGTGAACCCAGTAGGT']
3191 NM_000512.4(GALNS):c. l460A> 2588 GALNS ['TTGGTCCCCGCGCAGCCCCAGCTCARCGTG G (p.Asn487Ser) TGCAACTGGGCGGTCATGGTA]
3192 NM_015702.2(MMADHC):c.746A 27249 MMADHC ['ACTCTTTTTGAAACTGATGAACGCTRCCGA >G (p.Tyr249Cys) CATTTAGGATTCTCTGTTGAT']
3193 NM_015141.3(GPDlL):c.370A>G 23171 GPD1L ['TAACTTCTTGGCATCCTTGTAGGGCRTAGA (p.Ilel24Val) CGAGGGCCCCGAGGGGCTGAA']
3194 NM_013319.2(UBIADl):c.305A>G 29914 UBIAD1 ['GTGCACGGGGCCGGTAATTTGGTCARCAC (p.Asnl02Ser) TTACTATGACTTTTCCAAGGGC]
3195 NM_013319.2(UBIADl):c.355A>G 29914 UBIAD1 ['CATTGACCACAAAAAGAGTGATGACRGGA (p.Argl l9Gly) CACTTGTGGACCGAATCTTGGA']
3196 NM_013319.2(UBIADl):c.695A>G 29914 UBIAD1 ['AGCACCGAGGCCATTCTCCATTCCARCAAC (p.Asn232Ser) ACCAGGGACATGGAGTCCGAC]
3197 NM_013319.2(UBIADl):c.335A>G 29914 UBIAD1 ['TACTATGACTTTTCCAAGGGCATTGRCCAC (p.Aspl l2Gly) AAAAAGAGTGATGACAGGACA]
3198 NM_000046.3(ARSB):c.629A>G 411 ARSB ['GTTGCAACAGGATATAAAAATATGTRTTC (p.Tyr210Cys) AACAAACATATTCACCAAAAGG]
3199 NM_006331.7(EMGl):c.257A>G 10436 EMG1 ['CGGGACCCTGGGGAAGCGCGGCCAGRTAT (p.Asp86Gly) CACCCACCAGGTAACTCCAGGG]
3200 NM_000181.3(GUSB):c.l484A>G 2990 GUSB ['CTGCTGCTCTGGTCCTAGGCTCCGTRTGTG (p.Tyr495Cys) GATGTGATCTGTTTGAACAGC]
3201 NM_000067.2(CA2):c.754A>G 760 CA2 ['CTGGCGCCCAGCTCAGCCACTGAAGRACA (p.Asn252Asp) GGCAAATCAAAGCTTCCTTCAA]
3202 NM_000067.2(CA2):c.52A>G 760 CA2 [TCCCCCAGGACCTGAGCACTGGCATVAGG (p.Lysl8Glu) ACTTCCCCATTGCCAAGGGAGA]
3203 M_000404.2(GLBl):c.947A>G 2720 GLB1 ['TTTATAGGTGGGACCAATTTTGCCTRTTGG (p.Tyr316Cys) AATGGTAAGAGCACTTTAATA]
3204 M_000404.2(GLBl):c. l498A>G 2720 GLB1 ['TTTGCAGGGTTTGGTTTCTAACCTGRCTCT (p.Thr500Ala) CAGTTCCAATATCCTCACGGA']
3205 NM_000404.2(GLBl):c. l480- 2720 GLB1 ['GAGAGTCAGGTTAGAAACCAAACCCYGCA 2A>G AAGCAGAAACAGAGCACAGTGA']
3206 M_000404.2(GLBl):c. l772A>G 2720 GLB1 ['ATTAATGGCTTTAACCTTGGCCGCTRTTGG (p.Tyr591Cys) CCAGCCCGGGGCCCTCAGTTG]
3207 NM_203447.3(DOCK8):c.l418A> 81704 D0CK8 ['ACTCTGAGCGTTAGCAGCTTTTTCARGCAG G (p.Lys473Arg) GTATCTCTTCACATTACAGTG]
3208 NM_000275.2(OCA2):c.l465A>G 4948 0CA2 ['TGCCACTGCCATCGGGGACCCTCCARATGT (p.Asn489Asp) CATTATTGTTTCCAACCAAGA']
3209 NM_152778.2(MFSD8):c.362A>G 25647 MFSD8 ['ATTTCCGTGGCAGCCAACTGCCTCTVTGCA (p.Tyrl21Cys) 1 TATCTCCACATCCCAGCTTCT']
3210 NM_139241.3(FGD4):c. l762- 12151 FGD4 ['ACTGTTCATTTTTCTTTTAAATTTARGGTGG 2A>G 2 TTTGTTGGAAATGCTCCGAC]
3211 NM_020223.3(FAM20C):c.l364- 56975 FAM20C ['TGTGACACTTTCTGCCTCTCTCCGCRGGAA 2A>G ACATGGACCGTCACCACTACG]
3212 NM_138387.3(G6PC3):c.346A>G 92579 G6PC3 ['GGCAGGCAGCCCTTCTGGACACTGCRTGA (p.Metl l6Val) TCACAGGAGCAGCCCTCTGGCC]
3213 NM_018122.4(DARS2):c.l33A>G 55157 DARS2 TTTTTTTTTTTTTTTTAAAG^TTCRGTAGC (p.Ser45Gly) TTTGTTGTCCGGACCAACAC]
3214 NM_000642.2(AGL):c.4260- 178 AGL ['CATCTTTTATTTAACTTAAATTTCARTCATT 12A>G TTGCAGTGATATGGTTTACT']
3215 NM_000642.2(AGL):c.3439A>G 178 AGL ['TCTACTGGGTGAAGGAATTTATGCCRGATA (p.Argl l47Gly) CAATTGTCGGGATGCTGTGTG]
3216 M_145014.2(HYLSl):c.632A>G -1 ['TTAAGCCGAAACCGGGGCAAGACAGRCCG (p.Asp211Gly) GGTAGCCCGGTATTTTGAGTAC]
3217 NM_014362.3(HIBCH):c.365A>G 26275 HIBCH ['GCTCCAGTTTTCTTCAGAGAAGAATRTATG (p.Tyrl22Cys) CTGAATAATGCTGTTGGTATG]
3218 M_014846.3 (KIAAO 196) :c .1411 9897 KIAAO 196 ['TTTTCTTATTTCTGTATTACTAGAARACCTT A>G (p.Asn471Asp) CAAGCTTGGTTCAGAGAGAT']
3219 NM_000505.3(F12):c. l58A>G 2161 F12 ['GAGCCCTGCCACTTCCCCTTCCAGTRCCAC (p.Tyr53Cys) CGGCAGCTGTACCACAAATGT']
3220 NM_001029871.3(RSPO4):c.l94A 34363 RSP04 ['TTCATCCGCCGGGAAGGCATCCGCCRGTA >G (p.Gln65Arg) 7 CGGCAAGTGCCTGCACGACTGT']
3221 NM_017654.3(SAMD9):c.4483A> 54809 SAMD9 ['TAAAAGACTGGAAAGACTTGTTCACRAAG G (p.Lysl495Glu) GAAAAATTGACCAGTGCTTTAA]
3222 NM_152419.2(HGSNAT):c.372- 13805 HGSNAT ['TGTCTTAATTTTACCTAATGTTTGTRGGTTG 2A>G 0 GAATACAGATTTGGAGAATT']
3223 NM_001174089.1(SLC4Al l):c.251 83959 SLC4A11 ['CATGAGCTCCCTGCCCTACATGAAGRTGAT 8A>G (p.Met840Val) CTTTCCCCTCATCATGATCGC]
3224 NM_012073.4(CCT5):c.440A>G 22948 CCT5 ['CAGGCTGCTCGTGTTGCTATTGAACRCCTG (p.Hisl47Arg) GACAAGATCAGCGATAGCGTC]
3225 NM_025114.3(CEP290):c.2991+16 80184 CEP290 ['CACCTGGCCCCAGTTGTAATTGTGARTATC 55A>G TCATACCTATCCCTATTGGCA']
3226 NM_153704.5(TMEM67):c.870- 91147 TMEM67 ['TATTAAAACAGTTGTAACTGTTTATRGGAG 2A>G ACAGAATCTTCCTTGGCTGTT']
3227 NM_153704.5(TMEM67):c.l538A 91147 TMEM67 ['TATCAGGTTTCTTTCTCAGTCACATDTGAA >G (p.Tyr513Cys) ATGGATCATGGAGAAGCACAT']
3228 NM_001041.3(SI):c.350A>G 6476 SI ['GTTGATAATCATGGTTATAACGTTCRAGAC (p.Glnl l7Arg) ATGACAACAACAAGTATTGGT']
3229 NM_015697.7(COQ2):c.890A>G 27235 COQ2 ['TCTGGAGTTATGTGGACACTAATATRTGAT (p.Tyr297Cys) ACTATTTATGCCCATCAGGTA']
3230 NM_015697.7(COQ2):c.683A>G 27235 COQ2 ['GCACTGGGTGTTCTTCTGTGTCTAARTTAC (p.Asn228Ser) TACAGGTATATTAAACGTTTT']
3231 NM_000190.3 (HMB S) : c.1 A>G 3145 HMBS ['CACAGCCTACTTTCCAAGCGGAGCCRTGTC (p.MetlVal) TGGTAACGGCAATGCGGCTGC]
3232 NM_004035.6(ACOXl):c.832A>G 51 ACOX1 ['GAGTAACAAGCTGACTTACGGGACCRTGG (p.Met278Val) TGTTTGTCAGGTCCTTCCTTGT']
3233 NM_004035.6(ACOXl):c.926A>G 51 ACOX1 ['ATCCGATACAGCGCTGTGAGGCACCRGTC (p.Gln309Arg) TGAAATCAAGCCAGGGTAAGGA']
3234 NM_000237.2(LPL):c.548A>G 4023 LPL ['TGCTTTTTTCCCTTTTAAGGCCTCGRTCCAG (p.Aspl83Gly) CTGGACCTAACTTTGAGTAT']
3235 NM_000237.2(LPL):c.953A>G 4023 LPL ['TGCAACAATCTGGGCTATGAGATCARTAA (p.Asn318Ser) AGTCAGAGCCAAAAGAAGCAGC]
3236 NM_001171993.1(HPD):c.362A>G 3242 HPD ['TACATCGGCCAATTCTTGCCTGGATRTGAG (p.Tyrl21Cys) GCCCCAGCGTTCATGGACCCC]
3237 NM_139281.2(WDR36):c.l064A> 13443 WDR36 ['CTTCTTGTCACAAATGGCGCTGACARTGCT G (p.Asn355Ser) 0 CTTAGGGTATTATGATTATTG]
3238 NM_001127255.1(NLRP7):c.2738 -1 ['CTCACAAACCTGGACTTGAGTATCARCCA A>G (p.Asn913Ser) GATAGCTCGTGGATTGTGGATT']
3239 NM_016417.2(GLRX5):c.294A>G 51218 GLRX5 ['TGCTGGACGACCCGGAGCTCCGACARGGT (p.Gln98=) CAGGCCAGTGTGCCGGGCAGGC]
3240 NM_024884.2(L2HGDH):c.293A> 79944 L2HGDH ['ACTGGACATAACAGTGGTGTCATACRTAG G (p.His98Arg) TGGAATTTATTATAAACCTGAG]
3241 NM_000382.2(ALDH3 A2):c.1157 224 ALDH3A2 ['ACATCCAGTGGAGGTGTCACAGGCARTGA A>G (p.Asn386Ser) CGTCATTATGCACTTCACGCTC]
3242 NM_018105.2(THAPl):c.266A>G 55145 THAP1 ['TTTCTTTGTACTGAGCCACATGACARGGTA (p.Lys89Arg) ATATGCATTTTAAAATATTGG]
3243 NM_000785.3(CYP27Bl):c.566A> 1594 CYP27B1 ['GCCCTGGTTCGGGACGTGGCGGGGGRATT G (p.Glul89Gly) TTACAAGTTCGGACTGGAAGGT']
3244 NM_182548.3(LHFPL5):c.380A>G 22266 LHFPL5 ['TTCATCTGCAACACGGCCACAGTCTRTAAG (p.Tyrl27Cys) 2 ATCTGTGCATGGATGCAGCTG]
3245 NM_015040.3 (PIKFYVE) : c.3308 A 20057 PIKFYVE ['TTCAAAGAAATGGAGAACAGGAGGARGA >G (p.Lysl l03Arg) 6 AACAGCTGCTCAGGGATCTCTCT']
3246 NM_138701.3(MPLKIP):c.430A>G 13664 MPLKIP ['GTTGGAAAATTATTTCAAGCCTTCARTGCT (p.Metl44Val) 7 TGAAGATCCTTGGGCTGGCCT']
3247 NM_152783.4(D2HGDH):c. l315A 72829 D2HGDH ['TGCCCTTGTCCCTCCAGGAGATGGTRACCT >G (p.Asn439Asp) 4 GCACCTCAATGTGACGGCGGA]
3248 NM_022912.2(REEPl):c. l83- 65055 REEP1 ['AACTTGTGTTTTCATCTCTCTCTCCRGGTTT 2A>G CCATTCTATTATGAACTAAA']
3249 NM_000060.3(BTD):c.755A>G 686 BTD ['ACATGCTTTGATATATTGTTCTTTGRCCCT (p.Asp252Gly) GCCATCAGAGTCCTCAGAGAC]
3250 NM_022132.4(MCCC2):c.l309A> 64087 MCCC2 ['TGTGGCCTGTGCCCAAGTGCCTAAGDTAA G (p.Ile437Val) CCCTCATCATTGGGGGCTCCTA']
3251 NM_022132.4(MCCC2):c.569A>G 64087 MCCC2 ['GCAGATGTGTTTCCAGATCGAGACCRCTTT (p.Hisl90Arg) GGCCGTACATTCTATAATCAG]
3252 NM_198578.3(LRRK2):c.5096A>G 12089 LRRK2 ['ATCATCCGACTATATGAAATGCCTTRTTTT (p.Tyrl699Cys) 2 CCAATGGGATTTTGGTCAAGA]
3253 NM_198578.3(LRRK2):c.3364A>G 12089 LRRK2 ['TGTGACTAGAAATAAAATATCAGGGRTAT (p.Ilel l22Val) 2 GCTCCCCCTTGAGACTGAAGGA']
3254 NM_000022.2(ADA):c.219-2A>G 100 ADA ['TTCCCAACCCCTTTCTTCCCTTCCCRGGGG
CTGCCGGGAGGCTATCAAAAG]
3255 NM_000022.2(ADA):c.290A>G 100 ADA ['ATGAAGGCCAAAGAGGGCGTGGTGTDTGT (p.Tyr97Cys) GGAGGTGCGGTACAGTCCGCAC]
3256 NM_017780.3(CHD7):c.3082A>G 55636 CHD7 ['TTTAGTAATTGCCCCATTGTCCACARTCCC (p.Ilel028Val) CAACTGGGAAAGGGAATTCCG]
3257 NM_017780.3(CHD7):c.l64A>G 55636 CHD7 ['TTTGCCTCTTTACAGCCATCCCTTCRTCATC (p.His55Arg) CTTCAACTAATCAAAATCAA]
3258 NM_152443.2(RDH12):c.677A>G 14522 RDH12 ['GTCCCAGGCACCGGGGTCACCACCTRCGC (p.Tyr226Cys) 6 AGTGCACCCAGGCGTCGTCCGC]
3259 NM_015335.4(MED13L):c.752A> 23389 MED13L ['TACCCGATGGTGCTAAAAAAGAAAGRAGA G (p.Glu251Gly) ATCGAAAGAGGAAGACGAGTTG]
3260 NM_015335.4(MED13L):c.6068A> 23389 MED13L ['GCTTTTTTTCCCCCCTTCCCTCTAGRTGATA G (p.Asp2023Gly) TGTTTGTTGACCTTCCATTC]
3261 NM_025265.3(TSEN2):c.926A>G 80746 TSEN2 ['TATTTTCAGGCCTTTTTCTTGGTCTRTGCTC (p.Tyr309Cys) TGGGATGTTTAAGTATTTAC]
3262 NM_015384.4(NIPBL):c.7289A>G 25836 NIPBL ['AAAACAGACGTGACTATGCTCTTGTRTATA (p.Tyr2430Cys) GCAGACAATCTAGCCTGTTTT']
3263 NM_207352.3(CYP4V2):c.l091- 28544 CYP4V2 ['GTCATCTTATCTACTTGCTTTCATCRGGGA 2A>G 0 AGTCTGACCGTCCCGCTACAG]
3264 NM_024006.5 (VKORC 1 ) :c .172 A> 79001 VKORC 1 ['CAGCTGTTCGCGCGTCTTCTCCTCCRGGTG G (p.Arg58Gly) TGCACGGGAGTGGGAGGCGTG]
3265 NM_000551.3(VHL):c.491A>G 7428 VHL ['TATACTCTGAAAGAGCGATGCCTCCRGGTT (p.Glnl64Arg) GTCCGGAGCCTAGTCAAGCCT']
3266 NM_000101.3(CYBA):c.281A>G 1535 CYBA ['AATTACTATGTTCGGGCCGTCCTGCRTCTC (p.His94Arg) CTGTGAGTCCCCGTCCCGCAC']
3267 M_014874.3 (MFN2) : c.827 A>G 9927 MFN2 ['TTGTTTGGGCTCCAGGTGCGGCGGCRGCAC (p.Gln276Arg) ATGGAGCGTTGTACCAGCTTC]
3268 NM_015046.5 (SETX) :c .1807 A>G 23064 SETX ['GCAGAAGTCAGATCCACAAAAGTGTYACA (p.Asn603Asp) TGGAGGTGCTTTGAATTTTATG]
3269 NM_005609.2(PYGM):c.lA>G 5837 PYGM ['CAGTCCGGCCCGCCCTCCTGCAGCCVTGTC (p.MetlVal) CCGGCCCCTGTCAGACCAAGA']
3270 NM_033071.3(SYNEl):c.15705- 23345 SYNE1 ['ACTTCACTTCTGTTTTATCCCTGTARTGTTT 12A>G CTGAAGCATGCAGGAGAAAG]
3271 NM_130468.3(CHST14):c.878A>G 11318 CHST14 ['CTGTGCCAGCCTTGTGCCGTGCACTRTGAC (p.Tyr293Cys) 9 TTTGTGGGCTCCTATGAGAGG]
3272 NM_206933.2(USH2A):c. l4020A> 7399 USH2A ['AAAAGTTTTGTATTACGAATTATACRGAAG G (p.Arg4674Gly) ACAAATAGCAACTCAGCCTAG]
3273 NM_000048.3(ASL):c.857A>G 435 ASL ['AGCACGGGAAGCAGCCTGATGCCCCRGAA (p.Gln286Arg) GAAAAACCCCGACAGTTTGGAG]
3274 NM_001875.4(CPSl):c. l010A>G 1373 CPS1 ['CAGGCTTTCATTACTGCTCAGAATCRTGGC (p.His337Arg) TATGCCTTGGACAACACCCTC]
3275 NM_001173464.1(KIF21A):c.2839 55605 KIF21A ['GACCATTTCCAACATGGAGGCAGATRTGA A>G (p.Met947Val) ATAGACTCCTCAAGGTGTGGAA']
3276 NM_000026.2(ADSL):c.736A>G 158 ADSL ['CATCACAGGGCAGACATATACACGARAAG (p.Lys246Glu) TGGATATTGAAGTACTGTCTGT']
3277 NM_024577.3(SH3TC2):c.530- 79628 SH3TC2 ['AGCCATTGCTTTTCTCATTATCCACRGGCC 2A>G ACTTCTTCTGCAGAGCCCTGT']
3278 NM_018249.5(CDK5RAP2):c.4005 55755 CDK5RAP ['AGCATGGGAGATGATTTATCTTTCARTCTC -15A>G 2 AATGGTTAAGGATTGAGGAAG]
3279 NM_000346.3(SOX9):c.517A>G 6662 SOX9 ['GCACAAGAAGGACCACCCGGATTACRAGT (p.Lysl73Glu) ACCAGCCGCGGCGGAGGAAGTC]
3280 M_144596.3(TTC8):c.115-2A>G 12301 TTC8 ['GTTTACTGCCTTCTTAATGCTTTCCRGGAA
6 CCAGATCCTGAATTGCCAGTG]
3281 NM_000243.2(MEFV):c.2080A>G 4210 MEFV ['GAATGGCTACTGGGTGGTGATAATGDTGA (p.Met694Val) AGGAAAATGAGTACCAGGCGTC]
3282 NM_000243.2(MEFV):c.2084A>G 4210 MEFV ['GGCTACTGGGTGGTGATAATGATGADGGA (p.Lys695Arg) AAATGAGTACCAGGCGTCCAGC]
3283 NM_006493.2(CLN5):c.l l21A>G 1203 CLN5 ['GTGCACAAACAGTTCTATTTGTTTTRTAAT (p.Tyr374Cys) TTTGAATATTGGTTTTTACCT']
3284 NM_000483.4(APOC2):c.lA>G -1 ['TCAATGTTCCAGGTCTCTGGACACTRTGGG (p.MetlVal) CACACGACTCCTCCCAGCTCT']
3285 NM_058172.5(ANTXR2):c.l l42A 11842 ANTXR2 ['TGGCCAACTGTGGATGCTTCCTATTDTGGT >G (p.Tyr381Cys) 9 GGTCGAGGGGTTGGAGGAATT']
3286 NM_001128085.1(ASPA):c.692A> -1 ['TATAAAATTATAGAGAAAGTTGATTRCCCC G (p.Tyr231Cys) CGGGATGAAAATGGAGAAATT']
3287 NM_001128085.1(ASPA):c.71A>G -1 - ['ATCTTTGGAGGAACCCATGGGAATGRGCT (p.Glu24Gly) AACCGGAGTATTTCTGGTTAAG]
3288 NM_014365.2(HSPB8):c.421A>G 26353 HSPB8 ['TGGCATTGTTTCTAAGAACTTCACARAGAA (p.Lysl41Glu) AATCCAGTAAGTAACCTGGAG]
3289 NM_000391.3(TPPl):c.857A>G 1200 TPP1 ['CAGTACCTGATGAGTGCTGGTGCCARCATC (p.Asn286Ser) TCCACCTGGGTCTACAGTAGC]
3290 NM_000391.3(TPPl):c.887-10A>G 1200 TPP1 ['TGTCCCTCATGCCGGCCTGGATTTTYTTTTT
TTTTTTTTTTGAGGGATGGG]
3291 NM_182760.3(SUMFl):c.lA>G 28536 SUMF1 ['CGGGTCACATGGCCCGCGGGACAACRTGG (p.MetlVal) 2 CTGCGCCCGCACTAGGGCTGGT']
3292 M_031443.3(CCM2):c.lA>G 83605 CCM2 ['GGCCGCGGGAGCCGCACGCGGCGATRTGG (p.MetlVal) AAGAGGAGGGCAAGAAGGGCAA']
3293 NM_004183.3(BESTl):c.707A>G 7439 BEST1 ['GACTGGATTAGTATCCCACTGGTGTRTACA (p.Tyr236Cys) CAGGTGAGGACTAGGCTGGTG]
3294 NM_004183.3(BESTl):c.680A>G 7439 BEST1 ['ACTCAGTGTGGACACCTGTATGCCTRCGAC (p.Tyr227Cys) TGGATTAGTATCCCACTGGTG]
3295 NM_000158.3(GBEl):c.l634A>G 2632 GBE1 ['TGTAATGCAGGTAATGAATTTGGGCRTCCT (p.His545Arg) GAATGGTTAGACTTCCCAAGA]
3296 NM_000158.3(GBEl):c.l883A>G 2632 GBE1 ['GGTCTTCTTTTCATTTTCAACTTCCRTCCAA (p.His628Arg) GCAAGAGCTACACTGACTAC]
3297 NM_017890.4(VPS13B):c.8978A> 15768 VPS13B ['CTTCTGCCCTGGGCCCTGCTTATCARTGAA G (p.Asn2993Ser) 0 TCCAAATGGGACCTCTGGCTA']
3298 NM_000019.3(ACATl):c.278A>G 38 AC ATI ['GAAGTGAAAGAAGCATACATGGGTARTGT (p.Asn93Ser) TCTACAAGGAGGTGAAGGACAA']
3299 NM_173076.2(ABCA12):c.4139A> 26154 ABCA12 ['CATATTACTTCATTGCTGGGGCCCARTGGA G (p.Asnl380Ser) GCTGGGAAAACTACTACCATG]
3300 NM_030665.3(RAIl):c.4685A>G 10743 RAI1 ['AAGGGGCGTGCCAAGCGACGACGACRGCA (p.Glnl562Arg) GCAGGTGCTGCCCCTGGATCCC]
3301 NM_000271.4(NPCl):c.3467A>G 4864 NPC1 ['AGTCTGAACGCTGTATCCTTGGTCARCCTG (p.Asnl l56Ser) GTGATGGTGAGTCCTCATACA']
3302 NM_000271.4(NPCl):c.3263A>G 4864 NPC1 ['CCCTCCAGTGTGTTTTATGTCTTCTRCGAA (p.Tyrl088Cys) CAGTACCTGACCATCATTGAC]
3303 NM_000543.4(SMPDl):c.l l54A> 6609 SMPD1 ['CTCCGCCTCATCTCTCTCAATATGARTTTTT G (p.Asn385Ser) GTTCCCGTGAGAACTTCTGG']
3304 NM_000226.3(KRT9):c.469A>G 3857 KRT9 ['TCTGACTGCTAATGAGAAGAGCACCRTGC (p.Metl57Val) AGGAACTCAATTCTCGGCTGGC]
3305 NM_000226.3(KRT9):c.482A>G 3857 KRT9 ['GAGAAGAGCACCATGCAGGAACTCADTTC (p.Asnl61Ser) TCGGCTGGCCTCTTACTTGGAT']
3306 NM_176824.2(BBS7):c.968A>G 55212 BBS7 ['ACAGGTCTGACAACAGAGCCCATTCRTAA (p.His323Arg) GGAAAGTGGACCAGGAGAAGAA']
3307 NM_000051.3(ATM):c.3118A>G 472 ATM ['GAGGAAATATATATTCTCTGTAAGARTGG (p.Metl040Val) CCCTAGTAAATTGCCTTAAAAC]
3308 NM_000051.3(ATM):c.7268A>G 472 ATM ['GCTCTCCTGAAAAGAGCCAAAGAGGRAGT (p.Glu2423Gly) AGGTCTCCTTAGGGAACATAAA']
3309 NM_000051.3(ATM):c.8030A>G -1 - ['TATTAGGTGGACCACACAGGAGAATRTGG (p.Tyr2677Cys) AAATCTGGTGACTATACAGTCA]
3310 NM_000487.5(ARSA):c.*96A>G 410 ARSA ['GAGGGGGTTTGTGCCTGATAACGTARTAA
CACCAGTGGAGACTTGCAGATG]
3311 NM_000487.5(ARSA):c.1055 A>G 410 ARSA ['GCCCTGGCTGGGGCCCCACTGCCCARTGTC (p.Asn352Ser) ACCTTGGATGGCTTTGACCTC]
3312 NM_000218.2(KCNQl):c.418A>G 3784 KCNQ1 ['CATCGTCCTGGTCTGCCTCATCTTCRGCGT (p.Serl40Gly) GCTGTCCACCATCGAGCAGTA]
3313 NM_172250.2(MMAA):c.620A>G 16678 MMAA ['GAGTTATCAAGAGATATGAATGCATRCAT (p.Tyr207Cys) 5 CAGGCCATCTCCTACTAGAGGA']
3314 NM_000187.3(HGD):c.l l l2A>G 3081 HGD ['AGTCTACACAGCACAATGACCCCCCRTGG (p.His371Arg) ACCTGATGCTGACTGCTTTGAG]
3315 NM_000187.3(HGD):c.l l02A>G 3081 HGD ['AGGGGGAGGGAGTCTACACAGCACARTGA (p.Met368Val) CCCCCCATGGACCTGATGCTGA']
3316 NM_138477.2(CDANl):c.l796A> 14605 CDAN1 ['CTGAGCTTGAAGATCCAGGAGCTCARTGG G (p.Asn599Ser) 9 TCTTGCCCTGCCCCAGCATGAG]
3317 NM_001079802.1(FKTN):c.l l l2A 2218 FKTN ['GTAAAACTTGATGTTTTTTTCTTCTRTGAA >G (p.Tyr371Cys) GAAACTGATCACATGTGGAAT']
3318 NM_013382.5(POMT2):c.l997A> 29954 POMT2 ['GCTTGAGAAGAGCATGGCTGGGAAGYAGT G (p.Tyr666Cys) GGTGGAAGTAGAGGACCCGGCC]
3319 NM_000529.2(MC2R):c.761A>G 4158 MC2R ['CCAAGTAACCCCTACTGCGCCTGCTRCATG (p.Tyr254Cys) TCTCTCTTCCAGGTGAACGGC]
3320 NM_000383.3(AIRE):c.247A>G 326 AIRE ['CCTGGACTTCTGGAGGGTGCTGTTCRAGGA (p.Lys83Glu) CTACAACCTGGAGCGCTATGG]
3321 NM_020436.3(SALL4):c.2663A>G 57167 SALL4 ['TCGTCTGCTAGCGCTCTTCAGATCCRCGAG (p.His888Arg) CGGACTCACACTGGAGAGAAG]
3322 NM_203288.1(RP9):c.509A>G 6100 RP9 ['CAGTTACTGGAGGATTCTACCTCAGRTGAA (p.Aspl70Gly) GATAGGAGCAGCTCCAGTTCC]
3323 NM_000348.3(SRD5A2):c.692A>G 6716 SRD5A2 ['TTCCTTGGGCTGCGAGCTTTTCACCRCCAT (p.His231Arg) AGGTAAATTTTTCAATAAAAG]
3324 M_006445.3(PRPF8):c.6926A>G 10594 PRPF8 ['CCCAAAGAGTTCTACCACGAGGTGCVCAG (p.His2309Arg) GCCCTCTCACTTCCTCAACTTT']
3325 NM_018319.3(TDPl):c.l478A>G 55775 TDP1 ['TCTGGCCGCAGCAATGCCATGCCACRTATT (p.His493Arg) AAGACATATATGAGGCCTTCT']
3326 M_144773.2(PROKR2):c.629A> 12867 PROKR2 ['AGCCAGGAGAAGATCTTCTGTGGCCRGAT G (p.Gln210Arg) 4 CTGGCCTGTGGATCAGCAGCTC]
3327 NM_001604.5(PAX6):c.l075- 5080 PAX6 ['ACCACAGGTTTGCCTCTCTCCTCACRGCCC 2A>G CCAGTCCCCAGCCAGACCTCC]
3328 NM_000280.4(PAX6):c.l l71A>G 5080 PAX6 ['CAGTCAGCCAATGGGCACCTCGGGCRCCA (p.Thr391Ala) CTTCAACAGGTGAGCCACTGCT']
3329 NM_024426.4(WTl):c.l391A>G 7490 WT1 ['TGTCAGCGAAAGTTCTCCCGGTCCGRCCAC (p.Asp464Gly) CTGAAGACCCACACCAGGACT']
3330 NM_024426.4(WTl):c.l021A>G 7490 WT1 ['TTGCAGCCACAGCACAGGGTACGAGRGCG (p.Ser341Gly) ATAACCACACAACGCCCATCCT']
3331 NM_005957.4(MTHFR):c.971A>G 4524 MTHFR ['CCAGGCCTCCACTTCTACACCCTCARCCGC (p.Asn324Ser) GAGATGGCTACCACAGAGGTG]
3332 NM_001127328.2(ACADM):c.997 34 ACADM ['TAACTCATTCTAGCTAGTTCAACTTYCATT A>G (p.Lys333Glu) GCCATTTCAGCCAGCATAAAT']
3333 NM_001127328.2(ACADM):c.589 34 ACADM ['TATTAATGGTCAGAAGATGTGGATARCCA A>G (p.Thrl97Ala) ACGGAGGAAAAGCTAATTGGTA']
3334 NM_000155.3(GALT):c.940A>G 2592 GALT ['AGGATCAGAGGCTGGGGCCAACTGGRACC (p.Asn314Asp) ATTGGCAGCTGCACGCTCATTA]
3335 NM_000155.3(GALT):c.563A>G 2592 GALT ['TGTTCTAACCCCCACCCCCACTGCCRGGTA (p.Glnl88Arg) AGGGTGTCAGGGGCTCCAGTG]
3336 NM_000250.1(MPO):c.518A>G 4353 MPO ['GTTGCACATCCCGGTGATGGTGCGGYATTT (p.Tyrl73Cys) GTCCTGCTCCGGGCAAGTCAC]
3337 NM_020247.4(ADCK3):c.l541A> 56997 ADCK3 ['TTGGATTTTGGGGCAACGCGGGAATRTGA G (p.Tyr514Cys) CAGATCCTTCACCGACCTCTAC]
3338 NM_000229.1(LCAT):c.463A>G 3931 LCAT ['CACACTGGTGCAGAACCTGGTCAACRATG (p.Asnl55Asp) GCTACGTGCGGGACGAGACTGT']
3339 NM_000403.3 (GALE) : c.101 A>G 2582 GALE ['GGCTACTTGCCTGTGGTCATCGATARCTTC (p.Asn34Ser) CATAATGCCTTCCGTGGTGAG]
3340 NM_001008216.1(GALE):c.308A> 2582 GALE ['GGCGAGTCGGTGCAGAAGCCTCTGGRTTA G (p.Aspl03Gly) TTACAGAGTTAACCTGACCGGG]
3341 NM_000403.3(GALE):c.770A>G 2582 GALE ['AAGGGCCACATTGCAGCCTTAAGGARGCT (p.Lys257Arg) GAAAGAACAGTGTGGCTGCCGG]
3342 NM_000527.4(LDLR):c.2483A>G 3949 LDLR ['AGCATCAACTTTGACAACCCCGTCTRTCAG (p.Tyr828Cys) AAGACCACAGAGGATGAGGTC]
3343 NM_024740.2(ALG9):c.860A>G 79796 ALG9 ['ATTGCACCACTCAACATTGTTTTGTRTAAT (p.Tyr287Cys) GTCTTTACTCCTCATGGACCT']
3344 NM_000375.2(UROS):c.l84A>G 7390 UROS ['TGAAGATTACGGGGGACTCATTTTTRCCAG (p.Thr62Ala) CCCCAGAGCAGTGGAAGCAGC]
3345 NM_000372.4(TYR):c.l25A>G 7299 TYR ['GAATGCTGTCCACCGTGGAGCGGGGRCAG (p.Asp42Gly) GAGTCCCTGTGGCCAGCTTTCA']
3346 NM_000372.4(TYR):c.lA>G 7299 TYR ['AGACCTTGTGAGGACTAGAGGAAGARTGC (p.MetlVal) TCCTGGCTGTTTTGTACTGCCT']
3347 NM_000053.3(ATP7B):c.3809A>G 540 ATP7B ['GTCGCCATGGTGGGGGATGGGGTCADTGA (p.Asnl270Ser) CTCCCCGGCCTTGGCCCAGGCA']
3348 NM_000520.4(HEXA):c.lA>G 3073 HEXA ['CTCCGAGAGGGGAGACCAGCGGGCCVTGA (p.MetlVal) CAAGCTCCAGGCTTTGGTTTTC]
3349 NM_000520.4(HEXA):c.611A>G 3073 HEXA ['AATAAATTGAACGTGTTCCACTGGCRTCTG (p.His204Arg) GTAGATGATCCTTCCTTCCCA]
3350 NM_000356.3 (TCOF 1 ) :c .149 A>G 6949 TCOF1 ['CAGCCCGTAACCCTTCTGGACATCTRTACA (p.Tyr50Cys) CACTGGCAACAGTAAGTGGTG]
3351 M_000144.4(FXN):c.385-2A>G 2395 FXN ['ATGCTTTTTTTCCACCTAATCCCCTRGAGT
GGTGTCTTAACTGTCAAACTG]
3352 NM_016335.4(PRODH) :c.1562 A> 5625 PRODH ['GCCTAGCAGCTGTCCAAAGTACACCYGGT G (p.Gln521Arg) GGTCAGCAGGATGCAGGCCCAG]
3353 M_015474.3(SAMHDl):c.760A> 25939 SAMHD1 ['TAATTCTAATGGAATTAAGCCTGTCRTGGA G (p.Met254Val) ACAATATGGTCTCATCCCTGA]
3354 NM_012464.4(TLLl):c.l885A>G 7092 TLL1 [ACTTCTTACCAAACTTAACGGCACCRTAAC (p.Ile629Val) CACCCCTGGCTGGCCCAAGGA]
3355 NM_000112.3(SLC26A2):c.l273A 1836 SLC26A2 ['GGAAATGTATGCCATTGGCTTTTGTRATAT >G (p.Asn425Asp) CATCCCTTCCTTCTTCCACTG]
3356 NM_138691.2(TMCl):c.l960A>G 11753 TMC1 ['CCTGTCCACAATGCCTGTCTTGTACRTGAT (p.Met654Val) 1 CGTGTCCCTCCCACCATCTTT']
3357 NM_000173.6(GPlBA):c.763A>G 2811 GP1BA ['GAAGCAAGGTGTGGACGTCAAGGCCRTGA (p.Met255Val) CCTCTAATGTGGCCAGTGTGCA']
3358 NM_024996.5(GFMl):c.521A>G 85476 GFM1 ['AACGTTCCGTTTCTAACTTTTATTARCAAA (p.Asnl74Ser) TTGGACCGAATGGGCTCCAAC]
3359 NM_024301.4(FKRP):c.926A>G 79147 FKRP ['GTGGGCGACACGCCCGCCTACCTCTRCGA (p.Tyr309Cys) GGAGCGCTGGACGCCCCCCTGC]
3360 NM_024301.4(FKRP) :c.1387 A>G 79147 FKRP ['TGCCGGCTTCGTGGCGCAGGCGCCTRACA (p.Asn463Asp) ACTACCGCCGCTTCCTGGAGCT']
3361 NM_021020.3(LZTSl):c.355A>G 11178 LZTS1 ['TCCTTTTCCTCTACAGGGCTCCGAGRAGGG (p.Lysl l9Glu) TGCAGTGAGGCCCACAGCCTT']
3362 NM_001005741.2(GBA):c.l226A> 2629 GBA ['CCAGCCGACCACATGGTACAGGAGGBTCT G (p.Asn409Ser) AGGGTAAGGACAAAGGCAAAGA']
3363 NM_000157.3(GBA):c.680A>G 2629 GBA ['ACATCACCCACTTGGCTCAAGACCARTGG (p.Asn227Ser) AGCGGTGAATGGGAAGGGGTCA']
3364 NM_001005741.2(GBA):c.l049A> 2629 GBA ['AAATATGTTCATGGCATTGCTGTACRTTGG G (p.His350Arg) TACCTGGACTTTCTGGCTCCA']
3365 NM_014239.3(EIF2B2):c.638A>G 8892 EIF2B2 ['GTGAATTTGTCCAAAGCAGGTATTGRGAC (p.Glu213Gly) AACTGTCATGACTGATGCTGCC]
3366 NM_015915.4(ATLl):c.773A>G 51062 ATL1 ['CTACAGAACGTCAGAAAACACATCCRTTC (p.His258Arg) CTGTTTCACCAACATTTCCTGT']
3367 NM_015915.4(ATLl):c.l222A>G 51062 ATL1 ['GAAGCTATTCCGAGGGGTGAAGAAGRTGG (p.Met408Val) GTGGGGAAGAATTTAGCCGGCG]
3368 NM_022051.2(EGLNl):c. l l21A>G 54583 EGLN1 ['TTCTGGTCTGACCGTCGCAACCCTCRTGAA (p.His374Arg) GTACAACCAGCATATGCTACA']
3369 NM_015629.3(PRPF31):c.527+3A> 26121 PRPF31 ['GTCACCGCCTCCACCACCCAGGGGTRTGTC G CGCTTCGAGGGAGGCGCCGGG]
3370 NM_001243133.1(NLRP3):c.l880 11454 NLRP3 ['CTGCAGATCCAGCCCAGCCAGCTGGRATT A>G (p.Glu627Gly) 8 GTTCTACTGTTTGTACGAGATG]
3371 NM_020919.3(ALS2):c.2980- 57679 ALS2 ['CTTATTGACGTTACTTTTTGCTCCTRGACA 2A>G AAGTGGCTACGAGCTATAAGC]
3372 NM_175073.2(APTX):c.602A>G 54840 APTX ['GATAAATACCCAAAGGCCCGTTACCRTTG (p.His201Arg) GCTGGTCTTACCGTGGACCTCC]
3373 NM_001002010.2(NT5C3A):c.686 51251 NT5C3A ['CATCCCAATGTCAAAGTTGTGTCCARTTTT A>G (p.Asn229Ser) ATGGATTTTGATGAAACTGTA']
3374 NM_020451.2(SEPNl):c. lA>G 57190 SEPN1 ['CCGGCAGCCGCCGCCAGCCGCAGCCRTGG (p.MetlVal) GCCGGGCCCGGCCGGGCCAACG]
3375 NM_032667.6(BSCL2):c.263A>G -1 - ['TCACTCTGCTCCTTCCCTGTTGCCARTGTCT (p.Asn88Ser) CGCTGACTAAGGGTGGACGT']
3376 NM_153638.2(PANK2):c.700A>G 80025 PANK2 ['GGTATATTTTGAACCCAAAGACATCRCTGC (p.Thr234Ala) TGAAGAAGAAGAGGAAGAAGT']
3377 NM_025243.3(SLC19A3):c.l264A 80704 SLC19A3 ['TGCCTTGGTGATTCAGACCATCATGRCTGT >G (p.Thr422Ala) GATTGTAGTAGATCAGAGAGG]
3378 NM_025243.3(SLC19A3):c.l30A> 80704 SLC19A3 ['TATCCCATATTTATCTGGACCAGATRAAAA G (p.Lys44Glu) CCTGACCAGTGCAGAGGTAAG]
3379 NM_031885.3(BBS2):c.209A>G 583 BBS2 ['CAGACAGCTGACTGCCTGGTTAATGYTGA (p.Asn70Ser) GAAGAGAAACATCAGATTCCAG]
3380 NM_032383.4(HPS3):c.2482-2A>G -1 ['TTTATGAGAAATTCTTTTATGTTTTRGATA
AATGCCTGTAGTCATTATGGC]
3381 NM_021830.4(C10orf2):c.955A>G 56652 C10orf2 ['TGACCTTCGGTCCTGGGAAGCCGCCVAGTT (p.Lys319Glu) GTTTGCACGAAAACTGAACCC]
3382 NM_021830.4(C10orf2):c.l523A> 56652 C10orf2 ['ACAATGCAACATGCAGTCTACGTCTRTGAC G (p.Tyr508Cys) ATTTGTCATGTGATCATCGAC]
3383 NM_006492.2(ALX3):c.608A>G 257 ALX3 ['ACCTGCCCCCAGGTCTGGTTCCAGARCCGC (p.Asn203Ser) AGAGCCAAGTGGCGGAAGCGC]
3384 NM_174916.2(UBRl):c.407A>G 19713 UBR1 ['TTCCAGGACAGTGTTCATAAAAATCRTCGT (p.Hisl36Arg) 1 TACAAGGTAAGAAAATATAAC]
3385 NM_015166.3(MLCl):c.422A>G 23209 MLC1 ['CTAGTCCTGAACCCATCAGCAATAARCGT (p.Asnl41Ser) GAGTTCACACGAGCTTCGCGCA']
3386 NM_013391.3(DMGDH):c.326A> 29958 DMGDH ['CCTGGAATAAACTTGAAGAAAATACRTTA G (p.Hisl09Arg) TGATAGCATCAAACTTTATGAG]
3387 NM_014795.3(ZEB2):c.3356A>G 9839 ZEB2 ['GCTTACTTGCAGAGCATTACCCCTCRGGGG (p.Glnl ll9Arg) TACTCTGACTCGGAGGAGAGG]
3388 M_000441.1 (SLC26 A4) :c.1151 A 5172 SLC26A4 ['GTTGTCATCCAGTCTCTTCCTTAGGRATTC >G (p.Glu384Gly) ATTGCCTTTGGGATCAGCAAC]
3389 M_000441.1 (SLC26 A4) :c.1105 A 5172 SLC26A4 ['TTATGCTATTGCAGTGTCAGTAGGARAAGT >G (p.Lys369Glu) ATATGCCACCAAGTATGATTA']
3390 M_000441.1 (SLC26 A4) :c.2168A 5172 SLC26A4 ['AAGGACACATTCTTTTTGACGGTCCRTGAT >G (p.His723Arg) GCTATACTCTATCTACAGAAC]
3391 M_000441.1 (SLC26 A4) :c.919- 5172 SLC26A4 ['TTTTTAACATCTTTTGTTTTATTTCRGACGA 2A>G TAATTGCTACTGCCATTTCA']
3392 NM_000197.1(HSD17B3):c.703A> 3293 HSD17B3 ['GACCCCATATGCTGTCTCGACTGCARTGAC G (p.Met235Val) AAAGTATCTAAATACAAATGT']
3393 NM_000197.1(HSD17B3):c.389A> 3293 HSD17B3 ['TTGTTTTGCTTCTTTCTGCCAGTCARCAATG G (p.Asnl30Ser) TCGGAATGCTTCCAAACCTT']
3394 NM_022458.3(LMBRl):c.423+525 64327 LMBR1 ['GTTTTGATCTTAGTGTTTATTACAGRAAAT 2A>G GAAGCCATATCTCACTAACTA']
3395 NM_020366.3(RPGRIPl):c.3341A 57096 RPGRIP1 ['CTAAATAAACATTTTCCTTATCAGGRTTCA >G (p.Aspl l l4Gly) GAGAAGATGTGCATTGAAATT']
3396 NM_021625.4(TRPV4):c.998A>G 59341 TRPV4 ['CTGCATGCGCTGGTGGCCATTGCTGRCAAC (p.Asp333Gly) ACCCGTGAGAACACCAAGTTT']
3397 NM_004897.4(MINPPl):c.809A>G 9562 MINPP1 ['TTAAAAAAAGTTGCAGCTACTTTGCRAGTG (p.Gln270Arg) CCAGTAAATGATTTAAATGCA']
3398 NM_020638.2(FGF23):c.211A>G 8074 FGF23 ['TGGCGCACCCCATCAGACCATCTACRGTG (p.Ser71Gly) AGTAGGGCTTCAGGCTGGGAAG]
3399 NM_015071.4(ARHGAP26):c.l250 23092 ARHGAP2 ['GGGCTGTATCGAATTGTGGGTGTCAVCTCC A>G (p.Asn417Ser) 6 AGAGTGCAGAAGTTGCTGAGT']
3400 NM_021615.4(CHST6):c.521A>G 4166 CHST6 ['CGCTCCTACAGCCACGTGGTGCTCARGGA (p.Lysl74Arg) GGTGCGCTTCTTCAACCTGCAG]
3401 NM_021615.4(CHST6):c.329A>G 4166 CHST6 ['TGCGACATGGACGTGTTTGATGCCTRTCTG (p.Tyrl lOCys) CCTTGGCGCCGCAACCTGTCC]
3402 NM_015560.2(OPAl):c.l745A>G 4976 OPA1 ['CTTGAAACTGAATGGAAGAATAACTRTCC (p.Tyr582Cys) TCGCCTGCGGGAACTTGACCGG]
3403 NM_000368.4(TSCl):c.1760 A>G 7248 TSC1 ['AGTATCTTCACTCCCAGTCCTTGTARAATT (p.Lys587Arg) CCACCTCCGACGAGAGTGGGC]
3404 NM_020661.2(AICDA):c.415A>G 57379 AICDA ['CCGCGCCGGGGTGCAAATAGCCATCRTGA (p.Metl39Val) CCTTCAAAGGTGCGAAAGGGCC]
3405 NM_020533.2(MCOLNl):c.406- 57192 MCOLN1 ['ACAGGCCCTCCCCTTCTCTGCCCACRGTAC 2A>G CTGGCGTTGCCTGACGTGTCA']
3406 NM_021102.3(SPINT2):c.488A>G 10653 SPINT2 ['AGGAACTCCTGCAATAACTTCATCTRTGGA (p.Tyrl63Cys) GGCTGCCGGGGCAATAAGAAC]
3407 NM_006610.3 (M ASP2) :c .359 A>G 10747 MASP2 ['GGGAGGGCTGGGGTTTCTCAGGGTCRGGG (p.Aspl20Gly) GGTCCCCAAGGAGTAGCCAGGG, 3410 AGGGGCCAGGCTTGGCCAGGAGGGASATC
AGGCCTGGGTCTTGCCTTCACT',
'GGGCAGGAGAGCACAGACACGGAGCRGGC
CCCTGGCAAGGACACTTTCTAC,
AGCCTGGACATTACCTTCCGCTCCGRCTAC
TCCAACGAGAAGCYGTTCACG]
3411 NM_018965.3(TREM2):c.401A>G 54209 TREM2 ['GCTCTGCCTCCCATAGACCCCCTGGRTCAC (p.Aspl34Gly) CGGGATGCTGGAGATCTCTGG]
3412 NM_007375.3(TARDBP):c.l009A 23435 TARDBP ['AGCACTACAGAGCAGTTGGGGTATGRTGG >G (p.Met337Val) GCATGTTAGCCAGCCAGCAGAA']
3413 NM_007375.3(TARDBP):c.506A> 23435 TARDBP ['GTAATGTCACAGCGACATATGATAGRTGG G (p.Aspl69Gly) ACGATGGTGTGACTGCAAACTT']
3414 NM_007375.3(TARDBP):c.l028A 23435 TARDBP ['GGTATGATGGGCATGTTAGCCAGCCRGCA >G (p.Gln343Arg) GAACCAGTCAGGCCCATCGGGT']
3415 NM_007375.3(TARDBP):c.787A> 23435 TARDBP ['CGTTCATATATCCAATGCCGAACCTRAGCA G (p.Lys263Glu) CAATAGCAATAGACAGTTAGA']
3416 NM_015247.2(CYLD):c.2240 A>G 1540 CYLD ['ATCAACAGTAACCTGAAATTTGCAGRGGT (p.Glu747Gly) TAGTGATACTCACCTGTGGTAT']
3417 NM_001128425.1(MUTYH):c.536 4595 MUTYH ['AATCAACTCTGGGCTGGCCTGGGCTRCTAT A>G (p.Tyrl79Cys) TCTCGTGGCCGGCGGCTGCAG]
3418 NM_001128425.1(MUTYH):c. l241 4595 MUTYH ['TCCGTGACCTGGGAGCCCTCAGAGCRGCTT A>G (p.Gln414Arg) CAGCGCAAGGCCCTGCTGCAG]
3419 NM_170784.2(MKKS):c. llOA>G 8195 MKKS ['TTGAAAAGAATTGTAACATCATGCTRTGGC (p.Tyr37Cys) CCCTCAGGTAGGCTGAAGCAG]
3420 NM_170784.2(MKKS):c.169A>G 8195 MKKS ['TGGCTTTGGAGGTTACGTGTGTACARCCTC (p.Thr57Ala) ACAGTCCTCAGCTCTGCTCAG]
3421 NM_004795.3(KL):c.578A>G 9365 KL ['GTGCAGCCCGTGGTCACCCTGTACCRCTGG (p.Hisl93Arg) GACCTGCCCCAGCGCCTGCAG]
3422 NM_014625.3(NPHS2):c.479A>G 7827 NPHS2 ['CTTTTCTTTTTTTTGCCCTGCCTGGRTACCT (p.Aspl60Gly) ACCACAAGGTTGACCTTCGT']
3423 NM_015713.4(RRM2B):c.322- 50484 RRM2B ['CACCTCCTGACTAAAGCGCTCCACCBAAG 2A>G AAGATAAGGAAAATAGATATAT']
3424 NM_006343.2(MERTK):c.l605- 10461 MERTK ['GAAGTATCTTTGTTTTCATTCACCCRGGAA 2A>G TGCATTCACAGAGGAGGATTC]
3425 NM_014585.5(SLC40Al):c.470A> 30061 SLC40A1 ['GCTACTGCAATCACAATCCAAAGGGRTTG G (p.Aspl57Gly) GATTGTTGTTGTTGCAGGAGAA']
3426 NM_004924.4(ACTN4):c.763A>G 81 ACTN4 ['CGTGAACACGGCCCGGCCCGACGAGRAGG (p.Lys255Glu) CCATAATGACCTATGTGTCCAG]
3427 NM_012193.3 (FZD4) :c .1024 A>G -1 ['CAAATGGGGTCATGAAGCCATTGAARTGC (p.Met342Val) ACAGCTCTTATTTCCACATTGC]
3428 NM_012193.3(FZD4):c.766A>G -1 ['GTTTTCCTACCCTGAGCGCCCCATCRTATT (p.Ile256Val) TCTCAGTATGTGCTATAATAT']
NM_004239.3(TRIPll):c.202- 9321 TRIP 11
2A>G
3429 NM_004239.3(TRIPll):c.2102A>G 9321 TRIP 11 ['AGTGTTTTTTTCCAGAGAAAGCTGAYTGTT (p.Asn701Ser) ACCAGCAAGACATTCTTCTAA']
3430 NM_012434.4(SLC17A5):c.548A> 26503 SLC17A5 ['CAGGGTGTTACATTTCCAGCCATGCRTGCC G (p.Hisl83Arg) ATGTGGTCTTCTTGGGCTCCC]
3431 NM_001099274.1(TINF2):c.838A> 26277 TINF2 ['ATGGGCCTCCACTAGGGGAGGCCATDAGG G (p.Lys280Glu) AGCGCCCCACAGTCATGCTGTT']
3432 NM_012415.3(RAD54B):c.l778A> 25788 RAD54B ['AGAGTTGAACAAAAGGCAGGGGTGAYTGC G (p.Asn593Ser) ACAGTTTTTTAAGAGCTCCTAT']
3433 NM_014946.3(SPAST):c.l688- 6683 SPAST ['TAAGTGCCTGACTTTTATGTTTTACRGAAC 2A>G TAAAACCAGAACAGGTGAAGA']
3434 M_014946.3(SPAST):c.l322A>G 6683 SPAST ['AGTCTTATACTTGTATTTCCTCTAGRTGAA (p.Asp441Gly) GTTGATAGCCTTTTGTGTGAA']
3435 M_014946.3(SPAST):c.l245+4A 6683 SPAST ['TGCAAGTTTAACTTCAAAATACGTGRGTGC >G TCTGTTTCCAATATTGTCGTA]
3436 M_014946.3(SPAST):c.l l57A>G 6683 SPAST ['CTGTTACTCTTTGGTCCACCTGGGARTGGG (p.Asn386Ser) AAGACAATGCTGGTAAGGGTT']
3437 M_014946.3 (SP AST) :c .1216 A>G 6683 SPAST ['AGAATCGAATGCAACCTTCTTTAATRTAAG (p.Ile406Val) TGCTGCAAGTTTAACTTCAAA']
3438 NM_182643.2(DLCl):c.2875A>G 10395 DLC1 ['ACACCTGGATGTGGACAACGACCGARCCA (p.Thr959Ala) CACCCAGCGACCTGGACAGCAC]
3439 M_194456.1(KRITl):c.410A>G 889 KRIT1 ['TGCCCAATTTTTTACTGCTTACAAGRTATT (p.Aspl37Gly) ATGCGAGTCTGTAGTGAATCC]
3440 NM_005094.3(SLC27A4):c.899A> 10999 SLC27A4 ['CCAGGAAACATCGTGGGAATCGGCCRGTG G (p.Gln300Arg) CCTGCTGCATGGCATGACGGTG]
3441 NM_004211.3(SLC6A5):c.l472A> 9152 SLC6A5 ['GGAGGCCTGATCACTCTCTCTTCTTRCAAC G (p.Tyr491Cys) AAATTCCACAACAACTGCTAC]
3442 NM_004211.3 (SLC6 A5) :c.1526A> 9152 SLC6A5 ['GACACTCTAATTGTCACCTGCACCARCAGT G (p.Asn509Ser) GCCACAAGCATCTTTGCCGGC]
3443 NM_014270.4(SLC7A9):c.695A>G 11136 SLC7A9 ['GCGTTTTACAATGGACTCTGGGCCTRTGAT (p.Tyr232Cys) GGATGGTGAGGTGTCCTGAGA']
3444 NM_139025.4(ADAMTS13):c.l58 11093 ADAMTS1 ['GAGCCTGTGTGTGTCGGGCAGCTGCRGGG 2A>G (p.Arg528Gly) 3 TAGGCGTGTGTGGACATTGGCG]
3445 NM_002894.2(RBBP8):c.l009A>G 5932 RBBP8 ['TGTATTTGGAGCTACCTCTAGTATCRAAAG (p.Lys337Glu) TGGTTTAGATTTGAATACAAG]
3446 NM_005682.6(ADGRGl):c.263A> 9289 ADGRG1 ['TCCTTCCCTGACCCCAGGGGCCTCTRCCAC G (p.Tyr88Cys) TTCTGCCTCTACTGGAACCGA']
3447 NM_006502.2(POLH):c.1603 A>G 5429 POLH ['AGGAACTGAGCCCTTCTTTAAGCAGRAAA (p.Lys535Glu) GTCTGCTTCTAAAGCAGAAACA']
3448 NM_000334.4(SCN4A):c.4774A>G 6329 SCN4A ['CATCTCCTTCCTCATCGTGGTCAACRTGTA (p.Metl592Val) CATCGCCATCATCCTGGAGAA']
3449 NM_000334.4(SCN4A):c.3478A>G 6329 SCN4A ['CGCCCTCCTAGGCGCCATCCCCTCCRTCAT (p.Ilel l60Val) GAATGTGCTGCTTGTCTGCCT']
3450 NM_000334.4(SCN4A):c.421A>G 6329 SCN4A ['GTTCAGCATGTTCATCATGATCACCRTCTT (p.Ilel41Val) GACCAACTGCGTATTCATGAC]
3451 NM_003907.2(EIF2B5):c.271A>G 8893 EIF2B5 ['CCTGACTGCCACAGGTGTACAGGAARCAT (p.Thr91Ala) TTGTCTTTTGTTGCTGGAAAGC]
3452 NM_001128227.2(GNE):c.604A>G 10020 GNE ['CAGTGCAGAGCAGCACCTGATATCCRTGT (p.Met202Val) GTGAGGACCATGATCGCATCCT']
3453 NM_001029.3(RPS26):c.lA>G 6231 RPS26 ['CCTCTCTCCGGTCCGTGCCTCCAAGDTGGT (p.MetlVal) GAGTCTTCTTGCGTGGTGAGG]
3454 NM_012082.3(ZFPM2):c.l969A>G -1 ['TCAAACTAAGAAGCTCTCCACCTCCRGTAA (p.Ser657Gly) CAATGATGACAAAATTAATGG]
3455 NM_012082.3(ZFPM2):c.89A>G 23414 ZFPM2 ['GATGAGGAAGAAGAATGTCCATCAGRGGA (p.Glu30Gly) AACAGACATCATCTCCAAAGGA']
3456 NM_012082.3(ZFPM2):c.2527A>G -1 ['AAAGTGTTTATCTCAGTCTGAGCGGRCGAC (p.Thr843Ala) CACGTCTCCCAAAAGGCTGCT']
3457 NM_194248.2(OTOF):c.766-2A>G 9381 OTOF ['TCTGGCTCCCCCTTCTCCTGCCTGCRGGTC
AGCATCACGGTGATCGAGGCC]
3458 NM_003705.4(SLC25A12):c.l769 8604 SLC25A12 ['GCTCGAGTGTTTCGATCCTCTCCCCRGTTT A>G (p.Gln590Arg) GGTGTTACCTTGGTCACTTAT']
3459 NM_004621.5(TRPC6):c.428A>G 7225 TRPC6 ['AATGCCCTACAGTTGGCAGTGGCCARTGA (p.Asnl43Ser) GCATCTGGAAATTACAGAACTT']
3460 NM_152384.2(BBS5):c.522+3A>G 12988 BBS5 ['TTTGGAATTTATCCAGTGATCAGGTRTTGT
0 GCAAAGAGCTAGTGAACCTTT']
3461 NM_152384.2(BBS5):c.547A>G 12988 BBS5 ['GGGCAATTTAGGAACCTTTTTTATTRCCAA (p.Thrl83Ala) 0 TGTGAGAATTGTGTGGCATGC]
3462 NM_001257342.1(BCSlL):c.232A 617 BCS1L ['CCACAGTACCCGTACTCAGCACCTCRGTGT >G (p.Ser78Gly) CGAGACTTCGTACCTTCAGCA]
3463 NM_004328.4(BCSlL):c. l48A>G 617 BCS1L ['GGCATTCCGGCGCCATTACATGATCRCACT (p.Thr50Ala) GGAAGTCCCTGCTCGAGACAG]
3464 NM_003839.3(TNFRSFl lA):c.508 8792 TNFRSF11 ['TGCCTTTTCCTCCACGGACAAATGCRGACC A>G (p.Argl70Gly) A CTGGACCAAGTAAGTAACAAC]
3465 NM_030761.4(WNT4):c.647A>G 54361 WNT4 ['TGCCACGGGGTGTCAGGCTCCTGTGRGGT (p.Glu216Gly) AAAGACGTGCTGGCGAGCCGTG]
3466 NM_022817.2(PER2):c. l984A>G 8864 PER2 ['GCTGGCACTGCCGGGCAAGGCAGAGRGTG (p.Ser662Gly) TGGCGTCGCTCACCAGCCAGTG]
3467 NM_002977.3(SCN9A):c. l964A>G -1 ['TAGGGCACGACCAATCAAATACACARGAA (p.Lys655Arg) AAGGCGTTGTAGTTCCTATCTC]
3468 NM_002977.3(SCN9A):c. l84A>G 6335 SCN9A ['GGAAGCTGGCAAACAGCTGCCCTTCRTCT (p.Ile62Val) ATGGGGACATTCCTCCCGGCAT']
3469 NM_002977.3(SCN9A):c.29A>G 6335 SCN9A ['GCAATGTTGCCTCCCCCAGGACCTCRGAGC (p.GlnlOArg) TTTGTCCATTTCACAAAACAG]
3470 NM_001457.3(FLNB):c.604A>G 2317 FLNB ['GCCTGTGGATAATGCACGAGAAGCCRTGC (p.Met202Val) AGCAGGCAGATGACTGGCTGGG]
3471 NM_003060.3(SLC22A5):c.632A> 6584 SLC22A5 ['GTAGGCATGGGCCAGATCTCCAACTRTGT G (p.Tyr211Cys) GGCAGCATTTGTCCTGGGTATG]
3472 NM_000369.2(TSHR):c.l856A>G 7253 TSHR ['CCGCAGTACAACCCAGGGGACAAAGRTAC (p.Asp619Gly) CAAAATTGCCAAGAGGATGGCT']
3473 NM_000369.2(TSHR):c.548A>G 7253 TSHR ['TCTCTTCTCTCTGTTGGTTGTAGGARGCTG (p.Lysl83Arg) TACAACAATGGCTTTACTTCA']
3474 NM_001430.4(EPASl):c. l603A>G 2034 EPAS1 ['GGAGACACTGGCACCCTATATCCCCRTGG (p.Met535Val) ACGGGGAAGACTTCCAGCTAAG]
3475 NM_024009.2(GJB3):c.421A>G 2707 GJB3 ['GTTCAGCCTCATCTTCAAGCTCATCRTTGA (p.Ilel41Val) GTTCCTCTTCCTCTACCTGCT']
3476 NM_024009.2(GJB3):c.497A>G 2707 GJB3 ['ATGCCGCGCCTGGTGCAGTGTGCCADCGT (p.Asnl66Ser) GGCCCCCTGCCCCAACATCGTG]
3477 NM_001080463.1(DYNC2Hl):c.l l 79659 DYNC2H1 ['TGTTTTTTTGCTTTTGTAGGTTGCCRTGGGT 284A>G (p.Met3762Val) CAAGGTCAAGCTGATTTAGC]
3478 NM_001080463.1(DYNC2Hl):c.90 79659 DYNC2H1 ['CGCATGCCACCTGATGTAATTAGAGRTATT 44A>G (p.Asp3015Gly) CTTGAAGGAGTTTTAAGGTTG]
3479 NM_001080463.1(DYNC2Hl):c.46 79659 DYNC2H1 ['GTTGACCCATCTCTGTTCCCTTCACRGGTA 10A>G (p.Glnl537Arg) AGGGGGCTTACGTGTAGAAGC]
3480 NM_001080463.1(DYNC2Hl):c.59 79659 DYNC2H1 ['TGGTCCAAGTGGTGCTGGAAAATCARCGC 59A>G (p.Thrl987Ala) TTTGGAGAATGTTAAGGGCTGC]
3481 NM_007035.3 (KERA) :c.740 A>G 11081 KERA ['GTGGCCTTTTTGAGACTAAATCACARCAAA (p.Asn247Ser) CTGTCAGATGAGGGTCTCCCA]
3482 NM_003722.4(TP63):c.697A>G 8626 TP63 ['TATCCGCGCCATGCCTGTCTACAAARAAGC (p.Lys233Glu) TGAGCACGTCACGGAGGTGGT']
3483 NM_003722.4(TP63):c.1052A>G 8626 TP63 ['CGGATCTGTGCTTGCCCAGGAAGAGRCAG (p.Asp351Gly) GAAGGCGGATGAAGATAGCATC]
3484 NM_003722.4(TP63):c.1054A>G 8626 TP63 ['GATCTGTGCTTGCCCAGGAAGAGACRGGA (p.Arg352Gly) AGGCGGATGAAGATAGCATCAG]
3485 NM_003742.2(ABCBl l):c.890A> 8647 ABCB11 ['AGAACAGTGGCTGCTTTTGGTGGTGRGAA G (p.Glu297Gly) AAGAGAGGTTGAAAGGTTGGTT]
3486 NM_006702.4(PNPLA6):c.3034A> 10908 PNPLA6 ['GGACCTCACGTACCCAGTCACCTCCRTGTT G (p.Metl012Val) CACTGGGTCTGCCTTTAACCG]
3487 NM_006412.3 ( AGP AT2) : c.589- 10555 AGPAT2 ['GTACACCACGGGGACGATGGGCACCYGCA 2A>G GGCAGGGAGACGCACAGCTGAG]
3488 NM_001084.4(PLOD3):c.668A>G 8985 PLOD 3 ['AAGTCTCGGATCTTTCAGAACCTCARCGGG (p.Asn223Ser) GCTTTAGGTGAGGAGGAAGAC]
3489 NM_138554.4(TLR4):c.896A>G 7099 TLR4 ['GCATACTTAGACTACTACCTCGATGRTATT (p.Asp299Gly) ATTGACTTATTTAATTGTTTG]
3490 NM_001130978.1(DYSF):c.3892A 8291 DYSF ['GGGCCAGGTGCAGGAGACATCAAGGRTCC >G (p.Ilel298Val) TGGATGAGGTGAGCTGGGCGTG]
3491 NM_001130978.1(DYSF):c.5264A 8291 DYSF ['CTTTTTTGTCTTCTCTCTGGGGCAGRGGCT >G (p.Glul755Gly) GGCAGGATCCCAAACCCACAC]
3492 NM_003494.3(DYSF):c3443- 8291 DYSF ['CAGCTCTTAACCACTCCAGCCACTCRCTCT
33A>G GGCACCTCTGTTTTTTCCCTT']
3493 NM_003494.3(DYSF):c.l285- 8291 DYSF ['AACTTGTCCCCTCCCTGTGTCTTCTRGCTGT 2A>G GCAGCAAGATCTTGGAGAAG]
3494 NM_005450.4(NOG):c.665A>G 9241 NOG ['CGCTGCGGCTGGATTCCCATCCAGTRCCCC (p.Tyr222Cys) ATCATTTCCGAGTGCAAGTGC]
3495 NM_004629.1(FANCG):c.925- 2189 FANCG ['GATACAATTTTTTTCTTTCTCTTTTRGGCCT 2A>G TGAATGTCCCATGCAGTTCC]
3496 NM_001701.3(BAAT):c.226A>G 570 BAAT ['AGGGGATTATATGGGAGTCCACCCCRTGG (p.Met76Val) GTCTCTTCTGGTCTCTGAAACC]
3497 NM_006892.3(DNMT3B):c.2450A 1789 DNMT3B ['TTTGGCTTTCCTGTGCACTACACAGRCGTG >G (p.Asp817Gly) TCCAACATGGGCCGTGGTGCC]
3498 NM_001360.2(DHCR7):c.839A>G 1717 DHCR7 ['GCTGCTTCTGTCTTGCAGGCCATCTRCGTG (p.Tyr280Cys) ATTGACTTCTTCTGGAACGAA']
3499 NM_001360.2(DHCR7):c.lA>G 1717 DHCR7 ['AAGGTTCTCTTTCTTGCAGGGCCCARTGGC (p.MetlVal) TGCAAAATCGCAACCCAACAT']
3500 NM_032119.3(ADGRVl):c.18131 84059 ADGRV1 ['TATCATCAGAGCATGTCACAGATCTRTGGA A>G (p.Tyr6044Cys) CTCATTCATGGTGACCTGTAA]
3501 M_004984.2(KIF5A):c.767A>G 3798 KIF5A ['GTGCTGGACGAGGCAAAGAATATCARCAA (p.Asn256Ser) GTCACTGTCAGCTCTGGGCAAT']
3502 M_004984.2(KIF5A):c.827A>G 3798 KIF5A ['GTCTCCTTCCTCCCCCAGAAAAGCTRTGTT (p.Tyr276Cys) CCATATCGTGACAGCAAAATG]
3503 NM_007373.3(SHOC2):c.4A>G 8036 SHOC2 ['TTTTGTCCAGGCTTGAGTCACCATGRGTAG (p.Ser2Gly) TAGTTTAGGAAAAGAAAAAGA']
3504 NM_016203.3(PRKAG2):c.1148A> 51422 PRKAG2 ['TACTCCTTGATCAAAAATAAAATCCRCAG G (p.His383Arg) ATTGCCCGTTATTGACCCTATC]
3505 NM_016203.3 (PRKAG2) : c.1589 A> 51422 PRKAG2 ['GTCCTGCTTTTCTCTTTGCAGGTCCRTCGG G (p.His530Arg) CTGGTGGTGGTAAATGAAGCA']
3506 NM_003816.2(ADAM9):c.411- 8754 ADAM9 ['TTAAAATTTGTATACGTGTAATGCARCATT 8A>G CAGAGGATTGCTGCATTTAGA]
3507 NM_003002.3(SDHD):c.341A>G 6392 SDHD ['GGCCTTGGACAAGTTGTTACTGACTRTGTT (p.Tyrl l4Cys) CATGGGGATGCCTTGCAGAAA]
3508 NM_003002.3(SDHD):c.l49A>G 6392 SDHD ['GAATGGTGTGGAGTGCAGCACATACRCTT (p.His50Arg) GTCACCGAGCCACCATTGTATG]
3509 NM_003002.3(SDHD):c.lA>G 6392 SDHD ['ATGACCTTGAGCCCTCAGGAACGAGDTGG (p.MetlVal) CGGTTCTCTGGAGGCTGAGTGC]
3510 NM_002485.4(NBN):c.511A>G 4683 NBN ['TCAGTAAAATATTCTGGCTTTACAAYTGGA (p.Ilel71Val) CGTCCACAAATGAGTGCACAT']
3511 NM_170695.3(TGIFl):c.838A>G 7050 TGIF1 ['TTCCTGTACAGCTGGGCCAAACCCARCCCT (p.Thr280Ala) AGGGAGGCCACTGTCTCCTAA']
3512 NM_002408.3(MGAT2):c.785A>G 4247 MGAT2 ['CTTATACTTTTCCTAGAAGAGGATCRCTAC (p.His262Arg) TTAGCCCCAGACTTTTACCAT']
3513 NM_002408.3(MGAT2):c.952A>G 4247 MGAT2 ['GAAAACTTGGAAATCCACAGAGCACRATA (p.Asn318Asp) TGGGTCTAGCCTTGACCCGGAA']
3514 NM_005422.2(TECTA):c.5609A> 7007 TECTA ['CAGTCCAATGGCACGCATATCATGTRTAA G (p.Tyrl870Cys) AAACACACTCTGGATCGAAAGC]
3515 NM_012233.2(RAB3GAPl):c.649- 22930 RAB3GAP ['GGTATTGTCTTTGCATGTATTTCCTRGGGA 2A>G 1 TGTCCTTTAACTCCATTGCCT']
3516 NM_005025.4(SERPINIl):c. l013A 5274 SERPINI1 ['GAGATTTTTCTTTCCAAAGCAATTCRCAAG >G (p.His338Arg) TCCTTCCTAGAGGTTAATGAA']
3517 NM_001040667.2(HSF4):c.256A> 3299 HSF4 ['AGACGGTTTTCGGAAGGTGGTGAGCRTCG G (p.Ile86Val) AGCAGGGCGGCCTGCTTAGGCC]
3518 NM_001008211.1(OPTN):c.l433A 10133 OPTN ['GTTTACTGTTCTGATTTTCATGCTGRAAGA >G (p.Glu478Gly) GCAGCGAGAGAGAAAATTCAT']
3519 NM_000492.3(CFTR):c.2738A>G 1080 CFTR ['GTGATTATCACCAGCACCAGTTCGTRTTAT (p.Tyr913Cys) GTGTTTTACATTTACGTGGGA']
3520 NM_000492.3(CFTR):c.3717+4A> 1080 CFTR ['CTCAATAAGTCCTGGCCAGAGGGTGRGAT G TTGAACACTGCTTGCTTTGTTA]
3521 NM_000492.3 (CFTR) : c.1666 A>G 1080 CFTR ['ACTGAGTGGAGGTCAACGAGCAAGARTTT (p.Ile556Val) CTTTAGCAAGGTGAATAACTAA']
3522 NM_000492.3(CFTR):c.326A>G 1080 CFTR ['TTACTGGGAAGAATCATAGCTTCCTRTGAC (p.Tyrl09Cys) CCGGATAACAAGGAGGAACGC]
3523 NM_000492.3(CFTR):c.273+4A>G 1080 CFTR ['TGGAATCTTTTTATATTTAGGGGTARGGAT
CTCATTTGTACATTCATTATG]
3524 NM_000492.3(CFTR):c.3254A>G 1080 CFTR ['CTGTTCCACAAAGCTCTGAATTTACRTACT (p.Hisl085Arg) GCCAACTGGTTCTTGTACCTG]
3525 NM_000492.3 (CFTR) : c.3700 A>G 1080 CFTR ['CATATTAGAGAACATTTCCTTCTCANTAAG (p.Ilel234Val) TCCTGGCCAGAGGGTGAGATT']
3526 NM_000492.3(CFTR):c.650A>G 1080 CFTR ['GCACTCCTCATGGGGCTAATCTGGGRGTTG (p.Glu217Gly) TTACAGGCGTCTGCCTTCTGT']
3527 NM_001005360.2(DNM2):c. l684A 1785 DNM2 ['CCTCCACCCTCAGGAGAAAGAGAAGRAGT >G (p.Lys562Glu) ACATGCTGCCTCTGGACAACCT']
3528 NM_001814.4(CTSC):c.857A>G 1075 CTSC ['TCTCAGACCCCAATCCTAAGCCCTCRGGAG (p.Gln286Arg) GTTGTGTCTTGTAGCCAGTAT']
3529 NM_001814.4(CTSC):c.l235A>G 1075 CTSC ['AATCATGCTGTTCTGCTTGTGGGCTRTGGC (p.Tyr412Cys) ACTGACTCAGCCTCTGGGATG]
3530 NM_001814.4(CTSC):c.l040A>G 1075 CTSC ['CGTTATTACTCCTCTGAGTACCACTRTGTA (p.Tyr347Cys) GGAGGTTTCTATGGAGGCTGC]
3531 M_005144.4(HR):c.-218A>G 55806 HR ['TCCGACCCCTCCAACCTGCGGCCCTRGAGC
GCCCCCGCCGCCCCGGGGGAA']
3532 NM_172107.2(KCNQ2):c.851A>G 3785 KCNQ2 ['ACCACCATTGGCTACGGGGACAAGTRCCC (p.Tyr284Cys) CCAGACCTGGAACGGCAGGCTC]
3533 NM_001303.3(COX10):c.l007A>G 1352 COX10 ['GCCCTGAGCTGGGGCCTCCGTGAAGDCTA (p.Asp336Gly) CTCCCGGGGCGGCTACTGCATG]
3534 NM_006214.3 (PHYH) :c .135 -2 A>G 5264 PHYH ['AGAACGTTATTATCCAGAGTATACCYAAA
GGAGAAAAAGAATCCCAAAATA']
3535 NM_002284.3(KRT86):c.340A>G -1 ['GGAGAAGGAGCAGATCAAGTCCCTCVACA (p.Asnl l4Asp) GCAGGTTCGCGGCCTTCATCGA']
3536 NM_003865.2(HESXl):c.541A>G 8820 HESX1 ['TCTAATGGCGAAAAAAAATTTCAACRCAA (p.Thrl81Ala) ATCTGCTGGAATAGATAGAAAA']
3537 NM_000303.2(PMM2):c.563A>G 5373 PMM2 ['TTTGATGTCTTTCCTGATGGATGGGRCAAG (p.Aspl88Gly) AGATACTGTCTGCGACATGTG]
3538 NM_000288.3(PEX7):c.340- 5191 PEX7 ['TCTTTTGCTTTCTAAACACTTTTCARTGTTT 10A>G TTAGGTGTATAGTGTTGATT']
3539 M_004044.6(ATIC):c.l277A>G 471 ATIC ['CTCATCGTAGCCACCATTGCTGTCARGTAC (p.Lys426Arg) ACTCAGTCTAACTCTGTGTGC]
3540 NM_000314.6(PTEN):c.368A>G 5728 PTEN ['GATGACAATCATGTTGCAGCAATTCRCTGT (p.Hisl23Arg) AAAGCTGGAAAGGGACGAACT']
3541 NM_000314.6(PTEN):c.278A>G 5728 PTEN ['GTTGCACAATATCCTTTTGAAGACCRTAAC (p.His93Arg) CCACCACAGCTAGAACTTATC]
3542 NM_000314.6(PTEN):c.755A>G 5728 PTEN ['CCTCAGCCGTTACCTGTGTGTGGTGRTATC (p.Asp252Gly) AAAGTAGAGTTCTTCCACAAA']
3543 NM_018488.2(TBX4):c.l592A>G 9496 TBX4 ['TCCTTGTCCCGAGAATCTTCCTTACRGTAC (p.Gln531Arg) CATTCAGGAATGGGGACTGTG]
3544 NM_000223.3(KRT12):c.403A>G 3859 KRT12 ['AGAAACTATGCAAAATCTTAATGATRGAT (p.Argl35Gly) TAGCTTCCTACCTGGATAAGGT']
3545 NM_000503.5(EYAl):c. l639A>G 2138 EYA1 ['TGAGAGAATAATTCAAAGGTTTGGARGAA (p.Arg547Gly) AAGTGGTGTATGTTGTTATAGG]
3546 NM 000261.1 (MYOC) : c.1010 A>G 4653 MYOC ['GTGTACTCGGGGAGCCTCTATTTCCRGGGC (p.Gln337Arg) GCTGAGTCCAGAACTGTCATA']
3547 NM 000261.1 (MYOC) : c.1267 A>G 4653 MYOC ['ACAAACCTGGGAGACAAACATCCGTRAGC (p.Lys423Glu) AGTCAGTCGCCAATGCCTTCAT']
3548 M_000474.3(TWISTl):c.466A>G 7291 TWIST1 ['GACCCTCAAGCTGGCGGCCAGGTACRTCG (p.Ilel56Val) ACTTCCTCTACCAGGTCCTCCA']
3549 NM_001089.2(ABCA3):c. l702A> 21 ABC A3 ['ACAGATCACCGTCCTGCTGGGCCACRACG G (p.Asn568Asp) GTGCCGGGAAGACCACCACCCT']
3550 NM_005055.4(RAPSN):c.-210A>G 5913 RAPSN ['ATTCCTCAGAGGCCATGTGGCCCCARCTGG CAGCGACAGCTGCAGACGGGC]
3551 NM_198217.2(INGl):c.515A>G 3621 ING1 ['AACGAACCCACGTACTGTCTGTGCARCCA (p.Asnl72Ser) GGTCTCCTATGGGGAGATGATC]
3552 NM_000430.3(PAFAHlBl):c.446A 5048 PAFAH1B ['GATTTTGAACGAACTCTTAAAGGACRTAC >G (p.Hisl49Arg) 1 AGACTCTGTACAGGACATTTCA']
3553 NM_000579.3(CCR5):c- -1 ['TACGGGGAGAGTGGAGAAAAAGGGGRCA 301+246A>G CAGGGTTAATGTGAAGTCCAGGA']
3554 NM_000264.3(PTCHl):c.2479A>G -1 ['ACTTTACGACCTACACAGGAGTTTCRGTAA (p.Ser827Gly) CGTGAAGTATGTCATGTTGGA']
3555 NM_001184.3 ( ATR) : c.2022 A>G 545 ATR ['TCTGCTGCTGCAATAAGATAAAAAAYCCA (p.Gly674=) CTAACACAACTAGCCCGGATTA]
3556 NM_005982.3(SIXl):c.386A>G 6495 SIX1 ['ATCTGGGACGGCGAGGAGACCAGCTRCTG (p.Tyrl29Cys) CTTCAAGGAGAAGTCGAGGGGT']
3557 NM_006267.4(RANBP2):c.l966A> 5903 RANBP2 ['AGAAGACGCACACATAACTTTTGCTRTATT G (p.Ile656Val) GGATGCAGTAAATGGAAATAT']
3558 NM_001001557.2(GDF6):c.l271A 39225 GDF6 ['CCGCCCAGCTGCTGCGTGCCCACCARATTG >G (p.Lys424Arg) 5 ACTCCCATCAGCATTCTATAC]
3559 NM_000557.4(GDF5):c.517A>G 8200 GDF5 ['ACCCCCCATCACACCCCACGAGTACVTGCT (p.Metl73Val) CTCGCTGTACAGGACGCTGTC]
3560 NM_000392.4(ABCC2):c.4145A> 1244 ABCC2 ['CGAGAGAAGCTGACCATCATCCCCCRGGT G (p.Glnl382Arg) GAGCTCTAGAACTTACTCGGGC]
3561 NM_000396.3(CTSK):c.990A>G 1513 CTSK ['ACCTGGCCAGCTTCCCCAAGATGTGRCTCC (p.Ter330Trp) AGCCAGCCAAATCCATCCTGC]
3562 NM_001127221.1 (C ACN Al A) : c .4 773 CACNA1A ['AACGTCTTCAACATCCTCATCGTCTRCATG 151A>G (p.Tyrl384Cys) CTATTCATGTTCATCTTCGCC]
3563 NM_000178.2(GSS):c.656A>G 2937 GSS ['CAAGAGAAGGAAAGAAACATATTTGRCCA (p.Asp219Gly) GCGTGCCATAGAGAATGAGCTA']
3564 NM_000901.4(NR3C2):c.2327A>G 4306 NR3C2 ['ACGCTCAACCGCTTAGCAGGCAAACRGAT (p.Gln776Arg) GATCCAAGTCGTGAAGTGGGCA']
3565 NM_000901.4(NR3C2):c.2915A>G 4306 NR3C2 ['ATCAGCGACCAGCTGCCCAAGGTGGRGTC (p.Glu972Gly) GGGGAACGCCAAGCCGCTCTAC]
3566 M_004407.3 (DMP 1 ) : c.1 A>G 1758 DMP1 ['CCAGGTAGAGGTATCACACCCAACTRTGA (p.MetlVal) AGATCAGCATCCTGCTCATGTT']
3567 NM_004999.3(MYO6):c.737A>G 4646 MY06 ['CAAGGCAAAGAGGAAAGAAATTATCRTAT (p.His246Arg) CTTTTATAGGTTGTGTGCTGGT']
3568 NM_000256.3(MYBPC3):c.l75A> 4607 MYBPC3 ['CGCCAGCAACAAGTACGGCCTGGCCRCAG G (p.Thr59Ala) AGGGCACACGGCATACGCTGAC]
3569 NM_000163.4(GHR):c.594A>G 2690 GHR ['TGGAGTATGAACTTCAATACAAAGARGTA (p.Glul98=) AATGAAACTAAATGGAAAATGG]
3570 NM_000525.3(KCNJl l):c.509A>G 3767 KCNJ11 ['ATCATGCTTGGCTGCATCTTCATGARGACT (p.Lysl70Arg) GCCCAAGCCCACCGCAGGGCT']
3571 NM_000525.3(KCNJl l):c.776A>G 3767 KCNJ11 ['CTGGTGGCCCCGCTGATCATCTACCRTGTC (p.His259Arg) ATTGATGCCAACAGCCCACTC]
3572 NM_000182.4(H ADH A) : c .180+3 A 3030 HADHA ['GAAAAAAACTGCAAATTAAATGAGAYACC >G TTTGAATTGGGAGAGTTAATTC']
3573 NM_005263.3(GFIl):c.l l45A>G 2672 GFI1 ['GGCAAGGCATTCAGCCAGAGCTCCARCCT (p.Asn382Ser) CATCACCCACAGCCGCAAACAC]
3574 NM_005263.3(GFIl):c.l208A>G 2672 GFI1 ['CCCTTCGGCTGCGACCTCTGTGGGARGGGT (p.Lys403Arg) TTCCAGAGGAAGGTGGACCTC]
3575 NM_001893.4(CSNKlD):c.l30A> 1453 CSNK1D ['TGCCATCAAGCTTGAATGTGTCAAARCCA G (p.Thr44Ala) AACACCCTCAGCTCCACATTGA']
3576 NM_006204.3(PDE6C):c.l363A>G 5146 PDE6C ['AAACAGAAAGGACATTGCTCAGGAARTGC (p.Met455Val) TCATGAACCAAACCAAAGCCAC]
3577 NM_006204.3(PDE6C):c.l483- 5146 PDE6C ['TGAAACAACCCATCCTTATTTCAACRGAAA 2A>G GAGGACTTGCCAGACCCACGC]
3578 NM_003476.4(CSRP3):c.206A>G 8048 CSRP3 ['TGCTATGGGCGCAGATATGGCCCCARAGG (p.Lys69Arg) GATCGGGTATGGACAAGGCGCT']
3579 NM_005591.3(MREllA):c.350A> 4361 MRE11A ['GTGAACTATCAAGATGGCAACCTCARCAT G (p.Asnl l7Ser) TTCAATTCCAGTGTTTAGTATT']
3580 NM_000107.2(DDB2):c.730A>G 1643 DDB2 ['TTGGAATCTCAGAATGCACAAAAAGRAAG (p.Lys244Glu) TGACGCATGTGGCCCTGAACCC]
3581 NM_001204.6(BMPR2):c.l454A> 659 BMPR2 ['AAGGAGACAATCGAAGACTGTTGGGRCCA G (p.Asp485Gly) GGATGCAGAGGCTCGGCTTACT']
3582 NM_000336.2(SCNNlB):c.863A> 6338 SCNN1B ['ACAGAGAAGGCACTTCCTTCGGCCARCCC G (p.Asn288Ser) TGGAACTGAATTCGGTGAGTTT']
3583 M_000447.2(PSEN2):c.715A>G 5664 PSEN2 ['CTACCTCATCATGATCAGTGCGCTCRTGGC (p.Met239Val) CCTAGTGTTCATCAAGTACCT']
3584 NM_002181.3(IHH):c.284A>G 3549 IHH ['CCAGACATCATCTTCAAGGACGAGGRGAA (p.Glu95Gly) CACAGGCGCCGACCGCCTCATG]
3585 NM_000310.3(PPTl):c.236A>G 5538 PPT1 ['ACTTCTCTCTGGCTTCTTTTTTAGGRCGTGG (p.Asp79Gly) AGAACAGCTTCTTCTTGAAT']
3586 NM_003051.3(SLC16Al):c.610A> 6566 SLC16A1 ['GCGACCAATCGGGCCCAAGCCAACCRAGG G (p.Lys204Glu) CAGGGAAAGATAAGTCTAAAGC]
3587 NM_005587.2(MEF2A):c.788A>G 4205 MEF2A ['TCTCCCCCTCCACCAGGTGGTGGTARTCTT (p.Asn263Ser) GGAATGAACAGTAGGAAACCA']
3588 NM_000098.2(CPT2):c.638A>G 1376 CPT2 ['TACCTGGTCAATGCGTATCCCCTGGRTATG (p.Asp213Gly) TCCCAGTATTTTCGGCTTTTC]
3589 NM_000098.2(CPT2):c.359A>G 1376 CPT2 ['TTTTTAGGACCCTGGTTTGATATGTRCCTA (p.Tyrl20Cys) TCTGCTCGAGACTCCGTTGTT']
3590 NM_001079668.2(NKX2-l):c.464- 7080 NKX2-1 ['TCGCCGGGCCCATGAAGCGGGAGACHGTA 2A>G AGCGACAAACGCACAGCGTCGG]
3591 NM_004387.3(NKX2-5):c.896A>G 1482 NKX2-5 ['AACTTCGTGAACTTCGGCGTCGGGGRCTTG (p.Asp299Gly) AATGCGGTTCAGAGCCCCGGG]
3592 NM_004387.3(NKX2-5):c.547A>G 1482 NKX2-5 ['GCTGAAACTCACGTCCACGCAGGTCRAGA (p.Lysl83Glu) TCTGGTTCCAGAACCGGCGCTA]
3593 NM_178138.4(LHX3):c.332A>G 8022 LHX3 ['GTGCGCCGCGCCCAGGACTTCGTGTRCCAC (p.Tyrl l lCys) CTGCACTGCTTTGCCTGCGTC]
3594 NM_001698.2(AUH):c.263-2A>G 549 AUH ['CTTGTACTTTTTTTCCCCTTTAACTRGGAAT TGTGGTGCTTGGAATAAACA]
3595 NM_001698.2(AUH):c.943-2A>G 549 AUH ['ACATATTTAATATTTTGTTTTTCTTRGACCA
TTCCAACAAAAGACAGACTT']
3596 NM_001876.3(CPTlA):c. l361A>G 1374 CPT1A ['ATGTGTGTTTCACGTAGGTGGTTTGRCAAG (p.Asp454Gly) TCGTTCACGTTTGTTGTCTTC]
3597 NM_001876.3(CPTlA):c. l079A>G 1374 CPT1A ['CGGCTGCTGAAGCCCCGGGAGATGGRGCA (p.Glu360Gly) GCAGATGCAGAGGATCCTGGAC]
3598 NM_001876.3(CPTlA):c. l493A>G 1374 CPT1A ['TCCATTGACAGCCTCCAGCTGGGCTRTGCG (p.Tyr498Cys) GAGGATGGGCACTGCAAAGGC]
3599 NM_000352.4(ABCC8):c.4270A> 6833 ABCC8 ['CACCCTGCGCTCACGCCTCTCCATCRTCCT G (p.Ilel424Val) GCAGGACCCCGTCCTCTTCAG]
3600 NM_000352.4(ABCC8):c.215A>G 6833 ABCC8 ['ACATGGCTTCATTTCCCTGGGCACARCCTG (p.Asn72Ser) CGGTGGATCCTGACCTTCATG]
3601 NM_002180.2(IGHMBP2):c.638A> 3508 IGHMBP2 ['TCTCAGAAAGAACTTGCCATCATCCRTGGA G (p.His213Arg) CCTCCTGGCACTGGGAAAACC]
3602 NM_033163.3(FGF8):c.298A>G 2253 FGF8 ['GAAGCACGTGCAGGTCCTGGCCAACRAGC (p.LyslOOGlu) GCATCAACGCCATGGCAGAGGA']
3603 NM_006180.4(NTRK2):c.2165A> 4915 NTRK2 ['TCCCGGGACGTGTACAGCACTGACTRCTAC G (p.Tyr722Cys) AGGGTGAGTAGCTGTGCAGAT']
3604 NM_033028.4(BBS4):c.l57-2A>G 585 BBS4 ['TCAGAAGCATTTTTCTCCCTCTTTCRGGCT
GTTATCAAAGAACAGCTTCAA']
3605 NM_000409.3(GUCAlA):c.296A> 2978 GUCA1A ['AAGCTCCGCTGGTACTTCAAGCTCTRTGAT G (p.Tyr99Cys) GTAGATGGCAACGGCTGCATT']
3606 M_000344.3(SMNl):c.815A>G 6606 SMN1 ['TTAATTTCATGGTACATGAGTGGCTRTCAT (p.Tyr272Cys) ACTGGCTATTATATGGTAAGT']
3607 M_000344.3(SMNl):c.784A>G 6606 SMN1 ['TCTTGATGATGCTGATGCTTTGGGARGTAT (p.Ser262Gly) GTTAATTTCATGGTACATGAG]
3608 NM_000095.2(COMP):c. l358A>G 1311 COMP ['CGGGACAACTGTCCCACGGTGCCTARCAG (p.Asn453Ser) TGCCCAGGAGGACTCAGACCAC]
3609 NM_000095.2(COMP):c. l418A>G 1311 COMP ['GGTGATGCCTGCGACGACGACGACGRCAA (p.Asp473Gly) TGACGGAGTCCCTGACAGTCGG]
3610 NM_002047.2(GARS):c.374A>G 2617 GARS ['GATATTGTAGACCGAGCAAAAATGGRAGA (p.Glul25Gly) TACCCTGAAGAGGAGGTTTTTC]
3611 NM_001166107.1(HMGCS2):c.500 3158 HMGCS2 ['GGCATAGATACCACCAATGCCTGCTRCGG A>G (p.Tyrl67Cys) TGGTACTGCCTCCCTCTTCAAT']
3612 NM_000161.2(GCHl):c.671A>G 2643 GCH1 ['CGAGGTGTACAGAAAATGAACAGCARAAC (p.Lys224Arg) TGTGACCAGCACAATGTTGGGT']
3613 NM_001024630.3(RUNX2):c.598A 860 RUNX2 ['ATCTGCAGGCAAGAGTTTCACCTTGRCCAT >G (p.Thr200Ala) AACCGTCTTCACAAATCCTCC]
3614 NM_000423.2(KRT2):c.556A>G 3849 KRT2 ['AGAGCGTGAGCAGATCAAAACTCTCDACA (p.Asnl86Asp) ACAAATTTGCCTCCTTCATTGA']
3615 NM_000215.3 ( JAK3 ) : c.299 A>G 3718 JAK3 ['GATGCCAGCACCCAAGTCCTGCTGTRCAG (p.TyrlOOCys) GATTCGGTAGGAAGTGCCCCCC]
3616 NM_000335.4(SCN5A):c.3971A>G 6331 SCN5A ['CTCTGTCCACTTGAGGTGGTGGTCARTGCC (p.Asnl324Ser) CTGGTGGGCGCCATCCCGTCC]
3617 NM_000335.4(SCN5A):c.5381A>G 6331 SCN5A ['AGTGAGGACGACTTCGATATGTTCTRTGAG (p.Tyrl794Cys) ATCTGGGAGAAATTTGACCCA]
3618 NM_001014797.2(KCNMAl):c. l3 3778 KCNMA1 ['AAGGACTTTCTGCACAAGGACCGGGRTGA 01A>G (p.Asp434Gly) CGTCAATGTGGAGATCGTTTTT']
3619 NM_004380.2(CREBBP):c.3524A> 1387 CREBBP ['TATAATCGCAAGACATCCCGAGTCTRTAA G (p.Tyrl l75Cys) GTTTTGCAGTAAGCTTGCAGAG]
3620 NM_000023.2(SGCA):c.410A>G 6442 SGCA ['GGCCCCCTGCTGCCATACCAAGCCGRGTTC (p.Glul37Gly) CTGGTGCGCAGCCACGATGCG]
3621 NM_002835.3(PTPN12):c.l82A>G 5782 PTPN12 ['GGAGAAAAAGAAGAAAATGTTAAAARGA (p.Lys61Arg) ACAGATACAAGGACATACTGCCA']
3622 NM_000211.4(ITGB2):c.l052A>G 3689 ITGB2 ['GGGGAGCTGTCTGAGGACTCCAGCARTGT (p.Asn351Ser) GGTCCAACTCATTAAGAATGCT']
3623 NM_005502.3(ABCAl):c. l790A> 19 ABCA1 ['GTCTGGGGGGGCTTCGCCTACTTGCRGGAT G (p.Gln597Arg) GTGGTGGAGCAGGCAATCATC]
3624 NM_005502.3(ABCAl):c.2804A> 19 ABCA1 ['CAGATCACCTCCTTCCTGGGCCACARTGGA G (p.Asn935Ser) GCGGGGAAGACGACCACCATG]
3625 m.5843A>G 4579 MT-TY ['CTCGGAGCTGGTAAAAAGAGGCCTARCCC
CTGTCTTTAGATTTACAGTCCA']
3626 m.7445A>G -1 ['AAGAACCCGTATACATAAAATCTAGVCAA
AAAAGGAAGGAATCGAACCCCC]
3627 m.8344A>G 4566 MT-TK ['ACCTTTTAAGTTAAAGATTAAGAGARCCA
ACACCTCTTTACAGTGAAATGC]
3628 m.8296A>G 4566 MT-TK ['ACCCCCTCTACCCCCTCTAGAGCCCRCTGT
AAAGCTAACTTAGCATTAACC]
3629 m.12320 A>G 4568 MT-TL2 ['TCTTAGGCCCCAAAAATTTTGGTGCRACTC
CAAATAAAAGTAATAACCATG]
3630 m.3243A>G 4567 MT-TL1 ['AGAACAGGGTTTGTTAAGATGGCAGRGCC
CGGTAATCGCATAAAACTTAAA']
3631 m.3252A>G 4567 MT-TL1 ['TTTGTTAAGATGGCAGAGCCCGGTARTCGC
ATAAAACTTAAAACTTTACAG]
3632 m.3251A>G 4567 MT-TL1 ['GTTTGTTAAGATGGCAGAGCCCGGTRATC
GCATAAAACTTAAAACTTTACA']
3633 m.3260A>G 4567 MT-TL1 ['GATGGCAGAGCCCGGTAATCGCATARAAC
TTAAAACTTTACAGTCAGAGGT']
3634 m.3274A>G 4567 MT-TL1 ['GTAATCGCATAAAACTTAAAACTTTRCAGT
CAGAGGTTCAATTCCTCTTCT']
3635 m.4317A>G 4565 MT-TI ['GATAGAGTAAATAATAGGAGCTTAARCCC
CCTTATTTCTAGGACTATGAGA']
3636 m.4269A>G 4565 MT-TI ['GCATTCCCCCTCAAACCTAAGAAATRTGTC
TGATAAAAGAGTTACTTTGAT']
3637 m.4295A>G 4565 MT-TI ['TGTCTGATAAAAGAGTTACTTTGATRGAGT
AAATAATAGGAGCTTAAACCC]
3638 m.4300A>G 4565 MT-TI ['GATAAAAGAGTTACTTTGATAGAGTRAAT AATAGGAGCTTAAACCCCCTTA]
3639 m. l0044A>G 4563 MT-TG ['CTTCCAATTAACTAGTTTTGACAACRTTCA
AA A A AG AGT A AT A A ACTTC GC ']
3640 m.7526A>G 4555 MT-TD ['TCCATGACTTTTTCAAAAAGGTATTRGAAA
AACCATTTCATAACTTTGTCA']
3641 m. l0438A>G 4573 MT-TR ['AGTTTAAACAAAACGAATGATTTCGRCTC
ATTAAATTATGATAATCATATT']
3642 m. l555A>G 4549 MT-RNR1 ['ACCCCTACGCATTTATATAGAGGAGRCAA
GTCGTAACATGGTAAGTGTACT']
3643 m.827A>G 4549 MT-RNR1 ['CACCCCCACGGGAAACAGCAGTGATNARC
CTTTAGCAATAAACGAAAGTTT']
3644 m. l5579A>G 4519 MT-CYB ['CCCGAATGATATTTCCTATTCGCCTRCACA
ATTCTCCGATCCGTCCCTAAC]
3645 m.14495 A>G 4541 MT-ND6 ['TCCAAAGACAACCATCATTCCCCCTRAATA
AATTAAAAAAACTATTAAACC]
3646 m. l2770A>G 4540 MT-ND5 ['CTATTCCAACTGTTCATCGGCTGAGRGGGC
GTAGGAATTATATCCTTCTTG]
3647 m. l l084A>G 4538 MT-ND4 ['CTCCCTACAAATCTCCTTAATTATARCATT
CACAGCCACAGAACTAATCAT']
3648 m.3397A>G 4535 MT-ND1 ['TACCGAACGAAAAATTCTAGGCTATRTAC
AACTACGCAAAGGCCCCAACGT']
3649 m.4136A>G 4535 MT-ND1 ['CTGTTCTTATGAATTCGAACAGCATRCCCC
CGATTCCGCTACGACCAACTC]
3650 m.3796A>G 4535 MT-ND1 ['CCGTTTACTCAATCCTCTGATCAGGNTGAG
CATCAAACTCAAACTACGCCC,
3654 ATAAGTGGCTCCTTTAACCTCTCCDCCCTT
ATCACAACACAAGAACACCT',
CCCCCTTGACCTTGCCGAAGGGGANTCCG
AACTAGTCTCAGGCTTCAACA',
'CGAATACGCCGCAGGCCCCTTCGCCNTATT
CTTCATAGCCGAATACACAAA,
TTTTGTCACCAAGACCCTACTTCTNACCTC
CCTGTTCTTATGAATTCGAA']
3655 NM_003334.3(UBAl):c.l639A>G 7317 UBA1 ['AATGAATCCACATATCCGGGTGACARGCC (p.Ser547Gly) ACCAGAACCGTGTGGGTCCTGA']
3656 NM_000354.5(SERPINA7):c.623- 6906 SERPINA7 ['GATCAAAAGGATTTGCCCACTGGGCYTAA 2A>G AATACAAAGAAAAGAGAGGTGT']
3657 M_000044.3(AR):c.2291A>G 367 AR ['ACCAATGTCAACTCCAGGATGCTCTRCTTC (p.Tyr764Cys) GCCCCTGATCTGGTTTTCAAT']
3658 M_000044.3(AR):c.2362A>G 367 AR ['CCGGATGTACAGCCAGTGTGTCCGARTGA (p.Met788Val) GGCACCTCTCTCAAGAGTTTGG]
3659 M_000044.3(AR):c.2632A>G 367 AR ['GATTGCGAGAGAGCTGCATCAGTTCRCTTT (p.Thr878Ala) TGACCTGCTAATCAAGTCACA]
3660 M_000044.3(AR):c.2708A>G 367 AR ['ATGATGGCAGAGATCATCTCTGTGCRAGT (p.Gln903Arg) GCCCAAGATCCTTTCTGGGAAA]
3661 NM_002764.3(PRPSl):c.341A>G 5631 PRPS1 ['CCAATCTCAGCCAAGCTTGTTGCAARTATG (p.Asnl l4Ser) CTATCTGTAGCAGGTGCAGAT']
3662 NM_000194.2(HPRTl):c.602A>G 3251 HPRT1 ['CTTGACTATAATGAATACTTCAGGGRTTTG (p.Asp201Gly) AATGTAAGTAATTGCTTCTTT']
3663 NM_000194.2(HPRTl):c.l55A>G 3251 HPRT1 ['TGTAGGACTGAACGTCTTGCTCGAGRTGTG (p.Asp52Gly) ATGAAGGAGATGGGAGGCCAT']
3664 NM_000132.3(F8):c.872A>G 2157 F8 ['CCTGAAGTGCACTCAATATTCCTCGRAGGT (p.Glu291Gly) CACACATTTCTTGTGAGGAAC]
3665 NM_000132.3(F8):c.5183A>G 2157 F8 ['GCTGCAGTGGAGAGGCTCTGGGATTRTGG (p.Tyrl728Cys) GATGAGTAGCTCCCCACATGTT']
3666 NM_000132.3(F8):c.5821A>G 2157 F8 ['TTCTCTGTGTCCTTCTCCAGCAATCRATGG (p.Asnl941Asp) CTACATAATGGATACACTACC]
3667 NM_000132.3(F8):c.328A>G 2157 F8 ['TACAGTGGTCATTACACTTAAGAACRTGGC (p.Metl lOVal) TTCCCATCCTGTCAGTCTTCA]
3668 NM_000132.3(F8):c.398A>G 2157 F8 ['TTTCTTCCTGCTATAGGAGCTGAATRTGAT (p.Tyrl33Cys) GATCAGACCAGTCAAAGGGAG]
3669 NM_000132.3(F8):c.404A>G 2157 F8 ['CCTGCTATAGGAGCTGAATATGATGRTCA (p.Aspl35Gly) GACCAGTCAAAGGGAGAAAGAA]
3670 NM_000132.3(F8):c.940A>G 2157 F8 ['GGAAATCTCGCCAATAACTTTCCTTRCTGC (p.Thr314Ala) TCAAACACTCTTGATGGACCT']
3671 NM_000132.3(F8):c.l226A>G 2157 F8 ['TGGGTACATTACATTGCTGCTGAAGRGGA (p.Glu409Gly) GGACTGGGACTATGCTCCCTTA]
3672 NM_000132.3(F8):c.l331A>G 2157 F8 ['CAGCGGATTGGTAGGAAGTACAAAARAGT (p.Lys444Arg) CCGATTTATGGCATACACAGAT']
3673 NM_000132.3(F8):c.l418A>G 2157 F8 ['TCAGGAATCTTGGGACCTTTACTTTRTGGG (p.Tyr473Cys) GAAGTTGGAGACACACTGTTG]
3674 NM_000132.3(F8):c.l660A>G 2157 F8 ['TCGGTGCCTGACCCGCTATTACTCTRGTTT (p.Ser554Gly) CGTTAATATGGAGAGAGATCT']
3675 NM_000132.3(F8):c.l682A>G 2157 F8 ['TCTAGTTTCGTTAATATGGAGAGAGRTCTA (p.Asp561Gly) GCTTCAGGACTCATTGGCCCT']
3676 NM_000132.3(F8):c.l892A>G 2157 F8 ['GAGGATCCAGAGTTCCAAGCCTCCARCAT (p.Asn631Ser) CATGCACAGTGAGTAAAGCAGC]
3677 NM_000132.3(F8):c.5600A>G 2157 F8 ['TTCCCTCCCTAGGAAAAAGATGTGCRCTCA (p.Hisl867Arg) GGCCTGATTGGACCCCTTCTG]
3678 NM_000132.3(F8):c.5822A>G 2157 F8 ['TCTCTGTGTCCTTCTCCAGCAATCARTGGC (p.Asnl941Ser) TACATAATGGATACACTACCT']
3679 NM_000132.3(F8):c.6113A>G 2157 F8 ['AGCACACTTTTTCTGGTGTACAGCARTAGT (p.Asn2038Ser) GAGTAGCAATGTGGGCAGAGG]
3680 NM_000132.3(F8):c.6278A>G 2157 F8 ['AAGTGTTATTTTAATTGGTAGGTGGRTCTG (p.Asp2093Gly) TTGGCACCAATGATTATTCAC]
3681 NM_000132.3(F8):c.6371A>G 2157 F8 ['TACATCTCTCAGTTTATCATCATGTRTAGT
CTTGATGGGAAGAAGTGGCAG]
3682 NM_000132.3(F8):c.6794A>G 2157 F8 ['ATGAAAGTCACAGGAGTAACTACTCRGGG (p.Gln2265Arg) AGTAAAATCTCTGCTTACCAGC]
3683 NM_000132.3(F8):c.l04A>G 2157 F8 ['GGTGCAGTGGAACTGTCATGGGACTRTAT (p.Tyr35Cys) GCAAAGTGATCTCGGTGAGCTG]
3684 NM_000402.4(G6PD):c.466A>G 2539 G6PD ['CAACTCCTATGTGGCTGGCCAGTACRATGA (p.Asnl56Asp) TGCAGCCTCCTACCAGCGCCT']
3685 NM_000402.4(G6PD):c.583A>G 2539 G6PD ['GCTCCGGGCTCCCAGCAGAGGCTGGRACC (p.Asnl95Asp) GCATCATCGTGGAGAAGCCCTT']
3686 NM_002049.3(GATAl):c.653A>G 2623 GATA1 ['ACAGCCACTCCACTGTGGCGGAGGGRCAG (p.Asp218Gly) GACAGGCCACTACCTATGCAAC]
3687 NM_001097642.2(GJBl):c. l94A> 2705 GJB1 ['CAGCCTGGCTGCAACAGCGTTTGCTRTGAC G (p.Tyr65Cys) CAATTCTTCCCCATCTCCCAT']
3688 NM_000166.5(GJBl):c.614A>G 2705 GJB1 ['GCCTCTGGCATCTGCATCATCCTCARTGTG (p.Asn205Ser) GCCGAGGTGGTGTACCTCATC]
3689 NM_000032.4(ALAS2):c.1702A>G 212 ALAS2 ['CCGTCCTGTACACTTTGAGCTCATGRGTGA (p.Ser568Gly) GTGGGAACGTTCCTACTTCGG]
3690 NM_000202.6(IDS):c.404A>G 3423 IDS ['GGCTATGTGACCATGTCGGTGGGAARAGT (p.Lysl35Arg) CTTTCACCCTGGTACTGCTCCA']
3691 NM_000292.2(PHKA2):c.896A>G 5256 PHKA2 ['TATGGATGCTGTCGCTTCCTTCGAGRTGGT (p.Asp299Gly) TATAAAACTCCAAGAGAGGTT']
3692 NM_000292.2(PHKA2):c.565A>G 5256 PHKA2 ['TTATGGAATGTGGGAGCGTGGAGATRAGA (p.Lysl89Glu) CTAATCAGGGCATCCCGGAATT']
3693 NM_000351.4(STS):c. l331A>G 412 STS ['CGCTCCGATCATGAGTTTCTCTTCCRTTAC (p.His444Arg) TGCAACGCCTACTTAAATGCT']
3694 NM_000133.3(F9):c.278A>G 2158 F9 ['TTCAATTTCTTAACCTATCTCAAAGRTGGA (p.Asp93Gly) GATCAGTGTGAGTCCAATCCA']
3695 NM_000133.3(F9):c.329A>G 2158 F9 ['TGTTTAAATGGCGGCAGTTGCAAGGRTGA (p.Aspl lOGly) CATTAATTCCTATGAATGTTGG]
3696 NM_000133.3(F9):c.917A>G 2158 F9 ['CGAATTATTCCTCACCACAACTACARTGCA (p.Asn306Ser) GCTATTAATAAGTACAACCAT']
3697 NM_000133.3(F9):c.l l80A>G 2158 F9 ['TACAAAGTTCACCATCTATAACAACRTGTT (p.Met394Val) CTGTGCTGGCTTCCATGAAGG]
3698 NM_000133.3(F9):c.l231A>G 2158 F9 ['AGGTAGAGATTCATGTCAAGGAGATRGTG (p.Ser411Gly) GGGGACCCCATGTTACTGAAGT']
3699 NM_000266.3 (NDP) :c .131 A>G 4693 NDP ['CCTCGACGCTGCATGAGGCACCACTRTGTG (p.Tyr44Cys) GATTCTATCAGTCACCCATTG]
3700 NM_000266.3 (NDP) :c .1 A>G 4693 NDP ['TCTAGAGAAGTTTTTCCTTACAACARTGAG (p.MetlVal) AAAACATGTACTAGCTGCATC]
3701 NM_000266.3(NDP):c.l25A>G 4693 NDP ['TCGGACCCTCGACGCTGCATGAGGCRCCA (p.His42Arg) CTATGTGGATTCTATCAGTCAC]
3702 NM_000169.2(GLA):c.886A>G -1 ['GGCTATCATGGCTGCTCCTTTATTCRTGTC (p.Met296Val) TAATGACCTCCGACACATCAG]
3703 NM_000169.2(GLA):c. l01A>G -1 ['ATCCCTGGGGCTAGAGCACTGGACARTGG (p.Asn34Ser) ATTGGCAAGGACGCCTACCATG]
3704 NM_000169.2(GLA):c.644A>G -1 - ['GAGTCATATCTGTTTTCACAGCCCARTTAT (p.Asn215Ser) ACAGAAATCCGACAGTACTGC']
3705 NM_000169.2(GLA):c.1228A>G -1 ['AAGGTTAAGAAGTCACATAAATCCCRCAG (p.Thr410Ala) GCACTGTTTTGCTTCAGCTAGA]
3706 NM_000169.2(GLA):c.815A>G -1 ['TCTTTTTCTCAGTTAGTGATTGGCARCTTTG (p.Asn272Ser) GCCTCAGCTGGAATCAGCAA']
3707 NM_153252.4(BRWD3):c.4786A> 25406 BRWD3 ['AGAAGATAAAGAGAAAAAAGAAACARAA G (p.Lysl596Glu) 5 GAGAAATCTCATTTATCCACCTC]
3708 M_004463.2(FGDl):c. l396A>G 2245 FGD1 ['GCAGAAACTGGCCCCCTTCCTCAAGRTGTA (p.Met466Val) TGGTGAGTATGTGAAGAACTT']
3709 NM_000054.4(AVPR2):c.614A>G 554 AVPR2 ['GCGGAGCCCTGGGGCCGTCGCACCTRTGT (p.Tyr205Cys) CACCTGGATTGCCCTGATGGTG]
3710 NM_000054.4(AVPR2):c.839A>G 554 AVPR2 ['ATGACGCTAGTGATTGTGGTCGTCTRTGTG (p.Tyr280Cys) CTGTGCTGGGCACCCTTCTTC]
3711 NM_000276.3(OCRL):c.l436A>G 4952 OCRL ['ATCAAGTTCATCCCCACTTATAAGTRTGAC (p.Tyr479Cys) TCTAAAACAGACCGGTGGGAT']
3712 NM_000397.3(CYBB):c.302A>G 1536 CYBB ['CAACTGGACAGGAATCTCACCTTTCRTAAA (p.HislOlArg) ATGGTGGCATGGATGATTGCA']
3713 NM_000397.3(CYBB):c.l499A>G 1536 CYBB ['GCTGTGCACCATGATGAGGAGAAAGRTGT (p.Asp500Gly) GATCACAGGCCTGAAACAAAAG]
3714 NM_001205019.1(GK):c.880A>G 2710 GK ['TGGAACAGGATGTTTCTTACTATGTRATAC (p.Asn294Asp) AGGCCATAAGGTTGGTTTTTT']
3715 NM_005710.2(PQBPl):c.l94A>G 10084 PQBP1 ['CGGCCCCACAGCGGGCTCCCTTACTRCTGG (p.Tyr65Cys) AATGCAGACACAGACCTTGTA]
3716 NM_198270.3(NHS):c.853-2A>G 4810 NHS ['CTGAACCTGATTGTACTTTGTTTGCRGTCC
CATCCCCCAGAGGATGAAGAT']
3717 NM_000252.2(MTMl):c.566A>G 4534 MTM1 ['CACCATTGGAGAATAACTTTTATTARTAAG (p.Asnl89Ser) TGCTATGAGCTCTGTGACACT']
3718 NM_000252.2(MTMl):c. ll90A>G 4534 MTM1 ['GCCATGCTGATGTTGGATAGCTTCTRTAGG (p.Tyr397Cys) AGCATTGAAGGGTTCGAAATA]
3719 NM_000252.2(MTMl):c. l261- 4534 MTM1 ['TAATTAAAACAAATTATCTTCATCARTTTA 10A>G TTCAGCGAATAGGTCATGGTG]
3720 NM_001015877.1(PHF6):c.700A> 84295 PHF6 ['AGGAAAACTGCATATATTTAATGCCRAGA G (p.Lys234Glu) AGGCAGCTGCCCATTATAAGTG]
3721 NM_001015877.1(PHF6):c.686A> 84295 PHF6 ['GAAAATGAAGCACGAGGAAAACTGCRTAT G (p.His229Arg) ATTTAATGCCAAGAAGGCAGCT']
3722 NM_001015877.1(PHF6):c.769A> 84295 PHF6 ['CACAGTCCAGCTCACAACAACATCARGAG G (p.Arg257Gly) CAGAATTTGGAGACTTTGATAT']
3723 NM_000117.2(EMD):c.1 A>G 2010 EMD ['GCCTCCGCCTGAGCCCGCACCCGCCRTGG (p.MetlVal) ACAACTACGCAGATCTTTCGGA']
3724 NM_004006.2(DMD):c.2317A>G 1756 DMD ['GGCCATAGAGCGAGAAAAAGCTGAGRAGT (p.Lys773Glu) TCAGAAAACTGCAAGATGCCAG]
3725 NM_004006.2(DMD):c.8734A>G 1756 DMD ['TCTACGAAAGCAGGCTGAGGAGGTCRATA (p.Asn2912Asp) CTGAGTGGGAAAAATTGAACCT']
3726 NM_004006.2(DMD):c.8762A>G 1756 DMD ['ACTGAGTGGGAAAAATTGAACCTGCRCTC (p.His2921Arg) CGCTGACTGGCAGAGAAAAATA]
3727 NM_004006.2(DMD):c.835A>G 1756 DMD ['TCCCCCAAACCCTTCTCTGCAGATCRCGGT (p.Thr279Ala) CAGTCTAGCACAGGGATATGA']
3728 NM_004006.2(DMD):c.9225- 1756 DMD ['TCGATCGCACTTCAGTTATGATAAAYTGAC 285A>G CTTGTTATGTGATCAATAATC]
3729 NM_000033.3(ABCDl):c.443A>G 215 ABCD1 ['ATCGCCCTCCCTGCTACCTTCGTCARCAGT (p.Asnl48Ser) GCCATCCGTTACCTGGAGGGC]
3730 NM_003588.3(CUL4B):c.901- 8450 CUL4B ['TTTGATTTCTTTTTTTTTCATTGGCRGATCA 2A>G TGATCAGGAGCATTTTTTTG]
3731 NM_000061.2(BTK):c.l288A>G 695 BTK ['GAGAGGCCAGTACGACGTGGCCATCRAGA (p.Lys430Glu) TGATCAAAGAAGGCTCCATGTC]
3732 NM_000061.2(BTK):c.l082A>G 695 BTK ['AGCACCATCCCTGAGCTCATTAACTRCCAT (p.Tyr361Cys) CAGCACAACTCTGCAGGTGAG]
3733 NM_000061.2(BTK):c.919A>G 695 BTK ['GGGGAAAGAAGGAGGTTTCATTGTCRGAG (p.Arg307Gly) ACTCCAGCAAAGCTGGCAAATA']
3734 NM_000061.2(BTK):c.l766A>G 695 BTK ['CACCTTCTAGGGGTTTTGATGTGGGRAATT (p.Glu589Gly) TACTCCCTGGGGAAGATGCCA']
3735 NM_003413.3(ZIC3):c.l213A>G 7547 ZIC3 ['CTACACGCACCCGAGCTCCCTGCGCRAAC (p.Lys405Glu) ACATGAAGGTAATTACCTCTTT']
3736 NM_001037811.2(HSD17B10):c.71 3028 HSD17B10 ['GCCATCATCGAGAACCCATTCCTCARTGGA 3A>G (p.Asn238Ser) GAGGTCATCCGGCTGGATGGG]
3737 NM_003639.4(TKBKG):c. l219A>G 8517 IKBKG ['CAAGTGCCAGTATCAGGCCCCTGATRTGG (p.Met407Val) ACACCCTGCAGATACATGTCAT']
3738 NM_003639.4(TKBKG):c. l259A>G 8517 IKBKG ['ATACATGTCATGGAGTGCATTGAGTRGGG (p.Ter420Trp) CCGGCCAGTGCAAGGCCACTGC]
3739 M_005448.2(BMP15):c.704A>G 9210 BMP15 ['TTGGACATTGCCTTCTTGTTACTCTRTTTCA (p.Tyr235Cys) ATGATACTCATAAAAGCATT']
3740 NM_005120.2(MED12):c.3020A> 9968 MED 12 ['AAGGTGAAGAACACCATCTACTGCARCGT G (p.Asnl007Ser) GGAGCCATCGGAATCAAATATG]
3741 NM_003688.3(CASK):c.2129A>G 8573 CASK ['GGCAAGAAAAAGAAGCAGTACAAAGRTA (p.Asp710Gly) AATATTTGGCAAAGCACAATGCA]
3742 NM_001363.4(DKCl):c.361A>G 1736 DKC1 ['ACTTCGGGTGGAGAAGACAGGGCACRGTG (p.Serl21Gly) GTACTCTGGATCCCAAGGTGAC]
3743 NM_001363.4(DKCl):c.l069A>G 1736 DKC1 ['ATTAATGACCACAGCGGTCATCTCTRCCTG (p.Thr357Ala) CGACCATGGTATAGTAGCCAA']
3744 NM_000307.4(POU3F4):c.1000A> 5456 POU3F4 ['GTTCTGTAATCGAAGACAAAAAGAGRAAA G (p.Lys334Glu) GAATGACTCCGCCAGGGGATCA']
3745 NM_004429.4(EFNBl):c.472A>G 1947 EFNB1 ['GGGCGGTGTGTGCCGCACACGCACCRTGA (p.Metl58Val) AGATCATCATGAAGGTTGGGCA']
3746 NM_000489.4(ATRX):c.4826A>G 546 ATRX ['TTCTTATAGGTGGTAAGTTTTCTTCRTACA (p.Hisl609Arg) GTTCTTTTGTGTGACAAACTG]
3747 NM_000489.4(ATRX):c.5579A>G 546 ATRX ['TTCTTTTGATCAGGTGTGGGCAATAVTAGT (p.Asnl860Ser) GAAGGTGGAAGAGGAAAGGCA']
3748 NM_000489.4(ATRX):c.6488A>G 546 ATRX ['GGACAAACTAAGCCTGTTTATGTATRTAGG (p.Tyr2163Cys) TTCTTAGCTCAGGTAGGTTTA]
3749 NM_000489.4(ATRX):c.6811A>G 546 ATRX ['AGAAGAAGAGTTGACTGAAGAAGAARGA (p.Arg2271Gly) AAAGCAGCTTGGGCTGAGTATGA]
3750 NM_000052.6(ATP7A):c.3911A>G 538 ATP7A ['GTAGCAATGGTGGGAGATGGAATCARTGA (p.Asnl304Ser) CTCCCCAGCTCTGGCAATGGCT']
3751 NM_004992.3(MECP2):c.410A>G 4204 MECP2 ['GGAAAAGCCTTTCGCTCTAAAGTGGRGTT (p.Glul37Gly) GATTGCGTACTTCGAAAAGGTA']
3752 NM_000137.2(FAH):c. l l41A>G 2184 FAH ['CATAGACCTGGGGAATGGTCAGACCRGGA (p.Arg381Gly) AGTTTCTGCTGGACGGGGATGA']
3753 NM_000137.2(FAH):c.836A>G 2184 FAH ['CCCTTTGCTGTGCCCAACCCGAAGCRGGTA (p.Gln279Arg) AGCACATTCTCTGCAGGAAGC]
3754 NM_002769.4(PRSSl):c.68A>G -1 ['GCTGCCCCCTTTGATGATGATGACARGATC (p.Lys23Arg) GTTGGGGGCTACAACTGTGAG]
3755 NM_002769.4(PRSSl):c. l61A>G -1 ['CACTTCTGTGGTGGCTCCCTCATCARCGAA (p.Asn54Ser) CAGTGGGTGGTATCAGCAGGC]
3756 NM_000373.3(UMPS):c.286A>G 7372 UMPS ['AACCAATCAAATTCCAATGCTTATTRGAAG (p.Arg96Gly) GAAAGAAACAAAGGATTATGG]
3757 NM_001918.3(DBT):c.l355A>G 1629 DBT ['ATGAATGTGAGCTGGTCAGCTGATCRCAG (p.His452Arg) AGTTATTGATGGTGCTACAATG]
3758 NM_000108.4(DLD):c.214A>G 1738 DLD ['TTGGTTGTAGACAGTCTGCATTGAGRAAA (p.Lys72Glu) ATGAAACACTTGGTGGAACATG]
3759 NM_000108.4(DLD):c.l483A>G 1738 DLD ['CTTGCAGACCTTATCAGAAGCTTTTRGAGA (p.Arg495Gly) AGCAAATCTTGCTGCGTCATT']
3760 NM_000108.4(DLD):c.l081A>G 1738 DLD ['CATTGGTGATGTAGTTGCTGGTCCARTGCT (p.Met361Val) GGCTCACAAAGCAGAGGATGA']
3761 NM_000481.3(AMT):c.l25A>G 275 AMT ['CGCAGGACACCGCTCTATGACTTCCRCCTG (p.His42Arg) GCCCACGGCGGGAAAATGGTG]
3762 NM_000151.3(G6PC):c.230+4A>G 2538 G6PC ['GGCTCAACCTCGTCTTTAAGTGGTARGAAC
CATATAGAGAGGAGATCAGCA']
3763 NM_000532.4(PCCB):c.l304A>G 5096 PCCB ['CAGCATTTGGATCTGTTTTAGGCCTRTGGA (p.Tyr435Cys) GGTGCCTATGATGTCATGAGC]
3764 NM_000387.5(SLC25A20):c.713A 788 SLC25A20 ['CCAGATGTGCTCAAGTCTCGATTCCRGACT >G (p.Gln238Arg) GGTGAGTGGAAGGTAGTGGGG]
3765 NM_004360.3(CDHl):c.2512A>G 999 CDH1 ['TCTGCTCGTGTTTGACTATGAAGGARGCGG (p.Ser838Gly) TTCCGAAGCTGCTAGTCTGAG]
3766 NM_004360.3(CDHl):c.l018A>G 999 CDH1 ['GTCGATCTCTCTGCAGAGTTTCCCTDCGTA (p.Thr340Ala) TACCCTGGTGGTTCAAGCTGC]
3767 NM_003361.3(UMOD):c.383A>G 7369 UMOD ['TGCCACGCCCTGGCCACATGTGTCARTGTG (p.Asnl28Ser) GTGGGCAGCTACTTGTGCGTA']
3768 NM_000463.2(UGTlAl):c.992A> -1 ['GCTGATGCTTTGGGCAAAATCCCTCRGACA G (p.Gln331Arg) GTAAGAAGATTCTATACCATG]
3769 NM_000463.2(UGTlAl):c.l085- -1 ['TGACATCCTCCCTATTTTGCATCTCRGGTC 2A>G ACCCGATGACCCGTGCCTTTA]
3770 NM_000463.2(UGTlAl):c.l070A> -1 - ['ACGATACTTGTTAAGTGGCTACCCCRAAAC G (p.Gln357Arg) GATCTGCTTGGTATGTTGGGC]
3771 NM_000463.2(UGTlAl):c.l l98A> -1 ['GCCCTTGTTTGGTGATCAGATGGACVATGC G (p.Asn400Asp) AAAGCGCATGGAGACTAAGGG]
3772 NM_001382.3(DPAGTl):c.509A> 1798 DPAGT1 ['TCTCTCCCCGCAGGAATCCTGTACTRTGTC G (p.Tyrl70Cys) TACATGGGGCTGCTGGCAGTG]
3773 NM_001007792.1(NTRKl):c.986A 4914 NTRK1 ['CCCACCCACGTCAACAACGGCAACTRCAC >G (p.Tyr329Cys) GCTGCTGGCTGCCAACCCCTTC]
3774 NM_001007792.1(NTRKl):c.l651 4914 NTRK1 ['CTGCACCGAGGGCCGCCCCCTGCTCRTGGT A>G (p.Met551Val) CTTTGAGTATATGCGGCACGG]
3775 NM_000363.4(TNNI3):c.569A>G 7137 TNNI3 ['CTCCAGGAAAACCGGGAGGTGGGAGRCTG (p.Aspl90Gly) GCGCAAGAACATCGATGCACTG]
3776 NM_000363.4(TNNI3):c.532A>G 7137 TNNI3 ['GCGGGCCCACCTCAAGCAGGTGAAGRAGG (p.Lysl78Glu) AGGACACCGAGAAGGTGAGTGT']
3777 NM_001018005.1(TPMl):c.539A> 7168 TPM1 ['ATTGAGAGCGACCTGGAACGTGCAGDGGA G (p.Glul80Gly) GCGGGCTGAGCTCTCAGAAGGG]
3778 NM_001159287.1(TPIl):c.622A>G 7167 TPI1 ['CCTGGCCTATGAGCCTGTGTGGGCCRTTGG (p.Ile208Val) TACTGGCAAGACTGCAACACC]
3779 NM_000359.2(TGMl):c.l469A>G 7051 TGM1 ['AATGGCCTGGTCTACATGAAGTACGRCAC (p.Asp490Gly) GCCTTTCATTTTTGCTGAGGTG]
3780 NM_001024847.2(TGFBR2):c. l47 7048 TGFBR2 ['CCCTGTGTTTGCTGGCTTTCTTCACRGAAG 2-2A>G TAAAAGATTATGAGCCTCCAT']
3781 NM_003242.5(TGFBR2):c.1273 A> 7048 TGFBR2 ['GCTATAGGTGGGAACTGCAAGATACRTGG G (p.Met425Val) CTCCAGAAGTCCTAGAATCCAG]
3782 NM_004612.3(TGFBRl):c. l l99A> 7046 TGFBR1 ['CATTTTGAATCCTTCAAACGTGCTGRCATC G (p.Asp400Gly) TATGCAATGGGCTTAGTATTC]
3783 NM_001128177.1(THRB):c.l324A 7068 THRB ['CTGCCATGCCAGCCGCTTCCTGCACRTGAA >G (p.Met442Val) GGTGGAATGCCCCACAGAACT']
3784 NM_001128177.1(THRB):c.l327A 7068 THRB ['CCATGCCAGCCGCTTCCTGCACATGRAGGT >G (p.Lys443Glu) GGAATGCCCCACAGAACTCTT']
3785 NM_001128177.1(THRB):c.l009A 7068 THRB ['AACCTTGAATGGGGAAATGGCAGTGRCAC >G (p.Thr337Ala) GGGGCCAGCTGAAAAATGGGGG]
3786 NM_033360.3(KRAS):c.l3A>G 3845 KRAS ['AGGCCTGCTGAAAATGACTGAATATRAAC (p.Lys5Glu) TTGTGGTAGTTGGAGCTGGTGG]
3787 NM_005343.2(HRAS):c.350A>G -1 ['GTGCCCATGGTGCTGGTGGGGAACARGTG (p.Lysl l7Arg) TGACCTGGCTGCACGCACTGTG]
3788 NM_001063.3(TF):c.956A>G 7018 TF ['GACCTGCTGTTTAAGGACTCTGCCCRCGGG (p.His319Arg) TTTTTAAAAGTCCCCCCCAGG]
3789 NM_001063.3(TF):c.l936A>G 7018 TF ['CTTTTGTTTGTTCCGGTCGGAAACCRAGGA (p.Lys646Glu) CCTTCTGTTCAGAGATGACAC]
3790 NM_212472.2(PRKARlA):c.891+3 5573 PRKARIA ['ATGAGTTCTTCATTATTTTAGAGGTRAAGA A>G ACTCAGAATTTAATACTTGAA']
3791 NM_212472.2(PRKARlA):c.lA>G 5573 PRKARIA ['GTGTGTTTTTTTCTCGCAGAGAACCRTGGA (p.MetlVal) GTCTGGCAGTACCGCCGCCAG]
3792 NM_000362.4(TIMP3):c.572A>G -1 - ['GCCTGCATCCGGCAGAAGGGCGGCTRCTG (p.Tyrl91Cys) CAGCTGGTACCGAGGATGGGCC]
3793 NM_000367.3(TPMT):c.719A>G 7172 TPMT ['GATTACAGGTGTGAGCCACCGCACCNAGC (p.Tyr240Cys) C A ATTTT GAGT ATTTTT A A A AG ,
3795 'TAACATGTTACTCTTTCTTGTTTCARGTAAA
ATATGCAATATACRTYGTCT',
AGGTTGATGCTTTTGAAGAACGACAKAAAA
GTTGGGGAATTGACTGTCTTT']
3796 NM_198253.2(TERT):c.2315A>G 7015 TERT ['TCTACCTTGACAGACCTCCAGCCGTRCATG (p.Tyr772Cys) CGACAGTTCGTGGCTCACCTG]
3797 NM_000073.2(CD3G):c. lA>G 917 CD3G ['CTTTTGCCGGAGGACAGAGACTGACRTGG (p.MetlVal) AACAGGGGAAGGGCCTGGCTGT']
3798 NM_000899.4(KITLG):c.l07A>G 4254 KITLG ['ATCTGCAGGAATCGTGTGACTAATARTGTA (p.Asn36Ser) AAAGACGTCACTAAATTGGTA]
3799 NM_001024858.2(SPTB):c.lA>G 6710 SPTB ['GCGGAGCTGCTAAGAGCCTGCTGACRTGA (p.MetlVal) CATCGGCCACAGAGTTTGAAAA']
3800 NM_003126.2(SPTAl):c.l43A>G 6708 SPTA1 ['GAGCGGGTCGCTGAGAGGGGTCAGARGCT (p.Lys48Arg) TGAGGATTCCTATCACTTACAA']
3801 NM_005633.3(SOSl):c.l654A>G 6654 SOS1 ['TTTACAGTACCGGAGTACACTGGAARGGA (p.Arg552Gly) TGCTTGATGTAACAATGCTACA']
3802 NM_003041.3(SLC5A2):c.l961A> -1 ['GACCCGAGCTGGGCCCGTGTGGTCARCCT G (p.Asn654Ser) CAATGCCCTGCTCATGATGGCA']
3803 NM_000343.3(SLC5Al):c.83A>G 6523 SLC5A1 ['CACGAGCTCATTCGCAATGCAGCCGRTATC (p.Asp28Gly) TCCATCATCGTTATCTACTTC]
3804 NM_000702.3(ATPlA2):c. l033A> 477 ATP1A2 ['TCTCTACCAGGTGTGCCTGACCCTGRCAGC G (p.Thr345Ala) CAAGCGCATGGCACGGAAGAA']
3805 NM_003124.4(SPR):c.448A>G 6697 SPR ['CTTCCCGGACAGTCCTGGCCTCAACRGAAC (p.Argl50Gly) CGTGGTTAACATCTCGTCCCT']
3806 NM_001161766.1 ( AHCY) :c .344 A> 191 AHCY ['CTCACCAACCTCATCCACACCAAGTRCCCG G (p.Tyrl l5Cys) CAGCTTCTGCCAGGTGAGCAG]
3807 NM_001035.2(RYR2):c.l2602A>G 6262 RYR2 ['TGCGAGGACACCATCTTTGAAATGCRGCT (p.Gln4201Arg) GGCGGCTCAGATCTCGGAGTCG]
3808 NM_000540.2(RYRl):c.14387 A>G 6261 RYRl ['CAGTCCTTCCTGTACCTGGGCTGGTRTATG (p.Tyr4796Cys) GTGATGTCCCTCTTGGGACAC]
3809 NM_000540.2(RYRl):c.14647- 6261 RYRl ['CTCTGTCTCAAAAAAAAAAAAAAACRTAT 1449A>G GTAAAGTTGTTCCCAAATGCCA']
3810 NM_000540.2(RYRl):c.l3909A>G 6261 RYRl ['GGTGTACTACTTCCTGGAGGAAAGCRCAG (p.Thr4637Ala) GCTACATGGAACCCGCCCTGCG]
3811 NM_000539.3(RHO):c.533A>G 6010 RHO ['TCTCCCTACCTGCCTGTCCTCAGGTRCATC (p.Tyrl78Cys) CCCGAGGGCCTGCAGTGCTCG]
3812 NM_000539.3(RHO):c.569A>G 6010 RHO ['GGCCTGCAGTGCTCGTGTGGAATCGRCTAC (p.Aspl90Gly) TACACGCTCAAGCCGGAGGTC]
3813 NM_000539.3(RHO):c.886A>G 6010 RHO ['CATGACCATCCCAGCGTTCTTTGCCRAGAG (p.Lys296Glu) CGCCGCCATCTACAACCCTGT']
3814 NM_000539.3(RHO):c.44A>G 6010 RHO ['CCTAACTTCTACGTGCCCTTCTCCARTGCG (p.Asnl5Ser) ACGGGTGTGGTACGCAGCCCC]
3815 NM_000321.2(RBl):c.2490- 5925 RBI ['AAGGGTGCTGTGGATCAGGGAAATGRTGA 1398A>G GTATGAAGCTGTTTTAAATTCT']
3816 NM_000536.3(RAG2):c. l l5A>G 5897 RAG2 ['CTTTGGACAAAAAGGCTGGCCCAAARGAT (p.Arg39Gly) CCTGCCCCACTGGAGTTTTCCA']
3817 M_000448.2(RAGl):c.2735A>G 5896 RAG1 ['GAGTGCCCAGAATCCCTCTGCCAGTRCAGT (p.Tyr912Cys) TTCAATTCACAGCGTTTTGCT']
3818 M_000448.2(RAGl):c.1286A>G 5896 RAG1 ['TTTGCTGACAAAGAAGAAGGTGGAGRTGT (p.Asp429Gly) GAAGTCCGTGTGCATGACCTTG]
3819 NM_000925.3(PDHB):c.395A>G 5162 PDHB ['ATAAACTCAGCTGCCAAGACCTACTRCAT (p.Tyrl32Cys) GTCTGGTGGCCTTCAGCCTGTG]
3820 NM_000055.2(BCHE):c.293A>G 590 BCHE ['GCAAATTCTTGCTGTCAGAACATAGRTCAA (p.Asp98Gly) AGTTTTCCAGGCTTCCATGGA]
3821 NM_000055.2(BCHE):c.467A>G 590 BCHE ['ACTGGAACATCATCTTTACATGTTTDTGAT (p.Tyrl56Cys) GGCAAGTTTCTGGCTCGGGTT']
3822 NM_005360.4(MAF):c.890A>G 4094 MAF ['CTGAAGCAGAAGAGGCGGACCCTGARAAA (p.Lys297Arg) CCGCGGCTATGCCCAGTCCTGC]
3823 NM_002739.3(PRKCG):c.380A>G 5582 PRKCG ['TCCCTCCTCTACGGGCTTGTGCACCRGGGC (p.Glnl27Arg) ATGAAATGCTCCTGTGAGTGA']
3824 NM_002739.3(PRKCG):c. l081A> 5582 PRKCG ['CTTCCTCATGGTTCTAGGAAAAGGCRGTTT G (p.Ser361Gly) TGGGAAGGTTGGATTCCTGGG]
3825 NM_000141.4(FGFR2):c.983A>G 2263 FGFR2 ['ACGGACAAAGAGATTGAGGTTCTCTRTATT (p.Tyr328Cys) CGGAATGTAACTTTTGAGGAC]
3826 NM_000141.4(FGFR2):c.1124 A>G 2263 FGFR2 ['AAGGAGATTACAGCTTCCCCAGACTRCCT (p.Tyr375Cys) GGAGATAGCCATTTACTGCATA']
3827 NM_000141.4(FGFR2):c.874A>G 2263 FGFR2 ['TGCCCAGCCCCACATCCAGTGGATCRAGC (p.Lys292Glu) ACGTGGAAAAGAACGGCAGTAA']
3828 NM_000141.4(FGFR2):c. l576A>G 2263 FGFR2 ['ACTGTTCATAGATGATGCCACAGAGRAAG (p.Lys526Glu) ACCTTTCTGATCTGGTGTCAGA']
3829 NM_000313.3(PROSl):c.773A>G 5627 PROS1 ['AACATGTGTGCTCAGCTTTGTGTCARTTAC (p.Asn258Ser) CCTGGAGGTTACACTTGCTAT']
3830 NM_000313.3 (PROS 1 ) :c .586 A>G 5627 PROS1 ['AAATGGTTTTGTTATGCTTTCAAATRAGAA (p.Lysl96Glu) AGATTGTAAAGGTAAGAGCAG]
3831 NM_002834.3(PTPNl l):c.922A>G 5781 PTPN11 ['GCCTGTTTCAGATTACATCAATGCARATAT (p.Asn308Asp) CATCATGGTAAGCTTTGCTTT']
3832 NM_002834.3(PTPNl l):c.923A>G 5781 PTPN11 ['CCTGTTTCAGATTACATCAATGCAAVTATC (p.Asn308Ser) ATCATGGTAAGCTTTGCTTTT']
3833 NM_002834.3(PTPNl l):c.836A>G 5781 PTPN11 ['CAAGAAAACAAAAACAAAAATAGATVTA (p.Tyr279Cys) AAAACATCCTGCCCTGTAAGTAT']
3834 NM_002834.3(PTPNl l):c.l82A>G 5781 PTPN11 ['CACATCAAGATTCAGAACACTGGTGNTTA (p.Asp61Gly) CTATGACCTGTATGGAGGGGAG]
3835 NM_002834.3(PTPNl l):c.l88A>G 5781 PTPN11 ['AAGATTCAGAACACTGGTGATTACTRTGA (p.Tyr63Cys) CCTGTATGGAGGGGAGAAATTT']
3836 NM_002834.3(PTPNl l):c.227A>G 5781 PTPN11 ['GGGGAGAAATTTGCCACTTTGGCTGNGTT (p.Glu76Gly) GGTCCAGTATTACATGGAACAT']
3837 NM_002834.3(PTPNl l):c.236A>G 5781 PTPN11 ['TTTGCCACTTTGGCTGAGTTGGTCCRGTAT (p.Gln79Arg) TACATGGAACATCACGGGCAA]
3838 NM_002834.3(PTPNl l):c.l529A> 5781 PTPN11 ['TCAGGGATGGTCCAGACAGAAGCACVGTA G (p.Gln510Arg) CCGATTTATCTATATGGCGGTC]
3839 NM_002755.3(MAP2Kl):c.389A> 5604 MAP2K1 ['AACTCTCCGTACATCGTGGGCTTCTRTGGT G (p.Tyrl30Cys) GCGTTCTACAGCGATGGCGAG]
3840 NM_006006.4(ZBTB16):c. l849A> 7704 ZBTB16 ['CCAGCGCTCCCGGGACTACTCGGCCRTGAT G (p.Met617Val) CAAGCACCTGAGAACGCACAA]
3841 NM_000311.3(PRNP):c.385A>G 5621 PRNP ['AGTGGTGGGGGGCCTTGGCGGCTACRTGC (p.Metl29Val) TGGGAAGTGCCATGAGCAGGCC]
3842 NM_000311.3(PRNP):c.650A>G 5621 PRNP ['GTGGTTGAGCAGATGTGTATCACCCRGTAC (p.Gln217Arg) GAGAGGGAATCTCAGGCCTAT']
3843 NM_000311.3(PRNP):c.547A>G 5621 PRNP ['CTTTGTGCACGACTGCGTCAATATCRCAAT (p.Thrl83Ala) CAAGCAGCACACGGTCACCAC]
3844 NM_000311.3(PRNP):c.560A>G 5621 PRNP ['TGCGTCAATATCACAATCAAGCAGCRCAC (p.Hisl87Arg) GGTCACCACAACCACCAAGGGG]
3845 NM_000371.3 (TTR) : c.401 A>G 7276 TTR ['ACCATTGCCGCCCTGCTGAGCCCCTRCTCC (p.Tyrl34Cys) TATTCCACCACGGCTGTCGTC]
3846 NM_000371.3 (TTR) : c.238 A>G 7276 TTR ['GTCTGGAGAGCTGCATGGGCTCACARCTG (p.Thr80Ala) AGGAGGAATTTGTAGAAGGGAT']
3847 NM_000371.3(TTR):c. l85A>G 7276 TTR ['AGAAAGGCTGCTGATGACACCTGGGRGCC (p.Glu62Gly) ATTTGCCTCTGGGTAAGTTGCC]
3848 NM_000371.3(TTR):c.205A>G 7276 TTR ['CCAGACTTTCACACCTTATAGGAAARCCA (p.Thr69Ala) GTGAGTCTGGAGAGCTGCATGG]
3849 NM_000371.3 (TTR) : c.379 A>G 7276 TTR ['CGACTCCGGCCCCCGCCGCTACACCRTTGC (p.Ilel27Val) CGCCCTGCTGAGCCCCTACTC]
3850 NM_000371.3 (TTR) : c.113 A>G 7276 TTR ['TGTCCTCTGATGGTCAAAGTTCTAGRTGCT (p.Asp38Gly) GTCCGAGGCAGTCCTGCCATC]
3851 NM_000217.2(KCNAl):c.676A>G 3736 KCNA1 ['CACAGACCCCTTCTTCATCGTGGAARCGCT (p.Thr226Ala) GTGTATCATCTGGTTCTCCTT']
3852 NM_000217.2(KCNAl):c.763A>G 3736 KCNA1 ['GACGGACTTCTTCAAAAACATCATGRACTT (p.Asn255Asp) CATAGACATTGTGGCCATCAT']
3853 NM_002693.2(POLG):c.2864A>G 5428 POLG ['AAAATCTTCAACTACGGCCGCATCTRTGGT (p.Tyr955Cys) GCTGGGCAGCCCTTTGCTGAG]
3854 NM_002693.2(POLG):c.2591A>G 5428 POLG ['GAGCCCACATGGCTCACCGCCAGCARTGC (p.Asn864Ser) CCGGGTATGTGACCTCTGTACC]
3855 NM_000174.4(GP9):c.l82A>G 2815 GP9 ['ACCCGCCACCTTCTGCTGGCCAACARCAGC (p.Asn61Ser) CTTCAGTCCGTGCCCCCGGGA']
3856 NM_000174.4(GP9):c.l lOA>G 2815 GP9 ['CTGGAAACCATGGGGCTGTGGGTGGRCTG (p.Asp37Gly) CAGGGGCCACGGACTCACGGCC]
3857 NM_006206.4(PDGFRA):c.1664A 5156 PDGFRA ['CCTGGTCATTTATAGAAACCGAGGTRTGA >G (p.Tyr555Cys) AATTCGCTGGAGGGTCATTGAA']
3858 NM_000301.3(PLG):c. l l2A>G 5340 PLG ['GGGGGCTTCACTGTTCAGTGTCACTRAGAA (p.Lys38Glu) GCAGCTGGGAGCAGGAAGTAT']
3859 NM_000293.2(PHKB):c.306-2A>G 5257 PHKB ['GTTTCATGAGTTATCTCTCTCACCCRGGCG
AATTGATGATGACAAGGGAAG]
3860 NM_000175.3(GPI):c. l028A>G 2821 GPI ['ACACACGCCATGCTGCCCTATGACCRGTAC (p.Gln343Arg) CTGCACCGCTTTGCTGCGTAC]
3861 NM_002633.2(PGMl):c.343A>G 5236 PGM1 ['CAAAGCCATTGGTGGGATCATTCTGRCAG (p.Thrl l5Ala) CCAGTCACAACCCAGGGGGCCC]
3862 NM_006218.2(PIK3CA):c.3140A> 5290 PIK3CA ['TTCATGAAACAAATGAATGATGCACDTCA G (p.Hisl047Arg) TGGTGGCTGGACAACAAAAATG]
3863 NM_006218.2(PIK3CA):c.l634A> 5290 PIK3CA ['CGAGATCCTCTCTCTGAAATCACTGVGCAG G (p.Glu545Gly) GAGAAAGATTTTCTATGGAGT']
3864 NM_000478.4(ALPL):c.1250A>G 249 ALPL ['CCCTTCACTGCCATCCTGTATGGCARTGGG (p.Asn417Ser) CCTGGCTACAAGGTGGTGGGC]
3865 NM_018849.2(ABCB4):c.523A>G 5244 ABCB4 ['AGAAATAAACAGGTATAAGATGTGARTTC (p.Thrl75Ala) AGTCCTCAAATAAACCTACTAT',
3867 'TTCTATATGAAAGTGTGACATTAACRATGT
ACCTACTCTGTTAGCCGCGYA',
'TTTCCTGTCGTAGAATAGCATGAAARAACT
TCTGCCTAATTTTCCTGATCT']
3868 NM_001083116.1(PRFl):c.755A> 5551 PRF1 ['CTGGCCCTGGAAGGGCTCACGGACARCGA G (p.Asn252Ser) GGTGGAGGACTGCCTGACTGTC]
3869 NM_198965.1(PTHLH):c.534A>G 5744 PTHLH ['TTCCTTCTTTTTGCAGGAGGCATTGRAATT (p.Terl78Trp) TTCAGCAGAGACCTTCCAAGG]
3870 NM_000316.2(PTHlR):c.668A>G 5745 PTH1R ['CTGCACTGCACGCGCAACTACATCCRCATG (p.His223Arg) CACCTGTTCCTGTCCTTCATG]
3871 NM_003122.4(SPINKl):c.l01A>G 6690 SPINK1 ['TTCCATTTTTAGGCCAAATGTTACARTGAA (p.Asn34Ser) CTTAATGGATGCACCAAGATA]
3872 NM_006194.3(PAX9):c.271A>G 5083 PAX9 ['CGTGGTGAAACACATCCGGACCTACRAGC (p.Lys91Glu) AGAGAGACCCCGGCATCTTCGC]
3873 NM_013953.3 (P AX8) :c .160 A>G -1 ['CGACATCTCTCGCCAGCTCCGCGTCRGCCA (p.Ser54Gly) TGGCTGCGTCAGCAAGATCCT']
3874 NM_005188.3(CBL):c.l l44A>G 867 CBL ['GATGGGCTCCACATTCCAACTATGTRAAAT (p.Lys382Glu) ATGTGCTGAAAATGATAAGGA]
3875 NM_000222.2(KIT):c.2459A>G 3815 KIT ['GGTCTAGCCAGAGACATCAAGAATGRTTC (p.Asp820Gly) TAATTATGTGGTTAAAGGAAAC]
3876 NM_000222.2(KIT):c.2386A>G 3815 KIT ['GTGTATTCACAGAGACTTGGCAGCCRGAA (p.Arg796Gly) ATATCCTCCTTACTCATGGTCG]
3877 NM_000222.2(KIT):c.1924 A>G 3815 KIT ['ACGGGAAGCCCTCATGTCTGAACTCRAAG (p.Lys642Glu) TCCTGAGTTACCTTGGTAATCA']
3878 NM_001005862.2(ERBB2):c.2480 2064 ERBB2 ['CGGAACGTGCTGGTCAAGAGTCCCARCCA A>G (p.Asn827Ser) TGTCAAAATTACAGACTTCGGG]
3879 NM_001127500.1(MET):c.3743A> 4233 MET ['GATTTTGGTCTTGCCAGAGACATGTRTGAT G (p.Tyrl248Cys) AAAGAATACTATAGTGTACAC]
3880 NM_001127500.1(MET):c.3335A> 4233 MET ['ACAGGGCATTTTGGTTGTGTATATCVTGGG G (p.Hisl l l2Arg) ACTTTGTTGGACAATGATGGC]
3881 NM_001127500.1(MET):c.3785A> 4233 MET ['AGTGTACACAACAAAACAGGTGCAARGCT G (p.Lysl262Arg) GCCAGTGAAGTGGATGGCTTTG]
3882 NM_002524.4(NRAS):c.l82A>G 4893 NRAS ['TTGGACATACTGGATACAGCTGGACNAGA (p.Gln61Arg) AGAGTACAGTGCCATGAGAGAC]
3883 NM_004333.4(BRAF):c.l801A>G 673 BRAF ['AGGTGATTTTGGTCTAGCTACAGTGVAATC (p.Lys601Glu) TCGATGGAGTGGGTCCCATCA']
3884 NM_004333.4(BRAF):c.l781A>G 673 BRAF ['GAAGACCTCACAGTAAAAATAGGTGDTTT (p.Asp594Gly) TGGTCTAGCTACAGTGAAATCT']
3885 NM_004333.4(BRAF):c.770A>G 673 BRAF ['GACTTTTGTCGAAAGCTGCTTTTCCRGGGT (p.Gln257Arg) TTCCGCTGTCAAACATGTGGT']
3886 NM_004333.4(BRAF):c.l495A>G 673 BRAF ['TACACCTCAGCAGTTACAAGCCTTCRAAA (p.Lys499Glu) ATGAAGTAGGAGTACTCAGGTG]
3887 NM_004333.4(BRAF):c.l502A>G 673 BRAF ['CAGCAGTTACAAGCCTTCAAAAATGNAGT (p.Glu501Gly) AGGAGTACTCAGGTGAGCTTGT']
3888 NM_004333.4(BRAF):c.l741A>G 673 BRAF ['CATCCACAGAGACCTCAAGAGTAATVGTA (p.Asn581Asp) TCCTTCCTGAAATTTGTCTGCG]
3889 NM_000270.3 (PNP) :c .383 A>G 4860 PNP ['CTGAACCCCAAGTTTGAGGTTGGAGRTATC (p.Aspl28Gly) ATGCTGATCCGTGACCATATC]
3890 NM_000270.3(PNP):c.575A>G 4860 PNP ['CAACGTGAGCTACAGGAAGGCACCTRTGT (p.Tyrl92Cys) GATGGTGGCAGGCCCCAGCTTT']
3891 NM_000258.2(MYL3):c.445A>G 4634 MYL3 ['CGACAAGGAGGGCAATGGCACTGTCRTGG (p.Metl49Val) GTGCTGAGCTTCGCCACGTGCT']
3892 NM_000257.3(MYH7):c.2333A>G 4625 MYH7 ['CTGGGGCTGCTGGAGGAAATGAGGGRCGA (p.Asp778Gly) GAGGCTGAGCCGCATCATCACG]
3893 NM_000257.3(MYH7):c.2717A>G 4625 MYH7 ['CTGGCAGATGCTGAGGAGCGCTGTGRTCA (p.Asp906Gly) GCTGATCAAAAACAAGATTCAG]
3894 NM_002470.3(MYH3):c. l385A>G 4621 MYH3 ['AGACAACACTTCATTGGTGTTTTGGRCATT (p.Asp462Gly) GCAGGCTTTGAAATCTTTGAG]
3895 NM_000530.6(MPZ):c.286A>G 4359 MPZ ['CTACATTGACGAGGTGGGGACCTTCRAAG (p.Lys96Glu) AGCGCATCCAGTGGGTAGGGGA]
3896 NM_000530.6(MPZ):c.242A>G 4359 MPZ ['TCCCCTCATTCCTCATAGATCTTCCRCTAT (p.His81Arg) GCCAAGGGACAACCCTACATT']
3897 NG_012123.1 :g.2493A>G 6347 CCL2 ['GAAAAGAAAGTCTTCTGGAAAGTGAYAGC
TGTCTGCCTCCCACTTCTGCTC]
3898 RMRP:n.71A>G 6023 RMRP ['TGTTCCTCCCCTTTCCGCCTAGGGGRAAGT
CCCCGGACCTCGGGCAGAGAG]
3899 NM_005006.6(NDUFSl):c.755A> 4719 NDUFS1 ['TTTCTCAGAAAGACAGAATCCATTGRTGTA G (p.Asp252Gly) ATGGATGCGGTTGGAAGTAAT']
3900 NM_005912.2(MC4R):c.508A>G 4160 MC4R ['GACAGTTAAGCGGGTTGGGATCATCRTAA (p.Ilel70Val) GTTGTATCTGGGCAGCTTGCAC]
3901 NM_005912.2(MC4R):c.821A>G 4160 MC4R ['ATATTCTACATCTCTTGTCCTCAGARTCCA (p.Asn274Ser) TATTGTGTGTGCTTCATGTCT']
3902 NM_005912.2(MC4R):c.289A>G 4160 MC4R ['GGCTGATATGCTGGTGAGCGTTTCARATGG (p.Asn97Asp) ATCAGAAACCATTGTCATCAC]
3903 NM_005912.2(MC4R):c.l85A>G 4160 MC4R ['CTGGGTGTCATCAGCTTGTTGGAGARTATC (p.Asn62Ser) TTAGTGATTGTGGCAATAGCC]
3904 NM_000900.3(MGP):c.62-2A>G 4256 MGP ['AAGATTCCATGCTTTCATGTGATTCHGAAA
TTAAAAAAAAAAGATTCATTA]
3905 NM_012064.3 (MIP) :c .401 A>G 4284 MIP ['AGCGTGGGCCAGGCAACCACAGTGGRGAT (p.Glul34Gly) CTTCCTGACGCTCCAGTTCGTG]
3906 NM_000233.3(LHCGR):c. l733A> -1 ['AAAATGGCAATCCTCATCTTCACCGRTTTC G (p.Asp578Gly) ACCTGCATGGCACCTATCTCT']
3907 NM_000233.3(LHCGR):c. l691A> -1 ['CCAGAATTAATGGCTACCAATAAAGRTAC G (p.Asp564Gly) AAAGATTGCTAAGAAAATGGCA']
3908 NM_000894.2(LHB):c.221A>G 3972 LHB ['CAGGCGGTCCTGCCGCCCCTGCCTCRGGTG (p.Gln74Arg) GTGTGCACCTACCGTGATGTG]
3909 NM_000238.3(KCNH2):c.l408A> 3757 KCNH2 ['CATGTTCATTGTGGACATCCTCATCRACTT G (p.Asn470Asp) CCGCACCACCTACGTCAATGC]
3910 NM_001754.4(RUNXl):c.328A>G 861 RUNX1 ['GCTGCCTACGCACTGGCGCTGCAACRAGA (p.Lysl lOGlu) CCCTGCCCATCGCTTTCAAGGT']
3911 NM_170707.3(LMNA):c.608A>G 4000 LMNA ['AACAGGCTGCAGACCATGAAGGAGGDACT (p.Glu203Gly) GGACTTCCAGAAGAACATCTAC]
3912 NM_000421.3(KRT10):c. l315A>G -1 ['TGAATACCAACAACTCCTGGATATTDAGA (p.Lys439Glu) TCCGACTGGAGAATGAAATTCA']
3913 NM_000421.3(KRT10):c. l374- -1 ['CCGCCGCGTCCGCCGCCTCCGGAACYAAA 2A>G CGGGGTGAGGTCACATTCGGTT']
3914 NM_000422.2(KRT17):c.274A>G 3872 KRT17 ['TGAGAAGGCCACCATGCAGAACCTCVATG (p.Asn92Asp) ACCGCCTGGCCTCCTACCTGGA']
3915 NM_000422.2(KRT17):c.275A>G 3872 KRT17 ['GAGAAGGCCACCATGCAGAACCTCARTGA (p.Asn92Ser) CCGCCTGGCCTCCTACCTGGAC]
3916 NM_005557.3(KRT16):c.374A>G 3868 KRT16 ['GAGAAGGTGACCATGCAGAACCTCARTGA (p.Asnl25Ser) CCGCCTGGCCTCCTACCTGGAC]
3917 NM_000526.4(KRT14):c.368A>G 3861 KRT14 ['GAGAAGGTGACCATGCAGAACCTCARTGA (p.Asnl23Ser) CCGCCTGGCCTCCTACCTGGAC]
3918 NM_000424.3 (KRT5) :c .1424 A>G 3852 KRT5 ['ATCGCCACTTACCGCAAGCTGCTGGRGGG (p.Glu475Gly) CGAGGAATGCAGGTGAGTAGAC]
3919 NM_000418.3(IL4R):c.223A>G 3566 IL4R ['CTGTGTCTGCAGAGCCCACACGTGTNTCCC (p.Ile75Val) TGAGAACAACGGAGGCGCGGG]
3920 NM_001079817.1(INSR):c.l459A> 3643 INSR ['CCAGGAGAGAAACGACATTGCCCTGRAGA G (p.Lys487Glu) CCAATGGGGACCAGGCATCCTG]
3921 NM_000208.2(INSR):c.707A>G 3643 INSR ['TGCACCGCCGAAGGCCTCTGTTGCCRCAGC (p.His236Arg) GAGTGCCTGGGCAACTGTTCT']
3922 NM_000208.2(INSR):c.1466A>G 3643 INSR ['AGAAACGACATTGCCCTGAAGACCARTGG (p.Asn489Ser) GGACCAGGCATCCTGTAAGTCA']
3923 NM_000208.2(INSR):c. ll24-2A>G 3643 INSR ['CTTCTAGCTCAGCTGCCAGATTGTCYAAGG
AAAGGAGAGAATATCCAGTGG]
3924 NM_000208.2(INSR):c.1372A>G 3643 INSR ['TCAGGGGAAACTCTTCTTCCACTATRACCC (p.Asn458Asp) CAAACTCTGCTTGTCAGAAAT']
3925 M_000454.4(SODl):c.l31A>G 6647 SOD1 ['ATTAAAGGACTGACTGAAGGCCTGCRTGG (p.His44Arg) ATTCCATGTTCATGAGTTTGGA]
3926 M_000454.4(SODl):c.302A>G 6647 SOD1 ['GATGGTGTGGCCGATGTGTCTATTGRAGAT (p.GlulOlGly) TCTGTGATCTCACTCTCAGGA']
3927 M_000454.4(SODl):c.l40A>G 6647 SOD1 ['CTGACTGAAGGCCTGCATGGATTCCRTGTT (p.His47Arg) CATGAGTTTGGAGATAATACA]
3928 M_000454.4(SODl):c.242A>G 6647 SOD1 ['ATCTGATGCTTTTTCATTATTAGGCRTGTT (p.His81Arg) GGAGACTTGGGCAATGTGACT']
3929 NM_000183.2(HADHB):c.788A>G 3032 HADHB ['GCACAGGATGAAGGACTCCTTTCTGRTGTG (p.Asp263Gly) GTACCCTTCAAAGTACCAGGT']
3930 NM_000523.3(HOXD13):c.974A> 3239 HOXD13 ['GAGAGACAAGTGACCATTTGGTTTCRGAA G (p.Gln325Arg) CCGAAGAGTGAAGGACAAGAAA']
3931 NM_000545.6(HNFlA):c.365A>G 6927 HNF1A ['CGTGTGGCGAAGATGGTCAAGTCCTRCCT (p.Tyrl22Cys) GCAGCAGCACAACATCCCACAG]
3932 NM_000519.3(HBD):c.-81A>G 3045 HBD ['CTGGAGCAGGGAGGACAGGACCAGCRTAA
AAGGCAGGGCAGAGTCGACTGT']
3933 NM_000518.4(HBB):c.l99A>G 3043 HBB ['CCCTAAGGTGAAGGCTCATGGCAAGRAAG (p.Lys67Glu) TGCTCGGTGCCTTTAGTGATGG]
3934 NM_000518.4(HBB):c.59A>G 3043 HBB ['GTTACTGCCCTGTGGGGCAAGGTGARCGT (p.Asn20Ser) GGATGAAGTTGGTGGTGAGGCC]
3935 NM_000518.4(HBB):c.-81A>G 3043 HBB ['GGGAGGGCAGGAGCCAGGGCTGGGCVTA
AAAGTCAGGGCAGAGCCATCTAT']
3936 NM_000518.4(HBB):c.-50-29A>G 3043 HBB ['GAGGGCAGGAGCCAGGGCTGGGCATRAAA
GTCAGGGCAGAGCCATCTATTG]
3937 NM_000518.4(HBB):c.-78A>G 3043 HBB ['AGGGCAGGAGCCAGGGCTGGGCATAVAA
GTCAGGGCAGAGCCATCTATTGC]
3938 NM_000518.4(HBB):c.*113A>G 3043 HBB ['TGAGCATCTGGATTCTGCCTAATAARAAAC
ATTTATTTTCATTGCAATGAT']
3939 NM_000518.4(HBB):c.*112A>G 3043 HBB ['TTGAGCATCTGGATTCTGCCTAATADAAAA
CATTTATTTTCATTGCAATGA']
3940 NM_000518.4(HBB):c.*l l lA>G 3043 HBB ['CTTGAGCATCTGGATTCTGCCTAATRAAAA
ACATTTATTTTCATTGCAATG]
3941 NM_000518.4(HBB):c.80A>G 3043 HBB ['GTGAACGTGGATGAAGTTGGTGGTGNGGC (p.Glu27Gly) CCTGGGCAGGTTGGTATCAAGG]
3942 NM_000518.4(HBB):c.247A>G 3043 HBB ['TGGCCTGGCTCACCTGGACAACCTCVAGG (p.Lys83Glu) GCACCTTTGCCACACTGAGTGA]
3943 NM_000517.4(HBA2):c.lA>G 3040 HBA2 ['CCCACAGACTCAGAGAGAACCCACCRTGG (p.MetlVal) TGCTGTCTCCTGCCGACAAGAC]
3944 NM_000517.4(HBA2):c.*92A>G 3040 HBA2 ['CACCGGCCCTTCCTGGTCTTTGAATRAAGT
CTGAGTGGGCAGCAGCCTGTG]
3945 NM_000517.4(HBA2):c.96-2A>G 3040 HBA2 ['CACCCCTCACTCTGCTTCTCCCCGCRGGAT
GTTCCTGTCCTTCCCCACCAC]
3946 NM_006121.3(KRTl):c.l445A>G 3848 KRT1 ['GCCCTGGATCTGGAGATTGCCACCTRCAG (p.Tyr482Cys) GACCCTCCTGGAGGGAGAAGAA]
3947 NM_001077488.3(GNAS):c.lA>G 2778 GNAS ['GCGCCCCGCCGCCGCCGCCGCCGCCRTGG (p.MetlVal) GCTGCCTCGGGAACAGTAAGAC]
3948 NM_000516.5(GNAS):c.680A>G 2778 GNAS ['ACCAGCATGTTTGACGTGGGTGGCCDGCG (p.Gln227Arg) CGATGAACGCCGCAAGTGGATC]
3949 NM_000515.4(GHl):c.413A>G 2688 GH1 ['GGCGCCTCTGACAGCAACGTCTATGRCCTC (p.Aspl38Gly) CTAAAGGACCTAGAGGAAGGC]
3950 NM_000823.3(GHRHR):c.985A>G 2692 GHRHR ['TTGTCTTTCCTGCAGGCGTCTCTCCRAGTC (p.Lys329Glu) GACACTTTTCCTGATCCCACT']
3951 NM_002890.2(RASAl):c.1198A>G 5921 RASA1 ['GACCAATGAAAATATTCAGCGATTTRAAA (p.Lys400Glu) TATGTCCAACGCCAAACAATCA']
3952 NM_002890.2(RASAl):c.1201 A>G 5921 RASA1 ['CAATGAAAATATTCAGCGATTTAAARTAT (p.Ile401Val) GTCCAACGCCAAACAATCAGTT']
3953 NM_000406.2(GNRHR):c.317A>G 2798 GNRHR ['GATGGGATGTGGAACATTACAGTCCRATG (p.Glnl06Arg) GTATGCTGGAGAGTTACTCTGC]
3954 NM_000406.2(GNRHR):c.851A>G 2798 GNRHR ['TTTACTGTCTGCTGGACTCCCTACTRTGTC (p.Tyr284Cys) CTAGGAATTTGGTATTGGTTT']
3955 NM_000407.4(GPlBB):c.338A>G -1 ['GCCGGCCGCCCCGAGCGTGCGCCCTDCCG (p.Tyrl l3Cys) CGACCTGCGTTGCGTGGCGCCC]
3956 NM_021957.3(GYS2):c.l l6A>G 2998 GYS2 ['TTTGAAGTTGCTTGGGAAGTGACCARTAA (p.Asn39Ser) AGGTTTGTACTGCTCCTGAAGG]
3957 NM_001146040.1(GLRAl):c.920A 2741 GLRA1 ['CCTCCACCCCCACTCTAGGTGTCCTVTGTG >G (p.Tyr307Cys) AAAGCCATTGACATTTGGATG]
3958 NM_001146040.1(GLRAl):c.910A 2741 GLRA1 ['CTCCGGCTCTCGAGCATCTCTGCCCRAGGT >G (p.Lys304Glu) AAGTCCCATTGCCCAAGAGCA']
3959 NM_000171.3(GLRAl):c.523A>G 2741 GLRA1 ['CCCCATGGACTTGAAGAATTTCCCCRTGGA (p.Metl75Val) TGTCCAGACATGTATCATGCA']
3960 NM_000162.3(GCK):c.641A>G 2645 GCK ['ACGGTGGCCACGATGATCTCCTGCTRCTAC (p.Tyr214Cys) GAAGACCATCAGTGCGAGGTC]
3961 NM_000145.3(FSHR):c.l345A>G 2492 FSHR ['AGGCTGTGATGCTGCTGGCTTTTTCRCTGT (p.Thr449Ala) CTTTGCCAGTGAGCTGTCAGT']
3962 NM_182925.4(FLT4):c.3104A>G 2324 FLT4 ['CGCCTCCCCGCACCCCAGTGCATCCRCAGA (p.Hisl035Arg) GACCTGGCTGCTCGGAACATT']
3963 NM_023110.2(FGFRl):c.1121 A>G 2260 FGFR1 ['CCGGCAGTGATGACCTCGCCCCTGTRCCTG (p.Tyr374Cys) GAGATCATCATCTATTGCACA]
3964 NM_006894.5(FMO3):c.l82A>G 2328 FM03 ['AGCATTTACAAATCAGTCTTTTCCARCTCT (p.Asn61Ser) TCCAAAGAGATGATGTGTTTC]
3965 NM_001002294.2(FMO3):c.923A> 2328 FM03 ['AAGCCTAACGTGAAGGAATTCACAGRGAC G (p.Glu308Gly) CTCGGCCATTTTTGAGGATGGG]
3966 NM_212482.1(FNl):c.2918A>G 2335 FN1 ['ACCGGGCTGTCCCCTGGGGTCACCTRTTAC (p.Tyr973Cys) TTCAAAGTCTTTGCAGTGAGC]
3967 NM_000142.4(FGFR3):c. l948A>G 2261 FGFR3 ['CGTGCACAACCTCGACTACTACAAGVAGA (p.Lys650Glu) CAACCAACGTGAGCCCGGCCCT']
3968 NM_000142.4(FGFR3):c.1118A>G 2261 FGFR3 ['GAGGCTGACGAGGCGGGCAGTGTGTRTGC (p.Tyr373Cys) AGGCATCCTCAGCTACGGGGTG]
3969 NM_000142.4(FGFR3):c.1612A>G 2261 FGFR3 ['GTGCAGGCGCCCAGCAGGTTGATGAYGTT (p.Ile538Val) TTTGTGTTTCCCGATCATCTTC']
3970 NM_000142.4(FGFR3):c. l619A>G 2261 FGFR3 ['GCCCTGCGTGCAGGCGCCCAGCAGGBTGA (p.Asn540Ser) TGATGTTTTTGTGTTTCCCGAT']
3971 NM_000142.4(FGFR3):c.833A>G 2261 FGFR3 ['GACGTGGAGTTCCACTGCAAGGTGTRCAG (p.Tyr278Cys) TGACGCACAGCCCCACATCCAG]
3972 NM_000138.4(FBNl):c.6431A>G 2200 FBN1 ['GTCTGTAAACATGGACAGTGCATCARTAC (p.Asn2144Ser) AGATGGTTCCTATCGCTGCGAG]
3973 NM_000138.4(FBNl):c.3128A>G 2200 FBN1 ['ATACCCAGCCTCTGCACCCACGGCARGTG (p.Lysl043Arg) CAGAAACACCATTGGCAGCTTT']
3974 NM_000138.4(FBNl):c.2261A>G 2200 FBN1 ['TATAAATGTATATGCAATTCAGGATRTGAA (p.Tyr754Cys) GTGGATTCAACTGGGAAAAAC]
3975 NM_000146.3(FTL):c.-160A>G 2512 FTL ['CCGCGGGTCTGTCTCTTGCTTCAACRGTGT
TTGGACGGAACAGATCCGGGG]
3976 NM_000043.4(FAS):c.695A>G 355 FAS ['TTTTCAGATGTTGACTTGAGTAAATRTATC (p.Tyr232Cys) ACCACTATTGCTGGAGTCATG]
3977 NM_000043.4(FAS):c.763A>G 355 FAS ['AGGCTTTGTTCGAAAGAATGGTGTCRATG (p.Asn255Asp) AAGCCAAAATAGATGAGATCAA']
3978 NM_000043.4(FAS):c.353A>G 355 FAS ['TTTCTAGGCTTAGAAGTGGAAATAARCTGC (p.Asnl l8Ser) ACCCGGACCCAGAATACCAAG]
3979 NM_000129.3(F13Al):c.851A>G 2162 F13A1 ['CTCGTTGGATCCTGGGACAATATCTRTGCC (p.Tyr284Cys) TATGGCGTCCCCCCATCGGCC]
3980 NM_000121.3 (EPOR) :c .1460 A>G 2057 EPOR ['GGCTTATCCGATGGCCCCTACTCCARCCCT (p.Asn487Ser) TATGAGAACAGCCTTATCCCA]
3981 NM_207034.2(EDN3):c.335A>G 1908 EDN3 ['GACAAGGAGTGTGTCTACTATTGCCRCCTG (p.Hisll2Arg) GACATCATTTGGATCAACACT']
3982 NM_001257988.1(TYMP):c.665A> 1890 TYMP ['CAGAGCGGACAGCCCCTCCACGAGTYTCT G (p.Lys222Arg) TACTGAGAATGGAGGCTTTGGG]
3983 NM_003286.2(TOPl):c.l598A>G -1 ['GTAGAGTTTGACTTCCTCGGGAAGGRCTCC (p.Asp533Gly) ATCAGATACTATAACAAGGTC]
3984 NM_001943.3(DSG2):c.797A>G 1829 DSG2 ['GTTCAGATTCGTATTTTGGATGTCARTGAC (p.Asn266Ser) AATATACCTGTAGTAGAAAAT']
3985 NM_001943.3(DSG2):c. l880- 1829 DSG2 ['TCTGTGTTCAATTTTGTGTCTGTACRGTGG 2A>G TACCACTTTTACTGCTGATGT']
3986 NM_024422.4(DSC2):c.631-2A>G 1824 DSC2 ['TTTCTCCTTATTTTACTCTCTTCACRGATAA
TTGCCTTTGCAACAACTCCA']
3987 NG_012088.1 :g.2209A>G 3586 IL10 ['CCAGGATGGTCTCGATCTCCTGACCYTATG
ATCCGCCCGCCTTGGCCTCCC]
3988 NM_000498.3(CYPl lB2):c.l492A -1 ['GAGGCCTGGCACGTCCCCCCTCCTCRCTTT >G (p.Thr498Ala) CAGAGCGATTAACTAGTCTTG]
3989 NM_000941.2(POR):c.l733A>G 5447 POR ['CGCCGCTCGGATGAGGACTACCTGTRCCG (p.Tyr578Cys) GGAGGAGCTGGCGCAGTTCCAC]
3990 NM_000941.2(POR):c.l5A>G 5447 POR ['CTAACAGTTTCATGATCAACATGGGRGACT (p.Gly5=) CCCACGTGGACACCAGCTCCA]
3991 NM_001885.2(CRYAB):c.358A>G 1410 CRYAB ['TGGTTTCATCTCCAGGGAGTTCCACRGGAA (p.Argl20Gly) ATACCGGATCCCAGCTGATGT']
3992 NM_021954.3(GJA3):c.l88A>G 2700 GJA3 ['AACACCCAGCAGCCGGGCTGCGAGARCGT (p.Asn63Ser) CTGCTACGACAGGGCCTTCCCC]
3993 M_004004.5(GJB2):c.218A>G 2706 GJB2 ['TACGATCACTACTTCCCCATCTCCCRCATC (p.His73Arg) CGGCTATGGGCCCTGCAGCTG]
3994 NM_001735.2(C5):c.l l l5A>G 727 C5 ['CGTCTACCCCCTCACCCAATCTACCYTGAT (p.Lys372Arg) GGGATATGGAATCCCAGGCTT']
3995 NM_001848.2(COL6Al):c.362A> 1291 COL6A1 ['CTCAAAAGCAGCGTGGACGCGGTCARGTA G (p.Lysl21Arg) CTTTGGGAAGGGCACCTACACC]
3996 NM_000093.4(COL5Al):c.655- 1289 COL5A1 ['TTTTCATGAGCGTCTCTTCTTTTCCRGGGTG 2A>G ACATCCAGCAGCTGCTCTTT']
3997 NM_000089.3(COLlA2):c.226- 1278 COL1A2 ['TATAATTTTTTTTTTTTACTTCTCTRGAACT 2A>G TTGCTGCTCAGTATGATGGA']
3998 NM_000089.3(COLlA2):c.70+717 1278 COL1A2 ['GAGTGGGTACATTCTGAAAAGTAATRTAA A>G GTGTCTCAATTCACTTTCTAGT']
3999 M_001844.4(COL2Al):c.4172A> 1280 COL2A1 ['ACGGAAGGCTCCCAGAACATCACCTRCCA G (p.Tyrl391Cys) CTGCAAGAACAGCATTGCCTAT']
4000 M_001844.4(COL2Al):c.2974A> 1280 COL2A1 ['CGGTCTGCCTGGGCAACGTGGTGAGRGAG G (p.Arg992Gly) GATTCCCTGGCTTGCCTGGCCC]
4001 NM_000493.3(COL10Al):c. l790A -1 ['TTTACTTGTCAGATACCAGGAATATRCTAT >G (p.Tyr597Cys) TTTTCATACCACGTGCATGTG]
4002 NM_004385.4(VCAN):c.4004- 1462 VCAN ['GTATTGTGAAAACTCTGTTTTTTTCDGGTC 2A>G GAATGAGTGATTTGAGTGTAA']
4003 NM_020549.4(CHAT):c.1444 A>G 1103 CHAT ['CGTCAGCGAGCTCCCCGCCCCCCGGVGGC (p.Arg482Gly) TGCGGTGGAAATGCTCCCCGGA']
4004 NM_000078.2(CETP):c.l376A>G 1071 CETP ['AACAGCAAAGGCGTGAGCCTCTTCGRCAT (p.Asp459Gly) CATCAACCCTGAGATTATCACT']
4005 NM_000083.2(CLCNl):c.l655A>G 1180 CLCN1 ['GTGATTTGCTTCGAATTAACGGGTCDGATT (p.Gln552Arg) GCTCACATCCTGCCCATGATG]
4006 NM_000083.2(CLCNl):c.382A>G 1180 CLCN1 ['CTTTCTGGTGCTTCTGGGACTGCTGRTGGC (p.Metl28Val) TCTGGTCAGCTGGAGCATGGA']
4007 M_199440.1(HSPDl):c.86A>G 3329 HSPD1 ['CATCTCACTCGGGCTTATGCCAAAGRTGTA (p.Asp29Gly) AAATTTGGTGCAGATGCCCGA']
4008 NM_001904.3(CTNNBl):c.95A>G 1499 CTNNB1 ['CACTGGCAGCAACAGTCTTACCTGGNCTCT (p.Asp32Gly) GGAATCCATTCTGGTGCCACT']
4009 NM_001904.3(CTNNBl):c.l21A> 1499 CTNNB1 ['CTCTGGAATCCATTCTGGTGCCACTNCCAC G (p.Thr41Ala) AGCTCCTTCTCTGAGTGGTAA']
4010 NM_007294.3(BRCAl):c.211A>G 672 BRCA1 ['TTTATGTAAGAATGATATAACCAAARGGT (p.Arg71Gly) ATATAATTTGGTAATGATGCTA']
4011 NM_001202.3(BMP4):c.278A>G 652 BMP4 ['GATCTTTACCGGCTTCAGTCTGGGGRGGAG (p.Glu93Gly) GAGGAAGAGCAGATCCACAGC]
4012 NM_000342.3(SLC4Al):c.l66A>G 6521 SLC4A1 ['CACCACATCACACCCGGGTACCCACRAGG (p.Lys56Glu) TGAGGACCCCAGCCTCCTCCGT']
4013 NM_000342.3(SLC4Al):c.2509A> 6521 SLC4A1 ['GAAGACCTGGCGCATGCACTTATTCRCGG G (p.Thr837Ala) GCATCCAGATCATCTGCCTGGC]
4014 NM_001681.3(ATP2A2):c.2300A> 488 ATP2A2 ['TTCATCCGCTACCTCATCTCGTCCARCGTC G (p.Asn767Ser) GGGGAAGTTGTCTGGTAGGTC]
4015 NM_000486.5(AQP2):c.203A>G 359 AQP2 ['GGCCACATAAGCGGGGCCCACATCAVCCC (p.Asn68Ser) TGCCGTGACTGTGGCCTGCCTG]
4016 NM_000041.3(APOE):c.237-2A>G 348 APOE ['GACACCCTCCCGCCCTCTCGGCCGCRGGGC
GCTGATGGACGAGACCATGAA]
4017 NM_000041.3 (APOE) :c.490 A>G 348 APOE ['CGCCTCCCACCTGCGCAAGCTGCGTVAGC (p.Lysl64Glu) GGCTCCTCCGCGATGCCGATGA']
4018 NM_000041.3(APOE):c.l78A>G 348 APOE ['TTGGGATTACCTGCGCTGGGTGCAGRCACT (p.Thr60Ala) GTCTGAGCAGGTGCAGGAGGA']
4019 NM_000040.1(APOC3):c.280A>G 345 APOC3 ['GGATTTGGACCCTGAGGTCAGACCARCTTC (p.Thr94Ala) AGCCGTGGCTGCCTGAGACCT']
4020 NM_000040.1(APOC3):c.232A>G 345 APOC3 ['CCTGAAAGACTACTGGAGCACCGTTRAGG (p.Lys78Glu) ACAAGTTCTCTGAGTTCTGGGA']
4021 NM_001042425.1(TFAP2A):c.751 7020 TFAP2A ['GTCGCTGCTGGGCGGAGTGCTCCGGVGGT A>G (p.Arg251Gly) GAGGCCCGGCACGGCCCCGCCC]
4022 NM_000488.3(SERPINCl):c.655A 462 SERPINC1 ['TGCAGAGCAATCCAGAGCGGCCATCRACA >G (p.Asn219Asp) AATGGGTGTCCAATAAGACCGA']
4023 NM_001085.4(SERPINA3):c.l240 12 SERPINA3 ['TACAGACACCCAGAACATCTTCTTCRTGAG A>G (p.Met414Val) CAAAGTCACCAATCCCAAGCA]
4024 NM_001148.4(ANK2):c.4373A>G 287 ANK2 ['TGCATGGCATCTTGGGGCGGAAAGGRATC (p.Glul458Gly) AGAGTCAGATCAAGAACAGGAG]
4025 NM_001145.4(ANG):c. l21A>G -1 ['CTTCCTGACCCAGCACTATGATGCCRAACC (p.Lys41Glu) ACAGGGCCGGGATGACAGATA']
4026 NM_001145.4(ANG):c.208A>G -1 ['ACCCTGCAAAGACATCAACACATTTRTTCA (p.Ile70Val) TGGCAACAAGCGCAGCATCAA]
4027 M_000484.3(APP):c.2146A>G 351 APP ['GGGCGGTGTTGTCATAGCGACAGTGRTCG (p.Ile716Val) TCATCACCTTGGTGATGCTGAA']
4028 M_000484.3(APP):c.2078A>G 351 APP ['TTTGTTTTCAAGGTGTTCTTTGCAGRAGAT (p.Glu693Gly) GTGGGTTCAAACAAAGGTGCA]
4029 M_000484.3(APP):c.2140A>G 351 APP ['CATGGTGGGCGGTGTTGTCATAGCGRCAG (p.Thr714Ala) TGATCGTCATCACCTTGGTGAT']
4030 NM_000021.3(PSENl):c.488A>G 5663 PSEN1 ['AAATGCTTTCTTTTCTAGGTCATCCRTGCC (p.Hisl63Arg) TGGCTTATTATATCATCTCTA']
4031 NM_000021.3(PSENl):c.415A>G 5663 PSEN1 ['GCACTCAATTCTGAATGCTGCCATCRTGAT (p.Metl39Val) CAGTGTCATTGTTGTCATGAC]
4032 NM_000021.3(PSENl):c.436A>G 5663 PSEN1 ['CATCATGATCAGTGTCATTGTTGTCNTGAC (p.Metl46Val) TATCCTCCTGGTGGTTCTGTA']
4033 NM_000021.3(PSENl):c.839A>G 5663 PSEN1 ['GTTGAAACAGCTCAGGAGAGAAATGVAAC
GCTTTTTCCAGCTCTCATTTAC]
(p.Glu280Gly)
4034 NM_000021.3(PSENl):c.998A>G 5663 PSEN1 ['CAAGACACTGTTGCAGAGAATGATGRTGG (p.Asp333Gly) CGGGTTCAGTGAGGAATGGGAA]
4035 NM_000034.3 (ALDO A) : c.386 A>G 226 ALDOA ['CCCCTTCCTCTTCTCTTAGGGTTGGRTGGG (p.Aspl29Gly) CTGTCTGAGCGCTGTGCCCAG]
4036 NM_000477.5(ALB):c.714-2A>G 213 ALB ['CATTTTGATTGGCGATTTTCTTTTTDGGGC
AGTAGCTCGCCTGAGCCAGAG]
4037 NM_001151.3(SLC25A4):c.311A> 291 SLC25A4 ['AAGCAGCTCTTCTTAGGGGGTGTGGRTCG G (p.Aspl04Gly) GCATAAGCAGTTCTGGCGCTAC]
4038 NM_013411.4(AK2):c.lA>G 204 AK2 ['GTGGCAGTGAGAGACTTCGGCGGACRTGG (p.MetlVal) CTCCCAGCGTGCCAGCGGCAGA']
4039 NM_013411.4(AK2):c.494A>G 204 AK2 ['AACCCTCCAAAAGAGCCCATGAAAGRTGA (p.Aspl65Gly) CGTATGTAAACTCAGGACAAAA]
4040 NM_000476.2(AKl):c.491A>G 203 AK1 ['GCCACAGAACCCGTCATCGCCTTCTRTGAG (p.Tyrl64Cys) AAACGTGGCATTGTGCGCAAG]
4041 NM_001100.3(ACTAl):c.350A>G 58 ACTA1 ['GAGGCCCCCCTCAATCCCAAGGCCARCCG (p.Asnl l7Ser) CGAGAAGATGACCCAGATCATG]
4042 NM_001103.3(ACTN2):c.26A>G 88 ACTN2 ['ATGAACCAGATAGAGCCCGGCGTGCRGTA (p.Gln9Arg) CAACTACGTGTACGACGAGGAT']
4043 NM_005159.4(ACTCl):c. l088A>G -1 ['CAGCAAATGTGGATTAGCAAGCAAGRGTA (p.Glu363Gly) CGATGAGGCAGGCCCATCCATT']
4044 NM_005159.4(ACTCl):c.373A>G -1 ['CAACCGGGAGAAGATGACTCAGATCRTGT (p.Metl25Val) TTGAGACCTTCAATGTCCCTGC]
4045 NM_018109.3(MTPAP):c.l432A> 55149 MTPAP ['TGATTCTTCTCCTCTGTACATTCAGRATCC G (p.Asn478Asp) ATTTGAAACTTCTCTCAACAT']
4046 NM_016955.3(SEPSECS):c.l001A 51091 SEPSECS ['TTATTGTCACTTGGATCAAATGGCTRTAAG >G (p.Tyr334Cys) AAGCTACTAAAAGAAAGAAAG]
4047 NM_014053.3(FLVCRl):c.361A> 28982 FLVCR1 ['GATCTTCAGCCTGTACTCGCTGGTCRACGC G (p.Asnl21Asp) CTTTCAGTGGATCCAGTACAG]
4048 NM_000021.3(PSENl):c.697A>G 5663 PSEN1 ['ATATCTCATTATGATTAGTGCCCTCDTGGC (p.Met233Val) CCTGGTGTTTATCAAGTACCT']
4049 NM_000207.2(INS):c.323A>G -1 ['TGCTCCCTCTACCAGCTGGAGAACTRCTGC (p.Tyrl08Cys) AACTAGACGCAGCCCGCAGGC]
4050 NM_000334.4(SCN4A):c.4078A>G 6329 SCN4A ['GAAGCAGGCCTTCGACATCACCATCRTGA (p.Metl360Val) TCCTCATCTGCCTCAACATGGT']
4051 NM_000334.4(SCN4A):c.4108A>G 6329 SCN4A ['CCTCATCTGCCTCAACATGGTCACCRTGAT (p.Metl370Val) GGTGGAGACAGACAACCAGAG]
4052 NM_000518.4(HBB):c.316-2A>G 3043 HBB ['TTCATACCTCTTATCTTCCTCCCACVGCTCC
TGGGCAACGTGCTGGTCTGT']
4053 NM_000525.3(KCNJl l):c. l55A>G 3767 KCNJ11 ['GTGGCCCACAAGAACATCCGGGAGCRGGG (p.Gln52Arg) CCGCTTCCTGCAGGACGTGTTC]
4054 NM_000525.3(KCNJl l):c.544A>G 3767 KCNJ11 ['AGCCCACCGCAGGGCTGAGACCCTCRTCTT (p.Ilel82Val) CAGCAAGCATGCGGTGATCGC]
4055 NM_000525.3(KCNJl l):c.886A>G 3767 KCNJ11 ['GGAAGGCGTGGTGGAAACCACGGGCVTCA (p.Ile296Val) CCACCCAGGCCCGCACCTCCTA]
4056 NM_000525.3(KCNJl l):c.989A>G 3767 KCNJ11 ['GAGGACGGACGTTACTCTGTGGACTRCTCC (p.Tyr330Cys) AAGTTTGGCAACACCGTCAAA]
4057 NM_000528.3(MAN2Bl):c.l831- 4125 MAN2B1 ['CCCATCTGTGGACCCTTTTCTGCCCRGCAC 2A>G ATCCGGGCAACGTTTGATCCT']
4058 NM_000639.2(FASLG):c.466A>G 356 FASLG ['ATTTATTTCAGGCAAGTCCAACTCARGGTC (p.Argl56Gly) CATGCCTCTGGAATGGGAAGA']
4059 NM_000920.3(PC):c.l705A>G 5091 PC ['CCCGGGGCTGCTGCTGATGGACACGRCCTT (p.Thr569Ala) CAGGGACGCCCACCAGTCACT']
4060 NM_001017420.2(ESCO2):c.l l32- 15757 ESC02 ['AATGGGTTTCTTTTTTTACCCCCCARTTATA 7A>G 0 GGACGCTGGTCAGAAACATT']
4061 NM_001017420.2(ESCO2):c.l674- 15757 ESC02 ['ATTAAATCATCTTTTCTTCTCTTTTRGGAAT 2A>G 0 TGCTTCATGTTTGGCTGTTT']
4062 NM_001129765.1(NSDHL):c.l046 50814 NSDHL ['GAGAGAGCCAAAAAGGCCATGGGCTVCCA A>G (p.Tyr349Cys) GCCACTAGTGACCATGGATGAT']
4063 NM_001701.3(BAAT):c.967A>G 570 BAAT ['AGAGGCCCAGGGGCAATTCCTCTTCRTTGT (p.Ile323Val) AGGAGAAGGTGATAAGACTAT']
4064 NM_002977.3(SCN9A):c.406A>G 6335 SCN9A ['ATTCAGCATGCTCATCATGTGCACTRTTCT (p.Ilel36Val) GACAAACTGCATATTTATGAC]
4065 M_004004.5(GJB2):c.487A>G 2706 GJB2 ['CTATGTCATGTACGACGGCTTCTCCRTGCA (p.Metl63Val) GCGGCTGGTGAAGTGCAACGC]
4066 NM_004519.3 (KCNQ3 ) :c .1403 A> 3786 KCNQ3 ['GAACCAAAGCCTGTTGGCTTAAACARTAA G (p.Asn468Ser) AGAGCGTTTCCGCACGGCCTTC]
4067 NM_004519.3 (KCNQ3 ) :c .2462 A> 3786 KCNQ3 ['AGAGATGATTATGTGTTCGGCCCCARTGG G (p.Asn821Ser) GGGGTCGAGCTGGATGAGGGAG]
4068 NM_004519.3 (KCNQ3 ) :c .914 A>G 3786 KCNQ3 ['AAAGAGGAGTTTGAGACCTATGCAGRTGC (p.Asp305Gly) CCTGTGGTGGGGCCTGGTGAGT']
4069 NM_004525.2(LRP2):c.770-2A>G 4036 LRP2 ['TGTAACTCTCTCTTTTTCCCCCCACRGAAA
GCGGTCCTCATGATGTTCATA']
4070 NM_007375.3(TARDBP):c.l055A 23435 TARDBP ['CAGAACCAGTCAGGCCCATCGGGTARTAA >G (p.Asn352Ser) CCAAAACCAAGGCAACATGCAG]
4071 NM_007375.3 (TARDBP) :c .800 A> 23435 TARDBP ['AATGCCGAACCTAAGCACAATAGCARTAG G (p.Asn267Ser) ACAGTTAGAAAGAAGTGGAAGA]
4072 NM_012434.4(SLC17A5):c.406A> 26503 SLC17A5 ['ATATGTTGCCAGCAAAATAGGGGGGDAAA G (p.Lysl36Glu) TGCTGCTAGGATTTGGGATCCT']
4073 NM_012463.3(ATP6V0A2):c.732- 23545 ATP6V0A ['AGACTGTGTTCAACTCTTGTCTTCCRGCTA 2A>G 2 CCACTGCCACGTGTACCCCTA']
4074 M_014043.3(CHMP2B):c.85A>G 25978 CHMP2B ['GTTACGAGGTACACAGAGGGCTATARTCA (p.Ile29Val) GAGATCGAGCAGCTTTAGAGAA']
4075 NM_018136.4(ASPM):c.2761- 25926 ASPM ['AGCAAAATTATAATATTGGAATATARTATC 25A>G 6 TGGAACTTATTTCTTTATAGG]
4076 NM_022081.5(HPS4):c.461A>G 89781 HPS4 ['ATTCTGAAAAACACCAGTGATCTGCRTAA
GATTTTCAATTCCCTCTGGAAC]
(p.Hisl54Arg)
4077 NM_024649.4(BBSl):c.l340- -1 ['GTCAGCCTCTGGGACCCTTCTCCACRGCCA 2A>G TGCACCGGGCCTTCCAGACAG]
4078 NM_032520.4(GNPTG):c.610- 84572 GNPTG ['TGCTGCCCCTGCATCCTCCACCTTCRGGGC 2A>G CATGAGAAGTTGCTGAGGACA]
4079 NM_172107.2(KCNQ2):c.lA>G 3785 KCNQ2 ['CCCGGGGCGCCTCCCGCCAGGCACCRTGG (p.MetlVal) TGCAGAAGTCGCGCAACGGCGG]
4080 NM_172107.2(KCNQ2):c.356A>G 3785 KCNQ2 ['GTGTTTTCCACCATCAAGGAGTATGRGAA (p.Glul l9Gly) GAGCTCGGAGGGGGCCCTCTAC]
4081 NM_172107.2(KCNQ2):c.622A>G 3785 KCNQ2 ['CCTGCGCTTCCTGCAGATTCTGCGGRTGAT (p.Met208Val) CCGCATGGACCGGCGGGGAGG]
4082 NM_172107.2(KCNQ2):c.635A>G 3785 KCNQ2 ['CAGATTCTGCGGATGATCCGCATGGRCCG (p.Asp212Gly) GCGGGGAGGCACCTGGAAGCTG]
4083 NM_172107.2(KCNQ2):c.773A>G 3785 KCNQ2 ['GTGTACTTGGCAGAGAAGGGGGAGARCGA (p.Asn258Ser) CCACTTTGACACCTACGCGGAT']
4084 NM_172107.2(KCNQ2):c.l764- 3785 KCNQ2 ['ATGCTTTGGGGTCTCTGTTCCCGGTRGAGT 2A>G GGACCAGATCGTGGGGCGGGG]
4085 NM_000495.4(COL4A5):c. lA>G 1287 COL4A5 ['AAGGAGCTGCGGGAGCCGGAGAAGARTG (p.MetlVal) AAACTGCGTGGAGTCAGCCTGGC]
4086 NM_000495.4(COL4A5):c.466- 1287 COL4A5 ['AGAACTTCCATTGATGGCTTCTTTTRGGGT 2A>G GAACCAGGTAGTATAATTATG]
4087 NM_000495.4(COL4A5):c.547- 1287 COL4A5 ['TCATTTTCTTTACTCACTTTATAACRGGGC 2A>G CTACCTGGTCCCACTGGTATA']
4088 NM_000495.4(COL4A5):c.610- 1287 COL4A5 ['ATTTTCTCTTTTGTCTTCTCTTCTTRGGGCC 2A>G CTCCTGGTCCACCAGGACTT']
4089 NM_000495.4(COL4A5):c.892- 1287 COL4A5 ['GCCCTATCATTTCTTTGTATCCTATRGGGT 2A>G AAACCAGGCAAAGATGGAGAA']
4090 NM_000495.4(COL4A5):c. l340- 1287 COL4A5 ['TTGCTATCCTTTCTTTATCTTACTCRGGTGA 2A>G TGAGATATGTGAACCAGGCC]
4091 NM_000495.4(COL4A5):c.2042- 1287 COL4A5 ['TTCTTTGAACGTTTTCCTTTCAATARCTGCT 18A>G GTTTCTCCATAGGTGACCCT']
4092 NM_000495.4(COL4A5):c.2147- 1287 COL4A5 ['GTTAAAAAATGACTTATCATTTTACRGGCT 2A>G TTCCTGGAATTCCAGGACCTC]
4093 NM_000495.4(COL4A5):c.2394A> 1287 COL4A5 ['GCTTAGATGGGCTCCCTGGACCAAARGGT G (p.Lys798=) ATGGAGGCTGTCACTGCATCTC]
4094 NM_000495.4(COL4A5):c.2510- 1287 COL4A5 ['CAGATACATCTTTTAAAACTGCTTCRGTAC 33A>G TTATTAATATTGATATTGTAT']
4095 NM_000495.4(COL4A5):c.2692A> 1287 COL4A5 ['ATTCTTCAAAGGTACCAAAGGTGAARTGG G (p.Met898Val) GTATGATGGGACCTCCAGGCCC]
4096 NM_000495.4(COL4A5):c.2746A> 1287 COL4A5 ['AGGACCTTTGGGAATTCCTGGCAGGRGTG G (p.Ser916Gly) GTGTACCTGGTCTTAAAGGTAA']
4097 NM_000495.4(COL4A5):c.3107- 1287 COL4A5 ['ATATTATATATCACATATTTTCAACRGGGC 2A>G CTCAGGGTGTGGAAGGGCCTC]
4098 NM_000495.4(COL4A5):c.3455- 1287 COL4A5 ['AACTGGGTGTAACCTGCTGTACTCARTTTT 9A>G TTAGGTGGTGGAGGTCATCCT']
4099 NM_000495.4(COL4A5):c.3605- 1287 COL4A5 ['TCTTCTAATTATACTTTACTTTCATRGGCCA 2A>G AAAGGGTGATGGAGGATTAC]
4100 NM_000495.4(COL4A5):c.3925- 1287 COL4A5 ['GTAACATTAATGATTTTATTTATTCRGGGT 2A>G AATCCTGGCCGGCCGGGTCTC]
4101 NM_000495.4(COL4A5):c.3998- 1287 COL4A5 ['ATAAAACTGTATGTACCTTCTGTGCDGGCA 2A>G TGAAAGGACCCAGTGGAGTAC]
4102 NM_000495.4(COL4A5):c.4790A> 1287 COL4A5 ['GGATGGGATTCTCTGTGGATTGGTTRTTCC G (p.Tyrl597Cys) TTCATGATGGTATTTTACACT']
4103 NM_000495.4(COL4A5):c.4977- 1287 COL4A5 ['CTGATTGTCTTATTTCTTATTTCCCRGTAAA 2A>G CCTCAGTCAGAAACGCTGAA']
4104 NM_005359.5(SMAD4):c.425- 4089 SMAD4 ['TTTCATTTGTTTTCCCCTTTAAACARTTAAG 6A>G ATCTCTCAGGATTAACACTG']
4105 NM_005359.5(SMAD4):c.989A>G 4089 SMAD4 ['TATTGGTGTTCCATTGCTTACTTTGRAATG (p.Glu330Gly) GATGTTCAGGTAGGAGAGACA']
4106 NM_020630.4(RET):c. l996A>G 5979 RET ['CCACTGCTACCACAAGTTTGCCCACVAGCC (p.Lys666Glu) ACCCATCTCCTCAGCTGAGAT']
4107 NM_020630.4(RET):c.2342A>G 5979 RET ['CTGTCAGAGTTCAACGTCCTGAAGCRGGTC (p.Gln781Arg) AACCACCCACATGTCATCAAA']
4108 NM_000060.3(BTD):c.l94A>G 686 BTD ['TATTATGTGGCTGCCGTGTATGAGCRTCCA (p.His65Arg) TCCATCCTGAGTCTGAACCCT']
4109 NM_000060.3(BTD):c.278A>G 686 BTD ['CTCATGAACCAGAACCTTGACATCTRTGAA (p.Tyr93Cys) CAGCAAGTGATGACTGCAGCC]
4110 NM_000060.3(BTD):c.356A>G 686 BTD ['CCAGAAGATGGCATTCATGGATTCARCTTT (p.Asnl l9Ser) ACAAGAACATCCATTTATCCA']
4111 NM_000060.3(BTD):c.364A>G 686 BTD ['TGGCATTCATGGATTCAACTTTACARGAAC (p.Argl22Gly) ATCCATTTATCCATTTTTGGA]
4112 NM_000060.3(BTD):c.515A>G 686 BTD ['AGGGGAGATATGTTCTTGGTGGCCARTCTT (p.Asnl72Ser) GGGACAAAGGAGCCTTGTCAT']
4113 NM_000060.3(BTD):c.583A>G 686 BTD ['CCCAAAAGATGGGAGATACCAGTTCRACA (p.Asnl95Asp) CAAATGTCGTGTTCAGCAATAA']
4114 NM_000060.3(BTD):c.584A>G 686 BTD ['CCAAAAGATGGGAGATACCAGTTCARCAC (p.Asnl95Ser) AAATGTCGTGTTCAGCAATAAT']
4115 NM_000060.3(BTD):c.641A>G 686 BTD ['CTTGTTGACCGCTACCGTAAACACARCCTC (p.Asn214Ser) TACTTTGAGGCAGCATTCGAT']
4116 NM_000060.3(BTD):c.880A>G 686 BTD ['GAAAGCTTTTGCTGTTGCCTTTGGCRTCAA (p.Ile294Val) CGTTCTGGCAGCTAATGTCCA]
4117 NM_000060.3(BTD):c.l205A>G 686 BTD ['TTTCACTCTGAGATGATGTATGACARTTTC (p.Asn402Ser) ACCCTGGTCCCTGTCTGGGGA']
4118 NM_000060.3(BTD):c.l313A>G 686 BTD ['AGGCCCACCTTATCCAAAGAGCTGTRTGCC (p.Tyr438Cys) CTGGGGGTCTTTGATGGGCTT']
4119 NM_000060.3(BTD):c.l619A>G 686 BTD ['ACGGCGGCTCTCTATGGGCGCTTGTRTGAG (p.Tyr540Cys) AGGGACTAGGAAAAGTGTGTG]
4120 NM_000155.3 (GALT) : c.1 A>G 2592 GALT ['TTCCAGCGGATCCCCCGGTGGCCTCRTGTC (p.MetlVal) GCGCAGTGGAACCGATCCTCA']
4121 NM_000155.3(GALT):c.67A>G 2592 GALT ['GTCAGAGGCGGACGCCGCAGCAGCARCCT (p.Thr23Ala) TCCGGGCAAACGGTAACTGCAC]
4122 NM_000155.3(GALT):c.253-2A>G 2592 GALT ['GTGCTTCTAGCCTATCCTTGTCGGTRGGTG AATCCCCAGTACGATAGCACC]
4123 NM_000155.3(GALT):c.290A>G 2592 GALT ['TACGATAGCACCTTCCTGTTTGACARCGAC (p.Asn97Ser) TTCCCAGCTCTGCAGCCTGAT']
4124 NM_000155.3(GALT):c.308A>G 2592 GALT ['TTTGACAACGACTTCCCAGCTCTGCRGCCT (p.Glnl03Arg) GATGCCCCCAGTCCAGGTAAC]
4125 NM_000155.3(GALT):c.379A>G 2592 GALT ['ATCTTTTCTCCCGTCACCACCCAGTRAGGT (p.Lysl27Glu) CATGTGCTTCCACCCCTGGTC]
4126 NM_000155.3(GALT):c.424A>G 2592 GALT ['CTGGTCGGATGTAACGCTGCCACTCRTGTC (p.Metl42Val) GGTCCCTGAGATCCGGGCTGT']
4127 NM_000155.3(GALT):c.565-2A>G 2592 GALT ['TTCTTCTCTGCTTTTGCCCCTTGACRGGTAT
GGGCCAGCAGTTTCCTGCCA']
4128 NM_000155.3(GALT):c.574A>G 2592 GALT ['TTTTGCCCCTTGACAGGTATGGGCCRGCAG (p.Serl92Gly) TTTCCTGCCAGATATTGCCCA']
4129 NM_000155.3(GALT):c.626A>G 2592 GALT ['CGTGAGGAGCGATCTCAGCAGGCCTVTAA (p.Tyr209Cys) GAGTCAGCATGGAGAGCCCCTG]
4130 NM_000155.3(GALT):c.752A>G 2592 GALT ['GTCCCCTTCTGGGCAACATGGCCCTVCCAG (p.Tyr251Cys) ACACTGCTGCTGCCCGTCGGC]
4131 NM_000155.3 (GALT) : c.812 A>G 2592 GALT ['CGGCTACCTGAGCTGACCCCTGCTGRGCGT (p.Glu271Gly) GATGGTCAGTCTCCCAAGTAG]
4132 NM_000155.3(GALT):c.821-2A>G 2592 GALT ['AGGCTGAGAGTCAGGCTCTGATTCCRGAT
CTAGCCTCCATCATGAAGAAGC]
4133 NM_000155.3(GALT):c.854A>G 2592 GALT ['TCCATCATGAAGAAGCTCTTGACCARGTAT (p.Lys285Arg) GACAACCTCTTTGAGACGTCC]
4134 NM_000155.3(GALT):c.968A>G 2592 GALT ['CATTGGCAGCTGCACGCTCATTACTRCCCT (p.Tyr323Cys) CCGCTCCTGCGCTCTGCCACT']
4135 NM_000155.3(GALT):c. l001A>G 2592 GALT ['CTCCTGCGCTCTGCCACTGTCCGGARATTC (p.Lys334Arg) ATGGTTGGCTACGAAATGCTT']
4136 NM_000155.3(GALT):c. l048A>G 2592 GALT ['GCTTGCTCAGGCTCAGAGGGACCTCRCCCC (p.Thr350Ala) TGAGCAGGTCAGGACTCAGAA']
4137 NM_000155.3(GALT):c. l l32A>G 2592 GALT ['GCAGAAGGACAGGGAGACAGCAACCRTCG (p.Ile378Val) CCTGACCACGCCGACCACAGGG]
4138 NM_000553.4(WRN):c.403A>G 7486 WRN ['GTTGCTTGAAAATAAAGCAGTTAAARAGG (p.Lysl35Glu) CAGGTGTAGGAATTGAAGGAGA']
4139 NM_000433.3(NCF2):c.481A>G 4688 NCF2 ['CTTACCCAGACACACTCCATCGCCTYGTCG (p.Lysl61Glu) ATTTTGGAATGTCTGGGCTCA]
4140 NM_198056.2(SCN5A):c. l673A>G 6331 SCN5A ['ACAGCGGGGGAGAGCGAGAGCCACCRCAC (p.His558Arg) ATCACTGCTGGTGCCCTGGCCC]
4141 NM_000074.2(CD40LG):c.386A> 959 CD40LG ['CAAATTGCGGCACATGTCATAAGTGRGGC G (p.Glul29Gly) CAGCAGTAAAACAACATCTGGT']
4142 NM_002863.4(PYGL):c. l016A>G 5836 PYGL ['CCCACCCAGGTGGCCATCCAGCTGARTGA (p.Asn339Ser) CACTCACCCTGCACTCGCGATC]
4143 NM_000142.4(FGFR3):c.1454A>G 2261 FGFR3 ['CCCCTTGGGGAGGGCTGCTTCGGCCRGGT (p.Gln485Arg) GGTCATGGCGGAGGCCATCGGC]
4144 NM_001101.3(ACTB):c.34A>G 60 ACTB ['TGATATCGCCGCGCTCGTCGTCGACVACG (p.Asnl2Asp) GCTCCGGCATGTGCAAGGCCGG]
4145 NM_001202.3(BMP4):c.362A>G 652 BMP4 ['TGGGGGAAGAGACTGACCTTCGTGGYGGA (p.Hisl21Arg) AGCTCCTCACGGTGTTGGCCCG]
4146 NM_000094.3(COL7Al):c.425A> 1294 COL7A1 ['CAGCTGGCCCGACCTGGTGTCCCCARGGT G (p.Lysl42Arg) GATCCCTACCCCTACCATGCCT']
NM_001130823.1(DNMTl):c. l532 1786 DNMT1 []
A>G (p.Tyr511Cys)
4147 NM_000138.4(FBNl):c.5096A>G 2200 FBN1 ['AGAAGAAGTTTGTGCTACAGAAACTRCTA (p.Tyrl699Cys) TGCTGACAACCAGACCTGTGAT']
4148 NM_000138.4(FBNl):c.5087A>G 2200 FBN1 ['CTAGATATGAGAAGAAGTTTGTGCTRCAG (p.Tyrl696Cys) AAACTACTATGCTGACAACCAG]
4149 NM_000138.4(FBNl):c.5099A>G 2200 FBN1 ['AGAAGTTTGTGCTACAGAAACTACTRTGCT (p.Tyrl700Cys) GACAACCAGACCTGTGATGGA]
4150 NM_001244710.1(GFPTl):c.43A> 2673 GFPT1 ['TTACTTAAACTACCATGTTCCTCGARCGAG G (p.Thrl5Ala) ACGAGAAATCCTGGAGACCCT']
4151 NM_002292.3(LAMB2):c.440A>G 3913 LAMB2 ['CTGGAGGCTGAGTTTCATTTCACACRCCTC (p.Hisl47Arg) ATTATGACCTTCAAGGTGCCT']
4152 NM_005211.3(CSFlR):c. l754- 1436 CSF1R ['GACTTAAGGGACCTGTGTGCGTGGCRGGT 2A>G AAGACCCTCGGAGCTGGAGCCT']
4153 NM_005247.2(FGF3):c.146A>G 2248 FGF3 ['GGGGCGCCCCGGCGCCGCAAGCTCTRCTG (p.Tyr49Cys) CGCCACGAAGTACCACCTCCAG]
4154 NM_005247.2(FGF3):c.317A>G 2248 FGF3 ['GCCATGAACAAGAGGGGACGACTCTRTGC (p.Tyrl06Cys) TTCGGTGAGTCCAGGCTGTCAC]
4155 NM_005188.3(CBL):c.l l l2A>G 867 CBL ['TAATCAAAGGAACAATATGAATTATRCTG (p.Tyr371Cys) TGAGATGGGCTCCACATTCCAA']
4156 NM_000313.3(PROSl):c.701A>G 5627 PROS1 ['TGTGAATGCCCCGAAGGCTACAGATRTAA (p.Tyr234Cys) TCTCAAATCAAAGTCTTGTGAA']
4157 NM_000329.2(RPE65):c.1292A>G 6121 RPE65 ['TACCAGAAGTATTGTGGGAAACCTTRCAC (p.Tyr431Cys) ATATGCGTATGGACTTGGCTTG]
4158 NM_001040142.1(SCN2A):c.4419 6326 SCN2A ['TGAATCTTTTCATTGGTGTCATCATRGATA A>G (p.Ilel473Met) ACTTCAACCAACAGAAAAAGA']
4159 NM_001040142.1(SCN2A):c.754A 6326 SCN2A ['GTCAGTGAAGAAGCTTTCTGATGTCRTGAT >G (p.Met252Val) CTTGACTGTGTTCTGTCTAAG]
4160 NM_004612.3(TGFBRl):c. l34A> 7046 TGFBR1 ['TTCTGCCACCTCTGTACAAAAGACARTTTT G (p.Asn45Ser) ACTTGTGTGACAGATGGGCTC]
4161 NM_003688.3(CASK):c.2168A>G 8573 CASK ['TTTGATCAATTAGATCTTGTCACATRTGAA (p.Tyr723Cys) GAAGTAGTAAAACTGCCAGCA]
4162 NM_015884.3(MBTPS2):c.l523A> 51360 MBTPS2 ['GGTGGCAGTGTACTTTTGGCTGCCARTGTG G (p.Asn508Ser) ACCCTGGGACTCTGGATGGTT']
4163 m. l0450A>G 4573 MT-TR ['ACGAATGATTTCGACTCATTAAATTRTGAT
AATCATATTTACCAAATGCCC]
4164 m.5816A>G 4511 MT-TC ['GAATTTGCAATTCAATATGAAAATCRCCTC
GGAGCTGGTAAAAAGAGGCCT']
4165 m.608A>G 4558 MT-TF ['GTAGCTTACCTCCTCAAAGCAATACRCTGA AAATGTTTAGACGGGCTCACA]
4166 NM_172337.2(OTX2):c.674A>G 5015 OTX2 ['CTGATTGAGATGGCTGGTGACTGCAYTGG (p.Asn225Ser) TACCCATGGGACTGAGTGTGGC]
4167 NM_001376.4(DYNClHl):c.917A 1778 DYNC1H1 ['CTCCTGACTCTGGATATCTTGAAACRTGGC >G (p.His306Arg) AAGCGCTTCCATGCCACCGTC]
4168 NM_001376.4(DYNClHl):c.2011 1778 DYNC1H1 ['GAAGCGGGTGGAAGATGTCCTTGGCRAGG A>G (p.Lys671Glu) GCTGGGAGAATCACGTGGAGGG]
4169 NM_001376.4(DYNClHl):c.2909 1778 DYNC1H1 ['CTAAGAATAACCAATCAGGTAATCTRCTTG A>G (p.Tyr970Cys) AATCCACCAATTGAAGAGTGC]
4170 NM_004380.2(CREBBP):c.2728A> 1387 CREBBP ['ACTGTAGGGGTGCTCTGGGTTTGGGHAGC G (p.Thr910Ala) ACTGGGCACTGAGCCAGGAGTC]
4171 NM_000459.4(TEK):c.2690A>G 7010 TEK ['ATGCTCTCTTCCTTCCCTCCAGGCTVCTTGT (p.Tyr897Cys) ACCTGGCCATTGAGTACGCG]
4172 NM_001354.5(AKRlC2):c.235A> 1646 AKR1C2 ['AGATGGCAGTGTGAAGAGAGAAGACRTAT G (p.Ile79Val) TCTACACTTCAAAGGTACTGTG]
4173 NM_007315.3(STATl):c.604A>G 6772 STAT1 ['ACAAGAACAGCTGTTACTCAAGAAGRTGT (p.Met202Val) ATTTAATGCTTGACAATAAGAG]
4174 NM_007315.3(STATl):c.494A>G 6772 STAT1 ['GAGCATGAAATCAAGAGCCTGGAAGRTTT (p.Aspl65Gly) ACAAGATGAATATGACTTCAAA']
4175 NM_007315.3(STATl):c.862A>G 6772 STAT1 ['GTTGGAGGAATTGGAACAGAAATACRCCT (p.Thr288Ala) ACGAACATGACCCTATCACAAA]
4176 NM_002052.4(GATA4):c.928A>G 2626 GATA4 ['CCTCCAGGTCCCCAGGCCTCTTGCARTGCG (p.Met310Val) GAAAGAGGGGATCCAAACCAG]
4177 NM_014191.3(SCN8A):c.5302A>G 6334 SCN8A ['CATGTACATTGCCATCATCCTGGAGRACTT (p.Asnl768Asp) CAGTGTAGCCACAGAGGAAAG]
4178 NM_000209.3(PDXl):c.533A>G 3651 PDX1 ['TACATCTCACGGCCGCGCCGGGTGGRGCT (p.Glul78Gly) GGCTGTCATGTTGAACTTGACC]
4179 NM_000890.3(KCNJ5):c.472A>G 3762 KCNJ5 ['CATTGGGTATGGCTTCCGAGTCATCRCAGA (p.Thrl58Ala) GAAGTGTCCAGAGGGGATTAT']
4180 NM_000256.3(MYBPC3):c.2234A 4607 MYBPC3 ['ACGGTCGAGGGGGCAGAGAAGGAAGRTG >G (p.Asp745Gly) AGGGCGTCTACACGGTCACAGTG]
4181 NM_005359.5(SMAD4):c.l498A> 4089 SMAD4 ['TGTTGATGACCTTCGTCGCTTATGCRTACT G (p.Ile500Val) CAGGATGAGTTTTGTGAAAGG]
4182 NM_005359.5(SMAD4):c.l500A> 4089 SMAD4 ['TTGATGACCTTCGTCGCTTATGCATRCTCA G (p.Ile500Met) GGATGAGTTTTGTGAAAGGCT']
4183 NM_001184.3 ( ATR) : c.6431 A>G 545 ATR ['TATCAATTTTTGACTGCTTTTTCACRATTGA (p.Gln2144Arg) TCTCTCGAATTTGTCATTCT']
4184 NM_153427.2(PITX2):c.262A>G 5308 PITX2 ['CCCCAACCGCCCCCAGGTTTGGTTCRAGAA (p.Lys88Glu) TCGTCGGGCCAAATGGAGAAA']
4185 NM_005257.5(GATA6):c. l354A> 2627 GATA6 ['CTGTGCCAACTGTCACACCACAACTRCCAC G (p.Thr452Ala) CTTATGGCGCAGAAACGCCGA]
4186 NM_005257.5(GATA6):c. l396A> 2627 GATA6 ['AAACGCCGAGGGTGAACCCGTGTGCVATG G (p.Asn466Asp) CTTGTGGACTCTACATGAAACT']
4187 M_000414.3(HSD17B4):c.650A> 3295 HSD17B4 ['CTTGTGGAAGCCCTGAAGCCAGAGTRTGT G (p.Tyr217Cys) GGCACCTCTTGTCCTTTGGCTT']
4188 NM_004153.3(ORCl):c.380A>G 4998 ORC1 ['GCCTGTGACAGCAACATTAATGCGGRGAC (p.Glul27Gly) CATCATTGGCCTTGTTCGGGTA']
4189 NM_002552.4(ORC4):c.521A>G 5000 ORC4 ['CATCATAAAAACCAAACACTTCTCTRTAAT (p.Tyrl74Cys) CTTTTTGACATTTCTCAGTCT']
4190 NM_004656.3(BAPl):c.2057- 8314 BAP1 ['GCTCCACTAGGTTGGCCAGCATGCCYGCG 2A>G AAGAGGTAGAGACCCTTGAGCA']
4191 NM_004656.3(BAPl):c.438-2A>G 8314 BAP1 ['TCAGGGAGGTGGCGTGGCTCGGGCCYGGG
GAAAAACAGAGTCAGGGCCCAA']
NM_003590.4(CUL3):c.l238A>G 8452 CUL3 []
(p.Asp413Gly)
4192 NM_004813.2(PEX16):c.992A>G 9409 PEX16 ['TACTTGCCCACCTGGCAGAAAATCTRCTTC (p.Tyr331Cys) TACAGTTGGGGCTGACAGACC]
4193 M_004544.3 (NDUFA10) :c .1 A>G 4705 NDUFA10 ['TTGATCCTGAGCTGACCGGGTAGCCRTGGC (p.MetlVal) CTTGCGGCTCCTGAAGCTGGC]
4194 M_004544.3(NDUFA10):c.425A 4705 NDUFA10 ['TGGTTGTACAGCAGTCGCCTGCTGCRGTAC >G (p.Glnl42Arg) TCAGATGCCTTGGAGCACTTG]
4195 NM_006796.2(AFG3L2):c.l996A> 10939 AFG3L2 ['TATTTTTCAGATTGTTCAGTTTGGCDTGAA G (p.Met666Val) TGAAAAGGTTGGGCAAATCTC]
4196 NM_006796.2(AFG3L2):c.l847A> 10939 AFG3L2 ['TATTTACCAAAAGAACAATACCTCTRTACC G (p.Tyr616Cys) AAAGAGCAGCTCTTGGATAGG]
4197 NM_001199397.1(NEKl):c.869- 4750 NEK1 ['CAAAATTCTTTGTATCTTTTCATCTRGCTA 2A>G AAAGACCAGCTTCAGGACAAA']
4198 NM_006587.3 (CORIN) :c .949 A>G 10699 CORIN ['GAATCTGTTTCACTGTCACACAGGCRAGTG (p.Lys317Glu) CCTTAATTACAGCCTTGTGTG]
4199 NM 006587.3 (CORIN) :c .1414 A>G 10699 CORIN ['CATGAATTTGCCCTACAACAGTACARGTTA (p.Ser472Gly) TCCAAATTATTTTGGCCACAG]
4200 NM_015560.2(OPAl):c.l294A>G 4976 OPA1 ['AGCTTACATGCAGAATCCTAATGCCRTCAT (p.Ile432Val) ACTGTGTATTCAAGGTAAATC]
4201 NM_021625.4(TRPV4):c.l805A>G 59341 TRPV4 ['CGTGGGCTGAAGCTGACGGGGACCTRTAG (p.Tyr602Cys) CATCATGATCCAGAAGGTACGG]
4202 NM_021625.4(TRPV4):c.590A>G 59341 TRPV4 ['TCTACGGGGAAGACCTGCCTGCCCARGGC (p.Lysl97Arg) CTTGCTGAACCTGAGCAATGGC]
4203 NM_021625.4(TRPV4) :c.826 A>G 59341 TRPV4 ['GGCCCGTGGGCGCTTCTTCCAGCCCRAGG (p.Lys276Glu) ATGAGGGGGGCTACTTCTACTT']
4204 NM_024022.2(TMPRSS3):c.308A> 64699 TMPRSS3 ['GTCTCGGATTGCAAAGACGGGGAGGRCGA G (p.Aspl03Gly) GTACCGCTGTGGTAAGGTCATG]
4205 NM_016599.4(MYOZ2):c.738A>G 51778 MYOZ2 ['GATGGATATCTGAGAATATTCCTATRGTGA (p.Ile246Met) TAACAACCGAACCTACAGATG]
NM_017415.2(KLHL3):c. l670A>G 26249 KLHL3 []
(p.Tyr557Cys)
4206 NM_019109.4(ALGl):c. l l29A>G 56052 ALG1 ['GTCCTCCAGTGGCCTGGACCTGCCCRTGAA (p.Met377Val) GGTGGTGGACATGTTCGGGTG]
4207 NM_031885.3(BBS2):c.472-2A>G 583 BBS2 ['GCTAATGGTTTGGGGTTTTATTTTCRGGTT ACTGGAGACAATGTTAATTCC]
4208 NM_006886.3(ATP5E):c.35A>G -1 ['TACCTTCTCTCATTTTCTCCCAGCTRCATCC (p.Tyrl2Cys) GATACTCCCAGATCTGTGCA']
4209 NM_022445.3(TPKl):c.656A>G 27010 TPK1 ['CACAACACCAGACCCGTCGTAGGTAYTGG (p.Asn219Ser) AAGTACTGACCAATGTTCCAAA']
4210 NM_000017.3(ACADS):c. l031A> 35 ACADS ['CTCTGACTGTACCCCCATGTTTAGGRGGCA G (p.Glu344Gly) GCCATGGCCAAGCTGGCCGCC]
4211 NM_016013.3(NDUFAFl):c.758A 51103 NDUFAF1 ['GGGGGACCCTACTGGCAGGAGGTCARGGT >G (p.Lys253Arg) AACAGCATAAATCTTCATTGTT']
4212 NM_032580.3 (HES7) :c .172 A>G 84667 HES7 ['GAACCCGAAGCTGGAGAAAGCGGAGRTAT (p.Ile58Val) TGGAGTTCGCCGTGGGCTACTT']
4213 NM_024887.3 (DHDD S) : c.124 A>G 79947 DHDDS ['GGACGGGAACCGTCGCTATGCCAAGRAGT (p.Lys42Glu) GCCAGGTGGAGCGGCAGGAAGG]
4214 NM_024700.3(SNIPl):c.l097A>G 79753 SNIP1 ['CTCAAATTTGGATTCAGTAGCAGAGRATA (p.Glu366Gly) CGTCTTGCTCCATGAGTCGTCG]
4215 NM_206933.2(USH2A):c.7595- 7399 USH2A ['AATTGAACACCTCTCCTTTCCCAAGRTAAG 2144A>G AGATCATCTTTAAGAAAAGGC]
4216 NM_016952.4(CDON):c.2368A>G 50937 CDON ['GTTTTTGTTTTCCCTCAAAGGTTCARCATA (p.Thr790Ala) CAAATTTAGGGTCATTGCCAT']
4217 NM_020435.3(GJC2):c.-167A>G 57165 GJC2 ['AGACCCTGAGGCCGAGGGGGGAACARTGG
GGCCCTTGAGGGCCCCTCCTCC]
4218 NM_024549.5(TCTNl):c.221- 79600 TCTN1 ['TGGATCCTACCCCTCTTTTTTCTGCRGTTGC 2A>G TGTTCTCTGTGTCTGTGACT']
4219 NM_031427.3(DNALl):c.449A>G 83544 DNALl ['CTCGAAGACCTGGTGTTTGTAGGCARTCCC (p.Asnl50Ser) TTGGAAGAGAAACATTCTGCT']
4220 M_145046.4(CALR3):c.245A>G 12597 CALR3 ['AGTTTTCCCTTTATTGCTGAACGGTYTGAA (p.Lys82Arg) 2 GCGTGCAGAGATGGCATAGAA']
4221 NM_020320.3 (RARS2) :c .1024 A>G 57038 RARS2 ['AATGGACAAGTATAATTTTGATACARTGAT (p.Met342Val) ATATGTGGTAAGTAATCAGAA']
4222 NM_020320.3(RARS2):c.35A>G 57038 RARS2 ['CTCTGCGCGCTCCGGGATCCATACCYGGC (p.Glnl2Arg) AAGCAATAGCGCGGCGAAAGCC]
4223 NM_001017361.2(KHDC3L):c.lA 15428 KHDC3L ['TGTCTCCTGCAGGACCGGCCGCAGCRTGG >G (p.MetlVal) 8 ACGCTCCCAGGCGGTTTCCGAC]
4224 NM_024753.4(TTC21B):c.2758- 79809 TTC21B ['TAATCGTGCCAGTTCCAACATAATCYGTAG 2A>G AGCAAAGGGCTAGATTCATCA]
4225 NM_001145901.1(SARS2):c.l l75 54938 SARS2 ['TTCGTCCTTGACCGCAGGGTCCTGGRTATG A>G (p.Asp392Gly) CCCACCCAAGAACTGGGCCTC]
4226 NM_000552.3(VWF):c.3437A>G 7450 VWF ['AACGGGTATGAGTGTGAGTGGCGCTRTAA (p.Tyrl l46Cys) CAGCTGTGCACCTGCCTGTCAA']
4227 NM_014985.3(CEP152):c.2000A> 22995 CEP152 ['ACCTTACCTATCCACAGCTTCTTGTYTGTC G (p.Lys667Arg) ATGGTCAAAATCTTGTACCAT']
4228 NM_024809.4(TCTN2):c. l506- 79867 TCTN2 ['GCTGAGAAATGTCTTACTCTCTTGCRGGGA 2A>G GAATGCTGTTGAAAGACTTGA']
4229 NM_198994.2(TGM6):c.980A>G 34364 TGM6 ['CGGACCCTGGAGGACCTGACAGAAGRCAG (p.Asp327Gly) 1 CATGTGGTGGGTCCTGCCCCCA']
4230 NM_052873.2(IFT43):c.lA>G 11275 IFT43 ['GAAGTGACGTCAGGCGGCCGCGGAGRTGG (p.MetlVal) 2 AGGATTTGCTCGACTTGGACGA']
4231 NM_201269.2(ZNF644):c.2014A> 84146 ZNF644 ['AACATTTGGATCAACCTCACAATCARGTA G (p.Ser672Gly) GTTTTTCAAAAATTCATAAGCG]
4232 NM_201269.2(ZNF644):c.l759A> 84146 ZNF644 ['GTAGTAAAAGGACACATCTTACATAYGTA G (p.Ile587Val) GGTAGCTGATTTTTTGGATGAT']
4233 NM_018699.3(PRDM5):c.320A>G 11107 PRDM5 ['TTTCAGGAAGGAGAAAACATTTTCTRTTTG (p.Tyrl07Cys) GCAGTTGAAGATATAGAAACA']
4234 NM_001198799.2(ASCCl):c.953A 51008 ASCC1 ['CTATAGTTCTCTGGGGGACTTACCAYTGGG >G (p.Asn318Ser) GTCTTTCCTGAATAGTGTATT']
4235 NM_007055.3(POLR3A):c.2554A> 11128 POLR3A ['ACCAACTGAGTTTTTCTTCCACACARTGGC G (p.Met852Val) CGGCCGGGAAGGTCTAGTCGA']
4236 NM_001256047.1(C19orfl2):c.391 83636 C19orfl2 ['TACTGGATCTCGGCCCGCAGCTCCTYGGTG A>G (p.Lysl31Glu) ACGTAGTTCACCAGCATGGCC]
4237 M_016464.4(TMEM138):c.287A 51524 TMEM138 ['TACTTTGCCCTCAGCATCTCCCTTCRTGTCT >G (p.His96Arg) GGGTCATGGTAAGAGTGGCA']
4238 M_016464.4(TMEM138):c.389A 51524 TMEM138 ['TTCCTCCCCACAGCAGCAGTGTTGTRCTGC >G (p.Tyrl30Cys) TACTTCTATAAACGGACAGCC]
4239 NM_177965.3(C8orf37):c.545A>G 15765 C8orf37 ['AAAGGAACACGGGCATATGCCTGCCRGTG (p.Glnl82Arg) 7 TAGCTGGAGAACTATTGAAGAA']
4240 NM_001004334.3(GPR179):c.659A 44043 GPR179 ['CCCAAGTGGCCGCAGGCAGATGGATRTGT >G (p.Tyr220Cys) 5 GGGGGACACGCAGCAGGTGAGG]
4241 NM_004963.3(GUCY2C):c.l l60A 2984 GUCY2C ['AGCAGTGAGACATACTTTCTTGGTGYCCAC >G (p.Asp387Gly) AGAGGTATACAGAAGCACCAT']
4242 NM_024110.4(CARD14):c.425A> 79092 CARD14 ['AGCCTGCAGGAGGAGCTGAACCAGGRAAA G (p.Glul42Gly) GGGGCAGAAGGAGGTGCTGCTG]
4243 NM_018105.2(THAPl):c.70A>G 55145 THAP1 ['CAAGGACAAGCCCGTTTCTTTCCACRAGTG (p.Lys24Glu) AGGACCCTGCGCGCCTCGCGG]
4244 NM_000933.3 (PLCB4) :c.1868 A>G 5332 PLCB4 ['AACAAACGGCAAATGAGTCGCATTTRCCC (p.Tyr623Cys) CAAGGGAGGCCGAGTCGATTCC]
4245 NM_001172646.1(PLCB4):c.986A 5332 PLCB4 ['CACTACTTCATCAGTTCTTCCCATAVCACT >G (p.Asn329Ser) TATCTCACTGGCAGACAGTTC]
4246 NM_005850.4(SF3B4):c.lA>G 10262 SF3B4 ['GGGAGACGGCGGGATCTCTTTCGCCRTGG (p.MetlVal) CTGCCGGGCCGATCTCCGAGCG]
4247 M_014714.3(IFT140):c.932A>G 9742 IFT140 ['TGGGACATAGAACGAGGAGAGAATTRTAT (p.Tyr311Cys) ACTGAGTCCAGATGAGAAGTTT']
4248 NM_000258.2(MYL3):c.517A>G 4634 MYL3 ['GACAGAAGACGAAGTGGAGAAGTTGRTGG (p.Metl73Val) CTGGGCAAGAGGACTCCAATGG]
4249 NM_032578.3(MYPN):c.59A>G 84665 MYPN ['ATATCTCAGCTTCTAAGAGAGAGCTRTTTA (p.Tyr20Cys) GCTGAAACCAGACATCGGGGA']
4250 NM_001018005.1(TPMl):c.742A> 7168 TPM1 ['TGAGTTTGCGGAGAGGTCAGTAACTRAAT G (p.Lys248Glu) TGGAGAAAAGCATTGATGACTT']
4251 NM_005006.6(NDUFSl):c.l783A> 4719 NDUFS1 ['AGCTGCTTACACAGAGAAGTCTGCTRCAT G (p.Thr595Ala) ATGTCAACACTGAGGGTAGAGC']
4252 NM_033360.3(KRAS):c.439A>G 3845 KRAS ['AATTCCTTTTATTGAAACATCAGCARAGAC (p.Lysl47Glu) AAGACAGGTAAGTAACACTGA]
4253 NM_014236.3(GNPAT):c. l556A> 8443 GNPAT ['GAAGATGAACTCATCTGCAAAAACAHCAC G (p.Asp519Gly) GTAGGAAGCGAAAGCAACTGTA']
4254 NM_017565.3(FAM20A):c.813- -1 ['GGCACCCGTCGGAAGTCCAGAATCCYGCA 2A>G AGAGAGGAAGCTCTGTTCCATC]
4255 NM_017565.3(FAM20A):c.590- 54757 FAM20A ['AGGCTTTCTCATCTTGACTGTAATCYGCAA 2A>G AGGAGGAGAAGGGCAATGAGA']
4256 NM_017636.3(TRPM4):c.2741A> 54795 TRPM4 ['CTGCTTCACATCTTCACGGTCAACARACAG G (p.Lys914Arg) CTGGGGCCCAAGATCGTCATC]
4257 NM_000076.2(CDKNlC):c.832A> 1028 CDKN1C ['GCTGTCGCCCGCAGATTTCTTCGCCRAGCG G (p.Lys278Glu) CAAGAGATCAGCGCCTGAGAA]
4258 NM_022912.2(REEPl):c.304- 65055 REEP1 ['AGTGTGCCTCTGTTTTTCCTTTGACRGGAA 2A>G ATCGATGATTGTCTGGTCCAA']
4259 NM_000053.3(ATP7B):c.2305A>G 540 ATP7B ['TGTGACATTCTTCGACACGCCCCCCRTGCT (p.Met769Val) CTTTGTGTTCATTGCCCTGGG]
4260 NM_000053.3(ATP7B):c.3620A>G 540 ATP7B ['GTCCACACCCATGCTCTGCAGCGTGYGCA (p.Hisl207Arg) CAGCCAGGGCAGCCTCCTGCTT']
4261 NM_000492.3(CFTR):c.3140- 1080 CFTR ['ACATTTTGTGTTTATGTTATTTGCARTGTTT 26A>G TCTATGGAAATATTTCACAG]
4262 NM_000570.4(FCGR3B):c. l94A> 2215 FCGR3B ['GCTCGAGGCCTGGCTTGAGATGAGGYTCT G (p.Asn65Ser) CATTGTGAAACCACTGTGTGGA]
4263 NM_198253.2(TERT):c.2705A>G 7015 TERT ['TATGGCTGCGTGGTGAACTTGCGGARGAC (p.Lys902Arg) AGTGGTGAACTTCCCTGTAGAA']
4264 NM_005022.3(PFNl):c.350A>G 5216 PFN1 ['GTTGATCAAACCACCGTGGACACCTYCTTT (p.Glul l7Gly) GCCCATCAGCAGGACTAGCGC]
4265 NM_005349.3(RBPJ):c. l88A>G 3516 RBPJ ['GTTGCACAGAAGTCATATGGAAATGRAAA (p.Glu63Gly) AAGGTAAGATTATTTTTCTGGT']
4266 NM_005349.3(RBPJ):c.505A>G 3516 RBPJ ['GATAAAAGTCATCTCCAAACCTTCCRAAA (p.Lysl69Glu) AGAAGCAGTCATTGAAAAATGC]
4267 NM_022787.3(NMNATl):c.817A> 64802 NMNAT1 ['GGTCATCCTGGCCCCTTTGCAGAGARACAC G (p.Asn273Asp) TGCAGAAGCTAAGACATAGGA]
4268 NM_020921.3(NIN):c.3665A>G 51199 NIN ['CACAGAAACATCAAAAAGTAGGTCCYGTT (p.Glnl222Arg) TCTTTTCAGAAGCTCGATCACA']
4269 NM_020921.3 (NIN) :c .5126 A>G 51199 NIN ['AAAATCTCTAGTGTTCTAAGCTACARCGAA (p.Asnl709Ser) AAACTGCTGAAAGAAAAGGAA']
4270 NM_005340.6(HINTl):c.152A>G 3094 HINT1 ['GACATTTCCCCTCAAGCACCAACACRTTTT (p.His51Arg) CTGGTGATACCCAAGAAACAT']
4271 NM_005050.3(ABCD4):c.956A>G 5826 ABCD4 ['GAGCTGGGTGAAGCAGCTGATGAGGYAGA (p.Tyr319Cys) TGCACACAAAGGCATTCTGGAC]
4272 NM_000155.3(GALT):c.950A>G 2592 GALT ['GCTGGGGCCAACTGGAACCATTGGCRGCT (p.Gln317Arg) GCACGCTCATTACTACCCTCCG]
4273 NM_007294.3(BRCAl):c.213- 672 BRCA1 ['ACTTGCTGAGTGTGTTTCTCAAACARTTTA 12A>G ATTTCAGGAGCCTACAAGAAA]
4274 NM_007294.3(BRCAl):c.4096+3A 672 BRCA1 ['GCAAAGCATGGATTCAAACTTAGGTRTTG >G GAACCAGGTTTTTGTGTTTGCC]
4275 NM_007294.3(BRCAl):c.5194- 672 BRCA1 ['TGATGGGTTGTGTTTGGTTTCTTTCVGCAT 2A>G GATTTTGAAGTCAGAGGAGAT']
4276 NM_007294.3(BRCAl):c.5453A> 672 BRCA1 ['GTGCAGCCAGATGCCTGGACAGAGGRCAA G (p.Aspl818Gly) TGGCTTCCATGGTAAGGTGCCT']
4277 NM_000059.3(BRCA2):c.l799A> 675 BRCA2 ['TATGCTATACATGATGAAACATCTTRTAAA G (p.Tyr600Cys) GGAAAAAAAATACCGAAAGAC]
4278 NM_000059.3(BRCA2):c.476- 675 BRCA2 ['ACAATTTTCCCCTTTTTTTACCCCCRGTGGT 2A>G ATGTGGGAGTTTGTTTCATA']
4279 NM_000059.3 (BRC A2) :c .8168 A> 675 BRCA2 ['AAAGTGGCCATTATTGAACTTACAGNTGG G (p.Asp2723Gly) GTGGTATGCTGTTAAGGCCCAG]
4280 NM_000059.3(BRCA2):c.8633- 675 BRCA2 ['GAATTAATAATCCTTTTGTTTTCTTDGAAA 2A>G ACACAACAAAACCATATTTAC]
4281 NM_000060.3(BTD):c.629A>G 686 BTD ['AATAATGGAACCCTTGTTGACCGCTRCCGT (p.Tyr210Cys) AAACACAACCTCTACTTTGAG]
4282 NM_000060.3(BTD):c.968A>G 686 BTD ['ACCCCTCTGGAGTCCTTTTGGTACCRTGAC (p.His323Arg) ATGGAAAATCCCAAAAGTCAC]
4283 NM_000155.3(GALT):c.857A>G 2592 GALT ['ATCATGAAGAAGCTCTTGACCAAGTRTGA (p.Tyr286Cys) CAACCTCTTTGAGACGTCCTTT']
4284 NM_000060.3(BTD):c.l28A>G 686 BTD ['TGTTACGTGGTTGCCCTGGGAGCCCRCACC (p.His43Arg) GGGGAGGAGAGCGTGGCTGAC]
4285 NM_002437.4(MPV17):c.262A>G 4358 MPV17 ['CACCACCAAAGTGGATGCACTGAAGRAGA (p.Lys88Glu) TGTTGTTGGATCAGGTGAGCAG]
4286 NM_002769.4(PRSSl):c.65A>G -1 ['GTTGCTGCCCCCTTTGATGATGATGRCAAG (p.Asp22Gly) ATCGTTGGGGGCTACAACTGT']
4287 NM_005211.3(CSFlR):c.2320- 1436 CSF1R ['GACTAACCCTGCAGTGCTTTCCCTCRGTGC 2A>G ATCCACCGGGACGTGGCAGCG]
4288 NM_024312.4(GNPTAB):c.118- 79158 GNPTAB ['GAAAACGTTTCTTTTTCTTTGTTCTRGGTG 2A>G GTTCTGGAATGGAGCCGAGAT']
4289 NM_000495.4(COL4A5):c.3107- 1287 COL4A5 ['AAATATTATATATCACATATTTTCARCAGG 4A>G GCCTCAGGGTGTGGAAGGGCC]
4290 NM_000282.3(PCCA):c.862A>G 5095 PCCA ['TGGGAATGCTTTATGGCTTAATGAANGAG (p.Arg288Gly) AGTGCTCAATTCAGAGAAGAAA']
4291 NM_000288.3(PEX7):c.854A>G 5191 PEX7 ['TCTCTTCTTGAAACAGTGGAGCATCRTACA (p.His285Arg) GAGTTTACTTGTGGTTTAGAC]
4292 NM_000532.4(PCCB):c.l606A>G 5096 PCCB ['ACAACGTCCTTGGAGAAAACATGCARATA (p.Asn536Asp) TTCCATTGTAAACAAATCAAAG]
4293 NM_000553.4(WRN):c.2089- 7486 WRN ['TCAAAGGAAAAATACATTTAAGATTVTAA 3024A>G GTCTGGTTATAAGCTTAAAAAG]
4294 NM_001039958.1(MESP2):c.271A 14587 MESP2 ['GCGGCAGAGCGCCAGCGAGCGGGAGRAA >G (p.Lys91Glu) 3 CTGCGCATGCGCACGCTGGCCCG]
4295 NM_001099274.1(TINF2):c.850A> 26277 TINF2 ['TAGGGGAGGCCATAAGGAGCGCCCCRCAG G (p.Thr284Ala) TCATGCTGTTTCCCTTTAGGAA]
4296 NM_001099274.1(TINF2):c.871A> 26277 TINF2 ['CCCCACAGTCATGCTGTTTCCCTTTRGGAA G (p.Arg291Gly) TCTCGGCTCACCAACCCAGGT']
4297 NM_001363.4(DKCl):c.l l5A>G 1736 DKC1 ['ACAACACGCTGAAGAATTTCTTATCRAACC (p.Lys39Glu) TGAATCCAAAGTTGCTAAGTT']
4298 NM_001363.4(DKCl):c.l27A>G 1736 DKC1 ['AGAATTTCTTATCAAACCTGAATCCRAAGT (p.Lys43Glu) TGCTAAGTTGGACACGTCTCA']
4299 NM_001363.4(DKCl):c.l96A>G 1736 DKC1 ['GAATTTTGATAAGCTGAATGTAAGGRCAA (p.Thr66Ala) CACACTATACACCTCTTGCATG]
4300 NM_001363.4(DKCl):c.941A>G 1736 DKC1 ['GTAAATGCCATCTGCTATGGGGCCARGATT (p.Lys314Arg) ATGCTTCCAGGTGTTCTTCGA']
4301 M_004614.4(TK2):c.l73A>G 7084 TK2 ['GCATGTCGTCTTCCCACTTGCAATAYTGCC (p.Asn58Ser) CTCGACACAGATCTGGCAAAA]
4302 M_004614.4(TK2):c.278A>G 7084 TK2 ['AACCAACAACCCACTCACCAGAGGAYTGT (p.Asn93Ser) GGCCACGGACATTTCTCCACTT']
4303 M_004614.4(TK2):c.562A>G 7084 TK2 ['AGTTTACCTTCGGACCAATCCTGAGRCTTG (p.Thrl88Ala) TTACCAGAGGTTAAAGAAGAG]
4304 NM_024312.4(GNPTAB):c.1285- 79158 GNPTAB ['TTTATTTTCTCTTTGGTTTTATCGTRGGTTT 2A>G ATTTGACATGGCCTGTGCCA']
4305 NM_024312.4(GNPTAB):c.2867A 79158 GNPTAB ['TTCACATCGCGGAAAGTCCCTGCTCRCATG >G (p.His956Arg) CCTCACATGATTGACCGGATT']
4306 NM_024312.4(GNPTAB):c.3458A 79158 GNPTAB ['AGGAAGTTTGTTTGCCTGAATGACARCATT >G (p.Asnl l53Ser) GACCACAATCATAAAGATGCT']
4307 NM_024312.4(GNPTAB):c.2783A 79158 GNPTAB ['AGCAAAAATACTGGGAGGCAACTAARAGA >G (p.Lys928Arg) TACATTTGCAGATTCCCTCAGA']
4308 NM_198253.2(TERT):c.2537A>G 7015 TERT ['TCCACGCTGCTCTGCAGCCTGTGCTRCGGC (p.Tyr846Cys) GACATGGAGAACAAGCTGTTT']
4309 NM_198578.3(LRRK2):c.3342A>G 12089 LRRK2 ['TAGAGAAACTGGAGCAGCTCATTTTRGAA (p.Leul ll4=) 2 GGGTAAGAAAGAGCTCATTAAA']
4310 NM_198578.3(LRRK2):c.5605A>G 12089 LRRK2 ['TTTGGCTGACCTGCCTAGAAATATTRTGTT (p.Metl869Val) 2 GAATAATGATGAGTTGGAATT']
4311 NM_207352.3 (CYP4 V2) :c .367 A>G 28544 CYP4V2 ['TTCAAAGCAAATTGACAAATCCTCTRTGTA (p.Metl23Val) 0 CAAGTTTTTAGAACCATGGCT']
4312 NM_207352.3(CYP4V2):c.761A>G 28544 CYP4V2 ['CTTATGTTTAAAGAAGGATGGGAACRCAA (p.His254Arg) 0 AAAGAGCCTTCAGATCCTACAT']
4313 NR_001566.1 (TERC) : n.37 A>G 7012 TERC ['GGTGGGCCTGGGAGGGGTGGTGGCCDTTT
TTTGTCTAACCCTAACTGAGAA']
4314 NR_001566.1(TERC):n.48A>G 7012 TERC ['GAGGGGTGGTGGCCATTTTTTGTCTRACCC
TAACTGAGAAGGGCGTAGGCG]
4315 NM_007171.3(POMTl):c.430A>G 10585 POMT1 ['CATGTGTTTCCTCTTTGAAACAGAGRATGC (p.Asnl44Asp) TCTCATCACTCAGTCAAGGCT']
4316 NM_003863.3(DPM2):c.68A>G 8818 DPM2 ['GCCGTTAGCCTGATCATCTTCACCTRCTAC (p.Tyr23Cys) ACCGCCTGGGTGATTCTCTTG]
4317 NM_000030.2(AGXT):c.1020 A>G 189 AGXT ['GGAGAGACATCGTCAGCTACGTCATRGAC (p.Ile340Met) CACTTCGACATTGAGATCATGG]
4318 NM_031418.2(ANO3):c.2053A>G 63982 AN03 ['TTATGTTCTATTTCAGTGTCATCCTRGTGG (p.Ser685Gly) CTGTTTGATAGACCTCTGCCT']
4319 NM_183075.2(CYP2Ul):c.l l39A> 11361 CYP2U1 ['CCTTTTTACATAGAAAAGGTTCATGRAGAA G (p.Glu380Gly) 2 ATTGAAAGAGTCATTGGCGCC]
4320 NM_003094.3(SNRPE):c.lA>G 6635 SNRPE ['GGTGTGCTCTTTGTGAAATTCCACCRTGGC (p.MetlVal) GTACCGTGGCCAGGGTCAGAA']
4321 M_000344.3(SMNl):c.389A>G 6606 SMN1 ['ACCTGTGTTGTGGTTTACACTGGATRTGGA (p.Tyrl30Cys) AATAGAGAGGAGCAAAATCTG]
4322 NM_012082.3(ZFPM2):c.2209A>G -1 ['CATGCAGAGAACCATGCGCACACGCRAGC (p.Lys737Glu) GCAGAAAGATGTATGAGATGTG]
4323 NM_006364.2(SEC23A):c.2104A> 10484 SEC23A ['TGTTCAGTGTCAATGTATCTTGGCAYTGGA G (p.Met702Val) AATCTGGAGTGAAGAATTTCC]
4324 NM_001139.2(ALOX12B):c.l562A 242 ALOX12B ['ACCCTCCACGGCTGCGTCACTCGGGYAAT >G (p.Tyr521Cys) AATAGGTGATGATCTCCGTCAC]
4325 NM_001004434.2(SLC30A2):c. l61 7780 SLC30A2 ['GTGACTGTCAGGACCCTTCTGAGCAYGGC A>G (p.His54Arg) AGTGATGGTTGCTCTGGGCAGC]
4326 NM_001168272.1(ITPRl):c. l759A 3708 ITPR1 ['CACTATCACTGCCCTGCTCCACAATRATCG >G (p.Asn587Asp) GAAACTCCTGGAAAAACACAT']
4327 m.15923 A>G -1 ['ATAAACTAATACACCAGTCTTGTAARCCG
GAGATGAAAACCTTTTTCCAAG]
4328 NM_007332.2(TRPAl):c.2564A>G -1 ['TTTTTTTACTTTTCTAGATTTGAAARTTGTG (p.Asn855Ser) GAATTTTTATTGTTATGTTG]
4329 NM_014254.2(TMEM5):c.l016A> 10329 TMEM5 ['CCGGTCGGAGTAAACACAGAATGCTRTCG G (p.Tyr339Cys) AATCTATGAGGCTTGCTCCTAT']
4330 NM_144577.3(CCDC114):c.487- 93233 CCDC114 ['ACTGATTTTTTTCTCCTCCCCCCACRGGAG 2A>G ATCCACCACCTGCATCACCTG]
4331 NM_000834.3(GRIN2B):c.2172- 2904 GRIN2B ['GGATTTGTTTGCTTTTTTCCTGTACRGGAA 2A>G ACTGGATGCCTTCATCTATGA']
4332 NM_018486.2(HDAC8):c.539A>G 55869 HDAC8 ['ATTCTCTACGTGGATTTGGATCTGCRCCAT (p.Hisl80Arg) GGAGATGGTAAGCCCTTTGGT']
4333 NM_018486.2(HDAC8):c.l001A> 55869 HDAC8 ['ACACTATCCTCTGAGATCCCAGATCRTGAG G (p.His334Arg) GTAAGTAAGGCTCTGACAAGT']
4334 NM_178012.4(TUBB2B):c.767A> 34773 TUBB2B ['GCAGACCTGCGCAAGCTGGCGGTGARCAT G (p.Asn256Ser) 3 GGTGCCCTTCCCTCGCCTGCAC]
4335 NM_006888.4(CALMl):c.293A>G 801 CALM1 ['ATTGCTGAATGTTCACAGGATGGCARTGGT (p.Asn98Ser) TATATCAGTGCAGCAGAACTA]
4336 NM_172107.2(KCNQ2):c.l636A> 3785 KCNQ2 ['GCCCCACCCACCCCCCTGCAGTGTCRTGCG G (p.Met546Val) GTTCCTGGTGTCCAAGCGGAA]
4337 NM_001866.2(COX7B):c.41-2A>G 1349 COX7B ['TGTATTCTTTTTTCGTTTTCCTGTARGTTCG
AAGCATTCAGCAAACAATGG]
4338 NM_001099922.2(ALG13):c.339A 79868 ALG13 ['TGAACAATCATCAGCTGGAACTGGCRAAG >G (p.Alal l3=) CAGCTACACAAAGAGGGTCATC]
4339 NM_001083614.1(EARS2):c.502A 12445 EARS2 ['CCCCATCAGGTATGACAATCGGTGCRGGA >G (p.Argl68Gly) 4 ACATGAGCCAGGAGCAGGTGGC]
4340 NM_001083614.1(EARS2):c.l93A 12445 EARS2 ['TGCCTTGTACAACTACATCTTTGCTRAGAA >G (p.Lys65Glu) 4 GTACCAGGGGAGCTTCATCCT']
4341 NM_033109.4(PNPTl):c. ll60A>G 87178 PNPT1 ['ACCCTTCATGGATCAGCATTATTTCRAAGA (p.Gln387Arg) GGACAAACACAGGTAATTTAT']
4342 NM_033109.4(PNPTl):c. l424A>G 87178 PNPT1 ['CCTTTCACCATAAGAGTTACATCTGRAGTC (p.Glu475Gly) CTAGAGTCAAATGGTATGGTA]
4343 NM_000390.2(CHM):c. l520A>G 1121 CHM ['ATTTTTTTTTTAACAGATTTGGTTCRTTTGA (p.His507Arg) CTTGCACATCTTCTAAAACA']
4344 NM_181690.2(AKT3):c.686A>G 10000 AKT3 ['TTGTGTTTTGTGATGGAATATGTTARTGGG (p.Asn229Ser) GGCGAGGTGAGTCAAGAAGTA']
4345 NM_006567.3(FARS2):c.431A>G 10667 FARS2 ['CCCAGCAGGAAGAAGGGGGACAACTRTTA (p.Tyrl44Cys) CCTGAATCGGACTCACATGCTG]
4346 NM_001410.2(MEGF8):c.7099A> 1954 MEGF8 ['CAAGTGCCGGGAATCATTTCACGGGRGTC G (p.Ser2367Gly) CGCTGGGCGGCCAGCAGTGCTA]
4347 NM_003124.4(SPR):c.596-2A>G 6697 SPR ['CCTCATCGTCTCCTTTTCATCCTCTRGGTCC
TCTGGACACAGACATGCAGC]
4348 NM_005609.2(PYGM):c.l52A>G 5837 PYGM ['GACCGCAATGTGGCCACCCCACGAGRCTA (p.Asp51Gly) CTACTTTGCTCTGGCCCATACC]
4349 NM_004247.3 (EFTUD2) : c.623 A> 9343 EFTUD2 ['TTACTTAGTATTTGCTTTTCAGGACRTGTG G (p.His208Arg) AATTTCTCTGATGAGGTCACA']
4350 NM_001310338.1(MGMEl):c.743 92667 MGME1 ['GCTGTTCAACATGAAACCTTAAACTRTATA A>G (p.Tyr248Cys) GGTCTGCTGGACTGTGTGGCT']
4351 NM_001128085.1(ASPA):c.433- -1 ['AAGAAAGACGTTTTTGATTTTTTTCRGACT
2A>G TCTCTGGCTCCACTACCCTGC]
4352 NM_000108.4(DLD):c.l444A>G 1738 DLD ['TGGAGCATCCTGTGAAGATATAGCTRGAG (p.Arg482Gly) TCTGTCATGCACATCCGGTAAT']
4353 NM_007215.3(POLG2):c.l l05A>G 11232 POLG2 ['ACTAACATTAAGAACAAACAAACCCNTAT (p.Arg369Gly) TTTTAGTTTCCCAAGTCTATCT']
4354 NM_004333.4(BRAF):c.2126A>G 673 BRAF ['AGAGATGAGAGACCACTCTTTCCCCRAGT (p.Gln709Arg) AAGTAAAAGCTTCATGCTATCC]
4355 NM_004985.4(KRAS):c.65A>G 3845 KRAS ['GTAGGCAAGAGTGCCTTGACGATACDGCT (p.Gln22Arg) AATTCAGAATCATTTTGTGGAC]
4356 NM_004985.4(KRAS):c.458A>G 3845 KRAS ['ACTTTTTATGTATTTCAGGGTGTTGDTGAT (p.Aspl53Gly) GCCTTCTATACATTAGTTCGA]
4357 NM_002834.3(PTPNl l):c.l24A>G 5781 PTPN11 ['TAGTAAAAGTAACCCTGGAGACTTCRCAC (p.Thr42Ala) TTTCCGTTAGGTAAGTTGGAAT']
4358 NM_002834.3(PTPNl l):c.l72A>G 5781 PTPN11 ['AGCTGTCACCCACATCAAGATTCAGNACA (p.Asn58Asp) CTGGTGATTACTATGACCTGTA']
4359 NM_002834.3(PTPNl l):c.767A>G 5781 PTPN11 ['TTTCTTTCTTTCCAGACACTACAACRACAG (p.Gln256Arg) GAGTGCAAACTTCTCTACAGC]
4360 NM_002834.3(PTPNl l):c.844A>G 5781 PTPN11 ['CAAAAACAAAAATAGATATAAAAACRTCC (p.Ile282Val) TGCCCTGTAAGTATCAATATTC]
4361 NM_002834.3(PTPNl l):c.l510A> 5781 PTPN11 ['GATGGTGCGGTCTCAGAGGTCAGGGRTGG G (p.Met504Val) TCCAGACAGAAGCACAGTACCG]
4362 NM_002880.3(RAFl):c.524A>G 5894 RAF1 ['ACTTGTGGCTACAAATTTCATGAGCRCTGT (p.Hisl75Arg) AGCACCAAAGTACCTACTATG]
4363 NM_002880.3(RAFl):c.l279A>G 5894 RAF1 ['AATTGTGACCCAGTGGTGCGAGGGCRGCA (p.Ser427Gly) GCCTCTACAAACACCTGCATGT']
4364 NM_005633.3(SOSl):c.508A>G 6654 SOS1 ['TATTAAAGTGGCAATGTGTGCTGACRAGG (p.Lysl70Glu) TAGGAAACTGAGCTTTTCTATT']
4365 NM_030662.3 (M AP2K2) :c .181 A> 5605 MAP2K2 ['GCGGCTGGAAGCCTTTCTCACCCAGRAAG G (p.Lys61Glu) CCAAGGTCGGCGAACTCAAAGA']
4366 NM_024334.2(TMEM43):c.271A> 79188 TMEM43 ['GGAGAATGAAGGAAGGCTGGTGCACRTCA G (p.Ile91Val) TTGGCGCCTTACGGACATCCAA']
4367 NM_000084.4(CLCN5):c.l637A>G 1184 CLCN5 ['CTGATGGCTGCAGCCATGACAAGCARGTG (p.Lys546Arg) GGTGGCAGATGCTCTTGGGCGG]
4368 NM_000084.4(CLCN5):c.815A>G 1184 CLCN5 ['CCTTCTTTCTTCTAGGTCAGCTACTRTTTTC (p.Tyr272Cys) CCCTCAAAACATTGTGGCGT']
4369 NM_000095.2(COMP):c. l760A>G 1311 COMP ['GGCGTGGACTTCGAGGGCACGTTCCRTGT (p.His587Arg) GAACACGGTCACGGATGACGAC]
4370 NM_000530.6(MPZ):c.389A>G 4359 MPZ ['AATGGCACGTTCACTTGTGACGTCARAAA (p.Lysl30Arg) CCCTCCAGACATAGTGGGCAAG]
4371 NM_000530.6(MRZ):c.347A>G 4359 MPZ ['AAGGATGGCTCCATTGTCATACACARCCTA (p.Asnl l6Ser) GACTACAGTGACAATGGCACG]
4372 NM_003611.2(OFDl):c.260A>G 8481 OFD1 ['GCAGATCACTTACAAAGATGTGGCTDTGA (p.Tyr87Cys) ATATTCACTTTCTGTTTTCTTT']
4373 NM_003611.2(OFDl):c.290A>G 8481 OFD1 ['TATTCACTTTCTGTTTTCTTTCCAGRAAGTG (p.Glu97Gly) GTTTGGCAAAAGAAAAGGTA']
4374 NM_003611.2(OFDl):c.382-2A>G 8481 OFD1 ['TAAAAGTGAAATATTTTCTTTTAACRGGTT
TCAGGATCTGATAAAGAAAAT']
4375 NM_003977.3(AIP):c.721A>G 9049 AIP ['GCTGCTGCTCAACTACTGCCAGTGCDAGCT (p.Lys241Glu) GGTGGTCGAGGAGTACTACGA']
4376 NM_006158.4(NEFL):c.293A>G 4747 NEFL ['GAGAAGGCGCAGCTCCAGGACCTCARTGA (p.Asn98Ser) CCGCTTCGCCAGCTTCATCGAG]
4377 NM_024312.4(GNPTAB):c.3053A 79158 GNPTAB ['ATATCTCAAGTCTTTGATGAAGTTGRTACA >G (p.Aspl018Gly) GATCAATCTGGTGTCTTGTCT']
4378 NM_025137.3(SPGl l):c. l457- 80208 SPG11 ['TAAAGCTAACTTTTATTTTTCCTATRGAGA 2A>G ATGGACTCTCTCTGATTTTGT']
4379 NM_025137.3(SPGl l):c.2608A>G 80208 SPG11 ['ACAAGAATCCATCCTTCTCCCCAGGRTAAG (p.Ile870Val) TCCAGAAGGCAAGTGTGAGAG]
4380 NM_025137.3(SPGl l):c.2833A>G 80208 SPG11 ['GAATGAAATTTTAGATAAGCTGGCCRGGT (p.Arg945Gly) ATTATAACTGTTGAACTAATAC]
4381 NM_025137.3(SPGl l):c.6477+4A> 80208 SPG11 ['CAGTGAGGAGTATGGGCTGGTGGTARGTA G GCCCCCTCAACCCCAGTCTCCA']
4382 NM_212472.2(PRKARlA):c.l78- 5573 PRKARIA ['ATTTTGCAAACTCGTAATTTCTTTCRGGAG 2A>G GAGGCAAAACAGATTCAGAAT']
4383 NM_006231.3 (POLE) : c.4444+3 A> 5426 POLE ['CCAGTTCAGCTACCTGGAACCAGGTRTGG G CCTGCACCAGCCGCCCATCATG]
4384 NM_003156.3(STIMl):c.251A>G 6786 STIM1 ['GACGATGATGCCAATGGTGATGTGGRTGT (p.Asp84Gly) GGAAGAAAGTGATGAGGTGAGC]
4385 NM_003156.3(STIMl):c.326A>G 6786 STIM1 ['CCAACAGTGAAACACAGCACCTTCCRTGG (p.Hisl09Arg) TGAGGATAAGCTCATCAGCGTG]
4386 NM_001128425.1(MUTYH):c.934- 4595 MUTYH ['GGCTAAGAGCTGTTCCTGCTCCACCYGAG
2A>G AGGCACAGGGTTGAGTGTCATA']
4387 NM_133499.2(SYNl):c.l699A>G 6853 SYN1 ['GGCGGAGCCGGGCCAGAGACGGATGYCTG (p.Thr567Ala) ACGGGTAGCCTGTGGGGGGCCC]
4388 NM_021629.3(GNB4):c.265A>G 59345 GNB4 ['TATTTGGGATAGCTATACAACAAATRAGG (p.Lys89Glu) TAGAATTTCTTCATAATTCTTT']
4389 NM_138425.3(C12orf57):c.lA>G 11324 C12orf57 ['CTGAACCTAGAGCTTCAGACGCCCTRTGGC (p.MetlVal) 6 GTCCGCCTCGACCCAACCGGC]
4390 NM_000096.3(CP):c.2953A>G 1356 CP ['GGGAGATGAAGTCAACTGGTATCTGRTGG (p.Met985Val) GAATGGGCAATGAAATAGACTT']
4391 NM_000057.3(BLM):c. l088-2A>G 641 BLM ['AATATTAACAACATAATTATTTTATRGCTA
GACAGATAAGTTTACAGCAGC]
4392 NM_000257.3(MYH7):c.5807A>G 4625 MYH7 ['TTTCAAAAGGGCTTGAATGAGGAGTRGCT (p.Terl936Trp) TTGCCACATCTTGATCTGCTCA']
4393 NM_152263.3(TPM3):c.505A>G 7170 TPM3 ['GGATCTTTTCCTGTAGGTGGCTCGTRAGTT (p.Lysl69Glu) GGTGATCATTGAAGGAGACTT']
4394 NM_152263.3(TPM3):c.733A>G 7170 TPM3 ['AGAGACCCGTGCTGAGTTTGCTGAGRGAT (p.Arg245Gly) CGGTAGCCAAGCTGGAAAAGAC]
4395 NM_000096.3(CP):c.l209-2A>G 1356 CP ['GCATTAAACACTTTTTTCCCCCTGCRGTGA
CTCAGCGGTGTTTTTTGAACA']
4396 NM_002739.3(PRKCG):c.76A>G 5582 PRKCG ['CCTGTTTTGCAGAAAGGGGGCCCTGRGGC (p.Arg26Gly) AGAAGGTGGTCCACGAAGTCAA']
4397 NM_000138.4(FBNl):c.l l48- 2200 FBN1 ['GTGTTTTGTTTTGTTGTGTTTTTCTRGAGGA 2A>G TTTCAACAAGCTGTGCTCTG]
4398 NM_000138.4(FBNl):c.3058A>G 2200 FBN1 ['ACCCGGATTTGCCACAAAAGAAATTRCAA (p.Thrl020Ala) ATGGAAAGCCTTTCTTCAAAGG]
4399 NM_000169.2(GLA):c.1153 A>G -1 ['GGCCTGTAATCCTGCCTGCTTCATCRCACA (p.Thr385Ala) GCTCCTCCCTGTGAAAAGGAA]
4400 NM_000256.3(MYBPC3):c.l224- 4607 MYBPC3 ['ACTTCAACGGCCCCTTCTGTTCTACRGCAA 2A>G GTAAGTTCCCCTCTGGATGGC]
4401 NM_000256.3(MYBPC3):c.l814A 4607 MYBPC3 ['GTCAGCCTCGTCGGCAGGTGTGACGYCGT >G (p.Asp605Gly) CAATGGTCAGTTTGTGGACCCT']
4402 NM_000256.3(MYBPC3):c.l928- 4607 MYBPC3 ['CTCTGAACTACATTGTGTCTTCTGCRGAAC 2A>G CTCCCAAGATCCACCTGGACT']
4403 NM_000256.3(MYBPC3):c.2309- 4607 MYBPC3 ['GGGCCGCAGGTGCGTCTGGCACGTCBGGA 2A>G TGGGGTGGGATGGACCCACATC]
4404 NM_000256.3(MYBPC3):c.26- 4607 MYBPC3 ['GTGGCTTCTTGCTAAAAGCTGAGACYGAA 2A>G GGGCCAGGTGGAGGCTACAGCG]
4405 NM_000256.3(MYBPC3):c.927- 4607 MYBPC3 ['GGCCACAGCCTAGACTGCGGGACACRGGG 2A>G ACTCGAAGCTGGAGGCACCAGC]
4406 NM_000257.3(MYH7):c.2206A>G 4625 MYH7 ['AGCGGCCATCCCTGAGGGACAGTTCRTTG (p.Ile736Val) ATAGCAGGAAGGGGGCAGAGAA']
4407 NM_000257.3(MYH7):c.2681A>G 4625 MYH7 ['CTCCCCTCTGTTCCTCACCTTCAGGDACAA (p.Glu894Gly) GACAACCTGGCAGATGCTGAG]
4408 NM_000260.3 (MY07 A) :c .1344- 4647 MY07A ['CCTTACCCCATCCCTGTGCCCCTGCRGCTT 2A>G TGAGCAGCTCTGCATCAACTT']
4409 NM_000260.3(MYO7A):c.6029A> 4647 MY07A ['GTGCCAGGGAAGGATCCCATGGCCGRTTC G (p.Asp2010Gly) CATCTTCCACTATTACCAGGTG]
4410 NM_000260.3(MYO7A):c.6439- 4647 MY07A ['CTCTCTATGCCCTTTCTGCTCCCCCRGGAT 2A>G ATCCTCACCACTCATCCCTTC]
4411 M_000441.1 (SLC26 A4) :c . -3 - -1 ['CCCTCCTCGCTGTCCTCTGGCTCGCRGGTC 2A>G ATGGCAGCGCCAGGCGGCAGG]
4412 M_000441.1 (SLC26 A4) :c.1149+3 5172 SLC26A4 ['ATTACACCATCGATGGGAACCAGGTDTGG A>G GTGCCCTTTTGCTGAACTGGTT']
4413 NM_000551.3(VHL):c.467A>G 7428 VHL ['GATTTGGTTTTTGCCCTTCCAGTGTRTACTC (p.Tyrl56Cys) TGAAAGAGCGATGCCTCCAG]
4414 NM_002294.2(LAMP2):c.65-2A>G 3920 LAMP2 ['AAATATTATTTTTTTAAATGAATCCRGGAG
CTGTGCGGTCTTATGCATTGG]
4415 M_004004.5(GJB2):c.1 A>G 2706 GJB2 ['CAGAGCAAACCGCCCAGAGTAGAAGRTGG (p.MetlVal) ATTGGGGCACGCTGCAGACGAT']
4416 M_004004.5(GJB2):c.617A>G 2706 GJB2 ['GTGTCTGGAATTTGCATCCTGCTGARTGTC (p.Asn206Ser) ACTGAATTGTGTTATTTGCTA']
4417 NM_033360.3(KRAS):c.l82A>G 3845 KRAS ['TTGGATATTCTCGACACAGCAGGTCNAGA (p.Gln61Arg) GGAGTACAGTGCAATGAGGGAC]
4418 NM_006218.2(PIK3CA):c.l637A> 5290 PIK3CA ['GATCCTCTCTCTGAAATCACTGAGCRGGAG G (p.Gln546Arg) AAAGATTTTCTATGGAGTCAC]
4419 NM_006218.2(PIK3CA):c.3073A> 5290 PIK3CA ['TGATGACATTGCATACATTCGAAAGRCCCT G (p.Thrl025Ala) AGCCTTAGATAAAACTGAGCA']
4420 NM_032119.3(ADGRVl):c.14973- 84059 ADGRV1 ['TTCTTCATGATTTAATTTTTTTCCCRGATCA 2A>G GGTTTCATTGTTGCTGAAAT']
4421 NM_033056.3(PCDH15):c.l998- 65217 PCDH15 ['TTATTTGTTTGTTTGTTTTGTCACTRGCACG 2A>G GGGATTCTAACCTTAGGGAA']
4422 NM_138691.2(TMCl):c.l763+3A> 11753 TMC1 ['ATCTTCAACCAAGGCATGATCTGGTRGGCC G 1 AGCTGTTGGACAGCTTATCAC]
4423 NM_206933.2(USH2A):c. l2067- 7399 USH2A ['CAACTTAACCTGTTAATTTTCTTACRGGGA 2A>G ACAAGCCATCAAGCCCACCTG]
4424 NM_206933.2(USH2A):c. l2295- 7399 USH2A ['CCCGTCACTGAAGATGTTGTATGTCYACAG 2A>G AAGGACAGAAGCAAAAGGGAT']
4425 NM_206933.2(USH2A):c. l841- 7399 USH2A ['ATAATGCATAACCTTTCCCTGATGCRGGAA 2A>G GGAACTGTGAGCTGTGCAAGG]
4426 NM_206933.2(USH2A):c.8559- 7399 USH2A ['GATGTTCCTGCTTGTCTTTTGCTTTRGATAT 2A>G GAGCTTCTGAGACGTAAAAT']
4427 NM_032415.5(CARDl l):c.401A> 84433 CARD11 ['GGCCTCACGCACTTCCTGATGAACGRGGTC G (p.Glul34Gly) ATCAAGCTGCAGCAGCAGATG]
4428 NM_000548.3(TSC2):c.226-2A>G 7249 TSC2 ['CACCGCTGTCCCCTCTGCTGGTGACRGCAC
GCAGTGGAAGCACTCTGGAAG]
4429 NM_000548.3(TSC2):c. l444-2A>G 7249 TSC2 ['TCATTGGCCTCCCTTGTGCCTGTGCRGGAG
GAGCTGATTAACTCAGTGGTC]
4430 NM_000548.3(TSC2):c.2546-2A>G 7249 TSC2 ['CCCTGACCACCCTCTCCATTACCGCDGCTC
TGGCCAGGCTGCCGCACCTCT']
4431 NM_130466.3(UBE3B):c.545- 89910 UBE3B ['TTTGTTCTCACTGTTTTCTTTCTTTRGGTGA 2A>G AAGTCTTCGACCAGCGATGA']
4432 NM_005430.3(WNTl):c.624+4A> 7471 WNT1 ['CAACAACGAGGCAGGCCGTACGGTGRGCT G TTGAGAGGCTCCGCACCCTAAG]
4433 NM_001893.4(CSNKlD):c.l37A> 1453 CSNK1D ['AAGCTTGAATGTGTCAAAACCAAACRCCC G (p.His46Arg) TCAGCTCCACATTGAGAGCAAA']
4434 NM_018972.2(GDAPl):c.368A>G 54332 GDAP1 ['AGCATGTATTACCCACGGGTACAACRTTAC (p.Hisl23Arg) CGAGAGCTGCTTGACTCCTTG]
4435 NM_032237.4(POMK):c.773A>G 84197 POMK ['CATGGGGATTTCGTGGCTCCAGAGCRACT (p.Gln258Arg) GTGGCCCTATGGAGAGGACGTG]
4436 NM_201647.2(STAMBP):c.l25A> 10617 STAMBP ['CGTCGGTACTTCCGCTCTGGAGTTGRGATT G (p.Glu42Gly) ATCCGAATGGCATCCATTTAC]
4437 NM_001946.3(DUSP6):c.566A>G 1848 DUSP6 ['ACTACCATCCGAGTCTGTTGCACTAYTGGG (p.Asnl89Ser) GTCTCGGTCAAGGTCAGACTC]
4438 NM_003867.3(FGF17):c.560A>G 8822 FGF17 ['TACCAAGGCCAGCTGCCCTTCCCCARCCAC (p.Asnl87Ser) GCCGAGAAGCAGAAGCAGTTC]
4439 NM_013281.3(FLRT3):c.l016A>G -1 ['GGGCTCATGTGCCAAGCCCCAGAAARGGT (p.Lys339Arg) TCGTGGGATGGCTATTAAGGAT']
4440 NM_015560.2(OPAl):c.l l46A>G 4976 OPA1 ['TTTTTATTTTTCCTGAGTAGACCATRTCCTT (p.Ile382Met) AAATGTAAAAGGCCCTGGAC]
4441 NM_030964.3(SPRY4):c.530A>G 81848 SPRY4 ['CCGGCGGTCCCACCCGAGCTGGACARGCA (p.Lysl77Arg) CTTCTTGCTGTGCGAGGCCTGT']
4442 NM_002972.3(SBFl):c. l249A>G 6305 SBF1 ['AAGGCCATGCCCTCCAGCACCTTCAYCAG (p.Met417Val) GAAATCGTCCTCTACCAGCCCA]
4443 NM_002972.3(SBFl):c.4768A>G 6305 SBF1 ['TACATGTAATTGTGGAACACAGGCGYCCT (p.Thrl590Ala) CTTGCTCAGCCGGTCCACATAC]
4444 NM_006876.2(B4GATl):c.l l68A> 11041 B4GAT1 ['GTTCCATCCCCAAAAGGAGGCTGAARATC G (p.Asn390Asp) AGCACAATAAGATCCTATATCG]
4445 NM_000059.3(BRCA2):c.517- 675 BRCA2 ['AAAATAAACTATTTTCTTTCCTCCCVGGGT 2A>G CGTCAGACACCAAAACATATT']
4446 NM_000059.3(BRCA2):c.6938- 675 BRCA2 ['ATGTAATATAAAATAATTGTTTCCTRGGCA 2A>G CAATAAAAGATCGAAGATTGT']
4447 NM_000059.3(BRCA2):c.7008- 675 BRCA2 ['AACTTATATATTTTCTCCCCATTGCDGCAC 2A>G AACTAAGGAACGTCAAGAGAT']
4448 NM_000059.3(BRCA2):c.7806- 675 BRCA2 ['GATAATATTCTACTTTTATTTGTTCRGGGC 2A>G TCTGTGTGACACTCCAGGTGT']
4449 NM_000059.3(BRCA2):c.8754+4A 675 BRCA2 ['AGCAGACCCAGCTTACCTTGAGGTGRGAG >G AGTAAGAGGACATATAATGAGG]
4450 NM_000059.3(BRCA2):c.9118- 675 BRCA2 ['GTTGAATTTTTGTTTTGTTTTCTGTRGGTTT 2A>G CAGATGAAATTTTATTTCAG]
4451 NM_000059.3(BRCA2):c.9649- 675 BRCA2 ['TAGGCTACGTTTTCATTTTTTTATCRGATGT
2A>G CTTCTCCTAATTGTGAGATA]
NM_000218.2(KCNQl):c.l070A> 3784 KCNQ1 []
G (p.Gln357Arg)
4452 NM_000218.2(KCNQl):c.l085A> 3784 KCNQ1 ['AAGGTGCAGCAGAAGCAGAGGCAGARGC G (p.Lys362Arg) ACTTCAACCGGCAGATCCCGGCG]
4453 NM_000218.2(KCNQl):c.l576A> 3784 KCNQ1 ['TCGACGCATGCAGTACTTTGTGGCCVAGA G (p.Lys526Glu) AGAAATTCCAGGTAAGCCCTGT']
NM_000218.2(KCNQl):c.l756A> 3784 KCNQ1 []
G (p.Asn586Asp)
4454 NM_000218.2(KCNQl):c.332A>G 3784 KCNQ1 ['CGCACCCACGTCCAGGGCCGCGTCTRCAA (p.Tyrl l lCys) CTTCCTCGAGCGTCCCACCGGC]
NM_000218.2(KCNQl):c.344A>G 3784 KCNQ1 []
(p.Glul l5Gly)
4455 NM_000218.2(KCNQl):c.773A>G 3784 KCNQ1 ['CTCCTGGGCTCCGTGGTCTTCATCCVCCGC (p.His258Arg) CAGGTGGGTGGCCCGGGTTAG]
4456 NM_000218.2(KCNQl):c.944A>G 3784 KCNQ1 ['CAGGTCACAGTCACCACCATCGGCTNTGG (p.Tyr315Cys) GGACAAGGTGCCCCAGACGTGG]
NM_000218.2(KCNQl):c.964A>G 3784 KCNQ1 []
(p.Thr322Ala)
4457 NM_000492.3 (CFTR) : c.1393 - 1080 CFTR ['CCTAATAATGATGGGTTTTATTTCCRGACT 2A>G TCACTTCTAATGGTGATTATG]
4458 NM_000492.3(CFTR):c.1766+3 A> 1080 CFTR ['ACAGAAAAAGAAATATTTGAAAGGTVTGT G TCTTTGAATACCTTACTTATAA']
4459 NM_000492.3(CFTR):c. lA>G 1080 CFTR ['CAGGGACCCCAGCGCCCGAGAGACCRTGC (p.MetlVal) AGAGGTCGCCTCTGGAAAAGGC]
4460 NM_000492.3(CFTR):c.2989- 1080 CFTR ['ACCAACATGTTTTCTTTGATCTTACDGTTG 2A>G TTATTAATTGTGATTGGAGCT']
4461 NM_000492.3(CFTR):c.579+3A>G 1080 CFTR ['ACAACCTGAACAAATTTGATGAAGTNTGT
ACCTATTGATTTAATCTTTTAG]
4462 NM_007294.3(BRCAl):c.l22A>G 672 BRCA1 ['GAACCTGTCTCCACAAAGTGTGACCRCAT (p.His41Arg) ATTTTGCAAGTAAGTTTGAATG]
4463 NM_007294.3 (BRCA1 ) :c .1 A>G 672 BRCA1 ['TTAAAGTTCATTGGAACAGAAAGAARTGG (p.MetlVal) ATTTATCTGCTCTTCGCGTTGA']
4464 NM_007294.3(BRCAl):c.212+3A> 672 BRCA1 ['TGTAAGAATGATATAACCAAAAGGTRTAT G AATTTGGTAATGATGCTAGGTT']
4465 NM_007294.3(BRCAl):c.4097- 672 BRCA1 ['TCTGAACCTCTGTTTTTGTTATTTAVGGTG 2A>G AAGCAGCATCTGGGTGTGAGA']
4466 NM_007294.3(BRCAl):c.4485- 672 BRCA1 ['GTTTTCTCCTTCCATTTATCTTTCTRGGTCA
2A>G TCCCCTTCTAAATGCCCATC]
4467 NM_007294.3(BRCAl):c.4987- 672 BRCA1 ['ATAATGGAATATTTGATTTAATTTCRGATG 2A>G CTCGTGTACAAGTTTGCCAGA]
4468 NM_007294.3(BRCAl):c.5053A> 672 BRCA1 ['AACTAATCTAATTACTGAAGAGACTRCTCA G (p.Thrl685Ala) TGTTGTTATGAAAACAGGTAT']
4469 NM_007294.3(BRCAl):c.5407- 672 BRCA1 ['AATGCTCTTTCCTTCCTGGGGATCCDGGGT 2A>G GTCCACCCAATTGTGGTTGTG]
4470 NM_000540.2(RYRl):c.97A>G 6261 RYR1 ['CGCTACCGTGCTCAAGGAGCAGCTCRAGC (p.Lys33Glu) TCTGCCTGGCCGCCGAGGGCTT']
4471 NM_015250.3(BICD2):c.2321A>G 23299 BICD2 ['CGGCAGCTGGCGGCTGCTGAGGACGRGAA (p.Glu774Gly) GAAGACGCTGAACTCGCTGCTG]
4472 NM_006012.2(CLPP):c.270+4A>G 8192 CLPP ['CATCGTGTGCGTCATGGGCCCGGTGRGCG
CCCCGCGCCGGGACCCTCCCCA]
4473 NM_004656.3(BAPl):c.277A>G 8314 BAP1 ['AGGAGCACGCTCAGCAAGGCATGAGHTGC (p.Thr93Ala) ACAAGAGTTGGGTATCAGCTGT']
4474 NM_004315.4(ASAHl):c.965+4A> 427 ASAH1 ['AGGAATCATTGGATGTATATGAGTARGTA G GGTTTGTTAAAGCAAAAGAAGT']
4475 NM_000100.3(CSTB):c. l69-2A>G 1476 CSTB ['GCTTCGCTCACTCCGCTCTCTTCCCRGGTG
CACGTCGGCGACGAGGACTTC]
4476 NM_015268.3(DNAJC13):c.2564A 23317 DNAJC13 ['TTAAAATCTAGGTATGAATTTTTCARTGAG >G (p.Asn855Ser) CTTTATCATCGCTTCTTGCTC]
4477 NM_001003722.1(GLEl):c.433- 2733 GLE1 ['CTTAAAAAAAAAAAAAAAAAAAAAARCCT 10A>G TTTCAGGAGGGCCTGAGGCTAT']
4478 NM_001142519.1(FAMl llA):c. l5 63901 FAM111A ['TTCCAGAAAATAGTTCACAACCCTGDTGTG 83A>G (p.Asp528Gly) ATTACCTATGACACTGAATTT']
4479 NM_001142519.1(FAMl llA):c. lO 63901 FAM111A ['GCATAGAACAACGTTTGGGAAAGTARCAA 12A>G (p.Thr338Ala) AAAATTCTTCTTCGATTAAAGT']
4480 NM_001927.3(DES):c.l289-2A>G 1674 DES ['CTGAGTGTGCGATGGACCCTGTTACRGAA
ACCAGCCCTGAGCAAAGGGGTT']
4481 NM_014795.3(ZEB2):c.3134A>G 9839 ZEB2 ['AAACACAAGCACCACCTTATCGAGCRCTC (p.Hisl045Arg) AAGGCTTCACTCGGGCGAGAAG]
4482 NM_002163.2(IRF8):c.322A>G 3394 IRF8 ['CCAACTGGACATTTCCGAGCCATACRAAG (p.Lysl08Glu) TTTACCGAATTGTTCCTGAGGA']
4483 NM_002163.2(IRF8):c.238A>G 3394 IRF8 ['CAAAGCTGAACCAGCCACTTGGAAGRCGA (p.Thr80Ala) GGTTACGCTGTGCTTTGAATAA']
4484 NM_001287.5(CLCN7):c.296A>G 1186 CLCN7 ['TGTCCCGGCCTGCAGAGCTTGGACTRTGAC (p.Tyr99Cys) AACAGTGAGAACCAGCTGTTC]
4485 NM_001127217.2(SMAD9):c. l27A 4093 SMAD9 ['AGAGAAGGCAGTGGACTCTCTAGTGRAGA >G (p.Lys43Glu) AGTTAAAGAAGAAGAAGGGAGC]
4486 NM_002246.2(KCNK3):c.575A>G 3777 KCNK3 ['TGGACCTTCTTCCAGGCCTACTACTRCTGC (p.Tyrl92Cys) TTCATCACCCTCACCACCATC]
4487 NM_080605.3(B3GALT6):c.lA>G 12679 B3GALT6 ['CGCCACGCCCGCCGCAGCAGCTTCAYGGC (p.MetlVal) 2 GCCCGCGCCGGGCCGGCGGCCC]
4488 NM_080605.3(B3GALT6):c.l93A> 12679 B3GALT6 ['CGGCGCTCGGCGGCGCGGGGCGCGCYGGC G (p.Ser65Gly) 2 CACCAGCACTGCCAGGAAGGCG]
4489 NM_000388.3(CASR):c.85A>G 846 CASR ['CGGGCCAGACCAGCGAGCCCAAAAGRAGG (p.Lys29Glu) GGGACATTATCCTTGGGGGGCT']
4490 NM_003793.3(CTSF):c.962A>G 8722 CTSF ['GGGACCCTGCTCTCCCTCTCTGAACRGGGT (p.Gln321Arg) GAGCATCTCGCTCTACTCCTC]
4491 NM_003793.3(CTSF):c.692A>G 8722 CTSF ['GAGATCACTGAACTTGGTGACTCCAYACT (p.Tyr231Cys) GAGCTGTGCCACGGTCCAGGGC]
4492 NM_022114.3(PRDM16):c.2447A> 63976 PRDM16 ['GGCAGCCGGGCCCGTGCCAGCCAAARCGG G (p.Asn816Ser) CGGCGGGCGGGAGCCCCGCAAG]
4493 NM_173551.4(ANKS6):c.l322A> 20328 ANKS6 ['GGGCAGCACTGGGATGCTCCAGGGCYGTC G (p.Gln441Arg) 6 GGACCTTCGAGTGGGGCAGGGG]
4494 NM_005689.2(ABCB6):c.508A>G 10058 ABCB6 ['GAACTTGGCCCTGGTGTCTTGGAACRGCCC (p.Serl70Gly) ACAGTGGTGGTGGGCAAGGGC]
4495 NM_001070.4(TUBGl):c.275A>G 7283 TUBG1 ['AAGCTCTACAACCCAGAGAACATCTRCCT (p.Tyr92Cys) GTCGGAACATGGAGGAGGAGCT']
4496 NM_001613.2(ACTA2):c. l45A>G 59 ACTA2 ['ACCTTTTTAGGGGGTGATGGTGGGARTGG (p.Met49Val) GACAAAAAGACAGCTACGTGGG]
4497 NM_031157.2(HNRNPAl):c.956A 3178 HNRNPA1 ['AGCTACAATGATTTTGGGAATTACARCAAT >G (p.Asn319Ser) CAGTCTTCAAATTTTGGACCC]
4498 NM_020117.9(LARS):c.1118A>G 51520 LARS ['CTTAATAGTTAGCATTGGGAGAACAYAGA (p.Tyr373Cys) TCACCTTGTATGATGTTAAAGG]
4499 NM_001651.3(AQP5):c.367A>G 362 AQP5 ['CTAACCCGCTATCCCCTTGCAGCTCRACAA (p.Asnl23Asp) CAACACAACGCAGGGCCAGGC]
4500 m. l3637A>G 4540 MT-ND5 ['ATAATTCTTCTCACCCTAACAGGTCRACCT
CGCTTCCCCACCCTTACTAAC]
4501 NM_000081.3 (LYST) : c.10127 A>G 1130 LYST ['GGGAAGGCTTCTGTTCAAGCGATCARTGTT (p.Asn3376Ser) TTTCATCCTGCTGTAAGTGAC]
4502 NM_000142.4(FGFR3):c.2421A>G 2261 FGFR3 ['CCAGCAGTGGGGGCTCGCGGACGTGNAGG (p.Ter807Trp) GCCACTGGTCCCCAACAATGTG]
4503 NM_000207.2(INS):c.*59A>G -1 ['TCCTGCACCGAGAGAGATGGAATAARGCC
CTTGAACCAGCCCTGCTGTGCC]
4504 NM_000370.3 (TTP A) : c.191 A>G 7274 TTPA ['CTGCGCGCCCGGGATTTCGATCTGGRCCTG (p.Asp64Gly) GCCTGGCGGGTAAGCGTGCGT']
4505 NM_001006657.1(WDR35):c.2912 57539 WDR35 ['AAACCTTTACGTGTCAAGAAGCTCTRTGTA A>G (p.Tyr971Cys) CTGTCAGCCTTACTTATAGAG]
4506 NM_004595.4(SMS):c.443A>G 6611 SMS ['GTATATGACGAAGATTCACCTTATCRAAAT (p.Glnl48Arg) ATAAAAATTCTACACTCGAAG]
4507 NM_005259.2(MSTN):c.458A>G -1 ['AAAATACAATACAATAAAGTAGTAARGGC (p.Lysl53Arg) CCAACTATGGATATATTTGAGA]
4508 NM_000784.3(CYP27Al):c. l061A 1593 CYP27A1 ['TGGGCCCTGTACCACCTCTCAAAGGRCCCT >G (p.Asp354Gly) GAGATCCAGGAGGCCTTGCAC]
4509 NM_000784.3(CYP27Al):c.776A> 1593 CYP27A1 ['TCACTCTATGCCACCTTCCTCCCCARGTGG G (p.Lys259Arg) ACTCGCCCCGTGCTGCCTTTC]
4510 NM_000540.2(RYRl):c.l0100A>G 6261 RYRl ['ATCCCAACTATCGGGCGGCTGCGCARGAG (p.Lys3367Arg) GGCAGGGAAGGTGGTGTCCGAG]
4511 NM_000540.2(RYRl):c.l4572A>G 6261 RYRl ['CTACCTGTACACCGTGGTGGCCTTCRACTT (p.Asn4858Asp) CTTCCGCAAGTTCTACAACAA]
4512 NM_000540.2(RYRl):c.l4740A>G 6261 RYR1 ['CGCGGGTGACGAATACGAGCTCTACRGGG (p.Arg4914Gly) TGGTCTTCGACATCACCTTCTT']
4513 NM_000540.2(RYRl):c.l4591A>G 6261 RYR1 ['GCCTTCAACTTCTTCCGCAAGTTCTRCAAC (p.Tyr4864Cys) AAGAGCGAGGATGAGGATGAA']
4514 NM_002336.2(LRP6):c. l298A>G 4040 LRP6 ['GATCGAATAGAAGTGACAAGGCTCARTGG (p.Asn433Ser) GACCATGAGGAAGATCTTGATT']
4515 NM_001257235.1(ALG13):c.8A>G 79868 ALG13 ['GTTATAAACGAAAAGTTGATGAACARTCA (p.Asn3Ser) TCAGCTGGAACTGGCAAAGCAG]
4516 NM_001015879.1(AURKC):c.379- 6795 AURKC ['CAGGGTGACTTTTCTTTGCACCCACRGATA 2A>G ATAGAGGAGTTGGCAGATGCC]
4517 NM_012160.4(FBXL4):c.l694A>G 26235 FBXL4 ['AATTGTACCAGGTTACAGCAGCTGGRCAT (p.Asp565Gly) ATTAGGTAAGGTTACAATATAT']
4518 NM_020988.2(GNAOl):c.521A>G 2775 GNAOl ['GCCGACTACCAGCCCACCGAGCAGGRCAT (p.Aspl74Gly) CCTCCGAACCAGGGTCAAAACC]
4519 NM_001927.3 (DES) :c .1024 A>G 1674 DES ['GACCTGGGTTCCCCCTCTCCTGCAGRACGA (p.Asn342Asp) TTCCCTGATGAGGCAGATGCG]
4520 NM_001927.3(DES):c.l333A>G 1674 DES ['GGGTTCTGAGGTCCATACCAAGAAGRCGG (p.Thr445Ala) TGATGATCAAGACCATCGAGAC]
4521 NM_001927.3(DES):c.735+3A>G 1674 DES ['TCCTTAAGAAAGTGCATGAAGAGGTRTAC
CTTGGCCCCTCTTCCTGGGGTC]
4522 NM_002055.4(GFAP):c.l097A>G 2670 GFAP ['GCCCTGGACATCGAGATCGCCACCTRCAG (p.Tyr366Cys) GAAGCTGCTAGAGGGCGAGGAG]
4523 NM_002055.4(GFAP):c.l l l2A>G 2670 GFAP ['ATCGCCACCTACAGGAAGCTGCTAGDGGG (p.Glu371Gly) CGAGGAGAACCGGTGAGCCCTC]
4524 NM_002055.4(GFAP):c.l l21A>G 2670 GFAP ['TACAGGAAGCTGCTAGAGGGCGAGGRGAA (p.Glu374Gly) CCGGTGAGCCCTCATCACAGCC]
4525 NM_002055.4(GFAP):c.230A>G 2670 GFAP ['GAGCGGGCAGAGATGATGGAGCTCARTGA (p.Asn77Ser) CCGCTTTGCCAGCTACATCGAG]
4526 NM_002055.4(GFAP):c.770A>G 2670 GFAP ['AACATGCATGAAGCCGAAGAGTGGTRCCG (p.Tyr257Cys) CTCCAAGGTAGCCCTGCCTGTG]
4527 NM_002055.4(GFAP):c.835A>G 2670 GFAP ['CAACGCGGAGCTGCTCCGCCAGGCCRAGC (p.Lys279Glu) ACGAAGCCAACGACTACCGGCG]
4528 NM_005554.3(KRT6A):c.511A>G 3853 KRT6A ['GGAGCGTGAACAGATCAAGACCCTCDACA (p.Asnl71Asp) ACAAGTTTGCCTCCTTCATCGA]
4529 NM_005554.3(KRT6A):c.512A>G 3853 KRT6A ['GAGCGTGAACAGATCAAGACCCTCAVCAA (p.Asnl71Ser) CAAGTTTGCCTCCTTCATCGAC]
4530 NM_005557.3(KRT16):c.373A>G 3868 KRT16 ['TGAGAAGGTGACCATGCAGAACCTCRATG (p.Asnl25Asp) ACCGCCTGGCCTCCTACCTGGA']
4531 NM_170707.3(LMNA):c.640- 4000 LMNA ['TTTTGGTTTCTGTGTCCTTCCTCCAVCCCTT 10A>G CCAGGAGCTGCGTGAGACCA']
NM_000218.2(KCNQl):c.l061A> 3784 KCNQ1 []
G (p.Lys354Arg)
NM_000218.2(KCNQl):c.l l38A> 3784 KCNQ1 [] G (p.Arg380Gly)
NM_000218.2(KCNQl):c.l l93A> 3784 KCNQ1 []
G (p.Lys398Arg)
NM_000218.2(KCNQl):c.l640A> 3784 KCNQ1 []
G (p.Gln547Arg)
NM_000218.2(KCNQl):c.l669A> 3784 KCNQ1 []
G (p.Lys557Glu)
NM_000218.2(KCNQl):c.l705A> 3784 KCNQ1 []
G (p.Lys569Glu)
NM_000218.2(KCNQl):c.l793A> 3784 KCNQ1 []
G (p.Lys598Arg)
NM_000218.2(KCNQl):c.430A>G 3784 KCNQ1 []
(p.Thrl44Ala)
NM_000218.2(KCNQl):c.440A>G 3784 KCNQ1 []
(p.Glnl47Arg)
NM_000218.2(KCNQl):c.548A>G 3784 KCNQ1 []
(p.Lysl83Arg)
4532 NM_000218.2(KCNQl):c.592A>G 3784 KCNQ1 ['GCGGCTGCGCTTTGCCCGGAAGCCCRTTTC (p.Ilel98Val) CATCATCGGTGAGTCATGCCT']
4533 NM_000218.2(KCNQl):c.652A>G 3784 KCNQ1 ['CATGGTGGTCCTCTGCGTGGGCTCCRAGGG (p.Lys218Glu) GCAGGTGTTTGCCACGTCGGC]
4534 NM_000218.2(KCNQl):c.820A>G 3784 KCNQ1 ['CCTGTACATCGGCTTCCTGGGCCTCRTCTT (p.Ile274Val) CTCCTCGTACTTTGTGTACCT']
NM_000218.2(KCNQl):c.842A>G 3784 KCNQ1 []
(p.Tyr281Cys)
NM_000218.2(KCNQl):c.931A>G 3784 KCNQ1 []
(p.Thr311Ala)
NM_000218.2(KCNQl):c.950A>G 3784 KCNQ1 []
(p.Asp317Gly)
NM_000238.3(KCNH2):c.l205A> 3757 KCNH2 []
G (p.His402Arg)
NM_000238.3(KCNH2):c.l259A> 3757 KCNH2 []
G (p.Tyr420Cys)
4535 NM_000238.3(KCNH2):c.l280A> 3757 KCNH2 ['ATCTACACGGCTGTCTTCACACCCTVCTCG G (p.Tyr427Cys) GCTGCCTTCCTGCTGAAGGAG]
NM_000238.3(KCNH2):c.l28A>G 3757 KCNH2 []
(p.Tyr43Cys)
NM_000238.3 (KCNH2) :c .1424 A> 3757 KCNH2 []
G (p.Tyr475Cys)
4536 NM_000238.3(KCNH2):c.l478A> 3757 KCNH2 ['CACCCCGGCCGCATCGCCGTCCACTNCTTC G (p.Tyr493Cys) AAGGGCTGGTTCCTCATCGAC]
NM_000238.3(KCNH2):c.l502A> 3757 KCNH2 []
G (p.Asp501Gly)
4537 NM_000238.3(KCNH2):c.l685A> 3757 KCNH2 ['ATGTGCACCTTTGCGCTCATCGCGCVCTGG G (p.His562Arg) CTAGCCTGCATCTGGTACGCC]
4538 NM_000238.3 (KCNH2) :c .1711 A> 3757 KCNH2 ['CTGGCTAGCCTGCATCTGGTACGCCVTCGG G (p.Ile571Val) CAACATGGAGCAGCCACACAT']
4539 NM_000238.3 (KCNH2) :c .1720 A> 3757 KCNH2 ['CTGCATCTGGTACGCCATCGGCAACVTGG G (p.Met574Val) AGCAGCCACACATGGACTCACG]
NM_000238.3 (KCNH2) :c .1724 A> 3757 KCNH2 []
G (p.Glu575Gly)
4540 NM_000238.3(KCNH2):c.l73A>G 3757 KCNH2 ['GAGCTGTGCGGCTACTCGCGGGCCGVGGT (p.Glu58Gly) GATGCAGCGACCCTGCACCTGC]
NM_000238.3 (KCNH2) :c .1747 A> 3757 KCNH2 []
G (p.Ile583Val)
NM_000238.3 (KCNH2) :c .1762 A> 3757 KCNH2 []
G (p.Asn588Asp)
NM_000238.3 (KCNH2) :c .1777 A> 3757 KCNH2 []
G (p.Ile593Val)
NM_000238.3(KCNH2):c.l783A> 3757 KCNH2 []
G (p.Lys595Glu)
NM_000238.3(KCNH2):c.l790A> 3757 KCNH2 []
G (p.Tyr597Cys)
NM_000238.3 (KCNH2) :c .1826 A> 3757 KCNH2 []
G (p.Asp609Gly)
NM_000238.3 (KCNH2) :c .1847 A> 3757 KCNH2 []
G (p.Tyr616Cys)
NM_000238.3(KCNH2):c.l885A> 3757 KCNH2 []
G (p.Asn629Asp)
4541 NM_000238.3(KCNH2):c.l886A> 3757 KCNH2 ['AGCCTCACCAGTGTGGGCTTCGGCANCGT G (p.Asn629Ser) CTCTCCCAACACCAACTCAGAG]
NM_000238.3(KCNH2):c.l897A> 3757 KCNH2 []
G (p.Asn633Asp)
4542 NM_000238.3(KCNH2):c.l898A> 3757 KCNH2 ['GTGGGCTTCGGCAACGTCTCTCCCADCACC G (p.Asn633Ser) AACTCAGAGAAGATCTTCTCC]
NM_000238.3(KCNH2):c.l903A> 3757 KCNH2 []
G (p.Asn635Asp)
NM_000238.3 (KCNH2) :c .1910 A> 3757 KCNH2 []
G (p.Glu637Gly)
NM_000238.3 (KCNH2) :c .1912 A> 3757 KCNH2 []
G (p.Lys638Glu)
4543 NM_000238.3(KCNH2):c.l933A> 3757 KCNH2 ['AGAGAAGATCTTCTCCATCTGCGTCDTGCT G (p.Met645Val) CATTGGCTGTGAGTGTGCCCA]
NM_000238.3(KCNH2):c.209A>G 3757 KCNH2 []
(p.His70Arg)
4544 NM_000238.3(KCNH2):c.2131A> 3757 KCNH2 ['GCACGCCTGGTCCTACACCAACGGCRTCG G (p.Ile711Val) ACATGAACGCGGTGAGGCCACC]
NM_000238.3(KCNH2):c.2266A> 3757 KCNH2 [] G (p.Met756Val)
NM_000238.3(KCNH2):c.2510A> 3757 KCNH2 []
G (p.Asp837Gly)
NM_000238.3(KCNH2):c.2591A> 3757 KCNH2 []
G (p.Asp864Gly)
NM_000238.3(KCNH2):c.286A>G 3757 KCNH2 []
(p.Ile96Val)
4545 NM_000238.3 (KCNH2) :c .301 A>G 3757 KCNH2 ['CAAAGTGGAAATCGCCTTCTACCGGDAAG (p.LyslOlGlu) ATGGTAGGAGCGGGCCGGGGCG]
4546 NM_000238.3 (KCNH2) :c .3118 A> 3757 KCNH2 ['TCGGCGGCCCCGGGGCGACGTGGAGRGCA G (p.Serl040Gly) GGCTGGATGCCCTCCAGCGCCA]
NM_000238.3(KCNH2):c.3233A> 3757 KCNH2 []
G (p.Tyrl078Cys)
NM_000238.3(KCNH2):c.3343A> 3757 KCNH2 []
G (p.Metl l l5Val)
NM_000238.3(KCNH2):c.652A>G 3757 KCNH2 []
(p.Met218Val)
NM_000238.3 (KCNH2) :c .82 A>G 3757 KCNH2 []
(p.Lys28Glu)
NM_000891.2(KCNJ2):c.220A>G 3759 KCNJ2 []
(p.Thr74Ala)
NM_000891.2(KCNJ2):c.223A>G 3759 KCNJ2 []
(p.Thr75Ala)
NM_000891.2(KCNJ2):c.233A>G 3759 KCNJ2 []
(p.Asp78Gly)
NM_000891.2(KCNJ2):c.574A>G 3759 KCNJ2 []
(p.Thrl92Ala)
4547 NM_000891.2(KCNJ2):c.913A>G 3759 KCNJ2 ['CATACTGGAAGGCATGGTGGAAGCCVCTG (p.Thr305Ala) CCATGACGACACAGTGCCGTAG]
NM_172201.1 (KCNE2) :c.269 A>G 9992 KCNE2 []
(p.Glu90Gly)
4548 NM_172201.1(KCNE2):c.281A>G 9992 KCNE2 ['CAGTACATTGTAGAGGACTGGCAGGRAAA (p.Glu94Gly) GTACAAGAGCCAAATCTTGAAT']
NM_000335.4(SCN5A):c. l217A>G 6331 SCN5A []
(p.Asn406Ser)
NM_000335.4(SCN5A):c. l502A>G 6331 SCN5A []
(p.Asp501Gly)
NM_000335.4(SCN5A):c.2249A>G 6331 SCN5A []
(p.Gln750Arg)
NM_198056.2(SCN5A):c.2527A>G 6331 SCN5A []
(p.Thr843Ala)
NM_000335.4(SCN5A):c.2780A>G 6331 SCN5A []
(p.Asn927Ser)
NM_000335.4(SCN5A):c.3164A>G 6331 SCN5A [] (p.Aspl055Gly)
NM_000335.4(SCN5A):c.343A>G 6331 SCN5A []
(p.Serll5Gly)
NM_000335.4(SCN5A):c.3755A>G 6331 SCN5A []
(p.Glul252Gly)
4549 NM_000335.4(SCN5A):c.376A>G 6331 SCN5A ['AAAGGATATGAGTGAACCAGAATCTYCAC (p.Lysl26Glu) AGCCGCTCTCCGGATGGGGTGG]
4550 NM_198056.2(SCN5A):c.4000A>G 6331 SCN5A ['TGCCCTGGTGGGCGCCATCCCGTCCRTCAT (p.Ilel334Val) GAACGTCCTCCTCGTCTGCCT']
NM_000335.4(SCN5A):c.4223A>G 6331 SCN5A []
(p.Tyrl408Cys)
NM_000335.4(SCN5A):c.4252A>G 6331 SCN5A []
(p.Lysl418Glu)
NM_000335.4(SCN5A):c.4291A>G 6331 SCN5A []
(p.Argl431Gly)
NM_198056.2(SCN5A):c.4346A>G 6331 SCN5A []
(p.Tyrl449Cys)
NM_000335.4(SCN5A):c.4412A>G 6331 SCN5A []
(p.Asnl471Ser)
4551 NM_198056.2(SCN5A):c.4478A>G 6331 SCN5A ['ATCTTCATGACAGAGGAGCAGAAGARGTA (p.Lysl493Arg) CTACAATGCCATGAAGAAGCTG]
NM_000335.4(SCN5A):c.4489A>G 6331 SCN5A []
(p.Metl497Val)
NM_000335.4(SCN5A):c.4577A>G 6331 SCN5A []
(p.Lysl526Arg)
4552 NM_198056.2(SCN5A):c.4978A>G 6331 SCN5A ['GATGTCCCTGCCTGCCCTCTTCAACRTCGG (p.Ilel660Val) GCTGCTGCTCTTCCTCGTCAT']
NM_000335.4(SCN5A):c.5138A>G 6331 SCN5A []
(p.Aspl713Gly)
NM_000335.4(SCN5A):c.5161A>G 6331 SCN5A []
(p.Asnl721Asp)
NM_000335.4(SCN5A):c.5297A>G 6331 SCN5A []
(p.Tyrl766Cys)
NM_198056.2(SCN5A):c.5302A>G 6331 SCN5A []
(p.Ilel768Val)
NM_000335.4(SCN5A):c.5317A>G 6331 SCN5A []
(p.Asnl773Asp)
NM_000335.4(SCN5A):c.5318A>G 6331 SCN5A []
(p.Asnl773Ser)
NM_000335.4(SCN5A):c.5366A>G 6331 SCN5A []
(p.Aspl789Gly)
NM_000335.4(SCN5A):c.5402A>G 6331 SCN5A []
(p.Aspl801Gly)
NM_000335.4(SCN5A):c.5513A>G 6331 SCN5A [] (p.Aspl838Gly)
NM_198056.2(SCN5A):c.5726A>G 6331 SCN5A []
(p.Glnl909Arg)
4553 NM_000335.4(SCN5A):c.688A>G 6331 SCN5A ['CCGAGTCCTCCGGGCCCTGAAAACTRTATC (p.Ile230Val) AGTCATTTCAGGTGAAAATCA]
NM_000335.4(SCN5A):c.715A>G 6331 SCN5A []
(p.Ile239Val)
NM_000335.4(SCN5A):c.89A>G 6331 SCN5A []
(p.Glu30Gly)
4554 NM_000383.3(AIRE):c.254A>G 326 AIRE ['TTCTGGAGGGTGCTGTTCAAGGACTRCAAC (p.Tyr85Cys) CTGGAGCGCTATGGCCGGCTG]
4555 NM_006920.4(SCNlA):c. l876A>G 6323 SCN1A ['ACGCAACAGCAACCTGAGTCAGACCRGTA (p.Ser626Gly) GGTCATCCCGGATGCTGGCAGT']
4556 NM_006920.4(SCNlA):c.4352A>G -1 ['GAAGAAAGTCTGTACATGTATCTTTRCTTT (p.Tyrl451Cys) GTTATTTTCATCATCTTTGGG]
4557 NM_000165.4(GJAl):c.617A>G 2697 GJA1 ['TGTTTCCTCTCTCGCCCCACGGAGARAACC (p.Lys206Arg) ATCTTCATCATCTTCATGCTG]
4558 NM_000833.4(GRIN2A):c.l l23- 2903 GRIN2A ['AGCTGTGTCTTTGTGTTTGTGCTGCRGGTG 2A>G GGCAAGTGGGAGAACCATACG]
4559 NC_000007.14:g.62535490A>G -1 ['GGAGAGTTTTGAGGCCTGTGGTTGARATG
GAAATATCTTCACAGAAAAACT']
4560 NM_004595.4(SMS):c.983A>G 6611 SMS ['AATCTGACAGAAGCACTGTCGCTCTVTGA (p.Tyr328Cys) AGAACAGCTGGGGCGCCTGTAT']
4561 NM_001256864.1(DNAJC6):c.801- 9829 DNAJC6 ['CAAGAGAGTGCCAACCTTCTGTTTCRGATA 2A>G CCTGGGCTATATGTGTGACCT']
4562 NM_001204316.1(PRLR):c.635A> 5618 PRLR ['GTCCAGGTTCGCTGCAAACCAGACCRTGG G (p.His212Arg) ATACTGGAGTGCATGGAGTCCA']
4563 NM_012243.2(SLC35A3):c.886A> 23443 SLC35A3 ['TTGGCTTCAAGATTTTGTGCCAACCRGGTA G (p.Ser296Gly) AAATGTTCTTTTCTATTTTTT']
4564 NM_000179.2(MSH6):c.3439- 2956 MSH6 ['AAAGACCTTTTCCTCCCTCATTCACRGGCT 2A>G GGCTTATTAGCTGTAATGGCC]
4565 NM_000249.3(MLHl):c.l l3A>G 4292 MLH1 ['AATGCTATCAAAGAGATGATTGAGARCTG (p.Asn38Ser) GTACGGAGGGAGTCGAGCCGGG]
4566 NM_000249.3(MLHl):c.l22A>G 4292 MLH1 ['TTTTCTGTTTGATTTGCCAGTTTAGRTGCA (p.Asp41Gly) AAATCCACAAGTATTCAAGTG]
4567 NM_000249.3(MLHl):c.l559- 4292 MLH1 ['TTTTTGGTTTTATTTTTTGTTTTGCNGTTCT 2A>G CCGGGAGATGTTGCATAACC]
4568 NM_000249.3(MLHl):c.l990- 4292 MLH1 ['TTGAGGTATTGAATTTCTTTGGACCRGGTG 2A>G AATTGGGACGAAGAAAAGGAA]
4569 NM_000249.3(MLHl):c.208-2A>G 4292 MLH1 ['TTTACTCATCTTTTTGGTATCTAACVGAAA
GAAGATCTGGATATTGTATGT']
4570 NM_000249.3(MLHl):c.544A>G 4292 MLH1 ['TGGGAAAATTTTGGAAGTTGTTGGCRGGT (p.Argl82Gly) ACAGTCCAAAATCTGGGAGTGG]
4571 NM_000249.3(MLHl):c.545+3A> 4292 MLH1 ['AAAATTTTGGAAGTTGTTGGCAGGTRCAGT G CCAAAATCTGGGAGTGGGTCT']
4572 NM_000249.3(MLHl):c.546-2A>G 4292 MLH1 ['TCTTACTCTTTTGTTTTTCTTTTCCVGGTAT
TCAGTACACAATGCAGGCAT']
4573 NM_000249.3(MLHl):c.589-2A>G 4292 MLH1 ['TTGTGTCTTCTGCTGTTTGTTTATCRGCAAG
GAGAGACAGTAGCTGATGTT']
4574 NM_000249.3(MLHl):c.677+3A> 4292 MLH1 ['GATTTTTTTATATAGGTTATCGACABACCG G ACTAACAGCATTTCCAAAGAT']
4575 NM_000249.3(MLHl):c.791-2A>G 4292 MLH1 ['ACTGGTTGCTTTCTTTTTATTGTTTRGATCG
TCTGGTAGAATCAACTTCCT']
4576 NM_000249.3(MLHl):c.883A>G 4292 MLH1 ['AAACACACACCCATTCCTGTACCTCVGGTA (p.Ser295Gly) ATGTAGCACCAAACTCCTCAA']
4577 NM_000249.3(MLHl):c.884+4A> 4292 MLH1 ['CACACCCATTCCTGTACCTCAGGTARTGTA G GCACCAAACTCCTCAACCAAG]
4578 NM_000251.2(MSH2):c.l277- 4436 MSH2 ['TTTGTTTGTTTTACTACTTTCTTTTVGGAAA 2A>G ACACCAGAAATTATTGTTGG']
4579 NM_000251.2(MSH2):c.1511 - 4436 MSH2 ['CTTTTTCTTTTCTTCTTGATTATCARGGCTT 2A>G GGACCCTGGCAAACAGATTA']
4580 NM_000251.2(MSH2):c.1660 A>G 4436 MSH2 ['GAAGAATGGTGTTAAATTTACCAACNGGT (p.Ser554Gly) TTGCAAGTCGTTATTATATTTT']
4581 NM_000535.5(PMS2):c.lA>G 5395 PMS2 ['CCGAGGCGGATCGGGTGTTGCATCCDTGG (p.MetlVal) AGCGAGCTGAGAGCTCGAGGTG]
4582 NM_000535.5(PMS2):c.989-2A>G 5395 PMS2 ['ATAAATATGTTTTCTTTTTTGCCTTRGAATG
CGTTGATATCAATGTTACTC]
4583 NM_000059.3(BRCA2):c.426- 675 BRCA2 ['TAAGGGATTTGCTTTGTTTTATTTTRGTCCT 2A>G GTTGTTCTACAATGTACACA']
4584 NM_024876.3(ADCK4):c.857A>G 79934 ADCK4 ['CAGCAGGAGCTGGCTTGGGAGTGTGRCTA (p.Asp286Gly) CCGTCGTGAGGCGGCTTGTGCC]
4585 NM_006005.3(WFSl):c.l385A>G 7466 WFS1 ['TACACGCGCAGGGCCCTGGCCACCGRGGT (p.Glu462Gly) CACCGCCGGCCTGCTATCGCTG]
4586 NM_000019.3 (AC AT 1 ) : c.472 A>G 38 AC ATI ['GGCAGGTGGGATGGAGAGCATGTCCRATG (p.Asnl58Asp) TTCCATATGTAATGAACAGAGG]
4587 NM_000050.4(ASSl):c.496-2A>G 445 ASS1 ['TCCACCTGTGCTGTCTCTTTCCTGCRGCAA
CACGGGATTCCCATCCCGGTC]
4588 NM_000117.2(EMD):c.450-2A>G 2010 EMD ['CCCACTTGCTCCCCTCTTTTGCCTCRGGGA
ACGCCCCATGTACGGCCGGGA']
4589 NM_000153.3(GALC):c.334A>G 2581 GALC ['GC ATAATGC ATGTGGGAGGGCTCAGB GCC (p.Thrl l2Ala) GTCTGAATAGAGGAGAGCAAAA]
4590 NM_000155.3(GALT):c.905-2A>G 2592 GALT ['CCCCACTGTCTCTCTTCTTTCTGTCRGGGG
CTCCCACAGGATCAGAGGCTG]
4591 NM_000159.3 (GCDH) :c .542 A>G 2639 GCDH ['CTCCTGGGCTGCTTCGGGCTCACAGRGCCC (p.Glul81Gly) AACAGCGGAAGTGACCCCAGC]
4592 NM_000169.2(GLA):c.509A>G -1 ['TGGGGAGTAGATCTGCTAAAATTTGRTGGT (p.Aspl70Gly) TGTTACTGTGACAGTTTGGAA']
4593 NM_000169.2(GLA):c.548-2A>G -1 - ['TATTTTACCCATTGTTTTCTCATACRGGTTA TAAGCACATGTCCTTGGCCC]
4594 NM_000169.2(GLA):c.647A>G -1 ['TCATATCTGTTTTCACAGCCCAATTRTACA (p.Tyr216Cys) GAAATCCGACAGTACTGCAAT']
4595 NM_000232.4(SGCB):c.1 A>G 6443 SGCB ['GCTCGGCGGCGGCGGGCGCGGGAAGRTGG (p.MetlVal) CGGCAGCGGCGGCGGCGGCTGC]
4596 NM_000255.3(MUT):c.l445-2A>G 4594 MUT ['TAAAATTTTTCTTTGGGAAATTACCRGGTT
CTGAAGTAATTGTTGGAGTAA']
4597 NM_000277.1 (P AH) :c .533 A>G 5053 PAH ['AGTGGGCAGCCCATCCCTCGAGTGGDATA (p.Glul78Gly) CATGGAGGAAGAAAAGAAAACA']
4598 NM_000277.1(PAH):c.974A>G 5053 PAH ['CAGATTGACTTTCCATTCCAGATTTRCTGG (p.Tyr325Cys) TTTACTGTGGAGTTTGGGCTC]
4599 NM_000328.2(RPGR):c.l55-2A>G 6103 RPGR ['TGATTATTTCTTTTTCCCTCCTACCRGGAA
ATAATAAACTTTACATGTTTG]
4600 NM_000350.2(ABCA4):c.4540- 24 ABCA4 ['ATTAACGTGGGTGTCTCATTGCCTCRGAGA 2A>G ACACAGCGCAGCACGGAAATT']
4601 NM_000350.2(ABCA4):c.67-2A>G 24 ABCA4 ['TTCTCTCTTTTTGTTTTGTTTTTCCRGATTC
GCTTTGTGGTGGAACTCGTG]
4602 NM_000487.5(ARSA):c.1108- 410 ARSA ['CCCCGTGACCCCTGACTCTGCCCCCRGAGC 2A>G CCTCGGCAGTCTCTCTTCTTC]
4603 NM_000489.4(ATRX):c.l34-2A>G 546 ATRX ['TAATGTTCTTTATTTCTTCTTTTTTRGATAA
AATCAGTGGTTCTGGAAGTA]
4604 NM_000489.4(ATRX):c.536A>G 546 ATRX ['TGCACTGCTTGTGGACAACAGGTCARTCAT (p.Asnl79Ser) TTTCAAAAAGATTCCATTTAT']
4605 NM_000512.4(GALNS):c.1171 A> 2588 GALNS ['CTTCTATTACCGTGGCGACACGCTGRTGGC G (p.Met391Val) GGCCACCCTCGGGCAGCACAA']
4606 NM_000521.3(HEXB):c.l243- 3074 HEXB ['ATGTATTGCAATTTGTAACGTTAATRGCTT 2A>G GCGCCGGGCACAATAGTTGAA']
4607 NM_000531.5(OTC):c.238A>G 5009 OTC ['ATAGTATTTGCCTTTATTGCAAGGGRAGTC (p.Lys80Glu) CTTAGGCATGATTTTTGAGAA']
4608 NM_000551.3(VHL):c.233A>G 7428 VHL ['GAGCCCTCCCAGGTCATCTTCTGCARTCGC (p.Asn78Ser) AGTCCGCGCGTCGTGCTGCCC]
4609 NM_001848.2(COL6Al):c.805- 1291 COL6A1 ['CCAACCTTGACCTGTTTTGTGTTCCRGGGA 2A>G GAACGAGGCAAGCCGGGGCTC]
4610 NM_001918.3(DBT):c.773-2A>G 1629 DBT ['AATGAATAACAATTTAATGCTTTTCRGGCT
TTCAAAAAGCAATGGTCAAGA']
4611 NM_003482.3(KMT2D):c.5645- 8085 KMT2D ['TCAACAGTGTCCTTCATTCCCCCACRGAAC 2A>G TGCCCAAGATGGAATCCAAGG]
4612 NM_003494.3(DYSF):c.l398- 8291 DYSF ['CAGGCCCTCTCTGCTCCCTTGCTCTRGGGA 2A>G CCGCCTGACTCACAATGACAT']
4613 NM_004006.2(DMD):c.1332-9 A>G 1756 DMD ['AAGAGGTCATAATAGGCTTCTTTCAVATTT
TCAGTTTACATAGAGTTTTAA]
4614 NM_004006.2(DMD):c.3432+3A> 1756 DMD ['AGTGGGATCACATGTGCCAACAGGTRTAG G ACAATCTCTTTCACTGTGGCTT']
4615 NM_004006.2(DMD):c.6763-2A>G 1756 DMD ['AAACGTTGTTGCATTTGTCTGTTTCRGTTA CTGGTGGAAGAGTTGCCCCTG]
4616 NM_004006.2(DMD):c.9224+6193 1756 DMD ['AGCTGTGAATGCTTCATTCAGGCCCRAGTA 4A>G AATATAGGAAGAGGTGTAGTG]
4617 NM_004006.2(DMD):c.9225- 1756 DMD ['GCTGTGAATGCTTCATTCAGGCCCARGTAA 647A>G ATATAGGAAGAGGTGTAGTGG]
4618 NM_004006.2(DMD):c.9650-2A>G 1756 DMD ['TGTTGCAATTTTCTTCTTCCTTTGTRGACCT
TTTCAAGCAAGTGGCAAGTT']
4619 NM_015560.2(OPAl):c.983A>G 4976 OPA1 ['GAGATGATGACACGTTCTCCAGTTAVGGT (p.Lys328Arg) AAGAACATAGGCCGTCTCAGTG]
4620 NM_144997.5(FLCN):c. l433- 20116 FLCN ['TTGCTCTGCCCCTGCCCTTCTCCCCRGTGG 2A>G 3 GCCCCACCATCCTGAATAAGA]
4621 M_144997.5(FLCN):c.250-2A>G 20116 FLCN ['AGATTTACTTTTCCTTTTCATGGACRGGGC
3 TGCCGGTCACTTGCTGCAGGG]
4622 NM_000146.3(FTL):c.lA>G 2512 FTL ['GTTAGCTCCTTCTTGCCAACCAACCRTGAG (p.MetlVal) CTCCCAGATTCGTCAGAATTA']
4623 NM_024531.4(SLC52A2):c.914A> 79581 SLC52A2 ['GTGCAGAGCTTTTCCTGCTTACCCTRCGGG G (p.Tyr305Cys) CGTCTGGCCTACCACCTGGCT']
4624 NM_001743.5(CALM2):c.293A>G 805 CALM2 ['TACTAAATTTTTTGCTAGGATGGCADTGGC (p.Asn98Ser) TATATTAGTGCTGCAGAACTT']
4625 M_014754.2(PTDSSl):c. l058A> 9791 PTDSS1 ['ACACAGTGCAAGCGCGTAGGAACACRATG G (p.Gln353Arg) CTGGGTGTTTGGGTGAGTAATC]
4626 NM_052844.3(WDR34):c.l307A> 89891 WDR34 ['GGACCAGCGCACAGCAAACAGATACYTGA G (p.Lys436Arg) GGGAGAGCTGCAGCGAAGTCAA']
4627 NM_001130010.2(C15orf41):c.281 84529 C15orf41 ['TACTTCTGTTTTATAAAGGTGGACTVTGCG A>G (p.Tyr94Cys) CCCTCATTAATGGCTCGGCTT']
4628 NM_001290048.1(ATL3):c.521A> 25923 ATL3 ['AATTTCATCCATTGCCAGACGACCGYATTC G (p.Tyrl74Cys) TGTGAAGAGCTTTAAAAAAGA']
4629 NM_000531.5(OTC):c.l034A>G 5009 OTC ['GTCATGGTGTCCCTGCTGACAGATTRCTCA (p.Tyr345Cys) CCTCAGCTCCAGAAGCCTAAA']
4630 NM_000531.5(OTC):c.l22A>G 5009 OTC ['AATAAAGTGCAGCTGAAGGGCCGTGRCCT (p.Asp41Gly) TCTCACTCTAAAAAACTTTACC]
4631 NM_000531.5(OTC):c.l55A>G 5009 OTC ['ACTCTAAAAAACTTTACCGGAGAAGRAAT (p.Glu52Gly) TAAATATATGCTATGGCTATCA']
4632 NM_000531.5 (OTC) :c .1 A>G 5009 OTC ['TCGTCCTTTACACAATTAAAAGAAGDTGCT (p.MetlVal) GTTTAATCTGAGGATCCTGTT']
4633 NM_000531.5(OTC):c.268A>G 5009 OTC ['CTTAGGCATGATTTTTGAGAAAAGARGTA (p.Ser90Gly) CTCGAACAAGATTGTCTACAGA']
4634 NM_000531.5(OTC):c.277A>G 5009 OTC ['GATTTTTGAGAAAAGAAGTACTCGARCAA (p.Thr93Ala) GATTGTCTACAGAAACAGGTAA']
4635 NM_000531.5(OTC):c.350A>G 5009 OTC ['TGTTTTCTTACCACACAAGATATTCDTTTG (p.Hisll7Arg) GGTGTGAATGAAAGTCTCACG]
4636 NM_000531.5(OTC):c.377A>G 5009 OTC ['TTGGGTGTGAATGAAAGTCTCACGGRCAC (p.Aspl26Gly) GGCCCGGTTTGTAAATATTTTC]
4637 NM_000531.5(OTC):c.387-2A>G 5009 OTC ['GATTATCTTTTTCTTGGTTTGCCACNGTGT ATTGTCTAGCATGGCAGATGC]
4638 NM_000531.5(OTC):c.481A>G 5009 OTC ['TAAAGAAGCATCCATCCCAATTATCRATG (p.Asnl61Asp) GGCTGTCAGATTTGTACCATCC]
4639 NM_000531.5(OTC):c.482A>G 5009 OTC ['AAAGAAGCATCCATCCCAATTATCARTGG (p.Asnl61Ser) GCTGTCAGATTTGTACCATCCT']
4640 NM_000531.5(OTC):c.503A>G 5009 OTC ['ATCAATGGGCTGTCAGATTTGTACCVTCCT (p.Hisl68Arg) ATCCAGATCCTGGCTGATTAC]
4641 NM_000531.5(OTC):c.524A>G 5009 OTC ['TACCATCCTATCCAGATCCTGGCTGDTTAC (p.Aspl75Gly) CTCACGCTCCAGGTTGGTTTA']
4642 NM_000531.5(OTC):c.527A>G 5009 OTC ['CATCCTATCCAGATCCTGGCTGATTRCCTC (p.Tyrl76Cys) ACGCTCCAGGTTGGTTTATTT']
4643 NM_000531.5(OTC):c.541-2A>G 5009 OTC ['TCATCTCCTTCATCCCGTGCCTTTTRGGAA
CACTATAGCTCTCTGAAAGGT']
4644 NM_000531.5(OTC):c.542A>G 5009 OTC ['TCTCCTTCATCCCGTGCCTTTTAGGRACAC (p.Glul81Gly) TATAGCTCTCTGAAAGGTCTT']
4645 NM_000531.5(OTC):c.548A>G 5009 OTC ['TCATCCCGTGCCTTTTAGGAACACTRTAGC (p.Tyrl83Cys) TCTCTGAAAGGTCTTACCCTC]
4646 NM_000531.5(OTC):c.595A>G 5009 OTC ['CCTCAGCTGGATCGGGGATGGGAACRATA (p.Asnl99Asp) TCCTGCACTCCATCATGATGAG]
4647 NM_000531.5(OTC):c.596A>G 5009 OTC ['CTCAGCTGGATCGGGGATGGGAACARTAT (p.Asnl99Ser) CCTGCACTCCATCATGATGAGC]
4648 NM_000531.5(OTC):c.613A>G 5009 OTC ['TGGGAACAATATCCTGCACTCCATCRTGAT (p.Met205Val) GAGC GC AGC G A A ATTC GG A AT']
4649 NM_000531.5(OTC):c.716A>G 5009 OTC ['AAGTTGGC AGAGC AGT ATGCC AAAGD GGT (p.Glu239Gly) ATGCTCTTTACATGTAAAGCTA]
4650 NM_000531.5 (OTC) :c .717+3 A>G 5009 OTC ['TGGCAGAGCAGTATGCCAAAGAGGTRTGC
TCTTTACATGTAAAGCTATTAT']
4651 NM_000531.5(OTC):c.718-2A>G 5009 OTC ['TTTAACCAGCGTGTTTATGTATGCTRGAAT
GGTACCAAGCTGTTGCTGACA']
4652 NM_000531.5(OTC):c.788A>G 5009 OTC ['CATGGAGGCAATGTATTAATTACAGRCAC (p.Asp263Gly) TTGGATAAGCATGGGACAAGAA']
4653 NM_000531.5(OTC):c.790A>G 5009 OTC ['TGGAGGCAATGTATTAATTACAGACRCTTG (p.Thr264Ala) GATAAGCATGGGACAAGAAGA]
4654 NM_000531.5(OTC):c.905A>G 5009 OTC ['GCTGCCTCTGACTGGACATTTTTACDCTGC (p.His302Arg) TTGCCCAGAAAGCCAGAAGAA']
4655 NM_000531.5(OTC):c.929A>G 5009 OTC ['CACTGCTTGCCCAGAAAGCCAGAAGRAGT (p.Glu310Gly) GGATGATGAAGTCTTTTATTCT']
4656 NM_000531.5(OTC):c.988A>G 5009 OTC ['ACTAGTGTTCCCAGAGGCAGAAAACRGAA (p.Arg330Gly) AGTGGACAATCATGGTAAGCAA']
4657 NM_000322.4(PRPH2):c.422A>G 5961 PRPH2 ['GGGCTCAAGAACGGCATGAAGTACTRCCG (p.Tyrl41Cys) GGACACAGACACCCCTGGCAGG]
NM_003590.4(CUL3):c.l207- 8452 CUL3 []
26A>G
NM_003590.4(CUL3):c.l376A>G 8452 CUL3 [] (p.Lys459Arg)
NM_003590.4(CUL3):c.l377+3A> 8452 CUL3 []
G
4658 NM_017415.2(KLHL3):c.232A>G 26249 KLHL3 ['AGCCTGCAGCCCCTACTTCTGTGCGDTGTT (p.Met78Val) CACAGGTATGGTGAGTGGCCA]
NM_017415.2(KLHL3):c.926A>G 26249 KLHL3 []
(p.Gln309Arg)
4659 NM_005763.3(AASS):c.874A>G 10157 AASS ['CTCACATCAGTATTAAAACGACTTAYGTA (p.Ile292Val) GCGCTCCGGATGTTTGTCATAC]
4660 NM_000203.4(IDUA):c. l874A>G 3425 IDUA ['TCCTACCGAGTTCGAGCCCTGGACTRCTGG (p.Tyr625Cys) GCCCGACCAGGCCCCTTCTCG]
4661 NM_000546.5(TP53):c.736A>G 7157 TP53 ['GTGTAACAGTTCCTGCATGGGCGGCVTGA (p.Met246Val) ACCGGAGGCCCATCCTCACCAT']
4662 M_194442.2(LBR):c.l639A>G 3930 LBR ['GCCATGATGAGATCACCCAAGTAATYGGG (p.Asn547Asp) GTGGCGAACAAAGCCCCACCAT']
4663 NM_000090.3(COL3Al):c.2284- 1281 COL3A1 ['ATTAAAAAATATTTTTATTTCCTCTRGGGT 2A>G (p.Gly762_Lys779del) CCTACTGGTCCTATTGGTCCT']
4664 NM_000090.3(COL3Al):c.997- 1281 COL3A1 ['TCTTGAAATTGTATTTAATTTTTTCRGGGC 2A>G (p.Gly333_Lys350del+) CCTCCTGGTCCTCCTGGAACT']
4665 NM_000090.3(COL3Al):c.3418- 1281 COL3A1 ['CATTGTGATGTCATGATACTTTCTTDGGGA 2A>G CCTGTTGGACCCAGTGGACCT']
(p. Argl 139_Glyl 140insVSSTERY
YRSTCFRCLHFRKIFWHCDVMI LSW)
4666 NM_000090.3(COL3Al):c.997- 1281 COL3A1 ['AAAAGAGCTCTTGAAATTGTATTTARTTTT 10A>G (p.Pro332_Gly333insFFQ) TTCAGGGCCCTCCTGGTCCTC]
4667 NM_000090.3(COL3Al):c. l870- 1281 COL3A1 ['ACAGAGTGTATCATTATACTTTTCTDGGGG 2A>G (p.Gly624_Gln641del) CCTGGTGGTGACAAAGGAGAC]
4668 NM_000090.3(COL3Al):c.3202- 1281 COL3A1 ['CTTCTCAATTGAATGTTTTCATCTTRGGGC 2A>G (p.Glyl068_Prol085del) CCTGCTGGCCCTGCTGGTGCT']
4669 NM_000090.3(COL3Al):c. l762- 1281 COL3A1 ['AGTAAATACCGACCACTTCTTCTTTRGGGT 2A>G (p.Gly588_Gln605del) GCTCCTGGTAAGAATGGAGAA']
4670 NM_003611.2(OFDl):c.935+706A 8481 OFD1 ['CTTTTTGGCAATAATGAAAAGGTAARTTGA >G TCAAGAGAGAGGAAATAGGCA']
4671 M_014740.3 (EIF4 A3 ) :c .809 A>G 9775 EIF4A3 ['AGTGATGGTCAGTGTGTCGTAGAGGYCAC (p.Asp270Gly) ACAGAGTGTCAAATTTCCACTC]
4672 NM_001040436.2(YARS2):c.l303 51067 YARS2 ['TTTGTTACTTGTTGGTGATTTATGCYGACT A>G (p.Ser435Gly) CCGCCTTCTGTTATCATTCGA']
4673 NM_000277.1 (P AH) :c .1157 A>G 5053 PAH ['ACTGTCACGGAGTTCCAGCCCCTCTRTTAC (p.Tyr386Cys) GTGGCAGAGAGTTTTAATGAT']
4674 NM_000277.1(PAH):c.812A>G 5053 PAH ['TTCCACTGCACACAGTACATCAGACDTGG (p.His271Arg) ATCCAAGCCCATGTATACCCCC]
4675 NM_004820.3(CYP7Bl):c.889A>G 9420 CYP7B1 ['ATTGCCCAGAACATAGTTGGAATAGYGTT (p.Thr297Ala) TGCCACAGAGGCCCAGAGAAAG] 4676 NM_024301.4(FKRP):c.lA>G 79147 FKRP ['CCAGCTAGCCCCAGACTTCGGCCCCRTGCG (p.MetlVal) GCTCACCCGCTGCCAGGCTGC]
4677 NM_001955.4(EDNl):c.271A>G 1906 EDN1 ['GTATGGACTTGGAAGCCCTAGGTCCRAGA (p.Lys91Glu) GAGCCTTGGAGAATTTACTTCC]
4678 NM_198947.3(FAMl l lB):c.l879A 37439 FAM111B ['TAATGTATACTGTATGTTTACCCAARGAAG >G (p.Arg627Gly) 3 TTTCCTATCAGAGGTTTGGAA']
4679 NM_001282227.1(CECRl):c.l232 51816 CECR1 ['GCCCATGAAGACCTCATAGAAATCAYAGG A>G (p.Tyr411Cys) ACAAGCCTTTGGCACCAAACAT']
4680 NM_033419.4(PGAP3):c.914A>G 93210 PGAP3 ['TGATTCCTTCAGCAGGTACAGGCTGYCATC (p.Asp305Gly) TTCCAGAAAGCTGTGGGCCAA]
4681 NM_007294.3(BRCAl):c.l35- 672 BRCA1 ['TGTTCTTTCTTTCTTTATAATTTATRGATTT 2A>G TGCATGCTGAAACTTCTCAA']
4682 NM_007294.3(BRCAl):c.4676- 672 BRCA1 ['AAATTAAACTTCTCCCATTCCTTTCRGAGG
2A>G GAACCCCTTACCTGGAATCTG]
4683 M_015474.3(SAMHDl):c.l l53A 25939 SAMHD1 ['GGAAATGACAATCAAGTTTCTTACAYTGT >G (p.Met385Val) ATCAATAATGTTGCCAACTTTG]
4684 NM_015474.3(SAMHDl):c.l411- 25939 SAMHD1 ['TTTTGGAAGAGATTCATAGTCCTCCYGGAA 2A>G AACACAAGACTCCCCATGTTA']
4685 NM_000097.5(CPOX):c.980A>G 1371 CPOX ['ACCAATGCCCCGCCGTTCTCCACGAYGGG (p.His327Arg) CTATAAAGAAGTAATCATCACA]
4686 NM_012338.3(TSPAN12):c.413A> 23554 T SPAN 12 ['AAGCCACCGATATCTAGGTAATCCAYAAT G (p.Tyrl38Cys) TTGTCATCCTGGCTTTCAAAGT']
4687 NM_000406.2(GNRHR):c.94A>G 2798 GNRHR ['GTCACTCGGATCTTTCCAGACAAGGYCAG (p.Thr32Ala) AGTGGGGAGGTTGCCCTGCATC]
4688 NM_199189.2(MATR3):c. l864A> 9782 MATR3 ['TGGTTCCCAGAAGACTGAGAGTTCARCCG G (p.Thr622Ala) AAGGTAAAGAACAAGAAGAGAA']
4689 NM_003181.3(T):c.512A>G 6862 T ['CTGTGGACCCCCAACTCTCACTATGYGGAT (p.Hisl71Arg) TCGAGGCTCATACTTATGCAA']
4690 NM_000321.2(RBl):c.l927A>G 5925 RBI ['AGCCTTCCAGACCCAGAAGCCATTGRAAT (p.Lys643Glu) CTACCTCTCTTTCACTGTTTTA]
4691 NM_002234.3(KCNA5):c.l43A>G 3741 KCNA5 ['GCTGGGCTCAGCGATGGGCCCAAGGRGCC (p.Glu48Gly) GGCGCCAAAGGGGCGCGGCGCG]
4692 NM_178014.3(TUBB):c.895A>G 20306 TUBB ['CCAGCAGGTCTTCGATGCCAAGAACRTGA (p.Met299Val) 8 TGGCTGCCTGTGACCCCCGCCA']
4693 NM_000136.2(FANCC):c.-78- 2176 FANCC ['TGCTTCTATTTGTTCCCTTTCTTACRGATTT 2A>G AATGTGTGCCGACCATTTCC]
4694 NM_000546.5(TP53):c.488A>G 7157 TP53 ['CTCCGTCATGTGCTGTGACTGCTTGYAGAT (p.Tyrl63Cys) GGCCATGGCGCGGACGCGGGT']
4695 NM_000546.5(TP53):c.659A>G 7157 TP53 ['TTTCGACATAGTGTGGTGGTGCCCTVTGAG (p.Tyr220Cys) CCGCCTGAGGTCTGGTTTGCA]
4696 NM_000546.5(TP53):c.701A>G 7157 TP53 ['GGCTCTGACTGTACCACCATCCACTRCAAC (p.Tyr234Cys) TACATGTGTAACAGTTCCTGC]
4697 NM_002878.3(RAD51D):c.lA>G -1 ['CACAGTCCGACCCTGAGCACGCCCAYGTT (p.MetlVal) CCCCGCAGGCCGGAACAGCCCC] 4698 NM_058216.2(RAD51C):c.706- 5889 RAD51C ['ATCTAATATTATCTCTTCTGTATTTRGGTTC 2A>G GACTAGTGATAGTGGATGGT']
4699 NM_015713.4(RRM2B):c.556A>G 50484 RRM2B ['TCTACAGCAGCAAAGGCCACCACTCYTTC (p.Argl86Gly) CCCTGGGAGACATAAAATCGTT']
4700 NM_015713.4(RRM2B):c.581A>G 50484 RRM2B ['AAAAGATCCTGAGAAGAAAACTCCTYCTA (p.Glul94Gly) CAGCAGCAAAGGCCACCACTCT']
4701 NM_000219.5(KCNEl):c.242A>G 3753 KCNE1 ['CACTCGAACGACCCATTCAACGTCTDCATC (p.Tyr81Cys) GAGTCCGATGCCTGGCAAGAG]
4702 NM_000271.4(NPCl):c.l832A>G 4864 NPC1 ['TTCACTGCTGAACGAAGTATTGAAGRTGA (p.Asp611Gly) ACTAAATCGTGAAAGTGACAGT']
4703 NM_000257.3(MYH7):c. l952A>G 4625 MYH7 ['CTGGGGCTGTGTCCCACTCACCCTGYGCAG (p.His651Arg) AGCTGACACAGTCTGAAAGGA']
4704 NM_000540.2(RYRl):c.7043A>G 6261 RYR1 ['GGGTGGCCAGGCGAGAGCGTGGAGGRGA (p.Glu2348Gly) ACGCCAATGTGGTGGTGCGGCTG]
4705 NM_058216.2(RAD51C):c.l027- 5889 RAD51C ['TTTGTATATATATTTTTTATCTTTCRGCCTC 2A>G AGGGATTTAGAGATACTGTT']
4706 NM_130838.1(UBE3A):c. l694- 7337 UBE3A ['TGTATTTTTAAAAATCATTTCTTATRGGTA 2A>G TGTTCACATACGATGAATCTA]
4707 NM_022168.3(IFIHl):c.l009A>G 64135 IFIH1 ['TCCTTGGCAATGTAAACAGCCACTCYGGTT (p.Arg337Gly) TTTCCACTCCCTGTAGGGAGG]
4708 NM_022068.3(PIEZO2):c.2134A> 63895 PIEZ02 ['GCCACACAGAACAGGAACAGCACCAYGTA G (p.Met712Val) GATGATTTTGTACATTACGATT']
4709 NM_001164342.2(ZBTB20):c.l787 26137 ZBTB20 ['ACCGCCAAACAGAACTACGTCAAGCRCAT A>G (p.His596Arg) GTTCGTACACACAGGTGAGTGT']
4710 NM_001128159.2(VPS53):c.2084A 55275 VPS53 ['TGCCTGATACTACGTCCATCTCACCYGTTC >G (p.Gln695Arg) TGCTCCCACCATGCTAATTGG]
4711 NM_003108.3(SOXl l):c.347A>G 6664 SOX11 ['AAGCACATGGCCGACTACCCCGACTRCAA (p.Tyrl l6Cys) GTACCGGCCCCGGAAAAAGCCC]
4712 NM_020435.3(GJC2):c.-170A>G 57165 GJC2 ['TTCAGACCCTGAGGCCGAGGGGGGARCAA
TGGGGCCCTTGAGGGCCCCTCC]
4713 NM_004817.3(TJP2):c.l992-2A>G 9414 TJP2 ['GATTTACTTCCCGTGGTTTCTTCTCRGAGC
TGAACAAATGGCCAGTGTTCA']
4714 NM_017565.3(FAM20A):c.720- -1 ['GGTGTCTCCTCATCTCGCTGCTGTCYGGAA 2A>G GGAAGGAAGGAATCACGCCCT']
4715 NM_002764.3(PRPSl):c.343A>G 5631 PRPS1 ['AATCTCAGCCAAGCTTGTTGCAAATRTGCT (p.Metl l5Val) ATCTGTAGCAGGTGCAGATCA']
4716 NM_000216.2(ANOSl):c.lA>G 3730 ANOS1 ['TCGCCCTCGCCCTCGACCCGCAGCCRTGGT (p.MetlVal) GCCCGGGGTGCCCGGCGCGGT']
4717 NM_031229.2(RBCKl):c.1160 A> 10616 RBCK1 ['TGGTGCTTCTTTGAGGATGATGTCARTGAG G (p.Asn387Ser) TTCACCTGCCCTGTGTGTTTC]
4718 NM_015599.2(PGM3):c.737A>G 5238 PGM3 ['CACAAAGTCAGCTCCACATAAATGAYTGA (p.Asn246Ser) GTTTGCCCTTGGACCCATCATT']
4719 NM_015599.2(PGM3):c.l352A>G 5238 PGM3 ['TTTCTCTCACACCTGAACTTTAAGTYGTCT (p.Gln451Arg) GTTTGGAAGATCTGTATAGAG] 4720 NM_000535.5(PMS2):c.904-2A>G 5395 PMS2 ['CTTTTCTACTCCTTGTATTTTGTGCRGGTCT
GCAGACTCGTGAATGAGGTC]
4721 NM_000546.5(TP53):c.358A>G 7157 TP53 ['GGGCTTCTTGCATTCTGGGACAGCCDAGTC (p.Lysl20Glu) TGTGACTTGCACGGTCAGTTG]
4722 NM_000546.5(TP53):c.842A>G 7157 TP53 ['CGTGTTTGTGCCTGTCCTGGGAGAGDCCGG (p.Asp281Gly) CGCACAGAGGAAGAGAATCTC]
4723 NM_001128425.1(MUTYH):c. ll87 4595 MUTYH ['CCCCTGCCTGGCTGCCCTCCCTCTCRGGTC -2A>G TGCTGGCAGGACTGTGGGAGT']
4724 NM_000546.5(TP53):c. ll01-2A>G 7157 TP53 ['TCTCCTCCCTGCTTCTGTCTCCTACRGCCAC
CTGAAGTCCAAAAAGGGTCA']
4725 NM_000314.6(PTEN):c.493-2A>G 5728 PTEN ['GGCTTCTCTTTTTTTTCTGTCCACCRGGGA
GTAACTATTCCCAGTCAGAGG]
4726 NM_000051.3(ATM):c.3994-2A>G 472 ATM ['ATATATTTTAATTTTGTGCCCTTGCRGATT
GATCACTTATTCATTAGTAAT']
4727 NM_000314.6(PTEN):c.403A>G 5728 PTEN ['TGGAAAGGGACGAACTGGTGTAATGRTAT (p.Ilel35Val) GTGCATATTTATTACATCGGGG]
4728 NM_000249.3(MLHl):c.l l7-2A>G 4292 MLH1 ['TAAATTATTTTCTGTTTGATTTGCCDGTTTA
GATGCAAAATCCACAAGTAT']
4729 NM_025150.4(TARS2):c.695+3A> 80222 TARS2 ['GGTCCAACAGCAACAGTATATGGGTRAGA G GTTGTCAAGATTAAGGCAAACA']
4730 NM_206933.2(USH2A):c. l0544A> 7399 USH2A ['TGGACCAAAATAGACAATCTTGAAGVTAC G (p.Asp3515Gly) AATTGTCTTAAACTGGAGAAAA']
4731 NM_000834.3(GRIN2B):c. l238A> 2904 GRIN2B ['CATCTGAGCATTGTGACCCTGGAGGRGGC G (p.Glu413Gly) ACCATTTGTCATTGTGGAAAGT']
4732 NM_004830.3(MED23):c.3638A> 9439 MED23 ['TGTAGCTATACGTTAGCTCTTGCACRTGCT G (p.Hisl213Arg) GTGTGGCACCATTCTAGCATC]
4733 NM_003159.2(CDKL5):c.l25A>G 6792 CDKL5 ['GAAACACATGAAATTGTGGCGATCARGAA (p.Lys42Arg) ATTCAAGGACAGTGAAGGTAGA']
4734 NM_003159.2(CDKL5):c.380A>G 6792 CDKL5 ['CTAATCAAGGCTATTCACTGGTGCCRTAAG (p.Hisl27Arg) AATGATATTGTCCATCGAGGT']
4735 NM_003159.2(CDKL5):c.578A>G 6792 CDKL5 ['AGCGCTCCCTATGGAAAGTCCGTGGRCAT (p.Aspl93Gly) GTGGTCGGTGGGCTGTATTCTT']
4736 NM_198282.3(TMEM173):c.461A 34006 TMEM173 ['TGACCATGCCAGCCCATGGGCCACGYTGA >G (p.Asnl54Ser) 1 AATTCCCTTTTTCACACACTGC]
4737 NM_032018.6(SPRTN):c.350A>G 83932 SPRTN ['CTCCTGCATGAAATGATACATGCCTRTTTA (p.Tyrl l7Cys) TTTGTCACTAATAACGACAAA]
4738 NM_001759.3(CCND2):c.838A>G 894 CCND2 ['GGAGGATGAACTGGACCAAGCCAGCRCCC (p.Thr280Ala) CTACAGACGTGCGGGATATCGA']
4739 NM_007315.3(STATl):c.854A>G 6772 STAT1 ['AGGGTCATGTTCGTAGGTGTATTTCYGTTC (p.Gln285Arg) CAATTCCTCCAACTTTTTAAG]
4740 NM_139276.2(STAT3):c.l l75A>G 6774 STAT3 ['GTTGGATTCTTCCATGTTCATCACTYTTGT (p.Lys392Arg) GTTTGTGCCCAGAATGTTAAA']
4741 NM_001037811.2(HSD17B10):c.25 3028 HSD17B10 ['GATGCCTGCACAGTTGACAGCTACAYCCA 7A>G (p.Asp86Gly) CACGGCCAAACTTTCCTTTTGC] 4742 NM_005726.5(TSFM):c.57+4A>G 10102 TSFM ['CGCGCGGACCGGGAGCTACCCGGTGRGAA
GTCCTGGTGCTGGTACCGACCT']
4743 NM_000166.5(GJBl):c.580A>G 2705 GJB1 ['CGAGAAAACCGTCTTCACCGTCTTCRTGCT (p.Metl94Val) AGCTGCCTCTGGCATCTGCAT']
4744 NM_001077494.3(NFKB2):c.2594 4791 NFKB2 ['TTACCCCCAGCAGAGGTGAAGGAAGRCAG A>G (p.Asp865Gly) TGCGTACGGGAGCCAGTCAGTG]
4745 NC_012920.1 :m.5559A>G 4578 MT-TW ['TGTTACAGAAATTAAGTATTGCAACYTACT
GAGGGCTTTGAAGGCTCTTGG]
4746 NC_012920.1 :m.l3514A>G 4540 MT-ND5 ['TTCCTCACAGGTTTCTACTCCAAAGRCCAC
ATCATCGAAACCGCAAACATA']
4747 NM_007315.3(STATl):c.2018A>G 6772 STAT1 ['GTAATACTTTCCAAAGGCATGGTCTYTGTC (p.Lys673Arg) AATATTTGGATACAGATACTT']
4748 NM_007315.3(STATl):c.l909A>G 6772 STAT1 ['GGGAAAGTAACAGCAGAAAGTTCTTYCTT (p.Lys637Glu) CGTGTAGGGTTCAACCGCATGG]
4749 NM_000060.3(BTD):c.683A>G 686 BTD ['GCATTCGATGTTCCTCTTAAAGTGGRTCTC (p.Asp228Gly) ATCACCTTTGATACCCCCTTT']
4750 NM_004992.3(MECP2):c.27-2A>G 4204 MECP2 ['TACTTACATACTTGTTTAACACTTCRGGGA
AGAAAAGTCAGAAGACCAGGA']
4751 NM_004992.3(MECP2):c378- 4204 MECP2 ['CTTGTGTCTTTCTGTTTGTCCCCACNGTCCC 2A>G CAGGGAAAAGCCTTTCGCTC]
4752 NM_003159.2(CDKL5):c.l00- 6792 CDKL5 ['TTTCCTTCTGCTTCTTTTCCCTTGCRGGAAA 2A>G CACATGAAATTGTGGCGATC]
4753 NM_003159.2(CDKL5):c.464- 6792 CDKL5 ['ACAACTTTGGACTTTGCTATCTTTCRGGTT 2A>G TTGCTCGTAATCTGTCAGAAG]
4754 NM_003159.2(CDKL5):c.978- 6792 CDKL5 ['GATATACTTCTTTTGTTTTTAACATRGAAA 2A>G CCAAGCCGGCAAAAGTACTGC]
4755 NM_032492.3(JAGNl):c.485A>G 84522 JAGN1 ['TTGGCAGTGCAAGTGCATGCCTGGCRGTTG (p.Glnl62Arg) TACTACAGCAAGAAGCTCCTA]
4756 NM_178517.3(PIGW):c.499A>G 28409 PIGW ['AACTGAGCTCTATGGGACAGGAGCARTGG (p.Metl67Val) 8 ATTTTGGAGTAGGTGGCTTTGT']
4757 NM_004387.3(NKX2-5):c.461A>G 1482 NKX2-5 ['TCGCAGGCGCAGGTCTATGAGCTGGRGCG (p.Glul54Gly) GCGCTTCAAGCAGCAGCGGTAC]
4758 NM_005859.4(PURA):c.289A>G 5813 PURA ['CGCCGAGGTGGGCGCGGGCGGCAACRAGA (p.Lys97Glu) GCCGCCTTACTCTCTCCATGTC]
4759 M_004046.5(ATP5Al):c.962A>G 498 ATP5A1 ['GCGGAGCAACAGAGACATCTGACGGHAAG (p.Tyr321Cys) CAACAGCCTATGGTACAGAATA']
4760 NM_000038.5(APC):c.l744-2A>G 324 APC ['GATGACCCATATTCTGTTTCTTACTRGGAA
TCAACCCTCAAAAGCGTATTG]
4761 NM_000751.2(CHRND):c. l319A> 1144 CHRND ['TTCAATGAGCTGAAGCCAGCTGTGGWTGG G (p.Asp440Gly) GGCAAACTTCATTGTTAACCAC]
4762 NM_130466.3(UBE3B):c.lA>G 89910 UBE3B ['GCAGGGTTTGTGCAAGTTTGCAAACRTGTT (p.MetlVal) CACCCTGTCTCAGACCTCGAG]
4763 NM_003159.2(CDKL5):c.211A>G 6792 CDKL5 ['AATGCTTCGGACTCTCAAGCAGGAARACA (p.Asn71Asp) TTGTGGAGTTGAAGGAAGCATT'] 4764 NM_003159.2(CDKL5):c.404- 6792 CDKL5 ['AATTTTTTTTTTATCTTGACACTCCRGATAT 2A>G AAAACCAGAAAATCTCTTAA']
4765 NM_003159.2(CDKL5):c.449A>G 6792 CDKL5 ['TTAATCAGCCACAATGATGTCCTAARACTG (p.Lysl50Arg) TGTGACTTTGGTAAGTTAAAA']
4766 NM_001813.2(CENPE):c.4063A>G 1062 CENPE ['ACTTCAAGGGCTTCTTTTATCGTTTYAAGG (p.Lysl355Glu) TTGTCTCTTTCCTTGGTTAGA']
4767 NM_023073.3(C5orf42):c.3290- 65250 C5orf42 ['ATTTTACCAAATTTTTGTATTTGATRGATC 2A>G CCATTGAAGAGGAAGATGCAA']
4768 NM_002977.3(SCN9A):c.2215A>G -1 ['GTGTTTAAAACTATGCAAATGGTAAYTGC (p.Ile739Val) AAGATCTACAAAAGGATCCATT']
4769 NM_002354.2(EPCAM):c.556- 4072 EPCAM ['TATTAGTATTAATTTGTATTATTCANTTTTT 14A>G TTCCCCAGTATGAGAATAAT']
4770 NM_002354.2(EPCAM):c.492- 4072 EPCAM ['TTAATACAGATTTTAAATTCTTTACRGTGC 2A>G ACTTCAGAAGGAGATCACAAC]
4771 NM_000053.3(ATP7B):c.l22A>G 540 ATP7B ['ATCCAGACCACCTTCATAGCCAACAYTGTC (p.Asn41Ser) AAAAGCAAAACTCTTCTTCAT']
4772 NM_022455.4(NSDl):c.4498- 64324 NSD1 ['ATGTGGGACATTATTTTTTCTTTGCRAGGG 3A>G AGAACTAATGCCTCACAGGAC]
4773 NM_022455.4(NSDl):c.5893- 64324 NSD1 ['TAAGTCAGGAGGTATTTCTTGTTCTRGGGT 2A>G GAATTTGTGAATGAGTATGTG]
4774 NM_022455.4(NSDl):c.6059A>G 64324 NSD1 ['AAAGGAAACTATGCTCGGTTCATGARTCA (p.Asn2020Ser) TTGCTGCCAGCCCAACTGTGAA']
4775 NM_022455.4(NSDl):c.6356A>G 64324 NSD1 ['GGTGAAATCACAAAGGAGCGAGAAGRTGA (p.Asp2119Gly) GTGTTTTAGTTGTGGGGATGCT']
4776 NM_133433.3(NIPBL):c.737A>G 25836 NIPBL ['AATCCTAGACATGGTTCAAGTGAGGRCTA (p.Asp246Gly) CCTACACATGGTGCACAGGCTA']
4777 NM_133433.3(NIPBL):c.5428- 25836 NIPBL ['TGTTTTTTTCTCTTCATTTTTCTTTRGCTTG 2A>G ATATGCAACGAGGTGTTCAT']
4778 NM_005249.4(FOXGl):c.757A>G 2290 FOXG1 ['CCACTACGACGACCCGGGCAAGGGCRACT (p.Asn253Asp) ACTGGATGCTGGACCCGTCGAG]
4779 NM_004380.2(CREBBP):c.4508A> 1387 CREBBP ['AAGCCAAAACGACTGCAGGAGTGGTRCAA G (p.Tyrl503Cys) AAAGATGCTGGACAAGGCGTTT']
4780 NM_004380.2(CREBBP):c3983- 1387 CREBBP ['CTCACCTGCTCCTTCTGGACTTCCTRGGGC 2A>G TGCAGACCACAAGACTGGGAA']
4781 NM_001083962.1(TCF4):c.991- 6925 TCF4 ['TTTTTTTTTTCTCCTTATTGTTTTARGATCT 2A>G ATTCTCCAGATCACACTAAC]
4782 NM_178151.2(DCX):c.l027-2A>G 1641 DCX ['TTAACTTTGTCTCTTCTCTTCTTATRGGACC
TGTACCTGCCTCTGTCCTTG]
4783 NM_178151.2(DCX):c.607A>G 1641 DCX ['TGTGCGTGTGCTTCTGAACAAGAAGRCAG (p.Thr203Ala) CCCACTCTTTTGAGCAAGTCCT']
4784 NM_178151.2(DCX):c.538A>G 1641 DCX ['GGAGAACAAGGACTTTGTGCGCCCCRAGC (p.Lysl80Glu) TGGTTACCATCATCCGCAGTGG]
4785 NM_178151.2(DCX):c.520A>G 1641 DCX ['CAACAGTGCACAGGCCAGGGAGAACRAGG (p.Lysl74Glu) ACTTTGTGCGCCCCAAGCTGGT'] 4786 NM_178151.2(DCX):c.451A>G 1641 DCX ['CAATCCCAACTGGTCTGTCAACGTADAAA (p.Lysl51Glu) CATCTGCCAATATGAAAGCCCC]
4787 NM_178151.2(DCX):c.413A>G 1641 DCX ['GACAACTTCTTTAAAAAGGTGGAGTRCAC (p.Tyrl38Cys) CAAGAATGTCAATCCCAACTGG]
4788 NM_000252.2(MTMl):c.301A>G 4534 MTM1 ['AATTGAAAAAATGGGAGGCGCGACARGTA (p.SerlOlGly) GAGGAGAAAATTCCTATGGTCT']
4789 NM_000252.2(MTMl):c343- 4534 MTM1 ['ACTGTCATACTTCTCCTTTGCCCCCRGGAC 2A>G ATGAGAAACCTGAGGTTCGCT']
4790 NM_000252.2(MTMl):c529- 4534 MTM1 ['GACTTGAATTTCTTTTTTTCCTCACRGGGCT 2A>G TGCCCAATCACCATTGGAGA']
4791 NM_000252.2(MTMl):c.550A>G 4534 MTM1 ['ACAGGGCTTGCCCAATCACCATTGGRGAA (p.Argl84Gly) TAACTTTTATTAATAAGTGCTA']
4792 NM_000252.2(MTMl):c.629A>G 4534 MTM1 ['TTGGTGGTTCCGTATCGTGCCTCAGRTGAT (p.Asp210Gly) GACCTCCGGAGAGTTGCAACT']
4793 NM_000252.2(MTMl):c.1406A>G 4534 MTM1 ['CAATTTTTGATTATAATTTTGGATCRTCTGT (p.His469Arg) ATAGTTGCCGATTTGGTACT']
4794 NM_003159.2(CDKL5):c.62A>G 6792 CDKL5 ['TTTGAGATCCTTGGGGTTGTAGGTGRAGGT (p.Glu21Gly) AAGTTGGAATTTTTGCGTTCC]
4795 NM_006306.3(SMClA):c.3254A> 8243 SMC1A ['GTGGCTACCAACATTGATGAGATCTRTAA G (p.Tyrl085Cys) GGCCCTGTCCCGCAATAGCAGT']
4796 NM_006306.3(SMClA):c.616- 8243 SMC1A ['CCTGCCACCATTCCCCTGTTTGCACRGGCT 2A>G GACCGGTACCAGCGCCTGAAG]
4797 NM_003937.2(KYNU):c.592A>G 8942 KYNU ['GCCTAACTTGATTTAGGGGGAAGAARCCT (p.Thrl98Ala) TAAGAATAGAGGATATCCTTGA']
4798 NM_005343.2(HRAS):c.l82A>G -1 ['TTGGACATCCTGGATACCGCCGGCCNGGA (p.Gln61Arg) GGAGTACAGCGCCATGCGGGAC]
4799 NM_012275.2(IL36RN):c.l04A>G 26525 IL36RN ['CTAGCTGGAGGGCTGCATGCAGGGARGGT (p.Lys35Arg) CATTAAAGGTTGGTGATGAAAC]
4800 NM_152296.4(ATPlA3):c.2318A> 478 ATP 1 A3 ['TCCATTGCCTACACCCTGACCAGCADTATC G (p.Asn773Ser) CCGGAGATCACGCCCTTCCTG]
4801 NM_000891.2(KCNJ2):c.953A>G 3759 KCNJ2 ['CAGTGCCGTAGCTCTTATCTAGCAARTGAA (p.Asn318Ser) ATCCTGTGGGGCCACCGCTAT']
4802 NM_017909.3(RMNDl):c.713A>G 55005 RMND1 ['TACACTTACAGTTTTGTCTTTCACAYTCCA (p.Asn238Ser) AAACACAGCAGCTCCTTCCCT']
4803 NM_005154.4(USP8):c.2150A>G 9101 USP8 ['GAACCTTCCAAACTGAAGCGCTCCTDCTCC (p.Tyr717Cys) TCCCCAGATATAACCCAGGCT']
4804 NM_014191.3(SCN8A):c.667A>G 6334 SCN8A ['CAATGTTTCAGCTCTACGCACTTTCRGGGT (p.Arg223Gly) ACTGAGGGCTTTGAAAACTAT']
4805 NM_021830.4(C10orf2):c.l754A> 56652 C10orf2 ['CCCCAGGCAAGCCAGGAAGCAGACARTGT G (p.Asn585Ser) TCTGATCCTGCAGGACAGGAAG]
4806 NM_001164405.1 (BHLHA9) : c.211 72785 BHLHA9 ['GTCCAAGGCGCGGCGCATGGCCGCCRACG A>G (p.Asn71Asp) 7 TGCGGGAGCGCAAGCGCATCCT']
4807 NM_002887.3(RARS):c.5A>G 5917 RARS ['GAGTGAGACGCTGATGGGAGGATGGRCGT (p.Asp2Gly) ACTGGTGTCTGAGTGCTCCGCG] 4808 NM_002887.3(RARS):c.lA>G 5917 RARS ['TGGCGAGTGAGACGCTGATGGGAGGRTGG (p.MetlVal) ACGTACTGGTGTCTGAGTGCTC]
4809 NM_005861.3(STUBl):c. l94A>G 10273 STUB1 ['CCGCTGGTGGCCGTGTATTACACCARCCGG (p.Asn65Ser) GCCTTGTGCTACCTGAAGATG]
4810 NM_005211.3(CSFlR):c.2655- 1436 CSF1R ['ATGGGCATCCTCTGTCCTATCTCCCRGATA 2A>G CAGCATCATGCAGGCCTGCTG]
4811 NM_032228.5(FARl):c.1094 A>G 84188 FAR1 ['CATAAGGCCCCAGCATTCCTGTATGRTATC (p.Asp365Gly) TACCTCAGGATGACTGGAAGA']
4812 NM_020461.3(TUBGCP6):c.2546A 85378 TUBGCP6 ['GCCATCCCAGGCAGGCGAGTGTTGCYCTG >G (p.Glu849Gly) CAGACCCAGAATCACAGCCTTG]
4813 NM_014305.3(TGDS):c.269A>G 23483 TGDS ['TTTGTGAAACTGCTTTTTGAAACAGRGAAA (p.Glu90Gly) ATAGATATAGTACTACATTTT']
4814 NM_014305.3(TGDS):c.892A>G 23483 TGDS ['TCTGTTTTGTTTTCCAAGACCCACCRATGA (p.Asn298Asp) CATGAGATACCCAATGAAGTC]
4815 NM_000118.3 (ENG) : c.1273 -2 A>G 2022 ENG ['GCTCGACAGGATATTGACCACCGCCYGCG
GGGATAAAGCCAGGGAGCTGGT']
4816 NM_005360.4(MAF):c.l72A>G 4094 MAF ['CATCGCCGGGGGCTCGCTGTCCTCCRCCCC (p.Thr58Ala) CATGAGCACGCCGTGCAGCTC]
4817 NM_002238.3(KCNHl):c.l399A> 3756 KCNH1 ['ACCTCTAGCACTTCTCTATGCCACCRTCTT G (p.Ile467Val) CGGGAATGTGACGACTATTTT']
4818 NM_172362.2(KCNHl):c.l508A> 3756 KCNH1 ['TTCGGGAATGTGACGACTATTTTCCRACAG G (p.Gln503Arg) ATGTATGCCAACACCAACAGA']
4819 NM_003392.4(WNT5A):c.257A>G 7474 WNT5A ['GGACAGAAGAAACTGTGCCACTTGTRTCA (p.Tyr86Cys) GGACCACATGCAGTACATCGGA']
4820 NM_001199252.2(SGOLl):c.67A> -1 ['GCCAAGTTTTTATTCCTTTTCTCTTYCATTC G (p.Lys23Glu) GCTTCTTTATGTCTTCAAGA']
4821 NM_000256.3(MYBPC3):c.2906- 4607 MYBPC3 ['ACTTAGCTACCCACTCTATACCCACRGAAC 2A>G GGCCACGGCTTCAGCTGCCCA']
4822 NM_000256.3(MYBPC3):c.l213A 4607 MYBPC3 ['GCTCAAGAATGGCCAGGAGATCCAGRTGA >G (p.Met405Val) GCGGCAGGTGCAGCCTGGGGTG]
4823 NM_005188.3(CBL):c.l228-2A>G 867 CBL ['TGTTACTATCTTTTGCTTCTTCTGCRGGAAT
CAGAAGGTCAGGGCTGTCCT']
4824 NM_000257.3(MYH7):c.5326A>G 4625 MYH7 ['TTCTTCATGCGCTCCAGGTGGGCGCYGGTG (p.Serl776Gly) TCCTGCTCCTTCTTCAGCTCC]
4825 NM_000257.3(MYH7):c.2708A>G 4625 MYH7 ['CAAGACAACCTGGCAGATGCTGAGGRGCG (p.Glu903Gly) CTGTGATCAGCTGATCAAAAAC]
4826 NM_000257.3(MYH7):c. l727A>G 4625 MYH7 ['AATATCAAGGGGAAGCCTGAAGCCCRCTT (p.His576Arg) CTCCCTGATCCACTATGCCGGC]
4827 NM_000257.3(MYH7):c. l496A>G 4625 MYH7 ['CACCACATGTTTGTGCTGGAGCAGGRGGA (p.Glu499Gly) GTACAAGAAGGAGGGCATCGAG]
4828 NM_000257.3(MYH7):c.2539A>G 4625 MYH7 ['GCTGCTGAAGAGTGCAGAAAGAGAGRAGG (p.Lys847Glu) AGATGGCCTCCATGAAGGAGGA]
4829 NM_000257.3(MYH7):c. l954A>G 4625 MYH7 ['CTTTCAGACTGTGTCAGCTCTGCACRGGGT (p.Arg652Gly) GAGTGGGACACAGCCCCAGCC] 4830 NM_000257.3(MYH7):c. ll57A>G 4625 MYH7 ['CTTCCAGAGGCTGACAAGTCTGCCTRCCTC (p.Tyr386Cys) ATGGGGCTGAACTCAGCCGAC]
4831 NM_000501.3(ELN):c.800-2A>G 2006 ELN ['TACATTGCACTGTCCCCATCTCAACRGGTG
CTGGAGCAGCCGGAGTCCTCC]
4832 NM_000117.2(EMD):c.266-2A>G 2010 EMD ['TCTGCTACCGCTGCCCCCCTTCCCARGGCT
ACAATGACGACTACTATGAAG]
4833 NM_000191.2(HMGCL):c.698A>G 3155 HMGCL ['GTGCCTCTGGCTGCCCTGGCTGTCCRCTGC (p.His233Arg) CATGACACCTATGGTCAAGCC]
4834 NM_207352.3(CYP4V2):c.l393A> 28544 CYP4V2 ['CTACGTGCCCTTCTCTGCTGGCCCCRGGAA G (p.Arg465Gly) 0 CTGTATAGGTTTGTATCCATC]
4835 NM_013382.5(POMT2):c.l726- 29954 POMT2 ['GTCAGCAGGGTGGTCTCTATTCCACRGGGC 2A>G CTACGCTTCTCAGGGGTCAAT']
4836 NM_000169.2(GLA):c.802-2A>G -1 ['TTTGAATTATTTCATTCTTTTTCTCRGTTAG
TGATTGGCAACTTTGGCCTC']
4837 NM_020166.4(MCCCl):c.l37- 56922 MCCC1 ['GTGTGATTTTCATGGTGTTTTAAACRGGAA 2A>G GAAACATTACCAAGGTCCTCA']
4838 NM_006920.4(SCNlA):c.2557- 6323 SCN1A ['AATATATATTAATCTTTCATTTTCCRGCTG 2A>G CGAGTTTTCAAGTTGGCAAAA']
4839 NM_000501.3(ELN):c.890-2A>G 2006 ELN ['CCTCACCCTCTGTGGCTGTGTTTTCRGGCG
TTGGGACTCCAGCTGCAGCTG]
4840 NM_006306.3(SMClA):c.2974- 8243 SMC1A ['TGACATTGCTGGGCCTGGGGCTTACRGGAT 2A>G GCCCAGGCTGAGGAAGAGATC]
4841 NM_001110792.1(MECP2):c.520A 4204 MECP2 ['TGATTTTGACTTCACGGTAACTGGGRGAGG >G (p.Argl74Gly) GAGCCCCTCCCGGCGAGAGCA]
4842 M_004646.3(NPHSl):c.l756A>G 4868 NPHS1 ['CTTGTCCTGGGACAAGGAAGGGGAGRGGT (p.Arg586Gly) GGGAGTGCGAGGGATCCCTCCC]
4843 NM_003002.3(SDHD):c.275A>G 6392 SDHD ['TATTTGAATCCTTGCTCTGCGATGGRCTAT (p.Asp92Gly) TCCCTGGCTGCAGCCCTCACT']
4844 NM_004793.3(LONPl):c.2353A>G 9361 LONP1 ['CACGCTGTTTGTGGAGACATCCCTGRGACG (p.Arg785Gly) GCCACAGGACAAGGATGCCAA]
4845 NC_012920.1 :m.4279A>G 4565 MT-TI ['TCAAACCTAAGAAATATGTCTGATARAAG
AGTTACTTTGATAGAGTAAATA]
4846 NM_005633.3(SOSl):c.l430A>G 6654 SOS1 ['ATTTGCTGTAAATCAAATCATGGGCRGCCA (p.Gln477Arg) AGACTTCCTGGTGCTAGCAAT']
4847 NM_000256.3(MYBPC3):c.l227- 4607 MYBPC3 ['TGCCACTTCCCTGCGGCCCCCACCCRGGTA 2A>G CATCTTTGAGTCCATCGGTGC]
4848 NM_002834.3(PTPNl l):c.661A>G 5781 PTPN11 ['CGATCAGCCCCTTAACACGACTCGTDTAA (p.Ile221Val) ATGCTGCTGAAATAGAAAGCAG]
4849 NM_000257.3(MYH7):c.4664A>G -1 ['TCCCAGGCCTCCCTGGAGCACGAGGRGGG (p.Glul555Gly) CAAGATCCTCCGGGCCCAGCTG]
4850 NM_000257.3(MYH7):c.2792A>G 4625 MYH7 ['AACGAGAGGCTGGAGGATGAGGAGGRGA (p.Glu931Gly) TGAATGCTGAGCTCACTGCCAAG]
4851 NM_000257.3(MYH7):c.2087A>G 4625 MYH7 ['CTGGTCATGCACCAGCTGCGCTGCARTGGT (p.Asn696Ser) GTGCTGGAGGGCATCCGCATC] 4852 NM_000257.3(MYH7):c. l805A>G 4625 MYH7 ['CTGCAGAAGAACAAGGATCCTCTCARTGA (p.Asn602Ser) GACTGTCGTGGGCTTGTATCAG]
4853 NM_000257.3(MYH7):c. l615A>G 4625 MYH7 ['CATGTCCATCCTGGAAGAGGAGTGCRTGTT (p.Met539Val) CCCCAAGGCCACCGACATGAC]
4854 NM_000257.3(MYH7):c. l477A>G 4625 MYH7 ['GCTGCAGCAGTTCTTCAACCACCACRTGTT (p.Met493Val) TGTGCTGGAGCAGGAGGAGTA']
4855 NM_000257.3(MYH7):c. l331A>G 4625 MYH7 ['TTCAACTGGATGGTGACGCGCATCAVTGC (p.Asn444Ser) CACCCTGGAGACCAAGCAGCCA']
4856 NM_000257.3(MYH7):c. l315A>G 4625 MYH7 ['AGGGTGGCATTGATGCGCGTCACCAHCCA (p.Met439Val) GTTGAACATCCTCTCATACACT']
4857 NM_000257.3(MYH7):c. l051A>G 4625 MYH7 ['TTCAGAGGAGAAAAACTCCATGTATRAGC (p.Lys351Glu) TGACAGGCGCCATCATGCACTT']
4858 NM_000257.3(MYH7):c.789A>G 4625 MYH7 ['CAGGAAAGTTGGCATCTGCAGACATRGAG (p.Ile263Met) ACCTGTGAGTGCCATGAATCTG]
4859 NM_000257.3(MYH7):c.617A>G 4625 MYH7 ['ATTGCAGCCATTGGGGACCGCAGCARGAA (p.Lys206Arg) GGACCAGAGCCCGGGCAAGGTA']
4860 NM_000363.4(TNNI3):c.616A>G 7137 TNNI3 ['ACTGAGTGGAATGGAGGGCCGCAAGVAAA (p.Lys206Glu) AGTTTGAGAGCTGAGCCTTCCT']
4861 NM_000363.4(TNNI3):c.547A>G 7137 TNNI3 ['GCAGGTGAAGAAGGAGGACACCGAGRAG (p.Lysl83Glu) GTGAGTGTGGGCTAAGGCCAGGA']
4862 NM_000169.2(GLA):c.370-2A>G -1 ['TGACTCTTTTCCTCCCTCTCATTTCRGGTTC
ACAGCAAAGGACTGAAGCTA']
4863 NM_000051.3(ATM):c.lA>G 472 ATM ['GATGTGTGTTCTGAAATTGTGAACCVTGAG (p.MetlVal) TCTAGTACTTAATGATCTGCT']
4864 NM_000051.3(ATM):c.3154-2A>G 472 ATM ['TATTTAACCACAGTTCTTTTCCCGTRGGCT
GATCCTTATTCAAAATGGGCC]
4865 NM_024675.3(PALB2):c.212- 79728 PALB2 ['AGTTATATACATTTTTTTCCTCCTCRGAAC 2A>G CTAAAAATAAAATATGTGTTT']
4866 NM_024675.3(PALB2):c. l09- 79728 PALB2 ['TTCTGGGGCTGTTTTTGTCTCCTCTRGCGTG 2A>G CCCAAAGAGCTGAAAAGATT']
4867 NM_000546.5(TP53):c.709A>G 7157 TP53 ['CTGTACCACCATCCACTACAACTACRTGTG (p.Met237Val) TAACAGTTCCTGCATGGGCGG]
4868 NM_000455.4(STKl l):c.889A>G 6794 STK11 ['GATGCTTGAGTACGAACCGGCCAAGRGGT (p.Arg297Gly) TCTCCATCCGGCAGATCCGGCA]
4869 NM_017777.3(MKSl):c.l382A>G 54903 MKS1 ['TCTCTGGAACTGGAGGACCTCTCCTRTGTA (p.Tyr461Cys) CGGATACCAGGATCCTTCAAG]
4870 NM_001231.4(CASQl):c.731A>G 844 CASQ1 ['ATGGAAGAGCCTGTGACCATCCCAGRCAA (p.Asp244Gly) GCCCAATAGCGAAGAGGAGATT']
4871 NM_001242896.1(DEPDC5):c.235 9681 DEPDC5 ['GTATGAGCAATCATCTGTTGTTTTCRGGAG 5-2A>G (p.Arg785_Gly839del) GGACGAAGATGGTGTGCAGAT']
4872 NM_001039550.1(DNAJB2):c. l4A 3300 DNAJB2 ['TGACCAGTTGCCATGGCATCCTACTRCGAG >G (p.Tyr5Cys) ATCCTAGACGTGCCGCGAAGT']
4873 NM_007294.3(BRCAl):c.5057A> 672 BRCA1 ['AATCTAATTACTGAAGAGACTACTCRTGTT G (p.Hisl686Arg) GTTATGAAAACAGGTATACCA] 4874 NM_006888.4(CALMl):c.389A>G 801 CALM1 ['GTAGATGAAATGATCAGAGAAGCAGRTAT (p.Aspl30Gly) TGATGGAGACGGACAAGTCAAC]
4875 NM_001082538.2(TCTNl):c.342- 79600 TCTN1 ['TTGTATTATTATTTTTTTAATTTTCRGGGGC 2A>G GACAGCCAGTTTTGTAGTCA']
4876 NM_003000.2(SDHB):c.541-2A>G 6390 SDHB ['TCCTGCCTCTCTTTTCTCCCCATACRGGAC
GGGCTCTACGAGTGCATTCTC]
4877 NM_000143.3(FH):c.700A>G 2271 FH ['AGTGGAACAGCATCCTGAGTATGAGYACG (p.Thr234Ala) TCCAATCTTGATGATCTGTGCA]
4878 NM_000038.5(APC):c.221-2A>G 324 APC ['ATAAAAACTTGTTTCTATTTTATTTRGAGC
TTAACTTAGATAGCAGTAATT']
4879 NM_000314.6(PTEN):c.527A>G 5728 PTEN ['ATTCCCAGTCAGAGGCGCTATGTGTRTTAT (p.Tyrl76Cys) TATAGCTACCTGTTAAAGAAT']
4880 NM_030813.5(CLPB):c.l850A>G 81570 CLPB ['CTGGTCGACGGCTACAATGTGCACTRTGGC (p.Tyr617Cys) GCCCGCTCCATCAAACATGAG]
4881 NM_030813.5(CLPB):c.l222A>G 81570 CLPB ['TCCTGGAACTCGGACATGTCCAGCCHGAT (p.Arg408Gly) GAAGCCCTGTGTGGAAACAAGC]
4882 NM_016069.9(PAM16):c.226A>G -1 ['CTCACCCGTCCCCTCTCCTCTGCAGRACTA (p.Asn76Asp) TGAACACTTATTTAAGGTGAA]
4883 NM_058163.1(TSR2):c. l91A>G 90121 TSR2 ['TACTTAGCTGACTTGGAGCTAGATGRGGTG (p.Glu64Gly) GAAGACTTCCTTGGAGAGCTG]
4884 NM_001031.4(RPS28):c.lA>G 6234 RPS28 ['ATAGGCTGCACACGGCTGGTGTCCAYGAT (p.MetlVal) GGCGGCGCGGCGGCGGTCTGGC]
4885 NM_005957.4(MTHFR):c.1114A> 4524 MTHFR ['TCCCATCTTCTGGGCCTCCAGACCARAGAG G (p.Lys372Glu) TTACATCTACCGTACCCAGGA]
4886 M_014946.3(SPAST):c.l l65A>G 6683 SPAST ['CTTTGGTCCACCTGGGAATGGGAAGRCAA (p.Thr389Ala) TGCTGGTAAGGGTTCTCTTCAA']
4887 NM_000228.2(LAMB3):c.565- 3914 LAMB3 ['TAAATCCATAAGGTTAAGTTGGACCYACA 2A>G GAGGGAAGGGAAAGAGAAGCGC]
4888 NM_000492.3(CFTR):c.3368- 1080 CFTR ['TCATTTACGTCTTTTGTGCATCTATDGGAG 2A>G AAGGAGAAGGAAGAGTTGGTA']
4889 NM_006785.3(MALTl):c. l019- 10892 MALT1 ['AACACCCCCTTTCTTTTTTTTTCAARGCGA 2A>G AGGACAAGGTTGCCCTTTTGA']
4890 NM_004771.3(MMP20):c.611A>G 9313 MMP20 ['GGAGAAGGCCTGGGAGGAGATACACRTTT (p.His204Arg) CGACAATGCTGAGAAGTGGACT']
4891 NM_000918.3(P4HB):c.l l78A>G 5034 P4HB ['CACCCTAGAACTGCTTTCTTTTCAGRTGCC (p.Tyr393Cys) CCATGGTGTGGTCACTGCAAA']
4892 NM_177405.2(CECRl):c.355A>G 51816 CECR1 ['TGCTCGCATCCCGCAGGCTCACCTGYTTCT (p.Thrl l9Ala) CCGGCGTGGAAGAAGTAAGGC]
4893 NM_004990.3(MARS):c.l031A>G 4141 MARS ['TACCACATCATCCATGCTGACATCTRCCGC (p.Tyr344Cys) TGGTTTAACATTTCGTTTGAT']
4894 NM_025132.3(WDR19):c.407- 57728 WDR19 ['TCTGTATAAAAATAATCTCTTTTTCRGGAA 2A>G AACATACTAAGAGAATCACTT']
4895 NM_000314.6(PTEN):c.l39A>G 5728 PTEN ['TGCAGAAAGACTTGAAGGCGTATACRGGA (p.Arg47Gly) ACAATATTGATGATGTAGTAAG] 4896 NM_000314.6(PTEN):c.l82A>G 5728 PTEN ['GTTTTAAGGTTTTTGGATTCAAAGCDTAAA (p.His61Arg) AACCATTACAAGATATACAAT']
4897 NM_000314.6(PTEN):c.254-2A>G 5728 PTEN ['TATTCTGAGGTTATCTTTTTACCACRGTTG
CACAATATCCTTTTGAAGACC]
4898 NM_000314.6(PTEN):c.320A>G 5728 PTEN ['GAACTTATCAAACCCTTTTGTGAAGRTCTT (p.Aspl07Gly) GACCAATGGCTAAGTGAAGAT']
4899 NM_000314.6(PTEN):c.512A>G 5728 PTEN ['CACCAGGGAGTAACTATTCCCAGTCRGAG (p.Glnl71Arg) GCGCTATGTGTATTATTATAGC]
4900 NM_000314.6(PTEN):c.802-2A>G 5728 PTEN ['TTTTCTTTTCTTTTTTTTTTTTTTTDGGACAA
AATGTTTCACTTTTGGGTA']
4901 NM_001103.3(ACTN2):c. l883A> 88 ACTN2 ['ATCCGCGATCAATCCCTGCAGGAGGRGCT G (p.Glu628Gly) GGCTCGCCAGCATGCTAACGAG]
4902 NM_003159.2(CDKL5):c.-162- 6792 CDKL5 ['GCTTTTAATTGTGTTTGTTTTTTTCRGGGAG 2A>G TCATTTAATACTTCATGATT']
4903 NM_003159.2(CDKL5):c.91A>G 6792 CDKL5 ['AGCCTATGGAGTTGTACTTAAATGCRGAC (p.Arg31Gly) ACAAGGCAAGTACATTATTTTT']
4904 NM_003159.2(CDKL5):c.458A>G 6792 CDKL5 ['CACAATGATGTCCTAAAACTGTGTGRCTTT (p.Aspl53Gly) GGTAAGTTAAAAAGAAATTAA']
4905 NM_003159.2(CDKL5):c.2277- 6792 CDKL5 ['ATATGATAAAAATGTCTTCTCATTTRGGAA 2A>G AAGTCCTGAAAATATTAGTCA']
4906 NM_021098.2(CACNAlH):c.4645 8912 CACNA1H ['CATCGTCAGCTTCTTCGTGCTCAACRTGTT A>G (p.Metl549Val) CGTGGGC GTC GTGGTC GAG A A']
4907 NM_003816.2(ADAM9):c.l396- 8754 ADAM9 ['TGTTTAATTTGAATTCTATTTCACTRGTTCC 2A>G TTCCAGGAGGTACTTTATGC]
4908 NM_212472.2(PRKARlA):c.177+3 5573 PRKARIA ['AATACTTTGAGAGGTTGGAGAAGGTRAAA A>G ATAAATGTGGGGAGATGATGAG]
4909 NM_001204830.1(LIPTl):c.535A> -1 ['CCGGACTACTGCCTATCACCATTGCRCTTT G (p.Thrl79Ala) ATTATGTAGTACTGATGGGAC]
4910 NM_001165963.1(SCNlA):c.5264 -1 ['AACCCTGGAAGCTCAGTTAAGGGAGRCTG A>G (p.Aspl755Gly) TGGGAACCCATCTGTTGGAATT']
4911 NM_001165963.1(SCNlA):c.3880- -1 ['TAATTGTTATTATTTTTGTGTGTGCRGGTTT 2A>G CATTGGTCAGTTTAACAGCA']
4912 NM_001165963.1(SCNlA):c.2537 6323 SCN1A ['TTTATTGTGACGCTTAGCCTGGTAGRACTT A>G (p.Glu846Gly) GGACTCGCCAATGTGGAAGGA']
4913 NM_001165963.1(SCNlA):c.2353 6323 SCN1A ['GTCATTGGATAGTGCTCCATGGCCAHGAA A>G (p.Met785Val) AAGAGTATTTAAGACAATACAG]
4914 NM_001165963.1(SCNlA):c.l662 6323 SCN1A ['AGAGGTACTCCTCCCCACACCAGGTRTGG
+3A>G CACTGCTGAGTTTACTGATGCA']
4915 NM_001165963.1(SCNlA):c.l076 6323 SCN1A ['TGTGTGAAAGCTGGTAGAAATCCCADTTA A>G (p.Asn359Ser) TGGCTACACAAGCTTTGATACC]
4916 NM_001165963.1(SCNlA):c.l048 6323 SCN1A ['TTGCAGCCAATGTCCAGAGGGATATRTGT A>G (p.Met350Val) GTGTGAAAGCTGGTAGAAATCC]
4917 NM_001165963.1(SCNlA):c.l046 6323 SCN1A ['ACTTGCAGCCAATGTCCAGAGGGATRTAT A>G (p.Tyr349Cys) GTGTGTGAAAGCTGGTAGAAAT'] 4918 NM_001165963.1(SCNlA):c.433A 6323 SCN1A ['CACTATTTTGACAAACTGTGTGTTTRTGAC >G (p.Metl45Val) AATGAGTAACCCTCCTGATTG]
4919 NM_001165963.1(SCNlA):c.383+ 6323 SCN1A ['TAGCTATTAAGATTTTGGTACATTCRTATC 1A>G CTTTTTCAAGTGATTAATATT']
4920 NM_001605.2(AARS):c.2251A>G 16 AARS [TCGGCACCTGTGACAGCCACAATCCYCCG (p.Arg751Gly) GATACCCTTGGCAATGGCTTCT']
4921 NM_000124.3(ERCC6):c.2830- 2074 ERCC6 ['TATTCTCCATGCTCGCTCCCGGGCCYGCAA 2A>G CAGAGAGAGAGAGACCTCTCA']
4922 NM_000124.3(ERCC6):c.2599- 2074 ERCC6 ['ACTGGGAATGTGTATTTGCTTTGCAVACTC 26A>G CTATCCCCCACCTCCAAACAG]
4923 NM_001110556.1(FLNA):c. l829- 2316 FLNA ['ACTGAGGGGACTGGTGGCTGTTGTCRGGC 2A>G TTCTCGGTGGAAGGGCCATCGC]
4924 NM_006129.4(BMPl):c.808A>G 649 BMP1 ['GGAGACCTATGACTTCGACAGCATCRTGC (p.Met270Val) ATTACGCTCGGAACACATTCTC]
4925 NM_001987.4(ETV6):c.l252A>G 2120 ETV6 ['GGAGCCAGGACAAAGGCTTTTGTTCRGGT (p.Arg418Gly) AGCACTTCCTTTTTCTCCTTTC]
4926 NM_014423.3(AFF4):c.760A>G 27125 AFF4 ['GTCCAATTCAATGTTACAGAAACCCRCTGC (p.Thr254Ala) CTATGTGCGGCCCATGGACGG]
4927 NM_002055.4(GFAP):c.l085A>G 2670 GFAP ['AATGTCAAGCTGGCCCTGGACATCGRGAT (p.Glu362Gly) CGCCACCTACAGGAAGCTGCTA']
4928 NM_002055.4(GFAP):c.256A>G 2670 GFAP ['TGACCGCTTTGCCAGCTACATCGAGRAGGT (p.Lys86Glu) TCGCTTCCTGGAACAGCAAAA']
4929 NM_006017.2(PROMl):c.2077- 8842 PROM1 ['ATTTGCTGTTCTTCACAGCTTTAGGRTATG 521A>G TATCCAATGTTTTCTTCAGGT']
4930 NM_002755.3(MAP2Kl):c.305A> 5604 MAP2K1 ['ACCTTTCTCCAGCTAATTCATCTGGRGATC G (p.Glul02Gly) AAACCCGCAATCCGGAACCAG]
4931 NM_001288953.1(TTC7A):c. l715 57217 TTC7A ['CGTCCCCACAGCCTGATGTTCACCARGGTG A>G (p.Lys572Arg) AAGCTGGAGCAGGTGCTGAAA']
4932 NM_016218.2(POLK):c. l81A>G 51426 POLK ['TGAGCTCAAGAAAGAAAAGCAAGTCRACC (p.Asn61Asp) AACGAATTGAAAATATGATGCA']
4933 NM_016218.2(POLK):c. l385A>G 51426 POLK ['AGAACTGTTACCATTAAGTTGAAGARTGT (p.Asn462Ser) GAATTTTGAAGTAAAAACTCGT']
4934 NM_016218.2(POLK):c. l477A>G 51426 POLK ['ATTTGCCATTGCTAAGGAATTGCTARAAAC (p.Lys493Glu) AGAAATTGATGCTGATTTTCC]
4935 NM_001040431.2(COA3):c.215A> 28958 COA3 ['GGAAATCGAGTAGAAGGTGTAACCAYCTG G (p.Tyr72Cys) GGGAGGTAGGTTCAGGAAACCA']
4936 NM_000891.2(KCNJ2):c.901A>G 3759 KCNJ2 ['TGAAATCGTGGTCATACTGGAAGGCRTGG (p.Met301Val) TGGAAGCCACTGCCATGACGAC]
4937 M_144499.2(GNATl):c.386A>G 2779 GNAT1 ['GACATCATCCAGCGGCTGTGGAAGGRCTC (p.Aspl29Gly) CGGTATCCAGGCCTGTTTTGAG]
4938 NM_018965.3 (TREM2) :c .113 A>G 54209 TREM2 ['CAGTCCCTGCAGGTGTCTTGCCCCTRTGAC (p.Tyr38Cys) TCCATGAAGCACTGGGGGAGG]
4939 NM_194277.2(FRMD7):c.556A>G 90167 FRMD7 ['ACTGGACATAGCAAGGAAGCTGGATRTGT (p.Metl86Val) ATGGCATCAGGCCTCACCCCGC] 4940 NM_001003811.1(TEXl l):c.511A 56159 TEX11 ['TCACTCTCAACAGTAATCTTCTCCAYGGTC >G (p.Metl71Val) AAGTCAGCCTCAGGGGAGCTC]
4941 NM_000921.4(PDE3A):c. l333A>G 5139 PDE3A ['AGTTTCTTCCACTTGGACCACCACCRCCTC (p.Thr445Ala) GGCCACAGGTCTACCCACCTT']
4942 NM_000033.3(ABCDl):c.887A>G 215 ABCD1 ['GCCAACTCGGAGGAGATCGCCTTCTRTGG (p.Tyr296Cys) GGGCCATGAGGTGGGGCAGGTT']
4943 NM_000169.2(GLA):c. l37A>G -1 ['AGGACGCCTACCATGGGCTGGCTGCDCTG (p.His46Arg) GGAGCGCTTCATGTGCAACCTT']
4944 NM_000033.3(ABCDl):c.l992- 215 ABCD1 ['CCCTGACCCTGTCCCTCTCCTGGCCRGGAA 2A>G ATACCACACACACTTGCTACA']
4945 NM_000182.4(HADHA):c.919- 3030 HADHA ['TTGCTCAATTCCAGTCTTTACCACCYAAAA 2A>G AACATATAAAGCACTTGCTCA']
4946 NM_000159.3(GCDH):c.l213A>G 2639 GCDH ['CGAGTATCACGTGATCCGGCACGCCRTGA (p.Met405Val) ACCTGGAGGCCGTGAACACCTA']
4947 NM_004006.2(DMD):c.1150-2A>G 1756 DMD ['ACAATTGTTAACTTCCTTCTTTGTCRGGGG
TACATGATGGATTTGACAGCC]
4948 NM_019109.4(ALGl):c. l l88- 56052 ALG1 ['CTCAGGCTCCCTTGGTTCTCTCTGCRGTTT 2A>G ACATGAGCTGGTGAAACATGA']
4949 NM_004463.2(FGDl):c.2016- 2245 FGD1 ['TCTTTCTTTTTTATTCCCCACCCCARGGACT 2A>G GAGGAGGAGAAGAAAGACTG]
4950 NM_198525.2(KIF7):c.2981A>G 37465 KIF7 ['CTGCTGCTGGCTCTGGGCGCTGCCCYGCCG (p.Gln994Arg) 4 CAGCTGCCCGCTCTTCTCGGA']
4951 NM_020366.3(RPGRIPT):c.3749- 57096 RPGRIP1 ['ATGCTGTTTTTTTCCCTTTCCCAACRGTTGT 2A>G TAGCCCTGAAGATCTGGCTA']
4952 M_003494.3(DYSF):c.3041A>G 8291 DYSF ['GTTCCCCCTCCCCCAGGCTGGGAGTRTAGC (p.Tyrl014Cys) ATCACCATCCCCCCGGAGCGG]
4953 NM_003494.3(DYSF):c.3349- 8291 DYSF ['CTGCCATAACCAGCTTCGTGTCTCCRGGGC 2A>G GGCGTGATGGATGACAAGAGT']
4954 NM_004006.2(DMD):c.4675-2A>G 1756 DMD ['ATTACATTTCATTATAATTCTTTTCRGGTA
ACAGAAAGAAAGCAACAGTTG]
4955 NM_000169.2(GLA):c.620A>G -1 ['GTGTACTCCTGTGAGTGGCCTCTTTRTATG (p.Tyr207Cys) TGGCCCTTTCAAAAGGTGAGA']
4956 NM_022124.5(CDH23):c.l46- -1 ['CTCTGCTCTCTCCCTTGGCTACTCCRGGTTC 2A>G TTCTGTGACCCAGTTGCTGG]
4957 NM_000169.2(GLA):c.801+3A>G -1 ['GGGGTTGGAATGACCCAGATATGGTRAAA
ACTTGAGCCCTCCTTGTTCAAG]
4958 NM_000019.3(ACATl):c.473A>G 38 AC ATI ['GCAGGTGGGATGGAGAGCATGTCCARTGT (p.Asnl58Ser) TCCATATGTAATGAACAGAGGA]
4959 NM_000553.4(WRN):c.561A>G 7486 WRN ['GTCTGGTTAAACACCTCTTAGGTAARCAGC (p.Lysl87=) TCCTGAAAGACAAGTCTATCC]
4960 NM_000050.4(ASSl):c.421-2A>G 445 ASS1 ['GGCTCTGACCCCTTGTCCTATGTCCDGGTC
ATTGCTCCCTGGAGGATGCCT']
4961 NM_020166.4(MCCCl):c.640- 56922 MCCC1 ['TTCTGATCTAACAATCCTCATTCCCYAAGA 2A>G GAGAAAAGATGATTATGACTA'] 4962 NM_004006.2(DMD):c.10554- 1756 DMD ['TCTTTTTTACTTTTTTGATGCCAATRGGAAT 2A>G CTGCAAGCAGAATATGACCG]
4963 NM_017653.3(DYM):c.621-2A>G 54808 DYM ['ACAAGTTTGCTGGTGTATGGAAGACYATA
CAAAAAGGAAAAAAAAATCAAA']
4964 NM_001098398.1(COPA):c.728A> -1 ['TCAGAATCAAAGGCATGGGAGGTTGRTAC G (p.Asp243Gly) CTGCCGGGGCCATTACAACAAT']
4965 NM_005045.3(RELN):c.2288A>G 5649 RELN ['CGTCAGCTAATTACATCTTTCCTTGRCAGC (p.Asp763Gly) TCACAATCCAGGTGAGTGAAG]
4966 NM_207111.3(RNF216):c.l616A> 54476 RNF216 ['TGCCATCTCTTTGATTTTCTGCTCAHAGAA G (p.Tyr539Cys) CTCCTGCTCTTGTTGCACAGC]
4967 NM_001035.2(RYR2):c.568A>G 6262 RYR2 ['CATCTTAGTTAGCGTGTCCTCTGAARGGTA (p.Argl90Gly) CTTGGTAAGTGTGGAAAGTAG]
4968 NM_001035.2(RYR2):c.l l965A>G 6262 RYR2 ['AAATGCAACTGCTTTACCACCAGGTVATGT (p.Asn3989Asp) TGTTAATGGAACGATTGGCAA']
4969 NM_001035.2(RYR2):c.l2290A>G 6262 RYR2 ['GAACCTGCGAAGGACATCGGCTTCARCGT (p.Asn4097Ser) CGCCGTCCTTCTGACAAACCTC]
4970 NM_001035.2(RYR2):c.l2533A>G 6262 RYR2 ['AGACAGTTCATATTTGACGTGGTCARCGA (p.Asn4178Ser) AGGCGGAGAGAAAGAGAAGATG]
4971 NM_000090.3(COL3Al):c.2338- 1281 COL3A1 ['ACAGTGACATGGCTTCTCTTTTTCCRGGGT 2A>G GAAGGTGGTGCCCCCGGACTT']
4972 NM_198056.2(SCN5A):c.4462A>G 6331 SCN5A ['CTTAGGGGGCCAGGACATCTTCATGRCAG (p.Thrl488Ala) AGGAGCAGAAGAAGTACTACAA']
4973 NM_198056.2(SCN5A):c.4453A>G 6331 SCN5A ['CTCTTTGCACTTAGGGGGCCAGGACRTCTT (p.Ilel485Val) CATGACAGAGGAGCAGAAGAA']
4974 NM_198056.2(SCN5A):c.2788- 6331 SCN5A ['GGTGAGCCTGACCCATTATCTCGACRGGTC 2A>G CTGAATCTCTTCCTGGCCTTG]
4975 NM_198056.2(SCN5A):c. l247A>G 6331 SCN5A ['GATGGTGGCTTGGTTTTGCTCCTCAYAGGC (p.Tyr416Cys) CATTGCGACCACGGCCAGGAT']
4976 M_004415.2(DSP):c.l l41-2A>G 1832 DSP ['TTCACTGATCACTCTCATCCTTCACRGTTTT
TTGAAGAGGCGCAGTCTACT']
4977 NM_000238.3(KCNH2):c.2582A> 3757 KCNH2 ['TGGTCCAGCCTGGAGATCACCTTCANCCTG G (p.Asn861Ser) CGAGATGTGAGTTGGCTGCCC]
4978 NM_000238.3(KCNH2):c.l913A> 3757 KCNH2 ['GTCTCTCCCAACACCAACTCAGAGARGAT G (p.Lys638Arg) CTTCTCCATCTGCGTCATGCTC]
4979 NM_000238.3 (KCNH2) :c .1904 A> 3757 KCNH2 ['TTCGGCAACGTCTCTCCCAACACCADCTCA G (p.Asn635Ser) GAGAAGATCTTCTCCATCTGC]
4980 NM_000238.3 (KCNH2) :c .1900 A> 3757 KCNH2 ['GGGCTTCGGCAACGTCTCTCCCAACRCCAA G (p.Thr634Ala) CTCAGAGAAGATCTTCTCCAT']
4981 NM_000238.3(KCNH2):c.l l29- 3757 KCNH2 ['CCACACCTCCGCCTTCCCCGGGTGCRGGTC 2A>G CTGTCCCTGGGCGCCGACGTG]
4982 NM_000238.3(KCNH2):c.296A>G 3757 KCNH2 ['GAGCGCAAAGTGGAAATCGCCTTCTVCCG (p.Tyr99Cys) GAAAGATGGTAGGAGCGGGCCG]
4983 NM_000238.3 (KCNH2) :c .133 A>G 3757 KCNH2 ['GGAGAACTGCGCCGTCATCTACTGCDACG (p.Asn45Asp) ACGGCTTCTGCGAGCTGTGCGG] 4984 NM_001613.2(ACTA2):c. lA>G 59 ACTA2 ['AGAATCCTGTGAAGCAGCTCCAGCTRTGT (p.MetlVal) GTGAAGAAGAGGACAGCACTGC]
4985 NM_000218.2(KCNQl):c.605A>G 3784 KCNQ1 ['GCTCCCCCTCTCCTGCACTCCACAGRCCTC (p.Asp202Gly) ATCGTGGTCGTGGCCTCCATG]
4986 NM_000218.2(KCNQl):c.l033- 3784 KCNQ1 ['GGGAGCCTCCTGTCCATTCCTTCCCVGGGG 2A>G ATTCTTGGCTCGGGGTTTGCC]
4987 NM_000218.2(KCNQl):c.l515- 3784 KCNQ1 ['CAATCTCCTCTCCTCTCTCCACTGCRGGCT 2A>G GCGGGAACACCATCGGGCCAC]
4988 NM_000218.2(KCNQl):c.l787A> 3784 KCNQ1 ['ATCGGCGCCCGCCTGAACCGAGTAGRAGA G (p.Glu596Gly) C A AGGT AGGCTC AC GC GCC GGC ']
4989 NM_000138.4(FBNl):c.7916A>G 2200 FBN1 ['TGCATGTGTCCCGCCGGCTTCCAGTRTGAA (p.Tyr2639Cys) CAGTTCAGTGGAGGATGCCAA']
4990 NM_000138.4(FBNl):c.4337- 2200 FBN1 ['TTTTGCTTTTTTCTCCCTCCCCCCARGATAT 2A>G TGATGAGTGCTCCCTTCCGA']
4991 NM_000138.4(FBNl):c.3344A>G 2200 FBN1 ['GGTCATTTCCATTTTGCAGATATTGRTGAG (p.Aspl l l5Gly) TGTCAGAGAGATCCTCTCCTA]
4992 NM_001943.3(DSG2):c.880A>G 1829 DSG2 ['AGTCAACGTAGAAGTTACGCGCATARAAG (p.Lys294Glu) TGTTCGATGCAGATGAAATAGG]
4993 NM_001927.3 (DES) :c .1324 A>G 1674 DES ['TGAGCAAAGGGGTTCTGAGGTCCATRCCA (p.Thr442Ala) AGAAGACGGTGATGATCAAGAC]
4994 NM_004572.3(PKP2):c.l l71-2A>G 5318 PKP2 ['AGAAATATGCATCTGCTTCTTCCCCRGGTT
AACCAGCTTCGTGGCATCCTC]
4995 NM_001256850.1(TTN):c.45629- -1 ['GATATGAATATTTCACTCTTTTCTCRGGTC 2A>G CTCCCTCACCACCCCTTGACC]
4996 NM_013254.3(TBKl):c.l201A>G 29110 TBK1 ['ACTTCATATTTCAGTTTCCCTCCCTRAAGT (p.Lys401Glu) ACATCCACGTTATGATTTAGA]
4997 NM_030973.3(MED25):c.l l6A>G 81857 MED25 ['TACTTCGAGGGGCTCCGCAAGCACTRCCTG (p.Tyr39Cys) CTCCCGGCCATCGAGTGAGTG]
4998 NM_145207.2(SPATA5):c.l883A> 16637 SPATA5 ['TCTATTTTTCAGGTATCCTGGTCAGRTATA G (p.Asp628Gly) 8 GGAGGACTGGAAAGTATCAAA']
4999 NM_000016.5 ( AC ADM) :c .329 A> 34 ACADM ['ACTTTTGATGCTTGTTTAATTAGTGRAGAA G (p.Glul lOGly) TTGGCTTATGGATGTACAGGG]
5000 NM_000016.5(ACADM):c.797A> 34 ACADM ['CCTAAAGAAAATGTTTTAATTGGTGRCGG G (p.Asp266Gly) AGCTGGTTTCAAAGTTGCAATG]
5001 NM_000532.4(PCCB):c.655-2A>G 5096 PCCB ['GACTGTTCTGGAAATCTTTTATTTCRGGAC
ACCTCCTACCTGTTCATCACT']
5002 M_004453.3(ETFDH):c.929A>G 2110 ETFDH ['CATACCTATGGAGGATCTTTCCTCTRTCAT (p.Tyr310Cys) TTGAATGAAGGTGAACCCCTA]
5003 NM_000255.3(MUT):c.l885A>G 4594 MUT ['AAAAATGGGACAAGATGGCCATGACRGAG (p.Arg629Gly) GAGCAAAAGTTATTGCTACAGG]
5004 NM_000255.3(MUT):c.329A>G 4594 MUT ['TTTAGGCCCTGGACCATCCGCCAGTRTGCT (p.Tyrl lOCys) GGTTTTAGTACTGTGGAAGAA']
5005 NM_000017.3 ( AC AD S) : c.1108 A> 35 ACADS ['TCAGGCCATCCAGATCCTGGGCGGCRTGG G (p.Met370Val) GCTACGTGACAGAGATGCCGGC] 5006 NM_174917.4(ACSF3):c.lA>G 19732 ACSF3 ['TCCAGCTCGGCCGCCTGTCAGTGCARTGCT (p.MetlVal) 2 GCCCCATGTGGTGCTCACCTT']
5007 NM_000531.5(OTC):c.919A>G 5009 OTC ['GACATTTTTACACTGCTTGCCCAGARAGCC (p.Lys307Glu) AGAAGAAGTGGATGATGAAGT']
5008 NM_000030.2(AGXT):c.248A>G 189 AGXT ['ACACTGGTCATCTCTGGCTCGGGACRCTGT (p.His83Arg) GCCCTGGAGGCCGCCCTGGTC]
5009 NM_000030.2(AGXT):c.424-2A>G 189 AGXT ['CACCCACAGCCGTCCCTGCTTCCTCRGGGC (p.Gly_142Glnl45del) CTGGCCCAGCACAAGCCAGTG]
5010 NM_000030.2(AGXT):c.596-2A>G 189 AGXT ['CGTCCCGAGCAAACCACCCATCTACRGGC
ATCGACATCCTGTACTCGGGCT']
5011 NM_000030.2(AGXT):c.777-2A>G 189 AGXT ['TGGACCAAGCCCCCTCGTGTCTTCCRGGTA
CCATCACACAATCCCCGTCAT']
5012 NM_012203.1(GRHPR):c.84-2A>G 9380 GRHPR ['CTCCTGAGGGCCTCCCTTTCCCCGCRGCTG
TGAGGTGGAGCAGTGGGACTC]
5013 NM_012203.1(GRHPR):c.934A>G 9380 GRHPR ['CACCATGTCCTTGTTGGCAGCTAACRACTT (p.Asn312Asp) GCTGGCTGGCCTGAGAGGGGA']
5014 NM_203290.2(POLRlC):c.221A> 9533 POLR1C ['GTGGGAATTGACGCAGCCATTGCCARTGC G (p.Asn74Ser) TTTTCGACGAATTCTGCTAGCT']
5015 NM_006516.2(SLC2Al):c.848A>G 6513 SLC2A1 ['GCTGTGGTGCTGCAGCTGTCCCAGCRGCTG (p.Gln283Arg) TCTGGCATCAACGCTGTGAGT']
5016 NM_006516.2(SLC2Al):c.l9- 6513 SLC2A1 ['ATAACAGTGTGGTTTGTTTCTCCGCRGAAG 2A>G CTGACGGGTCGCCTCATGCTG]
5017 NM_021007.2(SCN2A):c.387- 6326 SCN2A ['ACTTTGTCTTCCTTGACGATATTCTRCTTTA 2A>G TTCAATATGCTCATTATGTG]
5018 NM_021007.2(SCN2A):c.851A>G 6326 SCN2A ['AATAAATGTTTGCAATGGCCTCCAGRTAAT (p.Asp284Gly) TCTTCCTTTGAAATAAATATC]
5019 NM_021007.2(SCN2A):c.4036A>G 6326 SCN2A ['CATGAATGTACTTCTGGTTTGTCTGRTCTTT (p.Ilel346Val) TGGCTAATATTCAGTATCAT']
5020 NM_001165963.1(SCNlA):c.4476 -1 ['TAATTTCAACCAGCAGAAAAAGAAGDTAA
+1A>G GTATTTCTAATATTTTCTCTCC]
5021 NM_001165963.1(SCNlA):c.l277 6323 SCN1A ['ATCCTGGCTGTGGTGGCCATGGCCTRCGAG A>G (p.Tyr426Cys) GAACAGAATCAGGCCACCTTG]
5022 NM_000391.3(TPPl):c.833A>G 1200 TPP1 ['GGGATTGAGGCCAGTCTAGATGTGCRGTA (p.Gln278Arg) CCTGATGAGTGCTGGTGCCAAC]
5023 NM_017882.2(CLN6):c.767A>G 54982 CLN6 ['GGAGAAGAGGAAGAGGCCGTTGCTGYCCA (p.Asp256Gly) GGAAGAGGCGCTTGCGCTTCTG]
5024 NM_002693.2(POLG):c.3470A>G 5428 POLG ['GGGCCCCGCATACCTGGTCAAGAGGYTGG (p.Asnl l57Ser) TGATCTGCAAGGCCAGGGCAGC]
5025 NM_002693.2(POLG):c.2840A>G 5428 POLG ['GTGGGCATCAGCCGTGAGCATGCCARAAT (p.Lys947Arg) CTTCAACTACGGCCGCATCTAT']
5026 NM_002693.2(POLG):c.2636A>G 5428 POLG ['CACAAGGGTGTAGCCAGGTGGGGCCYGCA (p.Gln879Arg) CCATGGCTTTCAACTCACTGCC]
5027 NM_000833.4(GRIN2A):c.2449A> 2903 GRIN2A ['GAGCAGCCAGCTGGACATTGACAACRTGG G (p.Met817Val) CGGGCGTATTCTACATGCTGGC] 5028 NM_000833.4(GRIN2A):c.l930A> 2903 GRIN2A ['CTTCTTCGCTGTCATATTCCTGGCTRGCTA G (p.Ser644Gly) CACAGCCAATCTGGCTGCCTT']
5029 NM_000156.5 (GAMT) : c .1 A>G 2593 GAMT ['GTCGGGTCGCCGTCCAGCCTGCAGCRTGA (p.MetlVal) GCGCCCCCAGCGCGACCCCCAT']
5030 NM_172107.2(KCNQ2):c.848A>G 3785 KCNQ2 ['CTGACCACCATTGGCTACGGGGACARGTA (p.Lys283Arg) CCCCCAGACCTGGAACGGCAGG]
5031 NM_172107.2(KCNQ2):c.611A>G 3785 KCNQ2 ['GCGCTCCGGAGCCTGCGCTTCCTGCRGATT (p.Gln204Arg) CTGCGGATGATCCGCATGGAC]
5032 NM_172107.2(KCNQ2):c.297- 3785 KCNQ2 ['CTGAGAGCGCGCGTTCCCTGCCCCCRGGTT 2A>G CCTCCTGGTTTTCTCCTGCCT']
5033 NM_001105243.1(PCDH19):c.l019 57526 PCDH19 ['GTCACCGTCAGCGTGCTGGACACCARTGA A>G (p.Asn340Ser) CAATCCGCCGGTCATCAACCTG]
5034 NM_001105243.1(PCDH19):c.695 57526 PCDH19 ['CTTAGTATCAAGGTGACCGACTCCADTGA A>G (p.Asn232Ser) CAACAACCCGGTGTTTAGCGAG]
5035 NM_052859.3(RFTl):c.454A>G 91869 RFT1 ['TTC AC AGC AGAAGGTGC ACTGACCTB GAG (p.Lysl52Glu) CTTCACAAACATATGTGCTTGT']
5036 NM_052859.3(RFTl):c. l222A>G 91869 RFT1 ['TCTCCTCCCCAGGTACAATTTTGTGRTGCT (p.Met408Val) GGCCCTGTCCTCCTCATTCCT']
5037 NM_020533.2(MCOLNl):c.l406A 57192 MCOLN1 ['TCTGAGTGCCTGTTCTCGCTCATCARTGGG >G (p.Asn469Ser) GACGACATGTTTGTGACGTTC]
5038 M_004456.4(EZH2):c.458A>G 2146 EZH2 ['TTCATTGAAGAACTAATAAAAAATTRTGAT (p.Tyrl53Cys) GGGAAAGTACACGGGGATAGA']
5039 NM_005045.3(RELN):c.2168A>G 5649 RELN ['ACCACGGATAGAGTAAAAGTTATGGYAAG (p.Tyr723Cys) AGGAGAGCCTGGAACTGCCAAA']
5040 NM_006772.2(SYNGAPl):c.388- 8831 SYNGAP1 ['CCCACCCCATCCCCATTTCCCCCCCRGCAA
2A>G GGCTTCCTGAGCCGACGGCTA']
5041 NM_001080508.2(TBX18):c.487A 9096 TBX18 ['GATAGGCACTGAGATGATCATCACCRAGG >G (p.Lysl63Glu) CCGGCAGGTAATGGGCAAGCTG]
5042 M_004964.2(HDACl):c.461A>G 3065 HDAC1 ['GAGGCATCTGGCTTCTGTTACGTCARTGAT (p.Asnl54Ser) ATCGTCTTGGCCATCCTGGAA']
5043 M_014946.3(SPAST):c.l l68A>G 6683 SPAST ['TGGTCCACCTGGGAATGGGAAGACARTGC (p.Met390Val) TGGTAAGGGTTCTCTTCAAATT']
5044 NM_000314.6(PTEN):c.71A>G 5728 PTEN ['TATCAAGAGGATGGATTCGACTTAGRCTTG (p.Asp24Gly) ACCTGTATCCATTTCTGCGGC]
5045 NM_004380.2(CREBBP):c.4409A> 1387 CREBBP ['GGGTCCTGCAGGTATGTGACAGGGCRCAT G (p.Hisl470Arg) CTGGGCCTGTCCTCCAAGTGAA']
5046 NM_018206.4(VPS35):c. l463A>G 55737 VPS35 ['GATCCAGAAGATTTTGCTGATGAGCRGAG (p.Gln488Arg) CCTTGTGGGCCGCTTCATTCAT']
5047 NM_152296.4(ATPlA3):c.971A>G 478 ATP 1 A3 ['GGCATCATCGTGGCCAATGTCCCAGRGGG (p.Glu324Gly) TCTGCTGGCCACTGTCACTGTA']
5048 NM_172107.2(KCNQ2):c.710A>G 3785 KCNQ2 ['TCTCAGGAGCTGGTCACTGCCTGGTRCATC (p.Tyr237Cys) GGCTTCCTTTGTCTCATCCTG]
5049 NM_001017980.3(VMA21):c. l63+ 20354 VMA21 ['ACTAAATCTTACATATTTGAAGGTARTCTT 4A>G 7 AGACCCATTAAAACAAGATGT'] 5050 NM_000489.4(ATRX):c.740A>G 546 ATRX [TTCTGCAAGAAATGCATTCTACGCARCCTT (p.Asn247Ser) GGTCGAAAGGAGTTGTCCACA]
5051 NM_021147.4(CCNO):c.716A>G 10309 CCNO ['CCCACCATTAGCTTCTTCCTGGAGCRTTTC (p.His239Arg) ACGCACGCTCGCGTGGAGGCG]
5052 NM_031924.4(RSPH3):c.631- 83861 RSPH3 ['CTCTAGAGAATCAGGCCGTCCGAGCYAAC 2A>G AGTGATAGAAAATACTTCTAGA]
5053 NM_000069.2(CACNAlS):c.3526- 779 CACNA1S ['TCGCTTTCCCATCCTTTTCCTTCCCRGGGCT 2A>G ACTTTGGAGACCCCTGGAAT']
5054 NM_000533.4(PLPl):c. lA>G 5354 PLP1 ['CAATTGGAGTCAGAGTCCCAAAGACRTGG (p.MetlVal) GTAAGTTTCAAAAACTTTAGCA']
5055 NM_207352.3(CYP4V2):c.l396A> 28544 CYP4V2 ['CGTGCCCTTCTCTGCTGGCCCCAGGRACTG G (p.Asn466Asp) 0 TATAGGTTTGTATCCATCTGA']
5056 NM_033409.3(SLC52A3):c.403A> 11327 SLC52A3 ['ACAAAGAAGGTGGTGAGGTAGTAGGYGG G (p.Thrl35Ala) 8 GCAGCCGGCTCATGAACGGCAGG]
5057 NM_033409.3(SLC52A3):c.62A>G 11327 SLC52A3 ['CAGGGGCAGCTCTACCCAGAGCCCAYTGA (p.Asn21Ser) 8 TGGTCACCCAGGAGCCCATTCC]
5058 NM_017662.4(TRPM6):c.3173A> 14080 TRPM6 ['CAAGCTGTCTACCTCTTCGTGCAATRTATC G (p.Tyrl058Cys) 3 ATCATGGTGAACCTGTTGATT']
5059 NM_006642.3(SDCCAG8):c.221- 10806 SDCCAG8 ['AATAAACCCTCTGCTTTTGCTCTATRGTTA 2A>G ATCAGCTCAAAGATTTGTTGC]
5060 NM_022455.4(NSDl):c.5990A>G 64324 NSD1 ['CAAGAACATGATATCACTAATTTCTRTATG (p.Tyrl997Cys) CTCACCCTAGACAAAGTAAGT']
5061 NM_000352.4(ABCC8):c.563A>G 6833 ABCC8 ['GGGATGCTGCTCCTCGTGGAGGTCARTGTC (p.Asnl88Ser) ATCAGGGTGAGGGTAAGCAGG]
5062 NM_000275.2(OCA2):c.l427A>G 4948 OCA2 ['GATGGCAGTGGCAGCTCCTCCAATGYTTGT (p.Asn476Ser) GAAGATCACTTCTGCAATCAG]
5063 NM_001848.2(COL6Al):c. l003- 1291 COL6A1 ['ATTTTCTAGTTTTCTTCCTCTTTCCRGGGGG 2A>G AGATGGGGTACCCAGGCCTG]
5064 NM_003560.2(PLA2G6):c.l349- 8398 PLA2G6 ['CAGCATGCCCTGCTCTGTGCCTCACRGAAC 2A>G TACAGGATCTCATGCACATCT']
5065 NM_178151.2(DCX):c.280A>G 1641 DCX ['TGACCTGACGCGATCTCTGTCTGACRACAT (p.Asn94Asp) CAACCTGCCTCAGGGAGTGCG]
5066 NM_000425.4(LlCAM):c.2351A> 3897 L1CAM ['TCCAACACGTCCACCTTCGTGCCCTRTGAG G (p.Tyr784Cys) ATCAAAGTCCAGGCCGTCAAC]
5067 NM_000052.6(ATP7A):c.2173- 538 ATP7A ['TCAATGATTATCATTCCTATATTGCRGTTTT 2A>G TCGGAGGCTGGTACTTCTAC]
5068 NM_020247.4(ADCK3):c.l286A> 56997 ADCK3 ['CTGCTGAAGGGCCACCCCTTCTTCTRTGTG G (p.Tyr429Cys) CCTGAGATTGTGGATGAGCTC]
5069 NM_000143.3(FH):c.554A>G 2271 FH ['AAACAGCAAAGCTCACATACTGACCYGGC (p.Glnl85Arg) TTTTATTAACATGATCGTTGGG]
5070 NM_033109.4(PNPTl):c. l453A>G 87178 PNPT1 ['AAACTTCCGCCACATGCAGATGCCAKAGA (p.Met485Val) AGATGACCCTATAGAAAGAAAA']
5071 NM_005888.3(SLC25A3):c.l58- 5250 SLC25A3 ['TACTTACTTGATTTTTTTTTTTCCARTCAAA 9A>G CAGAGCAGTATAGCTGTGAC] 5072 NM_181426.1(CCDC39):c.610- 33982 CCDC39 ['TTGTGCTGCTTTATCCAATTCTAACYGTCA 2A>G 9 AACAGAGAGCAAAGAACATTT']
5073 NM_153704.5(TMEM67):c.725A> 91147 TMEM67 ['ATTGTTCTGTTGTAGGTATATGCCARTCTA G (p.Asn242Ser) ACATCTTGTCAAGCTCTTGGA']
5074 NM_000166.5(GJBl):c.305A>G 2705 GJB1 ['CACGTGGCTCACCAGCAACACATAGRGAA (p.Glul02Gly) GAAAATGCTACGGCTTGAGGGC]
5075 NM_019098.4(CNGB3):c.l l93A> 54714 CNGB3 ['AATTAAAGTTCGAACTGCCCAATAAYAAC G (p.Tyr398Cys) ATCTCAGATACCTGTGAAAACA']
5076 NM_000070.2(CAPN3):c.l l94- 825 CAPN3 ['CCATATGGCTCTCTCTCTTCTTCCARCCTCT 9A>G CAGGATGTCCTATGAGGATT']
5077 NM_002860.3(ALDH18Al):c2345 5832 ALDH18A [' AGGAAT AGGGAGGTTCTC ATGAAGAB ATT A>G (p.Tyr782Cys) 1 TTAAACTTCCATGCTCTGAGAA]
5078 M_001414.3(EIF2Bl):c.824A>G 1967 EIF2B1 ['CAGAGTGATTAAGGAAGGGGCAGTGYAGT (p.Tyr275Cys) CGACCCACGGATGCTCCTCTTT']
5079 NM_182896.2(ARL13B):c.461A>G 20089 ARL13B ['TGTCTATCTCTGGAAAAATTGGTCARTGAG (p.Asnl54Ser) 4 CACAAGTGCCTGTGTCAGATA']
5080 NM_001134831.1(AHIl):c. l l52- 54806 AHI1 ['TAGTAAGATGAAACAGGCCGTCCACYGTA 2A>G CAAAAAAAGATACTTCCATTAA']
5081 NM_153704.5(TMEM67):c.978+3 91147 TMEM67 ['TCAGTTTTAAAGGAGAAAACCAGGTRAAA A>G GTGTCTAATATCATTAGAGGAT']
5082 NM_015681.3(B9Dl):c.95A>G 27077 B9D1 ['CCAGTCCTGGCCGTACACAAAGCAGYACT (p.Tyr32Cys) TGCAGTAGAGGTCATCATACTC]
5083 M_014049.4(ACAD9):c. lA>G 28976 ACAD 9 ['CTGAGGCTGGGGAACATCGGGCAGCWTGA (p.MetlVal) GCGGCTGCGGGCTCTTCCTGCG]
Table 8. xCas9v3 Mutations (K294R/Q1256K Series)
Figure imgf000448_0001
Q1256K Q1256K Q1256K Q1256K Q1256K
Table 9. xCas9v3 Mutations (A262T/S409I Series)
Figure imgf000449_0001
Table 10. PAM Depletion Scores (xCas9v3.0-3.6 Mutations)
Figure imgf000449_0002
ATC 0.52 0.50 0.45 0.45 0.47 0.42 0.38
ATG 11.38 14.85 23.55 40.11 20.48 30.27 108.77
ATT 0.48 0.46 0.43 0.42 0.43 0.41 0.39
CAA 1.55 2.00 6.63 5.06 3.42 6.29 4.66
CAC 0.57 0.65 0.99 0.75 0.86 0.93 3.20
CAG 15.05 11.83 26.90 26.86 22.15 32.07 137.31
CAT 4.41 6.06 17.67 7.55 6.30 8.13 7.87
CCA 0.48 0.46 0.41 0.43 0.42 0.40 0.39
CCC 0.53 0.51 0.46 0.45 0.45 0.43 0.44
CCG 3.35 2.67 6.87 6.98 4.69 8.56 5.44
CCT 0.53 0.50 0.45 0.49 0.46 0.43 0.38
CGA 9.23 49.45 43.50 106.20 62.04 27.17 116.32
CGC 13.79 8.59 17.62 15.06 12.16 21.40 11.61
CGG 16.85 223.84 46.41 346.14 96.28 90.82 252.73
CGT 12.66 23.87 36.06 42.02 20.18 27.33 179.69
CTA 0.54 0.50 0.45 0.47 0.47 0.45 0.49
CTC 0.51 0.48 0.43 0.44 0.45 0.42 0.38
CTG 5.39 3.40 6.92 8.28 5.95 11.34 4.20
CTT 0.52 0.52 0.46 0.46 0.44 0.44 0.82
GAA 10.98 7.67 14.45 11.25 9.75 11.86 6.86
GAC 0.88 1.35 4.85 2.92 2.40 5.25 4.15
GAG 11.85 55.33 39.91 118.83 109.84 85.83 390.44
GAT 7.69 5.68 10.55 9.22 6.41 11.03 9.53
GCA 0.49 0.49 0.47 0.52 0.53 0.59 0.61
GCC 0.53 0.52 0.50 0.50 0.49 0.46 0.52
GCG 13.68 13.44 22.56 46.72 32.75 35.86 97.69
GCT 0.51 0.50 0.45 0.48 0.46 0.45 0.61
GGA 9.74 82.32 39.45 172.39 102.30 85.53 77.46
GGC 12.21 10.04 17.84 15.18 14.04 27.07 17.46
GGG 18.90 381.76 70.36 281.12 164.21 111.87 718.40
GGT 10.87 22.11 32.25 88.31 40.66 40.16 257.92
GTA 0.56 0.59 0.77 0.72 0.76 1.03 1.55
GTC 0.52 0.51 0.46 0.52 0.49 0.45 0.58
GTG 11.43 16.42 28.54 72.25 33.31 47.65 382.48
GTT 0.48 0.45 0.41 0.43 0.43 0.42 0.76
TAA 0.58 0.67 1.59 0.99 1.04 1.69 1.53
TAC 0.56 0.54 0.51 0.51 0.52 0.50 0.44
TAG 11.34 10.19 15.99 22.04 15.24 27.89 35.59
TAT 0.56 0.64 1.26 0.85 0.89 1.21 2.60 TCA 0.50 0.48 0.43 0.45 0.46 0.45 0.44
TCC 0.50 0.48 0.43 0.46 0.44 0.42 0.47
TCG 10.38 8.24 14.95 15.64 9.96 15.57 34.80
TCT 0.52 0.50 0.45 0.44 0.46 0.41 0.46
TGA 9.68 61.64 44.45 188.12 99.42 46.89 186.41
TGC 13.64 9.07 15.11 11.69 11.22 15.01 8.15
TGG 12.90 223.88 63.67 259.65 115.56 80.51 210.65
TGT 11.53 18.90 31.99 36.30 18.72 21.90 122.87
TTA 0.61 0.57 0.52 0.54 0.51 0.52 0.30
TTC 0.53 0.50 0.44 0.45 0.44 0.43 0.27
TTG 13.57 6.61 10.15 13.27 7.38 14.26 12.24
TTT 0.53 0.49 0.44 0.45 0.48 0.44 0.28
Table 10 Continued. PAM Depletion Scores (xCas9v3.7-3.12 Mutations)
Figure imgf000451_0001
CCG 4.35 5.28 5.57 1.37 0.94 0.83
CCT 0.40 1.04 0.36 1.22 0.67 0.59
CGA 4.47 7.60 5.26 1.35 1.36 2.02
CGC 13.35 10.98 5.45 4.03 5.37 3.66
CGG 6.06 5.52 25.23 31.85 19.44 34.65
CGT 17.13 7.41 17.31 0.63 1.44 0.66
CTA 0.76 0.50 0.50 1.97 1.45 1.05
CTC 0.40 0.26 0.65 0.58 0.45 0.81
CTG 5.64 9.49 6.82 1.35 1.41 2.11
CTT 0.50 0.63 0.68 0.54 0.73 0.88
GAA 9.81 6.07 4.68 2.07 0.87 1.09
GAC 3.91 3.95 2.82 0.44 0.86 0.56
GAG 23.26 21.32 9.88 16.93 18.42 40.73
GAT 5.06 9.85 1.07 0.75 1.06 0.63
GCA 0.56 0.81 0.79 1.46 0.44 0.89
GCC 0.35 0.52 0.71 0.65 3.67 0.73
GCG 16.11 12.53 9.43 1.59 1.98 2.22
GCT 0.42 0.88 0.27 0.66 1.14 0.76
GGA 3.01 18.40 33.07 27.28 16.20 46.82
GGC 6.03 3.83 11.69 8.03 22.56 3.92
GGG 12.16 10.26 15.08 17.30 25.85 128.03
GGT 11.25 13.77 2.94 12.71 16.11 16.22
GTA 1.38 1.08 1.24 0.75 3.52 1.09
GTC 0.96 0.31 0.50 0.93 0.72 0.81
GTG 6.68 17.93 26.86 9.93 9.61 2.72
GTT 0.45 0.33 0.99 0.65 1.61 1.01
TAA 3.04 2.16 1.84 1.21 1.08 0.68
TAC 0.61 0.52 0.68 0.95 0.68 0.86
TAG 4.76 15.71 1.10 8.15 8.25 8.87
TAT 1.62 2.10 1.01 0.73 0.74 0.66
TCA 0.41 0.66 0.58 0.46 0.77 0.68
TCC 0.54 0.29 0.38 1.36 0.86 0.82
TCG 1.41 4.20 9.11 0.84 0.46 0.69
TCT 0.47 0.44 0.38 0.60 1.00 0.94
TGA 22.42 5.39 15.72 1.78 3.13 3.69
TGC 6.78 6.81 11.35 2.41 6.55 4.08
TGG 20.36 11.36 11.56 9.97 21.64 19.87
TGT 10.32 8.82 21.17 0.94 0.79 0.73
TTA 0.65 0.29 0.77 0.94 1.35 0.75 TTC 0.62 1.07 0.55 0.86 1.07 0.58
TTG 8.41 6.07 9.07 0.67 0.56 0.72
TTT 0.43 0.56 0.44 0.68 0.60 0.75
REFERENCES
Humbert O, Davis L, Maizels N. Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol.2012; 47(3):264-81. PMID: 22530743.
Perez -Pinera P, Ousterout DG, Gersbach CA. Advances in targeted genome editing. Curr Opin Chem Biol. 2012; 16(3-4):268-77. PMID: 22819644.
Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010; 11(9):636-46. PMID: 20717154. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013; 14(l):49-55. PMID: 23169466.
Charpentier E, Doudna JA. Biotechnology: Rewriting a genome. Nature. 2013; 495, (7439):50-l . PMID: 23467164.
Pan Y, Xia L, Li AS, Zhang X, Sirois P, Zhang J, Li K. Biological and biomedical applications of engineered nucleases. Mol Biotechnol. 2013; 55(l):54-62. PMID:
23089945.
De Souza, N. Primer: genome editing with engineered nucleases. Nat Methods. 2012; 9(1):27. PMID: 22312638.
Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, Holmes MC, Guschin D, Waite A, Miller JC, Rebar EJ, Gregory PD, Klug A, Collingwood TN. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci USA. 2008; 105(15):5809-14. PMID: 18359850.
Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Lane CR, Lim EP,
Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999; 22(3):231-8. PMID: 10391209.
Jansen R, van Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002; 43(6): 1565-75.
PMID: 11952905.
Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013; 10(10):957-63. PMID: 24076990.
Jore MM, Lundgren M, van Duijin E, Bultema JB, Westra ER, Waghmare SP,
Wiedenheft B, Pul U, Wurm R, Wagner R, Beijer MR, Barendregt A, Shou K, Snijders AP, Dickman MJ, Doudna JA, Boekema EJ, Heck AJ, van der Oost J, Brouns SJ.
Structural basis for CRISPR RNA-guided DNA recognition by Cascade. Nat Struct Mol Biol. 2011; 18(5):529-36. PMID: 21460843.
Horvath P, Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science. 2010; 327(5962): 167-70. PMID: 20056882.
Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012; 482(7385):331-8. PMID: 22337052. Gasiunas G, Siksnys V. RNA-dependent DNA endonuclease Cas9 of the CRISPR system: Holy Grail of genome editing? Trends Microbiol.2013; 21(11):562-7. PMID: 24095303.
Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA.
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell.2013; 152(5): 1173-83. PMID: 23452860.
Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods.2013; 10(10):973-6. PMID: 23892895.
Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L, Church GM. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol.2013; 31(9):833-8. PMID: 23907171. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS. CRISPR- mediated modular RNA-guided regulation of transcription in eukaryotes. Cell.2013; 154(2):442-51. PMID: 23849981.
Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS. CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat Protoc.2013;
8(l l):2180-96. PMID: 24136345.
Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science.2013; 339(6121):823-6. PMID: 23287722.
Cole-Strauss A, Yoon K, Xiang Y, Byrne BC, Rice MC, Gryn J, Holloman WK, Kmiec EB. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science.1996; 273(5280): 1386-9. PMID: 8703073.
Tagalakis AD, Owen JS, Simons JP. Lack of RNA-DNA oligonucleotide (chimeraplast) mutagenic activity in mouse embryos. Mol Reprod Dev.2005; 71(2): 140-4. PMID:
15791601.
Ray A, Langer M. Homologous recombination: ends as the means. Trends Plant Sci. 2002; 7(10):435-40. PMID 12399177.
Britt AB, May GD. Re-engineering plant gene targeting. Trends Plant Sci.2003; 8(2): 90- 5. PMID: 12597876.
Vagner V, Ehrlich SD. Efficiency of homologous DNA recombination varies along the Bacillus subtilis chromosome. J Bacteriol.1988; 170(9):3978-82. PMID: 3137211.
Saleh-Gohari N, Helleday T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res.2004; 32(12):3683-8. PMID: 15252152.
Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, Ando D, Urnov FD, Galli C, Gregory PD, Holmes MC, Naldini L. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol.2007; 25(11): 1298-306. PMID: 17965707.
Conticello SG. The AID/APOBEC family of nucleic acid mutators. Genome Biol.2008; 9(6):229. PMID: 18598372. 30. Reynaud CA, Aoufouchi S, Faili A, Weill JC. What role for AID: mutator, or assembler of the immunoglobulin mutasome? Nat Immunol. 2003; 4(7):631-8.
31. Bhagwat AS. DNA-cytosine deaminases: from antibody maturation to antiviral defense.
DNA Repair (Amst). 2004; 3(l):85-9. PMID: 14697763.
32. Navaratnam N, Sarwar R. An overview of cytidine deaminases. Int J Hematol. 2006;
83(3): 195-200. PMID: 16720547.
33. Holden LG, Prochnow C, Chang YP, Bransteitter R, Chelico L, Sen U, Stevens RC, Goodman MF, Chen XS. Crystal structure of the anti -viral APOBEC3G catalytic domain and functional implications. Nature. 2008; 456(7218): 121-4. PMID: 18849968.
34. Chelico L, Pham P, Petruska J, Goodman MF. Biochemical basis of immunological and retroviral responses to DNA-targeted cytosine deamination by activation-induced cytidine deaminase and APOBEC3G. JBiol Chem. 2009; 284(41). 27761-5. PMID: 19684020.
35. Pham P, Bransteitter R, Goodman MF. Reward versus risk: DNA cytidine deaminases triggering immunity and disease. Biochemistry. 2005; 44(8):2703-15. PMID 15723516.
36. Chen X, Zaro JL, Shen WC. Fusion protein linkers: property, design and functionality.
Adv Drug Deliv Rev. 2013; 65(10): 1357-69. PMID: 23026637.
37. Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved
specificity. Science, doi: 10.1126/science.aad5227 (2015).
38. Kleinstiver, B. P. et al. Engineered CRISPR-Cas9 nucleases with altered PAM
specificities. Nature 523, 481 -485, doi: 10.1038/nature 14592 (2015).
39. Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals RNA- programmed Cas9 nuclease specificity. Nature Biotechnology 31, 839-843, doi: 10.1038/nbt.2673 (2013).
40. Shcherbakova, D. M. & Verkhusha, V. V. Near-infrared fluorescent proteins for
multicolor in vivo imaging. Nature Methods 10, 751-754, doi: 10.1038/nmeth.2521 (2013).
41. Kleinstiver, et al., High-fidelity CRISPR-Cas9 nucleases with no detectable genome- wide off-target effects. Nature 529, 490-495 doi: 10.1038/naturel6526 (2016).
[00275] All publications, patents, patent applications, publication, and database entries {e.g., sequence database entries) mentioned herein, e.g., in the Background, Summary, Detailed Description, Examples, and/or References sections, are hereby incorporated by reference in their entirety as if each individual publication, patent, patent application, publication, and database entry was specifically and individually incorporated herein by reference. In case of conflict, the present application, including any definitions herein, will control.
EQUIVALENTS AND SCOPE
[00276] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the embodiments described herein. The scope of the present disclosure is not intended to be limited to the above description, but rather is as set forth in the appended claims.
[00277] Articles such as "a," "an," and "the" may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include "or" between two or more members of a group are considered satisfied if one, more than one, or all of the group members are present, unless indicated to the contrary or otherwise evident from the context. The disclosure of a group that includes "or" between two or more group members provides embodiments in which exactly one member of the group is present, embodiments in which more than one members of the group are present, and embodiments in which all of the group members are present. For purposes of brevity those embodiments have not been individually spelled out herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or disclaimed.
[00278] It is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitation, element, clause, or descriptive term, from one or more of the claims or from one or more relevant portion of the description, is introduced into another claim. For example, a claim that is dependent on another claim can be modified to include one or more of the limitations found in any other claim that is dependent on the same base claim. Furthermore, where the claims recite a composition, it is to be understood that methods of making or using the composition according to any of the methods of making or using disclosed herein or according to methods known in the art, if any, are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.
[00279] Where elements are presented as lists, e.g., in Markush group format, it is to be understood that every possible subgroup of the elements is also disclosed, and that any element or subgroup of elements can be removed from the group. It is also noted that the term "comprising" is intended to be open and permits the inclusion of additional elements or steps. It should be understood that, in general, where an embodiment, product, or method is referred to as comprising particular elements, features, or steps, embodiments, products, or methods that consist, or consist essentially of, such elements, features, or steps, are provided as well. For purposes of brevity those embodiments have not been individually spelled out herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or disclaimed.
[00280] Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in some embodiments, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. For purposes of brevity, the values in each range have not been individually spelled out herein, but it will be understood that each of these values is provided herein and may be specifically claimed or disclaimed. It is also to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.
[00281] In addition, it is to be understood that any particular embodiment of the present invention may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may explicitly be excluded from any one or more of the claims. Any embodiment, element, feature, application, or aspect of the compositions and/or methods of the invention, can be excluded from any one or more claims. For purposes of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects is excluded are not set forth explicitly herein.

Claims

What is claimed is:
1. A recombinant Cas9 protein comprising an amino acid sequence that is at least 80%, identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 9- 262,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and
wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein.
2. The Cas9 protein of claim 1 comprising an amino acid sequence that is at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 9-262.
3. The Cas9 protein of claim 1, wherein the Cas9 protein comprises a RuvC and an HNH domain.
4. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X267G, X294R, X405I, X409I, X480K, X543D, X694I, X1219V, X1224K, X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
5. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, S267G, K294R, F405I, S409I, E480K, E543D, M694I, E1219V, N1224K, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
6. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
7. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
8. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an X294R mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
9. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an K294R mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
10. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an X1256K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
11. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an Q1256K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
12. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an X694I mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
13. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an M694I mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
14. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an X543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
15. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an E543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
16. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an X480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
17. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an E480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
18. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an X409I mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
19. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an S409I mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
20. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an X262T mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
21. The Cas9 protein of claim 1, wherein the amino acid sequence of the Cas9 protein comprises an A262T mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
22. A recombinant Cas9 protein comprising an amino acid sequence that is at least 80%, identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 9- 262,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and
wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein.
23. The Cas9 protein of claim 22 comprising an amino acid sequence that is at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 9-262.
24. The Cas9 protein of claim 22 or 23, wherein the Cas9 protein comprises a RuvC and an HNH domain.
25. The Cas9 protein of any one of claims 22-24, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X267G, X294R, X405I, X409I, X480K, X543D, X694I, X1219V, X1224K, X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
26. The Cas9 protein of any one of claims 22-25, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, S267G, K294R, F405I, S409I, E480K, E543D, M694I, E1219V, N1224K, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
27. The Cas9 protein of any one of claims 22-26, wherein the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
28. The Cas9 protein of any one of claims 22-27, wherein the amino acid sequence of the Cas9 protein comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
29. The Cas9 protein of any one of claims 22-28, wherein the amino acid sequence of the Cas9 protein comprises an X480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
30. The Cas9 protein of any one of claims 22-29, wherein the amino acid sequence of the Cas9 protein comprises an E480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
31. The Cas9 protein of any one of claims 22-30, wherein the amino acid sequence of the Cas9 protein comprises an X543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
32. The Cas9 protein of any one of claims 22-31, wherein the amino acid sequence of the Cas9 protein comprises an E543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
33. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations X480K, X543D, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
34. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
35. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
36. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
37. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations X267G, X294R, X480K, X543D, X1219V, X1224K, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
38. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, X405I, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
39. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations E480K, E543D, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
40. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
41. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations K294R, E480K, E543D, E1219V, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
42. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
43. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations S267G, K294R, E480K, E543DE1219V, N1224K, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
44. The Cas9 protein of any of claims 22-32, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, F405I, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
45. The Cas9 protein of any one of claims 24-44, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
46. The Cas9 protein of any one of claims 24-45, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
47. The Cas9 protein of any one of claims 24-46, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
48. The Cas9 protein of any one of claims 24-47, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
49. The Cas9 protein of any one of claims 22-48, wherein the Cas9 protein comprises a DIOA and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
50. The Cas9 protein of any one of claims 22-48, wherein the Cas9 protein comprises a DlOXi and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X1 is any amino acid except for D and wherein X2 is any amino acid except for H.
51. The Cas9 protein of any one of claims 22-50, wherein the Cas9 protein comprises an D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
52. The Cas9 protein of claim 51, wherein the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
53. The Cas9 protein of any one of claims 22-51, wherein the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
54. The Cas9 protein of claim 53, wherein the Cas9 protein comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
55. The Cas9 protein of any one of claims 22-54, wherein the Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5 '-NOGS ') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
56. A recombinant Cas9 protein comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, or to a fragment thereof,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 262, 267, 294, 405, 409, 480, 543, 694, 1219, 1224, 1256, and 1362 of the amino acid sequence provided in SEQ ID NO: 9, wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and
wherein the recombinant Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3 ') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
57. The Cas9 protein of claim 56, wherein the Cas9 protein comprises a RuvC and an HNH domain.
58. The Cas9 protein of claim 56 or 57, wherein the Cas9 protein exhibits an activity on a target sequence having a 3' end that is not directly adjacent to the canonical PAM sequence (5'-NGG-3 ') that is at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence.
59. The Cas9 protein of claim 58, wherein the 3' end of the target sequence is directly adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
60. The Cas9 protein of claim 58 or 59, wherein the 3' end of the target sequence is directly adjacent to a sequence selected from the group consisting of CAC, GAT, TAA, ACG, CGA, and CGT.
61. The Cas9 protein of any one of claims 56-60, wherein the Cas9 protein activity is measured by a nuclease assay, a deamination assay, or a transcriptional activation assay.
62. The Cas9 protein of claim 61, wherein the transcriptional activation assay is a GFP activation assay.
63. The Cas9 protein of any one of claims 56-62, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X267G, X294R, X405I, X409I, X480K, X543D, X694I, X1219V, X1224K, X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
64. The Cas9 protein of any one of claims 56-63, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, S267G, K294R, F405I, S409I, E480K, E543D, M694I, E1219V, N1224K, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
65. The Cas9 protein of any one of claims 56-64, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
66. The Cas9 protein of any one of claims 56-65, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
67. The Cas9 protein of any one of claims 56-66, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises an X480k mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
68. The Cas9 protein of any one of claims 56-67, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises an E480K mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
69. The Cas9 protein of any one of claims 56-68, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises an X543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
70. The Cas9 protein of any one of claims 56-69, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises an E543D mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
71. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X480K, X543D, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
72. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
73. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X294R, X480K, X543D, X1219V, X1256K, and X1362P of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
74. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
75. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X267G, X294R, X480K, X543D, X1219V, X1224K, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
76. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, X405I, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
77. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations E480K, E543D, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
78. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
79. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations K294R, E480K, E543D, E1219V, Q1256K, and L1362P of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
80. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
81. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations S267G, K294R, E480K, E543DE1219V, N1224K, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
82. The Cas9 protein of any of claims 56-70, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, F405I, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
83. The Cas9 protein of any one of claims 57-82, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
84. The Cas9 protein of any one of claims 57-83, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
85. The Cas9 protein of any one of claims 57-84, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
86. The Cas9 protein of any one of claims 57-85, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
87. The Cas9 protein of any one of claims 56-86, wherein the Cas9 protein or the fragment thereof comprises at D10A and/or a H840A mutation in the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
88. The Cas9 protein of any one of claims 56-86, wherein the Cas9 protein or the fragment thereof comprises a D10X1 and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein Xi is any amino acid except for D and wherein X2 is any amino acid except for H.
89. The Cas9 protein of any one of claims 56-88, wherein the Cas9 protein or the fragment thereof comprises an DIOA mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
90. The Cas9 protein of claim 89, wherein the Cas9 protein or the fragment thereof comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
91. The Cas9 protein of any one of claims 56-89, wherein the Cas9 protein or the fragment thereof comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
92. The Cas9 protein of claim 91, wherein the Cas9 protein or the fragment thereof comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
93. A recombinant Cas9 protein comprising an amino acid sequence that is at least 80%, identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 9- 262,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and
wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein.
94. The Cas9 protein of claim 93, wherein the Cas9 protein comprises a RuvC and an HNH domain.
95. The Cas9 protein of claim 93 or 94, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
96. The Cas9 protein of any one of claims 93-95, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, K294R, S409I, E480K, E543D, M694I, or E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
97. The Cas9 protein of any one of claims 93-96, wherein the amino acid sequence of the Cas9 protein comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
98. The Cas9 protein of any one of claims 93-97, wherein the amino acid sequence of the Cas9 protein comprises an E1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
99. The Cas9 protein of any one of claims 94-98, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
100. The Cas9 protein of any one of claims 94-99, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
101. The Cas9 protein of any one of claims 94-100, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
102. The Cas9 protein of any one of claims 94-101, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
103. The Cas9 protein of any one of claims 93-102, wherein the Cas9 protein comprises a DIOA and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
104. The Cas9 protein of any one of claims 93-102, wherein the Cas9 protein comprises an DIOA mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
105. The Cas9 protein of claim 104, wherein the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
106. The Cas9 protein of any one of claims 93-105, wherein the Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5 '-NOGS ') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
107. A recombinant Cas9 protein comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, or to a fragment thereof, comprising the RuvC and HNH domains of SEQ ID NO: 9, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 122, 137, 182, 262, 294, 409, 480, 543, 660, 694, 1219, and 1329 of the amino acid sequence provided in SEQ ID NO: 9,
wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and
wherein the recombinant Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3 ') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
108. The Cas9 protein of claim 107, wherein the Cas9 protein comprises a RuvC and an HNH domain.
109. The Cas9 protein of claim 107 or 108, wherein the Cas9 protein exhibits an activity on a target sequence having a 3' end that is not directly adjacent to the canonical PAM sequence (5'-NGG-3 ') that is at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence.
110. The Cas9 protein of claim 109, wherein the 3' end of the target sequence is directly adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
111. The Cas9 protein of any one of claims 107-110, wherein the Cas9 protein activity is measured by a nuclease assay, a deamination assay, or a transcriptional activation assay.
112. The Cas9 protein of claim 111, wherein the transcriptional activation assay is a GFP activation assay.
113. The Cas9 protein of any one of claims 107-112, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X262T, X294R, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
114. The Cas9 protein of any one of claims 107-113, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of A262T, K294R, S409I, E480K, E543D, M694I, or E1219V of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
115. The Cas9 protein of any one of claims 107-114, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises an X1219 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
116. The Cas9 protein of any one of claims 107-115, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises an X1219V mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
117. The Cas9 protein of any one of claims 108-116, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
118. The Cas9 protein of any one of claims 108-117, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
119. The Cas9 protein of any one of claims 108-118, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
120. The Cas9 protein of any one of claims 108-119, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
121. The Cas9 protein of any one of claims 107-120, wherein the Cas9 protein or the fragment thereof comprises at D10A and/or a H840A mutation in the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
122. The Cas9 protein of any one of claims 107-121, wherein the Cas9 protein comprises an D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
123. The Cas9 protein of claim 122, wherein the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
124. A recombinant Cas9 protein comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%), or at least 99.5% identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 9-262,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten mutations in an amino acid residue selected from the group consisting of amino acid residues 23, 108, 115, 141, 180, 230, 257, 262, 267, 284, 294, 324, 409, 455, 466, 474, 480, 543, 554, 654, 694, 711, 727, 763, 1063, 1100, 1219, 1244, 1256, 1289, and 1323 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and
wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein.
125. The Cas9 protein of claim 124, wherein the Cas9 protein comprises a RuvC and an HNH domain.
126. The Cas9 protein of claim 124 or 125, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten mutations selected from the group consisting of X23N, X108G, X115H, X141Q, X180N, X230S, X257N, X262T, X267G, X284N, X294R, X324L, X409I, X455F, X466A, X474I, X480K, X543D, X554R, X654L, X694I, X711E, X727P, X763I, X1063V, XI 1001, X1219V, X1244N, X1256K, X1289Q, and X1323S of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
127. The Cas9 protein of any one of claims 124-126, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at lest eight, at least nine, or at least ten mutations selected from the group consisting of D23N, E108G, R115H, K141Q, D180N, P230S, D257N, A262T, S267G, D284N, K294R, R324L, S409I, L455F, T466A, T474I, E480K, E543D, K554R, R654L, M694I, A711E, L727P, M763I, I1063V, VI 1001, E1219V, K1244N, Q1256K, K1289Q, and A1323S of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
128. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations XI 15H, X141Q, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
129. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
130. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X23N, X108G, X262T, X409I, X480K, X543D, X694I, X727P, X1219V, and X1289Q of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
131. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X257N, X267G, X294R, X466A, X480K, X543D, X1063V, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
132. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X409I, X455F, X480K, X543D, X654L, XI 1001, X1219V, and X1323S of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
133. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
134. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, X324L, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
135. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X71 IE, XI 219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
136. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X230S, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
137. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X180N, X284N, X474I, X480K, X543D, X554R, X763I, X1219V, and X1244N of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
138. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
139. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
140. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X230S, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
141. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X267G, X294R, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
142. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, and X409I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
143. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations Rl 15H, K141Q, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
144. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
145. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations D23N, E108G, A262T, S409I, E480K, E543D, M694I, L727P, E1219V, and K1289Q of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
146. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations D257N, S267G, K294R, T466A, E480K, E543D, I1063V, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
147. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations S409I, L455F, E480K, E543D, R654L, VI 1001, E1219V, and A1323S of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
148. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
149. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, R324L, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
150. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations K294R, E480K, E543D, A71 IE, E1219V, and
Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
151. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations P230S, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
152. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations D180N, D284N, T474I, E480K, E543D, K554R, M763I, E1219V, and K1244N of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
153. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
154. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
155. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations P230S, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
156. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations S267G, K294R, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
157. The Cas9 protein of any of claims 124-127, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, and S409I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
158. The Cas9 protein of any one of claims 124-157, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
159. The Cas9 protein of any one of claims 125-158, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
160. The Cas9 protein of any one of claims 125-159, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
161. The Cas9 protein of any one of claims 125-160, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
162. The Cas9 protein of any one of claims 124-161, wherein the Cas9 protein comprises a D10A and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
163. The Cas9 protein of any one of claims 124-162, wherein the Cas9 protein comprises a DlOXi and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X1 is any amino acid except for D and wherein X2 is any amino acid except for H.
164. The Cas9 protein of any one of claims 124-163, wherein the Cas9 protein comprises an D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
165. The Cas9 protein of claim 164, wherein the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
166. The Cas9 protein of any one of claims 124-164, wherein the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
167. The Cas9 protein of claim 166, wherein the Cas9 protein comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
168. The Cas9 protein of any one of claims 124-167, wherein the Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5 '-NOGS ') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
169. A recombinant Cas9 protein comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, or to a fragment thereof,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten mutations in an amino acid residue selected from the group consisting of amino acid residues 23, 108, 115, 141, 180, 230, 257, 262, 267, 284, 294, 324, 409, 455, 466, 474, 480, 543, 554, 654, 694, 711, 727, 763, 1063, 1100, 1219, 1244, 1256, 1289, and 1323 of the amino acid sequence provided in SEQ ID NO: 9,
wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and
wherein the recombinant Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
170. The Cas9 protein of claim 169, wherein the Cas9 protein comprises a RuvC and an HNH domain.
171. The Cas9 protein of claim 169 or 170, wherein the Cas9 protein exhibits an activity on a target sequence having a 3' end that is not directly adjacent to the canonical PAM sequence (5'-NGG-3 ') that is at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence.
172. The Cas9 protein of claim 171, wherein the 3' end of the target sequence is directly adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
173. The Cas9 protein of claim 171 or 172, wherein the 3' end of the target sequence is directly adjacent to a sequence selected from the group consisting of CAC, GAT, TAA, ACG, CGA, and CGT.
174. The Cas9 protein of any one of claims 169-173, wherein the Cas9 protein activity is measured by a nuclease assay, a deamination assay, or a transcriptional activation assay.
175. The Cas9 protein of claim 174, wherein the transcriptional activation assay is a GFP activation assay.
176. The Cas9 protein of any one of claims 169-175, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of X23N, X108G, X115H, X141Q, X180N, X230S, X257N, X262T, X267G, X284N, X294R, X324L, X409I, X455F, X466A, X474I, X480K, X543D, X554R, X654L, X694I, X711E, X727P, X763I, X1063V, XI 1001, X1219V, X1244N, X1256K, X1289Q, and X1323S of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
177. The Cas9 protein of any one of claims 169-176, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations selected from the group consisting of D23N, E108G, R115H, K141Q, D180N, P230S, D257N, A262T, S267G, D284N, K294R, R324L, S409I, L455F, T466A, T474I, E480K, E543D, K554R, R654L, M694I, A711E, L727P, M7631, 11063 V, VI 1001, E1219V, K1244N, Q1256K, K1289Q, and A1323S of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
178. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations XI 15H, X141Q, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
179. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
180. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X23N, X108G, X262T, X409I, X480K, X543D, X694I, X727P, X1219V, and X1289Q of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
181. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X257N, X267G, X294R, X466A, X480K, X543D, X1063V, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
182. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X409I, X455F, X480K, X543D, X654L, XI 1001, X1219V, and X1323S of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
183. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
184. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, X324L, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
185. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X294R, X480K, X543D, X71 IE, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
186. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X230S, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
187. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X180N, X284N, X474I, X480K, X543D, X554R, X763I, X1219V, and X1244N of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
188. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
189. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
190. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X230S, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
191. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X267G, X294R, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
192. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, and X409I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
193. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations Rl 15H, K141Q, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
194. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
195. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations D23N, E108G, A262T, S409I, E480K, E543D, M694I, L727P, E1219V, and K1289Q of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
196. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations D257N, S267G, K294R, T466A, E480K, E543D, I1063V, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
197. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations S409I, L455F, E480K, E543D, R654L, VI 1001, E1219V, and A1323S of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
198. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
199. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, R324L, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
200. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations K294R, E480K, E543D, A71 IE, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
201. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations P230S, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
202. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations D180N, D284N, T474I, E480K, E543D, K554R, M763I, E1219V, and K1244N of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
203. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
204. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
205. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations P230S, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
206. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations S267G, K294R, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
207. The Cas9 protein of any of claims 169-177, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, and S409I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
208. The Cas9 protein of any one of claims 170-207, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
209. The Cas9 protein of any one of claims 170-208, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
210. The Cas9 protein of any one of claims 170-209, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
211. The Cas9 protein of any one of claims 170-210, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
212. The Cas9 protein of any one of claims 169-211, wherein the Cas9 protein or the fragment thereof comprises at D10A and/or a H840A mutation in the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
213. The Cas9 protein of any one of claims 169-211, wherein the Cas9 protein or the fragment thereof comprises a D10X1 and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X1 is any amino acid except for D and wherein X2 is any amino acid except for H.
214. The Cas9 protein of any one of claims 169-213, wherein the Cas9 protein or the fragment thereof comprises an D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
215. The Cas9 protein of claim 214, wherein the Cas9 protein or the fragment thereof comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
216. The Cas9 protein of any one of claims 169-214, wherein the Cas9 protein or the fragment thereof comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
217. The Cas9 protein of claim 216, wherein the Cas9 protein or the fragment thereof comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
218. A recombinant Cas9 protein comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%), or at least 99.5% identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 9-262,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine mutations in an amino acid residue selected from the group consisting of amino acid residues 175, 230, 257, 267, 294, 466, 480, 543, 711, 1063, 1207, 1219, and 1256 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and
wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein.
219. The Cas9 protein of claim 218, wherein the Cas9 protein comprises a RuvC and an HNH domain.
220. The Cas9 protein of claim 218 or 219, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine mutations selected from the group consisting of X175T, X230F, X257N, X267G, X294R, X466A, X480K, X543D, X711E, X1207G, X1063V, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
221. The Cas9 protein of any one of claims 218-220, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at lest eight, or at least nine mutations selected from the group consisting of N175T, P230F, D257N, S267G, K294R, T466A, E480K, E543D, A711E, E1207G, I1063V, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
222. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations X230F, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
223. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X711E, X1207G, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
224. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations X175T, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
225. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations X257N, X267G, X294R, X466A, X480K, X543D, X1063V, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
226. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
227. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations X294R, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
228. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations P230F, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
229. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations K294R, E480K, E543D, A71 IE, E1207G, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
230. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations N175T, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
231. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations D257N, S267G, K294R, T466A, E480K, E543D, I1063V, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
232. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
233. The Cas9 protein of any of claims 218-221, wherein the amino acid sequence of the Cas9 protein comprises the mutations K294R, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
234. The Cas9 protein of any one of claims 218-233, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
235. The Cas9 protein of any one of claims 219-234, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
236. The Cas9 protein of any one of claims 219-235, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
237. The Cas9 protein of any one of claims 219-236, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
238. The Cas9 protein of any one of claims 218-237, wherein the Cas9 protein comprises a D10A and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
239. The Cas9 protein of any one of claims 218-238, wherein the Cas9 protein comprises a DIOXi and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein Xi is any amino acid except for D and wherein X2 is any amino acid except for H.
240. The Cas9 protein of any one of claims 218-239, wherein the Cas9 protein comprises an D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
241. The Cas9 protein of claim 240, wherein the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
242. The Cas9 protein of any one of claims 218-240, wherein the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
243. The Cas9 protein of claim 242, wherein the Cas9 protein comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
244. The Cas9 protein of any one of claims 218-243, wherein the Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5 '-NOGS ') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
245. A recombinant Cas9 protein comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, or to a fragment thereof,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 175, 230, 257, 267, 294, 466, 480, 543, 711, 1063, 1207, 1219, and 1256 of the amino acid sequence provided in SEQ ID NO: 9,
wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and
wherein the recombinant Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
246. The Cas9 protein of claim 245, wherein the Cas9 protein comprises a RuvC and an HNH domain.
247. The Cas9 protein of claim 245 or 246, wherein the Cas9 protein exhibits an activity on a target sequence having a 3' end that is not directly adjacent to the canonical PAM sequence (5'-NGG-3 ') that is at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence.
248. The Cas9 protein of claim 247, wherein the 3' end of the target sequence is directly adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
249. The Cas9 protein of claim 247 or 248, wherein the 3' end of the target sequence is directly adjacent to a sequence selected from the group consisting of CAC, GAT, TAA, ACG, CGA, and CGT.
250. The Cas9 protein of any one of claims 246-249, wherein the Cas9 protein activity is measured by a nuclease assay, a deamination assay, or a transcriptional activation assay.
251. The Cas9 protein of claim 250, wherein the transcriptional activation assay is a GFP activation assay.
252. The Cas9 protein of any one of claims 245-251, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine mutations selected from the group consisting of X175T, X230F, X257N, X267G, X294R, X466A, X480K, X543D, X711E, X1207G, X1063V, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
253. The Cas9 protein of any one of claims 245-252, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine mutations selected from the group consisting of N175T, P230F, D257N, S267G, K294R, T466A, E480K, E543D, A711E, E1207G, I1063V, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
254. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X230F, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
255. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X294R, X480K, X543D, X71 IE, X1207G, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
256. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X175T, X267G, X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
257. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X257N, X267G, X294R, X466A, X480K, X543D, X1063V, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
258. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X294R, X480K, X543D, X1219V, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
259. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X294R, and X1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
260. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations P230F, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
261. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations K294R, E480K, E543D,
A71 IE, E1207G, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
262. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations N175T, S267G, K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
263. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations D257N, S267G, K294R, T466A, E480K, E543D, I1063V, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
264. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations K294R, E480K, E543D, E1219V, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
265. The Cas9 protein of any of claims 245-253, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations K294R, and Q1256K of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
266. The Cas9 protein of any one of claims 246-265, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
267. The Cas9 protein of any one of claims 246-266, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
268. The Cas9 protein of any one of claims 246-267, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
269. The Cas9 protein of any one of claims 247-268, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
270. The Cas9 protein of any one of claims 245-269, wherein the Cas9 protein or the fragment thereof comprises at D10A and/or a H840A mutation in the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
271. The Cas9 protein of any one of claims 245-269, wherein the Cas9 protein or the fragment thereof comprises a D10X1 and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein Xi is any amino acid except for D and wherein X2 is any amino acid except for H.
272. The Cas9 protein of any one of claims 245-271, wherein the Cas9 protein or the fragment thereof comprises an DIOA mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
273. The Cas9 protein of claim 272, wherein the Cas9 protein or the fragment thereof comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
274. The Cas9 protein of any one of claims 245-272, wherein the Cas9 protein or the fragment thereof comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
275. The Cas9 protein of claim 274, wherein the Cas9 protein or the fragment thereof comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
276. A recombinant Cas9 protein comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%), or at least 99.5% identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 9-262,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 108, 217, 262, 324, 409, 480, 543, 673, 694, 1219, 1264, and 1365 of the amino acid sequence provided in SEQ ID NO: 9, or in a corresponding amino acid residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262, and wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein.
277. The Cas9 protein of claim 276, wherein the Cas9 protein comprises a RuvC and an HNH domain.
278. The Cas9 protein of claim 276 or 277, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine mutations selected from the group consisting of X108G, X217A, X262T, X324L, X409I, X480K, X543D, X673E, X694I, X1219V, X1264Y, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
279. The Cas9 protein of any one of claims 276-278, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at lest eight, or at least nine mutations selected from the group consisting of E108G, S217A, A262T, R324L, S409I, E480K, E543D, K673E, M694I, E1219V, H1264Y, and L1365I of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
280. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations X108G, X262T, X409I, X480K, X543D, X673E, X694I, X1219V, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
281. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations X108G, X217A, X262T, X409I, X480K, X543D, X694I, X1219V, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
281. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, X324L, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
283. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, X409I, X480K, X543D, X694I, X1219V, and X1264Y of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
284. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
285. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, X409I, X480K, X543D, X694I, X1219V, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
286. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations X108G, X262T, X409I, X480K, X543D, X673E, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
287. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations X108G, X262T, X409I, X480K, X543D, X694I, X1219V, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
288. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations X262T, and X409I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
289. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations E108G, A262T, S409I, E480K, E543D, K673E, M694I, E1219V, and LI 3651 of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
290. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations E108G, S217A, A262T, S409I, E480K, E543D, M694I, E1219V, and LI 365 of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
291. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, R324L, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
292. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, S409I, E480K, E543D, M694I, E1219V, and H1264Y of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
293. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
294. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, S409I, E480K, E543D, M694I, E1219V, and L1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
295. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations E108G, A262T, S409I, E480K, E543D, K673E, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
296. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations E108G, A262T, S409I, E480K, E543D, M694I, E1219V, and LI 3651 of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
297. The Cas9 protein of any of claims 276-279, wherein the amino acid sequence of the Cas9 protein comprises the mutations A262T, and S409I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
298. The Cas9 protein of any one of claims 276-297, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%>, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
299. The Cas9 protein of any one of claims 277-298, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
300. The Cas9 protein of any one of claims 277-299, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
301. The Cas9 protein of any one of claims 277-300, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
302. The Cas9 protein of any one of claims 276-301, wherein the Cas9 protein comprises a DIOA and/or a H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
303. The Cas9 protein of any one of claims 276-302, wherein the Cas9 protein comprises a DIOXi and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X1 is any amino acid except for D and wherein X2 is any amino acid except for H.
304. The Cas9 protein of any one of claims 276-303, wherein the Cas9 protein comprises an DIOA mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
305. The Cas9 protein of claim 304, wherein the Cas9 protein comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
306. The Cas9 protein of any one of claims 276-304, wherein the Cas9 protein comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
307. The Cas9 protein of claim 306, wherein the Cas9 protein comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
308. The Cas9 protein of any one of claims 276-307, wherein the Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5 '-NOGS ') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
309. A recombinant Cas9 protein comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9, or to a fragment thereof,
wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations in an amino acid residue selected from the group consisting of amino acid residues 108, 217, 262, 324, 409, 480, 543, 673, 694, 1219, 1264, and 1365 of the amino acid sequence provided in SEQ ID NO: 9,
wherein the amino acid sequence of the recombinant Cas9 protein is not identical to the amino acid sequence of a naturally occurring Cas9 protein, and
wherein the recombinant Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3' end as compared to Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9.
310. The Cas9 protein of claim 309, wherein the Cas9 protein comprises a RuvC and an HNH domain.
311. The Cas9 protein of claim 309 or 310, wherein the Cas9 protein exhibits an activity on a target sequence having a 3' end that is not directly adjacent to the canonical PAM sequence (5'-NGG-3 ') that is at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 9 on the same target sequence.
312. The Cas9 protein of claim 311, wherein the 3' end of the target sequence is directly adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
313. The Cas9 protein of claim 311 or 312, wherein the 3' end of the target sequence is directly adjacent to a sequence selected from the group consisting of CAC, GAT, TAA, ACG, CGA, and CGT.
314. The Cas9 protein of any one of claims 310-313, wherein the Cas9 protein activity is measured by a nuclease assay, a deamination assay, or a transcriptional activation assay.
315. The Cas9 protein of claim 314, wherein the transcriptional activation assay is a GFP activation assay.
316. The Cas9 protein of any one of claims 309-315, wherein the amino acid sequence of the Cas9 protein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine mutations selected from the group consisting of X108G, X217A, X262T, X324L, X409I, X480K, X543D, X673E, X694I, X1219V, X1264Y, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
317. The Cas9 protein of any one of claims 309-316, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine mutations selected from the group consisting of E108G, S217A, A262T, R324L, S409I, E480K, E543D, K673E, M694I, E1219V, H1264Y, and L1365I of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
318. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X108G, X262T, X409I, X480K, X543D, X673E, X694I, X1219V, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
319. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X108G, X217A, X262T, X409I, X480K, X543D, X694I, X1219V, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
320. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, X324L, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
321. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, X409I, X480K, X543D, X694I, X1219V, and X1264Y of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
322. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, X409I, X480K, X543D, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
323. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, X409I, X480K, X543D, X694I, X1219V, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262, wherein X represents any amino acid.
234. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X108G, X262T, X409I, X480K, X543D, X673E, X694I, and X1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
235. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X108G, X262T, X409I, X480K, X543D, X694I, X1219V, and X1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
326. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations X262T, and X409I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X represents any amino acid.
327. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations E108G, A262T, S409I, E480K, E543D, K673E, M694I, E1219V, and LI 3651 of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
328. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations E108G, S217A, A262T, S409I, E480K, E543D, M694I, E1219V, and LI 3651 of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
329. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, R324L, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
330. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, S409I, E480K, E543D, M694I, E1219V, and H1264Y of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
331. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, S409I, E480K, E543D, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or
corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
332. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, S409I, E480K, E543D, M694I, E1219V, and LI 3651 of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
333. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations E108G, A262T, S409I, E480K, E543D, K673E, M694I, and E1219V of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
334. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations E108G, A262T, S409I, E480K, E543D, M694I, E1219V, and L1365I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10- 262.
335. The Cas9 protein of any of claims 309-317, wherein the amino acid sequence of the Cas9 protein or the fragment thereof comprises the mutations A262T, and S409I of the amino acid sequence provided in SEQ ID NO: 9, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
336. The Cas9 protein of any one of claims 310-335, wherein the amino acid sequence of the HNH domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the HNH domain of any of SEQ ID NOs: 9-262.
337. The Cas9 protein of any one of claims 310-330, wherein the amino acid sequence of the HNH domain is identical to the amino acid sequence of the HNH domain of SEQ ID NO: 9.
338. The Cas9 protein of any one of claims 310-337, wherein the amino acid sequence of the RuvC domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of the RuvC domain of any of SEQ ID NOs: 9-262.
339. The Cas9 protein of any one of claims 310-338, wherein the amino acid sequence of the RuvC domain is identical to the amino acid sequence of the RuvC domain of SEQ ID NO: 9.
340. The Cas9 protein of any one of claims 309-339, wherein the Cas9 protein or the fragment thereof comprises at D10A and/or a H840A mutation in the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
341. The Cas9 protein of any one of claims 309-339, wherein the Cas9 protein or the fragment thereof comprises a D10X1 and/or a H840X2 mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262, wherein X1 is any amino acid except for D and wherein X2 is any amino acid except for H.
342. The Cas9 protein of any one of claims 309-341, wherein the Cas9 protein or the fragment thereof comprises an D10A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
343. The Cas9 protein of claim 342, wherein the Cas9 protein or the fragment thereof comprises an H at amino acid residue 840 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
344. The Cas9 protein of any one of claims 309-342, wherein the Cas9 protein or the fragment thereof comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
345. The Cas9 protein of claim 344, wherein the Cas9 protein or the fragment thereof comprises an D at amino acid residue 10 of the amino acid sequence provided in SEQ ID NO: 9, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 10-262.
346. A fusion protein comprising the Cas9 protein of any one of claims 1-345, wherein the Cas9 protein or fragment is fused to an effector domain, thus forming a fusion protein.
347. The fusion protein of claim 346, wherein the effector domain is fused to the N-terminus of the Cas9 protein.
348. The fusion protein of claim 346, wherein the effector domain is fused to the C-terminus of the Cas9 protein.
349. The fusion protein of any one of claims 346-348, wherein the Cas9 protein and the effector domain are fused via a linker.
350 The fusion protein of any one of claims 346-349, wherein the effector dimain is a nucleic acid editing-domain.
351. The fusion protein of claim 349 or 350, wherein the linker comprises a (GGGGS)n (SEQ ID NO: 5), a (G)„, an (EAAAK)n (SEQ ID NO: 6), a (GGS)„, an
SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP)n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30.
352. The fusion protein of any one of claims 349-351, wherein the linker comprises a (GGS)3 motif.
353. The fusion protein of any one of claims 346-352, wherein the effector domain comprises an enzyme domain.
354. The fusion protein of any one of claims 346-353, wherein the effector domain comprises a nuclease domain, a nickase domain, a recombinase domain, a deaminase domain, a methyltransferase domain, a methylase domain, an acetylase domain, an acetyltransferase domain, a transcriptional activator domain, or a transcriptional repressor domain.
355. The fusion protein of claim 354, wherein the effector domain is a domain that comprises nuclease activity, nickase activity, recombinase activity, deaminase activity, methyltransferase activity, methylase activity, acetylase activity, acetyltransferase activity, transcriptional activation activity, or transcriptional repression activity.
356. The fusion protein of claim 350, wherein the effector domain is a deaminase domain.
357. The fusion protein of claim 356, wherein the deaminase is a cytosine deaminase or a cytidine deaminase.
358. The fusion protein of claim 357, wherein the deaminase is an apolipoprotein B mRNA- editing complex (APOBEC) family deaminase.
359. The fusion protein of claim 357, wherein the deaminase is an APOBEC 1 deaminase.
360. The fusion protein of claim 357, wherein the deaminase is an APOBEC2 deaminase.
361. The fusion protein of claim 357, wherein the deaminase is an APOBEC3 deaminase.
362. The fusion protein of claim 357, wherein the deaminase is an APOBEC3A deaminase.
363. The fusion protein of claim 357, wherein the deaminase is an APOBEC3D deaminase.
364. The fusion protein of claim 357, wherein the deaminase is an APOBEC3E deaminase.
365. The fusion protein of claim 357, wherein the deaminase is an APOBEC3F deaminase.
366. The fusion protein of claim 357, wherein the deaminase is an APOBEC3G deaminase.
367. The fusion protein of claim 357, wherein the deaminase is an APOBEC3H deaminase.
368. The fusion protein of claim 357, wherein the deaminase is an APOBEC4 deaminase.
369. The fusion protein of claim 357, wherein the deaminase is an activation-induced deaminase (AID).
370. The fusion protein of any one of claims 350-369, wherein the effector domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%), at least 99%, or at least 99.5% identical to the deaminase domain of any one of SEQ ID NOs: 263-281.
371. The fusion protein of claim 353, wherein the enzyme domain is a nuclease domain.
372. The fusion protein of claim 371, wherein the nuclease domain is a Fokl DNA cleavage domain.
373. A dimer of the fusion protein of claim 371 or 372.
374. The fusion protein of any one of claims 346-373, wherein the fusion protein is fused to a second Cas9 protein.
375. The fusion protein of claim 374, wherein the second Cas9 protein is Cas9.
376. The fusion protein of claim 374 or 375, wherein the second Cas9 protein is the Cas9 protein of any one of claims 1-345.
377. The fusion protein of claim 374 or 376, wherein the second Cas9 protein is fused to the N-terminus of the fusion protein.
378. The fusion protein of claim 374 or 376, wherein the second Cas9 protein is fused to the C-terminus of the fusion protein.
379. The fusion protein of any one of claims 375-378, wherein the Cas9 protein and the second Cas9 protein are fused via a second linker.
380. The fusion protein of claim 379, wherein the second linker comprises a (GGGGS)n (SEQ ID NO: 5), a (G)„, an (EAAAK)n (SEQ ID NO: 6), a (GGS)„, an
SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP)n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30.
381. The fusion protein of claim 379, wherein the second linker comprises a (GGS)3 motif.
382. A fusion protein comprising the Cas9 protein of any one of claims 22-345 fused to a second Cas9 protein.
383. The fusion protein of claim 382, wherein the second Cas9 protein is the Cas9 protein of any one of claims 22-345.
384. The fusion protein of claim 382, wherein the second Cas9 protein is the fusion protein of any one of claims 346-373.
385. The fusion protein of claim 383 or 384, wherein the second Cas9 protein is fused to the N-terminus of the the Cas9 protein.
386. The fusion protein of claim 383 or 384, wherein the second Cas9 protein is fused to the C-terminus of the Cas9 protein.
387. The fusion protein of any one of claims 382-386, wherein the second Cas9 protein and the Cas9 protein are fused via a linker.
388. The fusion protein of claim 387, wherein the linker comprises a (GGGGS)n(SEQ ID NO: 5), a (G)n, an (EAAAK)n (SEQ ID NO: 6), a (GGS)n, an SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP)n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30.
389. The fusion protein of claim 387, wherein the linker comprises a (GGS)3 motif.
390. The fusion protein of claim 387, wherein the linker is an SGSETPGTSESATPES (SEQ ID NO: 7) sequence.
391. A complex comprising the Cas9 protein of any one of claims 22-345 or the fusion protein of any one of claims 346-390, and a guide RNA bound to the Cas9 protein or the Cas9 fusion protein.
392. The complex of claim 391, wherein the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence.
393. The complex of claim 392, wherein the guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long.
394. The complex of any one of claims 391-393, wherein the guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a target sequence.
395. The complex of any one of claims 391-394, wherein the target sequence is a DNA sequence.
396. The complex of claim 395, wherein the target sequence is a sequence in the genome of a mammal.
397. The complex of claim 396, wherein the target sequence is a sequence in the genome of a human.
398. The complex of any one of claims 392-397, wherein the 3' end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3 ').
399. A complex comprising the fusion protein of any one of claims 374-390,
a first guide RNA bound to the Cas9 protein of the fusion protein, and
a second guide RNA bound to the second Cas9 protein of the fusion protein.
400. The complex of claim 399, wherein the first guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a first target sequence and the second guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a second target sequence.
401. The complex of claim 400, wherein the first guide RNA and/or the second guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long.
402. The complex of any one of claims 399-401, wherein the first guide RNA and the second guide RNA are different.
403. The complex of any one of claims 399-402, wherein the first guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a first target sequence and wherein the second guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a second target sequence.
404. The complex of any one of claims 400-403, wherein the first target sequence and the second target sequence are different.
405. The complex of any one of claims 400-404, wherein the first target sequence and the second target sequence are DNA sequences.
406. The complex of claim 405, wherein the first target sequence and the second target sequence are in the genome of a mammal.
407. The complex of claim 406, wherein the first target sequence and the second target sequence are in the genome of a human.
408. The complex of any one of claims 405-407, wherein the first target sequence is within 30 nucleotides of the second target sequence.
409. The complex of any one of claims 405-408, wherein the 3' end of the first target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3 ').
410. The complex of any one of claims 405-409, wherein the 3' end of the second target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3 ').
411. A method comprising contacting a DNA molecule:
(a) with the Cas9 protein of any one of claims 22-123 or the fusion protein of any one of claims 346-373, and with a guide RNA, wherein the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence; or
(b) with the complex of any one of claims 391-410.
412. The method of claim 411, wherein the target sequence is a DNA sequence.
413. The method of claim 411 or 412, wherein the 3' end of the target sequence is not immediately adjacent to the canonical PAM sequence (5'-NGG-3').
414. The method of any one of claims 411, wherein the 3' end of the target sequence is immediately adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
415. The method of any one of claims 411-414, wherein the target sequence comprises a sequence associated with a disease or disorder.
416. The method of claim 415, wherein the target DNA sequence comprises a point mutation associated with a disease or disorder.
417. The method of claim 416, wherein the activity of the Cas9 protein, the Cas9 fusion protein, or the complex results in a correction of the point mutation.
418. The method of any one of claims 411-417, wherein the target DNA sequence comprises a T→C point mutation associated with a disease or disorder, and wherein the deamination of the mutant C base results in a sequence that is not associated with a disease or disorder.
419. The method of claim 418, wherein the target DNA sequence encodes a protein and wherein the point mutation is in a codon and results in a change in the amino acid encoded by the mutant codon as compared to the wild-type codon.
420. The method of claim 419, wherein the deamination of the mutant C results in a change of the amino acid encoded by the mutant codon.
421. The method of claim 420, wherein the deamination of the mutant C results in the codon encoding the wild-type amino acid.
422. The method of any one of claims 411-421, wherein the contacting is in vivo in a subject.
423. The method of claim 422, wherein the subject has or has been diagnosed with a disease or disorder.
424. The method of any one of claims 418-423, wherein the disease or disorder is cystic fibrosis, phenylketonuria, epidermolytic hyperkeratosis (EHK), Charcot-Marie-Toot disease type 4J, neuroblastoma (NB), von Willebrand disease (vWD), myotonia congenital, hereditary renal amyloidosis, dilated cardiomyopathy (DCM), hereditary lymphedema, familial Alzheimer's disease, HIV, Prion disease, chronic infantile neurologic cutaneous articular syndrome (CINCA), desmin-related myopathy (DRM), a neoplastic disease associated with a mutant PI3KCA protein, a mutant CTNNBl protein, a mutant HRAS protein, or a mutant p53 protein.
425. The method of any one of claims 415-423, wherein the disease or disorder is associated with a T>C or A>G mutation in a gene selected from the genes disclosed in Table 6 and 7, respectively.
426. The method of any one of claims 415-423, wherein the disease or disorder is associated with a T>C or A>G mutation in a gene selected from the genes disclosed in Table 6 and 7, respectively.
427. A kit comprising a nucleic acid construct, comprising
(a) a sequence encoding the Cas9 protein of any one of claims 22-123 or the fusion protein of any one of claims 246-373; and
(b) a heterologous promoter that drives expression of the sequence of (a).
428. The kit of claim 427, further comprising an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow the cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.
429. A polynucleotide encoding the Cas9 protein of any one of claims 22-345 or the fusion protein of any one of claims 346-373.
430. A vector comprising a polynucleotide of claim 429.
431. The vector of claim 430, wherein the vector comprises a heterologous promoter driving expression of polynucleotide.
432. A cell comprising the Cas9 protein of any one of claims 22-345 or the fusion protein of any one of claims 346-373, or a nucleic acid molecule encoding the Cas9 protein of any one of claims 22-345 or the fusion protein of any one of claims 346-373.
433. A mutated Cas9 protein that recognizes a non-canonical PAM sequence selected from the group consisting of AAA, AAC, AAG, AAT, CAA, CAC, CAG, CAT, GAA, GAC, GAG, GAT, TAA, TAC, TAG, TAT, ACA, ACC, ACG, ACT, CCA, CCC, CCG, CCT, GCA, GCC, GCG, GCT, TCA, TCC, TCG, TCT, AGA, AGC, AGT, CGA, CGC, CGT, GGA, GGC, GGT, TGA, TGC, TGT, ATA, ATC, ATG, ATT, CTA, CTC, CTG, CTT, GTA, GTC, GTG, GTT, TTA, TTC, TTG, and TTT.
434. The mutated cas9 protein of claim 433, wherein the mutated Cas9 protein comprises any one of the Cas9 proteins of claims 1-345.
PCT/US2016/058345 2015-10-23 2016-10-22 Evolved cas9 proteins for gene editing WO2017070633A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP16794114.5A EP3365357B1 (en) 2015-10-23 2016-10-22 Evolved cas9 proteins for gene editing
CN201680075426.0A CN108699116A (en) 2015-10-23 2016-10-22 The CAS9 albumen of evolution for gene editing
US15/770,076 US20190225955A1 (en) 2015-10-23 2016-10-22 Evolved cas9 proteins for gene editing
JP2018521045A JP7109784B2 (en) 2015-10-23 2016-10-22 Evolved Cas9 protein for gene editing
JP2022058736A JP2022124487A (en) 2015-10-23 2022-03-31 Evolved Cas9 protein for gene editing

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201562245828P 2015-10-23 2015-10-23
US62/245,828 2015-10-23
US201662279346P 2016-01-15 2016-01-15
US62/279,346 2016-01-15
US201662311763P 2016-03-22 2016-03-22
US62/311,763 2016-03-22
US201662322178P 2016-04-13 2016-04-13
US62/322,178 2016-04-13
US201662357332P 2016-06-30 2016-06-30
US201662357352P 2016-06-30 2016-06-30
US62/357,332 2016-06-30
US62/357,352 2016-06-30
US201662370700P 2016-08-03 2016-08-03
US62/370,700 2016-08-03
US201662398490P 2016-09-22 2016-09-22
US62/398,490 2016-09-22
US201662408686P 2016-10-14 2016-10-14
US62/408,686 2016-10-14

Publications (2)

Publication Number Publication Date
WO2017070633A2 true WO2017070633A2 (en) 2017-04-27
WO2017070633A3 WO2017070633A3 (en) 2017-07-13

Family

ID=57249890

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2016/058345 WO2017070633A2 (en) 2015-10-23 2016-10-22 Evolved cas9 proteins for gene editing
PCT/US2016/058344 WO2017070632A2 (en) 2015-10-23 2016-10-22 Nucleobase editors and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2016/058344 WO2017070632A2 (en) 2015-10-23 2016-10-22 Nucleobase editors and uses thereof

Country Status (10)

Country Link
US (4) US20190225955A1 (en)
EP (3) EP3365356B1 (en)
JP (4) JP7067793B2 (en)
KR (1) KR20180069898A (en)
CN (2) CN108699116A (en)
AU (2) AU2016342380B2 (en)
CA (1) CA3002827A1 (en)
IL (3) IL258821B (en)
SG (2) SG11201803173VA (en)
WO (2) WO2017070633A2 (en)

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
WO2018119359A1 (en) * 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
WO2018226855A1 (en) * 2017-06-06 2018-12-13 The General Hospital Corporation Engineered crispr-cas9 nucleases
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019040650A1 (en) * 2017-08-23 2019-02-28 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
WO2019049913A1 (en) * 2017-09-05 2019-03-14 国立大学法人 東京大学 Modified cas9 protein, and use thereof
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2019123429A1 (en) * 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019161251A1 (en) 2018-02-15 2019-08-22 The Broad Institute, Inc. Cell data recorders and uses thereof
CN110184339A (en) * 2019-06-13 2019-08-30 复旦大学附属眼耳鼻喉科医院 The new mutation site of Wolfram syndrome i type and its application
WO2019168953A1 (en) 2018-02-27 2019-09-06 President And Fellows Of Harvard College Evolved cas9 variants and uses thereof
US10428319B2 (en) 2017-06-09 2019-10-01 Editas Medicine, Inc. Engineered Cas9 nucleases
WO2019194320A1 (en) * 2018-04-06 2019-10-10 国立大学法人東京大学 Engineered b1cas9 nuclease
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2019234132A1 (en) 2018-06-05 2019-12-12 KWS SAAT SE & Co. KGaA Base editing in polymerase theta deficient plants
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2020007325A1 (en) * 2018-07-05 2020-01-09 Tsinghua University Cas9 variants and application thereof
WO2020051360A1 (en) 2018-09-05 2020-03-12 The Broad Institute, Inc. Base editing for treating hutchinson-gilford progeria syndrome
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
WO2020081568A1 (en) * 2018-10-15 2020-04-23 University Of Massachusetts Programmable dna base editing by nme2cas9-deaminase fusion proteins
CN111065647A (en) * 2017-09-01 2020-04-24 上海科技大学 Fusion protein for improving base editing precision
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020089489A1 (en) 2018-11-01 2020-05-07 KWS SAAT SE & Co. KGaA Targeted mutagenesis using base editors
WO2020102659A1 (en) 2018-11-15 2020-05-22 The Broad Institute, Inc. G-to-t base editors and uses thereof
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020206461A1 (en) * 2019-04-05 2020-10-08 Children's Hospital Of Philadelphia Compositions and methods for in utero gene editing for monogenic lung disease
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020214619A1 (en) * 2019-04-15 2020-10-22 Emendobio Inc. Crispr compositions and methods for promoting gene editing of gata2
WO2020229241A1 (en) 2019-05-10 2020-11-19 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2020236982A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Aav delivery of nucleobase editors
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
WO2021025750A1 (en) 2019-08-08 2021-02-11 The Broad Institute, Inc. Base editors with diversified targeting scope
WO2021030666A1 (en) 2019-08-15 2021-02-18 The Broad Institute, Inc. Base editing by transglycosylation
EP3783104A1 (en) * 2019-08-20 2021-02-24 Kemijski Institut Coiled-coil mediated tethering of crispr-cas and exonucleases for enhanced genome editing
WO2021046442A1 (en) * 2019-09-05 2021-03-11 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
WO2021050512A1 (en) * 2019-09-09 2021-03-18 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
WO2021048316A1 (en) 2019-09-12 2021-03-18 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2021069387A1 (en) 2019-10-07 2021-04-15 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2021108717A2 (en) 2019-11-26 2021-06-03 The Broad Institute, Inc Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
WO2021110582A1 (en) 2019-12-03 2021-06-10 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
WO2021158995A1 (en) 2020-02-05 2021-08-12 The Broad Institute, Inc. Base editor predictive algorithm and method of use
WO2021158921A2 (en) 2020-02-05 2021-08-12 The Broad Institute, Inc. Adenine base editors and uses thereof
WO2021158999A1 (en) 2020-02-05 2021-08-12 The Broad Institute, Inc. Gene editing methods for treating spinal muscular atrophy
US20210261932A1 (en) * 2020-01-24 2021-08-26 The General Hospital Corporation Crispr-cas enzymes with enhanced on-target activity
US11118177B2 (en) 2017-12-21 2021-09-14 Crispr Therapeutics Ag Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
US20210284978A1 (en) * 2020-01-24 2021-09-16 The General Hospital Corporation Unconstrained Genome Targeting with near-PAMless Engineered CRISPR-Cas9 Variants
WO2021183693A1 (en) 2020-03-11 2021-09-16 The Broad Institute, Inc. Stat3-targeted based editor therapeutics for the treatment of melanoma and other cancers
WO2021216622A1 (en) * 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
WO2021222318A1 (en) 2020-04-28 2021-11-04 The Broad Institute, Inc. Targeted base editing of the ush2a gene
JP2021536229A (en) * 2018-08-23 2021-12-27 サンガモ セラピューティクス, インコーポレイテッド Manipulated target-specific base editor
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
CN114350671A (en) * 2021-12-22 2022-04-15 湖北省妇幼保健院 KIF11 gene mutant and application thereof
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2022129905A1 (en) 2020-12-16 2022-06-23 Oxford Genetics Limited Crispr polypeptides
US11390884B2 (en) 2015-05-11 2022-07-19 Editas Medicine, Inc. Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
WO2022162200A1 (en) 2021-01-29 2022-08-04 Nuntius Therapeutics Ltd. Nucleic Acid Delivery
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
WO2022248651A2 (en) 2021-05-27 2022-12-01 Complement Therapeutics Limited Inhibitory nucleic acids for factor h family proteins
WO2022261509A1 (en) 2021-06-11 2022-12-15 The Broad Institute, Inc. Improved cytosine to guanine base editors
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11591589B2 (en) 2017-04-21 2023-02-28 The General Hospital Corporation Variants of Cpf1 (Cas12a) with altered PAM specificity
WO2023278886A3 (en) * 2021-07-02 2023-03-02 Integrated Dna Technologies, Inc. Novel mutations in streptococcus pyogenes cas9 discovered by broad scanning mutagenesis demonstrate enhancement of dna cleavage activity
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11667911B2 (en) 2015-09-24 2023-06-06 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/CAS-mediated genome editing
WO2023102537A2 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023155901A1 (en) * 2022-02-17 2023-08-24 Correctsequence Therapeutics Mutant cytidine deaminases with improved editing precision
WO2023196802A1 (en) 2022-04-04 2023-10-12 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
US11789027B2 (en) 2020-10-29 2023-10-17 Ambergen, Inc. Photocleavable mass-tags for multiplexed mass spectrometric imaging of tissues using biomolecular probes
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2023212715A1 (en) 2022-04-28 2023-11-02 The Broad Institute, Inc. Aav vectors encoding base editors and uses thereof
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
US11845987B2 (en) 2018-04-17 2023-12-19 The General Hospital Corporation Highly sensitive in vitro assays to define substrate preferences and sites of nucleic acid cleaving agents
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024028465A1 (en) 2022-08-03 2024-02-08 Nuntius Therapeutics Limited Hybrid peptide dendrimer systems and extrahepatic delivery
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2024040083A1 (en) 2022-08-16 2024-02-22 The Broad Institute, Inc. Evolved cytosine deaminases and methods of editing dna using same
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024047246A1 (en) 2022-09-02 2024-03-07 Nuntius Therapeutics Limited Methods for characterisation of nanocarriers
WO2024052681A1 (en) 2022-09-08 2024-03-14 The University Court Of The University Of Edinburgh Rett syndrome therapy
WO2024077247A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Base editing methods and compositions for treating triplet repeat disorders

Families Citing this family (271)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6088438B2 (en) 2010-12-22 2017-03-01 プレジデント アンド フェローズ オブ ハーバード カレッジ Continuous directed evolution
CN111471674A (en) 2014-03-05 2020-07-31 国立大学法人神户大学 Method for modifying genome sequence of nucleic acid base for specifically converting target DNA sequence, and molecular complex used therefor
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2017011721A1 (en) 2015-07-15 2017-01-19 Rutgers, The State University Of New Jersey Nuclease-independent targeted gene editing platform and uses thereof
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
JP6664693B2 (en) 2015-09-09 2020-03-13 国立大学法人神戸大学 Method for converting genomic sequence of gram-positive bacteria, specifically converting nucleobase of targeted DNA sequence, and molecular complex used therein
DK3382019T3 (en) * 2015-11-27 2022-05-30 Univ Kobe Nat Univ Corp A method of converting a single-seeded plant genome sequence in which nucleic acid base in specific DNA sequence is specifically converted and molecular complex used therein
WO2017183724A1 (en) * 2016-04-21 2017-10-26 国立大学法人神戸大学 Method for increasing mutation introduction efficiency in genome sequence modification technique, and molecular complex to be used therefor
CN109843914B (en) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 Materials and methods for treating pain-related disorders
US11801313B2 (en) 2016-07-06 2023-10-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
KR102026421B1 (en) * 2016-09-13 2019-09-27 주식회사 툴젠 Method of identifying base editing by cytosine deaminase in DNA
KR20190039430A (en) 2016-11-14 2019-04-11 인스티튜트 오브 제네틱스 앤드 디벨롭멘털 바이오롤지, 차이니즈 아카데미 오브 사이언시스 How to edit bases in plants
CN107043779B (en) * 2016-12-01 2020-05-12 中国农业科学院作物科学研究所 Application of CRISPR/nCas 9-mediated site-specific base substitution in plants
US11192929B2 (en) * 2016-12-08 2021-12-07 Regents Of The University Of Minnesota Site-specific DNA base editing using modified APOBEC enzymes
KR20230125856A (en) 2016-12-23 2023-08-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Gene editing of pcsk9
CN110300802A (en) * 2016-12-23 2019-10-01 基础科学研究院 Composition and base edit methods for animal embryo base editor
WO2018165631A1 (en) * 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
EP3622061A4 (en) 2017-05-11 2021-01-27 Institute Of Genetics And Developmental Biology Chinese Academy of Sciences Creation of herbicide resistant gene and use thereof
AU2018272067A1 (en) * 2017-05-25 2019-11-28 The General Hospital Corporation Base editors with improved precision and specificity
CN109136272A (en) * 2017-06-15 2019-01-04 中山大学 Base editing system, method, kit and its application in people's system genitale of the mutation of people's HBB gene are repaired for specificity
CN108823202A (en) * 2017-06-15 2018-11-16 中山大学 Base editing system, method, kit and its application of the mutation of people's HBB gene are repaired for specificity
WO2019005886A1 (en) * 2017-06-26 2019-01-03 The Broad Institute, Inc. Crispr/cas-cytidine deaminase based compositions, systems, and methods for targeted nucleic acid editing
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College Evolution of trna synthetases
US20210355508A1 (en) * 2017-07-25 2021-11-18 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences Method for Modulating RNA Splicing by Inducing Base Mutation at Splice Site or Base Substitution in Polypyrimidine Region
CN107619833B (en) * 2017-08-14 2021-03-02 华中农业大学 Plasmid pZF17-30 for constructing Brucella mutant strain and construction method and application thereof
AU2018320864B2 (en) 2017-08-22 2024-02-22 Napigen, Inc. Organelle genome modification using polynucleotide guided endonuclease
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California Rna-guided endonuclease fusion polypeptides and methods of use thereof
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
EP3684397A4 (en) 2017-09-21 2021-08-18 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US20210130800A1 (en) * 2017-10-23 2021-05-06 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US20210214724A1 (en) * 2017-10-23 2021-07-15 The Broad Institute, Inc. Novel nucleic acid modifiers
CN107841509B (en) * 2017-12-06 2021-03-23 南方医科大学南方医院 Kit for knocking out glioblastoma DHC2 gene
AU2018386301A1 (en) 2017-12-14 2020-06-18 Bayer Healthcare Llc Novel RNA-programmable endonuclease systems and their use in genome editing and other applications
WO2019126762A2 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
JP7075170B2 (en) * 2018-01-23 2022-05-25 インスティチュート フォー ベーシック サイエンス Extended single guide RNA and its uses
BR112020014989A2 (en) * 2018-02-01 2020-12-29 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences IMPROVED METHOD FOR GENOME EDITING
CN108504676B (en) * 2018-02-05 2021-12-10 上海科技大学 pnCasSA-BEC plasmid and application thereof
CN111788232A (en) * 2018-02-23 2020-10-16 上海科技大学 Fusion proteins for base editing
CN109021111B (en) * 2018-02-23 2021-12-07 上海科技大学 Gene base editor
US20190264232A1 (en) * 2018-02-23 2019-08-29 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
JP2021517815A (en) * 2018-03-13 2021-07-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Lymphopoiesis manipulation using the CAS9 base editor
US20210054353A1 (en) 2018-03-19 2021-02-25 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and uses thereof
CN112153990A (en) 2018-03-23 2020-12-29 纽约市哥伦比亚大学理事会 Gene editing for autosomal dominant diseases
BR112020019301A2 (en) * 2018-03-26 2021-01-05 National University Corporation Kobe University METHOD FOR MODIFYING A TARGET SITE OF A CELL DOUBLE TAPE DNA.
CN108753775B (en) * 2018-05-04 2021-08-24 华南农业大学 sgRNA of targeting APOBEC3G gene and method for knocking out APOBEC3G gene of cynomolgus monkey
KR20210023830A (en) * 2018-05-11 2021-03-04 빔 테라퓨틱스, 인크. How to Inhibit Pathogenic Mutations Using a Programmable Base Editor System
SG11202011146TA (en) * 2018-05-17 2020-12-30 Univ Minnesota Drug-resistant immune cells and methods of use thereof
WO2019222537A1 (en) 2018-05-18 2019-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Catalytically hyperactive variants of human apobec3g protein
CA3101477A1 (en) * 2018-05-30 2019-12-05 M2X2 Therapeutics, Inc. Cell therapy
US20230158110A1 (en) * 2018-05-30 2023-05-25 The Regents Of The University Of California Gene editing of monogenic disorders in human hematopoietic stem cells -- correction of x-linked hyper-igm syndrome (xhim)
KR20210089629A (en) 2018-06-05 2021-07-16 라이프에디트 테라퓨틱스, 인크. RNA-guided nucleases and active fragments and variants thereof and methods of use
CN109022477A (en) * 2018-07-12 2018-12-18 上海科技大学 A kind of pnCasPA-BEC plasmid and its application
CN112805385B (en) * 2018-07-24 2023-05-30 苏州齐禾生科生物科技有限公司 Base editor based on human APOBEC3A deaminase and application thereof
AU2019314433A1 (en) 2018-07-31 2021-03-25 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
BR112021001904A2 (en) * 2018-08-03 2021-05-04 Beam Therapeutics Inc. multi-effect nucleobase editors and methods of using them to modify a target nucleic acid sequence
AU2019318079A1 (en) 2018-08-07 2021-01-28 Massachusetts Institute Of Technology Novel Cas12b enzymes and systems
CN110819620B (en) * 2018-08-09 2022-11-01 北京大学 Method for carrying out gene mutation on rhodobacter sphaeroides
WO2020033083A1 (en) * 2018-08-10 2020-02-13 Cornell University Optimized base editors enable efficient editing in cells, organoids and mice
WO2020041751A1 (en) * 2018-08-23 2020-02-27 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
SG11202101994XA (en) 2018-08-28 2021-03-30 Vor Biopharma Inc Genetically engineered hematopoietic stem cells and uses thereof
US20210310002A1 (en) * 2018-08-31 2021-10-07 City Of Hope Cationic compounds for delivery of nucleic acids
US20220127622A1 (en) * 2018-09-07 2022-04-28 Beam Therapeutics Inc. Compositions and Methods for Improving Base Editing
CN109265562B (en) * 2018-09-26 2021-03-30 北京市农林科学院 Nicking enzyme and application thereof in genome base replacement
US20220010305A1 (en) * 2018-10-31 2022-01-13 Novozymes A/S Genome Editing by Guided Endonuclease and Single-stranded Oligonucleotide
WO2020092725A1 (en) * 2018-11-01 2020-05-07 Montana State University Gene modulation with crispr system type i
MX2021007835A (en) 2018-12-27 2021-08-11 Lifeedit Therapeutics Inc Polypeptides useful for gene editing and methods of use.
CN109652440A (en) * 2018-12-28 2019-04-19 北京市农林科学院 Application of the VQRn-Cas9&PmCDA1&UGI base editing system in plant gene editor
CN109456973A (en) * 2018-12-28 2019-03-12 北京市农林科学院 Application of the SpCas9n&PmCDA1&UGI base editing system in plant gene editor
CN109679989A (en) * 2018-12-29 2019-04-26 北京市农林科学院 A method of improving base editing system editorial efficiency
CN114072509A (en) * 2019-01-31 2022-02-18 比姆医疗股份有限公司 Nucleobase editor with reduced off-target of deamination and method of modifying nucleobase target sequence using same
CA3127493A1 (en) * 2019-01-31 2020-08-06 Beam Therapeutics Inc. Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors
CN109706185B (en) * 2019-02-01 2021-07-27 国家卫生健康委科学技术研究所 Method for realizing gene knockout based on base editing system mutation initiation codon and application
BR112021015092A2 (en) * 2019-02-02 2022-10-11 Univ Shanghai Tech FUSION PROTEIN, DUAL GUIDE RNA SYSTEM, E, GUIDE RNA
US11946040B2 (en) 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing
CN114026237A (en) * 2019-02-13 2022-02-08 比姆医疗股份有限公司 Compositions and methods for treating glycogen storage disease type 1a
US20220098593A1 (en) * 2019-02-13 2022-03-31 Beam Therapeutics Inc. Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
US20230101597A1 (en) * 2019-02-13 2023-03-30 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
KR20210138603A (en) * 2019-02-13 2021-11-19 빔 테라퓨틱스, 인크. Modified immune cells with an adenosine deaminase base editor for modifying nucleobases in a target sequence
WO2020168133A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
CN110804628B (en) * 2019-02-28 2023-05-12 中国科学院脑科学与智能技术卓越创新中心 High-specificity off-target-free single-base gene editing tool
WO2020209959A1 (en) 2019-03-08 2020-10-15 Crispr Therapeutics Ag Nucleobase-editing fusion protein systems, compositions, and uses thereof
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
CN109929878A (en) * 2019-03-26 2019-06-25 西北农林科技大学 A method of FGF5 gene editing goat is produced using genome base editor system
CN111748546B (en) * 2019-03-26 2023-05-09 复旦大学附属中山医院 Fusion protein for generating gene point mutation and induction method of gene point mutation
MA55598A (en) 2019-04-12 2022-02-16 Astrazeneca Ab COMPOSITIONS AND METHODS FOR ENHANCED GENE EDITING
CN110272900B (en) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 sgRNA for preparing skeletal dysplasia pig model and application thereof
SG11202112161TA (en) * 2019-05-03 2021-12-30 Specific Biologics Inc Lipid-encapsulated dual-cleaving endonuclease for dna and gene editing
US20220220469A1 (en) 2019-05-20 2022-07-14 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
EP3973057A1 (en) 2019-05-23 2022-03-30 Vor Biopharma, Inc. Compositions and methods for cd33 modification
WO2020241869A1 (en) * 2019-05-30 2020-12-03 国立大学法人東京大学 GENOME EDITING SYSTEM USING Cas PROTEIN HAVING TWO TYPES OF NUCLEIC ACID BASE-CONVERTING ENZYMES FUSED THERETO
CN111304180B (en) * 2019-06-04 2023-05-26 山东舜丰生物科技有限公司 Novel DNA nucleic acid cutting enzyme and application thereof
CN112048497B (en) * 2019-06-06 2023-11-03 辉大(上海)生物科技有限公司 Novel single-base editing technology and application thereof
CN110172507A (en) * 2019-06-11 2019-08-27 中国人民解放军第四军医大学 A kind of Large Vestibular Aqueduct/Pendred syndrome Disease-causing gene SLC26A4 abrupt climatic change kit
CN114729383A (en) 2019-07-02 2022-07-08 弗莱德哈钦森癌症研究中心 Recombinant AD35 vectors and related gene therapy improvements
CN110467679B (en) * 2019-08-06 2021-04-23 广州大学 Fusion protein, base editing tool and method and application thereof
US20220315938A1 (en) * 2019-08-09 2022-10-06 Regents Of The University Of Minnesota AUGMENTED sgRNAS AND METHODS FOR THEIR USE TO ENHANCE SOMATIC AND GERMLINE PLANT GENOME ENGINEERING
CN114641568A (en) 2019-08-12 2022-06-17 生命编辑制药股份有限公司 RNA-guided nucleases and active fragments and variants thereof and methods of use
WO2021030738A1 (en) * 2019-08-14 2021-02-18 Pairwise Plants Services, Inc. Alteration of flavor traits in consumer crops via disablement of the myrosinase/glucosinolate system
CN111763686B (en) * 2019-08-20 2023-03-28 中国科学院天津工业生物技术研究所 Base editing system for realizing C-to-A and C-to-G base mutation and application thereof
MX2022002461A (en) 2019-08-28 2022-06-02 Vor Biopharma Inc Compositions and methods for cd123 modification.
KR20220047380A (en) 2019-08-28 2022-04-15 보르 바이오파마 인크. Compositions and methods for CLL1 modification
WO2021041885A2 (en) * 2019-08-29 2021-03-04 Beam Therapeutics Inc. Compositions and methods for editing a mutation to permit transcription or expression
CN110551752B (en) * 2019-08-30 2023-03-14 北京市农林科学院 xCas9n-epBE base editing system and application thereof in genome base replacement
CN110577965B (en) * 2019-08-30 2022-12-20 北京市农林科学院 Application of xCas9n-epBE base editing system in gene editing
US20220333133A1 (en) 2019-09-03 2022-10-20 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
JP2022549120A (en) * 2019-09-17 2022-11-24 ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー Highly Efficient RNA-Aptamer Recruitment-Mediated DNA Base Editors and Their Use for Targeted Genome Modification
WO2021056302A1 (en) * 2019-09-26 2021-04-01 Syngenta Crop Protection Ag Methods and compositions for dna base editing
CN110564752B (en) * 2019-09-30 2021-07-16 北京市农林科学院 Application of differential agent technology in enrichment of C.T base substitution cells
CN110734900B (en) * 2019-11-06 2022-09-30 上海科技大学 Cytosine base editing tool and application thereof
WO2021097118A1 (en) * 2019-11-12 2021-05-20 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
CN114981426A (en) 2019-12-03 2022-08-30 比姆医疗股份有限公司 Synthetic guide RNA, compositions, methods and uses thereof
CN114829612A (en) 2019-12-16 2022-07-29 巴斯夫农业种子解决方案美国有限责任公司 Improved genome editing using paired nickases
KR20220116173A (en) 2019-12-16 2022-08-22 바스프 아그리컬쳐럴 솔루션즈 시드 유에스 엘엘씨 Precise introduction of DNA or mutations into the genome of wheat
JP2023507163A (en) * 2019-12-17 2023-02-21 シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー Genome editing in Bacteroidetes
CN114829607A (en) * 2019-12-18 2022-07-29 因思科瑞普特公司 Cascade/dCas3 complementation assay for in vivo detection of nucleic acid guided nuclease edited cells
CN112979821B (en) * 2019-12-18 2022-02-08 华东师范大学 Fusion protein for improving gene editing efficiency and application thereof
CN110951736B (en) * 2019-12-20 2023-03-14 北京市农林科学院 Nuclear localization signal F4NLS and application thereof in improving base editing efficiency and expanding editable base range
CN115190912A (en) 2019-12-30 2022-10-14 生命编辑制药股份有限公司 RNA-guided nucleases, active fragments and variants thereof, and methods of use
US20230070731A1 (en) * 2020-01-25 2023-03-09 The Trustees Of The University Of Pennsylvania Compositions for small molecule control of precise base editing of target nucleic acids and methods of use thereof
WO2021151756A1 (en) 2020-01-27 2021-08-05 Eth Zurich Base editor lacking hnh and use thereof
CN115380111A (en) 2020-01-30 2022-11-22 成对植物服务股份有限公司 Compositions, systems, and methods for base diversification
AR121242A1 (en) 2020-01-31 2022-05-04 Pairwise Plants Services Inc SUPPRESSION OF THE ESCAPE RESPONSE TO SHADE IN PLANTS
US20230063560A1 (en) 2020-02-04 2023-03-02 Pairwise Plans Services, Inc. Thornless and/or prickleless rubus plants
WO2021155607A1 (en) * 2020-02-07 2021-08-12 辉大(上海)生物科技有限公司 Modified cytosine base editor and application thereof
MX2022010215A (en) 2020-02-21 2022-10-07 Pairwise Plants Services Inc Improved resistance to soybean cyst nematode through gene editing.
CN115176018A (en) 2020-03-04 2022-10-11 巴斯夫欧洲公司 Shuttle vectors for expression in E.coli and Bacillus
WO2021175288A1 (en) * 2020-03-04 2021-09-10 中国科学院遗传与发育生物学研究所 Improved cytosine base editing system
EP4114954A1 (en) 2020-03-04 2023-01-11 Basf Se Method for the production of constitutive bacterial promoters conferring low to medium expression
CN111172133B (en) * 2020-03-10 2021-12-31 上海科技大学 Base editing tool and application thereof
WO2021188840A1 (en) 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
CN111508558B (en) * 2020-03-23 2021-12-14 广州赛业百沐生物科技有限公司 Method and system for designing point mutation model based on CRISPR-Cas9 technology
US20210301282A1 (en) 2020-03-26 2021-09-30 Pairwise Plants Services, Inc. Methods for controlling meristem size for crop improvement
US11882808B2 (en) 2020-03-27 2024-01-30 Pairwise Plants Services, Inc. Methods for improving resistance to soybean rust
US20230175006A1 (en) 2020-04-06 2023-06-08 Pairwise Plants Services, Inc. Methods and compositions for increasing resistance to ear rot and stem rot disease in maize
US20230212600A1 (en) 2020-04-16 2023-07-06 Pairwise Plants Services, Inc. Methods for controlling meristem size for crop improvement
TW202208626A (en) 2020-04-24 2022-03-01 美商生命編輯公司 Rna-guided nucleases and active fragments and variants thereof and methods of use
CA3173882A1 (en) 2020-05-11 2021-11-18 Alexandra Briner CRAWLEY Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
WO2021231675A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231698A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231685A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
EP4150076A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231692A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150064A1 (en) 2020-05-15 2023-03-22 Basf Se Improved method for the production of isoprenoids
EP4150089A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
WO2021231679A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231673A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
MX2022015107A (en) 2020-06-02 2023-03-01 Pairwise Plants Services Inc Methods for controlling meristem size for crop improvement.
WO2021250058A2 (en) 2020-06-12 2021-12-16 Bayer Aktiengesellschaft CRISPR-Cas12a DIRECTED RANDOM MUTAGENESIS AGENTS AND METHODS
WO2021257775A1 (en) 2020-06-17 2021-12-23 Pairwise Plants Services, Inc. Methods for controlling meristem size for crop improvement
AU2021300169A1 (en) 2020-06-30 2023-02-02 Pairwise Plants Services, Inc. Compositions, systems, and methods for base diversification
GB202010348D0 (en) 2020-07-06 2020-08-19 Univ Wageningen Base editing tools
JP2022037603A (en) * 2020-08-25 2022-03-09 国立大学法人 東京大学 Engineered cjcas9 proteins
CN112442532B (en) * 2020-08-27 2023-09-26 深圳市卫生健康发展研究中心 Primer group and kit for simultaneously detecting 20 glucose-6-phosphate dehydrogenase deficiency diseases
JP2023540277A (en) 2020-08-28 2023-09-22 ブイオーアール バイオファーマ インコーポレーテッド Compositions and methods for CD123 modification
JP2023540276A (en) 2020-08-28 2023-09-22 ブイオーアール バイオファーマ インコーポレーテッド Compositions and methods for CLL1 modification
JP2023539668A (en) 2020-08-28 2023-09-15 ペアワイズ・プランツ・サーヴィシズ,インコーポレイテッド Engineered CRISPR-Cas proteins and methods for their use
JPWO2022050377A1 (en) * 2020-09-04 2022-03-10
WO2022056489A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
EP4211245A1 (en) 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
EP4214318A1 (en) 2020-09-18 2023-07-26 Vor Biopharma Inc. Compositions and methods for cd7 modification
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
WO2022072643A1 (en) 2020-09-30 2022-04-07 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
WO2022093983A1 (en) 2020-10-27 2022-05-05 Vor Biopharma, Inc. Compositions and methods for treating hematopoietic malignancy
WO2022092317A1 (en) * 2020-10-30 2022-05-05 国立大学法人東京大学 ENGINEERED Cas12f PROTEIN
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
KR20230107610A (en) 2020-11-13 2023-07-17 보르 바이오파마 인크. Methods and compositions involving genetically engineered cells expressing chimeric antigen receptors
JP2024502820A (en) 2020-12-31 2024-01-23 ブイオーアール バイオファーマ インコーポレーテッド Compositions and methods for CD34 gene modification
JP2024502630A (en) * 2021-01-12 2024-01-22 マーチ セラピューティクス, インコーポレイテッド Context-dependent double-stranded DNA-specific deaminases and their uses
CN112626070A (en) * 2021-01-13 2021-04-09 海南微氪生物科技股份有限公司 Directional repair system based on excision enzyme gene editing technology
CA3210785A1 (en) 2021-02-11 2022-08-18 Pairwise Plants Services, Inc. Methods and compositions for modifying cytokinin oxidase levels in plants
WO2022178307A1 (en) 2021-02-19 2022-08-25 Beam Therapeutics Inc. Recombinant rabies viruses for gene therapy
CN117203227A (en) 2021-02-25 2023-12-08 成对植物服务股份有限公司 Methods and compositions for modifying root architecture in plants
WO2022204268A2 (en) 2021-03-23 2022-09-29 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
WO2022204476A1 (en) 2021-03-26 2022-09-29 The Board Of Regents Of The University Of Texas System Nucleotide editing to reframe dmd transcripts by base editing and prime editing
WO2022217086A1 (en) 2021-04-09 2022-10-13 Vor Biopharma Inc. Photocleavable guide rnas and methods of use thereof
WO2022221337A2 (en) * 2021-04-12 2022-10-20 The Broad Institute, Inc. Evolved double-stranded dna deaminase base editors and methods of use
AU2022256513A1 (en) 2021-04-16 2023-11-02 Beam Therapeutics Inc. Genetic modification of hepatocytes
EP4337701A1 (en) 2021-05-10 2024-03-20 Mammoth Biosciences, Inc. Effector proteins and methods of use
US20220372497A1 (en) * 2021-05-18 2022-11-24 Shanghaitech University Base Editing Tool And Use Thereof
EP4341405A1 (en) 2021-05-20 2024-03-27 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
CA3177712A1 (en) 2021-06-02 2022-12-02 Lyell Immunopharma, Inc. Nr4a-deficient cells expressing c-jun and uses thereof
EP4347830A2 (en) 2021-06-02 2024-04-10 Beam Therapeutics Inc. Circular guide rnas for crispr/cas editing systems
WO2022261394A1 (en) 2021-06-11 2022-12-15 LifeEDIT Therapeutics, Inc. Rna polymerase iii promoters and methods of use
CN117897050A (en) 2021-06-17 2024-04-16 成对植物服务股份有限公司 Modification of growth regulator family transcription factors in soybean
UY39827A (en) 2021-06-24 2023-01-31 Pairwise Plants Services Inc MODIFICATION OF UBIQUITIN LIGASE E3 HECT GENES TO IMPROVE PERFORMANCE TRAITS
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
EP4363574A1 (en) 2021-06-29 2024-05-08 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2023279106A1 (en) * 2021-07-01 2023-01-05 The Board Of Regents Of The University Of Texas System Compositions and methods for myosin heavy chain base editing
CA3224982A1 (en) 2021-07-01 2023-01-05 Pairwise Plants Services, Inc. Methods and compositions for enhancing root system development
WO2023279118A2 (en) * 2021-07-02 2023-01-05 University Of Maryland, College Park Cytidine deaminases and methods of genome editing using the same
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
CN113621634B (en) * 2021-07-07 2023-09-15 浙江大学杭州国际科创中心 Base editing system and base editing method for increasing mutation rate of genome
AU2022313315A1 (en) 2021-07-23 2024-02-08 Beam Therapeutics Inc. Guide rnas for crispr/cas editing systems
AU2022324093A1 (en) 2021-08-02 2024-02-08 Vor Biopharma Inc. Compositions and methods for gene modification
US20230193289A1 (en) * 2021-08-06 2023-06-22 Taipei Veterans General Hospital Compositions and methods for treating fabry disease
US20230078990A1 (en) 2021-08-12 2023-03-16 Pairwise Plants Services, Inc. Modification of brassinosteroid receptor genes to improve yield traits
WO2023023496A1 (en) 2021-08-17 2023-02-23 Pairwise Plants Services, Inc. Methods and compositions for modifying cytokinin receptor histidine kinase genes in plants
WO2023034731A1 (en) 2021-08-30 2023-03-09 Pairwise Plants Services, Inc. Modification of ubiquitin binding peptidase genes in plants for yield trait improvement
CN113684271A (en) * 2021-09-01 2021-11-23 大连医科大学附属第二医院 Fusion gene PSMD9-RNF34 in congenital dyskeratosis and application and detection kit thereof
AR126938A1 (en) 2021-09-02 2023-11-29 Pairwise Plants Services Inc METHODS AND COMPOSITIONS TO IMPROVE PLANT ARCHITECTURE AND PERFORMANCE TRAITS
US20230270840A1 (en) 2021-09-08 2023-08-31 Beam Therapeutics Inc. Viral guide rna delivery
CA3232804A1 (en) 2021-09-21 2023-03-30 Pairwise Plants Services, Inc. Methods and compositions for reducing pod shatter in canola
US20230266293A1 (en) 2021-09-21 2023-08-24 Pairwise Plants Services, Inc. Color-based and/or visual methods for identifying the presence of a transgene and compositions and constructs relating to the same
AU2022349449A1 (en) * 2021-09-22 2024-04-18 Verve Therapeutics, Inc. Gene editing of pcsk9 or angptl3 and compositions and methods of using same for treatment of disease
WO2023049926A2 (en) 2021-09-27 2023-03-30 Vor Biopharma Inc. Fusion polypeptides for genetic editing and methods of use thereof
WO2023052366A1 (en) 2021-09-28 2023-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Base editing approaches for the treatment of beta-hemoglobinopathies
AR127236A1 (en) 2021-10-04 2024-01-03 Pairwise Plants Services Inc METHODS TO IMPROVE FLOWER FERTILITY AND SEED YIELD
CA3234455A1 (en) 2021-10-07 2023-04-13 Pairwise Plants Services, Inc. Methods for improving floret fertility and seed yield
WO2023069603A1 (en) 2021-10-22 2023-04-27 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
WO2023077149A1 (en) 2021-11-01 2023-05-04 Sigma-Aldrich Co. Llc Electroporation enhancers for crispr-cas systems
WO2023077148A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2023081070A1 (en) 2021-11-02 2023-05-11 University Of Massachusetts Nme2Cas9 INLAID DOMAIN FUSION PROTEINS
WO2023086422A1 (en) 2021-11-09 2023-05-19 Vor Biopharma Inc. Compositions and methods for erm2 modification
CN113957138B (en) * 2021-11-22 2022-07-12 百世诺(北京)医学检验实验室有限公司 Mutant gene related to rare genetic disease and application thereof
WO2023099591A1 (en) 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer
WO2023102550A2 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
WO2023107902A1 (en) 2021-12-06 2023-06-15 Napigen, Inc. Phosphite dehydrogenase as a selectable marker for mitochondrial transformation
AR127904A1 (en) 2021-12-09 2024-03-06 Pairwise Plants Services Inc METHODS TO IMPROVE FLOWER FERTILITY AND SEED YIELD
US20230295646A1 (en) 2021-12-13 2023-09-21 Pairwise Plants Services, Inc. Model editing systems and methods relating to the same
WO2023114953A2 (en) 2021-12-17 2023-06-22 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
WO2023121971A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising tetravalent lipid compounds
WO2023121975A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Ionizable amine lipids and lipid nanoparticles
WO2023121965A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterial comprising diamines
WO2023121964A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising disulfides
WO2023121970A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Ionizable amine and ester lipids and lipid nanoparticles
WO2023122764A1 (en) 2021-12-22 2023-06-29 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
WO2023118136A1 (en) 2021-12-22 2023-06-29 BASF Agricultural Solutions Seed US LLC Improved screening method for genome edited events
WO2023133440A1 (en) 2022-01-06 2023-07-13 Pairwise Plants Services, Inc. Methods and compositions for trichome removal
WO2023141504A2 (en) * 2022-01-19 2023-07-27 Genomeminer, Inc. (Formally Tupac Bio, Inc.) Dcas9-integrase for targeted genome editing
WO2023139557A1 (en) 2022-01-24 2023-07-27 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2023144104A1 (en) 2022-01-25 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Base editing approaches for the treatment of βeta-thalassemia
AR128372A1 (en) 2022-01-31 2024-04-24 Pairwise Plants Services Inc SUPPRESSION OF THE SHADE AVOIDANCE RESPONSE IN PLANTS
WO2023150393A2 (en) 2022-02-07 2023-08-10 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
WO2023164722A1 (en) 2022-02-28 2023-08-31 Pairwise Plants Services, Inc. Engineered crispr-cas effector proteins and methods of use thereof
WO2023168217A1 (en) 2022-03-02 2023-09-07 Pairwise Plants Services, Inc. Modification of brassinosteroid receptor genes to improve yield traits
WO2023192838A1 (en) 2022-03-31 2023-10-05 Pairwise Plants Services, Inc. Early flowering rosaceae plants with improved characteristics
WO2023196816A1 (en) 2022-04-04 2023-10-12 Vor Biopharma Inc. Compositions and methods for mediating epitope engineering
WO2023196772A1 (en) 2022-04-04 2023-10-12 Beam Therapeutics Inc. Novel rna base editing compositions, systems, methods and uses thereof
WO2023196886A1 (en) 2022-04-07 2023-10-12 Pairwise Plants Services, Inc. Methods and compositions for improving resistance to fusarium head blight
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023205714A1 (en) 2022-04-21 2023-10-26 Pairwise Plants Services, Inc. Methods and compositions for improving yield traits
WO2023215704A1 (en) 2022-05-02 2023-11-09 Pairwise Plants Services, Inc. Methods and compositions for enhancing yield and disease resistance
US20230416767A1 (en) 2022-05-05 2023-12-28 Pairwise Plants Services, Inc. Methods and compositions for modifying root architecture and/or improving plant yield traits
WO2023217888A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from βeta-thalassemia
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
CN114934031B (en) * 2022-05-25 2023-08-01 广州瑞风生物科技有限公司 Novel Cas effect protein, gene editing system and application
WO2023227669A2 (en) 2022-05-26 2023-11-30 UCB Biopharma SRL Novel nucleic acid-editing proteins
WO2023230601A1 (en) 2022-05-27 2023-11-30 Beam Therapeutics Inc. Identification of nanoparticles for preferential tissue or cell targeting
US20230416771A1 (en) 2022-06-27 2023-12-28 Pairwise Plants Services, Inc. Methods and compositions for modifying shade avoidance in plants
US20240000031A1 (en) 2022-06-29 2024-01-04 Pairwise Plants Services, Inc. Methods and compositions for controlling meristem size for crop improvement
WO2024006792A1 (en) 2022-06-29 2024-01-04 Pairwise Plants Services, Inc. Methods and compositions for controlling meristem size for crop improvement
CN115820728A (en) * 2022-07-11 2023-03-21 上海贝斯昂科生物科技有限公司 Gene editing method and application
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024019936A1 (en) 2022-07-20 2024-01-25 Beam Therapeutics Inc. Nanomaterials comprising triols
WO2024018056A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024030432A1 (en) 2022-08-01 2024-02-08 Gensaic, Inc. Therapeutic phage-derived particles
US20240043857A1 (en) 2022-08-04 2024-02-08 Pairwise Plants Services, Inc. Methods and compositions for improving yield traits
WO2024036240A1 (en) 2022-08-11 2024-02-15 Pairwise Plants Services, Inc. Methods and compositions for controlling meristem size for crop improvement
WO2024033901A1 (en) 2022-08-12 2024-02-15 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2024042489A1 (en) 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
WO2024054880A1 (en) 2022-09-08 2024-03-14 Pairwise Plants Services, Inc. Methods and compositions for improving yield characteristics in plants
WO2024059791A1 (en) 2022-09-16 2024-03-21 Beam Therapeutics Inc. Large serine recombinases, systems and uses thereof
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment

Family Cites Families (1697)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4182449A (en) 1978-04-18 1980-01-08 Kozlow William J Adhesive bandage and package
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4663290A (en) 1982-01-21 1987-05-05 Molecular Genetics, Inc. Production of reverse transcriptase
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5017492A (en) 1986-02-27 1991-05-21 Life Technologies, Inc. Reverse transcriptase and method for its production
JP2874751B2 (en) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション Transgenic animals secreting the desired protein into milk
US5374553A (en) 1986-08-22 1994-12-20 Hoffmann-La Roche Inc. DNA encoding a thermostable nucleic acid polymerase enzyme from thermotoga maritima
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5079352A (en) 1986-08-22 1992-01-07 Cetus Corporation Purified thermostable enzyme
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (en) 1987-02-09 1996-03-13 株式会社ビタミン研究所 Antitumor agent-embedded liposome preparation
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
RO108522B1 (en) 1987-04-23 1994-06-30 Fmc Corp Derivates of di(aryl)-cyclopropyl, its substitutes and intermediaries thereof
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5244797B1 (en) 1988-01-13 1998-08-25 Life Technologies Inc Cloned genes encoding reverse transcriptase lacking rnase h activity
US4965185A (en) 1988-06-22 1990-10-23 Grischenko Valentin I Method for low-temperature preservation of embryos
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1026240A3 (en) 1988-09-02 2004-04-07 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5047342A (en) 1989-08-10 1991-09-10 Life Technologies, Inc. Cloning and expression of T5 DNA polymerase
US5270179A (en) 1989-08-10 1993-12-14 Life Technologies, Inc. Cloning and expression of T5 DNA polymerase reduced in 3'- to-5' exonuclease activity
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
CA2090614C (en) 1990-09-28 2001-12-11 David H. Gelfand 5' to 3' exonuclease mutations of thermostable dna polymerases
DE553264T1 (en) 1990-10-05 1994-04-28 Wayne M Barnes THERMOSTABLE DNA POLYMERASE.
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US6872816B1 (en) 1996-01-24 2005-03-29 Third Wave Technologies, Inc. Nucleic acid detection kits
JPH05274181A (en) 1992-03-25 1993-10-22 Nec Corp Setting/canceling system for break point
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5834247A (en) 1992-12-09 1998-11-10 New England Biolabs, Inc. Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein
US5496714A (en) 1992-12-09 1996-03-05 New England Biolabs, Inc. Modification of protein by use of a controllable interveining protein sequence
US5434058A (en) 1993-02-09 1995-07-18 Arch Development Corporation Apolipoprotein B MRNA editing protein compositions and methods
US5436149A (en) 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
EP0702716A4 (en) 1993-05-17 1999-05-26 Univ California Ribozyme gene therapy for hiv infection and aids
US5512462A (en) 1994-02-25 1996-04-30 Hoffmann-La Roche Inc. Methods and reagents for the polymerase chain reaction amplification of long DNA sequences
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5912155A (en) 1994-09-30 1999-06-15 Life Technologies, Inc. Cloned DNA polymerases from Thermotoga neapolitana
US5614365A (en) 1994-10-17 1997-03-25 President & Fellow Of Harvard College DNA polymerase having modified nucleotide binding site for DNA sequencing
US5449639A (en) 1994-10-24 1995-09-12 Taiwan Semiconductor Manufacturing Company Ltd. Disposable metal anti-reflection coating process used together with metal dry/wet etch
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US6057153A (en) 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
US5773258A (en) 1995-08-25 1998-06-30 Roche Molecular Systems, Inc. Nucleic acid amplification using a reversibly inactivated thermostable enzyme
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US5981182A (en) 1997-03-13 1999-11-09 Albert Einstein College Of Medicine Of Yeshiva University Vector constructs for the selection and identification of open reading frames
US20040203109A1 (en) 1997-06-06 2004-10-14 Incyte Corporation Human regulatory proteins
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
US6156509A (en) 1997-11-12 2000-12-05 Genencor International, Inc. Method of increasing efficiency of directed evolution of a gene using phagemid
US6183998B1 (en) 1998-05-29 2001-02-06 Qiagen Gmbh Max-Volmer-Strasse 4 Method for reversible modification of thermostable enzymes
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
WO2000022115A2 (en) 1998-10-13 2000-04-20 Board Of Regents, The University Of Texas System Assays for identifying functional alterations in the p53 tumor suppressor
PT1129064E (en) 1998-11-12 2008-01-31 Invitrogen Corp Transfection reagents
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20090130718A1 (en) 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
EP1174509A4 (en) 1999-03-29 2003-10-22 Kansai Tech Licensing Org Co Novel cytidine deaminase
US6365410B1 (en) 1999-05-19 2002-04-02 Genencor International, Inc. Directed evolution of microorganisms
GB9920194D0 (en) 1999-08-27 1999-10-27 Advanced Biotech Ltd A heat-stable thermostable DNA polymerase for use in nucleic acid amplification
CA2386341A1 (en) 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs and related methods
WO2001038547A2 (en) 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
ATE309536T1 (en) 1999-12-06 2005-11-15 Sangamo Biosciences Inc METHODS OF USING RANDOMIZED ZINC FINGER PROTEIN LIBRARIES TO IDENTIFY GENE FUNCTIONS
ATE483970T1 (en) 2000-02-08 2010-10-15 Sangamo Biosciences Inc CELLS FOR DRUG DISCOVERY
US7078208B2 (en) 2000-05-26 2006-07-18 Invitrogen Corporation Thermostable reverse transcriptases and uses thereof
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
NZ583028A (en) 2000-10-27 2011-10-28 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
HU230875B1 (en) 2000-10-30 2018-11-29 Euro-Celtique S.A. Controlled release hydrocodone compositions
US20040003420A1 (en) 2000-11-10 2004-01-01 Ralf Kuhn Modified recombinase
JP2004525623A (en) 2001-01-25 2004-08-26 エボルバ バイオテック アクティーゼルスカブ Concatemers of differentially expressed synonyms
US20050222030A1 (en) 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
EP1392846B1 (en) 2001-02-27 2008-06-11 University of Rochester METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING
DK1456360T3 (en) 2001-04-19 2015-08-31 Scripps Research Inst Methods and Composition for Preparation of Orthogonal TRNA-Aminoacyl-TRNA Synthetase Pairs
CA2449042A1 (en) 2001-05-30 2002-12-27 Biomedical Center In silico screening for phenotype-associated expressed sequences
CA2454319A1 (en) 2001-07-26 2003-03-27 Stratagene Multi-site mutagenesis
US20030167533A1 (en) 2002-02-04 2003-09-04 Yadav Narendra S. Intein-mediated protein splicing
ES2421596T3 (en) 2002-05-10 2013-09-04 Medical Res Council Activation-induced deaminase (AID)
US9388459B2 (en) 2002-06-17 2016-07-12 Affymetrix, Inc. Methods for genotyping
AU2003251905A1 (en) 2002-07-12 2004-02-02 Affymetrix, Inc. Synthetic tag genes
EP1546170A4 (en) 2002-09-20 2007-08-29 Univ Yale Riboswitches, methods for their use, and compositions for use with riboswitches
ES2317016T3 (en) 2003-04-14 2009-04-16 Caliper Life Sciences, Inc. REDUCTION OF INTERFERENCE IN A MIGRATION DISPLACEMENT TEST.
WO2005002527A2 (en) 2003-07-03 2005-01-13 Massachusetts Institute Of Technology Sirt1 modulation of adipogenesis and adipose function
DE602004011789T2 (en) 2003-07-07 2009-02-12 The Scripps Research Institute, La Jolla Compositions of orthogonal lysyl tRNA and aminoacyl-tRNA synthetase pairs and their uses
AU2004263865B2 (en) 2003-08-08 2007-05-17 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7670807B2 (en) 2004-03-10 2010-03-02 East Tennessee State Univ. Research Foundation RNA-dependent DNA polymerase from Geobacillus stearothermophilus
US7192739B2 (en) 2004-03-30 2007-03-20 President And Fellows Of Harvard College Ligand-dependent protein splicing
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US7919277B2 (en) 2004-04-28 2011-04-05 Danisco A/S Detection and typing of bacterial strains
WO2006002547A1 (en) 2004-07-06 2006-01-12 UNIVERSITé DE SHERBROOKE A target-dependent nucleic acid adapter
WO2006023207A2 (en) 2004-08-19 2006-03-02 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Coacervate of anionic and cationic polymer forming microparticles for the sustained release of therapeutic agents
JP5101288B2 (en) 2004-10-05 2012-12-19 カリフォルニア インスティテュート オブ テクノロジー Aptamer-regulated nucleic acids and uses thereof
WO2006089045A2 (en) 2005-02-18 2006-08-24 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of hiv-1 to non-nucleoside reverse transcriptase inhibitors
JP2006248978A (en) 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
US9783791B2 (en) 2005-08-10 2017-10-10 Agilent Technologies, Inc. Mutant reverse transcriptase and methods of use
DK2341149T3 (en) 2005-08-26 2017-02-27 Dupont Nutrition Biosci Aps Use of CRISPR-associated genes (Cas)
AU2015252023B2 (en) 2005-08-26 2017-06-29 Dupont Nutrition Biosciences Aps Use
AU2012244264B2 (en) 2005-08-26 2015-08-06 Dupont Nutrition Biosciences Aps Use
KR100784478B1 (en) 2005-12-05 2007-12-11 한국과학기술원 A Prepartion method for a protein with new function through simultaneous incorporation of functional elements
US20080051317A1 (en) 2005-12-15 2008-02-28 George Church Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
JP5364574B2 (en) 2006-05-05 2013-12-11 モレキュラー、トランスファー、インコーポレイテッド New reagents for transfection of eukaryotic cells
DK2018441T3 (en) 2006-05-19 2012-01-02 Danisco Labeled microorganisms and method of labeling
US9150626B2 (en) 2006-06-02 2015-10-06 President And Fellows Of Harvard College Protein surface remodeling
WO2008005529A2 (en) 2006-07-07 2008-01-10 The Trustees Columbia University In The City Of New York Cell-mediated directed evolution
NZ579002A (en) 2007-03-02 2012-03-30 Danisco Cultures with improved phage resistance
US8183221B2 (en) 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
WO2009042163A2 (en) 2007-09-27 2009-04-02 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
US9029524B2 (en) 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
WO2009100373A1 (en) 2008-02-08 2009-08-13 Sangamo Biosciences, Inc. Treatment of chronic pain with zinc finger proteins
GB0806562D0 (en) 2008-04-10 2008-05-14 Fermentas Uab Production of nucleic acid
WO2009146179A1 (en) 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
CA2725601A1 (en) 2008-04-28 2009-11-05 President And Fellows Of Harvard College Supercharged proteins for cell penetration
US8394604B2 (en) 2008-04-30 2013-03-12 Paul Xiang-Qin Liu Protein splicing using short terminal split inteins
US8546553B2 (en) 2008-07-25 2013-10-01 University Of Georgia Research Foundation, Inc. Prokaryotic RNAi-like system and methods of use
EP2159286A1 (en) 2008-09-01 2010-03-03 Consiglio Nazionale Delle Ricerche Method for obtaining oligonucleotide aptamers and uses thereof
WO2010026537A1 (en) 2008-09-05 2010-03-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel multimodular assembly useful for intracellular delivery
CA3073384A1 (en) 2008-09-05 2010-03-11 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
US8636884B2 (en) 2008-09-15 2014-01-28 Abbott Diabetes Care Inc. Cationic polymer based wired enzyme formulations for use in analyte sensors
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
EP2362915B1 (en) 2008-11-07 2016-12-21 DuPont Nutrition Biosciences ApS Bifidobacteria crispr sequences
US20110016540A1 (en) 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
CN102317473A (en) 2008-12-11 2012-01-11 加利福尼亚太平洋生物科学股份有限公司 Shenzhen tcl new technology co. , ltd
US9175338B2 (en) 2008-12-11 2015-11-03 Pacific Biosciences Of California, Inc. Methods for identifying nucleic acid modifications
WO2010075424A2 (en) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
US20100305197A1 (en) 2009-02-05 2010-12-02 Massachusetts Institute Of Technology Conditionally Active Ribozymes And Uses Thereof
CN102421791A (en) 2009-03-04 2012-04-18 得克萨斯系统大学评议会 Stabilized reverse transcriptase fusion proteins
CN102421897B (en) 2009-03-06 2015-12-16 合成基因组股份有限公司 For cloning and operating genomic method
WO2010129019A2 (en) 2009-04-27 2010-11-11 Pacific Biosciences Of California, Inc. Real-time sequencing methods and systems
JP2012525146A (en) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Overcharged protein for cell penetration
WO2010132092A2 (en) 2009-05-12 2010-11-18 The Scripps Research Institute Cytidine deaminase fusions and related methods
US9063156B2 (en) 2009-06-12 2015-06-23 Pacific Biosciences Of California, Inc. Real-time analytical methods and systems
WO2011002503A1 (en) 2009-06-30 2011-01-06 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US20120178647A1 (en) 2009-08-03 2012-07-12 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
AU2010279572B2 (en) 2009-08-03 2017-02-02 Recombinetics, Inc. Methods and compositions for targeted gene modification
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
MX2012005069A (en) 2009-10-30 2012-07-17 Synthetic Genomics Inc Encoding text into nucleic acid sequences.
SG10201406801XA (en) 2009-11-02 2014-11-27 Univ Washington Therapeutic nuclease compositions and methods
US20110104787A1 (en) * 2009-11-05 2011-05-05 President And Fellows Of Harvard College Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
RS57314B1 (en) 2009-12-01 2018-08-31 Translate Bio Inc Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US20110142886A1 (en) 2009-12-01 2011-06-16 Intezyne Technologies, Incorporated Pegylated polyplexes for polynucleotide delivery
PT2510096E (en) 2009-12-10 2015-02-04 Univ Iowa State Res Found Inc Tal effector-mediated dna modification
US20130011380A1 (en) 2009-12-18 2013-01-10 Blau Helen M Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming
MX2012008485A (en) 2010-01-22 2012-08-17 Dow Agrosciences Llc Excision of transgenes in genetically modified organisms.
JP2013520989A (en) 2010-03-05 2013-06-10 シンセティック ジェノミクス インコーポレーテッド Methods for genome cloning and manipulation
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP2569425B1 (en) 2010-05-10 2016-07-06 The Regents of The University of California Endoribonuclease compositions and methods of use thereof
CN103025344B (en) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 Novel DNA-associated proteins and application thereof
GB201008267D0 (en) 2010-05-18 2010-06-30 Univ Edinburgh Cationic lipids
AU2011257555B2 (en) 2010-05-27 2015-01-22 Leibniz-Institut Für Virologie Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
JP5957646B2 (en) 2010-06-04 2016-07-27 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
EP2580331A4 (en) 2010-06-14 2013-11-27 Univ Iowa State Res Found Inc Nuclease activity of tal effector and foki fusion protein
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
JPWO2012020759A1 (en) 2010-08-13 2013-10-28 国立大学法人京都大学 Mutant reverse transcriptase
AU2011305572B2 (en) 2010-09-20 2016-08-04 Diane Goll Microencapsulation process and product
AU2011316980A1 (en) 2010-10-20 2013-04-18 Dupont Nutrition Biosciences Aps Lactococcus CRISPR-Cas sequences
WO2012054727A1 (en) 2010-10-22 2012-04-26 Bio-Rad Laboratories, Inc. Reverse transcriptase mixtures with improved storage stability
CN103327970A (en) 2010-11-26 2013-09-25 约翰内斯堡威特沃特斯兰德大学 Polymeric matrix of polymer-lipid nanoparticles as a pharmaceutical dosage form
KR101255338B1 (en) 2010-12-15 2013-04-16 포항공과대학교 산학협력단 Polynucleotide delivering complex for a targeting cell
JP6143675B2 (en) 2010-12-16 2017-06-07 セルジーン コーポレイション Controlled release oral dosage forms of poorly soluble drugs and their use
JP6088438B2 (en) 2010-12-22 2017-03-01 プレジデント アンド フェローズ オブ ハーバード カレッジ Continuous directed evolution
US9499592B2 (en) 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
KR101818126B1 (en) 2011-02-09 2018-01-15 (주)바이오니아 Reverse Transcriptase Having Improved Thermostability
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
WO2012125445A2 (en) 2011-03-11 2012-09-20 President And Fellows Of Harvard College Small molecule-dependent inteins and uses thereof
US9164079B2 (en) 2011-03-17 2015-10-20 Greyledge Technologies Llc Systems for autologous biological therapeutics
US20120244601A1 (en) 2011-03-22 2012-09-27 Bertozzi Carolyn R Riboswitch based inducible gene expression platform
US8709466B2 (en) 2011-03-31 2014-04-29 International Business Machines Corporation Cationic polymers for antimicrobial applications and delivery of bioactive materials
EP2694091B1 (en) 2011-04-05 2019-03-13 Cellectis Method for the generation of compact tale-nucleases and uses thereof
WO2012148953A1 (en) 2011-04-25 2012-11-01 Stc.Unm Solid compositions for pharmaceutical use
CA2834375C (en) 2011-04-27 2020-07-14 Amyris, Inc. Methods for genomic modification
WO2012158986A2 (en) 2011-05-17 2012-11-22 Transposagen Biopharmaceuticals, Inc. Methods for site-specific genetic modification in stem cells using xanthomonas tal nucleases (xtn) for the creation of model organisms
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2012158985A2 (en) 2011-05-17 2012-11-22 Transposagen Biopharmaceuticals, Inc. Methods for site-specific genetic modification in spermatogonial stem cells using zinc finger nuclease (zfn) for the creation of model organisms
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
JP6184945B2 (en) 2011-06-08 2017-08-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Lipid nanoparticle compositions and methods for mRNA delivery
WO2013012674A1 (en) 2011-07-15 2013-01-24 The General Hospital Corporation Methods of transcription activator like effector assembly
EP2734622B1 (en) 2011-07-19 2018-09-05 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for repairing cartilage damage
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2013039857A1 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
EP2755693A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc Engineered nucleic acids and methods of use thereof
JP6177780B2 (en) 2011-09-28 2017-08-09 エラ、ビオテック、ソシエダッド、アノニマEra Biotech, S.A. Split inteins and their use
JP6118724B2 (en) 2011-09-28 2017-04-19 株式会社リボミック Aptamers to NGF and uses thereof
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
LT2791160T (en) 2011-12-16 2022-06-10 Modernatx, Inc. Modified mrna compositions
CN104080462B (en) 2011-12-16 2019-08-09 塔尔盖特基因生物技术有限公司 For modifying the composition and method of scheduled target nucleic acid sequence
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9737480B2 (en) 2012-02-06 2017-08-22 President And Fellows Of Harvard College ARRDC1-mediated microvesicles (ARMMs) and uses thereof
NZ630900A (en) 2012-02-24 2016-10-28 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
CN104204225A (en) 2012-02-29 2014-12-10 桑格摩生物科学股份有限公司 Methods and compositions for treating huntington's disease
SG11201405783VA (en) 2012-03-17 2014-10-30 Univ California Fast diagnosis and personalized treatments for acne
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013152359A1 (en) 2012-04-06 2013-10-10 The Regents Of The University Of California Novel tetrazines and method of synthesizing the same
US11518997B2 (en) 2012-04-23 2022-12-06 BASF Agricultural Solutions Seed US LLC Targeted genome engineering in plants
RU2658437C2 (en) 2012-05-02 2018-06-21 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Targeted modification of malate dehydrogenase
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
WO2013169398A2 (en) 2012-05-09 2013-11-14 Georgia Tech Research Corporation Systems and methods for improving nuclease specificity and activity
BR112014029417B1 (en) 2012-05-25 2023-03-07 Cellectis EX VIVO METHOD FOR THE PREPARATION OF T CELLS FOR IMMUNOTHERAPY
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2014184143A1 (en) 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
DK3241902T3 (en) 2012-05-25 2018-05-07 Univ California METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
US20140056868A1 (en) 2012-05-30 2014-02-27 University of Washington Center for Commercialization Supercoiled MiniVectors as a Tool for DNA Repair, Alteration and Replacement
WO2013188037A2 (en) 2012-06-11 2013-12-19 Agilent Technologies, Inc Method of adaptor-dimer subtraction using a crispr cas6 protein
BR112014031080A2 (en) 2012-06-12 2018-05-08 Genentech Inc methods and compositions for generating conditional knock-out alleles.
EP2674501A1 (en) 2012-06-14 2013-12-18 Agence nationale de sécurité sanitaire de l'alimentation,de l'environnement et du travail Method for detecting and identifying enterohemorrhagic Escherichia coli
US9688971B2 (en) 2012-06-15 2017-06-27 The Regents Of The University Of California Endoribonuclease and methods of use thereof
EP2861737B1 (en) 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
US9267127B2 (en) 2012-06-21 2016-02-23 President And Fellows Of Harvard College Evolution of bond-forming enzymes
US20150344549A1 (en) 2012-06-27 2015-12-03 The Trustees Of Princeton University Split inteins, conjugates and uses thereof
AU2013282323B2 (en) 2012-06-29 2018-05-10 Massachusetts Institute Of Technology Massively parallel combinatorial genetics
US9125508B2 (en) 2012-06-30 2015-09-08 Seasons 4, Inc. Collapsible tree system
JP6329537B2 (en) 2012-07-11 2018-05-23 サンガモ セラピューティクス, インコーポレイテッド Methods and compositions for delivery of biological agents
DK3196301T3 (en) 2012-07-11 2019-01-14 Sangamo Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING MONOGENIC DISEASES
EP3494997B1 (en) 2012-07-25 2019-09-18 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
US10058078B2 (en) 2012-07-31 2018-08-28 Recombinetics, Inc. Production of FMDV-resistant livestock by allele substitution
JP6340366B2 (en) 2012-07-31 2018-06-06 イェダ リサーチ アンド デベロップメント カンパニー リミテッド Methods for diagnosing and treating motor neuron disease
EP2880171B1 (en) 2012-08-03 2018-10-03 The Regents of The University of California Methods and compositions for controlling gene expression by rna processing
DK2890780T3 (en) 2012-08-29 2020-09-21 Sangamo Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING A GENETIC CONDITION
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
CN109517068B (en) 2012-09-04 2023-07-25 斯克利普斯研究院 Chimeric polypeptides with targeted binding specificity
CA2883502C (en) 2012-09-04 2021-05-04 Cellectis Multi-chain chimeric antigen receptor and uses thereof
US20140075593A1 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Fluorescence activated cell sorting (facs) enrichment to generate plants
UA119135C2 (en) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Engineered transgene integration platform (etip) for gene targeting and trait stacking
RU2665811C2 (en) 2012-09-07 2018-09-04 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
UA118090C2 (en) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
WO2014043143A1 (en) 2012-09-11 2014-03-20 Life Technologies Corporation Nucleic acid amplification
GB201216564D0 (en) 2012-09-17 2012-10-31 Univ Edinburgh Genetically edited animal
US10612053B2 (en) 2012-09-18 2020-04-07 The Translational Genomics Research Institute Isolated genes and transgenic organisms for producing biofuels
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
EP2904101B1 (en) 2012-10-03 2019-06-12 Agrivida, Inc. Intein-modified proteases, their production and industrial applications
JO3470B1 (en) 2012-10-08 2020-07-05 Merck Sharp & Dohme 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
US20150267176A1 (en) 2012-10-12 2015-09-24 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
CA3233048A1 (en) 2012-10-23 2014-05-01 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
US20140115728A1 (en) 2012-10-24 2014-04-24 A. Joseph Tector Double knockout (gt/cmah-ko) pigs, organs and tissues
CA2889502A1 (en) 2012-10-30 2014-05-08 Recombinetics, Inc. Control of sexual maturation in animals
BR112015009931A2 (en) 2012-10-31 2017-12-05 Two Blades Found gene, protein, nucleic acid molecule, vector, host cell, methods for in vitro preparation of a mutant gene and for generating a plant, mutant plant, product, mutant plant seed, antibody, use of an antibody, gene probe, pair of primer oligonucleotides, and use of genetic probe
BR112015009812A2 (en) 2012-10-31 2017-08-22 Cellectis METHOD FOR SPECIFIC GENETIC INSERTION INTO A PLANT GENOME, TRANSFORMED PLANT CELL AND ITS USE, HERBICIDIDE RESISTANT PLANT, KIT, VECTOR, AND HOST CELL
BR122019025678B1 (en) 2012-11-01 2023-04-18 Factor Bioscience Inc COMPOSITIONS COMPRISING NUCLEIC ACID ENCODING A GENE-EDITING PROTEIN
US20150315576A1 (en) 2012-11-01 2015-11-05 Massachusetts Institute Of Technology Genetic device for the controlled destruction of dna
US20140127752A1 (en) 2012-11-07 2014-05-08 Zhaohui Zhou Method, composition, and reagent kit for targeted genomic enrichment
US9879227B2 (en) 2012-11-09 2018-01-30 Marco Archetti Diffusible factors and cancer cells
AU2013348113A1 (en) 2012-11-20 2015-06-11 J.R. Simplot Company TAL-mediated transfer DNA insertion
WO2014081855A1 (en) 2012-11-20 2014-05-30 Universite De Montreal Methods and compositions for muscular dystrophies
WO2014081730A1 (en) 2012-11-20 2014-05-30 Cold Spring Harbor Laboratory Mutations in solanaceae plants that modulate shoot architecture and enhance yield-related phenotypes
DK2925864T3 (en) 2012-11-27 2019-02-11 Childrens Medical Ct Corp DIRECTIONAL TARGETING OF DISTANT BCL11A CONTROLS FOR FETAL HEMOGLOBIN REINUCTION
WO2014085261A1 (en) 2012-11-29 2014-06-05 North Carolina State University Synthetic pathway for biological carbon dioxide sequestration
US20160010154A1 (en) 2012-11-30 2016-01-14 The Parkinson's Institute Screening assays for therapeutics for parkinson's disease
WO2014082644A1 (en) 2012-11-30 2014-06-05 WULFF, Peter, Samuel Circular rna for inhibition of microrna
JP2016500254A (en) 2012-12-05 2016-01-12 サンガモ バイオサイエンシーズ, インコーポレイテッド Methods and compositions for the regulation of metabolic diseases
WO2014089513A1 (en) 2012-12-06 2014-06-12 Synthetic Genomics, Inc. Autonomous replication sequences and episomal dna molecules
ES2757325T3 (en) 2012-12-06 2020-04-28 Sigma Aldrich Co Llc Modification and regulation of the genome based on CRISPR
CA2892821C (en) 2012-12-06 2022-04-26 Synthetic Genomics, Inc. Algal mutants having a locked-in high light acclimated phenotype
BR112015013311A2 (en) 2012-12-07 2017-11-14 Haplomics Inc tolerance induction and factor 8 mutation repair
WO2014089348A1 (en) 2012-12-07 2014-06-12 Synthetic Genomics, Inc. Nannochloropsis spliced leader sequences and uses therefor
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
ES2861623T3 (en) 2012-12-12 2021-10-06 Broad Inst Inc CRISPR-Cas Systems, Methods, and Component Compositions for Sequence Manipulation
IL239344B1 (en) 2012-12-12 2024-02-01 Broad Inst Inc Engineering of systems, methods and optimized guide compositions for sequence manipulation
EP2931892B1 (en) 2012-12-12 2018-09-12 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
PL2931898T3 (en) 2012-12-12 2016-09-30 Le Cong Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
EP2784162B1 (en) 2012-12-12 2015-04-08 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
IL300461A (en) 2012-12-12 2023-04-01 Harvard College Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
EP4234696A3 (en) 2012-12-12 2023-09-06 The Broad Institute Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
CA2893579A1 (en) 2012-12-13 2014-06-19 Dow Agrosciences Llc Dna detection methods for site specific nuclease activity
WO2014093852A1 (en) 2012-12-13 2014-06-19 Massachusetts Institute Of Technology Recombinase-based logic and memory systems
RU2015128052A (en) 2012-12-13 2017-01-19 Дау Агросайенсиз Ллс PRECISE TARGETING OF GENES REGARDING SPECIFIC LOCUS OF CORN
KR20220139433A (en) 2012-12-17 2022-10-14 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Rna-guided human genome engineering
PL2934097T3 (en) 2012-12-21 2018-11-30 Cellectis Potatoes with reduced cold-induced sweetening
WO2014104878A1 (en) 2012-12-27 2014-07-03 Keygene N.V. Method for removing genetic linkage in a plant
AU2014205648B2 (en) 2013-01-10 2017-05-04 Dharmacon, Inc. Templates, libraries, kits and methods for generating molecules
CN105142396A (en) 2013-01-14 2015-12-09 重组股份有限公司 Hornless livestock
AU2014207618A1 (en) 2013-01-16 2015-08-06 Emory University Cas9-nucleic acid complexes and uses related thereto
CN103233028B (en) 2013-01-25 2015-05-13 南京徇齐生物技术有限公司 Specie limitation-free eucaryote gene targeting method having no bio-safety influence and helical-structure DNA sequence
BR112015018493A2 (en) 2013-02-05 2017-08-22 Univ Georgia CELL LINES FOR VIRUS PRODUCTION AND METHODS OF USE
WO2014124226A1 (en) 2013-02-07 2014-08-14 The Rockefeller University Sequence specific antimicrobials
WO2014127287A1 (en) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Method for in vivo tergated mutagenesis
EP2963113B1 (en) 2013-02-14 2019-11-06 Osaka University Method for isolating specific genomic region using molecule binding specifically to endogenous dna sequence
JP6475172B2 (en) 2013-02-20 2019-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Rat genetic recombination
US20150353885A1 (en) 2013-02-21 2015-12-10 Cellectis Method to counter-select cells or organisms by linking loci to nuclease components
ES2522765B2 (en) 2013-02-22 2015-03-18 Universidad De Alicante Method to detect spacer insertions in CRISPR structures
AU2014218621B2 (en) 2013-02-25 2019-11-07 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
WO2014138379A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University The telomerator-a tool for chromosome engineering
US10612043B2 (en) 2013-03-09 2020-04-07 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
CA2905289C (en) 2013-03-12 2023-03-07 Pioneer Hi-Bred International, Inc. Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof
CN105283539A (en) 2013-03-12 2016-01-27 桑格摩生物科学股份有限公司 Methods and compositions for modification of HLA
US9777262B2 (en) 2013-03-13 2017-10-03 President And Fellows Of Harvard College Mutants of Cre recombinase
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
JP2016519652A (en) 2013-03-14 2016-07-07 カリブー・バイオサイエンシーズ・インコーポレイテッド Nucleic acid targeting nucleic acid compositions and methods
WO2014153118A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
WO2014144094A1 (en) 2013-03-15 2014-09-18 J.R. Simplot Company Tal-mediated transfer dna insertion
KR102339732B1 (en) 2013-03-15 2021-12-15 시버스 유에스 엘엘씨 Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
JP2016512048A (en) 2013-03-15 2016-04-25 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Plant genome manipulation using the CRISPR / Cas system
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
EP2971041B1 (en) 2013-03-15 2018-11-28 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
EP2971006A4 (en) 2013-03-15 2017-02-08 Transposagen Biopharmaceuticals, Inc. Reproducible method for testis-mediated genetic modification (tgm) and sperm-mediated genetic modification (sgm)
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
CA2906970C (en) 2013-03-21 2021-05-18 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
CN105121650A (en) 2013-04-02 2015-12-02 拜尔作物科学公司 Targeted genome engineering in eukaryotes
EP2981607B1 (en) 2013-04-03 2020-08-19 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CA2908253C (en) 2013-04-04 2024-01-09 Trustees Of Dartmouth College Compositions and methods for in vivo excision of hiv-1 proviral dna
JP2016522679A (en) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ Therapeutic use of genome editing with the CRISPR / Cas system
CN105263312A (en) 2013-04-05 2016-01-20 美国陶氏益农公司 Methods and compositions for integration of an exogenous sequence within the genome of plants
US20150056629A1 (en) 2013-04-14 2015-02-26 Katriona Guthrie-Honea Compositions, systems, and methods for detecting a DNA sequence
WO2014172470A2 (en) 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
US20160040155A1 (en) 2013-04-16 2016-02-11 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
SG11201508028QA (en) 2013-04-16 2015-10-29 Regeneron Pharma Targeted modification of rat genome
EP2796558A1 (en) 2013-04-23 2014-10-29 Rheinische Friedrich-Wilhelms-Universität Bonn Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants
CN103224947B (en) 2013-04-28 2015-06-10 陕西师范大学 Gene targeting system
WO2014183071A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research In vitro production of red blood cells with sortaggable proteins
WO2014182700A1 (en) 2013-05-10 2014-11-13 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2014184744A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
AU2014265331B2 (en) 2013-05-15 2019-12-05 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
WO2014186686A2 (en) 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
WO2014190181A1 (en) 2013-05-22 2014-11-27 Northwestern University Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
US20160122774A1 (en) 2013-05-29 2016-05-05 Cellectis A method for producing precise dna cleavage using cas9 nickase activity
EP3004339B1 (en) 2013-05-29 2021-07-07 Cellectis New compact scaffold of cas9 in the type ii crispr system
CA2913830C (en) 2013-05-29 2021-06-29 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
US20150067922A1 (en) 2013-05-30 2015-03-05 The Penn State Research Foundation Gene targeting and genetic modification of plants via rna-guided genome editing
JP6488283B2 (en) 2013-05-31 2019-03-20 セレクティスCellectis LAGLIDADG homing endonuclease that cleaves CC chemokine receptor type 5 (CCR5) gene and its use
US20140359796A1 (en) 2013-05-31 2014-12-04 Recombinetics, Inc. Genetically sterile animals
AU2014273091B2 (en) 2013-05-31 2019-12-12 Cellectis A LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
EP3603679B1 (en) 2013-06-04 2022-08-10 President and Fellows of Harvard College Rna-guided transcriptional regulation
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
US20150315252A1 (en) 2013-06-11 2015-11-05 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
EP3008181B1 (en) 2013-06-11 2019-11-06 The Regents of The University of California Methods and compositions for target dna modification
CN105283553B (en) 2013-06-11 2021-06-25 克隆技术实验室有限公司 Protein-enriched microvesicles and methods of making and using same
AU2014279694B2 (en) 2013-06-14 2020-07-23 Cellectis Methods for non-transgenic genome editing in plants
KR20160030187A (en) 2013-06-17 2016-03-16 더 브로드 인스티튜트, 인코퍼레이티드 Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
AU2014281027A1 (en) 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
EP3011033B1 (en) 2013-06-17 2020-02-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
EP3011034B1 (en) 2013-06-17 2019-08-07 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
SG11201510327TA (en) 2013-06-17 2016-01-28 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
KR20160021812A (en) 2013-06-19 2016-02-26 시그마-알드리치 컴퍼니., 엘엘씨 Targeted integration
AU2014301147B2 (en) 2013-06-25 2020-07-30 Cellectis Modified diatoms for biofuel production
US20160369268A1 (en) 2013-07-01 2016-12-22 The Board Of Regents Of The University Of Texas System Transcription activator-like effector (tale) libraries and methods of synthesis and use
EP3019595A4 (en) 2013-07-09 2016-11-30 Therapeutic uses of genome editing with crispr/cas systems
SG11201600059QA (en) 2013-07-09 2016-02-26 Harvard College Multiplex rna-guided genome engineering
KR102285485B1 (en) 2013-07-10 2021-08-04 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Orthogonal cas9 proteins for rna-guided gene regulation and editing
WO2015004241A2 (en) 2013-07-10 2015-01-15 Novartis Ag Multiple proteases deficient filamentous fungal cells and methods of use thereof
WO2015006437A1 (en) 2013-07-10 2015-01-15 Majzoub Joseph A Mrap2 knockouts
SI3019619T1 (en) 2013-07-11 2021-12-31 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
CN104293828B (en) 2013-07-16 2017-07-21 中国科学院上海生命科学研究院 Plant Genome pointed decoration method
CN105392885B (en) 2013-07-19 2020-11-03 赖瑞克斯生物科技公司 Methods and compositions for generating double allele knockouts
GB201313235D0 (en) 2013-07-24 2013-09-04 Univ Edinburgh Antiviral Compositions Methods and Animals
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
CN103388006B (en) 2013-07-26 2015-10-28 华东师范大学 A kind of construction process of site-directed point mutation
US10421957B2 (en) 2013-07-29 2019-09-24 Agilent Technologies, Inc. DNA assembly using an RNA-programmable nickase
WO2015017866A1 (en) 2013-08-02 2015-02-05 Enevolv, Inc. Processes and host cells for genome, pathway, and biomolecular engineering
ITTO20130669A1 (en) 2013-08-05 2015-02-06 Consiglio Nazionale Ricerche ADENO-ASSOCIATED MOMCULAR-SPECIFIC VECTOR AND ITS EMPLOYMENT IN THE TREATMENT OF MUSCLE PATHOLOGIES
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
WO2015024017A2 (en) 2013-08-16 2015-02-19 President And Fellows Of Harvard College Rna polymerase, methods of purification and methods of use
WO2015021990A1 (en) 2013-08-16 2015-02-19 University Of Copenhagen Rna probing method and reagents
USRE48801E1 (en) 2013-08-20 2021-11-02 Vib Vzw Inhibition of a lncRNA for treatment of melanoma
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
CN105829536A (en) 2013-08-22 2016-08-03 纳幕尔杜邦公司 Methods for producing genetic modifications in a plant genome without incorporating a selectable transgene marker, and compositions thereof
AU2014312295C1 (en) 2013-08-28 2020-08-13 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
GB201315321D0 (en) 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
SG10201801658XA (en) 2013-08-29 2018-03-28 Univ Temple Methods and compositions for rna-guided treatment of hiv infection
JP6535333B2 (en) 2013-09-04 2019-06-26 シーエスアイアール Site-specific nuclease single cell assay targeting gene regulatory elements that silence gene expression
CN105705005B (en) 2013-09-04 2019-11-29 Kws种子欧洲股份公司 The long compacted spore resistance plant of leaf blight
AU2014315335B2 (en) 2013-09-04 2017-08-24 Corteva Agriscience Llc Rapid targeting analysis in crops for determining donor insertion
DK3041498T3 (en) 2013-09-05 2022-05-09 Massachusetts Inst Technology RECONCILIATION OF MICROBIAL POPULATIONS WITH PROGRAMMABLE NUCLEASES
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
WO2015040075A1 (en) 2013-09-18 2015-03-26 Genome Research Limited Genomic screening methods using rna-guided endonucleases
TW201542816A (en) 2013-09-18 2015-11-16 Kymab Ltd Methods, cells & organisms
CA2924535C (en) 2013-09-23 2022-12-13 Shiva Prasad KOTHA Nanoparticle-mediated gene delivery, genomic editing and ligand-targete d modification in various cell populations
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
US10822606B2 (en) 2013-09-27 2020-11-03 The Regents Of The University Of California Optimized small guide RNAs and methods of use
WO2015048707A2 (en) 2013-09-30 2015-04-02 Regents Of The University Of Minnesota Conferring resistance to geminiviruses in plants using crispr/cas systems
EP3052659A4 (en) 2013-09-30 2017-06-14 The Regents of the University of California Identification of cxcr8, a novel chemokine receptor
EP3052110A4 (en) 2013-10-02 2017-07-12 Northeastern University Methods and compositions for generation of developmentally-incompetent eggs in recipients of nuclear genetic transfer
JP5774657B2 (en) 2013-10-04 2015-09-09 国立大学法人京都大学 Method for genetic modification of mammals using electroporation
WO2015054315A1 (en) 2013-10-07 2015-04-16 Northeastern University Methods and compositions for ex vivo generation of developmentally competent eggs from germ line cells using autologous cell systems
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
WO2015052231A2 (en) 2013-10-08 2015-04-16 Technical University Of Denmark Multiplex editing system
DE102013111099B4 (en) 2013-10-08 2023-11-30 Eberhard Karls Universität Tübingen Medizinische Fakultät Permanent gene correction using nucleotide-modified messenger RNA
WO2015052335A1 (en) 2013-10-11 2015-04-16 Cellectis Methods and kits for detecting nucleic acid sequences of interest using dna-binding protein domain
WO2015057671A1 (en) 2013-10-14 2015-04-23 The Broad Institute, Inc. Artificial transcription factors comprising a sliding domain and uses thereof
CA2927543C (en) 2013-10-15 2021-07-20 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
ES2741308T3 (en) 2013-10-15 2020-02-10 Scripps Research Inst T-cell switches with chimeric antigen receptors and uses thereof
EP3057432B1 (en) 2013-10-17 2018-11-21 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
AU2014337248B2 (en) 2013-10-17 2020-09-24 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CN105916983A (en) 2013-10-25 2016-08-31 塞勒克提斯公司 Design of rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motives
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
EP3065540B1 (en) 2013-11-04 2021-12-15 Corteva Agriscience LLC Optimal maize loci
UA120503C2 (en) 2013-11-04 2019-12-26 Дау Агросайєнсиз Елелсі Optimal maize loci
RU2687369C2 (en) 2013-11-04 2019-05-13 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Universal donor system for directed action on genes
EP3066202B1 (en) 2013-11-04 2021-03-03 Dow AgroSciences LLC Optimal soybean loci
MX362066B (en) 2013-11-04 2019-01-07 Dow Agrosciences Llc Optimal soybean loci.
WO2015069682A2 (en) 2013-11-05 2015-05-14 President And Fellows Of Harvard College Precise microbiota engineering at the cellular level
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
WO2015077058A2 (en) 2013-11-08 2015-05-28 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
WO2015070193A1 (en) 2013-11-11 2015-05-14 Liu Oliver Compositions and methods for targeted gene disruption in prokaryotes
EP3068905A4 (en) 2013-11-11 2017-07-05 Sangamo BioSciences, Inc. Methods and compositions for treating huntington's disease
DK3492593T3 (en) 2013-11-13 2021-11-08 Childrens Medical Center NUCLEASE MEDIATED REGULATION OF GENE EXPRESSION
WO2015073867A1 (en) 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Engineering neural stem cells using homologous recombination
CA2930315A1 (en) 2013-11-18 2015-05-21 Yale University Compositions and methods of using transposons
AU2014350051A1 (en) 2013-11-18 2016-07-07 Crispr Therapeutics Ag CRISPR-Cas system materials and methods
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
WO2015075056A1 (en) 2013-11-19 2015-05-28 Thermo Fisher Scientific Baltics Uab Programmable enzymes for isolation of specific dna fragments
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
CN105960413B (en) 2013-11-20 2020-03-27 泰莱托恩基金会 Artificial DNA-binding proteins and uses thereof
BR112016011169A2 (en) 2013-11-22 2017-09-19 Cellectis METHOD FOR PRODUCING EX VIVO IMMUNE CELLS THAT ARE RESISTANT TO A PURINE ANALOG DRUG, ISOLATED T CELL RESISTANT TO A PURINE ANALOG, PHARMACEUTICAL COMPOSITION AND USE THEREOF
SI3594348T1 (en) 2013-11-22 2022-04-29 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
AU2014351871B2 (en) 2013-11-22 2020-02-13 Cellectis Method for generating batches of allogeneic T-cells with averaged potency
CN103642836A (en) 2013-11-26 2014-03-19 苏州同善生物科技有限公司 Method for establishing fragile X-syndrome non-human primate model on basis of CRISPR gene knockout technology
CN103614415A (en) 2013-11-27 2014-03-05 苏州同善生物科技有限公司 Method for establishing obese rat animal model based on CRISPR (clustered regularly interspaced short palindromic repeat) gene knockout technology
EP3074515B1 (en) 2013-11-28 2018-11-14 Horizon Discovery Limited Somatic haploid human cell line
EP3080143B1 (en) 2013-12-09 2019-02-20 Sangamo Therapeutics, Inc. Methods and compositions for treating hemophilia
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome
CA2932475A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
EP3079725B1 (en) 2013-12-12 2019-10-16 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
CA2932439A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
RU2016128077A (en) 2013-12-12 2018-12-06 Те Брод Инститьют Инк. DELIVERY, APPLICATION AND APPLICATIONS IN THE THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TREATMENT OF CONDITIONED HBV AND VIRAL DISEASES AND DISORDERS
BR112016013520A2 (en) 2013-12-12 2017-10-03 Broad Inst Inc COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS
EP4219699A1 (en) 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2015089277A1 (en) * 2013-12-12 2015-06-18 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
JP6793547B2 (en) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド Optimization Function Systems, methods and compositions for sequence manipulation with the CRISPR-Cas system
JP6542226B2 (en) 2013-12-13 2019-07-10 セレクティス A new method to select algal transformed cells using nucleases
JP2016539653A (en) 2013-12-13 2016-12-22 セレクティス Cas9 nuclease platform for genome manipulation of microalgae
US20150191744A1 (en) 2013-12-17 2015-07-09 University Of Massachusetts Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
PT3083958T (en) 2013-12-19 2019-06-27 Amyris Inc Methods for genomic integration
EP3985124A1 (en) 2013-12-26 2022-04-20 The General Hospital Corporation Multiplex guide rnas
ES2818625T3 (en) 2013-12-30 2021-04-13 Univ Pittsburgh Commonwealth Sys Higher Education Fusion genes associated with progressive prostate cancer
EP3089989B1 (en) 2013-12-31 2020-06-24 The Regents of The University of California Cas9 crystals and methods of use thereof
CN103668472B (en) 2013-12-31 2014-12-24 北京大学 Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system
WO2015105928A1 (en) 2014-01-08 2015-07-16 President And Fellows Of Harvard College Rna-guided gene drives
MX2016009243A (en) 2014-01-14 2017-03-08 Lam Therapeutics Inc Mutagenesis methods.
US10774338B2 (en) 2014-01-16 2020-09-15 The Regents Of The University Of California Generation of heritable chimeric plant traits
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
GB201400962D0 (en) 2014-01-21 2014-03-05 Kloehn Peter C Screening for target-specific affinity binders using RNA interference
US10557146B2 (en) 2014-01-21 2020-02-11 The Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Modified plants
CA2936646A1 (en) 2014-01-24 2015-07-30 North Carolina State University Methods and compositions for sequences guiding cas9 targeting
EP3096609B1 (en) 2014-01-24 2021-09-22 Children's Medical Center Corporation High-throughput mouse model for optimizing antibody affinities
US10354746B2 (en) 2014-01-27 2019-07-16 Georgia Tech Research Corporation Methods and systems for identifying CRISPR/Cas off-target sites
CN104805078A (en) 2014-01-28 2015-07-29 北京大学 Design, synthesis and use of RNA molecule for high-efficiency genome editing
US9850525B2 (en) 2014-01-29 2017-12-26 Agilent Technologies, Inc. CAS9-based isothermal method of detection of specific DNA sequence
US20150291969A1 (en) 2014-01-30 2015-10-15 Chromatin, Inc. Compositions for reduced lignin content in sorghum and improving cell wall digestibility, and methods of making the same
US10233456B2 (en) 2014-01-30 2019-03-19 The Board Of Trustees Of The University Of Arkansas Method, vectors, cells, seeds and kits for stacking genes into a single genomic site
RU2020104969A (en) 2014-01-31 2020-03-13 Фэктор Байосайенс Инк. METHODS AND PRODUCTS FOR THE PRODUCTION AND DELIVERY OF NUCLEIC ACIDS
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
PT3102673T (en) 2014-02-03 2020-05-21 Sangamo Biosciences Inc Methods and compositions for treatment of a beta thalessemia
WO2015115903A1 (en) 2014-02-03 2015-08-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Site-specific dna break-induced genome editing using engineered nucleases
CA2938669A1 (en) 2014-02-04 2015-08-13 Igenomx International Genomics Corporation Genome fractioning
EP3102680B1 (en) 2014-02-07 2018-12-19 VIB vzw Inhibition of neat1 for treatment of solid tumors
ES2802984T3 (en) 2014-02-11 2021-01-22 Univ Colorado Regents Multiplex Genome Engineering Using CRISPR
EP3105325B1 (en) 2014-02-13 2019-12-04 Takara Bio USA, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
CA2937711C (en) 2014-02-14 2020-10-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
BR112016019068A2 (en) 2014-02-18 2017-10-10 Univ Duke construct, recombinant vector, pharmaceutical composition, method of inhibiting viral replication or expression of a target sequence in a cell infected with a virus, recombinant sau cas9 polypeptide, recombinant sau cas9 construct, recombinant construct for expression of an individual guide and kit
US10041135B2 (en) 2014-02-20 2018-08-07 Dsm Ip Assets B.V. Phage insensitive Streptococcus thermophilus
WO2015124715A1 (en) 2014-02-21 2015-08-27 Cellectis Method for in situ inhibition of regulatory t cells
US20170015994A1 (en) 2014-02-24 2017-01-19 Massachusetts Institute Of Technology Methods for in vivo genome editing
EP3110454B1 (en) 2014-02-24 2020-11-18 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration
JP6521669B2 (en) 2014-02-25 2019-05-29 国立研究開発法人農業・食品産業技術総合研究機構 Plant cell in which mutation is introduced into target DNA, and method for producing the same
CN106232803A (en) 2014-02-27 2016-12-14 孟山都技术公司 For pinpointing compositions and the method for genomic modification
CN103820441B (en) 2014-03-04 2017-05-17 黄行许 Method for human CTLA4 gene specific knockout through CRISPR-Cas9 (clustered regularly interspaced short palindromic repeat) and sgRNA(single guide RNA)for specially targeting CTLA4 gene
CN103820454B (en) 2014-03-04 2016-03-30 上海金卫生物技术有限公司 The method of CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene
EP3114227B1 (en) 2014-03-05 2021-07-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
CN111471674A (en) * 2014-03-05 2020-07-31 国立大学法人神户大学 Method for modifying genome sequence of nucleic acid base for specifically converting target DNA sequence, and molecular complex used therefor
EP3553176A1 (en) 2014-03-10 2019-10-16 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
EP3693384B1 (en) 2014-03-11 2024-01-24 Cellectis Method for generating t-cells compatible for allogenic transplantation
JP2017512767A (en) 2014-03-12 2017-05-25 プレシジョン バイオサイエンシズ,インク. Deletion of dystrophin gene exons using a modified nuclease
WO2015138870A2 (en) 2014-03-13 2015-09-17 The Trustees Of The University Of Pennsylvania Compositions and methods for targeted epigenetic modification
WO2015138855A1 (en) 2014-03-14 2015-09-17 The Regents Of The University Of California Vectors and methods for fungal genome engineering by crispr-cas9
JP6777549B2 (en) 2014-03-14 2020-10-28 サイバス ユーエス エルエルシー Methods and Compositions for Increasing the Efficiency of Target Gene Modification Using Oligonucleotide Mediated Gene Repair
CA2942762C (en) 2014-03-18 2023-10-17 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
US10323073B2 (en) 2014-03-20 2019-06-18 UNIVERSITé LAVAL CRISPR-based methods and products for increasing frataxin levels and uses thereof
CA2939847C (en) 2014-03-21 2023-09-05 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
ES2870592T3 (en) 2014-03-24 2021-10-27 Immco Diagnostics Inc Enhanced antinuclear antibody detection and diagnosis for systemic and non-systemic autoimmune disorders
PT3122878T (en) 2014-03-24 2019-02-01 Translate Bio Inc Mrna therapy for the treatment of ocular diseases
WO2015148670A1 (en) 2014-03-25 2015-10-01 Editas Medicine Inc. Crispr/cas-related methods and compositions for treating hiv infection and aids
EP3122870B1 (en) 2014-03-25 2022-06-29 Ginkgo Bioworks Inc. Methods and genetic systems for cell engineering
WO2015148860A1 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating beta-thalassemia
CA2943794C (en) 2014-03-26 2023-01-24 University Of Maryland, College Park Targeted genome editing in zygotes of domestic large animals
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
CN106456804B (en) 2014-03-28 2020-03-17 阿波森斯有限公司 Compounds and methods for transmembrane delivery of molecules
US9993563B2 (en) 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
WO2015153791A1 (en) 2014-04-01 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
WO2015153760A2 (en) 2014-04-01 2015-10-08 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a nervous system disorder
EP3498845B1 (en) 2014-04-01 2022-06-22 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
EP3126495A1 (en) 2014-04-02 2017-02-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
US10507232B2 (en) 2014-04-02 2019-12-17 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
US20170022499A1 (en) 2014-04-03 2017-01-26 Massachusetts Institute Of Techology Methods and compositions for the production of guide rna
CN103911376B (en) 2014-04-03 2017-02-15 黄行许 CRISPR-Cas9 targeted knockout hepatitis b virus cccDNA and specific sgRNA thereof
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
WO2015157070A2 (en) 2014-04-09 2015-10-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
WO2015157534A1 (en) 2014-04-10 2015-10-15 The Regents Of The University Of California Methods and compositions for using argonaute to modify a single stranded target nucleic acid
AU2015245469B2 (en) 2014-04-11 2020-11-12 Cellectis Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
CN106536739B (en) 2014-04-14 2021-08-03 内梅西斯生物有限公司 Therapeutic agents
US20170029805A1 (en) 2014-04-14 2017-02-02 Maxcyte, Inc. Methods and compositions for modifying genomic dna
CN103923911B (en) 2014-04-14 2016-06-08 上海金卫生物技术有限公司 The method of CRISPR-Cas9 specific knockdown CCR5 gene and the sgRNA for selectively targeted CCR5 gene
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
GB201406970D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
SG10201809157VA (en) 2014-04-18 2018-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
CN105039399A (en) 2014-04-23 2015-11-11 复旦大学 Pluripotent stem cell-hereditary cardiomyopathy cardiac muscle cell and preparation method thereof
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
WO2015163733A1 (en) 2014-04-24 2015-10-29 Institute For Basic Science A method of selecting a nuclease target sequence for gene knockout based on microhomology
US20170044500A1 (en) 2014-04-24 2017-02-16 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CA2946987A1 (en) 2014-04-28 2015-11-05 Joseph F. Petolino Haploid maize transformation
WO2015168158A1 (en) 2014-04-28 2015-11-05 Fredy Altpeter Targeted genome editing to modify lignin biosynthesis and cell wall composition
MX2016014066A (en) 2014-04-28 2017-05-03 Recombinetics Inc Multiplex gene editing in swine.
GB2540694A (en) 2014-04-29 2017-01-25 Seattle Children's Hospital (Dba Seattle Children's Res Institute) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
WO2015165276A1 (en) 2014-04-30 2015-11-05 清华大学 Reagent kit using tale transcriptional repressor for modular construction of synthetic gene line in mammalian cell
CN104178506B (en) 2014-04-30 2017-03-01 清华大学 TALER albumen is by sterically hindered performance transcripting suppressioning action and its application
EP3156493B1 (en) 2014-04-30 2020-05-06 Tsinghua University Use of tale transcriptional repressor for modular construction of synthetic gene line in mammalian cell
WO2015168404A1 (en) 2014-04-30 2015-11-05 Massachusetts Institute Of Technology Toehold-gated guide rna for programmable cas9 circuitry with rna input
EP3137120A4 (en) 2014-05-01 2018-03-14 University Of Washington In vivo gene engineering with adenoviral vectors
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2015171603A1 (en) 2014-05-06 2015-11-12 Two Blades Foundation Methods for producing plants with enhanced resistance to oomycete pathogens
RU2691102C2 (en) 2014-05-08 2019-06-11 Сангамо Байосайенсиз, Инк. Methods and compositions for treating huntington's disease
US20170266197A1 (en) 2014-05-09 2017-09-21 Indiana University Research And Technology Corporation Methods and compositions for treating hepatitis b virus infections
WO2015171894A1 (en) 2014-05-09 2015-11-12 The Regents Of The University Of California Methods for selecting plants after genome editing
WO2015168800A1 (en) 2014-05-09 2015-11-12 UNIVERSITé LAVAL Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
CA2947622A1 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Genome editing methods and compositions for prevention or treatment of a disease
CN103981211B (en) 2014-05-16 2016-07-06 安徽省农业科学院水稻研究所 A kind of breeding method formulating cleistogamous rice material
US20170088819A1 (en) 2014-05-16 2017-03-30 Vrije Universiteit Brussel Genetic correction of myotonic dystrophy type 1
CN104017821B (en) 2014-05-16 2016-07-06 安徽省农业科学院水稻研究所 Directed editor's grain husk shell color determines the gene OsCHI method formulating brown shell rice material
CN103981212B (en) 2014-05-16 2016-06-01 安徽省农业科学院水稻研究所 The clever shell color of the rice varieties of yellow grain husk shell is changed into the breeding method of brown
CN104004782B (en) 2014-05-16 2016-06-08 安徽省农业科学院水稻研究所 A kind of breeding method extending paddy rice breeding time
CA2949697A1 (en) 2014-05-20 2015-11-26 Regents Of The University Of Minnesota Method for editing a genetic sequence
CA2852593A1 (en) 2014-05-23 2015-11-23 Universite Laval Methods for producing dopaminergic neurons and uses thereof
WO2015183885A1 (en) 2014-05-27 2015-12-03 Dana-Farber Cancer Institute, Inc. Methods and compositions for perturbing gene expression in hematopoietic stem cell lineages in vivo
CN106687601A (en) 2014-05-28 2017-05-17 株式会社图尔金 Method for sensitive detection of target DNA using target-specific nuclease
EP3149170A1 (en) 2014-05-30 2017-04-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods to treat latent viral infections
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
CN106661128A (en) 2014-06-06 2017-05-10 加州生物医学研究所 Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
HUE049776T2 (en) 2014-06-06 2020-10-28 Regeneron Pharma Methods and compositions for modifying a targeted locus
EP3155018A4 (en) 2014-06-06 2018-01-10 The California Institute for Biomedical Research Constant region antibody fusion proteins and compositions thereof
US11030531B2 (en) 2014-06-06 2021-06-08 Trustees Of Boston University DNA recombinase circuits for logical control of gene expression
WO2015188094A1 (en) 2014-06-06 2015-12-10 President And Fellows Of Harvard College Methods for targeted modification of genomic dna
CN104004778B (en) 2014-06-06 2016-03-02 重庆高圣生物医药有限责任公司 Targeting knockout carrier containing CRISPR/Cas9 system and adenovirus thereof and application
US11274302B2 (en) 2016-08-17 2022-03-15 Diacarta Ltd Specific synthetic chimeric Xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
MY187588A (en) 2014-06-11 2021-09-30 Univ Duke Compositions and methods for rapid and dynamic flux control using synthetic metabolic valves
EP3155098A4 (en) 2014-06-11 2018-01-03 Howard, Tom E. FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION AND RELATED CDNAs, COMPOSITIONS, METHODS AND SYSTEMS
WO2015191911A2 (en) 2014-06-12 2015-12-17 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
WO2015189693A1 (en) 2014-06-12 2015-12-17 King Abdullah University Of Science And Technology Targeted viral-mediated plant genome editing using crispr/cas9
WO2015195547A1 (en) 2014-06-16 2015-12-23 University Of Washington Methods for controlling stem cell potential and for gene editing in stem cells
AU2015277369B2 (en) 2014-06-16 2021-08-19 The Johns Hopkins University Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
JP2017518082A (en) 2014-06-17 2017-07-06 ポセイダ セラピューティクス, インコーポレイテッド Methods and uses for directing proteins to specific loci in the genome
WO2015193858A1 (en) 2014-06-20 2015-12-23 Cellectis Potatoes with reduced granule-bound starch synthase
SG11201610481YA (en) 2014-06-23 2017-01-27 Regeneron Pharma Nuclease-mediated dna assembly
KR102598819B1 (en) 2014-06-23 2023-11-03 더 제너럴 하스피탈 코포레이션 Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
WO2015200555A2 (en) 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
GB201411344D0 (en) 2014-06-26 2014-08-13 Univ Leicester Cloning
EP3161128B1 (en) 2014-06-26 2018-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
JP6342491B2 (en) 2014-06-30 2018-06-13 花王株式会社 Adhesive sheet for cooling
US20170152787A1 (en) 2014-06-30 2017-06-01 Nissan Motor Co., Ltd. Internal combustion engine
US20180187172A1 (en) 2014-07-01 2018-07-05 Board Of Regents, The University Of Texas System Regulated gene expression from viral vectors
CN114344275A (en) 2014-07-02 2022-04-15 川斯勒佰尔公司 Encapsulation of messenger RNA
WO2016007604A1 (en) 2014-07-09 2016-01-14 Gen9, Inc. Compositions and methods for site-directed dna nicking and cleaving
EP2966170A1 (en) 2014-07-10 2016-01-13 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - HBV inactivation
BR122023024818A2 (en) 2014-07-11 2023-12-26 Pioneer Hi-Bred International, Inc. GUIDE RNA, POLYNUCLEOTIDE AND RIBONUCLEOPROTEIN COMPLEX
AU2015288157A1 (en) 2014-07-11 2017-01-19 E. I. Du Pont De Nemours And Company Compositions and methods for producing plants resistant to glyphosate herbicide
CN104109687A (en) 2014-07-14 2014-10-22 四川大学 Construction and application of Zymomonas mobilis CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-association proteins)9 system
EP3169776A4 (en) 2014-07-14 2018-07-04 The Regents of The University of California Crispr/cas transcriptional modulation
CN107075483A (en) 2014-07-15 2017-08-18 朱诺治疗学股份有限公司 The engineered cell treated for adoptive cellular
US9944933B2 (en) 2014-07-17 2018-04-17 Georgia Tech Research Corporation Aptamer-guided gene targeting
EP3193944B1 (en) 2014-07-17 2021-04-07 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating cells containing fusion genes
US20160053304A1 (en) 2014-07-18 2016-02-25 Whitehead Institute For Biomedical Research Methods Of Depleting Target Sequences Using CRISPR
US10975406B2 (en) 2014-07-18 2021-04-13 Massachusetts Institute Of Technology Directed endonucleases for repeatable nucleic acid cleavage
US20160053272A1 (en) 2014-07-18 2016-02-25 Whitehead Institute For Biomedical Research Methods Of Modifying A Sequence Using CRISPR
BR112017001183A2 (en) 2014-07-21 2017-11-28 Novartis Ag cancer treatment using humanized anti-bcma chimeric antigen receptor
CA2955382C (en) 2014-07-21 2023-07-18 Illumina, Inc. Polynucleotide enrichment using crispr-cas systems
WO2016013183A1 (en) 2014-07-22 2016-01-28 パナソニックIpマネジメント株式会社 Composite magnetic material, coil component using same, and composite magnetic material manufacturing method
WO2016012552A1 (en) 2014-07-24 2016-01-28 Dsm Ip Assets B.V. Phage resistant lactic acid bacteria
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
WO2016014837A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
US20170211048A1 (en) 2014-07-25 2017-07-27 Boehringer Ingelheim International Gmbh Enhanced reprogramming to ips cells
EP3194600B1 (en) 2014-07-26 2019-08-28 Consiglio Nazionale Delle Ricerche Compositions and methods for treatment of muscular dystrophy
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
FR3024464A1 (en) 2014-07-30 2016-02-05 Centre Nat Rech Scient TARGETING NON-VIRAL INTEGRATIVE VECTORS IN NUCLEOLAR DNA SEQUENCES IN EUKARYOTES
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US9850521B2 (en) 2014-08-01 2017-12-26 Agilent Technologies, Inc. In vitro assay buffer for Cas9
EP2982758A1 (en) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
US20160076093A1 (en) 2014-08-04 2016-03-17 University Of Washington Multiplex homology-directed repair
EP3178935B1 (en) 2014-08-06 2022-12-21 Toolgen Incorporated Genome editing using campylobacter jejuni crispr/cas system-derived rgen
CN106536721B (en) 2014-08-06 2020-12-04 车医科学大学校产学协力团 Nuclease-mediated generation of immune-compatible cells by editing HLA-encoding genes
US9932566B2 (en) 2014-08-07 2018-04-03 Agilent Technologies, Inc. CIS-blocked guide RNA
US11299732B2 (en) 2014-08-07 2022-04-12 The Rockefeller University Compositions and methods for transcription-based CRISPR-Cas DNA editing
EP3180034B1 (en) 2014-08-11 2022-04-20 The Board of Regents of The University of Texas System Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
US10513711B2 (en) 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
WO2016025759A1 (en) 2014-08-14 2016-02-18 Shen Yuelei Dna knock-in system
CN104178461B (en) 2014-08-14 2017-02-01 北京蛋白质组研究中心 CAS9-carrying recombinant adenovirus and application thereof
US9879270B2 (en) 2014-08-15 2018-01-30 Wisconsin Alumni Research Foundation Constructs and methods for genome editing and genetic engineering of fungi and protists
ES2780904T3 (en) 2014-08-17 2020-08-27 Broad Inst Inc Genomic editing using Cas9 nickases
WO2016028887A1 (en) 2014-08-19 2016-02-25 Pacific Biosciences Of California, Inc. Compositions and methods for enrichment of nucleic acids
KR20170036801A (en) 2014-08-19 2017-04-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Rna-guided systems for probing and mapping of nucleic acids
WO2016026444A1 (en) 2014-08-20 2016-02-25 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences Biomarker and therapeutic target for triple negative breast cancer
KR101946180B1 (en) 2014-08-25 2019-02-08 지니위브 바이오사이언시스, 인코포레이티드 Non-replicative transduction particles and transduction particle-based reporter systems
CN107207573A (en) 2014-08-26 2017-09-26 加利福尼亚大学董事会 Super quick ABA acceptors
CA2959070C (en) 2014-08-27 2020-11-10 Caribou Biosciences, Inc. Methods for increasing cas9-mediated engineering efficiency
WO2016033298A1 (en) 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
EP3188746A4 (en) 2014-09-05 2018-05-02 The Johns Hopkins University Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
EP3189140B1 (en) 2014-09-05 2019-10-23 Vilnius University Programmable rna shredding by the type iii-a crispr-cas system of streptococcus thermophilus
US20170298450A1 (en) 2014-09-10 2017-10-19 The Regents Of The University Of California Reconstruction of ancestral cells by enzymatic recording
RU2017112324A (en) 2014-09-12 2018-10-15 Пайонир Хай-Бред Интернэшнл, Инк. CREATION OF WEBSITES OF SITE-SPECIFIC INTEGRATION FOR COMPLEX SIGNS LOCUSES IN CORN AND SOY, AND ALSO WAYS OF APPLICATION
EP3878948A1 (en) 2014-09-16 2021-09-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
US9738646B2 (en) 2014-09-16 2017-08-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
WO2016049024A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
PT3198018T (en) 2014-09-24 2021-02-24 Hope City Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016046635A1 (en) 2014-09-25 2016-03-31 Institut Pasteur Methods for characterizing human papillomavirus associated cervical lesions
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
WO2016054225A1 (en) 2014-09-30 2016-04-07 Stc.Unm Plasmid delivery in the treatment of cancer and other disease states
IL287561B2 (en) 2014-10-01 2024-03-01 Massachusetts Gen Hospital Methods for increasing efficiency of nuclease-induced homology-directed repair
CN107002078A (en) 2014-10-09 2017-08-01 生命技术公司 CRISPR oligonucleotides and gene editing
EP3204399A4 (en) 2014-10-09 2018-04-25 Seattle Children's Hospital, dba Seattle Children's Research Institute Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016057061A2 (en) 2014-10-10 2016-04-14 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo
WO2016061073A1 (en) 2014-10-14 2016-04-21 Memorial Sloan-Kettering Cancer Center Composition and method for in vivo engineering of chromosomal rearrangements
US10428310B2 (en) 2014-10-15 2019-10-01 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
US11174506B2 (en) 2014-10-17 2021-11-16 Howard Hughes Medical Institute Genomic probes
CN104342457A (en) 2014-10-17 2015-02-11 杭州师范大学 Method for targetedly integrating exogenous gene into target gene
BR112017007923B1 (en) 2014-10-17 2023-12-12 The Penn State Research Foundation METHOD FOR PRODUCING GENETIC MANIPULATION MEDIATED BY MULTIPLEX REACTIONS WITH RNA IN A RECEIVING CELL, CONSTRUCTION OF NUCLEIC ACID, EXPRESSION CASSETTE, VECTOR, RECEIVING CELL AND GENETICALLY MODIFIED CELL
MX2017005159A (en) 2014-10-20 2017-08-18 Envirologix Inc Compositions and methods for detecting an rna virus.
WO2016069591A2 (en) 2014-10-27 2016-05-06 The Broad Institute Inc. Compositions, methods and use of synthetic lethal screening
BR112017008938B1 (en) 2014-10-28 2023-09-26 Agrivida, Inc COMPOSITION, EXPRESSION CASSETTE, HOME CARE PRODUCT, METHOD OF REGULATING PROTEASE ACTIVITY AND METHOD OF STORING A PROTEASE IN A MIXTURE
WO2016069910A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Methods for efficient delivery of therapeutic molecules in vitro and in vivo
EP3212165B1 (en) 2014-10-30 2024-02-28 President and Fellows of Harvard College Delivery of negatively charged proteins using cationic lipids
MA40880A (en) 2014-10-30 2017-09-05 Temple Univ Of The Commonwealth RNA-GUIDED ERADICATION OF HUMAN JC VIRUS AND OTHER POLYOMAVIRUSES
EP3212789B1 (en) 2014-10-31 2020-04-22 Massachusetts Institute of Technology Massively parallel combinatorial genetics for crispr
EP3215168B1 (en) 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Altering gene expression in modified t cells and uses thereof
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
CN104404036B (en) 2014-11-03 2017-12-01 赛业(苏州)生物科技有限公司 Conditional gene knockout method based on CRISPR/Cas9 technologies
CN104504304B (en) 2014-11-03 2017-08-25 深圳先进技术研究院 A kind of short palindrome repetitive sequence recognition methods of regular intervals of cluster and device
WO2016072936A1 (en) 2014-11-03 2016-05-12 Nanyang Technological University Novel recombinant expression systems
EP3739047A1 (en) 2014-11-04 2020-11-18 National University Corporation Kobe University Method for modifying genome sequence to introduce specific mutation to targeted dna sequence by base-removal reaction, and molecular complex used therein
WO2016073559A1 (en) 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing
KR102424721B1 (en) * 2014-11-06 2022-07-25 이 아이 듀폰 디 네모아 앤드 캄파니 Peptide-mediated delivery of rna-guided endonuclease into cells
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
CN114438174A (en) 2014-11-11 2022-05-06 伊鲁米那股份有限公司 Polynucleotide amplification using CRISPR-CAS system
CN107532142A (en) 2014-11-11 2018-01-02 应用干细胞有限公司 Mescenchymal stem cell is transformed using homologous recombination
CN107109486B (en) 2014-11-14 2021-08-13 基础科学研究院 Method for detecting off-target sites of genetic scissors in genome
DK3218490T3 (en) 2014-11-15 2019-02-18 Zumutor Biologics Inc DNA BINDING DOMAIN OF CRISPR SYSTEM FOR PRODUCING NON-FUCOSYLED AND PARTICULAR FUCOSYLED PROTEINS
JP6190995B2 (en) 2014-11-17 2017-09-06 国立大学法人 東京医科歯科大学 Simple and highly efficient method for producing genetically modified non-human mammals
WO2016080795A1 (en) 2014-11-19 2016-05-26 기초과학연구원 Method for regulating gene expression using cas9 protein expressed from two vectors
WO2016081924A1 (en) 2014-11-20 2016-05-26 Duke University Compositions, systems and methods for cell therapy
US10227661B2 (en) 2014-11-21 2019-03-12 GeneWeave Biosciences, Inc. Sequence-specific detection and phenotype determination
KR20230070319A (en) 2014-11-21 2023-05-22 리제너론 파마슈티칼스 인코포레이티드 METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs
WO2016086177A2 (en) 2014-11-25 2016-06-02 Drexel University Compositions and methods for hiv quasi-species excision from hiv-1-infected patients
JP6860483B2 (en) 2014-11-26 2021-04-14 テクノロジー イノベーション モメンタム ファンド(イスラエル)リミテッド パートナーシップTechnology Innovation Momentum Fund(israel)Limited Partnership Bacterial gene targeting reduction
US20180105834A1 (en) 2014-11-27 2018-04-19 Institute Of Animal Sciences, Chinese Academy Of Agrigultural Sciences A method of site-directed insertion to h11 locus in pigs by using site-directed cutting system
JP2017535296A (en) 2014-11-27 2017-11-30 ダンツィガー イノベイションズ リミテッドDanziger Innovations Ltd. Nucleic acid constructs for genome editing
GB201421096D0 (en) 2014-11-27 2015-01-14 Imp Innovations Ltd Genome editing methods
CN105695485B (en) 2014-11-27 2020-02-21 中国科学院上海生命科学研究院 Cas9 encoding gene for filamentous fungus Crispr-Cas system and application thereof
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
US20170266320A1 (en) 2014-12-01 2017-09-21 President And Fellows Of Harvard College RNA-Guided Systems for In Vivo Gene Editing
WO2016089433A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
CN104450774A (en) 2014-12-04 2015-03-25 中国农业科学院作物科学研究所 Construction of soybean CRISPR/Cas9 system and application of soybean CRISPR/Cas9 system in soybean gene modification
WO2016090385A1 (en) 2014-12-05 2016-06-09 Applied Stemcell, Inc. Site-directed crispr/recombinase compositions and methods of integrating transgenes
CN104531705A (en) 2014-12-09 2015-04-22 中国农业大学 Method for knocking off animal myostatin gene by using CRISPR-Cas9 system
CN104531704B (en) 2014-12-09 2019-05-21 中国农业大学 Utilize the method for CRISPR-Cas9 system knock-out animal FGF5 gene
KR102656470B1 (en) 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 Genetically modified cells, tissues, and organs for treating disease
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
CN104480144B (en) 2014-12-12 2017-04-12 武汉大学 CRISPR/Cas9 recombinant lentiviral vector for human immunodeficiency virus gene therapy and lentivirus of CRISPR/Cas9 recombinant lentiviral vector
CA2969464A1 (en) 2014-12-12 2016-06-16 Tod M. Woolf Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
JP6814155B2 (en) 2014-12-12 2021-01-13 ジュー,ジェイムズ Methods and compositions for selectively removing cells of interest
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
US10221398B2 (en) 2014-12-16 2019-03-05 C3J Therapeutics, Inc. Compositions of and methods for in vitro viral genome engineering
KR102350405B1 (en) 2014-12-16 2022-01-11 다니스코 유에스 인크. Fungal genome modification systems and methods of use
EP3233095A2 (en) 2014-12-17 2017-10-25 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
PL3234134T3 (en) 2014-12-17 2020-12-28 Proqr Therapeutics Ii B.V. Targeted rna editing
AU2015363113B2 (en) 2014-12-17 2021-03-11 E. I. Du Pont De Nemours And Company Compositions and methods for efficient gene editing in E. coli using guide RNA/Cas endonuclease systems in combination with circular polynucleotide modification templates
WO2016097751A1 (en) 2014-12-18 2016-06-23 The University Of Bath Method of cas9 mediated genome engineering
DK3234133T3 (en) 2014-12-18 2021-02-08 Integrated Dna Tech Inc CRISPR-BASED COMPOSITIONS AND METHODS OF USE
CN104745626B (en) 2014-12-19 2018-05-01 中国航天员科研训练中心 A kind of fast construction method of conditional gene knockout animal model and application
EP3234192B1 (en) 2014-12-19 2021-07-14 The Broad Institute, Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
EP3957745A1 (en) 2014-12-20 2022-02-23 Arc Bio, LLC Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
CN104560864B (en) 2014-12-22 2017-08-11 中国科学院微生物研究所 Utilize the 293T cell lines of the knockout IFN β genes of CRISPR Cas9 system constructings
US10190106B2 (en) 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
US11053271B2 (en) 2014-12-23 2021-07-06 The Regents Of The University Of California Methods and compositions for nucleic acid integration
CN104651398A (en) 2014-12-24 2015-05-27 杭州师范大学 Method for knocking out microRNA gene family by utilizing CRISPR-Cas9 specificity
AU2015101792A4 (en) 2014-12-24 2016-01-28 Massachusetts Institute Of Technology Engineering of systems, methods and optimized enzyme and guide scaffolds for sequence manipulation
WO2016103233A2 (en) 2014-12-24 2016-06-30 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
EP3239298A4 (en) 2014-12-26 2018-06-13 Riken Gene knockout method
CN104498493B (en) 2014-12-30 2017-12-26 武汉大学 The method of CRISPR/Cas9 specific knockdown hepatitis type B viruses and the gRNA for selectively targeted HBV DNA
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
US20180002706A1 (en) 2014-12-30 2018-01-04 University Of South Florida Methods and compositions for cloning into large vectors
JP2018500037A (en) 2014-12-31 2018-01-11 シンセティック ジェノミクス インコーポレーテッド Compositions and methods for highly efficient in vivo genome editing
CN104651399B (en) 2014-12-31 2018-11-16 广西大学 A method of gene knockout being realized in Pig embryos cell using CRISPR/Cas system
DK3242950T3 (en) 2015-01-06 2021-12-20 Dsm Ip Assets Bv CRISPR-CAS SYSTEM FOR A WIRED MUSHROOM MUSHROOM HOST CELL
CN108064280B (en) 2015-01-06 2021-10-29 延世大学校产学协力团 Composition for treating hemophilia A using endonuclease with coagulation factor VIII gene as target
EP3242948B1 (en) 2015-01-06 2021-12-22 DSM IP Assets B.V. A crispr-cas system for a yarrowia host cell
CN104651392B (en) 2015-01-06 2018-07-31 华南农业大学 A method of obtaining temp-sensing sterile line using CRISPR/Cas9 system rite-directed mutagenesis P/TMS12-1
US10619170B2 (en) 2015-01-06 2020-04-14 Dsm Ip Assets B.V. CRISPR-CAS system for a yeast host cell
CN104593422A (en) 2015-01-08 2015-05-06 中国农业大学 Method of cloning reproductive and respiratory syndrome resisting pig
WO2016112242A1 (en) 2015-01-08 2016-07-14 President And Fellows Of Harvard College Split cas9 proteins
CN107406842B (en) 2015-01-09 2021-05-11 生物辐射实验室股份有限公司 Detecting genome editing
CN107250373A (en) 2015-01-12 2017-10-13 麻省理工学院 The gene editing realized is delivered by microfluid
US11208638B2 (en) 2015-01-12 2021-12-28 The Regents Of The University Of California Heterodimeric Cas9 and methods of use thereof
WO2016112963A1 (en) 2015-01-13 2016-07-21 Riboxx Gmbh Delivery of biomolecules into cells
MA41349A (en) 2015-01-14 2017-11-21 Univ Temple RNA-GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER ASSOCIATED HERPES VIRUSES
WO2016115326A1 (en) 2015-01-15 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating genome editing
CN104611370A (en) 2015-01-16 2015-05-13 深圳市科晖瑞生物医药有限公司 Method for rejecting B2M (beta 2-microglobulin) gene segment
EA201791633A1 (en) 2015-01-19 2018-03-30 Инститьют Оф Дженетикс Энд Девелопментал Байолоджи, Чайниз Акэдеми Оф Сайенсиз METHOD OF PRECISE MODIFICATION OF A PLANT BY MEANS OF TRANSIENT EXPRESSION OF THE GENE
CN104725626B (en) 2015-01-22 2016-06-29 漳州亚邦化学有限公司 A kind of preparation method of the unsaturated-resin suitable in artificial quartz in lump
CN105821072A (en) 2015-01-23 2016-08-03 深圳华大基因研究院 CRISPR-Cas9 system used for assembling DNA and DNA assembly method
WO2016123071A1 (en) 2015-01-26 2016-08-04 Cold Spring Harbor Laboratory Methods of identifying essential protein domains
CN104561095B (en) 2015-01-27 2017-08-22 深圳市国创纳米抗体技术有限公司 A kind of preparation method for the transgenic mice that can produce growth factor of human nerve
US10059940B2 (en) 2015-01-27 2018-08-28 Minghong Zhong Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
WO2016123243A1 (en) 2015-01-28 2016-08-04 The Regents Of The University Of California Methods and compositions for labeling a single-stranded target nucleic acid
KR20170126875A (en) 2015-01-28 2017-11-20 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 CRISPR hybrid DNA / RNA polynucleotides and methods of use
EP3798302A1 (en) 2015-01-29 2021-03-31 Meiogenix Method for inducing targeted meiotic recombinations
EP3250693B2 (en) 2015-01-30 2023-12-20 The Regents of The University of California Protein delivery in primary hematopoietic cells
RS61924B1 (en) 2015-02-02 2021-06-30 Meiragtx Uk Ii Ltd Regulation of gene expression by aptamer-mediated modulation of alternative splicing
CN104593418A (en) 2015-02-06 2015-05-06 中国医学科学院医学实验动物研究所 Method for establishing humanized rat drug evaluation animal model
EP3256487A4 (en) 2015-02-09 2018-07-18 Duke University Compositions and methods for epigenome editing
KR101584933B1 (en) 2015-02-10 2016-01-13 성균관대학교산학협력단 Recombinant vector for inhibiting antibiotic resistance and uses thereof
WO2016130697A1 (en) 2015-02-11 2016-08-18 Memorial Sloan Kettering Cancer Center Methods and kits for generating vectors that co-express multiple target molecules
CN104928321B (en) 2015-02-12 2018-06-01 中国科学院西北高原生物研究所 A kind of scale loss zebra fish pattern and method for building up by Crispr/Cas9 inductions
CN104726494B (en) 2015-02-12 2018-10-23 中国人民解放军第二军医大学 The method that CRISPR-Cas9 technologies build chromosome translocation stem cell and animal model
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
US20160244784A1 (en) 2015-02-15 2016-08-25 Massachusetts Institute Of Technology Population-Hastened Assembly Genetic Engineering
WO2016132122A1 (en) 2015-02-17 2016-08-25 University Of Edinburgh Assay construct
WO2016133165A1 (en) 2015-02-19 2016-08-25 国立大学法人徳島大学 METHOD FOR TRANSFERRING Cas9 mRNA INTO MAMMALIAN FERTILIZED EGG BY ELECTROPORATION
SG11201706767RA (en) 2015-02-23 2017-09-28 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
WO2016137949A1 (en) 2015-02-23 2016-09-01 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
CA2985991A1 (en) 2015-02-25 2016-09-01 Andrew Mark CIGAN Composition and methods for regulated expression of a guide rna/cas endonuclease complex
KR20160103953A (en) 2015-02-25 2016-09-02 연세대학교 산학협력단 Method for target DNA enrichment using CRISPR system
WO2016135507A1 (en) 2015-02-27 2016-09-01 University Of Edinburgh Nucleic acid editing systems
CN104805099B (en) 2015-03-02 2018-04-13 中国人民解放军第二军医大学 A kind of nucleic acid molecules and its expression vector of safe coding Cas9 albumen
KR102598856B1 (en) 2015-03-03 2023-11-07 더 제너럴 하스피탈 코포레이션 Engineered CRISPR-Cas9 nuclease with altered PAM specificity
CN104673816A (en) 2015-03-05 2015-06-03 广东医学院 PCr-NHEJ (non-homologous end joining) carrier as well as construction method of pCr-NHEJ carrier and application of pCr-NHEJ carrier in site-specific knockout of bacterial genes
CN104651401B (en) 2015-03-05 2019-03-08 东华大学 A kind of method that mir-505 diallele knocks out
EP3268044A2 (en) 2015-03-11 2018-01-17 The Broad Institute Inc. Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
US20160264934A1 (en) 2015-03-11 2016-09-15 The General Hospital Corporation METHODS FOR MODULATING AND ASSAYING m6A IN STEM CELL POPULATIONS
GB201504223D0 (en) 2015-03-12 2015-04-29 Genome Res Ltd Biallelic genetic modification
JP2018507705A (en) 2015-03-12 2018-03-22 中国科学院遺▲伝▼与▲発▼育生物学研究所Institute of Genetics and Developmental Biology, Chinese Academy of Sciences Method for increasing the resistance of plants to invading DNA viruses
EP3268472B1 (en) 2015-03-13 2021-05-05 The Jackson Laboratory A three-component crispr/cas complex system and uses thereof
CN106032540B (en) 2015-03-16 2019-10-25 中国科学院上海生命科学研究院 Gland relevant viral vector building of CRISPR/Cas9 endonuclease enzyme system and application thereof
AR103926A1 (en) 2015-03-16 2017-06-14 Inst Genetics & Dev Biolog Cas METHOD FOR MAKING MODIFICATIONS DIRECTED SITE IN THE GENOMA OF A PLANT USING NON-HEREDABLE MATERIALS
WO2016149547A1 (en) 2015-03-17 2016-09-22 Bio-Rad Laboratories, Inc. Detection of genome editing
WO2016149484A2 (en) 2015-03-17 2016-09-22 Temple University Of The Commonwealth System Of Higher Education Compositions and methods for specific reactivation of hiv latent reservoir
MA41382A (en) 2015-03-20 2017-11-28 Univ Temple GENE EDITING BASED ON THE TAT-INDUCED CRISPR / ENDONUCLEASE SYSTEM
WO2016150855A1 (en) 2015-03-20 2016-09-29 Danmarks Tekniske Universitet Crispr/cas9 based engineering of actinomycetal genomes
CN104726449A (en) 2015-03-23 2015-06-24 国家纳米科学中心 CRISPR-Cas9 system for preventing and/or treating HIV, as well as preparation method and application thereof
CN106148416B (en) 2015-03-24 2019-12-17 华东师范大学 Method for breeding Cyp gene knockout rat and method for preparing liver microsome thereof
US20180112213A1 (en) 2015-03-25 2018-04-26 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
US20160281111A1 (en) 2015-03-26 2016-09-29 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
CA2981509A1 (en) 2015-03-30 2016-10-06 The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La Compositions comprising talens and methods of treating hiv
JP2018513681A (en) 2015-03-31 2018-05-31 エクセリゲン サイエンティフィック, インコーポレイテッドExeligen Scientific, Inc. Cas9 retroviral integrase and Cas9 recombinase system for targeted integration of DNA sequences into the genome of a cell or organism
EP3277816B1 (en) 2015-04-01 2020-06-17 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
CA3000187A1 (en) 2015-04-02 2016-10-06 Agenovir Corporation Gene delivery methods and compositions
US20170166928A1 (en) 2015-04-03 2017-06-15 Whitehead Institute For Biomedical Research Compositions And Methods For Genetically Modifying Yeast
EP3277823B1 (en) 2015-04-03 2023-09-13 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
CN106434737A (en) 2015-04-03 2017-02-22 内蒙古中科正标生物科技有限责任公司 CRISPR/Cas9 technology-based monocotyledon gene knockout vector and application thereof
EP3280803B1 (en) 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
WO2016164797A1 (en) 2015-04-08 2016-10-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activatable crispr/cas9 for spatial and temporal control of genome editing
EP3284749A4 (en) 2015-04-13 2018-11-14 The University of Tokyo Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene
US10155938B2 (en) 2015-04-14 2018-12-18 City Of Hope Coexpression of CAS9 and TREX2 for targeted mutagenesis
GB201506509D0 (en) 2015-04-16 2015-06-03 Univ Wageningen Nuclease-mediated genome editing
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
EP3286322A1 (en) 2015-04-21 2018-02-28 Novartis AG Rna-guided gene editing system and uses thereof
CN104762321A (en) 2015-04-22 2015-07-08 东北林业大学 Knockout vector construction method based on CRISPR/Cas9 system target knockout KHV gene and crNRA prototype thereof
CN104805118A (en) 2015-04-22 2015-07-29 扬州大学 Method for targeted knockout of specific gene of Suqin yellow chicken embryonic stem cell
US11180793B2 (en) 2015-04-24 2021-11-23 Editas Medicine, Inc. Evaluation of Cas9 molecule/guide RNA molecule complexes
CN107614012A (en) 2015-04-24 2018-01-19 加利福尼亚大学董事会 Using the cell detection of engineering, monitoring or treatment disease or the system of the patient's condition and preparation and use their method
US11268158B2 (en) 2015-04-24 2022-03-08 St. Jude Children's Research Hospital, Inc. Assay for safety assessment of therapeutic genetic manipulations, gene therapy vectors and compounds
JP6851319B2 (en) 2015-04-27 2021-03-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Dual AAV vector system for CRISPR / Cas9 mediated modification of human disease
US11104897B2 (en) 2015-04-27 2021-08-31 Genethon Compositions and methods for the treatment of nucleotide repeat expansion disorders
EP3087974A1 (en) 2015-04-29 2016-11-02 Rodos BioTarget GmbH Targeted nanocarriers for targeted drug delivery of gene therapeutics
EP4008780A1 (en) 2015-04-30 2022-06-08 The Trustees of Columbia University in the City of New York Gene therapy for autosomal dominant diseases
WO2016176404A1 (en) 2015-04-30 2016-11-03 The Brigham And Women's Hospital, Inc. Methods and kits for cloning-free genome editing
WO2016179038A1 (en) 2015-05-01 2016-11-10 Spark Therapeutics, Inc. ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE
DK3289076T3 (en) 2015-05-01 2022-01-17 Prec Biosciences Inc PRECISE DELETION OF CHROMOSOMAL SEQUENCES IN VIVO
CN104894068A (en) 2015-05-04 2015-09-09 南京凯地生物科技有限公司 Method for preparing CAR-T cell by CRISPR/Cas9
CN108026566A (en) 2015-05-04 2018-05-11 特拉维夫大学拉莫特有限公司 For making the method and kit of DNA fragmentation
CN114099712A (en) 2015-05-06 2022-03-01 斯尼普技术有限公司 Altering microbial population and improving microbial populations
GB2531454A (en) 2016-01-10 2016-04-20 Snipr Technologies Ltd Recombinogenic nucleic acid strands in situ
EP3763814A1 (en) 2015-05-08 2021-01-13 The Children's Medical Center Corporation Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
WO2016182959A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2016183236A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hiv infection and aids
KR101785847B1 (en) 2015-05-12 2017-10-17 연세대학교 산학협력단 Targeted genome editing based on CRISPR/Cas9 system using short linearized double-stranded DNA
IL284707B2 (en) 2015-05-12 2024-01-01 Sangamo Therapeutics Inc Nuclease-mediated regulation of gene expression
WO2016183402A2 (en) 2015-05-13 2016-11-17 President And Fellows Of Harvard College Methods of making and using guide rna for use with cas9 systems
CN105886498A (en) 2015-05-13 2016-08-24 沈志荣 Method for specifically knocking out human PCSK9 gene by virtue of CRISPR-Cas9 and sgRNA for specifically targeting PCSK9 gene
WO2016181357A1 (en) 2015-05-13 2016-11-17 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
US20180119174A1 (en) 2015-05-13 2018-05-03 Seattle Children's Hospita (dba Seattle Children's Research Institute Enhancing endonuclease based gene editing in primary cells
US20180291372A1 (en) 2015-05-14 2018-10-11 Massachusetts Institute Of Technology Self-targeting genome editing system
CN107614680A (en) 2015-05-14 2018-01-19 南加利福尼亚大学 Utilize the optimization gene editing of recombinant nucleic acid inscribe enzyme system
EP3294880A4 (en) 2015-05-15 2018-12-26 Dharmacon, Inc. Synthetic single guide rna for cas9-mediated gene editing
MX2017014560A (en) 2015-05-15 2018-03-01 Pioneer Hi Bred Int Rapid characterization of cas endonuclease systems, pam sequences and guide rna elements.
AU2016265255B2 (en) 2015-05-16 2022-03-17 Genzyme Corporation Gene editing of deep intronic mutations
CN104846010B (en) 2015-05-18 2018-07-06 安徽省农业科学院水稻研究所 A kind of method for deleting transgenic paddy rice riddled basins
US10662437B2 (en) 2015-05-18 2020-05-26 King Abdullah University Of Science And Technology Method of inhibiting plant virus pathogen infections by CRISPR/Cas9-mediated interference
EP3095870A1 (en) 2015-05-19 2016-11-23 Kws Saat Se Methods for the in planta transformation of plants and manufacturing processes and products based and obtainable therefrom
CN106011104B (en) 2015-05-21 2019-09-27 清华大学 Gene editing and expression regulation method are carried out using Cas system is split
US20160340622A1 (en) 2015-05-22 2016-11-24 Nabil Radi Abdou Bar Soap Anchoring Core
WO2016187904A1 (en) 2015-05-22 2016-12-01 深圳市第二人民医院 Method for pig cmah gene specific knockout by means of crispr-cas9 and sgrna for specially targeting cmah gene
CN105518135B (en) 2015-05-22 2020-11-24 深圳市第二人民医院 Method for specifically knocking out pig CMAH gene by CRISPR-Cas9 and sgRNA for specifically targeting CMAH gene
WO2016187717A1 (en) 2015-05-26 2016-12-01 Exerkine Corporation Exosomes useful for genome editing
US20180148711A1 (en) 2015-05-28 2018-05-31 Coda Biotherapeutics, Inc. Genome editing vectors
CN104894075B (en) 2015-05-28 2019-08-06 华中农业大学 CRISPR/Cas9 and Cre/lox system editor's Pseudorabies virus genome prepares vaccine approach and application
CN105624146B (en) 2015-05-28 2019-02-15 中国科学院微生物研究所 Molecular cloning method based on CRISPR/Cas9 and brewing yeast cell endogenous homologous recombination
CA3000182A1 (en) 2015-05-29 2016-12-08 Agenovir Corporation Methods and compositions for treating cells for transplant
US20160346362A1 (en) 2015-05-29 2016-12-01 Agenovir Corporation Methods and compositions for treating cytomegalovirus infections
WO2016196499A1 (en) 2015-05-29 2016-12-08 Clark Atlanta University Human cell lines mutant for zic2
GB2543873A (en) 2015-05-29 2017-05-03 Agenovir Corp Compositions and methods for cell targeted HPV treatment
US20160350476A1 (en) 2015-05-29 2016-12-01 Agenovir Corporation Antiviral methods and compositions
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
CN108026536A (en) 2015-05-29 2018-05-11 北卡罗来纳州立大学 Use the method for CRISPR nucleic acid screening bacterium, archeobacteria, algae and yeast
JP2018516983A (en) 2015-05-29 2018-06-28 アジェノビア コーポレーション Compositions and methods for treating viral infections
EP3302709B1 (en) 2015-06-01 2021-05-19 Temple University - Of The Commonwealth System of Higher Education Methods and compositions for rna-guided treatment of hiv infection
WO2016191869A1 (en) 2015-06-01 2016-12-08 The Hospital For Sick Children Delivery of structurally diverse polypeptide cargo into mammalian cells by a bacterial toxin
CN105112445B (en) 2015-06-02 2018-08-10 广州辉园苑医药科技有限公司 A kind of miR-205 gene knockout kits based on CRISPR-Cas9 gene Knockouts
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
EP3303585A4 (en) 2015-06-03 2018-10-31 Board of Regents of the University of Nebraska Dna editing using single-stranded dna
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
US10626393B2 (en) 2015-06-04 2020-04-21 Arbutus Biopharma Corporation Delivering CRISPR therapeutics with lipid nanoparticles
CA3001683A1 (en) 2015-06-05 2016-12-08 The Regents Of The University Of California Methods and compositions for generating crispr/cas guide rnas
CN105039339B (en) 2015-06-05 2017-12-19 新疆畜牧科学院生物技术研究所 A kind of method of specific knockdown sheep FecB genes with RNA mediations and its special sgRNA
WO2016201047A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
WO2016198500A1 (en) 2015-06-10 2016-12-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for rna-guided treatment of human cytomegalovirus (hcmv) infection
CN107912047A (en) 2015-06-10 2018-04-13 弗门尼舍有限公司 For screening the cell line of odorant agent and fragrant acceptor
US20160362667A1 (en) 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
EP3307770B1 (en) 2015-06-10 2020-05-27 Firmenich SA Method of identifying musk compounds
WO2016197360A1 (en) 2015-06-11 2016-12-15 深圳市第二人民医院 Method for specific knockout of swine gfra1 gene using crispr-cas9 specificity, and sgrna used for specifically targeting gfra1 gene
WO2016197356A1 (en) 2015-06-11 2016-12-15 深圳市第二人民医院 Method for knockout of swine sla-2 gene using crispr-cas9 specificity, and sgrna used for specifically targeting sla-2 gene
CN105492609A (en) 2015-06-11 2016-04-13 深圳市第二人民医院 Method for CRISPR-Cas9 specific knockout of pig GGTA1 gene and sgRNA for specific targeted GGTA1 gene
WO2016197354A1 (en) 2015-06-11 2016-12-15 深圳市第二人民医院 Crispr-cas9 method for specific knockout of swine pdx1 gene and sgrna for use in targeting specifically pdx1 gene
CN105518140A (en) 2015-06-11 2016-04-20 深圳市第二人民医院 Method for pig vWF gene specific knockout through CRISPR-Cas9 and sgRNA for specially targeting vWF gene
CN105518137B (en) 2015-06-11 2021-04-30 深圳市第二人民医院 Method for specifically knocking out pig SALL1 gene by CRISPR-Cas9 and sgRNA for specifically targeting SALL1 gene
CN105518139B (en) 2015-06-11 2021-02-02 深圳市第二人民医院 Method for specifically knocking out pig FGL2 gene by CRISPR-Cas9 and sgRNA for specifically targeting FGL2 gene
WO2016197357A1 (en) 2015-06-11 2016-12-15 深圳市第二人民医院 Method for specific knockout of swine sla-3 gene using crispr-cas9 specificity, and sgrna used for specifically targeting sla-3 gene
CN105593367A (en) 2015-06-11 2016-05-18 深圳市第二人民医院 CRISPR-Cas9 specificity pig SLA-1 gene knockout method and sgRNA used for specific targeting SLA-1 gene
US20180142222A1 (en) 2015-06-12 2018-05-24 The Regents Of The University Of California Reporter cas9 variants and methods of use thereof
GB201510296D0 (en) 2015-06-12 2015-07-29 Univ Wageningen Thermostable CAS9 nucleases
US20180187190A1 (en) 2015-06-12 2018-07-05 Erasmus University Medical Center Rotterdam New crispr assays
AU2016280002B2 (en) 2015-06-15 2022-04-14 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
WO2016205728A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
WO2016205623A1 (en) 2015-06-17 2016-12-22 North Carolina State University Methods and compositions for genome editing in bacteria using crispr-cas9 systems
US11555207B2 (en) 2015-06-17 2023-01-17 The Uab Research Foundation CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
CA2989831A1 (en) 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for genomic editing
EP3666895A1 (en) 2015-06-18 2020-06-17 The Broad Institute, Inc. Novel crispr enzymes and systems
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205688A2 (en) 2015-06-18 2016-12-22 Bowles Robert D Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzymes and systems
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
RU2021120582A (en) 2015-06-18 2021-09-02 Те Брод Инститьют, Инк. CRISPR ENZYME MUTATIONS TO REDUCE NON-TARGET EFFECTS
CN112159321A (en) * 2015-06-22 2021-01-01 拜耳作物科学股份公司 Novel alkynyl-substituted 3-phenylpyrrolidine-2, 4-diones and their use as herbicides
WO2017004279A2 (en) 2015-06-29 2017-01-05 Massachusetts Institute Of Technology Compositions comprising nucleic acids and methods of using the same
GB201511376D0 (en) 2015-06-29 2015-08-12 Ecolab Usa Inc Process for the treatment of produced water from chemical enhanced oil recovery
EP3313989A4 (en) 2015-06-29 2018-12-05 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
JP7033453B2 (en) 2015-06-30 2022-03-10 セレクティス How to Improve NK Cell Functionality by Gene Inactivation Using Specific Endonucleases
JP2018520149A (en) 2015-07-02 2018-07-26 ザ・ジョンズ・ホプキンス・ユニバーシティー CRISPR / CAS9 based treatment
EP3320091B1 (en) 2015-07-06 2020-11-11 DSM IP Assets B.V. Guide rna assembly vector
US20170009242A1 (en) 2015-07-06 2017-01-12 Whitehead Institute For Biomedical Research CRISPR-Mediated Genome Engineering for Protein Depletion
CN105132451B (en) 2015-07-08 2019-07-23 电子科技大学 A kind of single transcriptional units directed modification skeleton carrier of CRISPR/Cas9 and its application
WO2017011519A1 (en) 2015-07-13 2017-01-19 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US20170014449A1 (en) 2015-07-13 2017-01-19 Elwha LLC, a limited liability company of the State of Delaware Site-specific epigenetic editing
WO2017009399A1 (en) 2015-07-13 2017-01-19 Institut Pasteur Improving sequence-specific antimicrobials by blocking dna repair
JP6624743B2 (en) 2015-07-14 2019-12-25 学校法人福岡大学 Site-specific RNA mutagenesis method, target editing guide RNA used therefor, and target RNA-target editing guide RNA complex
WO2017011721A1 (en) 2015-07-15 2017-01-19 Rutgers, The State University Of New Jersey Nuclease-independent targeted gene editing platform and uses thereof
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
US20170020922A1 (en) 2015-07-16 2017-01-26 Batu Biologics Inc. Gene editing for immunological destruction of neoplasia
WO2017015015A1 (en) 2015-07-17 2017-01-26 Emory University Crispr-associated protein from francisella and uses related thereto
WO2017015101A1 (en) 2015-07-17 2017-01-26 University Of Washington Methods for maximizing the efficiency of targeted gene correction
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US10676735B2 (en) 2015-07-22 2020-06-09 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
AU2016297167A1 (en) 2015-07-23 2018-02-22 Mayo Foundation For Medical Education And Research Editing mitochondrial DNA
US20180360994A1 (en) 2015-07-25 2018-12-20 Habib Frost System, device and a method for providing a therapy or a cure for cancer and other pathological states
CN106399360A (en) 2015-07-27 2017-02-15 上海药明生物技术有限公司 FUT8 gene knockout method based on CRISPR technology
JP6937740B2 (en) 2015-07-28 2021-09-22 ダニスコ・ユーエス・インク Genome editing system and usage
CN105063061B (en) 2015-07-28 2018-10-30 华南农业大学 A kind of rice mass of 1000 kernel gene tgw6 mutant and the preparation method and application thereof
CN106701808A (en) 2015-07-29 2017-05-24 深圳华大基因研究院 DNA polymerase I defective strain and construction method thereof
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
CN108472314A (en) 2015-07-31 2018-08-31 明尼苏达大学董事会 The cell and therapy of modification
US20200123533A1 (en) 2015-07-31 2020-04-23 The Trustees Of Columbia University In The City Of New York High-throughput strategy for dissecting mammalian genetic interactions
WO2017024047A1 (en) 2015-08-03 2017-02-09 Emendobio Inc. Compositions and methods for increasing nuclease induced recombination rate in cells
US20180230450A1 (en) 2015-08-03 2018-08-16 President And Fellows Of Harvard College Cas9 Genome Editing and Transcriptional Regulation
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
AU2016305490B2 (en) 2015-08-07 2022-07-14 Commonwealth Scientific And Industrial Research Organisation Method for producing an animal comprising a germline genetic modification
CN104962523B (en) 2015-08-07 2018-05-25 苏州大学 A kind of method for measuring non-homologous end joining repairing activity
US9580727B1 (en) 2015-08-07 2017-02-28 Caribou Biosciences, Inc. Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
JP2018522907A (en) 2015-08-11 2018-08-16 セレクティスCellectis Cells for immunotherapy engineered to target the CD38 antigen and to inactivate the CD38 gene
CN105255937A (en) 2015-08-14 2016-01-20 西北农林科技大学 Method for expression of CRISPR sgRNA by eukaryotic cell III-type promoter and use thereof
BR112018002026A2 (en) 2015-08-14 2018-09-18 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences method for obtaining glyphosate resistant rice by nucleotide substitution directed at the site
EP3985111A1 (en) 2015-08-19 2022-04-20 Arc Bio, LLC Capture of nucleic acids using a nucleic acid-guided nuclease-based system
US11339408B2 (en) 2015-08-20 2022-05-24 Applied Stemcell, Inc. Nuclease with enhanced efficiency of genome editing
CN105112519A (en) 2015-08-20 2015-12-02 郑州大学 CRISPR-based Escherichia coli O157:H7 strain detection reagent box and detection method
CN105177126B (en) 2015-08-21 2018-12-04 东华大学 It is a kind of using Fluorescence PCR assay to the Classification Identification method of mouse
MX2018002339A (en) 2015-08-25 2018-12-19 Univ Duke Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases.
CN106480083B (en) 2015-08-26 2021-12-14 中国科学院分子植物科学卓越创新中心 CRISPR/Cas 9-mediated large-fragment DNA splicing method
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
JP6799586B2 (en) 2015-08-28 2020-12-16 ザ ジェネラル ホスピタル コーポレイション Genetic manipulation CRISPR-Cas9 nuclease
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US10526590B2 (en) 2015-08-31 2020-01-07 Agilent Technologies, Inc. Compounds and methods for CRISPR/Cas-based genome editing by homologous recombination
CN105087620B (en) 2015-08-31 2017-12-29 中国农业大学 One kind is overexpressed the 1BB carriers of pig costimulation acceptor 4 and its application
WO2017040709A1 (en) 2015-08-31 2017-03-09 Caribou Biosciences, Inc. Directed nucleic acid repair
US20180245057A1 (en) 2015-09-01 2018-08-30 Dana-Farber Cancer Institute, Inc. Systems and methods for selection of grna targeting strands for cas9 localization
CA3035810A1 (en) 2015-09-02 2017-03-09 University Of Massachusetts Detection of gene loci with crispr arrayed repeats and/or polychromatic single guide ribonucleic acids
WO2017040786A1 (en) 2015-09-04 2017-03-09 Massachusetts Institute Of Technology Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells
CN105400810B (en) 2015-09-06 2019-05-07 吉林大学 The method that phosphopenic rickets model is established using knockout technology
EP3347464B1 (en) 2015-09-08 2024-01-24 University of Massachusetts Dnase h activity of neisseria meningitidis cas9
CA2998087A1 (en) 2015-09-09 2017-03-16 National University Corporation Kobe University Method for modifying genome sequence that specifically converts nucleobase of targeted dna sequence, and molecular complex used in said method
JP6664693B2 (en) 2015-09-09 2020-03-13 国立大学法人神戸大学 Method for converting genomic sequence of gram-positive bacteria, specifically converting nucleobase of targeted DNA sequence, and molecular complex used therein
WO2017044776A1 (en) 2015-09-10 2017-03-16 Texas Tech University System Single-guide rna (sgrna) with improved knockout efficiency
WO2017044857A2 (en) 2015-09-10 2017-03-16 Youhealth Biotech, Limited Methods and compositions for the treatment of glaucoma
CN105274144A (en) 2015-09-14 2016-01-27 徐又佳 Preparation method of zebrafish with hepcidin gene knocked out by use of CRISPR / Cas9 technology
US10109551B2 (en) 2015-09-15 2018-10-23 Intel Corporation Methods and apparatuses for determining a parameter of a die
US10301613B2 (en) 2015-09-15 2019-05-28 Arizona Board Of Regents On Behalf Of Arizona State University Targeted remodeling of prokaryotic genomes using CRISPR-nickases
CN105210981B (en) 2015-09-15 2018-09-28 中国科学院生物物理研究所 Establish the method and its application for the ferret model that can be applied to human diseases research
CN105112422B (en) 2015-09-16 2019-11-08 中山大学 Gene miR408 and UCL is cultivating the application in high-yield rice
WO2017049129A2 (en) 2015-09-18 2017-03-23 President And Fellows Of Harvard College Methods of making guide rna
CA3002647A1 (en) 2015-09-21 2017-03-30 Arcturus Therapeutics, Inc. Allele selective gene editing and uses thereof
WO2017053312A1 (en) 2015-09-21 2017-03-30 The Regents Of The University Of California Compositions and methods for target nucleic acid modification
CN105132427B (en) 2015-09-21 2019-01-08 新疆畜牧科学院生物技术研究所 A kind of dual-gene method for obtaining gene editing sheep of specific knockdown mediated with RNA and its dedicated sgRNA
EA037993B1 (en) 2015-09-23 2021-06-21 Сангамо Терапьютикс, Инк. Htt repressors and uses thereof
EP3353297A1 (en) 2015-09-24 2018-08-01 Crispr Therapeutics AG Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
AU2016326711B2 (en) 2015-09-24 2022-11-03 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/Cas-mediated genome editing
ES2788176T3 (en) 2015-09-24 2020-10-20 Sigma Aldrich Co Llc Methods and reagents for the detection of molecular proximity using RNA-guided nucleic acid-binding proteins
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
WO2017053713A1 (en) 2015-09-25 2017-03-30 Tarveda Therapeutics, Inc. Compositions and methods for genome editing
KR101795999B1 (en) 2015-09-25 2017-11-09 전남대학교산학협력단 Primer for Beta2-Microglobulin gene remove using CRISPR/CAS9 system
KR101745863B1 (en) 2015-09-25 2017-06-12 전남대학교산학협력단 Primer for prohibitin2 gene remove using CRISPR/CAS9 system
EP3147363B1 (en) 2015-09-26 2019-10-16 B.R.A.I.N. Ag Activation of taste receptor genes in mammalian cells using crispr-cas-9
AU2016332345A1 (en) 2015-09-28 2018-04-12 Temple University - Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
CN105177038B (en) 2015-09-29 2018-08-24 中国科学院遗传与发育生物学研究所 A kind of CRISPR/Cas9 systems of efficient fixed point editor Plant Genome
WO2017058791A1 (en) 2015-09-29 2017-04-06 Agenovir Corporation Compositions and methods for treatment of latent viral infections
WO2017058793A1 (en) 2015-09-29 2017-04-06 Agenovir Corporation Delivery methods and compositions
WO2017058796A1 (en) 2015-09-29 2017-04-06 Agenovir Corporation Antiviral fusion proteins and genes
CA2999923A1 (en) 2015-09-29 2017-04-06 Agenovir Corporation Compositions and methods for latent viral transcription regulation
CN105331627B (en) 2015-09-30 2019-04-02 华中农业大学 A method of prokaryotic gene group editor is carried out using endogenous CRISPR-Cas system
EP3356520B1 (en) 2015-10-02 2022-03-23 The U.S.A. as represented by the Secretary, Department of Health and Human Services Lentiviral protein delivery system for rna-guided genome editing
CA3004710A1 (en) 2015-10-06 2017-04-13 The Children's Hospital Of Philadelphia Compositions and methods for treating fragile x syndrome and related syndromes
WO2017062754A1 (en) 2015-10-07 2017-04-13 New York University Compositions and methods for enhancing crispr activity by polq inhibition
WO2017062886A1 (en) 2015-10-08 2017-04-13 Cellink Corporation Battery interconnects
MX2018004263A (en) 2015-10-08 2019-08-16 Harvard College Multiplexed genome editing.
CN108513579B (en) 2015-10-09 2022-10-04 孟山都技术公司 Novel RNA-guided nucleases and uses thereof
WO2017062983A1 (en) 2015-10-09 2017-04-13 The Children's Hospital Of Philadelphia Compositions and methods for treating huntington's disease and related disorders
JP7011590B2 (en) 2015-10-12 2022-02-10 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Protected DNA template and method of use for increased intracellular gene recombination and homologous recombination
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
EP3362102A1 (en) 2015-10-14 2018-08-22 Life Technologies Corporation Ribonucleoprotein transfection agents
CN105400779A (en) 2015-10-15 2016-03-16 芜湖医诺生物技术有限公司 Target sequence, recognized by streptococcus thermophilus CRISPR-Cas9 system, of human CCR5 gene, sgRNA and application of CRISPR-Cas9 system
EP3362561A2 (en) 2015-10-16 2018-08-22 Astrazeneca AB Inducible modification of a cell genome
US20190218546A1 (en) 2015-10-16 2019-07-18 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
FR3042506B1 (en) 2015-10-16 2018-11-30 IFP Energies Nouvelles GENETIC TOOL FOR PROCESSING BACTERIA CLOSTRIDIUM
AU2016340078A1 (en) 2015-10-16 2018-04-12 Temple University - Of The Commonwealth System Of Higher Education Methods and compositions utilizing Cpf1 for RNA-guided gene editing
EP3365269A4 (en) 2015-10-19 2019-06-19 The Methodist Hospital Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
CN105331607A (en) 2015-10-19 2016-02-17 芜湖医诺生物技术有限公司 Human CCR5 gene target sequence recognized by streptococcus thermophilus CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR-associated protein 9) system, sgRNA (single guide ribonucleic acid) and application
CN105316337A (en) 2015-10-20 2016-02-10 芜湖医诺生物技术有限公司 Streptococcus thermophilus derived human CXCR3 gene target sequence recognizable by CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR associated 9) system and sgRNA (single guide ribonucleic acid) and application thereof
CN105316324A (en) 2015-10-20 2016-02-10 芜湖医诺生物技术有限公司 Streptococcus thermophilus derived human CXCR3 gene target sequence recognizable by CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR associated 9) system and sgRNA (single guide ribonucleic acid) and application thereof
BR112018008109A2 (en) 2015-10-20 2018-11-06 Pioneer Hi Bred Int methods for modifying a nucleotide sequence in the genome of a plant cell, producing a plant, producing plant callus tissue that has a modified nucleotide sequence in its genome without the use of a selectable marker, and plant progeny plant
CN105331608A (en) 2015-10-20 2016-02-17 芜湖医诺生物技术有限公司 Human CXCR4 gene target sequence identified by neisseria meningitidis CRISPR-Cas9 system, sgRNA and application of target sequence and sgRNA
US10968253B2 (en) 2015-10-20 2021-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
CN105331609A (en) 2015-10-20 2016-02-17 芜湖医诺生物技术有限公司 Human CCR5 gene target sequence identified by neisseria meningitidis CRISPR-Cas9 system, sgRNA and application of target sequence and sgRNA
AU2016341919A1 (en) 2015-10-21 2018-04-19 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating hepatitis b virus
US20170211142A1 (en) 2015-10-22 2017-07-27 The Broad Institute, Inc. Novel crispr enzymes and systems
CN105219799A (en) 2015-10-22 2016-01-06 天津吉诺沃生物科技有限公司 The breeding method of a kind of English ryegrass based on CRISPR/Cas system
EP3159407A1 (en) 2015-10-23 2017-04-26 Silence Therapeutics (London) Ltd Guide rnas, methods and uses
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
DK3350327T3 (en) 2015-10-23 2019-01-21 Caribou Biosciences Inc CONSTRUCTED CRISPR CLASS-2-NUCLEIC ACID TARGETING-NUCLEIC ACID
TW201715041A (en) 2015-10-26 2017-05-01 國立清華大學 Method for bacterial genome editing
US9988637B2 (en) 2015-10-26 2018-06-05 National Tsing Hua Univeristy Cas9 plasmid, genome editing system and method of Escherichia coli
CA3006465A1 (en) 2015-10-27 2017-05-04 Recombinetics, Inc. Engineering of humanized car t-cells and platelets by genetic complementation
US10280411B2 (en) 2015-10-27 2019-05-07 Pacific Biosciences of California, In.c Methods, systems, and reagents for direct RNA sequencing
CN108513546A (en) 2015-10-28 2018-09-07 克里斯珀医疗股份公司 Material for treating duchenne muscular dystrophy and method
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
BR112018008519A2 (en) 2015-10-28 2018-11-06 Sangamo Therapeutics Inc liver-specific constructs, factor viii expression cassettes and methods of use thereof
EP3368670A1 (en) 2015-10-30 2018-09-05 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
US11111508B2 (en) 2015-10-30 2021-09-07 Brandeis University Modified CAS9 compositions and methods of use
CN105238806B (en) 2015-11-02 2018-11-27 中国科学院天津工业生物技术研究所 A kind of building and its application of the CRISPR/Cas9 gene editing carrier for microorganism
CN105316327B (en) 2015-11-03 2019-01-29 中国农业科学院作物科学研究所 Wheat TaAGO4a gene C RISPR/Cas9 carrier and its application
WO2017079428A1 (en) 2015-11-04 2017-05-11 President And Fellows Of Harvard College Site specific germline modification
EP3371314B1 (en) 2015-11-04 2023-07-05 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CA3004053A1 (en) 2015-11-04 2017-05-11 The Trustees Of The University Of Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
GB2544270A (en) 2015-11-05 2017-05-17 Fundació Centre De Regulació Genòmica Nucleic acids, peptides and methods
AU2016348782A1 (en) 2015-11-05 2018-05-31 Cellectis Process of gene-editing of cells isolated from a subject suffering from a metabolic disease affecting the erythroid lineage, cells obtained by said process and uses thereof.
WO2017078751A1 (en) 2015-11-06 2017-05-11 The Methodist Hospital Micoluidic cell deomailiy assay for enabling rapid and efficient kinase screening via the crispr-cas9 system
AU2016349738A1 (en) 2015-11-06 2018-05-24 The Jackson Laboratory Large genomic DNA knock-in and uses thereof
WO2017081097A1 (en) 2015-11-09 2017-05-18 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Crispr-cas sgrna library
EP3374494A4 (en) 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. Crispr compositions and methods of using the same for gene therapy
EP3374501B1 (en) 2015-11-11 2023-07-12 Lonza Ltd Crispr-associated (cas) proteins with reduced immunogenicity
CA2947904A1 (en) 2015-11-12 2017-05-12 Pfizer Inc. Tissue-specific genome engineering using crispr-cas9
US20170191047A1 (en) 2015-11-13 2017-07-06 University Of Georgia Research Foundation, Inc. Adenosine-specific rnase and methods of use
KR101885901B1 (en) 2015-11-13 2018-08-07 기초과학연구원 RGEN RNP delivery method using 5'-phosphate removed RNA
WO2017083766A1 (en) 2015-11-13 2017-05-18 Massachusetts Institute Of Technology High-throughput crispr-based library screening
MX2018006116A (en) 2015-11-16 2019-04-04 Res Institute At Nationwide Children´S Hospital Materials and methods for treatment of titin-based myopathies and other titinopaties.
US11905521B2 (en) 2015-11-17 2024-02-20 The Chinese University Of Hong Kong Methods and systems for targeted gene manipulation
EP4163374A1 (en) 2015-11-23 2023-04-12 The Regents of the University of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
CN105602987A (en) 2015-11-23 2016-05-25 深圳市默赛尔生物医学科技发展有限公司 High-efficiency knockout method for XBP1 gene in DC cell
US20170145438A1 (en) 2015-11-24 2017-05-25 University Of South Carolina Viral Vectors for Gene Editing
US10240145B2 (en) 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
JP6500293B2 (en) 2015-11-25 2019-04-17 国立大学法人群馬大学 DNA methylation editing kit and DNA methylation editing method
US20180346940A1 (en) 2015-11-27 2018-12-06 The Regents Of The University Of California Compositions and methods for the production of hydrocarbons, hydrogen and carbon monoxide using engineered azotobacter strains
CN105505979A (en) 2015-11-28 2016-04-20 湖北大学 Method for acquiring aromatic rice strain by targeting Badh2 gene via CRISPR/Cas9 gene editing technology
CN106811479B (en) 2015-11-30 2019-10-25 中国农业科学院作物科学研究所 The system and its application of Herbicide Resistant Rice are obtained using CRISPR/Cas9 system pointed decoration als gene
WO2017095111A1 (en) 2015-11-30 2017-06-08 기초과학연구원 Composition for genome editing, containing cas9 derived from f. novicida
CN105296518A (en) 2015-12-01 2016-02-03 中国农业大学 Homologous arm vector construction method used for CRISPR/Cas 9 technology
RU2634395C1 (en) 2015-12-01 2017-10-26 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) GENETIC CONSTRUCT BASED ON CRISPR/Cas9 GENOME SYSTEM EDITING, CODING Cas9 NUCLEASE, SPECIFICALLY IMPORTED IN HUMAN CELLS MITOCHONDRIA
MX2018006814A (en) 2015-12-02 2019-08-05 Ceres Inc Methods for genetic modification of plants.
US11085057B2 (en) 2015-12-02 2021-08-10 The Regents Of The University Of California Compositions and methods for modifying a target nucleic acid
WO2017093370A1 (en) 2015-12-03 2017-06-08 Technische Universität München T-cell specific genome editing
CN105779449B (en) 2015-12-04 2018-11-27 新疆农业大学 A kind of cotton promoters GbU6-5PS and application
CN105779448B (en) 2015-12-04 2018-11-27 新疆农业大学 A kind of cotton promoters GbU6-7PS and application
EA201891338A1 (en) 2015-12-04 2018-12-28 Новартис Аг COMPOSITIONS AND METHODS FOR IMMUNICOLOGY
CN105462968B (en) 2015-12-07 2018-10-16 北京信生元生物医学科技有限公司 It is a kind of targeting apoC III CRISPR-Cas9 systems and its application
CN106845151B (en) 2015-12-07 2019-03-26 中国农业大学 The screening technique and device of CRISPR-Cas9 system sgRNA action target spot
JP2019508364A (en) 2015-12-09 2019-03-28 エクシジョン バイオセラピューティクス インコーポレイテッド Gene editing methods and compositions for eliminating JC virus activation and risk of PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy
WO2017100158A1 (en) 2015-12-11 2017-06-15 Danisco Us Inc. Methods and compositions for enhanced nuclease-mediated genome modification and reduced off-target site effects
CN105463003A (en) 2015-12-11 2016-04-06 扬州大学 Recombinant vector for eliminating activity of kanamycin drug resistance gene and building method of recombinant vector
CN105296537A (en) 2015-12-12 2016-02-03 西南大学 Fixed-point gene editing method based on intratestis injection
WO2017105350A1 (en) 2015-12-14 2017-06-22 Cellresearch Corporation Pte Ltd A method of generating a mammalian stem cell carrying a transgene, a mammalian stem cell generated by the method and pharmaceuticals uses of the mammalian stem cell
CN105400773B (en) 2015-12-14 2018-06-26 同济大学 CRISPR/Cas9 applied to Large-scale Screening cancer gene is enriched with sequencing approach
NO343153B1 (en) 2015-12-17 2018-11-19 Hydra Systems As A method of assessing the integrity status of a barrier plug
CN105463027A (en) 2015-12-17 2016-04-06 中国农业大学 Method for preparing high muscle content and hypertrophic cardiomyopathy model cloned pig
WO2017106616A1 (en) 2015-12-17 2017-06-22 The Regents Of The University Of Colorado, A Body Corporate Varicella zoster virus encoding regulatable cas9 nuclease
MX2018007290A (en) 2015-12-18 2019-01-10 Danisco Us Inc Methods and compositions for polymerase ii (pol-ii) based guide rna expression.
US11761007B2 (en) 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
AU2016369490C1 (en) 2015-12-18 2021-12-23 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
EP3390624A4 (en) 2015-12-18 2019-07-10 The Regents of The University of California Modified site-directed modifying polypeptides and methods of use thereof
WO2017106537A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
WO2017104404A1 (en) 2015-12-18 2017-06-22 国立研究開発法人科学技術振興機構 Genetic modification non-human organism, egg cells, fertilized eggs, and method for modifying target genes
EP3708665A1 (en) 2015-12-18 2020-09-16 Danisco US Inc. Methods and compositions for t-rna based guide rna expression
DK3319622T3 (en) 2015-12-22 2020-05-04 Curevac Ag PROCEDURE FOR PREPARING RNA MOLECULE COMPOSITIONS
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
JP6947729B2 (en) 2015-12-23 2021-10-13 クリスパー セラピューティクス アクチェンゲゼルシャフト Materials and methods for the treatment of amyotrophic lateral sclerosis and / or frontotemporal lobar degeneration
CN105543270A (en) 2015-12-24 2016-05-04 中国农业科学院作物科学研究所 Double resistance CRISPR/Cas9 carrier and application
CN105543266A (en) 2015-12-25 2016-05-04 安徽大学 CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat sequences)-Cas (CRISPR-associated proteins) system in Streptomyces virginiae IBL14 and method for carrying out gene editing by using CRISPR-Cas system
CN105505976A (en) 2015-12-25 2016-04-20 安徽大学 Construction method of penicillin-producing recombined strain of streptomyces virginiae IBL14
MY192848A (en) 2015-12-28 2022-09-12 Intellia Therapeutics Inc Compositions and methods for the treatment of hemoglobinopathies
EP4159849A1 (en) 2015-12-29 2023-04-05 Monsanto Technology LLC Novel crispr-associated transposases and uses thereof
CN105441451B (en) 2015-12-31 2019-03-22 暨南大学 A kind of sgRNA targeting sequencing of special target people ABCB1 gene and application
CN105567735A (en) 2016-01-05 2016-05-11 华东师范大学 Site specific repairing carrier system and method of blood coagulation factor genetic mutation
US20190024123A1 (en) 2016-01-08 2019-01-24 Novozymes A/S Genome Editing In Bacillus Host Cells
US11441146B2 (en) 2016-01-11 2022-09-13 Christiana Care Health Services, Inc. Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system
CN105647922A (en) 2016-01-11 2016-06-08 中国人民解放军疾病预防控制所 Application of CRISPR-Cas9 system based on new gRNA (guide ribonucleic acid) sequence in preparing drugs for treating hepatitis B
US11427837B2 (en) 2016-01-12 2022-08-30 The Regents Of The University Of California Compositions and methods for enhanced genome editing
WO2017124100A1 (en) 2016-01-14 2017-07-20 Memphis Meats, Inc. Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process
CA3011458A1 (en) 2016-01-14 2017-07-20 The Brigham And Women's Hospital, Inc. Genome editing for treating glioblastoma
KR20180097756A (en) 2016-01-15 2018-08-31 더 잭슨 래보라토리 Genetically engineered non-human mammals by multi-cycle electroporation of CAS9 protein
WO2017126987A1 (en) 2016-01-18 2017-07-27 Анатолий Викторович ЗАЗУЛЯ Red blood cells for targeted drug delivery
CN105567738A (en) 2016-01-18 2016-05-11 南开大学 Method for inducing CCR5-delta32 deletion with genome editing technology CRISPR-Cas9
CN105567734A (en) 2016-01-18 2016-05-11 丹弥优生物技术(湖北)有限公司 Method for precisely editing genome DNA sequence
JP6914274B2 (en) 2016-01-22 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド Crystal structure of CRISPRCPF1
WO2017132112A1 (en) 2016-01-25 2017-08-03 Excision Biotherapeutics Methods and compositions for rna-guided treatment of hiv infection
RU2018130641A (en) 2016-01-25 2020-02-26 Эксижн Биотерапьютикс GUIDED RNA REMOVING HUMAN JC VIRUS AND OTHER POLIOMAVIRUSES
CN105567689B (en) 2016-01-25 2019-04-09 重庆威斯腾生物医药科技有限责任公司 CRISPR/Cas9 targeting knockout people TCAB1 gene and its specificity gRNA
CN105543228A (en) 2016-01-25 2016-05-04 宁夏农林科学院 Method for transforming rice into fragrant rice rapidly
EP3199632A1 (en) 2016-01-26 2017-08-02 ACIB GmbH Temperature-inducible crispr/cas system
CN105567688A (en) 2016-01-27 2016-05-11 武汉大学 CRISPR/SaCas9 system for gene therapy of AIDS
HUE062276T2 (en) 2016-01-29 2023-10-28 Univ Princeton Split inteins with exceptional splicing activity
JP6800171B2 (en) 2016-01-30 2020-12-16 株式会社ボナック Artificial single guide RNA and its uses
CN107022562B (en) 2016-02-02 2020-07-17 中国种子集团有限公司 Method for site-directed mutagenesis of maize gene by using CRISPR/Cas9 system
CN105647968B (en) 2016-02-02 2019-07-23 浙江大学 A kind of CRISPR/Cas9 working efficiency fast testing system and its application
CN105671083B (en) 2016-02-03 2017-09-29 安徽柯顿生物科技有限公司 The gene recombined virus plasmids of PD 1 and structure, the Puro of recombinant retrovirus Lenti PD 1 and packaging and application
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
WO2017136520A1 (en) 2016-02-04 2017-08-10 President And Fellows Of Harvard College Mitochondrial genome editing and regulation
US20190038780A1 (en) 2016-02-05 2019-02-07 Regents Of The University Of Minnesota Vectors and system for modulating gene expression
US11746349B2 (en) 2016-02-09 2023-09-05 President And Fellows Of Harvard College DNA-guided gene editing and regulation
RU2016104674A (en) 2016-02-11 2017-08-16 Анатолий Викторович Зазуля ERYTHROCYT MODIFICATION DEVICE WITH DIRECTED MEDICINAL TRANSPORT MECHANISM FOR CRISPR / CAS9 GENE THERAPY FUNCTIONS
EP3413908A4 (en) 2016-02-11 2019-09-25 The Regents of The University of California Methods and compositions for modifying a mutant dystrophin gene in a cell's genome
US9896696B2 (en) 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
EP3417062A4 (en) 2016-02-15 2019-12-11 Temple University - Of The Commonwealth System of Higher Education Excision of retroviral nucleic acid sequences
CN105647962A (en) 2016-02-15 2016-06-08 浙江大学 Gene editing method for knocking out rice MIRNA393b stem-loop sequences with application of CRISPR(clustered regulatory interspersed short palindromic repeat)-Cas9 system
CN105647969B (en) 2016-02-16 2020-12-15 湖南师范大学 Method for breeding zebra fish with stat1a gene deletion by gene knockout
CN105594664B (en) 2016-02-16 2018-10-02 湖南师范大学 A kind of method of gene knockout selection and breeding stat1a Gene Deletion zebra fish
WO2017143042A2 (en) 2016-02-16 2017-08-24 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CN105624187A (en) 2016-02-17 2016-06-01 天津大学 Site-directed mutation method for genomes of saccharomyces cerevisiae
US11326161B2 (en) 2016-02-18 2022-05-10 President And Fellows Of Harvard College Methods and systems of molecular recording by CRISPR-Cas system
US20170275665A1 (en) 2016-02-24 2017-09-28 Board Of Regents, The University Of Texas System Direct crispr spacer acquisition from rna by a reverse-transcriptase-cas1 fusion protein
CN105646719B (en) 2016-02-24 2019-12-20 无锡市妇幼保健院 Efficient fixed-point transgenic tool and application thereof
US11530253B2 (en) 2016-02-25 2022-12-20 The Children's Medical Center Corporation Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
US20170247703A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Antiviral nuclease methods
WO2017147446A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Viral and oncoviral nuclease treatment
US20170246260A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Modified antiviral nuclease
SG11201807025SA (en) 2016-02-26 2018-09-27 Lanzatech New Zealand Ltd Crispr/cas systems for c-1 fixing bacteria
WO2017151444A1 (en) 2016-02-29 2017-09-08 Agilent Technologies, Inc. Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
US11447768B2 (en) 2016-03-01 2022-09-20 University Of Florida Research Foundation, Incorporated Molecular cell diary system
CN105671070B (en) 2016-03-03 2019-03-19 江南大学 A kind of CRISPRCas9 system and its construction method for Bacillus subtilis genes group editor
CA3016331A1 (en) 2016-03-04 2017-09-08 Editas Medicine, Inc. Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
CN105821040B (en) 2016-03-09 2018-12-14 李旭 Combined immunization gene inhibits sgRNA, gene knockout carrier and its application of high-risk HPV expression
CN105821039B (en) 2016-03-09 2020-02-07 李旭 Specific sgRNA combined with immune gene to inhibit HBV replication, expression vector and application of specific sgRNA
CN107177591A (en) 2016-03-09 2017-09-19 北京大学 SgRNA sequences using CRISPR technical editor's CCR5 genes and application thereof
CN105861547A (en) 2016-03-10 2016-08-17 黄捷 Method for permanently embedding identity card number into genome
US20190100762A1 (en) 2016-03-11 2019-04-04 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2017160752A1 (en) 2016-03-14 2017-09-21 Intellia Therapeutics, Inc. Methods and compositions for gene editing
SG11201807859WA (en) 2016-03-14 2018-10-30 Editas Medicine Inc Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
EP3430332B1 (en) 2016-03-15 2020-01-01 Carrier Corporation Refrigerated sales cabinet
CA3029735A1 (en) 2016-03-15 2017-09-21 University Of Massachusetts Anti-crispr compounds and methods of use
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
WO2017161068A1 (en) 2016-03-18 2017-09-21 President And Fellows Of Harvard College Mutant cas proteins
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
JP2019515662A (en) 2016-03-28 2019-06-13 ザ・チャールズ・スターク・ドレイパ・ラボラトリー・インコーポレイテッド Bacterial identification and antibiotic sensitivity profiling equipment
CN106047803A (en) 2016-03-28 2016-10-26 青岛市胶州中心医院 Cell model obtained after targeted knockout of rabbit bone morphogenetic protein-2 (BMP2) gene based on CRISPR/Cas9 and application thereof
WO2017173004A1 (en) 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing
EP3436077A1 (en) 2016-03-30 2019-02-06 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
US20190112599A1 (en) 2016-03-31 2019-04-18 President And Fellows Of Harvard College Methods and Compositions for the Single Tube Preparation of Sequencing Libraries Using Cas9
WO2017173092A1 (en) 2016-03-31 2017-10-05 The Regents Of The University Of California Methods for genome editing in zygotes
CN106167525B (en) 2016-04-01 2019-03-19 北京康明百奥新药研发有限公司 Screen the methods and applications of ultralow fucose cell line
US10301619B2 (en) 2016-04-01 2019-05-28 New England Biolabs, Inc. Compositions and methods relating to synthetic RNA polynucleotides created from synthetic DNA oligonucleotides
BR112018070353A2 (en) 2016-04-04 2019-01-29 Eth Zuerich mammalian cell line for protein production and library generation
WO2017176529A1 (en) 2016-04-06 2017-10-12 Temple Univesity-Of The Commonwealth System Of Higher Education Compositions for eradicating flavivirus infections in subjects
CN105802980A (en) 2016-04-08 2016-07-27 北京大学 CRISPR/Cas9 system with Gateway compatibility and application of CRISPR/Cas9 system
CN106399306B (en) 2016-04-12 2019-11-05 西安交通大学第一附属医院 Target sgRNA, genophore and its application that people lncRNA-UCA1 inhibits bladder cancer
US20190062734A1 (en) 2016-04-13 2019-02-28 Editas Medicine, Inc. Grna fusion molecules, gene editing systems, and methods of use thereof
EP3443086B1 (en) 2016-04-13 2021-11-24 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
WO2017180915A2 (en) 2016-04-13 2017-10-19 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2017178590A1 (en) 2016-04-14 2017-10-19 Université de Lausanne Treatment and/or prevention of dna-triplet repeat diseases or disorders
SG11201808920RA (en) 2016-04-14 2018-11-29 Boco Silicon Valley Inc Genome editing of human neural stem cells using nucleases
CN105821116A (en) 2016-04-15 2016-08-03 扬州大学 Directional knockout on sheep MSTN gene and detection method for influence thereof on myogenic differentiation
US20200172935A1 (en) 2016-04-16 2020-06-04 Ohio State Innovation Foundation Modified cpf1 mrna, modified guide rna, and uses thereof
US20190134227A1 (en) 2016-04-18 2019-05-09 The Board Of Regents Of The University Of Texas System Generation of genetically engineered animals by crispr/cas9 genome editing in spermatogonial stem cells
EP3445852A1 (en) 2016-04-18 2019-02-27 Ruprecht-Karls-Universität Heidelberg Means and methods for inactivating therapeutic dna in a cell
CN106086062A (en) 2016-04-19 2016-11-09 上海市农业科学院 A kind of tomato dna group that obtains pinpoints the method knocking out mutant
WO2017189308A1 (en) 2016-04-19 2017-11-02 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017184768A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Novel crispr enzymes and systems
US11286478B2 (en) 2016-04-19 2022-03-29 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
CN105886616B (en) 2016-04-20 2020-08-07 广东省农业科学院农业生物基因研究中心 Efficient specific sgRNA recognition site guide sequence for pig gene editing and screening method thereof
CN105821075B (en) 2016-04-22 2017-09-12 湖南农业大学 A kind of construction method of tea tree CaMTL5 CRISPR/Cas9 genome editor's carriers
CN107304435A (en) 2016-04-22 2017-10-31 中国科学院青岛生物能源与过程研究所 A kind of Cas9/RNA systems and its application
CN105861552B (en) 2016-04-25 2019-10-11 西北农林科技大学 A kind of construction method for the CRISPR/Cas9 gene editing system that T7 RNA polymerase mediates
US11248216B2 (en) 2016-04-25 2022-02-15 The Regents Of The University Of California Methods and compositions for genomic editing
CN107326046A (en) 2016-04-28 2017-11-07 上海邦耀生物科技有限公司 A kind of method for improving foreign gene homologous recombination efficiency
CN105821049B (en) 2016-04-29 2019-06-04 中国农业大学 A kind of preparation method of Fbxo40 gene knock-out pig
KR102370675B1 (en) 2016-04-29 2022-03-04 바스프 플랜트 사이언스 컴퍼니 게엠베하 Improved methods for modification of target nucleic acids
CN105886534A (en) 2016-04-29 2016-08-24 苏州溯源精微生物科技有限公司 Tumor metastasis inhibition method
SG11201810755TA (en) 2016-05-01 2019-01-30 Neemo Inc Harnessing heterologous and endogenous crispr-cas machineries for efficient markerless genome editing in clostridium
WO2017192512A2 (en) 2016-05-02 2017-11-09 Massachusetts Institute Of Technology Amphiphilic nanoparticles for delivery of crispr based therapy
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
CN105950639A (en) 2016-05-04 2016-09-21 广州美格生物科技有限公司 Preparation method of staphylococcus aureus CRISPR/Cas9 system and application of system in constructing mouse model
WO2017191210A1 (en) 2016-05-04 2017-11-09 Novozymes A/S Genome editing by crispr-cas9 in filamentous fungal host cells
WO2017190664A1 (en) 2016-05-05 2017-11-09 苏州吉玛基因股份有限公司 Use of chemosynthetic crrna and modified crrna in crispr/cpf1 gene editing systems
US20190093092A1 (en) 2016-05-05 2019-03-28 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of varicella zoster virus
CN105907785B (en) 2016-05-05 2020-02-07 苏州吉玛基因股份有限公司 Application of chemically synthesized crRNA in CRISPR/Cpf1 system in gene editing
JP7075597B2 (en) 2016-05-05 2022-05-26 デューク ユニバーシティ CRISPR / CAS-related methods and compositions for treating Duchenne muscular dystrophy
CN106244591A (en) 2016-08-23 2016-12-21 苏州吉玛基因股份有限公司 Modify crRNA application in CRISPR/Cpf1 gene editing system
US20190300872A1 (en) 2016-05-06 2019-10-03 Tod M. Woolf Improved Methods of Genome Editing with and without Programmable Nucleases
CN105985985B (en) 2016-05-06 2019-12-31 苏州大学 Preparation method of allogeneic mesenchymal stem cells edited by CRISPR technology and optimized by IGF (insulin-like growth factor) and application of allogeneic mesenchymal stem cells in treatment of myocardial infarction
WO2017196768A1 (en) 2016-05-09 2017-11-16 President And Fellows Of Harvard College Self-targeting guide rnas in crispr system
CN105861554B (en) 2016-05-10 2020-01-31 华南农业大学 method for realizing animal sex control based on editing Rbmy gene and application
CA3024494A1 (en) 2016-05-10 2017-11-16 United States Government As Represented By The Department Of Veterans Affairs Lentiviral delivery of crispr/cas constructs that cleave genes essential for hiv-1 infection and replication
JP2019519501A (en) 2016-05-12 2019-07-11 ブライアン ピー. ハンリーBrian P. HANLEY Safe delivery of CRISPR and other gene therapeutics to the majority of somatic cells in humans and animals
CN107365786A (en) 2016-05-12 2017-11-21 中国科学院微生物研究所 A kind of method and its application being cloned into spacer sequences in CRISPR-Cas9 systems
US20190345483A1 (en) 2016-05-12 2019-11-14 President And Fellows Of Harvard College AAV Split Cas9 Genome Editing and Transcriptional Regulation
CN105907758B (en) 2016-05-18 2020-06-05 世翱(上海)生物医药科技有限公司 CRISPR-Cas9 guide sequence and primer thereof, transgenic expression vector and construction method thereof
CN106011171B (en) 2016-05-18 2019-10-11 西北农林科技大学 A kind of gene seamless edit method repaired using CRISPR/Cas9 technology based on SSA
CN105838733A (en) 2016-05-18 2016-08-10 云南省农业科学院花卉研究所 Cas9 mediated carnation gene editing carrier and application
CN106446600B (en) 2016-05-20 2019-10-18 同济大学 A kind of design method of the sgRNA based on CRISPR/Cas9
KR102356542B1 (en) 2016-05-20 2022-01-28 리제너론 파마슈티칼스 인코포레이티드 A method for disrupting immunological resistance using multiple guide RNAs
WO2017205290A1 (en) 2016-05-23 2017-11-30 The Trustees Of Columbia University In The City Of New York Bypassing the pam requirement of the crispr-cas system
WO2017205423A1 (en) 2016-05-23 2017-11-30 Washington University Pulmonary targeted cas9/crispr for in vivo editing of disease genes
CN105950560B (en) 2016-05-24 2019-07-23 苏州系统医学研究所 Humanization PD-L1 tumor cell line and animal model and application with the cell line
CN106011167B (en) 2016-05-27 2019-11-01 上海交通大学 The method of the application and rice fertility restorer of male sterility gene OsDPW2
AU2017272623A1 (en) 2016-06-01 2018-11-29 Kws Saat Se Hybrid nucleic acid sequences for genome engineering
WO2017208247A1 (en) 2016-06-02 2017-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Assay for the removal of methyl-cytosine residues from dna
DK3272867T3 (en) 2016-06-02 2019-12-02 Sigma Aldrich Co Llc USE OF PROGRAMMABLE DNA BINDING PROTEINS FOR IMPROVING TARGETED RE-MODIFICATION
US11140883B2 (en) 2016-06-03 2021-10-12 Auburn University Gene editing of reproductive hormones to sterilize aquatic animals
EP3463290A4 (en) 2016-06-03 2019-10-30 Temple University - Of The Commonwealth System of Higher Education Negative feedback regulation of hiv-1 by gene editing strategy
CN106119275A (en) 2016-06-07 2016-11-16 湖北大学 Based on CRISPR/Cas9 technology, nonglutinous rice strain is transformed into targeting vector and the method for waxy strain
WO2017213898A2 (en) 2016-06-07 2017-12-14 Temple University - Of The Commonwealth System Of Higher Education Rna guided compositions for preventing and treating hepatitis b virus infections
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CN106086008B (en) 2016-06-10 2019-03-12 中国农业科学院植物保护研究所 The CRISPR/cas9 system and its application of hidden kind of TRP gene of Bemisia tabaci MED
WO2017222834A1 (en) 2016-06-10 2017-12-28 City Of Hope Compositions and methods for mitochondrial genome editing
CN106434752A (en) 2016-06-14 2017-02-22 南通大学附属医院 Process of knocking out Wnt3a gene and verification method thereof
BR112018076027A2 (en) 2016-06-14 2019-03-26 Pioneer Hi-Bred International, Inc. method for modifying a target sequence in the genome of a plant cell; method for editing a nucleotide sequence in the genome of a plant cell; method for simultaneously modifying multiple target sequences in the genome of a plant cell; method for modifying a DNA target sequence in a plant cell genome and polynucleotide modification model
CN106167808A (en) 2016-06-16 2016-11-30 郑州大学 A kind of method eliminating mecA plasmid based on CRISPR/Cas9 technology
CN106167821A (en) 2016-06-16 2016-11-30 郑州大学 A kind of staphylococcus aureus CRISPR site detection kit and detection method
CN105950633B (en) 2016-06-16 2019-05-03 复旦大学 Application of the gene OsARF4 in control rice grain length and mass of 1000 kernel
CN105950626B (en) 2016-06-17 2018-09-28 新疆畜牧科学院生物技术研究所 The method of different hair color sheep is obtained based on CRISPR/Cas9 and targets the sgRNA of ASIP genes
JP7267013B2 (en) 2016-06-17 2023-05-01 ザ・ブロード・インスティテュート・インコーポレイテッド Type VI CRISPR orthologs and systems
US20190330603A1 (en) 2016-06-17 2019-10-31 Genesis Technologies Limited Crispr-cas system, materials and methods
EP3472311A4 (en) 2016-06-17 2020-03-04 Montana State University Bidirectional targeting for genome editing
US20170362635A1 (en) 2016-06-20 2017-12-21 University Of Washington Muscle-specific crispr/cas9 editing of genes
WO2017222773A1 (en) 2016-06-20 2017-12-28 Pioneer Hi-Bred International, Inc. Novel cas systems and methods of use
WO2017223107A1 (en) 2016-06-20 2017-12-28 Unity Biotechnology, Inc. Genome modifying enzyme therapy for diseases modulated by senescent cells
CA3027869A1 (en) 2016-06-20 2017-12-28 Keygene N.V. Method for targeted dna alteration in plant cells
CN106148370A (en) 2016-06-21 2016-11-23 苏州瑞奇生物医药科技有限公司 Fat rats animal model and construction method
CN109477103A (en) 2016-06-22 2019-03-15 ProQR治疗上市公司Ⅱ Single stranded RNA-editor's oligonucleotides
EP3475416A4 (en) 2016-06-22 2020-04-29 Icahn School of Medicine at Mount Sinai Viral delivery of rna utilizing self-cleaving ribozymes and crispr-based applications thereof
CN106047877B (en) 2016-06-24 2019-01-11 中山大学附属第一医院 A kind of sgRNA and CRISPR/Cas9 slow virus system of targeting knockout FTO gene and application
CN106119283A (en) 2016-06-24 2016-11-16 广西壮族自治区水牛研究所 A kind of method that the CRISPR of utilization Cas9 targeting knocks out MSTN gene
CN105925608A (en) 2016-06-24 2016-09-07 广西壮族自治区水牛研究所 Method for targeted knockout of gene ALK6 by using CRISPR-Cas9
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
US11913017B2 (en) 2016-06-29 2024-02-27 The Regents Of The University Of California Efficient genetic screening method
US20190185849A1 (en) 2016-06-29 2019-06-20 Crispr Therapeutics Ag Compositions and methods for gene editing
CN106148286B (en) 2016-06-29 2019-10-29 牛刚 A kind of construction method and cell model and pyrogen test kit for detecting the cell model of pyrogen
US10927383B2 (en) 2016-06-30 2021-02-23 Ethris Gmbh Cas9 mRNAs
US10892034B2 (en) 2016-07-01 2021-01-12 Microsoft Technology Licensing, Llc Use of homology direct repair to record timing of a molecular event
US20180004537A1 (en) 2016-07-01 2018-01-04 Microsoft Technology Licensing, Llc Molecular State Machines
EP3478852B1 (en) 2016-07-01 2020-08-12 Microsoft Technology Licensing, LLC Storage through iterative dna editing
CA3029874A1 (en) 2016-07-05 2018-01-11 The Johns Hopkins University Crispr/cas9-based compositions and methods for treating retinal degenerations
CN106191057B (en) 2016-07-06 2018-12-25 中山大学 A kind of sgRNA sequence for knocking out people's CYP2E1 gene, the construction method of CYP2E1 gene deleted cell strains and its application
EP3481959A1 (en) 2016-07-06 2019-05-15 Novozymes A/S Improving a microorganism by crispr-inhibition
CN106051058A (en) 2016-07-07 2016-10-26 上海格昆机电科技有限公司 Rotating rack used for spaceflight storage tank and particle treatment instrument and transmission mechanism of rotation rack
CN107586777A (en) 2016-07-08 2018-01-16 上海吉倍生物技术有限公司 People's PDCD1 genes sgRNA purposes and its related drugs
US11845929B2 (en) 2016-07-08 2023-12-19 Ohio State Innovation Foundation Modified nucleic acids, hybrid guide RNAs, and uses thereof
CN106047930B (en) 2016-07-12 2020-05-19 北京百奥赛图基因生物技术有限公司 Preparation method of Flox rat with conditional knockout of PS1 gene
KR102319845B1 (en) 2016-07-13 2021-11-01 디에스엠 아이피 어셋츠 비.브이. CRISPR-CAS system for avian host cells
US20190330659A1 (en) 2016-07-15 2019-10-31 Zymergen Inc. Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase
CN106190903B (en) 2016-07-18 2019-04-02 华中农业大学 Riemerlla anatipestifer Cas9 gene deletion mutants and its application
CN106191062B (en) 2016-07-18 2019-06-14 广东华南疫苗股份有限公司 A kind of TCR-/PD-1- double negative t cells and its construction method
CN106191061B (en) 2016-07-18 2019-06-18 暨南大学 A kind of sgRNA targeting sequencing of special target people ABCG2 gene and its application
EP4275747A3 (en) 2016-07-19 2024-01-24 Duke University Therapeutic applications of cpf1-based genome editing
CN106434651B (en) 2016-07-19 2021-05-18 广西大学 Agrobacterium tumefaciens and CRISPR-Cas9 mediated gene site-directed insertion inactivation method and application thereof
JP2019520844A (en) 2016-07-21 2019-07-25 マックスサイト インコーポレーティッド Methods and compositions for modifying genomic DNA
WO2018015444A1 (en) 2016-07-22 2018-01-25 Novozymes A/S Crispr-cas9 genome editing with multiple guide rnas in filamentous fungi
CN106191064B (en) 2016-07-22 2019-06-07 中国农业大学 A method of preparing MC4R gene knock-out pig
CN106191107B (en) 2016-07-22 2020-03-20 湖南农业大学 Molecular improvement method for reducing rice grain falling property
WO2018022480A1 (en) 2016-07-25 2018-02-01 Mayo Foundation For Medical Education And Research Treating cancer
EP3491133A4 (en) 2016-07-26 2020-05-06 The General Hospital Corporation Variants of crispr from prevotella and francisella 1 (cpf1)
CN106222193B (en) 2016-07-26 2019-09-20 浙江大学 A kind of recombinant vector and the screening technique without transgene gene editor plant
WO2018018979A1 (en) 2016-07-26 2018-02-01 浙江大学 Recombinant plant vector and method for screening non-transgenic gene-edited strain
CN106086061A (en) 2016-07-27 2016-11-09 苏州泓迅生物科技有限公司 A kind of genes of brewing yeast group editor's carrier based on CRISPR Cas9 system and application thereof
CN106191099A (en) 2016-07-27 2016-12-07 苏州泓迅生物科技有限公司 A kind of parallel multiple editor's carrier of genes of brewing yeast group based on CRISPR Cas9 system and application thereof
WO2018021878A1 (en) 2016-07-28 2018-02-01 주식회사 비엠티 Heating jacket for outdoor piping
CN106191114B (en) 2016-07-29 2020-02-11 中国科学院重庆绿色智能技术研究院 Breeding method for knocking out fish MC4R gene by using CRISPR-Cas9 system
CN106434748A (en) 2016-07-29 2017-02-22 中国科学院重庆绿色智能技术研究院 Development and applications of heat shock induced Cas9 enzyme transgene danio rerio
GB201613135D0 (en) 2016-07-29 2016-09-14 Medical Res Council Genome editing
CN106191113B (en) 2016-07-29 2020-01-14 中国农业大学 Preparation method of MC3R gene knockout pig
CN106191124B (en) 2016-07-29 2019-10-11 中国科学院重庆绿色智能技术研究院 It is a kind of to save the fish breeding method that liquid improves CRISPR-Cas9 gene editing and passaging efficiency using fish-egg
CN106011150A (en) 2016-08-01 2016-10-12 云南纳博生物科技有限公司 Rice grain number per ear Gn1a gene artificial site-directed mutant and application thereof
US11866733B2 (en) 2016-08-01 2024-01-09 University of Pittsburgh—of the Commonwealth System of Higher Education Human induced pluripotent stem cells for high efficiency genetic engineering
CN106434688A (en) 2016-08-01 2017-02-22 云南纳博生物科技有限公司 Artificial fixed-point rice dense and erect panicle (DEP1) gene mutant body and application thereof
JP7184364B2 (en) 2016-08-02 2022-12-06 国立大学法人京都大学 Methods for genome editing
BR112019001887A2 (en) 2016-08-02 2019-07-09 Editas Medicine Inc compositions and methods for treating cep290-associated disease
IL308426A (en) 2016-08-03 2024-01-01 Harvard College Adenosine nucleobase editors and uses thereof
CN106282241A (en) 2016-08-05 2017-01-04 无锡市第二人民医院 The method obtaining knocking out the Brachydanio rerio of bmp2a gene by CRISPR/Cas9
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
KR101710026B1 (en) 2016-08-10 2017-02-27 주식회사 무진메디 Composition comprising delivery carrier of nano-liposome having Cas9 protein and guide RNA
CN106222203A (en) 2016-08-10 2016-12-14 云南纳博生物科技有限公司 CRISPR/Cas technology is utilized to obtain bombyx mori silk fibroin heavy chain gene mutant and mutation method and application
CN106172238B (en) 2016-08-12 2019-01-22 中南大学 The construction method of miR-124 knock out mice animal model and application
CN106222177B (en) 2016-08-13 2018-06-26 江苏集萃药康生物科技有限公司 A kind of CRISPR-Cas9 systems for targeting people STAT6 and its application for treating anaphylactia
WO2018035250A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018035300A1 (en) 2016-08-17 2018-02-22 The Regents Of The University Of California Split trans-complementing gene-drive system for suppressing aedes aegypti mosquitos
US11810649B2 (en) 2016-08-17 2023-11-07 The Broad Institute, Inc. Methods for identifying novel gene editing elements
KR20190065251A (en) 2016-08-18 2019-06-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 CRISPR-Cas Genome Processing with Modular AAV Delivery System
CN109715171A (en) 2016-08-19 2019-05-03 蓝鸟生物公司 Genome editor's enhancer
KR102594051B1 (en) 2016-08-20 2023-10-26 아벨리노 랩 유에스에이, 인크. Single guide RNA, CRISPR/Cas9 system, and methods of use thereof
CN106191116B (en) 2016-08-22 2019-10-08 西北农林科技大学 Foreign gene based on CRISPR/Cas9 knocks in integration system and its method for building up and application
CN106191071B (en) 2016-08-22 2018-09-04 广州资生生物科技有限公司 A kind of CRISPR-Cas9 systems and its application for treating breast cancer disease
CN106244555A (en) 2016-08-23 2016-12-21 广州医科大学附属第三医院 A kind of method of efficiency improving gene targeting and the base in-situ remediation method in beta globin gene site
CN106086028B (en) 2016-08-23 2019-04-23 中国农业科学院作物科学研究所 A kind of method by genome editor raising rice resistance starch content and its dedicated sgRNA
CN106244609A (en) 2016-08-24 2016-12-21 浙江理工大学 The screening system of a kind of Noncoding gene regulating PI3K AKT signal path and screening technique
SG10201913948PA (en) 2016-08-24 2020-03-30 Sangamo Therapeutics Inc Engineered target specific nucleases
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN106109417A (en) 2016-08-24 2016-11-16 李因传 A kind of bionical lipidosome drug carrier of liver plasma membrane, manufacture method and application thereof
AU2017315406B2 (en) 2016-08-24 2021-04-01 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
KR101856345B1 (en) 2016-08-24 2018-06-20 경상대학교산학협력단 Method for generation of APOBEC3H and APOBEC3CH double-knocked out cat using CRISPR/Cas9 system
CN106544357B (en) 2016-08-25 2018-08-21 湖南杂交水稻研究中心 A method of cultivating low cadmium-accumulation rice variety
CN107784200B (en) 2016-08-26 2020-11-06 深圳华大生命科学研究院 Method and device for screening novel CRISPR-Cas system
CN106350540A (en) 2016-08-26 2017-01-25 苏州系统医学研究所 High-efficient inducible type CRISPR/Cas9 gene knockout carrier mediated by lentivirus and application thereof
CN106318973B (en) 2016-08-26 2019-09-13 深圳市第二人民医院 A kind of gene regulation device and gene regulation method based on CRISPR-Cas9
CN106480097A (en) 2016-10-13 2017-03-08 南京凯地生物科技有限公司 Knocking out that people PD 1 is gene constructed using CRISPR/Cas9 technology can the method for targeting MSLN novel C AR T cell and its application
CN106399375A (en) 2016-08-31 2017-02-15 南京凯地生物科技有限公司 Method for constructing CD19 targeting CAR-T (chimeric antigen receptor-T) cells by knocking out PD-1 (programmed death 1) genes by virtue of CRISPR/Cas9
CN106399367A (en) 2016-08-31 2017-02-15 深圳市卫光生物制品股份有限公司 Method for improving efficiency of CRISPR mediated homologous recombination
CN107794272B (en) 2016-09-06 2021-10-12 中国科学院上海营养与健康研究所 High-specificity CRISPR genome editing system
CN106399311A (en) 2016-09-07 2017-02-15 同济大学 Endogenous protein marking method used for Chip-seq genome-wide binding spectrum
CN106367435B (en) 2016-09-07 2019-11-08 电子科技大学 A kind of method that rice miRNA orientation knocks out
WO2018048827A1 (en) 2016-09-07 2018-03-15 Massachusetts Institute Of Technology Rna-guided endonuclease-based dna assembly
CN106399377A (en) 2016-09-07 2017-02-15 同济大学 Method for screening drug target genes based on CRISPR/Cas9 high-throughput technology
EP3510151A4 (en) 2016-09-09 2020-04-15 The Board of Trustees of the Leland Stanford Junior University High-throughput precision genome editing
CN107574179B (en) 2016-09-09 2018-07-10 康码(上海)生物科技有限公司 A kind of CRISPR/Cas9 high efficiency gene editing systems for kluyveromyces optimization
EP3512943B1 (en) 2016-09-14 2023-04-12 Yeda Research and Development Co. Ltd. Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens
CN106318934B (en) 2016-09-21 2020-06-05 上海交通大学 Gene complete sequence of carrot β (1,2) xylose transferase and plasmid construction of CRISPR/CAS9 for transfecting dicotyledonous plants
CN106957858A (en) 2016-09-23 2017-07-18 西北农林科技大学 A kind of method that utilization CRISPR/Cas9 systems knock out sheep MSTN, ASIP, BCO2 gene jointly
EP3516056A1 (en) 2016-09-23 2019-07-31 DSM IP Assets B.V. A guide-rna expression system for a host cell
US9580698B1 (en) 2016-09-23 2017-02-28 New England Biolabs, Inc. Mutant reverse transcriptase
US20180127786A1 (en) 2016-09-23 2018-05-10 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing
WO2018062866A2 (en) 2016-09-28 2018-04-05 Cellivery Therapeutics, Inc. CELL-PERMEABLE (CP)-Cas9 RECOMBINANT PROTEIN AND USES THEREOF
CN107881184B (en) 2016-09-30 2021-08-27 中国科学院分子植物科学卓越创新中心 Cpf 1-based DNA in-vitro splicing method
CN106480027A (en) 2016-09-30 2017-03-08 重庆高圣生物医药有限责任公司 CRISPR/Cas9 targeting knock out people PD 1 gene and its specificity gRNA
CN107880132B (en) 2016-09-30 2022-06-17 北京大学 Fusion protein and method for carrying out homologous recombination by using same
EP3532089A4 (en) 2016-09-30 2020-05-13 The Regents of The University of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
EP3518656A4 (en) 2016-09-30 2020-09-30 Monsanto Technology LLC Method for selecting target sites for site-specific genome modification in plants
GB2569733B (en) 2016-09-30 2022-09-14 Univ California RNA-guided nucleic acid modifying enzymes and methods of use thereof
US11730823B2 (en) 2016-10-03 2023-08-22 President And Fellows Of Harvard College Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles
WO2018067846A1 (en) 2016-10-05 2018-04-12 President And Fellows Of Harvard College Methods of crispr mediated genome modulation in v. natriegens
US10669539B2 (en) 2016-10-06 2020-06-02 Pioneer Biolabs, Llc Methods and compositions for generating CRISPR guide RNA libraries
KR20230164759A (en) 2016-10-07 2023-12-04 인티그레이티드 디엔에이 테크놀로지스 아이엔씨. S. pyogenes cas9 mutant genes and polypeptides encoded by same
CN106479985A (en) 2016-10-09 2017-03-08 上海吉玛制药技术有限公司 Application of the virus-mediated Cpf1 albumen in CRISPR/Cpf1 gene editing system
CN106434663A (en) 2016-10-12 2017-02-22 遵义医学院 Method for CRISPR/Cas9 targeted knockout of human ezrin gene enhancer key region and specific gRNA thereof
US20190365862A1 (en) 2016-10-12 2019-12-05 Temple University - Of The Commonwealth System Of Higher Education Combination therapies for eradicating flavivirus infections in subjects
IT201600102542A1 (en) 2016-10-12 2018-04-12 Univ Degli Studi Di Trento Plasmid and lentiviral system containing a self-limiting Cas9 circuit that increases its safety.
CN110290813A (en) 2016-10-14 2019-09-27 通用医疗公司 The site specific nucleic acid enzyme of epigenetic regulation
WO2018071663A1 (en) 2016-10-14 2018-04-19 Emendobio Inc. Rna compositions for genome editing
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
CN106434782B (en) 2016-10-14 2020-01-10 南京工业大学 Method for producing cis-4-hydroxyproline
WO2018074979A1 (en) 2016-10-17 2018-04-26 Nanyang Technological University Truncated crispr-cas proteins for dna targeting
US10640810B2 (en) 2016-10-19 2020-05-05 Drexel University Methods of specifically labeling nucleic acids using CRISPR/Cas
WO2018081535A2 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Dynamic genome engineering
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
EP3532616A1 (en) 2016-10-28 2019-09-04 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
BR112019001996A2 (en) 2016-10-31 2019-05-07 Eguchi High Frequency Co., Ltd. reactor
US11795453B2 (en) 2016-10-31 2023-10-24 Emendobio, Inc. Compositions for genome editing
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
WO2018085288A1 (en) 2016-11-01 2018-05-11 President And Fellows Of Harvard College Inhibitors of rna guided nucleases and uses thereof
GB201618507D0 (en) 2016-11-02 2016-12-14 Stichting Voor De Technische Wetenschappen And Wageningen Univ Microbial genome editing
US11732258B2 (en) 2016-11-02 2023-08-22 President And Fellows Of Harvard College Engineered guide RNA sequences for in situ detection and sequencing
CN106544353A (en) 2016-11-08 2017-03-29 宁夏医科大学总医院 A kind of method that utilization CRISPR Cas9 remove Acinetobacter bauamnnii drug resistance gene
EP3538561A4 (en) 2016-11-11 2020-10-21 The Regents of The University of California Variant rna-guided polypeptides and methods of use
CN106755088A (en) 2016-11-11 2017-05-31 广东万海细胞生物科技有限公司 A kind of autologous CAR T cells preparation method and application
KR20190039430A (en) 2016-11-14 2019-04-11 인스티튜트 오브 제네틱스 앤드 디벨롭멘털 바이오롤지, 차이니즈 아카데미 오브 사이언시스 How to edit bases in plants
CN106566838B (en) 2016-11-14 2019-11-01 上海伯豪生物技术有限公司 A kind of miR-126 full-length gene knockout kit and its application based on CRISPR-Cas9 technology
CN106554969A (en) 2016-11-15 2017-04-05 陕西理工学院 Mutiple Targets CRISPR/Cas9 expression vectors based on bacteriostasis and sterilization
CN106754912B (en) 2016-11-16 2019-11-08 上海交通大学 One kind orientation removes the plasmid and preparation of HBVcccDNA in liver cell
KR20190077568A (en) 2016-11-16 2019-07-03 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Inhibitors of CRISPR-Cas9
US20180282722A1 (en) 2016-11-21 2018-10-04 Massachusetts Institute Of Technology Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
CN106480067A (en) 2016-11-21 2017-03-08 中国农业科学院烟草研究所 The old and feeble application of Nicotiana tabacum L. NtNAC096 Gene Handling Nicotiana tabacum L.
JP2019535287A (en) 2016-11-22 2019-12-12 インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド CRISPR / CPF1 system and method
CN106755091A (en) 2016-11-28 2017-05-31 中国人民解放军第三军医大学第附属医院 Gene knockout carrier, MH7A cell NLRP1 gene knockout methods
US20200046854A1 (en) 2016-11-28 2020-02-13 The Board Of Regents Of The University Of Texas System Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing
CN106480036B (en) 2016-11-30 2019-04-09 华南理工大学 A kind of DNA fragmentation and its application with promoter function
CA3045335A1 (en) 2016-12-01 2018-06-07 Universite Laval Crispr-based treatment of friedreich ataxia
CN106834323A (en) 2016-12-01 2017-06-13 安徽大学 A kind of gene editing method based on Virginia streptomycete IBL14 genes cas7 53
CN107043779B (en) 2016-12-01 2020-05-12 中国农业科学院作物科学研究所 Application of CRISPR/nCas 9-mediated site-specific base substitution in plants
US9816093B1 (en) 2016-12-06 2017-11-14 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
CN106701830B (en) 2016-12-07 2020-01-03 湖南人文科技学院 Pig embryo p66 knock-outshcMethod for gene
WO2018103686A1 (en) 2016-12-07 2018-06-14 中国科学院上海生命科学研究院 Chloroplast genome editing method
US11192929B2 (en) 2016-12-08 2021-12-07 Regents Of The University Of Minnesota Site-specific DNA base editing using modified APOBEC enzymes
JP2019536464A (en) 2016-12-08 2019-12-19 インテリア セラピューティクス,インコーポレイテッド Modified guide RNA
CN106544351B (en) 2016-12-08 2019-09-10 江苏省农业科学院 CRISPR-Cas9 knock out in vitro drug resistant gene mcr-1 method and its dedicated cell-penetrating peptides
WO2018107103A1 (en) 2016-12-09 2018-06-14 The Broad Institute, Inc. Crispr-systems for modifying a trait of interest in a plant
PT3551753T (en) 2016-12-09 2022-09-02 Harvard College Crispr effector system based diagnostics
WO2018111946A1 (en) 2016-12-12 2018-06-21 Integrated Dna Technologies, Inc. Genome editing detection
US11293022B2 (en) 2016-12-12 2022-04-05 Integrated Dna Technologies, Inc. Genome editing enhancement
CN107893074A (en) 2016-12-13 2018-04-10 广东赤萌医疗科技有限公司 A kind of gRNA, expression vector, knockout system, kit for being used to knock out CXCR4 genes
WO2018109101A1 (en) 2016-12-14 2018-06-21 Wageningen Universiteit Thermostable cas9 nucleases
CN110312792B (en) 2016-12-14 2024-04-09 瓦赫宁根大学 Thermostable Cas9 nucleases
KR101748575B1 (en) 2016-12-16 2017-06-20 주식회사 엠젠플러스 INSulin gene knockout diabetes mellitus or diabetic complications animal model and a method for producing the same
WO2018112336A1 (en) 2016-12-16 2018-06-21 Ohio State Innovation Foundation Systems and methods for dna-guided rna cleavage
EP3555629A4 (en) 2016-12-18 2020-11-25 Selonterra, Inc. Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
CN106755026A (en) 2016-12-18 2017-05-31 吉林大学 The foundation of the structure and enamel hypocalcification model of sgRNA expression vectors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
KR20230125856A (en) 2016-12-23 2023-08-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Gene editing of pcsk9
CN106755424B (en) 2016-12-26 2020-11-06 郑州大学 Escherichia coli ST131 strain detection primer, kit and detection method based on CRISPR
CN107354173A (en) 2016-12-26 2017-11-17 浙江省医学科学院 The method that liver specificity knock-out mice model is established based on CRISPR technologies and hydrodynamic force tail vein injection
CN106834347A (en) 2016-12-27 2017-06-13 安徽省农业科学院畜牧兽医研究所 A kind of goat CDK2 gene knockout carriers and its construction method
CN106755097A (en) 2016-12-27 2017-05-31 安徽省农业科学院畜牧兽医研究所 A kind of goat TLR4 gene knockout carriers and its construction method
CN106597260B (en) 2016-12-29 2020-04-03 合肥工业大学 Analog circuit fault diagnosis method based on continuous wavelet analysis and ELM network
CN106868008A (en) 2016-12-30 2017-06-20 重庆高圣生物医药有限责任公司 CRISPR/Cas9 targeting knock outs people Lin28A genes and its specificity gRNA
CN106834341B (en) 2016-12-30 2020-06-16 中国农业大学 Gene site-directed mutagenesis vector and construction method and application thereof
CN106701763B (en) 2016-12-30 2019-07-19 重庆高圣生物医药有限责任公司 CRISPR/Cas9 targeting knockout human hepatitis B virus P gene and its specificity gRNA
CN106755077A (en) 2016-12-30 2017-05-31 华智水稻生物技术有限公司 Using CRISPR CAS9 technologies to the method for paddy rice CENH3 site-directed point mutations
CN106701818B (en) 2017-01-09 2020-04-24 湖南杂交水稻研究中心 Method for cultivating common genic male sterile line of rice
EP3568476A1 (en) 2017-01-11 2019-11-20 Oxford University Innovation Limited Crispr rna
CN107012164B (en) 2017-01-11 2023-03-03 电子科技大学 CRISPR/Cpf1 plant genome directed modification functional unit, vector containing functional unit and application of functional unit
KR102084186B1 (en) 2017-01-17 2020-03-03 기초과학연구원 Method of identifying genome-wide off-target sites of base editors by detecting single strand breaks in genomic DNA
CN106701823A (en) 2017-01-18 2017-05-24 上海交通大学 Establishment and application of CHO cell line for producing fucose-free monoclonal antibody
US20180201921A1 (en) 2017-01-18 2018-07-19 Excision Biotherapeutics, Inc. CRISPRs
CN107058372A (en) 2017-01-18 2017-08-18 四川农业大学 A kind of construction method of CRISPR/Cas9 carriers applied on plant
CN106801056A (en) 2017-01-24 2017-06-06 中国科学院广州生物医药与健康研究院 The slow virus carrier and application of a kind of sgRNA and its structure
AU2018212624A1 (en) 2017-01-30 2019-08-22 KWS SAAT SE & Co. KGaA Repair template linkage to endonucleases for genome engineering
TWI608100B (en) 2017-02-03 2017-12-11 國立清華大學 Cas9 expression plasmid, gene editing system of escherichia coli and method thereof
WO2018148246A1 (en) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
CN110612113B (en) 2017-02-07 2024-03-26 加利福尼亚大学董事会 Gene therapy for haploid insufficiency
US11866699B2 (en) 2017-02-10 2024-01-09 University Of Washington Genome editing reagents and their use
IT201700016321A1 (en) 2017-02-14 2018-08-14 Univ Degli Studi Di Trento HIGH-SPECIFICITY CAS9 MUTANTS AND THEIR APPLICATIONS.
US20200063127A1 (en) 2017-02-15 2020-02-27 Massachusetts Institute Of Technology Dna writers, molecular recorders and uses thereof
CN106957855B (en) 2017-02-16 2020-04-17 上海市农业科学院 Method for targeted knockout of rice dwarf gene SD1 by using CRISPR/Cas9 technology
US20190367924A1 (en) 2017-02-17 2019-12-05 Temple University - Of The Commonwealth System Of Higher Education Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5
WO2018149418A1 (en) 2017-02-20 2018-08-23 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Genome editing system and method
CA3053709A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (pcsk9)-related disorders
EP3585898A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
WO2018154412A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of merosin-deficient cogenital muscular dystrophy (mdcmd) and other laminin, alpha 2 (lama2) gene related conditions or disorders
JP2020508056A (en) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG Compositions and methods for gene editing
WO2018156372A1 (en) 2017-02-22 2018-08-30 The Regents Of The University Of California Genetically modified non-human animals and products thereof
WO2018154462A2 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
WO2018154418A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
WO2018154459A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
WO2018154413A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders
CN106868031A (en) 2017-02-24 2017-06-20 北京大学 A kind of cloning process of multiple sgRNA series parallels expression based on classification assembling and application
WO2018161009A1 (en) 2017-03-03 2018-09-07 Yale University Aav-mediated direct in vivo crispr screen in glioblastoma
US11111492B2 (en) 2017-03-06 2021-09-07 Florida State University Research Foundation, Inc. Genome engineering methods using a cytosine-specific Cas9
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
CN110914310A (en) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 Cytosine to guanine base editor
JP2020513814A (en) 2017-03-14 2020-05-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Operation of CRISPR CAS9 Immune Stealth
JP2020513815A (en) 2017-03-15 2020-05-21 ザ・ブロード・インスティテュート・インコーポレイテッド Diagnostic method for virus detection based on clustered short repeat palindrome effector system
CN106978428A (en) 2017-03-15 2017-07-25 上海吐露港生物科技有限公司 A kind of Cas albumen specific bond target DNA, the method for regulation and control target gene transcription and kit
CN106906242A (en) 2017-03-16 2017-06-30 重庆高圣生物医药有限责任公司 A kind of method that raising CRIPSR/Cas9 targeting knock outs gene produces nonhomologous end joint efficiency
EP3600382A4 (en) 2017-03-21 2020-12-30 Anthony P. Shuber Treating cancer with cas endonuclease complexes
SG11201908658TA (en) 2017-03-23 2019-10-30 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
CN107012213A (en) 2017-03-24 2017-08-04 南开大学 The biomarker of colorectal cancer
CN106947780A (en) 2017-03-28 2017-07-14 扬州大学 A kind of edit methods of rabbit MSTN genes
EP3985113A1 (en) 2017-03-28 2022-04-20 Locanabio, Inc. Crispr-associated (cas) protein
CN106906240A (en) 2017-03-29 2017-06-30 浙江大学 The method that the key gene HPT in barley VE synthesis paths is knocked out with CRISPR Cas9 systems
CA3058584A1 (en) 2017-03-30 2018-10-04 Kyoto University Method for inducing exon skipping by genome editing
CN108660161B (en) 2017-03-31 2023-05-09 中国科学院脑科学与智能技术卓越创新中心 Method for preparing chimeric gene-free knockout animal based on CRISPR/Cas9 technology
CN107058358B (en) 2017-04-01 2020-06-09 中国科学院微生物研究所 Construction of double-spacer sequence recognition and cleavage CRISPR-Cas9 vector and application of vector in Verticillium daemonii
CN106967726B (en) 2017-04-05 2020-12-29 华南农业大学 Method for creating interspecific hybrid compatible line of Asian cultivated rice and African cultivated rice and application
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
CN107142282A (en) 2017-04-06 2017-09-08 中山大学 A kind of method that utilization CRISPR/Cas9 realizes large fragment DNA site-directed integration in mammalian cell
CN107034229A (en) 2017-04-07 2017-08-11 江苏贝瑞利生物科技有限公司 High frequency zone CRISPR/CAS9 gene editings system candidate sgRNA systems and application in a kind of plant
CN107058320B (en) 2017-04-12 2019-08-02 南开大学 The preparation and its application of IL7R gene delection zebra fish mutant
CN106916852B (en) 2017-04-13 2020-12-04 上海科技大学 Base editing system and construction and application method thereof
CN108728476A (en) 2017-04-14 2018-11-02 复旦大学 A method of generating diversity antibody library using CRISPR systems
CN107298701B (en) 2017-04-18 2020-10-30 上海大学 Corn transcription factor ZmbZIP22 and application thereof
JP2020517301A (en) 2017-04-20 2020-06-18 イージェネシス,インコーポレイテッド Method for making genetically modified animals
CN106957844A (en) 2017-04-20 2017-07-18 华侨大学 It is a kind of effectively to knock out the virus genomic CRISPR/Cas9 of HTLV 1 gRNA sequences
US11773409B2 (en) 2017-04-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors
CN110799525A (en) 2017-04-21 2020-02-14 通用医疗公司 Variants of CPF1(CAS12a) with altered PAM specificity
EP3615665A1 (en) 2017-04-24 2020-03-04 DuPont Nutrition Biosciences ApS Novel anti-crispr genes and proteins and methods of use
CN107043775B (en) 2017-04-24 2020-06-16 中国农业科学院生物技术研究所 sgRNA capable of promoting development of cotton lateral roots and application thereof
CN206970581U (en) 2017-04-26 2018-02-06 重庆威斯腾生物医药科技有限责任公司 A kind of kit for being used to aid in CRISPR/cas9 gene knockouts
US20180312822A1 (en) 2017-04-26 2018-11-01 10X Genomics, Inc. Mmlv reverse transcriptase variants
WO2018197020A1 (en) 2017-04-27 2018-11-01 Novozymes A/S Genome editing by crispr-cas9 using short donor oligonucleotides
WO2018202800A1 (en) 2017-05-03 2018-11-08 Kws Saat Se Use of crispr-cas endonucleases for plant genome engineering
CN110785489A (en) 2017-05-04 2020-02-11 宾夕法尼亚大学董事会 Compositions and methods for gene editing in T cells using CRISPR/Cpf1
CN107012174A (en) 2017-05-04 2017-08-04 昆明理工大学 Application of the CRISPR/Cas9 technologies in silkworm zinc finger protein gene mutant is obtained
CN107254485A (en) 2017-05-08 2017-10-17 南京农业大学 A kind of new reaction system for being capable of rapid build plant gene fixed point knockout carrier
WO2018208755A1 (en) 2017-05-09 2018-11-15 The Regents Of The University Of California Compositions and methods for tagging target proteins in proximity to a nucleotide sequence of interest
CN107129999A (en) 2017-05-09 2017-09-05 福建省农业科学院畜牧兽医研究所 Using surely turn CRISPR/Cas9 systems to viral genome carry out target editor method
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
EP3622062A4 (en) 2017-05-10 2020-10-14 The Regents of the University of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN107130000B (en) 2017-05-12 2019-12-17 浙江卫未生物医药科技有限公司 CRISPR-Cas9 system for simultaneously knocking out KRAS gene and EGFR gene and application thereof
CN106957830B (en) 2017-05-16 2020-12-25 上海交通大学 Cas9 nuclease delta F916 and application thereof
CN107326042A (en) 2017-05-16 2017-11-07 上海交通大学 The fixed point of paddy rice TMS10 genes knocks out system and its application
CN106947750B (en) 2017-05-16 2020-12-08 上海交通大学 Cas9 nuclease Q920P and application thereof
CN106939303B (en) 2017-05-16 2021-02-23 上海交通大学 Cas9 nuclease R919P and application thereof
CN106987570A (en) 2017-05-16 2017-07-28 上海交通大学 A kind of Cas9 Nuclease Rs 780A and application thereof
CN106916820B (en) 2017-05-16 2019-09-27 吉林大学 SgRNA and its application of porcine ROSA 26 gene can effectively be edited
CN106967697B (en) 2017-05-16 2021-03-26 上海交通大学 Cas9 nuclease G915F and application thereof
CN107012250B (en) 2017-05-16 2021-01-29 上海交通大学 Analysis method and application of genome DNA fragment editing accuracy suitable for CRISPR/Cas9 system
CN106957831B (en) 2017-05-16 2021-03-12 上海交通大学 Cas9 nuclease K918A and application thereof
KR20200026804A (en) 2017-05-18 2020-03-11 더 브로드 인스티튜트, 인코퍼레이티드 Systems, Methods, and Compositions for Targeted Nucleic Acid Editing
US20200181623A1 (en) 2017-05-18 2020-06-11 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US11591620B2 (en) 2017-05-18 2023-02-28 Cargill, Incorporated Genome editing system
WO2018213791A1 (en) 2017-05-18 2018-11-22 Children's National Medical Center Compositions comprising aptamers and nucleic acid payloads and methods of using the same
CN107236737A (en) 2017-05-19 2017-10-10 上海交通大学 The sgRNA sequences of special target arabidopsis ILK2 genes and its application
CN107043787B (en) 2017-05-19 2017-12-26 南京医科大学 A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9
WO2018217852A1 (en) 2017-05-23 2018-11-29 Gettysburg College Crispr based tool for characterizing bacterial serovar diversity
CN107034188B (en) 2017-05-24 2018-07-24 中山大学附属口腔医院 A kind of excretion body carrier, CRISPR/Cas9 gene editings system and the application of targeting bone
AU2018272067A1 (en) 2017-05-25 2019-11-28 The General Hospital Corporation Base editors with improved precision and specificity
EP3630975A4 (en) 2017-05-26 2021-03-10 North Carolina State University Altered guide rnas for modulating cas9 activity and methods of use
CN107287245B (en) 2017-05-27 2020-03-17 南京农业大学 Construction method of Glrx1 gene knockout animal model based on CRISPR/Cas9 technology
CN107142272A (en) 2017-06-05 2017-09-08 南京金斯瑞生物科技有限公司 A kind of method for controlling plasmid replication in Escherichia coli
CN107034218A (en) 2017-06-07 2017-08-11 浙江大学 Targeting sgRNA, modification carrier for pig APN gene editings and its preparation method and application
CN107119071A (en) 2017-06-07 2017-09-01 江苏三黍生物科技有限公司 A kind of method for reducing plant amylose content and application
CN107177595A (en) 2017-06-07 2017-09-19 浙江大学 Targeting sgRNA, modification carrier for pig CD163 gene editings and its preparation method and application
CN106987757A (en) 2017-06-12 2017-07-28 苏州双金实业有限公司 A kind of corrosion resistant type austenitic based alloy
CN107236739A (en) 2017-06-12 2017-10-10 上海捷易生物科技有限公司 The method of CRISPR/SaCas9 specific knockdown people's CXCR4 genes
CN107083392B (en) 2017-06-13 2020-09-08 中国医学科学院病原生物学研究所 CRISPR/Cpf1 gene editing system and application thereof in mycobacteria
CN107227352A (en) 2017-06-13 2017-10-03 西安医学院 The detection method of GPR120 gene expressions based on eGFP and application
CN107245502B (en) 2017-06-14 2020-11-03 中国科学院武汉病毒研究所 CD 2-binding protein (CD2AP) and its interacting protein
CN107312798B (en) 2017-06-16 2020-06-23 武汉大学 CRISPR/Cas9 recombinant lentiviral vector containing gRNA sequence of specific targeting CCR5 gene and application
CN107099850B (en) 2017-06-19 2018-05-04 东北农业大学 A kind of method that CRISPR/Cas9 genomic knockouts library is built by digestion genome
CN107266541B (en) 2017-06-20 2021-06-04 上海大学 Corn transcription factor ZmbHLH167 and application thereof
CN107446951B (en) 2017-06-20 2021-01-08 温氏食品集团股份有限公司 Method for rapidly screening recombinant fowlpox virus through CRISPR/Cas9 system and application thereof
CN107058328A (en) 2017-06-22 2017-08-18 江苏三黍生物科技有限公司 A kind of method for improving plant amylose content and application
CN107119053A (en) 2017-06-23 2017-09-01 东北农业大学 A kind of sgRNA targeting sequencings of special target pig MC4R genes and its application
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
CN107227307A (en) 2017-06-23 2017-10-03 东北农业大学 A kind of sgRNA targeting sequencings of special target pig IRS1 genes and its application
CN107099533A (en) 2017-06-23 2017-08-29 东北农业大学 A kind of sgRNA targeting sequencings of special target pig IGFBP3 genes and application
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. Crispr/cas-cytidine deaminase based compositions, systems, and methods for targeted nucleic acid editing
CN107177631B (en) 2017-06-26 2020-11-24 中国农业大学 Method for knocking out NRK cell Slc22a2 gene by using CRISPR-CAS9 technology
CN107217075B (en) 2017-06-28 2021-07-02 西安交通大学医学院第一附属医院 Method for constructing EPO gene knockout zebra fish animal model, primer, plasmid and preparation method
CN107356793A (en) 2017-07-01 2017-11-17 合肥东玖电气有限公司 A kind of fire-proof ammeter box
CN107312793A (en) 2017-07-05 2017-11-03 新疆农业科学院园艺作物研究所 The tomato dna editor carrier of Cas9 mediations and its application
US20200202981A1 (en) 2017-07-07 2020-06-25 The Broad Institute, Inc. Methods for designing guide sequences for guided nucleases
CN107190006A (en) 2017-07-07 2017-09-22 南通大学附属医院 A kind of sgRNA of targeting IGF IR genes and its application
CN107190008A (en) 2017-07-19 2017-09-22 苏州吉赛基因测序科技有限公司 A kind of method of capture genome target sequence based on Crispr/cas9 and its application in high-flux sequence
CN107236741A (en) 2017-07-19 2017-10-10 广州医科大学附属第五医院 A kind of gRNA and method for knocking out wild-type T cells TCR alpha chains
CN107400677B (en) 2017-07-19 2020-05-22 江南大学 Bacillus licheniformis genome editing vector based on CRISPR-Cas9 system and preparation method thereof
CN107354156B (en) 2017-07-19 2021-02-09 广州医科大学附属第五医院 gRNA for knocking out TCR beta chain of wild T cell and method
CN107267515B (en) 2017-07-28 2020-08-25 重庆医科大学附属儿童医院 CRISPR/Cas9 targeted knockout human CNE10 gene and specific gRNA thereof
CN107384922A (en) 2017-07-28 2017-11-24 重庆医科大学附属儿童医院 CRISPR/Cas9 targeting knock outs people CNE9 genes and its specific gRNA
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
CN107435051B (en) 2017-07-28 2020-06-02 新乡医学院 Cell line gene knockout method for rapidly obtaining large fragment deletion through CRISPR/Cas9 system
CN107418974A (en) 2017-07-28 2017-12-01 新乡医学院 It is a kind of to sort the quick method for obtaining CRISPR/Cas9 gene knockout stable cell lines using monoclonal cell
CN107446954A (en) 2017-07-28 2017-12-08 新乡医学院 A kind of preparation method of SD rat T cells deleting genetic model
CN107435069A (en) 2017-07-28 2017-12-05 新乡医学院 A kind of quick determination method of cell line CRISPR/Cas9 gene knockouts
CN107217042B (en) 2017-07-31 2020-03-06 江苏东抗生物医药科技有限公司 Genetic engineering cell line for producing afucosylated protein and establishing method thereof
CN107446922A (en) 2017-08-03 2017-12-08 无锡市第二人民医院 A kind of gRNA sequences and its application method for knocking out hepcidin gene in human osteoblast cell's strain
CN107502618B (en) 2017-08-08 2021-03-12 中国科学院微生物研究所 Controllable vector elimination method and easy-to-use CRISPR-Cas9 tool
CN107312785B (en) 2017-08-09 2019-12-06 四川农业大学 Application of OsKTN80b gene in reducing plant height of rice
CN107446923B (en) 2017-08-13 2019-12-31 中国人民解放军疾病预防控制所 rAAV8-CRISPR-SaCas9 system and application thereof in preparation of hepatitis B treatment drug
CN107384926B (en) 2017-08-13 2020-06-26 中国人民解放军疾病预防控制所 CRISPR-Cas9 system for targeted removal of bacterial drug-resistant plasmids and application
CN107365804B (en) 2017-08-13 2019-12-20 中国人民解放军疾病预防控制所 Method for packaging CRISPR-Cas9 system by using temperate phage vector
CN107815463A (en) 2017-08-15 2018-03-20 西南大学 CRISPR/Cas9 technologies mediate the method for building up of miR167 precursor sequence editor's systems
CN107446924B (en) 2017-08-16 2020-01-14 中国科学院华南植物园 Kiwi fruit gene AcPDS editing vector based on CRISPR-Cas9 and construction method and application thereof
CN108034656A (en) 2017-08-16 2018-05-15 四川省农业科学院生物技术核技术研究所 SgRNA, CRISPR/Cas9 carrier related with rice bronzing glume character, vector construction, application
CN107384894B (en) 2017-08-21 2019-10-22 华南师范大学 Functional graphene oxide efficiently delivers method of the CRISPR/Cas9 for gene editing
CN107299114B (en) 2017-08-23 2021-08-27 中国科学院分子植物科学卓越创新中心 Efficient yeast chromosome fusion method
CN107557393B (en) 2017-08-23 2020-05-08 中国科学院上海应用物理研究所 Magnetic nanomaterial-mediated CRISPR/Cas 9T cell internal delivery system and preparation method and application thereof
CN107312795A (en) 2017-08-24 2017-11-03 浙江省农业科学院 The gene editing method of pink colour fruit tomato is formulated with CRISPR/Cas9 systems
CN107460196A (en) 2017-08-25 2017-12-12 同济大学 A kind of construction method of immunodeficient mouse animal model and application
CN107488649A (en) 2017-08-25 2017-12-19 南方医科大学 A kind of fusion protein of Cpf1 and p300 Core domains, corresponding DNA target are to activation system and application
CN107541525B (en) 2017-08-26 2021-12-10 内蒙古大学 Method for mediating goat Tbeta 4 gene fixed-point knock-in based on CRISPR/Cas9 technology
CN107446932B (en) 2017-08-29 2020-02-21 江西省农业科学院 Gene for controlling male reproductive development of rice and application thereof
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
CN107519492B (en) 2017-09-06 2019-01-25 武汉迈特维尔生物科技有限公司 Application of the miR-3187-3p in coronary atherosclerotic heart disease is knocked out using CRISPR technology
CN107641631A (en) 2017-09-07 2018-01-30 浙江工业大学 A kind of method that bacillus coli gene is knocked out based on CRISPR/Cas9 systems by chemical conversion mediation
CN107362372B (en) 2017-09-07 2019-01-11 佛山波若恩生物科技有限公司 Use application of the CRISPR technology in coronary atherosclerotic heart disease
CN107502608B (en) 2017-09-08 2020-10-16 中山大学 Construction method and application of sgRNA and ALDH2 gene-deleted cell strain for knocking out human ALDH2 gene
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California Rna-guided endonuclease fusion polypeptides and methods of use thereof
CN107557455A (en) 2017-09-15 2018-01-09 国家纳米科学中心 A kind of detection method of the nucleic acid specific fragment based on CRISPR Cas13a
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
CN107557390A (en) 2017-09-18 2018-01-09 江南大学 A kind of method for screening the high expression sites of Chinese hamster ovary celI system
CN107475300B (en) 2017-09-18 2020-04-21 上海市同济医院 Construction method and application of Ifit3-eKO1 gene knockout mouse animal model
CN107523583A (en) 2017-09-19 2017-12-29 安徽大学 A kind of prokaryotic gene edit methods for coming from gene cas5 3 in I type CRISPR Cas systems
CN107557378A (en) 2017-09-19 2018-01-09 安徽大学 Gene cas7 3 eukaryotic gene edit methods in a kind of type CRISPR Cas systems based on I
CN107557373A (en) 2017-09-19 2018-01-09 安徽大学 A kind of gene editing method based on I Type B CRISPR Cas system genes cas3
CN107630042A (en) 2017-09-19 2018-01-26 安徽大学 A kind of prokaryotic gene edit methods for coming from I type Cas 4 cas genes of system
CN107630041A (en) 2017-09-19 2018-01-26 安徽大学 A kind of eukaryotic gene edit methods based on Virginia streptomycete IBL14 I Type B Cas systems
CN107619837A (en) 2017-09-20 2018-01-23 西北农林科技大学 The method that nuclease-mediated Ipr1 fixed points insertion acquisition transgenic cow fetal fibroblast is cut using Cas9
CN107513531B (en) 2017-09-21 2020-02-21 无锡市妇幼保健院 gRNA target sequence for endogenously over-expressing lncRNA-XIST and application thereof
CN107686848A (en) 2017-09-26 2018-02-13 中山大学孙逸仙纪念医院 The stable of transposons collaboration CRISPR/Cas9 systems knocks out single plasmid vector and its application
CN107760652A (en) 2017-09-29 2018-03-06 华南理工大学 The cell models of caco 2 and its method that CRISPR/CAS9 mediate drugs transporter target knocks out
CN107557394A (en) 2017-09-29 2018-01-09 南京鼓楼医院 The method for reducing embryonic gene editor's miss rate of CRISPR/Cas9 mediations
CN107760663A (en) 2017-09-30 2018-03-06 新疆大学 The clone of chufa pepc genes and structure and the application of expression vector
CN107630006B (en) 2017-09-30 2020-09-11 山东兴瑞生物科技有限公司 Method for preparing T cell with double knockout genes of TCR and HLA
CN107828794A (en) 2017-09-30 2018-03-23 上海市农业生物基因中心 A kind of method for creating of Rice Salt gene OsRR22 mutant, its amino acid sequence encoded, plant and the mutant
CN107604003A (en) 2017-10-10 2018-01-19 南方医科大学 One kind knocks out kit and its application based on linearisation CRISPR CAS9 lentiviral vector genomes
CN107474129B (en) 2017-10-12 2018-10-19 江西汉氏联合干细胞科技有限公司 The method of specificity enhancing CRISPR-CAS system gene editorial efficiencies
CN107557381A (en) 2017-10-12 2018-01-09 南京农业大学 A kind of foundation and its application of Chinese cabbage CRISPR Cas9 gene editing systems
CN108102940B (en) 2017-10-12 2021-07-13 中石化上海工程有限公司 Industrial saccharomyces cerevisiae strain with XKS1 gene knocked out by CRISPR/Cas9 system and construction method
CN108103586A (en) 2017-10-13 2018-06-01 上海科技大学 A kind of CRISPR/Cas9 random libraries and its structure and application
CN107619829B (en) 2017-10-14 2018-08-24 南京平港生物技术有限公司 The method that GINS2 gene knockouts are carried out to mescenchymal stem cell using CRISPR-CAS systems
CN107586779B (en) 2017-10-14 2018-08-28 天津金匙生物科技有限公司 The method that CASP3 gene knockouts are carried out to mescenchymal stem cell using CRISPR-CAS systems
AU2018352592A1 (en) 2017-10-16 2020-06-04 Beam Therapeutics, Inc. Uses of adenosine base editors
CN107523567A (en) 2017-10-16 2017-12-29 遵义医学院 A kind of construction method for the esophageal cancer cell strain for knocking out people's ezrin genetic enhancers
CN107760715B (en) 2017-10-17 2021-12-10 张业胜 Transgenic vector and construction method and application thereof
CN107937427A (en) 2017-10-20 2018-04-20 广东石油化工学院 A kind of homologous repair vector construction method based on CRISPR/Cas9 systems
CN107893086B (en) 2017-10-24 2021-09-03 中国科学院武汉植物园 Method for rapidly constructing Cas9 binary expression vector library of paired sgRNAs
CN107760684B (en) 2017-11-03 2018-09-25 上海拉德钫斯生物科技有限公司 The method that RBM17 gene knockouts are carried out to mescenchymal stem cell using CRISPR-CAS systems
CN107858346B (en) 2017-11-06 2020-06-16 天津大学 Method for knocking out saccharomyces cerevisiae chromosome
CN107794276A (en) 2017-11-08 2018-03-13 中国农业科学院作物科学研究所 Fast and effectively crops pinpoint genetic fragment or allele replacement method and system for a kind of CRISPR mediations
CN107630043A (en) 2017-11-14 2018-01-26 吉林大学 The method that Gadd45a knockout rabbit models are established using knockout technology
CN108441519A (en) 2017-11-15 2018-08-24 中国农业大学 The method that homologous remediation efficiency is improved in CRISPR/CAS9 gene editings
CN107858373B (en) 2017-11-16 2020-03-17 山东省千佛山医院 Construction method of endothelial cell conditional knockout CCR5 gene mouse model
CN107893075A (en) 2017-11-17 2018-04-10 和元生物技术(上海)股份有限公司 CRISPR Cas9 targeting knock out people colon-cancer cell RITA genes and its specific sgRNA
CN108192956B (en) 2017-11-17 2021-06-01 东南大学 Cas9 nuclease-based DNA detection and analysis method and application thereof
CN107828874B (en) 2017-11-20 2020-10-16 东南大学 DNA detection and typing method based on CRISPR and application thereof
CN107904261A (en) 2017-11-21 2018-04-13 福州大学 The preparation of CRISPR/Cas9 nano gene systems and its application in terms of transfection
CN107653256A (en) 2017-11-21 2018-02-02 云南省烟草农业科学研究院 A kind of Polyphenol Oxidase in Tobacco gene NtPPO1 and its directed mutagenesis method and application
CN107893076A (en) 2017-11-23 2018-04-10 和元生物技术(上海)股份有限公司 CRISPR Cas9 targeting knock outs human breast cancer cell RASSF2 genes and its specific sgRNA
CN107937501A (en) 2017-11-24 2018-04-20 安徽师范大学 A kind of method of fast and convenient screening CRISPR/Cas gene editing positive objects
CN107937432B (en) 2017-11-24 2020-05-01 华中农业大学 Genome editing method based on CRISPR system and application thereof
CN107828738A (en) 2017-11-28 2018-03-23 新乡医学院 A kind of dnmt rna deficiency Chinese hamster ovary celI system and preparation method and application
CN107988256B (en) 2017-12-01 2020-07-28 暨南大学 Recombinant vector for knocking-in human Huntington gene, construction method thereof and application thereof in construction of model pig
CN108570479B (en) 2017-12-06 2020-04-03 内蒙古大学 Method for mediating down producing goat VEGF gene fixed-point knock-in based on CRISPR/Cas9 technology
CN108148873A (en) 2017-12-06 2018-06-12 南方医科大学 A kind of CAV-1 gene delections zebra fish and preparation method thereof
CN108315330B (en) 2017-12-07 2020-05-19 嘉兴市第一医院 sgRNA of CRISPR-Cas9 system specific targeting human RSPO2 gene, knockout method and application
CN108251423B (en) 2017-12-07 2020-11-06 嘉兴市第一医院 sgRNA of CRISPR-Cas9 system specific targeting human RSPO2 gene, activation method and application
CN108148835A (en) 2017-12-07 2018-06-12 和元生物技术(上海)股份有限公司 The sgRNA of CRISPR-Cas9 targeting knock out SLC30A1 genes and its specificity
CN107974466B (en) 2017-12-07 2020-09-29 中国科学院水生生物研究所 Sturgeon CRISPR/Cas9 gene editing method
CN107828826A (en) 2017-12-12 2018-03-23 南开大学 A kind of external method for efficiently obtaining NSC
CN108103098B (en) 2017-12-14 2020-07-28 华南理工大学 Compound skin sensitization in-vitro evaluation cell model and construction method thereof
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN107988268A (en) 2017-12-18 2018-05-04 湖南师范大学 A kind of method of gene knockout selection and breeding tcf25 Gene Deletion zebra fish
CN108018316A (en) 2017-12-20 2018-05-11 湖南师范大学 A kind of method of gene knockout selection and breeding rmnd5b Gene Deletion zebra fish
CN108048466B (en) 2017-12-21 2020-02-07 嘉兴市第一医院 CRRNA of CRISPR-Cas13a system specific targeting human RSPO2 gene, system and application
RU2652899C1 (en) 2017-12-28 2018-05-03 Федеральное бюджетное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Rna-conductors to suppress the replication of hepatitis b virus and for the elimination of hepatitis b virus from host cell
CN107893080A (en) 2017-12-29 2018-04-10 江苏省农业科学院 A kind of sgRNA for targetting rat Inhba genes and its application
CN107988229B (en) 2018-01-05 2020-01-07 中国农业科学院作物科学研究所 Method for obtaining tillering-changed rice by modifying OsTAC1 gene through CRISPR-Cas
CN107988246A (en) 2018-01-05 2018-05-04 汕头大学医学院 A kind of gene knockout carrier and its zebra fish Glioma Model
CN108103092B (en) 2018-01-05 2021-02-12 中国农业科学院作物科学研究所 System for modifying OsHPH gene by using CRISPR-Cas system to obtain dwarf rice and application thereof
CN108559760A (en) 2018-01-09 2018-09-21 陕西师范大学 The method for establishing luciferase knock-in cell lines based on CRISPR targeted genomic modification technologies
WO2019139951A1 (en) 2018-01-09 2019-07-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Detecting protein interaction sites in nucleic acids
CN108559730B (en) 2018-01-12 2021-09-24 中国人民解放军第四军医大学 Experimental method for constructing Hutat2 Fc gene knock-in monocyte by CRISPR/Cas9 technology
CN108148837A (en) 2018-01-12 2018-06-12 南京医科大学 ApoE-CRISPR/Cas9 carriers and its application in ApoE genes are knocked out
CN108251451A (en) 2018-01-16 2018-07-06 西南大学 CRISPR/Cas9-gRNA target practices sequence pair, plasmid and its application of HTT
CN108251452A (en) 2018-01-17 2018-07-06 扬州大学 A kind of transgenic zebrafish for expressing Cas9 genes and its construction method and application
CN108359712B (en) 2018-02-09 2020-06-26 广东省农业科学院农业生物基因研究中心 Method for rapidly and efficiently screening SgRNA target DNA sequence
CN108559745A (en) 2018-02-10 2018-09-21 和元生物技术(上海)股份有限公司 The method for improving B16F10 cell transfecting efficiencies based on CRISPR-Cas9 technologies
CN108359691B (en) 2018-02-12 2021-09-28 中国科学院重庆绿色智能技术研究院 Kit and method for knocking out abnormal mitochondrial DNA by mito-CRISPR/Cas9 system
CN108486145A (en) 2018-02-12 2018-09-04 中国科学院遗传与发育生物学研究所 Plant efficient methods of homologous recombination based on CRISPR/Cas9
CN109021111B (en) 2018-02-23 2021-12-07 上海科技大学 Gene base editor
CN108396027A (en) 2018-02-27 2018-08-14 和元生物技术(上海)股份有限公司 The sgRNA of CRISPR-Cas9 targeting knock out people colon-cancer cell DEAF1 genes and its specificity
CN108486159B (en) 2018-03-01 2021-10-22 南通大学附属医院 CRISPR-Cas9 system for knocking out GRIN2D gene and application thereof
CN108410906A (en) 2018-03-05 2018-08-17 淮海工学院 A kind of CRISPR/Cpf1 gene editing methods being applicable in Yu Haiyang shell-fish mitochondrial genomes
CN108342480B (en) 2018-03-05 2022-03-01 北京医院 Gene variation detection quality control substance and preparation method thereof
CN108410907B (en) 2018-03-08 2021-08-27 湖南农业大学 Method for realizing HMGCR gene knockout based on CRISPR/Cas9 technology
CN108410911B (en) 2018-03-09 2021-08-20 广西医科大学 LMNA gene knockout cell line constructed based on CRISPR/Cas9 technology
CN108486146B (en) 2018-03-16 2021-02-19 中国农业科学院作物科学研究所 Application of LbCpf1-RR mutant in CRISPR/Cpf1 system in plant gene editing
CN108486108B (en) 2018-03-16 2020-10-09 华南农业大学 Cell strain for knocking out human HMGB1 gene and application thereof
CN108384784A (en) 2018-03-23 2018-08-10 广西医科大学 A method of knocking out Endoglin genes using CRISPR/Cas9 technologies
CN108410877A (en) 2018-03-27 2018-08-17 和元生物技术(上海)股份有限公司 The sgRNA of CRISPR-Cas9 targeting knock outs people's cell SANIL1 genes and its specificity
CN108504685A (en) 2018-03-27 2018-09-07 宜明细胞生物科技有限公司 A method of utilizing CRISPR/Cas9 system homologous recombination repair IL-2RG dcc genes
CN108424931A (en) 2018-03-29 2018-08-21 内蒙古大学 The method that CRISPR/Cas9 technologies mediate goat VEGF Gene targetings
CN108486234B (en) 2018-03-29 2022-02-11 东南大学 CRISPR (clustered regularly interspaced short palindromic repeats) typing PCR (polymerase chain reaction) method and application thereof
CN108486111A (en) 2018-04-04 2018-09-04 山西医科大学 The method and its specificity sgRNA of CRISPR-Cas9 targeting knock out people's SMYD3 genes
CN108504693A (en) 2018-04-04 2018-09-07 首都医科大学附属北京朝阳医院 The O-type that T synthase genes structure is knocked out using Crispr technologies glycosylates abnormal colon carcinoma cell line
CN108441520B (en) 2018-04-04 2020-07-31 苏州大学 Gene conditional knockout method constructed by using CRISPR/Cas9 system
CN108753772B (en) 2018-04-04 2020-10-30 南华大学 Construction method of human neuroblastoma cell line with CAPNS1 gene knocked out based on CRISPR/Cas technology
CN108486154A (en) 2018-04-04 2018-09-04 福州大学 A kind of construction method of sialidase gene knock-out mice model and its application
CN108504657B (en) 2018-04-12 2019-06-14 中南民族大学 The method for knocking out HEK293T cell KDM2A gene using CRISPR-CAS9 technology
CN108753817A (en) 2018-04-13 2018-11-06 北京华伟康信生物科技有限公司 The enhanced cell for enhancing the method for the anti-cancer ability of cell and being obtained using this method
CN108588182A (en) 2018-04-13 2018-09-28 中国科学院深圳先进技术研究院 Isothermal duplication and detection technique based on the substitution of CRISPR- chains
CN108753832A (en) 2018-04-20 2018-11-06 中山大学 A method of editing Large White CD163 genes using CRISPR/Cas9
CN108823248A (en) 2018-04-20 2018-11-16 中山大学 A method of Luchuan pigs CD163 gene is edited using CRISPR/Cas9
CN108588071A (en) 2018-04-25 2018-09-28 和元生物技术(上海)股份有限公司 The sgRNA of CRISPR-Cas9 targeting knock out people colon-cancer cell CNR1 genes and its specificity
CN108707621B (en) 2018-04-26 2021-02-12 中国农业科学院作物科学研究所 CRISPR/Cpf1 system-mediated homologous recombination method taking RNA transcript as repair template
CN108588128A (en) 2018-04-26 2018-09-28 南昌大学 A kind of construction method of high efficiency soybean CRISPR/Cas9 systems and application
CN108546712B (en) 2018-04-26 2020-08-07 中国农业科学院作物科学研究所 Method for realizing homologous recombination of target gene in plant by using CRISPR/L bcPf1 system
CN108642053A (en) 2018-04-28 2018-10-12 和元生物技术(上海)股份有限公司 The sgRNA of CRISPR-Cas9 targeting knock out people colon-cancer cell PPP1R1C genes and its specificity
CN108611364A (en) 2018-05-03 2018-10-02 南京农业大学 A kind of preparation method of non-transgenic CRISPR mutant
CN108588123A (en) 2018-05-07 2018-09-28 南京医科大学 CRISPR/Cas9 carriers combine the application in the blood product for preparing gene knock-out pig
CN108610399B (en) 2018-05-14 2019-09-27 河北万玛生物医药有限公司 The method that specificity enhancing CRISPR-CAS system carries out gene editing efficiency in epidermal stem cells
CN108546717A (en) 2018-05-15 2018-09-18 吉林大学 The method that antisense lncRNA mediates cis regulatory inhibition expression of target gene
CN108624622A (en) 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 A kind of genetically engineered cell strain that can secrete mouse interleukin -6 based on CRISPR-Cas9 systems structure
CN108546718B (en) 2018-05-16 2021-07-09 康春生 Application of crRNA-mediated CRISPR/Cas13a gene editing system in tumor cells
CN108642055B (en) 2018-05-17 2021-12-03 吉林大学 sgRNA capable of effectively editing pig miR-17-92 gene cluster
CN108642090A (en) 2018-05-18 2018-10-12 中国人民解放军总医院 Method and the application that Nogo-B knocks out pattern mouse are obtained based on CRISPR/Cas9 technologies
CN108642077A (en) 2018-05-18 2018-10-12 江苏省农业科学院 Method based on CRISPR/Cas9 gene editing technology selection and breeding mung bean sterile mutants and special gRNA
CN108642078A (en) 2018-05-18 2018-10-12 江苏省农业科学院 Method based on CRISPR/Cas9 gene editing technology selection and breeding Mung Bean Bloomings pollination mutant and special gRNA
CN108559732A (en) 2018-05-21 2018-09-21 陕西师范大学 The method for establishing KI-T2A-luciferase cell lines based on CRISPR/Cas9 targeted genomic modification technologies
CN108707620A (en) 2018-05-22 2018-10-26 西北农林科技大学 A kind of Gene drive carriers and construction method
US20210198330A1 (en) 2018-05-23 2021-07-01 The Broad Institute, Inc. Base editors and uses thereof
CN108690844B (en) 2018-05-25 2021-10-15 西南大学 CRISPR/Cas9-gRNA targeting sequence pair of HTT, plasmid and HD cell model
CN108823249A (en) 2018-05-28 2018-11-16 上海海洋大学 The method of CRISPR/Cas9 building notch1a mutant zebra fish
CN108707628B (en) 2018-05-28 2021-11-23 上海海洋大学 Preparation method of zebra fish notch2 gene mutant
CN108707629A (en) 2018-05-28 2018-10-26 上海海洋大学 The preparation method of zebra fish notch1b gene mutation bodies
CN108707604B (en) 2018-05-30 2019-07-23 江西汉氏联合干细胞科技有限公司 CNE10 gene knockout is carried out using CRISPR-Cas system in epidermal stem cells
CN108753835A (en) 2018-05-30 2018-11-06 中山大学 A method of editing pig BMP15 genes using CRISPR/Cas9
CN108753836B (en) 2018-06-04 2021-10-12 北京大学 Gene regulation or editing system utilizing RNA interference mechanism
CN108715850B (en) 2018-06-05 2020-10-23 艾一生命科技(广东)有限公司 GING2 gene knockout in epidermal stem cells by using CRISPR-Cas system
CN108753813B (en) 2018-06-08 2021-08-24 中国水稻研究所 Method for obtaining marker-free transgenic plants
CN108753783A (en) 2018-06-13 2018-11-06 上海市同济医院 The construction method of Sqstm1 full genome knock-out mice animal models and application
CN108728486A (en) 2018-06-20 2018-11-02 江苏省农业科学院 A kind of construction method of eggplant CRISPR/Cas9 gene knockout carriers and application
CN108841845A (en) 2018-06-21 2018-11-20 广东石油化工学院 A kind of CRISPR/Cas9 carrier and its construction method with selection markers
CN108893529A (en) 2018-06-25 2018-11-27 武汉博杰生物医学科技有限公司 A kind of crRNA being mutated based on CRISPR technology specific detection people KRAS gene 2 and 3 exons
CN108866093B (en) 2018-07-04 2021-07-09 广东三杰牧草生物科技有限公司 Method for performing site-directed mutagenesis on alfalfa gene by using CRISPR/Cas9 system
CN108913714A (en) 2018-07-05 2018-11-30 江西省超级水稻研究发展中心 A method of BADH2 gene, which is knocked out, using CRISPR/Cas9 system formulates fragrant rice
CN108795902A (en) 2018-07-05 2018-11-13 深圳三智医学科技有限公司 A kind of safe and efficient CRISPR/Cas9 gene editings technology
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. Rna programmable epigenetic rna modifiers and uses thereof
CN108913691B (en) 2018-07-16 2020-09-01 山东华御生物科技有限公司 Card3 gene knockout in epidermal stem cells by using CRISPR-Cas system
CN108913664B (en) 2018-07-20 2020-09-04 嘉兴学院 Method for knocking out CFP1 gene in ovarian cancer cell by CRISPR/Cas9 gene editing method
CN108823291B (en) 2018-07-25 2022-04-12 领航医学科技(深圳)有限公司 Specific nucleic acid fragment quantitative detection method based on CRISPR technology
CN108853133A (en) 2018-07-25 2018-11-23 福州大学 A kind of preparation method of PAMAM and CRISPR/Cas9 System reorganization plasmid delivery nanoparticle
CN108913717A (en) 2018-08-01 2018-11-30 河南农业大学 A method of using CRISPR/Cas9 system to rice PHYB site-directed point mutation
WO2020041751A1 (en) 2018-08-23 2020-02-27 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
WO2020051360A1 (en) 2018-09-05 2020-03-12 The Broad Institute, Inc. Base editing for treating hutchinson-gilford progeria syndrome
WO2020086908A1 (en) 2018-10-24 2020-04-30 The Broad Institute, Inc. Constructs for improved hdr-dependent genomic editing
US20220389395A1 (en) 2018-10-29 2022-12-08 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020102659A1 (en) 2018-11-15 2020-05-22 The Broad Institute, Inc. G-to-t base editors and uses thereof
CN109517841B (en) 2018-12-05 2020-10-30 华东师范大学 Composition, method and application for nucleotide sequence modification
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
US20220170013A1 (en) 2019-03-06 2022-06-02 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
WO2020191246A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020210751A1 (en) 2019-04-12 2020-10-15 The Broad Institute, Inc. System for genome editing
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020236982A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Aav delivery of nucleobase editors
EP4010474A1 (en) 2019-08-08 2022-06-15 The Broad Institute, Inc. Base editors with diversified targeting scope
WO2021030666A1 (en) 2019-08-15 2021-02-18 The Broad Institute, Inc. Base editing by transglycosylation

Non-Patent Citations (61)

* Cited by examiner, † Cited by third party
Title
ALI ET AL., HEMATOL, vol. 93, 2014, pages 381 - 384
BIKARD ET AL., NUCLEIC ACIDS RES., vol. 41, no. 15, August 2013 (2013-08-01), pages 7429 - 7437
CHAVEZ A.: "Highly efficient Cas9-mediated transcriptional programming", NATURE METHODS, vol. 12, 2015, pages 326 - 328
CHEN ET AL.: "Fusion protein linkers: property, design and functionality", ADV DRUG DELIV REV., vol. 65, no. 10, 2013, pages 1357 - 69, XP055341428, DOI: doi:10.1016/j.addr.2012.09.039
CHIPEV ET AL., CELL, vol. 70, 1992, pages 821 - 828
CHYLINSKI; RHUN; CHARPENTIER: "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems", RNA BIOLOGY, vol. 10, no. 5, 2013, pages 726 - 737, XP055116068, DOI: doi:10.4161/rna.24321
CONG, L. ET AL.: "Multiplex genome engineering using CRISPR/Cas systems", SCIENCE, vol. 339, 2013, pages 819 - 823
DELTCHEVA E.; CHYLINSKI K.; SHARMA C.M.; GONZALES K.; CHAO Y.; PIRZADA Z.A.; ECKERT M.R.; VOGEL J.; CHARPENTIER E.: "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III", NATURE, vol. 471, 2011, pages 602 - 607, XP055308803, DOI: doi:10.1038/nature09886
DICARLO, J.E. ET AL.: "Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems", NUCLEIC ACIDS RESEARCH, 2013
DINGWALL C.: "The nucleoplasmin nuclear location sequence is larger and more complex than that of SV-40 large T antigen", J CELL BIOL., vol. 107, no. 3, 1988, pages 841 - 9
FERRETTI ET AI., J.J.; MCSHAN W.M.; AJDIC D.J.; SAVIC D.J.; SAVIC G.; LYON K.; PRIMEAUX C.; SEZATE S.; SUVOROV A.N.; KENTON S., PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 4658 - 4663
FERRETTI J.J.; MCSHAN W.M.; AJDIC D.J.; SAVIC D.J.; SAVIC G.; LYON K.; PRIMEAUX C.; SEZATE S.; SUVOROV A.N.; KENTON S.: "Complete genome sequence of an M1 strain of Streptococcus pyogenes", PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 4658 - 4663, XP002344854, DOI: doi:10.1073/pnas.071559398
FONFARA ET AL.: "Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems", NUCL. ACIDS RES., 2013
FUJISAWA, BLOOD, vol. 109, 2007, pages 2903 - 2911
GALLO, J. ALZHEIMER'S DISEASE., vol. 25, 2011, pages 425 - 431
GILBERT ET AL.: "CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes", CELL, vol. 154, no. 2, 2013, pages 442 - 51, XP055321615, DOI: doi:10.1016/j.cell.2013.06.044
GILBERT: "CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes", CELL, vol. 154, no. 2, 2013, pages 442 - 51, XP055321615, DOI: doi:10.1016/j.cell.2013.06.044
GREEN; SAMBROOK: "Molecular Cloning: A Laboratory Manual, 4th ed.", 2012, COLD SPRING HARBOR LABORATORY PRESS
GUILINGER JP; THOMPSON DB; LIU DR: "Fusion of catalytically inactive Cas9 to Fokl nuclease improves the specificity of genome modification", NAT. BIOTECHNOL., vol. 32, no. 6, 2014, pages 577 - 82, XP055157221, DOI: doi:10.1038/nbt.2909
HWANG, W.Y. ET AL.: "Efficient genome editing in zebrafish using a CRISPR-Cas system", NATURE BIOTECHNOLOGY, vol. 31, 2013, pages 227 - 229, XP055086625, DOI: doi:10.1038/nbt.2501
IRRTHUM ET AL., AM. J. HUM. GENET., vol. 67, 2000, pages 295 - 301
JIANG, W. ET AL.: "RNA-guided editing of bacterial genomes using CRISPR-Cas systems", NATURE BIOTECHNOLOGY, vol. 31, 2013, pages 233 - 239, XP055249123, DOI: doi:10.1038/nbt.2508
JINEK M.; CHYLINSKI K.; FONFARA I.; HAUER M.; DOUDNA J.A.; CHARPENTIER E., SCIENCE, vol. 337, 2012, pages 816 - 821
JINEK M.; CHYLINSKI K.; FONFARA I.; HAUER M.; DOUDNA J.A.; CHARPENTIER E.: "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", SCIENCE, vol. 337, 2012, pages 816 - 821, XP055299674, DOI: doi:10.1126/science.1225829
JINEK, M. ET AL.: "RNA-programmed genome editing in human cells", ELIFE, vol. 2, 2013, pages E00471
JINEK, SCIENCE, vol. 337, 2012, pages 816 - 821
KALDERON D.: "A short amino acid sequence able to specify nuclear location", CELL, vol. 39, no. 3, 1984, pages 499 - 509, XP023912340, DOI: doi:10.1016/0092-8674(84)90457-4
KLEINSTIVER, B. P. ET AL.: "Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition", NATURE BIOTECHNOLOGY, vol. 33, 2015, pages 1293 - 1298, XP055309933, DOI: doi:10.1038/nbt.3404
KLEINSTIVER, B. P. ET AL.: "Engineered CRISPR-Cas9 nucleases with altered PAM specificities", NATURE, vol. 523, 2015, pages 481 - 485, XP055293257, DOI: doi:10.1038/nature14592
KLEINSTIVER, B.P. ET AL.: "High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects", NATURE, vol. 529, 2016, pages 490 - 495, XP055303390, DOI: doi:10.1038/nature16526
KUMAR, J. BIOL. CHEM., vol. 274, 1999, pages 24137 - 24141
KUNDU, 3 BIOTECH., vol. 3, 2013, pages 225 - 234
LAVERGNE, BR. J. HAEMATOL., 1992
LENK ET AL., PLOS GENETICS, vol. 7, 2011, pages EL002104
LEWIS, J. OF GENERAL VIROLOGY, vol. 87, 2006, pages 2443 - 2449
LUNDQUIST ET AL.: "Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase", J. BIOL. CHEM., vol. 272, 1997, pages 21408 - 21419
MAEDER ET AL.: "CRISPR RNA-guided activation of endogenous human genes", NAT METHODS, vol. 10, 2013, pages 977 - 979, XP055291599, DOI: doi:10.1038/nmeth.2598
MAKKERH J.P.: "Comparative mutagenesis of nuclear localization signals reveals the importance of neutral and acidic amino acids", CURR BIOL., vol. 6, no. 8, 1996, pages 1025 - 7
MALI ET AL.: "Cas9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering", NAT BIOTECHNOL., vol. 31, no. 9, 2013, pages 833 - 8, XP055294730, DOI: doi:10.1038/nbt.2675
MALI, P. ET AL.: "RNA-guided human genome engineering via Cas9", SCIENCE, vol. 339, 2013, pages 823 - 826
MALI: "CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering", NAT BIOTECHNOL., vol. 31, no. 9, 2013, pages 833 - 8, XP055294730, DOI: doi:10.1038/nbt.2675
MCDONALD ET AL., GENOMICS, vol. 39, 1997, pages 402 - 405
MINORETTI, INT. J. OFMOL. MED., vol. 19, 2007, pages 369 - 372
NORIS ET AL., BRITISH JOURNAL OFHAEMATOLOGY, vol. 97, 1997, pages 312 - 320
POLLER, GENOMICS, vol. 17, 1993, pages 740 - 743
PRASHANT ET AL.: "CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering", NATURE BIOTECHNOLOGY, vol. 31, no. 9, 2013, pages 833 - 838, XP055294730, DOI: doi:10.1038/nbt.2675
PRASHANT: "CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering", NATURE BIOTECHNOLOGY, vol. 31, no. 9, 2013, pages 833 - 838, XP055294730, DOI: doi:10.1038/nbt.2675
PUTNAM ET AL.: "Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase", J. MOL. BIOL., vol. 287, 1999, pages 331 - 346, XP004462617, DOI: doi:10.1006/jmbi.1999.2605
QI ET AL., CELL, vol. 152, no. 5, 28 December 2012 (2012-12-28), pages 1173 - 83
QI: "Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression", CELL, vol. 152, no. 5, 2013, pages 1173 - 83, XP055346792, DOI: doi:10.1016/j.cell.2013.02.022
QI: "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression", CELL, vol. 152, no. 5, 28 December 2012 (2012-12-28), pages 1173 - 83, XP055346792, DOI: doi:10.1016/j.cell.2013.02.022
RAVISHANKAR ET AL.: "X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG", NUCLEIC ACIDS RES., vol. 26, 1998, pages 4880 - 4887
RAY M.: "Quantitative tracking of protein trafficking to the nucleus using cytosolic protein delivery by nanoparticle-stabilized nanocapsules", BIOCONJUG. CHEM., vol. 26, no. 6, 2015, pages 1004 - 7
SCHWANK: "Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients", CELL STEM CELL, vol. 13, 2013, pages 653 - 658, XP055102691, DOI: doi:10.1016/j.stem.2013.11.002
SLAYMAKER, I.M. ET AL.: "Rationally engineered Cas9 nucleases with improved specificity", SCIENCE, vol. 351, 2015, pages 84 - 88, XP002757561, DOI: doi:10.1126/science.aad5227
TSAI SQ; WYVEKENS N; KHAYTER C; FODEN JA; THAPAR V; REYON D; GOODWIN MJ; ARYEE MJ; JOUNG JK: "Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome editing", NAT BIOTECHNOL., vol. 32, no. 6, 2014, pages 569 - 76, XP055178523, DOI: doi:10.1038/nbt.2908
TSAI SQ; WYVEKENS N; KHAYTER C; FODEN JA; THAPAR V; REYON D; GOODWIN MJ; ARYEE MJ; JOUNG JK: "Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome editing", NAT. BIOTECHNOL., vol. 32, no. 6, 2014, pages 569 - 76, XP055178523, DOI: doi:10.1038/nbt.2908
WANG ET AL.: "Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase", J. BIOL. CHEM., vol. 264, 1989, pages 1163 - 1171
WEINBERGER ET AL., THE J. OF PHYSIOLOGY, vol. 590, 2012, pages 3449 - 3464
WU: "Correction of a genetic disease in mouse via use of CRISPR-Cas9", CELL STEM CELL, vol. 13, 2013, pages 659 - 662, XP055196555, DOI: doi:10.1016/j.stem.2013.10.016
YAZAKI, KIDNEY INT., vol. 64, 2003, pages 11 - 16

Cited By (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
US11390884B2 (en) 2015-05-11 2022-07-19 Editas Medicine, Inc. Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
US11667911B2 (en) 2015-09-24 2023-06-06 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/CAS-mediated genome editing
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) * 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11591589B2 (en) 2017-04-21 2023-02-28 The General Hospital Corporation Variants of Cpf1 (Cas12a) with altered PAM specificity
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2018226855A1 (en) * 2017-06-06 2018-12-13 The General Hospital Corporation Engineered crispr-cas9 nucleases
US11098297B2 (en) 2017-06-09 2021-08-24 Editas Medicine, Inc. Engineered Cas9 nucleases
US10428319B2 (en) 2017-06-09 2019-10-01 Editas Medicine, Inc. Engineered Cas9 nucleases
CN110997908A (en) * 2017-06-09 2020-04-10 爱迪塔斯医药公司 Engineered CAS9 nucleases
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11624058B2 (en) 2017-08-23 2023-04-11 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
US11286468B2 (en) * 2017-08-23 2022-03-29 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
JP2020532967A (en) * 2017-08-23 2020-11-19 ザ ジェネラル ホスピタル コーポレイション Genetically engineered CRISPR-Cas9 nuclease with altered PAM specificity
CN111278450B (en) * 2017-08-23 2024-04-09 通用医疗公司 Engineered CRISPR-Cas9 nucleases with altered PAM specificity
US20230407277A1 (en) * 2017-08-23 2023-12-21 The General Hospital Corporation Engineered CRISPR-Cas9 Nucleases with Altered PAM Specificity
WO2019040650A1 (en) * 2017-08-23 2019-02-28 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
AU2018320865B2 (en) * 2017-08-23 2023-09-14 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
CN111278450A (en) * 2017-08-23 2020-06-12 通用医疗公司 Engineered CRISPR-Cas9 nucleases with altered PAM specificity
WO2019139645A3 (en) * 2017-08-30 2019-10-10 President And Fellows Of Harvard College High efficiency base editors comprising gam
US11932884B2 (en) 2017-08-30 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN111065647A (en) * 2017-09-01 2020-04-24 上海科技大学 Fusion protein for improving base editing precision
WO2019049913A1 (en) * 2017-09-05 2019-03-14 国立大学法人 東京大学 Modified cas9 protein, and use thereof
JPWO2019049913A1 (en) * 2017-09-05 2019-12-19 国立大学法人 東京大学 Modified Cas9 protein and use thereof
JP2020043869A (en) * 2017-09-05 2020-03-26 国立大学法人 東京大学 Modified cas9 protein and uses thereof
US11530396B2 (en) 2017-09-05 2022-12-20 The University Of Tokyo Modified CAS9 protein, and use thereof
JP7284469B2 (en) 2017-09-05 2023-05-31 国立大学法人 東京大学 Modified Cas9 protein and uses thereof
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019123429A1 (en) * 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a
US11118177B2 (en) 2017-12-21 2021-09-14 Crispr Therapeutics Ag Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
US11072792B2 (en) 2017-12-21 2021-07-27 Bayer Healthcare Llc Materials and methods for treatment of usher syndrome type 2A
WO2019161251A1 (en) 2018-02-15 2019-08-22 The Broad Institute, Inc. Cell data recorders and uses thereof
WO2019168953A1 (en) 2018-02-27 2019-09-06 President And Fellows Of Harvard College Evolved cas9 variants and uses thereof
JPWO2019194320A1 (en) * 2018-04-06 2021-04-08 国立大学法人 東京大学 Engineered BlCas9 nuclease
WO2019194320A1 (en) * 2018-04-06 2019-10-10 国立大学法人東京大学 Engineered b1cas9 nuclease
US11845987B2 (en) 2018-04-17 2023-12-19 The General Hospital Corporation Highly sensitive in vitro assays to define substrate preferences and sites of nucleic acid cleaving agents
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2019234132A1 (en) 2018-06-05 2019-12-12 KWS SAAT SE & Co. KGaA Base editing in polymerase theta deficient plants
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2020007325A1 (en) * 2018-07-05 2020-01-09 Tsinghua University Cas9 variants and application thereof
EP3841204A4 (en) * 2018-08-23 2022-05-18 Sangamo Therapeutics, Inc. Engineered target specific base editors
US11834686B2 (en) 2018-08-23 2023-12-05 Sangamo Therapeutics, Inc. Engineered target specific base editors
JP2021536229A (en) * 2018-08-23 2021-12-27 サンガモ セラピューティクス, インコーポレイテッド Manipulated target-specific base editor
WO2020051360A1 (en) 2018-09-05 2020-03-12 The Broad Institute, Inc. Base editing for treating hutchinson-gilford progeria syndrome
CN113166743A (en) * 2018-10-15 2021-07-23 马萨诸塞大学 Programmable DNA base editing of NME2CAS 9-deaminase fusion protein
WO2020081568A1 (en) * 2018-10-15 2020-04-23 University Of Massachusetts Programmable dna base editing by nme2cas9-deaminase fusion proteins
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020089489A1 (en) 2018-11-01 2020-05-07 KWS SAAT SE & Co. KGaA Targeted mutagenesis using base editors
WO2020102659A1 (en) 2018-11-15 2020-05-22 The Broad Institute, Inc. G-to-t base editors and uses thereof
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
WO2020206461A1 (en) * 2019-04-05 2020-10-08 Children's Hospital Of Philadelphia Compositions and methods for in utero gene editing for monogenic lung disease
WO2020214619A1 (en) * 2019-04-15 2020-10-22 Emendobio Inc. Crispr compositions and methods for promoting gene editing of gata2
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020229241A1 (en) 2019-05-10 2020-11-19 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2020236982A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Aav delivery of nucleobase editors
CN110184339B (en) * 2019-06-13 2022-09-20 复旦大学附属眼耳鼻喉科医院 Wolfram syndrome I type new mutation site and application thereof
CN110184339A (en) * 2019-06-13 2019-08-30 复旦大学附属眼耳鼻喉科医院 The new mutation site of Wolfram syndrome i type and its application
WO2021025750A1 (en) 2019-08-08 2021-02-11 The Broad Institute, Inc. Base editors with diversified targeting scope
WO2021030666A1 (en) 2019-08-15 2021-02-18 The Broad Institute, Inc. Base editing by transglycosylation
WO2021032759A1 (en) * 2019-08-20 2021-02-25 Kemijski Institut Coiled-coil mediated tethering of crispr/cas and exonucleases for enhanced genome editing
CN114269930A (en) * 2019-08-20 2022-04-01 凯米斯基协会 Coiled-coil mediated tethering of CRISPR/CAS and exonuclease for enhanced genome editing
EP3783104A1 (en) * 2019-08-20 2021-02-24 Kemijski Institut Coiled-coil mediated tethering of crispr-cas and exonucleases for enhanced genome editing
WO2021046442A1 (en) * 2019-09-05 2021-03-11 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
WO2021050512A1 (en) * 2019-09-09 2021-03-18 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
WO2021048316A1 (en) 2019-09-12 2021-03-18 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2021069387A1 (en) 2019-10-07 2021-04-15 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2021108717A3 (en) * 2019-11-26 2021-07-08 The Broad Institute, Inc Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
WO2021108717A2 (en) 2019-11-26 2021-06-03 The Broad Institute, Inc Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
WO2021110582A1 (en) 2019-12-03 2021-06-10 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
US20210261932A1 (en) * 2020-01-24 2021-08-26 The General Hospital Corporation Crispr-cas enzymes with enhanced on-target activity
US20210284978A1 (en) * 2020-01-24 2021-09-16 The General Hospital Corporation Unconstrained Genome Targeting with near-PAMless Engineered CRISPR-Cas9 Variants
EP4093864A4 (en) * 2020-01-24 2024-04-10 Massachusetts Gen Hospital Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
WO2021158921A2 (en) 2020-02-05 2021-08-12 The Broad Institute, Inc. Adenine base editors and uses thereof
WO2021158995A1 (en) 2020-02-05 2021-08-12 The Broad Institute, Inc. Base editor predictive algorithm and method of use
WO2021158999A1 (en) 2020-02-05 2021-08-12 The Broad Institute, Inc. Gene editing methods for treating spinal muscular atrophy
WO2021183693A1 (en) 2020-03-11 2021-09-16 The Broad Institute, Inc. Stat3-targeted based editor therapeutics for the treatment of melanoma and other cancers
WO2021216622A1 (en) * 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
WO2021222318A1 (en) 2020-04-28 2021-11-04 The Broad Institute, Inc. Targeted base editing of the ush2a gene
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11789027B2 (en) 2020-10-29 2023-10-17 Ambergen, Inc. Photocleavable mass-tags for multiplexed mass spectrometric imaging of tissues using biomolecular probes
WO2022129905A1 (en) 2020-12-16 2022-06-23 Oxford Genetics Limited Crispr polypeptides
WO2022162200A1 (en) 2021-01-29 2022-08-04 Nuntius Therapeutics Ltd. Nucleic Acid Delivery
WO2022248651A2 (en) 2021-05-27 2022-12-01 Complement Therapeutics Limited Inhibitory nucleic acids for factor h family proteins
WO2022261509A1 (en) 2021-06-11 2022-12-15 The Broad Institute, Inc. Improved cytosine to guanine base editors
WO2023278886A3 (en) * 2021-07-02 2023-03-02 Integrated Dna Technologies, Inc. Novel mutations in streptococcus pyogenes cas9 discovered by broad scanning mutagenesis demonstrate enhancement of dna cleavage activity
WO2023102537A2 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same
CN114350671A (en) * 2021-12-22 2022-04-15 湖北省妇幼保健院 KIF11 gene mutant and application thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023155901A1 (en) * 2022-02-17 2023-08-24 Correctsequence Therapeutics Mutant cytidine deaminases with improved editing precision
WO2023196802A1 (en) 2022-04-04 2023-10-12 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
WO2023212715A1 (en) 2022-04-28 2023-11-02 The Broad Institute, Inc. Aav vectors encoding base editors and uses thereof
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024028465A1 (en) 2022-08-03 2024-02-08 Nuntius Therapeutics Limited Hybrid peptide dendrimer systems and extrahepatic delivery
WO2024040083A1 (en) 2022-08-16 2024-02-22 The Broad Institute, Inc. Evolved cytosine deaminases and methods of editing dna using same
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024047246A1 (en) 2022-09-02 2024-03-07 Nuntius Therapeutics Limited Methods for characterisation of nanocarriers
WO2024052681A1 (en) 2022-09-08 2024-03-14 The University Court Of The University Of Edinburgh Rett syndrome therapy
WO2024077247A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Base editing methods and compositions for treating triplet repeat disorders

Also Published As

Publication number Publication date
EP3365356B1 (en) 2023-06-28
JP2018537963A (en) 2018-12-27
CA3002827A1 (en) 2017-04-27
EP3365357A2 (en) 2018-08-29
CN108513575A (en) 2018-09-07
AU2016342380B2 (en) 2022-04-07
IL258821B (en) 2022-07-01
US10167457B2 (en) 2019-01-01
US20190225955A1 (en) 2019-07-25
EP3365357B1 (en) 2024-02-14
WO2017070632A2 (en) 2017-04-27
IL294014A (en) 2022-08-01
US20220220462A1 (en) 2022-07-14
JP2019509012A (en) 2019-04-04
CN108699116A (en) 2018-10-23
JP2022124487A (en) 2022-08-25
IL258821A (en) 2018-06-28
US20180312825A1 (en) 2018-11-01
WO2017070632A3 (en) 2017-06-08
AU2016342380A1 (en) 2018-05-10
US11214780B2 (en) 2022-01-04
JP7067793B2 (en) 2022-05-16
IL310721A (en) 2024-04-01
AU2022204298A1 (en) 2022-07-07
SG10202104041PA (en) 2021-06-29
JP7109784B2 (en) 2022-08-01
KR20180069898A (en) 2018-06-25
EP3365356A2 (en) 2018-08-29
SG11201803173VA (en) 2018-05-30
US20170121693A1 (en) 2017-05-04
WO2017070633A3 (en) 2017-07-13
EP4269577A3 (en) 2024-01-17
EP4269577A2 (en) 2023-11-01
IL294014B1 (en) 2024-03-01
JP2022069439A (en) 2022-05-11

Similar Documents

Publication Publication Date Title
EP3365357B1 (en) Evolved cas9 proteins for gene editing
US20230348883A1 (en) Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11542496B2 (en) Cytosine to guanine base editor
US11124782B2 (en) Cas variants for gene editing
KR20200121782A (en) Uses of adenosine base editor
CN114072509A (en) Nucleobase editor with reduced off-target of deamination and method of modifying nucleobase target sequence using same
JP2022500017A (en) Compositions and Methods for Delivering Nucleobase Editing Systems
JP2022519507A (en) Assays for nucleobase editors and nucleobase editor characterization with reduced non-targeted deamination
US20240035017A1 (en) Cytosine to guanine base editor
US20230313173A1 (en) Systems and methods for identifying cells that have undergone genome editing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16794114

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2018521045

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016794114

Country of ref document: EP